FIELD OF THE INVENTION The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in lung cancer; and to the use of such expression profiles and compositions in diagnosis and therapy of lung cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit lung cancer or related conditions.

BACKGROUND OF THE INVENTION Lung cancer is the second most commonly occurring cancer in the United States and is the leading cause of cancer-related death. It is estimated that there are over 160,000 new cases of lung cancer in the United States every year. Of those who are diagnosed with lung cancer, 86 percent will die within five years. Lung cancer is the most common visceral cancer in men and accounts for nearly one third of all cancer deaths in both men and women.

In fact, lung cancer accounts for 7% of all deaths, due to any cause, in both men and women.

Smoking is the primary cause of lung cancer, with more than 80% of lung cancers resulting from smoking. About 400 to 500 separate gaseous substances are present in the smoke of a non-filter cigarette. The most noteworthy substances include nitrogen oxides, hydrogen cyanide, formaldehyde, benzene, and toluene. The particles present in cigarette smoke contain at least 3,500 individual compounds such as nicotine, tobacco alkaloids (nornicotine, anatabine, anabasine), polycyclic aromatic hydrocarbons (e. g., benzo (a) pyrene, B (a) P), naphthalenes, aromatic amines, phenols, and tobacco-specific nitrosamines.

Tobacco-specific nitrosamines are formed during tobacco curing and processing, and are suspected of causing lung cancer in humans. In rodent studies, regardless of the where or how it is applied, the tobacco-specific nitrosamine known as NNK produces lung adenomas and lung adenocarcinomas. The tobacco-specific nitrosamine known as NNAL also produces- lung adenocarcinomas in rodents.

Many of the chemicals found in cigarette smoke also affect the nonsmoker inhaling "secondhand"or sidestream smoke. Indeed, the smoke inhaled by non-smokers has a chemical composition similar to the smoke inhaled by smokers, but, importantly, the concentrations of the carcinogenic tobacco-specific nitrosamines are present in higher concentrations in second hand smoke. For this and other reasons,"passive smoking"is an important cause of lung cancer, causing as many as 3,000 lung cancer deaths in nonsmokers each year.

In addition to smoking, other factors thought to be causes of lung cancer include on- the-job exposure to carcinogens such as asbestos and uranium, exposure to chemical hazards such as radon, polycyclic aromatic hydrocarbons, chromium, nickel, and inorganic arsenic, genetic factors, and diet.

Histological classification of various lung cancers define the types of cancer that begin in the lung. See, e. g., Travis, et al. (1999) Histological Typing of Lung and Pleural Tumours (International Histological Classification of Tumours, No 1. Four major cell types make up more than 88% of all primary lung neoplasms. These are: squamous or epidermoid carcinoma, small cell (also called oat cell) carcinoma, adenocarcinoma, and large cell (also called large cell anaplastic) carcinoma. The remainder include undifferentiated carcinomas, carcinoids, bronchial gland tumors, and other rarer types. The various cell types have different natural histories and responses to therapy, and, thus, a correct histologic diagnosis is the first step of effective treatment.

Small cell lung cancer (SCLC) accounts for 18-25% of all lung cancers, and occurs less frequently than non-small cell lung cancers, and generally spread to distant organs more rapidly than non-small cell lung cancer. In general, at the time of presentation small cell lung cancers have already spread beyond the beyond the bounds where surgery and curative intent can be undertaken. Hoever, if identified early enough, these cancers are often responsive to chemotherapy and thoracic radiation treatment.

Non-small cell lung cancers (NSCLC) are the more frequently occurring form of lung cancer. They comprise squamous cell carcinoma, adenocarcinoma, and large cell carcinoma

and account for more than 75% of all lung cancers. Non-small cell tumors that are localized at the time of presentation can sometimes be cured with surgery and/or radiotherapy, but usually are not identified until significant metastasis has occurred, which are typically not very responsive to surgical, chemotherapy, or radiation treatment..

The screening of asymptomatic persons at high risk for lung cancer has often proven ineffective. In general, only 5 to 15 percent of lung cancer patients have their disease detected while they are asymptomatic. Of course, early detection and treatment are critical factors in the fight against lung cancer. The average survival rate is 49% for those whose cancer is detected early, before the cancer has spread from the lung. Lung cancer often spreads outside of the lung, and it may have spread to the bones or brain by the time it is diagnosed. While the prognosis may be better for lung cancers that are detected early, because of the lack ofv effective curative treatments, early detection does not necessarily alter the total death rate from lung cancer.

Thus, methods for diagnosis and prognosis of lung cancer and effective treatment of lung cancer would be desirable. Accordingly, provided herein are methods that can be used in diagnosis and prognosis of lung cancer. Further provided are methods that can be used to screen candidate therapeutic agents for the ability to modulate, e. g., treat, lung cancer.

Additionally, provided herein are molecular targets and compositions for therapeutic intervention in lung disease and other metastatic cancers.

SUMMARY OF THE INVENTION The present invention provides nucleotide sequences of genes that are up-and down- regulated in lung cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate lung cancer, such as antibodies. The methods of detecting nucleic acids of the invention or their encoded proteins can be used for a number of purposes. Examples include early detection of lung cancers, monitoring and early detection of relapse following treatment of lung cancers, monitoring response to therapy of lung cancers, determining prognosis of lung cancers, directing therapy of lung cancers, selecting patients for postoperative chemotherapy or radiation therapy, selecting therapy, determining tumor prognosis, treatment, or response to treatment, and early detection of precancerous lesions of the lung. Examples of benign or precancerous lesions include: atelectasis, emphysema, brochitis, chronic obstructive pulmonary disease, fibrosis, hypersensitivity pneumonitis (HP), interstitial pulmonary fibrosis (IPF), asthma, and

bronchiectasis. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

In one aspect, the present invention provides a method of detecting a lung cancer- associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables lA-16. Alternatively, the sample may be contacted with a specific binding reagent, e. g., antibody.

In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables lA-16. In another embodiment, the polynucleotide comprises a sequence as shown in Tables 1A-16.

In one embodiment, the biological sample is a tissue sample, or a body fluid. In another embodiment, the biological sample comprises isolated nucleic acids, e. g., mRNA.

In one embodiment, the polynucleotide is labeled, e. g., with a fluorescent label. In one embodiment, the polynucleotide is immobilized on a solid surface. In one embodiment, the patient is undergoing a therapeutic regimen to treat lung cancer. In another embodiment, the patient is suspected of having lung cancer. In one embodiment, the patient is a primate, e. g., a human.

In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of lung cancer, the method comprising the steps of : (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a lung cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1A-16, thereby monitoring the efficacy of the therapy. Or the sample may be evaluated for protein, e. g., contacting the sample with an antibody.

In one embodiment, the method further comprises the step of : (iii) comparing the level of the lung cancer-associated transcript to a level of the lung cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment. Or the sample may be evalated for comparison of protein.

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of lung cancer, the method comprising the steps of : (i) providing a

biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a lung cancer-associated antibody in the biological sample by contacting the biological sample with a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables lA-16, wherein the polypeptide specifically binds to the lung cancer-associated antibody, thereby monitoring the efficacy of the therapy.

In one embodiment, the method further comprises the step of : (iii) comparing the level of the lung cancer-associated antibody to a level of the lung cancer-associated antibody in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of lung cancer, the method comprising the steps of : (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a lung cancer-associated polypeptide in the biological sample by contacting the biological sample with an antibody, wherein the antibody specifically binds to a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables lA-16, thereby monitoring the efficacy of the therapy.

In one embodiment, the method further comprises the step of : (iii) comparing the level of the lung cancer-associated polypeptide to a level of the lung cancer-associated polypeptide in a biological sample from the patient prior to, or earlier in, the therapeutic treatment. In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables lA-16. In one embodiment, an expression vector or cell comprises the isolated nucleic acid. In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables lA-16.

In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables lA-16. In one embodiment, the antibody is conjugated to an effector component, e. g., a fluorescent label, a radioisotope or a cytotoxic chemical. In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized.

In one aspect, the present invention provides a method of detecting lung cancer in a a patient, the method comprising contacting a biological sample from the patient with an antibody or protein as described herein.

In another aspect, the present invention provides a method of detecting antibodies specific to a lung cancer gene in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprises a sequence from Tables lA-16.

In another aspect, the present invention provides a method for identifying a compound that modulates a lung cancer-associated polypeptide, the method comprising the steps of : (i) contacting the compound with a lung cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables lA-16 ; and (ii) determining the functional effect of the compound upon the polypeptide.

In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect. In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant. In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.

In another aspect, the present invention provides a method of inhibiting proliferation or another critical process of a lung cancer-associated cell to treat lung cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein. In one embodiment, the compound is an antibody.

In another aspect, the present invention provides a drug screening assay comprising the steps of : (i) administering a test compound to a mammal having lung cancer or a cell isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1A-16 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of lung cancer.

In one embodiment, the control is a mammal with lung cancer or a cell therefrom that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal, or a non-malignant lung disease.

In another aspect, the present invention provides a method for treating a mammal having lung cancer comprising administering a compound identified by the assay described herein.

In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having lung cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.

DETAILED DESCRIPTION OF THE INVENTION In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and treatment of lung disease or cancer, as well as methods for screening for compositions which modulate lung cancer."Treatment, monitoring, detection or modulation of lung disease or cancer"includes treatment, monitoring, detection, or modulation of lung disease in those patients who have lung disease (whether malignant or non-malignant, e. g., emphysema, bronchitis, or fibrosis) as well as patients with lung cancers in which gene expression from a gene in Tables lA-16 is increased or decreased, indicating that the subject is more likely to have disease. In particular, while these targets are identified primarily from lung cancer samples, these same targets are likely to be similarly found in analyses of other medical conditions. These other conditions may result from similar pathological processes which affect similar tissues, e. g., lung cancer, small cell lung carcinoma (oat cell carcinoma), non-small cell carcinomas (e. g., squamous cell carcinoma, adenocarcinoma, large cell lung carcinoma, carcinoid, granulomatous), fibrosis (idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), interstitial pneumonitis, nonspecific idiopathic pneumonitis (NSIP)), chronic obstructive pulmonary disease (COPD, e. g., emphysema, chronic bronchitis), asthma, bronchiectasis, and esophageal cancer. See, e. g., the NCI webpage and USSN 60/347,349 and USSN 60/xxx, xxx (docket LFBR-001-1P, filed March 29,2002), each of which is incorporated herein by reference. The treatment may be of lung cancer or related condition itself, or treatment of metastasis.

In particular, identification of markers selectively expressed on these cancers allows for use of that expression in diagnostic, prognostic, or therapeutic methods. As such, the invention defines various compositions, e. g., nucleic acids, polypeptides, antibodies, and small molecule agonists/antagonists, which will be useful to selectively identify those markers. For example, therapeutic methods may take the form of protein therapeutics which use the marker expression for selective localization or modulation of function (for those markers which have a causative disease effect), for vaccines, identification of binding partners, or antagonism, e. g., using antisense or RNAi. The markers may be useful for molecular characterization of subsets of lung diseases, which subsets may actually require

very different treatments. Moreover, the markers may also be important in related diseases to the specific cancers, e. g., which affect similar tissues in non-malignant diseases, or have similar mechanisms of induction/maintenance. Metastatic processes or characteristics may also be targeted. Diagnostic and prognostic uses are made available, e. g., to subset related but distinct diseases, or to determine treatment strategy. The detection methods may be based upon nucleic acid, e. g., PCR or hybridization techniques, or protein, e. g., ELISA, imaging, IHC, etc. The diagnosis may be qualitative or quantitative, and may detect increases or decreases in expression levels.

Tables lA-16 provide unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in lung cancer samples. The tables also provide an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster. In Table 1A, genes marked as"target 1"or"target 2"are particularly useful as therapeutic targets. Genes marked as"target 3"are particularly useful as diagnostic markers. Genes marked as"chron"are upregulated in chronically diseased lung (e. g., emphysema, bronchitis, fibrosis) relative to lung tumors and normal tissue. In certain analyses, the ratio for the"chron"category was determined using the 70th percentile of chronically diseases lung samples divided by the 90th percentile of normal lung samples.

The ratio for the targets was determined using the 70th percentile of lung tumor samples divided by the 90th percentile of normal lung samples.

Definitions The term"lung cancer protein"or"lung cancer polynucleotide"or"lung cancer- associated transcript"refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologs that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25,50,100,200,500,1000, or more nucleotides, to a nucleotide sequence of or associated with a unigene cluster of Tables lA-16 ; (2) bind to antibodies, e. g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a unigene cluster of Tables lA-16, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables lA-16 and conservatively modified variants thereof ; or (4)

have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25,50,100,200,500,1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a unigene cluster of Tables lA-16. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e. g., human; rodent, e. g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. A"lung cancer polypeptide"and a"lung cancer polynucleotide,"include both naturally occurring or recombinant forms.

A"full length"lung cancer protein or nucleic acid refers to a lung cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains the elements normally contained in one or more naturally occurring, wild type lung cancer polynucleotide or polypeptide sequences. The"full length"may be prior to, or after, various stages of post- translational processing or splicing, including alternative splicing.

"Biological sample"as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e. g., of a lung cancer protein, polynucleotide, or transcript. Such samples include, but are not limited to, tissue isolated from primates, e. g., humans, or rodents, e. g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, archival materials, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc.

Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate, e. g., chimpanzee or human; cow; dog; cat; a rodent, e. g., guinea pig, rat, mouse; rabbit; or other mammal; or a bird; reptile; fish. Livestock and domestic animals are of interest.

"Providing a biological sample"means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e. g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention in vivo. Archival tissues or materials, having treatment or outcome history, will be particularly useful.

The terms"identical"or percent"identity,"in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the

same or have a specified percentage of amino acid residues or nucleotides that are the same (e. g., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using, e. g., a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e. g., NCBI web site http ://www. ncbi. nhn. nih. gov/BLAST/ or the like). Such sequences are then said to be"substantially identical."This definition also refers to, or may be applied to, the complement of a test sequence. The definition also includes sequences that have deletions and/or insertions, substitutions, and naturally occurring, e. g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A"comparison window", as used herein, includes reference to a segment of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e. g., by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math.

2: 482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol.

48 : 443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'1. Acad.

Sci. USA 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer

Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e. g., Ausubel, et al. (eds. 1995 and supplements) Current Protocols in Molecular Biology.

Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms, which are described in Altschul, et al. (1977) Nuc. Acids Res. 25: 3389-3402 and Altschul, et al. (1990) J. Mol. Biol. 215: 403-410. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www. ncbi. nlm. nih. gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul, et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e. g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89 : 10915) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e. g., Karlin and Altschul (1993) Proc. Nat'1. Acad. Sci. USA 90: 5873- 5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P (N)), which provides an indication of the probability by which a match between

two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be negative large numbers, e. g., 5,10,20,30,40,40,70,90,110,150,170, etc.

An indication that two nucleic acid sequences are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid. Thus, a polypeptide is typically substantially identical to a second polypeptide, e. g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A"host cell"is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells in vivo, and the like. Host cells may be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (see, e. g., the American Type Culture Collection catalog or web site, www. atcc. org).

The terms"isolated,""purified,"or"biologically pure"refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term"purified"in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least about 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure."Purify"or"purification"in other embodiments means removing at least one contaminant or component from the composition to be purified.

In this sense, purification does not require that the purified compound be homogeneous, e. g., 100% pure.

The terms"polypeptide,""peptide"and"protein"are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

The term"amino acid"refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e. g., hydroxyproline, y- carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, e. g., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e. g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e. g., norleucine) or modified peptide backbones, but retain some basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that function similarly to another amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants"applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e. g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG, and GCU each encode the amino acid alanine. Thus, at each position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are"silent variations,"which are one species of

conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. In certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally similar molecule. Accordingly, a silent variation of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not necessarily with respect to actual probe sequences.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a"conservatively modified variant"where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention. Typically conservative substitutions include for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e. g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e. g., Alberts, et al. (1994) Molecular Biology of the Cell (3rd ed.) and Cantor and Schimmel (1980) Biophysical Chemistry Part I : The Conformation of Biological Macromolecules."Primary structure"refers to the amino acid sequence of a particular peptide."Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long.

Typical domains are made up of sections of lesser organization such as stretches of (3-sheet and a-helices."Tertiary structure"refers to the complete three dimensional structure of a polypeptide monomer."Quaternary structure"refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

"Nucleic acid"or"oligonucleotide"or"polynucleotide"or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5,6,7,8,9,10,12,15,25,30,40,50 or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e. g., 200,300,500,1000,2000,3000,5000,7000,10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have at least one different linkage, e. g., phosphoramidate, phosphorothioate, phosphorodithioate, or O- methylphophoroamidite linkages (see Eckstein (1992) Oligonucleotides and Analogues : A Practical Approach Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U. S. Patent Nos.

5,235,033 and 5,034,506, and Chapters 6 and 7, in Sanghui and Cook, eds. Carbohydrate Modifications in Antisense Research, ASC Symposium Series 580. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids.

Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e. g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids.

This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (Tm) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4° C drop in Tm for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9° C.

Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary

strand; thus the sequences described herein also provide the complement of the sequence.

The nucleic acid may be DNA, both genomic and cDNA, RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo-and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc."Transcript"typically refers to a naturally occurring RNA, e. g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside"includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition,"nucleoside"includes non- naturally occurring analog structures. Thus, e. g., the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

A"label"or a"detectable moiety"is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, physiological, chemical, or other physical means. For example, useful labels include 32p, fluorescent dyes, electron-dense reagents, enzymes (e. g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e. g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The labels may be incorporated into the cancer nucleic acids, proteins, and antibodies. Many methods known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter, et al. (1962) Nature 144: 945; David, et al. (1974) Biochemistry 13: 1014-1021; Pain, et al. (1981) J. Immunol. Meth., 40: 219-230; and Nygren (1982) J.

Histochem. and Cvtochem. 30: 407-412.

An"effector"or"effector moiety"or"effector component"is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody.

The"effector"can be a variety of molecules including, e. g., detection moieties including radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting"hard"e. g., beta radiation.

A"labeled nucleic acid probe or oligonucleotide"is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method

using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e. g., biotin, streptavidin.

As used herein a"nucleic acid probe or oligonucleotide"is a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, e. g., through hydrogen bond formation. As used herein, a probe may include natural (i. e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, preferably one that does not functionally interfere with hybridization. Thus, e. g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. Probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled, e. g., with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled, e. g., with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression.

The term"recombinant"when used with reference, e. g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e. g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all. By the term"recombinant nucleic acid"herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid, e. g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i. e., using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered

recombinant for the purposes of the invention. Similarly, a"recombinant protein"is a protein made using recombinant techniques, i. e., through the expression of a recombinant nucleic acid as depicted above.

The term"heterologous"when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e. g., from unrelated genes arranged to make a new functional nucleic acid, e. g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e. g., a fusion protein).

A"promoter"is typically an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A"constitutive"promoter is a promoter that is active under most environmental and developmental conditions. An"inducible"promoter is a promoter that is active under environmental or developmental regulation. The term"operably linked"refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, e. g., wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

An"expression vector"is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed in operable linkage to a promoter.

The phrase"selectively (or specifically) hybridizes to"refers to the binding, duplexing, or hybridizing of a molecule selectively to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e. g., total cellular or library DNA or RNA).

The phrase"stringent hybridization conditions"refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to essentially no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in "Overview of principles of hybridization and the strategy of nucleic acid assays"in Tijssen (1993) Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes (vol. 24) Elsevier. Generally, stringent conditions are selected to be about 5-10° C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8. 3 and the temperature is at least about 30° C for short probes (e. g., 10 to 50 nucleotides) and at least about 60° C for long probes (e. g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is typically at least two times background, preferably 10 times background hybridization.

Exemplary stringent hybridization conditions are often: 50% formamide, 5x SSC, and 1% SDS, incubating at 42° C, or, 5x SSC, 1% SDS, incubating at 65° C, with wash in 0.2x SSC, and 0.1% SDS at 65° C. For PCR, a temperature of about 36° C is typical for low stringency amplification, although annealing temperatures may vary between about 32° C and 48° C depending on primer length. For high stringency PCR amplification, a temperature of about 62° C is typical, although high stringency annealing temperatures can range from about 50° C to about 65° C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90° C-95° C for 0.5-2 min., an annealing phase lasting 0.5-2 min., and an extension phase of about 72° C for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e. g., in Innis, et al. (1990) PCR Protocols. A Guide to Methods and Applications.

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This

occurs, e. g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary"moderately stringent hybridization conditions"include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37° C, and a wash in 1X SSC at 45° C. A positive hybridization is at least twice background. Alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e. g., Ausubel, et al. (ed.) Current Protocols in Molecular Biologv Lippincott.

The phrase"functional effects"in the context of assays for testing compounds that modulate activity of a lung cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the lung cancer protein or nucleic acid, e. g., a physiological, enzymatic, functional, physical, or chemical effect, such as the ability to decrease lung cancer. It includes ligand binding activity; cell viability, cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo ; mRNA and protein expression in cells undergoing metastasis, and other characteristics of lung cancer cells."Functional effects"include in vitro, in vivo, and ex vivo activities.

By"determining the functional effect"is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a lung cancer protein sequence, e. g., physiological, functional, enzymatic, physical, or chemical effects. Such functional effects can be measured by many means known to those skilled in the art, e. g., changes in spectroscopic characteristics (e. g., fluorescence, absorbance, refractive index), hydrodynamic (e. g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the lung cancer protein; measuring binding activity or binding assays, e. g., binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on lung cancer can also be performed using lung cancer assays known to those of skill in the art such as an in vitro assays, e. g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation ; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo ; mRNA and protein

expression in cells undergoing metastasis, and other characteristics of lung cancer cells. The functional effects can be evaluated by many means known to those skilled in the art, e. g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for lung cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase, (3-gal, GFP, and the like), e. g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.

"Inhibitors","activators", and"modulators"of lung cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using in vitro and in vivo assays of lung cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e. g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of lung cancer proteins, e. g., antagonists. Antisense or inhibitory nucleic acids may seem to inhibit expression and subsequent function of the protein.

"Activators"are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate lung cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of lung cancer proteins, e. g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e. g., expressing the lung cancer protein in vitro, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of lung cancer can also be identified by incubating lung cancer cells with the test compound and determining increases or decreases in the expression of 1 or more lung cancer proteins, e. g., 1,2,3,4,5,10,15,20, 25,30,40,50 or more lung cancer proteins, such as lung cancer proteins encoded by the sequences set out in Tables lA-16.

Samples or assays comprising lung cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a lung cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more

preferably 200-500% (i. e., two to five fold higher relative to the control), more preferably 1000-3000% higher.

The phrase"changes in cell growth"refers to any change in cell growth and proliferation characteristics in vitro or in vivo, such as cell viability, formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell morphology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or immortalization of the cell. See, e. g., Freshney (1994) Culture of Animal Cells a Manual of Basic Technique pp. 231-241 (3rd ed.).

"Tumor cell"refers to precancerous, cancerous, and normal cells in a tumor.

"Cancer cells,""transformed"cells, or"transformation"in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene.

Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmorphological changes, and/or malignancy (see, Freshney (1994) Culture of Animal Cells a Manual of Basic Technique (3rd ed.)).

"Antibody"refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen.

The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul, Fundamental Immunology.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one"heavy"chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible

for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.

Antibodies exist, e. g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e. g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F (ab)'2, a dimer of Fab which itself is a light chain joined to VU-CHU by a disulfide bond. The F (ab)'2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F (ab)'2 dimer into an Fab'monomer. The Fab'monomer is essentially Fab with part of the hinge region (see Paul (ed. 1999) Fundamental Immunology (4th ed.). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e. g., single chain Fv) or those identified using phage display libraries (see, e. g., McCafferty, et al. (1990) Nature 348: 552- 554).

For preparation of antibodies, e. g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e. g., Kohler and Milstein (1975) Nature 256: 495-497; Kozbor, et al. (1983) Immunology Today 4: 72; Cole, et al.

(1985), pp. 77-96 in Monoclonal Antibodies and Cancer Therapy ; Coligan (1991 and supplements) Current Protocols in Immunology ; Harlow and Lane (1988) Antibodies. A Laboratory Manual ; and Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.)). Techniques for the production of single chain antibodies (U. S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies.

Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e. g., McCafferty, et al. (1990) Nature 348: 552-554; Marks, et al. (1992) Biotechnology 10: 779-783).

A"chimeric antibody"is an antibody molecule in which, e. g, (a) the constant region, or a portion thereof, is altered, replaced, or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function, and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e. g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the

variable region, or a portion thereof, is altered, replaced, or exchanged with a variable region having a different or altered antigen specificity.

Identification of lung cancer-associated sequences In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a"fingerprint"of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue may be distinguished from cancerous or metastatic cancerous tissue, or metastatic cancerous tissue can be compared with tissue from surviving cancer patients. By comparing expression profiles of tissue in known different lung cancer states, information regarding which genes are important (including both up-and down-regulation of genes) in each of these states is obtained.

Molecular profiling may distinguish subtypes of a currently collective disease designation, e. g., different forms of lung cancer (chronic disease, adenocarcinoma, etc.) The identification of sequences that are differentially expressed in lung cancer versus non-lung cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down- regulate lung cancer, and thus tumor growth or recurrence, in a particular patient.

Alternatively, a treatment step may induce other markers which may be used as targets to destroy tumor cells. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Malignant diseasemay be compared to non-malignant conditions. Metastatic tissue can also be analyzed to determine the stage of lung cancer in the tissue, or origin of primary tumor, e. g., metastasis from a remote primary site. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e. g., screening can be done for drugs that suppress the lung cancer expression profile.

This may be done by making biochips comprising sets of the important lung cancer genes, which can then be used in these screens. PCR methods may be applied with selected primer pairs, and analysis may be of RNA or of genomic sequences. These methods can also be done on the protein basis; that is, protein expression levels of the lung cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the lung cancer

nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the lung cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs or as protein or DNA vaccines.

Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in lung cancer relative to normal tissues and/or non-malignant lung disease, or in different types of lung disease, herein termed"lung cancer sequences."As outlined below, lung cancer sequences include those that are up-regulated (i. e., expressed at a higher level) in lung cancer, as well as those that are down-regulated (i. e., expressed at a lower level). In a preferred embodiment, the lung cancer sequences are from humans; however, as will be appreciated by those in the art, lung cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other lung cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets (dogs, cats, etc.). Lung cancer sequences from other organisms may be obtained using the techniques outlined below.

Lung cancer sequences can include both nucleic acid and amino acid sequences. As will be appreciated by those in the art and is more fully outlined below, lung cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e. g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the lung cancer sequences can be generated.

A lung cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the lung cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, e. g., using homology programs or hybridization conditions.

For identifying lung cancer-associated sequences, the lung cancer screen typically includes comparing genes identified in different tissues, e. g., normal and cancerous tissues, cancer and non-malignant conditions, non-malignant conditions and normal tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing lung cancer samples with metastatic cancer samples from other cancers, such as, breast, other gastrointestinal cancers, prostate, ovarian,

etc. Samples of, non metastatic disease tissue and tissue undergoing metastasis are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art for the preparation of mRNA. Suitable biochips are commercially available, e. g., from Affymetrix, Santa Clara, CA. Gene expression profiles as described herein are generated and the data analyzed.

In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal lung, but also including, and not limited to colon, heart, brain, liver, breast, kidney, muscle, prostate, small intestine, large intestine, spleen, bone, and/or placenta. In a preferred embodiment, those genes identified during the lung cancer screen that are expressed in significant amounts in other tissues (e. g., essential organs) are removed from the profile, although in some embodiments, this is not necessary (e. g., where organs may be dispensible at a later stage of life). That is, when screening for drugs, it is usually preferable that the target expression be disease specific, to minimize possible side effects on other organs.

In a preferred embodiment, lung cancer sequences are those that are up-regulated in lung cancer; that is, the expression of these genes is higher in cancerous tissue than in normal lung or other tissue."Up-regulation"as used herein means, when the ratio is presented as a number greater than one, that the ratio is greater than one, preferably 1.5 or greater, more preferably 2.0 or greater. Another embodiment is directed to sequences up-regulated in non- malignant conditions relative to normal. Unigene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e. g., Benson, DA, et al (1998) Nucleic Acids Research 26: 1-7 and http://www. ncbi. nlm. nih. gov/. Sequences are also available in other databases, e. g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ).

Another embodiment is directed to sequences up-regulated in non-malignant conditions relative to normal. In some situations, the sequences may be derived from assembly of available sequences or be predicted from genomic DNA using exon prediction algorithms, such as FGENESH (Salamov and Solovyev (2000) Genome Res. 10: 516-522). In other situations, sequences have been derived from cloning and sequencing of isolated nucleic acids.

In another preferred embodiment, lung cancer sequences are those that are down- regulated in the lung cancer; that is, the expression of these genes is lower in cancerous tissue

or normal lung or other tissue."Down-regulation"as used herein means, when the ratio is presented as a number greater than one, that the ratio is greater than one, preferably 1.5 or greater, more preferably 2.0 or greater, or, when the ratio is presented as a number less than one, that the ratio is less than one, preferably 0.5 or less, more preferably 0.25 or less.

Informatics The ability to identify genes that are over or under expressed in lung cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with lung cancer. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson (1998) Pharmaceutical Proteomics: Targets.

Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12,1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U. S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e. g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e. g., using array analysis either singly or in a library format. The database can be in a form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.

The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for assay data acquired using an assay of the invention.

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample representing lung cancer, i. e., the identification of lung cancer-associated sequences described herein, provide an abundance of information, which can be correlated with

pathological conditions, predisposition to disease, drug testing, therapeutic monitoring, gene- disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, data processing using high-speed computers is utilized.

An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U. S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U. S.

Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U. S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U. S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U. S. Patent 5,926,818 discloses a multi- dimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U. S.

Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures.

See also Mount, et al. (2001) Bioinformatics ; Durbin, et al. (eds., 1999) Biological Sequence Analysis : Probabilistic Models of Proteins and Nucleic Acids ( ; Baxevanis and Oeullette (eds., 1998) Bioinformatics : A Practical Guide to the Analysis of Genes and Proteins) ; Rashidi and Buehler (1999) Bioinformatics : Basic Applications in Biological Science and Medicine ; Setubal, et al. (eds 1997) Introduction to Computational Molecular Biology ; Misener and Krawetz (eds, 2000) Bioinformatics : Methods and Protocols ; Higgins and Taylor (eds., 2000) Bioinformatics : Sequence, Structure, and Databanks: A Practical

Approach ; Brown (2001) Bioinformatics : A Biologist's Guide to Biocomputing and the Internet ; Han and Kamber (2000) Data Mining : Concepts and Techniques (2000); and Waterman (1995) Introduction to Computational Biology : Maps. Sequences, and Genomes.

The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e. g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.

In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e. g., a neoplastic lesion or another tissue specimen to be analyzed for lung cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e. g., a target molecular structure and/or characteristic separation coordinate (e. g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e. g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source.

When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e. g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may

be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e. g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.

The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or lOBaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e. g., computer, disk array, etc.) comprises a pattern of magnetic domains (e. g., magnetic disk) and/or charge domains (e. g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention.

In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the assay results.

Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e. g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e. g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an VO device. For example, a central processor can be a conventional computer (e. g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC,

MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e. g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e. g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

Characteristics of lung cancer-associated proteins Lung cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment, the lung cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e. g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes (see, e. g., Alberts (ed. 1994) Molecular Biology of the Cell (3d ed.). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more structural motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2

domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of amino acid sequence ; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate.

One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains.

Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden (see, e. g., Bateman, et al (2000) Nuc. Acids Res. 28: 263-266; Sonnhammer, et al. (1997) Proteins 28: 405-420; Bateman, et al.

(1999) Nuc. Acids Res. 27: 260-262; and Sonnhammer, et al. (1998) Nuc. Acids Res. 26: 320- 322).

In another embodiment, the lung cancer sequences are transmembrane proteins.

Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

Transmembrane proteins may contain from one to many transmembrane domains.

For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain.

However, various other proteins including channels, pumps, and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as"seven transmembrane domain"proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 17 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the

localization and number of transmembrane domains within the protein may be predicted (see, e. g., PSORT web site http://psort. nibb. acjp/).

The extracellular domains of transmembrane proteins are diverse ; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF, and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenic factors, hormones, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they may mediate cell-cell interactions.

Cell-associated ligands can be tethered to the cell, e. g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains may also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

Lung cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for extracellular immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ or in histological analysis. Alternatively, antibodies can also label intracellular proteins, in which case analytical samples are typically permeablized to provide access to intracellular proteins. In addition, some membrane proteins can be processed to release a soluble protein, or to expose a residual fragment. Released soluble proteins may be useful diagnostic markers, processed residual protein fragments may be useful lung markers of disease.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e. g., through recombinant methods.

Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the lung cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins may have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; e. g., if circulating, they often serve to transmit

signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor), an endocrine manner (acting on cells at a distance, e. g., secretion into the blood stream), or exocrine (secretion, e. g., through a duct or to adjacent epithelial surface as sweat glands, sebaceous glands, pancreatic ducts, lacrimal glands, mammary glands, sax producing glands of the ear, etc.). Thus secreted molecules often find use in modulating or altering numerous aspects of physiology. Lung cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, e. g., for blood, plasma, serum, or stool tests.

Those which are enzymes may be antibody or small molecule targets. Others may be useful as vaccine targets, e. g., via CTL mechanisms.

Use of lung cancer nucleic acids As described above, lung cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the lung cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule.

The lung cancer nucleic acid sequences of the invention, e. g., the sequences in Tables lA-16, can be fragments of larger genes, i. e., they are nucleic acid segments."Genes"in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the lung cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al., supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e. g., systems such as UniGene (see, http://www. ncbi. nlm. nih. gov/UniGene/).

Once a lung cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire lung cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e. g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant lung cancer nucleic acid can be further-used as a probe to identify and isolate

other lung cancer nucleic acids, e. g., extended coding regions. It can also be used as a "precursor"nucleic acid to make modified or variant lung cancer nucleic acids and proteins.

The lung cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the lung cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e. g., for gene therapy, RNAi, vaccine, and/or antisense applications.

Alternatively, the lung cancer nucleic acids that include coding regions of lung cancer proteins can be put into expression vectors for the expression of lung cancer proteins, again for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to lung cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are made.

The nucleic acid probes attached to the biochip are designed to be substantially complementary to the lung cancer nucleic acids, i. e., the target sequence (either the target sequence of the sample or to other probe sequences, e. g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by"substantially complementary"herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under appropriate reaction conditions, particularly high stringency conditions, as outlined herein.

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally complements of ORFs or whole genes are not used. In some embodiments, nucleic acids of lengths up to hundreds of bases can be used.

In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a

particular target. The probes can be overlapping (i. e., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.

As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By"immobilized"and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By"non- covalent binding"and grammatical equivalents herein is typically meant one or more of electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non- covalent binding of the biotinylated probe to the streptavidin. By"covalent binding"and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

In general, the probes are attached to a biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

The biochip comprises a suitable solid substrate. By"substrate"or"solid support"or other grammatical equivalents herein is meant a material that can be modified for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. Often the substrate may contain discrete individual sites appropriate for ndivitual partitioning and identification. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, Teflon, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A preferred substrate is described in US application entitled Reusable Low Fluorescent Plastic Biochip, U. S.

Application Serial No. 09/270,214, filed March 15,1999, herein incorporated by reference in its entirety.

Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e. g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e. g., using linkers as are known in the art ; e. g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, oligonucleotides are synthesized, and then attached to the surface of the solid support. Either the 5'or 3'terminus may be attached to the solid support, or attachment may be via linkage to an internal nucleoside.

In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U. S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affymetrix GeneChipm technology.

Often, amplification-based assays are performed to measure the expression level of lung cancer-associated sequences. These assays are typically performed in conjunction with

reverse transcription. In such assays, a lung cancer-associated nucleic acid sequence acts as a template in an amplification reaction (e. g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of lung cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e. g., in Innis, et al. (1990) PCR Protocols, A Guide to Methods and Applications.

In some embodiments, a TaqMan based assay is used to measure expression.

TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5'fluorescent dye and a 3'quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3'end. When the PCR product is amplified in subsequent cycles, the 5'nuclease activity of the polymerase, e. g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5'fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e. g., literature provided by Perkin-Elmer, e. g., www2. perkin-elmer. com).

Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu and Wallace (1989) Genomics 4: 560, Landegren, et al. (1988) Science 241: 1077, and Barringer, et al. (1990) Gene 89: 117), transcription amplification (Kwoh, et al. (1989) Proc. Natl. Acad. Sci. USA 86: 1173), self-sustained sequence replication (Guatelli, et al. (1990) Proc. Nat. Acad. Sci. USA 87: 1874), dot PCR, and linker adapter PCR, etc.

Expression of lung cancer proteins from nucleic acids In a preferred embodiment, lung cancer nucleic acids, e. g., encoding lung cancer proteins, are used to make a variety of expression vectors to express lung cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known to those of skill in the art (see, e. g., Ausubel, supra, and Fernandez and Hoeffler (eds 1999) Gene Expression Systems) and are used to express proteins. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the lung cancer protein. The term"control sequences"refers to DNA

sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e. g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is"operably linked"when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide ; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked"means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the lung cancer protein.

Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences may be either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e. g., in mammalian or insect cells for expression and in a prokaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector often contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating

vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e. g., Fernandez and Hoeffler, supra).

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The lung cancer proteins of the present invention are usually produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a lung cancer protein, under the appropriate conditions to induce or cause expression of the lung cancer protein. Conditions appropriate for lung cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include. yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, HUVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines.

In a preferred embodiment, the lung cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral and adenoviral systems. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter (see, e. g., Fernandez and Hoeffler, supra). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenylation signals include those derived form SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide (s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, lung cancer proteins are expressed in bacterial systems.

Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e. g., the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the lung cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for Bacillus subtilis, E. coli, Streptococcus cremoris, and Streptococcus lividans, among others (e. g., Fernandez and Hoeffler, supra). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

In one embodiment, lung cancer proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, lung cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha,

Kluyveromyces fragilis and K lactis, Pichia guillerifnofzdii, and P. pastors, ScZzizosaccharomyces pombe, and Yarrowia lipolytica.

The lung cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e. g., for the creation of monoclonal antibodies, if the desired epitope is small, the lung cancer protein may be fused to a carrier protein to form an immunogen.

Alternatively, the lung cancer protein may be made as a fusion protein to increase expression for affinity purification purposes, or for other reasons. For example, when the lung cancer protein is a lung cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In a preferred embodiment, the lung cancer protein is purified or isolated after expression. Lung cancer proteins may be isolated or purified in a variety of appropriate ways. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse- phase HPLC chromatography, and chromatofocusing. For example, the lung cancer protein may be purified using a standard anti-lung cancer protein antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes (1982) Protein Purification.

The degree of purification necessary will vary depending on the use of the lung cancer protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the lung cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, therapeutic entities, for production of antibodies, as transcription or translation inhibitors, etc.

Variants of lung cancer proteins In one embodiment, the lung cancer proteins are derivative or variant lung cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative lung cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at a particular residue within the lung cancer peptide.

Also included within one embodiment of lung cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three

classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the lung cancer protein, using cassette or PCR mutagenesis or other techniques, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above.

However, variant lung cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the lung cancer protein amino acid sequence. The variants typically exhibit a similar qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is often predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed lung cancer variants screened for the optimal combination of desired activity. Techniques exist for making substitution mutations at predetermined sites in DNA having a known sequence, e. g., M13 primer mutagenesis and PCR mutagenesis. Screening of mutants is often done using assays of lung cancer protein activities.

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be occasionally tolerated. Deletions generally range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. Larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of a lung cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution chart provided in the definition section.

Variants typically exhibit essentially the same qualitative biological activity and will elicit the same immune response as a naturally-occurring analog, although variants also are selected to modify the characteristics of lung cancer proteins as needed. Alternatively, the

variant may be designed or reorganized such that a biological activity of the lung cancer protein is altered. For example, glycosylation sites may be added, altered, or removed.

Covalent modifications of lung cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a lung cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a lung cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking lung cancer polypeptides to a water-insoluble support matrix or surface for use in a method for purifying anti-lung cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e. g., 1, 1-bis (diazoacetyl)-2- phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e. g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'- dithiobis (succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8- octane and agents such as methyl-3- ( (p-azidophenyl) dithio) propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of serinyl, threonyl or tyrosyl residues, methylation of the y-amino groups of lysine, arginine, and histidine side chains (Creighton (1983) Proteins: Structure and Molecular Properties, pp. 79-86), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the lung cancer polypeptide encompassed by this invention is an altered native glycosylation pattern of the polypeptide."Altering the native glycosylation pattern"is intended herein to mean adding to or deleting one or more carbohydrate moieties of a native sequence lung cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express lung cancer-associated sequences can result in different glycosylation patterns.

Addition of glycosylation sites to lung cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e. g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence lung cancer polypeptide (for 0-linked glycosylation sites). The lung cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the lung cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the lung cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e. g., in WO 87/05330, and in Aplin and Wriston (1981) CRC Crit. Rev. Biochem., pp. 259-306.

Removal of carbohydrate moieties present on the lung cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al. (1987) Arch. Biochem. Biophys., 259: 52 and by Edge, et al. (1981) Anal. Biochem., 118: 131.

Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura, et al. (1987) Meth.

Enzvmol., 138 : 350.

Another type of covalent modification of lung cancer comprises linking the lung cancer polypeptide to one of a variety of nonproteinaceous polymers, e. g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U. S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192, or4, 179,337.

Lung cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a lung cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a lung cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the lung cancer polypeptide. The presence of such epitope-tagged forms of a lung cancer polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the lung cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a lung cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known and examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field, et al. (1988) Mol.

Cell. Biol. 8: 2159-2165); the c-myc tag and the 8F9, 3C7,6E10, G4, B7 and 9E10 antibodies

thereto (Evan, et al. (1985) Molecular and Cellular Biolosv 5: 3610-3616); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky, et al. (1990) Protein Engineering 3 (6): 547-553). Other tag polypeptides include the Flag-peptide (Hopp, et al.

(1988) BioTechnologv 6: 1204-1210); the KT3 epitope peptide (Martin, et al. (1992) Science 255: 192-194); tubulin epitope peptide (Skinner, et al. (1991) J. Biol. Chem. 266: 15163- 15166); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth, et al. (1990) Proc. Nat'1 Acad. Sci. USA 87: 6393-6397).

Also included are other lung cancer proteins of the lung cancer family, and lung cancer proteins from other organisms, which are cloned and expressed as outlined below.

Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related lung cancer proteins from primates or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include unique areas of the lung cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. PCR reaction conditions are well known in the art (e. g., Innis, PCR Protocols, supra).

Antibodies to lung cancer proteins In a preferred embodiment, when a lung cancer protein is to be used to generate antibodies, e. g., for immunotherapy or immunodiagnosis, the lung cancer protein should share at least one epitope or determinant with the full length protein. By"epitope"or "determinant"herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller lung cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

Methods of preparing polyclonal antibodies are well known (e. g., Coligan, supra ; and Harlow and Lane, supra). Polyclonal antibodies can be raised in a mammal, e. g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of Tables lA-16 or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal

being immunized. Immunogenic proteins include, e. g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Adjuvants include, e. g., Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art.

The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein (1975) Nature 256: 495. In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.

Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of the tables, or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non- human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding (1986) Monoclonal Antibodies: Principles and Practice, pp. 59-103).

Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovin, or primate origin. Usually, rat or mouse myeloma cell lines are employed.

The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.

For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are typically monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid of the tables or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

In a preferred embodiment, the antibodies to lung cancer protein are capable of reducing or eliminating a biological function of a lung cancer protein, in a naked form or conjugated to an effector moiety. That is, the addition of anti-lung cancer protein antibodies (either polyclonal or preferably monoclonal) to lung cancer tissue (or cells containing lung cancer) may reduce or eliminate the lung cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

In a preferred embodiment the antibodies to the lung cancer proteins are humanized antibodies (e. g., Xenerex Biosciences, Medarex, Inc., Abgenix, Inc., Protein Design Labs, Inc.) Humanized forms of non-human (e. g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F (ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of a human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. A humanized antibody optimally also will typically comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones, et al. (1986) Nature 321: 522-525; Riechmann, et al. (1988) Nature 332: 323-329; and Presta (1992) Curr. Op. Struct. Biol. 2: 593-596). Humanization can be performed following the method of Winter and co-workers (Jones, et al. (1986) Nature 321: 522-525; Riechmann, et al.

(1988) Nature 332: 323-327; Verhoeyen, et al. (1988) Science 239: 1534-1536), by substituting rodent CDRs or CDR sequences for corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U. S. Patent No.

4,816,567), wherein substantially less than an intact human variable domain has been substituted by corresponding sequence from a non-human species.

Human-like antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter (1991) J. Mol. Biol. 227: 381 ; Marks, et al. (1991) J. Mol. Biol. 222: 581). The techniques of Cole, et al. and Berner, et al. are also available for the preparation of human monoclonal antibodies (Cole, et al. (1985) Monoclonal Antibodies and Cancer Therapy, p. 77 and Berner, et al. (1991) J. Immunol.

147 (1) : 86-95). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e. g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in nearly all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e. g., in U. S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks, et al. (1992) Bio/Technolosv 10: 779-783; Lonberg, et al. (1994) Nature 368: 856-859 ; Morrison (1994) Nature 368 : 812-13; Fishwild, et al. (1996) Nature Biotechnology 14: 845-51 ; Neuberger (1996) Nature Biotechnology 14: 826; and Lonberg and Huszar (1995) Intern. Rev. Immunol.

13: 65-93.

By immunotherapy is meant treatment of lung cancer with an antibody raised against a lung cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient).

Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. The antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

In a preferred embodiment the lung cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, may bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted lung cancer protein.

In another preferred embodiment, the lung cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment may bind the extracellular domain of the lung cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The

antibody may cause down-regulation of the transmembrane lung cancer protein. The antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the lung cancer protein. The antibody may be an antagonist of the lung cancer protein or may prevent activation of a transmembrane lung cancer protein, or may induce or suppress a particular cellular pathway. In some embodiments, when the antibody prevents the binding of other molecules to the lung cancer protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-a, TNF-ß, IL-1, INF-y, and IL-2, or chemotherapeutic agents including SFU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody may belong to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, lung cancer may be treated by administering to a patient antibodies directed against the transmembrane lung cancer protein.

Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.

In another preferred embodiment, the antibody is conjugated to an effector moiety.

The effector moiety can be various molecules, including labeling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of a lung cancer protein. In another aspect the therapeutic moiety may modulate an activity of molecules associated with or in close proximity to a lung cancer protein. The therapeutic moiety may inhibit enzymatic or signaling activity such as protease or collagenase activity associated with lung cancer.

In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to lung cancer tissue or cells results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with lung cancer.

Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin, saporin, auristatin, and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against lung cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane lung cancer proteins not only serves to increase the local concentration of therapeutic moiety in the lung cancer

afflicted area, but also serves to reduce deleterious side effects that may be associated with the targeted therapeutic moiety.

In another preferred embodiment, the lung cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein or other entity which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the lung cancer protein can be targeted within a cell, i. e., the nucleus, an antibody theretomay contain a signal for that target localization, i. e., a nuclear localization signal.

The lung cancer antibodies of the invention specifically bind to lung cancer proteins.

By"specifically bind"herein is meant that the antibodies bind to the protein with a Kd of at least about 0.1 mM, more usually at least about 1 uM, preferably at least about 0.1 uM or better, and most preferably, 0.01 uM or better. Selectivity of binding to the specific target and not to related other sequences is also important.

Detection of lung cancer sequence for diagnostic and therapeutic applications In one aspect, the RNA expression levels of genes are determined for different cellular states in the lung cancer phenotype. Expression levels of genes in normal tissue (e. g., not undergoing lung cancer), in lung cancer tissue (and in some cases, for varying severities of lung cancer that relate to prognosis, as outlined below), or in non-malignant disease are evaluated to provide expression profiles. A gene expression profile of a particular cell state or point of development is essentially a"fingerprint"of the state of the cell. While two states may have a particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up-and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression,"or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, e. g.,

normal versus lung cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e. g., in that expression is increased or decreased ; i. e., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip expression arrays, Lockhart (1996) Nature Biotechnology 14: 1675-1680, hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis and RNase protection. As outlined above, preferably the change in expression (i. e., upregulation or downregulation) is typically at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred.

Evaluation may be at the gene transcript or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the RNA or DNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e. g., with antibodies to the lung cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to lung cancer genes, e. g., those identified as being important in a lung cancer or disease phenotype, can be evaluated in a lung cancer diagnostic test. In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes.

The lung cancer nucleic acid probes may be attached to biochips as outlined herein for the detection and quantification of lung cancer sequences in a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well.

In a preferred embodiment nucleic acids encoding the lung cancer protein are detected. Although DNA or RNA encoding the lung cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a lung cancer protein is detected.

Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a lung cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate.

In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The lung cancer proteins, antibodies, nucleic acids, modified proteins and cells containing lung cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.

As described and defined herein, lung cancer proteins, including intracellular, transmembrane, or secreted proteins, find use as markers of lung cancer, e. g., for prognostic or diagnostic purposes. Detection of these proteins in putative lung cancer tissue allows for detection, prognosis, or diagnosis of lung cancer or similar disease, and perhaps for selection of therapeutic strategy. In one embodiment, antibodies are used to detect lung cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the lung cancer protein is detected, e. g., by immunoblotting with antibodies raised against the lung cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

In another preferred method, antibodies to the lung cancer protein find use in in situ imaging techniques, e. g., in histology (e. g., Asai (ed. 1993) Methods in Cell Biology :

Antibodies in Cell Biology, volume 37. In this method cells are contacted with from one to many antibodies to the lung cancer protein (s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label, e. g., multicolor fluorescence or confocal imaging. In another method the primary antibody to the lung cancer protein (s) contains a detectable label, e. g., an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of lung cancer proteins. Many other histological imaging techniques are also provided by the invention.

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing lung cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of lung cancer proteins. Antibodies can be used to detect a lung cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous lung cancer protein or vaccine.

In a preferred embodiment, in situ hybridization of labeled lung cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including lung cancer tissue and/or normal tissue, are made. In situ hybridization (see, e. g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a preferred embodiment, the lung cancer proteins, antibodies, nucleic acids, modified proteins and cells containing lung cancer sequences are used in prognosis assays.

As above, gene expression profiles can be generated that correlate to lung cancer, clinical, pathological, or other information, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. Single or multiple

genes may be useful in various combinations. As above, lung cancer probes may be attached to biochips for the detection and quantification of lung cancer sequences in a tissue or patient.

The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

Assays for therapeutic compounds In a preferred embodiment, the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The lung cancer proteins, antibodies, nucleic acids, modified proteins and cells containing lung cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a"gene expression profile"or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e. g., Zlokarnik, et al. (1998) Science 279: 84-8; Heid (1996) Genome Res. 6: 986-94.

In a preferred embodiment, the lung cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified lung cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the lung cancer phenotype or an identified physiological function of a lung cancer protein. As above, this can be done on an individual gene level or by evaluating the effect of drug candidates on a"gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, supra.

Having identified differentially expressed genes herein, a variety of assays may be performed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene with altered regulation in lung cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the lung cancer protein."Modulation"thus includes an increase or a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing lung cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in lung cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in lung

cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e. g., through the use of antibodies to the lung cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a preferred embodiment, gene or protein expression monitoring of a number of entities, i. e., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein.

In this embodiment, the lung cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of lung cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e. g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Expression monitoring can be performed to identify compounds that modify the expression of one or more lung cancer-associated sequences, e. g., a polynucleotide sequence set out in the tables. Generally, in a preferred embodiment, a test compound is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate lung cancer, modulate lung cancer proteins, bind to a lung cancer protein, or interfere with the binding of a lung cancer protein and an antibody, substrate, or other binding partner.

The term"test compound"or"drug candidate"or"modulator"or grammatical equivalents as used herein describes a molecule, e. g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the lung cancer phenotype or the expression of a lung cancer sequence, e. g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles of nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a lung cancer phenotype, e. g., to a normal or non-malignant tissue fingerprint. In another embodiment, a modulator induces a lung cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i. e., at zero concentration or below the level of detection.

In one aspect, a modulator will neutralize the effect of a lung cancer protein. By "neutralize"is meant that activity of a protein and the consequent effect on the cell is inhibited or blocked.

In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a lung cancer polypeptide or to modulate activity.

Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a"lead compound") with some desirable property or activity, e. g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such"combinatorial chemical libraries"are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional"lead compounds"or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical"building blocks"such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e. g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i. e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop, et al. (1994) J. Med. Chem. 37 (9): 1233-1251).

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e. g., U. S. Patent No. 5,010,175, Furka (1991) Pept. Prot. Res. 37: 487- 493, Houghton, et al. (1991) Nature, 354: 84-88), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U. S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs, et al. (1993) Proc. Nat. Acad. Sci. USA 90: 6909-6913), vinylogous polypeptides (Hagihara, et al. (1992) J. Amer. Chem. Soc.

114: 6568), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann, et

al. (1992) J. Amer. Chem. Soc. 114: 9217-9218), analogous organic syntheses of small compound libraries (Chen, et al. (1994) J. Amer. Chem. Soc. 116: 2661), oligocarbamates (Cho, et al. (1993) Science 261: 1303), and/or peptidyl phosphonates (Campbell, et al. (1994) J. Org. Chem. 59: 658). See, generally, Gordon, et al. (1994) J. Med. Chem. 37: 1385, nucleic acid libraries (see, e. g., Stratagene, Corp.), peptide nucleic acid libraries (see, e. g., U. S.

Patent 5,539,083), antibody libraries (see, e. g., Vaughn, et al. (1996) Nature Biotechnology 14 (3): 309-314, and PCT/US96/10287), carbohydrate libraries (see, e. g., Liang, et al. (1996) Science 274: 1520-1522, and U. S. Patent No. 5,593,853), and small organic molecule libraries (see, e. g., benzodiazepines, Baum (1993) C&EN, Jan 18, page 33; isoprenoids, U. S. Patent No. 5,569,588 ; thiazolidinones and metathiazanones, U. S. Patent No. 5,549,974; pyrrolidines, U. S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U. S. Patent No.

5,506,337; benzodiazepines, U. S. Patent No. 5,288,514; and the like).

Devices for the preparation of combinatorial libraries are commercially available (see, e. g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA).

A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. The above devices, with appropriate modification, are suitable for use with the present invention. In addition, numerous combinatorial libraries are themselves commercially available (see, e. g., ComGenex, Princeton, N. J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening.

Preferred assays thus detect modulation of lung cancer gene transcription, polypeptide expression, and polypeptide activity.

High throughput assays for evaluating the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e. g., U. S. Patent No. 5,559,410 discloses high throughput screening methods for proteins,

U. S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i. e., in arrays), while U. S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

In addition, high throughput screening systems are commercially available (see, e. g., Zymark Corp., Hopkinton, MA ; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate procedures, including sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector (s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e. g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e. g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e. g., substrates for enzymes or ligands and receptors.

In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins, random peptides, or"biased"random peptides. By"randomized"or grammatical equivalents herein is meant that the nucleic acid or peptide consists of essentially random sequences of nucleotides and amino acids, respectively. Since these random peptides (or nucleic acids, discussed below) are often chemically synthesized, they may incorporate a nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. In a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e. g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc.

Modulators of lung cancer can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or"biased"random nucleic acids.

Digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.

After a candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence is analyzed. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an in vitro transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

In a preferred embodiment, the target sequence is labeled with, e. g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

Nucleic acid assays can be direct hybridization assays or can comprise"sandwich assays", which include the use of multiple probes, as is generally outlined in U. S. Patent Nos.

5,681,702,5,597,909,5,545,730,5,594,117,5,591,584,5,571,6 70,5,580,731,5,571,670, 5,591,584,5,624,802,5,635,352,5,594,118,5,359,100,5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allow formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration, pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U. S. Patent No. 5,681,697 : Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e. g., albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce non- specific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

Screens are performed to identify modulators of the lung cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e. g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state,

screens are performed to identify agents that bind and/or modulate the biological activity of the gene product, or evaluate genetic polymorphisms.

Genes can be screened for those that are induced in response to a candidate agent.

After identifying a modulator based upon its ability to suppress a lung cancer expression pattern leading to a normal expression pattern, or to modulate a single lung cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated lung cancer tissue reveals genes that are not expressed in normal tissue or lung cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for lung cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated lung cancer tissue sample.

Thus, in one embodiment, a test compound is administered to a population of lung cancer cells, that have an associated lung cancer expression profile. By"administration"or "contacting"herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i. e., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e. g., PCT US97/01019 . Regulatable gene therapy systems can also be used.

Once a test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, e. g., lung cancer or non-malignant tissue may be screened for agents that modulate, e. g., induce or suppress a lung cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on lung cancer activity. By defining such a signature for the lung cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

Measure of lung cancer polypeptide activity, or of lung cancer or the lung cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the metastatic polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of lung cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e. g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as cGMP. In the assays of the invention, mammalian lung cancer polypeptide is typically used, e. g., mouse, preferably human.

Assays to identify compounds with modulating activity can be performed in vitro.

For example, a lung cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e. g., from 0.5 to 48 hours. In one embodiment, the lung cancer polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is typically measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the lung cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e. g., using PCR, LCR, or hybridization assays, e. g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is typically detected using directly or indirectly labeled detection agents, e. g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using a lung cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or (3-gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed

genes are sometimes referred to herein as"lung cancer proteins."The lung cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein.

In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the lung cancer proteins can be used in the assays.

Thus, in a preferred embodiment, the methods comprise combining a lung cancer protein and a candidate compound, and determining the binding of the compound to the lung cancer protein. Preferred embodiments utilize the human lung cancer protein, although other mammalian proteins may also be used, e. g., for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative lung cancer proteins may be used.

Generally, in a preferred embodiment of the methods herein, the lung cancer protein or the candidate agent is non-diffusably bound to an insoluble support, preferably having isolated sample receiving areas (e. g., a microtiter plate, an array, etc.). The insoluble supports may be made of a composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of a convenient shape.

Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e. g., polystyrene), polysaccharides, nylon or nitrocellulose, teflonTM, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is typically not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition, and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation

sequence when the protein is bound to the support), direct binding to"sticky"or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc.

Following binding of the protein or agent, excess unbound material is removed by washing.

The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a preferred embodiment, the lung cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the lung cancer protein is added. Novel binding agents include specific antibodies, non- natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

The determination of the binding of the test modulating compound to the lung cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e. g., by attaching all or a portion of the lung cancer protein to a solid support, adding a labeled candidate agent (e. g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

In some embodiments, only one of the components is labeled, e. g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e. g., less for the proteins and a fluorophor for the compound. Proximity reagents, e. g., quenching or energy transfer reagents are also useful.

In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor may be a binding moiety known to bind to the target molecule (i. e., a lung cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40° C. Incubation periods are typically optimized, e. g., to facilitate rapid high throughput screening. Typically

between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by a test compound. Displacement of the competitor is an indication that the test compound is binding to the lung cancer protein and thus is capable of binding to, and potentially modulating, the activity of the lung cancer protein. In this embodiment, either component can be labeled.

Thus, e. g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the lung cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of- competitor binding, may indicate that the test compound is capable of binding to the lung cancer protein.

In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the lung cancer proteins. In one embodiment, the methods comprise combining a lung cancer protein and a competitor in a first sample. A second sample comprises a test compound, a lung cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the lung cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the lung cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native lung cancer protein, but cannot bind to modified lung cancer proteins. The structure of the lung cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of a lung cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results.

Incubation of all samples is for a time sufficient for the binding of the agent to the protein.

Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e. g., albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.

In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a lung cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising lung cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a lung cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e. g., hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (e. g., cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

In this way, compounds that modulate lung cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the lung cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.

In one embodiment, a method of inhibiting lung cancer cell division is provided. The method comprises administration of a lung cancer inhibitor. In another embodiment, a method of inhibiting lung cancer is provided. The method may comprise administration of a lung cancer inhibitor. In a further embodiment, methods of treating cells or individuals with lung cancer are provided, e. g., comprising administration of a lung cancer inhibitor.

In one embodiment, a lung cancer inhibitor is an antibody as discussed above. In another embodiment, the lung cancer inhibitor is an antisense molecule.

A variety of cell growth, proliferation, viability, and metastasis assays are known to those of skill in the art, as described below.

Soft agar growth or colony formation in suspension Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of lung cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells'ability to grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney (1994) Culture of Animal Cells a Manual of Basic Technique (3rd ed.), herein incorporated by reference. See also, the methods section of Garkavtsev, et al. (1996), supra, herein incorporated by reference.

Contact inhibition and density limitation of growth Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (3H)-thymidine at saturation density can be used to measure density limitation of growth. See Freshney (1994), supra. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with (3H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a lung cancer-associated sequence and are grown for 24 hours at saturation density in

non-limiting medium conditions. The percentage of cells labeling with (3H)-thymidine is determined autoradiographically. See, Freshney (1994), supra.

Growth factor or serum dependence Transformed cells typically have a lower serum dependence than their normal counterparts (see, e. g., Temin (1966) J. Natl. Cancer Insti. 37: 167-175; Eagle, et al. (1970) J.

Exp. Med. 131: 836-879); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.

Tumor specific markers levels Tumor cells release an increased amount of certain factors (hereinafter"tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e. g., Gullino,"Angiogenesis, tumor vascularization, and potential interference with tumor growth" in Mihich (ed. 1985) Biological Responses in Cancer, pp. 178-184). Similarly, Tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e. g., Folkman (1992)"Angiogenesis and Cancer"in Sem Cancer Biol.).

Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkeless, et al. (1974) J. Biol. Chem. 249: 4295-4305; Strickland and Beers (1976) J. Biol. Chem. 251: 5694-5702; Whur, et al. (1980) Br. J. Cancer 42: 305-312; Gullino,"Angiogenesis, tumor vascularization, and potential interference with tumor growth"in Mihich (ed. 1985) Biological Responses in Cancer, pp. 178-184 ; Freshney Anticancer Res. 5: 111-130 (1985).

Invasiveness into Matrigel The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate lung cancer- associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.

Techniques described in Freshney (1994), supra, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with 125I and counting the radioactivity on the distal side of the filter or bottom of the dish. See, e. g., Freshney (1984), supra.

Tumor growth in vivo Effects of lung cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the lung cancer gene is disrupted or in which a lung cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous lung cancer gene site in the mouse genome via homologous recombination.

Such mice can also be made by substituting the endogenous lung cancer gene with a mutated version of the lung cancer gene, or by mutating the endogenous lung cancer gene, e. g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e. g., Capecchi, et al. (1989) Science 244: 1288). Chimeric targeted mice can be derived according to Hogan, et al. (1988) Manipulating the Mouse Embryo : A Laboratory Manual, Cold Spring Harbor Laboratory and Robertson (ed. 1987) Teratocarcinomas and Embryonic Stem Cells: A Practical Approach,, IRL Press, Washington, D. C.

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic"nude"mouse (see, e. g., Giovanella, et al. (1974) J.

Natl. Cancer Inst. 52: 921), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e. g., Bradley, et al. (1978) Br. J. Cancer 38: 263; Selby, et al. (1980) Br. J. Cancer 41: 52) can be used as a host. Transplantable tumor cells (typically about 106 cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a lung cancer-associated sequences are injected subcutaneously. After a suitable length of time,

preferably 4-8 weeks, tumor growth is measured (e. g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e. g., Student's T test) are said to have inhibited growth.

Polynucleotide modulators of lung cancer Antisense and RNAi Polynucleotides In certain embodiments, the activity of a lung cancer-associated protein is downregulated, or entirely inhibited, by the use of antisense or an inhibitory polynucleotide, i. e., a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e. g., a lung cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally- occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter- sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the lung cancer protein mRNA. See, e. g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized in vitro. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or sense oligonucleotides.

Sense oligonucleotides can, e. g., be employed to block transcription by binding to the anti- sense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for lung cancer molecules. A preferred antisense molecule is for a lung cancer sequence in the tables, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein

is described in, e. g., Stein and Cohen (1988) Cancer Res. 48 : 2659 and van der Krol, et al.

(1988) BioTechniques 6: 958).

RNA interference is a mechanism to suppress gene expression in a sequence specific manner. See, e. g., Brumelkamp, et al. (2002) Sciencexpress (21March2002) ; Sharp (1999) Genes Dev. 13: 139-141; and Cathew (2001) Curr. Op. Cell Biol. 13: 244-248. In mammalian cells, short, e. g., 21 nt, double stranded small interfering RNAs (siRNA) have been shown to be effective at inducing an RNAi response. See, e. g., Elbashir, et al. (2001) Nature 411: 494- 498. The mechanism may be used to downregulate expression levels of identified genes, e. g., treatment of or validation of relevance to disease.

Ribozymes In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of lung cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (see, e. g., Castanotto, et al. (1994) Adv. in Pharmacology 25: 289-317 for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e. g., in Hampel, et al. (1990) Nucl. Acids Res. 18: 299-304; European Patent Publication No. 0 360 257; U. S. Patent No.

5,254,678. Methods of preparing are well known to those of skill in the art (see, e. g., WO 94/26877; Ojwang, et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6340-6344; Yamada, et al.

(1994) Human Gene Therapy 1: 39-45; Leavitt, et al. (1995) Proc. Natl. Acad. Sci. USA 92: 699-703; Leavitt, et al. (19994) Human Gene Therapy 5: 1151-120 ; and Yamada, et al.

(1994) Virology 205: 121-126).

Polynucleotide modulators of lung cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of lung cancer may be introduced into a cell containing the target nucleic acid sequence, e. g., by

formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating lung cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-lung cancer antibody that reduces or eliminates the biological activity of an endogenous lung cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a lung cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e. g., when the lung cancer sequence is down- regulated in lung cancer, such state may be reversed by increasing the amount of lung cancer gene product in the cell. This can be accomplished, e. g., by overexpressing the endogenous lung cancer gene or administering a gene encoding the lung cancer sequence, using known gene-therapy techniques. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), e. g., as described in PCT/US93/03868, hereby incorporated by reference in its entirety.

Alternatively, e. g., when the lung cancer sequence is up-regulated in lung cancer, the activity of the endogenous lung cancer gene is decreased, e. g., by the administration of a lung cancer antisense or RNAi nucleic acid.

In one embodiment, the lung cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to lung cancer proteins. Similarly, the lung cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify lung cancer antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to a lung cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. The lung cancer antibodies may be coupled to standard affinity chromatography columns and used to purify lung cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the lung cancer protein.

Methods of identifying variant lung cancer-associated sequences Without being bound by theory, expression of various lung cancer sequences is correlated with lung cancer. Accordingly, disorders based on mutant or variant lung cancer genes may be determined. In one embodiment, the invention provides methods for

identifying cells containing variant lung cancer genes, e. g., determining all or part of the sequence of at least one endogenous lung cancer genes in a cell. In a preferred embodiment, the invention provides methods of identifying the lung cancer genotype of an individual, e. g., determining all or part of the sequence of at least one lung cancer gene of the individual.

This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced lung cancer gene to a known lung cancer gene, i. e., a wild-type gene.

The sequence of all or part of the lung cancer gene can then be compared to the sequence of a known lung cancer gene to determine if any differences exist. This can be done using known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the lung cancer gene of the patient and the known lung cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the lung cancer genes are used as probes to determine the number of copies of the lung cancer gene in the genome.

In another preferred embodiment, the lung cancer genes are used as probes to determine the chromosomal localization of the lung cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the lung cancer gene locus.

Administration of pharmaceutical and vaccine compositions In one embodiment, a therapeutically effective dose of a lung cancer protein or modulator thereof, is administered to a patient. By"therapeutically effective dose"herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e. g., Ansel, et al. (1992) Pharmaceutical Dosage Forms and Drug Deliverv ; Lieberman, Pharmaceutical Dosaize Forms (vols. 1-3), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981 ; Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding ; and Pickar (1999) Dosage Calculations). Adjustments for lung cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration,

drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.

A"patient"for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.

The administration of the lung cancer proteins and modulators thereof of the present invention can be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e. g., in the treatment of wounds and inflammation, the lung cancer proteins and modulators may be directly applied as a solution or spray.

The pharmaceutical compositions of the present invention comprise a lung cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts."Pharmaceutically acceptable acid addition salt"refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

"Pharmaceutically acceptable base addition salts"include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose,

lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that lung cancer protein modulators (e. g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule (s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule (s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art.

The compositions for administration will commonly comprise a lung cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier.

A variety of aqueous carriers can be used, e. g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e. g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e. g., Remington's Pharmaceutical Science (15th ed., 1980) and Hardman, et al. (eds. 1996) Goodman and Gilman : The Pharmacologial Basis of Therapeutics).

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art, e. g., Remington's Pharmaceutical Science and Goodman and Gilman, The Pharmacologial Basis of Therapeutics, supra.

The compositions containing modulators of lung cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e. g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a"therapeutically effective dose."Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health.

Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a"prophylactically effective dose."The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e. g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer based, at least in part, upon gene expression profiles. Vaccine strategies may be used, in either a DNA vaccine form, or protein vaccine.

It will be appreciated that the present lung cancer protein-modulating compounds can be administered alone or in combination with additional lung cancer modulating compounds or with other therapeutic agent, e. g., other anti-cancer agents or treatments.

In numerous embodiments, one or more nucleic acids, e. g., polynucleotides comprising nucleic acid sequences set forth in the tables, such as antisense or RNAi polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and cells useful for expression of lung cancer- associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo, or in vivo (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e. g.,

Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymologv volume 152 (Berger), Ausubel, et al. (eds. 1999) Current Protocols (supplemented through 1999), and Sambrook, et al. (1989) Molecular Cloning-A Laboratory Manual (2nd ed., Vol.

1-3).

In a preferred embodiment, lung cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, lung cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the lung cancer coding regions) can be administered in a gene therapy application. These lung cancer genes can include antisense or inhibitory applications, e. g., as inhibitory RNA or gene therapy (e. g., for incorporation into the genome) or as antisense compositions.

Lung cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL, and antibody responses.. Such vaccine compositions can include, e. g., lipidated peptides (see, e. g., Vitiello, et al. (1995) J. Clin. Invest. 95: 341), peptide compositions encapsulated in poly (DL-lactide-co-glycolide) ("PLG") microspheres (see, e. g., Eldridge, et al. (1991) Molec. Immunol. 28: 287-294; Alonso, et al. (1994) Vaccine 12: 299-306; Jones, et al. (1995) Vaccine 13: 675-681), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e. g., Takahashi, et al. (1990) Nature 344: 873-875 ; Hu, et al. (1998) Clin Exp Immunol. 113: 235-243), multiple antigen peptide systems (MAPs) (see, e. g., Tam (1988) Proc. Natl. Acad. Sci. U. S. A. 85: 5409-5413; Tam (1996) J. Immunol. Methods 196: 17-32), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al., p. 379 In: Kaufmann (ed. 1996) Concepts in vaccine development ; Chakrabarti, et al. (1986) Nature 320: 535; Hu, et al. (1986) Nature 320: 537; Kieny, et al.

(1986) AIDS Bio/Technology 4: 790; Top, et al. (1971) J. Infect. Dis. 124: 148; Chanda, et al.

(1990) Virology 175: 535), particles of viral or synthetic origin (see, e. g., Kofler, et al. (1996) J. Immunol. Methods 192: 25; Eldridge, et al. (1993) Sem. Hematol. 30: 16; Falo, et al. (1995) Nature Med. 7: 649), adjuvants (Warren, et al. (1986) Annu. Rev. Immunol. 4: 369; Gupta, et al. (1993) Vaccine 11: 293), liposomes (Reddy, et al. (1992) J. Immunol. 148 : 1585; Rock (1996) Immunol. Today 17: 131), or, naked or particle absorbed cDNA (Ulmer, et al. (1993) Science 259: 1745; Robinson, et al. (1993) Vaccine 11: 957; Shiver, et al., p. 423 In: Kaufinann (ed. 1996) Concepts in vaccine development ; Cease and Berzofsky (1994) Annu.

Rev. Immunol. 12: 923 and Eldridge, et al. (1993) Sem. Hematol. 30: 16). Toxin-targeted

delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis derived proteins. Certain adjuvants are commercially available as, e. g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A.

Cytokines, such as GM-CSF, interleukin-2,-7,-12, and other like growth factors, may also be used as adjuvants.

Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient.

This approach is described, for instance, in Wolff, et. al. (1990) Science 247: 1465 as well as U. S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720 ; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e. g., U. S.

Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus, e. g., as a vector to express nucleotide sequences that encode lung cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response.

Vaccinia vectors and methods useful in immunization protocols are described in, e. g., U. S.

Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover, et al. (1991) Nature 351: 456-460. A wide variety of other vectors useful for therapeutic administration or immunization e. g., adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the

like, will be apparent to those skilled in the art from the description herein (see, e. g., Shata, et al. (2000) Mol Med Todav 6: 66-71; Shedlock, et al. (2000) J. Leukoc. Biol. 68: 793-806; Hipp, et al. (2000) In Vivo 14: 571-85).

Methods for the use of genes as DNA vaccines are well known, and include placing a lung cancer gene or portion of a lung cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in a lung cancer patient. The lung cancer gene used for DNA vaccines can encode full-length lung cancer proteins, but more preferably encodes portions of the lung cancer proteins including peptides derived from the lung cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a lung cancer gene. For example, lung cancer- associated genes or sequence encoding subfragments of a lung cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

In a preferred embodiment, DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the lung cancer polypeptide encoded by the DNA vaccine.

Additional or alternative adjuvants are available.

In another preferred embodiment lung cancer genes find use in generating animal models of lung cancer. When the lung cancer gene identified is repressed or diminished in metastatic tissue, gene therapy technology, e. g., wherein antisense or inhibitory RNA directed to the lung cancer gene will also diminish or repress expression of the gene. Animal models of lung cancer find use in screening for modulators of a lung cancer-associated sequence or modulators of lung cancer. Similarly, transgenic animal technology including gene knockout technology, e. g., as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the lung cancer protein. When desired, tissue-specific expression or knockout of the lung cancer protein may be necessary.

It is also possible that the lung cancer protein is overexpressed in lung cancer. As such, transgenic animals can be generated that overexpress the lung cancer protein.

Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene.

Animals generated by such methods will find use as animal models of lung cancer and are additionally useful in screening for modulators to treat lung cancer.

Kits for Use in Diagnostic and/or Prognostic Applications For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In diagnostic and research applications such kits may include at least one of the following: assay reagents, buffers, lung cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, RNAi, dominant negative lung cancer polypeptides or polynucleotides, small molecule inhibitors of lung cancer-associated sequences, etc. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instructional materials containing instructions (e. g., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. A medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e. g., magnetic discs, tapes, cartridges, chips), optical media (e. g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.

The present invention also provides for kits for screening for modulators of lung cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: a lung cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing lung cancer-associated activity. Optionally, the kit contains biologically active lung cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user.

Diagnosis would typically involve evaluation of a plurality of genes or products. The genes typically will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

EXAMPLES Example 1: Gene Chip Analysis Molecular profiles of various normal and cancerous tissues were determined and analyzed using gene chips. RNA was isolated and gene chip analysis was performed as described (Glynne, et al. (2000) Nature 403: 672-676; Zhao, et al. (2000) Genes Dev. 14: 981- 993).

Tables 1A and 1B were previously filed on April 18,2001 in USSN 601284, 770 (18501-001500US) and on November 29, 2001 in USSN 601334, 370 (18501-001520US) TablelA Pkey ExAccn UnigeneìD Unigene Title 70% chron/90% NL 70% SQAD/90% NL 100134 D13264 Hs. 49 macrophage scavenger receptor e1 1.61 0.74 100780 HG3731-HT4001""Immunoglobulin Heavy Chain, Vdjrc Reg 2.68 3.28 100971 J02874 Hs. 83213 fatty acid binding protein 4; adipocyte 1.96 0.14 101088 L05568 Hs. 553 solutecarrierfamily6 (neurotransmitte 0.79 0.07 101102 L07594 Hs. 79059 transforming growth factor ; beta recepto 2.55 1 101168 L15388 Hs. 211569 G protein-coupled receptor kinase 5 0.88 0.27 101277 L38486 Hs. 118223 microfibrillar-associated protein 4 0.89 0.26 101330 L43821 Hs. 80261 enhanceroffiiamentationlfcas-iikedo 0.59 0.29 101336 L49169 Hs. 75678 FBJ murine osteosarcoma viral oncogene h 1.15 0.41 101345 L76380 Hs. 152175 calcitonin receptor-like 0.81 0.31 101678 M62505 Hs. 2161 compìementcomponentSreceptorl (C5aì 1.31 0.77 101764 M80563 Hs. 81256 S100 calcium-binding protein A4 (calcium 1.44 0.82 101771 M81750 Hs. 153837 myeloid cell nuclear differentiation ant 0.96 0.45 101842 M93221 Hs. 75182 mannose receptor C type 1 1.27 0.37 102283 U31384 Hs. 83381 guanine nucleotide binding protein 11 1.04 0.3 102363 U39447 Hs. 198241 amine oxidase ; copper containing 3 (vasc 0.96 0.26 102507 U52154 Hs. 193044 potassiuminwardly-rectfyingchannel ; s 2. 81 3.45 102698 U75272 Hs. 1867 progastricsin (pepsinogen C) 0.95 0.23 103025 X54131 Hs. 123641 protein tyrosine phosphatase ; receptor t 1.62 0. 21 103280 X79981 Hs. 76206 cadherin 5 ; VE-cadherin (vascular epithe 0.9 0.41 103496 Y09267 Hs. 132821 flavin containing monooxygenase 2 1.27 0.49 103541 Z11697, Hs. 79197 CD83 antigen (activated B lymphocytes ; i 1.86 1 103554 Z18951 Hs. 74034 caveolin1 ; caveolae protein ; 22kD 1.27 0.47 104212 AB002298 Hs. 173035 KIAA0300 protein 1.17 0.16 104691 AA011176 Hs. 37744 ESTs 1.08 0.35 104825 AA035613 Hs. 141883 ESTs 0.75 0.27 104857 AA043219 Hs. 19058 ESTs 2.6 3.3 104865 AA045136 Hs. 22575 ESTs 1.23 0. 49 104989 AA102098 Hs. 118615 ESTs 0.63 0.32 105729 AA292694 Hs. 3807 ESTs ; Weakly similar to PHOSPHOLEMMAN PR 0.86 0.34 105847 AA398606 Hs. 32241 ESTs 1.32 0.4 105894 AA400979 Hs. 25691 calcitonin receptor-like receptor activi 0. 78 0.28 106490 AA451861 Hs. 115537 ESTs ; Weakly similar to dipeplidase prec 1.2 0. 47 106536 AA453997 Hs. 23804 ESTs 0.82 0.15 106605 AA457718 Hs. 21103 Homo sapiens mRNA ; cDNA DKFZp564B076 (fr 0.99 0.07 106667 AA461086 Hs. 16578 ESTs 1.17 0.4 106773 AA478109 Hs. 188833 ESTs 1.46 0.43 106797 AA478962 Hs. 169943 ESTs 1.18 0.32 106844 AA485055 Hs. 158213 sperm associated antigen 6 0.98 0.51 106870 AA487576 Hs. 26530 serum deprivation response (phosphatidyl 1.05 0.14 106954 AA496980 Hs. 204038 ESTs 1.25 0.33 107054 AA600150 Hs. 14366 ESTs 1.11 0.4 107292 T30407 Hs. 4789 ESTs ; Weakly similar to oxidative. stress 1.07 2.58 107994 AA036811 Hs. 165030 ESTs 0.7 0. 21 107997 AA037388 Hs. 82223 Human DNA sequence from clone 141 H5 on c 1.02 0.48 108041 AA041552 Hs. 61957 ESTs 1.44 0. 51 108087 AA045709 Hs. 40545 ESTs 1.98 1 106382 AA074885 Hs. 67726 macrophage receptor with collagenous str 1.52 0.72 108435 AA078787 Hs. 194101 ESTs 2. 53 1.53 108480 AA081093 Hs. 68055 ESTs 1.56 0.48 109252 AA194830 Hs. 85944 ESTs 2.69 3.18 109550 F01534 Hs. 26981 ESTs 1. 19 0.65 109613 F03031 Hs. 27519 ESTs 1.01 0.29 109837 H00656 Hs. 29792 ESTs 0.81 0.15 109893 H04768 Hs. 30484 ESTs 1.44 0.32 109984 H09594 Hs. 10299 ESTs 0.62 0.14 110099 H16568 Hs. 23748 ESTs 1.01 0.28 110837 N30796 Hs. 17424 ESTs ; Weakly similar to semaphorin F [H. 1. 1 0.22 111247 N69825 Hs. 16762 HomosapiensmRNA ; cDNA DKFZp564B2062 (f 1.26 0.26 111341 N80935 Hs. 22483 ESTs 1.57 0.52 111510 R07856 Hs. 16355 ESTs 3.96 1 111737 R25410 Hs. 9218 ESTs 0.97 0.24 113195 T67112 ***yc20g11.s1 Stratagene lung (#937210) 1.22 0. 35 113238 T62979 Hs. 189813 ESTs 2.27 0.45 113540 T90496 Hs. 16757 ESTs 1.06 0.22 113552 T90889 Hs. 16026 ESTs 1.16 0.42 113606 T93093 Hs. 17125 ESTs 1. 48 0.7 113695 T96965 Hs. 17948 ESTs 1.54 0.28 113946 W84753 Hs. 37896 ESTs 1.79 0.72 114251 Z39898 Hs. 21948 ESTs 1.95 0.25 114359 Z41589 Hs. 153483 ESTs ; Moderately similar to H1chloride 1.42 0.13 115230 AA278300 Hs. 182980 ESTs 2.62 0. 42 115279 AA279760 Hs. 63671 ESTs 1.79 0.91 115566 AA398083 Hs. 43977 ESTs 0.86 0. 2 115965 AA446661 Hs. 173233 ESTs 0.79 0.04 116166 AA461556 Hs. 202949 KIAA1102 protein 2.29 0.68 116279 AA486073 Hs. 57362 ESTs 2.27 0.78 117023 H88157 Hs. 41105 ESTs 1. 36 0.16

117209 H99959 Hs. 42768 ESTs 1.46 0.48 118901 N90719 Hs. 94445 ESTs 1.51 1 118981'N93839 Hs. 39288 ESTs 1.34 0.48 119073 R32894 Hs. 45514 v-ets avian erythroblastosis virus E26 o 1.14 0.27 119221 R98105""yr30g11. s1 Soares fetal liverspleen 1.32 0.53 119824 W74536 Hs. 184 advanced glycosylation end product-speci 1 0.19 119861 W80715 ESTs ; Moderately similar to ! ! !! ALU SUB 1.83 0.45 120041 W92775 Hs. 59368 ESTs 1. 23 0.55 120132 Z38839 Hs. 125019 ESTs ; Highly similar to KIAA0886 protein 0.91 0.37 120467 AA251579 Hs. 187628 ESTs 1.87 1. 91 121314 AA402799 Hs. 182538 ESTs 1.3 0.31 121643 AA417078 Hs. 193767 ESTs 2.31 0.68 121690 AA418074 Hs. 110286 ESTs 1.47 0.51 122633 AA454080 Hs. 34853 inhibitor of DNA binding 4; dominant neg 1.31 0.63 123978 C20653 Hs. 170278 ESTs 1.52 0.32 124214 H58608 Hs. 151323 ESTs 0.93 0.35 124357 N22401""yw37g07. s1 Morton Fetal Cochlea Homo 1.29 1 124438 N40188 Hs. 102550 ESTs 1.36 0.7 125167 W45560 Hs. 102541 ESTs 1.46 0.69 125174 W51835 Hs. 231082 EST 3.07 3.76 125422 AA903229 Hs. 153717 ESTs 1. 34 0.3 125561 AI417667 Hs. 22978 ESTs 1.89 0.63 125831 D60988"""HUM145B09B Clontech human fetal brain 0.94 0.36 127002 R35380 Hs. 24979 ESTs 3.02 4.06 127307 AA369367 Hs. 126712 ESTs ; Weakly similar to pIL2 hypothetica 1.01 0.69 127609 AA622559 Hs. 150318 ESTs 1.21 0.32 127959 A1302471 Hs. 124292 ESTs 2.5 1 128458 D52193 Hs. 56340 ESTs 1.13 0. 33 128624 AA479209 Hs. 102647 ESTs 1.45 0.58 128789 AA486567 Hs. 105695 ESTs 1. 1 0.34 128798 AF014958 Hs. 105938 chemokine (C-Cmotifjreceptor-like2 1.16 0. 55 128952 R51076 Hs. 10736i ESTs ; Highly similar to Rap2 interacting 2.04 2.4 129057 X62466 Hs. 214742 CDW52 antigen (CAMPATH-1 antigen) 1.77 0.73 129210 AA401654 Hs. 202949 KIAA1102 protein 1.11 0.36 129240 W24360 Hs. 237868 interleukin 7 receptor 0. 91 0.41 129402 T63781 ***yc21g01.s1 Stratagene lung (#937210) 1.36 0.43 129565 X77777 Hs. 198726 vasoactive intestinal peptide receptor 1 0.67 0. 08 129593 AA487015 Hs. 98314 Homo sapiens mRNA ; cDNA DKFZp586L0120 (f 1.3 0. 42 129626 AA447410 Hs. 11712 ESTs ; Weakly similar to ! ! ! ! ALU SUBFAMI 1. 28 0.46 129699 AA458578 Hs. 12017 KIAA0439 protein ; homolog of yeast ubiqu 1.58 1 129898 N48595 Hs. 13256 ESTs 1.13 0. 53 129958 L20591 Hs. 1378 annexinA3 0.81 0.31 130273 U59914 Hs. 153863 MAD (mothers against decapentaplegic ; Dr 0.59 0.22 130655 N92934 Hs. 17409 cysteine-rich protein 1 (intestinal) 1.44 0. 76 130657 T94452 Hs. 201591 ESTs 0. 96 0.42 131061 N64328 Hs. 22567 ESTs ; Moderately similar to HYPOTHETICAL 1.51 0.45 131066 F09006 Hs. 22588 ESTs 0.97 0.37 131263 R38334 Hs. 24950 regulator of G-protein signalling 5 2.34 2.82 131589 U52100 Hs. 29191 epithelial membrane protein 2 1.2 0.62 131686 AA157428 Hs. 30687 Grb2-associated binder 2 0.95 0.38 131751 H18335 Hs. 31562 ESTs 1.47 0.52 132430 T23630 Hs. 258675 EST 1.86 2.09 132476 N67192 Hs. 49476 HomosepienscloneTUA8Cri-du¢hatregi 1.73 0.58 132836 F09557 Hs. 57929 slit (Drosophila) homolog 3 0.91 0.29 133120 X64559 Hs. 65424 tetranectin (plasminogen-binding protein 0.82 0.2 133488 D45370 Hs. 74120 adipose specific 2 1.29 0.48 133565 H57056 Hs. 204831 ESTs 2.25 0.57 133651 U97105 Hs. 173381 dlhydropyrimidinase4ike 2 1.65 0. 62 133835 AA059489 Hs. 76640 ESTs ; Highly similar to RGG32 [R. norveg 1.16 0.34 133978 W73859 Hs. 78061 transcription factor 21 0.79 0.27 133985 L34657 Hs. 78146 plateletlendothelial cell adhesion molec 0.99 0.28 134299 AA487558 Hs. 8135 ESTs 1.02 0. 46 134300 U81984 Hs. 166082 endothelial PAS domain protein 1, 0.86 0.42 134323 AA028976 Hs. 8175 HomosapiensmRNA ; CDNA DKFZp564MO763 (f 1.19 0.27 134343 D50683 Hs. 82028 transforming growth factor; beta recepto 1.21 0.67 134417 D87969 Hs. 82921 solute carrier family 35 (CMP-sialic aci 1.28 1 134561 U76421 Hs. 85302 adenosinedeaminase ; RNA-specific; B1 (h 2.12 0.55 134624 W67147 Hs. 8700 deleted in liver cancer 1 2.35 2.74 134696 H88354 Hs. 8861 ESTs 1.35 0.33 134749 L10955 Hs. 89485 carbonic anhydrase IV 0.89 0.2 134786 L06139 Hs. 89640 TEK tyrosine kinase ; endothelial (venous 0.48 0.21 134869 T35288 Hs. 90421 ESTs ; Moderately similar to ! ! !! ALU SUB 2. 14 2.64 135346 M21056 Hs. 992 phospholipaseA2 ; group IB (pancreas) 0.63 0. 13 100113 D00591 Hs. 84746 Chromosome condensation 1 1 2.15 100147 D13666 Hs. 136348 Homo sapiens mRNA for osteoblast specifi 0.5 2 100280 D42085 Hs. 155314 KIAA0095 gene product 1.02 1.39 100335 D63391 Hs. 6793 platelet-activating factor acetylhydrola 1 5. 58 100360 D78335 Hs. 75939 Uridine monophosphate kinase 0.91 2.04 100372 D79997 Hs. 184339 KIAA0175 gene product 0.75 2.03 100486 HG1112-HT1112 TIGR : ras-like protein TC4 1.09 1.93 100559 HG2197-HT2267"collagen, type VII, alpha 1"0. 97 3.6 100576 HG2290-HT2386 *calcitonin/alpha-CGRP, alt. transcript 1 1 100668 HG2981-HT3938'TIGR : CD44 (epican, ait. transcript 12 0.85 1.9 100906 HG4716-HT5158 Guanosine 5'-Monophosphate Synthase 1.18 2.29 100930 HG721-HT4827'TIGR : placenta protein 14, endometrial 1 1.45

100960 J00124 Hs. 117729 keratin 14 (epidermolysis bullosa simple 0.84 2.6 101031 J05070 Hs. 151738 *Matrix metalloproteinase 9 (gelatinase 0.77 1.52 101111 L08424 Hs. 1619 Achaete-scute complex (Drosophila) homol 1 1 101124 L10343 Hs. 112341'Protease inhibitor 3, skin-derived (SKA 0.62 2.67 101175 L18920 Hs. 36980"Melanoma antigen, family A, 2"1 1 101204 L24203 Hs. 82237 Ataxia-telangiectasia group D-associated 0.74 4.1 101431 M19888 Hs. 1076 Small proline-rich protein 1B (cornifin) 0.85 2. 51 101448 M21389 Hs. 195850 keratin 5 (epidermolysis bullosa simplex 0.61 8.83 101511 M27826 Hs. 267319 Endogenous retroviral protease 1.03 1.13 101526 M29540 Hs. 220529 Carcinoembryonic antigen-related cell ad 1.07 4.61 101548 M31328 Hs. 71642'Guanine nucleoüde binding protein (G p 0.97 1.13 101625 M57293"Human parathyroid hormone-related pepti 1 1 101649 M60047 Hs. 1690 Heparin-binding growth factor binding pr 1 2.7 101724 M69225 Hs. 620 bullous pemphigoid antigen 1 (230/240kD) 1 8.98 101748 M76482 Hs. 1925 Desmoglein 3 (pemphigus vulgaris antigen 1 2.78 101759 M80244 Hs. 184601 "Solute carrier family 7 (calionic amino 1. 07 2.45 101804 M86699 Hs. 169840 TTK protein kinase 1 1 101806 M86757 Hs. 112408 S100 calcium-binding protein A7 (psorias 0.74 1.76 101809 M86849"Homo sapiens connexin 26 (GJB2) mRNA, c 1 7 101845 M93426 Hs. 78867"Protein tyrosine phosphatase, receptor- 1 1 101851 M94250 Hs. 82045 Midkinefneunte growth-promoting factor 1.13 2.6 102083 U10323 Hs. 75117"Interleukin enhancer binding factor 2, 1.03 1. 61 102154 U17760 Hs. 75517"Laminin, beta 3 (nicein (125kD), kalini 0. 94 3. 62 102193 U20758 Hs. 313 secreted phosphoprotein 1 (osteopontin ; 0.34 4.59 102305 U33286 Hs. 90073 chromosome segregation 1 (yeast homolog) 1.45 2.97 102348 U37519 Hs. 87539 Aldehyde dehydrogenase 8 0.52 2.25 102581 U61145 Hs. 77256 Enhancer of zeste (Drosophila) homolog 2 0.91 2.46 102610 U65011 Hs. 30743 Preferentially expressed antigen in mela 1 3.88 102623 U66083 Hs. 37110 "Melanoma antigen, family A, 9 (MAGE-9) 102669 U71207 Hs. 29279 Eyes absent (Drosophila) homolog 2 1 1 102696 U74612 Hs. 239 Forkhead box M1 1.06 2.77 102829 U91618 Hs. 80962 Neurotensin 1 1 102888 X04741 Hs. 76118 Ubiquitin carboxyl-terminal esterase Ll 1.13 2.59 102913 X07696 Hs. 80342 keratin 15 0. 7 4.72 102915 X07820 Hs. 2258 Matrix Metalloproteinase 10 (Stromolysin 1.15 3.35 102963 X15943 Hs. 37058 "Calcitonin/calcitonin-related polypepti 1 1 103021 X53587 Hs. 85266 "Integrin, beta 4" 1. 38 2.34 103036 X54925 Hs. 83169 Matrix metalloprotease 1 (interstitial c 1 14.93 103058 X57348 Hs. 184510 Stratifin 1.25 4.17 103060 X57766 Hs. 155324 matrix metalloproteinase 11 (stromelysin 1 1.72 103119 X63629 Hs. 2877"Cadherin 3, P-cadherin (placental)'1. 16 7.38 103206 X72755 Hs. 77367 monokine induced by gamma interferon 0.71 1. 48 103242 X76342 Hs. 389 "Alcohol dehydrogenase 7 (class IV), mu 1 1 103312 X82693 Hs. 3185 "Lymphocyte antigen 6 complex, locus D ; 0.92 1.28 103478 Y07755 Hs. 38991 S100 calcium-binding protein A2 1.05 5.81 103558 Z19574 Hs. 2785 keratin 17 0.65 6.68 103576 Z26317 Hs. 2631 Desmoglein 2 0.79 1.73 103587 Z29083, Hs. 82128 5T4 Oncofetal antigen 1 3.93 103594 Z31560 Hs. 816'SRY (sex determining region Y)-box 2, p 0.71 7.23 103768 AA089997'ESTs, Highly similar to integral membra 0. 99 1.8 104158 AA454908 Hs. 8127 KIAA0144 gene product 0.96 1.29 104558 R56678 Hs. 88959 Human DNA sequence from clone 967N21 on 1.23 7. 23 104689 AA010665 ESTs 0.96 2. 11 104733 AA019498 Hs. 23071 ESTs 1.18 1.88 104906 AA055809 Hs. 26802 Protein kinase domains containing protei 1.11 3.15 104978 AA088458 Hs. 19322 ESTs; Weakly similar to !!!! ALU SUBFAMI 1.64 2. 89 105012 AA116036 Hs. 9329'HomosapiensmRNAforfis353, complete 1.19 3.91 105175 AA186804 Hs. 25740 ESTs ; Weakly similar to unknown [S. cerev 0. 9 4. 63 105263 AA227926 Hs. 6682 ESTs 0.95 2.87 105298 AA233459 Hs. 26369 ESTs 1 1.13 105312 AA233854 Hs. 23348 S-phase kinase-associated protein 2 (p45 1.32 3.01 105719 AA291644 Hs. 36793 Hypothetical protein FLJ23188 1. 28 2.31 105743 AA293300 Hs. 9598 ESTs 1 1 106012 AA411621 Hs. 8895 ESTs ; same as BFH6 ? 0.94 2.04 106231 AA429571 Hs. 38002 KIAA1355 protein 1.04 1.5 106540 AA454607 Hs. 38114 Hypothetical protein FLJ11100 1.26 2.26 106575 AA456039 Hs. 105421 ESTs 1 2 106632 AA459897 Hs. 11950 GPI-anchored metastasis-associated prote 0.87 1.32 106727 AA465342 Hs. 34045 Hypothetical protein FLJ20764 0.87 1.59 106906 AA490237 Hs. 222024 Transcription factor BMAL2 (cycle-like f 0.61 1.6 107059 AA608545 Hs. 23044 RAD51 (S. cerevisiae) homolog (E coli Re 0.48 2.67 107104 AA609786 Hs. 15243 Nucleolar protein 1 (120kD) 1.01 1.44 107151 AA621169 Hs. 8687 ESTs ; procollagen I-N proteinase 0.97 2.89 107284 S74039 Hs. 291904 Accessory proteins BAP31/BAP29 1.15 3.65 107901 AA026418 Hs. 91539 ESTs 0.72 3.44 107922 AA028028 Hs. 61460 Ig superfamily receptor LNIR precursor 1 2.48 107932 AA029317 Hs. 18878 Hypothetical protein FLJ21620 1 1 108695 AA121315 Hs. 70823 KIAA1077 protein 0.91 3.53 108857 AA133250 Hs. 62180 ESTs 108860 AA133334 Hs. 129911 ESTs 0.73 7.3 108990 AA152296 Hs. 72045 ESTs 1 1 109166 AA179845 Hs. 73625 "RAB6 interacting, kinesin-like (rabkine 1 4.55 109424 AA227919 Hs. 85962 Hyaluronan synthase 3 1 1.28 109665 F05012 Hs. 27027 Hypothetical protein DKFZp762H1311 1.42 2 109970 H09281 Hs. 13234 ESTs 1.13 2.16

110015 H10998 Hs. 7164 A disintegrin and metalloproteinase doma 0.84 1.95 110156 H18957 Hs. 4213 ESTs 0.94 1.41 110561 H59617 Hs. 5199 HSPC150proteinsim ! iartoubiquitin-con 0.91 3.18 111223 N68921 Hs. 34806 ESTs ; Weakly similar to neogenin [H. sapi 0.91 3.13 111345 N89820 Hs. 14559 Hypothetical protein FLJ10540 1 1.25 111876 R38239 Hs. 293246'ESTs, Weakly similar to putative p150 [0. 83 1.27 111902 R39191 Hs. 109445 KIAA1020protein 0.91 0. 91 112244 R51309 Hs. 70823 KIM1077 protein 0.77 3.01 112973 T17271'cDNAFLJ13308fis, doneOVARC1001436, 1 1 112989 T23482 Hs. 89981"Diacylglycerol kinase, zeta (104kD)" 0. 55 1. 03 113047 T25867 Hs. 7549 ESTs 0.87 2 113095 T40920 Hs. 126733 ESTs 1 1 113531 T90345 Hs. 16740 Hypothetical protein FLJ11036 0.42 1.44 113970 W86748 Hs. 8109 ESTs 1.17 1.73 114346 Z41450 Hs. 130489"ATPase, aminophospholipid transporter-I 0.86 0.82 114407 AA010188 Hs. 103305 ESTs 0.8 1. 88 114471 AA028074 Hs. 104613 RP42 homolog 1. 06 1.34 114509 AA043551 Hs. 101799 KIAA1350 protein 1.82 2.32 115060 AA253214 Hs. 198249"Gap junction protein, beta 5 (connexin 0.79 1.49 115091 AA255900 Hs. 184523 KIAA0965 protein 0.72 1.92 115123 AA256642 Hs. 236894'ESTs, High sim to LRPl_hu low densib 1 0.59 1.97 115291 AA279943 Hs. 122579 ESTs 1 1.25 115506 AA292537 Hs. 45207 Hypothetical protein KIAA1335 1.15 1.48 115522 AA331393 Hs. 47378 ESTs 0.5 3.29 115536 AA347193 Hs. 62180 ESTs 1 1 115697 AA411502 Hs. 63325 Homo sapiens type 11 membrane serine pro 1 6.53 115909 AA436666 Hs. 59761 ESTs 1 6.98 115978 AA447522 Hs. 69517 Differentially expressed in Fanconi anem 1 2.31 116028 AA452112 Hs. 42644 thioredoxin-like 0.99 1. 68 116107 AA456968 Hs. 92030 ESTs 1.14 1.8 116134 AA460246 Hs. 50441 CGI-04 protein 1. 11 1. 86 116157 AA461063 Hs. 44298 Hypothetical protein 0.99 1.9 116158 AA461187 Hs. 61762 Hypoxia-inducible protein 2 0. 44 0.86 116335 AA495830 Hs. 87013"Homo sapiens cDNA FLJ10238 fis, clone H 0.62 3.89 116483 C14092 Hs. 76118 Ubiquitin carboxyl-terminal esterase Ll 1. 04 2.36 117320 N23239 Hs. 211092 LUNX protein ; PLUNC (palate lung & nasal 0. 51 0.64 117557 N33920 Hs. 44532 Diubiquitin 1.11 2.63 117693 N40939 Hs. 112110 PTD007 protein 0.98 1.79 117881 N50073 Hs. 260622 Butyrate-induced transcript 1 1 1.43 118368 N64339 Hs. 48956 ESTs 0. 67 2.86 118566 N68558 Hs. 42824 Hypothetical protein FLJ10718 1.21 0.83 118695 N71781 Hs. 50081 KIAA1199 see CVA7.doc 0.88 1.63 119780 W72967 Hs. 191381 ESTs ; Weakly similar to hypothetical pro 1 1 119845 W79920 Hs. 58561 G protein-coupled receptor 87 1 1 120102 W95428 Hs. 132927'ESTs, Moderately similar to p53 regulat 1 1 120104 W95477 Hs. 180479 ESTs 0. 69 3. 07 120486 AA253400 Hs. 137569 Tumor protein 63 kDa with strong homolog 1.08 12.05 120859 AA350158 Hs. 1619 Achaete-scute complex (Drosophila) homol 1 1 120880 AA360240 Hs. 97019 EST 1 1 120948 AA397822 Hs. 104650 Hypothetical protein FLJ10292 1.04 2.15 120983 AA398209 Hs. 97587 EST 1 1 121362 AA405500 Hs. 97932 Chondromodulin I precursor 1 1 121369 AA405657 Hs. 128791 CGI-09 protein 1 1.8 121791 AA423978 Hs. 293317 "ESTs, Weakly similar to JM27 [H. sapiens 1 1 123005 AA479726 Hs. 105577 ESTs 1 1 123044 AA481549 Hs. 130881 B-cell CLUymphoma i IA (zinc finger pro 0.95 1.88 123160 AA488687 Hs. 284235 ESTs 1.59 4.98 123479 AA599469 Hs. 135056 clone RP5-850E9 on chromosome 20 1.19 1.64 123571 AA608956 Hs. 112619 "ESTs, Weakly similar to PQ0109 Purkinje 1.03 1.14 123829 AA620697 Hs. 112208 XAGE-1 protein 1.39 2.2 124006 D60302 Hs. 108977 ESTs 1 4.85 124059 F13673 Hs. 99769 ESTs 1.49 8.62 124960 T15386 Hs. 194766 Seizure related gene 6 (mouse)-like 0.76 0.77 125218 W73561 Hs. 110024 NADH: ubiquinone oxidoreductase MLRQ subu 1.33 1.77 125453 R06041 Hs. 18048"Melanoma antigen, family A, 10" 0. 8 1.42 125759 AA425587 Hs. 82226 Glycoprotein (transmembrane) nmb 1. 52 2.26 125972 AA434562 Hs. 35406 "ESTs, Highly similar to unnamed protein 1.05 2.48 125994 H55782 Hs. 270799 EST 1 1.95 126395 N70. 192 Hs. 278956 Hypothetical protein FLJ12929. 1 1.35 126645 AI167942 Hs. 61635 STEAP1 (Homo sapiens BAC clone RG041D11 1 2. 23 127221 A1354332 Hs. 72365 ESTs 0.73 3.27 127479 AA513722 Hs. 179729 collagen ; type X; alpha 1 (Schmid metaph 0.51 1.94 128192 AI204246 KIAA1085 protein 1.8 3.16 128610 L38608 Hs. 10247 activated leucocyle cell adhesion molecu 0.89 0.97 128777 U46006 Hs. 10526 Cysteine and glycine-rich protein 2 1 1 128924 AA234962 Hs. 26557 Plakophilin 3 1.3 2.97 129041 H58873 Hs. 169902 "Sclute carrier family 2 (facilitated 0.84 2.04 129099 H50398 Hs. 108660'ATP-binding cassette, sub-family C (CFT 0.87 1. 04 129404 AA172056 Hs. 111128 ESTs 1 1 129466 L42583'Genbank Homo sapiens keratin 6 isoform 0.72 12.67 129605 S72493 Hs. 115947 Keratin 16 (focal non-epidermolytic palm 0.92 1.5 129628 U26727 Hs. 1174"Cyclin-dependent kinase inhibitor 2A (m 0.85 1.93 130023 X13461 Hs. 239600 Calmodulin-like 3 0. 84 1.22 130080 X14850 Hs. 147097"H2A histone family, member X"0. 98 1.96 130385 AA126474 Hs. 155223 stanniocalcin 2 1 1

130410 V01514 Hs. 155421 Alpha-fetoprotein 0.63 0.63 130441 U35835 Hs. 301387'Human DNA-PK mRNA, partial cds'1.15 3.65 130482 L32866 Hs. 1578 Baculoviral IAP repeat-containing 5 (sur 1 1.88 130553 AA430032 Hs. 252587 Pituitary tumor-transforming 1 0.92 1.96 130577 M35410 Hs. 162 Insulin-like growth factor binding prote 1.17 4.7 130627 L23808 Hs. 1695 Matrix metalloproteinase 12 (macrophage 0.69 4.05 130800 AA223386 Hs. 19574 ESTs Weaklysimilartokatanin p80subu 1.13 2.41 130939 AA598689 Hs. 21400 ESTs 0.8 0.89 131046 X02530 Hs. 2248 INTERFERON-GAMMA INDUCED PROTEIN PRECURS 0.8 1.15 131244 D38076 Hs. 24763 RAN binding protein 1 1.13 1.85 131877 J04088 Hs. 156346 Topoisomerase (DNA) 11 alpha (170kD) 1 1 131927 AA461549 Hs. 34780"Doublecortex ; lissencephaly, X-linked (0. 81 0.62 131965 W90146 Hs. 35962 ESTs 0.74 3.27 131978 D80008 Hs. 36232 KIAA0186 gene product 1 1 132354 L05187 Hs. 211913 Small proline-rich protein 1A 0.69 1. 43 132543 AA417152 Hs. 5101 ESTs ; Highly similar to protein regulati 0.79 4.27 132632 N59764 Hs. 5398 guanine-monophosphate synthelase 1 1.08 132653 U31201 Hs. 54451'laminin gamma2 chain gene (LAMC2), exon 1 1 132659 Z75190 Hs. 54481 "Low density lipoprotein receptor-relate 0.89 0.89 132710 W93726 Hs. 55279"Serine (or cysteine) proteinase inhibit 0.64 4.41 132758 W52432 Hs. 56105 "ESTs, Weakly similar to WDNM RAT WDNM1 1.55 2.08 132767 L05188 Hs. 231622 Small proline-rich protein 2B 0.83 1.66 132816 M74542 Hs. 575 Aldehyde dehydrogenase 3 0.55 0.55 132990 AA458761 Hs. 18387 transcriptionfactorAP-2alpha (activat 1 3.53 133070 U69611 Hs. 64311"A disintegrin and metalloproteinase dom 1.16 2 133282 U52960 Hs. 286145 "SRB7 (suppressor of RNA polymerase B, y 1 2.7 133317 AA215299 Hs. 70830 U6 snRNA-associated Sm-like protein LSm7 0.95 1.42 133370 AA156897 Hs. 72157 Homo sapiens mRNA ; cDNA DKFZp56411922 1.12 2.55 133391 X57579 Hs. 727 H. sapiens activin beta-A subunit (exon 2 1.65 1.76 133832 H03387 Hs. 241305 estrogen-responsive 8 box protein (EBBP) 1.02 1. 39 134032 Z81326 Hs. 78589'Serine (or cysteine) proteinase inhibit 1 1 134168 AA398908 Hs. 181634 "Homo sapiens cDNA : FLJ23602 fis, clone 0.95 1.53 134218 AA227480 Hs. 80205 Pim-2 oncogene 1.36 2.48 134405 R67275 Hs. 82772"""collagen, type XI, alpha 1"""0. 76 2. 86 134453 X70683 Hs. 83484 SRY (sex determining region Y)-box 4 1.89 3.78 134470 X54942 Hs. 83758 CDC28 protein kinase 2 1.82 4.11 134645 U87459 Hs. 167379"Cancer/tesUs antigen (NY-ESO-1, CTAG1, 0.82 0.83 134781 M17183 Hs. 89626 Parathyroid hormone-like hormone 1 1 135002 U19147 Hs. 272484 G antigen 6 1 1 100040 M97935 AFFX control : STAT1 0.92 1.25 101201 L22524 Hs. 2256 matrix metalloproteinase 7 (matrilysin ; 2.92 8.5 101664 M60752 Hs. 121017 H2Ahistonefami, y ; memberA 102025 U03911 Hs. 78934 mutS (E. coli) homolog 2 (colon cancer; 0.8 1.61 102031 U04898 Hs. 2156 RAR-related orphan receptor A 1 1 102221 U24576 LIM domain only 4 1 1 102270 U30255 Hs. 75888 phosphogluconate dehydrogenase 1.08 1.43 102339 U37022 Hs. 95577 cyclin-dependent kinase 4 0.88 1.32 102391 U41668 Hs. 77494 deoxyguanosine kinase 1.07 1.58 103000 X51956 Hs. 146580 enolase 2 ; (gamma; neuronal) 0. 91 1.49 103395 X94754 Hs. 119503 methionine-tRNAsynthetase 0.89 1.32 105638 AA281599 Hs. 20418 Homo sapiens mRNA for for histone H2B ; c 0.91 1.25 105726 AA292328 Hs. 9754 activating transcription factor 5 0.94 1.48 114841 AA234722 Hs. 55408 ESTs ; Moderately similar to CALCIUM-DEPE 0.78 1.56 115206 AA262491 Hs. 186572 ESTs 1 1 115906 AA436616 Hs. 82302 ESTs 0.74 2.52 119132 R49046 Hs. 107911 ATP-binding cassette ; sub-family B (MDR/ 1. 1 1.51 124163 H30539 Hs. 189838 ESTs 1 1 126487 AA482505 Hs. 184601 solutecarrierfemily7 (caüonicamino 1. 01 1.46 127141 AA307960 Hs. 75478 KIAA0956 protein 0. 85 1.4 128034 AA905754 Hs. 75103 tyrosine 3-monooxygenase/tryplophan 5-mo 1 1.18 128609 AA234365 Hs. 102456 survival of motor neuron protein interac 1 1.5 128895 R37753 Hs. 106985 ESTs 1.7 2 130199 Z48579 Hs. 172028 a disintegrin and metalloprotease domain 1 1 130524 U89995 Hs. 159234 forkhead box El 1 1 133000 U24152 Hs. 62402 p21/Cdc42/Rac1-activated kinase 1 (yeast 1 1 133658 M25756 Hs. 75426 secretogranin 11 (chromogranin C) 1 1 135047 AA460466 Hs. 93597 ESTs 1 1 100053 M27830 AFFX control : 28S ribosomal RNA 0.88 1.53 100114 D00596 Hs. 82962 thymidylate synthetase 0.68 1.86 100128 D11094 Hs. 61153 proteasome (prosome; macropain) 26S subu 1.29 2.03 100154 D14657 Hs. 81892 KIAA0101 gene product 0.71 4.26 100161 D14694 Hs. 77329 phosphatidylserinesynthasel 1.02 1.56 100168 D14874 Hs. 394 adrenomedullin 0.46 1.17 100187 D17793 Hs. 78183 aldo-keto reductase family 1 ; member C3 1 1 100188 D21063 Hs. 57101 minichromosome maintenance deficient (S. 0.97 1. 4 100217 D26600 Hs. 89545 proteasome (prosome; macropain) subunit; 1.13 1.9 100220 D28364'"HumanmRNAforannexin) i, 5'UTR (seq 1.11 1.53 100287 D43950 Hs. 1600 chaperonin containing TCP1 ; subunit 5 (e 1.13 2.09 100297 D49489 Hs. 182429 protein disulfide Isomerase-related prot 0.92 1. 78 100330 D55716 Hs. 77152 minichromosome maintenance deficient (S. 1.07 1.61 100355 D78129""Homo sapiens mRNA for squalene epoxid 0.96 1.87 100364 D78586 Hs. 154868 carbamoyl-phosphatesynthetase2 ; aspart 1.49 2.46 100368 D79987 Hs. 153479 extra spindle poles ; S. cerevisiae ; homo 0. 59 1.32 100398 D84557 Hs. 155462 minichromosome maintenance deficient (mi 1. 08 1.9 100438 D87448 Hs. 91417 topoisomerase (DNA) 11 binding protein 1 2, 15

100455 D87953 Hs. 75789 N-myc downstream regulated 0.91 1.48 100491 HG1153-HT1153 NucleosideDiphosphateKinaseNm23-H2s 0.99 1.41 100518 HG174-HT174 Desmoplakin 1 1.28 3.17 100528 HG1828-HT1857"'Nexin, Glia-Derived"'0. 68 1.9 100661 HG2874-HT3018 Ribosomal Protein L39 Homolog 1.1 5. 44 100667 HG2981-HT3127""Epican, Alt. Splice 1"" 0. 8 1.97 100830 HG4074-HT4344 Rad2 1.01 2.12 101061 K03515 Hs. 944 glucose phosphate isomerase 0. 91 1.79 101131 L10838 Hs. 167460 splicing factor ; argininelserine-rich 3 1.23 1.87 101162 L14595 Hs. 174203 solute carrier family 1 (glutamate/neutr 1.35 2.73 101181 L19686 Hs. 73798 macrophage migration inhibitory factor 1. 03 1.78 101183 L19779 Hs. 795 H2A histone family ; member 0 0.57 1.3 101216 L25876 Hs. 84113 cyclin-dependentkinaseinhibitor3 (CDK 0.7 2.2 101228 L27706 Hs. 82916 chaperonin containing TCP1 ; subunit 6A ( 0. 99 1.99 101233 L29008 Hs. 878 sorbitol dehydrogenase 0.82 2.11 101247 L33801 Hs. 78802 glycogen synthase kinase 3 beta 1.2 1.91 101332 L47276 ***Homo sapiens (cell line HL-6) alphat 0.69 2.78 101342 L76191 Hs. 182018 interleukin-1 receptor-associated kinase 1.04 1.84 101396 M15796 Hs. 78996 proliferating cell nuclear antigen 0.95 3. 55 101423 M18391 Hs. 89839 EphA1 1 1.5 101445 M21259 Hs. 1066 small nuclear ribonucleoprotein polypept 1.21 1.96 101505 M27396 Hs. 75692 asparagine synthelase 0.93 1.6 101525 M29536 Hs. 12163 eukaryotic translation initiation factor 1.19 1.93 101535 M30448 Hs. 251669 casein kinase 2 ; beta polypeptide 0.96 1.42 101607 M38690 Hs. 1244 CD9 antigen (p24) 1.11 1.25 101624 M55998"""Human alpha-1 collagen type I gene, 3 1.17 1.98 101758 M77836 Hs. 79217 pyrroline-5-carboxylate reductase 1 1.77 3.45 101839 M93036 Hs. 692 membrane component ; chromosomal 4; surfa 0.71 1.45 101853 M94362 Hs. 76084 lamin B2 0. 84 1.19 101977 S83364""putative RabS-interacting protein (cl 0.89 1.9 101992 U01038 Hs. 77597 polo (Drosophia)-like kinase 0.66 1.46 102009 U02680 Hs. 82643 protein tyrosine kinase 9 1.23 3.35 102012 U03057 Hs. 118400 singed (Drosophila)-like (sea urchin fas 0.85 1.88 102039 U05861 Hs. 201967 aido-keto reductase family 1 ; member C1 0.93 2.32 102123 U14518 Hs. 1594 centromere protein A (17kD) 1 4.28 102130 U15009 Hs. 1575 smaìlnucleardbonucleoprotein D3polyp Q89 1.42 102148 U16954 Hs. 75823 ALL1-fusedgenefromchromosomelq 0.8 2.95 102210 U23028 Hs. 2437 eukaryotic transiation initiation factor 1.01 1.34 102220 U24389 Hs. 65436 lysyl oxidase-like 1 1.15 2.34 102260 U28386 Hs. 159557 karyopherin alpha 2 (RAG cohort 1; impor 1. 14 2.69 102330 U35451 Hs. 77254 chromobox homolog 1 (Drosophila HP1 beta 1.05 1.7 102423 U44754 Hs. 179312 small nuclear RNA activating complex ; po 1.14 2.99 102455 U48705 Hs. 75562 discoidin domain receptor family ; member 1.05 201 102499 U51478 Hs. 76941 ATPase ; Na+/K+transporting ; beta3poly 1. 27 1.92 102522 U53347 Hs. 183556 solute carrier family 1 (neutral amino a 0.84 1.31 102590 U62136'"Homosapiensenterocytedifferentiati 1.11 1.6 102676 U72514 Hs. 12045 putative protein 1.04 2.17 102687 U73379 Hs. 93002 ubiquitin carrier protein E2-C 0.86 2.28 102704 U76638 Hs. 54089 BRCA1 associated RING domain 1 1.12 1.63 102781 U838843""Human HIV-1 Nefinteracting protein (0. 9 1.39 102784 U85658 Hs. 61796 transoWptionfactorAP-2gamma (acüvat 0.98 2.16 102827 U91327 Hs. 6456 chaperonin containing TCP1 ; subunit 2 (b 0.96 1.62 102935 X13482 Hs. 80506 small nuclear ribonucleoprotein polypept 1.21 4.2 102972 X16662 Hs. 87268 annexin A8 1.25 2.32 102983 X17620 Hs. 118638 non-metastatic cells 1 ; protein (NM23A) 1. 03 1.83 103023 X53793 Hs. 117950 multifunctional polypeptide similar to S 1.58 5.44 103038 X54941 Hs. 77550 CDC28 protein kinase 1 1.32 3.79 103075 X59543 Hs. 2934 ribonucleotide reductase M1 polypeptide 1.11 2.58 103168 X68314 Hs. 2704 glutathione peroxidase 2 (gastrointestin 0.75 3. 05 103185 X69910 Hs. 74368 transmembrane protein (63kD); endoplasmi 1. 01 1.97 103212 X73874 Hs. 2393 phosphorylase kinase ; alpha 1 (muscle) 0.95 1.72 103223 X74801 Hs. 1708 cheperonincontainingTCP1 subunit3 (g 0.97 1.77 103260 X78416 Hs. 3155 casein; alpha 1 1 103262 X78565 Hs. 204133 hexabrachion (lenascin C ; cytotactin) 1.23 3.09 103330 X85373 Hs. 77496 small nuclear flbonucleoprotein polypept 1.12 2. 25 103364 X90872 Hs. 75854 SULT1C sulfotransferase'2. 85 4.62 103375 X91868 Hs. 54416 sine oculis homeobox (Drosophila) homolo 1 2.48 103391 X94453 Hs. 114366 pyrroline-5-carboxylate synthetase (glut 1 1.53 103404 X95586 Hs. 78596 proteasome (prosome; macropain) subunit; 0.92 1.53 103437 X98260 Hs. 82254 M-phase phosphoprotein 11 0.92 1.54 103448 X99133 Hs. 204238 lipocalin 2 (oncogene 24p3) 0.5 0.96 103605 Z35402 Hs. 194657 cadherin 1; E-cadherin (epithelial) 1.32 2.51 103646 Z68228 Hs. 2340 junction plakoglobin 0.88 1.28 103658 Z74615 Hs. 172928 collagen ; type I ; alpha 1 1. 06 2.98 103774 AA092898 Hs. 92918 ESTs; Weakly similar to R07G3. 8 [C. elega 1.88 4.66 104261 AF008442 Hs. 5409 RNA polymerase I subunit 0.87 2.17 104276 C02193 Hs. 85222 ESTs ; Weakly similar to R27090_2 [H. sapi 1. 4 2.49 104289 C16281 Hs. 75478 KIAA0956 protein 1.15 1.68 104434 L02870 Hs. 1640 collagen ; type) ; alpha 1 (epidermolys 1.04 1.49 104453 M19169 Hs. 123114 cystatin SN 0.38 0.76 104611 R98280 Hs. 125845 ributose-5-phosphate-3-epimerase 1. 08 2.25 104758 AA024661 Hs. 7010 ESTs; Weakly similar to ACYL-COA DEHYDRO 1.14 1.65 105114 AA156532 Hs. 11801 adenosine A2b receptor pseudogene 0.91 1.38 105132 AA159501 Hs. 247280 HBV associated factor 1.08 1.7 105174 AA186613 Hs. 34744 ESTs 0.95 205

105280 AA232215 Hs. 14600 ESTs 1 1.4 105344 AA235303 Hs. 8645 ESTs 0.72 202 105516 AA257971 Hs. 21214 ESTs 1.35 3. 56 105621 AA280865 Hs. 6375 Homo sapiens mRNA ; cDNA DKFZp564K0222 (f 1.23 1.82 105698 AA287393 Hs. 15202 ESTs ; Weakly similar to oligodendrocyte-0. 98 1.28 105705 AA290767 Hs. 101282 Homo sapiens mRNA ; cDNA DKFZp434B102 (fr 0.92 1.32 105724 AA292098 Hs. 22934 ESTs ; Weakly similar to ZINC FINGER PROT 0.99 1.41 105782 AA350215 Hs. 21580 ESTs 1 1 105799 AA372018 Hs. 24743 ESTs 1.08 1.78 105807 AA393803 Hs. 16869 ESTs ; Moderately similar to COLLAGEN ALP 0.95 1.34 105891 AA400768 Hs. 26662 ESTs ; Weakly similar to tumor necrosis f 0.87 2.25 105936 AA404338 ESTs 1.14 1.46 106069 AA417741 Hs. 29899 ESTs ; Weakly similar to ZINC FINGER PROT 1 1 106103 AA421104 Hs. 12094 ESTs 1.04 1.44 106140 AA424524 Hs. 14912 KIAA0286 protein 1.23 2.11 106149 AA424881 Hs. 256301 ESTs 0.83 1.48 106154 AA425304 Hs. 6994 ESTs 0.77 2. 05 106182 AA426609 Hs. 10862 ESTs 0.74 2.23 106220 AA428582 Hs. 32196 ESTs ; Moderately similar to metargidin p 0.97 1.99 106228 AA429290 Hs. 17719 ESTs 0. 99 1. 54 106318 AA436570 Hs. 9605 pre-mRNA cleavage factor lm (25kD) 0.95 2.09 106341 AA441798 Hs. 5243 ESTs ; Moderately similar to pIL2 hypothe 0. 98 2.66 106432 AA448850 Hs. 17138 ESTs 0. 95 1. 93 106474 AA450212 Hs. 42484 Homo sapiens mRNA ; cDNA DKFZp564C053 (fr 1 1 106483 AA451676 Hs. 30299 IGF-II mRNA-binding protein 2 1.4 2.29 106599 AA457235 Hs. 12842 ESTs ; Moderately similar to non-function 1 1.82 106611 AA458904 Hs. 26267 ESTs ; Weakly similar to torsinA [H. sapie 1.49 2.78 106654 AA460449 Hs. 3784 ESTs ; Highly similar to phosphoserine am 1 1.4 107076 AA609145 Hs. 21143 ESTs ; Weakly similar to fos39554_1 [H. sa 1.11 1.49 107115 AA610108 Hs. 27693 ESTs ; HighlysimilartoCGI-124protein 1 1.03 107129 AA620553 Hs. 4756 Oap structure-specific endonudeasel 1. 13 3.63 107159 AA621340 Hs. 10600 ESTs ; Weakly similar toORF YKR081c [S. c 1.05 2.09 107444 W28391 Hs. 5181 proliferation-associated 2G4 ; 38kD 1.18 1.9 107481 W58247 Hs. 27437 Homo sapiens kinesin superfamily motor K 0.99 2.74 107516 X56597 Hs. 99853 fibrillarin 0.94 1. 77 107529 Y12065 Hs. 5092 nuclear protein (KKE/D repeat) 1.05 2.29 107531 Y13936 Hs. 17883 protein phosphatase 1G (formerly 2C) ; ma 1.06 1.62 107801 AA019433 Hs. 173100 ESTs 1.03 1.4 107957 AA031948 Hs. 57548 ESTs 0.95 1.46 108565 AA085342 Hs. 1526 ATPase; Ca-transporting ; cardiac muse) 0.59 1.35 108780 AA128561 Hs. 117938 collagen ; type XVIi ; alpha 1 1 7.63 108828 AA131584 Hs. 71435 DKFZP56400463 protein 1.33 2.56 109060 AA160879 Hs. 241551 chloride channel ; calcium activated ; fam 0.67 1.42 109112 AA169379 Hs. 72865 ESTs 1.03 2.31 109344 AA213696 Hs. 86559 poly (A)-binding protein-like 1 0.97 1.55 109412 AA227145 Hs. 209473 ESTs ; Weakly similar to REGULATOR OF MIT 0.76 1.87 110780 N23174 Hs. 22891 solute carrier family 7 (cationic amino 0.9 0.95 110958 N50550 Hs. 24587 signaltransductionprotein (SH3contain 1.17 2.26 111018 N54067 Hs. 3628 mitogen-activated protein kinase kinase 1.21 1.85 111337 N79612 Hs. 16607 ESTs ; Highly similar to Myosin heavy cha 1 1.45 112305 R54822 Hs. 26244 ESTs 1 1 112401 R61279 Hs. 237536 ESTs ; Weakly similarto F25B5. 3 [C. elega 1.24 1.64 112853 T02843 Hs. 4351 EST 1.56 1.96 112869 T03313 Hs. 4747 dyskeratosis congenita 1 ; dyskerin 1.03 1.57 112992 T23513 Hs. 7147 ESTs 1 1 113048 T25895 Hs. 184008 ESTs ; Weakly similar to RNA-binding prot 1.37 2.26 113063 T32438 Hs. 5027 ESTs 1 1 113179 T55182 Hs. 152571 ESTs ; HighlysimilartolGF-llmRNA-bind 1.33 2.7 113573 T91166 Hs. 15990 ESTs 0.76 1. 47 113811 W44928 Hs. 4878 ESTs 0.79 1.51 114086 Z38266 Hs. 12770 Homo sapiens PAC clone DJ0777023 from 7p 0.9 1.34 114587 AA070827 Hs. 180320 ESTs ; Weakly similarto GOLGI 4-TRANSMEM 1.02 1.76 114846 AA234929 Hs. 44343 ESTs 1.32 2.36 114964 AA243873 Hs. 82184 ring finger protein 3 1.1 1.84 115047 AA252627 Hs. 22554 homeo box B5 1.01 2.36 115166 AA258409 Hs. 198907 myelin protein zero-like 1 1.05 2.31 115167 AA258421 Hs. 43728 hypothetical protein 1. 52 2.52 115239 AA278650 Hs. 73291 ESTs ; Weakly similar to similar to the b 0.7 2.57 115278 AA279757 Hs. 67466 ESTs ; Weakly similar to BACN32G11. d [D. m 1.14 2.12 115652 AA405098 Hs. 38178 ESTs 0.82 4.67 115875 AA433943 Hs. 43946 ESTs ; Weakly similar to Weak similarity 1.2 1.98 116004 AA449122 Hs. 76086 ESTs ; Highly similar to small zinc finge 0.96 1.31 116121 AA459254 Hs. 48855 ESTs 0.97 1.55 116129 AA459956 Hs. 49163 ESTs ; Highly similar to putative ribonuc 1.08 2.73 116190 AA464963 Hs. 67776 ESTs 0.8 1.57 116312 AA490494 Hs. 65403 ESTs 1.37 2.65 116732 F13779 Hs. 165909 ESTs 0.92 1.8 117602 N35020 Hs. 44685 ESTs ; Weakly similar to GOLIATH PROTEIN 1.15 1.84 117950 N51394 Hs. 75478 KIAA0956 protein 1.04 2.36 117992 N52000 Hs. 172089 HomosapiensmRNA ; cDNA DKFZp586B0222 (f 0.62 1.29 118785 N75386 Hs. 111867 GL--KruppelfamilymemberGL12 119717 W69134 Hs. 57987 ESTs 1 1.4 119814 W74069 Hs. 58350 ESTs 0.78 1.77 120128 Z38499 Hs. 91448 MKP-1 like protein tyrosine phosphatase 0.86 1.46 120242 Z98443 Hs. 86366 ESTs 0.83 2.01

120483 AA252994 Hs. 1578 apoptosis inhibitor 4 (survivin) 0.74 1.64 121054 AA398604 Hs. 97387 ESTs 1.05 1.93 121326 AA404246 Hs. 97031 ESTs ; Weakly similar to Similar to phyto 0.98 1. 3 121376 AA405699 Hs. 166232 ESTs ; ModeratelysimilartoSODIUM-AND 0.91 1.83 121457 AA411448 Hs. 208985 ESTs 0.91 1.59 121780 AA422086 Hs. 124660 ESTs 0.46 0.55 121781 AA422150 Hs. 98370 cytochrome P540 family member predicted 1.07 1.54 121844 AA425732 Hs. 98485 gap junction protein ; beta 2; 26kD (conn 0.94 1.4 122059 AA431737 Hs. 98749 EST 1.93 2. 33 122338 AA443311 Hs. 98998 ESTs 1 1 122354 AA443772 Hs. 186692 ESTs 0.88 1.39 122591 AA453265 Hs. 99311 ESTs ; Weakly similar to MRJ [H. sapiens] 2.28 2.93 122790 AA460156 Hs. 99556 ESTs 0.88 1.3 123398 AA521265 Hs. 105514 ESTs 1 1. 93 123518 AA608531 Hs. 170313 ESTs 1 1 123673 AA609471 Hs. 112712 ESTs 1 1.15 124000 D57317 Hs. 74861 activated RNA polymerase 11 transcripüo Q74 1.12 124367 N24006 Hs. 99348 distal-less homeo box 5 0.67 1.1 124447 N48000 Hs. 140945 Homo sapiens mRNA ; cDNA DKFZp586L141 (fr 1.19 1.7 125756 W25498 Hs. 81634 ATP synthase ; H+transporting ; mitochond 0.93 1.59 125769 AI382972 Hs. 82128 5T4 oncofetal trophoblast glycoprotein 1.65 6.76 125852 H09290 Hs. 76550 Homo sapiens mRNA ; cDNA DKFZp564B1264 (f 0. 72 2.26 125924 AA526849 Hs. 82109 syndecan 1 1.22 2.25 126037 M85772 Hs. 6066 KIAAL 112 protein 1.36 1.63 126214 N29455 Hs. 74316 desmoplakin (DPI ; DPII) 1.93 3.55 126414 N78770 Hs. 223439 ESTs 1.21 1.66 126737 AA488132 Hs. 62741 ESTs 1 1 126743 AA179253 Hs. 172182 poly (A)-binding protein; cytoplasmic 1 1. 3 2.16 126926 AA179546 Hs. 832 ESTs ; HighlysimilartolNTEGRINBETA-8 2.53 2.8 127432 AA501734 Hs. 170311 heterogeneousnucieardbonuc ! eoprotein 1.57 2. 12 128218 H02682 Hs. 99189 ESTs ; Moderately similar to recombinatio 1.24 2.09 128527 M31523 Hs. 101047 transcription factor 3 (E2A immunoglobul 1. 08 1.78 128568 X60673 Hs. 247568 adenylate kinase 3 1.23 3.48 128584 M11433 Hs. 101850 retinol-binding protein 1 ; cellular 0.87 2.42 128628 C14037 Hs. 251978 EST 1.22 1.9 128691 W27939 Hs. 103834 ESTs 1.1 1.73 128714 V00599 Hs. 179661 Homosapiensclone24703beta-tubuìinmR 0.92 1.17 128733 AA328993 Hs. 104558 ESTs 1.34 1.94 128781 X85372 Hs. 105465 small nuclear ribonucleoprotein polypept 0.9 1.34 129052 AA496297 Hs. 182740 ribosome protein S11 2.59 3.19 129095 L12350 Hs. 108623 thrombospondin 2 1.04 3.2 129241 AA435665 Hs. 109706 ESTs, ModeratelysimilartoHN1tM. muscu 0.95 1.61 129665 M88458 Hs. 118778 KDEL (Lys-Asp-Glu-Leu) endoplasmic retic 1.28 2.63 129703 AA401348 Hs. 179999 ESTs 0.97 1. 63 129720 AA476582 Hs. 12152 ESTs ; Moderately similar to SIGNAL RECOG 1. 09 1.79 129850 N20593 Hs. 56845 GDP dissociation inhibitor 2 0.74 1.68 129896 AA043021 Hs. 13225 UDP-Gal : betaGIcNAcbeta 1 ; 4-galactosylt 1.43 4.19 130069 AA055896 Hs. 146428 collagen ; type V; alpha 1 1. 17 1.98 130405 H88359 Hs. 155396 nuclearfactor (erythroid-defived2)-! ik 1.26 1.79 130541 X05608 Hs. 211584 neurofilament ; light polypeptide (68kD) 1 1 130599 M91670 Hs. 174070 ubiquitin carrier protein 1.07 1.66 130867 J04093 Hs. 2056 UDP glycosyltransferase 1 1 4. 8 131009 AA063596 Hs. 22142 ESTs ; WeaklysimilartoNADH-CYTOCHROME 0.93 1. 05 131028 U20240 Hs. 2227 CCAAT/enhancer binding protein (CIEBP) ; 1 1.23 131083 U66661 Hs. 22785 gamma-aminobuv (ic acid (GABA) A recepto 1.1 1.8 131091 T35341 Hs. 22880 ESTs ; Highly similar to dipeptidyl pepti 1.28 1. 98 131144 C14412 Hs. 23528 ESTs, HighlysimilartoHSPC038protein 1.43 2.06 131148 C00038 Hs. 23579 ESTs 0.88 3.38 131164 Y00503 Hs. 182265 keratin 19 1.19 2.77 131185 M25753 Hs. 23960 cyclin B1 0. 86 3.84 131219 C00476 Hs. 24395 small inducible cytokine subfamily B (Cy 0.66 2.96 131454 AA455896 Hs. 2699 glypican 1 0.99 1.54 131687 L11066 Hs. 3069 heat shock 70kD protein 9B (mortalin-2) 1 1. 18 131689 AA599653 Hs. 30696 transcription factor-like 5 (basic helix 1 1.95 131692 D50914 Hs. 30736 KIAA0124 protein 1.55 2.39 131786 AA135554 Hs. 32125 ESTs 1 1.33 131843 AA195893 Hs. 184062 ESTS ; Moderately similar to putative Rab 0.83 1.63 131860 U02082 Hs. 334 Oncogene TIM 1.08 2.2 131884 H90124 Hs. 3463 ribosomal protein S23 1.23 1.24 131903 AA481723 Hs. 3436 deleted in oral cancer (mouse; homolog) 0, 91 1.18 131945 M87339 Hs. 35120 replication factor C (activator 1) 4 (37 1 2.8 131958 AA093998 Hs. 3566 ESTs ; Highly similar to phosphorylation 0.87 1.36 131964 W42508 Hs. 3593 ESTs 1 1.25 132001 J00277 Hs. 37003 v-Ha-rasHarveyretsarcomaviraloncoge 1.12 1.43 132040 AA146843 Hs. 172894 BH3 interacting domain death agonist 1 1.55 132065 D82226 Hs. 211594 proteasome (prosome; macropain) 26S subu 0.89 1.27 132109 AA599801 Hs. 40098 ESTs 1 1.05 132112 AA150661 Hs. 40154 jumonji (mouse) homolog 0.99 1.44 132123 AA447123 Hs. 250705 ESTs 1.06 2.46 132162 H89551 Hs. 41241 ESTs 1. 08 2.46 132180 AA405569 Hs. 418 fibroblast activation protein ; alpha ; se 1.02 4. 56 132309 AA460917 Hs. 2780 jun D proto-oncogene 1.16 1.8 132371 AA235448 Hs. 46677 ESTs 0. 8 1.26 132618 AA253330 Hs. 5344 adaptor-related protein complex 1; gamma 0.5 1.49 132736 U68019 Hs. 211578 MAD (mothers against decapentaplegic ; Dr 1.21 1.81

132771 AA488432 Hs. 56407 phosphoserine phosphatase 1 1.3 132833 U78525 Hs. 57783 eukaryotic translation initiation factor 0.91 1. 43 132922 T23641 Hs. 6066 KlM1112protein 1.16 1.53 132959 AA028103 Hs. 61472 ESTs ; Weakly similar to unknown [S. cerev 1.02 1. 88 132994 AA505133 Hs. 7594 solute carrier family 2 (facilitated glu 0.72 2.97 133005 C21400 Hs. 103329 KIAA0970 protein 0. 88 1.34 133065 X62535 Hs. 172690 diacylglycerol kinase ; alpha (80kD) 0.93 1.23 133083 N70633 Hs. 6456 chaperonin containing TCP1 ; subunit 2 (b 1.14 1.76 133086 L17131 Hs. 139800 high-mobility group (nonhistone chromoso 0.97 1.43 133134 T89703 Hs. 65648 RNA binding motif protein 8 1.1 1.8 133195 AA350744 Hs. 181409 KIAA1007protein 2.29 2. 69 133313 AA249427 Hs. 70704 ESTs 1.07 1.68 133331 T62039 Hs. 158675 ribosomal protein L14 0.85 1.18 133438 D13370 Hs. 73722 APEX nuclease (multifunctional DNA repai 0. 91 1.45 133445 T99303 Hs. 73797 guanine nucleotide binding protein (G pr 0.94 1.68 133483 X52426 Hs. 74070 keratin 13 0.85 1. 14 133492 L40397 Hs. 74137 transmembrane trafficking protein 1.1 1.69 133504 W95070 Hs. 74316 desmoplakin (DPI ; DPII) 0.7 6.21 133517 X52947 Hs. 74471 gap junction protein; alpha 1 ; 43kD (con 0.95 1. 3 133540 D78151 Hs. 74619 proteasome (prosome; macropain) 26S subu 0. 91 1.25 133594 L07758 Hs. 172589 nuclear phosphoprotein similar to S. cer 0.84 1.29 133627 U09587 Hs. 75280 glycyl-tRNA synthetase 1.09 1.99 133671 T25747 Hs. 75471 zinc finger protein 146 1.02 1.5 133859 U86782 Hs. 178761 26S proteasome-associated padl homolog 1. 11 3.33 133865 F09315 Hs. 170290 discs; large (Drosophila) homolog 5 1.84 6.7 133913 W84712 Hs. 7753 calumenin 1. 15 1.86 133963 L34587 Hs. 184693 transcription elongation factor B (Slil) 1.3 1.91 133982 U47621 Hs. 207251 nucleolar autoanUgen (55kD) similar to 1.3 1. 99 134100 L07540 Hs. 171075 replication factor C (activator 1) 5 (36 0.72 1.65 134110 U41060 Hs. 79136 LIV-1 protein ; estrogen regulated 1. 04 1.62 134158 U15174 Hs. 79428 BCL21adenovirus E1B 19kD-interacting pro 1 1.55 134161 U97188 Hs. 79440 IGF-II mRNA-binding protein 3 0.82 1. 95 134193 F09570 Hs. 7980 ESTs 0.98 1.48 134367 X54199 Hs. 82285 phosphoribosylglycinamide formyltransfer 1 2.8 134402 U25165 Hs. 82712 fragile X mental retardation ; autosomal 1.26 2 134457 D86963 Hs. 174044 dishevelled 3 (homologous to Drosophila 1 1.47 134469 X17567 Hs. 83753 small nuclear ribonucleoprotein polypept 0.94 1.57 134498 M63180 Hs. 84131 threonyl-tRNA synthetase 1.2 2.64 134501 W84870 Hs. 211568 eukaryotic translation initiation factor 0.84 1.36 134507 M63488 Hs. 84318 replication protein A1 (70kD) 1.7 2.93 134548 U41515 Hs. 85215 Deteted in split-hand/split-foot 1 regio 1. 46 2.73 134599 X99226 Hs. 86297 Fanconianemia, compfementationgroupA 1.36 2.22 134692 R73567 Hs. 8850 a disintegrin and metalloproteinase doma 0.77 1.64 134693 N70361 Hs. 8854 ESTs 1.09 1.82 134806 Z49099 Hs. 89718 spermine synthase 0.98 1.35 134821 Z34974 Hs. 198382 plakophilin 1 (ectodermal dysplasia/skin 0.99 1.4 134864 Y08999 Hs. 90370 acon related protein 213 complex ; subun 0.95 1. 42 134914 U29615 Hs. 91093 chitinase 1 (chitotriosidase) 1.16 1.29 134953 L10678 Hs. 91747 profilin 2 0.95 1.76 134993 AA282343 Hs. 9242 purine-rich element binding protein B 0.98 1.73 135051 C15324 Hs. 93668 ESTs 1.35 2.11 135158 U51711 Human desmocollin-2 mRNA; 3'UTR 0. 86 1.16 Table 1 B shows the accession numbers for those pkeys in Table lAlacking unigeneìD's. Foreach probesetwe have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland Califomia). The Genbank accession numbers for sequences comprising each cluster are listed in the Accession column.

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT Accessions 100661 23182 1 BE623001 L05096 AA383604 AW966416 N53295 AA460213 AW571519 AA603655 100667 26401_3 L05424 X56794 S66400 X55150 W60071 AW351820 X55938 M83326 BE005289 BE070059 M83324 BE005248 BE069717 BE181648 BE069700 AW606203 BE069721 AW382138 AW803776 BE463954 BE005334 BE005274 T27386 AA932714 AA972695 AW377728 AI632506 T29066 AI783934 AW377727 BE163715 AL047291 AA279047 AA523003 BE008048 BE440141 W23614 BE090519 BE092193 N29181 N20358 N44153 BE546944 T69231 AW377441 AA907406 H50799AW051416A) 420712 BE620922 At279161 AA992549 W47198 BE005241 A1342696 H50700 A1969974 A1863855 AA374490 AW13067 A1950633 AA146687 H99482 X55150 BE005414 BE005339 N28294 AI673068 AI887890 AW804171 AI675961 AW804172 AA778841 AL048050 A1127767 A1095568 AW204965 AW468978 W31898 A1052595 AI278771 BE464018 A1081503 A1824196 AA513211 AA411062 AW084376 N48752 AA703209 N35580 AW059918AA054563A1280942T27619 BE621435 N66010AW589527A) 160414 AA283090 AA962536 H82726 W52115 W45432 W60433 AA577548 AA146714 BE150994 AA054615 AW796025 AW382768 BE565671 C00444 AA054555 100668 264013 L05424 X56794 S66400 X55150 W60071 AW351820 X55938 M83326 BE005289 BE070059 M83324 BE005248 BE069717 BE181648 BE069700 AW606203 BE069721 AW382138 AW803776 BE463954 BE005334 BE005274 T27386 AA932714 AA972695 AW377728 AI632506 T29066 A1783934 AW377727 BE163715 AL047291 AA279047 AA523003 BE008048 BE440141 W23614 BE090519 BE092193 N29181 N20358 N44153 BE546944 T69231 AW377441 AA907406 H50799 AW051416 AI420712 BE620922 AI279161 AA992549 W47198 BE005241 AI342696 H50700 AI969974 AI863855 AA374490 AW130675 AI950633 AI146687 H99482 X55150 BE005414 BE005339 N28294 AI673068 AI887890 AW804171 AI675961AW804172 AA778841 AL048050 AI127757 AI095568 AW204965 AW468978 W31898 AI052595 AI278771 BE464018 AI081503 AI824196 AA513211 AA411062 AW084376 N48752 AA703209 N35580 AW059918AA054563Ai280942T27619 BE621435 N66010AW589527Ai160414 AA283090 AA962536 H82726 W52115 W45432 W60433 AA577548 AA146714 BE150994 AA054615 AW796025 AW382768 BE565671 C00444 AA054555 101332 25130_1 J04088 NM_001067 AF071747 AJ011741 N85424 AL042407 AA218572 BE296748 BE083981 AL040877 AW499918 AW675045 H17813 BE081283 AA670403 AW504327 BE094229 AA104024 A1471482 M970337 AA737616 A1827444 AW003286 A1742333 AI344044 AI765634

AI948838 AW235336 AW172827 AA095289 BE046383 AI734240 W16699 AI660329 AI289433 AA933778 AW469242 AA468838 AA806983 AA625873 W78031 BE206307 AA550803 AI743147 AI990075 AA948274 AA129533 AI635399 AA605313 AI624669 AW594319 AI221834 AI337434 AA307706 BE550282 AI760467 AI630636 AI221521 AW674314 AW078889 AI933732 AI686969 AI186928 AW074595 A1127486 AL079644 A) 910815 H17814 AA310903 AW137854 T19279 AA026682 AA306035 AW383390 AW383389 AW383422 AW383427 AW383395 H09977 AA306247 AA352501 AW403639 F05421 AA224473 AA305321 H93904 AA089612 AW391543 AW402915 AW173382 AW402701 AW403113 R94438 N73126 H93466 AA090928 AA095051 T29025 AW951071 L47277 L47276 AI375913 BE384156 W24652 AA746288 AA568223 BE090591 H93033 N57027 AA504348 AA327653 AW959913 N53767 AA843715 AI453437 AW263710 A1076594 AA583483 AW873194 AW575166 AI128799 Api803319 AL042776 AW074313 AI887722 AI032284 AA447521 AI123885 N29334 AI354911 AW090687 AA236763 AA435535 AA236910 AA047124 AA236734 AW514610 H93467 AA962007 AI446783 AA127259 A) 613495 A1686720 A1587374 AA936731 AA702453 A) 859757 AA216786 AI251819 AI469227 AI806022 AI092324 N71868 AA968782 AA236919 AA809450 AA227220 AA765284 A1192007 AA768810 AA805794 AA729280 AA806238 AW768817 N71879 A1050686 AA505822 AA668974 A1688160 BE045915 AW466315 AA731314 AA649568 AA834316 AW591901 AW063876 AW294770 AI300266 AI336094 AI560380 AA721755 H09978 D20305 D29155 AW821790 BE150864 F01675 AI457474 AW466316 AA550969 AA630788 100780 458_127 BE561958 BE561728 BE397612 BE514391 BE269037 BE514207 BE562381 BE514256 BE514403 BE514250 BE397832 BE269598 BE559865 BE396881 BE560031 BE514199 BE560037 BE560454 100830 4002_1 AC004770 W05005 AA356068 AA094281 H29358 T56781 AW875313 L37374 BE312466 BE311755 BE207106 BE293320 BE018115 AW239090 BE548830 AW247547 AA776062 BE397382 AA486713 T10111 T09340 AW498981 BE547280 AA356003 AW581520 AW875331 AA580720 AW875336 BE276873 BE408229 AW188148 BE255166 BE253761 AW793727 AW373141 AW581548 AA471223 AA305950 BE263976 AA626820 BE257409 AW360962 AA090655 C00312 BE312741 BE407213 AA209352 AW298199 AW248553 AW297794 AW731722 BE300586 AW731972 AW615446BE301599AW615520AA486714AW440257AA196516AA564630AA61 8079AW192592AW474985AA604580At627461AA765440 AI680394 AL135548 AI683224 AI581126 AW245096 AW194154 H29274 N70363 AA629758 AA580602 AA862006 AI863841 AI097667 AI928583 AI358774 BE243487 AA620553 AA653297 AA292690 T10110 Z38906 AA908544 AA340930 A) 185438 T03328 T28844 At687010 A1864965 AI872575 BE388740 T56780 AW373138 BE258717 AA699671 100906 4312_1 AU076916 BE298110 AW239395 AW672700 NM_003875 U10860 AW651755 BE297958 C03806 AI795876 AA644165 T36030 AW392852 AA446421 AW881866 AI469428 BE548103 T96204 R94457 N78225 A1564549 AW004984 AW780423 AW675448 AW087890 AA971454 AA305698 AA879433 AA535069 AI394371 AA928053 AI378367 N59764 AI364000 AI431285 T81090 AW674657 AW674987 AA897396 AW673412 BE063175 AW674408 AI202011 R00723 AI753769 AI460161 AW079585 AW275744 AI873729 D25791 BE537846 T81139 R00722 100930 16865_1 J04129 NM_002571 AA293088 AA477016 AA404631 T28299 AA476904 AA433965 AA430486 AA495907 AI151391 AA291495 AA402723 W25651 AA706816 A1826712 AW296294 AA293479 A1276581 AW044154 AI080180 AI417985 AI274168 AI474212 AA495908 AA635664 AI092114 AI804952 AA479874 AI597661 AI420511 AA479738 AA421417 AA421247 AA436220 AL047797 M34046 N42277 AA228076 W02698 AI420297 AA434011 Al369971 AA479731 AI85541 A1418020M421246M452764AL048051 102221 3861_1 NM_006769 U24576 AW161961 AW160473 AW160465 AW160472 AW161069 AI824931 AW162635 AI990356 AW162477 AW162571 AI520836 AW162352 AW162351 AW162752 AI962216 AI537346 AA853902 H17667 BE045346 BE559802 BE255391 AA985217 AA235051 AI129757 AW366451 T34489 D56106 D56351 AI936579 AW023219 AW889335 AW889120 AW889232 AW889175 BE093702 AW889349 AA147546 AI952998 AA912579 AI143356 AW902211 R64717 AW157236 AI815242 D45272 AW263991 AA442920 AA129965 AL035713 AI923255 AI949082 AI142826 AI684160 AI701987 AI678954 AI827349 BE463635 AW628092 AW302281 AA493203 BE348856 BE536419 AW193969 AW673561 AW592609 AI224044 H43943 AA091912 R49632 R48353 AI568409 R48256 All 98046 H27986 H43899 A1678759 A) 680310 At624220 H17052 AA156410 N56062 AI699430 AA664529 T09406 T10459 AA627506 AI379584 N83831 N88633 AW022651 AA971281 AA248036 A1039197 A1914689 AA973825 AL047305 AA129966 AI798369 AW264348 AI445879 AI658759 N67924 AI933507 AI216121 AI333174 T10972 Al375028 AI186756 AI273778 AA610487 AI797946 AA853903 AA903939 AI338587 AI278494 AW627595 AA904019 101809 32963 J M86849 AA315280 NM_004004 AA315269 BE142653 AA461400 AW802042 BE152893 AW383155 AA490688 AW117930 AW384563 AW384544 AW384566 AW378307 AW378323 AW839085 AA257102 AW378317 AW276060 AW271245 AW378298 AW384497 A15981 14AW264544 A1018136 AW021810 AA961504 AW086214 AW771489 AW192483 A1290266 AW192488 AW384490 AW007451 AW890895 AA554460 AA613715 AW020066 A1783695 A1589498 A1917637 AW264471 AW384491 AI816732 AW368530 AW368521 AW368463 AA461087 At341438 AJ970613 AI040737 AI418400 AA947181 AA962716 AI280695 AW769275 AW023591 AI160977 AA055400 N71882 AA490466 AW243772 AW316636 A1076554 AW511702 N69323 H88912 AA257017 A1952506 H88913 AI912481 AA600714 BE465701 N64149 C00523 N64240 AA677120 102590 15932_1 R61573 BE005029 X98091 AA297307 BE537267 BE566138 BE566139 F11561 BE564795 BE568776 AW064005 BE566479 BE380035 BE567012 BE568634 BE566568 AA298060 BE566043 BE568813 BE568618 AA283070 BE565414 BE566738 BE568585 BE565667 BE566116 BE566433 U62136 AF049140 BE567057 BE567297 BE567403 BE564316 BE567400 BE568854 BE566588 AA448772AA071363AW732642 BE564996 AA297763 AA278550 AA421083 AA298184 AA091007 AA984577 AA205916 N28759 AL031291 C15757 C15761 H02728 BE566410 AA129335 AA419499 N87741 BE379689 BE004824 BE379611 D25874 AA148454 AA323654 AW950311 AA448795 AW749423 AA773386 AA773843 AW020327 BE348580 BE504258 BE649990 BE220200 AI67334 AI202679 AA975515 D61421 AI168688 AAE102843 AW246621 AI276203 AI074054 AI633824 AI962927 AI148926 N50969 AI308911 AA410994 AW373025 AA148455 H02620 AA688293 AI246318 N22220 AI917777 A1050943 A1097286 AA663794 AW368662 AW627826 AW078734 AI253060 AA749154 AA832236 AI192358 AW024676 AA448676 AA764891 BE439467 AA661534 AA258061 A1090546 AA995157 A1051011 AA584421 A1026032 AW591338 AW589563 AA776914 AW024684 AA421002 F09219 BE464500 AI383595 AA954244 AA601583 AA737304 AA195549 AA805778 A1055876 AA164942 AW013961 A1672608 AW514211 D59441 AW582574 AA160935 BE566501 BE564612 BE565353 BE568195 BE565447 BE568302 BE566097 BE565470 BE564249AL036217AW749424 BE567494 AA102842 AA314761 AV661237 C14211 AA651866 AW798997 AA470605 101977 29073_1 AF112213 AL050318 T24804 AW248136 BE386341 BE263177 W16677 BE250224 BE563669 BE267405 BE546577 AV651354 AV651292 AI346903 AI539128 AI189171 S83364 AW073849 AI816760 AW073309 AI422690 AA296692 AI860301 AI805446 N77735 A1340328 BE092530 AW028742 BE088442 AA657742 AA742438 AW170086 A ! 038920 Ai432379 N36073 A ! 936194 AA868655 AA983612 A) 077505 BE080433 A1375014 AI126547 AI348244 A1346077 A1748952 N26915 AI753574 A1093341 A1278762 BE092517 N74204 H06158 T58149 Al 129303 N58366 AA524456 BE122661 AA542925 A ! 246120 AI735203 AA706829 AA877544 A1082289 AA926687 N92840 AW249798 AA934763 AW998363 AI128632 N25202 AI240209 AW118892 N80744 R35655 AI342321 Ai340141 AW878792 M857321 H09610 W04601 AW006650 AA126006 AA553675 A1052791 AW059835 AI041906 AA814658 AW002059 AA729483 AI609301 AA994633 AA903651 AI459183 T95072 AW088630 AA126112 AI800091 AI561215 H17502 AW475072 AI819003 AI683272 AI262701 AW793140 T81787 R99586 AI275160 AI310420 AI698929 AA159174 AI827968 F30305 F30309 AA806662 AI091923 AW878722 AA583430 AW571913 AI674584 AA292533 AI079471 AA642325 AA719050 AW793172 AA305476 AW103745 T23459 N79525 AI784438 AA534551 AW193751 AI074360 BE281214 T32229 W25066 W01205 T63086 AW795348 At361287 AW795353 AW795349 AA594759 AM00295 D11489 At370689 AA482356 AA485295 W40151 AA564661 AW300745 AI346938AI374975 AI423782 AW123899 AA612604 AI183409 AA996156 AW366963 AW366977 AI284860 AA846503 AI985064 AA844576 AA737921 AA873274 BE241546 BE241540M484058 AW468970 AA127876 AA159120 AW001568 AW795213 AW795258 AW795330 BE250589 BE387572 AA910895 AA161217 BE250380 W31500 T95167 A1719306 Al359224 102781 20812_1 BE258778 BE281230 BE410044 T33723 AW672694 AW410439 NM_006429 AF026292 T35505 BE542333 T08940 AU076737 AW247471 BE393215 AW328640 BE542408 T32170 BE302544 T31955 BE206898 BE275738 T32570 BE386426 BE298746 BE389937 BE293991 BE315289 BE389578 R34739 R15312 BE279365 BE277756 AL036019 T33725 BE277779 BE302962 AL047294 BE276505 T09070 T33673 BE312580 AW387774 BE257175AW674367 BE253331 BE270344BE299831 BE273576T32062At751831 BE618381 AA304899 BE252268 U46364 BE256790 BE207199 BE256209 BE251941 BE250791 BE313955 BE269806 BE543623 BE279212 BE252289 T31699 BE262220 T31669 AA315781 AA192212 N84547 BE292737 BE259631 AA232179 AI133144 T31292 AA315945 BE407301 BE251184 BE409006 AI880158 AI904003 A1904114 AW651768 AW651763 R58247 BE271897 U83843 C05298 BE261609 BE255973 AA351650 N84631 BE263637 AW452910 AA328465 AA324549 AW579525 BE252296 BE257551 AL048332 BE208630 AA359336 AW327897 AA151742 AA305816 BE076862 BE076796 BE263161 AA323785 AA676588 AA626565 AA078917 W87657 R09002 R94021 AA312032 BE276665 AA295608 AW407162 AA329374 AW877912 N27885 AA369256 AA360968 BE250476 N85427 BE265569 AI278639 AI816576 AI691037 AW328583 A1567949 A1983455 AI927732 AI811297 AI571508 AW073674 BE296039 BE467326 AI828796 AI816578 AW511604 AI921213 AW152427 AI795787 AI801618 AW168866 AI628144 AI890339 AW173690 AW511540 BE535620 AA383014 BE301164 A1866596 AW514909 AA658050 AW575243 AA074631 A1093488 AW575408 AW675443 AW615636 AW732207 AW377638 AA321784 AA641629 AA633105 AA527640 AW129146 AW615672 BE394607 AA483902 AW475032 BE378532

AA872808 AI469388 AW105268 BE047301 AW591843 AW410066 AW517153 AI950495 AA746641 AI914878 AA873185 AI696911 AA548625 AA911505 AI148762 AW674535 AI587329 BE328328 AW270348 AA158225 AW117705 17705AW474997 AW519193 AA614757 AW664383 A1082647 AW590973 A1476711 AA192213 N88741 BE464552 AW072679 AI453708 AA152166 AA805924 AI581078 AI125768 AW173484 AI961980 BE300766 AI199698 AI636792 AW247333 AW272861 AA078818 AA150012 AA551232 AA678821 AW873869 AW768266 AI660315 AA319210 AA814551 AA157994 AA318886 AI582962 AW089224 AI356098 AI343694 AW072598 N21054 At301249 AA742924 H17917 AW328584 AW248898AI751830 AA907816 R08898 AW087989 AI828300 AA148596 AI269577 T33426 AA213571 AI973201 AA666279 R49612 AI573183 AW799762 AW410068 AW769666 AI962097 AI475204 D57490 AW517531 BE245270 AW470008 T33427 AW005731 AI795795 T23753 AW272981 T15747 AA552875 T23644 AW361289 A1758558 BE207435 AA876958 T03361 AA883569 F37533 AA582321 AW082524 R42212 AA973847 T18900 AA086202AI559867AI302418 AA948667 AA745670 T08939 T33724T33722 BE621568 D57489 D25906 BE621151 F16510 C05966 T35127 AA630427 933481 AA309426 AI918440 BE561854 BE618866 BE394675 BE296173 AW951687 BE383739 BE616141 BE312730 BE535351 AW080575 BE313330 BE616664A1354390M847315 BE544509 BE515212 BE297833 BE278808 BE544844 AW090178 A1890664 BE546708 AW189943 BE274412 BE382399 BE266392 BE254949 BE280696 BE383237 BE261756 BE257721 BE312683 BE275476 BE514880 BE545314 BE313587 BE384537 BE386691 BE264813 AW592575 AI336332 AI278641 AI795791 BE222662 AW249316 AA314361 AL036012 AW402923 BE266845 AA075945 AA314436 BE384640 AW731769 AW957077 AA552234 AA573560 AW367038 AA313399 A1983873 BE410159 BE263803 BE514339 BE409073 BE281296 BE543396 BE395387 BE088360 BE546946 BE546570 BE390626 AA074638 AA301821 AW845230 AW582379 AI949222 AW029572 AA515843 AW272394 BE250234 119221 102947_1 C14322 W74050 AI074232 AA595624 BE048955 AI148417 AI583145 AI473460 AI801688 AW573593 AI950741 AI628140 AW467921 R98105 AI149258 AI247584 AI078378 AI139850 AA489411 W24744 R98104 AI033826 AA699589 AI033120 N55544 W88984 AW970771 AA703362 AA099138 AA706792 AA046150 H98981 A1916674 AA953018 A1972749 A1921343 AA909044 AA094751 A1203124 AA582143 A1446654 AW235415 R70377 AA099236 F20703 AA524436 R69484 125831 1522905 1 H04043 D60988 D60337 128192 45743_3 A1204246AI204250A1194050 113195 178688_1 H83265 T63524 AA304359 AW960551 AI672874 AI749427 AA227777 AW027055 AA971834 T49644 T54122 AI983239 AI808233 T91264 T96544 AI350945 AI709114 R72382 T48788 R48726 AW385418 A1095484 T49645 AA928653 AA570082 AW007545 T57178 AA516413 AA913118 T57112 AA564433 AA774503 AA367671 T59757 119861 238266_1 W78816 AI720806 AI633854 AI632086 AI668663 N70894 AW571809 AI383592 AI201348 W80715 N91880 AW963101 AA339011 112973 4868_1 AB033023 BE391906 BE275965 BE277872 BE003882 AA313774 BE019159 BE298024 BE299727 BE00011 BE390277 BE394764 N87550 BE409419 BE408652 BE408197 AL119332 AA622427 AI816265 AA610118 T07318 AA019839 AA634430 BE205794 BE049461 AI042322 A1652711 A1917645 AA630045 AW191969 AI817882 T17271 AI803663 AI095533 H46019 AW592438 A1624836 A) 675552 D51149 AW132058 AA639614 AI925762 AW088153 T17455 AA018640 AW751475 BE300241 AI816255 BE391981 AW408671 AA353910 AW875446 AW875703 AW875926 AW875645 AW875647 AW938037 AL138042 AW892619 BE243018 AW995454 BE246381 BE009082 BE278921 AW967842 AA262454 H30121 129402 47367_1 W72062 AF088057 W76255 A1827219 Api631461 AW449295 Al354957 A1913803 T62772 AI222040 T62921 T63781 105936 260931_1 AI678765 H12175 R14664 AI914049 AA995383 H08009 H19418 AW953728 AI358021 AA587361 AI269377 AA369905 AW957113 H27693 AI300474 H73776 W74397 AA579604 All 31018 W72331 AI719085 AA568348 AI859045 AI814819 AI888714 BE467470 AW131268 H19419 H27694 AI342165 AI914155 AA534872 BE018176 R60206 H11647 R45641 AI860466 BE301656 AI125453 AI498120 AA593735 AA879110 A1016404 T35018 AA588397 AW449767 AA470365 BE501139 AA588354 Api337500 AW078532 Z41279 AI125449 AA935725 AA404338 129466 2094_50 L42583 NM_005554 L42601 BE183076 AI541221 BE140567 L42610 V01516 J00269 AW275792 AW383052 AW380143 AI541102 BE612846 AI541344 AW238368 BE613405 BE615705 BE615530 BE615301 AW379823 AW794706 AA194806 AA194992 AW384024 AW384000 AA641239 AI246504AI540333 AW238681 AA640939 AI540863 AI608860 AW862564 AW366725 AW368983 AW366870 AA596020 AW794721 AW794511 A1591181 BE182523 AW794644 AW794620 Al935234 AI608903 AI608623 AW797060 AW084935 BE182517 BE182319 AI890082 AW238346 AW797012 BE182522 AW794838 A) 608794 AW304289 AA147193 AA595995 AW381128 AW366720 AA583718 A1828416 BE122864 AW368343 AA431080 AW082039 AW380976 AA587144 AA443636 AW872937 AW794448 AW378382 AW085761 AW794718 AW263895 AA583587 AA583991 AA583994 AA586886 AA586880 AW368365 AI814460 AA586991 AI282829 AW378406 AA586721 A1609242 AA431973 AA232959 AI831095 AW263854 AW378391 AW378415 AW378381 AA036990 AW238395 AI285446 BE208219 BE049526 AA583605 AA583918 AW366711 AI285580 AW082642 AI285712 AA582875 AW591216 AW368719 AW378408 BE122835 AA582976 BE350422 AA418328 AI541454 Api565930 AA583700 AA150575 AW238427A1287474 AA912658 AA584223AW238528 C17918 AW136169 AA159847 923797 A) 609009 BE182479 AI915198 AW378114 AA147179 AA584239 AA150532 AW168862 AW085999 AW082480 AA659742 AW079703 A1872793 AA583981 A1824571 BE182316 BE182507 AA233331 A1824572 A1540586 D29492 BE182931 AA036948 BE551821 D29401 AW378365 C00141 D29181 D29567 AW103359 W95238 A1991663 AA587298 BE184608 AA099833 W95121 W95150 D29584 Api934111 D29456 D29533 AW265380 D29290 AW238463 AA121041 D29204 AA595925 D29441 AW081840 AA587018 D29323 AA582891 BE182433 BE182437 BE158295 BE182434 100220 45374 1 AW015534 AA314369 AA290715 BE568683 AW629494 D28364 AW995678 100355 12538_1 AI907114 AA580734 AL041945 AA101515 AA121344 D78130 NM_003129 AA341650 T84166 AF098865 AA130976 BE089553 H05719 F13446 T66122 AW175590 F05344 AI114790 R12900 AA194871 AA132298 D78129 AA132213 AW948930 AW948919 AA263053 AW946593 AW948840 AA278558 R50895 N26940 N40818 AW021255 AA054851 AA663379 AW948795 AW948893 AA400356 AW948911 N85024 W78844 A1341546 AI760182 AA286783 BE617763 BE617263 AW263690 BE049454 BE617928 AW515038 AW950584 AA601009 A1079194 AAI 47204 AW083163 AA130981 AI218369 AA604784 AI806257 AI559556 AA232318 AA258065 AI471982 AA687949 AI143944 N30172 AA400196 AI769049 AI084342 AI221380 AA948469 AI802469 H05720 AA113270 AA158138 AA076231 AI521024 AI810962 AI33616 AI805106 AA101516 R40052 R50778 R43280 T65036 AW131924 AA114251 AA152331 F09650 AA580614 AA558927 C75491 Z38352 AA954595 C75606 W80742 100491 34803-1 D56165 M36981 X58965 Nul002512 BE379177 AA314836 BE256445 BE252016 AW248343 AI720933 AW085701 BE386050 BE619742 BE277805 AI147951 AA603113 BE253293 AI246588 AI183405 AI954174 AI126891 AI829101 AI123832 AW129670 AA471268 AW170242 AW873079 AA148011 AI608620 AA482961 A1003658 N43261 AA657978 AI735072 R83138 AA722002 AA626271 AW273877 SE464626 AA071483 AA429973 AA494342 AA620436 AA775597 AA775601 AA826847 AI192585 AA826359 AA411159 AI193419 AI204013 AA705323 AA716255 AI784611 AI081144 AI128227 AA828464 AI148911 AI493446 AI626084 AI189180 AI721196 AI190618 AA284987 AI28543 AA632064 AI333073 AI278470 AA131688 AI491768 AA937581 AA630065 AA834257 AW249841 AA583742 A ! 309756 AA961676 A) 760860 AA557818 AA954238 H43655 Api302564 AA127545 A1609219 H20426 A1042292 A1056466 AA581836 W47002 AA422057 AA937673 F29757 AA829208 AW327462 AA372098 W02144 AA036805 AA487365 AA961037 A) 139946 AA487250 AA737118 A) 952504 A) 242293 AA650552 Ai708401 A1633133 AA630848 AA654317 F24128 AI434165 W46252 AW043879 A1033763 F37228 AA687809 N49087 AA876981 AA506947 AI914572 AI833284 F22253 AA026222 R50166 AI21967 N27095 AA496512 AI784222 AI289904 AA513146 AA528547 AA418700 F36721 AI880700 AI601170 AI862851 AI708633 AA524499 AA642220 AA496628 AI718709 W80579 AI720547 F20718 AA649943 AA588229 N40503 H46029 BE262669 BE391069 BE537538 AI510751 A190696B AI318611 H46099 AI472604 T60667 AA373087 W32479 AA514034 BE619183 AA134672 AA127544 H26942 BE536689 AW327461.

AA422139 AW262357 AW327348 F33510 AI630382 AW827126 F27133 AI335189 AW517599 W80471 AA885814 N89681 BE393173 AA617760 AA584268 AA460537 AA446261 H20425 N64040 AW276801 AA316367 AA071232 BE545409 AA308292 BE274447 AA380861 AA340038 AA341806 AA865579 A1018634 A1766314 AI919302 AA872367 AA991404 AI906961 AA888375 BE621012 AA505388 AA935192 AA290828 R50220 H50814 H44721 AW951723 AA514796 AA418708 AW673377 AA379622 AA977995 AA708224 AA708216 AI318249 AI318233 AA411160 AA026221 AA316774 AA486908 AI500094 AA096362 AW583742 BE536422 BE618653 R70203 AA131732 AA345048 BE562720 T28342 100518 131651 NM004415 AL031058 M77830 BE149760 AW52599 AW848723 AW376697 AW376817 AW376699 AW848371 AW376782 AW848789 AW361413 AW849074 AW997139 AW799304 AW799309 BE077020 BE077017 BE185187 AW997196 BE156621 BE179915 BE006561 BE143155 AW890985 BE002107 AW103521 AA857316 AW383133 BE011378 AW170253 BE185750 AW886475 BE160433 J05211 BE082576 BE082584 BE004047 AW607238 AW377700 AW377699 BE082526 BE082505 BE082507 BE082514 AW178000 AW177933 AI905935 AW747877 AW748114 BE148516 AW265328 AW847678 AW847688 AW365151 AW365148 AW365153 AW365156 AW365175 AW365157 AW365154 AW068840 BE005272AW365145 BE001925 BE182166 BE144243 BE001923At951766A) 434518 BE184920 BE184933 AI284090 BE184941 AW804674 BE184924 C04715 W39488 AW995615 BE184948 BE159646 AW606653 AA099891 AA131128 AA337270 AA340777 AW384371 AA852212 R58704 AW366566 AW364859 AA025851 AA025852 AA455100 AA719958 AW352220 AW996245 BE165351 BE073467 AA377127 AW890264 AW609750 AW391912 AW849690 T87267 AW853812 AA852213 W74149 BE009090 AA056401 H91011 AW368529 AW390272 C18467

AW674920 N57176 AA026480 AW576767 H93284 AA026863 AW17778 AA026654 AW177786 BE092134 BE092137 BE092136 AW177784 AI022862 BE091653 AW376811 AW848592 AA040018 BE185331 BE182164 AA368564 AW951576 T29918 AA131077 W95048 W25458 AW205789H90899 N29754 W32490R20904BE167181 BE167165 N84767 H27408 H30146 AI190590 C03378 AI554403 AI205263 AI128470 AI392926 AF139065 AW370813 AW370827 AW798417 AW798780 AW798883 AW798569 R33557 AA149190 C03029 AW177783 AA088866 AW370829AA247685 BE002273AAI760816 AI439101 AW879451 AI700963AA451923 AI340326 AI590975 T487933AI568096 A 142882 AA039975 AI470146 AA946936 BE067737 BE067786 W19287 AA644381 AA702424 AI417612 AI306554 AI686869 AI568892 AI1905555 AI571075 AI220573 AA056527 AI471874 AI304772 AW517828 AI915596 AI627383 AI270345 AW021347 AW166807 AW105614 AI346078 AA552300 W95070 AI494069 AI911702 AI149191 AA026864 AI830049 AI887258 AW780435 AI910434 AI819984 AI858282 A1078449 A1025932 AI860584 AI635878 AA026047 AA703232 D12062 AW192085 AA658154 AW514597 AW591892 T87181 AA782066 AW243815 AW150038 AW268383 AW004633 A1927207 AA782109 AW473233 A1804485 AW169216 M572669 AA602182 AW015480 AW771865 AI270027 AA961816 AA283207 A1076962 AI498487 AI348053 AI783914 H44405 AW799118 AA128330 AA515500 AA918281 W02156 AI905927 AA022701 W38382 R20795 T77861 AW860878 100528 45979-1 BE386801 AU077299 AA143755 BE302747 AA853375 U30162 BE274163 BE277479 BE408180 BE274874 C15000 AA047476 N27099 AI359165 AI638794AI151283 AI863925 AW444977 AI207392 AA931263 AA44312 R40138 AW068538 AA351008 AA676972 R62503 AA916492 AW001865 H42334 H38280 AA121497 AA114137 AI750938 M17783 AA383786 BE274462 AI753182 C05975 AA347404 AW069298 A1754351 A1754044 AA188808 AA186879 AA565243 AL040655 AA456177 AI750722 AA045756 AA213580 C16936 AW578747 AW753731 H41632 N44761 R58560 R61260 AA039902 N59721 AW992543 R68380 AA149686 T29017 H03739 BE383822 BE387105 BE408251 BE410425 H41560 AA247591 BE389677 A1752233 A) 566195 AA868004 At424523 AW753720 AA852159 BE386803 100559 2260_1 NM_000094 L02870 D13694 S51236 M96984 AW946290 M65158 AI285422 D29523 AL119886 AW630655 L06862 A1884355 AW168737 T29085 AW797005 AW801340 A1355504 AW079048 AW801337 A1690455 A1972063 AW268565 W68588 AA587326 AA883498 AI033523 AW510356 AW591998 H98463 AL043852 AI150055 AI566239 AI624803 AA844717 H40670 AA922334 AI864424 AW615094 AW451233 AI302203 F31221 AI872170 W68589 AA904478 A1917631 AW014208 AW450759 AA847625 A1284033 AA848176 AA598507 100576 9986_1 X00356 NM_001741 M26095 X03662 M12667 X02330 X02330 AA716058 AW296074 X04861 A1695720 AA719597 124357 genbank_N22401 N22401 101624 entrez-M55998 M55998 101625 entrez_M57293 M57293 135158 57963_1 AL037551 AI804716 AW439811 AI569470 AA075299 AI738572 AI270388 AI816783 AW263026 AI633951 AI655285 AI990572 AI950425 AW241533 AA916883 AA576693 AA160156 AA613783 AW078884 AI888282 AI275241 AI133467 AA164921

Tables 2A-8C were previously filed on November 9,2001 in USSN 601339, 245 (18501-004100US) Table 2A shows 504 genes down-regulated in lung tumors relative to normal lung and chronically diseased lung. Chronically diseased lung samples represent chronic non- malignant lung diseases such as fibrosis, emphysema, and bronchitis. These genes were selected from 59680 probesets on the Eos/Affymetrix Hu03 Genechip array. Gen expression data for each probeset obtained from this analysis was expressed as average intensity (Al), a normalized value reflecting the relative level of mRNA expression.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD : Unigene number Unigene Title : Unigene gene title R1 : 90th percentile of Al for normal lung samples divided by the 80th percentile of Al for adenocarcinoma and squamous cell carcinoma lung tumor samples.

R2: median of Al for normal lung samples divided by 90th percent of Al for adenocarcinoma and squamous cell carcinoma lung tumor samples.

R3: median of Al for normal lung samples minus the 15th percentile of Al for all normal lung, chronically diseased lung and tumor samples divided by the 90th percentile of Al for adenocarcinoma and squamous cell carcinoma lung tumor samples minus the 15th percentile of AI for all normal lung, chronlcally diseased lung and tumor samples.

R4: average of Al for normal lung samples divided by average Al for squamous cell carcinoma and adenocarcinoma lung tumors.

R5 : median of Al for normal lung samples divided by the 90th percentile of AI for adenocarcinomas.

R6: median of Al for normal lung samples minus the 15th percentile of Al for all normal lung, chronically diseased lung and tumor samples divided by the 90th percentile of Al for adenocarcinomas minus the 15th percentile of AI for all normal lung, chronically diseased lung and tumor samples.

R7: average of Al for normal lung samples divided by the 90th percentile of Al for squamous cell carcinomas.

R8: median of At for normal lung samples minus the 15th percentile of Al for all normal lung, chronically diseased lung and tumor samples divided by the 90th percentile of AI for squamous cell carcinomas minus the 15th percentile of Al for all normal lung, chronically diseased lung and tumor samples.

Pkey ExAccn UnigeneìD UnigeneTitle R1 R2 R3 R4 R5 R6 R7 R8 100095 Z97171 Hs. 78454 myocilin; trabecular meshwork inducible 40.20 100115 NM002084 Hs. 336920 glutathione peroxidase 3 (plasma) 3.46 100138 U83508 Hs. 2463 angiopoietin 1 2.30 100299 D49493 Hs. 2171 growth differentiation factor 10 11. 00 100306 U86749 Hs. 80598 transcription enlongation factor A (SII); 3.06 100447 NM_014767 Hs. 74583 KIAA0275 gene product 3. 16 100458 S74019 Hs. 247979 Vpre-B 42.40 100862 AA005247 Hs. 285754 Hepatocyte Growth Factor Receptor 4.13 100959 AA359129 Hs. 118127 actin; alpha ; cardiac muscle 125.60 101032 BE206854 Hs. 46039 phosphoglycerate mutase 2 (muscle) 36.40 101081 AF047347 Hs. 4880 amyloid beta (A4) precursor protein-bind 34.60 101088 X70697 Hs. 553 soiute carrier famiiy 6 (neurotransmitte 193. 20 101125 AJ250562 Hs. 82749 transmembrane 4 superfamily member 2 3.10 101180 U11874 Hs. 846 interieukin 8 receptor ; beta 54.86 101308 L41390"Homo sapiens core 2 beta-1,6-N-acetylgl 33.20 101330 L43821 Hs. 80261 enhanceroffilamentation 1 (cas-likedo 36.40 101345 NM005795 Hs. 152175 Calcitonin receptor-like 2.29 101346 A1738616 Hs. 77348 hydroxyprostaglandin dehydrogenase 15- (N 70.55 101397 M26380 Hs. 180878 lipoprotein lipase 3.54 101414 NM_000066 Hs. 38069 complement component 8 ; beta polypeptide 3.81 101435 NM_001100 Hs. 1288 actin ; alpha 1 ; skeletal muscle 34.60 101507 X16896 Hs. 82112 interleukin 1 receptor ; type I 37.60 101530 M29874 Hs. 1360 cytochrome P450 ; subfamiiy IIB (phenobar 4.25 101537 AI469059 Hs. 184915 zinc finger protein ; Y-linked 2. 54 101542 NM_000102 Hs. 1363 cytochrome P450 ; subfamily XVII (steroid 5. 50 101545 BE246154 Hs. 154210 EDG1; endotheiiaidifferentation. sphin 39.40 101554 BE207611 Hs. 123078 thyroid stimulating hormone receptor 13.00 101560 AW958272 Hs. 83733 Intercellular adhesion molecule 2, exon 3.38 101574 M34182 Hs. 158029 protein kinase; cAMP-dependent ; catalyti 4.37 101605 M37984 Hs. 118845 troponinC ; slow 3.80 101621 BE391804 Hs. 62661 guanylate binding protein 1 ; interferon-30. 20 101680 AA299330 Hs. 1042 Sjogren syndrome antigen A1 (52kD; ribon 2.75 101829 AW452398 Hs. 129763 soìutecarrierfamily8 (sodiumMalcium 3.37 101842 M93221 Hs. 75182 mannose receptor; C type 1 38.20 101961 AW004056 Hs. 168357"Hs-TBX2=T-box gene {T-box region) [huma 2.32 101994 T92248 Hs. 2240 uteroglobin 6.85 102020 AU077315 Hs. 154970 transcription factor CP2 2.45 102091 BE280901 Hs. 83155 aldehyde dehydrogenase 7 6.75 102112 AW025430 Hs. 155591 forkhead box F1 54.60 102190 AA723157 Hs. 73769 folate receptor 1 (adult) 3.98 102202 NM_000507 Hs. 574 fructose-bisphosphatase 1 3.62 102241 NM007351 Hs. 268107 MulUmerin 2.32 102310 U33839 Accession not listed in Genbank 7.00 102397 U41898"Human sodium cotransporter RKST1 mRNA; 29.40 102571 U60115 Hs. 239069"Homo sapiens skeletal muscle LIM-protei 3.75 102620 AA976427 Hs. 121513 Human clone W2-6 mRNA from chromosome X 3.07 102636 U67092 "Human ataxia-telangiectasia focus prote 2.40 102667 U70867 Hs. 83974 solute carder family 21 (prostaglandin 3.15 102675 U72512 Hs. 7771"Human B-cell receptor associated protei 3.56 102698 M18667 Hs. 1867 progastricsin (pepsinogen C) 4.51 102727 U79251 Hs. 99902 opioid-binding protein/cell adhesion mol 12.00 102852 V00571 Hs. 75294 corticotropin releasing hormone 37.40 103026 X54162 Hs. 79386 thyroid and eye muscle autoantigen D1 (6 13.00 103028 X54380 Hs. 74094 pregnancy-zone protein 28.80 103098 M86361 HumanmRNAforTcellreceptor ; clone IG 10.00 103117 X63578 Hs. 295449 parvalbumin 6.00 103241 X76223 H. sapiens MAL gene exon 4 2.47 103280 U84722 Hs. 76206 Cahderin , Ve-cadherin (vascular epithe 2.69 103360 Y16791 Hs. 73082 keratin ; hair ; acidic; 5 2.16

103496 Y09267 Hs. 132821 fiavin containing monooxygenase 2 5. 97 103508 Y10141"H. sapiens DAT1 gene, partial, VNTR"3. 27 103561 NM 001843 Hs. 143434 contacting 2.40 103569 NM_005512 Hs. 151641 glycoprotein A repetitions predominant 2.99 103575 Z26256"H. sapiens isoform 1 gene for L-type cal 4.18 103627 Z48513 H. sapiens XG mRNA (clone PEP6) 3.44 103767 BE244667 Hs. 296155 CGI-100 protein 2.25 103850 AA187101 Hs. 213194 Hypothetical protein MGC10895 ; sim to SR 46.55 104078 AA402801 Hs. 303276 ESTs 3.05 104326 AW732858 Hs. 143067 ESTs 3.54 104352 BE219898 Hs. 173135 dual-specificity tyrosine- (Y)-phosphoryl 3.16 104398 AI423930 Hs. 36790 ESTs ; Weakly similar to putative p150 [H 64.80 104473 A1904823 Hs. 31297 ESTs 3.38 104493 AW960427 Hs. 79059 ESTs ; Moderately similar to TGF-BETA REC 2.47 104495 AW975687 Hs. 292979 ESTs 28.60 104595 A1799603 Hs. 271568 ESTs 3.42 104597 AI364504 Hs. 93967 ESTs ; Weakly similar to Slit-1 protein 6. 00 104659 AW969769 Hs. 105201 ESTs 34.00 104686 AA010539 Hs. 18912 ESTs 11.00 104691 U29690 Hs. 37744 ESTs ; Beta-1-adrenergicreceptor 56.80 104764 A1039243 Hs. 278585 ESTs 60.40 104776 AA026349 ESTs 34.20 104825 AA035613 Hs. 141883 ESTs 3.03 104865 T79340 Hs. 22575 Homo sapiens cDNA : FLJ21042 fis, clone C 41.20 104942 NM016348 Hs. 10235 ESTs 3.27 104989 R65998 Hs. 285243 ESTs 40.00 105062 AW954355 Hs. 36529 ESTs 3.20 105101 H63202 Hs. 38163 ESTs 34.20 105173 U54617 Hs. 8364 ESTs 4.17 105194 R06780 Hs. 19800 ESTs 16.00 105226 R58958 Hs. 26608 ESTs 2.34 105256 AA430650 Hs. 16529 transmembrane 4 supeaamily member (teir 2.72 105394 BE245812 Hs. 8941 ESTs 2.61 105647 Y09306 Hs. 30148 homeodomain-interacüng protein kinase 3 33.60 105789 AF106941 Hs. 18142 arrestin ; beta2 3.59 105817 AA397825 synaptopodin 4.46 105847 AW964490 Hs. 32241 ESTs 35.40 105894 AI904740 Hs. 25691 calcitonin receptor-like receptor activi 3.43 105999 BE268786 Hs. 21543 ESTs 7.00 106075 AA045290 Hs. 25930 ESTs 42.60 106178 AL049935 Hs. 301763 KIAA0554 protein 34.80 106381 AB040916 Hs. 24106 ESTs 12.00 106467 AA450040 Hs. 154162 ADP-ribosylation factor-like 2 3.69 106536 AA329648 Hs. 23804 ESTs 96.40 106569 R20909 Hs. 300741 sorcin 47. 20 106605 AW772298 Hs. 21103 HomosapiensmRNA ; cDNA DKFZp564B076 (fr 220.40 106842 AF124251 Hs. 26054 novel SH2-containing protein 3 2.55 106844 AA485055 Hs. 158213 sperm associated antigen 6 39.20 106870 A1983730 Hs. 26530 serum deprivation response (phosphaUdyl 2.28 106943 AW888222 Hs. 9973 ESTs 4.28 106954 AF128847 Hs. 204038 ESTs 4.32 107106 AA862496 Hs. 28482 ESTs 10.45 107163 AF233588 Hs. 27018 ESTs 2.57 107201 D20378 Hs. 30731 EST 3.84 107238 D59362 Hs. 330777 EST 8 00 107376 U90545 Hs. 327179 solute carrier family 17 (sodium phospha 10.67 107530 Y13622 Hs. 85087 latent transforming growth factor beta b 2. 32 107688 AW082221 Hs. 60536 ESTs 34.60 107706 AA015579 Hs. 29276 ESTs 28.40 107723 AA015967 EST 3.29 107727 AA149707 Hs. 173091 DKFZP434K151 protein 80.80 107750 AA017291 Hs. 60781 ESTs 51.40 107751 AA017301 Hs. 235390 ESTs 3.14 107873 AK000520 Hs. 143811 ESTs 9. 00 107899 BE019261 Hs. 83869 ESTs ; Weakly similar to ! ! 11 ALU SUBFAMI 3.65 107994 AA036811 Hs. 48469 ESTs 44.60 107997 AL049176 Hs. 82223 Human DNA sequence from clone 141 H5 on c 32.00 108041 AW204712 Hs. 61957 ESTs 30.80 108048 A1797341 Hs. 165195 ESTs 4.75 108338 AA070773 "zm53g11. s1 Stratagenefibrobtast (&num 9372 2.33 108434 AA078899'zm94bl. sl Stratagene colon HT29 (#93722 2.92 108447 AA079126 "zm92a11.s1 Stralagene ovarian cancer (# 3. 06 108480 AL133092 Hs. 68055 ESTs 34. 00 108499 AA083103'zn1b12. s1StratagenehNT neuron (#93723 3.36 108535 R13949 Hs. 226440 Homo sapiens clone 24881 mRNA sequence 19. 00 108550AA084867 "zn11f6.s1 Stratagene hNT neuron (#93723 12.00 108604 AA934589 Hs. 49696 ESTs 2. 33 108625 AW972330 Hs. 283022 ESTs 5.82 108629 AA102425'zn24c6. s1StratageneneuroepitheiiumNT 3.42 108855 AA099960'zm65c6. sl Stratagenefibroblast (&num 93721 7.00 108756 AA127221 Hs. 117037 Homo sapiens mRNA ; cDNA DKFZp564N1164 (f 6.05 108864 A1733852 Hs. 199957 ESTs 28.80 108895 AL138272 Hs. 62713 ESTs 32.80 108921 A1568801 Hs. 71721 ESTs 57.80 108967 AA142989 Hs. 71730 ESTs 28.80

109001 A1056548 Hs. 72116 ESTs, Moderately similar to hedgehog-int 2.57 109003 AA147497 Hs. 71825 ESTs 2.11 109004 AA156235 Hs. 139077 EST 5.60 109065 AA161125 Hs. 252739 EST 10. 00 109250 H83784 Hs. 62113 ESTs ; Weakly similar to PHOSPHATIDYLETHA 3.44 109490 AA233416 Hs. 139202 ESTs 2.92 109510 AI798863 Hs. 87191 ESTs 2.40 109578 F02208 Hs. 27214 ESTs 10.00 109601 F02695 Hs. 311662 EST 40.80 109613 H47315 Hs. 27519 ESTs 54.40 109650 R31770 Hs. 23540 ESTs 31.20 109682 H18017 Hs. 22869 ESTs 8.40 109724 D59899 Hs. 127842 ESTs 29.40 109782 AB020644 Hs. 14945 long fatty acyl-CoA synthetase 2 gene 8.00 109833 R79864 Hs. 29889 ESTs 10.00 109837 H00656 Hs. 29792 ESTs 6.49 109977 T64183 Hs. 282982 ESTs 2.75 109984 AI796320 Hs. 10299 ESTs 107.00 110146 H41324 Hs. 31581 ESTs ; Moderately similar to SYNTAXIN 1B 2.22 110271 H28985 Hs. 31330 ESTs 3.48 110280 AW874263 Hs. 32468 ESTs 44.20 110420 R93141 Hs. 184261 ESTs 32.00 110578 T62507 Hs. 11038 ESTs 28.40 110634 R98905 Hs. 35992 ESTs 20. 00 110726 AW961818 Hs. 24379 potassium voltage-gated channel ; shaker-4. 15 110837 H03109 Hs. 108920 ESTs ; Weakly similar to semaphorin F [H. 56.80 110875 N35070 Hs. 26401 tumor necrosis factor (ligand) superfami 3.13 110894 R92356 Hs. 66881 ESTs ; Moderately similar to cytoplasmic 5.33 110971 Api760098 Hs. 21411 ESTs 44.60 111023 AV655386 Hs. 7645 ESTs 32. 40 111057 T79639 Hs. 14629 ESTs 17.14 111247 AW058350 Hs. 16762 HomosapiensmRNA ; cDNADKFZp564B2062 (f 4.58 111330 BE247767 Hs. 18166 K ! M0670 protein 3.42 111374 BE250726 Hs. 283724 ESTs ; Moderately similar to HYA22 [H. sap 3.91 111442 AW449573 Hs. 181003 ESTs 33.20 111737 H04607 Hs. 9218 ESTs 53.00 111747 AI741471 Hs. 23666 ESTs 46.20 111807 R33508 Hs. 18827 ESTs 16.00 111862 R37472 Hs. 21559 EST 3.91 112045 AI372588 Hs. 8022 TU3A protein 2.74 112057 R43713 Hs. 22945 EST 4.92 112214 AW148652 Hs. 167398 ESTs 13.00 112263 R52393 Hs. 25917 ESTs 2.43 112314 AW206093 Hs. 748 ESTs 9.00 112324 R55965 Hs. 26479 limbic system-associated membrane protei 14.00 112362 AW300887 Hs. 26638 ESTs ; Weakly similar to CD20 receptor [H 2.49 112380 H63010 Hs. 5740 ESTs 2.34 112425 AA324998 Hs. 321677 ESTs; Weakkly similar to ! ! ! ! ALU SUBFAMI 8. 00 112473 R65993 Hs. 279798 pregnancy specific beta-1-glycoprotein 9 4.53 112492 N51620 Hs. 28694 ESTs 29.80 112541 AF038392 Hs. 116674 ESTs 3.62 112620 R80552 Hs. 29040 ESTs 2.37 112623 AW373104 Hs. 25094 ESTs 2.26 112867 T03254 Hs. 167393 ESTs 12.00 112894 T08188 Hs. 3770 ESTs 6.50 112954 AA928953 Hs. 6655 ESTs 7.00 113029 AW081710 Hs. 7369 ESTs ; Weakly similar to !! ! I ALU SUBFAMI 4. 39 113086 AA346839 Hs. 209100 DKFZP434C171 protein 4. 47 113140 T50405 Hs. 175967 ESTs 10. 00 113252 NM_004469 Hs. 11392 c-fos induced growth factor (vascular en 14.00 113257 A) 821378 Hs. 159367 ESTs 3.72 113394 T81473 Hs. 177894 ESTs 3.60 113437 T85349 Hs. 15923 EST 35.00 113454 A1022166 Hs. 16188 ESTs 6.00 113502 T89130 ESTs 39.60 113552 AI654223 Hs. 16026 ESTs 3.88 113645 T95358 Hs. 333181 ESTs 2.58 113691 T96935 Hs. 17932 EST 38.20 113706 AA004693 Hs. 269192 ESTs 3.09 113883 U89281 Hs. 11958 oxidative 3 alpha hydroxysteroid dehydro 2.31 113924 BE178285 Hs. 170056 Homo sapiens mRNA ; cDNA DKFZp58680220 (f 30.40 114035 W92798 Hs. 269181 ESTs 13.00 114058 AK002016 Hs. 114727 ESTs 5. 00 114084 AA708035 Hs. 12248 ESTs 40.60 114121 H05785 Hs. 25425 ESTs 2.31 114124 W57554 Hs. 125019 Human lymphoid nuclear protein (LAF-4) 7. 00 114275 AW515443 Hs. 306117 interleukin 13 receptor ; alpha 1 6.00 114297 AA149707 Hs. 173091 DKFZP434K151 protein 48.80 114427 AA017176 Hs. 33532 ESTs ; HighlysimilartoMiz-1proteinlH 345 114449 AA020736'ze63b1l. s1SoaresretinaN2b4HRHomosa 10.00 114452 AI369275 Hs. 243010 ESTS, Moderately similar to RTCLHUMAN G 14.00 114609 AI079505 "zm97a5.s1 Stratagene colon HT29 (#93722 3.13 114648 AA101056"zn25b3. sl Stratagene neuroepithelium NT 35.40 114731 BE094291 Hs. 155651 Homo sapiens HNF-3beta mRNA for hepatocy 3.42 114762 AA146979 Hs. 288464 ESTs 33.00

114776 AA151719 Hs. 95834 ESTs 34. 40 115009 AA251561 Hs. 48689 ESTs 30. 20 115272 AW015947 ESTs ; Weakly similar to hypothetical L1 32.60 115279 AW964897 Hs. 290825 ESTs 6.00 115302 AL109719 Hs. 47578 ESTs 12. 00 115365 AW976252 Hs. 268391 ESTs 3.32 115559 AL079707 Hs. 207443 ESTs 48.00 115566 AI142336 Hs. 43977 ESTs 56. 20 115683 AF255910 Hs. 54650 ESTs, Weakly similar to (defline not ava 31.40 115744 AA418538 Hs. 43945 ESTs ; Highly similar to dJ1178H5. 3 (H. sa 33.60 115819 AA486620 Hs. 41135 Endomucin 2 74.40 115949 AI478427 Hs. 43125 ESTs 3.18 115965 AA001732 Hs. 173233 ESTs 388. 80 116035 AA621405 Hs. 184664 ESTs 33.20 116049 AA454033 Hs. 41644 ESTs 45.80 116081 AI190W1 Hs. 55278 ESTs 3.57 116082 AB029496 Hs. 59729 ESTs 3.06 116213 AA292105 Hs. 326740 leucine rich repeat (in FLII) interactin 50.60 116228 Api767947 Hs. 50841 ESTs; Weakly similar to tufelin [M. musc 3.85 116250 N76712 Hs. 44829 ESTs 6. 00 116419 Api613480 Hs. 47152 ESTs ; Weakiy similar to testicular tekti 30. 00 116617 D80761 Hs. 45220 EST'2. 27 116784 AB007979 Hs. 301281 tenascinR (restrictin ; janusin) 47. 20 116835 N39230 Hs. 38218 ESTs 41.20 116970 AB023179 Hs. 9059 KIAA0962 protein 11.00 117023 AW070211 Hs. 102415 ESTs 91. 00 117027 AW085208 Hs. 130093 ESTs 49.40 117036 H68908 Hs. 41192 EST 32.60 117110 AA160079 Hs. 172932 ESTs 8.67 117209 W03011 Hs. 306881 ESTs 30.60 117325 N23599 Hs. 43396 ESTs 9.29 117454 N29569 Hs. 44055 ESTs 3.19 117475 N30205 Hs. 93740 ESTs 44.00 117543 BE219453 Hs. 42722 ESTs 16.00 117567 AW444761 Hs. 44565 ESTs 12.00 117570 N48649 Hs. 44583 ESTs 11.00 117600 N34963 Hs. 44676 EST 3. 74 117730 N45513 Hs. 46608 ESTs 6.00 117791 N48325 Hs. 93956 EST 9.00 117929 N51075 Hs. 47191 ESTs 29.20 117990 AA446167 Hs. 47385 ESTs 8.00 118224 N62275 Hs. 48503 EST 31. 40 118244 N62516 Hs. 48556 ESTs 32.80 118357 AL109667 Hs. 124154 HomosapiensmRNAfulllengthinsertcDN 2.40 118446 N66361 Hs. 269121 ESTs 2.28 118447 N66399 Hs. 49193 EST 30.80 118530 N67900 Hs. 118446 ESTs 3.10 118549 N68163 Hs. 322954 EST 3. 41 118823 W03754 Hs. 50813 ESTs ; Weakly similar to long chain fatty 3.94 118862 W17065 Hs. 54522 ESTs 3.58 118935 A1979247 Hs. 247043 KIAA0525 protein 33. 00 118944 M734233 Hs. 226142 ESTs ; Weakly similar to ! ! II ALU SUBFAMI 11. 43 118995 N94591 Hs. 323056 ESTs 14. 00 119073 BE245360 Hs. 279477 ERG-2/ERG-1 ; V-etsavianerythroblastosi 52.60 119268 T16335 Hs. 65325 EST 31.40 119514 W37937 Accession not listed in Genbank 3. 50 119824 W74536 Hs. 184 advanced glycosylation end product-speci 2.75 119831 AL117664 Hs. 58419 DKFZP586L2024 protein 3.21 119861 W78816 Hs. 49943 ESTs ; Moderately similar to 1 ! ! ! ALU SUB 33.80 119889 W84346 Hs. 58671 ESTs 30. 03 119921 W86192 Hs. 58815 ESTs 29. 00 120082 H80286 Hs. 40111 ESTs 3.80 120094 AA811339 Hs. 124049 ESTs 6.00 120132 W57554 Hs. 125019 Human lymphoid nuclear protein (LAF-4) 36.60 120378 AA223249 Hs. 285728 ESTs 12. 00 120404 AB023230 Hs. 96427 KIAA1013 protein 39.40 120504 AA256837 ESTs 8.00 120512 N55761 Hs. 194718 ESTs 33.00 120667 AA287740 Hs. 78335 microtubule-associated protein ; RP/EB fa 4.18 120777 AA287702 Hs. 10031 KIAA0955 protein 46.60 121082 AA398722 ESTs 39.00 121191 AA400205 Hs. 104447 ESTs 41.60 121248 AA400914 Hs. 97827 EST 5. 08 121363 A1287280 Hs. 97933 ESTs 12.00 121366 Al743515 ESTs 20.00 121483 A1660332 Hs. 25274 ESTs ; Moderately similar to putative sev 3.32 121518 AA412155 ESTs 30.20 121545 AA412442 Hs. 98132 ESTs 2. 29 121622 AA416931 Hs. 126065 ESTs 9.00 121665 AA416556 Hs. 98234 ESTs 34.80 121709 AI338247 Hs. 98314 Homo sapiens mRNA ; cDNA DKFZp586L0120 (f 34.80 121730 A1140683 Hs. 98328 ESTs 38.80 121740 AA421138 Hs. 98334 EST 7.00 121772 Ai590770 Hs. 110347 HomosapiensmRNAforalphaintegrinbin 36.20 121821 AL040235 Hs. 3346 ESTs 3.61

121835 AB033030 Hs. 300670 ESTs 2. 34 121841 AA427794 Hs. 104864 ESTs 2. 61 121885 AA934883 Hs. 98467 ESTs 2.25 121888 AA426429 Hs. 98463 ESTs 2.92 121938 AA428659 Hs. 98610 ESTs 46.80 121950 AA429515 EST 31. 40 122030 AA431310 Hs. 98724 ESTs 34.40 122054 AA431725 Hs. 98746 EST 3.58 122211 AA300900 Hs. 98849 ESTs ; Moderately similar to bithoraxoid-49. 40 122233 AA436455 Hs. 98872 EST 29.80 122247 AA436676 Hs. 98890 EST 39.80 122253 AA436703 Hs. 104936 ESTs ; Weakly similar to hypothetical pro 9. 00 122266 AA436840 Hs. 98907 EST 3.60 122285 AA436981 Hs. 121602 EST 3. 14 122409 AA446830 Hs. 99081 ESTs 30.80 122485 AA524547 Hs. 160318 phospholemman 2.65 122697 AA420683 Hs. 98321 Homo sapiens cDNA FLJ14103 fis clone MA 15.00 122772 AW117452 Hs. 99489 ESTs 6.67 122831 Ai857570 Hs. 5120 ESTs 3.37 122913 AI638774 Hs. 105328 ESTs 32.20 123049 BE047680 Hs. 211869 ESTs 41.80 123076 A1345569 Hs. 190046 ESTs 35.80 123136 AW451999 Hs. 194024 ESTs 2.58 123309 N52937 Hs. 102679 ESTs 19.00 123455 AA353113 Hs. 112497 ESTs 82.80 123691 AA609579 Hs. 112724 ESTs 3.95 123756 AA609971 Hs. 112795 EST 35.40 123802 AA620448 Homo sapiens clone 24760 mRNA sequence 58. 00 123837 AI807243 Hs. 112893 ESTs 32.40 123844 AA938905 Hs. 120017 olfactory receptor ; family 7; subfamily 2.63 123936 NM004673 Hs. 241519 ESTs 29.00 123987 C21171 Hs. 95497 ESTs ; Weakly similar to GLUCOSE TRANSPOR 70.60 124013 Api521936 Hs. 107149 ESTs ; Weakly similar to PTB-ASSOCIATED S 28. 40 124160 R40290 Hs. 124685 ESTs 13.00 124205 H77570 Hs. 108135 ESTs 4.74 124226 AA618527 Hs. 190266 ESTs 2.35 124246 H67680 Hs. 270962 ESTs 29.40 124348 A1796320 Hs. 10299 ESTs 17.00 124358 AW070211 Hs. 102415 "yw35g11.s1 Morton Fetal Cochlea Homo sa 3.07 124409 AI814166 Hs. 107197 ESTs 3. 14 124442 AW663632 Hs. 285625 TATA box binding protein (TBP)-associate 2.48 124468 N51413 Hs. 109284 ESTs 30.80 124479 AB011130 Hs. 127436 calcium channel ; voltage-dependent ; alph 03 124519 Api670056 Hs. 137274 ESTs ; Weakly similar to SPLICEOSOME ASSO 2. 50 124711 NM_004657 Hs. 26530 serum deprivation response (phosphatidyl 59.20 124866 AI768289 Hs. 304389 ESTs 8. 00 124874 BE550182 Hs. 127826 ESTs 37.60 125097 AW576389 Hs. 335774 ESTs 10.00 125179 AW206468 Hs. 103118 ESTs 3.12 125200 AW836591 Hs. 103156 ESTs 2.79 125299 T32982 Hs. 102720 ESTs 34.20 125400 AL110151 Hs. 128797 DKFZP586D0824protein 29. 00 125810 H00083 ary) hydrocarbon receptor-Interacting pr 32.20 126176 BE242256 Hs. 2441 KIAA0022 gene product 12.00 126303 D78841 HUM525A05B Human placenta polyA+ (TFuji 33.60 126403 AW629054 Hs. 125976 ESTs ; WeaMy simitar to metatfoprotease/35. 80 126507 AL040137 Hs. 23964 ESTs ; Weakly similar to HC1 ORF [M. muscu 29.80 126773 AA648284 Hs. 187584 ESTs 39.60 127307 AW962712 Hs. 126712 ESTs ; Weakly similar to pIL2 hypothetica 28.80 127462 AA760776 Hs.293977 aa59b04.s1 NCI_CGAP_GCB1 Homo sapiens c 34.40 127486 AW002846 Hs. 105468 ESTs 9.00 127572 AA594027 Hs. 191788 ESTs 2.36 127609 X80031 Hs. 530 ESTs 29. 40 127832 AW976035 Hs. 292396 ESTs 37.20 127898 AA774725 Hs. 128970 ESTs 4.42 128073 AW340720 Hs. 125983 ESTs 38.40 128101 AA905730 Hs. 128254 ESTs 7.33 128149 NM 012214 Hs. 177576 mannosyl (alpha-1 ; 3-)-glycoprotein beta-2. 58 128212 W27411 Hs. 336920 glutathione peroxidase 3 (plasma) 3.09 128333 W68800 Hs. 12126 ESTs ; Weakly simifar to LRB [H, sapiensj 34.40 128364 N76462 Hs. 269152 ESTs ; Weakly similar to ZINC FINGER PROT 10.00 128426 A1265784 Hs. 145197 ESTs 4.31 128598 AA305407 Hs. 102308 potassium inwardly-rectifying channel ; s 31.20 128634 AA464918 ESTs ; Moderately similar to ! ! ! ! ALU SUB 41.60 128687 AW271273 Hs. 23767 ESTs 87.00 128726 AI311238 Hs. 104476 ESTs 4.02 128773 NM004131 Hs. 1051 granzyme B (granzyme 2 ; cytotoxic T-lymp 9. 00 128833 W26667 Hs. 184581 ESTs 3.76 128870 H39537 Hs. 75309 eukaryotic translation elongation factor 2.66 128878 R25513 Hs. 10683 ESTs 3.10 128885 AF134803 Hs. 180141 cofilin 2 (muscle) 11. 00 128998 W04245 Hs. 107761 ESTs ;Weakly similar to PUTATIVE RHO/RAC 3.21 129000 AA744902 Hs. 107767 ESTs ; Moderately similar to CaM-KII inhi 3.68 129038 AW156903 Hs. 108124 ribosome ! protein L41 3.17 129098 AW580945 Hs. 330466 ESTs 34.60

129210 AL039940 Hs. 202949 KIAA1102 protein 4.09 129240 AA361258 Hs. 237868 interleukin 7 receptor 2.29 129262 BE222198 Hs. 109843 ESTs 3.30 129301 AF182277 Hs. 330780 Human cytochrome P450-IIB (hIIB3) mRNA ; 4.05 129331 AW167668 Hs. 279772 ESTs ; Highly similar to CGI-38 protein [4. 09 129381 AW245805 Hs. 110903 claudin 5 (transmembrane protein deleted 2.93 129565 X77777 Hs. 198726 vasoactive intestinal peptide receptor 1 160.80 129595 U09550 Hs. 1154 oviductalglycoprotein 1 ; 120kD 10.00 129613 AW978517 Hs. 172847 ESTs ; Weakly similar to collagen alpha 1 3.40 129782 AW016932 Hs. 104105 EST 9.00 129950 F07783 Hs. 1369 decay accelerating factor for complement 87. 80 129958 R27496 Hs. 1378 annexinA3 44.60 129959 AL036554 Hs. 274463 defensin; alpha 1 ; myeloid-related seque 2.72 130160 AA305688 Hs. 267695 UDP-Ga ! : betaGlcNAc beta 1, 3-galactosyltr 42.20 130259 NM_000328 Hs. 153614 retiniüspigmentosaGTPaseregulator 2.54 130273 AW972422 Hs. 153863 MAD (mothers against decapentaplegic ; Dr 51.60 130312 AF056195 Hs. 15430 DKFZP586G1219 protein 3.16 130436 NM_001928 Hs. 155597 Dcomponentofcomplement (adipsin) 4. 11 130523 AA999702 Hs. 214507 ESTs 4.77 130799 AB028945 Hs. 12696 ESTs 6.00 130885 NM_005883 Hs. 20912 adenomatouspoiyposiscoiiiike 3.54 131002 AL050295 Hs. 22039 KIAA0758 protein 3.50 131012 AL039940 Hs. 202949 KIAA1t02 protein 20.00 131031 NM_001650 Hs. 288650 aquaporin 4 41.20 131061 N64328 Hs. 268744 ESTs ; Moderately similar to KIAA0273 [H. 31.40 131066 AW169287 Hs. 22588 ESTs 29.60 131082 A1091121 Hs. 246218 ESTs ; Weakly similar to zinc finger prot 9.00 131087 AF147709 Hs. 22824 ESTs ; Weakly similar to p160 myb-binding 3.86 131161 AF033382 Hs. 23735 potassium voltage-gated channel ; subfami 3.14 131179 AA171388 Hs. 184482 DKFZP586D0624protein 3.80 131182 A1824144 Hs. 23912 ESTs 3.67 131205 NM_003102 Hs. 2420 superoxide dismutase 3 ; extracellular 2.98 131277 AA131466 Hs. 23767 ESTs 3.15 131281 AA251716 Hs. 25227 ESTs 32.20 131282 X03350 Hs. 4 alcohol dehydrogenase 3 (class I) ; gamma 3.44 131285 Api567943 Hs. 25274 ESTs ; Moderately similar to putative sev 6.40 131355 R52804 Hs. 25956 DKFZP564D206 protein 8.00 131391 AW085781 Hs. 26270 ESTs 10.00 131461 AA992841 Hs. 27263 butyrate response factor 2 (EGF-response 28.80 131487 F13036 Hs. 27373 Homo sapiens mRNA ; cDNADKFZp56401763 (f 4.03 131517 AB037789 Hs. 263395 ESTs ; Highly similar to semaphorin Via [ 39. 00 131545 AL137432 Hs. 28564 ESTs 11.00 131583 AK000383 Hs. 323092 ESTs ; Weakly similar to dual specificity 10.00 131647 AA359615 Hs. 30089 ESTs 2.47 131675 H15205 Hs. 30509 ESTs 3.06 131676 A) 126821 Hs. 30514 ESTs 45. 80 131708 S60415 Hs. 30941 calcium channel ; voltage-dependent ; beta 2.28 131717 X94630 Hs. 3107 CD97 antigen 131756 AA443966 Hs. 31595 ESTs 40.60 131762 AA744902 Hs. 107767 ESTs ; Moderately similar to CaM-KII inhi 3.67 131821 AA017247 Hs. 164577 ESTs 2.87 131839 AB014533 Hs. 33010 KIAA0633 protein 3. 48 131861 AL096858 Hs. 184245 KIAA0929 protein Msx2 interacting nuclea 54.00 132015 AI418006 Hs. 3731 ESTs 49.20 132070 BE622641 Hs. 38489 ESTs 34.80 132242 AA332697 Hs. 42721 ESTs 2.68 132334 AW080704 Hs. 45033 lacrimal proline rich protein 4.66 132476 AL119844 Hs. 49476 Homo sapiens clone TUA8 Cri-du-chat regi 34.20 132490 NM_001290 Hs. 4980 LIM binding domain 2 2.66 132533 A1922988 Hs. 172510 ESTs 13.00 132598 X80031 Hs. 530 collagen ; type) V ; alpha 3 (Goodpasture 30.60 132619 H28855 Hs. 53447 ESTs ; Moderately similar to kinesin ligh 4.02 132652 N41739 Hs. 61260 ESTs 3. 18 132726 N52298 Hs. 55608 ESTs; Wealy similar to cDNA EST yk484g1 11.43 133028 R51604 Hs. 300842 ESTs 2.37 133071 BE384932 Hs. 64313 ESTs 2.27 133120 NM_003278 Hs. 65424 tetranectin (plasminogen-binding protein 2.63 133129 AA428580 Hs. 65551 ESTs 5.49 133147 AA026533 Hs. 66 inter) 1 receptor-like 1 6. 20 133151 NM_014051 Hs. 94896 ESTs 3.69 133213 AA903424 Hs. 6786 ESTs 31.40 133276 AW978439 Hs. 69504 ESTs 9.00 133377 AJ131245 Hs. 7239 SEC24 (S. cerevisiae) related gene famil 41.20 133407 AF017987 Hs. 7306 secreted frizzled-related protein 1 50.20 133535 AL134030 Hs. 284180 protocadherin 2 (cadherin-like 2) 3.72 133537 U41518 Hs. 74602 aquapodn 1 (channel-forming integral pr 3. 35 133656 BE149455 Hs. 75415 Accession not listed in Genbank 2.65 133689 NM001872 Hs. 75572 carboxypeptidase B2 (plasma) 90.80 133779 T58486 Hs. 222566 ESTs 3. 05 133978 AF035718 Hs. 78061 transcription factor 21 2.92 133985 L34657 Hs. 78146 plateletlendothelial cell adhesion molec 3. 45 134000 AW175787 Hs. 334841 selenium binding protein 1 4. 05 134111 A137258B Hs. 8022 TU3A protein 4.49 134185 AA285136 Hs. 301914 HomosapiensmRNA ; cDNA DKFZp586K1220 (f 3.27 134204 AI873257 Hs. 7994 ESTs ; Weakly similar to CGI-69 protein ; 40. 80

134641 A) 092634 Hs. 156114 protein tyrosine phosphatase ; non-recept 3.76 134677 AA251363 Hs. 177711 ESTs 32.20 134745 NM_000685 Hs. 89472 angiotensin receptor 1B 15.00 134749 T28499 Hs. 89485 carbonic anhydrase IV 3.05 134786 T29618 Hs. 89640 angiopoietin 1 receptor ; TEK tyrosine ki 57.80 134825 U33749 Hs. 197764 thyroid transcription factor 1 3.73 134978 AI829008 Hs. 333383 ficolin (collagen/fibrinogen domain-cont 2.52 135010 N50465 Hs. 92927 ESTs 31.60 135053 AW796190 Hs. 93678 ESTs 3.21 135081 AF069517 Hs. 173993 RNA binding motif protein 6 28.80 135091 AA493650 Hs. 94367 ESTs 4.24 135135 AA775910 Hs. 95011 syntrophin; beta1 (dystrophin-associate 8. 00 135203 C15737 Hs. 269386 ESTs 4. 31 135236 A1636208 Hs. 96901 ESTs 43.00 135266 R41179 Hs. 97393 Human mRNA for KIAA0328 gene; partial cd 6.42 135346 NM_000928 Hs. 992 phospholipase A2 ; group 18 (pancreas) 3.82 135378 AW961818 Hs. 24379 potassium voltage-gated channel ; shaker-4.15 135387 NM_001972 Hs. 99863 elastase 2 ; neutrophil 37.20 135388 W27965 Hs. 99865 EST 38.80 135402 L12398 Hs. 99922 dopamine receptor D4 4. 21 TABLE 2B shows the accession numbers for those primekeys lacking unigene ! D's forTable 2A. For each probeset.we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on seque similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession"column.

Pkey: Unique Eos probeset identifier number CAT number Gene cluster number Accession : Genbank accession numbers Pkey CAT number Accessions 108447 43452_-7 AA079126 108550 120073_1 AA084867 AA084996 108655 127522J AA099960 AA113013 102397 44371_-1 U41898 126303 1525933_1 D78841 D78880 125810 1554054_1 H00083 R81062 103627 2615 2 Z48513Z48512 121366 280401_1 AI743515 AA405617 AW276706 114609 116777 1 AA079505 AA079537 115272 172113_1 AW015947 AA211890 AA279425 108338 112186_1 AA070773 AA070774 108434 114012_1 AA078899 AA078782 AA075788 123802 genbank_AA620448 AA620448 102310 NOT_FOUND_entrez U33839 U33839 102636 entrez_U67092 U67092 104776 genbanLAA026349 AA026349 120504 genbank_AA256837 AA256837 113502 genbank_T89130T89130 108499 genbankAA083103 AA083103 101308 entrez-L41390 L41390 108629 genbankAA102425 AA102425 103098 221_215 M86361 Z26593 X02850 D13070 AE000659 M17649 M87869 M87871 X61077 M16286 AF018169 X61079 S59351 X60142 AF043169 103241 entrez_X76223 X76223 103508 entrez_Y10141 Y10141 103575 entrez_Z26256 Z26256 119514 NOTFOUNDentrezW37937W37937 121082 genbank_AA398722 AA398722 128634 AA464918 at AA464918 105817 genbank_AA397825 AA397825 121518 genbankAA412155 AA412155 114449 genbankAA020736 AA020736 114648 genbankAA101056 AA101056 121950 genbankAA429515 AA429515 107723 genbank_AA015967 AA015967

Table 3A shows 452 genes up-regulated in chronically diseased lung relative to normal lung. Chronically diseased lung samples represent chronic non-malignant lung disease such as fibrosis, emphysema, and bronchitis. These genes were selected from 59680 probesets on the Eos/Affymetrix Hu03 Genechip array. Gene expression data for each probeset obtained from this analysis was expressed as average intensity (Al), a normalized value reflecting the relative level of mRNA expression.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD : Unigene number Unigene Title: Unigene gene title R1 : 80th percentile of AI for chronically diseased lung samples divided by the 90th percentile of Al for normal lung samples.

R2: 80th percentile of Al for chronically diseased lung samples divided by the 90th percentile of normal lung samples, squamous cell carcinomas and adenocarcinomas R3: 70th percentile of Aì for chronically diseased lung samples minus the 15th percentile of Al for all normal lung, chronically diseased lung and tumor samples divided by the 90th percentile of normal lung samples, squamous cell carcinomas and adenocarcinomas minus the 15th percentile of AI for all normal lung, chronically diseased lung and tumor samples Pkey ExAccn UnigeneìD Unigene Title R1 R2 R3 135423 U50531 Hs. 138751 Human BRCA2 region, mRNA sequence CG030 12.40 135378 AW961818 Hs. 24379 MUM2 protein 2.13 135346 NM_000928 Hs. 992 phospholipase A2, group IB (pancreas) 135235 AW298244 Hs. 293507 ESTs 12. 40 135057 U90268 Hs. 93810 cerebral cavernous malformations 1 11.67 134951 BE305081 Hs. 169358 hypothetical protein 8.00 134799 M36821 Hs. 89690 GR03 oncogene 8.20 134786 T29618 Hs. 89640 TEK lyrosine kinase, endothelial (venous 134772 Nom000829 Hs. 163697 glutamate receptor, ionotrophic, AMPA 4 29.80 134752 BE246762 Hs. 89499 arachidonate 5-lipoxygenase 1. 93 134749 T28499 Hs. 89485 carbonic anhydrase IV 2. 07 134696 BE326276 Hs. 8861 ESTs 134636 NM_005582 Hs. 87205 lymphocyte antigen 64 (mouse) homolog, r 13.60 134627 A1018768 Hs. 12482 glyceronephosphate 0-acyltransferase 1.92 134622 AW975159 Hs. 293097 ESTs, Weakly similar to A55380 faciogenl 1. 92 134570 U66615 Hs. 172280 SWI/SNFrelated, matrixassociated, acti 13.20 134561 U76421 Hs. 85302 adenosine deaminase, RNA-specific, B1 (h 1.78 134468 NM001772 Hs. 83731 CD33 antigen (gp67) 6. 20 134417 NM_006416 Hs. 82921 solute carrierfamily 35 (CMP-sialic aci 134343 D50683 Hs. 82028 transforming growth factor, beta recepto 134323 BE170651 Hs. 8700 deleted in liver cancer 1 134300 Nom001430 Hs. 8136 endothelial PAS domain protein 1 134299 AW580939 Hs. 97199 complement component C1q receptor 134253 X52075 Hs. 80738 sialophorin (gpL115, leukosialin, CD43) 20.60 134182 D52059 Hs. 7972 KIAA0871 protein 12.20 133985 L34657 Hs. 78146 plateletlendothelial cell adhesion molec 133978 AF035718 Hs. 78061 transcription factor21 133835 AI677897 Hs. 76640 RGC32 protein 133651 AI301740 Hs. 173381 dihydropyrimidinase-like 2 133633 D21262 Hs. 75337 nucleolar and coiled-body phosphprotein 15.20 133565 AW955776 Hs. 313500 ESTs, Moderately similar to ALU7-HUMAN A 133548 AW946384 Hs. 178112 DNA segment, single copy probe LNS-CAI/L 1.77 133488 AA335295 Hs. 74120 adipose specific 2 133478 X83703 Hs. 31432 cardiac ankyrin repeat protein 2.08 133337 AF085983 Hs. 293676 ESTs 9.60 133200 AB037715 Hs. 183639 hypothetical protein FLJ10210 1. 77 133153 AF070592 Hs. 66170 HSKM-B protein 30. 60 133130 A1128606 Hs. 6557 zinc finger protein 161 22. 60 133120 NM 003278 Hs. 65424 tetranectin (plasminogen-binding protein 132928 AW168082 Hs. 169449 protein kinase C, alpha 13.80 132836 AB023177 Hs. 29900 KIAA0960 protein 132799 W73311 Hs. 169407 SAC2 (suppressor of actin mutations 2, 41.60 132742 AA025480 Hs. 292812 ESTs, Weakly similar to T33468 hypotheti 40. 40 132548 X12830 Hs. 193400 interleukin 6 receptor 7.20 132476 AL119844 Hs. 49476 Homo sapiens clone TUA8 Cri-du-chat regi 4. 76 132439 AK001942 Hs. 4863 hypothetical protein DKFZp566A1524 1.88 132240 AB018324 Hs. 42676 KIAA0781 protein 21.20 132210 Nom007203 Hs. 42322 A kinase (PRKA) anchor protein 2 1.99 132199 AL041299 Hs. 165084 ESTs 15. 20 131751 T96555 Hs. 31562 ESTs 1.76 131745 AI828559 Hs. 31447 ESTs, ModeratelysimilartoA46010X-ìi 27.80 131694 NM_000246 Hs. 3076 MHC class 11 transactivator 4 00 131686 Nom012296 Hs. 30687 GRB2-associated binding protein 2 131676 AI126821 Hs. 30514 ESTs 6.20 131629 Z45794 Hs. 238809 ESTs 21.40 131589 C18825 Hs. 29191 epithelial membrane protein 2 131536 AA019201 Hs. 269210 ESTs 9.40 131517 AB037789 Hs. 263395 sema domain, transmembrane domain (TM), 3.59 131355 R52804 Hs. 25956 DKFZP564D206 protein 4.48 131253 R71802 Hs. 24853 ESTs 15.00 131207 AF104266 Hs. 24212 latrophilin 1.75 131156 AI472209 Hs. 323117 ESTs 1.84 131066 AW169287 Hs. 22588 ESTs 3.54 131061 N64328 Hs. 268744 KIAA1796 protein 131053 AA348541 Hs. 296261 guanine nucleotide binding protein (G pr 1. 93 130895 AA641767 Hs. 21015 hypothetical protein DKFZp564L0864 simil 16.60 130762 D84371 Hs. 1898 paraoxonase 1 12.00

130657 AW337575 Hs. 201591 ESTs 130655 At831962 Hs. 17409 cysteine-rich protein 1 (intestinal) 130589 AL110226 Hs. 16441 DKFZP434H204 protein 2.08 130562 D50402 Hs. 182611 solutecamerfamily 1 (proton-coupled 1.91 130555 R69743 Hs. 116774 integrin, alpha 1 9.60 130365 W56119 Hs. 155103 eukaryotictransiationinitiationfactor 11.60 130273 AW972422 Hs. 153863 MAD (mothers against decapentaplegic, Dr 6.60 130259 NM000328 Hs. 153614 retiniús pigmentosa GTPase regulator 1.91 130090 H97878 Hs. 132390 zinc finger protein 36 (KOX 18) 21.20 129958 R27496 Hs. 1378 annexinA3 505 129898 AI672731 Hs. 13256 ESTs 129875 AA181018 Hs. 13056 hypoifhe6calprotein FLJ13920 18.60 129699 AB007899 Hs. 12017 homologofyeastubiquitin-proteinìigas 129626 F13272 Hs. 111334 ferritin, lightpolypeptide 129598 N30436 Hs. 11556 Homo sapiens cDNA FLJ12566 fiis, clone NT 22, 63 129593 AI338247 Hs. 98314 Homo sapiens mRNA ; cDNA DKFZp586L0120 (f 129565 X77777 Hs. 198726 vasoactive intestinal peptide receptor 1 2.53 129527 AA769221 Hs. 270847 delta-tubulin 39. 20 129402 W72062 Hs. 11112 ESTs 2.11 129385 AA172106 Hs. 110950 Rag C protein 15.20 129315 NM_014563 Hs. 174038 spondyloepiphyseal dysplasia, late 12.40 129312 T97579 Hs. 110334 ESTs, Weakly similar to I78885 serine/th 20.83 129240 AA361258 Hs. 237868 interleukin 7 receptor 1.95 129210 AL039940 Hs. 202949 KIAA1102 protein 129122 AW958473 Hs. 301957 nudix (nucleoside diphosphate linked moi 4.20 129057 N90866 Hs. 276770 CDW52 antigen (CAMPATH-1 antigen) 128946 Y13153 Hs. 107318 kynurenine 3-monooxygenase (kynurenine 3 5. 20 128798 AF015525 Hs. 302043 chemokine (go moti receptor-like 2 128789 AW368576 Hs. 139851 caveolin 2 2.24 128778 AA504776 Hs. 186709 ESTs, Weakly similar to 138022 hypothet 12.20 128766 AW160432 Hs. 296460 craniofacial development protein 1 26.40 128631 R44238 Hs. 155546 KIAA1080 protein ; Golgi-associated, gamm 1.78 128624 BE154765 Hs. 102647 ESTsgWeaklysimilartoTRHY_HUMANTRICH 2.51 128609 NM 003616 Hs. 102456 survival of motor neuron protein interac 16.00 128603 NM_004915 Hs. 10237 ATP-binding cassette, sub-family G (WHIT 12.80 128598 AA305407 Hs. 102308 potassium inwardly-rectifying channel, s 4. 00 128458 H55864 Hs. 56340 ESTs 128061 AF150882 Hs. 186877 sodium channel, voltage-gated, type XII, 17.20 127968 AA830201 Hs. 124347 ESTs 21.30 127959 AI302471 Hs. 124292 Homo sapiens cDNA : FLJ23123 fis, clone L 127944 A1557081 Hs. 262476 S-adenosylmethionine decarboxylase 1 10.60 127925 AA805151 Hs. 3628 mitogen-activated protein kinase kinase 13.40 127896 A1669586 Hs. 222194 ESTs 7.00 127859 AA761802 Hs. 291559 ESTs 14.00 127817 AA836641 Hs. 163085 ESTs 14.00 127742 AW293496 Hs. 180138 ESTs 11.00 127628 AI240102 Hs. 322430 NDRG family, member 4 11. 10 127609 X80031 Hs. 530 collagen, type IV, alpha 3 (Goodpasture 127582 AA908954 Hs. 130844 ESTs 19.60 127543 AK000787 Hs. 157392 Homo sapiens cDNA FLJ20780 fis, clone CO 15.40 127535 AA568424 Hs. 164450 ESTs 17.50 127404 A1379920 Hs. 270224 ESTs 14.60 127396 L31968 Hs. 187991 DKFZP564A122 protein 15.40 127374 AA442797 Hs. 312110 ESTs, Weakly similar to 138022 hypothet 14.60 127346 AA203616 Hs. 44896 DnaJ (Hsp40) homolog, subfamily B, membe 21.00 127340 BE047653 Hs.119183 ESTs, Weakly similar to ZN91_HUMAN ZINC 15.80 127307 AW962712 Hs. 126712 ESTs, Weakly similar to AF1910201 E21G5 127242 AW390395 Hs. 181301 cathepsin S 22.60 127167 AA625690 Hs. 190272 ESTs 21.40 127046 AA321948 Hs. 293968 ESTs 41.20 126928 AA480902 Hs. 137401 ESTs 11.00 126900 AF137386 Hs. 12701 plasmolipin 1.78 126852 AA399961 gb: zu68c01. rl Soares testis_NHT Homo sap 5.60 126816 AA248234 gb: csg2228. seq. F Human fetal heart, Lamb 12.20 126812 AB037860 Hs. 173933 nuclearfactorl/A 17.19 126666 AA648886 Hs. 151999 ESTs 13.57 126645 AA316181 Hs. 61635 six transmembrane epithe) ial antigen of 15. 40 126592 AI611153 Hs. 6093 Homo sapiens cDNA : FLJ22783 fis, clone K 4.67 126556 AF255303 Hs. 112227 membrane-associated nucleic acid binding 18.00 126433 AA325606 gb: EST28707 Cerebellum 11 Homo sapiens c 16.77 126299 AW979155 Hs. 298275 amino acid transporter 2 14.60 126218 AL049801 Hs. 13649 Novel human gene mapping to chomosome 13 3.50 126182 AA721331 Hs. 293771 ESTs 13.40 126177 AW752782 Hs. 129750 hypothetical protein FLJ10546 18.20 126142 H86261 Hs. 40568 ESTs 14.00 126077 M78772 Hs. 210836 ESTs 16.59 125994 A1990529 Hs. 270799 ESTs 17. 40 125934 AA193325 Hs. 32646 hypothetical protein FLJ21901 13. 00 125847 AW161885 Hs. 249034 ESTs 49.57 125831 H04043 gb: yj45c03. rl Soares p ! æenta Nb2HP Homo 125731 R61771 Hs. 26912 ESTs 13.20 125676 BE612918 Hs. 151973 hypothetical protein FLJ23511 11.20 125561 F18572 Hs. 22978 ESTs, Weakly similar to ALU4_HUMAN ALU S 125552 H09701 Hs. 278366 ESTs, Weakly similar to 138022 hypotheti 12.60 125489 H49193 Hs.124984 ESTs, Moderately similar to ALU7_HUMAN A 33.40

125422 AA903229 Hs. 153717 ESTs 1.80 125331 AI422966 Hs. 161378 ESTs 38.00 125309 T12411 Hs. 183745 hypothetical protein FLJ13456 18.20 125167 AL137540 Hs. 102541 netrin 4 1.95 125139 AW194933 Hs. 9788 hypothetical protein MGC10924 similar to 1.84 125042 T78906 Hs. 269432 ESTs, Moderately similar to ALU1 HUMAN 21.80 124711 NM004657 Hs. 26530 serum deprivation response (phosphatidyt 10.60 124631 NM_014053 Hs. 270594 FLVCR protein 23.20 124578 N68321 Hs. 231500 EST 21.43 124574 AL036596 Hs. 42322 Akinase (PRKA) anchorprotein2 1.77 124472 N52517 Hs. 102670 EST 37.20 124438 BE178536 Hs. 11090 membrane-spanning 4-domains, subfamily A 124357 N22401 gb: yw37g07. s1 Morton Fetal Cochlea Homo 14.64 124306 AW973078 Hs. 293039 ESTs 4.00 124214 H58608 Hs. 151323 ESTs 124097 AW298235 Hs. 101689 ESTs 27.20 123978 T89832 Hs. 170278 ESTs 2.03 123972 T46848 Hs. 70337 immunoglobulin superfamily, member 4 6.00 123961 AL050184 Hs. 21610 DKFZP434B203 protein 1.79 123936 NM_004673 Hs. 241519 angiopoietin-like 1 15.80 123802 AA620448 gb: ae58c09. sl Stratagene lung carcinoma 4.23 123734 AA609861 Hs. 312447 ESTs 4.20 123619 AA602964 gb: no97c02 s1 NCI_CGAP_Pr2 Homo sapiens 33.60 123596 AA421130 Hs. 112640 EST 10.93 123476 AA384564 Hs. 108829 ESTs 2. 18 123340 AA504264 Hs. 182937 peptidylprolylisomeraseA (cyclophilin 11.20 123190 AA489212 Hs. 105228 EST 14.20 123136 AW451999 Hs. 194024 ESTs 7.00 123073 AA485061 Hs. 105652 ESTs 31. 20 123055 AA482005 Hs. 105102 ESTs, Weakly similar to reverse transcri 4.80 122699 AA456130 Hs. 301721 KIAA1255 protein 5.00 122679 AA811286 Hs. 192837 ESTs, Weakly similar to ALU5 HUMAN ALU S 14.40 122633 NM_001546 Hs. 34853 inhibitor of DNA binding 4, dominant neg 122553 AA451884 Hs. 190121 ESTs 40.00 122544 AW973253 Hs. 292689 ESTs 15.40 122485 AA524547 Hs. 160318 FXYD domain-containing ion transport reg 1.81 122211 AA300900 Hs. 98849 ESTs, ModeratelysimilartoAF1615111H 12.10 122127 AW207175 Hs. 106771 ESTs 1.95 122011 AA431082 gb: zw78a10. s1 Soares_testis_NHT Homo sap 1.89 121992 AI860775 Hs. 98506 ESTs 3.60 121989 W56487 Hs. 193784 Homo sapiens mRNA ; cDNA DKFZp586K1922 (f 2.01 121835 AB033030 Hs. 300670 KIAA1204 protein 1.85 121726 AF241254 Hs. 178098 angiotensin I converting enzyme (peptidy 12.43 121690 AV660305 Hs. 110286 ESTs 1.82 121643 AA640987 Hs. 193767 ESTs 121633 AA417011 Hs. 98175 EST 14.00 121622 AA416931 Hs. 126065 ESTs 16.40 121497 M412031 Hs. 97901 EST 11.20 121351 AW206227 Hs. 287727 hypothetical protein FLJ23132 12.20 121314 W07343 Hs. 182538 phospholipid scramblase 4 1.83 121242 AA400857 Hs. 97509 ESTs 22.40 121059 AA393283 gb: zt74e03. rl Soares_tesüs_NHTHomosap 14.80 120934 AA226198 gb: nc26aO7. s1 NCI_CGAP_Pr1 Homo sapiens 21.20 120755 AA312934 Hs. 190745 Homo sapiens cDNA : FLJ21326 fis, clone 1. 79 120637 AA811804 gb : ob39a05. s1 NCI_CGAP_GCB1 Homo sapiens 20.00 120484 AA253170 Hs. 96473 EST 40.20 120336 N85785 Hs. 181165 eukaryotic translation elongation factor 6.60 120266 AI807264 Hs. 205442 ESTs, Weakly similar to T34036 hypotheti 16.80 120132 W57554 Hs. 125019 ESTs 4.73 120041 AA830882 Hs. 59368 ESTs 1. 75 119996 W88996 Hs. 59134 EST 7.20 119970 AA767718 Hs. 93581 hypothetical protein FLJ10512 11.20 119861 W78816 Hs. 49943 ESTs, Weakly similar to S65657 alpha-1 C3. 78 119824 W74536 Hs. 184 advanced glycosylation end product-speci 119740 AW021407 Hs.21068 hypothetical protein 20.20 119271 A1061118 Hs. 65328 Fancni anemia, complementation group F 15.20 119221 C14322 Hs. 250700 tryptase beta 1 119126 R45175 Hs. 117183 ESTs 12.60 119073 BE245360 Hs. 279477 ESTs 118928 AA312799 Hs. 283689 activator of CREM in testis 10, 00 118901 AW292577 Hs. 94445 ESTs 3.96 118661 AL137554 Hs. 49927 protein kinase NYD-SP15 9. 60 118607 At377444 Hs. 54245 ESTs, Weakly similar to S65824 reverse t 10.40 118449 AI813865 Hs. 164478 hypothetical protein FLJ21939 similar to 1.90 118416 N66028 Hs. 491, 05 FKBP-associated protein 16.20 118379 N64491 Hs. 48990 ESTs 4.00 118329 N63520 gb: yy62fO1. sl Soares-multipte-sclerosis-6. 60 118320 N63451 Hs. 141600 ESTS, Weekly similar to alternatively s 3.80 118253 AA497044 Hs. 20887 hypothetical protein FLJ10392 17. 60 118124 N56968 Hs. 46707 chromosome 21 open reading frame 37 14.00 118056 AB037746 Hs. 42768 hypothetical protein DKFZp761O0113 1. 86 118032 N52802 Hs. 47544 EST 5 00 117840 T26379 Hs. 48802 Homo sapiens clone 23632 mRNA sequence 4. 00 117404 N39725 Hs. 15220 zinc finger protein 106 1.90 117314 N32498 Hs. 42829 ESTs 14.20

117209 W03011 Hs. 306881 MSTP043 protein 117023 AW070211 Hs. 102415 HomosapiensmRNA ; cDNA DKFZp586N0121 (f 2.31 116814 H50834 gb: yp86a10. s1 Soares fetal liver spleen 20.20 116784 AB007979 Hs. 301281 Homo sapiens mRNA, chromosome 1 specific 3.51 116766 A1608657 Hs 95097 ESTs 16.20 116712 AW901618 Hs61935 HomosapiensmRNA ; cDNA DKFZp7611071 (fr 6.80 116707 H10344 Hs. 49050 ESTs, Weakly similar to A Chain A, Human 18.60 116351 AL133623 Hs. 82501 similar to mouse Xm1 / Dhm2 protein 19.40 116279 AW971248 Hs. 291289 ESTs, WeaklysimilartoALU1 HUMANALUS 116166 AL039940 Hs. 202949 KlM1102protein 2.13 116152 AL040521 Hs. 15220 zinc finger protein 106 1.75 116117 BE613410 Hs. 31575 SEC63, endoplasmic reticulum translocon 13.20 116107 AL133916 Hs. 172572 hypothetical protein FLJ20093 30.11 115965 AA001732 Hs. 173233 hypothetical protein FLJ10970 2.36 115955 AF263613 Hs. 44198 intracellularmembrane-associatedcaciu 1820 115844 AI373062 Hs. 332938 hypothetical protein MGC5370 18.57 115683 AF255910 Hs. 54650 junctional adhesion molecule 2 23.00 115673 AA406341 Hs. 269908 Homo sapiens cDNA FLJ11991 fis, clone HE 11.82 115672 Api889110 Hs. 73251 ESTs 10.60 115566 AI142336 Hs. 43977 Human DNA sequence from clone RP11-196N1 1.76 115313 AA808001 Hs. 184411 albumin 25. 20 115279 AW964897 Hs. 290825 ESTs 8.00 115230 AA278300 Hs. 124292 HomosapienscDNA : FLJ23123 fis, clone L 1.80 115110 AK001671 Hs. 11387 KIAA1453 protein 14.20 114999 BE246481 Hs. 87856 ESTs 19.20 114930 AA237022 Hs. 188717 ESTs 5.60 114922 AA235672 Hs. 87491 ESTs 3.60 114837 BE244930 Hs. 166895 ESTs 43.70 114769 AA149060 Hs. 296100 ESTs 11.00 114761 AA143781 Hs. 126280 hypothetical protein FLJ23393 14.00 114736 AI610347 Hs. 103812 ESTs, ModeratetysimilartoAW1_HUMANA 4.20 114596 AA310162 Hs. 169248 cytochrome c 10.71 114518 AW163267 Hs. 106469 suppressorofvar1 (S, cerevisiae) 3-like 20.40 114455 H37908 Hs. 271616 ESTs Weakly similar to ALU8_HUMAN ALU S 20.40 114452 AI369275 Hs.243010 Homo sapiens cDNA FLJ14445 fis, clone HE 17.20 114359 NM_016929 Hs. 283021 chloride intracellular channel 5 2.09 114357 R41677 Hs. 6107 Homo sapiens cDNA FLJ14839 fis, clone OV 12.40 114251 H15261 Hs. 21948 ESTs 2.00 114138 AW384793 Hs. 15740 Homo sapiens mRNA ; cDNA DKFZp434E033 (fr 11.40 114124 W57554 Hs. 125019 ESTs 6.04 113946 AW083883 Hs. 37896 Homo sapiens cDNA FLJ 13510 fis, clone PL 1.82 113695 T96965 Hs. 17948 ESTs, Weakly similar to ALUB_HUMAN !!!! 113606 NM_013343 Hs. 278951 NAG-7 protein 2. 15 113590 R49642 Hs. 142447 ESTs, Weakly similar to ALU1 HUMAN ALU S 3.60 113560 T91015 Hs. 268626 ESTs 32.00 113552 Aì654223 Hs. 16026 hypothetical protein FLJ23191 113540 AW152618 Hs. 16757 ESTs 113502 T89130 gb: ye12d01. s1 Stratagene lung (937210) H 8.35 113288 A1076838 Hs. 12967 ESTs 12.40 113252 NM_004469 Hs. 11392 c-fos induced growth factor (vascular en 4.27 113238 R45467 Hs. 189813 ESTs 113203 AA743563 Hs. 10305 ESTs 21. 20 113195 H83265 Hs. 8881 ESTs, Weakly similar to S41044 chromosom 1. 92 113089 T40707 Hs. 270862 ESTs 14.33 113076 AF033199 Hs. 8198 zinc finger protein 204 6. 00 113009 T23699 Hs. 7246 ESTs 9. 40 112937 A ! 694320 Hs. 6295 ESTs, Weakly similar to T17248 hypotheti 12.20 112891 T03927 Hs. 293147 ESTs, Moderately similar to A46010 X-li 10. 57 112794 R97018 gy:yq74b08.s1 Soares fetal liver spleen 26. 60 112691 R88708 Hs. 220647 ESTs 15.33 112602 AW004045 Hs. 203365 ESTs 15. 60 112366 AF035318 Hs. 12533 Homo sapiens clone 23705 mRNA sequence 15. 40 112210 R49645 Hs. 7004 ESTs 14.00 112064 AL049390 Hs. 22689 Homo sapiens mRNA; cDNA DKFZp586O1318 (f 13. 00 111998 R42379 Hs. 138283 ESTs 11. 00 111987 NM_015310 Hs. 6763 KIAA0942 protein 22. 40 111803 AA593731 Hs. 325823 ESTs, Moderately similar to ALU5_HUMAN A 1.77 111737 H04607 Hs. 9218 ESTs 1.86 111605 T91061 Hs. 194178 ESTs, Moderately similar to PC4259 ferri 23.00 111510 R07856 Hs. 16355 ESTs 11.02 111341 AL157484 Hs. 22483 Homo sapiens mRNA ; cDNA DKFZp762M127 (fr 1.88 111280 AA373527 Hs. 19385 CGI-58 protein 18.40 111247 AW058350 Hs. 16762 HomosapiensmRNA ; cDNA DKFZp564B2062 (f 111232 Api247763 Hs. 16928 ESTs 27.60 110942 R63503 Hs. 28419 ESTs 14.80 110924 AW058463 Hs. 12940 zinc-fingers and homeoboxes 1 24.71 110837 H03109 Hs. 108920 HT018 protein 2.18 110824 A1767183 Hs. 26942 ESTs 12.20 110776 AB032417 Hs. 19545 frizzled (Drosophila) homolog 4 1. 75 110576 H60869 Hs. 37889 ESTs 13.00 110369 AK000768 Hs. 107872 hypothetical protein FLJ20761 5.60 110099 R44557 Hs. 23748 ESTs 2.31 109984 Ai796320 Hs. 10299 Homo sapiens cDNA FLJ13545 fis, clone PL 109958 AA001266 Hs. 133521 ESTs 11.25 109893 AA884208 Hs. 30484 ESTs 2.68

109842 AW818436 Hs. 23590 solute carrier family 16 (monocarboxylic 23. 83 109837 H00656 Hs. 29792 ESTs, Weakly similar to I38022 hypotheti 3.91 109796 A1800515 Hs. 12024 ESTs 17.20 109688 R41900 Hs. 22245 ESTs 9.60 109648 H17800 Hs. 7154 ESTs 22. 80 109613 H47315 Hs. 27519 ESTs 109550 AW021488 Hs. 26981 ESTs 109523 AW193342 Hs. 24144 ESTs 1.89 109472 AK001989 Hs. 91165 hypothetical protein 6.00 109355 AA524525 Hs. 48297 DKFZP586C1620 protein 15. 00 109260 AW978515 Hs. 131915 KIAA0863 protein 25. 60 108781 AA128654 gb: zn98g07. s1 Stratagene fetal relina 93 14.20 108663 BE219231 Hs. 292653 ESTs, Weakly similar to T26845 hypotheti 11.00 108573 AA086005 gb: zì84cO4. slStratagenecoìon (937204) 26. 00 108480 AL133092 Hs. 68055 hypothetical protein DKFZp43410428 108382 NM006770 Hs. 67726 macrophage receptor with coliagenous str 1.83 108174 AA055632 Hs. 303070 ESTs 15.20 108138 AL049990 Hs. 51515 Homo sapiens mRNA ; cDNA DKFZp564G112 (fr 3.60 108087 AA045708 Hs. 40545 ESTs 15.44 108048 A1797341 Hs. 165195 Homo sapiens cDNA FLJ14237 fis, clone NT 11.40 108041 AW204712 Hs. 61957 ESTs 107997 AL049176 Hs. 82223 chordin-like 4.76 107994 AA036811 Hs. 48469 LIM domains containing 1 107922 BE153855 Hs. 61460 Ig superfamily receptor LNIR 14.20 107681 BE379594 Hs. 49136 ESTs, Moderately similar to ALU7_HUMAN A 51.80 107666 AA010611 Hs. 60418 EST 29. 20 107332 T87750 Hs. 183297 DKFZP566F2124 protein 10. 73 107292 BE166479 Hs. 4789 Homo sapiens serologically defined breas 32.00 107230 A1034467 Hs. 34650 ESTs 17.40 107168 W57578 Hs. 237955 RAB7, memberRASoncogenefamily 1043 107160 AA314490 Hs. 27669 KIAA1563 protein 11.40 107054 A1076459 Hs. 15978 KIAA1272 protein 107029 AF264750 Hs. 288971 myeloidllymphoid or mixed-lineage leukem 21.40 106999 H93281 Hs. 10710 hypothetical protein FLJ20417 35.80 106954 AF128847 Hs. 204038 indolethylamine N-methyltransferase 1.76 106870 AI983730 Hs. 26530 serum deprivation response (phosphatidyl 106865 AW192535 Hs. 19479 ESTs 13. 40 106844 AA485055 Hs. 158213 sperm associated antigen 6 7.13 106820 NM016831 Hs. 12592 period (Drosophila) homolog 3 7.00 106818 AK002135 Hs. 3542 hypothetical protein FLJ11273 13. 00 106797 AI768801 Hs. 169943 Homo sapiens cDNA FLJ13569 fis, clone PL 2.05 106773 AA478109 Hs. 188833 ESTs 106747 NM_007118 Hs. 171957 triple functional domain (PTPRF interact 12.60 106743 BE613328 Hs. 21938 hypothetical protein FLJ12492 10.60 106667 AW360847 Hs. 16578 ESTs 106605 AW772298 Hs. 21103 Homo sapiens mRNA ; cDNA DKFZp564B076 (fr 2.40 106567 AW450408 Hs. 86412 chromosome 9 open reading frame 5 1.78 106562 AL031846 Hs. 152151 plakophilin4 1.76 106536 AA329648 Hs. 23804 ESTs, Weakly similar to PN0099 son3 prot 2.19 106533 AL134708 Hs. 145998 ESTs 23.20 106507 AA259068 Hs. 267819 protein phosphatase 1, regulatory (inhib 15.20 106490 AA404265 Hs. 115537 putativedipeptidase 106474 BE383668 Hs. 42484 hypothetical protein FLJ10618 10.44 106211 AA428240 Hs. 126083 ESTs 29.80 105986 AB037722 Hs. 8707 KIAA1301 protein 3.70 105894 A1904740 Hs. 25691 receptor (calcitonin) activity modifying 1.94 105847 AW964490 Hs. 32241 ESTs, Weakly similar to S65657 alpha- G 1. 75 105803 AW747996 Hs. 160999 ESTs, Moderately similar to A56194 throm 2.47 105731 AA834664 Hs. 29131 nuclear receptor coactivator 2 10.71 105729 H46612 Hs. 293815 Homo sapiens HSPC285 mRNA, partial cds 105688 A) 299139 Hs. 17517 ESTs 23.40 105510 Z42047 Hs. 283978 Homo sapiens PRO2751 mRNA, complete cds 37. 20 105101 H63202 Hs. 38163 ESTs 8.30 104989 R65998 Hs. 285243 hypothetical protein FLJ22029 8.09 104986 AW088826 Hs. 117176 poly (A)-binding protein, nuclear 1 1.92 104969 AI670947 Hs. 78406 phosphatidylinositol-4-phosphate 5-kinas 5. 40 104903 AI436323 Hs. 31141 Homo sapiens mRNA for KIAA1568 protein, 7.60 104896 AW015318 Hs. 23165 ESTs 13.80 104865 T79340 Hs. 22575 Homo sapiens cDNA : FLJ21042 fis, clone C 104825 M035613 Hs. 141883 ESTs 1.87 104781 AA099904 Hs. 21610 DKFZP434B203 protein 1.93 104776 AA026349 gb: zj99f01. s1 Soares_pregnant_uterus_NbH 10.20 104691 U29690 Hs. 37744 Homo sapiens beta-1 adrenergic receptor 5.69 104667 A1239923 Hs. 30098 ESTs 3.82 104404 H58762 gb: EST00057 HE6W Homo sapiens cDNA clone 4.20 104392 AA076049 Hs. 274415 Homo sapiens cDNA FLJ10229 fis, clone HE 27. 20 104212 AB002298 Hs. 173035 KIAA0300 protein 1.91 104074 AL162039 Hs. 31422 Homo sapiens mRNA; cDNA DKFZp434M229 (fr 11.20 103749 AL135301 Hs. 8768 hypothetical protein FLJ10849 10.86 103645 AW246253 Hs. 7043 succinate-CoA ligase, GDP-forming, alpha 12.00 103554 AI878826 Hs. 323469 caveolin 1, caveolae protein, 22kD 1.80 103541 AI815601 Hs. 79197 CD83 antigen (activated B lymphocytes, i 103496 Y09267 Hs. 132821 flavin containing monooxygenase 2 103428 BE383507 Hs. 78921 A kinase (PRKA) anchor protein 1 11.20 103353 X89399 Hs. 119274 RAS p21 protein activator (GTPase activa 19.80

103295 X81479 Hs. 2375 egf-like module containing, mucin-like, 3.60 103280 U84722 Hs. 76206 cadherin 5, type 2, VE-cadherin (vascula 103100 NM_005574 Hs. 184585 LIM domain only 2 (rhombotin-iiket) 1.76 103025 NM002837 Hs. 123641 protein tyrosine phosphatase, receptor t 2.15 102698 M18667 Hs. 1867 progastricsin (pepsinogen C) 102659 BE245169 Hs. 211610 CUG triplet repeat, RNA-binding protein 11.00 102580 U60808 Hs. 152981 CDP-diacylglycerol synthase (phosphatida 25.40 102417 AA034127 Hs. 153487 signal transducing adaptor molecule (SH3 14.00 102363 NM_003734 Hs. 198241 amine oxidase, copper containing 3 (vasc 102302 AA306342 Hs. 69171 protein kinase C-like 2 10. 86 102283 AW161552 Hs. 83381 guanine nucleotide binding protein 11 102188 U20350 Hs. 78913 chemokine (C-X3-C) receptor 1 7. 40 102151 T27013 Hs. 3132 steroidogenic acute regulatory protein 16.40 101957 L28824 Hs. 74101 spleen tyrosine kinase 15.40 101842 M93221 Hs. 75182 mannose receptor, C type 1 101771 NM_002432 Hs. 153837 myeloid cell nuclear differenliaGon ant 101764 A1198550 Hs. 81256 S100 calcium-binding protein A4 (calcium 1.78 101716 AF050658 Hs. 2563 tachykinin, precursor 1 (substance K, su 18.80 101678 M62505 Hs. 2161 complement component 5 receptor 1 (C5a) 2.22 101447 M21305 gb: Human alpha satellite and satellite 3 504. 80 101383 NM_000132 Hs. 79345 coagulationfactorVlll, procoagulantco 31.00 101346 A1738616 Hs. 77348 hydroxyprostaglandin dehydrogenase 15- (N 1.75 101345 NM_005795 Hs. 152175 calcitonin receptor-like 101336 NM_006732 Hs. 75678 FBJ murine osteosarcoma viral oncogene h 2.24 101330 L43821 Hs. 80261 enhancer of filamentation 1 (cas-like to 101277 BE297626 Hs. 296049 microfibrillar-associated protein 4 101262 L35854 gb: Human dystrophin (dp140) mRNA, 5'end 19.00 101168 NM_005308 Hs. 211569 G protein-coupled receptor kinase 5 2. 01 101102 NM_003243 Hs. 79059 transforming growth factor, beta recepto 101088 X70697 Hs. 553 solutecarrierfamily6 (neurotransmitte 7.52 101066 AW970254 Hs. 889 Charot-Leyden crystal protein 19.38 100971 BE379727 Hs. 83213 fatty acid binding protein 4, adipocyte 1.91 100893 BE245294 Hs. 180789 S164 protein 15.40 100770 W25797. comp Hs. 177486 amyloid beta (A4) precursor protein (pro 11.20 100716 X89887 Hs. 172350 HIR (histone cell cycle regulation defec 14.80 100555 M69181 gb: Human nonmuscle myosin heavy chain-B 33. 00 100425 NM_014747 Hs. 78748 KIAA0237 gene product 16.20 100408 D86640 Hs. 56045 src homology three (SH3) and cystein ri 4.00 100382 D83407 Hs. 156007 Down syndrome critical region gene 1-lik 4.24 100351 D64158 6.20 100299 D49493 Hs. 2171 growth differentiation factor 10 21. 20 100134 AA305746 Hs. 49 macrophage scavenger receptor 1 100108 U09577 Hs. 76873 hyaluronoglucosaminidase 2 1. 79 100095 Z97171 Hs. 78454 myocilin, trabecular meshwork inducible 5.40 100066 11.29 TABLE 3B shows the accession numbers for those primekeys lacking unigenelD's for Table 3A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession* column.

Pkey: Unique Eos probeset identifier number CAT number : Gene cluster number Accession: Genbank accession numbers Pkey CAT number Accessions 123619 37168111 AA602964 AA609200 126433 127143_1 AA325606 AA099517 N89423 125831 1522905_1 H04043 D60988 D60337 126816 122973_1 AA248234 AA090985 126852 136135_1 AA399961 AA128347 121059 273450_1 AA393283 AA398628 <BR> 120637 20088551 AA811804 AA809404 AA286907 AW977624<BR> <BR> <BR> <BR> <BR> 122011 7617-2 AA431082 120934 177521J AA226198AA226513AA383773 123802 genbank_AA620448 AA620448 116814 genbank_H50834 H50834 118329 genbankN63520 N63520 104404 H58762at H58762 104776 genbankAA026349 AA026349 113502 genbank_T89130T89130 101262 entrez_L35854 L35854 108573 genbank_AA086005 AA086005 101447 entrez_M21305 M21305 124357 genbank_N22401 N22401 108781 genbanLAA128654 AA128654 112794 genbank_R97018 R97018 100351 entrezD64158 D64158 100555 tigr_HT2245 M69181 M81105 U51039

Table 4A shows 202 genes up-regulated in samples from patients treated with chemotherapy or radiotherapy. These genes were selected from 59680 probesets on the Eos/Affymetrix Hu03 Genechip array. Gene expression data for each probeset obtained from this analysis was expressed as average intensity (Al) a normalized value reflecting the relative level of mRNA expression.

Pkey: Unique Eos probeset identifier number ExAccn : ExemplarAccession number, Genbank accession number UnigeneiD : Unigene number Unigene Title : Unigene gene title R1 : average of Al for samples from patients treated with chemotherapy or radiotherapy divided by the average of Al for normal lung samples.

Pkey ExAccn UnigenelD Unigene Title R1 100113 NM_001269 Hs. 84746 chromosome condensation 1 27. 20 100187 D17793 Hs. 78183 aldo-keto reductase family 1, member C3 20.60 100210 D26361 Hs. 3104 KIAA0042 gene product-20. 40 100225 D28539 Hs. 167185 glutamate receptor, metabotropic 5 20.60 100269 NM 001949 Hs 1189 E2Ftranscriptionfactor3 2940 100438 AA013051 Hs. 91417 topoisomerase (DNA) 11 binding protein 23. 50 100877 X80821 Hs. 27973 KIAA0874 protein 35.56 100893 BE245294 Hs. 180789 S164 protein 43.40 101273 Z11933 Hs. 182505 POUdomain, class3 transcriptionfacto 2180 101447 M21305 gb: Human alpha satellite and satellite 3 193.60 101649 AW959908 Hs. 1690 heparin-binding growth factor binding pr 38. 40 101724 L11690 Hs. 620 bullous pemphigoid antigen 1 (230/240kD) 198.80 101748 NM_001944 Hs. 1925 desmoglein 3 (pemphigus vulgaris antigen 78.60 101809 M86849 Hs. 323733 gap junction protein, beta 2,26kD (conn 162. 20 101879 AA176374 Hs. 243886 nuclear autoantigenic sperm protein (his 50. 00 101915 AF207881 Hs155185 cytosolicovariancarcinomaanUgen1 2600 101973 U41514 Hs. 80120 UDP-N-acetyl-alpha-D-galactosamine : polyp 37.20 102025 U04045 Hs. 78934 mutS (E. coli) homolog 2 (colon cancer, 102031 U04898 Hs. 2156 RAR-related orphan receptorA 32.00 102052 NM_002202 Hs 505 ISL1 transcription factor, LIM/homeodoma 51. 20 102391 AA296874 Hs. 77494 deoxyguanosine kinase 13. 90 102420 U44060 Hs. 14427 Homo sapiens cDNA : FLJ21800 fis, clone H 28.80 102610 U65011 Hs. 30743 preferentially expressed antigen in meta 110.60 102829 NM_006183 Hs. 80962 neurotensin 116, 80 103000 NM_001975 Hs. 146580 enolase 2, (gamma, neuron) 2.30 103036 M13509 Hs. 83169 matrix metalloproteinase 1 (interstitial 181.40 103507 AJ000512 Hs. 296323 serum/glucocorticoid regulated kinase 49. 20 103587 BE270266 Hs. 82128 5T4 oncofetal trophoblast glycoprotein 86.60 104660 BE298665 Hs. 14846 Homo sapiens mRNA ; cDNA DKFZp564D016 (fr 42. 60 104896 AW015318 Hs. 23165 ESTs 29. 40 105038 AW503733 Hs. 9414 KIAA1488 protein 21.50 105298 BE387790 Hs. 26369 hypothetical protein FLJ20287 32.80 105510 Z42047 Hs. 283978 Homo sapiens PR02751 mRNA, complete cds 20.20 105667 AA767526 Hs. 22030 paired box gene 5 (B-cell lineage specif 28.40 106073 AL157441 Hs. 17834 downstream neighbor of SON 25. 40 106205 AW965058 Hs. 1 11583 ESTS, Weakly similar to 138022 hypothefi 32. 00 106516 AL137311 Hs. 234074 HomosapiensmRNA ; cDNA DKFZp761G02121 (40. 60 106533 AL134708 Hs. 145998 ESTs 59.80 106575 AW970602 Hs. 105421 ESTs 43.40 106654 AW075485 Hs. 286049 phosphoserine aminotransferase 50 80 106851 Api458623 gb: tk04g09. x1 NCI_CGAP_Lu24 Homo sapiens 53.40 106995 AB023139 Hs. 37892 KIAA0922 protein 20.88 107332 T87750 Hs. 183297 DKFZP566F2124 protein 23.60 107532 AA443473 Hs. 173684 Homo sapiens mRNA ; cDNA DKFZp762G207 (fr 57.20 107922 BE153855 Hs. 61460 Ig superfamily receptor LNIR 49. 00 108609 BE409857 Hs. 69499 hypothetical protein 19. 67 108780 AU076442 Hs. 117938 collagen, type XVII, alpha 1 48.17 109166 AA219691 Hs. 73625 RAB6 interacting, kinesin-like (rabkines 59.20 109260 AW978515 Hs. 131915 KIAA0863 protein 28.60 109280 AK001355 Hs. 279610 hypothetical protein FLJ10493 22.80 109292 AW975746 Hs. 188662 KIAA1702 protein 109384 AA219172 Hs. 86849 ESTs 21.00 109415 U80736 Hs. 110826 binucìeotiderepeatcontaining9 31.60 109445 AA232103 Hs. 189915 ESTs 24.20 109502 AW967069 Hs. 211556 hypothetical protein MGC5487 21. 40 109633 AW003785 Hs. 170267 ESTs 20. 40 109786 AI989482 Hs. 146286 kinesin family member 13A 19.60 109958 AA001266 Hs. 133521 ESTs 24.00 110920 N47224 Hs. 20521 HMT1 (hnRNPmethyltransferase, S. cerevi 28. 40 110924 AW058463 Hs. 12940 zinc-fingers and homeoboxes 1 36. 00 111084 H44186 Hs. 15456 PDZ domain containing 1 61. 20 111132 AB037807 Hs. 83293 hypothetical protein 24.60 111229 AW389845 Hs. 110855 ESTs 27.20 111337 AA837396 Hs. 263925 LIS1-interacting protein NUDE1, rat homo 48.00 111987 NM_015310 Hs. 6763 KIAA0942 protein 37.80 112046 AA383343 Hs. 22116 CDC14 (cell division cycle 14, S. cerevi 26. 80 112268 W39609 Hs. 22003 soiutecarrierfamily6 (neurotransmiüe 6380 112685 R87650 Hs. 33439 ESTs, Weakly similar to ALU1 HUMAN ALU 26.40 112871 AL110216 Hs. 12285 ESTs, Weakly similar to I55214 salivary 47.64 112897 AW206453 Hs. 3782 ESTs 22.00 112973 AB033023 Hs.318127 hypothetical protein FLJ10201 65.00 112992 AL157425 Hs. 133315 Homo sapiens mRNA ; cDNA DKFZp761J1324 (f 42. 00 113073 N39342 Hs. 103042 microtubule-associated protein 1B 55.40

113494 T91451 Hs. 86538 ESTs 22. 80 113560 T91015 Hs. 268626 ESTs 22.80 113849 AA457211 Hs. 8858 bromodomain adjacent to zinc finger doma 51.80 113950 Aì267652 Hs. 30504 Homo sapiens mRNA ; cDNA DKFZp434E082 (fr 28.20 114339 AA782845 Hs. 22790 ESTs 20.20 114365 H42169 Hs. 18653 hypothetical protein FLJ14627 21.00 114455 H37908 Hs. 271616 ESTs, Weakly similar to ALUB HUMAN ALU S 25.80 114518 AW163267 Hs. 106469 suppressor of var1 (S. cerevisiae) 3-like 23.60 114824 AA960961 Hs. 305953 zincfingerprotein83 (HPF1) 27.20 114837 BE244930 Hs. 166895 ESTs 30.20 114974 AW966931 Hs. 179662 nucleosome assembly protein 1-like 1 20. 80 115075 AA814043 Hs. 88045 ESTs 30.60 115084 BE383668 Hs. 42484 hypothetical protein FLJ10618 28.86 115291 BE545072 Hs. 122579 hypothetical protein FLJ10461 38.00 115313 AA808001 Hs. 184411 albumin 22.60 115697 D31382 Hs. 63325 transmembrane protease, sedne 4 173.60 115909 AW872527 Hs. 59761 ESTsWeaklysimilartoDAP1_HUMANDEATH 27.77 116090 AI591147 Hs. 61232 ESTs 20.80 116107 AL133916 Hs. 172572 hypothetical protein FLJ20093 164.20 116399 AA889120 Hs. 110637 homeo box A10 38.00 117099 H93699 gb: yv16a11. s1 Soaresfetalliverspleen 21.60 117881 AF161470 Hs. 260622 butyrate-induced transcript1 49.40 118091 AW005054 Hs. 47883 ESTs, Weakly similar to KCC1_HUMAN CALCI 22.40 118138 AA374756 Hs.93560 Homo sapiens mRNA for KIAA1771 protein, 22.00 118720 N73515 gb: za49d07. s1 Soares fetal liver spleen 20.00 118873 Api824009 Hs. 44577 ESTs 19.40 119126 R45175 Hs. 117183 ESTs 111.20 119717 AA918317 Hs. 57987 B-cel, CLL/iymphomallB (zincfingerpro 33.00 119940 AL050097 Hs. 272531 DKFZP586B0319 protein 31.00 120266 AI807264 Hs. 205442 ESTs, Weakly similar to T34036 hypotheti 20.20 120515 AA258356 gb: zr59c10. s1 Soares_NhHMPu_S1 Homo sapi 25.00 120859 AA826434 Hs. 1619 achaete-scute complex (Drosophila) homol 95.40 120983 AA398209 Hs. 97587 EST 105.20 121054 AW976570 Hs. 97387 ESTs 38.80 121369 AW450737 Hs. 128791 CGI-09 protein 41.60 122335 AA443258 Hs. 241551 chloride channel, calcium activated, fam 30.80 122612 AA974832 Hs. 128708 ESTs 19. 60 123130 AA487200 gb: ab19f02. slStratagenelung (937210) H 33.20 123440 Ai733692 Hs. 112488 ESTs 23.17 123596 AA421130 Hs. 112640 EST 23.00 123619 AA602964 gb: no97c02. s1 NCI_CGAP_Pr2 Homo sapiens 28.80 124006 AI147155 Hs. 270016 ESTs 77.60 124169 BE079334 Hs. 271630 ESTs 22.20 124281 AI333756 Hs. 111801 arsenate resistance protein ARS2 42.20 124472 N52517 Hs. 102670 EST 32.60 124617 AW628168 Hs. 152684 ESTs 21. 80 124631 NM_014053 Hs. 270594 FLVCR protein 30.40 124839 R55784 Hs. 140942 ESTs 21. 20 125186 AA610620 Hs. 181244 major histocompatibility complex, class 42.80 125321 T86652 Hs.178294 ESTs 27. 00 125535 NM013243 Hs. 22215 secretogranin III 23.80 125646 AA628962 Hs. 75209 protein kinase (cAMP-dependent, catalyti 23.20 125684 AW589427 Hs. 158849 HomosapienscDNA : FLJ21663 fis, clone C 21.20 125724 AL360190 Hs.295978 Homo sapiens mRNA full length insert cDN 48.80 125847 AW161885 Hs. 249034" ESTs 31.00 125934 AA193325 Hs. 32646 hypothetical protein FLJ21901 21.20 126077 M78772 Hs. 210836 ESTs 49.80 126299 AW979155 Hs. 298275 amino acid transporter 2 21.80 126395 AI468004 Hs.278956 hypothetical protein FLJ12929 71. 00 126433 AA325606 gb: EST28707 Cerebellum II Homo sapiens c 23.20 126509 R47400 Hs. 23850 ESTs 23. 80 126538 AB030656 Hs. 17377 coronin, actin-binding protein, 1C 23.10 126666 AA648886 Hs. 151999 ESTs 36.00 126812 AB037860 Hs. 173933 nuclearfactor lA 20.80 126872 AW450979 gb: Ul-H-BI3-ala-a-12-0-Ul. s1 NCLCGAP_Su 46.29 127046 AA321948 Hs. 293968 ESTs 22.80 127431 AW771958 Hs. 175437 ESTs, Moderately similar to PC4259 ferri 30.00 127489 AA650250 Hs. 272076 ESTs 20.80 127521 AW297206 Hs. 164018 ESTs 25.20 127742 AW293496 Hs. 180138 ESTs 28.00 127925 AA805151 Hs. 3628 mitogen-activated protein kinase kinase 21.20 127930 AA809672 Hs. 123304 ESTs 20. 54 127968 AA830201 Hs. 124347 ESTs 28.20 127987 AI022103 Hs. 124511 ESTs 19.60 128116 H07103 Hs. 286014 Homo sapiens, clone IMAGE : 3867243, mRNA 20.40 128609 NM_003616 Hs. 102456 survival of motor neuron protein interac 34. 40 128777 Api878918 Hs. 10526 cysteine and glycine-rich protein 2 53.80 128949 AA009647 Hs. 8850 a disintegdn and metalloproteinase doma 23. 00 129168 AI132988 Hs. 109052 chromosome 14 open reading frame 2 37.60 129404 A1267700 Hs. 317584 ESTs 28.60 129527 AA769221 Hs. 270847 delta-tubulin 40.80 129574 AA026815 Hs. 11463 UMP-CMP kinase 31.20 129598 N30436 Hs. 11556 Homo sapiens cDNA FLJ12566 fis, clone NT 29.60 129785 H19006 Hs. 184780 ESTs 72.20 129970 AV655806 Hs. 296198 chromosome 12 open reading frame 4 22. 20

130149 AW067805 Hs. 172665 methylenetetrahydrofolate dehydrogenase 29.60 130199 Z48579 Hs. 172028 a disintegrin and metalloproteinase doma 27. 60 130441 U63630 Hs. 155637 protein kinase, DNA-activated, catalytic 28.36 130466 W19744 Hs. 180059 Homo sapiens cDNA FW20653 fis, ctone KA 20.20 130482 AW409701 Hs. 1578 baculoviral IAP repeat-containing 5 (sur 22.40 130617 M90516 Hs. 1674 glutamine-fructose-6-phosphate transamin 19.60 130703 R77776 Hs. 18103 ESTs 19. 40 130732 AW890487 Hs. 63984 cadherin 13, H-cadherin (heart) 21.40 130867 NM_001072 Hs. 284239 UDP glycosyltransferase 1 family, polype 110.00 131028 AI879165 Hs. 2227 CCAAT/enhancer binding protein (C/EBP), 25.20 131086 AL035461 Hs. 2281 chromogranin B (secretogranin 1) 40.60 131284 NM001429 Hs. 25272 ElAbindingproteinp300 24.60 131775 AB014548 Hs. 31921 KIAA0648 protein 21.00 131860 BE383676 Hs. 334 Rho guanine nucleotide exchange factor (33. 40 131945 NM_002916 Hs. 35120 replication factor C (activator 1) 4 (37 60.80 132040 NM_001196 Hs. 315689 HomosapienscDNA : FLJ22373 fis, clone H 20.40 132084 NM002267 Hs. 3886 karyopherinaipha3 (importinalpha4) 29.40 132389 AA310393 Hs. 190044 ESTs 32.40 132437 AA152106 Hs. 4859 cyclin L ania-6a 27.40 132550 AW969253 Hs. 170195 bone morphogenetic protein 7 (osteogenic 75.60 132617 AF037335 Hs. 5338 carbonic anhydrase XII 31.36 132632 AU076916 Hs. 5398 guanine monphosphate synthetase 32.40 132672 W27721 Hs. 54697 Cdc42 guanine exchange factor (GEF) 9 23.40 132742 AA025480 Hs. 292812 ESTs, Weakly similar to T33468 hypotheti 61. 20 132771 Y10275 Hs. 56407 phosphoserine phosphatase 22.33 133070 U92649 Hs. 64311 a disintegrin and metalloproteinase doma 23. 50 133153 AF070592 Hs. 66170 HSKM-B protein 30. 00 133181 X91662 Hs. 66744 twist (Drosophila) homolog (acrocephalos 23. 80 133282 AA449015 Hs. 286145 SRB7 (suppressor of RNA polymerase B, ye 51.60 133350 AI499220 Hs. 71573 hypothetical protein FLJ10074 33.00 133592 AV652066 Hs. 75113 general transcription factor IIIA 82.00 133658 AA319146 Hs. 75426 secretogranin # (chromogranin C) 133865 AB011155 Hs. 170290 discs, large (Drosophiia) homolog5 69.33 134032 NM_005025 Hs. 78589 serine (orcysteine) proteinaseinhibito 33.20 134125 NM014781 Hs. 50421 KIAA0203 gene product 31.60 134158 U15174 Hs. 79428 BCL2/adenovirusE1B19kD-interacCngpro 30.60 134321 BE538082 Hs. 8172 ESTs, Moderately similar to A46010 X-lin 23.40 134367 AA339449 Hs. 82285 phosphoribosylglycinamide formyltransfer 49.20 134570 U66615 Hs. 172280 SWIISNF related, matrix associated, acti 20.20 134753 NM_006482 Hs. 173135 dual-specificity tyrosine- (Y)-phosphoryl 20.80 135002 AA448542 Hs. 251677 G antigen 7B 37.60 135029 H58818 Hs. 187579 hydroxysteroid (17-beta) dehydrogenase 53.40 135047 AL134197 Hs. 93597 cyclin-dependent kinase 5, regulatory su 31.60 135345 X53655 Hs. 99171 neurotrophin 3 28.80 TABLE 4B shows the accession numbers for those primekeys lacking unigenelD's for Table 4A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession"column.

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT number Accessions 123619 371681 J AA602964AA609200 126433 127143_1 AA325606 AA099517 N89423 126872 142696_1 AW450979 AA136653 AA136656 AW419381 AA984358 AA492073 BE168945 AA809054 AW238038 BE011212 BE011359 BE011367 BE011368 BE011362 BE011215 BE011365 BE011363 106851 3229471 A1458623AA639708AA485409R22065AA485570 118720 genbankN73515 N73515 120515 genbankAA258356 AA258356 117099 321871 1 H93699 H97976 H80036 101447 entrezM21305 M21305 123130 genbank_M487200 AA487200

Table 5A shows 680 genes up-regulated in squamous cell carcinoma or adenocarcinoma lung tumors relative to normal lung and chronically diseased lung. These genes wen selected from 59680 probesets on the Eos/Affymetrix Hu03 Genechip array. Gene expression data for each probeset obtained from this analysis was expressed as average intensity (AI), a normalized value reflecting the relative level of mRNA expression.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigeneID : Unigene number Unigene Title : Unigene gene title R1 : 70th percentile of AI for squamous cell carcinoma and adenocarcinoma lung tumor samples divided by the 90th percentile of AI for normal and chronically diseased lung samples.

R2: 80th percentile of Al adenocarcinoma lung tumor samples divided by the 90th percentile of Al for normal and chronicaly diseased lung samples.

R3: 80th percentile of Al squamous cell carcinoma lung tumor samples divided by the 90th percentile of Al for normal and chronically diseased lung samples.

R4: 80th percentile of Al adenocarcinoma lung tumor samples divided by the 80th percentile of AI for squamous cell carcinoma lung tumor samples.

R5: 70th percentile of Al for squamous cell carcinoma and adenocarcinoma lung tumor samples minus the 15th percentile of Al for all normal lung, chronically diseased lung and tumor samples divided by 90th percentile of Al for normai and chronically diseased lung samples minus the 15th percentile of Al for all normal lung, chronically diseased lung and tumor samples Pkey ExAccn UnigenelD Unigene Title R1 R2 R3 R4 R5 100035 AFFX control: GAPDH 6.76 100036 AFFX control : GAPDH 5.77 100037 AFFX control : GAPDH 5.75 100071 A28102 Human GABAa receptor alpha-3 subunit 8.00 100114 X02308 Hs. 82962 thymidylate synthetase 5.71 100154 H60720 Hs. 81892 KIAA0101 gene product 3.84 100187 D17793 Hs. 78183 alto-koto reductase family 1, member C3 3.33 100188 AW247090 Hs. 57101 minichromosome maintenance deficient (S. 4.52 100202 BE294407 Hs. 99910 phosphofructokinase, platelet 5.49 100216 AA489908 Hs. 1390 proteasome (prosome, macropain) subunit, 5.67 100269 NM001949 Hs. 1189 E2F transcription factor 3 2.55 100287 AU076657 Hs. 1600 chaperonin containing TCP1 subunit 5 (e 5.66 100297 AU077258 Hs. 182429 protein disulfide isomerase-related prot 3.81 100330 AW410976 Hs. 77152 minichromosome maintenance deficient (S, 4.50 100335 AW247529 Hs. 6793 piatetet-activating factor acetylhydrola 5.07 100360 W70171 Hs. 75939 urdine monophosphate kinase 4.82 100372 NnL014791 Hs. 184339 KIAA0175 gene product 3.79 100474 NM_000699 Hs. 300280 amylase, alpha 2A; pancreatic 15.65 100486 T19006 Hs. 10842 RAN, member RAS oncogene family 5.49 100491 D56165 Hs. 275163 non-metastatic cells 2, protein (NM23B) 4. 17 100516 D90278 Hs. 11 carcinoembryonicantgen-reiatedceiiad 7.20 100522 X51501 Hs. 99949 prolactin-induced protein 14.20 100559 NM_000094 Hs. 1640 collagen, type Vil, alpha 1 (epidermolys 3.10 100576 X00356 Hs. 37058 calcitoninlcalcitonin-related polypeptid 9.30 100629 AA015693 Hs. 21291 mitogen-activated protien kinase kinase 20. 60 100661 BE623001 Hs. 132748 Homo sapiens ribosomal protein L39 mRNA, 3. 85 100677 AA353686 Hs. 57813 zinc ribbon domain containing, 1 8.60 100696 D14887 Hs. 121686 general transcription factor IIA, 1 (37k 10.00 100709 N26539 Hs. 100469 myeloid/lymphoid or mixed-lineage leukem 24. 80 100761 BE208491 Hs. 295112 KIAA061 gene product 7.60 100830 AC004770 Hs. 4756 flap structure-specific endonuclease 1 7.99 100867 U14622 gb: Human transketolase-like protein gene 10. 20 100902 M16029 Hs. 287270 ret proto-oncogene (multiple endocrine n 8.00 100906 AU076916 Hs. 5398 guanine monphosphate synthetase 5.16 100960 J00124 Hs. 117729 keratin 14 (epidermolysis bullosa simple 2. 57 101045 J05614 gb: Human proliferating cell nuclear anti 4.69 101061 Nom000175 Hs. 180532 glucose phosphate isomerase 4.19 101071 L02840 Hs. 84244 potassium voltage-gated channel, Shab-re 12.91 101124 L10343 Hs. 112341 protease inhibitor 3, skin-derived (SKAL 3.12 101175 U82671 Hs. 36980 melanoma antigen, family A, 2 3.50 101181 BE262621 Hs. 73798 macrophage migration inhibitory factor (5. 69 101204 L24203 Hs. 82237 ataxia-telangiectasia group D-associated 4.08 101210 L29301 Hs. 2353 opioid receptor, mu 1 6. 40 101216 AA284166 Hs. 84113 cyclin-dependent kinase inhibitor 3 (CDK 2.53 101228 AA333387 Hs. 82916 chaperonin containing TCP1, subunit 6A ( 7. 90 101233 AL135173 Hs. 878 sorbitol dehydrogenase 4.45 101273 Z11933 Hs, 182505 POU domain, class 3, transcription facto 8. 50 101342 U52112 Hs. 182018 interleukin-1 receptor-associated kinase 4.17 101346 AI738616 Hs. 77348 hydroxyprostaglandin dehydrogenase 15- (N 21.89 101369 NM_000892 Hs. 1901 kallikrein B, plasma (Fletcher factor) 1 12.80 101396 BE267931 Hs. 78996 proliferating cell nuclear antigen 3.24 101431 BE185289 Hs. 1076 small proline-rich protein 1B (cornifin) 7. 90 101448 NM_000424 H. 195850 keratin 5 (epidermolysis bullosa simplex 8.31 101462 AL035668 Hs. 73853 bone morphogenetic protein 2 38. 80 101466 BE262660 Hs. 170197 glutamic-oxaloacetic transaminase 2, mit 4.01 101484 AA053486 Hs. 20315 interferon-induced protein with tetratri 12.00 101502 M26958 gb: Human parathyroid hormone-related pro 10.50 101505 AA307680 Hs. 75692 asparagine synthetase 4.46 101526 NM_002197 Hs. 154721 aconitase 1, soluble 4.02 101535 X57152 Hs. 99853 fibrillarin 4.65 101577 M34353 Hs. 1041 v-ros avian UR2 sarcoma virus oncogene h 9.09 101649 AW959908 Hs. 1690 heparin-bindinggrowthfactorbindingpr 54.00 101663 NM003528 Hs. 2178 H2B histone family, member Q 5. 59 101664 AA436989 Hs. 121017 H2A histone family, member A 7. 00 101669 L24498 Hs. 80409 growth arrest and DNA-damage-inducible, 7.60

101695 M69136 Hs. 135626 chymase 1, mast cell 4. 79 101724 L11690 Hs. 620 bullous pemphigoid antigen 1 (230/240kD) 15.21 101748 NM_001944 Hs. 1925 desmoglein 3 (pemphigus vulgaris antigen 55.50 101759 M80244 Hs. 184601 solute carrier family 7 (catonic amino 4.10 101771 NM002432 Hs. 153837 myelold cell nuclear differenfiauon ant 18.57 101804 M86699 Hs. 169840 TTK protein kinase 4.50 101809 M86849 Hs. 323733 gap junction protein, beta 2, 26kD (conn 140.00 101833 AU076442 Hs. 117938 collagen, type XVII, alpha 1 2.56 101842 M93221 Hs. 75182 mannose receptor, C type 1 12.80 101851 BE260964 Hs. 82045 midkine (neurite growth-promoting factor 5.88 102002 NM_002484 Hs. 81469 nucleotide binding protein 1 (E. coli Min 7.80 102039 AL134223 Hs. 306098 aido-ketoreductase family 1, member C1 4.35 102072 U09410 Hs. 78743 zinc finger protein 131 (clone pHZ-10) 7.40 102083 T35901 Hs. 75117 interleukin enhancer binding'factor 2,4 5.12 102111 L36196 Hs. 81884 sulfotransferase family, ctosolic, 2A, 12.00 102123 NM_001809 Hs. 1594 centromere protein A (17kD) 6.20 102154 U17760 Hs. 75517 laminin, beta3 (nicein (125kD), kalinin 2.62 102193 AL036335 Hs. 313 secreted phosphoprotein 1 fosteopontin, 5.85 102217 AA829978 Hs. 301613 JTV1 gene 6.18 102224 NM_002810 Hs. 148495 proteasome (prosome, macropain) 26S subu 4.49 102234 AW163390 Hs. 278554 heterochromatin-likeprotein 1 5.80 102251 NM_004398 Hs. 41706 DEAD/H (Asp-G) u-A) a-Asp/His) boxpotypep 4.50 102305 AL043202 Hs. 90073 chromosome segregation 1 (yeast homolog) 5.15 102330 BE298063 Hs. 77254 chromobox homolog 1 (Drosophila HP1 beta 4.17 102340 U37055 Hs. 278657 macrophage stimulating 1 (hepatocyte go 9.33 102348 U37519 Hs. 87539 aldehyde dehydrogenase 3 family, member 8. 87 102368 U39817 Hs. 36820 Bloom syndrome 15.91 102394 NM_003816 Hs. 2442 a disintegrin and metalloproteinase doma 19. 20 102404 NM_005429 Hs. 79141 vascular endothelial growth factor C 14. 00 102537 U57094 Hs. 50477 RAB27A, member RAS oncogene family 12.00 102581 AU077228 Hs. 77256 enhancer of zeste (Drosophila) homolog 2 4.57 102605 AI435128 Hs. 181369 ubiquitin fusion degradation 1-like 3.98 102610 U65011 Hs. 30743 preferentially expressed antigen in mela 77.50 102623 AW249285 Hs. 37110 melanoma antigen, family A, 9 12.50 102642 AA205847 Hs. 23016 G protein-coupled receptor 22.00 102654 AV649989 Hs. 24385 Human hbc647 mRNA sequence 12.00 102659 BE245169 Hs. 211610 CUG triplet repeat, RNA-binding protein 12.80 102669 U71207 Hs. 29279 eyes absent (Drosophila) homolog 2 6. 50 102672 U72066 Hs. 29287 retinoblastoma-binding protein 8 8.50 102687 NM_007019 Hs. 93002 ubiquitin carrier protein E2-C 9.24 102696 BE540274 Hs. 239 forkhead box M1 5.54 102768 U82321 gb:Homo sapiens clone 14.9B mRNA sequenc 6.60 102781 BE258778 Hs. 108809 chaperonin containing TCP1, subunit 7 (e 3. 78 102784 U85658 Hs. 61796 transcription factorAP-2 gamma (activat 4.26 102824 U90916 Hs. 82845 Homo sapiens cDNA : FLJ21930 fis, clone H 14.40 102829 NM_006183 Hs. 80962 neurotensin 8. 00 102888 AI346201 Hs. 76118 ubiquitin carboxyl-teminal esterase L1 5.50 102892 BE440042 Hs. 83326 matrix metalloproteinase 3 (stromelysin 6.70 102913 NM_002275 Hs. 80342 keratin 15 4.64 102935 BE561850 Hs. 80506 small nuclear ribonucleoprotein polypept 2.93 102951 X15218 Hs. 2969 v-ski avian sarcoma viral oncogene homol 11.40 102983 BE387202 Hs. 118638 non-metastatic cells 1, protein (NM23A) 7. 26 103023 AW500470 Hs. 117950 multiFuncUona'polypeptidesimilartoS 3.01 103036 M13509 Hs. 83169 matrix metalloproteinase 1 (interstitial 27. 90 103038 AA926960 Hs. 334883 CDC28 protein kinase 1 8.79 103060 NM_005940 Hs. 155324 matrix metalloproteinase 11 (stromelysin 4.27 103099 A1693251 Hs. 8248 NADH dehydrogenase (ubiquinone) Fe-S pro 9. 80 103119 X63629 Hs. 2877 cadherin 3, type 1, P-cadherin (placenta 4.05 103168 X53463 Hs. 2704 glutathione peroxidase 2 (gastrointestin 3.07 103185 NM_006825 Hs. 74368 transmembrane protein (63kD), endoplasmi 5.62 103192 M22440 Hs. 170009 transforming growth factor, alpha 7.40 103223 BE275607 Hs. 1708 chaperonin containing TCP1, subunit 3 (g 4.70 103242 X76342 Hs. 389 alcohol dehydrogenase 7 (class IV), mu o 100.00 103316 X83301 Hs. 324728 SMA5 9.80 103375 NM_005982 Hs. 54416 sine oculis homeobox (Drosophila) homolo 9.71 103376 AL036166 Hs. 323378 coated vesicle membrane protein 14.00 103385 NM_007069 Hs. 37189 similartoratHREV107 11.00 103391 X94453 Hs. 114366 pyrroline-5-carboxylate synthetase (glut 2.93 103404 BE394784 Hs. 78596 proteasome (prosome, macropain) subunit, 5.15 103430 BE564090 Hs. 20716 translocase of inner mitochondrial membr 3.98 103446 X98834 Hs. 79971 sal (Drosophila)-like 2 21.40 103476 Y07701 Hs. 293007 aminopeptidase puromycin sensitive 13.00 103477 AJ011812 Hs. 119018 Uanscriptionfactor NRF 6.40 103478 BE514982 Hs. 38991 S100 calcium-binding protein A2 5.02 103515 Y10275 Hs. 56407 phosphoserine phosphatase 10. 50 103558 BE616547 Hs. 2785 keratin 17 6.41 103580 AA328046 Hs. 46405 polymerase (RNA) ll (DNA directed) polyp 3.84 103587 BE270266 Hs. 82128 5T4 oncofetal tophoblast glycoprotein 78.50 103594 AI368680 Hs. 816 SRY (sex determining region Y)-box 2 6.51 103636 NM006235 Hs. 2407 POU domain, class 2, associating factor 3.50 103768 AF086009 gb: HomosapiensfulilengthinsertcDNA 4.48 103841 AA314821 Hs. 38178 hypothetical protein FLJ23468 8.00 103847 AF219946 Hs. 102237 tubbysuper-familyprotein 10.40 103913 AW967500 Hs. 133543 ESTs 15.60 104094 AA418187 Hs. 330515 ESTs 6.60

104150 AL122044 Hs. 331633 hypotheticalprotein DKFZp566N034 26.00 104257 BE560621 Hs. 9222 estrogen receptor binding site associate 6.80 104261 AW248364 Hs. 5409 RNA polymerase I subunit 3.98 104331 AB040450 Hs. 279862 cdk inhibitor p21 binding protein 6.80 104415 BE410992 Hs. 258730 heme-regulated initiation factor 2-alpha 10.29 104558 R56678 Hs. 88959 hypothetical protein MGC4816 4.21 104590 AW373062 Hs. 83623 nuclearreceptorsubfamilyl, grouplsm 15.79 104658 AA360954 Hs. 27268 Homo sapiens cDNA : FLJ21933 fis, clone H 17.40 104660 BE298665 Hs. 14846 Homo sapiens mRNA ; cDNA DKFZp564D016 (fr 6.40 104689 AA420450 Hs. 292911 ESTs, Highly similar to S60712 band-6-pr 6.55 104754 AI206234 Hs. 155924 cAMP responsive element modulator 10.00 104758 BE560269 Hs. 7010 NPD002 protein 4.47 104971 BE311926 Hs. 15830 hypothetical protein FLJ12691 2.87 105011 BE091926 Hs. 16244 mitotic spindle coiled-coil related prot 3.83 105012 AF098158 Hs. 9329 chromosome 20 open reading frame 1 2.86 105026 AA809485 Hs. 124219 hypotheticalprotein FU12934 11. 00 105076 A1598252 Hs. 37810 hypothetical protein MGC14833 5.01 105132 AA148164 Hs. 247280 HBV associated factor 3.99 105143 AI368836 Hs. 24808 ESTs, Weakly similar to 138022 hypotheti 11. 00 105158 AW976357 Hs. 234545 hypothetical protein NUF2R 16.00 105175 AA305384 Hs. 25740 ER01 (S. cerevisiae) 4ike 4.32 105200 AA328102 Hs. 24641 cytoskeleton associated protein 2 3.00 105264 AA227934 gb: zr57e08. s1 Soares_NhHMPu-S1 Homo sapi 10.00 105298 BE387790 Hs. 26369 hypothetical protein FLJ20287 3.69 105409 AW505076 Hs. 301855 DiGeorge syndrome critical region gene 8 9.20 105460 AW296078 Hs. 271721 Homo sapiens, clone IMAGE : 4179986, mRNA, 7.80 105667 AA767526 Hs. 22030 paired box gene 5 (B-cell lineage specif 4.12 105743 BE246502 Hs. 9598 sema domain, immunoglobulin domain (Ig), 3.82 105782 H09748 Hs. 57987 B-cell CLUlymphoma 11 B (zinc finger pro 27.00 105848 AW954064 Hs. 24951 ESTs 7.60 105891 U55984 Hs. 289088 heat shock 90kD protein 1. alpha 4.14 106019 AF221993 Hs. 46743 McKusick-Kaufman syndrome 16.80 106069 BE566623 Hs. 29899 ESTs, Weakly similar to G02075 transcrip 23.40 106073 AL157441 Hs. 17834 downstream neighbor of SON 9.50 106126 AA576953 Hs. 22972 hypothetical protein FLJ13352, 6.00 106159 AK001301 Hs. 3487 hypothetical protein FU10439 3. 95 106220 D61329 Hs. 32196 mitochondrial ribosomal protein L36 6.04 106260 A1097144 Hs. 5250 ESTs, Weakly similar to ALU1-hUMAN ALU S 13.20 106300 Y10043 Hs. 19114 high-mobility group (nonhistone chromoso 5.02 106307 AA436174 Hs. 37751 ESTs, Weaklysimilartoputativepl50 [6. 60 106318 AA025610 Hs. 9605 cleavage and polyadenylation specific fa 5.04 106341 AF191020 Hs. 5243 hypothetical protein, estradiot-induced 7.25 106440 AA449563 Hs. 151393 glutamate-cysteine ligase, catalytic sub 13.80 106481 D61594 Hs. 17279 tyroslprotein sulfotransferase 1 4.75 106586 AA243837 Hs. 57787 ESTs 10.84 106605 AW772298 Hs. 21103 Homo sapiens mRNA ; cDNA DKFZp564B076 (fr 45.60 106654 AW075485 Hs. 286049 phosphoserine aminotransferase 28. 00 106785 Y15227 Hs. 20149 deleted in lymphocytic leukemia, 1 3.00 106813 C05766 Hs. 181022 CGI-07 protein 11.40 106895 AK001826 Hs. 25245 hypotheUcalprotein FLJ11269 6.00 106913 A1219346 Hs. 86178 M-phase phosphoprotein 9 6.56 106919 AW043637 Hs. 21766 ESTs, Weakly similar to ALU5_HUMAN ALU S 4.27 107054 A1076459 Hs. 15978 KIAA1272 protein 34.80 107059 BE614410 Hs. 23044 RAD51 (S. cerevisiae) homolog (E coli Re 4. 71 107098 AI823593 Hs. 27688 ESTs 24.80 107104 AU076640 Hs. 15243 nucleolar protein 1 (120kD) 7.05 107129 AC004770 Hs. 4756 flap structure-specific endonuclease 1 2.60 107198 AV657225 Hs. 9846 KIAA1040 protein 19.20 107203 D20426 Hs. 41639 programmed cell death 2 7.60 107217 AL080235 Hs. 35861 DKFZP586E1621 protein 9.50 107284 NM_005629 Hs, 187958 solute carrierfamily 6 (neurotransmitte 2.71 107318 T74445 Hs. 5957 Homo sapiens clone 24416 mRNA sequence 8.71 107516 X57152 Hs. 99853 fibrillarin 4.33 107529 BE515065 Hs. 296585 nudeoiar protein (KKBD repeat) 4.00 107728 AA019551 Hs. 294151 Homo sapiens, clone IMAGE : 3603836, mRNA, 10.80 107851 AA022953 Hs. 61172 EST 8.00 107901 L42612 Hs. 335952 keratin 6B 3.40 107922 BE153855 Hs. 61460 Ig superfamily receptor LNIR 2.88 107932 AW392555 Hs. 18878 hypothetical protein FLJ21620 7.50 108015 AW298357 Hs. 49927 protein kinase NYD-SP15 23.40 108056 AA043675 Hs. 62633 ESTs 12.80 108075 AI867370 Hs. 139709 hypothetical protein FLJ12572 12.80 108187 BE245374 Hs. 27842 hypothetical protein FLJ11210 7.00 108296 N31256 Hs. 161623 ESTs 6.60 108305 AA071391 gb: zm61e06. r1 Stratagenefibroblast (937 11.80 108393 AA075211 gb: zm86a08. r1 Stratagene ovarian cancer 11.80 108480 AL133092 Hs. 68055 hypothetical protein DKFZp43410428 20.80 108554 AA084948 gb: zn13b09. s1 Stratagene hNT neuron (937 6.40 108573 AA086005 gb: zl84c04. sl Stratagene colon (937204) 25.40 108584 AA088326 Hs. 120905 Homo sapiens cDNA FLJ11448 fis, clone HE 9.60 108597 AK000292 Hs. 278732 hypothetical protein FLJ20285 14.60 108695 AB029000 Hs. 70823 KIAA1077 protein 3.00 108699 AA121514 Hs. 70832 ESTs 10. 00 108700 AA121518 Hs. 193540 ESTs, Moderately similar to 2109260A B c 11. 00 108780 AU076442 Hs. 117938 coliagen, type XVII, alpha 1 11.21

108810 AW295647 Hs. 71331 hypothetical protein MGC5350 8.50 108816 AA130884 Hs. 270501 ESTs, ModeratelysimilartoALU2 HUMAN 7. 40 108857 AK001468 Hs. 62180 anillin (Drosophila Scraps homolog), act 4.00 108860 AA133334 Hs. 129911 ESTs 6.09 108937 AL050107 Hs. 24341 transcriptionalco-activatorwithPDZ-bi 3.00 109010 NM_007240 Hs. 44229 dualspecificityphosphatasel2 2. 69 109121 BE389387 Hs. 49767 NADH dehydrogenase (ubiquinone) Fe-S pro 4.53 109166 AA219691 Hs. 73625 RAB6 interacting, kinesin-like (rabkines 10.58 109227 AA766998 Hs. 85874 Human DNA sequence from clone RP11-16L21 9.00 109415 U80736 Hs. 110826 trinucleoüderepeatcontaining9 51.40 109418 AI866946 Hs. 161707 ESTs 11.00 109454 AA232255 Hs. 295232 ESTs, Moderately similar to A46010 X-li 17.60 109502 AW967069 Hs. 211556 hypothetical protein MGC5487 9.49 109543 AA564994 Hs. 222851 ESTs 12.67 109648 H17800 Hs. 7154 ESTs 10.40 109680 AB037734 Hs. 4993 KIAA1313 protein 33.20 109700 F09609 gb: HSC33H092 normalized infant brain cDN 16. 00 109704 AI743880 Hs. 12876 ESTs 11.00 109792 R49625 gb: yg61f03. sl Scares infant brain 1 NIB H 12.60 109981 BE546208 Hs. 26090 hypothetical protein FU20272 4. 00 109998 AL042201 Hs. 21273 transcription factor NYD-sp10 7.80 110039 H11938 Hs. 21907 histoneacetyitransferase 7.00 110156 AA581322 Hs. 4213 hypothetical protein MGC16207 4.24 110500 AA907723 Hs. 36962 ESTs 4.50 110551 AW450381 Hs. 14529 ESTs 8.60 110561 AA379597 Hs. 5199 HSPC150 protein similar to ubiquitin-con 3. 06 110854 BE612992 Hs. 27931 hypothetical protein FU10607 similarto 6.80 110886 AW274992 Hs. 72249 three-PDZ containing protein similar to 8.80 110916 BE178102 Hs. 24349 ESTs 6. 80 111003 N52980 Hs. 83765 dihydrofolate reductase 16.80 111337 AA837396 Hs. 263925 LIS1-interacting protein NUDE1, rat homo 2.54 111434 R01608 Hs. 142736 ESTs 9.80 111439 AI476429 Hs. 19238 ESTs 10.40 111540 U82670 Hs. 9786 zinc finger protein 275 15.40 111597 R11499 Hs. 189716 ESTs 9.20 111895 T80581 Hs. 12723 Homo sapiens clone 25153 mRNA sequence 6.80 111929 AF027208 Hs. 112360 prominin (mouse)-like 1 14. 67 112054 R43590 gb: yc85g02. s1 Soares infant brain 1NIB H 10.80 112210 R49645 Hs. 7004 ESTs 10.20 112244 AB029000 Hs. 70823 KIAA1077 protein 2.99 112382 R59904 gb: yh07g12. s1 Soares infant brain 1NIB H 6.60 112392 R60763 Hs. 193274 ESTs, Moderately similar to I57588 HSrel 7.10 112442 AA280174 Hs. 285681 Williams-Beuren syndrome chromosome regi 3.00 112539 R70318 Hs. 339730 ESTs 37.20 112772 AI992283 Hs.35437 ESTs, Moderately similar to I38026 MLN 6 14.60 112869 BE261750 Hs. 4747 dyskeratosis congenita 1, dyskerin 4.83 112935 R71449 Hs. 268760 ESTs 2.73 112970 AA694010 Hs. 6932 Homo sapiens clone 23809 mRNA sequence 12.00 112973 AB033023 Hs. 318127 hypothetical protein FLJ10201 11.50 112992 AL157425 Hs, 133315 Homo sapiens mRNA ; cDNA DKFZp761J1324 (f 10.89 113063 W15573 Hs. 5027 ESTs, Weakly similar to A47582 B-cell gr 15.00 113073 N39342 Hs. 103042 microtubule-associated protein 1B 15.31 113078 T40444 Hs. 118354 CAT56 protein 7.00 113238 R45467 Hs. 189813 ESTs 41.20 113591 T91881 Hs. 200597 KIAA0563 gene product 9.40 113702 T97307 gb: ye53h05. s1 Soares fetal liver spleen 25.00 113844 AI369275 Hs. 243010 Homo sapiens cDNA FW14445 fis clone HE 13.91 113984 R96696 Hs. 35598 ESTs 7.80 114073 R44953 Hs. 22908 Homo sapiens mRNA ; cDNA DKFZp434J1027 (f 7.20 114162 AF155661 Hs. 22265 pyruvatedehydrogenasephosphatase 3.42 114208 AL049466 Hs. 7859 ESTs 6.74 114251 H15261 Hs. 21948 ESTs 33.20 114285 R44338 Hs. 22974 ESTs 13.20 114313 H18456 Hs. 27946 ESTs 10.00 114339 AA782845 Hs. 22790 ESTs 7.80 114407 BE539976 Hs. 103305 Homo sapiens mRNA ; cDNA DKFZp434B0425 (f 4.14 114560 A1452469 Hs. 165221 ESTs 9.80 114699 AA127386 gb: zn90d09. rl Stratagene lung carcinoma 7. 60 114767 AI859865 Hs. 154443 minichromosome maintenance deficient (S 3.21 114793 AA158245 gb: zo76c03. s1 Stratagene pancreas (93720 6.00 114833 AI417215 Hs. 87159 hypothetical protein FLJ12577 11.40 115047 BE270930 Hs. 82916 chaperonincontainingTCP1, subunit6A (431 115060 AF052693 Hs. 198249 gap junction protein, beta 5 (connexin 3 4.03 115097 AA256213 Hs. 72010 ESTs 35.40 115113 AA256460 gb: zr81a04. s1 Scares Homo sapl 15.20 115123 AA256641 Hs. 236894 ESTs, Highly similarto S02392 alpha-2-m 4, 19 115134 AW968073 Hs. 194331 ESTs, Highly similar to A55713 inositol 12.40 115291 BE545072 Hs. 122579 hypothetical protein FLJ10461 25.00 115347 AA356792 Hs. 334824 hypothetical protein FLJ14825 7. 00 115414 AA662240 Hs. 283099 AF15q14 protein 3.25 115522 BE614387 Hs. 333893 c-MyctargetJP01 3.68 115536 AK001468 Hs. 62180 anillin (Drosophila Scraps homolog), act 10.50 115566 AI142336 Hs. 43977 Human DNA sequence from clone RP11-196N1 24.40 115645 Ai207410 Hs. 69280 Homo sapiens, clone IMAGE : 3636299, mRNA, 4.17 115648 AW016811 Hs. 234478 HomosapienscDNA : FLJ22648 fis, clone H 6. 00

115652 BE093589 Hs. 38178 hypothetical protein FLJ23468 3.81 115697 D31382 Hs. 63325 transmembrane protease, serine 4 62.14 115793 AA424883 Hs. 70333 hypothetical protein MGC10753 11.80 115816 BE042915 Hs. 287588 HomosapienscDNAFLJ13675fisclonePL 9.71 115892 AA291377 Hs. 50831 ESTs 27.40 115906 AI767756 Hs. 82302 HomosapienscDNAFW14814fis, cloneNT 2.53 115909 AW872527 Hs. 59761 ESTs, WeaklysimilartoDAP1_HUMANDEATH 11.82 115965 AA001732 Hs. 173233 hypothetical protein FLJ10970 34.29 115978 AL035864 Hs. 69517 cDNA for differentially expressed C016 g 8.23 115985 AA447709 Hs. 268115 ESTs, Weakly similar to T08599 probable 3. 00 116090 A1591147 Hs. 61232 ESTs 5.17 116096 AA682382 Hs. 59982 ESTs 8.20 116127 AF126743 Hs. 279884 DNAJ domain-containing 10.60 116157 BE439838 Hs. 44298 mitochondrial ribosomal protein S17 5.82 116190 AI949095 Hs. 67776 ESTs, Weakly similar to T22341 hypotheli 4.08 116278 NM003686 Hs. 47504 exonuclease 1 9.50 116335 AK001100 Hs. 41690 desmocollin 3 3.67 116496 AW450694 Hs. 21433 hypothefical protein DKFZp547JO36 7.00 116503 AI925316 Hs. 212617 ESTs 12.60 116674 Al768015 Hs. 92127 ESTs 32.00 116929 AA586922 Hs. 80475 polymerase (RNA) 11 (DNA directed) polyp 7.60 116973 AI702054 Hs. 166982 phosphatidylinositol glycan, class F 9.80 116993 A1417023 Hs. 40478 ESTs 10.20 117079 H92325 gb: ys85f05. s1 Soares retina N2b4HR Homo 15.20 117317 A1263517 Hs. 43322 ESTs 13.40 117326 N23629 Hs. 241420 Homo sapiens mRNA for KIAA1756 protein, 20.60 117396 W20128 Hs. 296039 ESTs 10.60 117412 N32536 Hs. 42645 ESTs 16.00 117519 N32528 Hs. 146286 kinesin family member 13A 9.11 117693 AW179019 Hs. 112110 mitochondrial ribosomal protein L42 4. 01 117721 N46100 Hs. 93939 EST 19.80 117881 AF161470 Hs. 260622 butyrate-induced transcript 1 2.71 117903 AA768283 Hs. 47111 ESTs 17.80 117992 A1015709 Hs. 172089 HomosapiensmRNA ; cDNA DKFZp58612022 (f 4.17 118013 AI674126 Hs. 94031 ESTs 10.60 118017 A1813444 Hs. 42197 ESTs 8.82 118186 N22886 Hs. 42380 ESTs 7.00 118325 AI868065 Hs. 166184 intersect ! n2 13.80 118367 N64269 Hs. 48946 EST 6.14 118368 N64339 Hs. 48956 gap junction protein, beta 6 (connexin 3 3.14 118472 AL157545 Hs. 42179 bromodomain and PHD finger containing, 3 12.40 118709 AA232970 Hs. 293774 ESTs 12.20 119025 BE003760 Hs. 55209 Homo sapiens mRNA ; cDNA DKFZp434K0514 (f 4.50 119027 AF086161 Hs. 114611 hypotheücàproteinFW11806 3.22 119052 R10889 gb: yf38d02. s1 Soaresfetalliverspleen 9.60 119164 AF221993 Hs. 46743 McKusick-Kautman syndrome 6.60 119186 A1979147 Hs. 101265 hypothetical protein FLJ22593 10.80 119243 T12603 gb: CHR90123 Chromosome 9 exon 11 Homo sa 9.44 119490 AA195276 Hs. 263858 ESTs, ModeratelysimilartoB34087hypot 11.80 119499 A1918908 Hs. 55080 ESTs 14. 80 119599 W45552 gb: zc26d03. s1 Soares senescenLfibroblas 12.60 119780 NM016625 Hs. 191381 hypothetical protein 17. 00 119845 W79123 Hs. 58561 G protein-coupled receptor 87 13.50 119941 AA699485 Hs. 58896 ESTs 8.00 119994 AA642402 Hs. 59142 ESTs 7.73 120102 W67353 Hs. 170218 KIAA0251 protein 39.60 120104 AK000123 Hs. 180479 hypothetical protein FLJ20116 2.91 120294 AK000059 Hs. 153881 Homo sapiens NY-REN-62 antigen mRNA, par 8.20 120486 AW368377 Hs. 137569 tumor protein 63 kDa with strong homolog 8.73 120599 AA804448 Hs. 104463 ESTs 7.00 120699 AI683243 Hs. 97258 ESTs, moderately similar to S29539 ribos 10. 00 120715 AA292700 gb : zs59a06. s1 NCI_CGAP_GCB1 Homo sapiens 9.40 120821 Y19062 Hs. 96870 staufen (Drosophila, RNA-binding protein 13.80 120859 AA826434 Hs. 1619 achaete-scute complex (Drosophila) homol 9.00 120880 AA360240 Hs. 97019 EST 15.60 120983 AA398209 Hs. 97587 EST 27.66 121034 AL389951 Hs. 271623 nucleoporin 50kD 20. 80 121121 AA399371 Hs. 189095 similar to SALL1 (sal(Drosophila)-like 22. 80 121313 AA402713 Hs. 97872 ESTs 10.00 121369 AW450737 Hs. 128791 CGI-09 protein 25. 71 121376 AA448103 Hs. 187958 solute carrier family 6 (neurotransmitte 5.42 121476 AA412311 Hs. 97903 ESTs 8.30 121509 AA868939 Hs. 97888 ESTs 8.59 121553 AA412488 Hs. 48820 TATA box binding protein (TBP)-associat 18. 50 121753 AK000552 Hs. 323518 WD repeat domain 5 7.00 121838 AA425680 Hs. 98441 ESTs 10.40 121857 BE387162 Hs. 280858 ESTs, Highly similar to A35661 DNA excis 6.00 121991 AA430058 Hs. 98649 EST 12.20 122089 AW016543 Hs. 98682 hypothetical protein FKSG32 8.60 122105 AW241685 Hs. 98699 ESTs 6. 14 122163 AA435702 Hs. 98829 EST 10.40 122318 AA429743 gb: zv60b05. rlSoares tesüs_NHTHomosap 18.20 122335 AA443258 Hs. 241551 chlorie channel, calcium activated, fam 13.50 122338 AA443311 Hs. 98998 ESTs 4.80 122414 Api313473 Hs. 99087 ESTs, Weakly similar to S47073 finger pr 8.00

122512 AF053305 Hs. 98658 budding uninhibited by benzimidazoles 1 8.80 122516 AA449352 Hs. 99217 ESTs 9.40 122702 AI220089 Hs. 99439 ESTs 9.20 122852 AI580056 Hs. 98992 ESTs 10.40 122925 AW268962 Hs. 111335 ESTs 6.80 123005 AW369771 Hs. 52620 integrin, beta 8 12.60 123044 AK001035 Hs. 130881 B-cell CLL/lymphoma 11A (zinc finger pro 5.35 123160 AA488687 Hs. 284235 ESTs, Weakly similar to I38022 hypotheti 6.06 123315 AA496369 gb: zv37d10. si Soares ovary tumor NbHOT H 12.40 123329 Z47542 Hs. 179312 small nuclear RNA activating complex, po 11.80 123497 AA765256 Hs. 135191 ESTs, Weakly similar to unnamed protein 12.00 123518 AL035414 Hs. 21068 hypothetical protein 13.00 123519 AW015887 Hs. 112574 ESTs 12.20 123614 AK000492 Hs. 98806 hypothetical protein 7.80 123616 AA680003 Hs. 109363 Homo sapiens cDNA : FLJ23603 fis, clone L 10.60 123673 BE550112 Hs. 158549 ESTs, Weakly similar to T2D3_HUMAN TRANS 23. 00 123727 A1083986 Hs. 282977 hypothetical protein FLJ13490 7.00 123731 AA609839 gb: ae62f01. s1 Stratagene lung carcinoma 9, 80 123752 AA227714 Hs. 179703 KIAA0129 gene product 3.50 123900 AA621223 Hs. 112953 EST 12.80 124006 AI147155 Hs. 270016 ESTs 97.00 124059 BE387335 Hs. 283713 ESTs, Weakly similar to S64054 hypotheti 3. 02 124069 AF134160 Hs. 7327 claudin 1 27. 80 124191 T96509 Hs. 248549 ESTs, Moderately similar to S65657 alpha 35.80 124273 AA457211 Hs. 8858 bromodomain adjacent to zinc finger doma 7. 20 124297 AL080215 Hs. 102301 Homo sapiens mRNA ; cDNA DKFZp586J0323 (f 11.00 124305 AW963221 gb: EST375294 MAGE resequences, MAGH Homo 16.00 124676 Ai360119. compHs. 181013 phosphoglycerate mutase 1 (brain) 6.08 124874 BE550182 Hs. 127826 RalGEF-like protein 3, mouse homolog 21. 00 124904 AK000483 Hs. 93872 KIAA1682 protein 9.40 124969 Api650360 Hs. 100256 ESTs 10 : 80 125000 T58615 Hs. 110640 ESTs 9. 80 125201 AA693960 Hs. 103158 ESTsgWeaklysimilartoT33296hypotheü 7.60 125266 W90022 Hs. 186809 ESTssHighlysimilartoLCT2_HUMANLEUK0 6.59 125299 T32982 Hs. 102720 ESTs 9.57 125356 A1057052 Hs. 133554 ESTs, Weakly similar to Z195_HUMAN ZINC 14.00 125370 AA256743 Hs. 134158 Homo sapiens, Similar to KIAA0092 gene p 8.20 125418 AA777690 Hs. 188501 ESTs 13.20 125433 AL162066 Hs. 54320 hypothetical protein DKFZp762D096 21.40 125437 AI609449 Hs. 140197 ESTs 6.96 125446 BE219987 Hs. 166982 phosphatidylinositoi glycan, class F 8.80 125711 AA305800 Hs. 5672 hypothetical protein AF140225 11.20 125756 BE174587 Hs. 289721 growth arrest specific transcript 5 4.31 125757 A1274906 Hs. 166835 ESTs Highly similar to 1814460Ap53-ass 15.60 125769 BE270266 Hs. 82128 5T4 oncofetaltrophoblastglycoprotein 3. 20 125839 AW836261 Hs. 337717 ESTs 8.20 125850 W85858 Hs. 99804 ESTs 2. 65 125875 H14480 gb : ym18b09. r1Soares infant brain 1NIB H 7.40 125924 BE272506 Hs. 82109 syndecan 1 4.23 125972 AI927475 Hs. 35406 ESTs, Highly similar to unnamed protein 3.98 126034 H60340 gb: yr39b04. r1 Soares fetal liver spleen 10.60 126327 AA432266 Hs. 44648 ESTs 11.60 126345 N49713 gb: yv23fO6, s1 Soaresfetalliverspleen 6.67 126435 AW614529 Hs. 285847 CGI-19 protein 10.60 126487 AA283809 Hs. 184601 solute carrier family 7 (cationic amino 4.38 126521 Al475110 Hs. 203933 ESTs 6.60 126522 W31912 gb: zc76d03. s1 Pancreatic Islet Homo sap ! 14.80 126543 AL035864 Hs. 69517 cDNA for differentially expressed CO16 g 4. 01 126567 AA058394 Hs. 57887 ESTs, Weakly similar to KIAA0758 protein 7.80 126605 AA676910 gb: zj65h07.s1 Soares_fetal_liver_spleen_ 11.60 126627 AA497044 Hs. 20887 hypothetical protein FLJ10392 14.60 126628 N49776 Hs. 170994 hypothetical protein MGC10946 8.00 126737 AW976516 Hs. 283707 Homo sapiens cDNA : FLJ21354fis, cbneC 2.92 126795 AW975076 Hs. 172589 nuclear phosphoprotein similar to S. cer 7.50 126802 AW805510 Hs. 97056 hypothetical protein FLJ21634 11.60 126892 AF121856 Hs. 284291 sorting nexin 6 3.50 126928 AA480902 Hs. 137401 ESTs 22.83 126979 AA210954 gb: zq89h01.r1 Stratagene hNT neuron (937 11.80 126986 AI279892 Hs. 46801 sorting nexin 14 11.60 126992 A1809521. gb : wf30e03. x1 Soares_NFL_T_GBC_S1 Homo s 20. 80 127066 R25066 gb : yg42c07. r1 Soares infant brain 1 NIB H 27.60 127099 AA347668 gb: EST54026 Fetal heart 11 Homo sapiens 21.60 127139 AA830233 Hs. 293585 ESTs 11.20 127209 AA305023 Hs. 81964 SEC24 (S. cerevisiae) related gene famil 3. 10 127221 BE062109 Hs. 241551 chloride channel, calcium activated, fam 2.76 127225 AA315933 Hs. 120879 ESTs 16.80 127313 AK002014 Hs. 47546 Homo sapiens cDNA FLJ11458 fis, clone HE 14.00 127444 AW978474 Hs. 7560 Homo sapiens MRNA for KIAA1729 protein, 13.60 127500 AW971353 Hs. 162115 ESTs 11.20 127524 A1243596 Hs. 94830 ESTs, Moderately similar to T03094 A-kin 7.80 127540 N45572 Hs. 105362 Homo sapiens, clone MGC : 18257, mRNA, com 3.53 127599 AA613204 Hs. 150399 ESTs 13.80 127609 X80031 Hs. 530 collagen, type IV, alpha 3 (Goodpasture 28.00 127662 W80755 Hs. 8294 KIAA0196 gene product 19.80 127668 AI343257 Hs. 139993 ESTs 11.20

127746 A1239495 Hs. 120189 ESTs 14.18 127812 AA741368 Hs. 291434 ESTs 4.50 127817 AA836641 Hs. 163085 ESTs 24.60 127959 A1302471 Hs. 124292 HomosapienscDNA : FLJ23123 fis, clone L 9.20 127960 AI613226 Hs. 41569 phosphatid ! c acid phosphatase type 2A 16.83 127969 F06498 Hs. 93748 Homo sapiens cDNA FLJ14676 fis, clone NT 13.60 128015 Z21169 Hs. 334659 hypothetical protein MGC14139 7.00 128027 AI433721 Hs. 164153 ESTs 37.40 128077 AI310330 Hs. 128720 ESTs 9.60 128166 NM_006147 Hs. 11801 interferon regulatory factor 6 9.24 128226 At284940 Hs. 289082 GM2 ganglioside activator protein 19.00 128305 AI954968 Hs. 279009 matrix Gla protein 10.40 128341 AA191420 Hs. 185030 ESTs 9.00 128527 AA504583 Hs. 101047 transcription factor 3 (E2A immunoglobul 4. 30 128539 R46163 Hs. 258618 ESTs 12.60 128568 H12912 Hs. 274691 adenylate kinase 3 4.56 128572 AA933022 Hs. 256583 interleukin enhancer binding factor 3, 9 10.00 128777 A1878918 Hs. 10526 cysteine and glycine-rich protein 2 16.80 128781 N71826 Hs. 105465 small nuclear dbonucleoprotein polypept 4.48 128796 AJ000152 Hs. 105924 defensin, beta 2 8.12 128920 AA622037 Hs. 166468 programmed cell death 5 4.62 128924 BE279383 Hs. 26557 plakophilin 3 4. 04 128971 H05132 Hs. 107510 ESTs 12.60 129008 AL079648 Hs. 301088 ESTs 8.80 129041 BE382756 Hs. 169902 solute carrier family 2 (facilitated glu 6.05 129075 BE250162 Hs. 83765 dihydrofolatereductase 2.59 129105 AI769160 Hs. 108681 Homo sapiens brain tumor associated prot 6. 67 129189 AB023179 Hs. 9059 KIAA0962 protein 8.00 129229 AF013758 Hs. 109643 polyadenylate binding protein-interactin 4.00 129241 AI878857 Hs. 109706 hematological and neurological expressed 4.06 129300 W94197 Hs. 110165 ribosomal protein L26 homolog 2.55 129404 A1267700 Hs. 317584 ESTs 18.00 129457 X61959 Hs. 207776 aspartylglucosaminidase 6.50 129466 L42583 Hs. 334309 keratin 6A 12. 94 129494 AI148976 Hs. 112062 ESTs 11.00 129605 AF061812 Hs. 1 15947 keratin 16 (focal non-epidermolytic palm 4.46 129641 AI911527 Hs. 11805 ESTs 12.00 129665 AW163331 Hs. 118778 KDEL (Lys-Asp-Glu-Leu) endoplasmicretic 4.70 129703 BE388665 Hs. 179999 Homosapiens, clonelMAGE : 3457003, mRNA 4.02 129720 AA156214 Hs. 12152 APMCF1 protein 5.71 129748 M16707 Hs. 123053 H4 histone, family 2 3.50 129890 A1868872 Hs. 282804 hypothetical protein FLJ22704 4.21 129896 BE295568 Hs. 13225 UDP-Gal : betaGIcNAc beta 1, 4- galactosylt 2.56 129945 BE514376 Hs. 165998 PAI-1 mRNA-binding protein 4.03 130010 AA301116 Hs. 142838 nucleolarphosphoprotein Nopp34 7.00 130026 T40480 Hs. 332112 EST 6.40 130080 X14850 Hs. 147097 H2A histone family, member X 4.65 130149 AW067805 Hs. 172665 methylenetetrahydrofolate dehydrogenase 2.74 130285 AA063546 Hs. 75981 ubiquitin specific protease 14 (tRNA-gua 7.40 130441 U63630 Hs. 155637 protein kinase, DNA-activated, catalytic 3.91 130482 AW409701 Hs. 1578 baculoviral IAP repeat-containing 5 (sur 4.87 130500 AB007913 Hs. 158291 KIAA0444 protein 9.60 130524 U89995 Hs. 159234 forkhead box El (thyroid transcription f 13.40 130541 X05608 Hs. 211584 neurofilament, light polypeptide (68kD) 8. 20 130553 AF062649 Hs. 252587 pituitary tumor-transforming 1 6.06 130567 AA383092 Hs. 1608 replication protein A3 (14kD) 7.00 130577 M69241 Hs. 162 insulin-like growth factor binding prote 3. 04 130627 BE003054 Hs. 1695 matrix metalloproteinase 12 (macrophage 3.87 130648 AI458165 Hs. 17296 hypothetical protein MGC2376 16.20 130697 L29472 Hs. 1802 majorhistocompatibiiitycompiex. dass 17.80 130744 H59696 Hs. 18747 POP7 (processing of precursor, S. cerevi 5.28 130800 AI187292 Hs. 19574 hypothetical protein MGC5469 4.43 130867 NM_01072 Hs. 284239 UDP glycosyltransferase 1 family, polype 16.84 130869 J03626 Hs. 2057. uridine monophosphate synthetase (orotat 4.92 130925 AF093419 Hs. 169378 multiple PDZdomain protein 9.60 130994 W17044 Hs. 327337 ESTs 12.40 131028 AI879165 Hs. 2227 CCAAT/enhancer binding protein (C/EBP), 10.21 131031 NM 001650 Hs. 288650 aquaporin 4 9. 80 131041 T15767 Hs. 22452 Homo sapiens mRNA for kIAA1737 protein, 9.60 131058 W28545 Hs. 101514 hypothetical protein FLJ10342 17.00 131090 AI143139 Hs. 2288 visinin-like 1 2. 74 131112 H15302 Hs. 168950 Homo sapiens mRNA ; cDNA DKFZp566A1046 (f 8.80 131148 AW953575 Hs. 303125 p53-induced protein PIGPC1 3.12 131185 BE280074 Hs. 23960 cyclin B1 3.07 131200 BE540516 Hs. 293732 hypothetical protein MGC3195 3. 07 131219 W25005 Hs. 24395 small inducible cytokine subfamily B (Cy 2.87 131257 AW339037 Hs. 24908 ESTs 14.67 131375 AW293165 Hs. 143134 ESTs 19.20 131460 NM_003729 Hs. 27076 RNA3'-terminal phosphate cyclase 3.50 131476 AI521663 Hs. 334644 hypothetical protein FLJ14668 15.00 131510 BE245374 Hs. 27842 hypothetical protein FLJ11210 7.80 131646 BE302464 Hs. 30057 MRS2 (S. cerevisiae)-like, magnesium hom 7.00 131786 BE000971 Hs. 306083 Novel human gene mapping to chomosome 22 2.65 131839 AB014533 Hs. 33010 KIAA0633 protein 35.20 131843 AA192315 Hs. 184062 putative RabS-interacting protein 4. 11

131877 J04088 Hs. 156346 topoisomerase (DNA) II alpha (170kD) 19.00 131885 BE502341 Hs. 3402 ESTs 6.48 131921 AA456093 Hs. 34720 ESTs 8.40 131945 NM_002916 Hs. 35120 replication factor C (activator 1) 4 (37 56.00 131958 NM_014062 Hs. 3566 ART-4 protein 3.82 131965 W79283 Hs. 35962 ESTs 3.03 132000 AW247017 Hs. 36978 melanoma antigen, family A, 3 9.80 132040 NM_001196 Hs. 315689 HomosapienscDNA : FLJ22373 fis, clone H 3.30 132109 AW190902 Hs. 40098 cysteine knot superfamily 1, BMP antagon 21.00 132114 Nom006152 Hs. 40202 lymphoid-restricted membrane protein 8.40 132162 AA315805 Hs. 94560 desmoglein 2 12.25 132164 A1752235 Hs. 41270 procollagen-lysine, 2-oxoglutrate 5-dio 2.70 132180 NM004460 Hs. 418 fibroblast activation protein, alpha 2.71 132181 AW961231 Hs. 16773 Homo sapiens clone TCCCIA00427 mRNA sequ 3.83 132182 NM_014210 Hs. 70499 ecotropic viral integration site 2A 13.20 132231 AA662910 Hs. 42635 hypothetical protein DKFZp434K2435 9.50 132277 AK001745 Hs. 184628 hypothetical protein FLJ 10883 4.50 132328 NM_014787 Hs. 44896 DnaJ (Hsp40) homolog, subfamily Bs membe 9.20 132394 AK001680 Hs. 30488 DKFZP434F091 protein 19.80 132424 AA417878 Hs. 48401 ESTs, Moderately similar to ALU8_HUMAN A 8.60 132528 T78736 Hs. 50758 SMC4 (structural maintenance of chromoso 27.40 132543 BE568452 Hs. 5101 protein reguiatorofcytokinesist 4. 38 132544 L19778 Hs. 51011 H2A histone family, member P 7. 00 132550 AW969253 Hs. 170195 bone morphogenetic protein 7 (osteogenic 2.64 132552 BE621985 Hs. 296922 thiopurine S-methyltransferase 15. 83 132581 AK000631 Hs. 52256 hypothetical protein FLJ20624 6.60 132617 AF037335 Hs. 5338 carbonic anhydrase XII 4.95 132638 AI796870 Hs. 54277 DNA segment on chromosome X (unique) 992 8.20 132653 Z15008 Hs. 54451 laminin, gamma 2 (nicein (100kD), kalini 4.38 132669 W38586 Hs. 293981 guanine nucleotide binding protein (G pr 4.36 132710 W74001 Hs. 55279 serine (or cysteine) proteinase Inhibito 4.60 132771 Y10275 Hs. 56407 phosphoserine phosphatase 3. 71 132799 W73311 Hs. 169407 SAC2 (suppressor of actin mutations 2, 9.48 132833 U78525 Hs. 57783 eukaryotic translation initiation factor 5. 83 132892 AW834050 Hs. 9973 tensin 12.00 132906 BE613337 Hs. 234896 geminin 3.09 132959 AW014195 Hs. 61472 ESTs, Weakly similar to YAE6_YEAST HYPOT 3.87 132962 AA576635 Hs. 6153 CGI-48 protein 3.50 132990 X77343 Hs. 334334 transcription factor AP-2 alpha (activat 6.18 132994 AA112748 Hs. 279905 clone HQ0310 PR00310p1 3.19 133000 AL042444 Hs. 62402 p21/Cdc42/Rac1-activated kinase 1 (yeast 2.96 133050 X73424 Hs. 63788 propionyi Coenzyme A carboxylase, beta p 2.55 133083 BE244588 Hs. 6456 chaperonin containing TCP1, subunit 2 (b 4. 00 133086 L17131 Hs. 139800 high-mobility group (nonhistone chromoso 8.96 133134 AF198620 Hs. 65648 RNA binding motif protein 8A 4.28 133155 M58583 Hs. 662 cerebeltin 1 precursor 10.80 133181 X91662 Hs. 66744 twist (Drosophila) homolog (acrocephalos 3.00 133204 BE267696 Hs. 254105 enolase 1, (alpha) 4.63 133412 U41493 Hs. 73112 guanine nucleotide binding protein (G pr 12.50 133421 AF134160 Hs. 7327 claudin 1 2.85 133451 AW970026 Hs. 73818 ubiquinol-cytochromecreductasehingep 4.66 133453 AI659306 Hs. 73826 protein tyrosine phosphatase, non-recept 6.80 133504 NM_004415 Hs. 74316 desmoplakin (DPI, DPII) 6.14 133506 BE562958 Hs. 74346 hypothetical protein MGC14353 4.55 133615 M62843 Hs. 75236 ELAV (embryonic lethal, abnormal vision, 17.80 133627 NM_002047 Hs. 75280 glycyl-tRNA synthetase 4. 85 133649 U25849 Hs. 75393 acid phosphatase 1, soluble 6.34 133669 NM_006925 Hs. 166975 splicing factor, argininelserine-rich 5 14.00 133749 L20852 Hs. 10018 solute carrier family 20 (phosphate tran 6.11 133776 BE268649 Hs. 177766 ADP-fibosyltransferase (NAD+ : poly (ADP-4. 91 133865 AB011155 Hs. 170290 discs, large (Drosophila) homolog 5 3.07 133946 AJ001258 Hs. 173878 NIPSNAP, C. elegans, homolog 1 4.60 133973 N55540 Hs. 78026 ESTs, Weakly similar to similar to ankyr 13.00 134047 BE262529 Hs. 78771 phosphoglycerate kinase 1 3.85 134098 BE513171 Hs. 79086 mitochondrial ribosomal protein L3 2.56 134107 NM_005629 Hs. 187958 solute carrier family 6 (neurotransmitte 8.20 134112 AW449809 Hs. 79150 chaperonin containg TCP1, subunit 4 (d 4.08 134158 U15174 Hs. 79428 BCL2/adenovirus E1B 19kD-interacting pro 31.00 134160 T98152 Hs. 79432 fibriliin 2 (congenital contractural ara 24. 60 134168 AA398908 Hs. 181634 Homo sapiens cDNA : FLJ23602 fis, clone L 6.71 134185 AA285136 Hs. 301914 neuronal specific transcription factor D 14.74 134201 L35035 Hs. 79886 ribose 5-phosphate isomerase A (ribose 5 8.40 134272 X76040 Hs. 278614 protease, serine, 15 4.50 134276 BE083936 Hs. 80976 antigen identified by monoclonal antibod 9.00 134353 AL138201 Hs. 82120 nuclear receptor subfamily 4, group A, m 16.40 134367 AA339449 Hs. 82285 phosphoribosylglycinamide formyltransfer 2. 80 134380 AU077143 Hs. 179565 minichromosome maintenance deficient (S. 4.68 134423 H53497 Hs. 83006 CGI-139 protein 3.84 134469 AA279661 Hs. 83753 small nuclear ribonucleoprotein polypept 5.81 134470 X54942 Hs. 83758 CDC28 protein kinase 2 4.21 134498 AW246273 Hs. 84131 threonyl-tRNA synthetase 7.30 134502 BE148534 Hs. 84168 UV-B repressed sequence, HUR 7 13.60 134510 NM_002757 Hs. 250870 mitogen-activated protein kinase kinase 9. 70 134548 N95406 Hs. 333495 Deleted in split-handisplit-foot 1 regio 4.63 134654 AK001741 Hs. 8739 hypothetical protein FLJ10879 6. 00

134724 AF045239 Hs. 321576 ring finger protein 22 12.00 134743 AA044163 Hs. 89463 potassium large conductance calcium-aeg 4.00 134781 AA374372 Hs. 89626 parathyroid hormone-like hormone 25.20 134806 AD001528 Hs. 89718 spermine synthase 4.58 134853 BE268326 Hs. 90280 5-aminoimidazole-4-carboxamide ribonucle 4.79 134859 D26488 Hs. 90315 KIAA0007 protein 6. 20 134891 R51083 Hs. 90787 ESTs 7.40 134960 BE246400 Hs. 285176 acetyl-Coenzyme A transporter 4.00 134993 BE409809 Hs. 301005 purine-rich element binding protein B 4.48 135047 AL134197 Hs. 93597 cyclin-dependent kinase 5, regulatory su 9.50 135080 At761180 Hs. 94211 rcdl (required for cell differenuation, 5. 00 135103 NM_003428 Hs. 9450 zinc finger protein 84 (HPF2) 11.00 135145 AW014729 Hs. 95262 nuclear factor related to kappa B bindin 4.01 135184 U13222 Hs. 96028 forkhead box D1 7.00 135242 AI583187 Hs. 9700 cyclin El 13.50 135286 AW023482 Hs. 97849 ESTs 6.46 135289 AW372569 Hs. 9788 hypothetical protein MGC10924 similar to 8. 80 135355 AK001652 Hs. 99423 ATP-dependent RNA helicase 10.00 135371 NM_006025 Hs. 997 protease, serine, 22 8.00 135393 L11244 Hs. 99886 complement component 4-binding protein, 14.60 TABLE 5B shows the accession numbers for those primekeys lacking unigenelD's for Table 5A. For each probeset we have listed the gene cluster number from which the ollgonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubIeTwist, Oakland California), The Genbank accession numbers for sequences comprising each cluster are listed in the 'Accession'column.

Pkey: Unique Eos probeset identifier number CAT number : Gene cluster number Accession: Genbank accession numbers Pkey CAT number Accessions 117079 1621717 1 H92325 T97125 124305 242183_t AW963221 AA344870 AA344871 H93331 101502 18202-6 M26958 109792 754958 1 R49625 F10674 126034 1598157 1 H60340 N91637 102768 44641_1 U62321 H66077 126345 1653833_1 N49713 N49819 W03810 127066 1703458 1 R25066 R20144 R20145 Z43845 127099 244301 1 AA347668 AW956810 Z44271 F07065 F07064 R13506 119243 1774795_1 T12603 T12604 125875 1566433 1 H14480 N98295 112054 1538292 1 R43590 F10439 126979 171411J AA210954AA211007 126992 880655_1 A1809521 H12174Z42556 122318 292419_1 AA42943 AA442754 114699 135322J AA127386 R15644 AA127404 114793 150742_1 AA158245AA158235 108305 111550 1 AA071391 AA069892 AA069891 108393 113411J AA075211AA075245AA075126AA074946 100867 tigr_HT4586 U14622 123731 genbanILAA609839 AA609839 109700 genbank_F09609 F09609 120715 genbank_AA292700 AA292700 113702 genbankT97307 T97307 115113 genbankAA256460 AA256460 101045 entrez_J05614 J05614 108554 genbankAA084948 AA084948 108573 genbank_AA086005 AA086005 119052 149538_1 R10889 R10888 126522 416020_1 W31912 AI167491 126605 439280 1 AA676910AA778853AA778865W86800 103768 46922_1 W42667 AI580740 AI690440 AI561350 AW467906 AW151450 AI825927 AL041716 AI885600 AI742213 AW246324 AI955498 AA033947 AA845593 AI623711 N68583 C00064 AA193567 AW083868 AW163216AA191595 AA522778 A) 628008 Ai915518AA843508 Ai926195 AA176265 AW167963 AA992115 W963647 AW103752 AI862994 AI342059 AA911719 AA176155 AA024712 AA069988 AA205591 AI591107 AI199673 AI811766 AI275832 AI422233 AI191852 AI096682 AI580124 AI683612 AA582453 AA927559 AA486415 T32414 AI084978 H44849 H44848 H20477 T91695 W47039 AA070055 AA024795 AA328855 AA379248 AA379330 AA385580 W25920 W03688 AA448359 AA093881 AW362477 AA089997 AI350265 W93479 N99688 AA932257 AW351469 H68590 AA663402 AA069771 AW087986 A1858420 AA600214 AI970774 AI857712 AI683081 AI885584 AW131150 AI567981 AW0072714 AW189973 AW075495 AW168303 AA953714 AW516881 AI357375 AI566663 AW512676 AI570580 AI023690 AA448216 AI079853 AI422707 AA779516 AW026972 AW130082 AW162307 AW438646 AA709332 AW192394 AI167350 AI217879 AI129152 AA719509 AI350480 AA663418 AI003634 AW118546 AA180261 AA442833 AI268625 AA888881 AI038759 AA5846723 AI248770 AA993694 AI280335 AI885107 AW518649 AA641563 AA995835 AA582521 AI276744 AA436478 AI017360 A1620763 A1859887 N73926 AI076327 AI741615 AI160617 AW17289 AI492005 AA677429 AA996334 AI693771 AI950039 AI245629 AI288515 AI866186 T93293 AA173262 AA599779 AI680092 AW439316 AM84555 A1272672 At583507 AW473219 AA738132 AW473283 AI367492 AA995410 AI689624 AA206353 AI033095 AI040382 AA873630 AI221074 AI934840 AI418680 AA844306 R94503 AA773520 AA843169 AA219425 AA629658 AI811719 AW411275 AI590981 W37907 AI591178 AI684051 AA983238 AA669347 AA976239 AA704570 AI628339 AI884391 AI241580 AI003539 AW176687 AA009650 N34566 Ai333493 A) 186070 AA070827 AA411683 A1280884 AA872023 AA207255 AA021576 N71953 AI885888 AW076039 T15777 Ai537673 AW248048 H09554 W93480 W47001 AW079114 AA063160 AA757453 R60788 AI85931 H20478 AA218882 AA757465 AA100995 AI864135 AI934209 AA070503 H47008 AA219646 W61039 W93907 AW385050 W37967 W78028 AA189007 AA479136 R93650 AA442312 T30287 AA847628 AA180262 AA009649 C03892 AW149464 AA310963 AA219693 AA069747 R29207 AA094784 AA293615 AA447848 AI984167 N90393 C05097 N56499 AW292351 AW149681 AW473258 AA629322 A1004409 AW1 05577 A1954937 A1811070 AA902422 AW514437 AA535460 AA91 6877 AW517122 AA974657 AA975649 AW517130 AW517129 F31737 W07688 Axa193645 AA378994 AA489273 F32267 W39303 AA021181 N86810 AA406524 AA062553 AA436801 H08985 H15979 N40310

AA436789 AA232172 AW360778 W25862 R60282 AA436530 AA378894 AA187461 AI940535 AA604210 AA08914 AA360421 N88243 N84281 AA209340N56174 N88374 AA191088 AW247691 AA249013 AA093111 AA972536 AW298594 AA37S893 T12139 W28186 AW243849 A1288629 AA843996 W15260 At188286 AW248079 R15836 119599 genbank_W45552 W45552 112382 genbank_R59904 R59904 105264 genbankAA227934 AA227934 100071 entrez_A28102 A28102 123315 714071_1 AA496369 AA496646 Table 6A shows 99 genes up-regulated nonsmokers with lung cancer relative to smokers with lung cancer. These genes were selected from 59680 probesets on the Eos/Affymetrix Hu03 Genechip array. Gene expression data for each probeset obtained from this analysis was expressed as average intensity (Al), a normalized value reflecting the relative level of MRNA expression.

Pkey : Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number Unigene, D : Ùnigene number Unigene Title : Unigene gene title R1 : average of AI for samples from non-smokers with adenocarcinoma divided by the 90th percentile of Ai for samples from smokers with adenocarcinoma R2: average of Al for samples from non-smokers with squamous cell carcinoma divided by the 90th percentile of Al for samples from smokers with squamous cell carcinoma Pkey ExAccn UnigenelD Unigene Title R1 R2 100971 BE379727 Hs. 83213 fatty acid binding protein 4, adipocyte 3. 64 101174 L17330 Hs. 280 pre-TINK cell associated protein 15.00 101296 Y12490 Hs. 85092 thyroid hormone receptor interactor 11 2.46 101304 AA001021 Hs. 6685 thyroid hormone receptor interactor 8 12.00 101806 AA586894 Hs. 112408 S100 calcium-binding protein A7 (psorias 2.68 101972 S82472 gb: beta-pol=DNApolymerasebeta (exona 2.11 102274 U30930 Hs. 158540 UDP glycosyltransferase 8 (UDP-galactose 7.50 102394 NM_003816 Hs. 2442 a disintegrin and metalloproteinase doma 7.50 102832 U92015 gb: Human clone 143789 defective mariner 13.50 103010 X52509 Hs. 161640 tyrosine aminotransferase 9.50 103439 X98266 gb : H. sapiens mRNA for ligase like protei 2.50 103563 L02911 Hs. 150402 acfivin A receptor, type 1 9.00 103857 A1076795 Hs. 45033 lacrimal proline rich protein 3.94 104239 AB002367 Hs. 21355 doub, ecortin and CaM kinase-, ike 1 13.50 104590 AW373062 Hs. 83623 nuclearreceptorsubfami, y1, 9roup"m 12.66 104907 AA055829 Hs. 196701 ESTs, Weakly similar to ALU1_HUMAN ALU 16.50 106131 BE514788 Hs. 296244 SNARE protein 2.17 106672 H47233 Hs. 30643 ESTs 7.00 106872 T56887 Hs. 18282 KIAA1134 protein 11.50 106960 AA156238 Hs. 32501 ESTs 2.38 106971 Z43846 Hs. 194478 Homo sapiens mRNA ; cDNA DKFZp43401572 (f 9.50 107982 M035375 Hs. 57887 ESTs, Weakly similar to KIAA0758 protei 2.95 108562 AA100796 gb: zm26cO6. s1 Stratagene pancreas (93720 16.50 108599 AB018549 Hs. 69328 MD-2 protein 13.00 108663 BE219231 Hs. 292653 ESTs, Weakly similar to T26845 hypotheti 2.40 109247 AA314907 Hs. 85950 ESTs 7.00 109630 R44607 Hs. 22672 ESTs 5. 00 110193 AM04874 Hs. 310764 Homo sapiens mRNA ; cDNA DKFZp434M082 (fr 12. 50 110234 H24458 Hs. 32085 EST 16.50 110644 R94207 Hs. 268989 ESTs, Highly similar to type II CALM/AF1 8.00 110886 AW274992 Hs. 72249 three-PDZcontainingproteinsimilarto 17.00 111057 T79639 Hs. 14629 ESTs 16. 50 111950 AF071594 Hs. 110457 Wolf-Hirschhorn syndrome candidate 1 11.00 112291 R53972 Hs. 26026 ESTs 3.00 112956 Z43784 Hs. 75893 ankyrin 3, node of Ranvier (ankyrin G) 2.79 113009 T23699 Hs. 7246 ESTs 4. 50 113060 BE564162 Hs. 250820 hypothetical protein FLJ14827 9.79 113073 N39342 Hs. 103042 microtubule-associated protein 1B 32.50 113074 AK001335 Hs. 31137 protein tyrosine phosphatase, receptor t 3.82 113121 T48011 Hs. 8764 EST 2.21 113125 AA968672 Hs. 8929 hypothetical protein FLJ11362 19.50 113757 AA703095 Hs. 18631 ESTs 2.65 113848 W52854 Hs. 27099 hypothetical protein FLJ23293 similar to 6.00 113884 AI333076 Hs. 28529 chromosome 12 open reading frame 2 6.00 113936 W17056 Hs. 83623 nuclear receptor subfamily 1, group I, m 4.63 114875 AA235609 Hs. 236443 Homo sapiens mRNA ; cDNA DKFZp564N1063 (7. 00 114987 AA251016 Hs. 87808 EST 6.00 115460 AW958439 Hs. 38613 ESTs 2.27 115722 W91892 Hs. 59609 ESTs 9. 00 116261 AA481788 Hs. 190150 ESTs 9.50 116830 H61037 Hs. 70404 ESTs, Weakly similar to ALU2_HUMAN ALU 8.50 116970 AB023179 Hs. 9059 KIAA0962 protein 7.50 117178 H98675 Hs. 269034 ESTs 2.68 117757 AF088019 Hs. 46732 EST 7.50 118283 AA287747 Hs. 173012 ESTs, Weakly similar to A46010 X-linked 16.50 118384 AF217525 Hs. 49002 Down syndrome cell adhesion molecule 2.50 118657 Ai822106 Hs. 49902 ESTs 2.39 120328 AA923278 Hs. 290905 ESTs, Weakly similar to protease [H, sapi 3.50 120404 AB023230 Hs. 96427 KIAA1013 protein 7. 00 120524 AA261852 Hs. 192905 ESTs 6. 00 120688 AW207555 Hs. 97093 Homo sapiens cDNA: FLJ23004 fis, clone L 17.92

121558 AA412497 gb: zt95g12. s1 Soares_testis_NHT Homo sap 2.95 121676 H56037 Hs. 108146 ESTs 10.00 121936 AI024600 Hs. 98612 ESTs 15.00 121938 AA428659 Hs. 98610 ESTs 14.00 122177 AA435789 Hs. 98833 EST 8.93 123442 AA299652 Hs. 111496 HomosapienscDNAFW11643fis, cloneHE 13.04 123551 AA608837 gb: af03h12. s1 Soares testis_NHT Homo sap 11.50 123756 AA609971 Hs. 112795 EST 11. 00 123861 AA620840 gb: af89g01. s1 Soares_testis_NHT Homo sap 2.50 124371 N24924 Hs. 188601 ESTs 6.50 127477 BE328720 Hs. 280651 ESTs 4.33 127591 AI190540 Hs. 131092 ESTs 3.02 128252 AA455924 Hs. 192228 ESTs 7.00 128426 A1265784 Hs. 145197 ESTs 2.08 128925 R67419 Hs. 21851 Homo sapiens cDNA FLJ12900 fis, clone NT 2.11 128945 AI990506 Hs. 8077 Homo sapiens mRNA ; cDNA DKFZp547E184 (fr 10.00 129105 A1769160 Hs. 108681 Homo sapiens brain tumor associated prot 15.50 129235 AW977238 Hs. 126084 KIAA1055 protein 4.25 129506 AB020684 Hs. 11217 KIAA0877 protein 6.50 129595 U09550 Hs. 1154 oviductal glycoprotein 1, 120kD (mucin 9 10. 00 130160 AA305688 Hs. 267695 UDP-Gal : betaGIcNAc beta 1, 3-galactosyltr 20.00 130340 D82326 Hs. 239106 solute carrier family 3 (cystein, dibasi 11.50 131220 AB023194 Hs. 300855 KIAA0977 protein 17.50 131430 AI879148 Hs. 26770 fatty acid binding protein 7, brain 6.10 132114 NM_006152 Hs. 40202 lymphoid-restricted membrane protein 6.15 132458 AA935315 Hs. 48965 Homo sapiens cDNA : FLj21693 fis, clone C 5.58 132647 NML006927 Hs. 54432 sialyl transferase 4B (beta-galactosidase 7.50 132655 D49372 Hs. 54460 small inducible cytokine subfamily A (Cy 2.53 132682 A1077500 Hs. 54900 serologically defined colon cancer antig 2.50 132747 AA345241 Hs. 55950 ESTs, Weakly similar to KIAA1330 protein 2.83 132812 R50333 Hs. 92186 Leman coiled-coil protein 3.82 133337 AF085983 Hs. 293676 ESTs 5.00 133876 AL134906 Hs. 771 phosphorylase, glycogen ; liver (Hers dis 3.00 134119 AW157837 Hs. 79226 fasciculation and elongation protein zet 2.06 134464 AA302983 Hs. 239720 CCR4-NOT transcription complex, subunit 2.27 134542 M14156 Hs. 85112 insulin-like growth factor 1 (somatomedi 11.50 135002 AA448542 Hs. 251677 G antigen 7B 87.00 135305 AA203555 Hs. 98288 Homo sapiens cDNA FLJ14903 fis, clone PL 6.50 TABLE 6B show the accession numbers for those primekeys lacking unigeneID's for Table 6A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the Accession-column.

Pkey : Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT number Accessions 108562 36375 1 AA100796 AF020589 AA074629 AA075946 AA100849 AA085347 AA126309 AA079311 AA079323 AA085274 103439 35330_1 X98266 N41124 123551 genbank_AA608837 AA608837 123861 genbankAA620840 AA620840 102832 entrez U92015 U92015 101972 entrez_S82472 S82472 121558 genbankAA412497 AA412497

i adie tA snows vu genes uown-reguiatea in non-smoKers witn lung cancer relative to smokers with lung cancer, I nese genes were selected trom 596ut prooesets on tne Eos/Affymetrix Hu03 Genechip array. Gene expression data for each probeset obtained from this analysis was expressed as average intensity (Ai), a normalized value reflecting the relative level of mRNA expression.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigeneID : Unigene number Unigene Title : Unigene gene title R1 : 90th percentile of AI for samples from smokers with adenocarcinoma divided by the average of Al for samples from non-smokers with adenocarcinoma.

R2: 90th percentile of Al for samples from smokers with squamous cell carcinoma divided by the average of AI for samples from non-smokers with squamous cell carcinoma.

Pkey ExAccn UnigeneID Unigene Title R1 R2 100187 D17793 Hs. 78183 aldo-keto reductase family 1, member C3 164.10 100380 D82343 Hs. 18551 neurobtastoma (nerve 6ssue) protein 77.40 100576 X00356 Hs. 37058 calcitonin/calcitonin-related polypeptid 102.40 100971 BE379727 Hs. 83213 fatty acid binding protein 4, adipocyte 463.80 101046 K01160 (NONE) 672.00 101066 AW970254 Hs. 889 Charot-Leyden crystal protein 66.00 101175 U82671 Hs. 36980 melanoma antigen, family A, 2 77.20 101497 W05150 Hs. 37034 homeo box A5 62.80 101663 NM_003528 Hs. 2178 H2B histone family, member Q 78. 00 101677 NM_000715 Hs. 1012 complement component 4-binding protein, 186. 20 101745 M88700 Hs. 150403 dopa decarboxylase (aromatic L-amino aci 80.08 101941 S77583 gb: HERVK10/HUMMTV reverse transcriptase 99.20 102125 NM_006456 Hs. 288215 sialyltransferase 103.10 102242 U27185 Hs. 82547 retinoic acid receptor responder (tazaro 67.00 102340 U37055 Hs. 278657 macrophagestimutating1 (hepatocytegro 71. 60 102369 U39840 Hs. 299867 hepatocyte nuclear factor 3, alpha 69.70 102457 NM001394 Hs. 2359 dual specificity phosphatase 4 153.00 102669 U71207 Hs. 29279 eyes absent (Drosophila) homolog 2 65.70 102796 AL079646 Hs. 107019 symplekin ; Huntingtin interacting protei 58.80 102829 NM_006183 Hs. 80962 neurotensin 268. 80 103207 X72790 gb: Human endogenous retrovirus mRNA for 70.00 103242 X76342 Hs. 389 alcohol dehydrogenase 7 (class IV), mu o 212.10 103260 X78416 Hs. 3155 casein, alpha 130. 70 103351 X89211 gb: H. sapiensDNAforendogenousretrovir 64.60 104212 AB002298 Hs. 173035 KIAA0300 protein 66.80 104252 AF002246 Hs. 210663 cell adhesion molecule with homology to 63.80 104258 AF007216 Hs. 5462 solute carrier family 4, sodium bicarbon 94.40 105024 AA126311 Hs. 9879 ESTs 68. 20 106260 A1097144 Hs. 5250 ESTs. Weakly similar to ALU1 HUMAN ALU S 74.60 106440 AA449563 Hs. 151393 glutamate-cysteine ligase, catalytic sub 71.10 106566 BE298210 gb: 60118016F1 NIH_MGC_17 Homo sapiens c 73.20 106605 AW772298 Hs. 21103 Homo sapiens mRNA ; DNA DKFZp564B076 (fr 83.80 106614 AA648459 Hs. 335951 hypothetical protein AF301222 62.30 106654 AW075485 Hs. 286049 phosphoserine aminotransferase 202.40 106999 H93281 Hs. 10710 hypothetical protein FLJ20417 89.60 108700 AA121518 Hs. 193540 ESTs, Moderately similar to 2109260A B c 66.40 108810 AW295647 Hs. 71331 hypothetical protein MGC5350 95.50 108857 AK001468 Hs. 62180 anillin (Drosophila Scraps homolog), act 63.40 109597 AA989362 Hs. 293780 ESTs 85.00 109691 T65568 Hs. 12860 ESTs 58. 70 109704 AI743880 Hs. 12876 ESTs 60.60 110942 R63503 Hs. 28419 ESTs 76.40 111722 R23924 Hs. 23596 EST 74.60 112891 T03927 Hs. 293147 ESTs, Moderately similar to A46010 X-11 64.80 112992 AL157425 Hs. 133315 Homo sapiens mRNA ; cDNA DKFZp761J1324 (f 76.70 113073 N39342 Hs. 103042 microtubule-associated protein 1B 120.20 114251 H15261 Hs. 21948 ESTs 127. 20 115230 AA278300 Hs. 124292 Homo sapiens cDNA : FLJ23123 fis, clone L 174.00 115291 BE545072 Hs. 122579 hypothetical protein FLJ10461 91.00 115815 AW905328 Hs. 180842 nbosomat protein L13 66.40 115909 AW872527 Hs. 59761 ESTs, Weakly similar to DAP1_Human DEATH 226.60 115965 AA001732 Hs. 173233 hypothetical protein FLJ10970 82.80 116107 AL133916 Hs. 172572 hypothetical protein FLJ20093 361.60 116552 D20508 Hs. 164649 hypothetical protein DKFZp434H247 69.00 116571 D45652 gb: HUMGS02848 Human adult lung 3'direct 64. 20 118466 N66741 gb: yz33gO8. s1 Morton Fetal Cochlea Homo 63.50 120484 AA253170 Hs. 96473 EST 81.60 120983 AA398209 Hs. 97587 EST 81.10 121034 AL389951 Hs. 271623 nucleoporin 50kD 66. 20 121423 AW973352 Hs. 290585 ESTs 64. 40 122553 AA451884 Hs. 190121 ESTs 60.40 122946 AI718702 Hs. 308026 major histocompatibility complex, class 188. 60 123130 AA487200 gb: ab19f02. sl Stratagene lung (937210) H 80.20 124472 N52517 Hs. 102670 EST 71.00 124526 N62096 Hs. 293185 ESTs Weakly similar to JC7328 amino aci 104. 90 125489 H49193 Hs. 124984 ESTs, Moderately similar to ALU7_HUMAN A 72.00 125731 R61771 Hs. 26912 ESTs 69.90 . 125747 NM_002884 Hs. 865 RAP1A, member of RAS oncogene family 69. 00 126020 H79863 Hs. 114243 ESTs 62.40 126547 U47732 Hs. 84072 transmembrane 4 superfamily member 3 62.80 126966 R38438 Hs. 182575 solute carrier family 15 (H+/peptide tra 60.10

127472 AA761378 Hs. 192013 ESTs 70.20 127610 AA960867 Hs. 150271 ESTs, Highly similar to unnamed protein 64.00 127742 AW293496 Hs. 180138 ESTs 85.20 127987 AI022103 Hs. 124511 ESTs 96.60 128233 AW889132 Hs. 11916 ribokinase 78.90 128420 AA650274 Hs. 41296 fibronectin leucine rich tansmembrane p 106.90 128766 AW160432 Hs. 296460 craniofacial development protein 1 66.80 129014 AW935187 Hs. 170162 KIAA1357 protein 58.53 129215 AB040930 Hs. 126085 KIAA1497 protein 64.20 130090 H97878 Hs. 132390 zinc finger protein 36 (KOX 18) 63.80 130385 AW067800 Hs. 155223 stanniocalcin 2 139.60 130732 AW890487 Hs. 63984 cadherin 13, H-cadherin (heart) 64.60 131025 AB040900 Hs. 6189 K ! M1467 protein 64.40 131241 BE501914 Hs. 24654 Homo sapiens cDNA FLJ11640 fis, clone HE 76.20 131775 AB014548 Hs. 31921 KIAA0648 protein 97.80 132240 AB018324 Hs. 42676 KIAA0781 protein 71.00 132856 NM_001448 Hs. 58367 glypican 4 88. 40 132977 AA093322 Hs. 301404 RNA binding motif protein 3 133.20 133749 L20852 Hs. 10018 solute carrier family 20 (phosphate tran 59.30 133818 AI110684 Hs. 7645 fibrinogen, B beta polypeptide 341.00 134264 AF149297 Hs. 8087 NAG-5 protein 64.30 134265 M83772 Hs. 80876 flavin containing monooxygenase 3 232.53 134346 X84002 Hs. 82037 TATA box binding protein (TBP)-associate 66.00 134395 AA456539 Hs. 8262 lysosomal-associated membrane protein 2 75.80 135047 AL134197 Hs. 93597 cyclin-dependent kinase 5, regulatory su 108.30 135056 N75765 Hs. 93765 lipoma HMGIC fusion partner 71.40 135309 AI564123 Hs. 42500 ADP-ribosylation factor-like 5 70.40 TABLE 78 shows the accession numbers for those primekeys lacking unigeneID's for Table 7A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubieTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the Accession-column.

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT number Accessions 103207 30635 : 4 X72790 106566 120358_1 BE298210 A1672315 AW086489 BE298417 AA455921 AA902537 BE327124 R14963 AA085210 AW274273 AI333584 AI369742 AI039658 AI885095 AI476470 AI287650 AI885299 AI985381 AW592624 AW340136 AI266556 AA456390 AI310815 AA484951 116571 genbank_D45652 D45652 118466 genbank_N66741 N66741 101046 entrez_K01160 K01160 101941 entrez_S77583 S77583 103351 entrez_X89211 X89211 123130 genbank_AA487200 AA487200

Table 8A shows 1720 genes either up or down-regulated in lung tumors or chronically diseased lung relative to a broad collection of over 40 distinct normal body tissues.

Chronically diseased lung samples represent chronic non-malignant lung diseases such as fibrosis, emphysema, and bronchitis. These genes were selected from 39494 probesets on the Eos/Aifymetrix Hu02 Genechip array. Gene expression data for each probeset obtained from this analysis was expressed as average intensity (AI), a normalized value reflecting the relative level of mRNA expression.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number Unigene ! D : Unigene number Unigene Title : Unigene gene title R1 : 70th percentile of AI for lung tumors divided by 90th percentile of AI for normal lung R2: 70th percentile of Al for chronically diseased lung divided by 90th percentile of At for normal lung Pkey ExAccn UnigeneID Unigene Title R1 R2 300097 AI916973 Hs. 213603 ESTs 5.46 4.69 300117 AW189787 Hs. 147474 ESTs 0.58 0.56 300197 AI686661 Hs. 218286 ESTs 4.26 5. 44 300201 AI308300 gb: ta90cO6. x1 NCI_CGAP_Bm20 Homo sapien 0.62 0.83 300225 AI989963 Hs. 197505 ESTs 1.68 1.75 300247 AW274682 Hs. 161394 ESTs 1. OS 2.28 300256 A1469095 Hs. 298241 Transmembrane protease, serine 3 0.86 1.00 300337 AI707881 Hs. 202090 ESTs 5.80 9, 09 300362 Z42308 gb: HSC0FB121 normalized infant brain cDN 4. 18 12. 78 300374 AI859947 Hs. 314158 ESTs 2.99 4. 38 300387 AW270150 Hs. 254516 ESTs 1.50 2.53 300440 A1421541 Hs. 146164 ESTs 3.98 5.25 300441 R10367 Hs. 307921 EST, Weakly similar to Z232_HUMAN ZINC F 3, 18 6. 80 300449 AI362967 Hs. 132221 hypothetical protein FLJ12401 0. 43 0.62 300469 AW135830 Hs. 233955 hypothetical protein FLJ20401 0.16 0.83 300552 X85711 Hs. 21838 hypothetical protein FLJ11191 4.10 9.75 300627 W27363 gb : ab37d01. r1 Stratagene HeLa cell s3 93 4.60 12. 60 300630 AW118822 Hs. 128757 ESTs 2.91 5.86 300716 AI216113 Hs. 126280 hypothetical protein FLJ23393 1.00 0.92 300738 AI623332 Hs. 130541 KIAA1542 protein 1.82 1.71 300777 AA235361 Hs. 96840 K, M1527 protein 4.48 8.22 300790 AI492471 Hs. 188270 ESTs 1.29 1.18 300832 AI688147 Hs. 220615 ESTs, Weakly similar to T03829 transcrip 5.51 8.56 300836 Z44942 Hs. 22958 calcium channel alpha2-delta3 subunit 4. 90 6.34 300838 AI582897 Hs. 192570 hypothetical protein FLJ22028 1.70 2.81 300878 AW449802 Hs. 285901 Homo sapiens cDNA FLJ20428 fis, clone KA 4.56 7. 91 300897 AI890356 Hs. 127804 ESTs, Weakly similar to T17233 hypotheti 2.23 1.58 300926 AA504860 gb: ab03a10.s1 Stratagene fetal retina 93 2.13 3.50 300960 A1041019 Hs. 152454 ESTs 2.74 4.46 300961 AW204069 Hs. 312716 ESTs, Weakly similar to unnamed protein 1.00 1.00 300962 AA593373 Hs. 293744 ESTs 1.46 1. 51 300967 AA565209 Hs. 269439 ESTs 0. 39 1.30 300987 AW450840 Hs. 148590 ESTs, Weakiy similar to AF2088461 BM-00 1.49 1.08 300988 AI927208 Hs. 208952 ESTs 0.16 0.37 301050 AW136973 Hs. 288516 ESTs, Weakly similar to S69890 mitogen i 3.23 1.94 301098 AA677570 Hs. 185918 ESTs 6.76 14.28 301157 AA729905 Hs. 231916 ESTs 3. 16 8.85 301162 AI142118 Hs. 129004 ESTs 1.68 7.18 301170 AA737594 Hs. 247606 ESTs 4.40 6.42 301192 AI808751 Hs. 121188 ESTs 6.38 11.59 301193 AA758115 Hs. 128350 ESTs, Weakly similar to JC5423 2-hydroxy 4.35 7.78 301267 AW297762 Hs. 255690 ESTs 1. 56 1.61 301281 AA843986 Hs. 190586 ESTs 2.19 1.78 301341 AI819198 Hs. 208229 ESTs 0.76 0.76 301382 AA912839 Hs. 163369 ESTs 1.00 1.81 301407 AW450466 Hs. 126830 ESTs 1.48 1.51 301452 AA975688 Hs. 159955 ESTs 0.51 1.46 301483 AW272467 Hs. 254655 Unfitted 2.40 5. 02 301494 AI68034 Hs. 131099 ESTs 2. 79 3.41 301521 Api733621 Hs. 133011 zinc finger protein 117 (HPF9) 0.67 0.67 301531 A1077462 Hs. 134084 ESTs 2.52 3.76 301580 AI878959 Hs. 73737 splicing factor, arginine/serine-dch 1 7.41 11.92 301676 Z43570 Hs. 27453 ESTs Moderately simiiar to G01251 Par p 8. 31 10.70 301690 F05865 Hs. 108323 ubiquitin-conjugating enzyme E2E 2 (homo 2.70 4.22 301718 F07744 Hs. 7987 DKFZP434F162 protein 4.20 8.78 301799 AA384252 Hs. 286132 D15F37 (pseudogene) 5.93 7.04 301804 AA581004 Hs. 62180 anillin (Drosophila Scraps homolog), act 1.70 0.76 301822 X17033 Hs. 271986 integrin, alpha 2 (CD49B, alpha 2 subuni 1.58 1.36 301846 R20002 Hs. 6823 hypothetical protein FLJ10430 1. 00 1. 00 301868 T71508 Hs. 13861 ESTs, Weakly similar to pH sensitive max 2.88 5.49 301882 T78054 gb: yc97g09.r1 Soares infant brain 1NIB H 2.28 3.80 301905 AI991127 Hs. 117202 ESTs 1.00 1.00 301948 AA344647 Hs. 116724 aldo-keto reductase family 1, member B11 5. 28 2.28 301960 AW070252 Hs. 27973 KIAA0874 protein 5.38 6. 48 302011 T91418 Hs. 125156 transcriptional adaptor 2 (ADA2, yeast, 3.03 3.42 302016 N40834 Hs. 23495 hypothetical protein FLJ11252 1.00 1.25 302041 NM001501 Hs. 129715 gonadotropin-releasing hormone 2 0.71 0. 99 302072 AJ238381 Hs. 132576 paired box gene 9 1.60 1.71 302094 AI286176 Hs. 6786 ESTs 0.52 1.20 302095 AW044300 Hs. 137506 Homo sapiens BAG clone RP11-120J2ffom 7 2. 75 4.93 302148 AW269618 Hs. 23244 ESTs 3.04 3.87

302155 A1088485 Hs. 144759 ESTs 0. 45 1.15 302201 AJ006276 Hs. 159003 transient receptor potential channel 6 0.33 0.84 302202 AF097159 Hs. 159140 UDP-Gai : betaGlcNAc beta, 1,4- galactosylt 0.52 0.94 302206 A, 937193 Hs. 41143 phosphoinositide-specificphosphoiipase 2. 76 3.65 302209 AF047445 Hs. 159297 killercelllectn-likereceptorsubfami 1.00 1.00 302235 AL049987 Hs. 166361 HomosapiensmRNA ; cDNADKFZp564F112 (fr 1.68 1.50 302290 AL117607 Hs. 175563 Homo sapiens mRNA ; cDNA DKFZp564N0763 (f 1.00 2.11 302328 AA354849 Hs. 23240 Homo sapiens cDNA FLJ13496 fis, clone PL 9.38 13. 08 302346 AL039101 Hs. 194625 dynein, cytoplasmic, light intermediate 3.27 7.24 302360 AJ010901 Hs. 198267 mucin 4, tracheobronchial 2.54 1.88 302384 Y08982 Hs. 202676 synaptonemal complex protein 2 1.00 0.91 302406 U86751 Hs. 211956 CD3-epsilon-associated protein ; antisens 2.63 2.67 302409 AF155156 Hs. 218028 adaptor-related protein complex 4, epsil 5.82 9.34 302423 AB028977 Hs. 225974 KIAA1054 protein 3.66 3.18 302432 AL080068 Hs. 272534 Homo sapiens mRNA ; cDNA DKFZp564J062 (fr 2.44 6.77 302435 AF092047 Hs. 227277 sine oculis homeobox (Drosophila) homolo 0.44 0.84 302437 AB024730 Hs. 227473 UDP-N-acetylglucosamine : a-1, 3-D-mannosid 4.18 5.64 302455 AA356923 Hs. 240770 nuclear cap binding protein subunit 2, 2 1.85 0.92 302472 AA317451 Hs. 6335 SW/SNF related, matrix associated, acti 2.04 2. 13 302476 AF182294 Hs. 241578 U6 snRNA-associated Sm-like protein LSm8 1, 44 1.89 302489 T80660 Hs. 230424 Homo sapiens DNA FLJ13540 fis, clone PL 0.51 1.10 302490 AA885502 Hs. 187032 ESTs 2. 64 4.87 302562 AJ005585 Hs. 48956 gap junction protein, beta 6 (connexin 3 5.34 2.68 302566 AA085996 Hs. 248572 hypothetical protein FLJ22965 1.00 1.21 302630 AB029488 Hs. 272100 SMS3 protein 0. 52 1.24 302634 AB032953 Hs. 173560 odd Oz/ten-m homolog 2 (Drosophila, mous 1. 00 1.00 302638 AA463798 Hs. 102696 MCT-1 protein 1.58 1. 02 302647 X57723 Hs. 198273 NADH dehydrogenase (ubiquinone) 1 betas 2.72 6.85 302655 AJ227892 Hs. 146274 ESTs 1.00 4. 32 302656 AW293005 Hs. 70704 Homo sapiens, clone IMAGE : 2823731, mRNAs 2. 97 0. 93 302668 AA580691 Hs. 180789 S164 protein 0.80 0.95 302679 H65022 gb: yu66g11. r1 Weizmann Olfactory Epithel 1.68 5. 04 302680 AW192334 Hs. 38218 ESTs 2. 70 7, 98 302697 AJ001408 gb: HomosapiensmRNAforimmunogRobutin 4. 25 8.13 302705 U09060 gb: Human immunoglobulin heavy chain, V-r 3.91 8. 68 302711 L08442 gb: Human autonomous replicating sequen 2.20 2.73 302719 W69724 Hs. 288959 hypothetical protein FLJ20920 0.54 1. 02 302742 L12069 gb: Homo sapiens (clone WR4.10VH) anti-th 4. 28 11.57 302755 AW384815 Hs. 149208 KIAA1555 protein 1.57 2.38 302771 H98476 Hs. 42522 ESTs 2.94 4.68 302789 AJ245067 gb: Homo sapiensmRNA for immunoglobulin 3. 49 6.31 302795 AJ245313 Hs. 272838 hypothetical protein FLJ10494 0.80 2.74 302802 Y08250 gb: H. sapiens mRNA for variable region of 1.13 0.77 302803 AA442824 Hs. 293961 ESTs, Moderately similar to putative DNA 3.14 10.68 302812 N31301 Hs. 152664 hypothetical protein FLJ20051 3.04 8.24 302847 X98940 gb: H. sapiens rearranged Ig heavy chain (1. 80 1. 92 302885 AL137763 Hs. 132127 hypothetical protein LOC57822 1.00 1.00 302943 AI581344 Hs. 127812 ESTs, Weakly similar to T17330 hypotheti 0.53 0.67 302977 AW263124 Hs. 315111 hypothetical protein FLJ12894 245 2.62 303006 AF078950 Hs. 24139 Homo sapiens cDNA : FLJ23137 fis, clone L 4.88 8.61 303011 AF090405 gb: Homo sapiens clone 2A1 scFV antibody 1. 41 1.86 303013 F07898 Hs. 288968 RAB22A, member RAS oncogene family 1. 51 1.19 303061 AF151882 Hs. 27693 peptidylprolyl isomerase (cycolphilin)-I 0.72 0.76 303077 AF163305 gb: H. sapiens T-cell receptor mRNA 1.17 3.90 303090 AA443259 Hs. 146286 kinesin family member 13A 4.08 6.46 303091 AF192913 Hs. 130683 zinc finger protein 180 (HHZ168) 2.50 4. 37 303094 AF195513 Hs. 278953 Pur-gamma 5.38 8.38 303095 AF202051 Hs. 134079 NM23-H8 3.26 4.08 303131 AW081061 Hs. 103180 DC2 protein 2. 02 1. 83 303195 AA082211 Hs. 233936 myosin, light polypeptide, regulatory, n 1.32 3.95 303196 AA082298 Hs. 59710 ESTs 0.77 0.53 303216 AA581439 Hs. 152328 ESTs 0. 24 0.63 303222 AA333538 Hs. 204501 hypothetical protein FLJ10534 3.56 6. 22 303234 AA132255 Hs. 143951 ESTs 2.28 3.17 303251 AW340037 Hs. 115897 protocadherin 12 0. 38 1.02 303295 AA205625 Hs. 208067 ESTs 2.30 1.00 303297 T80072 Hs. 13423 Homo sapiens clone 24468 mRNA sequence 1.86 4.48 303316 AF033122 Hs. 14125 p53 regulated PA26 nuclear protein 0.10 0.80 303467 AA398801 Hs. 323397 ESTs 4.54 9.65 303506 AA340605 Hs. 105887 ESTs, Weakly similar to Homolog of rat Z 0. 09 0.04 303552 AA359799 Hs. 224662 ESTs, Weakly similar to unnamed protein 1.00 1. 72 303598 AA382814 gb : EST96097 Testis I Homo sapiens cDNA 5 4.96 9.14 303637 AF056083 Hs. 24879 phosphatidic acid phosphatase type 2C 2, 06 2. 02 303655 AA504702 Hs. 258802 ATPase, (Na+) IK+ transporting, beta 4 po 1.00 1.24 303756 A1738488 Hs. 115838 ESTs 1.08 1.43 303856 AA968589 Hs. 180532 glucose phosphate isomerase 1.76 1.31 303893 N88597 Hs. 113503 karyopherin (importin) beta3 2.30 2.57 303907 AW467774 Hs. 171880 polymerase (RNA) l, (DNA directed) polyp 3.10 5.79 303946 AW474196 Hs. 306637 Homo sapiens cDNA FLJ12363 fis, clone MA 5.06 11.86 303978 AW513315 gb: xo43c12. x1 NCI_CGAP_Ut1 Homo sapiens 5.14 7.31 303981 AW513804 Hs. 278834 ESTs, Weakly similar to ALU1_HUMAN ALU S 2.83 4.06 303990 AW515465 gb: xu71a11.x1 NCI_CGAP_Kid8 Homo sapiens 1.15 2.35 303998 AW516449 gb : xt68f05. x1 NCI CGAP_Ut2 Homo sapiens 2.20 9.35 303999 AW516611 gb: xp70b11.x1 NCI_CGAP_Ov39 Homo sapiens 4.85 6.28 304006 AW517947 gb: xt66h02. x1 NCI_CGAP_Ut2 Homo sapiens 3.21 4.07

304008 AW518198 Hs. 3297 ribosomal protein S27a 6.50 11.08 304009 AW518206 Hs. 181165 eukaryotic translation elongation factor 1.88 3.27 304024 T03036 gb: FB21B7 Fetal brain, Stratagene Homo s 2.15 3.55 304026. T03160 gb: FB26F2 Fetal brain, Stratagene Homo s 5.88 11.80 304028 T03266 gb: FB7C1 Fetal brain, Stratagene Homo sa 5.59 13.46 304036 T16855 Hs. 244621 ribosomal protein S14 6.55 14.43 304046 T54803 gb: yb42d06. sl Stratagene fetal spleen (9 6.18 12.19 304061 T61521 gb: yb73g01. s1 Stratagene ovary (937217) 2.64 8.23 304063 T62536 gb: yc04c12. s1 Stratagene lung (937210) H 0.53 1.61 304097 R25376 Hs. 177592 ribosomal protein, large, Pi 6.49 11.67 304114 R78946 gb: yi87g02.s1 Soares placenta Nb2HP Homo 2.90 4.18 304122 H28966 gb: ym31a06. s1 Soares infant brain 1NIB H 1.00 2.76 304155 H68696 gb: yr78bO6, s1 Soares fetal liver spleen 0.79 1.18 304203 N56929 gb: yy82dO8. s1 Soares multiple sclerosis 4.28 11.34 304234 W81608 gb : zd88h06. sl Soares_fetal_heart_NbHH19W 6.47 11.03 304267 AA064862 Hs. 73742 ribosomal protein, large, PO 1.34 1.16 304270 AA069711 Hs. 297753 vimentin 3.40 5.40 304287 AA079286 Hs. 78466 proteasome (prosome, macropain) 26S sub 2.93 4. 42 304348 AA179868 gb: zp38g12. s1 Stratagene muscte 937209 H 3.98 10.96 304415 AA290747 Hs. 169476 glyceraldehyde-3-phosphate dehydrogenase 3.32 5. 99 304430 AA347682 gb: EST54044 Fetal heart II Homo sapiens 1.00 1.00 304456 AA411240 gb:zv26g05.s1 Soares_NhHMPu_S1 Homo sapi 1.42 3.33 304521 AA464716 gb: zx82cl1. s1 Soares ovary tumor NbHOTH 2.18 1.15 304526 AA476427 gb: zx02c05. s1 Soares_total_fetus_Nb2HF8_ 5.38 14.11 304542 AA482602 Hs. 169476 glyceraldehyde-3-phosphate dehydrogenase 4. 16 8. 23 304546 AA486074 Hs. 297681 serine (or cysteine) proteinase inhibito 0.55 1.20 304607 AA513322 gb : nh85e08, s1 NCI_CGAP_Br1.1 Homo sapien 1.95 2.10 304640 AA524440 Hs. 111334 ferritin, light polypeptide 2. 10 2.83 304650 AA527489 Hs. 3463 ribosomal protein S23 3. 33 12.62 304735 AA576453 gb: nm75h11. s1 NCI_CGAP_Co9 Homo sapiens 1.33 0.88 304760 AA580401 gb: nn13g09. s1 NCI_CGAP_Co12 Homo sapiens 3.68 8.14 304849 AA588157 Hs. 13801 KIAA1685 protein 2.77 3.70 304917 AA602685 Hs. 284136 PRO2047 protein 7.16 11.01 304921 AA603092 Hs. 297753 vimentin 2. 47 4.24 304966 AA613893 Hs. 282435 ESTs'6. 78 11.66 304987 AA618044 Hs. 300697 immunoglobulin heavy constant gamma 3 (G 0.90 1.23 305016 AA626876 gb: zu89h06. s1SoarestestisNHT Homo sap 6.46 10.17 305034 AA630128 gb: ab99c04. s1 Stratagenelung (937210) H 1.00 1.00 305072 AA641012 gb: nr72a12. s1 NCI_CGAP_Pr24Homosapiens 5.68 11.59 305111 AA644187 Hs. 303405 ESTs 1.48 1.37 305148 AA654070 gb: nt01g08. s1 NCI_CGAP_Lym3 Homo sapiens 1.76 4. 61 305159 AA659166 Hs. 275668 EST, Weakly similar to EF1 D_HUMAN ELONG 1.00 2.15 305190 AA665955 gb: ag57d12.s1 Gessler Wilms tumor Homo s 5.31 8.14 305232 AA670052 Hs. 169476 glyceraldehyde-3-phosphate dehydrogenase 0. 78 1.18 305235 AA670480 gb: ag37e01. s1 Jia bone marrow stroma Hom 3.11 8.66 305245 AA676695 Hs. 81328 nuclear factor of kappa light polypeptid 4.38 7.53 305312 AA700201 gb: zj44f07. s1 Soares fetal liver_spleen_ 2.13 2.66 305322 AA701597 Hs. 163019 EST 1.20 1.40 305394 AA720942 Hs. 300697 immunoglobulin heavy constant gamma 3 (G 1.16 0.68 305413 AA724659 gb: ai10f08. s1 Soares_parathyroid_tumor_N 5.86 9. 87 305447 AA737856 gb: nx10c08. s1 NC, _CGAP_GC3Homosapiens 2.21 2.86 305476 AA745664 Hs. 287445 hypothetical protein FLJ 11726 3.36 6.54 305483 AA748030 Hs. 303512 EST 1. 00 2.02 305528 AA769156 gb: nz12e05, sl NCI CGAP_GCB1 Homo sapiens 6.44 9. 10 305612 AA782347 Hs. 272572 hemoglobin, alpha 2 0. 19 0.79 305614 AA782866 gb: aj09h02. s1 Soares_parathyroid tumor_N 1.00 1. 00 305616 AA782884 Hs. 275865 ribosomal protein S18 7.57 10. 20 305637 AA806124 gb: oe29a12.s1 NCI_CGAP_Pr25 Homo sapiens 4.78 12.42 305639 AA806138 gb: oe29cl2. s1 NCI CGAP Pr25Homosapiens 0. 89 0.70 305650 AA807709 gb: nw31e04. s1 NCI_CGAP_GCB0 Homo sapiens4. 49 8.71 305690 AA813477 gb: ai67a05. s1 Soares_testis_NHTHomosap 4.91 9.40 305726 AA828156 Hs. 73742 ribosomal protein, large, PO 0.19 0.81 305728 AA828209 gb: of34a02. s1 NCI_CGAP_Kid6 Homo sapiens 5.12 9.29 305759 AA835353 gb: ak72bO6. s1 Barstead spllen HPLRB2 Hom 1.66 4.11 305792 AA845256 gb: akB4a08. s1Barstead spleenHPLRB2Hom 2.34 4. 25 305864 AA864374 Hs. 73742 ribosomal protein, large, PO 0.30 1.40 305901 AA872968 gb: oh63h08. s1 NCI CGAP Kid5 Homo sapiens 2.10 5.21 305910 AA875981 gb: nx21h02, sl NCI CGAP_GC3Homosapiens 0. 32 1.01 306015 AA897116 gb: am08b07. s1 Soares_NFL_T_GBC_S1 Hom S1. 56 1.12 306017 AA897221 Hs. 109058 ribosomal protein S6 kinase, 90kD, polyp 5. 21 7.90 306020 AA897630 Hs. 130027 EST 1.96 6.59 306063 AA906316 gb: ok03g03. s1 Soares_NFL_T_GBC_S1 Homos 7.38 20.69 306065 AA906725 gb: ok78g02, s1 NCI CGAP_GC4 Homo sapiens 7.19 13.48 306104 AA910956 gb: ok85hil. sl NC, CGAP Kid3Homosapiens 6.50 9.13 306109 AA911861 gb : og21a07.s1 NCI_CGAP_PNS1 Homo sapiens 4.21 5.25 306148 AA917409 Hs. 288036 tRNAisopentenyipyrophosphatetransferas 2.20 2.70 306242 AA932805 gb: oo60g04. s1 NCI_CGAP_Lu5 Homo sapiens Z84 5.35 306288 AA936900 gb: oi53hO5, s1 NCI CGAP_HN3 Homo sapiens 1.60 1.12 306325 AA953072 Hs. 210546 interleukin 21 receptor 1.65 2.26 306353 AA961382 Hs. 275865 ribosoma ! protein S18. 3.78 6.32 306375 AA968650 Hs. 276018 EST, Moderately similar to JC4662 ribos 4.30 5.74 306396 AA970223 gb: op09d05. s1NC) CGAPKid6 Homo sapiens 0.95 2. 45 306428 AA975110 Hs. 191228 hypothetical protein FLJ20284 3. 19 4. 10 306442 AA976899 gb: oq35e09. s1 NCI_CGAP_GC4 Homo sapiens 4.67 7.44 306446 AA977348 gb: oq72e12.s1 NCI_CGAP_Kid6 Homo sapiens 3. 92 6.27

306458 AA978186 gb : op33cO6, s1 Soares_NFL_T_GBC_S1 Homo s 3.35 5.77 306467 AA983508 Hs. 163593 ribosomal protein L18a 3.72 5.37 306510 AA988546 gb: or84d07, s1 NCI_CGAP_Lu5 Homo sapiens 1.00 1.00 306555 AA994304 Hs. 276083 EST, Weakly similar to RL23_HUMAN 60S R 6.61 10.91 306557 AA994530 gb: ou57e08. s1 NCI_CGAP_Br2 Homo sapiens 16. 20 31.83 306572 AA995686 gb: os25cl2. sl NCi CGAP_Kid5Homosapiens 2.51 6.52 306582 AA996248 gb: os18c10. sl NCI CGAP_Kid5 Homo sapiens 1.42 3.13 306598 A1000320 Hs. 169476 glyceraldehyde-3-hosphate dehydrogenase 4.91 8.68 306605 A1000497 Hs. 119500 ribosomal protein, large P2 1.96 8.60 306656 A1004024 gb: oul1bO7. x1 Soares_NFL_T_GBC_S1 Homo s 0.11 0.45 306676 AI05603 Hs. 284136 PR02047 protein 9.56 17.28 306686 A1015615 gb: ov29f10. xlSoares Homo sap 1.86 3.60 306702 A1022565 Hs. 307670 EST 1.47 1.19 306728 A1027359 Hs. 272572 hemoglobin, alpha 2 1.28 2.83 306751 A1032589 gb: ow70h12. s1 Soares_fetal_liver_spleen_ 3. 91 5.21 306767 A1038963 Hs. 249118 ESTs 3.33 6.06 306892 A1092465 gb: qa75h12. x1 Soares_fetal_heart_NbHH19W 3.77 7.46 306897 AI093967 gb: qa33cO6. s1 Soares-NHHMPu_S1 Homo sapi 2.12 2.85 306956 AI12511 gb: am66f03. s1 Barstead spllen HPLRB2 Hom 6.10 10.52 306958 AI125152 gb: am55e09. xl Johnston frontal cortex Ho 1.72 1.56 307035 AI142774 Hs. 119122 ribosome protein L13a 2.00 4. 70 307041 A1144243 gb: qb85b12. x1 Soares_fetal_heart_NbHH19W 9.12 12.56 307091 AI167439 gb: ox70hO6. s1 Soares_NhHMPu_S1 Homo sapi 4.88 8.52 307181 A1189251 gb: qc99gO6. x1 Soares_pregnant_uterus_NbH 3.55 6.44 307297 AI205798 Hs.111334 ferritin, light polypeptide 2.46 4.65 307317 AI208303 Hs. 147333 EST 5.64 10.13 307327 A) 214142 Hs. 246381 CD68 antigen 3.18 5. 15 307382 A1223158 Hs. 147885 ESTs 2.02 3.73 307410 AI241715 Hs. 77039 ribosomal protein S3A 0.72 0.48 307415 AI242118 gb: qh92b02. x1 Soares NFL_T_GBC_S1 Homo s 2.38 3.51 307423 AI243206 Hs. 179573 coliagen, type I, alpha 2 2.60 5.44 307426 Api243364 gb : qh30g11.x1 Soares_NFL_T_GBC_S1 Homo s 3.18 7.67 307517 AI275055 gb: qt72d03. x1SoaresNhHMPuS1 Homo sapi 1.00 1. 00 307551 AI281556 gb : qu52f11. xl NCI_CGAP_Lym6Homosapiens 3.40 11.20 307561 AI282207 gb : qp65a12. x1 Soares fetal lung_NbHL19W 4.74 15.51 307608 AI290295 gb: qm01f02. x1 Soares_NhHMPU_S1 Homo sapi 3.50 7. 19 307657 A1306428 Hs. 298262 ribosome protein S19 1.76 2.44 307691 AI318285 gb: tb17b01.x1 NCI_CGAP_Ov37 Homo sapiens 1.59 1.31 307701 AI318583 Hs. 276672 EST, Weakly similar to RL6_HUMAN 60S RI 1.90 2.13 307718 AI333406 Hs. 83753 small nuclear ribonucleoprotein polypept 0.45 0.99 307730 AI336092 gb: qt43b07. x1 Soares_fetal_lung_NbHL19W 1.51 0.99 307760 AI342387 gb: qt27f07. x1 Soares_pregnant_uterus_NbH 1. 00 1.00 307764 AI342731 gb: qo26a07. x1 NCI_CGAP_Lu5 Homo sapiens 4.52 12.58 307783 AI347274 gb: tc05d02. x1 NCLCGAP_Col6 Homo sapiens 1.42 1.00 307796 AI350556 gb: qt18f09. x1NCLCGAPGC4 Homo sapiens 6.57 9.61 307807 AI351799 gb: qt09d02. x1 NCI_CGAP_GC4 Homo sapiens 3.38 7.68 307808 AI351826 gb: qt09g03. x1 NCI CGAP_GC4 Homo sapiens 0.33 0.86 307820 AI355761 gb: qt94a11.x1 NCI_CGAP_Co14 Homo sapiens 7.94 21.57 307830 AI358722 Hs. 276737 EST, Weakly similar to R5HU22 ribosomal 2.05 3.32 307852 AI365541 gb: qz08g05. x1 NCI CGAP_CLL1 Homo sapiens 3.18 5.21 307902 AI380462 gb: tg02h05. xl NCI_CGAP_CLL1 Homo sapiens 3.13 4.99 307997 AI434512 Hs. 181165 eukaryotic translation elongation factor 1.00 3.01 308002 A1435240 Hs. 283442 ESTs 5.86 12.64 308011 At439473 gb: ti60a08. x1 NCI_CGAP_Lym12 Homo sapien 3.79 5.83 308023 AI452732 Hs. 251577 hemoglobin, alpha 1 0.38 0.88 308041 A1458824 Hs. 169476 glyceraldehyde-3-phosphate dehydrogenase 4. 36 6.06 308059 I468938 Hs. 276877 EST, Weakly similar to RL10_HUMAN 60S R 1.80 1.98 308085 AI474135 Hs.181165 eukaryotic translation elongation factor 3. 38 4.14 308101 AI479590 H. 181165 eukaryotic translation elongation factor 1.30 3.87 308106 AM76803 gb: tj77e12. xi Soares_NSF_F8_9W_OT_PA_P_S2. 38 8.72 308122 AI480123 Hs. 309411 EST 2.70 3.86 308154 AI500600 gb: tn93d08. x1 NCI_CGAP_Ut2 Homo sapiens 0.66 1.33 308171 AI523632 Hs. 298766 ESTs Weakly similar to schlafen4 [M. mu 2.48 4.86 308211 AI557029 Hs. 278572 anaplastic lymphoma kinase (Ki-1) 2.43 2.14 308213 AI557041 gb: PT2. 1_12_E04.r tumor2 Homo sapiens cD 3.34 3.79 308216 AI557135 gb: PT2.1 13_H06. rtumor2HomosapienscD 4.61 4.78 308219 AI557246 gb: PT2. 1_15_D07.r tumor2 Homo sapiens cD 4.87 7.94 308271 AI56844 Hs. 252259 ribosomal protein S3 2.40 6.35 308319 AI583983 Hs. 181165 eukaryotictransiation elongation factor 2.45 3.33 308362 Ai613519 Hs. 105749 kIAA0553 protein 1.24 1.41 308413 A1636253 Hs. 196511 ESTs 3.16 4.82 308450 A1660860 Hs. 96840 KIAA1527 protein 1.79 2.68 308464 AI672425 Hs. 277117 EST, Moderately similar to 138055 myosi 4.87 8.27 308588 AI718299 gb: as51g12.x1 Barstead aorta HPLRB6 Homo 3.90 5.64 308599 AI719893 gb: as47d07, x1 Barstead aorta HPLRB6 Homo 3.32 5, 12 308615 A1738593 Hs. 101774 hypothetical protein FLJ23045 3.11 2.36 308643 Ai745040 gb: tr9a12.x1 NCI_CGAP_Ov24 Homo sapiens 3. 98 3.69 308673 AI760864 gb: wi09c10. x1NCiCGAPCLL1 Homo sapiens 0.82 0.99 308697 A, 767143 gb : wi97aO7. xl NCLCGAP_Kidl2 Homo sapien 2.76 5.59 308762 AI807405 Hs. 259408 ESTs 3.17 6.30 308778 AI811109 gb: tr04c11.x1 NCI_CGAP_Ov23 Homo sapiens 1.00 1. 00 308782 AI811767 Hs. 2186 eukaryotic translation elongation factor 2.94 5.15 308808 AI818289 gb: wk52c01. xl NUI Homo sapiens 4.41 8.34 308823 A1824118 Hs. 217493 annexinA2 1.85 1.92 308875 AI832332 gb: at48g03. x1 Barstead colon HPLRB7 Homo 2.52 3.80

308879 AI832763 Hs. 75968 thymosin, beta 4, X chromosome 3.38 7.96 308886 AI833240 gb: at76d10. x1 Barstead colon HPLRB7 Homo 3.06 2.65 308898 AI858845 gb: wl32d10.x1 NCI_CGAP_Ut1 Homo sapiens 2.45 3.44 308934 AI865023 Hs. 177 phosphafldylinositol glycan, class H 4.14 6.76 308966 AI87074 gb: wl47h01.x1 NCI_CGAP_Ut1 Homo sapiens 1.00 1.00 308979 AI873111 gb: wl52h05.x1 NCI_CGAP_Bm25 Homo sapien 7.15 11.10 309045 Api910902 gb: tq39f01. x1 NCI CGAP_Ut1 Homosapiens 0.61 0.59 309051 Api911975 gb: wd78d01. x1 NCI CGAP_Lu24 Homo sapiens 1.78 4.42 309069 AI917366 Hs. 78202 SWI/SNF related, matrix associated, act 3.27 5.88 309083 A1922426 Hs. 119598 ribosomal protein L3 2.39 3.34 309105 A1925503 Hs. 265884 ESTs 5.54 17.78 309122 AI928178 gb: wo95a11. xl NCI CGAP_Kidll Homosapien 1.00 2.92 309128 AI928816 Hs. 180842 ribosomal protein L13 1.38 5.55 309164 AI937761 gb: wp84b09. xl NCl_CGAP_Brn25Homosapien 2.43 3.11 309177 AI951118 gb:wx63g05.x1 NCI_CGAP_Br18 Homo sapiens 0.81 0.97 309288 AI991525 Hs. 299426 ESTs 4. 86 7.46 309299 AW003478 gb: wq66cO6. xl CGAPGC6 Homo sapiens 4.36 9.43 309303 AW004823 gb: ws93a08. x1 NCI_CGAP_Co3 Homo sapiens 2.88 7. 54 309411 AW085201 Hs. 244144 EST 4. 30 7. 14 309437 AW090702 Hs. 278242 tubulin, alpha, ubiquitous 2.49 3. 11 309459 AW117645 Hs. 65114 keratin 18 Z88 4.55 309476 AW129368 gb: xe14b05. x1 NCI_CGAP_Ut4 Homo sapiens 2.08 6.60 309499 AW136325 Hs. 279771 Homo sapiens clone PP1596 unknown mRNA 2.82 3.55 309529 AW150807 Hs. 181357 laminin receptor 1 (67kD, ribosome pro 4. 78 3.95 309532 AW151119 gb: xg33e10. xl NCLCGAP_Utl Homosapiens 1.18 4.40 309626 AW192004 Hs. 297681 serine (or cysteine) proteinase inhibit 4.46 12.06 309641 AW194230 Hs. 253100 EST, Moderately similar to GHHU Ig gamm 1.47 1.39 309675 AW205681 Hs. 253506 EST, Moderately similar to ATPN HUMAN A 5.68 15.20 309693 AW237221 Hs. 181357 laminin receptor 1 (67kD, ribosome prot 1.00 1.00 309695 AW238011 Hs. 295605 mannosidase, alpha, class 2A, member 2 5, 45 9.61 309700 AW241170 Hs. 179661 tubulin, beta polypeptide 1.41 1.25 309747 AW264889 gb: xq36h02. x1 NCI_CGAP_Lu28 Homo sapiens 5. 00 8. 35 309769 AW272346 gb: xs13c10. xl NCI_CGAP_Kid11 Homo sapien 5.76 11.90 309782 AW275156 Hs. 156110 immunoglobulin kappa constant 0.42 0.69 309783 AW275401 Hs. 254798 EST 1.00 4. 11 309799 AW276964 gb : xp58hO1. xl NCt_CGAP_Ov39 Homo sapiens 1.68 1.44 309866 AW299916 gb: xs44c01. x1 NCI_CGAP_Kid11 Homo sapien 3. 02 5.04 309903 AW339071 Hs. 300697 immunoglobulin heavy constant gamma3 (G 1.05 1. 18 309923 AW340684 gb: hd05gO8. x1 Soares_NFL_T_GBC_S1 Homo s 2.30 3.67 309928 AW341418 gb: hd08c03. x1 Soares_NFL_T_GBC_S1 Homo s 7.41 13.71 309931 AW341683 gb: hdl3dOl. x1 Soares_NFL_T_GBC_S1 Homo s 1.20 12.70 309933 AW341936 gb: hb73f10. x1 NCI_CGAP_Ut2 Homo sapiens 4.90 18.29 309964 AW449111 Hs. 257111 hypothetical protein MGC3265 1.99 3.07 310002 AI439096 Hs. 323079 Homo sapiens mRNA ; cDNADKFZp564P116 (fr 0.20 0. 47 310096 AW136822 Hs. 172824 ESTs, Weakly similar to B48013 proline-r 1.51 1.22 310098 AI685841 Hs. 161354 ESTs 0.31 0.76 310109 A1203094 Hs. 148633 ESTs 2.06 5.83 310112 AW197233 Hs. 147253 ESTs 2.92 3.55 310115 A1611317 Hs. 223796 ESTs 1.25 0.84 310121 AW195642 Hs. 148901 ESTs 1.00 2.71 310146 AI206614 Hs. 197422 ESTs 9.50 15.31 310193 AI6247653 Hs. 147562 ESTs 2.85 4.18 310255 AW450439 Hs. 153378 ESTs 4.26 10.63 310261 AI240483 Hs. 201217 ESTs 3.28 4.40 310264 AI915771 Hs. 74170 metallothionein 1E (functional) 0. 26 0.86 310275 AI242102 Hs. 213636 ESTs 5.43 8.19 310282 AI243332 Hs. 156055 ESTs 3. 15 8.06 310290 AW013815 Hs. 149103 ESTs 2.19 3.12 310333 AI253200 Hs. 145402 ESTs 1.17 1.91 310346 AI261340 Hs. 145517 ESTs 4.81 9.95 310385 AI263392 Hs. 156151 ESTs 5. 96 7. 79 310443 AW119018 Hs. 164231 ESTs 2. 90 4.63 310444 AW196632 Hs. 252956 ESTs 0.85 1.01 310446 AI275715 Hs. 145926 ESTs Z18 3.85 310468 AI984074 Hs. 196398 ESTs 3.39 5.19 310477 A1948801 Hs. 171073 ESTs 1.00 1.00 310512 AW275603 Hs. 200712 ESTs 3.87 8. 12 310514 A ! 681145 Hs. 160724 ESTs 3.30 7.33 310524 AW082270 Hs. 12496 ESTs, Highly similar to AC004836 1 simil 0. 72 1. 44 310547 A1302654 Hs. 208024 ESTs 3.26 3.46 310584 AI653007 Hs. 156304 ESTs 2.39 4.08 310608 AI962234 Hs. 196102 ESTs 5.60 6.49 310624 AI341594 gb: Human endogenous retrovirus H proteas 4.91 9.09 310636 AI814373 Hs. 164175 ESTs 1.85 1.71 310648 M347863 Hs. 156672 ESTs 0.17 0.69 310694 AI654370 Hs. 157752 Homo sapiens mRNA full length insert cDN 5. 40 13.22 310695 Ai472124 Hs. 157757 ESTs 4.82 6.27 310714 AI418446 Hs. 157882 ESTs 1.76 3.51 310722 AI989803 Hs. 157289 ESTs 1.14 6.85 310756 AI916560 Hs. 158707 ESTs 8.46 13.01 310764 AI376769 Hs. 167172 ESTs 4.76 7. 37 310848 AI459554 Hs. 161286 ESTs 2. 84 1.96 310851 AW291714 Hs. 221703 ESTs 1.00 2.32 310854 AI421677 Hs. 161332 ESTs 6.37 7. 94 310858 AI871000 Hs. 161330 ESTs 6.07 9.84

310864 A, 924558 Hs. 161399 ESTs 0. 87 0.78 310875 T47764 Hs. 132917 ESTs 1.00 3.63 310896 AW157731 Hs. 270982 ESTs, Moderately similar to ALU7_HUMAN A 7.07 16.68 310922 AW195634 Hs. 170401 ESTs 1. 00 1.00 310955 A1560210 Hs. 263912 ESTs 10.08 17.66 310957 AW190974 Hs. 196918 ESTs 2.18 3.18 311000 A1521830 Hs. 171050 ESTs 3.06 6.64 311012 AW298070 Hs. 241097 ESTs 1. 23 3.77 311034 A, 564023 Hs. 311389 ESTs, Moderately similar to PT0375 natur 2.44 2.09 311074 AW290922 Hs. 199848 ESTs 6.04 14.19 311134 AI990849 Hs. 196971 ESTs 3.54 6.96 311174 AW450552 Hs. 205457 periaxin 0.65 0.95 311187 A1638374 Hs. 224189 ESTs 2. 46 2.78 311220 A1656040 Hs. 196532 ESTs 1. 10 2. 52 311230 A1989808 Hs. 197663 ESTs 1.41 1.75 311236 A1653378 Hs. 197674 ESTs 2.18 2.11 311242 AW016812 Hs. 200266 ESTs 0.63 5.11 311258 A1671221 Hs. 199887 ESTs 1.00 1.41 311277 AW072813 Hs. 270868 ESTs, Moderately similar to ALU4_HUMAN A 2.56 1.94 311294 AA826425 Hs. 291829 ESTs 1.04 2.69 311308 F12664 Hs. 49000 ESTs 1.96 6.70 311351 A1682303 Hs. 201274 ESTs 4.77 9.38 311390 AW392997 Hs. 202280 ESTs 2.80 6.06 311405 AW290961 Hs. 201815 ESTs 3. 80 11.66 311409 AI698839 gb: wd31f02.x1 Soares_NFL_T_GBC_S1 Homo s 3.84 6.94 311420 A1936291 Hs. 209867 ESTs 5.30 12.56 311443 AI791521 Hs. 192206 ESTs 4.39 6.09 311467 A1934909 Hs. 175377 ESTs 1.00 1.04 311479 A1933672 Hs. 211399 ESTs 2.76 5. 61 311488 R57390 Hs. 301064 arfaptin 1 2.50 5.73 311495 AW300077 Hs. 221358 ESTs 3.63 6.09 311511 AW444568 Hs. 210303 ESTs 2.00 2. 87 311534 AW130351 Hs. 243549 ESTs 0.31 1.33 311537 A1805121 Hs. 211828 ESTs 3.69 5.85 311543 A1681360 Hs. 201259 ESTs 1.73 1.34 311551 AW449774 Hs. 296380 POM (POM121 rat homolog) and ZP3 fusion 3.31 6.12 311557 Api819230 Hs. 211238 inter, eukin-lhomologl 1.00 1.00 311558 Z44432 Hs. 63128 KIAA1292 protein 2.25 3.41 311559 AW008271 Hs. 265848 similar to rat myomegalin 2.68 5.90 311563 AI922143 Hs. 211334 ESTs 2.39 3.32 311586 A1827834 Hs. 211227 ESTs 2.47 3.85 311616 AW450675 Hs. 212709 ESTs 1.00 1.00 311621 A1924307 Hs. 213464 ESTs 4.16 6.74 311635 AI928456 Hs. 213081 ESTs 2.17 3. 76 311668 AW193674 Hs. 240044 ESTs 2.60 3.12 311672 R11807 Hs. 20914 hypothetical protein FLJ23056 2.79 5. 18 311683 AW183738 Hs. 232644 ESTs 0.19 0.96 311700 R49601 Hs. 171495 retinoic acid receptor, beta 6.28 8.83 311714 AW131785 Hs. 246831 ESTs, Weakly similar to CIKG HUMAN VOLTA 5.00 8.17 311735 AW294416 Hs. 144687 Homo sapiens cDNA FLJ12981 fis, clone NT 0.96 0.72 311743 T99079 Hs. 191194 ESTs 1.00 1.95 311783 A1682478 Hs. 13528 hypothetical protein FLJ14054 0.16 0. 77 311785 AI056769 Hs. 133512 ESTs 1.34 3.97 311799 AA780791 Hs. 14014 ESTs, Weakly similar to KIAA0973 protein 8.52 13. 32 311819 AW265275 Hs. 254325 ESTs 3.58 3.91 311823 AI089422 Hs. 131297 ESTs 1.40 1.72 311877 AA349893 Hs. 85339 G protein-coupled receptor 39 0. 95 0.91 311886 AA522738 Hs. 132554 ESTs 0.88 0.87 311896 AW206447 gb: Ul-H-Bi1-afg-g-02-0-UI. s1 NCI CGAP_Su 1.66 1.13 311910 N28365 Hs. 22579 Homo sapiens clone CDABP0036 mRNA sequen 1.66 2.30 311923 T60843 Hs. 189679 ESTs 0.42 2.63 311933 A1597963 Hs. 118726 ESTs 1.88 3.02 311959 T67262 Hs. 124733 ESTs 2.02 2.33 311960 AW440133 Hs. 189690 ESTs 3.87 6.62 311967 AI382726 Hs. 182434 ESTs 5.80 8.14 311975 AA804374 Hs. 272203 Homo sapiens cDNA FLJ20843 fis, clone AD 0.98 3.26 312005 T78450 Hs. 13941 ESTs 0.12 1.39 312028 T78886 Hs. 284450 ESTs 3.78 4. 92 312046 A1580018 Hs, 268591 ESTs 4.11 7. 32 312056 T83748 Hs. 268594 ESTs 2.36 3.08 312064 AA676713 Hs. 191155 ESTs 3.34 5.28 312088 AW303760 Hs. 13685 ESTs 1.60 1.15 312093 T91809 Hs. 121296 ESTs 0.68 0.85 312094 Z78390 gb: HSZ78390 Human fetal brain S. Meier-E 3.05 4.48 312097 AI352096 Hs. 112180 zinc finger protein 148 (pHZ-52) 4.52 9.70 312118 T85332 Hs. 178294 ESTs 2.40 2.60 312128 A1052609 Hs. 17631 HomosapienscDNAFW20118fis, ctoneC0 2.39 3.53 312147 T89855 Hs. 195648 ESTs 0.67 1.03 312176 AA953383 Hs. 127554 ESTs 5.85 10.60 312179 AI052572 Hs. 269864 ESTs 2.41 3.32 312201 AI928365 Hs. 91139 solute carrierfamily 1 (neuronallepithe 0.24 0.89 312207 H90213 Hs. 191330 ESTs 2.20 4.55 312220 N74613 gb : za55a07. s1 Soares fetal liver spleen 4.28 11.13 312252 A1128388 Hs. 143655 ESTs 1.64 1.57 312304 AA491949 Hs. 269392 ESTs 0.12 2. 47

312318 AW235092 Hs. 143981 ESTs 3.46 5.69 312319 AA216698 Hs. 180780 TERA protein 5.78 4.46 312321 R66210 Hs. 186937 ESTs 0.44 1.74 312331 AA825512 Hs. 289101 glucose regulated protein, 58kD 3.73 5.96 312339 AA524394 Hs. 165544 ESTs 3.07 0.95 312363 AI675558 Hs. 181867 ESTs 10.08 16.73 312375 Api375096 Hs. 172405 cell division cycle 27 2.78 3.71 312376 R52089 Hs. 172717 ESTs 1.00 1.00 312389 Api863140 gb: tz43h12. x1 NCI_CGAP_Brn52 Homo sapien 2.37 3.98 312437 AA995028 gb: RC4-BT0629-120200-011-b10BT0629 Homo 4.06 5.41 312440 A1051133 Hs. 133315 HomosapiensmRNA ; cDNA DKFZp761J1324 (f 1.00 1.00 312451 R59989 Hs. 176539 ESTs 4.96 10.04 312458 Ai187637 Hs. 146924 ESTs 1.11 1.00 312507 Api168177 Hs. 143653 ESTs 5.89 8.24 312520 A1742591 Hs. 205392 ESTs 3.30 8.92 312548 AI566228 Hs. 159426 hypothetical protein PR02121 1.38 1.65 312564 H21520 Hs. 35088 ESTs 0.40 0.77 312583 AI193122 Hs. 124141 ESTs 0.13 0.94 312599 A1865073 Hs. 125720 ESTs 3.75 5. 29 312602 AA046451 Hs. 165200 ESTs 6.78 12.93 312645 H52121 Hs. 193007 ESTs 0.38 1.13 312666 A1240582 Hs. 214678 ESTs 0.98 2.03 312689 AW450461 Hs. 203965 ESTs 0.21 0.61 312817 H75459 Hs. 233425 ESTs 1. 51 0.85 312846 AW152104 Hs. 200879 ESTs 8.93 13.78 312873 AI690071 Hs. 283552 ESTs, Weakly similar to unnamed protein 4.20 6.23 312893 A1016204 Hs. 172922 ESTs 2.67 3. 15 312902 AW292797 Hs. 130316 ESTs, Weakly similar to T2D3_HUMAN TRANS 1.19 0.71 312925 N90868 Hs. 271695 ESTs 2.50 4.25 312936 Ai681581 Hs. 121525 ESTs 1.00 1.17 312975 AI640506 Hs. 293119 ESTs, Weakly similar to ALU7 HUMAN ALU S 2.30 4.80 312978 N24887 Hs. 292500 ESTs 0.80 1.05 312980 AA497043 Hs. 115685 ESTs 3.12 3.60 312984 N25871 Hs. 177337 ESTs 2.03 2.13 313000 A1147412 Hs. 146657 ESTs 5.52 8.42 313029 AA731520 Hs. 170504 ESTs 0.96 1.39 313039 AI419290 Hs. 149990 ESTs, Weakly similar to unnamed protein 6.48 13.20 313049 AW293055 Hs. 119357 ESTs 6.44 10.73 313056 Ai651930 Hs. 135684 ESTs 1.51 2.04 313058 D81015 Hs. 125382 ESTs 0.25 1.50 313070 AI422023 Hs. 161338 ESTs 8.56 11.60 313097 AI676164 Hs. 204339 ESTs 3.72 4.56 313130 AW449171 Hs. 168677 ESTs 3.28 5.06 313136 N59284 Hs. 288010 ESTs 0.49 1.36 313153 AI240838 Hs. 132750 ESTs 5.36 5. 52 313210 N74077 Hs. 197043 ESTs 0.30 0.66 313236 AW238169 Hs. 83513 ESTs, Weakly similar to ALU1 HUMAN ALU S 5. 16 8.76 313239 W19632 Hs. 124170 ESTs 1.00 3.87 313265 N93466 Hs. 121764 ESTs, Weakly similar to testicular tekti 0.74 2. 06 313267 AI770008 Hs. 129583 ESTs 0.23 1.30 313275 AI027640 Hs. 159650 ESTs 6.68 9.57 313290 Api753247 Hs. 29643 Homo sapiens cDNA FLJ13103 fis, clone NT 1.34 1.07 313292 Api362991 Hs. 202121 ESTs, Weakly similar to env protein [H. s 2.00 4.32 313325 A1420611 Hs. 127832 ESTs 1.20 2.27 313357 AW074848 Hs. 201501 ESTs 4.02 5.33 313393 A1674685 Hs. 200141 ESTs 1.36 2.84 313399 AW376889 Hs. 194097 ESTs 2.58 5.26 313414 A1241540 Hs. 132933 ESTs 6.57 15.07 313417 AA741151 Hs. 137323 ESTs 0.63 3. 01 313457 AA576052 Hs. 193223 Homo sapiens cDNA FLJ11646 fis, clone HE 2.78 4.70 313499 A1261390 Hs. 146085 KIAA1345 protein 0.91 2.37 313516 AA029058 Hs. 135145 ESTs 3.41 7.08 313556 AA628517 Hs. 118502 ESTs 0.23 0.70 313569 AI273419 Hs. 135146 hypothetical protein FLJ13984 1.88 1.00 313570 AA041455 Hs. 209312 ESTs 0.73 2. 27 313638 AI753075 Hs. 104627 Homo sapiens cDNA FLJ10158 fis, clone HE 1.00 1.72 313662 AA740151 Hs. 130425 ESTs 0. 20 1.42 313671 W49823 Hs. 104613 RP42 homolog 1.00 1.00 313672 AW468891 Hs. 122948 ESTs 3.46 5.80 313690 A1493591 Hs. 78146 platelet/endothelial cell adhesion molec 0.51 0.97 313711 AA398070 Hs. 133471 ESTs 0.18 1.01 313723 AA070412 gb: zm68c10. s1 Stratagene neuroepithelium 1. 08 1.03 313726 A1744687 Hs. 257806 ESTs 2.13 2.99 313774 AW136836 Hs. 144583 ESTs 1. 38 1.19 313784 AA910514 Hs. 134905 ESTs 3.88 5.78 313790 AW078569 Hs. 177043 ESTs 0.22 2.06 313832 AW271022 Hs. 133294 ESTs 1. 15 0.91 313834 AW418779 Hs. 114889 ESTs 0.68 3. 14 313835 A1538438 Hs. 159087 ESTs 5.74 8.88 313852 H18633 Hs. 123641 protein tyrosine phosphatase, receptor t 0.16 1.14 313854 AW470806 Hs. 275002 ESTs 2.09 4.06 313865 AA731470 Hs. 163839 ESTs 3.41 4.09 313871 AW471088 Hs. 145950 ESTs 5.28 6. 83 313883 AI949384 gb: nu76d01. s1 NCI_CGAP_Alv1 Homo sapiens 2.90 10.91 313915 AI969390 Hs. 163443 Homo sapiens cDNA FLJ11576 fis, clone HE 1.00 1.00

313926 AW473830 Hs. 171442 ESTs 3.40 4.11 313948 AW452823 Hs. 135268 ESTs 5.77 9.15 313978 A1870175 Hs. 13957 ESTs 0.46 0.75 313963 AI829133 Hs. 226780 ESTs 4.10 6.40 314035 AA164199 Hs. 270152 ESTs 5.88 7.90 314037 AW300048 Hs. 275272 ESTs 1. 00 3.79 314040 AA166970 Hs. 118748 ESTs 7.60 11.33 314067 AW293538 Hs. 51743 KIAA1340 protein 1.86 1.21 314103 A1028477 Hs. 132775 ESTs 2.90 5.29 314107 AA806113 Hs. 189025 ESTs 2.00 1.66 314113 AA218986 Hs. 118854 ESTs 0. 91 4.17 314124 AW118745 Hs. 9460 Homo sapiens mRNA ; cDNADKFZp547C244 (fr 2.53 3.32 314126 AA226431 gb: nc18b12. sl NCtCGAP_Prl Homosapiens 3.13 5.08 314128 AA935633 Hs. 194628 ESTs 2. 90 6.35 314151 AA236163 Hs. 202430 ESTs 4.15 6.45 314184 AW081795 Hs. 233465 ESTs 3. 44 4. 65 314192 AW290975 Hs. 118923 ESTs 1.00 1. 23 314244 AL036450 Hs. 103238 ESTs 2.88 3.67 314253 AA278679 Hs. 189510 ESTs 4.98 7.16 314262 AW086215 Hs. 246096 ESTs 0.38 1.94 314320 AA811598 Hs. 275809 ESTs 3.34 5.66 314332 AL037551 Hs. 95612 ESTs 2.85 2.09 314335 AA287443 Hs. 142570 Homo sapiens clone 24629 mRNA sequence 4.35 4.78 314340 AW304350 Hs. 130879 ESTs, Moderately similar to putative p15 0.77 0.86 314351 AA292275 Hs. 193746 ESTs 3.07 3.77 314376 A) 628633 Hs. 324679 ESTs 4. 10 6.11 314443 AA827125 Hs. 192043 ESTs 6.20 13.67 314458 A1217440 Hs. 143873 ESTs 0.58 2.49 314466 AA767818 Hs. 122707 ESTs 2.53 2.62 314478 AI521173 Hs. 125507 DEAD-box protein 3.94 5. 65 314482 AL043807 Hs. 134182 ESTs 1.30 1.44 314506 AA833655 Hs. 206868 Homo sapiens cDNA FLJ14056 fis, clone HE 3.28 3.47 314519 R42554 Hs. 210862 T-box, brain, 1 3.12 6.16 314529 AL046412 Hs. 202151 ESTs 3.43 6. 87 314546 AW007211 Hs. 16131 hypothetical protein FLJ12876 1.38 1.00 314562 A1564127 Hs. 143493 ESTs 2.29 5.27 314579 AW197442 Hs. 116998 ESTs 3.87 5.75 314580 AW451832 Hs. 255938 ESTs, Moderately similar to KIAA1200 pro 0.10 0.71 314585 AA918474 Hs. 216363 ESTs 1.08 1.40 314589 AW384790 Hs. 153408 Homo sapiens cDNA FLJ10570 fis, clone NT 1. 00 1.00 314592 AA435761 Hs. 192148 ESTs 0.90 2.60 314603 AA418024 Hs. 270670 ESTs 4.56 6.29 314604 AA946582 Hs. 8700 deleted in liver cancer 1 3.42 3. 92 314606 AA418241 Hs. 188767 ESTs 2.97 4.55 314648 AA878419 gb: EST391378 MAGE resequences, MAGP Homo1.42 1.36 314699 A1038719 Hs. 132801 ESTs 3.66 4.97 314701 A1754634 Hs. 131987 ESTs 0.03 0. 90 314710 A1669131 Hs. 290989 EST 3. 40 7.52 314750 AI095005 Hs. 135174 ESTs 2.80 6.54 314767 AW135412 Hs. 164002 ESTs 3.20 4.26 314801 AA481027 Hs. 109045 hypothetical protein FLJ10498 1. 00 1.00 314817 A1694139 Hs. 192855 ESTs 0.91 0.99 314835 Ai281370 Hs. 76064 ribosomal protein L27a 5.75 7. 44 314852 AI903735 gb: MR-BT035-200199-031 BT035 Homo sapien 1.68 4. 34 314853 AA729232 Hs. 153279 ESTs 0. 60 1.85 314940 AW452768 Hs. 162045 ESTs 10.10 16. 20 314941 AA515902 Hs. 130650 ESTs 0. 31 1. 02 314943 A, 476797 Hs. 184572 cell division cycle 2, G1 to S and G2 to 2.18 0.37 314955 AA521382 Hs. 192534 ESTs 2.59 3.90 314973 AW273128 Hs. 300268 ESTs 1.05 1.25 315004 AA527941 Hs. 325351 EST 5.64 13.63 315006 A, 538613 Hs. 298241 Transmembrane protease, serine 3 0.52 1.78 315033 AI493046 Hs. 146133 ESTs 2.46 1.00 315035 A1569476 Hs. 177135 ESTs 0.34 1.33 315056 A1202703 Hs. 152414 ESTs 2.10 2.64 315069 A1821517 Hs. 105866 ESTs 1.00 1.30 315071 AA552690 Hs. 152423 HomosapienscDNA : FLJ21274 fis, clone C 1.78 1.00 315073 AW452948 Hs. 257631 ESTs 1. 17 1. 52 315078 AA568548 Hs. 190616 ESTs 3.00 3.79 315080 AA744550 Hs. 136345 ESTs 1.00 1.00 315120 AA564991 Hs. 269477 ESTs 0.64 1.44 315175 AI025842 Hs. 152530 ESTs 0.61 1.91 315193 AI241331 Hs. 131765 ESTs 1.06 0.97 315196 AA972756 Hs. 44898 Homo sapiens clone TCCCTA00151 mRNA sequ 0.48 1.96 315200 Api808235 Hs. 307686 EST 3.76 9.40 315254 A1474433 Hs. 179556 ESTs 5.37 9.36 315353 AW452608 Hs. 279610 hypothetical protein FLJ10493 1.00 1. 30 315397 AA218940 Hs. 137516 fidgetin-, ike 1 3.38 2.24 315403 AW362980 Hs. 163924 ESTs 2.04 5.23 315431 AA622104 Hs. 184838 ESTs 2.36 8.04 315454 AI239473 gb: qh36f02. xl Soares_NFL_T_GBC_S1 Homos 3.46 7.64 315455 AW393391 Hs. 156919 ESTs 3.78 5. 76 315473 AI681671 Hs. 312671 ESTs, Moderately similar to OVCA1 0.89 2.15 315483 AW512763 Hs. 222024 transcription factor BMAL2 2.32 1.96 315526 Ail93048 Hs. 128685 ESTs 1.67 1.78

315530 At200852 Hs. 127780 ESTs 1.05 1.01 315541 A1168233 Hs. 123159 sperm associated antigen 4 0. 85 0.56 315552 AW445034 Hs. 256578 ESTs 1.00 2.22 315562 AA737415 Hs. 152826 ESTs 2.66 2.48 315577 AW513545 Hs. 17283 hypothetical protein FLJ10890 2.20 2.25 315587 AI268399 Hs. 140489 ESTs 1.00 1.04 315589 AW072387 Hs. 158258 Homo sapiens mRNA ; cDNA DKFZp434B1272 (f 0.14 1.05 315623 AA364078 Hs. 258189 ESTs 7.44 12.56 315634 AA837085 Hs. 220585 ESTs 0.50 1.40 315668 AA912347 Hs. 136585 ESTs 0.43 1.22 315677 A, 932662 Hs. 164073 ESTs 0.60 1.39 315706 AW440742 Hs. 155556 hypothetical protein FLJ20202 2.18 3.77 315707 At418055 Hs. 161160 ESTs 2.88 2.63 315730 H25899 Hs. 201591 ESTs 0.11 0.60 315745 A1821759 Hs. 191856 ESTs 3.50 7.25 315791 AA678177 gb: zi15a05. s1 Soares_fetaUiver_spleen_ 1. 78 2.63 315801 AA827752 Hs. 266134 ESTs 4.31 6.23 315820 A1652022 Hs. 258785 ESTs 2.35 3. 01 315878 AA683336 Hs. 189046 ESTs 2.12 2.64 315905 A1821911 Hs. 209452 ESTs 1.03 1.97 315923 Ai052789 Hs. 133263 ESTs 2. 63 5.06 315954 AW276810 Hs. 254859 ESTs. Moderate) ysimiiartoALU5HUMANA 1. 21 0.85 315978 AA830893 Hs. 119769 ESTs 3.09 3.41 316001 A) 248584 Hs. 190745 Homo sapiens cDNA : FLJ21326 fis, clone C 2.20 6. 82 316011 AW516953 Hs. 201372 ESTs 0.35 1.63 316012 AA764950 Hs. 119898 ESTs 6.56 8.13 316040 AI983409 Hs. 189226 ESTs 5.69 10.69 316048 AI720759 Hs. 224971 ESTs 2.84 10.45 316076 AW297895 Hs. 116424 ESTs 0.30 1.05 316124 A1308862 Hs. 167028 ESTs 1.00 1. 43 316151 A, 806016 Hs. 156520 ESTs 5.80 9.03 316187 AW518299 Hs. 192253 ESTs 1.20 3.96 316204 AA731509 Hs. 120257 ESTs 4.92 6.94 316232 AW297853 Hs. 251203 ESTs 1. 48 1.60 316275 AI671041 Hs. 292611 ESTs, Moderately ysimi, artoAW1_HUMANA 5.86 12.14 316291 AW375974 Hs. 156704 ESTs 2.73 2. 69 316303 AA740994 Hs. 209609 ESTs 1.53 1.26 316344 AA744518 Hs. 120610 ESTs 3.66 8. 34 316346 A1028478 Hs. 157447 ESTs 3.51 6.69 316365 A1627845 Hs. 210776 ESTs 2.50 4.33 316380 AI393378 Hs. 164496 ESTs 1. 16 2.16 316470 AA809902 Hs. 243813 ESTs 5.40 10.34 316509 AA767310 Hs. 291766 ESTs 2.46 2.89 316514 AA768037 Hs. 291671 ESTs 4. 70 6.04 316519 AI929097 gb: od10c11. s1NC ! CGAPGCB1 Homo sapiens 4.41 9.70 316609 AW292520 Hs. 122082 ESTs 1.00 2.89 316633 A1125586 Hs. 127955 ESTs 2.61 3.72 316700 AW172316 Hs. 252961 ESTs, Weakly similar to ALU1 HUMAN ALU S 3.46 4.64 316711 At743721 Hs. 285316 ESTs, Moderately similar to ALU7 HUMAN A 4.45 6.95 316713 A1090671 Hs. 134807 hypothetical protein FLJ12057 0.30 2.40 316715 AI440266 Hs. 170673 ESTs, Weakly similar to AF126780 1 retin 0.20 1.45 316787 AW369770 Hs. 130351 ESTs 4.05 5.53 316809 AA825839 Hs. 202238 ESTs 2.25 3.82 316811 AA922060 Hs. 132471 ESTs 1.00 1.32 316812 AW135045 Hs. 232001 ESTs 3. 28 4. 70 316818 AA827176 Hs. 124316 ESTs 0.67 1.81 316824 AA837416 Hs. 124299 ESTs 3.53 6.00 316827 AI380429 Hs. 172445 ESTs 0.72 1. 56 316891 AW298119 Hs. 202536 ESTs 1.64 2.97 316951 AA134365 Hs. 57548 ESTs 1.45 1. 08 316970 M860172 Hs. 132406 ESTs 1.00 1. 53 316971 AA860212 Hs. 170991 ESTs 1.08 1.96 316990 AA861611 Hs. 130643 ESTs 5.44 10. 04 317001 Api627917 Hs. 233694 hypothetical protein FLJ11350 3. 56 4. 37 317008 AW051597 Hs. 143707 ESTs 0.69 1.37 317051 AA873253 Hs. 126233 ESTs 6.18 12.72 317128 AA971374 Hs. 125674 ESTs 1.87 2.66 317129 H12523 Hs. 78521 HomosapienscDNA : FLJ21193 fis, clone C 4.12 6.64 317137 AW341567 Hs. 125710 ESTs 2.82 5.12 317196 A1348258 Hs. 153412 ESTs 1.98 2.51 317212 A1866468 Hs. 148294 ESTs 1.86 2.83 317223 AW297920 Hs. 130054 ESTs 0.83 1.57 317224 D56760 Hs. 93029 sparc/osteonectin, cwcv and kazal-like d 2. 74 0.86 317266 AA906289 Hs. 203614 ESTs 1.00 1.00 317282 A1807444 Hs. 176101 ESTs 2.60 4.21 317285 AW370882 Hs. 222080 ESTs 1.96 3.49 317302 AA908709 Hs. 135564 ESTs 7.16 8.32 317304 AW449899 Hs. 130184 ESTs 1.38 2.28 317320 AA927151 Hs. 130452 ESTs 3.58 8.13 317413 AW341701 Hs. 126622 ESTs 2.08 4.92 317417 AA918420 Hs. 145378 ESTs 3.06 4.79 317452 AA972965 Hs. 135568 ESTs 4.22 9.21 317519 A, 859695 Hs. 126860 ESTs 1.88 4.15 317521 AI824338 Hs. 126891 ESTs 3.12 4.55 317529 A1916517 Hs. 126865 ESTs 2.73 3.34

317570 A1733361 Hs. 127122 ESTs 1.00 2.43 317571 AA938663 Hs. 199828 ESTs 5. 20 11.95 317598 AW206035 Hs. 192123 ESTs 0.33 1.56 317627 AI346110 Hs. 132553 ESTs 1.50 1.39 317650 AI733310 Hs. 127346 ESTs 0.48 1.46 317659 AA961216 Hs. 127785 ESTs 4.18 7.14 317674 AW294909 Hs. 132208 ESTs 2.92 3.20 317686 AA969051 Hs. 187319 ESTs 1.00 1.01 317692 AI307659 Hs. 174794 ESTs 5. 33 9. 59 317701 AI674774 Hs.128014 ESTs 1.00 1.00 317711 A1733015 Hs. 272189 ESTs 5.13 7.81 317722 AI733373 Hs. 128119 ESTs 2.50 6. 03 317756 AA973667 Hs. 128320 ESTs 1.59 1.30 317777 A1143525 Hs. 47313 KIAA0258 gene product 1.00 2.48 317799 AI498273 Hs. 128808 ESTs 1.78 2.11 317803 AA983251 Hs. 128899 ESTs 0.80 1.06 317821 AI368158 Hs. 70983 PTPL1-associated RhoGAP 1 0.17 0.68 317848 AI820575 Hs. 129086 HomosapienscDNAFW12007fiscToneHE 5.30 8. 16 317850 N29974 Hs. 152982 hypothetical protein FLJ13117 1.30 2.28 317861 AW341064 Hs. 129119 ESTs 2. 18 5. 93 317865 A1298794 Hs. 129130 ESTs 4.48 8.20 317869 AW295184 Hs. 129142 deoxyribonuclease II beta 0.44 0.99 317881 A1827248 Hs. 224398 Homo sapiens cDNA FLJ11469 fis, clone HE 4. 06 2. 23 317890 A1915599 Hs. 129225 ESTs 4.68 7.48 317899 AI952430 Hs. 150614 ESTs, Weakly similar to ALU4_HUMAN ALU S 3.14 3.37 317986 A1005163 Hs. 201378 ESTs, WeaklysimilartoT12545hypotheti 0.28 1.66 318001 AW235697 Hs. 130980 ESTs 5.12 9.97 318016 A1016694 Hs. 256921 ESTs 1.86 4.50 318023 AW243058 Hs. 131155 ESTs 2.92 5. 22 318054 AW449270 Hs. 232140 ESTs 3.92 6.37 318068 A1024540 Hs. 131574 ESTs 1. 21 1.27 318117 A1208304 Hs. 250114 ESTs 0.86 1.17 318187 AI792585 Hs. 133272 ESTs, Weakly similar to ALUC_HUMAN !! ! ! 5.90 6.98 318223 A1077540 Hs. 134090 ESTs 1.05 0, 90 318240 AI085377 Hs. 143610 ESTs 3.10 2.40 318255 A1082692 Hs. 134662 ESTs 0.02 1.05 318266 AI554341 Hs. 271443 ESTs 6.12 10.55 318330 A1093840 Hs. 143758 ESTs 4.98 7. 90 318369 A1493501 Hs. 170974 ESTs 2.46 5.62 318428 A, 949409 Hs. 194591 ESTs 0.77 0.45 318458 A1149783 Hs. 158438 ESTs 3.54 4. 92 318467 AI151395 Hs. 144834 ESTs 4.56 5. 62 318473 A1939339 Hs. 146883 ESTs 2.08 4.05 318476 AI693927 Hs. 265165 ESTs 4.22 8.07 318487 AI167877 Hs. 143716 ESTs 1.47 1.05 318488 A1217431 Hs. 144709 ESTs 1.40 4.14 318491 T26477 Hs. 22883 ESTs, Weakly similar to ALU8_HUMAN ALU S 1.84 1.90 318499 T25451 gb: PTHI188 HTCDL1 Homo sapiens cDNA 5'/3 2.58 5. 20 318537 AA377908 Hs. 13254 ESTs 3.26 4.18 318538 N28625 Hs. 74034 Homo sapiens clone 24651 mRNA sequence 0.35 1.07 318547 R20578 Hs. 90431 ESTs 3.22 4.60 318552 R18364 Hs. 90363 ESTs 4.87 9.06 318575 R55102 Hs. 107761 ESTs, Weakly similar to unnamed protein 1.91 1.98 318580 T34571 Hs. 49007 poly (A) polymerase alpha 2.74 6. 22 318587 AA779704 Hs. 168830 Homo sapiens cDNA FLJ12136 fis, clone MA 0.85 2.46 318596 AI470235 Hs. 172698 EST 4.88 4. 93 318622 T48325 Hs. 237658 apo ! ipoproteinA-D 4. 80 12. 51 318629 N25163 Hs. 8861 ESTs 0.39 1.04 318637 AA243539 Hs. 9196 hypothetical protein 1.72 3.57 318648 T77141 Hs. 184411 albumin 6.27 9.91 318650 AA393302 Hs. 176626 hypothetica) protein EDAG-1 3.96 8.84 318671 AA188823 Hs. 299254 Homo sapiens cDNA : FLJ23597 fis, clone L 1.53 0.81 318679 T58115 Hs. 10336 ESTs 1.00 2.19 318711 AI936475 Hs. 101282 HomosapienscDNA : FLJ21238 fis, clone C 3.05 3.18 318725 AI962487 Hs. 242990 ESTs 1.08 2.46 318728 Z30201 Hs. 291289 ESTs, Weakly similar to ALU1 HUMAN ALU S 0.77 1.33 318740 NM002543 Hs. 77729 oxidised low density lipoprotein (lectin 0.25 1.49 318776 R24963 Hs. 23766 ESTs 1.00 3.01 318784 H00148 Hs. 5181 proliferation. associated 2G4, 38kD 2.70 3.86 318816 F07873 Hs. 21273 ESTs 3. 90 7.13 318865 H10818 gb: ymO4flO. rl Soaresinfantbrain 1N ! BH 2.25 3.56 318879 R56332 Hs. 18268 adenylate kinase 5 1.78 5. 00 318881 Z43224 Hs. 124952 ESTs 4. 79 14. 13 318894 F08138 Hs. 7387 DKFZP564B116 protein 5.31 7.00 318901 AW368520 Hs. 301528 L-kynurenine/alpha-aminoadipate aminotra 1.03 0.91 318925 Z43577 Hs. 21470 ESTs 2.23 3.80 318936 AI219221 Hs. 308298 ESTs 1. 86 7.16 318982 Z44140 Hs. 269622 ESTs 5.84 9. 79 318986 Z44186 Hs. 169161 ESTs, Highly similar to MAON_HUMAN NADP- 1.00 1.00 319041 Z44720 Hs. 98365 ESTs, Weakly similar to weak similarity 3.38 6.11 319103 H05896 Hs. 4993 KIAA1313 protein 1.00 1.07 319170 R13678 Hs. 285306 putative selenocystein lyase 3.79 5.03 319196 F07953 Hs. 16085 putative G-protein coupled receptor 1.00 2.98 319199 F07361 Hs. 13306 ESTs 3.53 5.66 319242 F11472 Hs. 12839 ESTs 5.87 7.26

319263 T65331 Hs. 81360 Homo sapiens cDNA : FLJ21927 fis, clone H 1.81 1.57 319267 F11802 Hs. 6818 ESTs 1.10 4.72 319270 R13474 Hs. 290263 ESTs 4.80 10.40 319279 T65094 Hs. 12677 CGI-147 protein 1.50 2.11 319282 AA461358 Hs. 12876 ESTs 1.00 1.00 319289 W07304 Hs. 79059 transforming growth factor, beta recepto 0.18 0.68 319291 W86578 Hs. 285243 hypothetical protein FLJ22029 0.26 0.62 319293 F12119 Hs. 12583 ESTs 3.13 4.50 319312 Z45481 gb: HSC2QE041 normalized infant brain cDN 1.10 1.00 319370 H54254 Hs. 325823 ESTs, Moderately similar to ALU5_HUMAN A 0.16 0.73 319391 R06304 Hs. 13911 ESTs 1.26 2.43 319396 H67130 Hs. 301743 ESTs 0.70 0.76 319398 AA359754 Hs. 191196 ESTs 2.45 3. 59 319407 R05329 gb: ye9 b04. rl Soares fetal liver spleen 2.00 3.54 319425 T82930 gb: yd39f07. r1 Soares fetal liver spleen 4.28 8.81 319433 R06050 Hs. 191198 ESTs 6.15 14. 13 319437 AA282420 Hs. 111991 ESTs, Weakly similar to Y48A5A. 1 [C. eleg 3.26 5.68 319466 A1809937 Hs. 116417 ESTs 1.76 5. 65 319471 R06546 Hs. 19717 ESTs 4.29 4.84 319480 R06933 Hs. 184221 ESTs 1.00 1.00 319484 T91772 gb : yd52a10. s1 Soaresfetalliverspleen 2.81 4.88 319486 A1382429 Hs. 250799 ESTs 2.08 2.82 319508 T99898 Hs. 270104 ESTs, Moderately similar to ALU8_HUMAN A 2.80 4. 39 319523 T69499 Hs. 191184 ESTs 1.55 3.25 319545 R83716 Hs. 14355 Homo sapiens cDNA FLJ13207 fis, clone NT 1.65 1.19 319546 R09692 gb: yf23bl2. rl Soaresfetal, iverspleen 5.11 8.54 319552 AA096106 Hs. 20403 ESTs 1.89 3. 36 319582 T82998 Hs. 250154 hypothetical protein FLJ12973 3.48 4. 82 319586 D78808 Hs. 283683 chromosome 8 open reading frame 4 0.26 0. 82 319604 R11679 Hs. 297753 viment'n 1.68 3.41 319609 AW247514 Hs. 12293 hypothetical protein FLJ21103 3.06 4.24 319611 H14957 gb: yml9clO. rl Soares infantbrain 1NIB H 2.76 4.24 319653 AA770183 Hs. 173515 uncharacterized hypothalamus protein HTO 2. 51 3.55 319657 R19897 Hs. 106604 ESTs 5.32 7.68 319658 R13432 Hs. 167481 syntrophin, gamma 1 3.35 5.00 319661 H08035 Hs. 21398 ESTs, Moderately similar to A Chain A, H 5.18 12.55 319662 H06382 Hs. 21400 ESTs 1.58 1. 56 319708 R15372 Hs. 22664 ESTs 1.00 1.22 319742 T77668 Hs. 21162 ESTs 2.48 3.13 319748 R18178 Hs. 295866 Homo sapiens mRNA ; cDNA DKFZp434N1923 (f 3.02 4.85 319772 R76633 Hs. 22646 ESTs 4.36 11. 61 319788 AA321932 Hs. 117414 KIAA1320 protein 2.56 3. 68 319805 R92857 Hs. 271350 likely ortholog of mouse polydom 4.63 6.56 319812 N74880 Hs. 264330 N-acyisphingosine amidohydrolase (acid c 0.63 1.32 319834 AA071267 gb: zm61g01. r1 Stratagenefibroblast (937 0. 30 0.94 319878 T78517 Hs. 13941 ESTs 3.99 6.44 319882 AA258981 Hs. 291392 ESTs 5. 09 7.36 319912 T77559 Hs. 94109 Homo sapiens cDNA FLJ 13634 fis, clone PL 3.24 3.21 319935 H79460 Hs. 271722 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.40 9.42 319944 T79248 Hs. 133510 ESTs 3.31 5.39 319947 AA160967 Hs. 14479 Homo sapiens cDNA FLJ14199 fis, clone NT 2.90 4.95 319962 H06350 Hs. 135056 Human DNA sequence from clone RP5-850E9 1.81 1.57 320007 AA336314 gb: EST40943 Endometrial tumor Homo sapie 3.42 6.29 320018 T83263 gb: yd40h09. rl Soaresfetal liverspleen 2.77 5. 14 320030 H63789 Hs. 296288 ESTs, Weaklysimilarto KIAA0638 protein 4.10 6. 69 320032 AI699772 Hs. 292664 ESTs, Weakly similar to A46010 X-linked 3.27 3.27 320040 AA233671 Hs. 87164 hypothetical protein FLJ14001 1.81 1.64 320047 T86564 Hs. 302256 EST 3.38 7.36 320063 AA074108 Hs. 120844 FOXJ2forkheadfactor 5.90 16.73 320096 H58138 Hs. 117915 ESTs 2.08 4.47 320099 AW411307 Hs. 114311 CDC45 (cell division cycle 45, S. cerevis 1. 00 1.00 320112 T92107 Hs. 188489 ESTs 2.27 2.06 320140 H94179 Hs. 119023 SMC2 (structural maintenance of chromoso 1.00 1.00 320188 AW419200 Hs. 172318 ESTs 1.26 1.00 320193 AA831259 Hs. 17132 ESTs 2.58 6.23 320195 R62203 Hs. 24321 Homo sapiens cDNA FLJ12028 fis, clone HE 2.85 4. 53 320199 R78659 Hs. 29792 ESTs 0.40 0.94 320203 AL049227 Hs. 124776 HomosapiensmRNA ; cDNADKFZp564N1116 (f 0.84 1.18 320219 AA327564 Hs. 127011 tubutointerstitiatnephntisantigen 1. 00 1. 17 320220 AF054910 Hs. 127111 tektin 2 (testicular) 0.18 1. 09 320225 AF058989 Hs. 128231 G antigen, family B, 1 (prostate associa 5.26 13. 75 320231 H03139 Hs. 24683 ESTs 1.59 1.93 320260 NM003608 Hs. 131924 G protein-coupled receptor 65 1.38 4.56 320267 AL049337 Hs. 132571 HomosapiensmRNA ; cDNa DKFZp564P016 (fr 1.00 1. 92 320268 H06019 Hs. 151293 Homo sapiens cdNA FLJ10664 fis, clone NT 5.58 5.70 320322 AF077374 Hs. 139322 small proline-rich protein 3 1.41 1.01 320325 Ai167978 Hs. 139851 caveolin 2 0.05 0.67 320330 AF026004 Hs. 141660 chloride channel 2 2.17 1.26 320339 H10807 Hs. 281434 Homo sapiens DNA FLJ14028 fis, clone HE 1.81 2.32 320388 H16065 Hs. 31286 ESTs 1.00 3.22 320402 R22291 Hs. 23368 Homo sapiens clone FLC0578 PR02852 mRNA, 1, 41 1.36 320413 AA203711 Hs. 173269 ESTs 2.31 3.61 320432 R62786 Hs. 124136 ESTs 11.25 20.78 320436 AA253352 Hs. 293663 ESTs 2. 22 3.49 320438 W24548 Hs. 5669 ESTs 3.53 8.14

320448 A) 240233 Hs. 80887 v-yes-1 Yamaguchi sarcoma viral related 1.42 3.46 320451 R26944 Hs. 180777 Homo sapiens mRNA ; cDNA DKFZp564M0264 (f 0.87 0.81 320484 AA094436 Hs. 296267 follistatin-like 1 0.65 1. 18 320499 R32555 Hs. 24321 Homo sapiens cDNA FLJ12028 fis, clone HE 3.44 7. 15 320514 AB007978 Hs. 158278 KIAA0509 protein 6. 44 13. 62 320521 N31464 Hs. 24743 hypothetical protein FLJ20171 1.48 1.04 320526 AW374205 Hs. 111314 ESTs 3.66 7.87 320527 R34672 Hs. 324522 ESTs 3.16 5.63 320536 AA331732 Hs. 137224 ESTs 2.83 5.83 320556 AF054177 Hs. 14570 hypothetical protein FLJ22530 1.28 1. 00 320564 AF056209 Hs. 159396 peptidyigiydneaipha-amidatingmonooxyg 1.22 0.81 320587 Z44524 Hs. 167456 Homo sapiens mRNA full length insert cDN 1.84 2.44 320635 R54159 Hs. 80506 small nuclear ribonucleoprotein polypept 1.00 6. 25 320639 AA243258 Hs. 7395 hypothetical protein FLJ23182 2.60 2.30 320648 N48521 Hs. 26549 Homo sapiens mRNA for KIAA1708 protein, 1.00 1.53 320651 AA489268 Hs. 111334 ferritin, light polypeptide 0.14 0. 79 320664 A1904216 Hs. 91251 hypothetical protein FLJ11198 5.02 8.84 320676 AA132650 Hs. 300511 ESTs 3. 63 5.37 320683 R59291 Hs. 26638 ESTs, Weakly similar to unnamed protein 0.37 1.31 320689 AA334609 Hs. 171929 ESTs, Weakly similar to A54849 collagen 1.27 1.02 320696 AW135016 Hs. 172780 ESTs 3.53 4.60 320714 A1445591 gb: yq04a10. rl Soaresfetalliverspleen 1.06 0.85 320727 U96044 Hs. 181125 immunoglobulin lambda locus 1.35 1.49 320771 Ai793266 Hs. 117176 poly (A)-binding protein, nuclear 1 0.04 0.82 320794 AA281993 Hs. 91226 ESTs 2.96 4.33 320822 AF100780 Hs. 194679 WNT1 inducible signaling pathway protein 0.10 0.79 320824 AF120274 Hs. 194689 artemin 1.16 1.11 320830 AJ132445 Hs. 266416 claudin 14 1.06 1.75 320843 AA317372 Hs. 34744 Homo sapiens mRNA ; cDNADKFZp547C136 (fr 1. 36 1.47 320849 D60031 Hs. 34771 ESTs 5.30 7.49 320853 A1473796 Hs. 135904 ESTs 1.00 1.00 320896 AB002155 Hs. 271580 uroplakin 1B 5, 90 2.55 320921 R94038-Hs. 199538 inhibin, beta C 2.20 1.17 320927 AI205786 Hs. 213923 ESTs 0.18 1.46 320957 AI878933 Hs. 92023 core histone macroH2A2. 2 1.67 2.18 320997 H22544 gb: yn69f11. r1 Soares adult brain N2b5HB5 3.26 3.62 321045 W88483 Hs. 293650 ESTs 2.25 4.55 321046 H27794 Hs. 269055 ESTs 2.69 4.25 321052 AW372884 Hs. 240770 nuclear cap binding protein subunit 2, 2 2.14 2.56 321059 A1092824 Hs. 126465 ESTs 1. 69 0. 53 321062 R87955 Hs. 241411 Homo sapiens mRNA full length insert cDN 2.76 5.20 321067 AF131782 Hs. 241438 Homo sapiens clone 24941 mRNA sequence 4.79 7.41 321102 AA018306 gb: ze40dO8. r1 Soares retina N2b4HR Homo 1.79 4.27 321130 H43750 Hs. 125494 ESTs 1.00 3.14 321142 AI817933 Hs. 298351 ASPL protein 8.73 15.36 321155 AA336635 Hs. 99598 hypothetical protein MGC5338 3.04 5. 03 321158 AA700289 gb: yu76fil. rl Soaresfetaììiverspleen 4.62 8. 39 321170 N53742 Hs. 172982 ESTs 2.21 4. 46 321199 AW385512 gb: yy56d10. s1 Soares_mulUple_scìerosis_ 5. 69 8.01 321206 H54178 Hs. 226469 Homo sapiens cDNA FLJ12417 fis, clone MA 4.00 7.32 321225 AL080073 Hs. 251414 Homo sapiens mRNA ; cDNADKFZp564B1462 (f 4.17 4.63 321236 AW371941 Hs. 18192 Ser/Arg-related nuclear matdx protein (1, 00 1. 00 321244 AF068654 gb : Homo sapiens isolate AN. timmunogtobu 2.18 9.13 321270 R83560 gb: yv76c06. s1 Soares fetal liver spleen 3.80 5. 26 321317 AI937060 Hs. 6298 KIAA1151 protein 1.81 1.65 321318 AB033041 Hs. 137507 KIAA1215 protein 1.00 1.00 321325 AB033100 Hs. 300646 KIAA protein (similar to mouse paladin) 0.44 0.93 321342 AA127984 Hs. 222024 transcription factor BMAL2 4.94 4.93 321356 R93443 Hs. 271770 ESTs 3.10 4.66 321418 AI739161 Hs. 161075 ESTs 2.28 2. 54 321420 A1368667 Hs. 132743 ESTs 1.13 0. 97 321430 U05890 gb: H. sapiens (DIG3) mRNA for immunoglobu 2. 42 3.35 321453 N50080 Hs. 82845 HomosapienscDNA : FLJ21930 fis, clone H 1.60 3.11 321467 X13075 gb: Human2a12mRNAforkappa-immunoglobu 0. 42 0. 72 321468 AA514198 Hs. 38540 ESTs 2.46 6. 50 321491 H70665 Hs. 292549 ESTs 1.00 1.25 321498 AW295517 Hs. 255436 ESTs 3. 19 6. 24 321504 W02356 Hs. 268980 ESTs 2.28 3.86 321510 AA703650 Hs. 255748 ESTs 2.14 3. 94 321513 H84972 Hs. 108551 ESTs 2.78 5. 37 321516 A1382803 Hs. 159235 ESTs 3.06 7.19 321565 A1525773 Hs. 266514 hypothetical protein FLJ11342 4.89 7.82 321577 H84260 gb: ys90g04. r1 Soares retina N2b5HR Homo 1.00 1.73 321581 AA019964 Hs. 28803 ESTs 4.88 6.73 321582 AA143755 Hs. 21858 trinucleotide repeat containing 3 1.00 2.08 321587 H95531 gb: ys76e02. rl Soares retina N2b4HR Homo 2. 26 4.52 321626 AA295430 Hs. 96322 hypotheticalprotein FLJ23560 1.95 3.83 321628 H87064 Hs. 161051 ESTs, ModeratelysimilartoALU6_HUMANA 0.47 1.02 321642 AW085917 Hs. 247084 ESTs 1.52 1. 38 321669 H95404 Hs. 294110 ESTs 2. 17 2. 45 321687 AA625149 gb: af70cl2. rl Soares_NhHMPu_S1 Homosapi 4.31 6.95 321688 H97646 Hs. 123158 Homo sapiens cDNA FLJ12830 fis, clone NT 2.82 3.28 321693 AA700017 Hs. 173737 ras-related C3 botulinum toxin substrate 0.51 1.08 321700 N55160 Hs. 167260 ESTs 4.57 7. 46 321701 AW390923 Hs. 42568 ESTs 1.00 1. 00

321709 N25847 Hs. 108923 RAB38, member RAS oncogene family 1.00 1. 00 321710 N35682 Hs. 259743 ESTs 2.97 5.26 321775 AI694875 Hs. 202312 HomosapiensConeN11NTera2D1teratoca 1.00 1.00 321777 Api637993 Hs. 202312 Homo sapiens clone N11 NTera2D1 teratoca 1.68 0.45 321779 N42729 Hs. 163835 ESTs 0.90 0.90 321829 D81993 Hs. 8966 tumor endothelial marker 8 2.69 3.89 321846 AA281594 Hs. 87902 ESTs 5.11 7.64 321879 AL109670 Hs. 302809 ESTs 6.49 9.58 321883 AA426494 Hs. 46901 KIAA1462 protein 0.28 0.95 321899 N55158 Hs. 29468 ESTs 0.39 0.95 321911 AF026944 Hs. 293797 ESTs 6.20 10.76 321949 R49202 Hs. 181694 EST 4.62 10.51 321955 AI651866 Hs. 195689 ESTs 2.89 5.47 321956 AL110177 Hs. 132882 ESTs 0.32 1.25 321987 AL133612 Hs. 272759 KIAA1457 protein 1.00 1.83 321991 AL133627 Hs. 158923 Homo sapiens mRNA ; cDNA DKFZp434K0722 (f 4.00 6.47 322002 AA328801 Hs. 84522 ESTs 2.10 3.48 322035 AL137517 Hs. 306201 hypothetical protein DKFZp56401278 1.00 1.90 322044 AW340926 gb : xy51b10. xl NCI_CGAP_Lu34. 1 Homosapie 3.20 9.67 322057 N92197 Hs. 154679 synaptotagmin 1 1.55 1.07 322060 AI341937 gb: qtlOeO3. xl NC, _CGAP_GC4Homosapiens 4.59 7.68 322070 U80769 Hs. 210322 Homo sapiens mRNA for KIAA1766 protein, 2.78 4.52 322083 AF074982 Hs. 226031 ESTs, Highly similar to KIAA0535 protein 3.10 5.52 322091 AI819863 Hs. 106243 ESTs 1.59 1. 75 322125 R93901 gb: yq16c12. rl Soares fetal liver spleen 2.06 5.27 322130 R98978 Hs. 117767 ESTs 10.12 16.49 322147 AF085919 Hs. 114176 ESTs 0.94 0.64 322166 AF085958 gb: yr88b03. r1 Soares fetal liver spleen 4.09 6.67 322173 H52567 gb: yt85d04. r1 Soares_pinea_gland_N3HPG 3.46 4.85 322178 H56535 gb: yt88g03. r1 Soares_pineal_gland_N3HPG 0. 44 2.54 322179 H92891 gb: yt94cO2. sl Soares_pineal_gland_N3HPG 4.52 7.50 322186 H67346 Hs. 269187 ESTs 0.15 0.98 322196 W87895 Hs. 211516 ESTs 2.20 5.04 322212 AF087995 Hs. 134877 ESTs 3.42 4.84 322221 Ai890619 Hs. 179662 nucleosomeassemblyprotein1-, ike1 0.82 2.14 322277 AI640193 Hs. 226389 ESTs 3.62 3. 98 322278 AF086283 gb: zd46f01, rl Soares_fetal_heart_NbHH19W 1.00 1.00 322284 A) 792140 Hs. 49265 ESTs 0.66 2.76 322288 AL037273 Hs. 7886 pellino (Drosophila) homolog 1 0.71 0.70 322320 AF086419 gb: zd78d03. r1 Soares_fetal_heart_NbHH19W 2.02 2.76 322336 AA308526 Hs. 76152 decorin 2.92 4. 44 322339 W17348 gb: zb18c07. x5 Soares_fetal_lung_NbHL19W 8.50 11.56 322366 AW404274 Hs. 122492 hypothetical protein 0.61 1.34 322372 W25624 Hs. 153943 ESTs 7.37 12.07 322374 AI394663 Hs. 122116 ESTs, Moderately similar to Osf2 [M. musc 4.78 10.50 322378 AF064819 Hs. 201877 DESC1 protein 1.00 1.00 322388 AI815730 Hs. 247474 hypothetical protein FLJ21032 7.09 8.49 322416 AA223183 Hs. 298442 adaptor-related protein complex 3, mu 1 3.20 5.80 322419 AA248987 Hs. 14084 ring finger protein 7 1.64 1.57 322425 W37943 Hs. 34892 KIAA1323 protein 0.83 1. 00 322431 AA069222 Hs. 141892 ESTs 3.96 5.22 322450 AA040131 Hs. 25144 ESTs 5. 18 12.67 322465 AA137152 Hs. 286049 phosphosedne aminotransferase 3.41 2.23 322467 AF116826 Hs. 180340 putative protein-tyrosine kinase 1.00 1.30 322473 AA744286 Hs. 266935 tRNA selenocysteine associated protein 1.75 2.03 322509 T52172 Hs. 302213 ESTs 1.00 2.27 322523 W80398 Hs. 193197 ESTs 2.75 5. 49 322527 AF147359 gb: Homo sapiens full length insert cDNA 1.25 1.27 322560 AI916847 Hs. 270947 ESTs 4.57 8.81 322566 W87285 Hs. 269587 ESTs 1.00 1.42 322585 AA837622 gb:zh69c01.r1 Soares_fetal_liver_spleen_ 4.18 6.94 322635 AA679084 gb: zh90h08. r1 Soaresjetaijiver spieen 2.40 4.85 322641 AA007352 Hs. 256042 ESTs 2. 94 4.64 322653 AI828854 Hs. 258538 strialin, calmodulin-binding protein 0.48 0.38 322664 AA011522 gb: zi03g07. r1 Soares_fetaUiver_spleen_ 1. 92 2.18 322687 AI110759 gb: AF074666 Human fetal liver cDNA libra 4.14 6.75 322692 AA018117 Hs. 60843 potassium voltage-gated channel, shaker-3. 50 5.00 322694 AI110872 Hs. 279812 PR00327 protein 1.80 1.72 322708 AF113674 Hs. 283773 clone oneFLB1727 1.00 3.43 322712 AA021328 Hs. 23607 hypothetical protein FLJ11109 3.28 3.86 322766 AW068805 Hs. 288467 Homo sapiens cDNA FLJ12280 fis, clone MA 1.63 1.53 322770 AA045796 Hs. 122682 ESTs 1.53 1.06 322794 A) 608591 Hs. 38991 S100 calcium-binding protein A2 12.06 1.94 322810 A1962276 Hs. 127444 ESTs 4.09 6.90 322818 AW043782 Hs. 293616 ESTs 1.20 1.63 322820 A1377755 Hs. 120695 ESTs 0.21 1.93 322872 AA827228 Hs. 126943 ESTs 2.04 1.63 322882 AW248508 Hs. 279727 Homo sapiens cDNA FLJ14035 fis, clone HE 5.26 1.22 322887 AI986306 Hs. 86149 phosphoinositol 3-phosphate-binding prot 2.80 2.24 322913 A1733737 Hs. 68837 ESTs 2.38 6.61 322926 A1825940 Hs. 211192 ESTs 4.02 5. 79 322929 A1365585 Hs. 146246 ESTs 0.30 1.14 322968 AI905228 Hs. 83484 SRY (sex determining region Y)-box 4 2.06 1. 13 322971 C15953 Hs. 212760 hypothetical protein FLJ13649 1.18 2.00 322981 AA493252 Hs. 159577 ESTs 2.28 2.61

322988 C18727 Hs. 171941 ESTs 0.39 2.00 323003 A1733859 Hs. 149089 ESTs 3.28 1.00 323013 AA134042 Hs. 191451 ESTs 3.38 5.68 323025 AL157565 Hs. 315369 HomosapienscDNA : FLJ2307 fis, clone L 0.06 1.10 323032 AW244073 Hs. 145946 ESTs 10.18 21.27 323052 R21124 Hs. 85573 Homo sapiens DC29 mRNA, complete cds 1.46 1.90 323064 AL119341 Hs. 49359 Homo sapiens mRNA ; cDNA DKFZp547E052 (fr 3.08 5.64 323098 A1700025 Hs. 270471 ESTs 2. 31 4. 49 323102 AL119913 Hs. 163615 ESTs 5.38 11.64 323155 AL135041 gb: DKFZp762K2310_r1 762 (synonym: hmel2) 2.38 5.56 323176 AW071648 Hs. 82101 pleckstrin homology-like domain, family 1.06 1.41 323191 AA195600 Hs. 301570 ESTs 0.73 1, 24 323225 AA205654 Hs. 24790 KIAA1573 protein 5.25 11.95 323232 AA148722 Hs. 224680 ESTs 0.45 1.35 323266 AW003362 Hs. 243886 nuclear autoantigenic sperm protein (his 1.71 1.83 323281 A1697556 Hs. 292659 ESTs 1.24 3. 21 323283 AA256014 Hs. 86682 Homo sapiens cDNA : FLJ21578 fis, clone C 12. 68 15.05 323314 AA226310 Hs. 191501 ESTs 4. 42 9. 61 323316 AL134620 Hs. 280175 ESTs 2. 98 5. 93 323334 AI336501 Hs. 77273 ras homolog gene family, member A 1.98 3. 30 323338 R74219 Hs. 23348 S-phase kinase-associated protein 2 (p45 1.62 1.00 323348 AA233056 Hs. 191518 ESTs 1.00 1.07 323351 AA704103 Hs. 24049 ESTs 1.43 1. 68 323359 AA234172 Hs. 137418 ESTs 0. 34 1. 18 323360 AA716061 Hs. 161719 ESTs 3.01 3.71 323405 AW139550 Hs. 115173 ESTs 1.90 8.81 323420 AI672386 Hs. 263780 ESTs 0.29 1.01 323434 AW081455 Hs. 120219 ESTs 2.27 1. 92 323445 AA253103 Hs. 135569 ESTs, Weakly similar to NEUROD [H. sapien 0.43 0. 80 323449 AA282865 Hs. 284153 Fanconi anemia, complementation group A 3.19 3.85 323492 H00978 Hs. 20887 hypothetical protein FLJ10392 270 3.20 323501 AA182461 Hs. 84520 ESTs 2.04 3.31 323505 Api652287 gb: EST382593 MAGE resequences, MAGK Homo2. 21 3.08 323515 AA282274 Hs. 256083 ESTs 2.69 3. 40 323541 AI185116 Hs. 104613 RP42 homolog 1. 20 1.09 323545 AI814405 Hs. 224569 ESTs 1.25 1.55 323635 R63117 Hs. 9691 Homo sapiens cDNA : FLJ23249 fis, clone C 0.27 0.72 323675 AA984759 Hs. 272168 tumor differentially expressed 1 3.70 5.80 323678 AL042121 Hs. 20880 ESTs 3.33 5.10 323691 AA317561 Hs. 145599 ESTs 1. 00 1.00 323693 AW297758 Hs. 249721 ESTs 2.01 1.54 323746 AW298611 Hs. 12808 MARK 4.11 5.53 323774 AA329806 Hs. 321056 Homo sapiens mRNA ; cDNA DKFZp586F1322 (f 2.06 3.70 323856 AA355264 Hs. 267604 hypothetical protein FLJ10450 3.42 8.13 323857 T18988 Hs. 293668 ESTs 5.97 12.51 323870 AA341774 Hs. 129212 ESTs 3.17 4.52 323876 AL042492 Hs. 147313 ESTs 0.36 1.00 323885 AA344308 Hs. 128427 Homo sapiens BAC clone RP11-335J18 from 2.31 3.33 323911 AL043212 Hs. 92550 ESTs 4.38 5.41 323919 AA862973 Hs. 220704 ESTs 5. 80 10.20 323972 A1869964 Hs. 182906 ESTs 3.10 5. 14 324005 AA610011 Hs. 208021 ESTs 5.34 10.07 324036 AI472078 Hs. 303662 ESTs 1.00 5.03 324055 AA528794 Hs. 128644 ESTs 0.86 1.00 324063 AW292740 Hs. 272813 dual oxidase 1 0.45 0. 91 324072 AA381829 gb: EST94855 Activated T-cells I Homo sap 2.82 5.12 324092 AW269931 Hs. 202473 Homo sapiens cDNA : FLJ22278 fis, clone H 2.40 2.52 324095 AW377983 Hs. 298140 Homo sapiens cDNA : FLJ22502 fis, clone H 1.32 4.30 324129 AI381918 Hs. 285833 Homo sapiens cDNA : FLJ22135 fis, clone H 1.40 1.77 324132 AW504860 Hs. 288836 hypothetical protein FLJ12673 4.24 6. 21 324214 AA412395 Hs. 225740 ESTs 6.96 10. 69 324227 AA295552 Hs. 28631 Homo sapiens cDNA : FLJ22141 fis, clone H 0.81 0.53 324266 AL047634 Hs. 231913 ESTs 2.42 4.05 324275 AA429088 Hs. 98523 ESTs 3.62 5.38 324281 AL048026 Hs. 124675 ESTs, Weakly similar to T14742 hypotheti 0.14 0.70 324290 AA432032 Hs. 304420 ESTs 3.71 4. 34 324303 AL118754 gb: DKFZp761P1910 rl 761 (synonym: hamy2) 0. 95 0.91 324312 A1198841 Hs. 128173 ESTs 4. 06 5.91 324325 AL138153 Hs. 300410 ESTs 5.88 8.25 324338 AL138357 Hs. 145078 regulator of different ! auon (in S, pomb 0.87 1.25 324341 AW197734 Hs. 99807 ESTs, Weakly similar to unnamed protein 1.28 1. 00 324343 AW452016 Hs. 293232 ESTs 2.54 3.46 324371 AA452305 Hs. 270319 ESTs 5.85 8.36 324382 AW502749 Hs. 24724 MFH-amplified sequences with leucine-ric 0.76 1.64 324384 AA453396 Hs. 127656 KIAA1349 protein 2.88 5.69 324385 F28212 Hs. 284247 K, M1491 protein 1.81 1.99 324388 AI924963 Hs. 306206 hypothetical protein FLJ11215 1.00 1.00 324432 AA464510 Hs. 152812 ESTs 2.73 2.17 324497 AW152624 Hs. 136340 ESTs, Weakly similar to unnamed protein 0.71 1.90 324510 At148353 Hs. 287425 Homo sapiens cDNA FLJ11569 fis, clone HE 1.00 1.00 324580 AA492588 gb : ng99c08. s1 NCI CGAP_Thy1 Homo sapiens 2.18 3.50 324582 AA506935 Hs. 132036 ESTs, Weakly similar to ALU1_HUMAN ALU S 5.96 11.36 324633 AA572994 Hs. 325489 ESTs 2.92 4. 22 324640 AW295832 Hs. 134798 ESTs, Moderately similar to TTL MOUSE TU 5.48 11.74 324675 AW014734 Hs. 157969 ESTs 0.39 0.73

324699 AW504732 Hs. 21275 hypothetical protein FLJ11011 0.93 0.93 324747 AA603532 Hs. 130807 ESTs 1.57 1. 81 324748 AA657457 Hs. 292385 ESTs 1.55 1.34 324801 AI819924 Hs. 14553 sterol 0-acyltransferase (acyl-Coenzyme 1.00 6.56 324804 Axe92552 gb: wd73fl2. x1 NC, _CGAP_Lu24Homosapiens 1.00 7.53 324828 AA843926 Hs. 124434 ESTs 2.00 3.25 324855 AW152305 Hs. 122364 ESTs 2.74 3.43 324866 AI541214 Hs. 46320 Small proline-rich protein SPRK [human, 1.07 0.95 324871 AW297755 Hs. 271923 Homo sapiens cDNA FW22785 fis, clone K 1.68 1. 21 324886 AA806794 Hs. 131511 ESTs 2.56 5.61 324889 D31010 gb: HUML12147 Human fetal lung Homo sapie 2.20 4.65 324948 AW383618 Hs. 265459 ESTs, Moderately similar to ALU2_HUMAN A 5.28 7. 05 324953 AI264628 Hs. 125428 ESTs 3.37 5. 51 324958 AA625076 Hs. 132892 protocadherin 20 5.12 9.81 324988 T06997 Hs. 121028 hypothetical protein FLJ10549 2.52 1.08 325024 F13254 Hs. 78672 laminin, alpha4 5. 24 10.22 325105 H97109 Hs. 105421 ESTs 1.00 1.00 325108 AA401863 Hs. 22380 ESTs 1.99 2.14 325114 D83901 Hs. 315562 ESTs 2.73 3. 17 325146 A1064690 Hs. 171176 ESTs 1.86 3. 41 325149 D61117 Hs. 187646 ESTs 0.42 0.93 325187 A ! 653682 Hs. 197812 ESTs 6.50 11.31 325228 6.18 15.76 325235 2.64 4.12 325328 2.87 4.42 325340 0.29 0.33 325367 16.56 24.29 325373 0.63 1.22 325389 0. 88 1. 05 325436 5. 75 14. 14 325471 8.46 17.82 325498 3.32 6.42 325557 5. 51 8.28 325559 7.48 21.40 325560 4.08 6.25 325569 4.20 5.24 325585 1.10 1, 13 325587 1.00 1.00 325597 2.98 13.40 325639 0.78 0. 78 325685 0.46 0.66 325686 0.95 1.55 325735 4. 48 9.20 325739 0.59 0.88 325740 2.42 6.61 325792 7.88 9. 83 325819 4.74 7.18 325883 2. 02 2.64 325895 7.78 15.98 325925 2. 04 10.60 325932 4.18 7. 36 325941 3.66 9.03 325969 0. 61 0.80 325971 4.88 7.42 326025 0.55 1.07 326046 7.21 14.72 326099 3.60 5.98 326108 1. 27 1.06 326163 3.27 5. 70 326165 0.45 1.11 326189 0.13 0.45 326204 5.60 9.00 326230 7.00 12.01 326274 1.00 8.09 326360 9.86 15. 35 326393 0.52 0.77 326505 1.00 1.42 326515 1.24 5. 84 326589 9.20 13.49 326592 2.77 4. 01 326605 2.01 2.53 326692 1.00 1.00 326693 1.00 1.31 326720 0.19 0.65 326742 2.34 7.20 326770 0.25 0.83 326818 3.09 4.56 326936 2.08 3.45 326964 0.41 1.70 326983 2.02 3. 80 326991 1.09 1.20 327036 1.00 8.04 327040 3.05 4.22 327053 3.55 6.31 327075 1. 59 1.40

327085 2.50 12.57 327130 5. 38 8.04 327156 3.74 6.58 327220 1.28 1.54 327224 6.56 12.91 327288 2.61 5.40 327321 2.42 3.11 327332 6.62 10.58 327361 2.69 4.41 327377 2.04 6.72 327396 2.61 4.50 327414 1.00 8.01 327442 5.91 9.65 327467 6.58 18.01 327473 3.79 7.48 327483 4. 08 8.87 327562 0.68 2.86 327568 1.00 2. 00 327606 2.06 3. 61 327611 5.90 14.26 327642 4.06 8.74 327654 1.05 2.08 327734 1.00 1. 00 327775 1.46 11. 79 327796 3.47 5.65 327840 3.26 6.64 327940 5.84 15.58 327984 0.36 1.50 328004 1.87 1.42 328021 0.42 0.59 328068 2.83 4.68 328100 3. 04 5. 39 328101 3.54 5.20 328113 0. 72 0.91 328157 5.58 5.16 328196, 5. 76 11.13 328197 5. 98 10.58 328264 3.11 4.88 328299 2.20 3.06 328342 1. 49 1. 94 328365 1. 00 1.00 328369 4.40 7. 36 328381 1.86 4.93 328451 5. 51 7.56 328481 0.13 0.72 328500 2.71 3.97 328530 5.41 7. 62 328600 3.14 10.68 328608 4.56 8.17 328616 2.24 11.91 328623 3.04 5.46 328632 0. 70 1. 19 328664 3.48 6.80 328666 10. 42 26.47 328698 9.68 14.56 328700 2. 74 10.22 328708 0.15 0.57 328735 6.23 8.91 328743 3.62 6.54 328806 0.22 0.78 328861 3.68 10.54 328908 5.42 16. 36 328933 2.02 5.29 328934 1.73 4.45 328949 3.34 5.41 329005 2.88 7.26 329011'2. 52 3. 72 329033 1. 00 1.03 329037 5.07 8.16 329067 1.98 2.41 329134 2.24 3.25 329157 2. 30 11.04 329178 2.64 5.02 329192 6.41 15.27 329194 0.31 0.79 329204 1.60 3.75 329224 2.99 6.11 329228 0.83 0.83 329288 0.63 1.01 329337 1.00 1. 00 329541 0.76 1.68 329560 1.34 2.02 329588 1.68 2.22 329643 4.18 11.77 329703 1.00 1.00

329764 5. 78 15.50 329816, 2.09 5.44 329860 3. 13 10. 77 329993 7.83 14.21 330020 5.58 13.12 330036 3.32 5.57 330052 4. 31 7.97 330085 1. 34 1.76 330088 4.70 12.46 330093 0.44 1.06 330100 3.47 4.83 330106 2.14 3.61 330107 3.17 6.87 330120 5.61 11.89 330123 4.50 12.74 330208 1.55 7.62 330263 13.10 23.38 330300 2. 81 4. 98 330313 3.00 4.41 330366 0.67 0.76 330372 4.76 11. 82 330385 AA449749 Hs. 182971 karyopherinalpha5 (importina ! pha6) 2.14 2.15 330397 D14659 Hs. 154387 KIAA0103 gene product 0.40 1.15 330468 L10343 Hs. 112341 protease inhibitor 3, skin-derived (SKAL 1.11 0.94 330472 L24203 Hs. 82237 ataxia-telangiectasia group D-associated 1.67 1.17 330478 L38486 Hs. 296049 microfibrillar-associated protein 4 0.46 1.07 330493 M27826 Hs. 267319 endogenous retroviral protease 1.07 0.95 330495 M31328 Hs. 71642 guanine nucleotide binding protein (G pr 0.97 0.96 330506 M61906 Hs. 6241 phosphoinositide-3-kinase, regulatory su 0.17 3.66 330512 M80563 Hs. 81256 S100 calcium-binding protein A4 (calcium 0.60 1.06 330537 U19765 Hs. 2110 zinc finger protein 9 (a cellular retrov 2.81 2.07 330547 U32989 Hs. 183671 tryptophan 2, 3-dioxygenase 3.91 1.49 330551 U39840 Hs. 299867 hepatocyte nuclear factor 3, alpha 1.15 1.03 330568 U56244 (NONE) 2.83 4.79 330599 U90437 gb: Human RP1 homolog mRNA, 3'UTR region 2.08 1.54 330601 U90916 Hs. 82845 HomosapienscDNA : FLJ21930 fis, clone H 0.89 1.35 330605 X02419 Hs. 77274 plasminogen activator, urokinase 1.87 1.55 330609 X04741 Hs. 76118 ubiquitin carboxyl-terminal esterase L1 1.83 1.30 330617 X53587 Hs. 85266 integrin, beta4 1.54 1.15 330630 X78669 Hs. 79088 retcuTocalbin 2, EF-hand caMcium bindin 1.39 1.19 330644 Y07755 Hs. 38991 S100 calcium-binding protein A2 3.83 1.13 330650 Z68228 Hs. 2340 junction plakoglobin 1.25 0. 95 330660 AA347868 Hs. 139293 ESTs, Weakly similar to ALU7 HUMAN ALU S 15.50 29.07 330692 AA017045 Hs. 6702 ESTs 1.00 1.00 330707 AA133891 lis. 293690 ESTs 0.20 1.35 330715 AA233707 Hs. 11571 Homo sapiens cDNA FLJ11570 fis, clone HE 0.12 1.40 330717 AA233926 Hs. 52620 integrin, beta 8 6.62 5.42 330722 AA243560 Hs. 34382 ESTs 1. 40 1.65 330740 AA297746 Hs. 22654 Homo sapiens voltage-gated sodium channe 0.27 2.04 330742 AA400979 Hs. 25691 receptor (calcitonin) activity modifying 0.44 0.90 330744 AA406142 Hs. 12393 dTDP-D-glucose 4, 6-dehydratase 0.71 3.23 330751 AA428286 Hs. 29643 Homo sapiens cDNA FLJ 13103 fis, clone NT 1.66 1.52 330760 AA448663 Hs. 30469 ESTs 0.52 0.90 330763 AA450200 Hs, 274337 hypothetical protein FLJ20666 0.37 0. 97 330786 D60374 Hs. 49136 ESTs, Moderately similar to ALU7 HUMAN A 0.78 0.84 330790 T48536 Hs. 105807 ESTs 0.23 3.17 330814 AA015730 Hs. 265398 ESTs, Weakly similar to transformauon-r 0.37 2.07 330827 AA040332 Hs. 12744 ESTs 1.60 1.00 330844 AA063037 Hs. 66803 ESTs 0. 93 1.16 330901 AA157818 Hs. 267319 endogenous retroviral protease 1.02 1.03 330931 F01443 Hs. 284256 hypothetical protein FLJ14033 similar to 0.24 0.88 330952 H02855 Hs. 29567 ESTs 0.08 1.31 330961 H10998 Hs. 7164 a disintegrin and metalloproteinase doma 1. 29 1.26 330968 H16568 Hs. 23748 ESTs 0.48 0.96 331014 H98597 Hs. 30340 hypothetical protein KIAA1165 0.29 0.74 331046 N66563 Hs. 191358 ESTs 0. 99 8.56 331060 N75081 Hs. 157148 Homo sapiens cDNA FLJ11883 fis, clone HE 1. 24 1.00 331099 R36671 Hs. 83937 hypothetical protein 0.75 1.03 331108 R41408 Hs. 21983 ESTs 1.00 2.75 331131 R54797 gb: yg87bO7. s1 Scares infant brain 1NIBH 6.04 10.68 331135 R61398 Hs. 4197 ESTs 0.80 0.96 331170 T23461 Hs. 159293 ESTs 2.63 4.29 331180 T32446 Hs. 6640 Human DNA sequence from PAC 75N13 on chr 1.78 2.71 331183 T40769 Hs. 8469 ESTs 1.00 3.01 331203 T82310 (NONE) 1.70 3.80 331271 AA059347 Hs. 82226 glycoprotein (transmembrane) nmb 1.20 3.19 331306 AA252079 Hs. 63931 dachshund (Drosophila) homolog 0.31 1.30 331327 AA281076 Hs. 109221 ESTs 2.09 2.41 331341 AA303125 Hs. 23240 Homo sapiens cDNA FLJ 13496 fis, clone PL 0.72 2.43 331359 AA416979 Hs. 46901 KIM1462 protein 0.09 0.91 331363 AA421562 Hs. 91011 anterior gradient 2 (Xenepus laevis) hom 1.02 0.87 331378 AA448881 Hs. 49282 hypothetical protein FLJ11088 1.03 1.23 331384 AA456001 Hs. 93847 NADPH oxidase 4 1.40 1.00 331402 AA505135 Hs. 44037 ESTs 1.80 3.93 331422 F10802 Hs. 163628 ESTs, Moderately similar to ALU7 HUMAN 1.65 1. 89

331490 N32912 Hs. 26813 CDA14 2.48 1.73 331531 N51343 gb: yz15g04. s1 Soares_mutüpte_scierosis_ 0.98 1.68 331547 N54811 gb: od74f04. s1 NCI_CGAP_Ov2 Homo sapiens 3.80 5.75 331578 N67960 Hs. 249989 ESTs 0.11 0.67 331589 N71027 Hs. 152618 ESTs 1.09 1.38 331608 N89861 Hs. 112110 PTD007 protein 0.93 0.76 331614 N92293 Hs. 240272 EST 0. 17 1.34 331668 W69707 Hs. 58030 EST 2. 24 3.82 331671 W72033 Hs. 194695 ras homolog gene family, member 1 1. 00 1.24 331676 W79834 Hs. 58559 ESTs, Weakly similar to rhotekin [M. musc 0.08 1.07 331681 W85712 Hs. 119571 collagen, type III, alpha 1 (Ehlers-Danl 8.72 4.27 331692 W93592 Hs. 152213 wingless-type MMTV integration site fami 0.94 0.54 331717 AA190888 Hs. 153881 HomosapiensNY-REN-62antigenmRNA, par 1.57 1.34 331718 AA191404 Hs. 104072 ESTs 6.80 11.77 331811 AA404500 Hs. 301570 ESTs 1.10 1.00 331820 AA405970 Hs. 97996 transcription termination factor, mitoc 0.73 0.59 331831 AA412031 Hs. 97901 EST 2.77 4.08 331852 AA418988 Hs. 98314 Homo sapiens mRNA ; cDNA DKFZp586L0120 (f 0.23 0.93 331943 AA453418 Hs. 21275 hypothetical protein FLJ11011 0.36 1.88 331969 AA460702 Hs. 82772 collagen, type XI, alpha 1 1.00 1.00 331990 AA478102 Hs. 139631 ESTs 3.04 3.87 332002 AA482009 Hs. 105104 ESTs 1.19 0.78 332027 AA489671 Hs. 65641 hypothetical protein FLJ20073 1.27 1. 03 332029 AA489697 Hs. 145053 ESTs 0. 30 1. 62 332033 AA489840 Hs. 251014 EST 2.30 3.70 332048 AA496019 Hs. 201591 ESTs 0. 17 0.52 332071 AA598594 Hs. 205293 KIAA1211 protein 1.35 1.23 332074 AA599012 gb: ae41ell. sl Gess, erWi ! mstumorHomos 0.19 2.00 332083 AA600200 Hs. 155546 KIAA1080 protein; Golgi-associated, gamm 0. 31 1.18 332085 AA600353 Hs. 173933 nuclear factor IIA 0.30 1.50 332125 AA609861 Hs. 312447 ESTs 0.22 0.62 332177 F10812 Hs. 101433 ESTs 8.21 18.03 332180 H03348 Hs. 7327 claudin 1 2.27 1.57 332185 H10356 Hs. 101689 ESTs 0.09 1.18 332203 H49388 Hs. 317769 EST 8.05 5. 02 332232 N48891 Hs. 101915 Stargardt disease 3 (autosomal dominant) 0.78 0.85 332240 N54803 Hs. 324267 ESTs, Weak ! ysimilartoputativepl50 [0. 96 1.23 332261 N70294 Hs. 269137 ESTs 2.40 3.74 332275 R08838 Hs. 26530 serum deprivation response (phosphatidyl 0.27 0.75 332280 R38100 Hs. 146381 RNAbindingmotifprotein, Xchromosome 0.39 1.88 332299 R69250 Hs. 21201 nectin 3 ; DKFZP56680846 protein 5.24 12.76 332304 R74041 Hs. 101539 ESTs 1.44 3.18 332314 T25862 Hs. 101774 hypothetical protein FLJ23045 0.68 1.32 332384 M11433 Hs. 101850 retinol-binding protein 1, cellular 1.71 0.88 332434 N75542 Hs. 289068 Homo sapiens cDNA FLJ 11918 fis, clone HE 0.43 0.86 332445 T63781 Hs. 11112 ESTs 0.68 1.00 332453 L00205 Hs. 111758 keratin 6A 31. 54 1. 00 332458 M33493 Hs. 250700 tryptase beta 1 0.51 1.00 332504 AA053917 Hs. 15106 chromosome 14 open reading frame 1 0.79 1.24 332525 M17252 Hs. 278430 cytochrome P450, subfamily XXIA (steroid 0.98 1.70 332530 M31682 Hs. 1735 inhibin, beta B (activin AB beta polypep 0. 88 0. 66 332535 N20284 Hs. 19280 cysteine-rich motor neuron 1 0.22 1.46 332539 AA412528 Hs. 20183 ESTs, Weakly similar to AF1647931 prote 0.93 1.49 332559 M13955 Hs. 166189 cytokeratin 2 0.35 1.13 332563 N92924 Hs. 274407 protease, serine, 16 (thymus) 1.00 1.00 332565 AA234896 Hs. 25272 E1A binding protein p300 0.36 1.05 332594 AA279313 Hs. 3239 methyl CpG binding protein 2 (Rettsyndr 0. 53 0.59 332634 S38953 Hs. 283750 tenascin XA 0.38 1.16 332638 AA283034 Hs. 50640 JAK binding protein 1.00 1.70 332640 AA417152 Hs. 5101 proteinregulatorofcytokinesisl 6.15 1.16 332654 AA001296 Hs. 288217 hypothetical protein MGC2941 1.50 2.73 332665 AA223335 Hs. 63788 propionyl Coenzyme A carboxylase, beta p 1.20 0.91 332692 AA496035 Hs. 247926 gap junction protein, alpha 5,40kD (con 0.17 1.12 332716 L00058 Hs. 79070 v-myc avian myeiocytomafosis viral oncog 1.00 1. 44 332736 L13773 Hs. 114765 myeloid/lymphoid or mixed-lineage leukem 1.00 1.81 332758 X93921 Hs. 296938 dual specificity phosphatase 7 0.53 0.78 332781 AA233258 Hs. 247112 hypothetical protein FLJ10902 1.44 1.56 332792 1. 70 1. 19 332816 1.85 2.47 332858 1. 04 1. 57 332906 3.48 8.04 332911 1. 00 1. 00 332912 1.06 4.40 332922 1.00 1.00 332956 0.42 0.88 332959 1.96 6.34 332982 0.56 0.99 332984 0.30 0.78 332998 1.47 2.01 333058 0.47 1.38 333097 2.14 3.19 333121 2.76 3.70 333122 1.92 1.21 333123 1.85 1.39 333138 0.47 0. 52

333139 1.88 0.84 333140 0.21 0.64 333221 1.51 1.11 333260 0.75 1.01 333380 6. 68 15.75 333387 4.56 12. 61 333512 5.05 8.01 333524 2.28 3.98 333585 2.31 1.53 333603 2.23 1. 17 333604 2.51 1.58 333618 0.52 0.98 333627 1.44 1.36 333628 1. 90 1. 90 333650 1.85 2.10 333678 1.85 2.35 333750 2. 18 5.67 333763 1.99 2.60 333767 1.02 0.96 333768 1.78 1.65 333769 2.15 2, 13 333772 1.46 2.53 333777 1.00 1.42 333846 2. 99 4. 50 333884 0.47 0.94 333887 0.50 1.00 333891 0.43 0.89 333892 0. 51 0. 91 333904 0.26 1.13 333906 0.55 0. 98 333948 1.70 2.15 333954 0. 37 1.09 333966 8.10 14.30 333968 0.63 1.38 334061 4.24 12.30 334094 1.30 12.03 334113 4.55 8.63 334161 0.82 1.59 334183 0.47 0. 76 334187 1.36 3.70 334219 0.69 1.04 334222 1.88 1.70 334223 4.72 3. 14 334239 0.79 0.62 334255 0.45 1.10 334333 1.00 3.56 334378 3.98 5.76 334382 1.50 1.31 334492 3.59 4.75 334562 5. 94 15. 40 334588 8.14 19.53 334616 1.55 1.56 334633 5.16 8.07 334648 0.59 2.13 334787 3.70 7.15 334866 8.13 10.60 334891 0.32 1, 14 334933 1.00 3.84 334934 4.01 7.43 334945 1.04 2. 96 334967 0.29 1.14 334990 1.50 1.39 335015 5.88 18.65 335093 0. 55 1.75 335120 4.31 8.01 335125 0.38 1.97 335179 1.24 1. 98 335188 0.46 1.47 335211 1.61 1.42 335288 0.73 0.97 335289 0.20 0. 26 335361 2.18 1.58 335379 0.50 0.71 335414 3.64 14. 94 335416 2.93 3.98 335496 0.96 0.91 335497 1.71 1.92 335548 1. 15 2.40 335551. 3.22 10.54 335558 3.42 4.89 335586 5.50 12.75 335619 2.99 3. 07 335620 3. 80 8.29 335621 0.28 0.57 335682 0.46 1.17

335686 2.55 3.81 335755 2.24 1.07 335784 0.20 0.97 335814 1.13 1.48 335815 2.45 3.51 335823 1.00 4.16 335835 0.49 1.70 335851 1.66 1.39 335868 2.98 6.43 335896 0. 98 0.99 335936 12.10 21.93 335948 1.00 1.64 335983 1.00 4.21 335995 0.37 1.17 336021 1.04 0.84 336034 11. 40 23. 54 336038 1.19 1.21 336066 0.54 1.63 336107 0.95 0.70 336205 3.13 6.29 336275 3.20 10.10 336292 2.34 3.09 336331 1. 00 1. 00 336419 0.65 0.79 336632 2.33 2.16 336633 2.55 2.23 336634 2.19 2.03 336635 2.69 2.48 336636 2.13 1.83 336637 2.43 2.24 336638 2.31 2.03 336659 0.60 1.31 336675 0.31 1.18 336684 1. 50 1. 14 336694 4. 74 7.10 336716 4.43 6.37 336721 2.20 0.74 336798 1.64 2.14 336900 6.14 12.73 336948 1. 00 1. 00 337028 1.30 2.09 337043 4. 01 11.53 337046 1.67 1.84 337054 2.78 7.35 337128 7.20 16.14 337162 3.45 5.34 337183 5. 72 11. 41 337184 3.72 5. 90 337192 1.27 1. 06 337194 1.88 1.68 337229 0.22 1.03 337268 1.00 3.31 337299 3.23 5. 14 337325 2.76 3. 72 337389 5.80 10.42 337493 2.06 6.30 337497 7.88 20. 29 337500 3. 80 4.48 337549 1.66 2, 31 337603 1.27 8.54 337605 5.76 7.16 337671 0.73 0.97 337755 1.54 0.92 337786 5. 07 9. 73 337809 6.18 12. 87 337862 3.78 12. 97 337871 2.66 8.16 337958 0.26 1.34 338008 1.48 1.12 338033 2.38 14.59 338083 0.65 2.16 338110 1.00 1.61 338112 5. 86 8. 25 338145 1.70 1.97 338148 8.07 18.19 338158 1. 30 4. 55 338161 2.58 3.57 338179 1.00 1.00 338182 3.32 4.63 338189 1. 00 3. 34 338197 0.99 1.69 338199 4. 58 7.62 338215 6.01 15.85 338279 0. 53 0.95 338316 20.58 38.66

338322 3.23 7.39 338357 4.10 11.39 338359 10.12 21.59 338366 0.69 1.02 338374 0. 40 1.18 338414 0.47 1.06 338418 6.12 13.86 338469 3. 09 5.11 338501 6.28 10.32 338506 6.97 12.41 338523 3. 10 5.84 338549 1.70 2.70 338561 0.79 0.81 338662 1.72 1.46 338671 0.17 0.91 338676 2. 10 15. 86 338726 1. 20 1.09 338779 0.12 0.57 338804 0.99 1.67 338836 1.00 1.00 338871 4.30 9. 81 338872 5. 02 12.81 338879 0.23 1.12 338937 6.55 12.26 338966 1.76 5.42 338993 1.00 2.40 339047 5. 26 10.81 339100 5.10 6.88 339114 1.00 1.70 339121 1, 00 3. 75 339170 10.36 19.67 339229 4.08 13.48 339264 2.64 3.83 339293 1.73 1.94 TABLE 8B shows the accession numbers for those Pkeys in Table 8A lacking unigene, D's. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the 'Accession'column.

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT number Accessions 322044 187363_1 AW340926 AA249063 N86075 322060 44320 1 Ai341937 AW003063 U34725 AA904742 321430 42705 1 X57414 X57415 321467 43034_1 X13075 X13076 322125 46779_1 R93901 AF075073 R93902 322166 46861_1 H69434 AF085958 H69846 322173 46873_1 H52567H52557AF085970HS2164 322178 46882_1 H56535 AF085980 H56712 322179 46885_1 H92891 AF085982 H92777 321577 1615102-1 H84849 H84252 H84260 H86664 H85320 321587 1615333_1 H95531 H95521 H84529 313723 111953J AA070412AA102346AA081885 320997 627492 1 H22544 H46842 A1204929 322278 47271 1 W69304 AF086283 W69200 321687 218439_1 AA625149 AA313030 AA313052 H97463 313883 129439_1 AA66589 AA135130 AA484059 AA102419 AW877765 322320 47422_1 W79150 AF086419 322339 814584 1 A1668646 A1734214 W17348 314648 293660_1 AW979268 AA878419 AA431342 AA431628 300201 682222_1 AI308300 AI308296 306897 25196-2 AM93967 323155 979809_1 AL120701 AL135041 AL121524 322527 38927_1 AF147359T58511 T58560 322585 473768 2 W88919 W89125 300362 1574395_1 Z42308 H23514 322635 82296 1 AA005129 AA679084 AA694399 322664 85042-1 AA011522 AA702841 AA011691 AA33097 315454 380580_1 AI39464 AI239473 AA6258312 AI208730 322687 37372_1 AF074666A, 110759AF090902 314852 327472J AI903735 AA491283 AI694953 AW976903 AA761362 307783 697809_1 AI347274 AW844024 324072 269032_1 AA381722 AA381829 AW963906 AW963902 AA381242 300627 221345_1 AA488472 W27363 AA317053 BE082689 AW967036 BE079872 323505 196389_1 AW970512 AA280251 AI652287 BE466438 AI650725 AA551854 AA281574 AW571481 315791 403558 1 AA678177 AA677034 324303 233842 1 AL118754 AA333202 H38001 316519 442885_1 AA847835 AA768376 300926 333127 1 AA504860AA504911

324580 328264_1 AA492588 AA492498 AA492571 301882 275087_1 T78054 T79888 AA398185 324804 398093_1 AI692552 AI393343 AI800510 AI377711 F24263 AA661876 324889 1515978_1 D31010 D30991 D31168 D31166 D31465 302697 43219_1 AJ001409AJ001410 302711 45419_1 L08442 D51348 302742 458_39 L12061 318499 364430_1 T25451 AA585296 AA58305 310624 34624 4 U88896 U88898 AA916056 T03285 A1341594 A1359534 A1634031 U88897 302847 458_105 X98941 X98942 X98943 X98953 X98949 304122 77271-5 H28966 303598 2702831 AA382814AA402411AA412355 311409 837264_1 A1698839 A1909260 A1909259 312094 797889_1 Z78390 T97427 319312 1540116_1 Z45481 F12393 T74437 319407 1688823_1 R05329 R01555 R08276 319425 1689571_1 T82930 R02424T85145 320007 229683_1 AA336314 T82938 AA327744 AW967388 AA639967 T01753 320018 1815987_1 T83263T85731 T85730 319484 1691553_1 T91772 R07257 R07098 318865 1535937_1 H10818 F07831 Z43072 312220 1671601_1 N74613 T98756 T98589 319546 243305_1 R09692 R09414 AA346353 312389 902067_1 AI863140 W80703 R43474 319611 1566863_1 H14957 R56522 R11908 312437 291472_1 BE080180 AW827313 AW231970 AA995028 AA428584 AW872716 AW892508 AW854593 AA578441 AW975234 AA664937 AA984131 AA528743 AA552874 AA564758 AW063245 AI267534 AW070190 AW893483 AA770330 AA906928 AA906582 AA758746 AA551717 AW063311 AA429538 311896 579192_1 AW206447 A1248530 A1084433 A1400976 R16553 319834 112523_1 AA071267 T65940 T64515 AA071334 321102 80531J AA018306H38925AA001221 321158 410938_1 H79670 H47798 AA700289 321199 212379_1 N34524 AA305071 AW954803 AA502335 AI433430 AI203597 AW026670 AW265323 AW850787 AA317554 AW993643 AW835572 AW385512 AI334966 W32951 H62656 H53902 R88904 AW835732 305528 28832-3 AA769156 321270 1662057_1 N59537 N78278 R83560 314126 177666_1 AA226431 AA226569 AA488748 320714 743644_1 R91883 AI445591 306442 AA976899 306446 AA977348 306458 AA978186 306510 AA988546 306557 AA994530 306572 AA995686 306582 AA996248 306656 AI004024 306686 AI015615 306751 AI032589 308011 A1439473 306892 AI092465 308106 A1476803 308154 AI500600 306956 A1125111 306958 A) 125152 308213 At557041 308216 AI557135 308219 A) 557246 308588 AI718299 308599 At719893 308643 A1745040 308673 A1760864 308697 AI767143 308778 A1811109 308808 A1818289 308875 AI832332 308886 AI833240 308898 A1858845 308966 A) 870704 308979 AI873111 303011 41689_1 AF090405 AF090407 AF090406 303077 44060_1 AF163305 AF163307 AF163303 305016 AA626876 305034 AA630128 305072 AA641012 305148 AA654070 305190 AA665955 303978 AW513315 303990 AW515465 303998 AW516449 303999 AW516611 305235 AA670480 305312 AA700201 305413 AA724659 305447 AA737856 321244 29327_1 AF068654 AF068656 AF068655

305614 AA782866 305637 AA806124 305639 AA806138 305650 AA807709 305690 AA813477 305728 AA828209 305759 AA835353 305792 AA845256 307041 AI144243 307091 AI167439 307181 A1189251 305901 AA872968 305910 AA875981 307415 A12421 18 307426 AI243364 307517 A, 275055 307551 A1281556 307561 AI282207 307608 A1290295 307691 A1318285 307730 AI336092 307760 AI342387 307764 A1342731 307796 AI350556 309045 A1910902 309051 A1911975 307807 A1351799 307808 A1351826 307820 AI355761 307852 AI365541 309122 A1928178 309164 A1937761 309177 A1951118 307902 A1380462 309299 AW003478 309303 AW004823 309476 AW129368 309532 AW151119 309747 AW264889 309769 AW272346 309799 AW276964 309866 AW299916 302679 3118531 H65022AA186889 309923 AW340684 309928 AW341418 309931 AW341683 309933 AW341936 302705 31765_1 U09060 U09061 302789 341611 AJ245067AJ245070 304006 AW517947 304024 T03036 304026 T03160 304028 T03266 304046 T54803 304061 T61521 304063 T62536 302802 34487_1 Y08250 Y08245 304114 R78946 304155 H68696 304203 N56929 304234 W81608 304348 AA179868 304430 AA347682 304456 AA411240 304521 AA464716 304526 AA476427 304607 AA513322 304735 AA576453 304760 AA580401 306015 AA897116 306063 AA906316 306065 AA906725 306104 AA910956 306109 AA911861 306242 AA932805 306288 AA936900 306396 AA970223 330568 NOT FOUND entrez U56244 330599 15323-12 U90437 331131 genbank_R54797 R54797 331203 NOT_FOUND_entrez T82310 331531 genbank_N51343 N51343 331547 467396 1 AA828597 N54811 332074 genbank_AA599012 AA599012

TABLE 8C shows the genomic position for those Pkeys in Table 8A lacking unigene ID's and accession numbers. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey : Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al."refers to the publication entitled The DNA sequence of human chromosome 22.'Dunham 1. et al., Nature (1999) 402: 489-495.

Strand : Indicates DNA strand from which exons were predicted.

Nt_position : indicates nucleotide positions of predicted exons.

Pkey Ref Strand Nt_position 332792 Dunham, I. et. al. Plus 73381-73768 332816 Dunham, I. et.al. Plus 359844-360030 332906 Dunham, I. et.al. Plus 1923101-1923205 332911 Dunham, I. et.al. Plus 1961767-1961858 332912 Dunham, I. et. al. Plus 1962120-1962246 332922 Dunham, I. et. al. Plus 2009620-2009738 332956 Dunham, I. et. al. Plus 2510528-2510658 332959 Dunham, 1. et, al, Plus 2518145-2518213 333138 Dunham, I. et. al. Plus 3369205-3369323 333139 Dunham, I. et. al. Plus 3369495-3369571 333221 Dunham, I. et. al. Plus 3978070-3978187 333380 Dunham, I. et. al. Plus 4904775-4904846 333387 Dunham, I. et. al. Plus 4910935-4910997 333512 Dunham, I. et.al. Plus 5560510-5560564 333524 Dunham, I. et, al. Plus 5612620-5612780 333585 Dunham, I. et. al. Plus 623477&6234894 333618 Dunham, I. et. al. Plus 6562391-6562566 333627 Dunham, I. et. al. Plus 6620584-6620903 333628 Dunham, I. et. al. Plus 6629004-6629233 333650 Dunham,,. et. al. Plus 6796852-6797128 333678 Dunham, I. et. al. Plus 7068223-7068288 333750 Dunham, I. et. al. Plus 7608165-7608234 333763 Dunham, I. et. al. Plus 7692491-7692630 333767 Dunham, I. et, al. Plus 7694407-7694623 333768 Dunham, I. et. al. Plus 7695440-7695697 333769 Dunham, I. et. al. Plus 7696625-7696707 333772 Dunham, I. et. al. Plus 7706773-7706902 333777 et. Dunham, I. 7746805-7746916 333846 al. P.us 333884 Dunham, I. et.al. Plus 8008623-8008757 et. al. Plus 8153960-8154161 333887 Dunham, I. et. Dunham, I. 8154882-8155025 333891 al. Plus 8156437-8156709 333892 Dunham, I. et.al. Plus et. al. Plus 8156825-8157001 333948 Dunham, I. et. al. Plus 8583497-8583627 333954 Dunham, I. et. al. Plus 6563186-6563335 333966 Dunham". et. al. Plus 8655643-8655826 333968 Dunham, I. et. Dunham, I. 8681004-8681241 334061 al. Plus et. Dunham, I. 9686941-9687077 334094 al. Plus et. Dunham, I. Plus 9889953-9890105 334113 al. et. Dunham, I. Plus 10282459-10282597 334161 al. et. Dunham, I. 10599033-10599180 334219 al. P.lus et. Dunham, I. Plus 12716160-12716384 334239 al. 13056569-13056693 334333 Dunham, I. et.al. Plus et. Dunham, I. Plus 13603544-13603657 334378 al. et. Dunham, I. 13907239-13907370 334382 Dunham, I, et. al. Plus 334562 al. Plus 13915866-13916036 Dunham, I. et. al. Plus 14987847-14987940 334588 Dunham, I. et. al. Plus 15032740-15032817 334616 Dunham". et. al. Plus 15176123-15176470 334633 Dunham, I. et. al. Plus 15333206-15333305 334866 Dunham, I. et. al. Plus 18872214-18872317 334891 Dunham, I. et.al. Plus 19229770-19299944 334934 Dunham, I. et. al. Plus 20103970-20104058 335015 Dunham, I. et. al. Plus 20682792-20682945 335120 Dunham, I. et. al. Pius 21436286-21436384 335125 Dunham, I. et. al. Plus 21441390-21441471 335179 Dunham, I. et. al. Plus 21634405-21634526 335188 Dunham, I. et al. Plus 21669118-21669328 335211 Dunham, 1. et. al. Plus 21774611-21774680 335361 Dunham, 1. et. al. Plus 22807292-22807445 335379 Dunham, I. et. al. Plus 22899306-22899420 335414 Dunham, I. et. al. Plus 23235546-23235684 335416 Dunham, I. et. al. Plus 23237354-23237465 335496 Dunham, t. et. a. Plus 24164386-24164545 335497 Dunham, I. et. al. Plus 24167666-24167869 335558 Dunham, 1. et. al. Plus 24740167-24740347 335586 Dunham, I. et. al. Plus 24990333-24990497 335686 Dunham, I. et.al. Plus 25439839-25439920 335784 Dunham, I. et. al. Plus 25942710-25942792 335823 Dunham, I. et. al. Plus 26365925-26366004 335983 Dunham, I. et. al. Plus 27938968-27939070 335995 Dunham, I. et. al. Plus 28009044-28009184 336021 Dunham, I. et. al. Plus 28686482-28686559

336034 Dunham, I. et. al. Plus 29014404-29014590 336038 Dunham, I. et. al. Plus 29022963-29023165 336107 Dunham, I. et. al. Plus 29987731-29987869 336632 Dunham, I. et. al. Plus 983890-985529 336633 Dunham, I. et. al. Plus 985591-986221 336634 Dunham, I. et. al. Plus 986296-986670 336635 Dunham". et. al. Plus 987908-988364 336636 Dunham, 1. et. al. Plus 988418-989185 336637 Dunham, I. et. al. Plus 989276-990813 336638 Dunham, I. et. al. Plus 991906-993240 336659 Dunham, 1. et. al. Plus 1896402-1896478 336694 Dunham, I. et. al. Plus 2420546-2420616 336721 Dunham, I. et. al. Plus 3371522-3371586 336900 Dunham, I. et. al. Plus 10236423-10236523 336948 Dunham, I. et. al. Plus 12692290-12692381 337028 Dunham, I. et. al. Plus 16644817-16644942 337054 Dunham, I. et. al. Plus 17821742-17821922 337162 Dunham, I. et. al. Plus 23478943-23479145 337183 Dunham, I. et.al. Plus 23943606-23943696 337184 Dunham". et. al. Plus 23973949-23974016 337268 dunham, I. et. al. Plus 28011979-28012034 337299 Dunham, I. et. al. Plus 29022656-29022775 337389 Dunham, I. et. al. Plus 31401509-31401579 337493 Dunham, I. et. al. Plus 33330760-33330981 337549 Dunham, I. et. al. Plus 34474472-34474531 337755 Dunham, I. et. al. Plus 3971764-3971900 337809 Dunham, I. et. al. Plus 4449069-4449193 337871 Dunham, I. et. al. Plus 5443027-5443101 337958 Dunham, I. et. al. Plus 6969162-6969270 338008 Dunham, I. et. al. Plus 7697068-7697236 338033 Dunham, I. et. al. Plus 8092128-8092271 338110 Dunham". et. al. Plus 10384481-10384621 338112 Dunham, Let. et. al. Plus 10391398-10391600 338145 Dunham, I. et. al. Plus 11386629-11386692 338148 Dunham". et. al. Plus 11448985-11449085 338179 Dunham, I. et.al. Plus 12808775-12808833 338197 dunham, I. et.al. Plus 13638107-13638181 338279 Dunham,,. et. al. Plus 16168944-16169091 338316 Dunham, I. et. al. Plus 17089711-17089988 338322 Dunham, I. et. al, Plus 17132477-17132547 338357 Dunham, I. et.al. Plus 18062184-18062402 338359 Dunham, I. et.al. Plus 18074402-18074501 338366 Dunham, I. et. al. Plus 18252026-18252189 338374 Dunham, I. et. al. Plus 18371200-18371282 338414 Dunham, 1. et. al. Plus 19345573-19345660 338418 Dunham, I. et.al. Plus 19435506-19435596 338501 Dunham". et. al. Plus 21244713-21244828 338506 Dunham,,. et. al. Plus 21221871-21221953 338523 Dunham, I. et.al. Plus 21509763-21509864 338662 Dunham". et. al. Plus 24404720-24404899 338804 Dunham, I. et.al. Plus 27236005-27236108 338836 Dunham, I. et. al. Plus 27792166-27792272 338879 Dunham, I. et.al. Plus 28410653-28410734 338937 Dunham, I. et. al. Plus 29160655-29160725 338993 Dunham, I. et. al. P) us 30077787-30078184 339047 Dunham, 1. et. al. Plus 30760793-30760968 339100 Dunham". et. al. Plus 31141580-31141765 339114 Dunham, I. et. al. Plus 31456454-31456519 339121 Dunham, I. et. al. Plus 31583467-31583536 339170 Dunham, I. et. al. Plus 32216399-32216527 339293 Dunham, I. et. al. Plus 33223671-33223819 332858 Dunham, I. et. al. Minus 1339607-1339397 332982 Dunham, I. et. al. Minus 2628296-2628109 332984 Dunham, I. et. al. Minus 2632606-2632457 332998 Dunham, 1. et. al. Minus 2711704-2711565 333058 Dunham, I. et. al. Minus 3028925-3028811 333097 Dunham, I. et. al. Minus 3204124-3204036 333121 Dunham, I. et. al. Minus 3308446-3308358 333122 Dunham, I. et. al. Minus 3309596-3309531 333123 Dunham, I. et. al. Minus 3310817-3310749 333140 Dunham, I. et. al. Minus 3377220-3376309 333260 Dunham, I. et. al. Minus 4308400-4308304 333603 Dunham". et. al. Minus 6466335-6465727 333604 Dunham, I. et.al. Minus 6467090-6466768 333904 dunham, I. et. al. Minus 8217374-8217261 333906 Dunham, I. et. al. Minus 8218238-8218063 334183 Dunham, I. et. al. Minus 11832582-11832508 334187 Dunham, I. et. al. Minus 11921456-11921205 334222 Dunham, I. et. al. Minus 12732417-12732289 334223 Dunham, I. et. al. Minus 12734365-12734269 334255 Dunham, I. et. ai. Minus 13200776-13200692 334492 Dunham, i. et. al. Minus 14478333-14478172 334648 Dunham, I. et. al. Minus 15363301-15363222 334787 Dunham, I. et. al. Minus 16299093-16298937 334933 Dunham". et. al. Minus 20078117-20077991

334945 Dunham, i. et. al. Minus 20138885-20138637 334967 Dunham". et. al. Minus 20173311-20173218 334990 Dunham, I. et. al. Minus 20341159-20341087 335093 Dunham, I. et. al. Minus 21297367-21297214 335288 Dunham, I. et. al. Minus 22304275-22303770 335289 Dunham, I. et. al. Minus 22305950-22305708 335548 Dunham, I. et. al. Minus 24662773-24662673 335551 Dunham, I. et. al. Minus 24679828-24678961 335619 Dunham, I. et. al. Minus 25082677-25082498 335620 Dunham, I. et. al. Minus 25092561-25092434 335621 Dunham, I. et. al, Minus 25098878-25098767 335682 Dunham, 1, et. al. Minus 25421215-25421093 335755 Dunham, I. et. al. Minus 25763806-25763747 335814 Dunham". et. a,. Minus 26320043-26319845 335815 Dunham, I. et. al. Minus 26320518-26320421 335835 Dunham, I. et. al. Minus 26393311-26393245 335851 Dunham, I. et. al. Minus 26604863-26604742 335868 Dunham, I. et. al. Minus 26711437-26711300 335896 Dunham, I. et. al. Minus 26977639-26977558 335936 Dunham, I. et. al. Minus 27360474-27360400 335948 Dunham, I. et. al. Minus 27555924-27555788 336066 Dunham, I. et. al. Minus 29241080-29240842 336205 Dunham, I. et. al. Minus 30477456-30477311 336275 Dunham, I. et. al. Minus 32086675-32086536 336292 Dunham, I. et. al. Minus 32818035-32817927 336331 Dunham, I. et. al. Minus 33594527-33594371 336419 Dunham, I. et. al. Minus 34052568-34052445 336675 Dunham, 1, et. al. Minus 2020758-2020664 336684 Dunham, I. et.al. Minus 2158060-2157993 336716 Dunham,,. et. a,. Minus 3259952-3259862 336796 Dunham, I. et.al. Minus 5888954-5888757 337043 Dunham, 1. et. al. Minus 17407330-17407251 337046 Dunham, I. et. al. Minus 17610892-17610821 337128 Dunham. et. al. Minus 22215251-22215034 337192 Dunham, I. et. al. Minus 24591853-24591771 337194 Dunham, I. et.al. Minus 24610510-24610359 337229 Dunham, I. et.al. Minus 26716579-26716481 337325 Dunham, I. et. al. Minus 30015948-30015800 337497 Dunham". et. a,. Minus 33371317-33371258 337500 Dunham, I. et. al. Minus 33376212-33376158 337603 Dunham, 1. et. al. Minus 1299296-1299194 337605 Dunham, I. et. al. Minus 1346555-1346397 337671 Dunham, I. et. al. Minus 3260634-3260547 337786 Dunham, I. et. al. Minus 4133203-4133081 337862 Dunham, I. et. al. Minus 5347658-5347550 338083 Dunham, 1. et. a,. Minus 9318438-9318301 338158 Dunham, 1. et. al. Minus 11794465-11794343 338161 Dunham, I. et. al. Minus 12124716-12124658 338182 Dunham. et. af. Minus 12824919-12824827 338189 Dunham, I. et. al. Minus 12878594-12878478 338199 Dunham". et. al. Minus 13760865-13760780 338215 Dunham, I. et. al. Minus 14055447-14055355 338469 Dunham, I. et. al. Minus 20520387-20520242 338549 Dunham, I. et. al. Minus 22049171-22049081 338561 Dunham,,. et. a,. Minus 22311966-22311856 338671 Dunham, et. ai. Minus 24508421-24508346 338676 Dunham, 1. et. al. Minus 24637427-24637369 338726 Dunham, 1. et, al, Minus 25926206-25925618 338779 Dunham". et. a,. Minus 27030151-27029795 338871 Dunham, 1. et. al. Minus 28301708-28301611 338872 Dunham". et. a,. Minus 28300921-28300790 338966 Dunham". et. a. Minus 29614876-29614749 339229 Dunham". et. a'. Minus 32722330-32722199 339264 Dunham, I. et. al. Minus 32975145-32975053 325228 6381940 Plus 2630-2694 325235 6381943 Minus 162154-162264 329588 3962484 Plus 1169-1619 329560 3962491 Plus 2095-2990 329541 3983503 Minus 2765-3059 325328 5866875 Plus 86780-86854 325340 6017033 Minus 166656-166819 325373 5866920 Minus 1136686-1136777 325367 5866920 Minus 922881-922958 325389 5866921 Plus 239672-239759 325436 5866939 Minus 29778-29907 325498 5866967 Plus 173372-173930 325471 6017034 Minus 289268-289342 325557 6056302 Plus 50921-51050 325559 6249595 Minus 118590-119172 325560 6249595 Minus 133794-133981 325569 6249599 Plus 79927-80217 325587 6682462 Plus 126724-126967 325585 6682462 Plus 73476-73574 325597 5866992 Plus 1065020-1065089 325639 5867002 Plus 253525-253608

325739 5867038 Minus 205138-205269 325740 5867038 Minus 207533-207690 325792 6469828 Minus 1018-1176 325735 6552447 Minus 269122-269190 325685 6682468 Plus 117397-117483 325686 6682468 Plus 118337-118439 325819 6682490 Minus 130314-130370 329764 6048195 Minus 109733-109968 329703 6065793 Minus 139994-140138 329643 6448539 Plus 53403-53537 329816 6624888 Minus 70296-70423 329860 6687260 Minus 163474-163605 325883 5867087 Plus 22498-22663 325895 5867097 Plus 358317-358476 325925 5867124 Plus 115749-115962 325932 5867127 Plus 7369-7441 325941 5867133 Minus 64228-64402 325969 5867153 Plus 101911-102081 325971 5867153 Plus 105841-106035 329993 4567166 Minus 101307-101434 330020 6671887 Plus 172397-172491 326163 5867168 Minus 7831-8035 326274 5867171 Minus 410289-410404 326025 5867176 Plus 70854-70915 326046 5867182 Minus 62668-62825 326099 5867186 Minus 661381-661510 326108 5867187 Minus 23784-23903 326165 5867208 Minus 62787-62929 326189 5867212 Plus 69288-69413 326204 5867218 Minus 148088-148200 326230 5867230 Minus 301868-301972 330052 4567182 Plus 352560-352963 330036 6042048 Plus 117120-117216 326360 5867293 Plus 13627-13844 326589 5867320 Plus 22760-22919 326393 5867341 Plus 41702-41841 326505 5867435 Minus 8818-8949 326515 5867439 Plus 36683-36809 326592 6138928 Plus 23689-23828 330107 6015249 Minus 100091-100282 330106 6015249 Minus 99443-99778 330100 6015253 Plus 21166-21301 330093 6015278 Plus 1043-1199 330088 6015293 Plus 37517-37638 330085 6015302 Minus 59613-59770 330120 6671864 Minus 127553-127656 330123 6671869 Minus 35311-35406 326742 5867611 Minus 95187-95248 326605 5867637 Plus 24656-24749 326818 6117831 Minus 15199-15309 326720 6552456 Plus 84525-84677 326770 6598307 Minus 513603-513668 326692 6682502 Plus 117697-117899 326693 6682502 Minus 335002-335095 326983 5867657 Minus 16023-16581 326991 5867660 Plus 18147-18339 326936 6004446 Minus 10217-10357 326964 6469836 Plus 75340-75456 327040 6531965 Plus 783670-783817 327053 6531965 Plus 2247267-2247437 327075 6531965 Plus 4041318-4041431 327085 6531965 Plus 4734947-4735069 327036 6531965 Plus 319951-320040 327130 6531976 Plus 20247-22343 327156 5866841 Minus 2462-2620 327288 5867481 Plus 48583-48773 327332 5867516 Minus 56361-56532 327220 5867525 Minus 65701-65781 327224 5867534 Plus 188468-188544 327321 6249562 Minus 99745-99836 327361 6552412 Minus 61013-62130 327396 5867743 Plus 8702-8820 327414 5867750 Plus 102461-102586 327442 5867759 Plus 111483-111618 327467 5867772 Plus 88030-88151 327473 5867775 Plus 75101-75181 327483 5867783 Plus 181573-181662 327377 5867793 Minus 37610-37676 327562 5867804 Minus 343989-344474 327568 5867811 Minus 46152-46287 327606 6004463 Plus 200262-200495 327611 5867868 Minus 175063-175392 327642 5867891 Minus 2513-2743 327654 5867910 Minus 97564-97710 327734 5867940 Minus 31003-31583

327775 5867964 Minus 130791-130871 327796 5867982 Plus 85267-85405 327840 6249578 Minus 73065-73206 330208 6013599 Plus 66517-66931 330263 6671884 Minus 101503-101634 328004 5867993 Minus 157407-157887 328101 5868020 Plus 289920-290014 328100 5868020 Minus 263545-263635 328113 5868024 Minus 80378-80491 328157 5868064 Plus 73326-73615 328196 5868080 Minus 16551-16729 328197 5868081 Minus 42133-42438 327940 5868197 Minus 95240-95428 327984 5868216 Plus 66611-66677 328021 5902482 Plus 713478-714590 328068 6117819 Plus 253903-254022 328264 6381912 Plus 55086-55404 330300 2905862 Minus 3246-3302 328608 5868222 Minus 87770-87953 328600 5868229 Minus 38889-40010 328616 5868239 Plus 293920-294224 328623 5868246 Minus 120020-120126 328632 5868247 Plus 76734-76853 328666 5868254 Minus 778-901 328698 5868264 Minus 625555-625633 328700 5868264 Plus 764089-764203 328708 5868271 Minus 68114-68854 328735 5868289 Plus 89389-89455 328743 5868289 Pius 274638-274726 328806 5868324 Plus 29408-29684 328299 5868366 Minus 149708-149889 328342 5868383 Plus 59955-60094 328365 5868387 Minus 270724-270798 328369 5868388 Plus 75371-75583 328381 5868392 Plus 662758-662848 328451 5868425 Minus 217275-217336 328481 5868449 Minus 8987-9180 328500 5868464 Plus 59098-59481 328530 5868482 Plus 334973-335406 328664 6004473 Plus 1193739-1193866 328861 6381928 Minus 108317-108403 328908 5868493 Pius 117002-117059 328933 5868500 Plus 771755-771889 328934 5868500 Plus 846342-846448 328949 6456765 Minus 43552-43619 330313 6042030 Minus 33642-33775 329005 5868542 Plus 85470-85673 330366 2944106 Plus 151837-151914 330372 6580495 Minus 317461-317688 329033 5868561 Minus 5390-5479 329037 5868562 Minus 32466-32562 329067 5868591 Minus 146417-147652 329134 5868679 Plus 29959-30018 329157 5868687 Minus 145940-146155 329178 5868704 Plus 179177-179463 329192 5868716 Plus 166936-167020 329194 5868716 Minus 304450-304559 329204 5868720 Minus 3050-3190 329224 5868728 Plus 27422-27664 329228 5868728 Minus 50118-50287 329288 5868771 Plus 25554-26299 329337 5868806 Minus 467155467222 329011 6682532 Plus 48658-48741

TABLE 9A: Potential Therapeutic, Diagnostic and Prognostic targets for Therapy of Lung Cancer Table 9A shows about 1312 genes up-regulated in lung tumors (including squamous cell carcinomas, adenocarcinomas, small cell carcinomas, granulomatous and carcinoid tumors) relative to normal body tissues. These genes were selected from about 59680 probesets on the Eos/Affymetrix Hu03 Genechip array.

Table 9B show the accession numbers for those Pkey's lacking UnigeneID's for table 9A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubIeTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the 'Accession"column.

Table 9C show the genomic positioning for those Pkey's lacking Unigene ID's and accession numbers in table 9A. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: Unique Eos probeset identifier number ExAccn : Exemplar Accession number, Genbank accession number Unigene, D : Unigene number Unigene Title : Unigene gene title R1 : Average of lung tumors (including squamous cell carcinomas, adenocarcinomas, small cell carcinomas, granulomatous and carcinoid tumors) divided by the average of normal lung samples R2: Average of non-malignant lung disease samples (including bronchitis, emphysema, fibrosis, atelectasis, asthma) divided by the average of normal lung samples Pkey ExAccn Unigene Unigene Title R1 R2 400195 NM_007057': Homo sapiens ZW10 interactor 1.00 1.00 400205 NM_006265 : Homo sapiens RAD21 (S. pombe) 15.80 396.00 400220 Eos Control 2.28 2.84 400277 Eos Control 7.68 9.72 400285 Eos Control 1.00 1.00 400288 X06256 Hs. 149609 integrin, alpha 5 (fibronectin receptor, 1.04 2.24 400289 X07820 Hs. 2258 matrix metalloproteinase 10 (stromelysin 132.45 4.00 400298 AA032279 Hs. 61635 six transmembrane epithelial antigen of 43.86 74.00 400301 X03635 Hs. 1657 estrogen receptor 1 1.00 1.00 400303 AA242758 Hs. 79136 LIV-1 protein, estrogen regulated 1.75 1.65 400328 X87344 Hs. 180062 transporter 2, ATP-binding cassette, sub 0.87 1.80 400419 AF084545 Target 156.55 253.00 400512 NM030878' : Homo sapiens cytochrome P450, 1.00 2.00 400517 AF242388 engsin 3.67 87.00 400560 NM_030878* : Homo sapiens cytochrome P450, 1.00 1.00 400664 NM_002425 : Homo sapiens matrix metallopro 20.26 45.00 400665 NM_002425 : Homo sapiens matrix metallopro 1.36 1.07 400666 NM_002425 : Homo sapiens matrix metallopro 3.26 3.22 400749 NM_003105*:Homo sapiens sortilin-related 1. 00 91.00 400763 Target Exon 7.63 24.00 401027 Target Exon 1.00 1.00 401093 C12000586* : gi#6330167#dbj#BAA86477.1# (A 1.00 155.00 401203 Target Exon 1.00 86.00 401212 C12000457*:gi#7512178#pir#T30337 polypr 1.00 400.00 401411 ENSP00000247172' : HYPOTHETICAL 126. 2 kDa 1.00 72.00 401435 C14000397*:gi#7499898#pir#T33295 hypoth 1. 00 64. 00 401464 AF039241 histone deacetylase 5 3.82 49.00 401714 ENSP00000241802' : CDNA FLJ11007 FIS, CLON 2.02 40.00 401747 Homo sapiens keratin 17 (KRT17) 128.43 68.00 401760 Target Exon 1.74 35.00 401780 NM 005557" : Homo sapiens keratin 16 (foca 26. 47 10.50 401781 Target Exon 10.33 4.61 401785 NM_002275* : Homo sapiens keratin 15 (KRT1 4. 13 2.70 401797 Target Exon 1.44 2.10 401961 NM_021626 : Homo sapiens serine carboxypep 1.41 1.86 401985 AF053004 class I cytokine receptor 1. 00 177.00 401994 Target Exon 61.84 47.00 402075 ENSP00000251056' : Plasma membrane calcium 1.00 1.00 402260 NM_001436*: Homo sapiens fibrillarin (FBL 1.58 1.39 402265 Target Exon 2.09 35.00 402297 Target Exon 1.00 92.00 402408 NM 030920* : Homo sapiens hypothetical pro 28.87 13.00 402420 C1000823*:gi#10432400#emb#CAC10290.1# (A 1.00 1.44 402674 Target Exon 7.44 243.00 402802 NM_001397 : Homo sapiens endothelin conver 1.00 70.00 402994 NM002463* : Homo sapiens myxovirus (influ 1.37 1.43 403137 NM_005381' : Homo sapiens nucleolin (NCL), 1.00 19.00 403306 NM_006825 transmembrane protein (63kD), endoplasmi 1.00 43.00 403329 Target Exon 1.00 61.00 403381 ENSP00000231844* : Ecotropic virus integra 1.00 119.00 403478 Nom022342 : Homo sapiens kinesin protein 9 28.13 136.00 403485 C3001813#:gi#12737279#ref#XP_012163.1#k 20.23 76. 00 403627 Target Exon 6.30 29.33 403715 Target Exon 1.30 35.00 404044 ENSP00000237855* : DJ398G3. 2 (NOVEL PROTE, 1.00 54.00 404076 NM_016020*:Homo sapiens CGI-75 protein ( 14. 29 91.00 404101 C8000950: gil423560lpirllA47318 RNA-bindi 1.00 1.00 404140 NM 006510 : Homo sapiens ret finger protei 1.42 1.44 404165 ENSP00000244562 : NRH dehydrogenase [quino 1.00 54.00 404185 Target Exon 1. 00 117.00 404210 NM 005936 : Homosapiensmyeloid/iymphoid 5.93 13.77 404253 NM_021058*: Homo sapiens H2B histone fami 1.00 1.00

404287 C6001909 : gil704441ldbjlBAA18909. 1 (D298 29.71 42.00 404298 C6001238*:gi#121715#sp#P26697#GTA3_CHICK 1.30 1.00 404347 Target Exon 1.00 1.00 404440 NM021048 : Homo sapiens melanoma antigen, 1. 00 15.00 404721 NM_005596*:Homo sapiens nuclear factor# 1.00 60.00 404794 NM 000078 cholesteryl ester transfer protein, plas 1.07 1.38 404854 Target Exon 1.61 2.01 404877 NM_005365 : Homo sapiens melanoma antigen, 1.00 1.00 404927 Target Exon 1.00 1.00 404996 Target Exon 1.00 1.00 405449 CY000047* : gi#11427234#ref#XP_009399.1#z 1.00 1. 00 405568 NM 031413* : Homo sapiens cat eye syndrome 1.00 78.00 405572 Target Exon 0.76 1.14 405646 C12000200: gi#4557225#ref#NP_000005.1#al 1.01 1.28 405676 BE336714 cytochrome c-1 1.13 2.89 405770 NM_002362 : Homo sapiens melanoma antigen, 45.52 37.00 405932 C15000305: gi#3806122#gb#AAC69198.1#(AF0 1.99 1.99 406137 NM_000179*: Homo sapiens mutS (E. coli) h 2. 77 2.38 406360 Target Exon 1.00 35.00 406399 NM_003122* : Homo sapiens serine protease 1.00 39, 00 406467 Target Exon 1.00 1.00 406621 X57809 Hs. 181125 immunoglobulin lambda locus 1.41 1.74 406642 AJ245210 gb: Homo sapiens mRNA for immunoglobulin 2. 16 3.91 406663 U24683 Hs. 293441 immunoglobulin heavy constant mu 2.07 2.93 406671 AA129547 Hs. 285754 met proto-oncogene (hepatocyte growth fa 15.00 51.00 406673 M34996 Hs. 198253 major histocompatibility complex, class 0.98 3.09 406676 X58399 Hs. 81221 Human L2-9 transcript of unrearranged im 1.30 1.53 406678 U77534 gb: Human clone 1A11 immunoglobulin varia 1.33 1. 45 406685 M18728 gb : Human nonspecific crossreacting antig 1.46 2.85 406687 M31126 Hs. 272822 pregnancy specific beta-1-glycoprotein 9 8.61 8.50 406690 M29540 Hs. 220529 carcinoembryonic antigen-related ce ! i ad 226.37 350.00 406698 X03068 Hs. 73931 major histocompatibility complex, class 1.01 2.52 406815 AA833930 Hs. 288036 tRNA isopentenylpyrophosphate transferas 20. 25 32.00 406851 AA609784 major histocompatibility complex, class 0.75 1. 91 406964 M21305 gb: Human alpha satellite and satellite 3 38.15 1114.00 406967 M24349 gb : Human parathyroid hormone-like protei 1. 00 1.00 406974 M57293 gb:Human parathyroid hormone-related pep 1. 00 1. 00 407103 AA424881 Hs. 256301 hypothetical protein MGC13170 1.77 1.10 407128 R83312 Hs. 237260 EST 1.00 1.00 407137 T97307 gb: ye53h05. s1 Soares fetal liver spleen 142.70 135.00 407168 R45175 Hs. 117183 ESTs 2.16 18.00 407239 AA076350 Hs. 67846 leukocyte immunoglobulin-like receptor, 1. 10 1.57 407242 M18728 gb: Human nonspecific crossreactingantig 1. 12 2.85 407244 M10014 Hs. 75431 fibrinogen, gamma polypeptide 3.24 15.38 407289 AA135159 Hs. 203349 Homo sapiens cDNA FLJ12149 fis, clone MA 3.53 3.68 407300 AA102616 Hs. 120769 gb: zn43e07. s1 Stratagene HeLa cell s3 93 19.74 73.00 407366 AF026942 Hs. 271530 gb: Homo sapiens cig33 mRNA, partial sequ 0.06 8. 25 407378 AA299264 Hs. 57776 ESTs, Moderately similar to 138022 hypot 1.00 26, 00 407430 AF169351 gb: Homo sapiens protein tyrosine phospha 1.00 25.00 407453 AJ132087 gb: HomosapiensmRNAforaxonemaldynein 1.00 75.00 407577 AW131324 Hs. 246759 hypothetical protein MGC12538 1.00 1.00 407634 AW016569 Hs. 136414 UDP-G ! cNAc : betaGal beta-1, 3-N-acetylgluc 111.20 228.00 407710 AW022727 Hs. 23616 ESTs 1.00 28.00 407720 AB037776 Hs. 38002 KIAA1355 protein 1.89 1.31 407746 AK001962 hypothetical protein FLJ 11100 1.00 1.00 407756 AA116021 Hs. 38260 ubiquitin specific protease 18 4.51 5.00 407758 D50915 Hs. 38365 KIAA0125 gene product 1.00 28.00 407782 AA608956 Hs. 112619 ESTs, Moderately similar to PURKINJE CEL 0.97 1.14 407788 BE514982 Hs. 38991 S100 calcium-binding protein A2 7.88 3.83 407790 A1027274 Hs. 288941 Homo sapiens DNA FLJ14866 fis, clone PL 3.63 42. 00 407811 AW190902 Hs. 40098 cysteine knot superfamily 1, BMP antagon 89.96 109.00 407839 AA045144 Hs. 161566 ESTs 173.91 108.00 407944 R34008 Hs. 239727 desmocollin 2 111. 30 70.00 408000 L11690 Hs. 620 bullous pemphigoid antigen 1 (230/240kD) 151.17 8.00 408031 AA081395 Hs. 42173 Homo sapiens cDNA FLJ10366 fis, clone NT 9.91 93.00 408063 BE086548 Hs. 42346 calcineurin-binding protein calsarcin-1 195. 78 231.00 408070 AW148852 gb: xf05d05. x1 NC, _CGAP_Bm35 Homo sapien 1.00 1. 00 408101 AW968504 Hs. 123073 CDC2-related protein kinase 7 37.84 61.00 408122 AI432652 Hs. 42824 hypothetical protein FLJ10718 0.85 1.71 408212 AA297567 Hs. 43728 hypothetical protein 5.88 7. 91 408243 Y00787 Hs. 624 interieukin 8 4.27 9.98 408349 BE546947 Hs. 44276 homeo box C10 3.79 3.46 408353 BE439838 Hs. 44298 mitochonddal ribosomal protein S17 1. 88 1. 65 408354 A1382803 Hs. 159235 ESTs 1.00 73.00 408369 R38438 Hs. 182576 solute carrier family 15 (H ? ? ? transport 1.41 16.50 408380 AF123050 Hs. 44532 diubiquiün 15.19 37.22 408482 NM_000676 Hs. 45743 adenosine A2b receptor 1.65 1. 19 408522 AI541214 Hs. 46320 Small proline-rich protein SPRK [human, 1.98 1.24 408536 AW381532 Hs. 135188 ESTs 1.55 1.50 408545 AW235405 Hs. 253690 ESTs 1. 00 1.00 408572 AA055611 Hs. 226568 ESTs, Moderately similar to ALU4_HUMAN A 1.00 44.00 408633 AW963372 Hs. 46677 PR02000 protein 107.16 56.00 408660 AA525775 ESTs, Moderately similar to PC4259 ferri 1.00 1.00 408761 AA057264 Hs. 238936 ESTs, Weakly similar to (define not ava 52.24 141.00 408771 AW732573 Hs. 47584 potassium voltage-gated channel, delayed 3.05 109.00

408783 AF192522 Hs. 47701 NPC1 (Niemann-Pick disease, type C1, gen 1.02 1.07 408790 AW580227 Hs. 47860 neurotrophic brosine kinase, receptor, 41.19 61.00 408805 H69912 Hs. 48269 vacciniaretatedkinase1 24.67 45.00 408841 AW438865 Hs. 256862 ESTs 1. 00 58.00 408873 AL046017 Hs. 182278 caimodulin 2 (phosphorylase kinase, delt 1.00 89.00 408908 BE296227 Hs. 250822 serine/threonine kinase 15 7.76 1.00 408992 AA059325 Hs. 71642 guanine nuc, eoüde binding protein (G pr 1.00 1.00 408996 A) 979168 Hs. 344096 glycoprotein (transmembrane) nmb 3.71 5.50 409015 BE389387 Hs. 49767 NM_004553 : Homo sapiens NADH dehydrogenas 1. 44 1.24 409038 T97490 Hs. 50002 small inducible cytokine subfamily A (Cy 4.28 5.32 409041 AB033025 Hs. 50081 Hypothetical protein, XP_051860 (KIAA119 112.42 195.00 409077 AA401369 Hs. 190721 ESTs 1.00 17.00 409093 BE243834 Hs. 50441 CGI-04 protein 2.02 1.93 409103 AF251237 Hs. 112208 XAGE-1 protein 80.44 40.00 409142 AL136877 Hs. 50758 SMC4 (structural maintenance of chromoso 14.87 6.00 409187 AF154830 Hs. 50966 carbamoyl-phosphate synthetase 1, mitoch 1.00 1.00 409228 AI654298 Hs. 271695 ESTs, Weakly similar to 2109260A B cell 1. 22 1.00 409234 AI879419 Hs. 27206 ESTs 1. 00 1.00 409268 AA625304 Hs. 187579 ESTs 11.90 23.00 409269 AA576953 Hs. 22972 hypothetical protein FLJ13352 1.00 1.00 409361 NM_005982 Hs. 54416 sineocuiishomeobox (Drosophiia) homoto 168.91 35. 00 409404 BE220053 Hs. 129056 ESTs 1.00 1. 00 409420 Z15008 Hs. 54451 laminin, gamma 2 (nicein (100kD), kalini 79.74 96. 00 409430 R21945 Hs. 346735 splicing factor, argininelserine-rich 5 1.45 2.10 409446 AI561173 Hs. 67688 ESTs 1. 00 4.00 409506 Nom006153 Hs. 54589 NCK adaptor protein 1 3.97 28.00 409522 AA075382 gb: zm87b03. s1 Stratagene ovarian cancer 15.98 141.00 409582 AA401369 Hs. 190721 ESTs 1.00 17. 00 409632 W74001 Hs. 55279 serine (orcysteine) proteinase inhibito 292. 12 79.00 409705 M37762 Hs. 56023 brain-derived neurotrophic factor 1.00 82.00 409719 A1769160 Hs. 108681 Homo sapiens brain tumor associated prot 1. 00 1.00 409731 AA125985 Hs. 56145 thymosin, beta, identified in neuroblast 0.12 18.12 409744 AW675258 Hs. 56265 Homo sapiens mRNA ; cDNA DKFZp586P2321 (f 20.75 51.00 409757 NM_001898 Hs. 123114 cystatinSN 22.46 15. 80 409866 AW502152 gb: UI-HF-BR0p-ajr-f-11-0-UI. r1 NIH_MGC_5 1.00 1.00 409893 AW247090 Hs. 57101 minichromosome maintenance deficient (S. 1.50 1. 09 409902 A1337658 Hs. 156351 ESTs 25. 92 50.00 409935 AW511413 Hs. 278025 ESTs 2.63 2.11 409956 AW103364 Hs. 727 inhibin, betaA (acüvinA, activinABa 2.17 4.01 409958 NM_001523 Hs. 57697 hyaluronan synthase 1 0.91 2.07 410001 AB041036 Hs. 57771 kallikrein 11 1.04 2.28 410032 BE065985 gb: RC3-BT0319-120200-014-aO9 BT0319 Homo 1.00 58. 00 410037 AB020725 Hs. 58009 KIAA0918 protein 1.00 34.00 410044 BE566742 Hs. 58169 highly expressed in cancer, rich in leuc 1.00 1.00 410048 W76467 Hs. 58218 proline oxidase homolog 1.03 1.44 410076 T05387 Hs. 7991 ESTs 1.12 1.50 410102 AW248508 Hs. 279727 Homo sapiens cDNA FLJ 14035 fis, clone HE 9.89 1.00 410153 BE311926 Hs. 15830 hypothetical protein FLJ12691 1.00 1. 00 410166 AK001376 Hs. 59346 hypothetical protein FLJ10514 1.00 1.00 410193 AJ132592 Hs. 59757 zincfingerprotein281 42.01 51. 00 410274 AA381807 Hs. 61762 hypoxia-inducible protein 2 1.72 1.32 410309 BE043077 Hs. 278153 ESTs 1.00 2.00 410340 AW182833 Hs. 112188 hypothetical protein FLJ13149 32. 08 75.00 410348 AW182663 Hs. 95469 ESTs 1.00 1.00 410407 X66839 Hs. 63287 carbonic anhydrase IX 1.40 1.11 410418 D31382 Hs. 63325 transmembrane protease, serine 4 4. 30 2.03 410438 AB037756 Hs. 45207 hypothetical protein KIAA1335 1.00 18. 00 410553 AW016824 Hs. 255527 hypothetical protein MGC14128 1.34 1.04 410555 W27235 Hs. 64311 a disintegrin and metalloproteinase doma 23. 99 1.41 410561 BE540255 Hs. 6994 Homo sapiens cDNA : FLJ22044 fis, clone H 10.04 1.00 410681 AW246890 Hs. 65425 calbindin 1, (28kD) 10.88 18.92 410781 A1375672 Hs. 165028 ESTs 1.00 57.00 411027 AF072099 Hs. 67846 leukocyte immunoglobulin-like receptor, 1.62 3.78 411074 X60435 Hs. 68137 adenylate cyclase activating polypeptide 1.00 1.15 411089 AA456454 cell division cycle 2-like 1 (PITSLRE pr 1.56 1. 58 411152 BE069199 gb: QV3-BT0379-010300-105-g03 BT0379 Homo 1.00 84.00 411248 AA551538 Hs. 334605 Homo sapiens cDNA FLJ14408 fis, clone HE 1.82 1.45 411252 AB018549 Hs. 69328 MD-2 protein 7.32 12.74 411263 BE297802 Hs. 69360 kinesin-like 6 (mitotic centromere-assoc 3.44 2.55 411365 M76477 Hs. 289082 GM2 ganglioside activator protein 1. 35 2.02 411402 BE297855 Hs. 69855 NRAS-related gene 1.00 46.00 411573 AB029000 Hs. 70823 KIAA1077 protein 11.40 11.35 411579 AC005258 Hs. 70830 U6 snRNA-associated Sm-like protein LSm7 1.08 1.90 411617 AA247994 Hs. 90063 neurocalcin delta 1.74 2.57 411732 AA059325 Hs. 71642 guanine nucleotide binding protein (G pr 1.02 1.00 411773 NM006799 Hs. 72026 protease, serine, 21 (testisin) 1.34 2.19 411789 AF245505 Hs. 72157 Adlican 2.19 2.79 411800 N39342 Hs. 103042 microtubute-associated protein 1B 23. 34 34.00 411945 AL033527 Hs. 92137 v-myc avian myelocytomatosis viral oncog 1. 00 8.00 412115 AK001763 Hs. 73239 hypothetical protein FLJ10901 2. 07 1.64 412140 AA219691 Hs. 73625 RAB6interacüng, kinesin-like (rabkines 118. 48 92.00 412276 BE262621 Hs. 73798 macrophage migration inhibitory factor 1. 98 1.49 412464 T78141 Hs. 22826 ESTs, Weakly similar to 155214 salivary 1. 16 1.34 412530 AA766268 Hs. 266273 hypothetical protein FLJ13346 41.52 84.00 412537 AL031778 nuclear transcription factor Y, alpha 17.90 55.00

412659 AW753865 Hs. 74376 olfactomedin related ER localized protei 14.65 47. 00 412719 AW016610 Hs. 816 ESTs 382.46 128.00 412723 AA648459 Hs. 335951 hypothetical protein AF301222 54.90 1.00 412811 H06382 ESTs 1.00 11.00 412817 AL037159 Hs. 74619 proteasome (prosome, macropain) 26S subu 1.63 1.42 412863 AA121673 Hs. 59757 zinc finger protein 281 17.63 56.00 412924 BE018422 Hs. 75258 H2A histone family, member Y 1. 00 22.00 413004 T35901 Hs. 75117 interleukin enhancer binding factor 2, 4 2.19 2.05 413011 AW068115 Hs. 821 biglycan 1.22 1.88 413048 M93221 Hs. 75182 mannose receptor, C type 1 0.30 6. 23 413063 AL035737 Hs. 75184 chitinase 3-like 1 (cartilage glycoprote 3.43 8.71 413129 AF292100 Hs. 104613 RP42 homolog 4.67 4.77 413142 M81740 Hs. 75212 ornithine decarboxylase 1 1.92 2.59 413223 A1732182 Hs. 191866 ESTs 5.73 27.00 413248 T64858 Hs. 21433 hypothetical protein DKFZp547J036 0.99 1.06 413273 U75679 Hs. 75257 stem-loop (histone) binding protein 1.00 18.00 413278 BE563085 Hs. 833 interferon-stimulated protein, 15 kDa 1. 10 1.09 413281 AA861271 Hs. 222024 transcription factor BMAL2 95.94 69. 00 413364 BE536218 Hs. 137516 fidgetin-like 1 1.00 1. 00 413385 M34455 Hs. 840 indoleamine-pyrrole 2, 3 dioxygenase 0.95 2.09 413409 AI638418 Hs. 1440 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 1.00 1.00 413453 Axai29640 Hs. 128065 ESTs 1.00 31.00 413527 BE250788 Hs. 179882 hypothetical protein FLJ12443 1.08 1.46 413554 AA319146 Hs. 75426 secretogranin II (chromogranin C) 79.15 114. 00 413573 A1733859 Hs. 149089 ESTs 1.00 1.00 413582 AW295647 Hs. 71331 hypothetical protein MGC5350 8. 80 10.00 413597 AW302885 Hs. 117183 ESTs 1.00 1.00 413690 BE157489 gb: RC1-HT0375-120200-011-e06 HT0375 Homo 1.00 1.00 413691 AB023173 Hs. 75478 ATPase, Class VI, type 11B 3.16 2. 32 413719 BE439580 Hs. 75498 small inducible cytokine subfamily A (Cy 2.88 9.52 413753 U17760 Hs. 75517 aminin, beta 3 (nicein (125kD), kalinin 144. 10 108. 00 413801 M62246 Hs. 35406 ESTs, Highly similar to unnamed protein 1. 00 17.00 413833 Z15005 Hs. 75573 centromere protein E (312kD) 1.00 1. 00 413882 AA132973 Hs. 184492 ESTs 64. 24 148.00 413926 AA133338 Hs. 54310 ESTs 1.00 67.00 413943 AW294416 Hs. 144687 Homo sapiens cDNA FLJ12981 fis, clone NT 43.42 42. 00 413995 BE048146 Hs. 75671 syntaxin 1A (brain) 1.23 1.11 414035 Y00630 Hs, 75716 serine (orcysteine) proteinaseinhibito 2.02 2.51 414142 AW368397 Hs. 334485 Homo sapiens cDNA FLJ14438 fis, clone HE 1.00 102.00 414180 AI863304 Hs. 120905 Homo sapiens cDNA FLJ11448 fis, clone HE 6.92 77.00 414245 BE148072 Hs. 75850 WAS protein family, member 1 1.00 1.00 414275 AW970254 Hs. 889 Charot-Leyden crystal protein 1. 00 59. 00 414317 BE263280 Hs. 75888 phosphogluconate dehydrogenase 1.52 1.73 414334 AA824298 Hs. 21331 hypothetical protein FLJ10036 1.78 1. 72 414341 D80004 Hs. 75909 K ! M0182 protein 33.90 151.00 414368 W70171 Hs. 75939 uridine monophosphate kinase 171.60 97.00 414416 AW409985 Hs. 76084 hypothetical protein MGC2721 2.32 1.85 414430 AI346201 Hs. 76118 ubiquitin carboxyl-terminal esterase L1 226.15 66.00 414570 Y00285 Hs. 76473 insulin-like growth factor 2 receptor 1.64 1. 98 414618 AI204600 Hs. 96978 hypothetical protein MGC10764 1.87 72.00 414675 R79015 Hs. 296281 interleukin enhancer binding factor 1 1.51 1.39 414683 S78296 Hs. 76888 hypothetical protein MGC12702 43.61 64.00 414696 AF002020 Hs. 76918 Niemann-Pick disease, type C1 28.63 71.00 414711 AI310440 Hs. 288735 Homo sapiens cDNA FLJ13522 fis, clone PL 14.86 42.00 414718 H95348 Hs. 107987 ESTs 1.00 5.00 414732 AW410976 Hs. 77152 minichromosome maintenance deficient (S. 1.64 1.44 414747 U30872 Hs. 77204 centromere protein F (350/400kD, mitosin 65.01 74.00 414761 AU077228 Hs. 77256 enhancer of zeste (Drosophila) homolog 2 130. 35 121. 00 414774 X02419 Hs. 77274 plasminogen activator, urokinase 2.24 2.19 414806 D14694 Hs. 77329 phosphatidylserine synthase 1 1.63 1.53 414809 A1434699 Hs. 77356 transferrin receptor (p90, CD71) 1.97 2.60 414812 X72755 Hs. 77367 monokine induced by gamma interferon 3.48 10.60 414825 X06370 Hs. 77432 epidermal growth factor receptor (avian 103.22 143.00 414839 X63692 Hs. 77462 DNA (cytosine-5-)-methyltransferase 1 1.80 1. 69 414883 M926960 CDC28 protein kinase 1 14.29 10.06 414907 X90725 Hs. 77597 polo (Drosophia)-like kinase 1. 95 2.20 414914 U49844 Hs. 77613 ataxia telangieclasia and Rad3 related 3.00 2.90 414945 BE076358 Hs. 77667 lymphocyte antigen 6 complex, locus E 1.02 1. 21 414972 BE263782 Hs. 77695 KIAA0008 gene product 1.00 1.00 415014 AW954064 Hs. 24951 ESTs 1.42 2.84 415091 AL044872 Hs. 77910 3-hydroxy-3-methylglutaryl-Coenzyme A sy 1. 00 30.00 415138 C18356 Hs. 295944 tissuefactorpathwayinhibitor2 34.72 107. 00 415227 AW821113 Hs. 72402 ESTs 1. 87 49.00 415238 R37780 Hs. 21422 ESTs 1.00 1.00 415263 AA948033 Hs. 130853 ESTs 1.00 1. 00 415295 R41450 Hs. 6546 ESTs 1.00 1.00 415339 NM_015156 Hs. 78398 KIAA0071 protein 51.18 166.00 415669 NM_005025 Hs. 78589 serine (orcysteine) proteinaseinhibito 30.84 63.00 415674 BE394784 Hs. 78596 proteasome (prosome, macropain) subunit, 1.48 1.39 415709 AA649850 Hs. 278558 ESTs 1.00 1.00 415735 AA704162 Hs. 120811 ESTs, Weakly similar to I38022 hypotheti 1.00 72.00 415799 AA653718 Hs. 225841 DKFZP434D193 protein 6.23 31.00 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t 24.30 1.00 415857 AA866115 Hs. 127797 Homo sapiens cDNA FLJ11381 fis, clone HE 32.51 35.00 415989 A, 267700 ESTs 78.89 1.00

416018 AW138239 Hs. 78977 proprotein convertase subtilisin/kexin t 1.00 1.00 416065 BE267931 Hs. 78996 proliferating cell nuclear antigen 3.35 2. 32 416111 AA033813 Hs. 79018 chromatin assembly factor 1, subunit A ( 39. 03 3.00 416177 AA174069 Hs. 187607 ESTs 1.00 9. 00 416178 A1808527 Hs. 192822 serotogicatlydefinedbreastcanceranü 3.83 3.76 416208 AW291168 Hs. 41295 ESTs, WeaklysimilartoMUC2_HUMANMUCIN 3. 67 1.00 416209 AA236776 Hs. 79078 MAD2 (mitohc arrest deficient, yeast, h 9.70 1.00 416239 AL038450 Hs. 48948 ESTs 83.87 129.00 416250 AA581386 Hs. 73452 hypothetical protein MGC10791 1.96 2.12 416322 BE019494 Hs. 79217 pyrroline-5-carboxylate reductase 1 2.08 1.73 416423 H54375 Hs. 268921 ESTs 1.00 89.00 416448 L13210 Hs. 79339 pectin, galactoside-binding, soluble, 3 1.28 1.54 416498 U33632 Hs. 79351 potassium channel, subfamily K, member 1 27.29 67.00 416658 U03272 Hs. 79432 fibrillin 2 (congenital contractural ara 53.29 51. 00 416661 AA634543 Hs. 79440 IGF-II mRNA-binding protein 3 9.96 5.00 416722 AA354604 Hs. 122546-hypothetical protein FLJ23017 3.68 33.00 416819 U77735 Hs. 80205 pim-2 oncogene 1. 59 1.84 416936 N21352 Hs. 42987 ESTs, Weakly similar to S21348 probable 1. 00 1. 00 417034 NM_006183 Hs. 80962 neurotensin 1. 00 1.00 417061 AI675944 Hs. 188691 Homo sapiens cDNA FLJ12033 fis, clone HE 32.95 156.00 417079 U65590 Hs. 81134 interleukin 1 receptor antagonist 3.91 4.93 417218 AA129547 Hs. 285754 metproto-oncogene (hepatocytegrowthfa 1.00 51.00 417233 W25005 Hs. 24395 small inducible cytokine subfamily B (Cy 3.38 2.05 417308 H60720 Hs. 81892 KIAA0101 gene product 82.94 25. 36 417315 AI080042 Hs. 180450 ribosomal protein S24 106.61 121.00 417324 AW265494 ESTs 1.20 1.28 417366 BE185289 Hs. 1076 small proline-rich protein 1B (cornifin) 8.97 3.27 417389 BE260964 Hs. 82045 midkine (neurite growth-promoting factor 2.59 1.82 417428 N87579 Hs. 278871 gb: LL2030F Human fetal heart, Lambda ZAP 1.00 52.00 417433 BE270266 Hs. 82128 5T4 oncofetal trophoblast glycoprotein 304.75 173.00 417466 AI681547 Hs. 59457 hypothetical protein FLJ22127 1.24 1.34 417512 AI979168 Hs. 344096 glycoprotein (transmembrane) nmb 2.14 5. 50 417515 L24203 Hs. 82237 ataxia-telangiectasia group D-associated 2.66 1.68 417542 J04129 Hs. 82269 progestagen-associatedendometrialprote 1.28 1.35 417576 AA339449 Hs. 82285 phosphoribosylglycinamide formyltransfer 42. 76 51. 00 417715 AW969587 Hs. 86366 ESTs 6.35 2.75 417720 AA205625 Hs. 208067 ESTs 113. 31 56. 00 417791 AW965339 Hs. 111471 ESTs 39. 98 16.00 417830 AW504786 Hs. 122579 hypotheticalproteinFLJ10461 2.61 31.00 417866 AW067903 Hs. 82772 collagen, type XI, alpha 1 2.35 2.44 417900 BE250127 Hs. 82906 CDC20 (cell division cycle 20, S. cerevi 1.52 1.11 417933 X02308 Hs. 82962 thymidylate synthetase 4.74 2.55 417944 AU077196 Hs. 82985 collagen, iype V, alpha 2 3. 61 5. 21 417975 AA641836 Hs. 30085 hypothetical protein FLJ23186 12.49 38.00 417991 AA731452 Hs. 190008 ESTs 1.00 26.00 418004 U37519 Hs. 87539 aldehyde dehydrogenase 3 family, member 3.02 2.12 418007 M13509 Hs. 83169 matrix metalloproteinase 1 (interstitial 187.59 1.00 418054 NM_002318 Hs. 83354 lysyl oxidase-like 2 2.85 2.63 418057 Nom012151 Hs. 83363 coagulation factor VIII-associated (intr 1.54 1.69 418113 AI272141 Hs. 83484 SRY (sex determining region Y)-box 4 6.82 5.22 418140 BE613836 Hs. 83551 microfibrillar-associated protein 2 1.26 1.46 418203 X54942 Hs. 83758 CDC28 protein kinase 2 134.19 144.00 418207 C14685 Hs. 34772 ESTs 1. 00 1. 00 418216 AA662240 Hs. 283099 AF15q14 protein 64.66 61. 00 418236 AW994005 Hs. 337534 ESTs 18.53 147. 00 418249 H89226 Hs. 34892 KIAA1323 protein 30.53 106.00 418281 U09550 Hs. 1154 oviductal glycoprotein 1, 120kD (mucin 9 1.00 3.00 418283 S79895 Hs. 83942 cathepsin K (pycnodysostosis) 3. 96 5. 16 418300 AI433074 Hs. 86682 Homo sapiens cDNA : FLJ21578 fis, clone C 3. 18 2.91 418322 AA284166 Hs. 84113 cyclin-dependent kinase inhibitor 3 (CDK 11.96 6.68 418327 U70370 Hs. 84136 paired-like homeodomain transcription fa 9.23 2.22 418345 AJ001696 Hs. 241407 serinetorcysteine) proteinaseinhibito 1.00 1.00 418379 AA218940 Hs. 137516 fidgetin-like 1 21.68 44.00 418397 NM_001269 Hs. 84746 chromosome condensation 1 1.00 8.00 418403 D86978 Hs. 84790 KIAA0225 protein 16.91 18.98 418462 BE001596 Hs. 85266 integrin, beta4 1.56 1.16 418478 U38945 Hs. 1174 cyclin-dependent kinase inhibitor 2A (me 3.22 2.38 418506 AA084248 Hs. 85339 G protein-coupled receptor 39 2. 66 2. 22 418526 BE019020 Hs. 85838 solute carrier family 16 (monocarboxylic 2. 04 2.21 418538 BE244323 Hs. 85951 exportin, tRNA (nuclear export receptor 1.33 37.00 418543 NM_005329 Hs. 85962 hyaluronan synthase 3 1. 04 1.23 418574 N28754 M-phase phosphoprotein 9 48.60 85. 00 418592 X99226 Hs. 284153 Fanconi anemia, complementation group A 18. 24 26. 00 418641 BE243136 Hs. 86947 a disintegrin and metalloproteinase doma 1.19 1.41 418661 NM_001949 Hs. 1189 E2F transcription factor 3 29.05 43. 00 418663 AK001100 Hs. 41690 desmocollin 3 112.17 19.00 418678 NM_001327 Hs. 87225 cancer/testis antigen 1.18 1.10 418686 Z36830 Hs. 87268 annexin A8 1. 54 1. 98 418689 AI360883 Hs. 274448 hypothetical protein FLJ11029 1.19 1. 04 418712 Z42183 gb: HSCOBF041 normalized infant brain cDN 1.00 12.00 418727 AA227609 Hs. 94834 ESTs 1.00 49.00 418738 AW388633 Hs. 6682 solute carrier family 7, (cationic amino 49.85 1.00 418819 AA228776 Hs. 191721 ESTs 1.00 140.00 418830 BE513731 Hs. 88959 hypothetical protein MGC4816 20.97 23.00 418882 NM_004996 Hs. 89433 ATP-binding cassette, sub-family C (CFTR 57.09 35.00

418971 AA360392 Hs. 87113 ESTs 1.00 12.00 418973 AA233056 Hs. 191518 ESTs 4.89 28.00 419078 M93119 Hs. 89584 insulinoma-associated 1 1.00 10.00 419079 AW014836 Hs. 18844 ESTs 1.09 1.98 419080 AW150835 Hs. 18878 hypothetical protein FLJ21620 2.06 1.68 419088 A, 538323'Hs. 52620 integrin beta8 15.60 51. 00 419092 J05581 Hs. 89603 mucin 1, transmembrane 1.11 1. 83 419121 AA374372 Hs. 89626 parathyroid hormone-like hormone 1.00 1.00 419171 NM_002846 Hs. 89655 protein tyrosine phosphatase, receptor t 1.10 1.14 419183 U60669 Hs. 89663 cytochrome P450, subfamily XXIV (vitamin 1.00 1. 00 419216 AU076718 Hs. 164021 small inducible cytokine subfamily B (Cy 3.18 2.43 419288 AA256106 Hs. 87507 ESTs 1. 00 34.00 419335 AW960146 Hs. 284137 hypothetical protein FLJ12888 1.00 8.00 419354 M62839 Hs. 1252 apolipoprotein H (beta-2-glycoprotein I) 22. 63 54.00 419359 AL043202 Hs. 90073 chromosome segregation 1 (yeast homolog) 2.50 1.98 419423 D26488 Hs. 90315 KIAA0007 protein 1. 00 7.00 419443 D62703 gb: HUM316G10B Clontech human aorta polyA 1.00 12.00 419452 U33635 Hs. 90572 PTK7 protein brosine hinase 7 1.64 1. 84 419474 AW968619 Hs. 155849 ESTs 13.63 62.00 419485 AA489023 Hs. 99807 ESTs, Weakly similar to unnamed protein 4. 27 2. 26 419488 AA316241 Hs. 90691 nucleophosmin/nucleoplasmin 3 3.66 3.63 419502 AU076704 fibrinogen, A alpha polypeptide 13.05 115.00 419539 AF070590 Hs. 90869 Homo sapiens clones 24622 and 24623 mRNA 74.60 117.00 419556 U29615 Hs. 91093 chitinase 1 (chitotriosidase) 1.47 4.98 419569 Ai971651 Hs. 91143 jagged 1 (Alagille syndrome) 1.00 4.00 419594 AA013051 Hs. 91417 topoisomerase (DNA) 11 binding protein 94.30 94.00 419703 A1793257 Hs. 128151 ESTs 15.26 50.00 419721 NM001650 Hs. 288650 aquaporin 4 1.00 191.00 419729 M586442 Hs. 21411 gb: no53a03. s1 NCI_CGAP_SS1 Homo sapiens 1.00 59.00 419741 NM_007019 Hs. 93002 ubiquitin carrier protein E2-C 2.02 1.08 419745 AF042001 Hs. 93005 slug (chicken homolog), zinc finger prot 1. 00 1.00 419752 AA249573 Hs. 152618 ESTs, Moderately similar to ZN91_HUMAN Z 29.87 77.00 419839 U24577 Hs. 93304 phospholipase A2, group VII (platelet-ac 50.99 214.00 419936 AI792788 gb: o, 9ldO5. y5NC, _CGAP_Kid5Homosapiens 1.00 1.00 419937 AB040959 Hs. 93836 DKFZP434N014 protein 1.64 2.47 419983 W55956 Hs. 94030 Homo sapiens mRNA ; cDNA DKFZp586E1624 (f 15. 72 94.00 420005 AW271106 Hs. 133294 ESTs 3.15 1.43 420047 AI478658 Hs. 94631 brefeldin Ainhibited guanine nucleotide 12.45 39. 00 420058 AK001423 Hs. 94694 Homo sapiens cDNA FLJ10561 fis, clone NT 1.00 117.00 420162 BE378432 Hs. 95577 cyclin-dependent kinase 4 1. 43 1.21 420251 AW374968 Hs. 348112 Human DNA sequence from clone RP5-1103G7 2.35 3.23 420259 AF004884 Hs. 96253 calcium channel, voltage-dependent, P.Q 0.77 1. 15 420281 A1623693 Hs. 323494 ESTs 45.04 54.00 420309 AW043637 Hs. 21766 ESTs, Weakly similar to ALU5 HUMAN ALU 5 49.22 31. 00 420332 NM001756 Hs. 1305 serine (orcysteine) proteinase inhibito 0.05 2.82 420380 AA640891 Hs. 102406 ESTs 0.99 2.74 420462 AF050147 Hs. 97932 chondromodulin I precursor 1.00 1.00 420520 AK001978 Hs. 98510 simitartorabil-bindingprotein 49.74 133.00 420552 AK000492 Hs. 98806 hypothetical protein 94. 65 88.00 420560 AW207748 Hs. 59115 ESTs 1. 00 17.00 420610 AI683183 Hs. 99348 distal-less homeo box 5 1.00 13.00 420689 H79979 Hs. 88678 ESTs 50.09 95.00 420721 AA927802 Hs. 159471 ZAP3 protein 1.00 31.00 420759 T11832 Hs. 127797 HomosapienscDNAFW11381fis, c, oneHE 1.00 48.00 420783 AI659838 Hs. 99923 lectin, galactoside-binding, soluble, 7 3. 04 1.25 420900 AL045633 Hs. 44269 ESTs 2.24 7.00 420931 AF044197 Hs. 100431 small inducible cytokine B subfamily (Cy 1.00 8.00 421002 AF116030 Hs. 100932 transcription factor 17 1.00 27.00 421027 AA761198 Hs. 55254 ESTs 2.87 38.00 421037 A1684808 Hs. 197653 ESTs 1. 00 46. 00 421041 N36914 Hs. 14691 ESTs, Moderately similar to 138022 hypot 1.00 98.00 421073 NM_004689 Hs. 101448 metastasis associated 1 1.34 1. 46 421110 AJ250717 Hs. 1355 cathepsin E 119. 47 427.00 421133 AA401369 Hs. 190721 ESTs 1.10 17. 00 421150 A1913562 Hs. 189902 ESTs 1.45 1.63 421155 H87879 Hs. 102267 lysyl oxidase 1.00 15.00 421307 BE539976 Hs. 103305 Homo sapiens mRNA ; cDNA DKFZp434B0425 (f 1. 37 1.10 421316 AA287203 Hs. 324728 SMA5 1.00 21.00 421379 Y15221 Hs. 103982 small inducible cytokine subfamily B (Cy 1.92 3.94 421451 AA291377 Hs. 50831 ESTs 5.89 14.00 421474 U76362 Hs. 104637 solute carrier family 1 (glutamate trans 1. 46 1.76 421506 BE302796 Hs. 105097 thymidinekinasel, soluble 1.56 1.08 421508 NM_004833 Hs. 105115 absent in melanoma 2 5.11 5.23 421515 Y11339 Hs. 105352 GaINAc alpha-2, 6-sialyltransferase I, I 1. 00 3.00 421524 AA312082 Hs. 105445 GDNF family receptor alpha 1 2.63 10.58 421526 AL080121 Hs. 105460 DKFZP56400823 protein 1.46 1.88 421552 AF026692 Hs. 105700 secreted frizzled-related protein 4 30.21 50.32 421574 AJ000152 Hs. 105924 defensin, beta2 1.67 1.74 421582 AI910275 trefoil factor 1 (breast cancer, estroge 1.23 1.00 421633 AF121860 Hs. 106260 sorting nexin 10 1.00 116.00 421659 NM_014459 Hs. 106511 protocadherin 17 0.05 6.33 421677 H64092 Hs. 38282 ESTs 1.31 1.42 421753 BE314828 Hs. 107911 ATP-binding cassette, sub-family B (MDR/ 1. 41 1.20 421773 W69233 Hs. 112457 ESTs 1. 12 1.14 421777 BE562088 Hs. 108196 HSPC037 protein 1.97 1.29

421800 AA298151 Hs. 222969 ESTs 1.03 1.30 421817 AF146074 Hs. 108660 ATP-binding cassette, sub-family C (CFTR 1.88 1.59 421896 N62293 Hs. 45107 ESTs 11.84 22. 80 421928 AF013758 Hs. 109643 polyadenylate binding protein-interactin 45. 89 90.00 421931 NM000814 Hs. 1440 gamma-aminobutyric acid (GABA) A recepto 1.13 1.49 421948 L42583 Hs. 334309 keratin 6A 51.83 20.25 421975 AW961017 Hs. 6459 hypothetical protein FLJ11856 1.17 1.15 422026 U80736 Hs. 110826 trinucleotide repeatcontaining 9 1.00 52.00 422094 AF129535 Hs. 272027 F-box only protein 5 67.61 62.00 422095 AI868872 Hs. 282804 hypothetical protein FLJ22704 4.37 2.34 422109 S73265 Hs. 1473 gastrin-releasing peptide 4.18 95.50 422128 AW881145 gb: QV0-OT0033-010400-182-a07 OT0033 Homo 40.89 71.00 422129 AU076635 Hs. 1478 serine (orcysteine) proteinaseinhibito 1. 13 1.38 422134 AW179019 Hs. 112110 mitochondrial ribosomal protein L42 41.59 96.00 422158 L10343 Hs. 112341 protease inhibitor 3, skin-derived (SKAL 2.37 1.10 422168 AA586894 Hs. 112408 S100 calcium-binding protein A7 (psorias 3.29 1.68 422278 AF072873 Hs. 114218 frizzled (Drosophila) homolog 6 4.93 5.73 422282 AF019225 Hs. 114309 apolipoprotein I. 1.49 1.71 422283 AW411307 Hs. 114311 CDC45 (cell division cycle 45, S. cerevis 25. 99 10.91 422310 AA316622 Hs. 98370 cytochrome P450, subfamily IIS, polypept 1.54 1.41 422311 AF073515 Hs. 114948 cytokine receptor-like factor 1 1.15 1.78 422330 D30783 Hs. 115263 epiregulin 1. 00 112.00 422364 AF067800 Hs. 115515 C-type (calcium dependent, carbohydrate-9. 39 60.00 422406 AF025441 Hs. 116206 Opa-interacting protein 5 18.33 53.00 422424 Api186431 Hs. 296638 prostate differentiation factor 1.71 3. 21 422440 NL004812 Hs. 116724 aldo-keto reductase family 1, member B10 47.53 32.00 422487. AJ010901 Hs. 198267 mucin 4, tracheobronchial 73.68 35. 54 422511 AU076442 Hs. 117938 collagen, type XVII, alpha 1 173.97 26. 00 422515 AW500470 Hs. 117950 multifunctionalpolypepGdesimilartoS 4. 68 2. 92 422656 AI870435 Hs. 1569 LIM homeobox protein 2 1.00 1.00 422737 M26939 Hs. 119571 collagen, type III, alpha 1 (Ehlers-Danl 3.89 4. 55 422756 AA441787 Hs. 119689 glycoprotein hormones, alpha polypeptide 1.05 1.46 422765 AW409701 Hs. 1578 baculoviral IAP repeat-containing 5 (sur 3.88 1.53 422809 AK001379 Hs. 121028 hypothetical protein FLJ10549 99. 56 53.00 422867 L32137 Hs. 1584 cartilage oligomeric matrix protein (pse 1.69 3.17 422938 NM_001809 Hs. 1594 centromereproteinA (17kD) 70.46 61. 00 422956 8E545072 Hs. 122579 ECT2 protein (Epithelial cell transformi 77.74 3. 00 422960 AW890487 Hs. 63984 cadherin 13, H-cadherin (heart) 5.88 8.55 422963 AA401369 Hs. 190721 ESTs 171.41 17.00 422976 AU076657 Hs. 1600 chaperonincontainingTCP1, subunit5 (e 2.12 1. 62 422981 AF026445 Hs. 122752 TATA box binding protein (TBP)-associate 10.49 35.00 422986 AA319777 Hs. 221974 ESTs 12.40 32.47 423034 AL119930 gb: DKFZp761A092_rl 761 (synonym: hamy2) 16.41 60.00 423049 X59373 Hs. 188023 ESTs, Moderately similar to HXDA_HUMAN H 1.00 1.00 423081 AF262992 Hs. 123159 sperm associated antigen 4 1.82 2.96 423184 NMJM4428 Hs. 1624 ephrin-A1 1.14 1.53 423217 NM000094 Hs. 1640 collagen, type VII, alpha 1 (epidemolys 2.14 1.69 423248 AA380177 Hs. 125845 ribulose-5-phosphate-3-epimerase 7.18 14.00 423309 BE006775 Hs. 126782 sushi-repeat protein 21.90 64. 00 423361 AW170055 Hs. 47628 ESTs 1.00 1.00 423453 AW450737 Hs. 128791 CGI-09 protein 55.52 66.00 423511 AF036329 Hs. 129715 gonadotropin-releasing hormone 2 0.88 1.17 423516 AB007933 Hs. 129729 iigandofneuronatnitriooxidesynthase 1.76 5.40 423551 AA327598 Hs. 233785 ESTs 3.54 4.33 423554 M90516 Hs. 1674 glutamine-fructose-6-phosphate transamin 1.00 50.00 423575 C18863 Hs. 163443 HomosapienscDNAFW11576fis, cloneHE 38.88 70. 00 423624 AI807408 Hs. 166368 ESTs 1. 00 67. 00 423634 AW959908 Hs. 1690 heparin-binding growth factor binding pr 76.02 1.00 423642 AW452650 Hs. 157148 hypotheSca, protein MGC13204 19.14 58.00 423662 AA642452 Hs. 130881 B-cell CLL/lymphoma 11A (zinc finger pro 3.61 13.57 423673 BE003054 Hs. 1695 matrix metalloproteinase 12 (macrophage 240.73 40.00 423698 AA329796 Hs. 1098 DKFZp434J1813 protein 1.00 59.00 423725 AJ403108 Hs. 132127 hypothetical protein LOC57822 4.20 1.00 423761 NM006194 Hs. 132576 paired box gene 9 1.00 1.00 423787 AJ295745 Hs. 236204 nuclear pore complex protein 7.18 6.64 423816 AF151064 hypothetical protein 1.00 44.00 423826 U20325 Hs. 1707 cocaine-and amphetamine-regulated trans 1.00 1.00 423849 AL157425 Hs. 133315 Homo sapiens mRNA ; cDNA DKFZp761J1324 (f 1. 00 1.00 423887 AL080207 Hs. 134585 DKFZP434G232 protein 1.00 1.00 423934 U89995 Hs. 159234 forkhead box E1 (thyroidtranscription f 31.33 31.00 423954 AW753164 Hs. 288604 KIAA1632 protein 5.81 10.87 423961 D13666 Hs. 136348 osteoblast specific factor 2 (fasciclin 3.55 3.30 424012 AW368377 Hs. 137569 tumor protein 63 kDa with strong homolog 233. 42 68. 00 424016 AW163729 Hs. 6140 hypothetical protein MGC15730 0.93 1.01 424028 AF055084 Hs. 153692 Homo sapiens CDNA FU14354 fis, clone Y7 21. 30 52.00 424046 AF027866 Hs. 138202 serine (orcysteine) proteinaseinhibito 1.00 1.00 424086 A1351010 Hs. 102267 lysyl oxidase 21.91 70.00 424098 AF077374 Hs. 139322 small proline-rich protein 3 137.82 54.00 424120 T80579 Hs. 290270 ESTs 1.00 1.00 424165 AW582904 Hs. 142255 islet amyloid polypeptide 1.00 34.00 424200 AA337221 gb: EST41944 Endometrial tumor Homo sapie 13.06 48.00 424279 L29306 Hs. 171814 tryptophan hydroxylase (tryptophan 5-mon 1.00 1. 00 424308 AW975531 Hs. 154443 minichromosomemaintenancedeficient (S. 164.58 87.00 424326 NML014479 Hs. 145296 disintegrin protease 53. 72 302.00 424340 AA339036 Hs. 7033 ESTs 0.88 1.15

424351 BE622117 Hs. 145567 hypothetical protein 0.93 1.03 424364 AW383226 Hs. 201189 ESTs, Weakly similar to G01763 atrophin-7. 02 3.24 424381 AA285249 Hs. 146329 protein kinase Chk2 95.55 92.00 424411 NM_005209 Hs. 146549 crystallin, betaA2 1.63 3.25 424420 BE614743 Hs. 146688 prostaglandin E synthase 1.63 1.33 424441 X14850 Hs. 147097 H2A histone family, member X 1. 82 1.29 424502 AF242388 Hs. 149585 engsin 1.00 1.00 424503 X06256 Hs. 149609 integrin, alpha 5 (fibroneclin receptor, 1.02 2.24 424513 BE385864 Hs. 149894 mitochondrial translational iniGaGon f 1.00 17. 00 424539 L02911 Hs. 150402 Activin A receptor, type I (aCVR1) (ALK 32.46 108.00 424568 AF005418 Hs. 150595 cytochrome P450, subfamily XXVIA, polype 3.40 2.58 424602 AK002055 Hs. 151046 hypothetical protein FU11193 31.87 25. 00 424629 M90656 Hs. 151393 glutamate-cysteine ligase, catalytic sub 3.58 2.37 424645 NM_014682 Hs. 151449 KIAA0535 gene product 1.00 1.00 424687 J05070 Hs. 151738 matrix metalloproteinase 9 (gelatinase B 2.12 2.23 424717 AW992292 Hs. 152213 wingless-type MMT integration site fami 1.00 1.00 424834 AK001432 Hs. 153408 Homo sapiens cDNA FLJ10570 fis, clone NT 56.19 12.00 424840 D79987 Hs. 153479 extra spindle poles, S. cerevisiae, homo 2.65 1. 30 424867 A1024860 Hs. 153591 Not56 (D. melanogaster)-like protein 1.23 1. 05 424905 NM_002497 Hs. 153704 NIMA (never in mitosis gene a)-related k 21.35 1.00 424979 D87989 Hs. 154073 UDP-galactose transporter related 1.36 1.35 424999 AW953120 gb: EST365190 MAGE resequences, MAGB Homo 1.24 1. 41 425048 H05468 Hs. 164502 ESTs 1.00 11.00 425057 AA826434 Hs. 1619 achaete-scute complex (Drosophila) homol 7.46 87. 00 425081 X74794 Hs. 154443 minichromosome maintenance deficient (S. 2.52 3.82 425118 AU076611 Hs. 154672 methylene tetrahydrofolate dehydrogenase 4.84 4.03 425159 NM_004341 Hs. 154868 carbamoyl-phosphate synthetase 2, aspart 3.62 2.73 425202 AW962282 Hs. 152049 ESTs, Weakly similar to I38022 hypotheti 1. 00 53. 00 425234 AW152225 Hs. 165909 ESTs, Weakly similar to 138022 hypotheti 100.77 44.00 425236 AW067800 Hs. 155223 stanniocalcin 2 3.30 2.90 425245 A) 751768 Hs. 155314 KIAA0095 gene product 1.91 2.32 425247 NM_005940 Hs. 155324 matrix metalloproteinase 11 (stromelysin 1. 41 1.49 425266 J00077 Hs. 155421 alpha-fetoprotein 1.00 68.00 425274 BE281191 Hs. 155462 minichromosome maintenance deficient (mi 1.97 1. 63 425322 U63630 Hs. 155637 protein kinase, DNA-activated, catalytic 141.49 123.00 425349 AA425234 Hs. 79886 ribose 5-phosphate isomerase A (ribose 5 1.00 84.00 425371 D49441 Hs. 155981 mesothelin 0.87 1.59 425397 J04088 Hs. 156346 topoisomerase (DNA) !, alpha (170kD) 14. 90 5. 76 425420 BE536911 Hs. 234545 hypothetical protein NUF2R 1.00 1.00 425424 NM_004954 Hs. 157199 ELKL motif kinase 10.58 9.74 425483 AF231022 Hs. 158159 FATtumorsuppressor (Drosophila) homolo 1.74 1.40 425566 AW162943 Hs. 250618 UL16 binding protein 2 1.49 1. 14 425580 L11144 Hs. 1907 galanin 53.29 233.00 425650 NM_001944 Hs. 1925 desmoglein 3 (pemphigus vulgaris antigen 33.45 1.00 425692 D90041 Hs. 155956 N-acetyltransferase 1 (arylamine N-acety 1.00 55.00 425695 NM_005401 Hs. 159238 protein tyrosine phosphatase, non-recept 1.00 10.00 425734 AF056209 Hs. 159396 peptidylglycine alpha-amidating monooxyg 1.00 41.00 425776 U25128 Hs. 159499 parathyroid hormone receptor 2 1.00 48.00 425810 AI923627 Hs. 31903 ESTs 27.39 98.00 425811 AL039104 Hs. 159557 karyopherinalpha2 (RAGcohortl, impor 1.99 1.58 425849 A1077288 Hs. 296323 serum/glucocorticoid regulated kinase 71.16 3.42 425852 AK001504 Hs. 159651 death receptor 6, TNF superfamily member 1.35 1.34 426067 AA401369 Hs. 190721 ESTs 1.01 17.00 426088 AF038007 Hs. 166196 ATPase, Class I, type 8B, member 1 26.26 47.00 426215 AW067800 Hs. 155223 stanniocalcin 2 1.91 2.90 426227 U67058 Hs. 154299 Human proteinase activated receptor-2 mR 22.40 25.00 426269 H15302 Hs. 168950 Homo sapiens mRNA ; cDNA DKFZp566A1046 (f 1.00 1.00 426283 NM_003937 Hs. 169139 kynureninase (L-kynurenine hydrolase) 91. 39 229.00 426329 AL389951 Hs. 271623 nucleoporin 50kD 4. 34 4.08 426427 M86699 Hs. 169840 TTK protein kinase 7.02 1.00 426432 AF001601 Hs. 169857 paraoxonase 2 1.16 1.68 426440 BE382756 Hs. 169902 solute carder family 2 (facilitated glu 2.59 1.71 426459 AF151812 Hs. 169992 hypothetical 2protein 1.56 1.66 426471 M22440 Hs. 170009 transforming growth factor, alpha 20.60 26.00 426496 D31765 Hs. 170114 KIAA0061 protein 9.81 22.00 426501 AA401369 Hs. 190721 ESTs 19.23 17.00 426514 BE616633 Hs. 170195 bone morphogenetic protein 7 (osteogenic 103.74 41.00 426536 AI949749 Hs. 44441 ESTs 4.65 23.00 426572 AB037783 Hs. 170623 hypothetical protein FLJ11183 1.00 43. 00 426682 AV660038 Hs. 2056 UDP glycosyitransferase 1 family, polype 160.06 8.00 426691 NM_006201 Hs. 171834 PCTAIRE protein kinase 1 1.51 1.35 426746 J03626 Hs. 2057 uridine monophosphate synthetase (orotat 2.13 1.68 426752 X69490 Hs. 172004 run 0.02 5.14 426784 U03749 Hs. 172216 chromogranin A (parathyroid secrelory pr 1.72 1.71 426807 AA385315 Hs. 156682 ESTs 1.30 1.64 426812 AF105365 Hs. 172613 solute carrier family 12 (potassium/chlo 1.47 1.53 426814 AF036943 Hs. 172619 myelin transcription factor 1-like 1.00 1.00 426831 BE296216 Hs. 172673 S-adenosylhomocysteine hydrolase 1.51 1.25 426897 AA401369 Hs. 190721 ESTs 141.56 17.00 426925 NM_001196 Hs. 315689 Homo sapiens cDNA : FLJ22373 fis, clone H 32.61 38.00 426935 NM000088 Hs. 172928 collagen, type I, alpha 1 2.65 3.16 426964 AA393739 Hs. 287416 Homo sapiens DNA FLJ11439 fis, clone HE 1.97 3.49 426966 A1493134 sclerostin 1.00 1.00 426991 AK001536 Homo sapiens cDNA FU10674 fis, clone NT 3.39 2.28 427099 AB032953 Hs. 173560 odd Oz/ten-m homolog 2 (Drosophila, mous 4.24 17.00

427239 BE270447 Hs. 174070 ubiquitin carrier protein 1.58 1.05 427260 AA663848 gb: ae70bO6. s1 Stratagene schizo brain S1 1.34 1.60 427281 AA906147 Hs. 102869 ESTs 1.00 66.00 427335 AA448542 Hs. 251677 G antigen 7B 51.83 4.00 427354 T57896 Hs. 191095 ESTs 1.17 1.95 427356 AW023482 Hs. 97849 ESTs 7.31 41.00 427376 AA401533 Hs. 19440 ESTs 1.00 57.00 427383 NM_005411 Hs. 177582 surfactant, pulmonary-associated protein 0. 42 1. 32 427427 AF077345 Hs. 177936 lectin, superfamily member 1 (cartilage-1. 00 20.00 427441 AA412605 Hs. 343879 SPANX family, member C 1. 00 1.00 427445 X80818 Hs. 178078 glutamate receptor, metabotropic 4 0.97 1.03 427505 AA361562 Hs. 178761 26S proteasome-associated padl homolog 4. 60 4.04 427510 Z47542 Hs. 179312 small nuclear RNA activating complex, po 22.00 45.00 427528 AU077143 Hs. 179565 minichromosome maintenance deficient (S. 97.45 92.00 427546 AA188763 Hs. 36793 hypothetical protein FLJ23188 1.50 3.24 427562 R56424 Hs. 26534 ESTs 6.81 40. 00 427585 D31152 Hs. 179729 collagen, type X, alpha 1 (Schmid metaph 69.91 62.00 427660 A1741320 Hs. 114121 Homo sapiens cDNA : FLJ23228 fis, clone C 2.70 49.00 427666 AI791495 Hs. 180142 calmodulin-like skin protein 1.37 1.88 427668 AA298760 Hs. 180191 hypothetical protein FLJ14904 29.55 67.00 427677 NM_007045 Hs. 180296 FGFRI oncogene partner 3.52 2.63 427701 AA411101 Hs. 243886 nuclear autoantigenic sperm protein (his 7. 41 34.00 427711 M31659 Hs. 180408 solute carrier family 25 (mitochondrial 15.84 70. 00 427719 A1393122 Hs. 134726 ESTs 7.03 4.52 427722 AK000123 Hs. 180479 hypothetical protein FLJ20116 2.92 1.74 427747 AW411425 Hs. 180655 serinelthreonine kinase 12 1.76 1. 26 427912 AL022310 Hs. 181097 tumor necrosis factor (ligand) superfami 9.63 59.00 427961 AW293165 Hs. 143134 ESTs 41. 97 118.00 428004 AA449563 Hs. 151393 glutamate-cysteine ligase, catalytic sub 23.82 1.00 428023 AL038843 Homo sapiens cDNA : FLJ23602 fis, clone L 1.40 1. 33 428046 AW812795 Hs. 337534 ESTs, Moderately similar to 138022 hypot 96.28 167. 00 428093 AW594506 Hs. 104830 ESTs 1.25 1. 29 428098 AU077258 Hs. 182429 protein disulfide isomerase-related prot 1.86 1.60 428129 A1244311 Hs. 26912 ESTs 1.00 42.00 428169 A1928984 Hs. 182793 golgi phosphoprotein 2 2.76 2.11 428182 BE386042 Hs. 293317 ESTs, Weakly similar to GGC1_HUMAN G ANT 1. 00 1.00 428227 AA321649 Hs. 2248 small inducible cytokine subfamily B (Cy 85.59 181.00 428242 H55709 Hs. 2250 leukemia inhibitory factor (cholinergic 8. 57 21. 64 428330 L22524 Hs. 2256 matrix metalloproteinase 7 (matrilysin, 7.77 15. 90 428434 A) 909935 Hs. 65551 Homo sapiens, Similar to DNA segment, Ch 0.58 1.43 428450 NM_014791 Hs. 184339 KIAA0175 gene product 237.53 204.00 428471 X57348 Hs. 184510 stratifin 6.00 4.60 428479 Y00272 Hs. 334562 cell division cycle 2, G1 to S and G2 to 56.54 16.00 428484 AF104032 Hs. 184601 solute carrier family 7 (cationic amino 3. 53 2.15 428505 AL035461 Hs. 2281 chromogranin B (secretogranin 1) 1.00 1.00 428532 AF157326 Hs. 184786 TBP-interacting protein 1.00 58.00 428645 AA431400 Hs. 98729 ESTs, Weakly similar to 2017205A dihydro 1.00 16.00 428664 AK001666 Hs. 189095 similar to SALL1 (sal (Drosophila)-like 1.00 1. 00 428698 AA852773 Hs. 334838 KIAA1866 protein 187.37 255.00 428728 NM_016625 Hs. 191381 hypothetical protein 47. 24 80.00 428748 AW593206 Hs. 98785 Ksp37 protein 1. 00 87.00 428758 AA433988 Hs. 98502 hypothetical protein FLJ14303 1.06 1.13 428771 AB028992 Hs. 193143 KIAA1069 protein 1.98 92. 00 428801 AW277121 Hs. 254881 ESTs 1.67 6. 15 428810 AF068236 Hs. 193788 nitric oxide synthase 2A (inducible, hep 1.03 1.27 428839 AI767756 Hs. 82302 Homo sapiens cDNA FLJ14814 fis, clone NT 124.17 43.00 428845 AL157579 Hs. 153610 KIAA0751 gene product 1. 00 1. 00 428959 AF100779 Hs. 194680 WNT1 inducible signaling pathway protein 15.16 27.00 428969 AF120274 Hs. 194689 artemin 1.36 1.24 429038 AL023513 Hs. 194766 seizure related gene 6 (mouse)-like 0.97 3.31 429065 AI753247 Hs. 29643 HomosapienscDNAFW13103fis, c, oneNT 6.82 16.47 429164 AI688663 Hs. 116586 ESTs 19.08 67.00 429170 NM_001394 Hs. 2359 dual specificity phosphatase 4 16.18 105.00 429183 AB014604 Hs. 197955 KIAA0704 protein 79.72 104.00 429201 X03178 Hs. 198246 group-specific component (vitamin D bind 1.00 1.00 429211 AF052693 Hs. 198249 gapjunction protein, beta 5 (connexin 3 1.33 1.09 429220 AW207206 ESTs 1.00 7.00 429228 A1553633 Hs. 326447 ESTs 39.47 29.25 429259 AA420450 Hs. 292911 ESTs, Highly similar to S60712 band-6-pr 2. 01 1.18 429263 AA019004 Hs. 198396 ATP-binding cassette, sub-family A (ABC1 1.07 1. 00 429276 AF056085 Hs. 198612 G protein-coupled receptor 51 3.70 142.00 429359 W00482 Hs. 2399 matrix metailoproteinase 14 (membrane-in 1.30 1.94 429412 NM_006235 Hs. 2407 POUdomain, c, ass2, associatingfactor 94.09 86.00 429413 NM_014058 Hs. 201877 DESC1 protein 41.91 10. 00 429486 AF155827 Hs. 203963 hypothetical protein FLJ10339 12.19 1.00 429504 X99133 Hs. 204238 lipocalin 2 (oncogene 24p3) 1.61 1.08 429538 BE182592 Hs. 11261 small proline-rich protein 2A 4.43 2.90 429547 AA401369 Hs. 190721 ESTs 1.06 17.00 429551 AW450624 Hs. 220931 ESTs 2. 89 65. 00 429563 BE619413 Hs. 2437 eukaryotic translation initiation factor 1.49 1.37 429597 NM_003816 Hs. 2442 a disintegrin and metalloproteinase doma 61.86 100.00 429610 AB024937 Hs. 211092 LUNX protein ; PLUNC (palate lung and nas 1.59 1.69 429612 AF062649 Hs. 252587 pituitary tumor-transforming 1 2.78 1.74 429616 A1982722 Hs. 120845 ESTs 1.00 1.00 429656 X05608 Hs. 211584 neurofilament, light polypeptide (68kD) 1.00 4.00

429663 M68874 Hs. 211587 phospho, ipaseA2, group, VA (cytosolic, 69.95 104. 00 429736 AF125304 Hs. 212680 tumornecrosisfactorreceptorsuperfami 1.25 1.21 429782 NMJM5754 Hs. 220689 Ras-GTPase-activating protein SH3-domain 1.00 7.00 429903 AL134197 Hs. 93597 cyclin-dependent kinase 5, regulatory su 11.80 1.00 429918 AW873986 Hs. 119383 ESTs 1.00 78.00 429978 AA249027 ribosome protein S6 1.98 3.09 429986 AF092047 Hs. 227277 sine oculis homeobox (Drosophila) homolo 1.00 48.00 430044 AA464510 Hs. 152812 ESTs 69.27 59.00 430114 AA847744 Hs. 99640 ESTs 1.00 1.00 430134 BE380149 Hs. 105223 ESTs, Weakly similar to T33188 hypotheti 1.00 51.00 430147 R60704 Hs. 234434 hairy/enhancer-of-split related with YRP 1. 10 2.22 430287 AW182459 Hs. 125759 ESTs, Weakly similar to LEU5_HUMAN LEUKE 1.00 127.00 430294 Ai538226 Hs. 32976 guanine nucleotide binding protein 4 3.80 1. 47 430300 U60805 Hs. 238648 oncostain M receptor 1.00 35.00 430315 NM_004293 Hs. 239147 guanine deaminase 92. 31 28.00 430337 M36707 Hs. 239600 calmodulin-like 3 1.18 1.08 430378 Z29572 Hs. 2556 tumor necrosis factor receptor superfami 5.28 66.00 430388 AA356923 Hs. 240770 nuclear cap binding protein subunit 2, 2 16.76 38.00 430393 BE185030 Hs. 241305 estrogen-responsive B box protein 1.63 1.50 430439 AL133561 DKFZP434B061 protein 1.00 1.00 430451 AA836472 Hs. 297939 cathepsin B 1.64 2.12 430454 AW469011 Hs. 105635 ESTs 63.35 44.00 430466 AF052573 Hs. 241517 polymerase (DNA directed), theta 2.47 1.91 430481 AA479678 Hs. 203269 ESTs, Moderately similar to ALU8-HUMAN A 1.00 31.00 430486 BE062109 Hs. 241551 chloride channel, calcium activated, fam 12.28 41.00 430508 AI015435 Hs. 104637 ESTs 4.75 7.27 430533 AA480895 Hs. 57749 ESTs, Weakly similar to T17288 hypotheti 1.00 1.00 430563 AF146074 Hs. 108660 ATP-binding cassette, sub-family C (CFTR 1.00 1.59 430677 Z26317 Hs. 94560 desmoglein 2 1.72 1.30 430678 AA401369 Hs. 190721 ESTs 0.90 17.00 430686 NM_001942 Hs. 2633 desmoglein 1 1.00 1.00 430788 AI742925 Hs. 7179 ESTs, Weakly similar to 2004399A chromos 1. 62 1.84 430890 X54232 Hs. 2699 gbpican 1 1. 58 1.40 430935 AW072916 zinc finger protein 131 (clone pHZ-10) 90.28 132.00 430985 AA490232 Hs. 27323 ESTs, Weakly similar to I78885 serine/th 0.94 1.28 431009 BE149762 Hs. 48956 gap junction protein, beta 6 (connexin 3 60.25 28.00 431089 BE041395 ESTs, Weakly similar to unknown protein 23. 32 941.00 431092 A1332764 Hs. 125757 ESTs 13.46 63.00 431124 AF284221 Hs. 59506 doublesex and mab-3 related transcripuo 49.43 62.00 431164 AA493650 Hs. 94367 Homo sapiens cDNA : FLJ23494 fis, clone L 0.44 2. 20 431211 M86849 Hs. 323733 gap junction protein, beta 2,26kD (conn 182. 26 101. 00 431221 AW207837 Hs. 286145 SRB7 (suppressor of RNA polymerase B, ye 4.15 13.97 431277 AA501806 Hs. 345824 ESTs 1.00 86.00 431322 AW970622 gb : EST382704 MAGE resequences, MAGK Homo 40.55 200. 00 431342 AW971018 Hs. 21659 ESTs 1.00 53.00 431384 BE158000 Hs. 285026 gb: MR2-HT0377-150200-202-e03 HT0377 Homo 0.94 1.14 431462 AW583672 Hs. 256311 granin-like neuroendocrine peptide precu 1.30 1.25 431494 AA991355 Hs. 298312 hypotheticalprotein DKFZp434A1315 3.90 26.00 431515 NM_012152 Hs. 258583 endothelialdifferentiation, lysophospha 1. 41 1.87 431548 AI834273 Hs. 9711 novel protein 5.66 15. 00 431630 NM_002204 Hs. 265829 integrin, alpha 3 (antigen CD49C, alpha 0.99 1.44 431745 AW972448 Hs. 163425 ESTs 0. 99 3. 51 431770 BE221880 Hs. 268555 5'-3'exoribonuclease 2 67.12 91. 00 431830 Y16645 Hs. 271387 small inducible cytokine subfamily A (Cy 3.36 4, 71 431846 BE019924 Hs. 271580 uroplakin 1B 4. d9 2.51 431890 X17033 Hs. 271986 integrin, alpha 2 (CD49B, alpha 2 subuni 2.20 3.32 431934 AB031481 Hs. 272214 STG protein 1.01 1.04 431958 X63629 Hs. 2877 cadherin 3, type 1, P-cadherin (placenta 51. 17 46.35 432006 AL137382 Hs. 272320 Homo sapiens mRNA ; cDNADKFZp434L1226 (f 0.94 1.65 432023 R43020 Hs. 236223 EST 0. 94 47. 00 432201 AI538613 Hs. 298241 Transmembrane protease, serine 3 1.10 2.24 432210 AI567421 Hs. 273330 Homo sapiens, clone IMAGE : 3544662, mRNA, 1.42 1.45 432226 AW182766 Hs. 273558 phosphate cyGdylyltransferase 1, cholin 1. 00 1.00 432239 X81334 Hs. 2936 matrix metalloproteinase 13 (coilagenase 18.67 1.00 432265 BE382679 Hs. 285753 SCG10-like-protein 1.09 1.21 432281 AK001239 Hs. 274263 hypothetical protein FLJ10377 40. 98 58.00 432365 AK001106 Hs. 274419 hypotheticalprotein FLJ10244 1.00 214. 00 432374 W68815 Hs. 301885 Homo sapiens cDNA FLJ11346 fis, clone PL 157.34 37.00 432375 BE536069 Hs. 2962 S100 calcium-binding protein P 1.65 1.06 432407 AA221036 gb : zr03f12. rt Stratagene NT2 neuronal pr 73.71 75.00 432441 AW292425 Hs. 163484 ESTs 56.35 72. 00 432489 A1804855 Hs. 207530 ESTs 1.00 24.00 432543 AA552690 Hs. 152423 Homo sapiens cDNA : FLJ21274 fis, clone C 137.72 98.00 432552 AI537170 Hs. 173725 ESTs, Weakly similar to ALUB_NUMAN ALU S 1.00 31.00 432583 AW023624 Hs. 162282 potassium channel TASK-4 : potassium chan 0.27 35.18 432606 NM_002104 Hs. 3066 granzyme K (serine protease, granzyme 3 ; 2.87 6. 22 432625 Ai243596 Hs. 94830 ESTs, Moderately similar to T03094 A-kin 26.63 56.00 432653 N62096 Hs. 293185 ESTs, Weakly similar to JC7328 amino aci 1.92 5. 29 432677 NM_004482 Hs. 278611 UDP-N-acetyt-alpha-D-galactosamine : polyp 1.00 48.00 432715 AA247152 Hs. 200483 ESTs, Weakly similar to KIAA1074 protein 45.13 31.00 432753 NM_014075 Hs. 336938 Homo sapiens PR00593 mRNA, complete cds 1. 00 68.00 432788 AA521091 Hs. 178499 Homo sapiens cDNA: FLJ23117 fis, clone L 2.69 3.67 432842 AW674093 Hs. 334822 hypothetical protein MGC4485 1. 22 1.34 432867 AW016936 Hs. 233364 ESTs 1.00 1.00 432917 NM_014125 Hs. 241517 PR00327 protein 10.25 6.62

432920 U37689 Hs. 3128 polymerase (RNA) II (DNA directed) polyp 1.44 1.30 433001 AF217513 Hs. 279905 clone HQ0310 PR00310pl 154.79 85.64 433023 AW864793 Hs. 87409 thrombospondin 1 20.96 100.00 433042 AW193534 Hs. 281895 Homo sapiens cDNA FLJ11660 fis, clone HE 1.00 10.00 433091 Y12642 Hs. 3185 lymphocyte antigen 6 complex, locus D 1.20 1.09 433159 AB035898 Hs. 150587 kinesin-like protein 2 13.82 39.00 433183 AF231338 Hs. 222024 transcdption factor BMAL2 1.00 69.00 433258 AA622788 Hs. 203613 ESTs, Weakly similar to ALUB_HUMAN !!!! 1.00 1.25 433409 AI278802 Hs. 25661 ESTs 44.81 117.00 433437 U20536 Hs. 3280 caspase 6, apoptosis-retated cysteine pr 70.39 105. 00 433485 A, 493076 Hs. 201967 aldo-keto reductase family 1, member C2 11.55 2.00 433537 AI733692 Hs. 112488 ESTs 8.66 55.00 433547 W04978 Hs. 303023 beta tubulin 1, class VI 25.16 83.00 433556 W56321 Hs. 111460 calciumicalmodulin-dependent protein kin 1.00 19.00 433647 M603367 Hs. 222294 ESTs 20.30 49.00 433658 L03678 Hs. 156110 immunoglobulin kappa constant 5. 92 10.03 433800 A1094221 Hs. 135150 iungtype-icei) membrane-associated giy 2.29 2.22 433819 AW511097 Hs. 112765 ESTs 3.71 8.00 433862 D86960 Hs. 3610 KIAA0205 gene product 62.08 104.00 433980 AA137152 Hs. 286049 phosphoserine aminotransferase 108.91 47.00 434088 AF116677 Hs. 249270 hypothetical protein PR01966 1.00 1.00 434094 AA305599 Hs. 238205 hypothetical protein PR02013 121.27 87.00 434105 AW952124 Hs. 13094 presenilins associated rhomboid-like pro 1.22 1.23 434217 AW014795 Hs. 23349 ESTs 14.11 57.00 434340 AI193043 Hs. 128685 ESTs, Weakly similar to T17226 hypotheti 2.10 2.56 434360 AA401369 Hs. 190721 ESTs 40.98 17.00 434414 AI798376 gb: tr34b07. x1 NCI_CGAP_Ov23 Homo sapiens 1.48 1.56 434424 AI811202 Hs. 325335 HomosapienscDNA : FLJ23523 fis, clone L 1.00 64.00 434467 BE552368 Hs. 231853 Homo sapiens cDNA FLJ13445 fis, clone PL 54.91 85. 00 434551 BE387162 Hs. 280858 ESTs, Highly similar to A35661 DNA excis 2.46 2.00 434627 AI221894 Hs. 39311 ESTs 1.00 1.00 434699 AA643687 Hs. 149425 Homo sapiens cDNA FLJ11980 fis, clone HE 1.00 23.00 434769 AA648884 Hs. 134278 Homo sapiens cDNA FLJ12676 fis, clone NT 7.08 56.00 434792 AA649253 Hs. 132458 ESTs 8.52 44.00 434808 AF155108 Hs. 256150 Homo sapiens, Similar lo RIKEN cDNA 2810 11.33 1.00 434828 D90070 Hs. 96 phorbol-12-myristate-13-acetate-induced 1.00 1.00 434876 AF160477 Hs. 61460 Ig superfamily receptor LNIR 1. 25 1.29 434891 AA814309 Hs. 123583 ESTs 1.00 6.00 434928 AW015595 Hs. 4267 Homo sapiens clones 24714 and 24715 mRNA 1.00 1.00 435013 H91923 Hs. 110024 Target CAT 1.26 1.10 435066 BE261750 Hs. 4747 dyskeratosis congenita 1, dyskerin 1.69 1.37 435087 AW975241 Hs. 23567 ESTs 1.00 1.00 435099 AC004770 Hs. 4756 flap structure-specific endonuclease 1 2.90 1.93 435159 M668879 Hs. 116649 ESTs 1.00 1.00 435205 X54136 Hs. 181125 immunoglobulin lambda locus 1.02 1.46 435232 NM_001262 Hs. 4854 cyclin-dependent kinase inhibitor 2C (pl 2.04 2.70 435304 H10709 Hs. 269524 ESTs 27.58 139.00 435313 AI769400 Hs. 189729 ESTs 1.00 14.00 435505 AF200492 Hs. 211238 interieukin-1 homolog 1 1.00 38.00 435509 A) 458679 Hs. 181915 ESTs 1.00 1.00 435525 AI831297 Hs. 123310 ESTs 1.00 56.00 435532 AW291488 Hs. 117305 Homo sapiens, clone IMAGE : 3682908, mRNA 1. 00 2.00 435550 A1224456 Hs. 324507 H. sapiens polyA site DNA 3.42 3.92 435602 AF217515 Hs. 283532 uncharacterized bone marrow protein BM03 3.95 1.80 435766 R11673 Hs. 186498 ESTs 1.00 28.00 435793 AB037734 Hs. 4993 KIAA1313 protein 23.68 42.00 436069 A1056879 Hs. 263209 ESTs 1.00 58.00 436170 AW450381 Hs. 14529 ESTs 1. 00 18.00 436211 AK001581 Hs. 334828 hypothetical protein FLJ10719 ; KIAA1794 5.84 22.00 436213 AA325512 Hs. 71472 hypothetical protein FLJ10774; KIAA1709 1.42 1.27 436217 T53925 Hs. 107 fibrinogen-iikel 57. 97 31. 00 436238 AK002163 Hs. 301724 hypothetical protein FLJ11301 2.51 1.71 436251 BE515065 Hs. 296585 nucleolar protein (KKE/D repeat) 2.33 1.64 436291 BE568452 Hs. 344037 protein regulator of cytokinesis 1 108.99 52.00 436302 AL355841 Hs. 99330 hypothetical protein FLJ23588 0.75 2.81 436396 AW992292 Hs. 152213 wingless-type MMN integration site fami 60.01 1.00 436414 BE264633 Hs. 143638 WD repeat domain 4 2.50 2.19 436419 A1948626 Hs. 171356 ESTs 0.95 1.33 436443 AW138211 Hs. 128746 ESTs 1. 12 9.26 436474 AJ270693 Hs. 199887 ESTs 1. 00 1.00 436481 AA379597 Hs. 5199 HSPC150 protein similar to ubiquitin-con 3.28 1.56 436486 AA742221 Hs. 120633 ESTs 1.00 19.00 436511 M721252 Hs. 291502 ESTs 16.76 14.00 436553 X57809 Hs. 181125 immunoglobulin lambda locus 1.08 1.74 436557 W15573 Hs. 5027 ESTs, Weakly similar to A47582 B-cell gr 19.20 9.75 436608 AA628980 down syndrome critical region protein DS 33.92 25.00 436667 AW025183 Hs. 127680 ESTs 0.89 1.19 436771 AW975687 Hs. 292979 ESTs 1.00 10.00 436839 AA401369 Hs. 190721 ESTs 1. 00 17. 00 436887 AW953157 Hs. 193235 hypothetical protein DKFZp547D155 1.06 1.15 436944 AW268614 Hs. 5840 ESTs 1.00 1.00 436961 AW375974 Hs. 156704 ESTs 25.13 25.00 436972 AA284679 Hs. 25640 claudin 3 1.59 1.46 437016 AU076916 Hs. 5398 guanine monphosphate synthetase 2.35 1.78 437044 AL035864 Hs. 69517 cDNA for differentially expressed CO16 g 1.34 1.13

437181 A1306615 Hs. 125343 ESTs, Weakly similar to KIAA0758 protein 1.00 17.00 437204 AL110216 Hs. 22826 ESTs, Weakly similar to 155214 salivary 40.55 82. 00 437205 AL110232 Hs. 279243 Homo sapiens mRNA ; cDNADKFZp564D2071 (f 1.00 112.00 437259 AI377755 Hs. 120695 ESTs 1.00 205. 00 437270 R18087 Hs. 323769 cisplatin resistance related protein CRR 1.56 1.54 437271 AL137445 Hs. 28646 HomosapiensmRNA ; cDNADKFZp5660134 (fr 113. 25 125.00 437370 AL359567 Hs. 161962 Homo sapiens mRNA ; cDNA DKFZp547D023 (fr 1.82 4.57 437390 A1125859 Hs. 112607 ESTs 1.35 1.75 437412 BE069288 Hs. 34744 Homo sapiens mRNA ; cDNADKFZp547C136 (fr 3.58 3.20 437435 AI306152 Hs. 27027 hypothetical protein DKFZp762H1311 3.03 1. 08 437444 H46008 Hs. 31518 ESTs 1. 00 39.00 437568 A1954795 Hs. 156135 ESTs 1.00 19.00 437623 063880 Hs. 5719 chromosome condensation-related SMC-asso 1.95 1.57 437789 AI581344 Hs. 127812 ESTs, Weakly artoT17330hypotheü 1.00 3.00 437814 A) 088192 Hs. 135474 ESTs, Weakly similar to DDX9_HUMAN ATP-D 1.00 45. 00 437840 AA884836 Hs. 292014 ESTs 1.07 1.78 437852 BE001836 Hs. 256897 ESTs, Weakly similar to dJ365012. 1 [H. sa 1.68 3.26 437879 BE262082 Hs. 5894 hypothetical protein FLJ10305 1.87 2.52 437915 AI637993 Hs. 202312 Homo sapiens clone N11 NTera2D1 teratoca 74.05 35.00 437916 BE566249 Hs. 20999 hypothetical protein FLJ23142 23.15 89.00 437937 A1917222 Hs. 121655 ESTs 1.00 1.00 437942 A1888256 Hs. 307526 ESTs 12. 28 31.00 438091 AW373062 nuclear receptor subfamily 1, group I, m 1.53 10.85 438113 A1467908 Hs. 8882 ESTs 1. 80 2.39 438119 AW963217 Hs. 203961 ESTs, Moderately similarto AF11672189 22. 67 36.90 438274 AI918906 Hs. 55080 ESTs 1.00 1.00 438378 AW970529 Hs. 86434 hypothetical protein FLJ21816 38.92 38.00 438403 AA806607 Hs. 292206 ESTs 1.00 1.00 438494 AA908678 Hs. 130183 ESTs 2.05 80.00 438546 AW297204 Hs. 125811 ESTs 1.00 131.00 438552 AJ245820 Hs. 6314 type I transmembrane receptor (seizure-r 1.43 1.45 438702 AI879064 Hs. 54618 ESTs 1.00 34.00 438724 AW612553 Hs. 114670 Human DNA sequence from clone RP11-16L21 1. 33 1.10 438746 AI885815 Hs. 184727 Human melanoma-associated antigen p97 (m 2.42 1.59 438779 NM_003787 Hs. 6414 nuclear protein 4 1.00 18.00 438821 AA826425 Hs. 192375 ESTs 2.03 2.57 438885 AI886558 Hs. 184987 ESTs 6.42 88.00 438898 AA401369 Hs. 190721 ESTs 22.41 17.00 438915 AA280174 Hs. 285681 Williams-Beuren syndrome chromosome regi 1.00 1.00 438956 W00847 Hs. 135056 Human DNA sequence from clone RP5-850E9 2.20 1. 88 439000 AW979121 gb : EST391231 MAGE resequences, MAGP Homo 2.78 4. 81 439023 AA745978 Hs. 28273 ESTs 1.17 1. 31 439024 R96696 Hs. 35598 ESTs 1.00 28.00 439128 A1949371 Hs. 153089 ESTs 1.00 67.00 439146 AW138909 Hs. 156110 immunoglobulin kappa constant 1.38 1.41 439223 AW238299 Hs. 250618 UL16 binding protein 2 1.93 1.64 439285 AL133916 hypothetical protein FLJ20093 46. 23 139.00 439318 AW837046 Hs. 6527 G protein-coupled receptor 56 2.00 2.20 439343 AF086161 Hs. 114611 hypothetical protein FLJ11808 6.10 7.37 439394 AA401369 Hs. 190721 ESTs 3.39 17.00 439410 AA632012 Hs. 188746 ESTs 1.83 3.07 439451 AF086270 Hs. 278554 heterochromatin-like protein 1 23.28 52.00 439452 AA918317 Hs. 57987 B-cell CLL/lymphoma 11B (zinc finger pro 18.76 122. 00 439453 BE264974 Hs. 6566 thyroid hormone receptor interactor 13 2. 78 1.58 439477 W69813 Hs. 58042 ESTs, Moderately similar to GFR3_HUMAN G 1.22 1.44 439492 AF086310 Hs. 103159 ESTs 7.46 39.00 439523 W72348 Hs. 185029 ESTs 1. 00 1.19 439592 AF086413 Hs. 58399 ESTs 1.00 1.00 439606 W79123 Hs. 58561 G protein-coupled receptor 87 33.61 1.00 439670 AF088076 Hs. 59507 ESTs, Weakly similar to AC004858 3 U1 sm 1. 00 1.00 439702 AW085525 Hs. 134182 ESTs 4. 30 10.00 439706 AW872527 Hs. 59761 ESTs, Weakly similar to DAP1HUMAN DEATH 86.55 11. 00 439738 BE246502 Hs. 9598 sema domain, immunoglobulin domain (lg), 2.36 1.88 439750 AL359053 Hs. 57664 Homo sapiens mRNA full length insert cDN 2.02 6.08 439759 AL359055 Hs. 67709 Homo sapiens MARNA full length insert cDN 1. 00 21. 00 439780 AL109688 gb : Homo sapiens mRNA full length insert 7.27 25.00 439840 AW449211 Hs. 105445 GDNFfamilyreceptoralphal 1, 00 1.00 439926 AW014875 Hs. 137007 ESTs 32.58 71.00 439963 AW247529 Hs. 6793 platelet-activating factor ace@, hydro, a 21.28 9.55 439979 AW600291 Hs. 6823 hypothetical protein FLJ10430 68.83 61.00 440006 AK000517 Hs. 6844 hypothetical protein FLJ20510 1. 83 4. 02 440028 AW473675 Hs. 125843 ESTs, Weakly similar to T17227 hypotheti 1.42 2.54 440106 AA864968 Hs. 127699 KIAA1603 protein 1.00 54. 00 440138 AB033023 Hs. 318127 hypothetical protein FLJ10201 24.18 52. 00 440273 AI805392 Hs. 325335 Homo sapiens cDNA : FLJ23523 fis, clone L 3.21 4.72 440289 AW450991 Hs. 192071 ESTs 38.63 113.00 440325 NM_003812 Hs. 7164 a disintegrin and metalloproteinase doma 62.88 147. 00 440492 R39127 Hs. 21433 hypothetical protein DKFZp547J036 2. 35 3. 62 440527 AV657117 Hs. 184164 ESTs, Moderately similar to S65657 alpha 10.84 57.00 440659 AF134160 Hs. 7327 claudin 1 3.18 2.37 440704 M69241 Hs. 162 insulin-like growth factor binding prote 2.89 2.09 440943 AW082298 Hs. 146161 hypothetical protein MGC2408 2.02 1.41 440994 AI160011 Hs. 272068 ESTs 1.29 1.14 441020 AA401369 Hs. 190721 ESTs 142.99 17.00 441031 Ai110684'Hs. 7645 fibrinogen, B beta polypeptide 1. 41 99.00

441128 AA570256 ESTs, Weakly similar to T23273 hypotheti 4.13 3.50 441290 W27501 Hs. 89605 cholinergic receptor, nicotinic, alpha p 1.00 1. 00 441362 BE614410 Hs. 23044 RAD51 (S. cerevisiae) homolog (E coli Re 130.23 43.00 441377 BE218239 Hs. 202656 ESTs 22.03 1. 00 441390 AI692560 Hs. 131175 ESTs 3.65 7.70 441497 R51064 Hs. 23172 ESTs 1. 00 1.00 441525 AW241867 Hs. 127728 ESTs 1. 53 1.42 441553 AA281219 Hs. 121296 ESTs 1.89 1.57 441607 Nul005010 Hs. 7912 neuronal cell adhesion molecule 1.47 2.11 441633 AW958544 Hs. 112242 normal mucosa of esophagus specific 1 216.22 363.00 441636 AA081846 Hs. 7921 Homo sapiens mRNA; cDNA DKFZp566E183 (fr 2.31 2.05 441737 X79449 Hs. 7957 adenosine deaminase, RNA-specific 1.30 1.49 441790 AA401369 Hs. 190721 ESTs 44.15 17.00 441801 AW242799 Hs. 86366 ESTs 1.00 1.00 441919 A1553802 Hs. 128121 ESTs 1.00 122. 00 441937 R41782 Hs. 22279 ESTs 0.86 1.37 441954 AI744935 Hs. 8047 Fanconi anemia, complementation group G 1.48 1. 39 442025 AW887434 Hs. 11810 CDA11 protein 1.00 46.00 442029 AW956698 Hs. 14456 neural precursor cell expressed, develop 9.92 45.00 442072 A) 740832 Hs. 12311 Homosapiensclone23570mRNAsequence 25.05 77.00 442108 AW452649 Hs. 166314 ESTs 3. 61 3.14 442117 AW664964 Hs. 128899 ESTs 3. 00 5.49 442137 AA977235 Hs. 128830 ESTs, Weakly similar to 1192_HUMAN ZINC 1.00 1.00 442159 AW163390 Hs. 278554 heterochromatin-iike protein 1 1.92 1.66 442179 AA983842 Hs. 333555 chromosome 2 open reading frame 2 27. 22 50. 00 442328 AI952430 Hs. 150614 ESTs, Weakly similar to ALU4_HUMAN ALU S 5.00 3.42 442432 BE093589 Hs. 38178 hypothetical protein FLJ23468 181.59 76.00 442530 AI580830 Hs. 176508 Homo sapiens cDNA FLJ14712 fis, clone NT 10. 59 144. 00 442547 AA306997 Hs. 217484 ESTs, WeaklysimilartoALU1_HUMANALUS 109.23 98.00 442556 AL137761 Hs. 8379 Homo sapiens mRNA ; cDNADKFZp586L2424 (f 1.00 53.00 442619 AA447492 Hs. 20183 ESTs, Weakly similar to AF164793 1 prote 29.02 50.00 442710 AIDI 5631 Hs. 23210 ESTs 1.00 19.00 442717 R88362 Hs. 180591 ESTs, Weakly similar to T23976 hypotheti 1. 00 5.00 442875 BE623003 Hs. 23625 Homo sapiens clone TCCCTA00142 mRNA sequ 22.85 50. 00 442914 AW188551 Hs. 99519 hypothetical protein FLJ14007 25. 33 82.00 442932 AA457211 Hs. 8858 bromodomain adjacent to zinc finger doma 3.18 4.41 442942 AW167087 Hs. 131562 ESTs 8.45 64. 00 443068 AN88710 ESTs 1.00 27.00 443204 AW205878 Hs. 29643 Homo sapiens cDNA FLJ13103 fis, clone NT 1.00 24.00 443211 A1128388 Hs. 143655 ESTs 12.42 2. 00 443247 BE614387 Hs. 333893 c-Myc target JP01 128.84 96.00 443324 R44013 Hs. 164225 ESTs 0. 02 4.59 443383 A1792453 Hs. 166507 ESTs 1.00 47.00 443400 R28424 Hs. 250648 ESTs 18.52 61.00 443426 AF098158 Hs. 9329 chromosome 20 open reading frame 1 4.02 1. 75 443572 AA025610 Hs. 9605 cleavage and potyadenytation specific fa 2.98 2.57 443575 A1078022 Hs. 269636 ESTs, Weakly similar to ALU1_HUMAN ALU S 1.00 29.00 443614 AV655386 Hs. 7645 fibrinogen, B beta polypeptide 1.00 16.00 443633 AL031290 Hs. 9654 similar to pregnancy-associated plasma p 1.00 39.00 443648 A1085377 Hs. 143610 ESTs 39.81 70.00 443715 AI583187 Hs. 9700 cyclin E1 48.74 7.00 443723 AI144442 Hs. 157144 syntaxin 6 1.29 1. 30 443802 AW504924 Hs. 9805 KIAA1291 protein 1.75 1.61 443859 Nul013409 Hs. 9914 follistatin 1.35 1.13 443892 AA401369 Hs. 190721 ESTs 1.00 17. 00 443947 W24187 gb: zb47f09. rl Soares_fetal_lung_NbHL19W 1.33 1.64 443991 NM-002250 Hs. 10082 potassium intermediate/small conductance 5.71 6.87 444006 BE395085 Hs. 10086 type I transmembrane protein F@14 1.47 1.92 444009 A1380792 Hs. 135104 ESTs 1.00 77. 00 444017 U04840 Hs. 214 neuro-oncological ventral antigen 1 1. 00 1.00 444127 N63620 Hs. 13281 ESTs 1.00 29.00 444129 AW294292 Hs. 256212 ESTs 1.00 1. 00 444279 U62432 Hs. 89605 cholinergic receptor, nicotinic, alpha p 0.60 7.80 444371 BE540274 Hs. 239 forkhead box M1 2.91 1.14 444378 R41339 Hs. 12569 ESTs 1.00 1.00 444381 BE387335 Hs. 283713 ESTs, Weakly similar to S64054 hypotheti 469.00 556. 00 444461 R53734 Hs. 25978 ESTs, Weakly similar to 2109260A B cell 12.88 105.00 444471 AB020684 Hs. 11217 KIAA0877 protein 24.91 90. 00 444489 A, 151010 Hs. 157774 ESTs 1.00 111. 00 444619 BE538082 Hs. 8172 ESTs, ModeratelysimilartoA46010X-lin 1.00 70.00 444665 BE613126 Hs. 47783 B aggressive lymphoma gene 30.56 139.00 444707 AI188613 Hs. 41690 desmocollin 3 1.00 1.00 444735 BE019923 Hs. 243122 hypothetical protein FLJ13057 similar to 77. 02 90.00 444781 NM_014400 Hs. 11950 GPI-anchored metastasis-associated prote 1.57 1.31 444783 AK001468 Hs. 62180 anillin (Drosophila Scraps homolog), act 77.55 2.00 445236 AK001676 Hs. 12457 hypothetical protein FLJ10814 1.00 27.00 445258 A1635931 Hs. 147613 ESTs 1. 00 73.00 445413 AA151342 Hs. 12677 CGI-147 protein 28.14 50.00 445417 AK001058 Hs. 12680 Homo sapiens cDNA FLJ10196 fis, clone HE 1.81 2.62 445443 AV653838 Hs. 322971 ESTs 1. 00 1.00 445462 AA378776 Hs. 288649 hypothetical protein MGC3077 2.09 1. 70 445517 AF208855 Hs. 12830 hypothetical protein 1.87 70. 00 445537 AJ245671 Hs. 12844 EGF-like-domain, multiple 6 1. 71 2. 72 445580 AF167572 Hs. 12912 skbl (S. pombe) homolog 1.52 1.34 445654 X91247 Hs. 13046 thioredoxin reductase 1 1.51 1.52

445669 AI570830 Hs. 174870 ESTs 10.95 11.45 445818 BE045321 Hs. 136017 ESTs 1.00 1. 00 445873 AA250970 Hs. 251946 poly (A)-binding protein, cytoplasmic 1-1 49.42 54.00 445885 A1734009 Hs. 127699 KIAA1603 protein 1.00 132.00 445898 AF070623 Hs. 13423 Homo sapiens clone 24468 mRNA sequence 1.00 1.00 445903 A1347487 Hs. 132781 class I cytokine receptor 1.00 36.00 445932 BE046441 Hs. 333555 Homo sapiens clone 24859 mRt4A sequence 241 2.88 445982 BE410233 Hs. 13501 pescadillo (zebrafish) homolog 1, contai 1.60 1.35 446078 AI339982 Hs. 156061 ESTs 1.00 42.00 446102 AW168067 Hs. 317694 ESTs 1.00 1.00 446157 BE270828 Hs. 131740 HomosapienscDNA : FLJ22562 fis, clone H 1. 70 1.53 446269 AW263155 Hs. 14559 hypothetical protein FLJ10540 73.01 48. 00 446292 AF081497 Hs. 279662 Rh type C glycoprotein 1.55 1.26 446293 AI420213 Hs. 149722 ESTs 1.00 2.00 446423 AW139655 Hs. 150120 ESTs 1.10 4.19 446428 AW082270 Hs. 12496 ESTs, Wealky similar to ALU4_HUMAN ALU S 0.53 3.26 446432 A1377320 Hs. 150058 ESTs 1.00 5. 00 446528 AU076640 Hs. 15243 nuclear protein 1 (120kD) 1. 36 1.31 446574 A) 310135 Hs. 335933 ESTs 3.89 72.00 446619 AU076643 Hs. 313 secreted phosphoprotein 1 (osteopontin, 32.03 20.23 446636 AC002563 Hs. 15767 citron (rho-interacting, se (inelthreonin 4. 19 5. 07 446783 AW138343 Hs. 141867 ESTs 2.82 9.47 446839 BE091926 Hs. 16244 mitotic spindle coiled-coil related prot 110.28 28.00 446849 AU076617 Hs. 16251 cleavage and polyadenylation specific fa 3.26 2.94 446856 A) 814373 Hs. 164175 ESTs 6.38 11.30 446872 X97058 Hs. 16362 pyrimidinergic receptor P2Y, G-protein c 1.98 2. 03 446880 AI 811807 Hs. 108646 Homo sapiens EDNA FU14934 fis, clone PL 94.90 113.00 446921 AB012113 Hs. 16530 small inducible cylokine subfamily A (Cy 1.67 3.90 446989 AK001898 Hs. 16740 hypothetical protein FLJ11036 2. 82 3. 12 447022 AW291223 Hs. 157573 ESTs 1.00 170.00 447033 AI357412 Hs. 157601 ESTs 7. 15 107.00 447078 AW885727 Hs. 9914 ESTs 47.24 24.00 447081 Y13896 Hs. 17287 potassium inwardly-rectifying channel, s 0.12 17. 88 447131 NM_004585 Hs. 17466 retinoicacidreceptorresponder (tazaro 0.97 1.48 447149 BE299857 Hs. 326 TAR (H, V) RNA binding protein 2 1. 24 1. 26 447153 AA805202 Hs. 315562 ESTs 1.00 54. 00 447164 AF026941 Hs. 17518 Homo sapiens cig5 mRNA, partial sequence 1.00 67.00 447178 AW594641 Hs. 192417 ESTs 3.42 50. 00 447250 A) 878909 Hs. 17883 protein phosphatase 1G (formerly 2C), ma 1.60 1.52 447289 AW247017 Hs. 36978 melanoma antigen, family A, 3 1.00 1.00 447342 Ait99268 Hs. 19322 Homo sapiens, Similar to RIKEN cDNA 2010 28.63 1.00 447343 AA256641 Hs. 236894 ESTs, Highly similar to S02392 alpha-2-m 146.62 51. 00 447350 A1375572 Hs. 172634 ESTs 1.00 12.00 447377 N27687 Hs. 334334 transcription factor AP-2 alpha (activant 2.55 63. 00 447415 AW937335 Hs. 28149 ESTs, Weakly artoKF3B_HUMANKINES 0.91 1.13 447425 A1963747 Hs. 18573 acylphosphatase 1, erythrocyte (common) 1.00 35.00 447519 U46258 Hs. 339665 ESTs 59.89 49.00 447532 AK000614 Hs. 18791 hypothetical protein FLJ20607 1.23 1.63 447534 AA401369 Hs. 190721 ESTs 1.00 17.00 447636 Y10043 high-mobility group (nonhistonechromoso 1. 41 1.11 447688 N87079 Hs. 19236 Target CAT 1.00 39. 00 447733 AF157482 Hs. 19400 MAD2 (mitoticarrestdeficient, yeast, h 1.17 1.12 447769 AW873704 Hs. 320831 Homo sapiens cDNA FLJ14597 fis, clone NT 6.47 5.95 447802 AW593432 Hs. 161455 ESTs 0. 73 2.34 447850 AB018298 Hs. 19822 SEC24 (S. cerevisiae) related gene famil 86.45 116.00 447924 AI817226 Hs. 313413 ESTs, Weakly similar to T23110 hypotheti 1.00 1.00 447973 AB011169 Hs. 20141 similar to S. cerevisiae SSM4 3.50 4.27 448030 N30714 Hs. 325960 membrane-spanning 4-domains, subfamily A 4.13 142.00 448105 AI538613 Hs. 298241 Transmembrane protease, serine 3 1. 15 2.24 448243 AW369771 Hs. 52620 integrin, beta 8 15.84 1.00 448278 W07369 Hs. 11782 ESTs 0.97 1. 90 448290 AK002107 Hs. 20843 Homo sapiens cDNA FLJ11245 fis, clone PL 1.00 1.00 448296 BE622756 Hs. 10949 Homo sapiens cDNA FLJ14162 fis, clone NT 2.42 2.17 448357 BE274396 Hs. 108923 RAB38, member RAS oncogene family 1.44 1.08 448390 AL035414 Hs. 21068 hypothetical protein 1.00 43.00 448469 AW504732 Hs. 21275 hypothetical protein FLJ11011 2.63 2. 49 448569 BE382657 Hs. 21486 signal transducer and activator of trans 1.84 2.53 448663 BE614599 Hs. 106823 hypothetical protein MGC14797 3.29 46.00 448672 A1955511 Hs. 225106 ESTs 1.00 21. 00 448733 NM_005629 Hs. 187958 solute carrier family 6 (neurotransmitte 1.82 1.08 448741 BE614567 Hs. 19574 hypothetical protein MGC5469 2. 48 1. 92 448757 AI366784 Hs. 48820 TATA box binding protein (TBP)-associate 23. 53 20.00 448775 AB025237 Hs. 388 nudix (nucleoside diphosphate linked moi 2.34 1. 97 448826 AI580252 Hs. 293246 ESTs, Weakly similar to putative p150 [H 74. 07 62. 67 448830 AL031658 Hs. 22181 hypothetical protein dJ310013. 3 1. 37 1. 31 448844 AI581519 Hs. 177164 ESTs 1.00 31.00 448988 Y09763 Hs. 22785 gamma-aminobutyric acid (GABA) A recepto 1. 84 1.95 448993 AI471630 KIAA0144 gene product 1. 63 1.49 449003 X76342 Hs. 389 alcohol dehydrogenase 7 (class IV), mu o 1.00 1.00 449029 N28989 Hs. 22891 solute carrier family 7 (calionic amino 1.97 2.26 449040 AF040704 Hs. 149443 putative tumor suppressor 0.97 1. 56 449048 Z45051 Hs. 22920 similar to S68401 (cattie) glucose induc 27.13 90.00 449053 A1625777 Hs. 344766 ESTs 8.33 44. 00 449054 AF148848 Hs. 22934 myoneurin 73.85 104.00 449101 AA205847 Hs. 23016 G protein-coupled receptor 2.58 27.00

449167 T05095 Hs. 19597 KIAA1694 protein 1.61 2.36 449207 AL044222 Hs. 23255 nucleoporin 155kD 2.36 1.56 449228 AJ403107 Hs. 148590 protein related with psoriasis 1.15 1.15 449230 BE613348 Hs. 211579 melanoma cell adhesion molecule 206. 65 151. 00 449305 AI638293 gb: tt09b07. x1 NCI_CGAP_GC6 Homo sapiens 17. 28 45.00 449318 AW236021 Hs. 78531 Homo sapiens, Similar to RIKEN cDNA 5730 26.39 35.00 449448 D60730 Hs. 57471 ESTs 1.00 1.00 449467 AW205006 Hs. 197042 ESTs 1.00 1.00 449523 NM000579 Hs. 54443 chemokine (GC motifj receptor 5 56. 80 216.86 449722 BE280074 Hs. 23960 cyclin Bt 150.03 1. 00 449976 H06350 Hs. 135056 Human DNA sequence from clone RP5-850E9 2. 16 2. 85 450001 Nom-001044 Hs. 406 solute carrier family 6 (neurotransmitte 1.17 1.45 450098 W27249 Hs. 8109 hypothetical protein FLJ21080 1.79 2. 38 450101 AV649989 Hs. 24385 Human hbc647 mRNA sequence 1.00 69.00 450149 AW969781 Hs. 132863 Zic family member 2 (odd-paired Drosophi 1.00 1.00 450193 At916071 Hs. 15607 Homo sapiens Fanconi anemia complementat 29.85 34.00 450221 AA328102 Hs. 24641 cytoskeleton associated protein 2 1.00 1.00 450372 BE218107 Hs. 202436 ESTs 1. 00 1. 00 450375 AA009647 Hs. 8850 a disintegrin and metalloproteinase doma 51.26 93.00 450447 AF212223 Hs. 25010 hypothetical protein P15-2 123.20 181. 00 450568 AL050078 Hs. 25159 Homo sapiens cDNA FLJ10784 fis, clone NT 1.00 19.00 450589 A1701505 Hs. 202526 ESTs 1. 00 23.00 450684 AA872605 Hs. 25333 interleukin 1 receptor, type II 1.00 100. 00 450701 H39960 Hs. 288467 Homo sapiens cDNA FLJ12280 fis, clone MA 1. 89 1. 65 450705 U90304 Hs. 25351 @roquois homeobox protein 2A (IRX-2A) ( 1. 00 45. 00 450832 AA401369 Hs. 190721 ESTs 25.17 17.00 450937 R49131 Hs. 26267 ATP-dependant interferon response protel 90. 92 90. 00 450983 AA305384 Hs. 25740 ER01 (S. cerevisiae)dike 3.33 1.70 451105 AI761324 gb:wi60b11.x1 NCI_CGAP_Co16 Homo sapiens 15.02 124. 00 451110 AI955040 Hs. 265398 ESTs, Weakiy simitar to transformation-r 1.00 143.00 451253 H48299 Hs. 26126 claudin 10 3.02 2.29 451291 R39288 Hs. 6702 ESTs 1. 00 1.00 451320 AW498974 diacylglycerol kinase, zeta (104kD) 2.92 18.00 451380 H09280 Hs. 13234 ESTs 6. 90 6.67 451386 AB029006 Hs. 26334 spastic paraplegia 4 (autosomal dominant 35.75 72.00 451437 H24143 Hs. 31945 hypothetical protein FU11071 1.00 69. 00 451462 AK000367 Hs. 26434 hypothetical protein FLJ20360 1.83 2.10 451524 AK001466 Hs. 26516 hypothetical protein FU10604 1.13 1.07 451541 BE279383 Hs. 26557 plakophilin 3 1.88 1.33 451592 AI805416 Hs. 213897 ESTs 1.00 1.00 451635 AA018899 Hs. 127179 cryptic gene 1.52 1. 92 451743 AA401369 Hs. 190721 ESTs 4. 95 17. 00 451806 NM_003729 Hs. 27076 RNA 3'-terminal phosphate cyclase 13.55 31.00 451807 W52854 hypothetical protein FLJ23293 similar to 1. 55 35. 00 451871 AI821005 Hs. 118599 ESTs 1.81 2.53 451952 AL120173 Hs. 301663 ESTs 1.00 22.00 452012 AA307703 Hs. 279766 kinesin family member 4A 3.43 2. 26 452046 AB018345 Hs. 27657 KIAA0802 protein 56.59 19. 00 452194 Ai694413 Hs. 332649 oifactory receptor, family 2, subfamily 1.67 4.09 452206 AW340281 Hs. 33074 Homo sapiens, clone MAGE : 3606519, mRNA, 9. 31 53.00 452240 AA401369 Hs. 190721 ESTs 13.42 17.00 452256 AK000933 Hs. 28661 Homo sapiens cDNA FLJ10071 fis, clone HE 39.03 94.00 452281 T93500 Hs. 28792 Homo sapiens cDNA FLJ11041 fis, clone PL 153.01 340. 00 452291 AF015592 Hs. 28853 CDC7 (cell division cycle 7, S, cerevisi 1.95 23.00 452295 BE379936 Hs. 28866 proarammedeeit death 10 42.33 61.00 452304 AA025386 Hs. 61311 ESTs, Weakly similar to S10590 cysteine 1.17 2.14 452340 NM002202 Hs. 505 ISL1 transcription factor, LIM/homeodoma 1.00 13. 00 452349 AB028944 Hs. 29189 ATPase, Class VI, type 11A 1. 09 1. 42 452367 U71207 Hs. 29279 eyes absent (Drosophila) homolog 2 54.49 53. 00 452401 NM_007115 Hs. 29352 tumor necrosis factor, alpha-induced pro 1. 00 32.00 452410 AL133619 Homo sapiens mRNA; cDAN DKFZp434E2321 (f 1.26 1.99 452461 N78223 Hs. 108106 transcription factor 24.47 35.00 452571 W31518 Hs. 34665 ESTs 54.61 102.00 452613 AA461599 Hs. 23459 ESTs 1.39 1.32 452699 AW295390 Hs. 213062 ESTs 1. 00 26.00 452705 H49805 Hs. 246005 ESTs 1.00 1.00 452747 AF160477 Hs. 61460 gsuperfamilyreceptor LNIR 112.87 1.29 452787 AW294022 Hs. 222707 KIAA1718 protein 1.00 1. 00 452795 AW392555 Hs. 18878 hypothetical protein FLJ21620 1.00 1.00 452823 Ab012124 Hs. 30696 transcription factor-like 5 (basic helix 7. 91 75. 00 452833 BE559681 Hs. 30736 KIAA0124 protein 3.16 1.92 452838 U65011 Hs. 30743 preferentially expressed antigen in meta 174. 35 1.00 452862 AA401369 Hs. 190721 ESTs 98.26 17. 00 452865 AW173720 Hs. 345805 ESTs, Weakly similar to A47582 B-ceil gr 1.55 1.00 452934 AA581322 Hs. 4213 hypothetical protein MGC16207 1.73 1.19 452946 X95425 Hs. 31092 EphA5 1.00 1. 00 452976 R44214 Hs. 101189 ESTs 1.58 1.98 453028 AB6532 Hs. 31442 RecQ protein-like 4 1.80 1.60 453095 AW295660 Hs. 252756 ESTs 0.77 1.50 453102 NM_007197 Hs. 31664 frizzled (Drosophila) homolog 10 1.00 1.00 453103 M301052 Hs. 153444 ESTs 1.00 1.00 453120 AA292891 Hs. 31773 pregnancy-induced growth inhibitor 1. 23 1.20 453153 N53893 Hs. 24360 ESTs 1.00 83.00 453160 AI263307 Hs. 239884 H2B histone family, member L 1. 00 30.00 453197 AI916269 Hs. 109057 ESTs, Weakly similar to ALU5_HUMAN ALU S 1.00 134.00

453210 AL133161 Hs. 32360 hypothetical protein FLJ10867 1. 69 1.93 453240 A1969564 Hs. 166254 hypothetical protein DKFZp566I133 1.00 1.00 453317 NM_002277 Hs. 41696 keratin, hair, acidic, 1 1.19 1.27 453323 AF034102 Hs. 32951 solute carrier family 29 (nucleoside tra 4.90 4.11 453331 AI240665 Hs. 8850 ESTs 199. 42 340.00 453392 U23752 Hs. 32964 SRY (sex determining region Y)-box 11 1. 00 16.00 453431 AF094754 Hs. 32973 glycine receptor, beta 1.00 1. 00 453439 AI572438 Hs. 32976 guanine nucleotide binding protein 4 3.44 5. 17 453459 BE047032 Hs. 257789 ESTs 2.84 5.58 453563 AW608906. comp Hs. 181163 hypothetical protein MGC5629 4.58 90.00 453633 AA357001 Hs. 34045 hypoehtetical protein FLJ20764 1.74 1. 60 453775 NM_002916 Hs. 35120 replication factor C (activator 1) 4 (37 19.49 1.00 453830 AA534296 Hs. 20953 ESTs 24. 92 25.00 453857 AL080235 Hs. 35861 DKFZP586E1621 protein 167.59 66.00 453867 AI929383 Hs. 33032 hypothetical protein DKFZp434N185 1.00 39.00 453883 AI638516 Hs. 347524 cofactor required for Sp1 transcriptiona 1. 97 1.58 453884 AA355925 Hs. 36232 KIAA0186 gene product 63.89 20.00 453900 AW003582 Hs. 226414 ESTs, Weakly similar to ALUB_HUMAN AW S 20, 41 16.00 453922 AF053306 Hs. 36708 budding uninhibited by benzimidazoles 1 7.09 22.00 453941 U39817 Hs. 36820 Bloom syndrome 29.75 19.00 453964 A) 961486 Hs. 12744 ESTs 1. 00 1.00 453968 AA847843 Hs. 62711 Homo sapiens, clone IMAGE: 3351295, mRNA 2.06 1.81 453976 BE463830 Hs. 163714 ESTs 3.02 131.00 454024 AA993527 Hs. 293907 hypothetical protein FLJ23403 1.00 131.00 454034 NM_000691 Hs. 575 aidehyde dehydrogenase 3 family, member 1.23 1.02 454042 T19228 Hs. 172572 hypothetical protein FLJ20093 30.63 171. 00 454059 NM_003154 Hs. 37048 statherin 1.00 1. 00 454066 X00356 Hs. 37058 calcitoninlcalcitonin-related polypeptid 1. 01 1.45 454098 W27953 Hs. 292911 ESTs, Highly similar to S60712 band-6-pr 1.26 1.11 454241 BE144666 gb: CM2-HT0176-041099-017-c02 HT0176 Homo 6.33 5.04 454417 A) 244459 Hs. 110826 trinucleotiderepeatcontaining9 4.30 7.82 454439 AW819152 Hs. 154320 DKFZP56601646 protein 1.00 1.00 455175 AW993247 gb : RC2-BN0033-180200-014-h09 BN0033 Homo 13.75 103.00 455601 AI368680 Hs. 816 SRY (sex determining region Y)-box 2 206.11 1.00 456237 AA203682 gb: zx52e07. r1 Soares_fetal_liver_spleen_ 1. 00 1.00 456321 NM 001327 Hs. 87225 cancerltestis antigen 1.14 1.10 456475 NM_000144 Hs. 95998 Friedreich ataxia 1.00 48. 00 456508 AA502764 Hs. 123469 ESTs, Weakly similar to AF208855 1 BM-01 162.25 189.00 456534 X91195 Hs. 100623 phospholipase C, beta 3, neighbor pseudo 2.12 1.80 456736 AW248217 Hs. 1619 achaete-scute complex (Drosophila) homoi 1.15 1.94 456759 BE259150 Hs. 127792 delta (Drosophila)-like 3 1. 00 1.00 456990 NU04504 Hs. 171545 HIV-1 Rev binding protein 16. 42 84. 00 457200 U33749 Hs. 197764 thyroid transcription factor 1 0.57 1.76 457234 AW968360 Hs. 14355 Homo sapiens cDNA FLJ13207 fis, clone NT 2.71 4.15 457465 AW301344 Hs. 122908 DNA replication factor 46, 37 47.00 457489 AI693815 Hs. 127179 cryptic gene 1.12 1.35 457646 AA725650 Hs. 112948 ESTs 1.55 2. 51 457733 AW974812 Hs. 291971 ESTs 1.00 55. 00 457819 AA057484 Hs. 35406 ESTs, Highly similar to unnamed protein 4. 36 3.18 458092 BE545684 Hs. 343566 KIAA0251 protein 1.00 1.32 458098 BE550224 metallothionein 1E (functional) 1. 00 2200 458207 T28472 Hs. 7655 U2 small nuclear ribonucleoprotein auxil 2. 06 1.88 458242 BE299588 Hs. 28465 Homo sapiens cDNA : FLJ21869 fis, clone H 1. 00 1.00 458247 R14439 Hs. 209194 ESTs 7.00 9.85 458679 AW975460 Hs. 142913 ESTs 1.00 3. 00 458778 AW451034 Hs. 326525 arylsulfatase D 1.31 2. 01 456933 At636429 Hs. 24763 RAN binding protein 1 1. 98 1.71 459352 AW810383 Hs. 206828 ESTs 12. 60 63. 00 459670 F01020 Hs. 172004 titin 1.00 1.00 459702 A1204995 gb : an03c03. xl Stratagene schizo brain S1 1.00 237.00 TABLE9B Pkey: Unique Eos probeset identifier number CAT number Gene cluster number Accession: Genbank accession numbers Pkey CAT Number Accession 407746 10125_1 AK001962 R69415 BE464605 AA418699 AA053293 AA149075 AA058396 AW338226 AW272659 AA454607 At139535 AW469852AJ275461 AW271982 AA730033 AA576507 AA991217 AA782067 A1985851 AA805864 AA505598 AW469857 R69546 AA988279 AW001647 N63320 D82661 T27343 AA306950 AA360989 R58778 408070 1036688_1 AW148852 BE350895 408660 107294_1 AA525775 AA056342 AI538978 AW975281 AA664986 409522 113735 1 AA076382AA075431 409866 1156522_1 AW502152H41202H29772 410032 1170435t BE065985 BE065944 BE066008 BE066083 BE066093 411089 1231721 AA456454 AA713730 AA091294 AA584921 N86077 AW836781 AA601031 AA579876 AA551106 AA633188 AW905577 AI955808 AI679386 AI679895 AA514764 AA454562 A1082382 AA595822 AA551351 AA586369 AA666384 AA188934 AA666398 AA551297 AA565188 411152 1234028_1 BE069199 AW936012 AW877466 AW819782 AW935798 AW835546 AW936042 BE069121 AW835625 AW877536 AW935885 BE069202 AW820019 AW935937 BE160180 AW935946 BE069101 BE069125AW877527 BE160316 BE160398 AW935794 AW835701 AW935784 412537 1304_1 AL031778 X59711 NM_002505 M59079 AI870439 AI494259 AW664010 AA405063 AA436132 BE174516 AA412691 AI400314 AA436024 T29403 BE079412 BE079428 N90322 AI631202 AI141758 AI016793 AI167566 AI862075 AI375230 AI208445 AW235763 AL044113 AA382656 AW953918 AA927051 AA889823 BE003094 AW390155 AW360805 AW360823 AW360810 AA425472 AI69482 AL044114 AI684577 AI809865

AI478773 AI160445 AI674630 N69088 AW665529 N49278 AI129239 AI457890 AI621264 AW297152 AI268215 AA907787 A 286170 A1017982 AI963541 AI469801 AI969353 BE552356 N66509 AA736741 AA382555 AW075811 AW292026 412811 132943_1 H06382 AW957730 AA352014 R13591 AA121201 D60420 BE263253 BE047862 Z41952 AI424991 AI693507 AI863108 AA599060 AI091148 AA598689 R39887 AA813482 AW016452 H06383 R41807 AI364268 AA620528 AI241940 AW089149 AW090733 AW088875 Z38240 AA121202 R17734 413690 1383256 1 BE157489 BE157560 414883 15024 1 AA926960 AA926959 W76521 W24270 W21526 AA037172 BE267636 H83186AA469909 N86396 AA001348 BE535736 AA081745 BE566245 AA082436 H72525 H77575 N49786 W80565 H78746 BE569085 W04339 R98127 T55938 BE279271 AW960304 T29812 AA476873 BE297387 AA292753 AA177048 NM_001826 X54941 BE314366 AA908783 Api719075 BE270172 BE269819 AA889955 AI204630 W25243A1935150 AA872039 W72395 T99630 A1422691 H98460 N31428 BE255916 H03265 A1857576 AA776920 AA910644 AA459522 AA293140 AW514667 R75953 AW662396 AA662522 AI865147 AI423153 AW262230 AA584410 AA583187 AW024595 AW069734 AI828996 AA282997 AA876046 AW613002 AA527373 AW972459 AI831360 AA621337 AA100926 AA772418 AA594628 AI033892 W95096 A1034317 AA398727 A1085031 N95210 AI459432 AI041437 AA932124 AA627684 AA935829 AI004827 AI423513 AI094597 H42079 R54703 AI630359 AA617681 AA978045 AA643280 W44561 AI991988 AI537692 AI090262 AA740817 AI312104 AI911822 AA416871 AI85409 AA129784 AA701623 AI075239 AI39549 AA633648 AI339996 AI336880 AA399239 AI078708 AI085351 AI362835 AI346618 AI146955 AI989380 AI348243 N92892 AA765850 AI494230 AI278887 AA962596 AI492600 W80435 AA001979 R97424 AI129015 N24127 AA157451 AA235549 AA459292 AA037114 AA129785 AI494211 AW059601 AW886710 R92790 N59755 AI361128 AW589407 H47725 H97534 H48076 H48450 T99631 AW300758 H03431 R76789 AA954344 H77576 R96823 A1457100 N92845 N49682 H42038 BE220698 BE220715 H99552 AA701624 N74173 R54704 H79520 H72923 H03266 BE261919 AA769633 AA480310 AA507454 AA910586 AI203723 AW104725 W25611 W25071 T88980 H03513 T77589 R99156 W95095 R97470 AA702275 T77551 AA911952 H82956 N83673 AA283672 415989 156454_1 AI267700 AI720344 AA191424 AI023543 AI469633 AA172056 AW958465 AA172236 AW953397 AA355086 417324 166714_1 AW265494 AA455904 AA195677 AW265432 AW991605 AA456370 418574 17690_1 N28754 N28747 AI568146 AI979339 AA322671 AA322672 AW955043 A) 990326 AA776406 AM16250 AA843678 AW451882 N23137 N23129 W70051At038748 AA831327 Ai925845 AW945895 418712 1784125-1 Z42183 T31621 T97478 419443 184788_1 D62703M242966 D79798 419502 18535-1 AU076704 T74854 T74860 T72098 T73265 T73873 T69180 T74658 T58786 T60385 T73410 T68781 T67845 T67593 T73952 T67864 T60630 T68367 T68401 T53959 T72360 T72099 T60377 T58961 T71712 T72821 T64738 T74645 T72037 T68688 T72063 T73258 T72826 T64242 T68220 T74673 T71800 T68355 T61227 T62738 T69317 T53850 T64692 T73768 T73962 T73382 T68914 T70975 T73400 T60631 T73277 T73203 T70498 T61409 T58925 NM000508 M64982 T68301 T73729 T69445 T60424 T67922 T67736 T68716 T67755 T74765 T73819 T58719 T74756 T60477 T74863 T61109 T68329 T58850 T71857 T73425 T53736 T68607 T58898 T64309 T72031 T72079 T64305 T71908 T68107 T71916 T73787 T56036 T64425 T71870 T60476 T61376 T67820 T71895 T41006 T69441 T68170 T74617 T71958 T69440 T61875 R06796 H48353 T71914 T53939 T64121 AA693996 T72525 T67779 T68078 AA011465 AA345378 AV654847 AV654272 AV656001 AI064740 T82897 N33594 AA344542 AW805054 AI207457 T61743 AA026737 H94389 AA382695 AA918409 T68044 S82092 T39959 A1017721 AA312395 AA312919 T40156 H66239 AV652989 H38728 R98521 AV655200 R95790 W03250 W00913 AA344136 AV660126 R97923 AA343596 AW470774 AV651256 N54417 AA812862 AW182929 A111192 H61463 H72060 AA344503 H38639 AI277511 AV661108 AI207625 T47810 Axa235252 T27853 T47778 R95746 N70620 AA701463 AW827166 R98475 C20925 AV657287 T71959 T71313 T73920 T73333 T61618 T69293 T69283 T73931 T72178 T72456 AV645639 AV653476 T72957 T72300 T58906 T71457 T70494 T72956 T70495 T68267 T74407 T85778 AA344726 T27854 T74485 T74101 T73868 T71518 T72304 AA343853 T73909 T68070 T72065 H72149 T73493 T73495 AV645993 R02293 T70475 T64751 AA344441 AA343657 AA345732 AA344328A) 110639 AA344603 AF063513T64696 T68516 T72223 T60507 T67633 R29500 T72517 R02292 T60599 T69206 T70452 T74677 R29366 T61277 T74914 T60352 R29675 T74843 AV645792 AA344408 T69197 T72057 T69368 T69358 T68258 AV650429 T73341 T61702 T74598 T40095 K02272 T40106 AA343045 AA341908 AA341907 AA342807 AA341964 T53747 T72042 T62764 A1064899 AA343060 T67832 T72440 T71770 T68091 T69108 T72449 T69167 T71289 T68251 AV654844 T64375 AA345234 T67598 AA011414 T68036 H48262 AI207557 T68219 W86031 T69081 T64232 R93196 T62136 AV650539 H67459 T72978 AA344583 T60362 H5821 T95711 T72803 T68055 T71715 R29036 T72793 T69122 T64595 T62888 T69139 T68291 T6465 T67971 T46862 AA693592 A1248502 R29454 T64764 T57001 T73052 T71429 T51176 T58866 AV655414 H90426 AA342489 T73666 T67848 T72512 T53835 T67837 T73317 T74273 T69420 T68245 T74380 T67862 T74474 T56068 419936 1891811 M792788BE142230AA252019 421582 2041_1 AI910275 X00474 X52003 X05030 NM_003225 AA314326 AA308400 AA506787 AA314825 AI571948 AA507595 AA614579 AA587613 R83818 AA568312 AA614409 AA307578 AI925552 AW950155 AI910083 M12075 BE074052 AW004668 AA578674 AA582084 BE074053 B074126 BE074140 AA514776 AA588034 BE074051 BE074068 AW009769 AW050690 AA858276 R55389 AI001051 AW050700 AW750216 AA614539 BE074045 AI307407 AW602303 BE073575 AI202532 AA524242 AI970839 AI909751 BE076078 AI909749 R55292 422128 211994_1 AW881145 AA490718 M85637 AA304575 T06067 AA331991 423034 224122_1 AL119930 M320696 AW752565 423816 23234_1 AL031985 AL137241 AI792386 AI733664 A1857654 A1049911 424200 236595J AA337221AA336756AW966196 424999 245835_1 AW953120R56325M349562 426966 273896_1 AI493134 AI498691 AW771508 AI498457 AI768408 AI783624 AI383985 AI580267 D79813 AA393768 426991 27415-1 AK001536 AA191092 AW510354 AI554256 AL353968 AA134266 427260 276598J AA663848AA400100AA401424 428023 28589_2 AL038843 AA161338 BE268213 AA425597 N87306 AA092969 BE566038 AA247451 N47392 AI928802 AW182584 AW027872 AI819831 AI936994 W56258 AI653448 AI278611 AI283557 AI824306 AW338658 AW150899 AA687514 N47393 N29885 AA973469 A1038904 A1292064 A1034339 AW674593 N72156 AI079733 AI038683 AI291616 AA491599 AA993675 AA837380 BE006554 BE006473 A1087090 T33044 AA652043 AI203503 AA583959 W35283 AI129926 Z41844 AW020925 AW575848 AI684603 AA493297 AI140689 AI277175 AA425444 AI932767 W02632 BE396786 R37261 429220 301384_1 AW207206 AW341473 AA448195 AI951341 429978 311501 AA249027 AL038984AK001993 AL080066 AV652725 BE566226 AA345557 AA315222 AA090585 AA375688 AA301092 AA298454 W05762 AW607939 H51658 D83880 N84323 BE296821 AW947007 D61461 AW079261 AA329482AW901780Ai354442AA772275 R31663A) 354441 Al767525 H92431 AI916735 H93575 AI394255 AW014741 AI573090 C06195 AW612857 AW265195 AI339558 AI377532 AI308821 AI919424 AI589705 AW055215 At336532 A1338051 AA806547 C75509 C00618 AW071172 AW769904 AA630381 AI678018 AI863985 D79662 BE221049 AW265018 AI589700 AW196655 N76573 AI370908 BE042393 N75017 AI698870 AW960115 430439 31808_1 AL133561 AL041090AL117481 AL122069AW439292A1968826 430935 3257721 AW072916 AI184913 AA489195 AW466994 AW469044 N59350 AI819642 AI280239 AI220572 AA789302 AI473611 AW841126 D60937 431089 327825 1 BE041395AA491826AA621946AA7159SOAA666102 431322 331543_1 AW970622 AA503009 AA502998 AA502989 AA502805 T92188 432407 34624_1 AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627 AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904 C16859 434414 38585_1 AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 Al829309 AW991957 N66951 AA527374 H66215 AA045564 A1694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570 436608 43261_3 AA628980 AI126603 BE504035

438091 44964 1 AW373062 T55662 AI299190 BE174210 AW579001 H01811 W40186 R67100 AI923886 AW952164 AA628440 AW898607 AW898616 AA709126 AW898628 AW898544 AA947932 AW898625 AW898622 AI276125 AI185720 AW510698 AA987230 T52522 BE467708 AW243400 AW043642 A ! 288245 A1186932 D52654 D55017 D52715 D52477 D53933 D54679 AI298739 AI146984 AI922204 N98343 BE174213 AA845571 AI813854 AI214518 AI635262 AI139455 AI707807 AI698085 AW884528 A1024768 A1004723 AW087420 Al585133 N94964 Al268939 AW513280AI061126 AI435818 AI859106 AI360506 AI024767 AA513019 AA757598 X56196 AA902959 AI334784 AI860794 AA010207 AW890091 AW513771 AI951391 AI337671 T52499 AA890205 AI640908 H75966 AA463487 AA358688 AI961767 AI866295 AA780994 AI985913 BE174196 AA029094 AW592159 T55581 N79072 AI611201 AA910812 AI220713 AW149306 AI758412 AA045713 R79750 N76096 439000 467716_1 AW979121 AA847986 AA829098 439285 47065_1 AL133916 N79113 AF086101 N76721 AW950828 AA364013 AW955684 AI346341 AI867454 N54784 AI655270 AI421279 AW014882 AA775552 N62351 N59253 AA626243A1341407 BE175639AA456968A) 358918AA457077 439780 47673_1 AL109688 R23665 R26578 441128 51021_2 AA570256 AW014761 AA573721 AI473237 AI022165 AA554071 AA127551 N90525 AW93623 AA447991 AA243852 BE328850 AI148171 Ai359627Ai005068Ai356567AA232991 AW016855AA906902AA233101 AA127550 BE512923 443068 558874_1 AI188710 AI032142 AW078833 N30308 AW675632 AI219028 AI341201 N22181 H9530 443947 586160 1 W24187 W24194 R17789 447636 7301 1 Y10043 NM 005342 L05085 AL034450 BE614226 AW749053 AA379173 AA248230 BE514634 AA34622 R70656 AA367593 AA214649 AA369318 AW957081 R05760 AA039903 AI886597 AW630122 AA906264 AA041527 R01145 AI088688 BE463637 AA398795 AI354883 AI768938 AI569996 AI452952 AI168582 AI189869 AI086670 AW262560 AW613854 AA862839 AA435840 AA670197 A1024032 AI990659 AI990089 N81095 AA847919 AW960150 AA21107 AA044704 AA367594 AW582587 AW858854 AW818630 AW818281 AW818433 AW582595 AA096002 N83992 448993 79225 1 A1471630 BE540637 BE265481 AW407710 BE513882 BE546739 AA053597 BE140503 BE218514 AW956702 AI656234 AI636283 AI567265 AW340858 BE207794 AA053085 R69173 AA292343 AA454908 AA293504 AI659741 AI927478 AA399460 AI760441 AA346416 BE047245 AA730380 AA394063 AA454833 AI982791 AI567270 AI813332 AI767858 AA427705 D20284 AI221458 BE048537 A1263048 AA346417 AA911497 BE537702 449305 804424_1 Al638293 AW813561 451105 859083 1 Al761324AW880941AW880937 451320 86576_1 AW118072 AI631982 T15734 AA224195 AI701458 W20198 F26326 AA890570 N90552 AW071907 AI671352 AI375892 T03517 R88265 AI24088 AA224388 AI084316 AI354686 T33652 A140719 AI720211 T03490 AI372637 T15415 AW205836 AA630384 T03515 T33230 AA017131 AA443303 T33623 AI222556 T33511 T33785 AI419606 D55612 451807 8865_1 W52854AL117600 BE208116 BE208432BE206239 BE082291 AW953423 AA351619 BE180648 BE140560W60080AA865478 N90291 AW450652 AW449519 AA993634 Al806539 AA351618 AW449522 A ! 827626 AA904788 AA380381 AA886045 AA774409 BE003229 Z41756 452410 9163_1 AL133619 AA468118 AA383064 AI476447 T09430 AI673758 AA524895 AI581345 AI300820 AW498812 AA256162 A1559724 A1685732 AA602400 AA905453 AI204595 AW166541 AA157456 AA156269 AA383652 AA431072 AW592707 AI435410 AW272464 AI215594 AA622747 R74039 N35031 AI804128 AW513621 AA868351 AI026826 AI493388 AA61464 W81604 AI567080 AI214351 AA730140 AI125754 AI200813 AI269603 AI565082 AI807095 AI476629 AA505909 AI368449 AI686077 AI582930 AW085038 AA757863 AA730154 A1767072 M466316 A1734130 AI734138 AA426284 AA433997 A1741241 AW043563 A) 732741 A) 732734 AA437369 AA425820 AA664048 R74130 454241 10678071 BE144666BE184942AW238414BE184946 455175 1257335_1 AW993247AW861464 456237 168730_1 AA203682 R11958 458098 47395_1 BE550224 AA832519 N45402 AW885857 N29245 BE465409 W07677 AW970089 AI299731 AA482971 BE503548 H18151 W79223 AF086393 AA461301 W74510 R34182 A1090689 N46003 BE071550 R28075 AW134982 AI240204 AI138906 AW026179 AI572316 BE466182 AI206395 AI276154 AI273269 AI42287 AI371014 AI188525 AA939164 BE549810 AW137865 AI694996 BE503841 AA459718 BE327407 BE467534 BE218421 BE467767 AA989054 BE467063 AI797130 BE327781 TABLE 9C Pkey: Unique number corresponding to an Eos probeset Ref : Sequence source. The 7 digit numbers in this column are Genbank identifier 9GI) numbers."Dunham I. et al."refers to the publication entitled'The DNA sequence of human chromosome 22.'Dunham ì. et al., Nature (1999) 402: 489-495.

Strand: indicates DNA strand from which exons were predicted.

Nt_position : Indicates nucleoude posifions of predicted exons.

Pkey Ref Strand NLposition 400512 9796593 Minus 1439-1615 400517 9796686 Minus 4999mu346 400560 9843598 Plus 94182-94323,97056-97243, 101095-101236,102824-103005 400664 8118496 Plus 13558-13721, 13942-14090, 14554-14679 400665 8118496 Plus 16879-17023 400666 8118496 Plus 17982-18115,20297-20456 400749 7331445 Minus 9162-9293 400763 8131616 Minus 35537-35784 401027 7230983 Minus 70407-70554, 71060-71160 401093 8516137 Minus 22335-23166 401203 9743387 Minus 172961-173056, 173868-173928 401212 9858408 Plus 87839-88028 401411 7799787 Minus 144144-144329 401435 8217934 Minus 54508-55233 401464 6682291 Minus 170688-170834 401714 6715702 Plus 96484-96681 401747 9789672 Minus 118596-118816, 119119-119244, 119609-119761,120422-120990, 130161-130381, 130468-130593,131097-131258,131866- 131932, 132451-132575, 133580-134011 401760 9929699 Plus 83126-83250,85320-85540,94719-95287 401780 7249190 Minus 28397-28617,28920-29045, 29135-29296,29411-29567,29705-29787,30224-30573 401781 7249190 Minus 83215-83435, 83531-83656, 83740-83901, 84237-84393,84955-85037,86290-86814 401785 7249190 Minus 165776-165996, 166189-166314, 166408-166569, 167112-167268, 167387-167469, 168634-168942 401797 6730720 Plus 6973-7118 401961 4581193 Minus 124054-124209 401985 2580474 Plus 61542-61750 401994 4153858 Minus 42904-43124,43211-43336,44607-44763,45199-45281,46337-46732 402075 8117407 Plus 121907-122035,122804-122921,124019-124161,124455-124610,1256 72-126076 402260 3399665 Minus 113765-113910, 115653-115765,116808-116940 402265 3287673 Plus 21059-21168 402297 6598824 Plus 35279-35405, 35573-35659 402408 9796239 Minus 110326-110491

402420 9796339 Plus 129750-129919 402674 8077108 Minus 39290-39502 402802 3287156 Minus 53242-53432 402994 2996643 Minus 4727-4969 403137 9211494 Minus 92349-92572,92958-93084,93579-93712, 93949-94D72, 94591-94748, 95214-95337 403306 8099945 Plus 127100-127251 403329 8516120 Plus 96450-96598 403381 9438267 Minus 26009-26178 403478 9958258 Plus 116458116564 403485 9966528 Plus 2888-3001, 3198 3532, 365S4117 403627 8569879 Minus 23868-24342 403715 7239669 Plus 85128-85292 404044 9558573 Minus 225757-225939 404076 9931752 Minus 3848-3967 404101 8076925 Minus 125742-125997 404140 9843520 Plus 37761-38147 404165 9926489 Minus 69025-69128 404185 4572584 Minus 129171-129327 404210 5006246 Plus 169926-170121 404253 9367202 Minus 55675-56055 404287 2326514 Plus 53134-53281 404298 9944263 Minus 73591-73723 404347 9838195 Plus 74493-74829 404440 7528051 Plus 80430-81581 404721 9856648 Minus 173763-174294 404794 4826439 Plus 101619-101898 404854 7143420 Plus 14260-14537 404877 1519284 Plus 1095-2107 404927 7342002 Plus 68690-69563 404996 6007890 Plus 37999-38145, 38652-38998, 39727-39872, 40557-40674, 42351-42450 405449 7622497 Plus 42236-42570 405568 6006906 Plus 35912-36065 405572 3800891 Pius 85230-85938 405646 4914350 Pius 741-969 405676 4557087 Plus 73195-73917 405770 2735037 Plus 61057-62075 405932 7767812 Minus 123525-123713 406137 9166422 Minus 30487-31058 406360 9256107 Minus 7513-7673 406399 9256288 Minus 63448-63554 406467 9795551 Plus 182212-182958 TABLE 10A : Potential Therapeutic, Diagnostic and Prognostic targets for Therapy of Lung Cancer and Non-malignant Lung Disease Table 2A shows about 307 genes up-regulated in non-malignant lung disease relative to lung tumors and normal body tissues and/or down-regulated in lung tumors relative to normal lung and non-malignant lung disease. These genes were selected from about 59680 probesets on the Eos/Affymetrix Hu03 Genechip array.

Table 108 show the accession numbers forthcse Pkey's lacking UnigenelD's for table 10A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession"column, Table 10C show the genomic positioning for those Pkey's lacking Unigene ID's and accession numbers in table 10A. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey, i Unique Eos probeset identifier number ExAccn : Exemplar Accession number, Genbank accession number UnigenelD : Unigene number Unigene Title : Unigene gene title R1 : Average of lung tumors (including squamous cell carcinomas, adenocarcinomas, small cell carcinomas, granulomatous and carcinoid tumors) divided by the average of normal lung samples R2: Average of non-malignant lung disease samples (including bronchitis, emphysema, fibrosis, atelectasis, asthma) divided by the average of normal lung samples Pkey ExAccn UnigenelD Unigene Title R1 R2 404394 ENSP00000241075 : TRRAP PROTEIN. 0.79 3. 10 404916 Target Exon 1.00 159. 00 405257 Target Exon 1.00 422.00 407228 M25079 Hs. 155376 hemoglobin, beta 0. 47 2.33 407568 AA740964 Hs. 62699 ESTs 1.00 123.00 408562 A) 436323 Hs. 31141 Homo sapiens mRNA for KIAA1568 protein, 1.00 230. 00 409031 AA376836 Hs. 76728 ESTs 1.00 128.00 410434 AF051152 Hs. 63668 toll-like receptor 2 39.65 149. 00 410467 AF102546 Hs. 63931 dachshund (Drosophila) homotog 1.00 109.00 410808 T40326 Hs. 167793 ESTs 1.14 13. 14 412351 AL135960 Hs. 73828 T-cell acute Iymphocyüc leukemia 1 0. 37 2. 27 412372 R65998 Hs. 285243 hypothetical protein FU22029 1.00 173.00 413795 AL040178 Hs. 142003 ESTs 0.10 11.90 414154 AW205314 Hs. 323060 ESTs 0.62 2. 09 414214 D49958 Hs. 75819 giycoprotein M6A 0.03 4.55 414998 NM_002543 Hs. 77729 oxidised low density lipoprotein (jecun 0.64 2.97 415122 D60708 Hs. 22245 ESTs 0.07 8.97 415765 NM005424 Hs. 78824 tyrosine kinase with immunoglobulin and 0. 67 1. 65 415775 H00747 Hs. 29792 ESTs, Weakly similar to 138022 hypotheti 0.29 2.64 415910 U20350 Hs. 78913 chemokine (CX3-C) receptor1 1.00 145.00

416319 A1815601 Hs. 79197 CD83 antigen (activated 8 lymphocytes, i 15.32 237.00 416402 NM_000715 Hs. 1012 complement component 4-binding protein, 0.64 4.00 417355 D13168 Hs. 82002 endothelin receptor type 8 0.01 3.90 417421 AL138201 Hs. 82120 nuclear receptor subfamily 4, group A, m 36.30 357.00 417511 AL049176 Hs. 82223 chordin-like 1.00 179.00 418489 U76421 Hs. 85302 adenosine deaminase, RNA-specific, B1 (h 0.02 6. 00 418726 BE241812 Hs. 87860 protein tyrosine phosphatase, non-recept 1.00 113.00 418741 H83265 Hs. 8881 ESTs, Weakly similar to S41044 chromosom 0.44 1.90 418883 BE387036 Hs. 1211 acid phosphatase 5, tartrate resistant 0. 96 2.04 419086 NM_000216 Hs. 89591 Kallmann syndrome 1 sequence 0.62 2.74 419150 T29618 Hs. 89640 TEK tyrosine kinase, endothelial (venous 0.03 6.90 419235 AW470411 Hs. 288433 neurotrimin 1.48 5.13 419407 AW410377 Hs. 41502 hypothetical protein FLJ21276 37.55 336.00 420556 AA278300 Hs. 124292 Homo sapiens cDNA : FLJ23123 fis, clone L 0.80 3.65 420656 AA279098 Hs. 187636 ESTs 1.65 8.07 420729 AW964897 Hs. 290825 ESTs 2.99 25.82 421177 AW070211 Hs. 102415 HomosapiensmRNA ; cDNADKFZp586N0121 (f 0.46 1.95 422060 R20893 Hs. 325823 ESTs, Moderately similar to ALU5_HUMAN A 1.00 156.00 422426 W79117 Hs. 58559 ESTs 0.03 7.44 422652 AW967969 Hs. 118958 syntaxin 11 0.14 3.62 423099 NM_002837 Hs. 123641 proteinbrosinephosphatase, receptort 0.01 3.16 424433 H04607 Hs. 9218 ESTs 0.75 141.75 424585 AA464840 Hs. 131987 ESTs 1. 00 167.00 424711 NM 005795 Hs. 152175 caicitonin receptor-tike 0. 43 3.01 424973 X92521 Hs. 154057 matrixmetalloproteinase 19 0. 37 19.45 425023 AW956889 Hs. 154210 endothelial differentiation, sphingolipi 0.14 3.35 425664 Al006276 Hs. 159003 transient receptor potential channel 6 1.00 94.00 425998 AU076629 Hs. 165950 fibroblast growth factor receptor 4 0.68 1.42 426657 NM_015865 Hs. 171731 solute carrier family 14 (urea transport 0.03 3. 74 426753 T89832 Hs. 170278 ESTs 1.00 141.00 427558 D49493 Hs. 2171 growth differentiation factor 10 1.00 117.00 427983 M17706 Hs. 2233 colony stimulating factor 3 (granulocyte 0.75 2.20 428467 AK002121 Hs. 184465 hypothetical protein FLJ11259 0.76 2.25 428927 AA441837 Hs. 90250 ESTs 0.01 3.62 429496 AA453800 Hs. 192793 ESTs 1. 00 138. 00 430468 NM_004673 Hs. 241519 angiopoietin-like 1 1. 00 132.00 431385 BE178536 Hs. 11090 membrane-spanning 4-domains, subfamily A 1.00 157. 00 431728 NM_007351 Hs. 268107 multimerin 1.00 157.00 431848 A1378857 Hs. 126758 ESTs, Highly similar to AF1752831 zinc 0.34 2.24 432128 AA127221 Hs. 117037 ESTs 0.00 1. 15 432519 AI221311 Hs. 130704 ESTs, Weakly similar to BCHUIA S-100 pro 0.01 2.06 433043 W57554 Hs. 125019 lymphoid nuclear protein (LAF-4) mRNA 1.00 267.00 433803 AI823593 Hs. 27688 ESTs 1.00 105.00 434730 AA644669 Hs. 193042 ESTs 1.05 3.15 435472 AW972330 Hs. 283022 triggering receptor expressed on myeloid 0.83 1.94 436532 AA721522 gb: nv54hl2. r1 NCl_CGAP_Ew1 Homo sapiens 1.00 218.00 437119 AI379921 Hs. 177043 ESTs 1. 00 133.00 437140 AA312799 Hs. 283689 activator of CREM int estis 0.67 122.67 437211 AA382207 Hs. 5509 ecotropic viral integration site 2B 1. 00 142.00 437960 A1669586 Hs. 222194 ESTs 1.00 147. 00 438202 AW169287 Hs. 22588 ESTs 1.00 141.00 438873 AI302471 Hs. 124292 Homo sapiens cDNA : FU23123 fis, clone L 0.71 3.66 438875 AA827640 Hs. 189059 ESTs 23.32 370.00 441048 AA913488 Hs. 192102 ESTs 0.77 8.50 441188 AW292830 Hs. 255609 ESTs 3. 43 16.36 441499 AW298235 Hs. 101689 ESTs 1.00 167.00 444513 AL120214 Hs. 7117 g ! utamatereceptor, ionotropic, AMPA1 1.00 151. 00 444527 NM_005408 Hs. 11383 small inducible cytokine subfamily A (Cy 46.47 153.00 444561 Nom004469 Hs. 11392 c-fos induced growth factor (vascular en 0.01 3. 08 445279 R41900 Hs. 22245 ESTs 0.60 141. 00 446017 N98238 Hs. 55185 ESTs 0. 18 2.39 446984 AB020722 Hs. 16714 Rho guanine exchange factor (GEF) 15 0.10 2. 16 446998 N99013 Hs. 16762 Homo sapiens mRNA ; cDNA DKFZp564B2062 (f 0.01 2.53 447357 A1375922 Hs. 159367 ESTs 0.46 2.64 448106 AI800470 Hs. 171941 ESTs 18.05 296.00 448253 H25899 Hs. 201591 ESTs 1.00 141.00 449275 AW450848 Hs. 205457 periaxin 0. 56 1.38 450400 AI694722 Hs. 279744 ESTs 0.88 4.33 450696 AI654223 Hs. 16026 hypothetical protein FLJ23191 0.52 2.08 450726 AW204600 Hs. 250505 retinoic acid receptor, alpha 0. 79 2.01 451497 H83294 Hs. 284122 Wnt inhibitory factor-1 0.35 2. 03 451533 NM 004657 Hs. 26530 serum deprivation response (phosphatidyl 0.13 2.25 453636 R67837 Hs. 169872 ESTs 1.00 116.00 458332 AI000341 Hs. 220491 ESTs 1.00 192.00 459580 AA022888 Hs. 176065 ESTs 0.20 2.98 400269 Eos Control 0. 40 2.40 403421 NM_016369-: Homosapiensclaudinl8 (CLDN 0.53 1.77 407570 Z19002 Hs. 37096 zinc finger protein 145 (Kruppel-like, e 0.01 3.18 412295 AW088826 Hs. 117176 poly (A)-binding protein, nuclear 1 0.56 1.74 414517 M24461 Hs. 76305 surfactant, pulmonary-associated protein 0.64 1.50 417204 N81037 Hs. 1074 surfactant, pulmonary-associated protein 0.33 1.16 418307 U70867 Hs, 83974 solute camer family 21 (prostaglandin 0.53 1.55 418935 T28499 Hs. 89485 carbonic anhydrase IV 0.20 1.28 421502 AF111856 Hs. 105039 solute carrier family 34 (sodium phospha 0.78 1.90 421798 N74880 Hs. 29877 N-acylsphingosine amidohydrolase (acid c 0.59 1.54

423354 AB011130 Hs. 127436 calcium channel, voltage-dependent, alph 0.59 1.55 423738 AB002134 Hs. 132195 airway trypsin-like protease 10.14 51.00 425211 M18667 Hs. 1867 progastricsin (pepsinogenC) 0.35 1.62 425438 T62216 Hs. 270840 ESTs 0.23 9.45 426828 NM_000020 Hs. 172670 activin A receptor type II-like I 0.03 1.71 427019 AA001732 Hs. 173233 hypothetical protein FLJ10970 0.01 1.49 428043 T92248 Hs. 2240 uteroglobin 0.42 1.26 430280 AA361258 Hs. 237868 interleukin 7 receptor 0.46 2. 43 431433 X65018 Hs. 253495 surfactant, pulmonary-associated protein 0.57 1. 59 431723 AW058350 Hs. 16762 HomosapiensmRNA ; cDNA DKFZp56482062 (f 0. 29 1.80 432985 T92363 Hs. 178703 ESTs 0.32 2.27 441835 AB036432 Hs. 184 advanced glycosylation end product-speci 0.31 1.51 442275 AW449467 Hs. 54795 ESTs 0.55 1.78 443709 A1082692 Hs. 134662 ESTs 0.00 3.02 444325 AW152618 Hs. 16757 ESTs 0.32 2.49 450954 A) 904740 Hs. 25691 receptor (calcitonin) activity modifying 0.46 1.74 451558 NM_001089 Hs. 26630 ATP-binding cassette, sub-family A (ABC1 0.52 1.87 453310 X70697 Hs. 553 solute carrier family 6 (neurotransmitte 0.00 3. 30 456855 AF035528 Hs. 153863 MAD (mothers against decapentaplegic, Dr 0.01 2.31 444342 NM 014398 Hs. 10887 similar to lysosome-associated membrane 0.66 2.20 400754 Target Exon 1.00 297.00 401045 C11001883' : gi#6753278#ref#NP_033938.1#c 1. 00 109.00 401083 NM016582' : Homosapienspeptdetranspor Q89 1.39 402474 NM_004079 : Homo sapiens cathepsin S (CTSS 1. 45 4.47 402808 ENSP00000235229 : SEMB. 1.00 1.87 403021 C21000030: gi#9955960#ref#NP_063957.1#AT 1.00 149. 00 403438 NM031419' : Homo sapiens molecule possess 1.06 2.96 403687 NM_007037* : Homo sapiens a disintegrin-li 0.04 4. 89 403764 NM005463 : Homo sapiens heterogeneous nuc 1.00 225.00 404277 NM_019111* : Homo sapiens major histocompa 0.97 1.93 404288 NM_002944* : Homo sapiens v-ros avian UR2 1.00 68. 00 404518 AI815601 CD83 antigen (activated B lymphocytes, i 0.02 1.83 405106 Cl 1001637* : gii5O32241 #5032241#ref#NP_005732.1#z 1.00 235.00 405381 Target Exon 1.00 93.00 406387 Target Exon 1.37 6.02 406646 M33600 major histocompatibility complex, class 0.86 2.46 406714 Api219304 Hs. 266959 hemoglobin, gamma G 0.01 3.19 406753 AA505665 Hs. 217493 annexin A2 1.00 147.00 406973 M34996 Hs. 198253 major histocompatibility complex, class 1.03 2.04 407248 U82275 Hs. 94498 leukocyte immunoglobulin-like receptor, 1.00 64.00 407510 U96191 gb : Human trophoblast hypoxia-regulated f 1. 00 90.00 407731 Nom000066 Hs. 38069 complement component 8, beta polypeptide 1.00 67. 00 407830 NM_001086 Hs. 587 arylacetamide deaceblase (esterase) 1. 00 102.00 408045 AW138959 Hs. 245123 ESTs 1.00 70. 00 408074 R20723 ESTs 1. 00 112.00 408374 AW025430 Hs. 155591 forkhead box F1 0.07 10.17 409064 AA062954 Hs. 141883 ESTs 0.39 2.31 409083 AF050083 Hs. 673 interleukin 12A (natural killer cell sti 1, 00 95. 00 409153 W03754 Hs. 50813 hypothetical protein FLJ20022 0.01 4.55 409203 AA780473 Hs. 687 cytochrome P450, subfamily IVB, polypept 0.01 3.72 409238 AL049990 Hs. 51515 HomosapiensmRNA ; cDNADKFZp564G112 (fr 1.00 79.00 409389 AB007979 Hs. 301281 Homo sapiens mRNA, chromosome 1 specific 0.14 27. 35 409718 D86640 Hs. 56045 src homology three (SH3) and cysteine ri 1.00 113.00 410798 BE178622 Hs. 16291 gb: PM3-HT0605-270200-001-a02 HT0605 Homo 0.64 2. 47 411020 NM006770 Hs. 67726 macrophage receptor with coliagenous str 0. 55 2.40 411667 BE160196 gb: QV1-HT0413-010200-059-hO3HT0413Homo 1.00 111.00 412000 AW576555 Hs. 15780 ATP-binding cassette, sub-family A (ABC1 1.00 95.00 412358 BE047490 Hs. 24172 ESTs 1.00 87.00 412420 AL035666 Hs. 73853 bone morphogenetic protein 2 1. 43 8. 07 412564 X83703 Hs. 31432 cardiac ankyrin repeat protein 0.02 3.07 412869 AA290712 Hs. 82407 CXC chemokine ligand 16 0.93 1.72 412870 N22788 Hs. 82407 CXC chemokine ligand 16 0.97 1.51 413529 U11874 Hs. 846 interleukin 8 receptor, beta 0.02 2.42 413533 BE146973 gb: QV4-HT0222-011199-019-e05 HT0222 Homo 0.65 1. 50 413689 BE157286 Hs. 20631 zinc finger protein, subfamily 1A, 5 (Pe 20.87 232.00 413724 AA131466 Hs. 23767 hypothetical protein FLJ12666 1.00 80. 00 413800 A1129238 Hs. 192235 ESTs 1.00 85.00 413802 AW964490 Hs. 32241 ESTs, Weakly similar to S65657 alpha-1C- 1. 00 213.00 413829 NM001872 Hs. 75572 carboxypeptidaseB2 (plasma) 0.02 3.93 414376 BE393856 Hs. 66915 ESTs, Weakly similar to 16. 7Kd protein 1. 00 115.00 414577 A1056548 Hs. 72116 hypothetical protein FLJ20992 similar to 0.49 1.94 414700 H63202 Hs. 38163 ESTs 0. 03 3. 75 415078 AA311223 Hs. 283091 found in inflammatory zone 3 0.86 1.95 415120 N64464 Hs. 34950 ESTs 1. 00 120.00 415323 BE269352 Hs. 949 neutrophilcytosolic factor2 (65kD, chr 0.60 2.48 415335 AA847758 Hs. 111030 ESTs 1.00 95. 00 415582 W92445 Hs. 165195 Homo sapiens cDNA FLJ 14237 fis, clone NT 1.00 136.00 416030 H15261 Hs. 21948 ESTs 0.02 8.07 416427 BE244050 Hs. 79307 Rac/Cdc42 guanine exhcange factor (GEF) 1. 00 73.00 416464 NM 000132 Hs. 79345 coagulationfactorVlil, procoagulantco 0. 70 3.36 416585 X54162 Hs. 79386 teiomodin 1 (smooth muscle) 0.06 6.56 416847 L43821 Hs. 80261 enhancer of filamentation 1 (cas-like do 0.70 3.66 417148 AA359896 Hs. 293885 hypothetical protein FLJ14902 1.00 114.00 417370 T28651 Hs. 82030 tryptophanyl-tRNAsynthetase 0.85 1.30 417673 T87281 Hs. 16355 ESTs 0.15 15. 54

418067 A1127958 Hs. 83393 cystatnE/M 0.81 1.74 418296 C01566 Hs. 86671 ESTs 1.00 99.00 418643 J03798 Hs. 86948 small nuclear ribonucleoprotein D1 polyp 1. 00 60.00 418832 X04011 Hs. 88974 cytochrome b-245, beta polypeptide (chro 2. 40 14.74 418945 BE246762 Hs. 89499 arachidonate 5-lipoxygenase 0. 67 3. 16 419261 X07876 Hs. 89791 wingless-type MMTV integration site fami 1.00 73.00 419564 U08989 Hs. 91139 solutecanierfamily1 (neuronal/epithe 1.00 192.00 419574 AK001989 Hs. 91165 hypothetical protein 1.00 94.00 419968 X04430 Hs. 93913 interleukin 6 (interferon, beta 2) 61.16 500.00 420256 U84722 Hs. 76206 cadherin 5, type 2, VE-cadhedn (vascula 0, 52 1.70 420285 AA258124 Hs. 293878 ESTs, moderately similar to ZN91_HUMAN Z 1.00 172.00 420577 AA278436 Hs. 186649 ESTs 1.00 97.00 421262 AA286746 Hs. 9343 Homo sapiens DNA FLJ14265 fis, clone PL 1. 00 64.00 421445 AA913059 Hs. 104433 Homo sapiens, clone IMAGE : 4054868, mRNA 0.88 1.51 421470 R27496 Hs. 1378 annexin A3 0.05 11.26 421478 AI683243 Hs. 97258 ESTs, Moderately similar to S29539ribos 1.00 73.00 421563 NM_006433 Hs. 105806 granulysin 0.82 2.42 421566 NM_000399 Hs. 1395 early growth response 2 (Krox-20 (Drosop 5.50 31.57 421855 F06504 Hs. 27384 ESTs, Moderately similar to ALU4_HUMAN A 1.00 129.00 421913 AI934365 Hs. 109439 osteoglycin (osteoinductive factor, mime 1.00 101.00 421952 AA300900 Hs. 98849 ESTs, Moderately ysimilartoAF1815111 H 0.60 63.60 422232 D43945 Hs. 113274 transcrip6on factor EC 1.00 148.00 422386 AF105374 Hs. 115830 heparan sulfate (glucosamine) 3-0-sulfot 1.40 3.98 423168 R34385 Hs. 124940 GTP-binding protein 0.34 3.59 423196 AK001866 Hs. 125139 hypothetical protein FLJ11004 0.55 2.00 423387 AJ012074 vasoactiveintestinal pepGdereceptor 1 0. 09 2.13 423424 AF150241 Hs. 128433 prostaglandinD2synthase, hematopoietic 1. 00 141.00 423456 AL110151 Hs. 128797 DKFZP586D0824 protein 1.00 66.00 423696 Z92546 Sushidomain (SCRrepeat) containing 0. 73 1.27 424027 AW337575 Hs. 201591 ESTs 0.54 2.58 424212 NM_005814 Hs. 143131 glycoprotein A33 (transmembrane) 0.77 2.47 425087 R62424 Hs. 126059 ESTs 1.00 74.00 425175 AF020202 Hs. 155001 UNC13 (C. elegans)-like 0.85 1.96 425771 BE561776 Hs. 159494 Bruton agammaglobulinemia tyrosine kinas 1.18 2.56 426486 BE178285 Hs. 170056 HomosapiensmRNA ; cDNADKFZp586B0220 (f 1.00 76.00 427507 AF240467 Hs. 179152 to@@-like receptor 7 1.00 63.00 427618 NM_000760 Hs. 2175 colony stimulating factor 3 receptor (gr 0.60 2.19 427732 NM_002980 Hs. 2199 secretin receptor 0.97 1.42 427952 AA765368 Hs. 293941 ESTs, Moderately similar to A53959 throm 1.00 105.00 428709 BE268717 Hs. 104916 hypothetical protein FLJ21940 1.00 80.00 428769 AW207175 Hs. 106771 ESTs 0.09 2.55 428780 AI478578 Hs. 50636 ESTs 1.00 98. 00 428833 AI928355 Hs. 185805 ESTs 1.00 113. 00 429657 D13626 Hs. 2465 KIAA0001 gene product; putative G-protei 1.00 52.00 430212 AA469153 gb: nc67f04. s1 NCI_CGAP_Pr1 Homo sapiens 1.00 132.00 430226 BE245562 Hs. 2551 adrenergic, beta-2-, receptor, surface 0.11 15.60 430376 AW292053 Hs. 12532 chromosome 1 open reading frame 21 1.00 103.00 430414 AW365665 Hs. 120388 ESTs 0.50 6.96 430656 AA482900 Hs. 162080 ESTs 1.00 70.00 430843 AI734149 Hs. 119514 ESTs 1. 00 90. 00 430998 AF128847 Hs. 204038 indolethylamine N-methyltransferase 0.29 1.84 431217 NM013427 Hs. 250830 Rho GTPase activating protein 6 1.00 79.00 431921 N46466 Hs. 58879 ESTs 0.91 1.67 432176 AW090386 Hs. 112278 arrest, beta 1 0. 66 2.63 432203 AA305746 Hs. 49 macrophage scavenger receptor 1 1. 00 76.00 432231 AA339977 Hs. 274127 CLST 11240 protein 0.46 1.46 432485 N90866 Hs. 276770 CDW52 antigen (CAMPATH-1 antigen) 0.79 2. 25 432522 D11466 Hs. 51 phosphatidylinositol glycan, class A (pa 1.93 4.83 432596 AJ224741 Hs. 278461 matrilin 3 0. 04 5.79 432850 X87723 Hs. 3110 anglotensin receptor 2 1. 00 167.00 433138 AB029496 Hs. 59729 semaphorin sem2 0.04 9.16 433563 Api732637 Hs. 277901 ESTs 1.00 91.00 433588 A1056872 Hs. 133386 ESTs 120. 16 315.00 434445 AI349306 Hs. 11782 ESTs 0.60 1.84 435496 AW840171 Hs. 265398 ESTs, Weakly similar to transformation-r 1.00 128.00 435974 U29690 Hs. 37744 Homo sapiens beta-1 adrenergic receptor 1.00 108. 00 436061 Api248584 Hs. 190745 HomosapienscDNA : FLJ21326 fis, clone C 1.00 91. 00 437157 BE048860 Hs. 120655 ESTs 1.00 87.00 437207 T27503 Hs. 15929 hypothetical protein FLJ12910 1.00 105. 00 437311 AA370041 Hs. 9456 SWI/SNF related, matrix associated, acti 1.00 71.00 437439 H29796 Hs. 269622 ESTs 1.00 115.00 438199 AW016531 Hs. 122147 ESTs 1.00 80.00 439551 W72062 Hs. 11112 ESTs 0.30 3.10 440515 AJ131245 Hs. 7239 SEC24 (S. cerevisiae) related gene famil 1.00 77. 00 440887 AI799488 Hs. 135905 ESTs 1.00 85.00 441025 AA913880 Hs. 176379 ESTs 1.00 82.00 441384 AA447849 Hs. 288660 Homo sapiens cDNA : FLJ22182 fis, clone H 0.79 1.89 441735 AI738675 Hs. 127346 ESTs 1.00 75. 00 442200 AW590572 Hs. 235768 ESTs 0.78 5.83 442832 AW206560 Hs. 253569 ESTs 0.03 10.88 442957 A1949952 Hs. 49397 ESTs 1. 00 70.00 443282 T47764 Hs. 132917 ESTs 1.00 197.00 443547 AW271273 Hs. 23767 hypothetical protein FLJ12666 1.00 253.00 443951 F13272 Hs. 111334 festin. light polypeptide 0.55 2.09 444330 At597655 Hs. 49265 ESTs 1. 00 90. 00

444515 AW204908 Hs. 169979 ESTs 1.00 84.00 445769 AI741471 Hs. 23666 ESTs 0. 02 4. 38 445908 R13580 Hs. 13436 Homo sapiens clone 24425 mRNA sequence 1.00 97.00 446291 BE397753 Hs. 14623 interferon, gamma-inducible protein 30 0. 93 1.69 446917 A1347863 Hs. 156672 ESTs 1.00 106.00 447261 NM 006691 Hs. 17917 extracellularlinkdomain-containing 1 0.40 47.20 447432 AW958473 Hs. 301957 nudix (nucleoside diphosphate linked moi 1.00 100. 00 447482 AB033059 Hs. 18705 Maza1233 protein 0.05 8.21 447997 H00656 Hs. 29792 ESTs, Weakly similar to 138022 hypotheti 0.02 5.42 448299 AA497044 Hs. 20887 hypothetical protein FLJ10392 1.00 79.00 448782 AL050295 Hs. 22039 KIAA0758 protein 0.42 1.56 450575 NM 005859 Hs. 29117 purine-rich element binding protein A 0.17 11.33 450584 M040403 Hs. 60371 ESTs 1.00 94.00 450693 AW450461 Hs. 203965 ESTs 1.00 91.00 450715 AI266484 Hs. 31570 ESTs, Weakly similar to KIAAL 324 protein 1.00 15ZOO 451103 R52804 Hs. 25956 DKFZP564D06 protein 1.00 86.00 451220 AF124251 Hs. 26054 novel SH2-containing protein 3 0.60 1.30 451668 Z43948 Hs. 326444 cartilage acidic protein 1 0.54 1. 91 452197 AW023595 Hs. 232048 ESTs 1.00 67.00 452331 AA598509 Hs. 29117 purine-rich element binding protein A 4.53 11.07 452353 C18825 Hs. 29191 epithelialmembraneprotein2 0. 72 Z24 453049 BE537217 Hs. 30343 ESTs 1.00 68.00 453107 NM_016113 Hs. 279746 vanilloid receptor-like protein 1 0.83 1.70 453355 AW295374 Hs. 31412 Homo sapiens cDNA FLJ11422 fis, clone HE 1.00 132.00 453390 AA862496 Hs. 28482 ESTs 1. 00 72.00 453531 AA417940 ESTs, Weakly similar to JC5795 CDEP prot 1.00 68.00 454741 BE154396 gb: CM2-HT0342-091299-050-b05 HT0342 Homo 0.57 2. 89 456579 AA287827 Hs. 284205 up-regulated by BCG-CWS 1.00 82.00 456672 AK002016 Hs. 114727 Homo sapiens, clone MGC : 16327, mRNA, com 0. 79 1.96 457400 AP032906 Hs. 252549 cathepsin Z 1.03 3.25 457718 F18572 Hs. 22978 ESTs, Weakly similar to ALU4_HUMAN ALU S 1.00 113.00 459696 F03027 gb: HSC1KA072 normalized infant brain cDN 1.00 544.00 TABLE 10B Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT Number Accession 408074 103684_1 R20723 AA263003 M333976 AA334725 AA334151 AW965490 AA310513 AI810530 D31302 AW134897 AA830127 AA046953 AI668930 C06094AW104534 411667 1253334_1 BE160198 AW935898 T11520 AW935930 AW856073 AW861034 413533 1375344_1 BE146973 BE146972 BE147042 BE147018 BE146783 BE147020 BE146781 BE147019 BE146766 BE147021 BE146952 BE146767 BE147044 BE146797 BE146776 BE146985 BE146793 BE146768 BE146771 BE146954 BE146760 BE147048 BE147025 BE147030 423387 22779 1 AJ012074 U11087 L13288 X75299 L20295 AW630780 H14880 T28037 AI872991 R72136 AW449839 T81622 T79697 T29519 R94105 T83923 R73300 A1797007 R73390 M961010 H74168 AI689932 BE045543 At808418 A1608912 A1806573 AW884084 AW872978 AW872985 AA565655 A1022915 R50647 R73210 H45098 R46451 AW166269 T71132Ai264547 R52146 Ai304920 R73391 AW884059 AW884085 H73241 T60038 T79612 R73145 R50549 AI094557 AI668793 R72302 AI564366 W01956 AA418962 W32571 R72840 H45409 R72085 R46356 R46758 AA508805 AA418798 T83751 R94072 T16182 AA928785 AA903896 423696 23112_1 Z92546 AA330586 AI570568 AW341487 AI827050 AW298668 AI792189 AI015693 AI733599 AI572251 AI672488 AW193262 AI244716 A1864375 Ai206100 AA912444 A1269365 A1640254 AW772466 A1867336 AA627604 H16914 AA358477 AA338009 430212 314437 1 AA469153A1718503AA469225 436532 4218021 AA721522AW975443T93070 453531 97026_1 AA417940 AA036735 T07025 454741 1232559_1 BE154396 AW817959 BE154393 TABLE 10C Pkey : Unique number corresponding to an Eos probeset Ref : Sequence source. The 7 digit numbers in this column are Genbank identifier (GI) numbers."Dunham 1. et al."refers to the publication entitled'The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402: 489-495.

Strand: Indicates DNA strand from which exons were predicted.

NLposition : Indicates nucleotide positions of predicted exons.

Pkey Ref Strand NLposition 400754 7331445 Plus 144559-144684 401045 8117619 Plus 90044-90184,91111-91345 401083 3242744 Plus 33192-33360 402474 7547175 Minus 53526-53628, 55755-55920, 57530-57757 402808 6456148 Minus 114964-115136,115461-115585,115931-116047,117666-117771,1180 04-118102 403021 7547270 Plus 120799-120966 403421 9665041 Minus 126609-126773,139986-140205 403438 9719679 Plus 90792-90938 403687 7387384 Plus 9009-9534 403764 7717105 Minus 118692-118853 404277 1834458 Minus 91665-91946 404288 2769644 Plus 3512-3691 404394 3135305 Minus 37121-37205,37491-37762,41053-41140,41322-41593,41773-41919 404518 8151988 Plus 84494-84603 404916 7341826 Plus 91057-91188 405106 8079395 Minus 80877-81418 405257 7329310 Plus 73121-73273 405381 6006920 Minus 7636-8054 406387 9256180 Plus 116229-116371, 117512-117651

TABLE 11A : Genes Distinguishing Adenocarcinoma from Other Lung Diseases and Normal Lung Table 11A shows about 84 genes upregulated in lung adenocarcinomas relative to other lung tumors, non-malignant lung disease, and normal lung. These genes were selected from about 59680 probesets on the Eos/Affymetrix Hu03 Genechip array.

Table 11 B show the accession numbers for those Pkey's lacking UnigenelID's for table 11A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and AlignmentTools (DoubleTwist, Oakland Califomia). The Genbank accession numbers for sequences comprising each cluster are listed in the 'Accession'column.

Table 11 C show the genomic positioning for those Pkey's lacking Unigene ID's and accession numbers in table 11A. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD : Unigene number Unigene Title : Unigene gene title R1 : Average of lung tumors (including squamous cell carcinomas, adenocarcinomas, small cell carcinomas, granulomatous and carcinoid tumors) divided by the average of normal lung samples R2: Average of non-malignant lung disease samples (including bronchitis, emphysema, fibrosis, atelectasis, asthma) divided by the average of normal lung samples Pkey ExAccn UnlgenelD Unigene Title R1 R2 403329 Target Exon 1.00 61.00 406399 NM_003122*; Homo sapiens serine protease 1.00 39. 00 406690 M29540 Hs. 220529 carcinoembryonic antigen-related cell ad 226.37 350.00 407869 AI827976 Hs.24391 hypothelical protein FLJ13612 0.77 1.18 407881 AW072003 Hs. 40968 heparan sulfate (glucosamine) 3-0-sulfot 1.00 10.00 408908 BE296227 Hs. 250822 serine/threonine kinase 15 7.76 1. 00 409103 AF251237 Hs. 112208 XAGE-1 protein 80.44 40.00 409187 AF154830 Hs. 50966 carbamoyi-phosphatesynthetasel. mitoch 1.00 1.00 409269 AA576953 Hs. 22972 hypothetical protein FLJ13352 1. 00 1. 00 410076 T05387 Hs. 7991 ESTs 1.12 1.50 410102 AW248508 Hs. 279727 Homo sapiens cDNA FLJ14035 fis, clone HE 9. 89 1.00 410399 BE068889 synuclein, gamma (breast cancer-specific 0. 92 1. 06 411908 L27943 Hs. 72924 cytidinedeaminase 1. 00 1. 00 412612 NM_000047 Hs. 74131 arylsulfatase E (chondrodysplasia puncta 1. 02 1.03 414075 U11862 Hs. 75741 amiioride binding protein 1 (amineoxida 0.84 1. 07 416208 AW291168 Hs. 41295 ESTs, Weakly similar to MUC2_HUMAN MUCIN 3. 67 1.00 417542 J04129 Hs. 82269 progestagen-associated endometdal prote 1. 28 1. 35 419183 U60669 Hs. 89663 cytochrome P450, subfamily XXIV (vitamin 1.00 1. 00 419502 AU076704 fibrinogen, A alpha polypeptide 13.05 115.00 419631 AW188117 Hs. 303154 popeye protein 3 1.00 13.00 420931 AF044197 Hs. 100431 small inducible cytokine B subfamily (Cy 1.00 aoo 421155 H87879 Hs. 102267 lysyloxidase 1, 00 15.00 421190 U95031 Hs. 102482 mucin 5, subtype B, tracheobronchial 1. 17 1.55 421474 U76362 Hs. 104637 solute carrier family 1 (glutamate trans 1.46 1. 76 421515 Y11339 Hs. 105352 GalNAc alpha-2,6-sialyltransferase I, I 1.00 3.00 421582 A1910275 trefoil factor 1 (breast cancer, estroge 1.23 1.00 422026 U80736 Hs. 110826 trinucleotide repeat containing 9 1.00 52. 00 422095 AI868872 Hs. 282804 hypothetical protein FLJ22704 4. 37 Z34 422311 AF073515 Hs. 114948 cytokine receptor-like factor 1 1.15 1.78 422867 L32137 Hs. 1584 carfilage oligomedc matrix protein (pse 1.69 3. 17 423472 AF041260 Hs. 129057 breast carcinoma amplified sequence 1 48.13 72.00 423554 M90516 Hs. 1674 glutamine-fructose-6-phosphate transamin 1.00 50.00 424502 AF242388 Hs. 149585 lengsin 1. 00 1.00 424544 M88700 Hs. 150403 dopa decarboxylase (aromatic L-amino aci 1.00 59.00 424905 NM_002497 Hs. 153704 NIMA (never in mitosis gene a)-related k 21.35 1.00 424960 BE245380 Hs. 153952 5'nucleotidase (CD73) 1.00 1.00 425523 AB007948 Hs. 158244 KIAA0479 protein 1. 00 35. 00 426230 AA367019 Hs.241395 protease, serine, 1 (trypsin 1) 1. 00 83. 00 427701 AA411101 Hs. 243886 nuciearautoantigenic sperm protein (his 7.41 34. 00 428585 AB007863 Hs. 185140 KIAA0403 protein 1.00 6.00 428758 AA433988 Hs. 98502 hypothetical protein FLJ14303 1.06 1. 13 429170 Nu. 001394 Hs. 2359 dual specificity phosphatase 4 16. 18 105.00 429263 AA019004 Hs. 198396 ATP-binding cassetle, sub-family A (ABC1 1.07 1.00 429610 AB024937 Hs. 211092 LUNX protein ; PLUNC (palate lung and nas 1.59 1.69 430508 A1015435 Hs. 104637 ESTs 4.75 7.27 430985 AA490232 Hs. 27323 ESTs, Weakly similar to 178885 serine/th 0.94 1.28 431548 AI834273 Hs. 9711 novel protein 5. 66 15.00 431566 AF176012 Hs. 260720 J domain containing protein 1 49. 76 37. 00 431986 AA536130 Hs. 149018 Novel human gene mapping to chomosome 20 1.19 1.47 432375 BE536069 Hs. 2962 S100 calcium-binding protein P 1.65 1.06 432677 NM_004482 Hs. 278611 UDP-N-acetyl-alpha-D-galactosamine : polyp 1.00 48. 00 433556 W56321 Hs. 111460 calcium/calmodulin-dependent protein kin 1. 00 19. 00 433819 AW511097 Hs. 112765 ESTs 3. 71 8. 00 434001 AW950905 Hs. 3697 serine (or cysteine) proteinase inhibito 29.31 72.00 434424 A1811202 Hs. 325335 Homo sapiens cDNA : FLJ23523 fis, clone L 1.00 64.00 434792 AA649253 Hs. 132458 ESTs 8.52 44.00 436217 T53925 Hs. 107 fibrinogen-like 1 57 97 31. 00 436749 AA584890 Hs. 5302 lectin, galactoside-binding, soluble, 4 1.10 1.41 436972 AA284679 Hs. 25640 claudin 3 1.59 1.46 437866 AA156781 metallothionein1E (functional) 3.62 101.00 437935 AW939591 Hs. 5940 mucin 13, epithelial transmembrane 1.60 1.39 438915 AA280174 Hs. 285681 Wittiams-Beurensyndromechromosomeregi 100 100 439451 AF086270 Hs. 278554 heterochromatin-like protein 1 23.28 52.00

439759 AL359055 Hs. 67709 Homo sapiens mRNA full length insert cDNA 1.00 21.00 441031 Al110684 Hs. 7645 fibrinogen, 8 beta polypeptide 1.41 99.00 441377 BE218239 Hs. 202656 ESTs 22.03 1.00 443614 AV655386 Hs. 7645 fibrinogen, B beta potypepfide 1.00 16.00 443813 AA876372 Hs. 93961 Homo sapiens mRNA ; cDNA OKFZp667D095 (fr 1.20 1. 99 443991 NM_002250 Hs. 10082 potassium intermediate/small conductance 5.71 6.87 444670 H58373 Hs. 332938 hypothetical protein MGC5370 1.98 38.00 444931 AV652066 Hs. 75113 general transcription factor IIIA 1.00 54.00 446102 AW168067 Hs. 317694 ESTs 1. 00 1. 00 446163 AA026880 Hs. 25252 Homo sapiens cDNA FLJ13603 fis, clone PL 1.00 36.00 446469 BE094848 Hs. 15113 homogentisate1, 2-dioxygenase (homogenti 1.00 11.00 447388 AW630534 Hs. 76277 Homo sapiens, clone MGC : 9381, mRNA, comp 1. 24 1.16 447532 AK000614 Hs. 18791 hypothetical protein FLJ20607 1.23 1.63 448243 AW369771 Hs. 52620 integrin, beta 8 15.84 1. 00 448844 AI581519 Hs. 177164 ESTs 1.00 31.00 449444 AW818436 Hs. 23590 solute carrier family 16 (monocarboxylic 1.00 83.00 451807 W52854 hypothetical protein FLJ23293 similar to 1.55 35.00 452689 F33868 Hs. 284176 transferrin 1.54 1.44 453392 U23752 Hs. 32964 SRY (sex determining region Y)-box 11 1.00 16.00 453464 AI884911 Hs. 32989 receptor (calcitonin) activity modifying 1.55 2.45 453735 AI066629 Hs. 125073 ESTs 1. 01 1. 30 TABLE 11 B Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession : Genbank accession numbers Pkey CAT Number Accession 410399 11995_1 BE068889 BE068882 AF044311 AF017256 NM_003087 AF037207 AF010126 AA633976 AA872836 BE298825 BE299889 A1016464 A1684600 AI936527 AA804675 AA394097 AI139933 AA946606 BE171313 AA722407 AA293803 A1468480 AA056035 AA055968 AW796957 A1637713 AA410737 H49348 AA486472 AA411094 AA235594 AA402624 AA443638 AW452137 AA421708 AW265211 AI493266 AA365132 AW966044 <BR> <BR> 419502 18535_1 AU076704 T74854 T74860 T72098 T73265 T73873 T69180 T74658 T58786 T60385 T73410 T68781 T67845 T67593 T73952 T67864 T60630 T68367 T68401 T53959 T72360 T72099 T60377 T58961 T71712 T72821 T64738 T74645 T72037 T68688 T72063 T73258 T72826 T64242 T68220 T74673 T71800 T68355 T61227 T62738 T69317 T53850 T64692 T73768 T73962 T73382 T68914 T70975 T73400 T60631 T73277 T73203 T70498 T61409 T58925 NM_000508 M64982 T68301 T73729 T69445 T60424 T67922 T67736 T68716 T67755 T74765 T73819 T58719 T74756 T60477 T74863 T61109 T68329 T58850 T71857 T73425 T53736 T68607 T58898 T64309 T72031 T72079 T64305 T71908 T68107 T71916 T73787 T56035 T64425 T71870 T60476 T61376 T67820 T71895 T41006 T69441 T68170 T74617 T71958 T69440 T61875 R06796 H48353 T71914 T53939 T64121 AA693996 T72525 T67779 T68078 AA011465 AA345378 AV654847 AV654272 AV656001 A1064740 T82897 N33594 AA344542 AW805054 A1207457 T61743 AA026737 H94389 AA382695 AA918409 T68044 S82092 T39959 A1017721 AA312395 AA312919 T40156 H66239 AV652989 H38728 R98521 AV655200 R95790 W03250 W00913 AA344136 AV660126 R97923 AA343596 AW470774 AV651256 N54417 AA812862 AW182929 Alt 11192 H61463 H72060 AA344503 H38639 AI277511 AV661108 A1207625 T47810 AA235252 T27853 T47778 R95746 H70620 AA701463 AW827166 R98475 C20925 AV657287 T71959 T71313 T73920 T73333 T61618 T69293 T69283 T73931 T72178 T72456 AV645639 AV653476 T72957 T72300 T58906 T71457 T70494 T72956 T70495 T68267 T74407 T85778 AA344726 T27854 T74485 T74101 T73868 T71518 T72304 AA343853 T73909 T68070 T72065 H72149 T73493 T73495 AV645993 R02293 T70475 T64751 AA344441 AA343657 AA345732 AA344328 AI110639 AA344603 AF063513 T64696 T68516 T72223 T60507 T67633 R29500 T72517 R02292 T60599 T69206 T70452 T74677 R29366 T61277 T74914 T60352 R29675 T74843 AV645792 AA344408 T69197 T72057 T69368 T69358 T68258 AV650429 T73341 T61702 T74598 T40095 K02272 T40106 AA34304SAA341908 AA341907 AA342807AA341964 T53747 T72042 T62764 A1064899 AA343060 T67832 T72440 T71770 T68091 T69108 T72449 T69167 T71289 T68251 AV654844 T64375 AA345234 T67598 AA011414 T68036 H48262 M207557 T68219 W86031 T69081 T64232 R93196 T62136 AV650539 H67459 T72978 AA344583 T60362 H58121 T95711 T72803 T68055 T71715 R29036 T72793 T69122 T64595 T62888 T69139 T68291 T64652 T67971 T46862 AA693592 AB48502 R29454 T64764 T57001 T73052 T71429 T51176 T58866 AV655414 H90426 AA342489 T73666 T67848 T72512 T53835 T67837 T73317 T74273 T69420 T68245 T74380 T67862 T74474 T56068 421582 2041 1 AI910275 X00474 X52003 X05030 NM_003225 AA314326 AA308400 AA506787 AA314825 AI571948 AA507595 AA614579 AA587613 R83818 AA568312 AA614409 AA307578 A1925552 AW950155 AI910083 M12075 BE074052 AW004668 AA578674 AA582084 BE074053 BE074126 BE074140 AA514776 AA588034 BE074051 BE074068 AW009769 AW050690 AA858276 R55389 A1001051 AW050700 AW750216 AA614539 BE074045 AI307407 AW602303 BE073575 At202532 AA524242 AI970839 AI909751 BE076078 AI909749 R55292 437866 44433_2 AA156781 AW293839 U52054 AA024963 AA778446 BE073977 AW44904 AW602574 BE164040 BE164012 BE163972 BE163974 BE163992 AA837481 AW468444 BE185091 AW468002AA687333AAB11830AA581806A ! 866686At572124AA043777AA040926 D20160Ai536733 AA812489 AW874142 AI471883 W84421 AA156850 451807 8865_1 W52854 AL117600 BE208116 BE208432 BE206239 BE082291 AW953423 AA351619 BE180648 BE140560 W60080 AA865478 N90291 AW450652 AW449519 AA993634 A1806539 AA351618 AW449522 A1827626 AA904788 AA380381 AA886045 AA774409 SE003229 Z41756 TABLE 11C Pkey: Unique number corresponding to an Eos probeset Ref : Sequence source. The 7 digit numbers in this column are Genbank identifier (GI) numbers."Dunham I. et al."refers to the publication entiUed'The DNA sequence of human chromosome 22."Dunham 1. et al., Nature (1999) 402: 489-495.

Strand : indicates DNA strand from which exons were predicted.

NLposition : indicates nucleotide positions of predicted exons.

Pkey Ref Strand NLposition 403329 8516120 Plus 96450-96598 406399 9256288 Minus 63448-63554

TABLE 12A : Genes Distinguishing Squamous Cell Carcinoma from Other Lung Diseases and Normal Lung Table 12A shows about 72 genes upregulated in squamous cell carcinomas of the lung relative to other lung tumors, non-malignant lung disease, and normal lung. These genes were selected from about 59680 probesets on the Eos/Affymetrix Hu03 Genechip array.

Table 12B show the accession numbers for those Pkey's lacking UnigenelD's for table 12A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (Double Twist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the 'Accession'column.

Table 12C show the genomic positioning for those Pkey's lacking Unigene ID's and accession numbers in table 12A. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey : Unique Eos probeset identifier number ExAccn : Exemplar Accession number, Genbank accession number UnigenetD : Unigene number Unigene Title : Unigene gene title R1 : Average of lung tumors (including squamous cell carcinomas, adenocarcinomas, small cell carcinomas, granulomatous and carcinoid tumors) divided by the average of normal lung samples R2: Average of non-malignant lung disease samples (including bronchitis, emphysema, fibrosis, atelectasis, asthma) divided by the average of normal lung samples Pkey ExAccn UnigenelD Unigene Title R1 R2 400289 X07820 Hs. 2258 matrix metalloproteinase 10 (stromelysin 132.45 4. 00 400666 NM_002425 : Homo sapiens matrix metallopro 3.26 3.22 401780 NM005557' : Homo sapiens keratin 16 (foca 26.47 10.50 401781 Target Exon 10.33 4. 61 401785 NM_002275* : Homo sapiens keratin 15 (KRT1 4.13 2.70 401994 Target Exon 61. 84 47.00 402075 ENSP00000251056' : Plasma membrane calcium 1. 00 1.00 404996 Target Exon 1. 00 1.00 407839 AA045144 Hs. 161566 ESTs 173.91 108.00 408000 L11690 Hs. 620 bullouspemphigoidanügenl (230/240kD) 151.17 8.00 408522 At541214 Hs. 46320 Small proline-rich protein SPRK [human, 1.98 1.24 410561 BE540255 Hs. 6994 HomosapienscDNA : FLJ22044 fis, clone H 10.04 1. 00 415091 AL044872 Hs. 77910 3-hydroxy-3-methylglutaryl-CoenzymeAsy 1.00 30.00 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t 24.30 1.00 416658 U03272 Hs. 79432 fibrillin 2 (congenital contractural ara 53.29 51.00 417034 NM_006183 Hs. 80962 neurotensin 1. 00 1. 00 417366 BE185289 Hs. 1076 small proline-rich protein 1B (comifin) 8.97 3.27 418663 AK001100 Hs. 41690 desmocollin 3 112.17 19.00 418678 NM001327 Hs. 87225 cancer/testis antigen 1. 18 1.10 419121 AA374372 Hs. 89626 parathyroid hormone-like hormone 1.00 1.00 420783 AI659838 Hs. 99923 lectin, galactoside-binding, soluble, 7 3.04 1.25 421773 W69233 Hs. 112457 ESTs 1.12 1.14 421948 L42583 Hs. 334309 keratin 6A 51.83 20.25 421978 AJ243662 Hs. 110196 NICE-1 protein 1.01 0.91 422158 L10343 Hs. 112341 protease inhibitor 3, skin-derived (SKAL 2.37 1.10 422440 NM_004812 Hs. 116724 a, do-ketoreductasefamily1, memberB10 47.53 32. 00 423634 AW959908 Hs. 1690 heparin-binding growth factor binding pr 76.02 1.00 423725 AJ403108 Hs. 132127 hypothetical protein LOC57822 4.20 1.00 423738 AB002134 Hs. 132195 airway trypsin-like protease 10.14 51. 00 424012 AW368377 Hs. 137569 tumor protein 63 kDa with strong homolog 233.42 68.00 424046 AF027866 Hs. 138202 serine (or cysteine) proteinase inhibito 1.00 1.00 424098 AF077374 Hs. 139322 small proline-rich protein 3 137.82 54.00 424834 AK001432 Hs. 153408 Homo sapiens cDNA FLJ 10570 fis, clone NT 56.19 12.00 425650 NM_001944 Hs. 1925 desmoglein 3 (pemphigus vulgaris antigen 33.45 1.00 427099 AB032953 Hs. 173560 odd Oz/ten-m homolog 2 (Drosophila, mous 4.24 17. 00 427335 AA448542 Hs. 251677 G antigen 7B 51.83 4.00 428182 BE386042 Hs. 293317 ESTs, Weakly similar to GGC1_HUMAN G ANT 1.00 1.00 428645 AA431400 Hs. 98729 ESTs, Weakly similar to 2017205A dihydro 1.00 16.00 428748 AW593206 Hs. 98785 Ksp37 protein 1.00 87.00 429259 AA420450 Hs. 292911 ESTs, Highly similar to S60712 band-6-pr 2.01 1.18 429538 BE182592 Hs. 11261 small proline-rich protein 2A 4.43 2.90 429903 AL134197 Hs. 93597 cyclin-dependent kinase 5, regulatory su 11.80 1. 00 430486 BE062109 Hs. 241551 chloride channel, calcium activated, fam 12.28 41.00 430890 X54232 Hs. 2699 glypican 1 1.58 1.40 431009 BE149762 Hs. 48956 gap junction protein, beta 6 (connexin 3 60.25 28.00 431846 BE019924 Hs. 271580 uroplakin 1B 4.49 2.51 433091 Y12642 Hs. 3185 lymphocyte antigen 6 complex, locus D 1. 20 1.09 434360 AW015415 Hs. 127780 ESTs 40.98 27.00 434880 U02388 Hs. 101 cytochrome P450, subfamily IVF, polypept 1.00 1.00 435505 AF200492 Hs. 211238 interleukin-1 homolog 1 1.00 38.00 435793 AB037734 Hs. 4993 KIAA1313 protein 23.68 42.00 436511 AA721252 Hs. 291502 ESTs 16.76 14.00 438403 AA806607 Hs. 292206 ESTs 1.00 1.00 439285 AL133916 hypothetical protein FLJ20093 46.23 139.00 439606 W79123 Hs. 58561 G protein-coupled receptor 87 33.61 1.00 439670 AF088076 Hs. 59507 ESTs, Weakly similar to AC004858 3 U1 sm 1.00 1.00 439706 AW872527 Hs. 59761 ESTs, Weakly similar to DAP1 IiUMAN DEATH 86.55 11.00 440325 NM_003812 Hs. 7164 adisintegrinandmetaitoproteinasedoma 62.88 147.00 441525 AW241867 Hs. 127728 ESTs 1.53 1.42 443162 T49951 Hs. 9029 DKFZP434G032 protein 31.11 38.00 444378 R41339 Hs. 12569 ESTs 1. 00 1.00

446292 AF081497 Hs. 279682 Rh type C glycoprotein 1. 55 1. 26 447078 AW885727 Hs. 9914 ESTs 47.24 24.00 447342 AI199268 Hs. 19322 Homo sapiens, Similar to RIKEN cDNA 2010 28.63 1.00 449003 X76342 Hs. 389 alcohol dehydrogenase 7 (class IV), mu o 1.00 1.00 449101 AA205847 Hs. 23016 G protein-coupled receptor 2.58 27.00 450832 AW970602 Hs. 105421 ESTs 25.17 36.00 452240 AI591147 Hs. 61232 ESTs 13.42 1.00 453317 NM_002277 Hs. 41696 keratin, hair, acidic, 1 1.19 1.27 453830 AA534296 Hs. 20953 ESTs 24.92 25.00 454098 W27953 Hs. 292911 ESTs, Highly similar to S60712 band-6-pr 1.26 1.11 455601 AI368680 Hs. 816 SRY (sex determining region Y)-box 2 206.11 1.00 TABLE 128 Pkey: Unique Eos probeset identifier number CAT number : Gene cluster number Accession: Genbank accession numbers Pkey CAT Number Accession 439285 47065_1 AL133916 N79113 AF086101 N76721 AW950828 AA364013 AW955684 AI346341 AI867454 N54784 AI655270 AI421279 AW014882 AA775552 N62351 N59253 AA626243 A1341407 BE175639 AA456968 A1358918 AA457077 TABLE 12C Pkey: Unique number corresponding to an Eos probeset Ref : Sequence source. The 7 digit numbers in this column are Genbank identifier (GI) numbers. Dunham I. et a. refers to the publication entitled'The DNA sequence of human chromosome 22. Dunham.. et a !"Nature (1999) 402 : 489-495.

Strand : Indicates DNA strand from which exons were predicted.

Preposition : Indicates nucleotide positions of predicted exons.

Pkey Ref Strand Nt_position 400666 8118496 Plus 17982-18115,20297-20456 401780 7249190 Minus 28397-28617,28920-29045,29135-29296,29411-29567,29705-29787, 30224-30573 401781 7249190 Minus 83215-83435, 83531-83656, 83740-83901, 84237-84393, 84955-85037, 86290-86814 401785 7249190 Minus 165776-165996, 166189-166314, 166408-166569, 167112-167268, 167387-167469,168634-168942 401994 4153858 Minus 42904-43124, 43211-43336, 44607-44763,45199-45281,46337-46732 402075 8117407 Plus 121907-122035, 122804-122921, 124019-124161, 124455-124610, 125672-126076 404996 6007890 Plus 37999-38145, 38652-38998, 39727-39872, 40557-40674,42351-42450

TABLE 13A : Genes Distinguishing Non-Malignant Lung Disease from Lung Tumors and Normal lung Table 13A shows about 23 genes upregulated in non-malignant lung disease relative to lung tumors and normal lung. These genes were selected from about 59680 probesets on the Eos/Affymetrix Hu03 Genechip array.

Table 13B show the accession numbers forthose Pkeys lacking UnigenetDs for table 13A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubieTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession'column.

Table 13Cshow the genomic positioning for those Pkey's lacking Unigene ID's and accession numbers in table 13A. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed, Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD : Unigene number Unigene Title: Unigene gene title R1 : Average of lung tumors (including squamous cell carcinomas, adenocarcinomas, small cell carcinomas, granulomatous and carcinoid tumors) divided by the average of normal lung samples R2: Average of non-malignant lung disease samples (including bronchitis, emphysema, fibrosis, atelectasis, asthma) divided by the average of normal lung samples Pkey ExAccn UnigeneID Unigene Title R1 R2 408562 AI436323 Hs. 31141 Homo sapiens mRNA for KIAA1568 protein, 1.00 230.00 409031 AA376836 Hs. 76728 ESTs 1.00 128.00 412372 R65998 Hs. 285243 hypothetical protein FLJ22029 1.00 173.00 415910 U20350 Hs. 78913 chemokine (C-X3-C) receptor 1 1.00 145.00 417511 AL049176 Hs. 82223 chordin-like 1.00 179.00 418819 AA228776 Hs. 191721 ESTs 1.00 140.00 422060 R20893 Hs. 325823 ESTs, Moderate. ysimitartoAW5_HUMANA 1. 00 156.00 424585 AA464840 Hs. 131987 ESTs 1.00 167.00 426753 T89832 Hs. 170278 ESTs 1. 00 141. 00 429496 AA453800 Hs. 192793 ESTs 1.00 138.00 430719 AA488988 Hs. 293796 ESTs 1.00 133.00 431089 BE041395 ESTs, Weakly similar to unknown protein 23.32 941. 00 431385 BE178536 Hs. 11090 membrane-spanning 4-domains, subfamily A 1.00 157.00 431728 NM_007351 Hs. 268107 multimerin 1.00 157.00 436532 AA721522 gb: nv54h12. rl NCl_CGAP_Ew1 Homosapiens 1.00 218.00 437960 Ai669586 Hs. 222194 ESTs 1. 00 147.00 438202 AW169287 Hs. 22588 ESTs 1. 00 141.00 441499 AW298235 Hs. 101689 ESTs 1. 00 167. 00 444513 AL120214 Hs. 7117 glutamate receptor, ionotropic, AMPA1 1.00 151.00 448253 H25899 Hs. 201591 ESTs 1.00 141.00 453636 R67837 Hs. 169872 ESTs 1.00 116. 00 458332 A1000341 Hs. 220491 ESTs 1.00 192.00 459587 AA031956 gb: zk15e04. s1SoarespregnantuterusNbH 1.00 154.00 TABLE 13B Pkey: Unique Eos probeset identifier number CAT number : Gene cluster number Accession: Genbank accession numbers Pkey CAT Number Accession 431089 327825_1 BE041395 AA491826 AA621946 AA715980 AA666102 436532 421802 1 AA721522 AW975443 T93070 TABLE 13C Pkey: Unique number corresponding to an Eos probeset Ref : Sequence source. The 7 digit numbers in this column are Genbank identifier (G.) numbers. Dunham et a !. refers to the publication entitled The DNA sequence of human chromosome 22."Dunham I. et al., Nature (1999) 402: 489-495.

Strand: indicates DNA strand from which exons were predicted.

NLposition: Indicates nucleotide positions of predicted exons.

Pkey Ref Strand NLposition 402075 8117407 Plus 121907-122035, 122804-122921, 124019-124161, 124455-124610, 125672-126076

TABLE 14A: Preferred Utility and Subcellular Localization for Potential Lung Disease Targets Table 14A shows the subcellular localization and preferred utility for the genes appearing in Tables 9A and 10A. mAb symbolizes monoclonal antibody, diag symbolizes diagnostic, s. m. symbolizes small molecule, and CTL symbolizes cytotoxic lymphocytic ligand. These genes were selected from 59680 probesets on the EoslAffymetrix Hu03 Genechip array.

Table 14B show the accession numbers for those Pkey's lacking UnigenelD's for table 14A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Toois (DoubIeTwist, Oakland Califomia). The Genbank accession numbers for sequences comprising each cluster are listed in the 'Accession'column.

Table 14C show the genomic positioning for those Pkey's lacking Unigene ID's and accession numbers in table 14A. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD : Unigene number Unigene Title : Unigene gene title Pref. Utility : Preferred Utility Pred. Loc: Predicted subcellular localization Pkey ExAccn UnigenetD Unigene Title Pref Utility Pred. Loc 400289 X07820 Hs. 2258 matrix metalloproteinase 10 (stromelysin mAb & diag & s. m. extracellular 400303 AA242758 Hs. 79136 LIV-1 protein, estrogen regulated mAb plasma membrane 402075 ENSP00000251056 : Plasma membrane calcium mAb & diag secreted 407811 AW190902 Hs. 40098 cysteine knot superfamily 1, BMP antagon diag secreted 408243 Y00787 Hs. 624 interleukin 8 diag secreted 408790 AW580227 Hs. 47860 neurotrophic tyrosine kinase. receptor, mAb & s. m. plasma membrane 408908 BE296227 Hs. 250822 serine/threonine kianse 15 s.m. cytoplasm 409041 AB033025 Hs. 50081 Hypothetical protein, XP 051860 (KIAA119 CTL & diag secreted 409103 AF251237 Hs. 112208 XAGE-1 protein CTL nuclear 409420 Z15008 Hs. 54451 laminin, gamma 2 (nicein (100kD), kalini diag secreted 409632 W74001 Hs. 55279 serine (or cysteine) proteinase inhibito diag secreted 409757 NM_001898 Hs. 123114 cystatin SN diag extracellular 409893 AW247090 Hs. 57101 minichromosome maintenance deficient (S. CTL nuclear 409956 AW103364 Hs. 727 inhibin, beta A (activin A, aclivin AB a diag extracellular 410001 AB041036 Hs. 57771 kallikrein 11 diag extracellular 410407 X66839 Hs. 63287 carbonic anhydrase IX mAb & s. m. plasma membrane 410418 D31382 Hs. 63325 transmembrane protease, seine 4 mAb & diag & s. m. plasma membrane 412140 AA219691 Hs. 73625 RAB6 interacting, kinesin-like (rabkines s. m.

412719 AW016610 Hs. 816 ESTs s. m. nuclear 414774 X02419 Hs. 77274 plasminogen activator, urokinase diag extracellular 414883 AA926960 CDC28 protein kinase 1 s.m.

415138 C18356 Hs. 295944 tissue factor pathway inhibitor 2 CTL & diag extracellular 415669 NM005025 Hs. 78589 serine (or cysteine) proteinase inhibito mAb & diag & s. m. secreted 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t mAb & s. m. plasma membrane 416658 U03272 Hs. 79432 fibriilin 2 (congenital contractural ara diag extracellular 417034 NM-006183 Hs. 80962 neurotensin diag extracellular 417079 U65590 Hs. 81134 interleukin 1 receptor antagonist diag extracellular 417308 H60720 Hs. 81892 KIAA0101 gene product s. m. mitochondrial 417389 BE260964 Hs. 82045 midkine (neurite growth-promoting factor mAb & diag secreted 417433 BE270266 Hs. 82128 5T4 oncofetal trophoblast glycoprotein mAb plasma membrane 417933 X02308 Hs. 82962 thymidylate synthetase s. m. endoplasmic reticulum 418478 U38945 Hs. 1174 cyclin-dependent kinase inhibitor 2A (me s. m. cytoplasm 418506 AA084248 Hs. 85339 G protein-coupled receptor 39 mAb & s. m. plasma membrane 418678 NM001327 Hs. 167379 cancer/testis antigen (NY-ESO-1) CTL cytoplasmic 419121 AA374372 Hs. 89626 parathyroid hormone-like hormone diag secreted 419171 NM_002846 Hs. 89655 protein tyrosine phosphatase, receptor t mAb & s. m. plasma membrane 419183 U60669 Hs. 89663 cytochrome P450, subfamily XXIV (vitamin CTL & s. m. mitochondrial 419216 AU076718 Hs. 164021 small inducible cytokine subfamily B (Cy diag secreted 419235 AW470411 Hs. 288433 neurotrimin mAb&diag ptasmamembrane 419452 U33635 Hs. 90572 PTK7 protein tyrosine kinase 7 mAb & s. m. plasma membrane 419556 U29615 Hs. 91093 chitinasel (chitotriosidase) mAb & diag extracellular* 420610 Ai683183 Hs. 99348 distal-less homeo box 5 CTL nuclear 421110 AJ250717 Hs. 1355 cathepsinE E sm & diag extracellular 421379 Y15221 Hs. 103982 small inducible cytokine subfamily B (Cy diag secreted 421474 U76362 Hs. 104637 solute carrier family 1 (glutamate trans mAb & s. m. plasma membrane 421552 AF026692 Hs. 105700 secreted frizled-related protein 4 diag secreted 421753 BE314828 Hs. 107911 ATP-binding cassette, sub-family B (MDR/mAb & s. m. plasma membrane 421817 AF146074 Hs. 108660 ATP-binding cassette, sub-family C (CFTR mAb & s. m. plasma membrane 422109 S73265 Hs. 1473 gastrin-releasing peplide diag secreted 422158 L10343 Hs. 112341 protease inhibitor 3, skin-derived (SKAL diag secreted 422282 AF019225 Hs. 114309 apolipoprotein L diag secreted 422283 AW411307 Hs. 114311 CDC45 (cell division cycle 45, S. cerevis s. m. nuclear 422424 Ai186431 Hs. 296638 prostate differentiation factor diag extacellular 422765 AW409701 Hs. 1578 bacutoviral IAP repeat-containing 5 (sur s. m. cytoplasm 422809 AK001379 Hs. 121028 hypothetical protein FLJ10549 s. m. nuclear 422867 L32137 Hs. 1584 cartilage oiigomeric matrix protein (pse diag extracellular 422956 BE545072 Hs. 122579 ECT2 protein (Epithelial cell tansformi CTL & s. m.

423634 AW959908 Hs. 1690 heparin-binding growth factor binding pr diag 423673 BE003054 Hs. 1695 matrix metalloproteinase 12 (macrophage mAb & diag & s. m. secreted 423961 D13666 Hs. 136348 periostin (OSF-2os) mAb&diag extracellular 424046 AF027866 Hs. 138202 serine (orcysteine) proteinaseinhibito diag secreted 424381 AA285249 Hs. 146329 protein kinase Chk2 s. m. nuclear

424502 AF242388 Hs. 149585 lengsin s. m. cytoptasmic 424503 NM002205 Hs. 149609 integrin, alpha 5 (fibronectin receptor, mAb & s. m. plasma membrane 424687 J05070 Hs. 151738 matrix metalloproteinase 9 (gelatinase B diag exiracellular 425247 NM005940 Hs. 155324 matrix metalloproteinase 11 (stromelysin mAb & diag & s. m. secreted 425322 U63630 Hs. 155637 protein kinase, DNA-activated, catalytic s. m. cytoplasmic 425650 NM_001944 Hs. 1925 desmoglein 3 (pemphigus vulgaris antigen mAb plasma membrane 425734 AF056209 Hs. 159396 peptidyigiycineaipha-amidatingmonooxyg s. m.

425776 U25128 Hs. 159499 parathyroid hormone receptor 2 mAb & diag plasma membrane 425852 AK001504 Hs. 159651 death receptor 6, TNF superfamily member mAb & s. m. plasma membrane 426215 AW963419 Hs. 155223 stanniocalcin 2 mAb & diag secreted 426427 M86699 Hs. 169840 TTK protein kinase CTL & s. m. nuclear 426514 BE616633 Hs. 170195 bone morphogenetic protein 7 (osteogenic mAb&diag secreted 427335 AA448542 Hs. 251677 G antigen 7B CTL cytoplasmic 427747 AW411425 Hs. 180655 serine/threonine kinase 12 s.m. cytoplasmic 428242 H55709 Hs. 2250 leukemia inhibitory factor (cholinergic diag 428330 L22524 Hs. 2256 matrix metalloproteinase 7 (matrilysin, mAb & diag & s. m. extracellular 428450 NM_014791 Hs. 184339 KIAA0175 gene product s. m. nuclear 428479 Y00272 Hs. 334562 cell division cycle 2, G1 to S and G2 to s. m. nuclear 428484 AF104032 Hs. 184601 solute carrier family 7 (cationic amino mAb & s. m. plasma membrane 428664 AK001666 Hs. 189095 similar to SALL1 (sal (Drosophila)-like CTL & s. m. nuclear 428698 AA852773 Hs. 334838 K1AA1866 protein mAb 428748 AW593206 Hs. 98785 Ksp37 protein diag extracellular 428758 AA433988 Hs. 98502 CA125 antigen ; mucin 16 diag mitochodria 428969 AF120274 Hs. 194689 artemin diag extraceliular 429211 AF052693 Hs. 198249 gap junction protein, beta 5 (connexin 3 mAb & s. m. plasma membrane 429263 AA019004 Hs. 198396 ATP-binding cassette, sub-family A (ABC1 mAb & s. m. plasma membrane 429547 AW009166 Hs. 99376 ESTs diag secreted 429610 AB024937 Hs. 211092 WNX protein ; PLUNC (palate lung and nas mAb & diag secreted 429903 AL134197 Hs. 93597 cyclin-dependent kinase 5, regulatory su s.m.

430486 BE062109 Hs. 241551 chloride channel, calcium activated, fam mAb & s. m. plasma membrane 431462 AW583672 Hs. 256311 granin-like neuroendocrine peptide precu diag extracellular 431515 NM_012152 Hs. 258583 endothelial differentiation, lysophospha mAb & s. m. plasma membrane 431846 BE019924 Hs. 271580 uroplakin 1 B mAb & diag plasma membrane 431958 X63629 Hs. 2877 cadherin 3, type 1, P-cadherin (placenta mAb & diag plasma membrane 432201 AI538613 Hs. 298241 Transmembrane protease, serine 3 mAb & diag & s. m. plasma membrane 433001 AF217513 Hs. 279905 clone HQ0310 PRO03310p1 s.m. nuclear 435505 AF200492 Hs. 211238 interleukin-1 homolog 1 diag secreted 436481 M379597 Hs. 5199 HSPC150 protein similar to ubiquitin-con s. m.

437016 AU076916 Hs. 5398 guanine monphosphate synthetase s. m. cytoplasm 437044 AL035864 Hs. 69517 differentially expressed in Fanconi's an CTL ER 437789 AI581344 Hs. 127812 ESTs, Weakly similar to T17330 hypotheti CTL nuclear 437852 BE001836 Hs. 256897 ESTs, Weakly similar to dJ365O12.1 [H. sa mAb&s. m. plasma membrane 439223 AW238299 Hs. 250618 UL16 binding protein 2 mAb plasma membrane 439477 W69813 Hs. 58042 ESTs, Moderately similar to GFR3_HUMAN G mAb & s. m.

439606 W79123 Hs. 58561 G protein-coupled receptor 87 mAb & s. m, plasma membrane 439738 BE246502 Hs. 9598 sema domain, immunoglobulin domain (zig), mAb & s. m. plasma membrane 440006 AK000517 Hs. 6844 NALP2 protein ; PYRIN-Containing APAF1-li s. m. nuclear 441362 BE614410 Hs. 23044 RAD51 (S. cerevisiae) homolog (E coli Re s. m.

442117 AW664964 Hs. 128899 ESTs ; hypothetical protein for IMAGE : 447 mAb&s. m. plasma membrane 443247 BE614387 Hs. 333893 c-Myc target JP01 CTL extracellular* 443426 AF098158 Hs. 9329 chromosome 20 open reading frame 1 CTL 443859 NM_013409 Hs. 9914 follistatin diag extracellular 444006 BE395085 Hs. 10086 type I transmembrane protein Fnl4 mAb plasma membrane 444371 BE540274 Hs. 239 forkhead box MI s. m. nuclear 444381 BE387335 Hs. 283713 ESTs, Weakly similar to S64054 hypotheo diag secreted 444781 NM_014400 Hs. 11950 GPI-anchored metastasis-associated prote mAb & diag plasma membrane 445537 AJ245671 Hs. 12844 EGF-like-domain, multiple 6 mAb & diag secreted 446619 AU076643 Hs. 313 secreted phosphoprotein 1 (osteopontin, diag secreted 446921 AB012113 Hs. 16530 small inducible cytokine subfamily A (Cy diag extracellular 447033 A1357412 Hs. 157601 ESTs CTL & diag secreted 447342 AI199268 Hs. 19322 Homo sapiens, Similar to RIKEN cDNA 2010 CTL 448243 AW369771 Hs. 52620 integrin, beta 8 mAb & s. m.-plasma membrane 448844 A1581519 Hs. 177164 ESTs mAb&s. m.

449048 Z45051 Hs. 22920 similar to S68401 (cattle) glucose induc mAb plasma membrane 449722 BE280074 Hs. 23960 cyclin Bi s. m. cytoplasm 450001 NM_001044 Hs. 406 solute carrier family 6 (neurotransmitte mAb & s. m. plasma membrane 450375 AA009647 a disintegrin and metalloproteinase doma mAb & diag & s. m. plasma membrane 450701 H39960 Hs. 288467 hypothetical protein XP_098151 (leucine-mAb & diag plasma membrane 450983 AA305384 Hs. 25740 ER01 (S, cerevisiae)-like diag secreted 451668 Z43948 Hs. 326444 cartilage acidic protein 1 mAb & diag plasma membrane 452281 T93500 Hs. 28792 Homo sapiens cDNA FLJ11041 fis, clone PL diag 452401 NM_007115 Hs. 29352 tumor necrosis factor, alpha-induced pro diag extracellular 452747 BE153855 Hs. 61460 Ig superfamily receptor LNIR mAb plasma membrane 452838 U65011 Hs. 30743 preferentially expressed antigen in mela CTL nuclear 453968 AA847843 Hs. 62711 High mobility group (nonhistone chromoso CTL & s, m. nuclear 457489 AI693815 Hs. 127179 crypbc gene diag secreted TABLE 148 Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT Number Accession

414883 15024_1 AA926960 AA926959 W76521 W24270 W21526 AA037172 BE267636 H83186 AA469909 N86396 AA001348 BE535736 AA081745 BE566245 AA082436 H72525 H77575 N49786 W80565 H78746 BE569085 W04339 R98127 T55938 BE279271 AW960304 T29812 AA476873 BE297387 AA292753 AA177048 NM_001826 X54941 BE314366 AA908783 At719075 BE270172 BE269819 AA889955 AI204630 W25243 Al935150 AA872039 W72395 T99630 AI422691 H98460 N31428 BE255916 H03265 AI857576 AA776920 AA910644 AA459522 AA293140 AW514667 R75953 AW662396 AA662522 AI865147 AI423153 AW262230 AA584410 AA583187 AW024595 AW069734 A1828996 AA282997 AA876046 AW613002 AA527373 AW972459 A1831360 AA621337 AA100926 AA772418 AA594628 A) 033892 W95096 A1034317 AA398727 A1085031 N95210 A1459432 AM41437 AA932124 AA627684 AA935829 AM04827 A1423513 A) 094597 H42079 R54703 AI630359 AA617681 AA978045 AA643280 W44561 AI991988 AI537692 AI090262 AA740817 AI312104 AI911822 AA416871 AI185409 AA129784 AA701623 AI075239 AI139549 AA633648 AI339996 AI336880 AA399239 AI078708 AI085351 AI362835 AI346618 AI146955 AI989380 AI348243 N92892 AA765850 AI494230 AI278887 AA962596 AI492600 W80435 AA001979 R97424 AI129015 N24127 AA157451 AA235549 AA459292 AA037114 AA129785 Ai494211 AW059601 AW886710 R92790 N59755 AI361128 AW589407 H47726 H97534 H48076 H48450 T99631 AW300758 H03431 R76789 AA954344 H77576 R96823 AI457100 N92845 N49682 H42038 BE220698 BE220715 H99552 AA701624 N74173 R54704 H79520 H72923 H03266 BE261919 AA769633 AA480310 AA507454 AA910586 A ! 203723 AW104725 W25611 W25071 T88980 H03513 T77589 R99156 W95095 R97470 AA702275 T77551 AA911952 H82956 N83673 AA283672 450375 83327_1 AA009647 AA131254 AA374293 AW954405 H04410 AW606284 AA151166 BE157467 BE157601 H04384 W46291 AW663674 H04021 H01532 AA190993 H03231 H59605 H01642 AA852876 AA113758 AA626915 AA746952 AI161014 AA099554 R69067 TABLE 14C Pkey : Unique number corresponding to an Eos probeset Ref : Sequence source. The 7 digit numbers in this column are Genbank identifier (GI) numbers."Dunham I. et al,"refers to the publication entitled"The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402 : 489-495.

Strand : indicates DNA strand from which exons were predicted.

Nt_position : indicates nucleotide positions of predicted exons.

Pkey Ref Strand Nt_position 402075 8117407 Plus 121907-122035, 122804-122921, 124019-124161, 124455-124610, 125672-126076

TABLE 15A : Information for all sequences in Table 16 Table 15A shows the Seq ID No, Pkey, ExAccn, Unigene, D, and Unigene Title for all of the sequences in Table 16.

Table 15B show the accession numbers for those Pkey's lacking UnigenelD's for table 15A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubIeTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the 'Accession'column.

Table 15C show the genomic positioning for those Pkey's lacking Unigene ID's and accession numbers in table 15A. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Seq D No : Sequence ID number Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD : Unigene number Unigene Title : Unigene gene title Seq ID No : Pkey ExAccn UnigenetD Unigene Title Seq ID No : 1 & 2 410407 X66839 Hs. 63287 carbonic anhydrase IX Seq ID No : 3&4 412719 AW016610 Hs. 816 ESTs Seq ID No : 5 & 6 417034 NM 006183 Hs. 80962 neurotensin Seq ID No : 7 & 8 430486 BE062109 Hs. 241551 chloride channel, calcium activated, fam Seq ID No : 9 & 10 407788 BE514982 Hs. 38991 S100 calcium-binding protein A2 Seq ID No : 11 & 12 407788 BE514982 Hs. 38991 S100 calcium-binding protein A2 Seq ID No: 13 & 14 407788 BE514982 Hs. 38991 S100 calcium-binding protein A2 Seq ID No: 15 & 16 407788 BE514982 Hs. 38991 S100 calcium-binding protein A2 Seq ID No: 17 & 18 439285 AL133916 hypothetical protein FLJ20093 Seq ID No: 19 & 20 413753 U17760 Hs. 75517 laminin, beta 3 (nicein (125kD), kalinin Seq ID No : 21&22 120486 AW368377 Hs. 137569 tumor protein 63 kDa with strong homolog Seq ID No: 23 & 24 425650 i NM_001944 Hs. 1925 desmoglein 3 (pemphigus vulgaris antigen Seq ID No: 25 & 26 412140 AA219691 Hs. 73625 RAB6 interacting, kinesin-like (rabkines Seq ID No: 27 & 28 423673 BE003054 Hs. 1695 matrix metalloproteinase 12 (macrophage Seq ID No: 29 & 30 452838 U65011 Hs. 30743 preferentially expressed antigen in mela Seq ID No: 31 & 32 418663 AK001100 Hs. 41690 desmocollin 3 Seq ID No: 33 & 34 418663 AK001100 Hs. 41690 desmocollin 3 Seq ID No: 35 & 36 409632 W74001 Hs. 55279 serine (or cysteine) proteinase inhibito Seq ID No: 37 & 38 429610 AB024937 Hs. 211092 LUNX protein; PLUNC (palate lung and nas Seq ID No: 39 & 40 406690 M29540 Hs. 220529 carcinoembryonic antigen-related cell ad Seq ID No: 41 & 42 431846 BE019924 Hs. 271580 uroplakin 1B Seq ID No: 43 & 44 418830 BE513731 Hs. 88959 hypothetical protein MGC4816 Seq ID No: 45 & 46 424098 AF077374 Hs. 139322 small proline-rich protein 3 Seq ID No: 47 & 48 443648 AI085377 Hs. 143610 ESTs Seq ID No: 49 311034 BE567130 Hs. 311389 ESTs, Highly similar to NKGD_HUMAN NKG2- Seq ID No : 50 & 51 408522 AI541214 Hs. 46320 Small proline-rich protein SPRK [human, Seq ID No: 52 & 53 422158 L10343 Hs. 112341 protease inhibitor 3, skin-derived (SKAL Seq ID No: 54 & 55 435505 AF200492 Hs. 211238 interleukin-1 homolog 1 Seq ID No: 56 & 57 417366 BE185289 Hs. 1076 small proline-rich protein 1B (cornifin) Seq ID No: 58 & 59 431958 X63629 Hs. 2877 cadherin 3, type 1, P-cadherin (placenta Seq ID No: 60 & 61 441020 W79283 Hs. 35962 ESTs Seq ID No: 62 & 63 423217 NM_000094 Hs. 1640 collagen, type VII, alpha 1 (epidermolys Seq D No: 64 & 65 429538 BE182592 Hs. 11261 small proline-rich protein 2A Seq ID No : 66 & 67 448733 NM_005629 Hs. 187958 solute carrier family 6 (neurotransmitte Seq ID No: 68 & 69 444371 BE540274 Hs. 239 forkhead box M1 Seq ID No: 70 & 71 444371 BE540274 Hs. 239 forkhead box M1 Seq ID No : 72 & 73 444371 BE540274 Hs. 239 forkhead box M1 Seq tO No : 74 & 75 422168 AA586894 Hs. 112408 S100 calcium-binding protein A7 (psorias Seq ID No : 76 & 77 422168 AA586894 Hs. 112408 S100 calcium-binding protein A7 (psorias Seq ID No: 78 & 79 429259 AA420450 Hs. 292911 Plakophilin Seq ID No: 80 & 81 426440 BE382756 Hs. 169902 solute carrier family 2 (facilitated glu Seq ID No: 82 & 83 437044 AL035864 Hs. 69517 differentially expressed in Fanconi's an Seq ID No: 84 & 85 423662 AK001035 Hs. 130881 B-cell CLUlymphoma 11A (zinc finger pro Seq ID No : 86&87 428484 AF104032 Hs. 184601 solute carrier family 7 (cationic amino Seq ID No: 88 & 89 429211 AF052693 Hs. 198249 gap junction protein, beta 5 (connexin 3 Seq ID No: 90 & 91 417389 BE260964 Hs. 82045 midkine (neurite growth-promoting factor Seq D No: 92 & 93 423634 AW959908 Hs. 1690 heparin-binding growth factor binding pr Seq ID No : 94 & 95 417515 L24203 Hs. 82237 ataxia-telangiectasia group D-associated Seq ID No: 96 & 97 441362 BE614410 Hs. 23044 RAD51 (S. cerevisiae) homolog (E coli Re Seq ID No: 98 & 99 425322 U63630 Hs. 155637 protein kinase, DNA-activated, catalytic Seq D No: 100 & 101 449003 X76342 Hs. 389 alcohol dehydrogenase 7 (class IV), mu o Seq ID No : 102 & 103 431009 BE149762 Hs. 48956 gap junction protein, beta 6 (connexin 3 Seq ID No: 104 & 105 409103 AF251237 Hs. 112208 XAGE-1 protein Seq ID No: 106 & 107 417542 J04129 Hs. 82269 progestagen-associated endometrial prote Seq ID No : 108 & 109 428471 X57348 Hs. 184510 stras'fin Seq ID No : 110&111 418004 U37519 Hs. 87539 aldehyde dehydrogenase 3 family, member Seq ID No : 112 & 113 414761 AU077228 Hs. 77256 enhancer of zeste (Drosophila) homolog 2 Seq ID No : 114 & 115 418203 X54942 Hs. 83758 CDC28 protein kinase 2 Seq ID No : 116 447343 AA256641 Hs. 236894 ESTs, Highly similar to S02392 alpha-2-m Seq ID No : 117 & 118 437016 AU076916 Hs. 5398 guanine monphosphate synthetase Seq ID No: 119 & 120 449230 BE613348 Hs. 211579 melanoma cell adhesion molecule Seq ID No: 121 & 122 446989 AK001898 Hs. 16740 hypothetical protein FLJ11036 Seq ID No: 123 & 124 457819 AA057484 Hs. 35406 ESTs, Highly similar to unnamed protein Seq ID No: 125 & 126 424687 J05070 Hs. 151738 matrix metalloproteinase 9 (gelatinase B

Seq D No: 127 & 128 414430 At346201 Hs. 76118 ubiquitin carboxyl-terminal esterase L1 Seq ID No : 129 & 130 418462 BE001596 Hs. 85266 integrin, beta 4 Seq ID No : 131 & 132 100668 L05424 Hs. 169610 CD44 antigen (homing function and Indian Seq ID No : 133 & 134 458933 AI638429 Hs. 24763 RAN binding protein 1 Seq ID No : 135&136 418478 U38945 Hs. 1174 cyclin-dependent kinase inhibitor 2A (me Seq ID No : 137&138 418478 U38945 Hs. 1174 cyclin-dependent kinase inhibitor 2A (me Seq DNo : 139&140 418478 U38945 Hs. 1174 cyclin-dependent kinase inhibitor 2A (me Seq ID No : 141&142 418478 U38945 Hs. 1174 cyclin-dependent kinase inhibitor 2A (me Seq ID No: 143 & 144 446269 AW263155 Hs. 14559 hypothetical protein FLJ10540 Seq ID No: 145 & 146 422765 AW409701 Hs. 1578 baculoviral IAP repeat-containing 5 (sur Seq ID No : 147 & 148 436481 AA379597 Hs. 5199 HSPC150 protein similar to ubiquitin-con Seq ID No: 149 & 150 440325 NM_003812 Hs. 7164 a disintegrin and metalloproteinase doma Seq ID No : 151 & 152 439606 W79123 Hs. 58561 G protein-coupled receptor 87 Seq ID No: 153 & 154 453884 AA355925 Hs. 36232 KIAA0186 gene product Seq tD No: 155 & 156 453884 AA355925 Hs. 36232 KIAA0186 gene product Seq ID No: 157 & 158 453884 AA355925 Hs. 36232 K M0186 gene product Seq ID No : 159&160 453884 AA355925 Hs. 36232 KIAA0186 gene product Seq ID No: 161 & 162 404877 NM005365 : Homo sapiens melanoma antigen, Seq ID No : 163 & 164 413129 AF292100 Hs. 104613 RP42 homolog Seq ID No: 165 & 166 413281 AA861271 Hs. 222024 transcription factor BMAL2 Seq ID No: 167 & 168 444781 NM_014400 Hs. 11950 GPI-anchored metastasis-associated prote Seq ID No : 169 & 170 416819 U77735 Hs. 80205 pim-2 oncogene Seq tD No: 171 & 172 451320 AW118072 diacylglycerol kinase, zeta (104kD) Seq tD No: 173 & 174 418543 NM005329 Hs. 85962 hyaluronan synthase 3 Seq ID No: 175 & 176 454034 NM 000691 Hs. 575 aidehyde dehydrogenase 3 family, member Seq ID No: 177 & 178 425397 J04088 Hs. 156346 topoisomerase (DNA) II alpha (170kD) Seq ID No: 179 & 180 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq ID No: 181 & 182 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq D No: 183 & 184 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq ID No: 185 & 186 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq tD No: 187 & 188 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq ID No: 189 & 190 419121 AA374372 Hs. 89626 parathyroid hormone-like hormone Seq ID No : 191&192 448993 AI471630 Hs. 8127 KIAA0144 gene product Seq ID No: 193 & 194 421817 AF146074 Hs. 108660 ATP-binding cassette, sub-family C (CFTR Seq ID No : 195 & 196 430393 BE185030 Hs. 241305 estrogen-responsive B box protein Seq ID No : 197&198 425057 AA826434 Hs. 1619 achaete-scute complex (Drosophila) homol Seq ID No: 199 & 200 420462 AF050147 Hs. 97932 chondromodulin I precursor Seq DNo : 201&202 102963 X02404 Hs. 274534 calcitonin-related polypeptide, beta Seq ID No: 203 & 204 100576 X00356 Hs. 37058 calcitonin/calcitonin-related polypeptid Seq ID No: 205 & 206 101175 U82671 Hs. 36980 melanoma antigen, family A, 2 Seq tD No: 207 & 208 429038 AL023513 Hs. 194766 seizure related gene 6 (mouse)-like Seq ID No: 209 & 210 418678 NM001327 Hs. 167379 cancer/testis antigen (NY-ESO-1) Seq ID No : 211 & 212 418678 NM001327 Hs. 167379 canet/lestis antigen (NY-ESO-1) Seq ID No: 213 & 214 131927 AJ003112 Hs. 34780 doublecortex ; lissencephaly, X-linked (d Seq ID No : 215 & 216 428182 BE386042 Hs. 293317 ESTs, Weakly similar to GGC1_HUMAN G ANT Seq ID No : 217 & 218 427335 AA448542 Hs. 251677 G antigen 7B Seq ID No: 219 & 220 409420 Z15008 Hs. 54451 laminin, gamma 2 (nicein (100kD), katini Seq ID No: 221 & 222 114346 AL137256 Hs. 130489 ATPase, aminophospholipid transporter-li Seq ID No: 223 & 224 438956 W00847 Hs. 135056 Human DNA sequence from clone RP5-850E9 Seq ID No: 225 & 226 404440 NM_021048 : Homo sapiens melanoma antigen, Seq ID No : 227&228 415669 NM_005025 Hs. 78589 serine (orcysteine) proteinaseinhibito Seq ID No : 229 & 230 103312 Y12642 Hs. 3185 lysosomal Seq D No: 231 & 232 320843 BE069288 Hs. 34744 Homo sapiens mRNA ; cDNA DKFZp547C136 (fr Seq ID No : 233 429065 Ai753247 Hs. 29643 Homo sapiens cDNA FLJ13103 fis, clone NT Seq ID No : 234&235 446102 AW168067 Hs. 317694 ESTs Seq ID No : 236 & 237 330495 U47924 Hs. 71642 guanine nucleotide binding protein (G pr Seq ID No : 238 413573 A1733859 Hs. 149089 ESTs Seq D No: 239 & 240 428479 Y00272 Hs. 334562 cell division cycle 2, G1 to S and G2 to Seq ID No: 241 & 242 428479 Y00272 Hs. 334562 cell division cycle 2, G1 to S and G2 to Seq ID No : 243 & 244 332180 AF134160 Hs. 7327 claudin 1 Seq ID No : 245 437915 AI637993 Hs. 202312 Homo sapiens clone N11 NTera2D1 teratoca Seq ID No: 246 & 247 441553 AA281219 Hs. 121296 ESTs Seq ID No: 248 & 249 331692 A1683487 Hs. 152213 wingless-type MMTV integration site fami Seq ID No: 250 & 251 429413 NM014058 Hs. 201877 DESC1 protein Seq ID No : 252 & 253 422283 AW411307 Hs. 114311 CDC45 (cell division cycle 45, S. cerevis Seq IN No: 254 & 255 448357 N20169 Hs. 108923 RAB38, member RAS oncogene family Seq ID No : 256 & 257 446292 AF081497 Hs. 279682 Rh type C glycoprotein Seq D No : 258 & 259 416209 AA236776 Hs. 79078 MAD2 (mitotic arrest deficient, yeast, h Seq D No: 260 & 261 453922 AF053306 Hs. 36708 budding uninhibited by benzimidazoles 1 Seq ID No : 262 & 263 424046 AF027866 Hs. 138202 serine (or cysteine) proteinase inhibito Seq ID No: 264 & 265 439223 AW238299 Hs. 250618 UL16 binding protein 2 Seq ID No: 266 & 267 429228 AI553633 Hs. 326447 ESTs Seq ID No : 268&269 409757 NM_001898 Hs. 123114 cystatin SN Seq ID No : 270 & 271 411089 AA456454 Hs. 214291 cell division cycle 2-like 1 (PITSLRE pr Seq ID No: 272 & 273 436511 AA721252 Hs. 291502 ESTs Seq ID No: 274 & 275 428969 AF120274 Hs. 194689 artemin Seq D No: 276 & 277 428969 AF120274 Hs. 194689 artemin Seq ID No: 278 & 279 428969 AF120274 Hs. 194689 artemin Seq ID No: 280 & 281 428969 AF120274 Hs. 194689 artemin Seq ID No: 282 407137 T97307 gb: ye53h05. sl Scares fetal liver spleen Seq ID No: 283 & 284 412723 AA648459 Hs. 335951 hypothetical protein AF301222 Seq ID No : 285 & 286 450701 H39960 Hs. 288467 hypothetical protein XP_098151 (leucine- Seq ID No : 287 & 288 405770 NM002362 : Homo sapiens melanoma antigen, Seq ID No: 289 & 290 439453 BE264974 Hs. 6566 thyroid hormone receptor interactor 13 Seq ID No: 291 & 292 414774 X02419 Hs. 77274 plasminogen activator, urokinase

Seq ID No : 293 & 294 424629 M90656 Hs. 151393 glutamate-cysteine ligase, catalytic sub Seq ID No : 295 & 296 437789 AI581344 Hs. 127812 ESTs, Weakly similar to T17330 hypotheti Seq ID No : 297 & 298 437789 AI581344 Hs. 127812 ESTs, Weakly similar to T17330 hypotheti Seq ID No : 299&300 437789 AI581344 Hs. 127812 ESTs, Weakly similar to T17330 hypotheti Seq ID No : 301 & 302 437789 AI581344 Hs. 127812 ESTs, Weakly similar to T17330 hypotheti Seq ID No : 303&304 437789 AI581344 Hs. 127812 ESTs, Weakly similar to T17330 hypotheu Seq ID No: 305 & 306 453968 AA847843 Hs. 62711 High mobility group (nonhistone chromoso Seq D No : 307 & 308 403478 NM_022342 : Homo sapiens kinesin protein 9 Seq ID No : 309 441525 AW241867 Hs. 127728 ESTs Seq ID No : 310 & 311 434105 AW952124 Hs. 13094 presenilins associated rhomboid-like pro Seq ID No : 312 & 313 428810 AF068236 Hs. 193788 nitric oxide synthase 2A (inducible, hep Seq ID No : 314&315 413691 AB023173 Hs. 75478 ATPase, Class Vi, type 11 B Seq ID No : 316 & 317 423934 U89995 Hs. 159234 forkhead box E1 (thyroid transcription f Seq ID No : 318 & 319 409228 R16811 Hs. 22010 ESTs, Weakly similar to 2109260A B cell Seq ID No : 320 & 321 425734 AF056209 Hs. 159396 peptidylglycine atpha-amidating monooxyg Seq ID No : 322 & 323 413582 AW295647 Hs. 71331 hypothetical protein MGC5350 Seq ID No : 324 & 325 438403 AA806607 Hs. 292206 ESTs Seq ID No : 326 & 327 403329 unnamed protein product [Homo sapiens] Seq ID No : 328 & 329 409893 AW247090 Hs. 57101 minichromosome maintenance deficient (S.

Seq ID No : 330 & 331 119073 BE245360 Hs. 279477 v-ets erythroblastosis virus E26 oncogen Seq ID No : 332&333 113195 H83265 Hs. 8881 ESTs, Weakly similar to S41044 chromosom Seq ID No : 334&335 102283 AW161552 Hs. 83381 guanine nucleotide binding protein 11 Seq ID No : 336 & 337 101345 NM_005795 Hs. 152175 calcitonin receptor-like Seq ID No : 338 & 339 103280 U84722 Hs. 76206 cadherin 5, type 2, VE-cadherin (vascula Seq ID No : 340&341 102012 BE259035 Hs. 118400 singed (Drosophila)-like (sea urchin fas Seq ID No : 342 & 343 105729 H46612 Hs. 293815 Homo sapiens HSPC285 mRNA, partial cds Seq ID No : 344 & 345 134299 AW580939 Hs. 97199 complement component Clq receptor Seq ID No : 346&347 412719 AW016610 Hs. 816 ESTs Seq ID No : 348&349 422158 L10343 Hs. 112341 protease inhibitor 3, skin-derived (SKAL Seq ID No : 350 & 351 128924 BE279383 Hs. 26557 plakophilin 3 Seq ID No : 352 & 353 100486 T19006 Hs. 10842 RAN, member RAS oncogene family Seq ID No : 354&355 419121 AA374372 Hs. 89626 parathyroid hormone-like hormone Seq ID No : 356 & 357 409459 D86407 Hs. 54481 low density lipoprotein receptor-related Seq ID No : 358 & 359 330493 M27826 endogenous retroviral protease Seq ID No : 360 & 361 417866 AW067903 Hs. 82772 collagen, type XI, alpha 1 Seq ID No : 362&363 418113 Ai272141 Hs. 83484 SRY (sex determining region Y)-box 4 Seq ID No : 364 & 365 437016 AU076916 Hs. 5398 guanine monphosphate synthetase Seq ID No : 366 & 367 429612 AF062649 Hs. 252587 pituitary tumor-transforming 1 Seq ID No : 368 & 369 440704 M69241 Hs. 162 insulin-like growth factor binding prote Seq ID No : 370 & 371 431221 AA449015 Hs. 286145 SRB7 (suppressor of RNA polymerase B, ye Seq ID No : 372 & 373 431565 AF161470 Hs. 260622 butyrate-induced transcript 1 Seq ID No : 374 & 375 431565 AF161470 Hs. 260622 butyrate-induced transcript 1 Seq ID No : 376 & 377 132354 BE185289 Hs. 1076 small proline-rich protein 18 (comifin) Seq ID No : 378 & 379 424441 X14850 Hs. 147097 H2A histone family, member X Seq ID No : 380 & 381 103768 AF086009 Hs. 296398 gb : Homo sapiens full length insert cDNA Seq ID No : 382 & 383 417512 X76534 Hs. 82226 glycoprotein (transmembrane) nmb Seq ID No : 384 & 385 425266 J00077 Hs. 155421 alpha-fetoprotein Seq ID No : 386 & 387 424503 NM002205 Hs. 149609 integrin, alpha 5 (fibronectin receptor, Seq ID No : 388 & 389 400289 X07820 Hs. 2258 matrix metalloproteinase 10 (stromelysin Seq ID No : 390 & 391 418007 M13509 Hs. 83169 matrix metalloproteinase 1 (interstitial Seq ID No : 392 & 393 418007 M13509 Hs. 83169 matrix metallproteinase 1 (interstitial Seq ID No : 394 & 395 418738 AW388633 Hs.6682 solute carrier family 7, (cationic amino Seq ID No : 396 & 397 415138 C18356 Hs. 295944 tissue factor pathway inhibitor 2 Seq ID No : 398 & 399 418506 AA084248 Hs. 85339 G protein-coupled receptor 39 Seq ID No : 400&401 423961 D13666 Hs. 136348 periostin (OSF-2os) Seq ID No: 402 & 403 414812 X72755 Hs. 77367 monokine induced by gamma interferon Seq ID No : 404 & 405 417433 BE270266 Hs. 82128 5T4 oncofetal trophoblast glycoprotein Seq ID No : 406 & 407 417433 BE270266 Hs. 82128 5T4 oncofetal trophoblast glycoprotein Seq ID No : 408 & 409 422867 L32137 Hs. 1584 cartilage oligomeric matrix protein (pse Seq ID No : 410&411 428227 AA321649 Hs. 2248 small inducible cytokine subfamily B (Cy Seq ID No : 412&413 444381 BE387335 Hs. 283713 ESTs, Weakly similar to S64054 hypotheti Seq ID No : 414 & 415 400303 AA242758 Hs. 79136 LIV-1 protein, estrogen regulated Seq ID No : 416 & 417 411789 AF245505 Hs. 72157 Adlican Seq ID No : 418 & 419 428698 AA852773 Hs. 334838 KIAA1866 protein Seq ID No : 420 & 421 450098 W27249 Hs. 8109 hypothetical protein FLJ21080 Seq ID No : 422 & 423 421552 AF026692 Hs. 105700 secreted frizzled-related protein 4 Seq ID No : 424 & 425 452747 BE153855 Hs. 61460 lg superfamily receptor LNIR Seq ID No : 426 & 427 450375 AA009647 a disintegrin and meta ! loproteinase doma Seq ID No : 428 & 429 426215 AW963419 Hs. 155223 stanniocatein 2 Seq ID No : 430 & 431 425247 NM_005940 Hs. 155324 matrix metalloproteinase 11 (stromelysin Seq ID No : 432 & 433 432201 AI538613 Hs. 298241 Transmembrane protease, serine 3 Seq ID No : 434&435 427585 D31152 Hs. 179729 collagen, type X, alpha 1 (Schmid metaph Seq ID No : 436 & 437 442117 AW664964 Hs. 128899 ESTS ; hypothetical protein for IMAGE : 447 Seq ID No : 438 & 439 431211 M86849 Hs. 323733 gap Junction protein, beta 2, 26kD (conn Seq ID No : 440 & 441 447033 At357412 Hs. 157601 ESTs Seq ID No : 442 & 443 447033 AI357412 Hs. 157601 ESTs Seq ID No : 444&445 447033 AI357412 Hs. 157601 ESTs Seq ID No : 446&447 115522 BE614387 Hs. 333893 c-Myc targetJP01 Seq ID No : 448 & 449 410418 D31382 Hs. 63325 transmembrane protease, serine 4 Seq ID No : 450&451 409041 AB033025 Hs. 50081 Hypothetical protein, XP_051860 (KIAA119 Seq ID No : 452 & 453 409041 AB033025 Hs. 50081 Hypothetical protein, XP-051860 (KIAA119 Seq ID No : 454 & 455 452461 N78223 Hs. 108106 transcription factor Seq ID No : 456 & 457 412420 AL035668 Hs. 73853 bone morphogenetic protein 2 Seq ID No : 458 & 459 416658 U03272 Hs. 79432 fibrillin 2 (congenital contractural ara Seq ID No : 460 & 461 407811 AW190902 Hs. 40098 cysteine knot superfamily 1, BMP antagon

Seq ID No: 462 & 463 437852 BE001836 Hs. 256897 ESTs, Weakly similar to dJ365O12. 1 [H. sa Seq ID No: 464 & 465 402075 ENSP0000251056* : Plasma membrane calcium Seq ID No : 466 & 467 421110 AJ250717 Hs. 1355 cathepsin E Seq ID No : 468 & 469 451668 Z43948 Hs. 326444 cartilage acidic protein 1 Seq ID No : 470 & 471 451668 Z43948 Hs. 326444 cartilage acidic protein 1 Seq ID No : 472 & 473 451668 Z43948 Hs. 326444 cartilage acidic protein 1 Seq ID No : 474&475 422282 AF019225 Hs. 114309 apolipoprolein L Seq ID No : 476 & 477 425852 AK001504 Hs. 159651 death receptor 6, TNF superfamily member Seq ID No : 478 & 479 439738 BE246502 Hs. 9598 sema domain, immunoglobulin domain (Ig), Seq ID No: 480 & 481 427747 AW411425 Hs. 180655 serine/threonine kinase 12 Seq ID No: 482 & 483 420281 AI623693 Hs. 323494 Predicted cation efflux pump Seq ID No : 484 & 485 405932 C15000305: gi#3806122#gb#AAC69198.1# (AFO Seq ID No: 486 & 487 405932 C15000305 : gi#3806122#gb#AAC69198.1# (AF0 Seq ID No: 488 & 489 444342 NM_014398 Hs. 10887 similar to lysosome-associated membrane Seq ID No : 490&491 421379 Y15221 Hs. 103982 small inducible cytokine subfamily B (Cy Seq ID No : 492&493 417079 U65590 Hs. 81134 interleukin 1 receptor antagonist Seq ID No : 494 & 495 430890 X54232 Hs. 2699 glypican 1 Seq ID No : 496 & 497 419721 NM001650 Hs. 288650 aquaporin 4 Seq D No: 498 & 499 444471 AB020684 Hs. 11217 KIAA0877 protein Seq ID No : 500 & 501 413063 AL035737 Hs. 75184 chitinase 3-like 1 (cartilage glycoprote Seq ID No: 502 & 503 433800 A1034361 Hs. 135150 lung type-I cell membrane-associated gly Seq tO No : 504 & 505 452401 NM_007115 Hs. 29352 tumor necrosis factor, alpha-induced pro Seq ID No: 506 & 507 452401 NM_007115 Hs. 29352 tumor necrosis factor, alpha-induced pro Seq ID No : 508 & 509 450001 NM001044 Hs. 406 solute carrier family 6 (neurotransmitte Seq ID No : 510 & 511 410407 X66839 Hs. 63287 carbonic anhydrase IX Seq ID No : 512 & 513 309931 AW341683 gb: hd13d01.x1 Soares_NFL_T_GBC_S1 Homo s Seq ID No: 514 & 515 412719 AW016610 Hs. 816 ESTs Seq D No: 516 & 517 417034 NM_006183 Hs. 80962 neurotensin Seq ID No: 518 & 519 430486 BE062109 Hs. 241551 chloride channel, calcium activated, fam Seq D No: 520 & 521 413753 U17760 Hs. 75517 laminin, beta 3 (nicein (125kD), kalinin Seq ID No: 522 & 523 425650 NM001944 Hs. 1925 desmogtein 3 (pemphigus vulgaris antigen Seq ID No : 524 & 525 423673 BE003054 Hs. 1695 matrix metalloproteinase 12 (macrophage Seq ID No : 526&527 418663 AK001100 Hs. 41690 desmocollin 3 Seq ID No : 528&529 418663 AK001100 Hs. 41690 desmocollin 3 Seq ID No : 530 & 531 429610 AB024937 Hs. 211092 LUNX protein ; PLUNC (palate lung and nas Seq tD No: 532 & 533 406690 M29540 Hs. 220529 carcinoembryonic antigen-related cell ad Seq ID No : 534 & 535 431846 BE019924 Hs. 271580 uroplakin 1B Seq ID No : 536 & 537 422158 L10343 Hs. 112341 protease inhibitor 3, skin-derived (SKAL Seq ID No : 538 & 539 431958 X63629 Hs. 2877 cadherin 3, type 1, P-cadherin (placenta Seq 10 No: 540 & 541 437044 AL035864 Hs. 69517 differentially expressed in Fanconi's an Seq ID No : 542 & 543 428484 AF104032 Hs. 184601 solute carrier family 7 (cationic amino Seq ID No: 544 & 545 429211 AF052693 Hs. 198249 gap junctionprotein, bela 5 (connexin 3 Seq ID No : 546 & 547 417389 BE260964 Hs. 82045 midkine (neurite growth-promoting factor Seq ID No: 548 & 549 431009 BE149762 Hs. 48956 gap junction protein, beta 6 (connexin 3 Seq D No: 550 & 551 417542 J04129 Hs. 82269 progestagen-associated endometrial prote Seq ID No : 552 & 553 449230 BE613348 Hs. 211579 melanoma ceil adhesion molecule Seq ID No : 554&555 410555 U92649 Hs. 64311 adisintegrinandmetaibproteinasedoma Seq ID No : 556 & 557 410555 U92649 Hs. 64311 a disintegrin and metalloproteinase doma Seq ID No : 558 & 559 424687 J05070 Hs. 151738 matrix metalloproteinase 9 (gelatinase B Seq ID No : 560 & 561 418462 BE001596 Hs. 85266 integrin, beta 4 Seq ID No : 562 & 563 410274 AA381807 Hs. 61762 hypoxia-inducible protein2.

Seq ID No: 564 & 565 439606 W79123 Hs. 58561 G protein-coupled receptor 87 Seq ID No: 566 & 567 404877 NM_005365 : Homo sapiens melanoma antigen, Seq D No : 568 & 569 444781 NM014400 Hs. 11950 GPI-anchored metastasis-associated prote Seq ID No: 570 & 571 418543 NM_005329 Hs. 85962 hyaluronan synthase 3 Seq ID No: 572 & 573 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq ID No: 574 & 575 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq ID No: 576 & 577 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq ID No: 578 & 579 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq ID No : 580 & 581 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq ID No : 582 & 583 415817 U88967 Hs. 78867 protein tyrosine phosphatase, receptor-t Seq ID No: 584 & 585 421817 AF146074 Hs. 108660 ATP-binding cassette, sub-family C (CFTR Seq ID No : 586 & 587 418678 NM_001327 Hs. 167379 cancer/testis antigen (NY-ESO-1) Seq ID No : 588 & 589 418678 NM_001327 Hs. 167379 cancer/lestis antigen (NY-ESO-1) Seq ID No : 590 & 591 409420 Z15008 Hs. 54451 laminin, gamma 2 (nicein (100kD), kaiini Seq ID No : 592 & 593 332180 AF134160 Hs. 7327 claudin 1 Seq D No: 594 & 595 408790 AW580227 Hs. 47860 neurotrophic tyrosine kinase, receptor, Seq ID No: 596 & 597 408790 AW580227 Hs. 47860 neurotrophic tyrosine kinasa, receptor, Seq ID No: 598 & 599 439223 AW238299 Hs. 250618 UL16 binding protein 2 Seq ID No : 600 & 601 409757 NM_001898 Hs. 123114 cystatin SN Seq ID No : 602 & 603 428969 AF120274 Hs. 194689 artemin Seq ID No : 604 & 605 428969 AF120274 Hs. 194689 artemin Seq ID No : 606 & 607 428969 AF120274 Hs. 194689 artemin Seq ID No : 608 & 609 428969 AF120274 Hs. 194689 artemin Seq ID No : 610&611 450701 H39960 Hs. 288467 hypothetical protein XP-098151 (leucine- Seq ID No : 612 & 613 450701 H39960 Hs. 288467 hypothetical protein XP_098151 (leucine- Seq ID No : 614 & 615 414774 X02419 Hs. 77274 plasminogen activator, urokinase Seq ID No : 616 & 617 407944 R34008 Hs. 239727 desmocollin 2 Seq ID No: 618 & 619 407944 R34008 Hs. 239727 desmocollin 2 Seq ID No : 620 & 621 457489 AI693815 Hs. 127179 cryptic gene Seq ID No: 622 & 623 429547 AW009166 Hs. 99376 ESTs Seq ID No: 624 & 625 407242 M18728 gb: Human nonspecific crossreacting antig Seq D No: 626 & 627 407242 M18728 gb: Human nonspecific crossreacting antig Seq ID No: 628 & 629 407242 M18728<BR> <BR> Seq ID No: 628 & 629 407242 M18728 gb:Human nonspecific crossreacting antig<BR> <BR> <BR> Seq ID No: 630 & 631 444006 BE395085 Hs. 10086 type I transmembrane protein Fn14

Seq ID No : 632 & 633 429597 NM_003816 Hs. 2442 a disintegrin and metalloproteinase doma Seq ID No : 634 & 635 422109 S73265 Hs. 1473 gastrin-releasing pepUde Seq ID No : 636 & 637 419235 AW470411 Hs. 288433 neurotnmin Seq ID No : 638 & 639 449048 Z45051 Hs. 22920 similar to S68401 (caHle) glucose induc Seq ID No : 640 & 641 419216 AU076718 Hs. 164021 small inducible cytokine subfamily B (Cy Seq ID No : 642 & 643 431462 AW583672 Hs. 256311 grainin-like neuroendocrine peptide precu Seq ID No : 644 & 645 448243 AW369771 Hs. 52620 integrin, beta 8 Seq ID No : 646 & 647 426427 M86699 Hs. 169840 TTK protein kinase Seq ID No : 648 & 649 445537 AJ245671 Hs. 12844 EGF-like-domain, multiple 6 Seq ID No : 650 & 651 422278 AF072873 Hs. 114218 frizzled (Drosophila) homolog 6 Seq ID No : 652 & 653 428450 NM_014791 Hs. 184339 KIAA0175 gene product Seq ID No : 654 & 655 446619 AU076643 Hs. 313 secreted phosphoprotein 1 (osteopontin, Seq ID No : 656 & 657 453392 U23752 Hs. 32964 SRY (sex determining region Y)-box 11 Seq ID No : 658 & 659 426514 BE616633 Hs. 170195 bone morphogenetic protein 7 (osteogenic Seq ID No : 660 & 661 425776 U25128 Hs. 159499 parathyroid hormone receptor 2 Seq ID No : 662 & 663 425776 U25128 Hs. 159499 parathyroid hormone receptor 2 Seq ID No : 664 & 665 431515 NM012152 Hs. 258583 endotheiiai differentiation, iysophospha Seq ID No : 666 & 667 419452 U33635 Hs. 90572 PTK7 protein tyrosine kinase 7 Seq ID No : 668 & 669 432653 N62096 Hs. 293185 ESTs, Weakly similar to JC7328 amino aci Seq D No : 670 & 671 432653 N62096 Hs. 293185 ESTs, Weakly similar to JC7328 amino aci Seq ID No : 672 & 673 432653 N62096 Hs. 293185 ESTs, Weakly similar to JC7328 amino aci Seq ID No : 674&675 432653 N62096 Hs. 293185 ESTs, Weakly similar to JC7328 amino aci Seq ID No : 676 & 677 410001 AB041036 Hs. 57771 kallikrein 11 Seq ID No : 678 & 679 426501 AW043782 Hs. 293616 ESTs Seq ID No : 680 & 681 408369 R38438 Hs. 182575 sotute carrier family 15 (H ? 7 ? transport Seq ID No : 682 & 683 445413 AA151342 Hs. 12677 CGI-147 protein SeqID No : 684&685 422424 AI186431 Hs. 296638 prostate differentiation factor Seq ID No : 686 & 687 428330 L22524 Hs. 2256 matrix metalloproteinase 7 (matrilysin, Seq ID No : 688 & 689 420610 AI683183 Hs. 99348 distal-less homeo box 5 TABLE 15B Pkey : Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT Number Accession 309931 AW341683 330493 33264_5 M27826 R78416 AA307645 AW957879 AW957800 AA633529 H03662 439285 47065_1 AL133916 N79113 AF086101 N76721 AW950828 AA364013 AW955684 AI346341 AI867454 N54784 AI655270 AI421279 AW014882 AA775552 N62351 N59253 AA626243 AI341407 BE175639 AA456968 AI358918 AA457077 450375 83327_1 AA009647 AA131254 AA374293 AW954405 H04410 AW606284 AA151166 BE157467 BE157601 H04384 W46291 AW663674 H04021 H01532.

AA190993 H03231 H59605 H01642 AA852876 AA113758 AA626915 AA746952 Ai161014 AA099554 R69067 451320 88576_1 AW118072 A1631982 T15734 AA224195 A1701458 W20198 F26326 AA890570 N90552 AW071907 AI671352 AI375892 T03517 R88265 AI124088 AA224388 AI084316 AI354686 T33652 AI140719 AI720211 T03490 A1372637 T15415 AW205836 AA630384 T03515 T33230 AA017131 AA443303 T33623 AI222556 T33511 T33785 AI419606 D55612 TABLE 15C Pkey: Unique number corresponding to an Eos probeset Ref : Sequence source. The 7 digit numbers in this column are Genbank identifier (GI) numbers. "Dunham I. et al."refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I, et al., Nature (1999) 402: 489-495.

Strand: indicates DNA strand from which exons were predicted.

Ntposition : indicates nucleotide positions of predicted exons.

Pkey Ref Strand Nt_position 402075 8117407 Plus 121907-122035, 122804-122921, 124019-124161, 124455-124610, 125672-126076 403329 8516120 Plus 96450-96598 403478 9958258 Plus 116458-116564 404440 7528051 Plus 80430-81581 404877 1519284 Plus 1095-2107 405770 2735037 Plus 61057-62075 405932 7767812 Minus 123525-123713

Table 16

IWISFFEIYN ELLYDLLEPP SQQRKRQTLR LCEDQNGNPY VKDLNWIHVQ DAEEAWKLLK 360 VGRKNQSFAS THLNQNSSRS HSIFSIRILH LQGEGDIVPK ISELSLCDLA GSERCKDQKS 420 GERLKEAGNI NTSLHTLGRC IAALRQNQQN RSKQNLVPFR DSKLTRVFQG FFTGRGRSCM 480 IVNVNPCAST YDETLHVAKF SAIASQVTCA CPTYATGIPI PALVHQGT Seq ID NO: 27 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 13-1424 1 11 21 31 41 51 TAGAAGTTTA CAATGAAGTT TCTTCTAATA CTGCTCCTGC AGGCCACTGC TTCTGGAGCT 60 CTTCCCCTGA ACAGCTCTAC AAGCCTGGAA AAAAATAATG TGCTATTTGG TGAAAGATAC 120 TTAGAAAAAT TTTATGGCCT TGAGATAAAC AAACTTCCAG TGACAAAAAT GAAATATAGT 180 GGAAACTTAA TGAAGGAAAA AATCCAAGAA ATGCAGCACT TCTTGGGTCT GAAAGTGACC 240 GGGCAACTGG ACACATCTAC CCTGGAGATG ATGCACGCAC CTCGATGTGG AGTCCCCGAT 300 GTCCATCATT TCAGGGAAAT GCCAGGGGGG CCCGTATGGA GGAAACATTA TATCACCTAC 360 AGAATCAATA ATTACACACC TGACATGAAC CGTGAGGATG TTGACTACGC AATCCGGAAA 420 GCTTTCCAAG TATGGAGTAA TGTTACCCCC TTGAAATTCA GCAAGATTAA CACAGGCATG 480 GCTGACATTT TGGTGGTTTT TGCCCGTGGA GCTCATGGAG ACTTCCATGC TTTTGATGGC 540 AAAGGTGGAA TCCTAGCCCA TGCTTTTGGA CCTGGATCTG GCATTGGAGG GGATGCACAT 600 TTCGATGAGG ACGAATTCTG GACTACACAT TCAGGAGGCA CAAACTTGTT CCTCACTGCT 660 GTTCACGAGA TTGGCCATTC CTTAGGTCTT GGCCATTCTA GTGATCCAAA GGCCGTAATG 720 TTCCCCACCT ACAAATATGT TGACATCAAC ACATTTCGCC TCTCTGCTGA TGACATACGT 780 GGCATTCAGT CCCTGTATGG AGACCCAAAA GAGAACCAAC GCTTGCCAAA TCCTGACAAT 840 TCAGAACCAG CTCTCTGTGA CCCCAATTTG AGTTTTGATG CTGTCACTAC CGTGGGAAAT 900 AAGATCTTTT TCTTCAAAGA CAGGTTCTTC TGGCTGAAGG TTTCTGAGAG ACCAAAGACC 960 AGTGTTAATT TAATTTCTTC CTTATGGCCA ACCTTGCCAT CTGGCATTGA AGCTGCTTAT 1020 GAAATTGAAG CCAGAAATCA AGTTTTTCTT TTTAAAGATG ACAAATACTG GTTAATTAGC 1080 AATTTAAGAC CAGAGCCAAA TTATCCCAAG AGCATACATT CTTTTGGTTT TCCTAACTTT 1140 GTGAAAAAAA TTGATGCAGC TGTTTTTAAC CCACGTTTTT ATAGGACCTA CTTCTTTGTA 1200 GATAACCAGT ATTGGAGGTA TGATGAAAGG AGACAGATGA TGGACCCTGG TTATCCCAAA 1260 CTGATTACCA AGAACTTCCA AGGAATCGGG CCTAAAATTG ATGCAGTCTT CTACTCTAAA 1320 AACAAATACT ACTATTTCTT CCAAGGATCT AACCAATTTG AATATGACTT CCTACTCCAA 1380 CGTATCACCA AAACACTGAA AAGCAATAGC TGGTTTGGTT GTTGAAAATG GTGTAATTAA 1440 TGGTTTTTGT TAGTTCACTT CAGCTTAATA AGTATTTATT GCATATTTGC TATGTCCTCA 1500 GTGTACCACT ACTTAGAGAT ATGTATCATA AAAATAAAAT CTGTAAACCA TAGGTAATGA 1560 TTATATAAAA TACATAATAT TTTTCAATTT TGAAAACTCT AATTGTCCAT TCTTGCTTGA 1620 CTCTACTATT AAGTTTGAAA ATAGTTACCT TCAAAGCAAG ATAATTCTAT TTGAAGCATG 1680 CTCTGTAAGT TGCTTCCTAA CATCCTTGGA CTGAGAAATT ATACTTACTT CTGGCATAAC 1740 TAAAATTAAG TATATATATT TTGGCTCAAA TAAAATTG Seq ID NO: 28 Protein sequence: Protein Accession &num : Eos sequence 1 11 21 31 41 51 MKFLLILLLQ ATASGALPLN SSTSLEKNNV LFGERYLEKF YGLEINKLPV TKMKYSGNLM 60 KEKIQEMQHF LGLKVTGQLD TSTLEMMHAP RCGVPDVHHF REMPGGPVWR KHYITYRINN 120 YTPDMNREDV DYAIRKAFQV WSNVTPLKFS KINTGMADIL WFARGAHGD FHAFDGKGGI 180 LAHAPGPGSG IGGDAHFDED EFWTTHSGGT NLFLTAVHEI GHSLGLGHSS DPKAVMFPTY 240 KYVDINTFRL SADDIRGIQS LYGDPKENQR LPNPDNSEPA LCDPNLSFDA VTTVGNKIFF 300 FKDRFFWLKV SERPKTSVNL ISSLWPTLPS GIEAAYEIEA RNQVFLFKDD KYWLISNLRP 360 EPNYPKSIHS FGFPNFVKKI DAAVFNPRFY RTYFFVDNQY WRYDERRQMM DPGYPKLITK 420 NFQGIGPKID AVFYSKNKYY YFFQGSNQFE YDFLLQRITK TLKSNSWFGC Seq ID NO: 29 DNA sequence Nucleic Acid Accession # : NM 006115. 1 Coding sequence: 236.. 1765 1 11 21 31 41 51 GCTTCAGGGT ACAGCTCCCC CGCAGCCAGA AGCCGGGCCT GCAGCCCCTC AGCACCGCTC 60 CGGGACACCC CACCCGCTTC CCAGGCGTGA CCTGTCAACA GCAACTTCGC GGTGTGGTGA 120 ACTCTCTGAG GAAAAACCAT TTTGATTATT ACTCTCAGAC GTGCGTGGCA ACAAGTGACT 180 GAGACCTAGA AATCCAAGCG TTGGAGGTCC TGAGGCCAGC CTAAGTCGCT TCAAAATGGA 240 ACGAAGGCGT TTGTGGGGTT CCATTCAGAG CCGATACATC AGCATGAGTG TGTGGACAAG 300 CCCACGGAGA CTTGTGGAGC TGGCAGGGCA GAGCCTGCTG AAGGATGAGG CCCTGGCCAT 360 TGCCGCCCTG GAGTTGCTGC CCAGGGAGCT CTTCCCGCCA CTCTTCATGG CAGCCTTTGA 420 CGGGAGACAC AGCCAGACCC TGAAGGCAAT GGTGCAGGCC TGGCCCTTCA CCTGCCTCCC 480 TCTGGGAGTG CTGATGAAGG GACAACATCT TCACCTGGAG ACCTTCAAAG CTGTGCTTGA 540 TGGACTTGAT GTGCTCCTTG CCCAGGAGGT TCGCCCCAGG AGGTGGAAAC TTCAAGTGCT 600 GGATTTACGG AAGAACTCTC ATCAGGACTT CTGGACTGTA TGGTCTGGAA ACAGGGCCAG 660 TCTGTACTCA TTTCCAGAGC CAGAAGCAGC TCAGCCCATG ACAAAGAAGC GAAAAGTAGA 720 TGGTTTGAGC ACAGAGGCAG AGCAGCCCTT CATTCCAGTA GAGGTGCTCG TAGACCTGTT 780 CCTCAAGGAA GGTGCCTGTG ATGAATTGTT CTCCTACCTC ATTGAGAAAG TGAAGCGAAA 840 GAAAAATGTA CTACGCCTGT GCTGTAAGAA GCTGAAGATT TTTGCAATGC CCATGCAGGA 900 TATCAAGATG ATCCTGAAAA TGGTGCAGCT GGACTCTATT GAAGATTTGG AAGTGACTTG 960 TACCTGGAAG CTACCCACCT TGGCGAAATT TTCTCCTTAC CTGGGCCAGA TGATTAATCT 1020 GCGTAGACTC CTCCTCTCCC ACATCCATGC ATCTTCCTAC ATTTCCCCGG AGAAGGAAGA 1080 GCAGTATATC GCCCAGTTCA CCTCTCAGTT CCTCAGTCTG CAGTGCCTGC AGGCTCTCTA 1140 TGTGGACTCT TTATTTTTCC TTAGAGGCCG CCTGGATCAG TTGCTCAGGC ACGTGATGAA 1200 CCCCTTGGAA ACCCTCTCAA TAACTAACTG CCGGCTTTCG GAAGGGGATG TGATGCATCT 1260 GTCCCAGAGT CCCAGCGTCA GTCAGCTAAG TGTCCTGAGT CTAAGTGGGG TCATGCTGAC 1320 CGATGTAAGT CCCGAGCCCC TCCAAGCTCT GCTGGAGAGA GCCTCTGCCA CCCTCCAGGA 1380 CCTGGTCTTT GATGAGTGTG GGATCACGGA TGATCAGCTC CTTGCCCTCC TGCCTTCCCT 1440 GAGCCACTGC TCCCAGCTTA CAACCTTAAG CTTCTACGGG AATTCCATCT CCATATCTGC 1500

CTTGCAGAGT CTCCTGCAGC ACCTCATCGG GCTGAGCAAT CTGACCCACG TGCTGTATCC 1560 TGTCCCCCTG GAGAGTTATG AGGACATCCA TGGTACCCTC CACCTGGAGA GGCTTGCCTA 1620 TCTGCATGCC AGGCTCAGGG AGTTGCTGTG TGAGTTGGGG CGGCCCAGCA TGGTCTGGCT 1680 TAGTGCCAAC CCCTGTCCTC ACTGTGGGGA CAGAACCTTC TATGACCCGG AGCCCATCCT 1740 GTGCCCCTGT TTCATGCCTA ACTAGCTGGG TGCACATATC AAATGCTTCA TTCTGCATAC 1800 TTGGACACTA AAGCCAGGAT GTGCATGCAT CTTGAAGCAA CAAAGCAGCC ACAGTTTCAG 1860 ACAAATGTTC AGTGTGAGTG AGGAAAACAT GTTCAGTGAG GAAAAAACAT TCAGACAAAT 1920 GTTCAGTGAG GAAAAAAAGG GGAAGTTGGG GATAGGCAGA TGTTGACTTG AGGAGTTAAT 1980 GTGATCTTTG GGGAGATACA TCTTATAGAG TTAGAAATAG AATCTGAATT TCTAAAGGGA 2040 GATTCTGGCT TGGGAAGTAC ATGTAGGAGT TAATCCCTGT GTAGACTGTT GTAAAGAAAC 2100 TGTTGAAAAT AAAGAGAAGC AATGTGAAGC AAAAAAAAAA AAAAAAAA Seq ID NO : 30 Protein sequence: Protein Accession # : NP 006106. 1 1 11 21 31 41 51 <BR> <BR> <BR> <BR> <BR> <BR> GCTTCAGGGT ACAGCTCCCC CGCAGCCAGA AGCCGGGCCT GCAGCGCCTC AGCACCGCTC 60 CGGGACACCC CACCCGCTTC CCAGGCGTGA CCTGTCAACA GCAACTTCGC GGTGTGGTGA 120 ACTCTCTGAG GAAAAACCAT TTTGATTATT ACTCTCAGAC GTGCGTGGCA ACAAGTGACT 180 GAGACCTAGA AATCCAAGCG TTGGAGGTCC TGAGGCCAGC CTAAGTCGCT TCAAAATGGA 240 ACGAAGGCGT TTGTGGGGTT CCATTCAGAG CCGATACATC AGCATGAGTG TGTGGACAAG 300 CCCACGGAGA CTTGTGGAGC TGGCAGGGCA GAGCCTGCTG AAGGATGAGG CCCTGGCCAT 360 TGCCGCCCTG GAGTTGCTGC CCAGGGAGCT CTTCCCGCCA CTCTTCATGG CAGCCTTTGA 420 CGGGAGACAC AGCCAGACCC TGAAGGCAAT GGTGCAGGCC TGGCCCTTCA CCTGCCTCCC 480 TCTGGGAGTG CTGATGAAGG GACAACATCT TCACCTGGAG ACCTTCAAAG CTGTGCTTGA 540 TGGACTTGAT GTGCTCCTTG CCCAGGAGGT TCGCCCCAGG AGGTGGAAAC TTCAAGTGCT 600 GGATTTACGG AAGAACTCTC ATCAGGACTT CTGGACTGTA TGGTCTGGAA ACAGGGCCAG 660 TCTGTACTCA TTTCCAGAGC CAGAAGCAGC TCAGCCCATG ACAAAGAAGC GAAAAGTAGA 720 TGGTTTGAGC ACAGAGGCAG AGCAGCCCTT CATTCCAGTA GAGGTGCTCG TAGACCTGTT 780 CCTCAAGGAA GGTGCCTGTG ATGAATTGTT CTCCTACCTC ATTGAGAAAG TGAAGCGAAA 840 GAAAAATGTA CTACGCCTGT GCTGTAAGAA GCTGAAGATT TTTGCAATGC CCATGCAGGA 900 TATCAAGATG ATCCTGAAAA TGGTGCAGCT GGACTCTATT GAAGATTTGG AAGTGACTTG 960 TACCTGGAAG CTACCCACCT TGGCGAAATT TTCTCCTTAC CTGGGCCAGA TGATTAATCT 1020 GCGTAGACTC CTCCTCTCCC ACATCCATGC ATCTTCCTAC ATTTCCCCGG AGAAGGAAGA 1080 GCAGTATATC GCCCAGTTCA CCTCTCAGTT CCTCAGTCTG CAGTGCCTGC AGGCTCTCTA 1140 TGTGGACTCT TTATTTTTCC TTAGAGGCCG CCTGGATCAG TTGCTCAGGC ACGTGATGAA 1200 CCCCTTGGAA ACCCTCTCAA TAACTAACTG CCGGCTTTCG GAAGGGGATG TGATGCATCT 1260 GTCCCAGAGT CCCAGCGTCA GTCAGCTAAG TGTCCTGAGT CTAAGTGGGG TCATGCTGAC 1320 CGATGTAAGT CCCGAGCCCC TCCAAGCTCT GCTGGAGAGA GCCTCTGCCA CCCTCCAGGA 1380 CCTGGTCTTT GATGAGTGTG GGATCACGGA TGATCAGCTC CTTGCCCTCC TGCCTTCCCT 1440 GAGCCACTGC TCCCAGCTTA CAACCTTAAG CTTCTACGGG AATTCCATCT CCATATCTGC 1500 CTTGCAGAGT CTCCTGCAGC ACCTCATCGG GCTGAGCAAT CTGACCCACG TGCTGTATCC 1560 TGTCCCCCTG GAGAGTTATG AGGACATCCA TGGTACCCTC CACCTGGAGA GGCTTGCCTA 1620 TCTGCATGCC AGGCTCAGGG AGTTGCTGTG TGAGTTGGGG CGGCCCAGCA TGGTCTGGCT 1680 TAGTGCCAAC CCCTGTCCTC ACTGTGGGGA CAGAACCTTC TATGACCCGG AGCCCATCCT 1740 GTGCCCCTGT TTCATGCCTA ACTAGCTGGG TGCACATATC AAATGCTTCA TTCTGCATAC 1800 TTGGACACTA AAGCCAGGAT GTGCATGCAT CTTGAAGCAA CAAAGCAGCC ACAGTTTCAG 1860 ACAAATGTTC AGTGTGAGTG AGGAAAACAT GTTCAGTGAG GAAAAAACAT TCAGACAAAT 1920 GTTCAGTGAG GAAAAAAAGG GGAAGTTGGG GATAGGCAGA TGTTGACTTG AGGAGTTAAT 1980 GTGATCTTTG GGGAGATACA TCTTATAGAG TTAGAAATAG AATCTGAATT TCTAAAGGGA 2040 GATTCTGGCT TGGGAAGTAC ATGTAGGAGT TAATCCCTGT GTAGACTGTT GTAAAGAAAC 2100 TGTTGAAAAT AAAGAGAAGC AATGTGAAGC AAAAAAAAAA AAAAAAAA Seq ID N0 : 31 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 64-2754 1 11 21 31 41 51 GGCAGGTCTC GCTCTCGGCA CCCTCCCGGC GCCCGCGTTC TCCTGGCCCT GCCCGGCATC 60 CCGATGGCCG CCGCTGGGCC CCGGCGCTCC GTGCGCGGAG CCGTCTGCCT GCATCTGCTG 120 CTGACCCTCG TGATCTTCAG TCGTGATGGT GAAGCCTGCA AAAAGGTGAT ACTTAATGTA 180 CCTTCTAAAC TAGAGGCAGA CAAAATAATT GGCAGAGTTA ATTTGGAAGA GTGCTTCAGG 240 TCTGCAGACC TCATCCGGTC AAGTGATCCT GATTTCAGAG TTCTAAATGA TGGGTCAGTG 300 TACACAGCCA GGGCTGTTGC GCTGTCTGAT AAGAAAAGAT CATTTACCAT ATGGCTTTCT 360 GACAAAAGGA AACAGACACA GAAAGAGGTT ACTGTGCTGC TAGAACATCA GAAGAAGGTA 420 TCGAAGACAA GACACACTAG AGAAACTGTT CTCAGGCGTG CCAAGAGGAG ATGGGCACCT 480 ATTCCTTGCT CTATGCAAGA GAATTCCTTG GGCCCTTTCC CATTGTTTCT TCAACAAGTT 540 GAATCTGATG CAGCACAGAA CTATACTGTC TTCTACTCAA TAAGTGGACG TGGAGTTGAT 600 AAAGAACCTT TAAATTTGTT TTATATAGAA AGAGACACTG GAAATCTATT TTGCACTCGG 660 CCTGTGGATC GTGAAGAATA TGATGTTTTT GATTTGATTG CTTATGCGTC AACTGCAGAT 720 GGATATTCAG CAGATCTGCC CCTCCCACTA CCCATCAGGG TAGAGGATGA AAATGACAAC 780 CACCCTGTTT TCACAGAAGC AATTTATAAT TTTGAAGTTT TGGAAAGTAG TAGACCTGGT 840 ACTACAGTGG GGGTGGTTTG TGCCACAGAC AGAGATGAAC CGGACACAAT GCATACGCGC 900 CTGAAATACA GCATTTTGCA GCAGACACCA AGGTCACCTG GGCTCTTTTC TGTGCATCCC 960 AGCACAGGCG TAATCACCAC AGTCTCTCAT TATTTGGACA GAGAGGTTGT AGACAAGTAC 1020 TCATTGATAA TGAAAGTACA AGACATGGAT GGCCAGTTTT TTGGATTGAT AGGCACATCA 1080 ACTTGTATCA TAACAGTAAC AGATTCAAAT GATAATGCAC CCACTTTCAG ACAAAATGCT 1140 TATGAAGCAT TTGTAGAGGA AAATGCATTC AATGTGGAAA TCTTACGAAT ACCTATAGAA 1200 GATAAGGATT TAATTAACAC TGCCAATTGG AGAGTCAATT TTACCATTTT AAAGGGAAAT 1260 GAAAATGGAC ATTTCAAAAT CAGCACAGAC AAAGAAACTA ATGAAGGTGT TCTTTCTGTT 1320 GTAAAGCCAC TGAATTATGA AGAAAACCGT CAAGTGAACC TGGAAATTGG AGTAAACAAT 1380 GAAGCGCCAT TTGCTAGAGA TATTCCCAGA GTGACAGCCT TGAACAGAGC CTTGGTTACA 1440 GTTCATGTGA GGGATCTGGA TGAGGGGCCT GAATGCACTC CTGCAGCCCA ATATGTGCGG 1500 ATTAAAGAAA ACTTAGCAGT GGGGTCAAAG ATCAACGGCT ATAAGGCATA TGACCCCGAA 1560

AATAGAAATG GCAATGGTTT AAGGTACAAA AAATTGCATG ATCCTAAAGG TTGGATCACC 1620 ATTGATGAAA TTTCAGGGTC AATCATAACT TCCAAAATCC TGGATAGGGA GGTTGAAACT 1680 CCCAAAAATG AGTTGTATAA TATTACAGTC CTGGCAATAG ACAAAGATGA TAGATCATGT 1740 ACTGGAACAC TTGCTGTGAA CATTGAAGAT GTAAATGATA ATCCACCAGA AATACTTCAA 1800 GAATATGTAG TCATTTGCAA ACCAAAAATG GGGTATACCG ACATTTTAGC TGTTGATCCT 1860 GATGAACCTG TCCATGGAGC TCCATTTTAT TTCAGTTTGC CCAATACTTC TCCAGAAATC 1920 AGTAGACTGT GGAGCCTCAC CAAAGTTAAT GATACAGCTG CCCGTCTTTC ATATCAGAAA 1980 AATGCTGGAT TTCAAGAATA TACCATTCCT ATTACTGTAA AAGACAGGGC CGGCCAAGCT 2040 GCAACAAAAT TATTGAGAGT TAATCTGTGT GAATGTACTC ATCCAACTCA GTGTCGTGCG 2100 ACTTCAAGGA GTACAGGAGT AATACTTGGA AAATGGGCAA TCCTTGCAAT ATTACTGGGT 2160 ATAGCACTGC TCTTTTCTGT ATTGCTAACT TTAGTATGTG GAGTTTTTGG TGCAACTAAA 2220 GGGAAACGTT TTCCTGAAGA TTTAGCACAG CAAAACTTAA TTATATCAAA CACAGAAGCA 2280 CCTGGAGACG ATAGAGTGTG CTCTGCCAAT GGATTTATGA CCCAAACTAC CAACAACTCT 2340 AGCCAAGGTT TTTGTGGTAC TATGGGATCA GGAATGAAAA ATGGAGGGCA GGAAACCATT 2400 GAAATGATGA AAGGAGGAAA CCAGACCTTG GAATCCTGCC GGGGGGCTGG GCATCATCAT 2460 ACCCTGGACT CCTGCAGGGG AGGACACACG GAGGTGGACA ACTGCAGATA CACTTACTCG 2520 GAGTGGCACA GTTTTACTCA ACCCCGTCTC GGTGAAAAAT TGCATCGATG TAATCAGAAT 2580 GAAGACCGCA TGCCATCCCA AGATTATGTC CTCACTTATA ACTATGAGGG AAGAGGATCT 2640 CCAGCTGGTT CTGTGGGCTG CTGCAGTGAA AAGCAGGAAG AAGATGGCCT TGACTTTTTA 2700 AATAATTTGG AACCCAAATT TATTACATTA GCAGAAGCAT GCACAAAGAG ATAATGTCAC 2760 AGTGCTACAA TTAGGTCTTT GTCAGACATT CTGGAGGTTT CCAAAAATAA TATTGTAAAG 2820 TTCAATTTCA ACATGTATGT ATATGATGAT TTTTTTCTCA ATTTTGAATT ATGCTACTCA 2880 CCAATTTATA TTTTTAAAGC CAGTTGTTGC TTATCTTTTC CAAAAAGTGA AAAATGTTAA 2940 AACAGACAAC TGGTAAATCT CAAACTCCAG CACTGGAATT AAGGTCTCTA AAGCATCTGC 3000 TCTTTTTTTT TTTTACGGAT ATTTTAGTAA TAAATATGCT GGATAAATAT TAGTCCAACA 3060 ATAGCTAAGT TATGCTAATA TCACATTATT ATGTATTCAC TTTAAGTGAT AGTTTAAAAA 3120 ATAAACAAGA AATATTGAGT ATCACTATGT GAAGAAAGTT TTGGAAAAGA AACAATGAAG 3180 ACTGAATTAA ATTAAAAATG TTGCAGCTCA TAAAGAATTG GGACTCACCC CTACTGCACT 3240 ACCAAATTCA TTTGACTTTG GAGGCAAAAT GTGTTGAAGT GCCCTATGAA GTAGCAATTT 3300 TCTATAGGAA TATAGTTGGA AATAAATGTG TGTGTGTATA TTATTATTAA TCAATGCAAT 3360 ATTTAAAATG AAATGAGAAC AAAGAGGAAA ATGGTAAAAA CTTGAAATGA GGCTGGGGTA 3420 TAGTTTGTCC TACAATAGAA AAAAGAGAGA GCTTCCTAGG CCTGGGCTCT TAAATGCTGC 3480 ATTATAACTG AGTCTATGAG GAAATAGTTC CTGTCCAATT TGTGTAATTT GTTTAAAATT 3540 GTAAATAAAT TAAACTTTTC TGGTTTCTGT GGGAAGGAAA TAGGGAATCC AATGGAACAG 3600 TAGCTTTGCT TTGCAGTCTG TTTCAAGATT TCTGCATCCA CAAGTTAGTA GCAAACTGGG 3660 GAATACTCGC TGCAGCTGGG GTTCCCTGCT TTTTGGTAGC AAGGGTCCAG AGATGAGGTG 3720 TTTTTTTCGG GGAGCTAATA ACAAAAACAT TTTAAAACTT ACCTTTACTG AAGTTAAATC 3780 CTCTATTGCT GTTTCTATTC TCTCTTATAG TGACCAACAT CTTTTTAATT TAGATCCAAA 3840 TAACCATGTC CTCCTAGAGT TTAGAGGCTA GAGGGAGCTG AGGGGAGGAT CTTACTGAAA 3900 GCACCCTGGG GAGATTGATT GTCCTTAAAC CTAAGCCCCA CAAACTTGAC ACCTGATCAG 3960 GTCTGGGAGC TACAAAATTT CATTTTTCTC CTCACTGCCC TTCTTCTGAG TGGCATTGGC 4020 CTGAATCAAG GAAAGCCAGG CCTTGTGGGC CCCCTTCTTT CGGCTTTCTG CTAAAGCAAC 4080 ACCTCCAGCA GAGATTCCCT TAAGTGACTC CAGGTTTTCC ACCATCCTTC AGCGTGAATT 4140 AATTTTTAAT CAGTTTGCTT TCTCCAGAGA AATTTTAAAA TAATAGAAGA AATAGAAATT 4200 TTGAATGTAT AAAAGAAAAA GATCAAGTTG TCATTTTAGA ACAGAGGGAA CTTTGGGAGA 4260 AAGCAGCCCA AGTAGGTTAT TTGTACAGTC AGAGGGCAAC AGGAAGATGC AGGCCTTCAA 4320 GGGCAAGGAG AGGCCACAAG GAATATGGGT GGGAGTAAAA GCAACATCGT CTGCTTCATA 4380 CTTTTTCCTA GGCTTGGCAC TGCCTTTTCC TTTCTCAGGC CAATGGCAAC TGCCATTTGA 4440 GTCCGGTGAG GGATCAGCCA ACCTCTTCTC TATGGCTCAC CTTATTTGGA GTGAGAAATC 4500 AAGGAGACAG AGCTGACTGC ATGATGAGTC TGAAGGCATT TGCAGGATGA GCCTGAACTG 4560 GTTGTGCAGA ACAAACAAGG CATTCATGGG AATTGTTGTA TTCCTTCTGC AGCCCTCCTT 4620 CTGGGCACTA AGAAGGTCTA TGAATTAAAT GCCTATCTAA AATTCTGATT TATTCCTACA 4680 TTTTCTGTTT TCTAATTTGA CCCTAAAATC TATGTGTTTT AGACTTAGAC TTTTTATTGC 4740 CCCCCCCCCC TTTTTTTTTG AGACGGAGTC TCGCTCTGAC GCACAGGCTG GAGTGCAGTG 4800 GCTCCGATCT CTGCTCACTG AAAGCTCCGC CTCCCGGGTT CATGCCATTC TCCTGCCTCA 4860 GCCTCCTGAG TAGCTGGGAC TACAGGCGCC CACCACCACG CCCGGCTAAT TTTTTGTATT 4920 TTTAATAGAG ACGGGGTTTC ACTGTGTTAG CCAGGATGGT CTCGATCTCC TGACCTCGTG 4980 ATCCGCCTGC CTCGGCCTCC CAAAGTGCTG GGATTACAGG CATGACCCAC CGCTCCCGGC 5040 CTTGTTTTCC GTTTAAAGTC GTCTTCTTTT AATGTAATCA TTTTGAACAT GTGTGAAAGT 5100 TGATCATACG AATTGGATCA ATCTTGAAAT ACTCAACCAA AAGACAGTCG AGAAGCCAGG 5160 GGGAGAAAGA ACTCAGGGCA CAAAATATTG GTCTGAGAAT GGAATTCTCT GTAAGCCTAG 5220 TTGCTGAAAT TTCCTGCTGT AACCAGAAGC CAGTTTTATC TAACGGCTAC TGAAACACCC 5280 ACTGTGTTTT GCTCACTCCC TCACTCACCG ATCAAAACCT GCTACCTCCC CAAGACTTTA 5340 CTAGTGCCGA TAAACTTTCT CAAAGAGCAA CCAGTATCAC TTCCCTGTTT ATAAAACCTC 5400 TAACCATCTC TTTGTTCTTT GAACATGCTG AAAACCACCT GGTCTGCATG TATGCCCGAA 5460 TTTGTAATTC TTTTCTCTCA AATGAAAATT TAATTTTAGG GATTCATTTC TATATTTTCA 5520 CATATGTAGT ATTATTATTT CCTTATATGT GTAAGGTGAA ATTTATGGTA TTTGAGTGTG 5580 CAAGAAAATA TATTTTTAAA GCTTTCATTT TTCCCCCAGT GAATGATTTA GAATTTTTTA 5640 TGTAAATATA CAGAATGTTT TTTCTTACTT TTATAAGGAA GCAGCTGTCT AAAATGCAGT 5700 GGGGTTTGTT TTGCAATGTT TTAAACAGAG TTTTAGTATT GCTATTAAAA GAAGTTACTT 5760 TGCTTTTAAA GAAACTTGGC TGCTTAAAAT AAGCAAAAAT TGGATGCATA AAGTAATATT 5820 TACAGATGTG GGGAGATGTA ATAAAACAAT ATTAACTTGG TTTCTTGTTT TTGCTGTATT 5880 TAGAGATTAA ATAATTCTAA GATGATCACT TTGCAAAATT ATGCTTATGG CTGGCATGGA 5940 AATAGAAATA CTCAATTATG TCTTTGTTGT ATTAATGGGG AATATTTTGG ACAATGTTTC 6000 ATTATCAAAT TGTCGACATC ATTAATATAT ATTGTAATGT TGGGAAGAGA TCACTATTTT 6060 GAAGCACAGC TTTACAGATG AGTATCTATG ATACATATGT ATAATAAATT TTGATCGGGT 6120 ATTAAAAGTA TTAGAAGGTG GTTATAATTG CAGAGTATTC CATGAATAGT ACACTGACAC 6180 AGGGGTTTTA CTTTGAGGAC CAGTGTAGTC AAGGGAAAAC ATGAGTTAAA AAGAAAAGCA 6240 GGCAATATTG CAGTCTTGAT TCTGCCACTT ACAGGATAGA TAATGCCTGA ACTTTAATGA 6300 CAAGATGATC CAACCATAAA GGTGCTCTGT GCTTCACAGT GAATCTTTTC CCCATGCAGG 6360 AGTGTGCTCC CCTACAAACG TTAAGACTGA TCATTTCAAA AATCTATTAG CTATATCAAA 6420 AGCCTTACAT TTTAATATAG GTTGAACCAA AATTTCAATT CCAGTAACTT CTATTGTAAC 6480 CATTATTTTT GTGTATGTCT TCAAGAATGT TCATTGGATT TTTGTTTGTA ATAGTAAAAT 6540 ACCGGATACA TTTCACGTGT CCTTCAGTAT TGATTTGGTT GAATATTGGG TCATAATGGT 6600 TGAGAAGCAT GGACACTAGA GCCAGAATGC TTGGATATGA ATCCTGGATC TGTCACTTAC 6660 TTCTGTGTGA CCTTTGAAAG GCTACTTATT TCCTCTCTTA GCTTTCTCAT TAAAATCAAT 6720 GAACAATGCC AGCCTCATGG GGTTGTTGAA TGATTAAATT AGTTAATATA CCTAAAGTAC 6780

ATAGAACACT GCCTGCACAT AGTAAAAGAA TTATAAGTGT GAGGTAGTTG GTAAAATTAT 6840 GTAGTTGGAT ATACTACCGA ACAATATCTA ATCTCTTTTT AGGGAAATAA AGTTTGTGCA 6900 TATATATAAT CCCGAAACAT G Seq ID NO : 32 Protein sequence: Protein Accession &num : NP 001932. 1 1 11 21 31 41 51 MAAAGPRRSV RGAVCLHLLL TLVIFSRDGE ACKKVILNVP SKLEADKIIG RVNLEECFRS 60 ADLIRSSDPD FRVLNDGSVY TARAVALSDK KRSFTIWLSD KRKQTQKEVT VLLEHQKKVS 120 KTRHTRETVL RRAKRRWAPI PCSMQENSLG PFPLFLQQVE SDAAQNYTVF YSISGRGVDK 180 EPLNLFYIER DTGNLFCTRP VDREEYDVFD LIAYASTADG YSADLPLPLP IRVEDENDNH 240 PVFTEAIYNF EVLESSRPGT TVGWCATDR DEPDTMHTRL KYSILQQTPR SPGLFSVHPS 300 TGVITTVSHY LDREWDKYS LIMKVQDMDG QFFGLIGTST CIITVTDSND NAPTFRQNAY 360 EAFVEENAFN VEILRIPIED KDLINTANWR VNFTILKGNE NGHFKISTDK ETNEGVLSW 420 KPLNYEENRQ VNLEIGVNNE APFARDIPRV TALNRALVTV HVRDLDEGPE CTPAAQYVRI 480 KENLAVGSKI NGYKAYDPEN RNGNGLRYKK LHDPKGWITI DEISGSIITS KILDREVETP 540 KNELYNITVL AIDKDDRSCT GTLAVNIEDV NDNPPEILQE YWICKPKMG YTDILAVDPD 600 EPVHGAPFYF SLPNTSPEIS RLWSLTKVND TAARLSYQKN AGFQEYTIPI TVKDRAGQAA 660 TKLLRVNLCE CTHPTQCRAT SRSTGVILGK WAILAILLGI ALLFSVLLTL VCGVFGATKG 720 KRFPEDLAQQ NLIISNTEAP GDDRVCSANG FMTQTTNNSS QGFCGTMGSG MKNGGQETIE 780 MMKGGNQTLE SCRGAGHHHT LDSCRGGHTE VDNCRYTYSE WHSFTQPRLG EKLHRCNQNE 840 DRMPSQDYVL TYNYEGRGSP AGSVGCCSEK QEEDGLDFLN NLEPKFITLA EACTKR Seq ID NO : 33 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 64-2583 1 11 21 31 41 51 <BR> <BR> <BR> <BR> <BR> GGCAGGTCTC GCTCTCGGCA CCCTCCCGGC GCCCGCGTTC TCCTGGCCCT GCCCGGCATC 60 CCGATGGCCG CCGCTGGGCC CCGGCGCTCC GTGCGCGGAG CCGTCTGCCT GCATCTGCTG 120 CTGACCCTCG TGATCTTCAG TCGTGATGGT GAAGCCTGCA AAAAGGTGAT ACTTAATGTA 180 CCTTCTAAAC TAGAGGCAGA CAAAATAATT GGCAGAGTTA ATTTGGAAGA GTGCTTCAGG 240 TCTGCAGACC TCATCCGGTC AAGTGATCCT GATTTCAGAG TTCTAAATGA TGGGTCAGTG 300 TACACAGCCA GGGCTGTTGC GCTGTCTGAT AAGAAAAGAT CATTTACCAT ATGGCTTTCT 360 GACAAAAGGA AACAGACACA GAAAGAGGTT ACTGTGCTGC TAGAACATCA GAAGAAGGTA 420 TCGAAGACAA GACACACTAG AGAAACTGTT CTCAGGCGTG CCAAGAGGAG ATGGGCACCT 480 ATTCCTTGCT CTATGCAAGA GAATTCCTTG GGCCCTTTCC CATTGTTTCT TCAACAAGTT 540 GAATCTGATG CAGCACAGAA CTATACTGTC TTCTACTCAA TAAGTGGACG TGGAGTTGAT 600 AAAGAACCTT TAAATTTGTT TTATATAGAA AGAGACACTG GAAATCTATT TTGCACTCGG 660 CCTGTGGATC GTGAAGAATA TGATGTTTTT GATTTGATTG CTTATGCGTC AACTGCAGAT 720 GGATATTCAG CAGATCTGCC CCTCCCACTA CCCATCAGGG TAGAGGATGA AAATGACAAC 780 CACCCTGTTT TCACAGAAGC AATTTATAAT TTTGAAGTTT TGGAAAGTAG TAGACCTGGT 840 ACTACAGTGG GGGTGGTTTG TGCCACAGAC AGAGATGAAC CGGACACAAT GCATACGCGC 900 CTGAAATACA GCATTTTGCA GCAGACACCA AGGTCACCTG GGCTCTTTTC TGTGCATCCC 960 AGCACAGGCG TAATCACCAC AGTCTCTCAT TATTTGGACA GAGAGGTTGT AGACAAGTAC 1020 TCATTGATAA TGAAAGTACA AGACATGGAT GGCCAGTTTT TTGGATTGAT AGGCACATCA 1080 ACTTGTATCA TAACAGTAAC AGATTCAAAT GATAATGCAC CCACTTTCAG ACAAAATGCT 1140 TATGAAGCAT TTGTAGAGGA AAATGCATTC AATGTGGAAA TCTTACGAAT ACCTATAGAA 1200 GATAAGGATT TAATTAACAC TGCCAATTGG AGAGTCAATT TTACCATTTT AAAGGGAAAT 1260 GAAAATGGAC ATTTCAAAAT CAGCACAGAC AAAGAAACTA ATGAAGGTGT TCTTTCTGTT 1320 GTAAAGCCAC TGAATTATGA AGAAAACCGT CAAGTGAACC TGGAAATTGG AGTAAACAAT 1380 GAAGCGCCAT TTGCTAGAGA TATTCCCAGA GTGACAGCCT TGAACAGAGC CTTGGTTACA 1440 GTTCATGTGA GGGATCTGGA TGAGGGGCCT GAATGCACTC CTGCAGCCCA ATATGTGCGG 1500 ATTAAAGAAA ACTTAGCAGT GGGGTCAAAG ATCAACGGCT ATAAGGCATA TGACCCCGAA 1560 AATAGAAATG GCAATGGTTT AAGGTACAAA AAATTGCATG ATCCTAAAGG TTGGATCACC 1620 ATTGATGAAA TTTCAGGGTC AATCATAACT TCCAAAATCC TGGATAGGGA GGTTGAAACT 1680 CCCAAAAATG AGTTGTATAA TATTACAGTC CTGGCAATAG ACAAAGATGA TAGATCATGT 1740 ACTGGAACAC TTGCTGTGAA CATTGAAGAT GTAAATGATA ATCCACCAGA AATACTTCAA 1800 GAATATGTAG TCATTTGCAA ACCAAAAATG GGGTATACCG ACATTTTAGC TGTTGATCCT 1860 GATGAACCTG TCCATGGAGC TCCATTTTAT TTCAGTTTGC CCAATACTTC TCCAGAAATC 1920 AGTAGACTGT GGAGCCTCAC CAAAGTTAAT GATACAGCTG CCCGTCTTTC ATATCAGAAA 1980 AATGCTGGAT TTCAAGAATA TACCATTCCT ATTACTGTAA AAGACAGGGC CGGCCAAGCT 2040 GCAACAAAAT TATTGAGAGT TAATCTGTGT GAATGTACTC ATCCAACTCA GTGTCGTGCG 2100 ACTTCAAGGA GTACAGGAGT AATACTTGGA AAATGGGCAA TCCTTGCAAT ATTACTGGGT 2160 ATAGCACTGC TCTTTTCTGT ATTGCTAACT TTAGTATGTG GAGTTTTTGG TGCAACTAAA 2220 GGGAAACGTT TTCCTGAAGA TTTAGCACAG CAAAACTTAA TTATATCAAA CACAGAAGCA 2280 CCTGGAGACG ATAGAGTGTG CTCTGCCAAT GGATTTATGA CCCAAACTAC CAACAACTCT 2340 AGCCAAGGTT TTTGTGGTAC TATGGGATCA GGAATGAAAA ATGGAGGGCA GGAAACCATT 2400 GAAATGATGA AAGGAGGAAA CCAGACCTTG GAATCCTGCC GGGGGGCTGG GCATCATCAT 2460 ACCCTGGACT CCTGCAGGGG AGGACACACG GAGGTGGACA ACTGCAGATA CACTTACTCG 2520 GAGTGGCACA GTTTTACTCA ACCCCGTCTC GGTGAAGAAT CCATTAGAGG ACACACTGGT 2580 TAAAAATTAA ACATAAAAGA AATTGCATCG ATGTAATCAG AATGAAGACC GCATGCCATC 2640 CCAAGATTAT GTCCTCACTT ATAACTATGA GGGAAGAGGA TCTCCAGCTG GTTCTGTGGG 2700 CTGCTGCAGT GAAAAGCAGG AAGAAGATGG CCTTGACTTT TTAAATAATT TGGAACCCAA 2760 ATTTATTACA TTAGCAGAAG CATGCACAAA GAGATAATGT CACAGTGCTA CAATTAGGTC 2820 TTTGTCAGAC ATTCTGGAGG TTTCCAAAAA TAATATTGTA AAGTTCAATT TCAACATGTA 2880 TGTATATGAT GATTTTTTTC TCAATTTTGA ATTATGCTAC TCACCAATTT ATATTTTTAA 2940 AGCCAGTTGT TGCTTATCTT TTCCAAAAAG TGAAAAATGT TAAAACAGAC AACTGGTAAA 3000 TCTCAAACTC CAGCACTGGA ATTAAGGTCT CTAAAGCATC TGCTCTTTTT TTTTTTTACG 3060 GATATTTTAG TAATAAATAT GCTGGATAAA TATTAGTCCA ACAATAGCTA AGTTATGCTA 3120 ATATCACATT ATTATGTATT CACTTTAAGT GATAGTTTAA AAAATAAACA AGAAATATTG 3180 AGTATCACTA TGTGAAGAAA GTTTTGGAAA AGAAACAATG AAGACTGAAT TAAATTAAAA 3240 ATGTTGCAGC TCATAAAGAA TTGGGACTCA CCCCTACTGC ACTACCAAAT TCATTTGACT 3300

TTGGAGGCAA AATGTGTTGA AGTGCCCTAT GAAGTAGCAA TTTTCTATAG GAATATAGTT 3360 GGAAATAAAT GTGTGTGTGT ATATTATTAT TAATCAATGC AATATTTAAA ATGAAATGAG 3420 AACAAAGAGG AAAATGGTAA AAACTTGAAA TGAGGCTGGG GTATAGTTTG TCCTACAATA 3480 GAAAAAAGAG AGAGCTTCCT AGGCCTGGGC TCTTAAATGC TGCATTATAA CTGAGTCTAT 3540 GAGGAAATAG TTCCTGTCCA ATTTGTGTAA TTTGTTTAAA ATTGTAAATA AATTAAACTT 3600 TTCTGGTTTC TGTGGGAAGG AAATAGGGAA TCCAATGGAA CAGTAGCTTT GCTTTGCAGT 3660 CTGTTTCAAG ATTTCTGCAT CCACAAGTTA GTAGCAAACT GGGGAATACT CGCTGCAGCT 3720 GGGGTTCCCT GCTTTTTGGT AGCAAGGGTC CAGAGATGAG GTGTTTTTTT CGGGGAGCTA 3780 ATAACAAAAA CATTTTAAAA CTTACCTTTA CTGAAGTTAA ATCCTCTATT GCTGTTTCTA 3840 TTCTCTCTTA TAGTGACCAA CATCTTTTTA ATTTAGATCC AAATAACCAT GTCCTCCTAG 3900 AGTTTAGAGG CTAGAGGGAG CTGAGGGGAG GATCTTACTG AAAGCACCCT GGGGAGATTG 3960 ATTGTCCTTA AACCTAAGCC CCACAAACTT GACACCTGAT CAGGTCTGGG AGCTACAAAA 4020 TTTCATTTTT CTCCTCACTG CCCTTCTTCT GAGTGGCATT GGCCTGAATC AAGGAAAGCC 4080 AGGCCTTGTG GGCCCCCTTC TTTCGGCTTT CTGCTAAAGC AACACCTCCA GCAGAGATTC 4140 CCTTAAGTGA CTCCAGGTTT TCCACCATCC TTCAGCGTGA ATTAATTTTT AATCAGTTTG 4200 CTTTCTCCAG AGAAATTTTA AAATAATAGA AGAAATAGAA ATTTTGAATG TATAAAAGAA 4260 AAAGATCAAG TTGTCATTTT AGAACAGAGG GAACTTTGGG AGAAAGCAGC CCAAGTAGGT 4320 TATTTGTACA GTCAGAGGGC AACAGGAAGA TGCAGGCCTT CAAGGGCAAG GAGAGGCCAC 4380 AAGGAATATG GGTGGGAGTA AAAGCAACAT CGTCTGCTTC ATACTTTTTC CTAGGCTTGG 4440 CACTGCCTTT TCCTTTCTCA GGCCAATGGC AACTGCCATT TGAGTCCGGT GAGGGATCAG 4500 CCAACCTCTT CTCTATGGCT CACCTTATTT GGAGTGAGAA ATCAAGGAGA CAGAGCTGAC 4560 TGCATGATGA GTCTGAAGGC ATTTGCAGGA TGAGCCTGAA CTGGTTGTGC AGAACAAACA 4620 AGGCATTCAT GGGAATTGTT GTATTCCTTC TGCAGCCCTC CTTCTGGGCA CTAAGAAGGT 4680 CTATGAATTA AATGCCTATC TAAAATTCTG ATTTATTCCT ACATTTTCTG TTTTCTAATT 4740 TGACCCTAAA ATCTATGTGT TTTAGACTTA GACTTTTTAT TGCCCCCCCC CCCTTTTTTT 4800 TTGAGACGGA GTCTCGCTCT GACGCACAGG CTGGAGTGCA GTGGCTCCGA TCTCTGCTCA 4860 CTGAAAGCTC CGCCTCCCGG GTTCATGCCA TTCTCCTGCC TCAGCCTCCT GAGTAGCTGG 4920 GACTACAGGC GCCCACCACC ACGCCCGGCT AATTTTTTGT ATTTTTAATA GAGACGGGGT 4980 TTCACTGTGT TAGCCAGGAT GGTCTCGATC TCCTGACCTC GTGATCCGCC TGCCTCGGCC 5040 TCCCAAAGTG CTGGGATTAC AGGCATGACC CACCGCTCCC GGCCTTGTTT TCCGTTTAAA 5100 GTCGTCTTCT TTTAATGTAA TCATTTTGAA CATGTGTGAA AGTTGATCAT ACGAATTGGA 5160 TCAATCTTGA AATACTCAAC CAAAAGACAG TCGAGAAGCC AGGGGGAGAA AGAACTCAGG 5220 GCACAAAATA TTGGTCTGAG AATGGAATTC TCTGTAAGCC TAGTTGCTGA AATTTCCTGC 5280 TGTAACCAGA AGCCAGTTTT ATCTAACGGC TACTGAAACA CCCACTGTGT TTTGCTCACT 5340 CCCACTCACC GATCAAAACC TGCTACCTCC CCAAGACTTT ACTAGTGCCG ATAAACTTTC 5400 TCAAAGAGCA ACCAGTATCA CTTCCCTGTT TATAAAACCT CTAACCATCT CTTTGTTCTT 5460 TGAACATGCT GAAAACCACC TGGTCTGCAT GTATGCCCGA ATTTGTAATT CTTTTCTCTC 5520 AAATGAAAAT TTAATTTTAG GGATTCATTT CTATATTTTC ACATATGTAG TATTATTATT 5580 TCCTTATATG TGTAAGGTGA AATTTATGGT ATTTGAGTGT GCAAGAAAAT ATATTTTTAA 5640 AGCTTTCATT TTTCCCCCAG TGAATGATTT AGAATTTTTT ATGTAAATAT ACAGAATGTT 5700 TTTTCTTACT TTTATAAGGA AGCAGCTGTC TAAAATGCAG TGGGGTTTGT TTTGCAATGT 5760 TTTAAACAGA GTTTTAGTAT TGCTATTAAA AGAAGTTACT TTGCTTTTAA AGAAACTTGG 5820 CTGCTTAAAA TAAGCAAAAA TTGGATGCAT AAAGTAATAT TTACAGATGT GGGGAGATGT 5880 AATAAAACAA TATTAACTTG GCTGCTTAAA ATAAGCAAAA ATTGGATGCA TAAAGTAATA 5940 TTTACAGATG TGGGGAGATG TAATAAAACA ATATTAACTT GGTTTCTTGT TTTTGCTGTA 6000 TTTAGAGATT AAATAATTCT AAGATGATCA CTTTGCAAAA TTATGCTTAT GGCTGGCATG 6060 GAAATAGAAA TACTCAATTA TGTCTTTGTT GTATTAATGG GGAATATTTT GGACAATGTT 6120 TCATTATCAA ATTGTCGACA TCATTAATAT ATATTGTAAT GTTGGGAAGA GATCACTATT 6180 TTGAAGCACA GCTTTACAGA TGAGTATCTA TGATACATAT GTATAATAAA TTTTGATCGG 6240 GTATTAAAAG TATTAGAAGG TGGTTATAAT TGCAGAGTAT TCCATGAATA GTACACTGAC 6300 ACAGGGGTTT TACTTTGAGG ACCAGTGTAG TCAAGGGAAA ACATGAGTTA AAAAGAAAAG 6360 CAGGCAATAT TGCAGTCTTG ATTCTGCCAC TTACAGGATA GATAATGCCT GAACTTTAAT 6420 GACAAGATGA TCCAACCATA AAGGTGCTCT GTGCTTCACA GTGAATCTTT TCCCCATGCA 6480 GGAGTGTGCT CCCCTACAAA CGTTAAGACT GATCATTTCA AAAATCTATT AGCTATATCA 6540 AAAGCCTTAC ATTTTAATAT AGGTTGAACC AAAATTTCAA TTCCAGTAAC TTCTATTGTA 6600 ACCATTATTT TTGTGTATGT CTTCAAGAAT GTTCATTGGA TTTTTGTTTG TAATAGTAAA 6660 ATACCGGATA CATTTCACGT GTCCTTCAGT ATTGATTTGG TTGAATATTG GGTCATAATG 6720 GTTGAGAAGC ATGGACACTA GAGCCAGAAT GCTTGGATAT GAATCCTGGA TCTGTCACTT 6780 ACTTCTGTGT GACCTTTGAA AGGCTACTTA TTTCCTCTCT TAGCTTTCTC ATTAAAATCA 6840 ATGAACAATG CCAGCCTCAT GGGGTTGTTG AATGATTAAA TTAGTTAATA TACCTAAAGT 6900 ACATAGAACA CTGCCTGCAC ATAGTAAAAG AATTATAAGT GTGAGGTAGT TGGTAAAATT 6960 ATGTAGTTGG ATATACTACC GAACAATATC TAATCTCTTT TTAGGGAAAT AAAGTTTGTG 7020 CATATATATA ATCCCGAAAC ATG Seq ID NO : 34 Protein sequence: Protein Accession # : NP 077741. 1 1 11 21 31 41 51 # # # # # # MAAAGPRRSV RGAVCLHLLL TLVIFSRDGE ACKKVILNVP SKLEADKIIG RVNLEECFRS 60 ADLIRSSDPD FRVLNDGSVY TARAVALSDK KRSFTIWLSD KRKQTQKEVT VLLEHQKKVS 120 KTRHTRETVL RRAKRRWAPI PCSMQENSLG PFPLFLQQVE SDAAQNYTVF YSISGRGVDK 180 EPLNLFYIER DTGNLFCTRP VDREEYDVFD LIAYASTADG YSADLPLPLP IRVEDENDNH 240 PVFTEAIYNF EVLESSRPGT TVGWCATDR DEPDTMHTRL KYSILQQTPR SPGLFSVHPS 300 TGVITTVSHY LDREVVDKYS LIMKVQDMDG QFFGLIGTST CIITVTDSND NAPTFRQNAY 360 EAFVEENAFN VEILRIPIED KDLINTANWR VNFTILKGNE NGHFKISTDK ETNEGVLSW 420 KPLNYEENRQ VNLEIGVNNE APFARDIPRV TALNRALVTV HVRDLDEGPE CTPAAQYVRI 460 KENLAVGSKI NGYKAYDPEN RNGNGLRYKK LHDPKGWITI DEISGSIITS KILDREVETP 540 KNELYNITVL AIDKDDRSCT GTLAVNIEDV NDNPPEILQE YVVICKPKMG YTDITAVDPD 600 EPVHGAPFYF SLPNTSPEIS RLWSLTKVND TAARLSYQKN AGFQEYTIPI TVKDRAGQAA 660 TKLLRVNLCE CTHPTQCRAT SRSTGVILGK WAILAILLGI ALLFSVLLTL VCGVFGATKG 720 KRFPEDLAQQ NLIISNTEAP GDDRVCSANG FMTQTTNNSS QGFCGTMGSG MKNGGQETIE 780 MMKGGNQTLE SCRGAGHHHT LDSCRGGHTE VDNCRYTYSE WHSFTQPRLG EESIRGHTG Seq ID NO: 35 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 146-1273

Seq ID NO : 41 DNA sequence Nucleic Acid Accession # : NM 006952. 1 Coding sequence: 11-793 1 11 21 31, 41 51 AATCCCGACA ATGGCGAAAG ACAACTCAAC TGTTCGTTGC TTCCAGGGCC TGCTGATTTT 60 TGGAAATGTG ATTATTGGTT GTTGCGGCAT TGCCCTGACT GCGGAGTGCA TCTTCTTTGT 120 ATCTGACCAA CACAGCCTCT ACCCACTGCT TGAAGCCACC GACAACGATG ACATCTATGG 180 GGCTGCCTGG ATCGGCATAT TTGTGGGCAT CTGCCTCTTC TGCCTGTCTG TTCTAGGCAT 240 TGTAGGCATC ATGAAGTCCA GCAGGAAAAT TCTTCTGGCG TATTTCATTC TGATGTTTAT 300 AGTATATGCC TTTGAAGTGG CATCTTGTAT CACAGCAGCA ACACAACGAG ACTTTTTCAC 360 ACCCAACCTC TTCCTGAAGC AGATGCTAGA GAGGTACCAA AACAACAGCC CTCCAAACAA 420 TGATGACCAG TGGAAAAACA ATGGAGTCAC CAAAACCTGG GACAGGCTCA TGCTCCAGGA 480 CAATTGCTGT GGCGTAAATG GTCCATCAGA CTGGCAAAAA TACACATCTG CCTTCCGGAC 540 TGAGAATAAT GATGCTGACT ATCCCTGGCC TCGTCAATGC TGTGTTATGA ACAATCTTAA 600 AGAACCTCTC AACCTGGAGG CTTGTAAACT AGGCGTGCCT GGTTTTTATC ACAATCAGGG 660 CTGCTATGAA CTGATCTCTG GTCCAATGAA CCGACACGCC TGGGGGGTTG CCTGGTTTGG 720 ATTTGCCATT CTCTGCTGGA CTTTTTGGGT TCTCCTGGGT ACCATGTTCT ACTGGAGCAG 780 AATTGAATAT TAAGAA Seq ID NO : 42 Protein sequence: Protein Accession # : NP 008883. 1 1 11 21 31 41 51 # # # # # # MAKDNSTVRC FQGLLIFGNV IIGCCGIALT AECIFFVSDQ HSLYPLLEAT DNDDIYGAAW 60 IGIFVGICLF CLSVLGIVGI MKSSRKILLA YFILMFIVYA FEVASCITAA TQRDFFTPNL 120 FLKQMLERYQ NNSPPNNDDQ WKNNGVTKTW DRLMLQDNCC GVNGPSDWQK YTSAFRTENN 180 DADYPWPRQC CVMNNLKEPL NLEACKLGVP GFYHNQGCYE LISGPMNRHA WGVAWFGFAI 240 LCWTFWVLLG TMFYWSRIEY Seq ID NO: 43 DNA sequence Nucleic Acid Accession &num : Eos sequence Coding sequence: 83-2605 1 11 21 31 41 51 1 1 1 1 1 1 GCCGGACAGA TCTGCGCGTA TCCTGGAGCC GGCCCAGTTG TGAACTAGGA GAGCTTTGGG 60 ACCTCTGTCC CAAGCAAGAG AGATGAATGG AGAGTATAGA GGCAGAGGAT TTGGACGAGG 120 AAGATTTCAA AGCTGGAAAA GGGGAAGAGG TGGTGGGAAC TTCTCAGGAA AATGGAGAGA 180 AAGAGAACAC AGACCTGATC TGAGTAAAAC CACAGGAAAA CGTACTTCTG AACAAACCCC 240 ACAGTTTTTG CTTTCAACAA AGACCCCACA GTCAATGCAG TCAACATTGG ATCGATTCAT 300 ACCATATAAA GGCTGGAAGC TTTATTTCTC TGAAGTTTAC AGCGATAGCT CTCCTTTGAT 360 TGAGAAGATT CAAGCATTTG AAAAATTTTT CACAAGGCAT ATTGATTTGT ATGACAAGGA 420 TGAAATAGAA AGAAAGGGAA GTATTTTGGT AGATTTTAAA GAACTGACAG AAGGTGGTGA 480 AGTAACTAAC TTGATACCAG ATATAGCAAC TGAACTAAGA GATGCACCTG AGAAAACCTT 540 GGCTTGCATG GGTTTGGCAA TACATCAGGT GTTAACTAAG GACCTTGAAA GGCATGCAGC 600 TGAGTTACAA GCCCAGGAAG GATTGTCTAA TGATGGAGAA ACAATGGTAA ATGTGCCACA 660 TATTCATGCA AGGGTGTACA ACTATGAGCC TTTGACACAG CTCAAGAATG TCAGAGCAAA 720 TTACTATGGA AAATACATTG CTCTAAGAGG GACAGTGGTT CGTGTCAGTA ATATAAAGCC 780 TCTTTGCACC AAGATGGCTT TTCTTTGTGC TGCATGTGGA GAAATTCAGA GCTTTCCTCT 840 TCCAGATGGA AAATACAGTC TTCCCACAAA GTGTCCTGTG CCTGTGTGTC GAGGCAGGTC 900 ATTTACTGCT CTCCGCAGCT CTCCTCTCAC AGTTACGATG GACTGGCAGT CAATCAAAAT 960 CCAGGAATTG ATGTCTGATG ATCAGAGAGA AGCAGGTCGG ATTCCACGAA CAATAGAATG 1020 TGAGCTTGTT CATGATCTTG TGGATAGCTG TGTCCCGGGA GACACAGTGA CTATTACTGG 1080 AATTGTCAAA GTCTCAAATG CGGAAGAAGG TTCTCGAAAT AAGAATGACA AGTGTATGTT 1140 CCTTTTGTAT ATTGAAGCAA ATTCTATTAG TAATAGCAAA GGACAGAAAA CAAAGAGTTC 1200 TGAGGATGGG TGTAAGCATG GAATGTTGAT GGAGTTCTCA CTTAAAGACC TTTATGCCAT 1260 CCAAGAGATT CAAGCTGAAG AAAACCTGTT TAAACTCATT GTCAACTCGC TTTGCCCTGT 1320 CATTTTTGGT CATGAACTTG TTAAAGCAGG TTTGGCATTA GCACTCTTTG GAGGAAGCCA 1380 GAAATACGCA GATGACAAAA ACAGAATTCC AATTCGGGGA GACCCCCACA TCCTTGTTGT 1440 TGGAGATCCA GGCCTAGGAA AAAGTCAAAT GCTACAGGCA GCGTGCAATG TTGCCCCACG 1500 TGGCGTGTAT GTTTGTGGTA ACACCACGAC CACCTCTGGT CTGACGGTAA CTCTTTCAAA 1560 AGATAGTTCC TCTGGAGATT TTGCTTTGGA AGCTGGTGCC CTGGTACTTG GTGATCAAGG 1620 TATTTGTGGA ATCGATGAAT TTGATAAGAT GGGGAATCAA CATCAAGCCT TGTTGGAAGC 1680 CATGGAGCAG CAAAGTATTA GTCTTGCTAA GGCTGGTGTG GTTTGTAGCC TTCCTGCAAG 1740 AACTTCCATT ATTGCTGCTG CAAATCCAGT TGGAGGACAT TACAATAAAG CCAAAACAGT 1800 TTCTGAGAAT TTAAAAATGG GGAGTGCACT ACTATCCAGA TTTGATTTGG TCTTTATCCT 1860 GTTAGATACT CCAAATGAGC ATCATGATCA CTTACTCTCT GAACATGTGA TTGCAATAAG 1920 AGCTGGAAAG CAGAGAACCA TTAGCAGTGC CACAGTAGCT CGTATGAATA GTCAAGATTC 1980 AAATACTTCC GTACTTGAAG TAGTTTCTGA GAAGCCATTA TCAGAAAGAC TAAAGGTGGT 2040 TCCTGGAGAA ACAATAGATC CCATTCCCCA CCAGCTATTG AGAAAGTACA TTGGCTATGC 2100 TCGGCAGTAT GTGTACCCAA GGCTATCCAC AGAAGCTGCT CGAGTTCTTC AAGATTTTTA 2160 CCTTGAGCTC CGGAAACAGA GCCAGAGGTT AAATAGCTCA CCAATCACTA CCAGGCAGCT 2220 GGAATCTTTG ATTCGTCTGA CAGAGGCACG AGCAAGGTTG GAATTGAGAG AGGAAGCAAC 2280 CAAAGAAGAC GCTGAGGATA TAGTGGAAAT TATGAAATAT AGCATGCTAG GAACTTACTC 2340 TGATGAATTT GGGAACCTAG ATTTTGAGCG ATCCCAGCAT GGTTCTGGAA TGAGCAACAG 2400 GTCAACAGCG AAAAGATTTA TTTCTGCTCT CAACAACGTT GCTGAAAGAA CTTATAATAA 2460 TATATTTCAA TTTCATCAAC TTCGGCAGAT TGCCAAAGAA CTAAACATTC AGGTTGCTGA 2520 TTTTGAAAAT TTTATTGGAT CACTAAATGA CCAGGGTTAC CTCTTGAAAA AAGGCCCAAA 2580 AGTTTACCAG CTTCAAACTA TGTAAAAGGA CTTCACCAAG TTAGGGCCTC CTGGGTTTAT 2640 TGCAGATTAA AGCCATCTCA GTGAAGATAT GCGTGCACGC ACAGACAGAC AGACACACAC 2700 ACACACACAC ACACACACAC ACACACACAC ACACACAGTC AAATACTGTT CTCTGAAAAA 2760 TGATGTCCCA AAAGTATTAT AATAGGAAAA AAGCATTAAA TATAATAAAC TAATTTAAGA 2820

1 11 21 31 41 51 GCGTCGTGTG CAGGCGTCCC CGGGCTGTGG ATAATTAGAC ACGTTCTTCC CTCATTGCCC 60 AAGGCTCGTT AGAATTCGCC CTAGAGCTGT ATCATGTATT TTCTTTCAAA TTAACTTTGC 120 TTGCAATTAA GCTTAGGGAA CCAGCAACAA AAGCAAACTT GGCCCGAGGT CGTTCACCGC 180 GAAAATGGAT TAGAGAAACT TCTTCCCCGA TTTAAGGGGA AAGATTCCTG CGGCCAGCGC 240 TTTGGGGAAA GTGCCCCGAC CGCAGAGGCG ACGACAGGGG AGCAGGAAGC TGCTCACGGT 300 AGTCGGCGTT GGCGGCAGCG GTGGCCTTCC TCATCTGGGC GATGTGGGCT CCTAGAAGAG 360 TAAGGATAAC ATCCTGGAAA TGACTTCTGT ACGGTTTGAG CCCAACTGCA CACTCATGAC 420 TTGGAGCTGC CCTGTGGAGT TACAGTTTAC CAAACACATT CATGAACATA ATCTCATTTA 480 CTAAAAACTT TGTGAGAATT TTCTTTTACT AAAATTTTTT CTTATTACAA A Seq ID NO : 48 DNA sequence: Nucleic Acid Accession &num : CAT cluster 1 11 21 31 41 51 TTCCAAATTT TTTTTTTTGT AATAAGAAAA AATTTTAGTA AAAGAAAATT CTCACAAAGT 60 TTTTAGTAAA TGAGATTATG TTCATGAATG TGTTTGGTAA ACTGTAACTC CACAGGGCAG 120 CTCCAAGTCA TGAGTGTGCA GTTGGGCTCA AACCGTACAG AAGTCATTTC CAGGATGTTA 180 TCCTTACTCT TCTCGGAGCC CACATCGCCC AGATGAGGAA GGCCACCGCT GCCGCCAACG 240 CCGACTACCG TGAGCAGCTT CCTGCTCCCC TGTCGTCGCC TCTGCGGTCG GGGCACTTTC 300 CCCAAAGCGC TGGCCGCAGG AATCTTTCCC CTTAAATCGG GGAAGAAGTT TCTCTAATCC 360 ATTTTCGCGG TGAACGACCT CGGGCCAAGT TTGCTTTTGT TGCTGGTTCC CTAAGCTTAA 420 TTGCAAGCAA AGTTAATTTG AAAGAAAATA CATGATACAG CTCTAGGGCG AATTCTAACG 480 AGCCTTGGGC AATGAGGGAA GAACGTGTCT AGTTATCCAC AGCCCGGGGA CGCCTGCACA 540 CGACGCT Seq ID NO: 49 DNA sequence Nucleic Acid Accession # : CAT cluster 1 11 21 31 41 51 # # # # # # TCTTTCTTCT GCTGCTCGTT TGTCTCTCCT GTGCTCTTCT TCTTTCTTTC CCTCGCCGCT 60 CCTGCCGACC TCTGTTGTCT CTTCTCTGAT GGCGGGGGGC GGGAGAAGCT GACCGGTGAG 120 ACCGTAGACC CGAAACCATT GGGTGTCACA AGCCGGTCGC CGGCTTTTTT GGGAGAACCC 180 GACACATGCA GACCAGTTTT CCTGGAACNG CATGACCATG TTATTACTAT GGGCCGCCTC 240 CCCAACCAAA GTGTTTAAAA CTTTTTAGGG CACCCCCAAA ATTTTTTTTT TTTTTTTTTT 300 TTCATTTAAA AAACTCTAAT ATTTATATTA AATACAAAGA TACCCAAACC CTTTATGCTT 360 CTTTCTCTGA TCTGTGTCTT TTTTCTTTGA CAGCATCTCC ATTTTTTTTC TGCTGCTTCA 420 TCGCTGTAGC CATGGGAATC CGTTTCATTA TTATGGTAGC AATATGGAGT GCTGTATTCC 480 TAAAGAAACT GACACAGGAG AATCACTTGA ACTTGGGAGG CAGAGTTTGC AGTGAGCCGA 540 GATTGAACCA GTGCACTCCA GCCTTGGCAG CGGAGCAAGA TTCTGTCACA GTTCCTGAAG 600 TGCTGGTATC GTCCTGCAGC CCCATCCTCG GTTCCATTGC GCTGCCAGGC AGGGTGCTGG 660 GACGTGGGGA GAGCTGGTCT ATATATCCGG GTGAAGCTCA GCTGTGGCAC ACCTTGGATG 720 CCGGGTCTCT CCTGGCCCCG GGGACCTAGT ATTTTTGCCA CGAGTGTACA CCAAACAAAG 780 GAGACAGCAT CATTTATGAG CCTGCAGCAT CCACCCTACT GCTGTATCCA GTTTCCATTG 840 ACTG Seq ID NO : 50 DNA sequence Nucleic Acid Accession # : L05187 Coding sequence: 1991.. 2260 1 11 21 31 41 51 # # # # # # CTGCAGGGAG GCAGGTAGAA AAGCTTTTG GGTTTTCAGG TGGGGGGCAG TCTAGCCTGA 60 TCAGAAAGGA GGAAAAGGCC AGGGCAGATG TCTGGGTGGA GTGAAGGGAA AAAGTGATCC 120 CAGAAGAAGG ATTAGCCCCT GAAAGTCCCT GAAGTAGGAG AAGGGTAAAG GTGTGGTTGG 180 TGAAGGAAAG CAGGTTTTCC CAGATTAGCA ACCAGTCAGG GGGAGGAAGG TGAGAGTGGG 240 AGAGTCATAA GTAAATTATT CTGAATGTGT GTAGTTTAAT GGAATTGGGA AAAAGATGGG 300 GGAAATGGAT GGAAGGTCTT GGACTCTGAG ACAAGGGGTC TATAATCAGT CCATTTCATT 360 ATTTCTAGCT TCCACCTTCA CCAAGGCAGA CAAGGAGGGC CCACCTCAGC TCCTCTGCTC 420 CCCCTCCCTT TCCCACCTAT TCATGTGTGC AAGAGTGCCC TGTCCCACAG AACACGGGGA 480 ACAACCATCT CAATGACAAG GACAGCAGGT GGCAAGGCTC AACAGGACTC AGATGTCCCC 540 CCAGGGTTAA CTCATGAAAC CCTCCATGAA GCCTGCTGCT CACCCCTCCC TCAAGGCAAG 600 CCCTGCACCT GGGTCTGAGG ATGAGGGTGG CAGTGAAAAT TAGGCCAGTG ACATCATTTT 660 CAGCCAGCTA GTGCCAAAAA ATATCAGGTG GTGTTCATCA AATAAGCCGA GCCAACCGGT 720 GATGAGGATG GTAGTGTGAG TCATGTGTGA CAGGTGAGGA ATGAAAACAG AGTGCCCGAG 780 AGCTTCTATT TCCTTGAGGC AGGGCTCATT CATCTTATAA AAGCCAGCTG GCCATTGCCT 840 TCACACCAAA CCCAAGGGAC CACACAGCCC ATTCTGCTCC GTATACCAGG TAAGTCTCTG 900 ATTGCAACAA ACTGGCAATT CTAGTGTACT TTTTCATTAT TAGAAATTAG CTAAAGGCAA 960 ATATGTGTAA GCAGGTTAAT CCAGGGTTTC AATGGGAGAT AGAGAATAGT GGAATATCTT 1020 TATTTTAAGT TAAATTACAG TCTGGATTTG AAAGGACCTT AGAGATGGTT AGGGCTCCCA 1080 CCTCAGTAGA TAGTCATTGA ACTGGGAGTC CTGGAGAAGA TTGTTCAAAT GCCCATGGGA 1140 AGTTCATAGC AGAACTAGAA CTCAGGCCAG AGCACTCTCA GTAACACTGC AATTTCCCCC 1200 TGACAAGATA TTTATAGAAA TTTTAATTTA TTAGATGGAT CTCTACTGAG CATTTATTCC 1260 ATTTAAGGCA GTATGCTAGG CACTTTGGAC AAATCAATGC CCTAACGTAC TTACTTAACA 1320 AACATAAAAC CTAGCAGGAA GGTAATACAT ATATATAAAT AAATGAAATG CAAAGTAGAT 1380 AGTAATTGGC ATGACGGAGA TGGGCAGAGA AGGGCTGTGC ACTTTTGGGA GACTTGCTCA 1440 AGGAGACCTC TAGGGTGTCA AGTGATGTGA GCTATGATGG AGGGGTATTT GGACAAGCAG 1500 AGATGGGAAG AAAAGCATTT GGAAGGGACT GTGTAAGCAC AGACCAGAAG CAAAACCATA 1560 GAGGCTTAGA TGAATATAAA GCCATCCTAT AAGTCACAGG CTTTCTACAT GGTACTAGGA 1620 GAGGAAAGTG GTCTGATGCC ATTTTCCAAA AGACCTAATA TGCGGACCTC ATGTCCCTCA 1680 GAAGCCAGCT TTAGTAGGGC ATTTTTCCAG AACAGATATA AGGTGCCTTG GGTAGGAAGG 1740 GAGCCAAGAA GAGAACTCCA ATAAAATGGA GCAGAAGAAA TTGCCTTTTA GCTCCTCCTC 1800 TTCAAAGGGC CTGAAAATTA TCCAAGCTTA TTTCATTTTT AAATGTAATG GGGGAGCTAA 1860

Protein Accession # : NP 001784. 2 1 11 21 31 41 51 # # # # # # MGLPRGPLAS LLLLQVCWLQ CAASEPCRAV FREAEVTLEA GGAEQEPGQA LGKVFMGCPG 60 QEPALFSTDN DDFTVRNGET VQERRSLKER NPLKIFPSKR ILRRHKRDWV VAPISVPENG 120 KGPFPQRLNQ LKSNKDRDTK IFYSITGPGA DSPPEGVFAV EKETGWLLLN KPLDREEIAK 180 YELFGHAVSE NGASVEDPMN ISIIVTDQND HKPKFTQDTF RGSVLEGVLP GTSVMQVTAT 240 DEDDAIYTYN GWAYSIHSQ EPKDPHDLMF TIHRSTGTIS VISSGLDREK VPEYTLTIQA 300 TDMDGDGSTT TAVAWEILD ANDNAPMFDP QKYEAHVPEN AVGHEVQRLT VTDLDAPNSP 360 AWRATYLIMG GDDGDHFTIT THPESNQGIL TTRKGLDFEA KNQHTLYVEV TNEAPFVLKL 420 PTSTATIWH VEDVNEAPVF VPPSKWEVQ EGIPTGEPVC VYTAEDPDKE NQKISYRILR 480 DPAGWLAMDP DSGQVTAVGT LDREDEQFVR NNIYEVMVLA MDNGSPPTTG TGTLLLTLID 540 VNDHGPVPEP RQITICNQSP VRQVLNITDK DLSPHTSPFQ AQLTDDSDIY WTAEVNEEGD 600 TWLSLKKFL KQDTYDVHLS LSDHGNKEQL TVIRATVCDC HGHVETCPGP WKGGFILPVL 660 GAVLALLFLL LVLLLLVRKK RKIKEPLLLP EDDTRDNVFY YGEEGGGEED QDYDITQLHR 720 GLEARPEWL RNDVAPTIIP TPMYRPRPAN PDEIGNFIIE NLKAANTDPT APPYDTLLVF 780 DYEGSGSDAA SLSSLTSSAS DQDQDYDYLN EWGSRFKKLA DMYGGGEDD Seq ID NO : 60 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 162-428 1 11 21 31 41 51 I I I I I I GCGTTCCGTT GGCGGCGGAT TCGAACGTTC GGACTGAGGT TTTTCTGCCT GAAGAAGCGT 60 CATACGGACC GGATTGTTTT CGCTGGCCCA GTGTCCCCGG AGCTTGTGTG CGATACAGAG 120 AGCACCTCGG AAGCTGAGGC AGCTGGTACT TGACAGAGAG GATGGCGCTG TCGACCATAG 180 TCTCCCAGAG GAAGCAGATA AAGCGGAAGG CTCCCCGTGG CTTTCTAAAG CGAGTCTTCA 240 AGCGAAAGAA GCCTCAACTT CGTCTGGAGA AAAGTGGTGA CTTATTGGTC CATCTGAACT 300 GTTTACTGTT TGTTCATCGA TTAGCAGAAG AGTCCAGGAC AAACGCTTGT GCGAGTAAAT 360 GTAGAGTCAT TAACAAGGAG CATGTACTGG CCGCAGCAAA GGTAATTCTA AAGAAGAGCA 420 GAGGTTAGAA GTCAAAGAAC ATATTCTTGA AAGTTATGAT GCATTCTTTT GGGTGGTAAC 480 AGATCATAAA GACATTTTTT ACACATCAGT TAATATGGGA TTATTAAATA TTGG Seq ID NO: 61 Protein sequence: Protein Accession &num : Eos sequence 1 11 21 31 41 51 MALSTIVSQR KQIKRKAPRG FLKRVFKRKK PQLRLEKSGD LLVHLNCLLF VHRLAEESRT 60 NACASKCRVI NKEHVLAAAK VILKKSRG Seq ID NO: 62 DNA sequence Nucleic Acid Accession # : NM 000094. 2 Coding sequence : 99-8933 1 11 21 31 41 51 GGGCTGGAGG GGCGCTGGGC TCGGACCTGC CAAGGCCACC GCAGGGGGGA GCAAGGGACA 60 GAGGCGGGGG TCCTAGCTGA CGGCTTTTAC TGCCTAGGAT GACGCTGCGG CTTCTGGTGG 120 CCGCGCTCTG CGCCGGGATC CTGGCAGAGG CGCCCCGAGT GCGAGCCCAG CACAGGGAGA 180 GAGTGACCTG CACGCGCCTT TACGCCGCTG ACATTGTGTT CTTACTGGAT GGCTCCTCAT 240 CCATTGGCCG CAGCAATTTC CGCGAGGTCC GCAGCTTTCT CGAAGGGCTG GTGCTGCCTT 300 TCTCTGGAGC AGCCAGTGCA CAGGGTGTGC GCTTTGCCAC AGTGCAGTAC AGCGATGACC 360 CACGGACAGA GTTCGGCCTG GATGCACTTG GCTCTGGGGG TGATGTGATC CGCGCCATCC 420 GTGAGCTTAG CTACAAGGGG GGCAACACTC GCACAGGGGC TGCAATTCTC CATGTGGCTG 480 ACCATGTCTT CCTGCCCCAG CTGGCCCGAC CTGGTGTCCC CAAGGTCTGC ATCCTGATCA 540 CAGACGGGAA GTCCCAGGAC CTGGTGGACA CAGCTGCCCA AAGGCTGAAG GGGCAGGGGG 600 TCAAGCTATT TGCTGTGGGG ATCAAGAATG CTGACCCTGA GGAGCTGAAG CGAGTTGCCT 660 CACAGCCAAC CTCCGACTTC TTCTTCTTCG TCAATGACTT CAGCATCTTG AGGACACTAC 720 TGCCCCTCGT TTCCCGGAGA GTGTGCACGA CTGCTGGTGG CGTGCCTGTG ACCCGACCTC 780 CGGATGACTC GACCTCTGCT CCACGAGACC TGGTGCTGTC TGAGCCAAGC AGCCAATCCT 840 TGAGAGTACA GTGGACAGCG GCCAGTGGCC CTGTGACTGG CTACAAGGTC CAGTACACTC 900 CTCTGACGGG GCTGGGACAG CCACTGCCGA GTGAGCGGCA GGAGGTGAAC GTCCCAGCTG 960 GTGAGACCAG TGTGCGGCTG CGGGGTCTCC GGCCACTGAC CGAGTACCAA GTGACTGTGA 1020 TTGCCCTCTA CGCCAACAGC ATCGGGGAGG CTGTGAGCGG GACAGCTCGG ACCACTGCCC 1080 TAGAAGGGCC GGAACTGACC ATCCAGAATA CCACAGCCCA CAGCCTCCTG GTGGCCTGGC 1140 GGAGTGTGCC AGGTGCCACT GGCTACCGTG TGACATGGCG GGTCCTCAGT GGTGGGCCCA 1200 CACAGCAGCA GGAGCTGGGC CCTGGGCAGG GTTCAGTGTT GCTGCGTGAC TTGGAGCCTG 1260 GCACGGACTA TGAGGTGACC GTGAGCACCC TATTTGGCCG CAGTGTGGGG CCCGCCACTT 1320 CCCTGATGGC TCGCACTGAC GCTTCTGTTG AGCAGACCCT GCGCCCGGTC ATCCTGGGCC 1380 CCACATCCAT CCTCCTTTCC TGGAACTTGG TGCCTGAGGC CCGTGGCTAC CGGTTGGAAT 1440 GGCGGCGTGA GACTGGCTTG GAGCCACCGC AGAAGGTGGT ACTGCCCTCT GATGTGACCC 1500 GCTACCAGTT GGATGGGCTG CAGCCGGGCA CTGAGTACCG CCTCACACTC TACACTCTGC 1560 TGGAGGGCCA CGAGGTGGCC ACCCCTGCAA CCGTGGTTCC CACTGGACCA GAGCTGCCTG 1620 TGAGCCCTGT AACAGACCTG CAAGCCACCG AGCTGCCCGG GCAGCGGGTG CGAGTGTCCT 1680 GGAGCCCAGT CCCTGGTGCC ACCCAGTACC GCATCATTGT GCGCAGCACC CAGGGGGTTG 1740 AGCGGACCCT GGTGCTTCCT GGGAGTCAGA CAGCATTCGA CTTGGATGAC GTTCAGGCTG 1800 GGCTTAGCTA CACTGTGCGG GTGTCTGCTC GAGTGGGTCC CCGTGAGGGC AGTGCCAGTG 1860 TCCTCACTGT CCGCCGGGAG CCGGAAACTC CACTTGCTGT TCCAGGGCTG CGGGTTGTGG 1920 TGTCAGATGC AACGCGAGTG AGGGTGGCCT GGGGACCCGT CCCTGGAGCC AGTGGATTTC 1980 GGATTAGCTG GAGCACAGGC AGTGGTCCGG AGTCCAGCCA GACACTGCCC CCAGACTCTA 2040 CTGCCACAGA CATCACAGGG CTGCAGCCTG GAACCACCTA CCAGGTGGCT GTGTCGGTAC 2100 TGCGAGGCAG AGAGGAGGGC CCTGCTGCAG TCATCGTGGC TCGAACGGAC CCACTGGGCC 2160 CAGTGAGGAC GGTCCATGTG ACTCAGGCCA GCAGCTCATC TGTCACCATT ACCTGGACCA 2220 GGGTTCCTGG CGCCACAGGA TACAGGGTTT CCTGGCACTC AGCCCACGGC CCAGAGAAAT 2280

CCCAGTTGGT TTCTGGGGAG GCCACGGTGG CTGAGCTGGA TGGACTGGAG CCAGATACTG 2340 AGTATACGGT GCATGTGAGG GCCCATGTGG CTGGCGTGGA TGGGCCCCCT GCCTCTGTGG 2400 TTGTGAGGAC TGCCCCTGAG CCTGTGGGTC GTGTGTCGAG GCTGCAGATC CTCAATGCTT 2460 CCAGCGACGT TCTACGGATC ACCTGGGTAG GGGTCACTGG AGCCACAGCT TACAGACTGG 2520 CCTGGGGCCG GAGTGAAGGC GGCCCCATGA GGCACCAGAT ACTCCCAGGA AACACAGACT 2580 CTGCAGAGAT CCGGGGTCTC GAAGGTGGAG TCAGCTACTC AGTGCGAGTG ACTGCACTTG 2640 TCGGGGACCG CGAGGGCACA CCTGTCTCCA TTGTTGTCAC TACGCCGCCT GAGGCTCCGC 2700 CAGCCCTGGG GACGCTTCAC GTGGTGCAGC GCGGGGAGCA CTCGCTGAGG CTGCGCTGGG 2760 AGCCGGTGCC CAGAGCGCAG GGCTTCCTTC TGCACTGGCA ACCTGAGGGT GGCCAGGAAC 2820 AGTCCCGGGT CCTGGGGCCC GAGCTCAGCA GCTATCACCT GGACGGGCTG GAGCCAGCGA 2880 CACAGTACCG CGTGAGGCTG AGTGTCCTAG GGCCGGCTGG AGAAGGGCCC TCTGCAGAGG 2940 TGACTGCGCG CACTGAGTCA CCTCGTGTTC CAAGCATTGA ACTACGTGTG GTGGACACCT 3000 CGATCGACTC GGTGACTTTG GCCTGGACTC CAGTGTCCAG GGCATCCAGC TACATCCTAT 3060 CCTGGCGGCC ACTCAGAGGC CCTGGCCAGG AAGTGCCTGG GTCCCCGCAG ACACTTCCAG 3120 GGATCTCAAG CTCCCAGCGG GTGACAGGGC TAGAGCCTGG CGTCTCTTAC ATCTTCTCCC 3180 TGACGCCTGT CCTGGATGGT GTGCGGGGTC CTGAGGCATC TGTCACACAG ACGCCAGTGT 3240 GCCCCCGTGG CCTGGCGGAT GTGGTGTTCC TACCACATGC CACTCAAGAC AATGCTCACC 3300 GTGCGGAGGC TACGAGGAGG GTCCTGGAGC GTCTGGTGTT GGCACTTGGG CCTCTTGGGC 3360 CACAGGCAGT TCAGGTTGGC CTGCTGTCTT ACAGTCATCG GCCCTCCCCA CTGTTCCCAC 3420 TGAATGGCTC CCATGACCTT GGCATTATCT TGCAAAGGAT CCGTGACATG CCCTACATGG 3480 ACCCAAGTGG GAACAACCTG GGCACAGCCG TGGTCACAGC TCACAGATAC ATGTTGGCAC 3540 CAGATGCTCC TGGGCGCCGC CAGCACGTAC CAGGGGTGAT GGTTCTGCTA GTGGATGAAC 3600 CCTTGAGAGG TGACATATTC AGCCCCATCC GTGAGGCCCA GGCTTCTGGG CTTAATGTGG 3660 TGATGTTGGG AATGGCTGGA GCGGACCCAG AGCAGCTGCG TCGCTTGGCG CCGGGTATGG 3720 ACTCTGTCCA GACCTTCTTC GCCGTGGATG ATGGGCCAAG CCTGGACCAG GCAGTCAGTG 3780 GTCTGGCCAC AGCCCTGTGT CAGGCATCCT TCACTACTCA GCCCCGGCCA GAGCCCTGCC 3840 CAGTGTATTG TCCAAAGGGC CAGAAGGGGG AACCTGGAGA GATGGGCCTG AGAGGACAAG 3900 TTGGGCCTCC TGGCGACCCT GGCCTCCCGG GCAGGACCGG TGCTCCCGGC CCCCAGGGGC 3960 CCCCTGGAAG TGCCACTGCC AAGGGCGAGA GGGGCTTCCC TGGAGCAGAT GGGCGTCCAG 4020 GCAGCCCTGG CCGCGCCGGG AATCCTGGGA CCCCTGGAGC CCCTGGCCTA AAGGGCTCTC 4080 CAGGGTTGCC TGGCCCTCGT GGGGACCCGG GAGAGCGAGG ACCTCGAGGC CCAAAGGGGG 4140 AGCCGGGGGC TCCCGGACAA GTCATCGGAG GTGAAGGACC TGGGCTTCCT GGGCGGAAAG 4200 GGGACCCTGG ACCATCGGGC CCCCCTGGAC CTCGTGGACC ACTGGGGGAC CCAGGACCCC 4260 GTGGCCCCCC AGGGCTTCCT GGAACAGCCA TGAAGGGTGA CAAAGGCGAT CGTGGGGAGC 4320 GGGGTCCCCC TGGACCAGGT GAAGGTGGCA TTGCTCCTGG GGAGCCTGGG CTGCCGGGTC 4380 TTCCCGGAAG CCCTGGACCC CAAGGCCCCG TTGGCCCCCC TGGAAAGAAA GGAGAAAAAG 4440 GTGACTCTGA GGATGGAGCT CCAGGCCTCC CAGGACAACC TGGGTCTCCG GGTGAGCAGG 4500 GCCCACGGGG ACCTCCTGGA GCTATTGGCC CCAAAGGTGA CCGGGGCTTT CCAGGGCCCC 4560 TGGGTGAGGC TGGAGAGAAG GGCGAACGTG GACCCCCAGG CCCAGCGGGA TCCCGGGGGC 4620 TGCCAGGGGT TGCTGGACGT CCTGGAGCCA AGGGTCCTGA AGGGCCACCA GGACCCACTG 4680 GCCGCCAAGG AGAGAAGGGG GAGCCTGGTC GCCCTGGGGA CCCTGCAGTG GTGGGACCTG 4740 CTGTTGCTGG ACCCAAAGGA GAAAAGGGAG ATGTGGGGCC CGCTGGGCCC AGAGGAGCTA 4800 CCGGAGTCCA AGGGGAACGG GGCCCACCCG GCTTGGTTCT TCCTGGAGAC CCTGGCCCCA 4860 AGGGAGACCC TGGAGACCGG GGTCCCATTG GCCTTACTGG CAGAGCAGGA CCCCCAGGTG 4920 ACTCAGGGCC TCCTGGAGAG AAGGGAGACC CTGGGCGGCC TGGCCCCCCA GGACCTGTTG 4980 GCCCCCGAGG ACGAGATGGT GAAGTTGGAG AGAAAGGTGA CGAGGGTCCT CCGGGTGACC 5040 CGGGTTTGCC TGGAAAAGCA GGCGAGCGTG GCCTTCGGGG GGCACCTGGA GTTCGGGGGC 5100 CTGTGGGTGA AAAGGGAGAC CAGGGAGATC CTGGAGAGGA TGGACGAAAT GGCAGCCCTG 5160 GATCATCTGG ACCCAAGGGT GACCGTGGGG AGCCGGGTCC CCCAGGACCC CCGGGACGGC 5220 TGGTAGACAC AGGACCTGGA GCCAGAGAGA AGGGAGAGCC TGGGGACCGC GGACAAGAGG 5280 GTCCTCGAGG GCCCAAGGGT GATCCTGGCC TCCCTGGAGC CCCTGGGGAA AGGGGCATTG 5340 AAGGGTTTCG GGGACCCCCA GGCCCACAGG GGGACCCAGG TGTCCGAGGC CCAGCAGGAG 5400 AAAAGGGTGA CCGGGGTCCC CCTGGGCTGG ATGGCCGGAG CGGACTGGAT GGGAAACCAG 5460 GAGCCGCTGG GCCCTCTGGG CCGAATGGTG CTGCAGGCAA AGCTGGGGAC CCAGGGAGAG 5520 ACGGGCTTCC AGGCCTCCGT GGAGAACAAG GCCTCCCTGG CCCCTCTGGT CCCCCTGGAT 5580 TACCGGGAAA GCCAGGCGAG GATGGGAAAC CTGGCCTGAA TGGAAAAAAC GGAGAACCTG 5640 GGGACCCTGG AGAAGACGGG AGGAAGGGAG AGAAAGGAGA TTCAGGCGCC TCTGGGAGAG 5700 AAGGTCGTGA TGGCCCCAAG GGTGAGCGTG GAGCTCCTGG TATCCTTGGA CCCCAGGGGC 5760 CTCCAGGCCT CCCAGGGCCA GTGGGCCCTC CTGGCCAGGG TTTTCCTGGT GTCCCAGGAG 5820 GCACGGGCCC CAAGGGTGAC CGTGGGGAGA CTGGATCCAA AGGGGAGCAG GGCCTCCCTG 5880 GAGAGCGTGG CCTGCGAGGA GAGCCTGGAA GTGTGCCGAA TGTGGATCGG TTGCTGGAAA 5940 CTGCTGGCAT CAAGGCATCT GCCCTGCGGG AGATCGTGGA GACCTGGGAT GAGAGCTCTG 6000 GTAGCTTCCT GCCTGTGCCC GAACGGCGTC GAGGCCCCAA GGGGGACTCA GGCGAACAGG 6060 GCCCCCCAGG CAAGGAGGGC CCCATCGGCT TTCCTGGAGA ACGCGGGCTG AAGGGCGACC 6120 GTGGAGACCC TGGCCCTCAG GGGCCACCTG GTCTGGCCCT TGGGGAGAGG GGCCCCCCCG 6180 GGCCTTCCGG CCTTGCCGGG GAGCCTGGAA AGCCTGGTAT TCCCGGGCTC CCAGGCAGGG 6240 CTGGGGGTGT GGGAGAGGCA GGAAGGCCAG GAGAGAGGGG AGAACGGGGA GAGAAAGGAG 6300 AACGTGGAGA ACAGGGCAGA GATGGCCCTC CTGGACTCCC TGGAACCCCT GGGCCCCCCG 6360 GACCCCCTGG CCCCAAGGTG TCTGTGGATG AGCCAGGTCC TGGACTCTCT GGAGAACAGG 6420 GACCCCCTGG ACTCAAGGGT GCTAAGGGGG AGCCGGGCAG CAATGGTGAC CAAGGTCCCA 6480 AAGGAGACAG GGGTGTGCCA GGCATCAAAG GAGACCGGGG AGAGCCTGGA CCGAGGGGTC 6540 AGGACGGCAA CCCGGGTCTA CCAGGAGAGC GTGGTATGGC TGGGCCTGAA GGGAAGCCGG 6600 GTCTGCAGGG TCCAAGAGGC CCCCCTGGCC CAGTGGGTGG TCATGGAGAC CCTGGACCAC 6660 CTGGTGCCCC GGGTCTTGCT GGCCCTGCAG GACCCCAAGG ACCTTCTGGC CTGAAGGGGG 6720 AGCCTGGAGA GACAGGACCT CCAGGACGGG GCCTGACTGG ACCTACTGGA GCTGTGGGAC 6780 TTCCTGGACC CCCCGGCCCT TCAGGCCTTG TGGGTCCACA GGGGTCTCCA GGTTTGCCTG 6840 GACAAGTGGG GGAGACAGGG AAGCCGGGAG CCCCAGGTCG AGATGGTGCC AGTGGAAAAG 6900 ATGGAGACAG AGGGAGCCCT GGTGTGCCAG GGTCACCAGG TCTGCCTGGC CCTGTCGGAC 6960 CTAAAGGAGA ACCTGGCCCC ACGGGGGCCC CTGGACAGGC TGTGGTCGGG CTCCCTGGAG 7020 CAAAGGGAGA GAAGGGAGCC CCTGGAGGCC TTGCTGGAGA CCTGGTGGGT GAGCCGGGAG 7080 CCAAAGGTGA CCGAGGACTG CCAGGGCCGC GAGGCGAGAA GGGTGAAGCT GGCCGTGCAG 7140 GGGAGCCCGG AGACCCTGGG GAAGATGGTC AGAAAGGGGC TCCAGGACCC AAAGGTTTCA 7200 AGGGTGACCC AGGAGTCGGG GTCCCGGGCT CCCCTGGGCC TCCTGGCCCT CCAGGTGTGA 7260 AGGGAGATCT GGGCCTCCCT GGCCTGCCCG GTGCTCCTGG TGTTGTTGGG TTCCCGGGTC 7320 AGACAGGCCC TCGAGGAGAG ATGGGTCAGC CAGGCCCTAG TGGAGAGCGG GGTCTGGCAG 7380 GCCCCCCAGG GAGAGAAGGA ATCCCAGGAC CCCTGGGGCC ACCTGGACCA CCGGGGTCAG 7440 TGGGACCACC TGGGGCCTCT GGACTCAAAG GAGACAAGGG AGACCCTGGA GTAGGGCTGC 7500

CTGGGCCCCG AGGCGAGCGT GGGGAGCCAG GCATCCGGGG TGAAGATGGC CGCCCCGGCC 7560 AGGAGGGACC CCGAGGACTC ACGGGGCCCC CTGGCAGCAG GGGAGAGCGT GGGGAGAAGG 7620 GTGATGTTGG GAGTGCAGGA CTAAAGGGTG ACAAGGGAGA CTCAGCTGTG ATCCTGGGGC 7680 CTCCAGGCCC ACGGGGTGCC AAGGGGGACA TGGGTGAACG AGGGCCTCGG GGCTTGGATG 7740 GTGACAAAGG ACCTCGGGGA GACAATGGGG ACCCTGGTGA CAAGGGCAGC AAGGGAGAGC 7800 CTGGTGACAA GGGCTCAGCC GGGTTGCCAG GACTGCGTGG ACTCCTGGGA CCCCAGGGTC 7860 AACCTGGTGC AGCAGGGATC CCTGGTGACC CGGGATCCCC AGGAAAGGAT GGAGTGCCTG 7920 GTATCCGAGG AGAAAAAGGA GATGTTGGCT TCATGGGTCC CCGGGGCCTC AAGGGTGAAC 7980 GGGGAGTGAA GGGAGCCTGT GGCCTTGATG GAGAGAAGGG AGACAAGGGA GAAGCTGGTC 8040 CCCCAGGCCG CCCCGGGCTG GCAGGACACA AAGGAGAGAT GGGGGAGCCT GGTGTGCCGG 8100 GCCAGTCGGG GGCCCCTGGC AAGGAGGGCC TGATCGGTCC CAAGGGTGAC CGAGGCTTTG 8160 ACGGGCAGCC AGGCCCCAAG GGTGACCAGG GCGAGAAAGG GGAGCGGGGA ACCCCAGGAA 8220 TTGGGGGCTT CCCAGGCCCC AGTGGAAATG ATGGCTCTGC TGGTCCCCCA GGGCCACCTG 8280 GCAGTGTTGG TCCCAGAGGC CCCGAAGGAC TTCAGGGCCA GAAGGGTGAG CGAGGTCCCC 8340 CCGGAGAGAG AGTGGTGGGG GCTCCTGGGG TCCCTGGAGC TCCTGGCGAG AGAGGGGAGC 8400 AGGGGCGGCC AGGGCCTGCC GGTCCTCGAG GCGAGAAGGG AGAAGCTGCA CTGACGGAGG 8460 ATGACATCCG GGGCTTTGTG CGCCAAGAGA TGAGTCAGCA CTGTGCCTGC CAGGGCCAGT 8520 TCATCGCATC TGGATCACGA CCCCTCCCTA GTTATGCTGC AGACACTGCC GGCTCCCAGC 8580 TCCATGCTGT GCCTGTGCTC CGCGTCTCTC ATGCAGAGGA GGAAGAGCGG GTACCCCCTG 8640 AGGATGATGA GTACTCTGAA TACTCCGAGT ATTCTGTGGA GGAGTACCAG GACCCTGAAG 8700 CTCCTTGGGA TAGTGATGAC CCCTGTTCCC TGCCACTGGA TGAGGGCTCC TGCACTGCCT 8760 ACACCCTGCG CTGGTACCAT CGGGCTGTGA CAGGCAGCAC AGAGGCCTGT CACCCTTTTG 8820 TCTATGGTGG CTGTGGAGGG AATGCCAACC GTTTTGGGAC CCGTGAGGCC TGCGAGCGCC 8880 GCTGCCCACC CCGGGTGGTC CAGAGCCAGG GGACAGGTAC TGCCCAGGAC TGAGGCCCAG 8940 ATAATGAGCT GAGATTCAGC ATCCCCTGGA GGAGTCGGGG TCTCAGCAGA ACCCCACTGT 9000 CCCTCCCCTT GGTGCTAGAG GCTTGTGTGC ACGTGAGCGT GCGAGTGCAC GTCCGTTATT 9060 TCAGTGACTT GGTCCCGTGG GTCTAGCCTT CCCCCCTGTG GACAAACCCC CATTGTGGCT 9120 CCTGCCACCC TGGCAGATGA CTCACTGTGG GGGGGTGGCT GTGGGCAGTG AGCGGATGTG 9180 ACTGGCGTCT GACCCGCCCC TTGACCCAAG CCTGTGATGA CATGGTGCTG ATTCTGGGGG 9240 GCATTAAAGC TGCTGTTTTA AAAGGCAAAA AA Seq ID NO : 63 Protein sequence: Protein Accession # : NP 000085. 1 1 11 21 31 41 51 MTLRLLVAAL CAGILAEAPR VRAQHRERVT CTRLYAADIV FLLDGSSSIG RSNFREVRSF 60 LEGLVLPFSG AASAQGVRFA TVQYSDDPRT EFGLDALGSG GDVIRAIREL SYKGGNTRTG 120 AAILHVADHV FLPQLARPGV PKVCILITDG KSQDLVDTAA QRLKGQGVKL FAVGIKNADP 180 EELKRVASQP TSDFFFFVND FSILRTLLPL VSRRVCTTAG GVPVTRPPDD STSAPRDLVL 240 SEPSSQSLRV QWTAASGPVT GYKVQYTPLT GLGQPLPSER QEVNVPAGET SVRLRGLRPL 300 TEYQVTVIAL YANSIGEAVS GTARTTALEG PELTIQNTTA HSLLVAWRSV PGATGYRVTW 360 RVLSGGPTQQ QELGPGQGSV LLRDLEPGTD YEVTVSTLFG RSVGPATSLM ARTDASVEQT 420 LRPVILGPTS ILLSWNLVPE ARGYRLEWRR ETGLEPPQKV VLPSDVTRYQ LDGLQPGTEY 480 RLTLYTLLEG HEVATPATW PTGPELPVSP VTDLQATELP GQRVRVSWSP VPGATQYRII 540 VRSTQGVERT LVLPGSQTAF DLDDVQAGLS YTVRVSARVG PREGSASVLT VRREPETPLA 600 VPGLRVWSD ATRVRVAWGP VPGASGFRIS WSTGSGPESS QTLPPDSTAT DITGLQPGTT 660 YQVAVSVLRG REEGPAAVIV ARTDPLGPVR TVHVTQASSS SVTITWTRVP GATGYRVSWH 720 SAHGPEKSQL VSGEATVAEL DGLEPDTEYT VHVRAHVAGV DGPPASVWR TAPEPVGRVS 780 RLQILNASSD VLRITWVGVT GATAYRLAWG RSEGGPMRHQ ILPGNTDSAE IRGLEGGVSY 840 SVRVTALVGD REGTPVSIW TTPPEAPPAL GTLHWQQRGE HSLRLRWEPV PRAQGFLLHW 900 QPEGGQEQSR VLGPELSSYH LDGLEPATQY RVRLSVLGPA GEGPSAEVTA RTESPRVPSI 960 ELRWDTSID SVTLAWTPVS RASSYILSWR PLRGPGQEVP GSPQTLPGIS SSQRVTGLEP 1020 GVSYIFSLTP VLDGVRGPEA SVTQTPVCPR GLADWFLPH ATQDNAHRAE ATRRVLERLV 1080 LALGPLGPQA VQVGLLSYSH RPSPLFPLNG SHDLGIILQR IRDMPYMDPS GNNLGTAWT 1140 AHRYMLAPDA PGRRQHVPGV MVLLVDEPLR GDIFSPIREA QASGLNVVML GMAGADPEQL 1200 RRLAPGMDSV QTFFAVDDGP SLDQAVSGLA TALCQASFTT QPRPEPCPVY CPKGQKGEPG 1260 EMGLRGQVGP PGDPGLPGRT GAPGPQGPPG SATAKGERGF PGADGRPGSP GRAGNPGTPG 1320 APGLKGSPGL PGPRGDPGER GPRGPKGEPG APGQVIGGEG PGLPGRKGDP GPSGPPGPRG 1380 PLGDPGPRGP PGLPGTAMKG DKGDRGERGP PGPGEGGIAP GEPGLPGLPG SPGPQGPVGP 1440 PGKKGEKGDS EDGAPGLPGQ PGSPGEQGPR GPPGAIGPKG DRGFPGPLGE AGEKGERGPP 1500 GPAGSRGLPG VAGRPGAKGP EGPPGPTGRQ GEKGEPGRPG DPAWGPAVA GPKGEKGDVG 1560 PAGPRGATGV QGERGPPGLV LPGDPGPKGD PGDRGPIGLT GRAGPPGDSG PPGEKGDPGR 1620 PGPPGPVGPR GRDGEVGEKG DEGPPGDPGL PGKAGERGLR GAPGVRGPVG EKGDQGDPGE 1680 DGRNGSPGSS GPKGDRGEPG PPGPPGRLVD TGPGAREKGE PGDRGQEGPR GPKGDPGLPG 1740 APGERGIEGF RGPPGPQGDP GVRGPAGEKG DRGPPGLDGR SGLDGKPGAA GPSGPNGAAG 1800 KAGDPGRDGL PGLRGEQGLP GPSGPPGLPG KPGEDGKPGL NGKNGEPGDP GEDGRKGEKG 1860 DSGASGREGR DGPKGERGAP GILGPQGPPG LPGPVGPPGQ GFPGVPGGTG PKGDRGETGS 1920 KGEQGLPGER GLRGEPGSVP NVDRLLETAG IKASALREIV ETWDESSGSF LPVPERRRGP 1980 KGDSGEQGPP GKEGPIGFPG ERGLKGDRGD PGPQGPPGLA LGERGPPGPS GLAGEPGKPG 2040 IPGLPGRAGG VGEAGRPGER GERGEKGERG EQGRDGPPGL PGTPGPPGPP GPKVSVDEPG 2100 PGLSGEQGPP GLKGAKGEPG SNGDQGPKGD RGVPGIKGDR GEPGPRGQDG NPGLPGERGM 2160 AGPEGKPGLQ GPRGPPGPVG GHGDPGPPGA PGLAGPAGPQ GPSGLKGEPG ETGPPGRGLT 2220 GPTGAVGLPG PPGPSGLVGP QGSPGLPGQV GETGKPGAPG RDGASGKDGD RGSPGVPGSP 2280 GLPGPVGPKG EPGPTGAPGQ AWGLPGAKG EKGAPGGLAG DLVGEPGAKG DRGLPGPRGE 2340 KGEAGRAGEP GDPGEDGQKG APGPKGFKGD PGVGVPGSPG PPGPPGVKGD LGLPGLPGAP 2400 GWGFPGQTG PRGEMGQPGP SGERGLAGPP GREGIPGPLG PPGPPGSVGP PGASGLKGDK 2460 GDPGVGLPGP RGERGEPGIR GEDGRPGQEG PRGLTGPPGS RGERGEKGDV GSAGLKGDKG 2520 DSAVILGPPG PRGAKGDMGE RGPRGLDGDK GPRGDNGDPG DKGSKGEPGD KGSAGLPGLR 2580 GLLGPQGQPG AAGIPGDPGS PGKDGVPGIR GEKGDVGFMG PRGLKGERGV KGACGLDGEK 2640 GDKGEAGPPG RPGLAGHKGE MGEPGVPGQS GAPGKEGLIG PKGDRGFDGQ PGPKGDQGEK 2700 GERGTPGIGG FPGPSGNDGS AGPPGPPGSV GPRGPEGLQG QKGERGPPGE RWGAPGVPG 2760 APGERGEQGR PGPAGPRGEK GEAALTEDDI RGFVRQEMSQ HCACQGQFIA SGSRPLPSYA 2820 ADTAGSQLHA VPVLRVSHAE EEERVPPEDD EYSEYSEYSV EEYQDPEAPW DSDDPCSLPL 2880 DEGSCTAYTL RWYHRAVTGS TEACHPFVYG GCGGNANRFG TREACERRCP PRWQSQGTG 2940 TAQD

CTTCTGTGTA GCAGCTTTAA CCCACGTTTG TCTGTCACGT CCAGTCCCGA GACGGCTGAG 3780 TGACCCCAAG AAAGGCTTCC CCGACACCCA GACAGAGGCT GCAGGGCTGG GGCTGGGTGA 3840 GGGTGGCGGG CCTGCGGGGA CATTCTACTG TGCTAAAAAG CCACTGCAGA CATAGCAATA 3900 AAAACATGTC ATTTTCC Seq ID NO: 67 Protein sequence: Protein Accession &num : NP 005620. 1 1 11 21 31 41 51 # # # # # # MAKKSAENGI YSVSGDEKKG PLIAPGPDGA PAKGDGPVGL GTPGGRLAVP PRETWTRQMD 60 FIMSCVGFAV GLGNVWRFPY LCYKNGGGVF LIPYVLIALV GGIPIFFLEI SLGQFMKAGS 120 INVWNICPLF KGLGYASMVI VFYCNTYYIM VLAWGFYYLV KSFTTTLPWA TCGHTWNTPD 180 CVEIFRHEDC ANASLANLTC DQLADRRSPV IEFWENKVLR LSGGLEVPGA LNWEVTLCLL 240 ACWVLVYFCV WKGVKSTGKI VYFTATFPYV VLWLLVRGV LLPGALDGII YYLKPDWSKL 300 GSPQVWIDAG TQIFFSYAIG LGALTALGSY NRFNNNCYKD AIILALINSG TSFFAGFWF 360 SILGFMAAEQ GVHISKVAES GPGLAFIAYP RAVTLMPVAP LWAALFFFML LLLGLDSQFV 420 GVEGFITGLL DLLPASYYFR FQREISVALC CALCFVIDLS MVTDGGMYVF QLFDYYSASG 480 TTLLWQAFWE CWVAWVYGA DRFMDDIACM IGYRPCPWMK WCWSFFTPLV CMGIFIFNW 540 YYEPLVYNNT YVYPWWGEAM GWAFALSSML CVPLHLLGCL LRAKGTMAER WQHLTQPIWG 600 LHHLEYRAQD ADVRGLTTLT PVSESSKVW VESVM Seq ID NO : 68 DNA sequence Nucleic Acid Accession # : NM 021953. 1 Coding sequence: 178-2469 1 11 21 31 41 51 GGCACGAGGG GGACCCGGCC GGTCCGGCGC GAGCCCCCGT CCGGGGCCCT GGCTCGGCCC 60 CCAGGTTGGA GGAGCCCGGA GCCCGCCTTC GGAGCTACGG CCTAACGGCG GCGGCGACTG 120 CAGTCTGGAG GGTCCACACT TGTGATTCTC AATGGAGAGT GAAAACGCAG ATTCATAATG 180 AAAGCTAGCC CCCGTCGGCC ACTGATTCTC AAAAGACGGA GGCTGCCCCT TCCTGTTCAA 240 AATGCCCCAA GTGAAACATC AGAGGAGGAA CCTAAGAGAT CCCCTGCCCA ACAGGAGTCT 300 AATCAAGCAG AGGCCTCCAA GGAAGTGGCG GAGTCCAACT CTTGCAAGTT TCCAGCTGGG 360 ATCAAGATTA TTAACCACCC CACCATGCCC AACACGCAAG TAGTGGCCAT CCCCAACAAT 420 GCTAATATTC ACAGCATCAT CACAGCACTG ACTGCCAAGG GAAAAGAGAG TGGCAGTAGT 480 GGGCCCAACA AATTCATCCT CATCAGCTGT GGGGGAGCCC CAACTCAGCC TCCAGGACTC 540 CGGCCTCAAA CCCAAACCAG CTATGATGCC AAAAGGACAG AAGTGACCCT GGAGACCTTG 600 GGACCAAAAC CTGCAGCTAG GGATGTGAAT CTTCCTAGAC CACCTGGAGC CCTTTGCGAG 660 CAGAAACGGG AGACCTGTGC AGATGGTGAG GCAGCAGGCT GCACTATCAA CAATAGCCTA 720 TCCAACATCC AGTGGCTTCG AAAGATGAGT TCTGATGGAC TGGGCTCCCG CAGCATCAAG 780 CAAGAGATGG AGGAAAAGGA GAATTGTCAC CTGGAGCAGC GACAGGTTAA GGTTGAGGAG 840 CCTTCGAGAC CATCAGCGTC CTGGCAGAAC TCTGTGTCTG AGCGGCCACC CTACTCTTAC 900 ATGGCCATGA TACAATTCGC CATCAACAGC ACTGAGAGGA AGCGCATGAC TTTGAAAGAC 960 ATCTATACGT GGATTGAGGA CCACTTTCCC TACTTTAAGC ACATTGCCAA GCCAGGCTGG 1020 AAGAACTCCA TCCGCCACAA CCTTTCCCTG CACGACATGT TTGTCCGGGA GACGTCTGCC 1080 AATGGCAAGG TCTCCTTCTG GACCATTCAC CCCAGTGCCA ACCGCTACTT GACATTGGAC 1140 CAGGTGTTTA AGCCACTGGA CCCAGGGTCT CCACAATTGC CCGAGCACTT GGAATCACAG 1200 CAGAAACGAC CGAATCCAGA GCTCCGCCGG AACATGACCA TCAAAACCGA ACTCCCCCTG 1260 GGCGCACGGC GGAAGATGAA GCCACTGCTA CCACGGGTCA GCTCATACCT GGTACCTATC 1320 CAGTTCCCGG TGAACCAGTC ACTGGTGTTG CAGCCCTCGG TGAAGGTGCC ATTGCCCCTG 1380 GCGGCTTCCC TCATGAGCTC AGAGCTTGCC CGCCATAGCA AGCGAGTCCG CATTGCCCCC 1440 AAGGTGCTGC TAGCTGAGGA GGGGATAGCT CCTCTTTCTT CTGCAGGACC AGGGAAAGAG 1500 GAGAAACTCC TGTTTGGAGA AGGGTTTTCT CCTTTGCTTC CAGTTCAGAC TATCAAGGAG 1560 GAAGAAATCC AGCCTGGGGA GGAAATGCCA CACTTAGCGA GACCCATCAA AGTGGAGAGC 1620 CCTCCCTTGG AAGAGTGGCC CTCCCCGGCC CCATCTTTCA AAGAGGAATC ATCTCACTCC 1680 TGGGAGGATT CGTCCCAATC TCCCACCCCA AGACCCAAGA AGTCCTACAG TGGGCTTAGG 1740 TCCCCAACCC GGTGTGTCTC GGAAATGCTT GTGATTCAAC ACAGGGAGAG GAGGGAGAGG 1800 AGCCGGTCTC GGAGGAAACA GCATCTACTG CCTCCCTGTG TGGATGAGCC GGAGCTGCTC 1860 TTCTCAGAGG GGCCCAGTAC TTCCCGCTGG GCCGCAGAGC TCCCGTTCCC AGCAGACTCC 1920 TCTGACCCTG CCTCCCAGCT CAGCTACTCC CAGGAAGTGG GAGGACCTTT TAAGACACCC 1980 ATTAAGGAAA CGCTGCCCAT CTCCTCCACC CCGAGCAAAT CTGTCCTCCC CAGAACCCCT 2040 GAATCCTGGA GGCTCACGCC CCCAGCCAAA GTAGGGGGAC TGGATTTCAG CCCAGTACAA 2100 ACCTCCCAGG GTGCCTCTGA CCCCTTGCCT GACCCCCTGG GGCTGATGGA TCTCAGCACC 2160 ACTCCCTTGC AAAGTGCTCC CCCCCTTGAA TCACCGCAAA GGCTCCTCAG TTCAGAACCC 2220 TTAGACCTCA TCTCCGTCCC CTTTGGCAAC TCTTCTCCCT CAGATATAGA CGTCCCCAAG 2280 CCAGGCTCCC CGGAGCCACA GGTTTCTGGC CTTGCAGCCA ATCGTTCTCT GACAGAAGGC 2340 CTGGTCCTGG ACACAATGAA TGACAGCCTC AGCAAGATCC TGCTGGACAT CAGCTTTCCT 2400 GGCCTGGACG AGGACCCACT GGGCCCTGAC AACATCAACT GGTCCCAGTT TATTCCTGAG 2460 CTACAGTAGA GCCCTGCCCT TGCCCCTGTG CTCAAGCTGT CCACCATCCC GGGCACTCCA 2520 AGGCTCAGTG CACCCCAAGC CTCTGAGTGA GGACAGCAGG CAGGGACTGT TCTGCTCCTC 2580 ATAGCTCCCT GCTGCCTGAT TATGCAAAAG TAGCAGTCAC ACCCTAGCCA CTGCTGGGAC 2640 CTTGTGTTCC CCAAGAGTAT CTGATTCCTC TGCTGTCCCT GCCAGGAGCT GAAGGGTGGG 2700 AACAACAAAG GCAATGGTGA AAAGAGATTA GGAACCCCCC AGCCTGTTTC CATTCTCTGC 2760 CCAGCAGTCT CTTACCTTCC CTGATCTTTG CAGGGTGGTC CGTGTAAATA GTATAAATTC 2820 TCCAAATTAT CCTCTAATTA TAAATGTAAG CTTATTTCCT TAGATCATTA TCCAGAGACT 2880 GCCAGAAGGT GGGTAGGATG ACCTGGGGTT TCAATTGACT TCTGTTCCTT GCTTTTAGTT 2940 TTGATAGAAG GGAAGACCTG CAGTGCACGG TTTCTTCCAG GCTGAGGTAC CTGGATCTTG 3000 GGTTCTTCAC TGCAGGGACC CAGACAAGTG GATCTGCTTG CCAGAGTCCT TTTTGCCCCT 3060 CCCTGCCACC TCCCCGTGTT TCCAAGTCAG CTTTCCTGCA AGAAGAAATC CTGGTTAAAA 3120 AAGTCTTTTG TATTGGGTCA GGAGTTGAAT TTGGGGTGGG AGGATGGATG CAACTGAAGC 3180 AGAGTGTGGG TGCCCAGATG TGCGCTATTA GATGTTTCTC TGATAATGTC CCCAATCATA 3240 CCAGGGAGAC TGGCATTGAC GAGAACTCAG GTGGAGGCTT GAGAAGGCCG AAAGGGCCCC 3300 TGACCTGCCT GGCTTCCTTA GCTTGCCCCT CAGCTTTGCA AAGAGCCACC CTAGGCCCCA 3360 GCTGACCGCA TGGGTGTGAG CCAGCTTGAG AACACTAACT ACTCAATAAA AGCGAAGGTG 3420 GACCNAAAAA AAAAAAAAAA AAAA

Seq ID NO : 69 Protein sequence: Protein Accession # : NP 068772. 1 1 11 21 31 41 51 1 1 1 1 1 1 MKASPRRPLI LKRRRLPLPV QNAPSETSEE EPKRSPAQQE SNQAEASKEV AESNSCKFPA 60 GIKIINHPTM PNTQWAIPN NANIHSIITA LTAKGKESGS SGPNKFILIS CGGAPTQPPG 120 LRPQTQTSYD AKRTEVTLET LGPKPAARDV NLPRPPGALC EQKRETCADG EAAGCTINNS 180 LSNIQWLRKM SSDGLGSRSI KQEMEEKENC HLEQRQVKVE EPSRPSASWQ NSVSERPPYS 240 YMAMIQFAIN STERKRMTLK DIYTWIEDHF PYFKHIAKPG WKNSIRHNLS LHDMFVRETS 300 ANGKVSFWTI HPSANRYLTL DQVFKPLDPG SPQLPEHLES QQKRPNPELR RNMTIKTELP 360 LGARRKMKPL LPRVSSYLVP IQFPVNQSLV LQPSVKVPLP LAASLMSSEL ARHSKRVRIA 420 PKVLLAEEGI APLSSAGPGK EEKLLFGEGF SPLLPVQTIK EEEIQPGEEM PHLARPIKVE 480 SPPLEEWPSP APSFKEESSH SWEDSSQSPT PRPKKSYSGL RSPTRCVSEM LVIQHRERRE 540 RSRSRRKQHL LPPCVDEPEL LFSEGPSTSR WAAELPFPAD SSDPASQLSY SQEVGGPFKT 600 PIKETLPISS TPSKSVLPRT PESWRLTPPA KVGGLDFSPV QTSQGASDPL PDPLGLMDLS 660 TTPLQSAPPL ESPQRLLSSE PLDLISVPFG NSSPSDIDVP KPGSPEPQVS GLAANRSLTE 720 GLVLDTMNDS LSKILLDISF PGLDEDPLGP DNINWSQFIP ELQ Seq ID NO : 70 DNA sequence Nucleic Acid Accession # : BC006529.1 Coding sequence: 178-2424 1 11 21 31 41 51 <BR> <BR> <BR> <BR> <BR> GGCACGAGGG GGACCCGGCC GGTCCGGCGC GAGCCCCCGT CCGGGGCCCT GGCTCGGCCC 60 CCAGGTTGGA GGAGCCCGGA GCCCGCCTTC GGAGCTACGG CCTAACGGCG GCGGCGACTG 120 CAGTCTGGAG GGTCCACACT TGTGATTCTC AATGGAGAGT GAAAACGCAG ATTCATAATG 180 AAAACTAGCC CCCGTCGGCC ACTGATTCTC AAAAGACGGA GGCTGCCCCT TCCTGTTCAA 240 AATGCCCCAA GTGAAACATC AGAGGAGGAA CCTAAGAGAT CCCCTGCCCA ACAGGAGTCT 300 AATCAAGCAG AGGCCTCCAA GGAAGTGGCA GAGTCCAACT CTTGCAAGTT TCCAGCTGGG 360 ATCAAGATTA TTAACCACCC CACCATGCCC AACACGCAAG TAGTGGCCAT CCCCAACAAT 420 GCTAATATTC ACAGCATCAT CACAGCACTG ACTGCCAAGG GAAAAGAGAG TGGCAGTAGT 480 GGGCCCAACA AATTCATCCT CATCAGCTGT GGGGGAGCCC CAACTCAGCC TCCAGGACTC 540 CGGCCTCAAA CCCAAACCAG CTATGATGCC AAAAGGACAG AAGTGACCCT GGAGACCTTG 600 GGACCAAAAC CTGCAGCTAG GGATGTGAAT CTTCCTAGAC CACCTGGAGC CCTTTGCGAG 660 CAGAAACGGG AGACCTGTGC AGATGGTGAG GCAGCAGGCT GCACTATCAA CAATAGCCTA 720 TCCAACATCC AGTGGCTTCG AAAGATGAGT TCTGATGGAC TGGGCTCCCG CAGCATCAAG 780 CAAGAGATGG AGGAAAAGGA GAATTGTCAC CTGGAGCAGC GACAGGTTAA GGTTGAGGAG 840 CCTTCGAGAC CATCAGCGTC CTGGCAGAAC TCTGTGTCTG AGCGGCCACC CTACTCTTAC 900 ATGGCCATGA TACAATTCGC CATCAACAGC ACTGAGAGGA AGCGCATGAC TTTGAAAGAC 960 ATCTATACGT GGATTGAGGA CCACTTTCCC TACTTTAAGC ACATTGCCAA GCCAGGCTGG 1020 AAGAACTCCA TCCGCCACAA CCTTTCCCTG CACGACATGT TTGTCCGGGA GACGTCTGCC 1080 AATGGCAAGG TCTCCTTCTG GACCATTCAC CCCAGTGCCA ACCGCTACTT GACATTGGAC 1140 CAGGTGTTTA AGCAGCAGAA ACGACCGAAT CCAGAGCTCC GCCGGAACAT GACCATCAAA 1200 ACCGAACTCC CCCTGGGCGC ACGGCGGAAG ATGAAGCCAC TGCTACCACG GGTCAGCTCA 1260 TACCTGGTAC CTATCCAGTT CCCGGTGAAC CAGTCACTGG TGTTGCAGCC CTCGGTGAAG 1320 GTGCCATTGC CCCTGGCGGC TTCCCTCATG AGCTCAGAGC TTGCCCGCCA TAGCAAGCGA 1380 GTCCGCATTG CCCCCAAGGT GCTGCTAGCT GAGGAGGGGA TAGCTCCTCT TTCTTCTGCA 1440 GGACCAGGGA AAGAGGAGAA ACTCCTGTTT GGAGAAGGGT TTTCTCCTTT GCTTCCAGTT 1500 CAGACTATCA AGGAGGAAGA AATCCAGCCT GGGGAGGAAA TGCCACACTT AGCGAGACCC 1560 ATCAAAGTGG AGAGCCCTCC CTTGGAAGAG TGGCCCTCCC CGGCCCCATC TTTCAAAGAG 1620 GAATCATCTC ACTCCTGGGA GGATTCGTCC CAATCTCCCA CCCCAAGACC CAAGAAGTCC 1680 TACAGTGGGC TTAGGTCCCC AACCCGGTGT GTCTCGGAAA TGCTTGTGAT TCAACACAGG 1740 GAGAGGAGGG AGAGGAGCCG GTCTCGGAGG AAACAGCATC TACTGCCTCC CTGTGTGGAT 1800 GAGCCGGAGC TGCTCTTCTC AGAGGGGCCC AGTACTTCCC GCTGGGCCGC AGAGCTCCCG 1860 TTCCCAGCAG ACTCCTCTGA CCCTGCCTCC CAGCTCAGCT ACTCCCAGGA AGTGGGAGGA 1920 CCTTTTAAGA CACCCATTAA GGAAACGCTG CCCATCTCCT CCACCCCGAG CAAATCTGTC 1980 CTCCCCAGAA CCCCTGAATC CTGGAGGCTC ACGCCCCCAG CCAAAGTAGG GGGACTGGAT 2040 TTCAGCCCAG TACAAACCCC CCAGGGTGCC TCTGACCCCT TGCCTGACCC CCTGGGGCTG 2100 ATGGATCTCA GCACCACTCC CTTGCAAAGT GCTCCCCCCC TTGAATCACC GCAAAGGCTC 2160 CTCAGTTCAG AACCCTTAGA CCTCATCTCC GTCCCCTTTG GCAACTCTTC TCCCTCAGAT 2220 ATAGACGTCC CCAAGCCAGG CTCCCCGGAG CCACAGGTTT CTGGCCTTGC AGCCAATCGT 2280 TCTCTGACAG AAGGCCTGGT CCTGGACACA ATGAATGACA GCCTCAGCAA GATCCTGCTG 2340 GACATCAGCT TTCCTGGCCT GGACGAGGAC CCACTGGGCC CTGACAACAT CAACTGGTCC 2400 CAGTTTATTC CTGAGCTACA GTAGAGCCCT GCCCTTGCCC CTGTGCTCAA GCTGTCCACC 2460 ATCCCGGGCA CTCCAAGGCT CAGTGCACCC CAAGCCTCTG AGTGAGGACA GCAGGCAGGG 2520 ACTGTTCTGC TCCTCATAGC TCCCTGCTGC CTGATTATGC AAAAGTAGCA GTCACACCCT 2580 AGCCACTGCT GGGACCTTGT GTTCCCCAAG AGTATCTGAT TCCTCTGCTG TCCCTGCCAG 2640 GAGCTGAAGG GTGGGAACAA CAAAGGCAAT GGTGAAAAGA GATTAGGAAC CCCCCAGCCT 2700 GTTTCCATTC TCTGCCCAGC AGTCTCTTAC CTTCCCTGAT CTTTGCAGGG TGGTCCGTGT 2760 AAATAGTATA AATTCTCCAA ATTATCCTCT AATTATAAAT GTAAGCTTAT TTCCTTAGAT 2820 CATTATCCAG AGACTGCCAG AAGGTGGGTA GGATGACCTG GGGTTTCAAT TGACTTCTGT 2880 TCCTTGCTTT TAGTTTTGAT AGAAGGGAAG ACCTGCAGTG CACGGTTTCT TCCAGGCTGA 2940 GGTACCTGGA TCTTGGGTTC TTCACTGCAG GGACCCAGAC AAGTGGATCT GCTTGCCAGA 3000 GTCCTTTTTG CCCCTCCCTG CCACCTCCCC GTGTTTCCAA GTCAGCTTTC CTGCAAGAAG 3060 AAATCCTGGT TAAAAAAGTC TTTTGTATTG GGTCAGGAGT TGAATTTGGG GTGGGAGGAT 3120 GGATGCAACT GAAGCAGAGT GTGGGTGCCC AGATGTGCGC TATTAGATGT TTCTCTGATA 3180 ATGTCCCCAA TCATACCAGG GAGACTGGCA TTGACGAGAA CTCAGGTGGA GGCTTGAGAA 3240 GGCCGAAAGG GCCCCTGACC TGCCTGGCTT CCTTAGCTTG CCCCTCAGCT TTGCAAAGAG 3300 CCACCCTAGG CCCCAGCTGA CCGCATGGGT GTGAGCCAGC TTGAGAACAC TAACTACTCA 3360 ATAAAAGCGA AGGTGGAAAA AAAAAAAAAA AAAAAAA Seq ID NO : 71 Protein sequence : Protein Accession # : AAH06529. 1

CCCATCTCCT GCAACAAGGA CCTGTCCTTT GGCCACTCTA GGGCCAGCTC CAAGATCTGC 960 AGTGAGGACA TCGAGTGCAG TGGGCTGACC ATCCCCAAGG CTGTGCAGTA CCTGAGCTCC 1020 CAGGATGAGA AGTACCAGGC CATTGGGGCC TATTACATCC AGCATACCTG CTTCCAGGAT 1080 GAATCTGCCA AGCAACAGGT CTATCAGCTG GGAGGCATCT GCAAGCTGGT GGACCTCCTC 1140 CGCAGCCCCA ACCAGAACGT CCAGCAGGCC GCGGCAGGGG CCCTGCGCAA CCTGGTGTTC 1200 AGGAGCACCA CCAACAAGCT GGAGACCCGG AGGCAGAATG GGATCCGCGA GGCAGTCAGC 1260 CTCCTGAGGA GAACCGGGAA CGCCGAGATC CAGAAGCAGC TGACTGGGCT GCTCTGGAAC 1320 CTGTCTTCCA CTGACGAGCT GAAGGAGGAA CTCATTGCCG ACGCCCTGCC TGTTCTGGCC 1380 GACCGCGTCA TCATTCCCTT CTCTGGCTGG TGCGATGGCA ATAGCAACAT GTCCCGGGAA 1440 GTGGTGGACC CTGAGGTCTT CTTCAATGCC ACAGGCTGCT TGAGGAACCT GAGCTCGGCC 1500 GATGCAGGCC GCCAGACCAT GCGTAACTAC TCAGGGCTCA TTGATTCCCT CATGGCCTAT 1560 GTCCAGAACT GTGTAGCGGC CAGCCGCTGT GACGACAAGT CTGTGGAAAA CTGCATGTGT 1620 GTTCTGCACA ACCTCTCCTA CCGCCTGGAC GCCGAGGTGC CCACCCGCTA CCGCCAGCTG 1680 GAGTATAACG CCCGCAACGC CTACACCGAG AAGTCCTCCA CTGGCTGCTT CAGCAACAAG 1740 AGCGACAAGA TGATGAACAA CAACTATGAC TGCCCCCTGC CTGAGGAAGA GACCAACCCC 1800 AAGGGCAGCG GCTGGTTGTA CCATTCAGAT GCCATCCGCA CCTACCTGAA CCTCATGGGC 1860 AAGAGCAAGA AAGATGCTAC CCTGGAGGCC TGTGCTGGTG CCCTGCAGAA CCTGACAGCC 1920 AGCAAGGGGC TGATGTCCAG TGGCATGAGC CAGTTGATTG GGCTGAAGGA AAAGGGCCTG 1980 CCACAAATTG CCCGCCTCCT GCAATCTGGC AACTCTGATG TGGTGCGGTC CGGAGCCTCC 2040 CTCCTGAGCA ACATGTCCCG CCACCCTCTG CTGCACAGAG TGATGGGGAA CCAGGTGTTC 2100 CCGGAGGTGA CCAGGCTCCT CACCAGCCAC ACTGGCAATA CCAGCAACTC CGAAGACATC 2160 TTGTCCTCGG CCTGCTACAC TGTGAGGAAC CTGATGGCCT CGCAGCCACA ACTGGCCAAG 2220 CAGTACTTCT CCAGCAGCAT GCTCAACAAC ATCATCAACC TGTGCCGAAG CAGTGCCTCA 2280 CCCAAGGCCG CAGAAGCTGC CCGGCTTCTC CTGTCTGACA TGTGGTCCAG CAAGGAACTG 2340 CAGGGTGTCC TCAGACAGCA AGGTTTCGAT AGGAACATGC TGGGAACCTT AGCTGGGGCC 2400 AACAGCCTCA GGAACTTCAC CTCCCGATTC TAAGAAGAGA CTGTCCAAGC AAGTTAGGCT 2460 TGCAGGAAGA TATGACCCAG CTGAGAAGCC CTCAGGCCTC GCTGGATGGG GTTTTCTGTC 2520 CATCCTGTGC AGTATTTGGG AAAGTTCACA AGAAACTGAG AAGAAACCTA AAAACTGTGG 2580 ATAGTGGAAA GATTTTTAGA TTTTTTTTTT CCTTGGGGAA ACTGGCAGGC AATGGGGGTT 2640 AGGGAGGTTG GGGCGGGGGG GGCTTTCTTG AGTTAAAGGG GCTTATATGT GATGTCAATA 2700 TTTCTTCCTC TGAGAAATGG TATATATATG TGTCTAATGT AAGTGTGTGC ATGCATGTGC 2760 GCGTGCATGT GTGTGTGTGT GAGTGTCTTA AAGCATAACC ACAAACTGCA AAAAGCTAGG 2820 TAAGCTATTT TGTTGCAGCT CATAAGGTGG TGAAAAGGAC TCTCCTGTGT TTCTTACTCA 2880 TAGGCAAGGA CAACATGTGC TTTTTGGTGA GCTGCTCATA ATTCCTGAAA TGTGTGGTGC 2940 CAGGGCAAGG GGGCCATCAC TGCAGTCAGG CCCTCAGAGG AGTCCTGCAG GCTTCCTACC 3000 AGTGGTCTCC AAGGGTGCAG GAGTAACTGG GGCTGGGCCA GCCTCCCCCC TTACAAGGCT 3060 GCTTTCCACG AAGGGAGGTC TGGTGTATCT CATGGGAGAA TCTGGGGTGT CTGTAGTGTC 3120 ACCCCTCCAG CAGCGCCACA AGGACTGAGG TTGGGTAGGT GTGAGGTTCC AGAGGACAGC 3180 AGGACACTCT CGCATACTTT GCCAAATGAG GCCTGCTCAG AGGAGTAGGA GCTGAAAGAT 3240 GGTGCCTTCC ACCCTCTTGG GCTGTGTGCC CATCAGAGCA GGCTCAGCCT GCAAAGGCCC 3300 TGCATTCAGA GGTCTTGTAA TCTACTTGTT GCAGGAGAAA GAAGGTAAAA AATGATTTTT 3360 TTAAGAAAAG CTATTTTATT GCAGCTCTTT CCCAAGAGCT GTTCTGGGAA TGGCTGGTCT 3420 TCATATTCCC AGTGGAGAGG GGAACAAGTG GGGCTGGGCA TATACCTATT CCGGCTTCTA 3480 GTGGGATGGA GTTGGGGTAT AGAAATTAAC CAGGAAGATG TTTCCACCAA GCCTGCTGTG 3540 AGTCAATTGA GGGAGTGTTT GGGTCCCAGG AGACTTGGAC GGGGGGAGTT TGGGTAGACT 3600 AGGAAAGGAA AGTGCCATAT CAGGGTACCG GTACCGGCAA GCTCACATCT CAGCCAGGGG 3660 CCATGCCCCA CTTCCCCTGA CCCCAGCTGT CTTGTCTCCA CTCTGTGAAA CCCACAGGGG 3720 ATGTGATAAA CAGGGCTATT AGGGGTATCA GCCACGTCGA GCCCCCAGAC TCTGTGCACT 3780 TCAGACCAGC AGCAGCAGGA GGGCTCCCGA GGGCCTTATG AGAAAACCTG TGTGGACATC 3840 CCTTGGTGTA CACTAAGACA GAGCAGAGCC CAGCGCTCCC AAGCCTTCCT CCTTCCAGCT 3900 TCTACCTCCA TGCTAGCATT GCTGGTGTTA GAGAGGAATT AACTTCCTGG TCTGTGCCCT 3960 TCTCTAGAAG AATATAAGAT GCTCCTCCTC CTCACCCCTT CTCAGCCTCC TCCCAAGTCT 4020 TCCTCTTCTG CACCACCCCC GAGTCCAAAC CCACCTCTTG CCCCAGCATT CAGGCTGGAA 4080 AACACTGATG TGGACTCAGT ATGACAACTG AGATGGGGGA AGCCAGACAT GTGAGGACGC 4140 TGTCCTCCGA GAGGTGTCCC CGGCTGTTAG CCAGCTGTGC TGTGGTGCTG TGGGTCTGTC 4200 ATACCCTCCC TTGCTTCTGT TCACACTGGG AGGCCCACTC CTGGCTCACC TCTCCCTCTC 4260 AGGGACCCAC GTGGGAGCCT GGATCCCTGG ACTGTCCTGG GCATAGGTTT CAGGGGCCTC 4320 CTTTGTTGTC ATCAGAACCC AGAGGAATTC TTCTCCTAAA AAATACGTAT GGCATACCAA 4380 TCTGTGCGGG GCAGTGTCCT AAGCACTTAG ACTACATCAG GGAAGAACAC AGACCACATC 4440 CCCGTCCTCA TGCGGCTTAT GTTTTCTGGA GGAAAGTGGA GACACAAGTC CTTGGCTTTA 4500 GGGCTCCCCC GGCTGGGGGC TGTGCAGTCC GGTCAGGGCG GGAGGGGAAA TGCACCGCTG 4560 CATGTGAACC TTACCAGCCC AGGCGGATGC CCCTTCCCCT TAGCACTACC CTGGCCTCCT 4620 GCATCCCCTC GCCTCATGTT CCTCCCACCT TCAAAGAATG AAGAGCCCCA TGGGCCCAGC 4680 CCCTGCCCTG GGAACCAGGC AGCCTTCCAG ACCTCAGGGG CTGAGGCAGA CTATTAGGGC 4740 AGGGCTGACT TTGGTGACAC TGCCCATTCC CTCTCAGGCC AGCTCAGGTC ACCCGGGCCT 4800 CTGACCCAGG CCTGTCACTT TGAGAGGGGC AAAACTGAGA GGGGCTTTTC CTAGAGAAAG 4860 AGAACAAGGA GCTTGCCAGG CTTCATGTAG CCGACACACG TCTCAGGATT TTAAGTCCAC 4920 ATTGGCCTCA CACTAGCCTA GGCCAATGCC CAAAATAAGG AGTTCCAATT TGGGGCCAAA 4980 TGAGGAAGGA CACAGACTCT GCCCTGGGAT CTCCTGTGCT AGCGGCCAAT GACAAATCCA 5040 GTCATTGGCC ACCAGCCACC TCTGCAGTGG GGACCACACT AGCAGCCCTG ACTCCACACT 5100 CCTCCTGGGG ACCCAAGAGG CAGTGTTGCT GTCTGCGTGT CCACCTTGGA ATCTGGCTGA 5160 ACTGGCTGGG AGGACCAAGA CTGCGGCTGG GGTGGGCAGG GAAGGGAAGC CGGGGGCTGC 5220 TGTGAGGGAT CTTGGAGCTT CCCTGTAGCC CACCTTCCCC TTGCTTCATG TTTGTAGAGG 5280 AACCTTGTGC CGGCCAGGCC CAGTTTCCTT GTGTGATACA CTAATGTATT TGCTTTTTTT 5340 GGAAATAGAG AAAATCAATA AATTGCTAGT GTTTCTTTGA AAAAAAAAA Seq ID NO : 79 Protein sequence: Protein Accession # : CAA98022. 1 1 11 21 31 41 51 MNHSPLKTAL AYECFQDQDN STLALPSDQK MKTGTSGRQR VQEQVMMTVK RQKSKSSQSS 60 TLSHSNRGSM YDGLADNYNY GTTSRSSYYS KFQAGNGSWG YPIYNGTLKR EPDNRRFSSY 120 SQMENWSRHY PRGSCNTTGA GSDICFMQKI KASRSEPDLY CDPRGTLRKG TLGSKGQKTT 180 QNRYSFYSTC SGQKAIKKCP VRPPSCASKQ DPVYIPPISC NKDLSFGHSR ASSKICSEDI 240 ECSGLTIPKA VQYLSSQDEK YQAIGAYYIQ HTCFQDESAK QQVYQLGGIC KLVDLLRSPN 300 QNVQQAAAGA LRNLVFRSTT NKLETRRQNG IREAVSLLRR TGNAEIQKQL TGLLWNLSST 360

DELKEELIAD ALPVLADRVI IPFSGWCDGN SNMSREWDP EVFFNATGCL RNLSSADAGR 420 QTMRNYSGLI DSLMAYVQNC VAASRCDDKS VENCMCVLHN LSYRLDAEVP TRYRQLEYNA 480 RNAYTEKSST GCFSNKSDKM MNNNYDCPLP EEETNPKGSG WLYHSDAIRT YLNLMGKSKK 540 DATLEACAGA LQNLTASKGL MSSGMSQLIG LKEKGLPQIA RLLQSGNSDV VRSGASLLSN 600 MSRHPLLHRV MGNQVFPEVT RLLTSHTGNT SNSEDILSSA CYTVRNLMAS QPQLAKQYFS 660 SSMLNNIINL CRSSASPKAA EAARLLLSDM WSSKELQGVL RQQGFDRNML GTLAGANSLR 720 NFTSRF Seq ID NO : BO DNA sequence Nucleic Acid Accession &num : NM 006516. 1 Coding sequence: 180-1658 1 11 21 31 41 51 <BR> <BR> <BR> <BR> <BR> TAGTCGCGGG TCCCCGAGTG AGCACGCCAG GGAGCAGGAG ACCAAACGAC GGGGGTCGGA 60 GTCAGAGTCG CAGTGGGAGT CCCCGGACCG GAGCACGAGC CTGAGCGGGA GAGCGCCGCT 120 CGCACGCCCG TCGCCACCCG CGTACCCGGC GCAGCCAGAG CCACCAGCGC AGCGCTGCCA 180 TGGAGCCCAG CAGCAAGAAG CTGACGGGTC GCCTCATGCT GGCTGTGGGA GGAGCAGTGC 240 TTGGCTCCCT GCAGTTTGGC TACAACACTG GAGTCATCAA TGCCCCCCAG AAGGTGATCG 300 AGGAGTTCTA CAACCAGACA TGGGTCCACC GCTATGGGGA GAGCATCCTG CCCACCACGC 360 TCACCACGCT CTGGTCCCTC TCAGTGGCCA TCTTTTCTGT TGGGGGCATG ATTGGCTCCT 420 TCTCTGTGGG CCTTTTCGTT AACCGCTTTG GCCGGCGGAA TTCAATGCTG ATGATGAACC 480 TGCTGGCCTT CGTGTCCGCC GTGCTCATGG GCTTCTCGAA ACTGGGCAAG TCCTTTGAGA 540 TGCTGATCCT GGGCCGCTTC ATCATCGGTG TGTACTGCGG CCTGACCACA GGCTTCGTGC 600 CCATGTATGT GGGTGAAGTG TCACCCACAG CCTTTCGTGG GGCCCTGGGC ACCCTGCACC 660 AGCTGGGCAT CGTCGTCGGC ATCCTCATCG CCCAGGTGTT CGGCCTGGAC TCCATCATGG 720 GCAACAAGGA CCTGTGGCCC CTGCTGCTGA GCATCATCTT CATCCCGGCC CTGCTGCAGT 780 GCATCGTGCT GCCCTTCTGC CCCGAGAGTC CCCGCTTCCT GCTCATCAAC CGCAACGAGG 840 AGAACCGGGC CAAGAGTGTG CTAAAGAAGC TGCGCGGGAC AGCTGACGTG ACCCATGACC 900 TGCAGGAGAT GAAGGAAGAG AGTCGGCAGA TGATGCGGGA GAAGAAGGTC ACCATCCTGG 960 AGCTGTTCCG CTCCCCCGCC TACCGCCAGC CCATCCTCAT CGCTGTGGTG CTGCAGCTGT 1020 CCCAGCAGCT GTCTGGCATC AACGCTGTCT TCTATTACTC CACGAGCATC TTCGAGAAGG 1080 CGGGGGTGCA GCAGCCTGTG TATGCCACCA TTGGCTCCGG TATCGTCAAC ACGGCCTTCA 1140 CTGTCGTGTC GCTGTTTGTG GTGGAGCGAG CAGGCCGGCG GACCCTGCAC CTCATAGGCC 1200 TCGCTGGCAT GGCGGGTTGT GCCATACTCA TGACCATCGC GCTAGCACTG CTGGAGCAGC 1260 TACCCTGGAT GTCCTATCTG AGCATCGTGG CCATCTTTGG CTTTGTGGCC TTCTTTGAAG 1320 TGGGTCCTGG CCCCATCCCA TGGTTCATCG TGGCTGAACT CTTCAGCCAG GGTCCACGTC 1380 CAGCTGCCAT TGCCGTTGCA GGCTTCTCCA ACTGGACCTC AAATTTCATT GTGGGCATGT 1440 GCTTCCAGTA TGTGGAGCAA CTGTGTGGTC CCTACGTCTT CATCATCTTC ACTGTGCTCC 1500 TGGTTCTGTT CTTCATCTTC ACCTACTTCA AAGTTCCTGA GACTAAAGGC CGGACCTTCG 1560 ATGAGATCGC TTCCGGCTTC CGGCAGGGGG GAGCCAGCCA AAGTGATAAG ACACCCGAGG 1620 AGCTGTTCCA TCCCCTGGGG GCTGATTCCC AAGTGTGAGT CGCCCCAGAT CACCAGCCCG 1680 GCCTGCTCCC AGCAGCCCTA AGGATCTCTC AGGAGCACAG GCAGCTGGAT GAGACTTCCA 1740 AACCTGACAG ATGTCAGCCG AGCCGGGCCT GGGGCTCCTT TCTCCAGCCA GCAATGATGT 1800 CCAGAAGAAT ATTCAGGACT TAACGGCTCC AGGATTTTAA CAAAAGCAAG ACTGTTGCTC 1860 AAATCTATTC AGACAAGCAA CAGGTTTTAT AATTTTTTTA TTACTGATTT TGTTATTTTT 1920 ATATCAGCCT GAGTCTCCTG TGCCCACATC CCAGGCTTCA CCCTGAATGG TTCCATGCCT 1980 GAGGGTGGAG ACTAAGCCCT GTCGAGACAC TTGCCTTCTT CACCCAGCTA ATCTGTAGGG 2040 CTGGACCTAT GTCCTAAGGA CACACTAATC GAACTATGAA CTACAAAGCT TCTATCCCAG 2100 GAGGTGGCTA TGGCCACCCG TTCTGCTGGC CTGGATCTCC CCACTCTAGG GGTCAGGCTC 2160 CATTAGGATT TGCCCCTTCC CATCTCTTCC TACCCAACCA CTCAAATTAA TCTTTCTTTA 2220 CCTGAGACCA GTTGGGAGCA CTGGAGTGCA GGGAGGAGAG GGGAAGGGCC AGTCTGGGCT 2280 GCCGGGTTCT AGTCTCCTTT GCACTGAGGG CCACACTATT ACCATGAGAA GAGGGCCTGT 2340 GGGAGCCTGC AAACTCACTG CTCAAGAAGA CATGGAGACT CCTGCCCTGT TGTGTATAGA 2400 TGCAAGATAT TTATATATAT TTTTGGTTGT CAATATTAAA TACAGACACT AAGTTATAGT 2460 ATATCTGGAC AAGCCAACTT GTAAATACAC CACCTCACTC CTGTTACTTA CCTAAACAGA 2520 TATAAATGGC TGGTTTTTAG AAACATGGTT TTGAAATGCT TGTGGATTGA GGGTAGGAGG 2580 TTTGGATGGG AGTGAGACAG AAGTAAGTGG GGTTGCAACC ACTGCAACGG CTTAGACTTC 2640 GACTCAGGAT CCAGTCCCTT ACACGTACCT CTCATCAGTG TCCTCTTGCT CAAAAATCTG 2700 TTTGATCCCT GTTACCCAGA GAATATATAC ATTCTTTATC TTGACATTCA AGGCATTTCT 2760 ATCACATATT TGATAGTTGG TGTTCAAAAA AACACTAGTT TTGTGCCAGC CGTGATGCTC 2820 AGGCTTGAAA TCGCATTATT TTGAATGTGA AGGGAA Seq ID NO : 81 Protein sequence: Protein Accession # : NP 006507. 1 1 11 21 31 41 51 MEPSSKKLTG RLMLAVGGAV LGSLQFGYNT GVINAPQKVI EEFYNQTWVH RYGESILPTT 60 LTTLWSLSVA IFSVGGMIGS FSVGLFVNRF GRRNSMLMMN LLAFVSAVLM GFSKLGKSFE 120 MLILGRFIIG VYCGLTTGFV PMYVGEVSPT AFRGALGTLH QLGIWGILI AQVFGLDSIM 180 GNKDLWPLLL SIIFIPALLQ CIVLPFCPES PRFLLINRNE ENRAKSVLKK LRGTADVTHD 240 LQEMKEESRQ MMREKKVTIL ELFRSPAYRQ PILIAWLQL SQQLSGINAV FYYSTSIFEK 300 AGVQQPVYAT IGSGIVNTAF TWSLFWER AGRRTLHLIG LAGMAGCAIL MTIALALLEQ 360 LPWMSYLSIV AIFGFVAFFE VGPGPIPWFI VAELFSQGPR PAAIAVAGFS NWTSNFIVGM 420 CFQYVEQLCG PYVFIIFTVL LVLFFIFTYF KVPETKGRTF DEIASGFRQG GASQSDKTPE 480 ELFHPLGADS QV Seq ID NO : 82 DNA sequence Nucleic Acid Accession # : BC001291 Coding sequence: 44-541 1 11 21 31 41 51 GGGGGCGCCG CGCGCTGACC CTCCCTGGGC ACCGCTGGGG ACGATGGCGC TGCTCGCCTT 60 GCTGCTGGTC GTGGCCCTAC CGCGGGTGTG GACAGACGCC AACCTGACTG CGAGACAACG 120

CTGCCCGGTG CCCGAGGAGG CAGCCAAGCT CGTGGCCTGC CTCTGCGTGC TGCTGCTCAC 600 GGCCGTGAAC TGCTACAGCG TGAAGGCCGC CACCCGGGTC CAGGATGCCT TTGCCGCCGC 660 CAAGCTCCTG GCCCTGGCCC TGATCATCCT GCTGGGCTTC GTCCAGATCG GGAAGGGTGA 720 TGTGTCCAAT CTAGATCCCA ACTTCTCATT TGAAGGCACC AAACTGGATG TGGGGAACAT 780 TGTGCTGGCA TTATACAGCG GCCTCTTTGC CTATGGAGGA TGGAATTACT TGAATTTCGT 840 CACAGAGGAA ATGATCAACC CCTACAGAAA CCTGCCCCTG GCCATCATCA TCTCCCTGCC 900 CATCGTGACG CTGGTGTACG TGCTGACCAA CCTGGCCTAC TTCACCACCC TGTCCACCGA 960 GCAGATGCTG TCGTCCGAGG CCGTGGCCGT GGACTTCGGG AACTATCACC TGGGCGTCAT 1020 GTCCTGGATC ATCCCCGTCT TCGTGGGCCT GTCCTGCTTC GGCTCCGTCA ATGGGTCCCT 1080 GTTCACATCC TCCAGGCTCT TCTTCGTGGG GTCCCGGGAA GGCCACCTGC CCTCCATCCT 1140 CTCCATGATC CACCCACAGC TCCTCACCCC CGTGCCGTCC CTCGTGTTCA CGTGTGTGAT 1200 GACGCTGCTC TACGCCTTCT CCAAGGACAT CTTCTCCGTC ATCAACTTCT TCAGCTTCTT 1260 CAACTGGCTC TGCGTGGCCC TGGCCATCAT CGGCATGATC TGGCTGCGCC ACAGAAAGCC 1320 TGAGCTTGAG CGGCCCATCA AGGTGAACCT GGCCCTGCCT GTGTTCTTCA TCCTGGCCTG 1380 CCTCTTCCTG ATCGCCGTCT CCTTCTGGAA GACACCCGTG GAGTGTGGCA TCGGCTTCAC 1440 CATCATCCTC AGCGGGCTGC CCGTCTACTT CTTCGGGGTC TGGTGGAAAA ACAAGCCCAA 1500 GTGGCTCCTC CAGGGCATCT TCTCCACGAC CGTCCTGTGT CAGAAGCTCA TGCAGGTGGT 1560 CCCCCAGGAG ACATAGCCAG GAGGCCGAGT GGCTGCCGGA GGAGCATGC Seq ID NO : 87 Protein sequence : Protein Accession # : XP 035292. 2 1 11 21 31 41 51 MAGAGPKRRA LAAPAAEEKE EAREKMLAAK SADGSAPAGE GEGVTLQRNI TLLNGVAIIV 60 GTIIGSGIFV TPTGVLKEAG SPGLALWWA ACGVFSIVGA LCYAELGTTI SKSGGDYAYM 120 LEVYGSLPAF LKLWIELLII RPSSQYIVAL VFATYLLKPL FPTCPVPEEA AKLVACLCVL 180 LLTAVNCYSV KAATRVQDAF AAAKLLALAL IILLGFVQIG KGDVSNLDPN FSFEGTKLDV 240 GNIVLALYSG LFAYGGWNYL NFVTEEMINP YRNLPLAIII SLPIVTLVYV LTNLAYFTTL 300 STEQMLSSEA VAVDFGNYHL GVMSWIIPVF VGLSCFGSVN GSLFTSSRLF FVGSREGHLP 360 SILSMIHPQL LTPVPSLVFT CVMTLLYAFS KDIFSVINFF SFFNWLCVAL AIIGMIWLRH 420 RKPELERPIK VNLALPVFFI LACLFLIAVS FWKTPVECGI GFTIILSGLP VYFFGVWWKN 480 KPKWLLQGIF STTVLCQKLM QWPQET Seq ID NO : 88 DNA sequence Nucleic Acid Accession # : NM 005268. 1 Coding sequence: 168-989 1 11 21 31 41 51 TAAAAAGCAA AAGAATTCGC GGCCGCGTCG ACACGGGCTT CCCCGAAAAC CTTCCCCGCT 60 TCTGGATATG AAATTCAAGC TGCTTGCTGA GTCCTATTGC CGGCTGCTGG GAGCCAGGAG 120 AGCCCTGAGG AGTAGTCACT CAGTAGCAGC TGACGCGTGG GTCCACCATG MCTGGAGTA ; 80 TCTTTGAGGG ACTCCTGAGT GGGGTCAACA AGTACTCCAC AGCCTTTGGG CGCATCTGGC 240 TGTCTCTGGT CTTCATCTTC CGCGTGCTGG TGTACCTGGT GACGGCCGAG CGTGTGTGGA 300 GTGATGACCA CAAGGACTTC GACTGCAATA CTCGCCAGCC CGGCTGCTCC AACGTCTGCT 360 TTGATGAGTT CTTCCCTGTG TCCCATGTGC GCCTCTGGGC CCTGCAGCTT ATCCTGGTGA 420 CATGCCCCTC ACTGCTCGTG GTCATGCACG TGGCCTACCG GGAGGTTCAG GAGAAGAGGC 480 ACCGAGAAGC CCATGGGGAG AACAGTGGGC GCCTCTACCT GAACCCCGGC AAGAAGCGGG 540 GTGGGCTCTG GTGGACATAT GTCTGCAGCC TAGTGTTCAA GGCGAGCGTG GACATCGCCT 600 TTCTCTATGT GTTCCACTCA TTCTACCCCA AATATATCCT CCCTCCTGTG GTCAAGTGCC 660 ACGCAGATCC ATGTCCCAAT ATAGTGGACT GCTTCATCTC CAAGCCCTCA GAGAAGAACA 720 TTTTCACCCT CTTCATGGTG GCCACAGCTG CCATCTGCAT CCTGCTCAAC CTCGTGGAGC 780 TCATCTACCT GGTGAGCAAG AGATGCCACG AGTGCCTGGC AGCAAGGAAA GCTCAAGCCA 840 TGTGCACAGG TCATCACCCC CACGGTACCA CCTCTTCCTG CAAACAAGAC GACCTCCTTT 900 CGGGTGACCT CATCTTTCTG GGCTCAGACA GTCATCCTCC TCTCTTACCA GACCGCCCCC 960 GAGACCATGT GAAGAAAACC ATCTTGTGAG GGGCTGCCTG GACTGGTCTG GCAGGTTGGG 1020 CCTGGATGGG GAGGCTCTAG CATCTCTCAT AGGTGCAACC TGAGAGTGGG GGAGCTAAGC 1080 CATGAGGTAG GGGCAGGCAA GAGAGAGGAT TCAGACGCTC TGGGAGCCAG TTCCTAGTCC 1140 TCAACTCCAG CCACCTGCCC CAGCTCGACG GCACTGGGCC AGTTCCCCCT CTGCTCTGCA 1200 GCTCGGTTTC CTTTTCTAGA ATGGAAATAG TGAGGGCCAA TGC Seq ID NO : 89 Protein sequence : Protein Accession # : NP 005259. 1 1 11 21 31 41 51 <BR> <BR> <BR> <BR> <BR> <BR> MNWSIFEGLL SGVNKYSTAF GRIWLSLVFI FRVLVYLVTA ERVWSDDHKD FDCNTRQPGC 60 SNVCFDEFFP VSHVRLWALQ LILVTCPSLL WMHVAYREV QEKRHREAHG ENSGRLYLNP 120 GKKRGGLWWT YVCSLVFKAS VDIAFLYVFH SFYPKYILPP WKCHADPCP NIVDCFISKP 180 SEKNIFTLFM VATAAICILL NLVELIYLVS KRCHECLAAR KAQAMCTGHH PHGTTSSCKQ 240 DDLLSGDLIF LGSDSHPPLL PDRPRDHVKK TIL Seq ID NO : 90 DNA sequence Nucleic Acid Accession # : NM 002391. 1 Coding sequence: 26-457 1 11 21 31 41 51 # # # # # # CGGGCGAAGC AGCGCGGGCA GCGAGATGCA GCACCGAGGC TTCCTCCTCC TCACCCTCCT 60 CGCCCTGCTG GCGCTCACCT CCGCGGTCGC CAAAAAGAAA GATAAGGTGA AGAAGGGCGG 120 CCCGGGGAGC GAGTGCGCTG AGTGGGCCTG GGGGCCCTGC ACCCCCAGCA GCAAGGATTG 180 CGGCGTGGGT TTCCGCGAGG GCACCTGCGG GGCCCAGACC CAGCGCATCC GGTGCAGGGT 240 GCCCTGCAAC TGGAAGAAGG AGTTTGGAGC CGACTGCAAG TACAAGTTTG AGAACTGGGG 300 TGCGTGTGAT GGGGGCACAG GCACCAAAGT CCGCCAAGGC ACCCTGAAGA AGGCGCGCTA 360

TCTGTGGTTT GTCAGACCTG CAAGCAAGCC CCCTGCTGGG GAAGCCTAGG TGTCCTTGAG 2280 CTGAACCGCA CTGAAGAACT CTTGTCCTCA CTGGCTGATG CAGCAGAACT CTTGGGAAAT 2340 GTCTTAGTCC TGCAGAATCA GGAGTCACCA GATGATGCAG AGTTGAGATC ATCATTGCAA 2400 AGTTCTCTGT TCCTGAGGAA CTAAATTTAA GGAAAAAATG GGATTTTGTT TTAGAGTTGG 2460 AAAAAAAGCC TGATTAAAGA GTTTCTGCCT GTTAAAAAAA AAAAAAAAAA AAAAAA Seq ID NO: 97 Protein sequence: Protein Accession # : NP 542399. 1 1 11 21 31 41 51 1 1 1 1 1 1 MSGRRTRSGG AAQRSGPRAP SPTKPLRRSQ RKSGSELPSI LPEIWPKTPS AAAVRKPIVL 60 KRIVAHAVEV PAVQSPRRSP RISFFLEKEN EPPGRELTKE DLFKTHSVPA TPTSTPVPNP 120 EAESSSKEGE LDARDLEMSK KVRRSYSRLE TLGSASTSTP GRRSCFGFEG LLGAEDLSGV 180 SPWCSKLTE VPRVCAKPWA PDMTLPGISP PPEKQKRKKK KMPEILKTEL DEWAAAMNAE 240 FEAAEQFDLL VE Seq ID NO: 98 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 58-12444 1 11 21 31 41 51 # # # # # # GGGGCATTTCCGGGTCCGGG CCGAGCGGGC GCACGCGCGG GAGCGGGACT CGGCGGCATG 60 GCGGGCTCCG GAGCCGGTGT GCGTTGCTCC CTGCTGCGGC TGCAGGAGAC CTTGTCCGCT 120 GCGGACCGCT GCGGTGCTGC CCTGGCCGGT CATCAACTGA TCCGCGGCCT GGGGCAGGAA 180 TGCGTCCTGA GCAGCAGCCC CGCGGTGCTG GCATTACAGA CATCTTTAGT TTTTTCCAGA 240 GATTTCGGTT TGCTTGTATT TGTCCGGAAG TCACTCAACA GTATTGAATT TCGTGAATGT 300 AGAGAAGAAA TCCTAAAGTT TTTATGTATT TTCTTAGAAA AAATGGGCCA GAAGATCGCA 360 CCTTACTCTG TTGAAATTAA GAACACTTGT ACCAGTGTTT ATACAAAAGA TAGAGCTGCT 420 AAATGTAAAA TTCCAGCCCT GGACCTTCTT ATTAAGTTAC TTCAGACTTT TAGAAGTTCT 480 AGACTCATGG ATGAATTTAA AATTGGAGAA TTATTTAGTA AATTCTATGG AGAACTTGCA 540 TTGAAAAAAA AAATACCAGA TACAGTTTTA GAAAAAGTAT ATGAGCTCCT AGGATTATTG 600 GGTGAAGTTC ATCCTAGTGA GATGATAAAT AATGCAGAAA ACCTGTTCCG CGCTTTTCTG 660 GGTGAACTTA AGACCCAGAT GACATCAGCA GTAAGAGAGC CCAAACTACC TGTTCTGGCA 720 GGATGTCTGA AGGGGTTGTC CTCACTTCTG TGCAACTTCA CTAAGTCCAT GGAAGAAGAT 780 CCCCAGACTT CAAGGGAGAT TTTTAATTTT GTACTAAAGG CAATTCGTCC TCAGATTGAT 840 CTGAAGAGAT ATGCTGTGCC CTCAGCTGGC TTGCGCCTAT TTGCCCTGCA TGCATCTCAG 900 TTTAGCACCT GCCTTCTGGA CAACTACGTG TCTCTATTTG AAGTCTTGTT AAAGTGGTGT 960 GCCCACACAA ATGTAGAATT GAAAAAAGCT GCACTTTCAG CCCTGGAATC CTTTCTGAAA 1020 CAGGTTTCTA ATATGGTGGC GAAAAATGCA GAAATGCATA AAAATAAACT GCAGTACTTT 1080 ATGGAGCAGT TTTATGGAAT CATCAGAAAT GTGGATTCGA ACAACAAGGA GTTATCTATT 1140 GCTATCCGTG GATATGGACT TTTTGCAGGA CCGTGCAAGG TTATAAACGC AAAAGATGTT 1200 GACTTCATGT ACGTTGAGCT CATTCAGCGC TGCAAGCAGA TGTTCCTCAC CCAGACAGAC 1260 ACTGGTGACG ACCGTGTTTA TCAGATGCCA AGCTTCCTCC AGTCTGTTGC AAGCGTCTTG 1320 CTGTACCTTG ACACAGTTCC TGAGGTGTAT ACTCCAGTTC TGGAGCACCT CGTGGTGATG 1380 CAGATAGACA GTTTCCCACA GTACAGTCCA AAAATGCAGC TGGTGTGTTG CAGAGCCATA 1440 GTGAAGGTGT TCCTAGCTTT GGCAGCAAAA GGGCCAGTTC TCAGGAATTG CATTAGTACT 1500 GTGGTGCATC AGGGTTTAAT CAGAATATGT TCTAAACCAG TGGTCCTTCC AAAGGGCCCT 1560 GAGTCTGAAT CTGAAGACCA CCGTGCTTCA GGGGAAGTCA GAACTGGCAA ATGGAAGGTG 1620 CCCACATACA AAGACTACGT GGATCTCTTC AGACATCTCC TGAGCTCTGA CCAGATGATG 1680 GATTCTATTT TAGCAGATGA AGCATTTTTC TCTGTGAATT CCTCCAGTGA AAGTCTGAAT 1740 CATTTACTTT ATGATGAATT TGTAAAATCC GTTTTGAAGA TTGTTGAGAA ATTGGATCTT 1800 ACACTTGAAA TACAGACTGT TGGGGAACAA GAGAATGGAG ATGAGGCGCC TGGTGTTTGG 1860 ATGATCCCAA CTTCAGATCC AGCGGCTAAC TTGCATCCAG CTAAACCTAA AGATTTTTCG 1920 GCTTTCATTA ACCTGGTGGA ATTTTGCAGA GAGATTCTCC CTGAGAAACA AGCAGAATTT 1980 TTTGAACCAT GGGTGTACTC ATTTTCATAT GAATTAATTT TGCAATCTAC AAGGTTGCCC 2040 CTCATCAGTG GTTTCTACAA ATTGCTTTCT ATTACAGTAA GAAATGCCAA GAAAATAAAA 2100 TATTTCGAGG GAGTTAGTCC AAAGAGTCTG AAACACTCTC CTGAAGACCC AGAAAAGTAT 2160 TCTTGCTTTG CTTTATTTGT GAAATTTGGC AAAGAGGTGG CAGTTAAAAT GAAGCAGTAC 2220 AAAGATGAAC TTTTGGCCTC TTGTTTGACC TTTCTTCTGT CCTTGCCACA CAACATCATT 2280 GAACTCGATG TTAGAGCCTA CGTTCCTGCA CTGCAGATGG CTTTCAAACT GGGCCTGAGC 2340 TATACCCCCT TGGCAGAAGT AGGCCTGAAT GCTCTAGAAG AATGGTCAAT TTATATTGAC 2400 AGACATGTAA TGCAGCCTTA TTACAAAGAC ATTCTCCCCT GCCTGGATGG ATACCTGAAG 2460 ACTTCAGCCT TGTCAGATGA GACCAAGAAT AACTGGGAAG TGTCAGCTCT TTCTCGGGCT 2520 GCCCAGAAAG GATTTAATAA AGTGGTGTTA AAGCATCTGA AGAAGACAAA GAACCTTTCA 2580 TCAAACGAAG CAATATCCTT AGAAGAAATA AGAATTAGAG TAGTACAAAT GCTTGGATCT 2640 CTAGGAGGAC AAATAAACAA AAATCTTCTG ACAGTCACGT CCTCAGATGA GATGATGAAG 2700 AGCTATGTGG CCTGGGACAG AGAGAAGCGG CTGAGCTTTG CAGTGCCCTT TAGAGAGATG 2760 AAACCTGTCA TTTTCCTGGA TGTGTTCCTG CCTCGAGTCA CAGAATTAGC GCTCACAGCC 2820 AGTGACAGAC AAACTAAAGT TGCAGCCTGT GAACTTTTAC ATAGCATGGT TATGTTTATG 2880 TTGGGCAAAG CCACGCAGAT GCCAGAAGGG GGACAGGGAG CCCCACCCAT GTACCAGCTC 2940 TATAAGCGGA CGTTTCCTGT GCTGCTTCGA CTTGCGTGTG ATGTTGATCA GGTGACAAGG 3000 CAACTGTATG AGCCACTAGT TATGCAGCTG ATTCACTGGT TCACTAACAA CAAGAAATTT 3060 GAAAGTCAGG ATACTGTTGC CTTACTAGAA GCTATATTGG ATGGAATTGT GGACCCTGTT 3120 GACAGTACTT TAAGAGATTT TTGTGGTCGG TGTATTCGAG AATTCCTTAA ATGGTCCATT 3180 AAGCAAATAA CACCACAGCA GCAGGAGAAG AGTCCAGTAA ACACCAAATC GCTTTTCAAG 3240 CGACTTTATA GCCTTGCGCT TCACCCCAAT GCTTTCAAGA GGCTGGGAGC ATCACTTGCC 3300 TTTAATAATA TCTACAGGGA ATTCAGGGAA GAAGAGTCTC TGGTGGAACA GTTTGTGTTT 3360 GAAGCCTTGG TGATATACAT GGAGAGTCTG GCCTTAGCAC ATGCAGATGA GAAGTCCTTA 3420 GGTACAATTC AACAGTGTTG TGATGCCATT GATCACCTAT GCCGCATCAT TGAAAAGAAG 3480 CATGTTTCTT TAAATAAAGC AAAGAAACGA CGTTTGCCGC GAGGATTTCC ACCTTCCGCA 3540 TCATTGTGTT TATTGGATCT GGTCAAGTGG CTTTTAGCTC ATTGTGGGAG GCCCCAGACA 3600 GAATGTCGAC ACAAATCCAT TGAACTCTTT TATAAATTCG TTCCTTTATT GCCAGGCAAC 3660 AGATCCCCTA ATTTGTGGCT GAAAGATGTT CTCAAGGAAG AAGGTGTCTC TTTTCTCATC 3720 AACACCTTTG AGGGGGGTGG CTGTGGCCAG CCCTCGGGCA TCCTGGCCCA GCCCACCCTC 3780 TTGTACCTTC GGGGGCCATT CAGCCTGCAG GCCACGCTAT GCTGGCTGGA CCTGCTCCTG 3840

GCCGCGTTGG AGTGCTACAA CACGTTCATT GGCGAGAGAA CTGTAGGAGC GCTCCAGGTC 3900 CTAGGTACTG AAGCCCAGTC TTCACTTTTG AAAGCAGTGG CTTTCTTCTT AGAAAGCATT 3960 GCCATGCATG ACATTATAGC AGCAGAAAAG TGCTTTGGCA CTGGGGCAGC AGGTAACAGA 4020 ACAAGCCCAC AAGAGGGAGA AAGGTACAAC TACAGCAAAT GCACCGTTGT GGTCCGGATT 4080 ATGGAGTTTA CCACGACTCT GCTAAACACC TCCCCGGAAG GATGGAAGCT CCTGAAGAAG 4140 GACTTGTGTA ATACACACCT GATGAGAGTC CTGGTGCAGA CGCTGTGTGA GCCCGCAAGC 4200 ATAGGTTTCA ACATCGGAGA CGTCCAGGTT ATGGCTCATC TTCCTGATGT TTGTGTGAAT 4260 CTGATGAAAG CTCTAAAGAT GTCCCCATAC AAAGATATCC TAGAGACCCA TCTGAGAGAG 4320 AAAATAACAG CACAGAGCAT TGAGGAGCTT TGTGCCGTCA ACTTGTATGG CCCTGACGCG 4380 CAAGTGGACA GGAGCAGGCT GGCTGCTGTT GTGTCTGCCT GTAAACAGCT TCACAGAGCT 4440 GGGCTTCTGC ATAATATATT ACCGTCTCAG TCCACAGATT TGCATCATTC TGTTGGCACA 4500 GAACTTCTTT CCCTGGTTTA TAAAGGCATT GCCCCTGGAG ATGAGAGACA GTGTCTGCCT 4560 TCTCTAGACC TCAGTTGTAA GCAGCTGGCC AGCGGACTTC TGGAGTTAGC CTTTGCTTTT 4620 GGAGGACTGT GTGAGCGCCT TGTGAGTCTT CTCCTGAACC CAGCGGTGCT GTCCACGGCG 4680 TCCTTGGGCA GCTCACAGGG CAGCGTCATC CACTTCTCCC ATGGGGAGTA TTTCTATAGC 4740 TTGTTCTCAG AAACGATCAA CACGGAATTA TTGAAAAATC TGGATCTTGC TGTATTGGAG 4800 CTCATGCAGT CTTCAGTGGA TAATACCAAA ATGGTGAGTG CCGTTTTGAA CGGCATGTTA 4860 GACCAGAGCT TCAGGGAGCG AGCAAACCAG AAACACCAAG GACTGAAACT TGCGACTACA 4920 ATTCTGCAAC ACTGGAAGAA GTGTGATTCA TGGTGGGCCA AAGATTCCCC TCTCGAAACT 4980 AAAATGGCAG TGCTGGCCTT ACTGGCAAAA ATTTTACAGA TTGATTCATC TGTATCTTTT 5040 AATACAAGTC ATGGTTCATT CCCTGAAGTC TTTACAACAT ATATTAGTCT ACTTGCTGAC 5100 ACAAAGCTGG ATCTACATTT AAAGGGCCAA GCTGTCACTC TTCTTCCATT CTTCACCAGC 5160 CTCACTGGAG GCAGTCTGGA GGAACTTAGA CGTGTTCTGG AGCAGCTCAT CGTTGCTCAC 5220 TTCCCCATGC AGTCCAGGGA ATTTCCTCCA GGAACTCCGC GGTTCAATAA TTATGTGGAC 5280 TGCATGAAAA AGTTTCTAGA TGCATTGGAA TTATCTCAAA GCCCTATGTT GTTGGAATTG 5340 ATGACAGAAG TTCTTTGTCG GGAACAGCAG CATGTCATGG AAGAATTATT TCAATCCAGT 5400 TTCAGGAGGA TTGCCAGAAG GGGTTCATGT GTCACACAAG TAGGCCTTCT GGAAAGCGTG 5460 TATGAAATGT TCAGGAAGGA TGACCCCCGC CTAAGTTTCA CACGCCAGTC CTTTGTGGAC 5520 CGCTCCCTCC TCACTCTGCT GTGGCACTGT AGCCTGGATG CTTTGAGAGA ATTCTTCAGC 5580 ACAATTGTGG TGGATGCCAT TGATGTGTTG AAGTCCAGGT TTACAAAGCT AAATGAATCT 5640 ACCTTTGATA CTCAAATCAC CAAGAAGATG GGCTACTATA AGATTCTAGA CGTGATGTAT 5700 TCTCGCCTTC CCAAAGATGA TGTTCATGCT AAGGAATCAA AAATTAATCA AGTTTTCCAT 5760 GGCTCGTGTA TTACAGAAGG AAATGAACTT ACAAAGACAT TGATTAAATT GTGCTACGAT 5820 GCATTTACAG AGAACATGGC AGGAGAGAAT CAGCTGCTGG AGAGGAGAAG ACTTTACCAT 5880 TGTGCAGCAT ACAACTGCGC CATATCTGTC ATCTGCTGTG TCTTCAATGA GTTAAAATTT 5940 TACCAAGGTT TTCTGTTTAG TGAAAAACCA GAAAAGAACT TGCTTATTTT TGAAAATCTG 6000 ATCGACCTGA AGCGCCGCTA TAATTTTCCT GTAGAAGTTG AGGTTCCTAT GGAAAGAAAG 6060 AAAAAGTACA TTGAAATTAG GAAAGAAGCC AGAGAAGCAG CAAATGGGGA TTCAGATGGT 6120 CCTTCCTATA TGTCTTCCCT GTCATATTTG GCAGACAGTA CCCTGAGTGA GGAAATGAGT 6180 CAATTTGATT TCTCAACCGG AGTTCAGAGC TATTCATACA GCTCCCAAGA CCCTAGACCT 6240 GCCACTGGTC GTTTTCGGAG ACGGGAGCAG CGGGACCCCA CGGTGCATGA TGATGTGCTG 6300 GAGCTGGAGA TGGACGAGCT CAATCGGCAT GAGTGCATGG CGCCCCTGAC GGCCCTGGTC 6360 AAGCACATGC ACAGAAGCCT GGGCCCGCCT CAAGGAGAAG AGGATTCAGT GCCAAGAGAT 6420 CTTCCTTCTT GGATGAAATT CCTCCATGGC AAACTGGGAA ATCCAATAGT ACCATTAAAT 6480 ATCCGTCTCT TCTTAGCCAA GCTTGTTATT AATACAGAAG AGGTCTTTCG CCCTTACGCG 6540 AAGCACTGGC TTAGCCCCTT GCTGCAGCTG GCTGCTTCTG AAAACAATGG AGGAGAAGGA 6600 ATTCACTACA TGGTGGTTGA GATAGTGGCC ACTATTCTTT CATGGACAGG CTTGGCCACT 6660 CCAACAGGGG TCCCTAAAGA TGAAGTGTTA GCAAATCGAT TGCTTAATTT CCTAATGAAA 6720 CATGTCTTTC ATCCAAAAAG AGCTGTGTTT AGACACAACC TTGAAATTAT AAAGACCCTT 6780 GTCGAGTGCT GGAAGGATTG TTTATCCATC CCTTATAGGT TAATATTTGA AAAGTTTTCC 6840 GGTAAAGATC CTAATTCTAA AGACAACTCA GTAGGGATTC AATTGCTAGG CATCGTGATG 6900 GCCAATGACC TGCCTCCCTA TGACCCACAG TGTGGCATCC AGAGTAGCGA ATACTTCCAG 6960 GCTTTGGTGA ATAATATGTC CTTTGTAAGA TATAAAGAAG TGTATGCCGC TGCAGCAGAA 7020 GTTCTAGGAC TTATACTTCG ATATGTTATG GAGAGAAAAA ACATACTGGA GGAGTCTCTG 7080 TGTGAACTGG TTGCGAAACA ATTGAAGCAA CATCAGAATA CTATGGAGGA CAAGTTTATT 7140 GTGTGCTTGA ACAAAGTGAC CAAGAGCTTC CCTCCTCTTG CAGACAGGTT CATGAATGCT 7200 GTGTTCTTTC TGCTGCCAAA ATTTCATGGA GTGTTGAAAA CACTCTGTCT GGAGGTGGTA 7260 CTTTGTCGTG TGGAGGGAAT GACAGAGCTG TACTTCCAGT TAAAGAGCAA GGACTTCGTT 7320 CAAGTCATGA GACATAGAGA TGATGAAAGA CAAAAAGTAT GTTTGGACAT AATTTATAAG 7380 ATGATGCCAA AGTTAAAACC AGTAGAACTC CGAGAACTTC TGAACCCCGT TGTGGAATTC 7440 GTTTCCCATC CTTCTACAAC ATGTAGGGAA CAAATGTATA ATATTCTCAT GTGGATTCAT 7500 GATAATTACA GAGATCCAGA AAGTGAGACA GATAATGACT CCCAGGAAAT ATTTAAGTTG 7560 GCAAAAGATG TGCTGATTCA AGGATTGATC GATGAGAACC CTGGACTTCA ATTAATTATT 7620 CGAAATTTCT GGAGCCATGA AACTAGGTTA CCTTCAAATA CCTTGGACCG GTTGCTGGCA 7680 CTAAATTCCT TATATTCTCC TAAGATAGAA GTGCACTTTT TAAGTTTAGC AACAAATTTT 7740 CTGCTCGAAA TGACCAGCAT GAGCCCAGAT TATCCAAACC CCATGTTCGA GCATCCTCTG 7800 TCAGAATGCG AATTTCAGGA ATATACCATT GATTCTGATT GGCGTTTCCG AAGTACTGTT 7860 CTCACTCCGA TGTTTGTGGA GACCCAGGCC TCCCAGGGCA CTCTCCAGAC CCGTACCCAG 7920 GAAGGGTCCC TCTCAGCTCG CTGGCCAGTG GCAGGGCAGA TAAGGGCCAC CCAGCAGCAG 7980 CATGACTTCA CACTGACACA GACTGCAGAT GGAAGAAGCT CATTTGATTG GCTGACCGGG 8040 AGCAGCACTG ACCCGCTGGT CGACCACACC AGTCCCTCAT CTGACTCCTT GCTGTTTGCC 8100 CACAAGAGGA GTGAAAGGTT ACAGAGAGCA CCCTTGAAGT CAGTGGGGCC TGATTTTGGG 8160 AAAAAAAGGC TGGGCCTTCC AGGGGACGAG GTGGATAACA AAGTGAAAGG TGCGGCCGGC 8220 CGGACGGACC TACTACGACT GCGCAGACGG TTTATGAGGG ACCAGGAGAA GCTCAGTTTG 8280 ATGTATGCCA GAAAAGGCGT TGCTGAGCAA AAACGAGAGA AGGAAATCAA GAGTGAGTTA 8340 AAAATGAAGC AGGATGCCCA GGTCGTTCTG TACAGAAGCT ACCGGCACGG AGACCTTCCT 8400 GACATTCAGA TCAAGCACAG CAGCCTCATC ACCCCGTTAC AGGCCGTGGC CCAGAGGGAC 8460 CCAATAATTG CAAAACAGCT CTTTAGCAGC TTGTTTTCTG GAATTTTGAA AGAGATGGAT 8520 AAATTTAAGA CACTGTCTGA AAAAAACAAC ATCACTCAAA AGTTGCTTCA AGACTTCAAT 8580 CGTTTTCTTA ATACCACCTT CTCTTTCTTT CCACCCTTTG TCTCTTGTAT TCAGGACATT 8640 AGCTGTCAGC ACGCAGCCCT GCTGAGCCTC GACCCAGCGG CTGTTAGCGC TGGTTGCCTG 8700 GCCAGCCTAC AGCAGCCCGT GGGCATCCGC CTGCTAGAGG AGGCTCTGCT CCGCCTGCTG 8760 CCTGCTGAGC TGCCTGCCAA GCGAGTCCGT GGGAAGGCCC GCCTCCCTCC TGATGTCCTC 8820 AGATGGGTGG AGCTTGCTAA GCTGTATAGA TCAATTGGAG AATACGACGT CCTCCGTGGG 8880 ATTTTTACCA GTGAGATAGG AACAAAGCAA ATCACTCAGA GTGCATTATT AGCAGAAGCC 8940 AGAAGTGATT ATTCTGAAGC TGCTAAGCAG TATGATGAGG CTCTCAATAA ACAAGACTGG 9000 GTAGATGGTG AGCCCACAGA AGCCGAGAAG GATTTTTGGG AACTTGCATC CCTTGACTGT 9060

TACAACCACC TTGCTGAGTG GAAATCACTT GAATACTGTT CTACAGCCAG TATAGACAGT 9120 GAGAACCCCC CAGACCTAAA TAAAATCTGG AGTGAACCAT TTTATCAGGA AACATATCTA 9180 CCTTACATGA TCCGCAGCAA GCTGAAGCTG CTGCTCCAGG GAGAGGCTGA CCAGTCCCTG 9240 CTGACATTTA TTGACAAAGC TATGCACGGG GAGCTCCAGA AGGCGATTCT AGAGCTTCAT 9300 TACAGTCAAG AGCTGAGTCT GCTTTACCTC CTGCAAGATG ATGTTGACAG AGCCAAATAT 9360 TACATTCAAA ATGGCATTCA GAGTTTTATG CAGAATTATT CTAGTATTGA TGTCCTCTTA 9420 CACCAAAGTA GACTCACCAA ATTGCAGTCT GTACAGGCTT TAACAGAAAT TCAGGAGTTC 9480 ATCAGCTTTA TAAGCAAACA AGGCAATTTA TCATCTCAAG TTCCCCTTAA GAGACTTCTG 9540 AACACCTGGA CAAACAGATA TCCAGATGCT AAAATGGACC CAATGAACAT CTGGGATGAC 9600 ATCATCACAA ATCGATGTTT CTTTCTCAGC AAAATAGAGG AGAAGCTTAC CCCTCTTCCA 9660 GAAGATAATA GTATGAATGT GGATCAAGAT GGAGACCCCA GTGACAGGAT GGAAGTGCAA 9720 GAGCAGGAAG AAGATATCAG CTCCCTGATC AGGAGTTGCA AGTTTTCCAT GAAAATGAAG 9780 ATGATAGACA GTGCCCGGAA GCAGAACAAT TTCTCACTTG CTATGAAACT ACTGAAGGAG 9840 CTGCATAAAG AGTCAAAAAC CAGAGACGAT TGGCTGGTGA GCTGGGTGCA GAGCTACTGC 9900 CGCCTGAGCC ACTGCCGGAG CCGGTCCCAG GGCTGCTCTG AGCAGGTGCT CACTGTGCTG 9960 AAAACAGTCT CTTTGTTGGA TGAGAACAAC GTGTCAAGCT ACTTAAGCAA AAATATTCTG 10020 GCTTTCCGTG ACCAGAACAT TCTCTTGGGT ACAACTTACA GGATCATAGC GAATGCTCTC 10080 AGCAGTGAGC CAGCCTGCCT TGCTGAAATC GAGGAGGACA AGGCTAGAAG AATCTTAGAG 10140 CTTTCTGGAT CCAGTTCAGA GGATTCAGAG AAGGTGATCG CGGGTCTGTA CCAGAGAGCA 10200 TTCCAGCACC TCTCTGAGGC TGTGCAGGCG GCTGAGGAGG AGGCCCAGCC TCCCTCCTGG 10260 AGCTGTGGGC CTGCAGCTGG GGTGATTGAT GCTTACATGA CGCTGGCAGA TTTCTGTGAC 10320 CAACAGCTGC GCAAGGAGGA AGAGAATGCA TCAGTTATTG ATTCTGCAGA ACTGCAGGCG 10380 TATCCAGCAC TTGTGGTGGA GAAAATGTTG AAAGCTTTAA AATTAAATTC CAATGAAGCC 10440 AGATTGAAGT TTCCTAGATT ACTTCAGATT ATAGAACGGT ATCCAGAGGA GACTTTGAGC 10500 CTCATGACAA AAGAGATCTC TTCCGTTCCC TGCTGGCAGT TCATCAGCTG GATCAGCCAC 10560 ATGGTGGCCT TACTGGACAA AGACCAAGCC GTTGCTGTTC AGCACTCTGT GGAAGAAATC 10620 ACTGATAACT ACCCGCAGGC TATTGTTTAT CCCTTCATCA TAAGCAGCGA AAGCTATTCC 10680 TTCAAGGATA CTTCTACTGG TCATAAGAAT AAGGAGTTTG TGGCAAGGAT TAAAAGTAAG 10740 TTGGATCAAG GAGGAGTGAT TCAAGATTTT ATTAATGCCT TAGATCAGCT CTCTAATCCT 10800 GAACTGCTCT TTAAGGATTG GAGCAATGAT GTAAGAGCTG AACTAGCAAA AACCCCTGTA 10860 AATAAAAAAA ACATTGAAAA AATGTATGAA AGAATGTATG CAGCCTTGGG TGACCCAAAG 10920 GCTCCAGGCC TGGGGGCCTT TAGAAGGAAG TTTATTCAGA CTTTTGGAAA AGAATTTGAT 10980 AAACATTTTG GGAAAGGAGG TTCTAAACTA CTGAGAATGA AGCTCAGTGA CTTCAACGAC 11040 ATTACCAACA TGCTACTTTT AAAAATGAAC AAAGACTCAA AGCCCCCTGG GAATCTGAAA 11100 GAATGTTCAC CCTGGATGAG CGACTTCAAA GTGGAGTTCC TGAGAAATGA GCTGGAGATT 11160 CCCGGTCAGT ATGACGGTAG GGGAAAGCCA TTGCCAGAGT ACCACGTGCG AATCGCCGGG 11220 TTTGATGAGC GGGTGACAGT CATGGCGTCT CTGCGAAGGC CCAAGCGCAT CATCATCCGT 11280 GGCCATGACG AGAGGGAACA CCCTTTCCTG GTGAAGGGTG GCGAGGACCT GCGGCAGGAC 11340 CAGCGCGTGG AGCAGCTCTT CCAGGTCATG AATGGGATCC TGGCCCAAGA CTCCGCCTGC 11400 AGCCAGAGGG CCCTGCAGCT GAGGACCTAT AGCGTTGTGC CCATGACCTC CAGGTTAGGA 11460 TTAATTGAGT GGCTTGAAAA TACTGTTACC TTGAAGGACC TTCTTTTGAA CACCATGTCC 11520 CAAGAGGAGA AGGCGGCTTA CCTGAGTGAT CCCAGGGCAC CGCCGTGTGA ATATAAAGAT 11580 TGGCTGACAA AAATGTCAGG AAAACATGAT GTTGGAGCTT ACATGCTAAT GTATAAGGGC 11640 GCTAATCGTA CTGAAACAGT CACGTCTTTT AGAAAACGAG AAAGTAAAGT GCCTGCTGAT 11700 CTCTTAAAGC GGGCCTTCGT GAGGATGAGT ACAAGCCCTG AGGCTTTCCT GGCGCTCCGC 11760 TCCCACTTCG CCAGCTCTCA CGCTCTGATA TGCATCAGCC ACTGGATCCT CGGGATTGGA 11820 GACAGACATC TGAACAACTT TATGGTGGCC ATGGAGACTG GCGGCGTGAT CGGGATCGAC 11880 TTTGGGCATG CGTTTGGATC CGCTACACAG TTTCTGCCAG TCCCTGAGTT GATGCCTTTT 11940 CGGCTAACTC GCCAGTTTAT CAATCTGATG TTACCAATGA AAGAAACGGG CCTTATGTAC 12000 AGCATCATGG TACACGCACT CCGGGCCTTC CGCTCAGACC CTGGCCTGCT CACCAACACC 12060 ATGGATGTGT TTGTCAAGGA GCCCTCCTTT GATTGGAAAA ATTTTGAACA GAAAATGCTG 12120 AAAAAAGGAG GGTCATGGAT TCAAGAAATA AATGTTGCTG AAAAAAATTG GTACCCCCGA 12180 CAGAAAATAT GTTACGCTAA GAGAAAGTTA GCAGGTGCCA ATCCAGCAGT CATTACTTGT 12240 GATGAGCTAC TCCTGGGTCA TGAGAAGGCC CCTGCCTTCA GAGACTATGT GGCTGTGGCA 12300 CGAGGAAGCA AAGATCACAA CATTCGTGCC CAAGAACCAG AGAGTGGGCT TTCAGAAGAG 12360 ACTCAAGTGA AGTGCCTGAT GGACCAGGCA ACAGACCCCA ACATCCTTGG CAGAACCTGG 12420 GAAGGATGGG AGCCCTGGAT GTGAGGTCTG TGGGAGTCTG CAGATAGAAA GCATTACATT 12480 GTTTAAAGAA TCTACTATAC TTTGGTTGGC AGCATTCCAT GAGCTGATTT TCCTGAAACA 12540 CTAAAGAGAA ATGTCTTTTG TGCTACAGTT TCGTAGCATG AGTTTAAATC AAGATTATGA 12600 TGAGTAAATG TGTATGGGTT AAATCAAAGA TAAGGTTATA GTAACATCAA AGATTAGGTG 12660 AGGTTTATAG AAAGATAGAT ATCCAGGCTT ACCAAAGTAT TAAGTCAAGA ATATAATATG 12720 TGATCAGCTT TCAAAGCATT TACAAGTGCT GCAAGTTAGT GAAACAGCTG TCTCCGTAAA 12780 TGGAGGAAAT GTGGGGAAGC CTTGGAATGC CCTTCTGGTT CTGGCACATT GGAAAGCACA 12840 CTCAGAAGGC TTCATCACCA AGATTTTGGG AGAGTAAAGC TAAGTATAGT TGATGTAACA 12900 TTGTAGAAGC AGCATAGGAA CAATAAGAAC AATAGGTAAA GCTATAATTA TGGCTTATAT 12960 TTAGAAATGA CTGCATTTGA TATTTTAGGA TATTTTTCTA GGTTTTTTCC TTTCATTTTA 13020 TTCTCTTCTA GTTTTGACAT TTTATGATAG ATTTGCTCTC TAGAAGGAAA CGTCTTTATT 13080 TAGGAGGGCA AAAATTTTGG TCATAGCATT CACTTTTGCT ATTCCAATCT ACAACTGGAA 13140 GATACATAAA AGTGCTTTGC ATTGAATTTG GGATAACTTC AAAAATCCCA TGGTTGTTGT 13200 TAGGGATAGT ACTAAGCATT TCAGTTCCAG GAGAATAAAA GAAATTCCTA TTTGAAATGA 13260 ATTCCTCATT TGGAGGAAAA AAAGCATGCA TTCTAGCACA ACAAGATGAA ATTATGGAAT 13320 ACAAAAGTGG CTCCTTCCCA TGTGCAGTCC CTGTCCCCCC CCGCCAGTCC TCCACACCCA 13380 AACTGTTTCT GATTGGCTTT TAGCTTTTTG TTGTTTTTTT TTTTCCTTCT AACACTTGTA 13440 TTTGGAGGCT CTTCTGTGAT TTTGAGAAGT ATACTCTTGA GTGTTTAATA AAGTTTTTTT 13500 CCAAAAGTA Seq ID NO: 99 Protein sequence: Protein Accession # : NP 008835. 5 1 11 21 31 41 51 MAGSGAGVRC SLLRLQETLS AADRCGAALA GHQLIRGLGQ ECVLSSSPAV LALQTSLVFS 60 RDFGLLVFVR KSLNSIEFRE CREEILKFLC IFLEKMGQKI APYSVEIKNT CTSVYTKDRA 120 AKCKIPALDL LIKLLQTFRS SRLMDEFKIG ELFSKFYGEL ALKKKIPDTV LEKVYELLGL 180 LGEVHPSEMI NNAENLFRAF LGELKTQMTS AVREPKLPVL AGCLKGLSSL LCNFTKSMEE 240 DPQTSREIFN FVLKAIRPQI DLKRYAVPSA GLRLFALHAS QFSTCLLDNY VSLFEVLLKW 300 CAHTNVELKK AALSALESFL KQVSNMVAKN AEMHKNKLQY FMEQFYGIIR NVDSNNKELS 360

I I I I I I MLLWCPPQCA CSLGVFPSAP SPVWGTRRSC EPATRVPEVW ILSPLLRHGG HTQTQNHTAS 60 PRSPVMESPK KKNQQLKVGI LHLGSRQKKI RIQLRSQCAT WKVICKSCIS QTPGINLDLG 120 SGVKVKIIPK EEHCKMPEAG EEQPQV Seq ID NO : 106 DNA sequence Nucleic Acid Accession # : J04129 Coding sequence: 99-587 1 11 21 31 41 51 1 1 1 1 1 1 CATCCCTCTG GCTCCAGAGC TCAGAGCCAC CCACAGCCGC AGCCATGCTG TGCCTCCTGC 60 TCACCCTGGG CGTGGCCCTG GTCTGTGGTG TCCCGGCCAT GGACATCCCC CAGACCAAGC 120 AGGACCTGGA GCTCCCAAAG TTGGCAGGGA CCTGGCACTC CATGGCCATG GCGACCAACA 180 ACATCTCCCT CATGGCGACA CTGAAGGCCC CTCTGAGGGT CCACATCACC TCACTGTTGC 240 CCACCCCCGA GGACAACCTG GAGATCGTTC TGCACAGATG GGAGAACAAC AGCTGTGTTG 300 AGAAGAAGGT CCTTGGAGAG AAGACTGGGA ATCCAAAGAA GTTCAAGATC AACTATACGG 360 TGGCGAACGA GGCCACGCTG CTCGATACTG ACTACGACAA TTTCCTGTTT CTCTGCCTAC 420 AGGACACCAC CACCCCCATC CAGAGCATGA TGTGCCAGTA CCTGGCCAGA GTCCTGGTGG 480 AGGACGATGA GATCATGCAG GGATTCATCA GGGCTTTCAG GCCCCTGCCC AGGCACCTAT 540 GGTACTTGCT GGACTTGAAA CAGATGGAAG AGCCGTGCCG TTTCTAGCTC ACCTCCGCCT 600 CCAGGAAGAC CAGACTCCCA CCCTTCCACA CCTCCAGAGC AGTGGGACTT CCTCCTGCCC 660 TTTCAAAGAA TAACCACAGC TCAGAAGACG ATGACGTGGT CATCTGTGTC GCCATCCCCT 720 TCCTGCTGCA CACCTGCACC ATTGCCATGG GGAGGCTGCT CCCTGGGGGC AGAGTCTCTG 780 GCAGAGGTTA TTAATAAACC CTTGGAGCAT G Seq ID NO : 107 Protein sequence: Protein Accession &num : AAA60147 1 11 21 31 41 51 MDIPQTKQDL ELPKLAGTWH SMAMATNNIS LMATLKAPLR VHITSLLPTP EDNLEIVLHR 60 WENNSCVEKK VLGEKTGNPK KFKINYTVAN EATLLDTDYD NFLFLCLQDT TTPIQSMMCQ 120 YLARVLVEDD EIMQGFIRAF RPLPRHLWYL LDLKQMEEPC RF Seq ID NO : 108 DNA sequence Nucleic Acid Accession &num : Eos sequence Coding sequence: 48-794 1 11 21 31 41 51 1 1 1 1 1 1 TCCCAGGCAG CAGTTAGCCC GCCGCCCGCC TGTGTGTCCC CAGAGCCATG GAGAGAGCCA 60 GTCTGATCCA GAAGGCCAAG CTGGCAGAGC AGGCCGAACG CTATGAGGAC ATGGCAGCCT 120 TCATGAAAGG CGCCGTGGAG AAGGGCGAGG AGCTCTCCTG CGAAGAGCGA AACCTGCTCT 180 CAGTAGCCTA TAAGAACGTG GTGGGCGGCC AGAGGGCTGC CTGGAGGGTG CTGTCCAGTA 240 TTGAGCAGAA AAGCAACGAG GAGGGCTCGG AGGAGAAGGG GCCCGAGGTG CGTGAGTACC 300 GGGAGAAGGT GGAGACTGAG CTCCAGGGCG TGTGCGACAC CGTGCTGGGC CTGCTGGACA 360 GCCACCTCAT CAAGGAGGCC GGGGACGCCG AGAGCCGGGT CTTCTACCTG AAGATGAAGG 420 GTGACTACTA CCGCTACCTG GCCGAGGTGG CCACCGGTGA CGACAAGAAG CGCATCATTG 480 ACTCAGCCCG GTCAGCCTAC CAGGAGGCCA TGGACATCAG CAAGAAGGAG ATGCCGCCCA 540 CCAACCCCAT CCGCCTGGGC CTGGCCCTGA ACTTTTCCGT CTTCCACTAC GAGATCGCCA 600 ACAGCCCCGA GGAGGCCATC TCTCTGGCCA AGACCACTTT CGACGAGGCC ATGGCTGATC 660 TGCACACCCT CAGCGAGGAC TCCTACAAAG ACAGCACCCT CATCATGCAG CTGCTGCGAG 720 ACAACCTGAC ACTGTGGACG GCCGACAACG CCGGGGAAGA GGGGGGCGAG GCTCCCCAGG 780 AGCCCCAGAG CTGAGTGTTG CCCGCCACCG CCCCGCCCTG CCCCCTCCAG TCCCCCACCC 840 TGCCGAGAGG ACTAGTATGG GGTGGGAGGC CCCACCCTTC TCCCCTAGGC GCTGTTCTTG 900 CTCCAAAGGG CTCCGTGGAG AGGGACTGGC AGAGCTGAGG CCACCTGGGG CTGGGGATCC 960 CACTCTTCTT GCAGCTGTTG AGCGCACCTA ACCACTGGTC ATGCCCCCAC CCCTGCTCTC 1020 CGCACCCGCT TCCTCCCGAC CCCAGGACCA GGCTACTTCT CCCCTCCTCT TGCCTCCCTC 1080 CTGCCCCTGC TGCCTCTGAT CGTAGGAATT GAGGAGTGTC CCGCCTTGTG GCTGAGAACT 1140 GGACAGTGGC AGGGGCTGGA GATGGGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG 1200 CGCGCGCGCC AGTGCAAGAC CGAGATTGAG GGAAAGCATG TCTGCTGGGT GTGACCATGT 1260 TTCCTCTCAA TAAAGTTCCC CTGTGACACT C Seq ID NO : 109 Protein sequence: Protein Accession # : NP 006133. 1 1 11 21 31 41 51 # # # # # # MERASLIQKA KLAEQAERYE DMAAFMKGAV EKGEELSCEE RNLLSVAYKN VVGGQRAAWR 60 VLSSIEQKSN EEGSEEKGPE VREYREKVET ELQGVCDTVL GLLDSHLIKE AGDAESRVFY 120 LKMKGDYYRY LAEVATGDDK KRIIDSARSA YQEAMDISKK EMPPTNPIRL GLALNFSVFH 180 YEIANSPEEA ISLAKTTFDE AMADLHTLSE DSYKDSTLIM QLLRDNLTLW TADNAGEEGG 240 EAPQEPQS Seq ID NO : 110 DNA sequence Nucleic Acid Accession # : NM 000695 Coding sequence: 407-1564 1 11 21 31 41 51 CACGAGTTGG TTTGGGAGCT GCCAGTCTCC TGGGAGGATC GCAGTCAGCA GAGCAGGGCT 60 GAGGCCTGGG GGTAGGAGCA GAGCCTGCGC ATCTGGAGGC AGCATGTCCA AGAAAGGGAG 120 TGGAGGTGCA GCGAAGGACC CAGGGGCAGA GCCCACGCTG GGGATGGACC CCTTCGAGGA 180 CACACTGCGG CGGCTGCGTG AGGCCTTCAA CTGAGGGCGC ACGCGGCCGG CCGAGTTCCG 240 GGCTGCGCAG CTCCAGGGCC TGGGCCACTT CCTTCAAGAA AACAAGCAGC TTCTGCGCGA 300

CGTGCTGGCC CAGGACCTGC ATAAGCCAGC TTTCGAGGCA GACATATCTG AGCTCATCCT 360 TTGCCAGAAC GAGGTTGACT ACGCTCTCAA GAACCTTCAG GCCTGGATGA AGGATGAACC 420 ACGGTCCACG AACCTGTTCA TGAAGCTGGA CTCGGTCTTC ATCTGGAAGG AACCCTTTGG 480 CCTGGTCCTC ATCATCGCAC CCTGGAACTA CCCATTGAAC CTGACCCTGG TGCTCCTGGT 540 GGGCACCCTC CCCGCAGGGA ATTGCGTGGT GCTGAAGCCG TCAGAAATCA GCCAGGGCAC 600 AGAGAAGGTC CTGGCTGAGG TGCTGCCCCA GTACCTGGAC CAGAGCTGCT TTGCCGTGGT 660 GCTGGGCGGA CCCCAGGAGA CAGGGCAGCT GCTAGAGCAC AAGTTGGACT ACATCTTCTT 720 CACAGGGAGC CCTCGTGTGG GCAAGATTGT CATGACTGCT GCCACCAAGC ACCTGACGCC 780 TGTCACCCTG GAGCTGGGGG GCAAGAACCC CTGCTACGTG GACGACAACT GCGACCCCCA 840 GACCGTGGCC AACCGCGTGG CCTGGTTCTG CTACTTCAAT GCCGGCCAGA CCTGCGTGGC 900 CCCTGACTAC GTCCTGTGCA GCCCCGAGAT GCAGGAGAGG CTGCTGCCCG CCCTGCAGAG 960 CACCATCACC CGTTTCTATG GCGACGACCC CCAGAGCTCC CCAAACCTGG GCCGCATCAT 1020 CAACCAGAAA CAGTTCCAGC GGCTGCGGGC ATTGCTGGGC TGCGGCCGCG TGGCCATTGG 1080 GGGCCAGAGC AACGAGAGCG ATCGCTACAT CGCCCCCACG GTGCTGGTGG ACGTGCAGGA 1140 GACGGAGCCT GTGATGCAGG AGGAGATCTT CGGGCCCATC CTGCCCATCG TGAACGTGCA 1200 GAGCGTGGAC GAGGCCATCA AGTTCATCAA CCGGCAGGAG AAGCCCCTGG CCCTGTACGC 1260 CTTCTCCAAC AGCAGACAGG TTGTGAACCA GATGCTGGAG CGGACCAGCA GCGGCAGCTT 1320 TGGAGGCAAT GAGGGCTTCA CCTACATATC TCTGCTGTCC GTGCCATTCG GGGGAGTCGG 1380 CCACAGTGGG ATGGGCCGGT ACCACGGCAA GTTCACCTTC GACACCTTCT CCCACCACCG 1440 CACCTGCCTG CTCGCCCCCT CCGGCCTGGA GAAATTAAAG GAGATCCGCT ACCCACCCTA 1500 TACCGACTGG AACCAGCAGC TGTTACGCTG GGGCATGGGC TCCCAGAGCT GCACCCTCCT 1560 GTGAGCGTCC CACCCGCCTC CAACGGGTCA CACAGAGAAA CCTGAGTCTA GCCATGAGGG 1620 GCTTATGCTC CCAACTCACA TTGTTCCTCC AGACCGCAGG CTCCCCCAGC CTCAGGTTGC 1680 TGGAGCTGTC ACATGACTGC ATCCTGCCTG CCAGGGCTGC AAAGCAAGGT CTTGCTTCTA 1740 TCTGGGGGAC GCTGCTCGAG AGAGGCCGAG AGGCCGCAGA ACATGCCAGG TGTCCTCACT 1800 CACCCCACCC TCCCCAATTC CAGCCCTTTG CCCTCTCGGT CAGGGTTGGC CAGGCCCAGT 1860 CACAGGGGCA GTGTCACCCT GGAAAATACA GTGCCCTGCC TTCTTAGGGG CATCAGCCCT 1920 GAACGGTTGA GAGCGTGGAG CCCTCCAGGC CTTTGCTCTC CCCTCTAGGC ACACGCGCAC 1980 TTCCACCTCT GCCCCATCCC AACTGCACCA GCACTGCCTC CCCCAGGGAT CCTCTCACAT 2040 CCCACACTGG TCTCTGCACC ACCCCTCTGG TTCACACCGC ACCCTGCACT CACCCACAGC 2100 AGCTCCATCC ACTGGGAAAA CTGGGGTTTG CATCACTCCA CTGCACAGTG TTAGTGGGAC 2160 CTGGGGGCAA GTCCCTTGAC TTCTCTGAGC CTCAGTTTCC TTATGTGAAA GTTGCTGGAA 2220 CCAAAATGGA GTCACTTATG CCAAACTCTA ATAAAATGGA GTCGGGGGGG CACATAGAAG 2280 CCCTCACACA CACATGCCCG TAACAGGATT TATCACCAAG ACACGCCTGC ATGTAAGACC 2340 AGACACAGGG CGTATGGAAA AGCACGTCCT CAAAGACTGT AGTATTCCAG ATGAGCTGCA 2400 GATGCTTACC TACCACGGCC GTCTCCACCA GAAAACCATC GCCAACTCCT GCGATCAGCT 2460 TGTGACTTAC AAACCTTGTT TAAAAGCTGC TTACATGGAC TTCTGTCCTT TAAAACGTTC 2520 CCCTTGGCTG TGGCCCTCTG TGTATGCCTG GGATCCTTCC AAGCACTCAT AGCCCAGATA 2580 GGAATCCTCT GCTCCTCCCA AATAAATTCA TCTGTTC Seq ID No: 111 Protein sequence: Protein Accession # : NP 000686 1 11 21 31 41 51 MKDEPRSTNL FMKLDSVFIW KEPFGLVLII APWNYPLNLT LVLLVGTLPA GNCWLKPSE 60 ISQGTEKVLA EVLPQYLDQS CFAWLGGPQ ETGQLLEHKL DYIFFTGSPR VGKIVMTAAT 120 KHLTPVTLEL GGKNPCYVDD NCDPQTVANR VAWFCYFNAG QTCVAPDYVL CSPEMQERLL 180 PALQSTITRF YGDDPQSSPN LGRIINQKQF QRLRALLGCG RVAIGGQSNE SDRYIAPTVL 240 VDVQETEPVM QEEIFGPILP IVNVQSVDEA IKFINRQEKP LALYAFSNSR QWNQMLERT 300 SSGSFGGNEG FTYISLLSVP FGGVGHSGMG RYHGKFTFDT FSHHRTCLLA PSGLEKLKEI 360 RYPPYTDWNQ QLLRWGMGSQ SCTLL Seq ID NO : 112 DNA sequence Nucleic Acid Accession # : NM 004456 Coding sequence: 58-2298 1 11 21 31 41 51 GAATTCCGGG CGACGCGCGG GAACAACGCG AGTCGGCGCG CGGGACGAAG AATAATCATG 60 GGCCAGACTG GGAAGAAATC TGAGAAGGGA CCAGTTTGTT GGCGGAAGCG TGTAAAATCA 120 GAGTACATGC GACTGAGACA GCTCAAGAGG TTCAGACGAG CTGATGAAGT AAAGAGTATG 180 TTTAGTTCCA ATCGTCAGAA AATTTTGGAA AGAACGGAAA TCTTAAACCA AGAATGGAAA 240 CAGCGAAGGA TACAGCCTGT GCACATCCTG ACTTCTGTGA GCTCATTGCG CGGGACTAGG 300 GAGTGTTCGG TGACCAGTGA CTTGGATTTT CCAACACAAG TCATCCCATT AAAGACTCTG 360 AATGCAGTTG CTTCAGTACC CATAATGTAT TCTTGGTCTC CCCTACAGCA GAATTTTATG 420 GTGGAAGATG AAACTGTTTT ACATAACATT CCTTATATGG GAGATGAAGT TTTAGATCAG 480 GATGGTACTT TCATTGAAGA ACTAATAAAA AATTATGATG GGAAAGTACA CGGGGATAGA 540 GAATGTGGGT TTATAAATGA TGAAATTTTT GTGGAGTTGG TGAATGCCCT TGGTCAATAT 600 AATGATGATG ACGATGATGA TGATGGAGAC GATCCTGAAG AAAGAGAAGA AAAGCAGAAA 660 GATCTGGAGG ATCACCGAGA TGATAAAGAA AGCCGCCCAC CTCGGAAATT TCCTTCTGAT 720 AAAATTTTGG AGGCCATTTC CTCAATGTTT CCAGATAAGG GCACAGCAGA AGAACTAAAG 780 GAAAAATATA AAGAACTCAC CGAACAGCAG CTCCCAGGCG CACTTCCTCC TGAATGTACC 840 CCCAACATAG ATGGACCAAA TGCTAAATCT GTTCAGAGAG AGCAAAGCTT ACACTCCTTT 900 CATACGCTTT TCTGTAGGCG ATGTTTTAAA TATGACTGCT TCCTACATCC TTTTCATGCA 960 ACACCCAACA CTTATAAGCG GAAGAACACA GAAACAGCTC TAGACAACAA ACCTTGTGGA 1020 CCACAGTGTT ACCAGCATTT GGAGGGAGCA AAGGAGTTTG CTGCTGCTCT CACCGCTGAG 1080 CGGATAAAGA CCCCACCAAA ACGTCCAGGA GGCCGCAGAA GAGGACGGCT TCCCAATAAC 1140 AGTAGCAGGC CCAGCACCCC CACCATTAAT GTGCTGGAAT CAAAGGATAC AGACAGTGAT 1200 AGGGAAGCAG GGACTGAAAC GGGGGGAGAG AACAATGATA AAGAAGAAGA AGAGAAGAAA 1260 GATGAAACTT CGAGCTCCTC TGAAGCAAAT TCTCGGTGTC AAACACCAAT AAAGATGAAG 1320 CCAAATATTG AACCTCCTGA GAATGTGGAG TGGAGTGGTG CTGAAGCCTC AATGTTTAGA 1380 GTCCTCATTG GCACTTACTA TGACAATTTC TGTGCCATTG CTAGGTTAAT TGGGACCAAA 1440 ACATGTAGAC AGGTGTATGA GTTTAGAGTC AAAGAATCTA GCATCATAGC TCCAGCTCCC 1500 GCTGAGGATG TGGATACTCC TCCAAGGAAA AAGAAGAGGA AACACCGGTT GTGGGCTGCA 1560 CACTGCAGAA AGATACAGCT GAAAAAGGAC GGCTCCTCTA ACCATGTTTA CAACTATCAA 1620

CCCTGTGATC ATCCACGGCA GCCTTGTGAC AGTTCGTGCC CTTGTGTGAT AGCACAAAAT 1680 TTTTGTGAAA AGTTTTGTCA ATGTAGTTCA GAGTGTCAAA ACCGCTTTCC GGGATGCCGC 1740 TGCAAAGCAC AGTGCAACAC CAAGCAGTGC CCGTGCTACC TGGCTGTCCG AGAGTGTGAC 1800 CCTGACCTCT GTCTTACTTG TGGAGCCGCT GACCATTGGG ACAGTAAAAA TGTGTCCTGC 1860 AAGAACTGCA GTATTCAGCG GGGCTCCAAA AAGCATCTAT TGCTGGCACC ATCTGACGTG 1920 GCAGGCTGGG GGATTTTTAT CAAAGATCCT GTGCAGAAAA ATGAATTCAT CTCAGAATAC 1980 TGTGGAGAGA TTATTTCTCA AGATGAAGCT GACAGAAGAG GGAAAGTGTA TGATAAATAC 2040 ATGTGCAGCT TTCTGTTCAA CTTGAACAAT GATTTTGTGG TGGATGCAAC CCGCAAGGGT 2100 AACAAAATTC GTTTTGCAAA TCATTCGGTA AATCCAAACT GCTATGCAAA AGTTATGATG 2160 GTTAACGGTG ATCACAGGAT AGGTATTTTT GCCAAGAGAG CCATCCAGAC TGGCGAAGAG 2220 CTGTTTGTTG ATTACAGATA CAGCCAGGCT GATGCCCTGA AGTATGTCGG CATCGAAAGA 2280 GAAATGGAAA TCCCTTGACA TCTGCTACCT CCTCCCCCTC CTCTGAAACA GCTGCCTTAG 2340 CTTCAGGAAC CTCGAGTACT GTGGGCAATT TAGAAAAAGA ACATGCAGTT TGAAATTCTG 2400 AATTTGCAAA GTACTGTAAG AATAATTTAT AGTAATGAGT TTAAAAATCA ACTTTTTATT 2460 GCCTTCTCAC CAGCTGCAAA GTGTTTTGTA CCAGTGAATT TTTGCAATAA TGCAGTATGG 2520 TACATTTTTC AACTTTGAAT AAAGAATACT TGAACTTGAA AAAAAAAAAA AAAAAA Seq ID NO : 113 Protein sequence: Protein Accession # : NP 004447 1 11 21 31 41 51 # # # # # # MGQTGKKSEK GPVCWRKRVK SEYMRLRQLK RFRRADEVKS MFSSNRQKIL ERTETLNQEW 60 KQRRIQPVHI LTSVSSLRGT RECSVTSDLD FPTQVIPLKT LNAVASVPIM YSWSPLQQNF 120 MVEDETVLHN IPYMGDEVLD QDGTFIEELI KNYDGKVHGD RECGFINDEI FVELVNALGQ 180 YNDDDDDDDG DDPEEREEKQ KDLEDHRDDK ESRPPRKFPS DKILEAISSM FPDKGTAEEL 240 KEKYKELTEQ QLPGALPPEC TPNIDGPNAK SVQREQSLHS FHTLFCRRCF KYDCFLHPFH 300 ATPNTYKRKN TETALDNKPC GPQCYQHLEG AKEFAAALTA ERIKTPPKRP GGRRRGRLPN 360 NSSRPSTPTI NVLESKDTDS DREAGTETGG ENNDKEEEEK KDETSSSSEA NSRCQTPIKM 420 KPNIEPPENV EWSGAEASMF RVLIGTYYDN FCAIARLIGT KTCRQVYEFR VKESSIIAPA 480 PAEDVDTPPR KKKRKHRLWA AHCRKIQLKK DGSSNHVYNY QPCDHPRQPC DSSCPCVIAQ 540 NFCEKFCQCS SECQNRFPGC RCKAQCNTKQ CPCYLAVREC DPDLCLTCGA ADHWDSKNVS 600 CKNCSIQRGS KKHLLLAPSD VAGWGIFIKD PVQKNEFISE YCGEIISQDE ADRRGKVYDK 660 YMCSFLFNLN NDFWDATRK GNKIRFANHS VNPNCYAKVM MVNGDHRIGI FAKRAIQTGE 720 ELFVDYRYSQ ADALKYVGIE REMEIP Seq ID NO : 114 DNA sequence Nucleic Acid Accession &num : NM 001827 Coding sequence: 96-335 1 11 21 31 41 51 AGTCTCCGGC GAGTTGTTGC CTGGGCTGGA CGTGGTTTTG TCTGCTGCGC CCGCTCTTCG 60 CGCTCTCGTT TCATTTTCTG CAGCGCGCCA CGAGGATGGC CCACAAGCAG ATCTACTACT 120 CGGACAAGTA CTTCGACGAA CACTACGAGT ACCGGCATGT TATGTTACCC AGAGAACTTT 180 CCAAACAAGT ACCTAAAACT CATCTGATGT CTGAAGAGGA GTGGAGGAGA CTTGGTGTCC 240 AACAGAGTCT AGGCTGGGTT CATTACATGA TTCATGAGCC AGAACCACAT ATTCTTCTCT 300 TTAGACGACC TCTTCCAAAA GATCAACAAA AATGAAGTTT ATCTGGGGAT CGTCAAATCT 360 TTTTCAAATT TAATGTATAT GTGTATATAA GGTAGTATTC AGTGAATACT TGAGAAATGT 420 ACAAATCTTT CATCCATACC TGTGCATGAG CTGTATTCTT CACAGCAACA GAGCTCAGTT 480 AAATGCAACT GCAAGTAGGT TACTGTAAGA TGTTTAAGAT AAAAGTTCTT CCAGTCAGTT 540 TTTCTCTTAA GTGCCTGTTT GAGTTTACTG AAACAGTTTA CTTTTGTTCA ATAAAGTTTG 600 TATGTTGCAT TTAAAAAAAA AAAAAAA Seq ID NO : 115 Protein sequence: Protein Accession &num : NP 001818 1 11 21 31 41 51 MAHKQIYYSD KYFDEHYEYR HVMLPRELSK QVPKTHLMSE EEWRRLGVQQ SLGWVHYMIH 60 EPEPHILLFR RPLPKDQQK Seq ID NO : 116 DNA sequence Nucleic Acid Accession # : CAT cluster 1 11 21 31 41 51 TCAGACCTCA TGAGTCACTT GGACTCTTGA GCCACCTCTG GGGGTGGAGT CTCTCTCCTG 60 GCATCTGGAC CCTTGGTGCT ATCGACGAAG CTTGGGTGGG GCTCTTAGCT GCTATGTGCA 120 AGAGGTGTGT TCCAGGGAAA GCCCCTATCT CTCTGCAGAG GTCAAGTGAA AGCGACGGCC 180 GCAGCCAACA GAGTTCAAAA TGCAGGCTTG GAAAGTACAG GGGGCTCTGT GGAGGATGGG 240 AAGGACTGAT CCACATTCCC ACCAGGAAGT TTAGCAGAAC CCCCGCGTGC CAACTGGACC 300 CCTTGGAAGG ACCTGGCTCA GGCTGGACCA CCTCTTGAGA GGGAGGAGCT CTGGATTTGA 360 TCAAGAATTC TTTGCTGAGC ATGGTGCCTC ATGCCTATAA TACCAACACT TTGGGAGGCC 420 AGTGTGGGAG GATCTCTTGA GCCCAGGAGT TCAAGACTAG CCTGGGCAAC ACAGAGAGAA 480 CCCATCTCTA AAATAATAAT AATAATAAAA TAAAAAATTA GCAGGGCATG GTGGCATGTG 540 CCTGTAGTTC CAGCTACCCA GGAGGCTGAG GCAAGAGGAT GGCTGGAGCC TGGGATGTTG 600 AGGCTGCAAT GAACTGTGAT TACCCCACTG CACTCCAGCC TGGGCAAAAG AGCGAGAGAA 660 CCTGTCTCAA ATAATAATAA TAATAATAAT CTTATTTTGG AGAATAAAGA GACCTCTGGA 720 TTTGAGGTGC CATTTGGGTA GAAAGAAAAG ACGTTTACAC CGAGAAATAG TCTGTGTTGC 780 CCTGAAGGAG CAGAGGGATG CATCGCTGGA GGTGACCTAC AGTTGAAGAA GACTCATTAT 840 GACAGACCTT GTCCTTCTTC CTTGTGGAAA GTGTTTCCTC TGCTGCTACT GCTCATGAGA 900 CTCTTCCCCC TCCCTGTCCC AGGGAACCAA AGGGCTTTCT ACCACACCCT TTCTTGCCCC 960 CCGCCTCCCA TGTCTGCTGT GCCTTTGTAC TCAGCAATTC TTGTTTGCTC CATTATCTTC 1020 CAGCCGGATA CAGAGTGAAT AGTTAACCAC ACTTAGGTCA AATAGGATCT AAATTTTTGT 1080 TCCTGCTCCG TGTAAAGAGG CCAGTGTTTG TGTGTTGCAA GCAGCCTTGG AATAGTAACT 1140

1 11 21 31 41 51 AGACACCTCT GCCCTCACCA TGAGCCTCTG GCAGCCCCTG GTCCTGGTGC TCCTGGTGCT 60 GGGCTGCTGC TTTGCTGCCC CCAGACAGCG CCAGTCCACC CTTGTGCTCT TCCCTGGAGA 120 CCTGAGAACC AATCTCACCG ACAGGCAGCT GGCAGAGGAA TACCTGTACC GCTATGGTTA 180 CACTCGGGTG GCAGAGATGC GTGGAGAGTC GAAATCTCTG GGGCCTGCGC TGCTGCTTCT 240 CCAGAAGCAA CTGTCCCTGC CCGAGACCGG TGAGCTGGAT AGCGCCACGC TGAAGGCCAT 300 GCGAACCCCA CGGTGCGGGG TCCCAGACCT GGGCAGATTC CAAACCTTTG AGGGCGACCT 360 CAAGTGGCAC CACCACAACA TCACCTATTG GATCCAAAAC TACTCGGAAG ACTTGCCGCG 420 GGCGGTGATT GACGACGCCT TTGCCCGCGC CTTCGCACTG TGGAGCGCGG TGACGCCGCT 480 CACCTTCACT CGCGTGTACA GCCGGGACGC AGACATCGTC ATCCAGTTTG GTGTCGCGGA 540 GCACGGAGAC GGGTATCCCT TCGACGGGAA GGACGGGCTC CTGGCACACG CCTTTCCTCC 600 TGGCCCCGGC ATTCAGGGAG ACGCCCATTT CGACGATGAC GAGTTGTGGT CCCTGGGCAA 660 GGGCGTCGTG GTTCCAACTC GGTTTGGAAA CGCAGATGGC GCGGCCTGCC ACTTCCCCTT 720 CATCTTCGAG GGCCGCTCCT ACTCTGCCTG CACCACCGAC GGTCGCTCCG ACGGCTTGCC 780 CTGGTGCAGT ACCACGGCCA ACTACGACAC CGACGACCGG TTTGGCTTCT GCCCCAGCGA 840 GAGACTCTAC ACCCGGGACG GCAATGCTGA TGGGAAACCC TGCCAGTTTC CATTCATCTT 900 CCAAGGCCAA TCCTACTCCG CCTGCACCAC GGACGGTCGC TCCGACGGCT ACCGCTGGTG 960 CGCCACCACC GCCAACTACG ACCGGGACAA GCTCTTCGGC TTCTGCCCGA CCCGAGCTGA 1020 CTCGACGGTG ATGGGGGGCA ACTCGGCGGG GGAGCTGTGC GTCTTCCCCT TCACTTTCCT 1080 GGGTAAGGAG TACTCGACCT GTACCAGCGA GGGCCGCGGA GATGGGCGCC TCTGGTGCGC 1140 TACCACCTCG AACTTTGACA GCGACAAGAA GTGGGGCTTC TGCCCGGACC AAGGATACAG 1200 TTTGTTCCTC GTGGCGGCGC ATGAGTTCGG CCACGCGCTG GGCTTAGATC ATTCCTCAGT 1260 GCCGGAGGCG CTCATGTACC CTATGTACCG CTTCACTGAG GGGCCCCCCT TGCATAAGGA 1320 CGACGTGAAT GGCATCCGGC ACCTCTATGG TCCTCGCCCT GAACCTGAGC CACGGCCTCC 1380 AACCACCACC ACACCGCAGC CCACGGCTCC CCCGACGGTC TGCCCCACCG GACCCCCCAC 1440 TGTCCACCCC TCAGAGCGCC CCACAGCTGG CCCCACAGGT CCCCCCTCAG CTGGCCCCAC 1500 AGGTCCCCCC ACTGCTGGCC CTTCTACGGC CACTACTGTG CCTTTGAGTC CGGTGGACGA 1560 TGCCTGCAAC GTGAACATCT TCGACGCCAT CGCGGAGATT GGGAACCAGC TGTATTTGTT 1620 CAAGGATGGG AAGTACTGGC GATTCTCTGA GGGCAGGGGG AGCCGGCCGC AGGGCCCCTT 1680 CCTTATCGCC GACAAGTGGC CCGCGCTGCC CCGCAAGCTG GACTCGGTCT TTGAGGAGCC 1740 GCTCTCCAAG AAGCTTTTCT TCTTCTCTGG GCGCCAGGTG TGGGTGTACA CAGGCGCGTC 1800 GGTGCTGGGC CCGAGGCGTC TGGACAAGCT GGGCCTGGGA GCCGACGTGG CCCAGGTGAC 186, 0 CGGGGCCCTC CGGAGTGGCA GGGGGAAGAT GCTGCTGTTC AGCGGGCGGC GCCTCTGGAG 1920 GTTCGACGTG AAGGCGCAGA TGGTGGATCC CCGGAGCGCC AGCGAGGTGG ACCGGATGTT 1980 CCCCGGGGTG CCTTTGGACA CGCACGACGT CTTCCAGTAC CGAGAGAAAG CCTATTTCTG 2040 CCAGGACCGC TTCTACTGGC GCGTGAGTTC CCGGAGTGAG TTGAACCAGG TGGACCAAGT 2100 GGGCTACGTG ACCTATGACA TCCTGCAGTG CCCTGAGGAC TAGGGCTCCC GTCCTGCTTT 2160 GCAGTGCCAT GTAAATCCCC ACTGGGACCA ACCCTGGGGA AGGAGCCAGT TTGCCGGATA 2220 CAAACTGGTA TTCTGTTCTG GAGGAAAGGG AGGAGTGGAG GTGGGCTGGG CCCTCTCTTC 2280 TCACCTTTGT TTTTTGTTGG AGTGTTTCTA ATAAACTTGG ATTCTCTAAC CTTT Seq ID NO : 126 Protein sequence: Protein Accession # : NP 004985. 1 1 11 21 31 41 51 MSLWQPLVLV LLVLGCCFRA PRQRQSTLVL FPGDLRTNLT DRQLAEEYLY RYGYTRVAEM 60 RGESKSLGPA LLLLQKQLSL PETGELDSAT LKAMRTPRCG VPDLGRFQTF EGDLKWHHHN 120 ITYWIQNYSE DLPRAVIDDA FARAFALWSA VTPLTFTRVY SRDADIVIQF GVAEHGDGYP 180 FDGKDGLLAH AFPPGPGIQG DAHFDDDELW SLGKGVWPT RFGNADGAAC HFPFIFEGRS 240 YSACTTDGRS DGLPWCSTTA NYDTDDRFGF CPSERLYTRD GNADGKPCQF PFIFQGQSYS 300 ACTTDGRSDG YRWCATTANY DRDKLFGFCP TRADSTVMGG NSAGELCVFP FTFLGKEYST 360 CTSEGRGDGR LWCATTSNFD SDKKWGFCPD QGYSLFLVAA HEFGHALGLD HSSVPEALMY 420 PMYRFTEGPP LHKDDVNGIR HLYGPRPEPE PRPPTTTTPQ PTAPPTVCPT GPPTVHPSER 480 PTAGPTGPPS AGPTGPPTAG PSTATTVPLS PVDDACNVNI FDAIAEIGNQ LYLFKDGKYW 540 RFSEGRGSRP QGPFLIADKW PALPRKLDSV FEEPLSKKLF FFSGRQVWVY TGASVLGPRR 600 LDKLGLGADV AQVTGALRSG RGKMLLFSGR RLWRFDVKAQ MVDPRSASEV DRMFPGVPLD 660 THDVFQYREK AYFCQDRFYW RVSSRSELNQ VDQVGYVTYD ILQCPED Seq ID NO : 127 DNA sequence Nucleic Acid Accession # : NM 004181 Coding sequence: 32-670 1 11 21 31 41 51 GCAGAAATAG CCTAGGGAGA TCAACCCCGA GATGCTGAAC AAAGTGCTGT CCCGGCTGGG 60 GGTCGCCGGC CAGTGGCGCT TCGTGGACGT GCTGGGGCTG GAAGAGGAGT CTCTGGGCTC 120 GGTGCCAGCG CCTGCCTGCG CGCTGCTGCT GCTGTTTCCC CTCACGGCCC AGCATGAGAA 180 CTTCAGGAAA AAGCAGATTG AAGAGCTGAA GGGACAAGAA GTTAGTCCTA AAGTGTACTT 240 CATGAAGCAG ACCATTGGGA ATTCCTGTGG CACAATCGGA CTTATTCACG CAGTGGCCAA 300 TAATCAAGAC AAACTGGGAT TTGAGGATGG ATCAGTTCTG AAACAGTTTC TTTCTGAAAC 360 AGAGAAAATG TCCCCTGAAG ACAGAGCAAA ATGCTTTGAA AAGAATGAGG CCATACAGGC 420 AGCCCATGAT GCCGTGGCAC AGGAAGGCCA ATGTCGGGTA GATGACAAGG TGAATTTCCA 480 TTTTATTCTG TTTAACAACG TGGATGGCCA CCTCTATGAA CTTGATGGAC GAATGCCTTT 540 TCCGGTGAAC CATGGCGCCA GTTCAGAGGA CACCCTGCTG AAGGACGCTG CCAAGGTGTG 600 CAGAGAATTC ACCGAGCGTG AGCAAGGAGA AGTCCGCTTC TCTGCCGTGG CTCTCTGCAA 660 GGCAGCCTAA TGCTCTGTGG GAGGGACTTT GCTGATTTCC CCTCTTCCCT TCAACATGAA 720 AATATATACC CCCCATGCAG TCTAAAATGC TTCAGTACTT GTGAAACACA GCTGTTCTTC 780 TGTTCTGCAG ACACGCCTTC CCCTCAGCCA CACCCAGGCA CTTAAGCACA AGCAGAGTGC 840 ACAGCTGTCC ACTGGGCCAT TGTGGTGTGA GCTTCAGATG GTGAAGCATT CTCCCCAGTG 900 TATGTCTTGT ATCCGATATC TAACGCTTTA AATGGCTACT TTGGTTTCTG TCTGTAAGTT 960 AAGACCTTGG ATGTGGTTAT GTTGTCCTAA AGAATAAATT TTGCTGATAG TAGC Seq ID NO: 128 Protein sequence : Protein Accession # : NP 004172

1 11 21 31 41 51 MLNKVLSRLG VAGQWRFVDV LGLEEESLGS VPAPACALLL LFPLTAQHEN FRKKQIEELK 60 GQEVSPKVYF MKQTIGNSCG TIGLIHAVAN NQDKLGFEDG SVLKQFLSET EKMSPEDRAK 120 CFEKNEAIQA AHDAVAQEGQ CRVDDKVNFH FILFNNVDGH LYELDGRMPF PVNHGASSED 180 TLLKDAAKVC REFTEREQGE VRFSAVALCK AA Seq ID NO: 129 DNA sequence Nucleic Acid Accession # : NM 000213 Coding sequence: 127-5385 1 11 21 31 41 51 i I I I I I CGCCCGCGCG CTGCAGCCCC ATCTCCTAGC GGCAGCCCAG GCGCGGAGGG AGCGAGTCCG 60 CCCCGAGGTA GGTCCAGGAC GGGCGCACAG CAGCAGCCGA GGCTGGCCGG GAGAGGGAGG 120 AAGAGGATGG CAGGGCCACG CCCCAGCCCA TGGGCCAGGC TGCTCCTGGC AGCCTTGATC 180 AGCGTCAGCC TCTCTGGGAC CTTGGCAAAC CGCTGCAAGA AGGCCCCAGT GAAGAGCTGC 240 ACGGAGTGTG TCCGTGTGGA TAAGGACTGC GCCTACTGCA CAGACGAGAT GTTCAGGGAC 300 CGGCGCTGCA ACACCCAGGC GGAGCTGCTG GCCGCGGGCT GCCAGCGGGA GAGCATCGTG 360 GTCATGGAGA GCAGCTTCCA AATCACAGAG GAGACCCAGA TTGACACCAC CCTGCGGCGC 420 AGCCAGATGT CCCCCCAAGG CCTGCGGGTC CGTCTGCGGC CCGGTGAGGA GCGGCATTTT 480 GAGCTGGAGG TGTTTGAGCC ACTGGAGAGC CCCGTGGACC TGTACATCCT CATGGACTTC 540 TCCAACTCCA TGTCCGATGA TCTGGACAAC CTCAAGAAGA TGGGGCAGAA CCTGGCTCGG 600 GTCCTGAGCC AGCTCACCAG CGACTACACT ATTGGATTTG GCAAGTTTGT GGACAAAGTC 660 AGCGTCCCGC AGACGGACAT GAGGCCTGAG AAGCTGAAGG AGCCCTGGCC CAACAGTGAC 720 CCCCCCTTCT CCTTCAAGAA CGTCATCAGC CTGACAGAAG ATGTGGATGA GTTCCGGAAT 780 AAACTGCAGG GAGAGCGGAT CTCAGGCAAC CTGGATGCTC CTGAGGGCGG CTTCGATGCC 840 ATCCTGCAGA CAGCTGTGTG CACGAGGGAC ATTGGCTGGC GCCCGGACAG CACCCACCTG 900 CTGGTCTTCT CCACCGAGTC AGCCTTCCAC TATGAGGCTG ATGGCGCCAA CGTGCTGGCT 960 GGCATCATGA GCCGCAACGA TGAACGGTGC CACCTGGACA CCACGGGCAC CTACACCCAG 1020 TACAGGACAC AGGACTACCC GTCGGTGCCC ACCCTGGTGC GCCTGCTCGC CAAGCACAAC 1080 ATCATCCCCA TCTTTGCTGT CACCAACTAC TCCTATAGCT ACTACGAGAA GCTTCACACC 1140 TATTTCCCTG TCTCCTCACT GGGGGTGCTG CAGGAGGACT CGTCCAACAT CGTGGAGCTG 1200 CTGGAGGAGG CCTTCAATCG GATCCGCTCC AACCTGGACA TCCGGGCCCT AGACAGCCCC 1260 CGAGGCCTTC GGACAGAGGT CACCTCCAAG ATGTTCCAGA AGACGAGGAC TGGGTCCTTT 1320 CACATCCGGC GGGGGGAAGT GGGTATATAC CAGGTGCAGC TGCGGGCCCT TGAGCACGTG 1380 GATGGGACGC ACGTGTGCCA GCTGCCGGAG GACCAGAAGG GCAACATCCA TCTGAAACCT 1440 TCCTTCTCCG ACGGCCTCAA GATGGACGCG GGCATCATCT GTGATGTGTG CACCTGCGAG 1500 CTGCAAAAAG AGGTGCGGTC AGCTCGCTGC AGCTTCAACG GAGACTTCGT GTGCGGACAG 1560 TGTGTGTGCA GCGAGGGCTG GAGTGGCCAG ACCTGCAACT GCTCCACCGG CTCTCTGAGT 1620 GACATTCAGC CCTGCCTGCG GGAGGGCGAG GACAAGCCGT GCTCCGGCCG TGGGGAGTGC 1680 CAGTGCGGGC ACTGTGTGTG CTACGGCGAA GGCCGCTACG AGGGTCAGTT CTGCGAGTAT 1740 GACAACTTCC AGTGTCCCCG CACTTCCGGG TTCCTCTGCA ATGACCGAGG ACGCTGCTCC 1800 ATGGGCCAGT GTGTGTGTGA GCCTGGTTGG ACAGGCCCAA GCTGTGACTG TCCCCTCAGC 1860 AATGCCACCT GCATCGACAG CAATGGGGGC ATCTGTAATG GACGTGGCCA CTGTGAGTGT 1920 GGCCGCTGCC ACTGCCACCA GCAGTCGCTC TACACGGACA CCATCTGCGA GATCAACTAC 1980 TCGGCGATCC ACCCGGGCCT CTGCGAGGAC CTACGCTCCT GCGTGCAGTG CCAGGCGTGG 2040 GGCACCGGCG AGAAGAAGGG GCGCACGTGT GAGGAATGCA ACTTCAAGGT CAAGATGGTG 2100 GACGAGCTTA AGAGAGCCGA GGAGGTGGTG GTGCGCTGCT CCTTCCGGGA CGAGGATGAC 2160 GACTGCACCT ACAGCTACAC CATGGAAGGT GACGGCGCCC CTGGGCCCAA CAGCACTGTC 2220 CTGGTGCACA AGAAGAAGGA CTGCCCTCCG GGCTCCTTCT GGTGGCTCAT CCCCCTGCTC 2280 CTCCTCCTCC TGCCGCTCCT GGCCCTGCTA CTGCTGCTAT GCTGGAAGTA CTGTGCCTGC 2340 TGCAAGGCCT GCCTGGCACT TCTCCCGTGC TGCAACCGAG GTCACATGGT GGGCTTTAAG 2400 GAAGACCACT ACATGCTGCG GGAGAACCTG ATGGCCTCTG ACCACTTGGA CACGCCCATG 2460 CTGCGCAGCG GGAACCTCAA GGGCCGTGAC GTGGTCCGCT GGAAGGTCAC CAACAACATG 2520 CAGCGGCCTG GCTTTGCCAC TCATGCCGCC AGCATCAACC CCACAGAGCT GGTGCCCTAC 2580 GGGCTGTCCT TGCGCCTGGC CCGCCTTTGC ACCGAGAACC TGCTGAAGCC TGACACTCGG 2640 GAGTGCGCCC AGCTGCGCCA GGAGGTGGAG GAGAACCTGA ACGAGGTCTA CAGGCAGATC 2700 TCCGGTGTAC ACAAGCTCCA GCAGACCAAG TTCCGGCAGC AGCCCAATGC CGGGAAAAAG 2760 CAAGACCACA CCATTGTGGA CACAGTGCTG ATGGCGCCCC GCTCGGCCAA GCCGGCCCTG 2820 CTGAAGCTTA CAGAGAAGCA GGTGGAACAG AGGGCCTTCC ACGACCTCAA GGTGGCCCCC 2880 GGCTACTACA CCCTCACTGC AGACCAGGAC GCCCGGGGCA TGGTGGAGTT CCAGGAGGGC 2940 GTGGAGCTGG TGGACGTACG GGTGCCCCTC TTTATCCGGC CTGAGGATGA CGACGAGAAG 3000 CAGCTGCTGG TGGAGGCCAT CGACGTGCCC GCAGGCACTG CCACCCTCGG CCGCCGCCTG 3060 GTAAACATCA CCATCATCAA GGAGCAAGCC AGAGACGTGG TGTCCTTTGA GCAGCCTGAG 3120 TTCTCGGTCA GCCGCGGGGA CCAGGTGGCC CGCATCCCTG TCATCCGGCG TGTCCTGGAC 3180 GGCGGGAAGT CCCAGGTCTC CTACCGCACA CAGGATGGCA CCGCGCAGGG CAACCGGGAC 3240 TACATCCCCG TGGAGGGTGA GCTGCTGTTC CAGCCTGGGG AGGCCTGGAA AGAGCTGCAG 3300 GTGAAGCTCC TGGAGCTGCA AGAAGTTGAC TCCCTCCTGC GGGGCCGCCA GGTCCGCCGT 3360 TTCCACGTCC AGCTCAGCAA CCCTAAGTTT GGGGCCCACC TGGGCCAGCC CCACTCCACC 3420 ACCATCATCA TCAGGGACCC AGATGAACTG GACCGGAGCT TCACGAGTCA GATGTTGTCA 3480 TCACAGCCAC CCCCTCACGG CGACCTGGGC GCCCCGCAGA ACCCCAATGC TAAGGCCGCT 3540 GGGTCCAGGA AGATCCATTT CAACTGGCTG CCCCCTTCTG GCAAGCCAAT GGGGTACAGG 3600 GTAAAGTACT GGATTCAGGG TGACTCCGAA TCCGAAGCCC ACCTGCTCGA CAGCAAGGTG 3660 CCCTCAGTGG AGCTCACCAA CCTGTACCCG TATTGCGACT ATGAGATGAA GGTGTGCGCC 3720 TACGGGGCTC AGGGCGAGGG ACCCTACAGC TCCCTGGTGT CCTGCCGCAC CCACCAGGAA 3780 GTGCCCAGCG AGCCAGGGCG TCTGGCCTTC AATGTCGTCT CCTCCACGGT GACCCAGCTG 3840 AGCTGGGCTG AGCCGGCTGA GACCAACGGT GAGATCACAG CCTACGAGGT CTGCTATGGC 3900 CTGGTCAACG ATGACAACCG ACCTATTGGG CCCATGAAGA AAGTGCTGGT TGACAACCCT 3960 AAGAACCGGA TGCTGCTTAT TGAGAACCTT CGGGAGTCCC AGCCCTACCG CTACACGGTG 4020 AAGGCGCGCA ACGGGGCCGG CTGGGGGCCT GAGCGGGAGG CCATCATCAA CCTGGCCACC 4080 CAGCCCAAGA GGCCCATGTC CATCCCCATC ATCCCTGACA TCCCTATCGT GGACGCCCAG 4140 AGCGGGGAGG ACTACGACAG CTTCCTTATG TACAGCGATG ACGTTCTACG CTCTCCATCG 4200 GGCAGCCAGA GGCCCAGCGT CTCCGATGAC ACTGAGCACC TGGTGAATGG CCGGATGGAC 4260 TTTGCCTTCC CGGGCAGCAC CAACTCCCTG CACAGGATGA CCACGACCAG TGCTGCTGCC 4320 TATGGCACCC ACCTGAGCCC ACACGTGCCC CACCGCGTGC TAAGCACATC CTCCACCCTC 4380

CAACTGCGCC GACCCCGCCA CTCTCACCCG ACCCGTGCAC GACGCTGCCC GGGAGGGCTT 540 CCTGGACACG CTGGTGGTGC TGCACCGGGC CGGGGCGCGG CTGGACGTGC GCGATGCCTG 600 GGGCCGTCTG CCCGTGGACC TGGCTGAGGA GCTGGGCCAT CGCGATGTCG CACGGTACCT 660 GCGCGCGGCT GCGGGGGGCA CCAGAGGCAG TAACCATGCC CGCATAGATG CCGCGGAAGG 720 TCCCTCAGAC ATCCCCGATT GAAAGAACCA GAGAGGCTCT GAGAAACCTC GGGAAACTTA 780 GATCATCAGT CACCGAAGGT CCTACAGGGC CACAACTGCC CCCGCCACAA CCCACCCCGC 840 TTTCGTAGTT TTCATTTAGA AAATAGAGCT TTTAAAAATG TCCTGCCTTT TAACGTAGAT 900 ATATGCCTTC CCCCACTACC GTAAATGTCC ATTTATATCA TTTTTTATAT ATTCTTATAA 960 AAATGTAAAA AAGAAAAACA CCGCTTCTGC CTTTTCACTG TGTTGGAGTT TTCTGGAGTG 1020 AG Q CTCACG CCCTAAGCGC ACATTCATGT GGGCATTTCT TGCGAGCCTC GCAGCCTCCG 1080 GAAGCTGTCG ACTTCATGAC AAGCATTTTG TGAACTAGGG AAGCTCAGGG GGGTTACTGG 1140 CTTCTCTTGA GTCACACTGC TAGCAAATGG CAGAACCAAA GCTCAAATAA AAATAAAATA 1200 ATTTTCATTC ATTCACTC Seq ID NO : 136 Protein sequence: Protein Accession # : NP 000068. 1 1 11 21 31 41 51 ) t)) i) MEPAAGSSME PSADWLATAA ARGRVEEVRA LLEAGALPNA PNSYGRRPIQ VMMMGSARVA 60 ELLLLHGAEP NCADPATLTR PVHDAAREGF LDTLWLHRA GARLDVRDAW GRLPVDLAEE 120 LGHRDVARYL RAAAGGTRGS NHARIDAAEG PSDIPD Seq ID NO : 137 DNA sequence Nucleic Acid Accession # : NM_058196. 1 Coding sequence: 104-421 1 11 21 31 41 51 TGTGTGGGGG TCTGCTTGGC GGTGAGGGGG CTCTACACAA GCTTCCTTTC CGTCATGCCG 60 GCCCCCACCC TGGCTCTGAC CATTCTGTTC TCTCTGGCAG GTCATGATGA TGGGCAGCGC 120 CCGAGTGGCG GAGCTGCTGC TGCTCCACGG CGCGGAGCCC AACTGCGCCG ACCCCGCCAC 180 TCTCACCCGA CCCGTGCACG ACGCTGCCCG GGAGGGCTTC CTGGACACGC TGGTGGTGCT 240 GCACCGGGCC GGGGCGCGGC TGGACGTGCG CGATGCCTGG GGCCGTCTGC CCGTGGACCT 300 GGCTGAGGAG CTGGGCCATC GCGATGTCGC ACGGTACCTG CGCGCGGCTG CGGGGGGCAC 360 CAGAGGCAGT AACCATGCCC GCATAGATGC CGCGGAAGGT CCCTCAGACA TCCCCGATTG 420 AAAGAACCAG AGAGGCTCTG AGAAACCTCG GGAAACTTAG ATCATCAGTC ACCGAAGGTC 480 CTACAGGGCC ACAACTGCCC CCGCCACAAC CCACCCCGCT TTCGTAGTTT TCATTTAGAA 540 AATAGAGCTT TTAAAAATGT CCTGCCTTTT AACGTAGATA TAAGCCTTCC CCCACTACCG 600 TAAATGTCCA TTTATATCAT TTTTTATATA TTCTTATAAA AATGTAAAAA AGAAAAACAC 660 CGCTTCTGCC TTTTCACTGT GTTGGAGTTT TCTGGAGTGA GCACTCACGC CCTAAGCGCA 720 CATTCATGTG GGCATTTCTT GCGAGCCTCG CAGCCTCCGG AAGCTGTCGA CTTCATGACA 780 AGCATTTTGT GAACTAGGGA AGCTCAGGGG GGTTACTGGC TTCTCTTGAG TCACACTGCT 840 AGCAAATGGC AGAACCAAAG CTCAAATAAA AATAAAATAA TTTTCATTCA TTCACTC Seq ID NO: 138 Protein sequence: Protein Accession # NP_478103. 1 1 11 21 31 41 51 I I I I I I MMMGSARVAE LLLLHGAEPN CADPATLTRP VHDAAREGFL DTLWLHRAG ARLDVRDAMG 60 RLPVDLAEEL GHRDVARYLR AAAGGTRGSN HARIDAAEGP SDIPD Seq ID NO: 139 DNA sequence Nucleic Acid Accession &num : NM 058197. 1 Coding sequence : 272-684 1 11 21 31 41 51 I I # # # # CCCAACCTGG GGCGACTTCA GGTGTGCCAC ATTCGCTAAG TGCTCGGAGT TAATAGCACC 60 TCCTCCGAGC ACTCGCTCAC GGCGTCCCCT TGCCTGGAAA GATACCGCGG TCCCTCCAGA 120 GGATTTGAGG GACAGGGTCG GAGGGGGCTC TTCCGCCAGC ACCGGAGGAA GAAAGAGGAG 180 GGGCTGGCTG GTCACCAGAG GGTGGGGCGG ACCGCGTGCG CTCGGCGGCT GCGGAGAGGG 240 GGAGAGCAGG CAGCGGGCGG CGGGGAGCAG CATGGAGCCG GCGGCGGGGA GCAGCATGGA 300 GCCGGCGGCG GGGAGCAGCA TGGAGCCTTC GGCTGACTGG CTGGCCACGG CCGCGGCCCG 360 GGGTCGGGTA GAGGAGGTGC GGGCGCTGCT GGAGGCGGGG GCGCTGCCCA ACGCACCGAA 420 TAGTTACGGT CGGAGGCCGA TCCAGGTGGG TAGAAGGTCT GCAGCGGGAG CAGGGGATGG 480 CGGGCGACTC TGGAGGACGA AGTTTGCAGG GGAATTGGAA TCAGGTAGCG CTTCGATTCT 540 CCGGAAAAAG GGGAGGCTTC CTGGGGAGTT TTCAGAAGGG GTTTGTAATC ACAGACCTCC 600 TCCTGGCGAC GCCCTGGGGG CTTGGGAAAC CAAGGAAGAG GAATGAGGAG CCACGCGCGT 660 ACAGATCTCT CGAATGCTGA GAAGATCTGA AGGGGGGAAC ATATTTGTAT TAGATGGAAG 720 TCATGATGAT GGGCAGCGCC CGAGTGGCGG AGCTGCTGCT GCTCCACGGC GCGGAGCCCA 780 ACTGCGCCGA CCCCGCCACT CTCACCCGAC CCGTGCACGA CGCTGCCCGG GAGGGCTTCC 840 TGGACACGCT GGTGGTGCTG CACCGGGCCG GGGCGCGGCT GGACGTGCGC GATGCCTGGG 900 GCCGTCTGCC CGTGGACCTG GCTGAGGAGC TGGGCCATCG CGATGTCGCA CGGTACCTGC 960 GCGCGGCTGC GGGGGGCACC AGAGGCAGTA ACCATGCCCG CATAGATGCC GCGGAAGGTC 1020 CCTCAGACAT CCCCGATTGA AAGAACCAGA GAGGCTCTGA GAAACCTCGG GAACTTAGAT 1080 CATCAGTCAC CGAAGGTCCT ACAGGGCCAC AACTGCCCCC GCCACAACCC ACCCCGCTTT 1140 CGTAGTTTTC ATTTAGAAAA TAGAGCTTTT AAAAATGTCC TGCCTTTTAA CGTAGATATA 1200 TGCCTTCCCC CACTACCGTA AATGTCCATT TATATCATTT TTTATATATT CTTATAAAAA 1260 TGTAAAAAAG AAAAACACCG CTTCTGCCTT TTCACTGTGT TGGAGTTTTC TGGAGTGAGC 1320 ACTCACGCCC TAAGCGCACA TTCATGTGGG CATTTCTTGC GAGCCTCGCA GCCTCCGGAA 1380 GCTGTCGACT TCATGACAAG CATTTTGTGA ACTAGGGAAG CTCAGGGGGG TTACTGGCTT 1440 CTCTTGAGTC ACACTGCTAG CAAATGGCAG AACCAAAGCT CAAATAAAAA TAAAATAATT 1500

LCTNLTRAPR IGQLQGEIIP TSFYHQGRVI DCSGAHWLD DDTDVGYVED GTPCGPSMMC 720 LDRKCLQIQA LNMSSCPLDS KGKVCSGHGV CSNEATCICD FTWAGTDCSI RDPVRNLHPP 780 KDEGPKGPSA TNLIIGSIAG AILVAAIVLG GTGWGFKNVK KRRFDPTQQG PI Seq ID NO : 151 DNA sequence Nucleic Acid Accession &num : NM 023915 Coding sequence: 250-1326 1 11 21 31 41 51 GGCACGAGGG TTTCGTTTTC ATGCTTTACC AGAAAATCCA CTTCCCTGCC GACCTTAGTT 60 TCAAAGCTTA TTCTTAATTA GAGACAAGAA ACCTGTTTCA ACTTGAAGAC ACCGTATGAG 120 GTGAATGGAC AGCCAGCCAC CACAATGAAA GAAATCAAAC CAGGAATAAC CTATGCTGAA 180 CCCACGCCTC AATCGTCCCC AAGTGTTTCC TGACACGCAT CTTTGCTTAC AGTGCATCAC 240 AACTGAAGAA TGGGGTTCAA CTTGACGCTT GCAAAATTAC CAAATAACGA GCTGCACGGC 300 CAAGAGAGTC ACAATTCAGG CAACAGGAGC GACGGGCCAG GAAAGAACAC CACCCTTCAC 360 AATGAATTTG ACACAATTGT CTTGCCGGTG CTTTATCTCA TTATATTTGT GGCAAGCATC 420 TTGCTGAATG GTTTAGCAGT GTGGATCTTC TTCCACATTA GGAATAAAAC CAGCTTCATA 480 TTCTATCTCA AAAACATAGT GGTTGCAGAC CTCATAATGA CGCTGACATT TCCATTTCGA 540 ATAGTCCATG ATGCAGGATT TGGACCTTGG TACTTCAAGT TTATTCTCTG CAGATACACT 600 TCAGTTTTGT TTTATGCAAA CATGTATACT TCCATCGTGT TCCTTGGGCT GATAAGCATT 660 GATCGCTATC TGAAGGTGGT CAAGCCATTT GGGGACTCTC GGATGTACAG CATAACCTTC 720 ACGAAGGTTT TATCTGTTTG TGTTTGGGTG ATCATGGCTG TTTTGTCTTT GCCAAACATC 780 ATCCTGACAA ATGGTCAGCC AACAGAGGAC AATATCCATG ACTGCTCAAA ACTTAAAAGT 840 CCTTTGGGGG TCAAATGGCA TACGGCAGTC ACCTATGTGA ACAGCTGCTT GTTTGTGGCC 900 GTGCTGGTGA TTCTGATCGG ATGTTACATA GCCATATCCA GGTACATCCA CAAATCCAGC 960 AGGCAATTCA TAAGTCAGTC AAGCCGAAAG CGAAAACATA ACCAGAGCAT CAGGGTTGTT 1020 GTGGCTGTGT TTTTTACCTG CTTTCTACCA TATCACTTGT GCAGAATTCC TTTTACTTTT 1080 AGTCACTTAG ACAGGCTTTT AGATGAATCT GCACAAAAAA TCCTATATTA CTGCAAAGAA 1140 ATTACACTTT TCTTGTCTGC GTGTAATGTT TGCCTGGATC CAATAATTTA CTTTTTCATG 1200 TGTAGGTCAT TTTCAAGAAG GCTGTTCAAA AAATCAAATA TCAGAACCAG GAGTGAAAGC 1260 ATCAGATCAC TGCAAAGTGT GAGAAGATCG GAAGTTCGCA TATATTATGA TTACACTGAT 1320 GTGTAGGCCT TTTATTGTTT GTTGGAATCG ATATGTACAA AGTGTAAATA AATGTTTCTT 1380 TTCATTATCC TTAAAAAAAA AA Seq ID NO : 152 Protein sequence : Protein Accession # : NP 076404 1 11 21 31 41 51 # # # # # # MGFNLTLAKL PNNELHGQES HNSGNRSDGP GKNTTLHNEF DTIVLPVLYL IIFVASILLN 60 GLAVWIFFHI RNKTSFIFYL KNIWADLIM TLTFPFRIVH DAGFGPWYFK FILCRYTSVL 120 FYANMYTSIV FLGLISIDRY LKVVKPFGDS RMYSITFTKV LSVCVWVIMA VLSLPNIILT 180 NGQPTEDNIH DCSKLKSPLG VKWHTAVTYV NSCLFVAVLV ILIGCYIAIS RYIHKSSRQF 240 ISQSSRKRKH NQSIRWVAV FFTCFLPYHL CRIPFTFSHL DRLLDESAQK ILYYCKEITL 300 FLSACNVCLD PIIYFFMCRS FSRRLFKKSN IRTRSESIRS LQSVRRSEVR IYYDYTDV Seq ID NO: 153 DNA sequence Nucleic Acid Accession # : D80008.1 Coding sequence: 149-739 1 11 21 31 41 51 1 1 1 1 1 1 GTTCGGCGCC AAAGCGCGGA GCGGAGGCCG AGGCGAGAGC CTGGCGCTGT AGGACTAGAA 60 CGAAAGGAGT GAGGCGCCGA GAGCCCAGAT ACCATTTTGG CGTGAGAGCT GGTGGTTGGC 120 AAGGCCGCGG GAGTGGGAAG CGTCCGCCAT GTTCTGCGAA AAAGCCATGG AACTGATCCG 180 CGAGCTGCAT CGCGCGCCCG AAGGGCAACT GCCTGCCTTC AACGAGGATG GACTCAGACA 240 AGTTCTGGAG GAGATGAAAG CTTTGTATGA ACAAAACCAG TCTGATGTGA ATGAAGCAAA 300 GTCAGGTGGA CGAAGTGATT TGATACCAAC TATCAAATTT CGACACTGTT CTCTGTTAAG 360 AAATCGACGC TGCACTGTAG CATACCTGTA TGACCGCTTG CTTCGGATCA GAGCACTCAG 420 ATGGGAATAT GGTAGCGTCT TGCCAAATGC ATTACGATTT CACATGGCTG CTGAAGAAAT 480 GGAGTGGTTT AATAATTATA AAAGATCTCT TGCTACTTAT ATGAGGTCAC TGGGAGGAGA 540 TGAAGGTTTG GACATTACAC AGGATATGAA ACCACCAAAA AGCCTATATA TTGAAGTCCG 600 GTGTCTAAAA GACTATGGAG AATTTGAAGT TGATGATGGC ACTTCAGTCC TATTAAAAAA 660 AAATAGCCAG CACTTTTTAC CTCGATGGAA ATGTGAGCAG CTGATCAGAC AAGGAGTCCT 720 GGAGCACATC CTGTCATGAC CATGCGCCGA GGCACTTCCA GGCTTCACTC AACTCATGGA 780 CTCCTCTGTA CTCACTCTCT CCACCACTCC CTTCACCTCC CTCTTTGATT TTAGAAGCTA 840 TAGACATTGT TTAAGATAAC TAAGAATACT TGGCTAAGAA GTATAATTTG CTAACTATTA 900 AGGACTTTCT TTTTTTAATG TTGTACACTA TTCTTCCTAC TCTTTTTTGG TTTTGGTTTT 960 GTTTTGTAGA GACTGTCTCA CTATGTTGCC CAAGCTGGTC TCAAACTCCT GGCCTCAAGC 1020 AGTCCTCCCA CCTTAGCTTC TCAAAGTGTT GAGATCACAG GCGTGAGCCA CTGCACCCGG 1080 CCCCTACTCC TTTTTCTAAT AAGCTGTATC TGTAATCACA GCATTCCTAC AGTTGTTACA 1140 GTGTGTTTTT TAAATGAAAG TAAACATGGT TACATTTGAA TCTCTTAAAT AAGCAGTCAC 1200 TTGGCTGGAC AGGAAGAAGG TAGATCCTGT GTGTCTTGTT TTCTGGTCAT GTGTATTGTA 1260 CAAGCTAGAG AGCTGAATTT CTGAGATACA CATTTTCAAA TCACATGCAA GTGAAGATGA 1320 TGGTCTGTAG AAATTTTCAG TATATATAAT GTTTAATGAC ATACTAATTT ATCATCTGGC 1380 TATTTGGGAA GGAAGGACAC ACATGGATTT TGCACATTTC CACCATGGTG GCTGGTGTGG 1440 CTTGTGGCTA TGGGGTGATC ACCAGTATCA CCACTTTGGA AGGGGACAGT GAAATTGGGG 1500 CTAGAGAAGG AACTTTGTAC AGTTTTCCCT GAGATTCAGA TTGACTGAAA AGTCACATGA 1560 AGAGTTGATT GTCTTTTAAT GGTATGTTTT AAACAGCTGA CATTTTAAAT TTTGATGAAA 1620 TCCAGTTTAT TCGTTTGTTC TTTTATGCTT TGGGTGTTGC ATCCGAGAAA TCTTTTCCCA 1680 TCCCAAGATC ACAATTTTTT TTCCTTTTTA CTTCTAGAAG TGTTATAATT TTAAGCTTTA 1740 TACTTTGGTC TATGACCCGT TTTTTTTTTT GTTTTGTTTT GTTTTTTCGT TTGTTTCTTT 1800 GTTTTGAGAT GGAGTCTTGT TCTGTCACCC AGGCTGGGGT GCAGTGGCGT GATCTTGGCT 1860 CACTGCAATC TCTATCCCCT GGGTTCAAGT GATTCTCTTG TCTCAGCCTC CCAAGTAGCT 1920 GGGATTACAG GCACAGGCCG CCACGCCTGG CTAATTTTTG TATTTTTAGT AGAGACAGAG 1980

Seq ID NO : 165 DNA sequence Nucleic Acid Accession # : AF256215 Coding sequence: 220-2028 1 11 21 31 41 51 CTCCAGTCCG CATGCTCAGT AGCTGCTGCC GGCCGGGCTG CGGGGCGGCG TCCGCTGCGC 60 GCCTACGGGC TGCGGTGGCG GCCGCCGCGG CACCCGGCAG GGCCCGCCAG TCCCCGCTTC 120 CCTGCTCCAG AGCCGCCGCC TGGGCCGGGG CAGGGCGGGC CCGGGGCTCC TCCATGCTGC 180 CAGCCGCCGG GCTGCGGAGC CGACCAAGTG GCTCCTGCGA TGGCGGCGGA AGAGGAGGCT 240 GCGGCGGGAG GTAAAGTGTT GAGAGAGGAG AACCAGTGCA TTGCTCCTGT GGTTTCCAGC 300 CGCGTGAGTC CAGGGACAAG ACCAACAGCT ATGGGGTCTT TCAGCTCACA CATGACAGAG 360 TTTCCACGAA AACGCAAAGG AAGTGATTCA GACCCATCCC AAGTGGAAGA TGGTGAACAC 420 CAAGTTAAAA TGAAGGCCTT CAGAGAAGCT CATAGCCAAA CTGAAAAGCG GAGGAGAGAT 480 AAAATGAATA ACCTGATTGA AGAACTGTCT GCAATGATCC CTCAGTGCAA CCCCATGGCG 540 CGTAAACTGG ACAAACTTAC AGTTTTAAGA ATGGCTGTTC AACACTTGAG ATCTTTAAAA 600 GGCTTGACAA ATTCTTATGT GGGAAGTAAT TATAGACCAT CATTTCTTCA GGATAATGAG 660 CTCAGACATT TAATCCTTAA GACTGCAGAA GGCTTCTTAT TTGTGGTTGG ATGTGAAAGA 720 GGAAAAATTC TCTTCGTTTC TAAGTCAGTC TCCAAAATAC TTAATTATGA TCAGGCTAGT 780 TTGACTGGAC AAAGCTTATT TGACTTCTTA CATCCAAAAG ATGTTGCCAA AGTAAAGGAA 840 CAACTTTCTT CTTTTGATAT TTCACCAAGA GAAAAGCTAA TAGATGCCAA AACTGGTTTG 900 CAAGTTCACA GTAATCTCCA CGCTGGAAGG ACACGTGTGT ATTCTGGCTC AAGACGATCT 960 TTTTTCTGTC GGATAAAGAG TTGTAAAATC TCTGTCAAAG AAGAGCATGG ATGCTTACCC 1020 AACTCAAAGA AGAAAGAGCA CAGAAAATTC TATACTATCC ATTGCACTGG TTACTTGAGA 1080 AGCTGGCCTC CAAATATTGT TGGAATGGAA GAAGAAAGGA ACAGTAAGAA AGACAACAGT 1140 AATTTTACCT GCCTTGTGGC CATTGGAAGA TTACAGCCAT ATATTGTTCC ACAGAACAGT 1200 GGAGAGATTA ATGTGAAACC AACTGAATTT ATAACCCGGT TTGCAGTGAA TGGAAAATTT 1260 GTCTATGTAG ATCAAAGGGC AACAGCGATT TTAGGATATC TGCCTCAGGA ACTTTTGGGA 1320 ACTTCTTGTT ATGAATATTT TCATCAAGAT GACCACAATA ATTTGACTGA CAAGCACAAA 1380 GCAGTTCTAC AGAGTAAGGA GAAAATACTT ACAGATTCCT ACAAATTCAG AGCAAAAGAT 1440 GGCTCTTTTG TAACTTTAAA AAGCCAATGG TTTAGTTTCA CAAATCCTTG GACAAAAGAA 1500 CTGGAATATA TTGTATCTGT CAACACTTTA GTTTTGGGAC ATAGTGAGCC TGGAGAAGCA 1560 TCATTTTTAC CTTGTAGCTC TCAATCATCA GAAGAATCCT CTAGACAGTC CTGTATGAGT 1620 GTACCTGGAA TGTCTACTGG AACAGTACTT GGTGCTGGTA GTATTGGAAC AGATATTGCA 1680 AATGAAATTC TGGATTTACA GAGGTTACAG TCTTCTTCAT ACCTTGATGA TTCGAGTCCA 1740 ACAGGTTTAA TGAAAGATAC TCATACTGTA AACTGCAGGA GTATGTCAAA TAAGGAGTTG 1800 TTTCCACCAA GTCCTTCTGA AATGGGGGAG CTAGAGGCTA CCAGGCAAAA CCAGAGTACT 1860 GTTGCTGTCC ACAGCCATGA GCCACTCCTC AGTGATGGTG CACAGTTGGA TTTCGATGCC 1920 CTATGTGACA ATGATGACAC AGCCATGGCT GCATTTATGA ATTACTTAGA AGCAGAGGGG 1980 GGCCTGGGAG ACCCTGGGGA CTTCAGTGAC ATCCAGTGGA CCCTCTAGCC TTTGATTTTT 2040 AACTCCAAAA ATGAGAAACA TTTTAAAGCA TTATTTACGA AAAAACTGTC TCAACTATTC 2100 TTAAGTACTG TATTGATATT GTTTGTATCT TTTATTAATG TTCTACCACT TTTTATAGAT 2160 TTGCATCTTC CTGTCACAGG GATGTGGGGA AATACGTTTT CCTCCCAAGA GAACCAAGTT 2220 TATTATAGAC TCCTTTATTC AGTGAAATGG CTTATAATCC ACTAGTTGCC ATATTTTTGC 2280 TAAAATATTT CTAACCAAGA ATACTACTTA CATATTGTTT TGGCTTTGTT TTATTTTTGA 2340 TGCAGTTTTT TTTAGTTGAG GTAATGTAAT ATATTGATGT TTTCCTTTGT GTCTAAGATT 2400 GATTTATAAT AGTAGGTTTG TATAATTTGG AACATTTTCC ATGCCTTGCG AATTTCCTTA 2460 ATTGAGGATA GGGCTTACAC ACTTTAAGAA AACAGTGAGT ACTTGAACAT TTAAAGGGAC 2520 AGTGCAATTT ATAGTCATAA TCACATTGAA TACTGTATTT GATCTTTGGA GACTTAGGCA 2580 AGCACAGAGC TGGGATATTT ATGCTCAGTT GAGCACTTTA AGATGAATTT TAAGTGAGAT 2640 GATTTCTTGC TTAAAACTCA GAAAGTCAAA AGAGTTTCAG CTTTCCTTAC AGAAAAGGAA 2700 GGATCTTGGG CCCTAGATCT TGGGGATTAA CCTCTGCATA TAAGATTTAC TCTTAATAGG 2760 CCAGACGTGG TGCTCACGCC TGTAATCCCA GTACTTTGGG AGGCTGAGAC GGGCAGATCA 2820 CTTGAGGTCA GGAGTTCAAG ACCAGCCTGG CCAATATGGT GAAACCCCGT TTCTACTAAA 2880 AATACAAAAA AAATTACCCA GGCACTCACT CTTGAGGTAA CTAACCAACT CCCACGATAA 2940 TGACAGTCCA TTCATGAGCG CAAAGGCCTC ATGACCTAAT GGCACACACC TGTAATCCCA 3000 ACTGCTTGGG AGGCTGAGGC GAGAGGATTG CTTGAACCTG GGAGGCAGAG GTTGCAGTGA 3060 GCCGAGATCG CACCACTGCA CTCCAGTCTG GGCAACAGAG TGAGACTTCA TCTCAAAAAA 3120 AGTAAAAAAA AAGATTTAAT ATAATCACTG AAGATCTCTA TTATAGATAG ATTAGGTTTT 3180 TGACATTGGA AACATACTTA GGGATAGATT TGTCCTAAAG GAAAAAAGTA GGCCCGGGCA 3240 GATTAAATGT CTTGTGTAAA GTCACACATT AAATTCAGTC ACACATTAAA TTCATAGAGT 3300 TTTAAATGTT TAATGTATAT AAACCAGTTT CTTTATACAC ATTTGGGAAA ACATTGGTCT 3360 CACAGATTAA ATGATTAACT AACTGACCCA GGAACTAGTT GTAGCTTTCT AAGTAATTAG 3420 GCAATTACAG TTATTGCCTG TAACCAAAGG TAATAAAACA AAATGACAAG TACATGTTTA 3480 AAATTATGAG GCAATGAGAA ATAATTTAAA AACCAATTTT CTAGTTATAA TTTAAAATTT 3540 GGAGAGCATT TTTAACAGTA ATTAATCCAG AGGTGGCTCA AATTGAGTAT AAGAATTAAG 3600 ATTATTTAAA ATACTGCATG TCTACCTTCT CGGGGATCAT ACTTTATAAC ACTTTCTGCT 3660 TCAGTAGCTC TTCATAGCTT GCCAAGTATG CTCCCATATT TTCTCTCTCG TGCCTCGCAA 3720 ATGAAAGTCA GATAGGCTGG GAACTCATGG GGCAGCCCTC AGACTTCAAT GTGGGCTTCA 3780 AATCCAGTTT CCTGTTCTAT ATGGTGCTAC ATCTTTCCAG AAAATTTCCC TCAGAGCCCC 3840 TCGCCAAAAC AAAGCATTAT TTTGACCCTG CATGCTATTT CTTTAGCTGT AGGTGATAGA 3900 TTAGAACTTC TGTCAGACAT GTTAATGACA AACATACCAA CAGACAATAA CCAAAGCAAA 3960 TGTTTCCTTC AAGTGTGAAA TGTGCAGGGG CTCGTGGGCA AGGATGTATT GGCACACTGT 4020 CCTCTTGAAC TGATAGTGTC CCAGCAATGT TGGAGGTTGG CACCATTCCT GGTCCGACAC 4080 TTGAGGACCT GAGAGACATC AGGTTTAGAA TGAGCCAAAG AAATCCTACA AGATGGGGAG 4140 AATTGGTGTG CAGCAGCCTA AGTGTTATAG TTAAGTCTAA AGAAGTATGA AAGATCCCCT 4200 GTGTTCTCTA AATTGAGCAG AGGGGCCTGC CTACCAATAT CACTTTTTAG GGGACTGAAC 4260 CATTGCAGGT TAGACTTGGC TTCCAAAGAG TCTGCCTAAG CCAGGGGTGG CAGGGTAGGC 4320 CATCATAGCT GGATGGCCTC AAAAGCAGAT GGGGGCAGAC TTGCCCTCGT GATGCCAGGA 4380 TTTGAGAGGC AGAGTTTCTA GAGGGAGACC AGTGCTGCCT CTCACAGTGG CAGTTTTTTC 4440 TCTTTGCAAG AGGAGGGGCT GTTCAATTCC ATAGACCAGT GGGCAGATAG CCAGTTGAAT 4500 ACTCTGTGCA TGGTTTGATC CTTTATTAGT TCGCTCTAAT ATTTTTCTGT AGATCCTTTT 4560 GTCCTGGACT CAAAATCTAA TCCATGCATT GTATGATACC GTAGCTCTCC TAAGGTTTGT 4620 GTTTCCTTCA AAATGTTTTA GTTTTCTTCA ACTAAATTTG ATTTTTGCTG TTAGAAGTGA 4680 CATATTTTTA TGGTATACAC TATGTTCCTT TTTTCTACTG CGAGTCAATT TTTTGAATTT 4740 TCGTGAGAAA GAATATATCT ACAAATTGCA CGAAAGTATC ATAAAAACAG TACTCTAGAG 4800

CAGCGCTGTC CAATAGAAAT ATAATCTGAG CCACATGTAT AATTTTATTT TCTTCTAGCC 4860 ACATTAAAGA AGTAAAAAGA TACAAGTAGA ACTAATTTTA ATGTTTTAAT TCAGTATATC 4920 CAAAATATCA TTTGAACATG TAATTAATAT AAAATTATTA ATGTGATATT TTACATTCTT 4980 TTGGTAATAC TAGTCTTCAA AATCTGGTAT GTATCTTACA TTGATAGCAC ATCTCACTTT 5040 GTACTAGCCA CATTGCAAGT GCTCAGTAGC CACATGTGGC TAGTGGCTAC TGCACTGGAC 5100 AGCACAGTTC TAGGTTCCAC CCTAACACCC AAGTCCTGTG GATTAGAATC CCAGAATCAG 5160 AGCTGGAAGT AAACATAGAG ATCAAACCTC CTTTTAAAAA TGAGGACGCT GAGGCACAGA 5220 GTTTAAATGG CTTGCATGAG GTCATACAGC TAAATTCAGC CTCAACAGGG TCTTCTGATT 5280 CCAGGCACTC TTCCCACTCC ACTACATTAC TGTAGTGGTA ATTCTTAGGG TTAAAAAAAG 5340 TGTAGAGTAG GCCGGGCGCA GTGGCTCATG CCTGTAATCC CAGCACTTTG GGAGGCCGAA 5400 GTGGGCGGAT CACGAGGTCA GGAGATCGAG ACCATCCTGG CCAACATGGT GAAACCCCGT 5460 CTCTACTGAA AATACAAAGC AAAATTAGCC AGGTGTGGTG GCGGGCGCCT GTGGTCCCAG 5520 CTGCTCTGGA GGCTGAGGCA GAATGGCGTG AACCCAGGAG GCAGAGATGG CAGTGAGCCA 5580 AGATCGCGCC ACTGCACCCC AGCCTGGGCG ACAGAGCGAG ACTCCATCTC AAAAAAAAAA 5640 AAAAAAAAAA AAGAAAAGAA AAGAAAAGTC TAGAGAACAT TATATTAAGT GGTTATTATT 5700 GAAGTAGACC AAAGTTTATA CCATAAGGAT ATTTTTCCTT AAATACCATG TTTGAAGAAC 5760 AATTATTTAT TGATCCTTGA ATCTGTAAGA TCAAATAACA AGTCTCTATC CATGTTACCA 5820 AATTTAACCT TTTGAAAATA ATAAACTTTA AAATATCAGA TGTGTTATTA CAGGATGATA 5880 CTTGGAATCA AGTGAAATGA GTTATATGGT CATCACTAAA TTTAGAAATC TATTGTGAAA 5940 CAAAGACAAA CAGGAAAGTA CAGAATAGAG ACTTTTAGTA AATAAATGGA ATTTAAAAGA 6000 AAGTGTTTAT TTACAGTGTC ACGACAGAAA AGGATGTCTT TGTTGTCATA GTCTTTGAGG 6060 GATCTCCGTA AAATCTGGGG CACAGGTACA AGAAATAGCC AATATTTAGT TCCCAGACCA 6120 TGTTTAGTAG TGTCCAGTTT CAGATCATGC TGCCAAGAGG TATCTCCCCC TCAGGTGGGT 6180 CATCACTGAG CCCTGGAATT GGAGACTCAT ACTTGCCCAG CACAATGTTA CGGGCAGACA 6240 GGCCGACATC TATGATTAGC TAGAAGCCAT AAAGAAAAGC TGCTAAGTGG CCACTAGGTG 6300 CCACTTTTCT GTTTTTGTAA TGCTTTCATT AGCAGATCTT TTTTTTCCAA GCTCCATGGG 6360 GCCTATGAGA GGCATTTATG ATTTTTGTGC CTACAATAAG TCAGCCTGTC TGGTGTGAGT 6420 TGTTTTATGA GAAATGCTTT CCAAGGGAGG TCTAGGAAGA TCCTGACACA TAAGAACTTT 6480 GGCTTAGAGA GCTTTCCAGG TGTAGTGCCA ATAAAAACTG ACCTGGAAAG AAAACCTGCC 6540 CAGCACGGAA CATGCTTTCT GAACTCACTT GAGAGTGTAT GGTGTATGTC ACTTCTCATA 6600 TATTCTTGAG TTTAGATTTG TCTTTTATAC AATTTTTAGC TCTTTTCCAG TTCACTTGTG 6660 CTCGTCTGTA TATTGGTATT TTTAAATTTT TGTGGTAAAT AATGAAAAGA GTGAAATTAT 6720 ATTTTATAAT TACTCATTTG TAGTTTTTTT. TTTTAATTTA ATAAACTTCC TCCAAAAAGT 6780 GCTCCCTTAA AA Seq ID NO : 166 Protein sequence: Protein Accession # : AAG34652 1 11 21 31 41 51 MAAEEEAAAG GKVLREENQC IAPWSSRVS PGTRPTAMGS FSSHMTEFPR KRKGSDSDPS 60 QVEDGEHQVK MKAFREAHSQ TEKRRRDKMN NLIEELSAMI PQCNPMARKL DKLTVLRMAV 120 QHLRSLKGLT NSYVGSNYRP SFLQDNELRH LILKTAEGFL FWGCERGKI LFVSKSVSKI 180 LNYDQASLTG QSLFDFLHPK DVAKVKEQLS SFDISPREKL IDAKTGLQVH SNLHAGRTRV 240 YSGSRRSFFC RIKSCKISVK EEHGCLPNSK KKEHRKFYTI HCTGYLRSWP PNIVGMEEER 300 NSKKDNSNFT CLVAIGRLQP YIVPQNSGEI NVKPTEFITR FAVNGKFVYV DQRATAILGY 360 LPQELLGTSC YEYFHQDDHN NLTDKHKAVL QSKEKILTDS YKFRAKDGSF VTLKSQWFSF 420 TNPWTKELEY IVSVNTLVLG HSEPGEASFL PCSSQSSEES SRQSCMSVPG MSTGTVLGAG 480 SIGTDIANEI LDLQRLQSSS YLDDSSPTGL MKDTHTVNCR SMSNKELFPP SPSEMGELEA 540 TRQNQSTVAV HSHEPLLSDG AQLDFDALCD NDDTAMAAFM NYLEAEGGLG DPGDFSDIQW 600 TL Seq ID NO: 167 DNA sequence Nucleic Acid Accession &num : NM 014400 Coding sequence : 86-1126 1 11 21 31 41 51 GGTTACTCAT CCTGGGCTCA GGTAAGAGGG CCCGAGCTCG GAGGCGGCAC ACCCAGGGGG 60 GACGCCAAGG GAGCAGGACG GAGCCATGGA CCCCGCCAGG AAAGCAGGTG CCCAGGCCAT 120 GATCTGGACT GCAGGCTGGC TGCTGCTGCT GCTGCTTCGC GGAGGAGCGC AGGCCCTGGA 180 GTGCTACAGC TGCGTGCAGA AAGCAGATGA CGGATGCTCC CCGAACAAGA TGAAGACAGT 240 GAAGTGCGCG CCGGGCGTGG ACGTCTGCAC CGAGGCCGTG GGGGCGGTGG AGACCATCCA 300 CGGACAATTC TCGCTGGCAG TGCSGGGTTG CGGTTCGGGA CTCCCCGGCA AGAATGACCG 360 CGGCCTGGAT CTTCACGGGC TTCTGGCGTT CATCCAGCTG CAGCAATGCG CTCAGGATCG 420 CTGCAACGCC AAGCTCAACC TCACCTCGCG GGCGCTCGAC CCGGCAGGTA ATGAGAGTGC 480 ATACCCGCCC AACGGCGTGG AGTGCTACAG CTGTGTGGGC CTGAGCCGGG AGGCGTGCCA 540 GGGTACATCG CCGCCGGTCG TGAGCTGCTA CAACGCCAGC GATCATGTCT ACAAGGGCTG 600 CTTCGACGGC AACGTCACCT TGACGGCAGC TAATGTGACT GTGTCCTTGC CTGTCCGGGG 660 CTGTGTCCAG GATGAATTCT GCACTCGGGA TGGAGTAACA GGCCCAGGGT TCACGCTCAG 720 TGGCTCCTGT TGCCAGGGGT CCCGCTGTAA CTCTGACCTC CGCAACAAGA CCTACTTCTC 780 CCCTCGAATC CCACCCCTTG TCCGGCTGCC CCCTCCAGAG CCCACGACTG TGGCCTCAAC 840 CACATCTGTC ACCACTTCTA CCTCGGCCCC AGTGAGACCC ACATCCACCA CCAAACCCAT 900 GCCAGCGCCA ACCAGTCAGA CTCCGAGACA GGGAGTAGAA CACGAGGCCT CCCGGGATGA 960 GGAGCCCAGG TTGACTGGAG GCGCCGCTGG CCACCAGGAC CGCAGCAATT CAGGGCAGTA 1020 TCCTGCAAAA GGGGGGCCCC AGCAGCCCCA TAATAAAGGC TGTGTGGCTC CCACAGCTGG 1080 ATTGGCAGCC CTTCTGTTGG CCGTGGCTGC TGGTGTCCTA CTGTGAGCTT CTCCACCTGG 1140 AAATTTCCCT CTCACCTACT TCTCTGGCCC TGGGTACCCC TCTTCTCATC ACTTCCTGTT 1200 CCCACCACTG GACTGGGCTG GCCCAGCCCC TGTTTTTCCA ACATTCCCCA GTATCCCCAG 1260 CTTCTGCTGC GCTGGTTTGC GGCTTTGGGA AATAAAATAC CGTTGTATAT ATTCTGGCAG 1320 GGGTGTTCTA GCTTTTTGAG GACAGCTCCT GTATCCTTCT CATCCTTGTC TCTCCGCTTG 1380 TCCTCTTGTG ATGTTAGGAC AGAGTGAGAG AAGTCAGCTG TCACGGGGAA GGTGAGAGAG 1440 AGGATGCTAA GCTTCCTACT CACTTTCTCC TAGCCAGCCT GGACTTTGGA GCGTGGGGTG 1500 GGTGGGACAA TGGCTCCCCA CTCTAAGCAC TGCCTCCCCT ACTCCCCGCA TCTTTGGGGA 1560 ATCGGTTCCC CATATGTCTT CCTTACTAGA CTGTGAGCTC CTCGAGGGCA GGGACCGTGC 1620 CTTATGTCTG TGTGTGATCA GTTTCTGGCA CATAAATGCC TCAATAAAGA TTTAATTACT 1680

GCAGGCATAC CACAGCAAGG TGTCCTGCTT CATGCTGCAG CAGATCGAGG AGCCGTGCTC 780 GCTGGGGGTC CACGCAGCCG TGGTCATCCC GCCCACCTGG ATCCTCCGCG CCCGGAGGCC 840 CCAGAATACT CTGAAAGCAA GCAAGAAGAA GAAGAGGGCA TCCTTCAAGA GGAAGTCCAG 900 CAAGAAAGGG CCTGAGGAGG GCCGCTGGAG ACCCTTCATC ATCAGGCCCA CCCCCTCCCC 960 GCTCATGAAG CCCCTGCTGG TGTTTGTGAA CCCCAAGAGT GGGGGCAACC AGGGTGCAAA 1020 GATCATCCAG TCTTTCCTCT GGTATCTCAA TCCCCGACAA GTCTTCGACC TGAGCCAGGG 1080 AGGGCCCAAG GAGGCGCTGG AGATGTACCG CAAAGTGCAC AACCTGCGGA TCCTGGCGTG 1140 CGGGGGCGAC GGCACGGTGG GCTGGATCCT CTCCACCCTG GACCAGCTAC GCCTGAAGCC 1200 GCCACCCCCT GTTGCCATCC TGCCCCTGGG TACTGGCAAC GACTTGGCCC GAACCCTCAA 1260 CTGGGGTGGG GGCTACACAG ATGAGCCTGT GTCCAAGATC CTCTCCCACG TGGAGGAGGG 1320 GAACGTGGTA CAGCTGGACC GCTGGGACCT CCACGCTGAG CCCAACCCCG AGGCAGGGCC 1380 TGAGGACCGA GATGAAGGCG CCACCGACCG GTTGCCCCTG GATGTCTTCA ACAACTACTT 1440 CAGCCTGGGC TTTGACGCCC ACGTCACCCT GGAGTTCCAC GAGTCTCGAG AGGCCAACCC 1500 AGAGAAATTC AACAGCCGCT TTCGGAATAA GATGTTCTAC GCCGGGACAG CTTTCTCTGA 1560 CTTCCTGATG GGCAGCTCCA AGGACCTGGC CAAGCACATC CGAGTGGTGT GTGATGGAAT 1620 GGACTTGACT CCCAAGATCC AGGACCTGAA ACCCCAGTGT GTTGTTTTCC TGAACATCCC 1680 CAGGTACTGT GCGGGCACCA TGCCCTGGGG CCACCCTGGG GAGCACCACG ACTTTGAGCC 1740 CCAGCGGCAT GACGACGGCT ACCTCGAGGT CATTGGCTTC ACCATGACGT CGTTGGCCGC 1800 GCTGCAGGTG GGCGGACACG GCGAGCGGCT GACGCAGTGT CGCGAGGTGG TGCTCACCAC 1860 ATCCAAGGCC ATCCCGGTGC AGGTGGATGG CGAGCCCTGC AAGCTTGCAG CCTCACGCAT 1920 CCGCATCGCC CTGCGCAACC AGGCCACCAT GGTGCAGAAG GCCAAGCGGC GGAGCGCCGC 1980 CCCCCTGCAC AGCGACCAGC AGCCGGTGCC AGAGCAGTTG CGCATCCAGG TGAGTCGCGT 2040 CAGCATGCAC GACTATGAGG CCCTGCACTA CGACAAGGAG CAGCTCAAGG AGGCCTCTGT 2100 GCCGCTGGGC ACTGTGGTGG TCCCAGGAGA CAGTGACCTA GAGCTCTGCC GTGCCCACAT 2160 TGAGAGACTC CAGCAGGAGC CCGATGGTGC TGGAGCCAAG TCCCCGACAT GCCAGAAACT 2220 GTCCCCCAAG TGGTGCTTCC TGGACGCCAC CACTGCCAGC CGCTTCTACA GGATCGACCG 2280 AGCCCAGGAG CACCTCAACT ATGTGACTGA GATCGCACAG GATGAGATTT ATATCCTGGA 2340 CCCTGAGCTG CTGGGGGCAT CGGCCCGGCC TGACCTCCCA ACCCCCACTT CCCCTCTCCC 2400 CACCTCACCC TGCTCACCCA CGCCCCGGTC ACTGCAAGGG GATGCTGCAC CCCCTCAAGG 2460 TGAAGAGCTG ATTGAGGCTG CCAAGAGGAA CGACTTCTGT AAGCTCCAGG AGCTGCACCG 2520 AGCTGGGGGC GACCTCATGC ACCGAGACGA GCAGAGTCGC ACGCTCCTGC ACCACGCAGT 2580 CAGCACTGGC AGCAAGGATG TGGTCCGCTA CCTGCTGGAC CACGCCCCCC CAGAGATCCT 2640 TGATGCGGTG GAGGAAAACG GGGAGACCTG TTTGCACCAA GCAGCGGCCC TGGGCCAGCG 2700 CACCATCTGC CACTACATCG TGGAGGCCGG GGCCTCGCTC ATGAAGACAG ACCAGCAGGG 2760 CGACACTCCC CGGCAGCGGG CTGAGAAGGC TCAGGACACC GAGCTGGCCG CCTACCTGGA 2820 GAACCGGCAG CACTACCAGA TGATCCAGCG GGAGGACCAG GAGACGGCTG TGTAGCGGGC 2880 Seq ID NO : 172 Protein sequence: Protein Accession # : NP 003637 1 11 21 31 41 51 MEPRDGSPEA RSSDSESASA SSSGSERDAG PEPDKAPRRL NKRRFPGLRL FGHRKAITKS 60 GLQHLAPPPP TPGAPCSESE RQIRSTVDWS ESATYGEHIW FETNVSGDFC YVGEQYCVAR 120 MLKSVSRRKC AACKIVVHTP CIEQLEKINF RCKPSFRESG SRNVREPTFV RHHWVHRRRQ 180 DGKCRHCGKG FQQKFTFHSK EIVAISCSWC KQAYHSKVSC FMLQQIEEPC SLGVHAAWI 240 PPTWILRARR PQNTLKASKK KKRASFKRKS SKKGPEEGRW RPFIIRPTPS PLMKPLLVFV 300 NPKSGGNQGA KIIQSFLWYL NPRQVFDLSQ GGPKEALEMY RKVHNLRILA CGGDGTVGWI 360 LSTLDQLRLK PPPPVAILPL GTGNDLARTL NWGGGYTDEP VSKILSHVEE GNWQLDRWD 420 LHAEPNPEAG PEDRDEGATD RLPLDVFNNY FSLGFDAHVT LEFHESREAN PEKFNSRFRN 480 KMFYAGTAFS DFLMGSSKDL AKHIRWCDG MDLTPKIQDL KPQCWFLNI PRYCAGTMPW 540 GHPGEHHDFE PQRHDDGYLE VIGFTMTSLA ALQVGGHGER LTQCREWLT TSKAIPVQVD 600 GEPCKLAASR IRIALRNQAT MVQKAKRRSA APLHSDQQPV PEQLRIQVSR VSMHDYEALH 660 YDKEQLKEAS VPLGTVVVPG DSDLELCRAH IERLQQEPDG AGAKSPTCQK LSPKWCFLDA 720 TTASRFYRID RAQEHLNYVT EIAQDEIYIL DPELLGASAR PDLPTPTSPL PTSPCSPTPR 780 SLQGDAAPPQ GEELIEAAKR NDFCKLQELH RAGGDLMHRD EQSRTLLHHA VSTGSKDWR 840 YLLDHAPPEI LDAVEENGET CLHQAAALGQ RTICHYIVEA GASLMKTDQQ GDTPRQRAEK 900 AQDTELAAYL ENRQHYQMIQ REDQETAV Seq ID NO : 173 DNA sequence Nucleic Acid Accession &num : AF232772 Coding sequence : 1-1662 1 11 21 31 41 51 ATGCCGGTGC AGCTGACGAC AGCCCTGCGT GTGGTGGGCA CCAGCCTGTT TGCCCTGGCA 60 GTGCTGGGTG GCATCCTGGC AGCCTATGTG ACGGGCTACC AGTTCATCCA CACGGAAAAG 120 CACTACCTGT CCTTCGGCCT GTACGGCGCC ATCCTGGGCC TGCACCTGCT CATTCAGAGC 180 CTTTTTGCCT TCCTGGAGCA CCGGCGCATG CGACGTGCCG GCCAGGCCCT GAAGCTGCCC 240 TCCCCGCGGC GGGGCTCGGT GGCACTGTGC ATTGCCGCAT ACCAGGAGGA CCCTGACTAC 300 TTGCGCAAGT GCCTGCGCTC GGCCCAGCGC ATCTCCTTCC CTGACCTCAA GGTGGTCATG 360 GTGGTGGATG GCAACCGCCA GGAGGACGCC TACATGCTGG ACATCTTCCA CGAGGTGCTG 420 GGCGGCACCG AGCAGGCCGG CTTCTTTGTG TGGCGCAGCA ACTTCCATGA GGCAGGCGAG 480 GGTGAGACGG AGGCCAGCCT GCAGGAGGGC ATGGACCGTG TGCGGGATGT GGTGCGGGCC 540 AGCACCTTCT CGTGCATCAT GCAGAAGTGG GGAGGCAAGC GCGAGGTCAT GTACACGGCC 600 TTCAAGGCCC TCGGCGATTC GGTGGACTAC ATCCAGGTGT GCGACTCTGA CACTGTGCTG 660 GATCCAGCCT GCACCATCGA GATGCTTCGA GTCCTGGAGG AGGATCCCCA AGTAGGGGGA 720 GTCGGGGGAG ATGTCCAGAT CCTCAACAAG TACGACTCAT GGATTTCCTT CCTGAGCAGC 780 GTGCGGTACT GGATGGCCTT CAACGTGGAG CGGGCCTGCC AGTCCTACTT TGGCTGTGTG 840 CAGTGTATTA GTGGGCCCTT GGGCATGTAC CGCAACAGCC TCCTCCAGCA GTTCCTGGAG 900 GACTGGTACC ATCAGAAGTT CCTAGGCAGC AAGTGCAGCT TCGGGGATGA CCGGCACCTC 960 ACCAACCGAG TCCTGAGCCT TGGCTACCGA ACTAAGTATA CCGCGCGCTC CAAGTGCCTC 1020 ACAGAGACCC CCACTAAGTA CCTCCGGTGG CTCAACCAGC AAACCCGCTG GAGCAAGTCT 1080 TACTTCCGGG AGTGGCTCTA CAACTCTCTG TGGTTCCATA AGCACCACCT CTGGATGACC 1140 TACGAGTCAG TGGTCACGGG TTTCTTCCCC TTCTTCCTCA TTGCCACGGT TATACAGCTT 1200 TTCTACCGGG GCCGCATCTG GAACATTCTC CTCTTCCTGC TGACGGTGCA GCTGGTGGGC 1260 ATTATCAAGG CCACCTACGC CTGCTTCCTT CGGGGCAATG CAGAGATGAT CTTCATGTCC 1320

CTCTACTCCC TCCTCTATAT GTCCAGCCTT CTGCCGGCCA AGATCTTTGC CATTGCTACC 1380 ATCAACAAAT CTGGCTGGGG CACCTCTGGC CGAAAAACCA TTGTGGTGAA CTTCATTGGC 1440 CTCATTCCTG TGTCCATCTG GGTGGCAGTT CTCCTGGAGG GGCTGGCCTA CACAGCTTAT 1500 TGCCAGGACC TGTTCAGTGA GACAGAGCTA GCCTTCCTTG. TCTCTGGGGC TATACTGTAT 1560 GGCTGCTACT GGGTGGCCCT CCTCATGCTA TATCTGGCCA TCATCGCCCG GCGATGTGGG 1620 AAGAAGCCGG AGCAGTACAG CTTGGCTTTT GCTGAGGTGT GACATGGCCC CCAAGCAGAG 1680 CGGGTAAAGT GCAATGGGTA AGGGAGGGAA GGGGAATGGA AGAGAAAAGA CAGGGTGGGA 1740 GGGAGGAGGG AGTGCTGTGT TTTAGTCTCT TAATGGTCCA AAGGACAAAT CTAAAATGCA 1800 AAGAACGGTG ATGTAGTATG GCCTGACAGC TCTGTTTAGA GGAGGCAACA CTGATCCCCC 1860 AGATGCAGGG CTGCAGGGGA TTCTGTGTTT TCAGACTGCC TGTCTGCTTG CATCTGCACA 1920 TAGGCAGTAG CCTCCTCCTG GGCTCCAGAG GGCACTCAGA AGTTGTGCTA AACCAAGTTA 1980 AGTCCCATTC AGTGGCAACT TGTGATAGGT ACCTGAGTGA CGGCAACCTG CGGAAGGAGG 2040 TTCTCCCAGC CCATCTGAAC ACAACCAGAG GTGGCAGGAG AATTTCTACT GAGCGAGGTG 2100 GGCCGGTTAG TGTATGTCAC CCCCACCCCA CCCATAAGTA GTCATCAATG CAATAAGATT 2160 GCGCGTGAGA TACAAGGCCC AGAAGCCTGA TCTTTGGGCA TCAGAAAACA GGGTCCAGGA 2220 ATGGTGCTTT ATGTGAGATA CCCCACTCCA CATCAACATT CCAGGGATGA GCCAAACCAG 2280 CAGGGAGTTA GCACTGAACT GCTTTTAAAA GTGCACATTA AAAAGGAAAG TTTGCCAGGA 2340 GGAACAAAGA GATTGTGGTG GTGCTAAAGG AGGCCATAAG CTACACAGAG GCCTTGGGTG 2400 TTCCACCTGG AAACTGCTCA GACGTCTAGA TGGGTTCTTA GCTTGTCTGT GATCTCTGCT 2460 GGGGAGATAA AAAGATTAAG CCCCAACATG TTCAGAAAAG AAGTGAAGTC TTGGGTATTT 2520 TAACCTGTAT ACTCTTGAAT TCCTCTCAAA TTCAGCTCTG ATCTGAGGCT AAGACACACT 2580 CCCCACTTCA CTTTCTTCAA AGCCACATTT TTTGAGGTAT CACTGCAGTC ACCTCTTCTA 2640 CCCTCATCAT CATAGGTAAG GTTTTCAAGG TGGCAATTGG GGCGGAGCCC CGGCTTCTTA 2700 TAGAAGCTTC AGCAGGAGGC AAGCGTGTTC TCAGCACATA TGGGAACTAT GAGGAGCCTC 2760 TGATCAAATT GGCTACAATC TTGGAGCTGC TTGGACGGAT TCCTTGGCAG CCGGGTTAGC 2820 ATGTGTGACT TTCAGGCTAC TGTTCTTGAC AATCATCTCC AATGGAAAGC TTTTCAGTGT 2880 TCCCAAAGTG AACTCTCAAA TCCAAAATGG TTATCTTTGA GACCATCCAT TCTCCTCAGT 2940 GGCTTCTCCA GGGAATTCTT ACAGCCAAGT TGTGACAGTC ACTGCATTTG CCTGCTTCTT 3000 TCCAGAAACC AAACTAGGAG ATGAAACTGG TTCCTACATC CTAAGGTTCT TGCTTTCTCT 3060 CTCATGCCTC CTGAGGCTGT TTTTGGCTGT TTTCCCTCTG CTGCTTTTGG GGAATGAGGG 3120 GAAGCCATTT TCCAAGTGAC TTGCAATCCA GGCTGTTCTC AGCGTTTTGA GTTTAAAACC 3180 TGGGATCCTG ACTAAGCCTT TGACTTAAGG GTTGCTTGCT TGCCCTCCAA ATGTCCTTTC 3240 TCAAAGGGGC CAACTAACCC GTGCAGAACC AGCACTAAGG TGGACAGCAG ACAAGAGGGC 3300 AAGCCTCTAA TGTACCAAGT GCTTCCTACA AAGACGCAAG GTGTGCTCCG AACCACAGAT 3360 GGGCAAACCC TGGTGCTTTC CTTCATCTCC CACGAACTCA AGGGTTTTCC AAGTGTAGCT 3420 AACAGTTGCC ACATCACACA GACCTCCAGT TTCTGGTAAG ACTGCTGGTT GACATCAGAC 3480 CCAACCCATT GAAGGCTGGA AGGCAGCAGG CATTTGCTAA GGCAGCTGAT CCAGGCAATC 3540 GTTCTGCTGG CCAAGAAGTT AAACTATTTT GAGCATTAGA ATGGAGGAAA TCCGGTCAGC 3600 CAAGTGCAGA GTTCAGACTT CGCTAAGGGC TTGTTTTTCT TCAGCATTTA CTTGAAGATT 3660 AATGTAGGAT GACAGGCTCT CCTGGCTGTC CTACCATCAG CTCTGCCTTG CACTGTGGTC 3720 GTCAACTTTC CTCAAATCAA AAACAGGCAG GTACAGGTAG TGGGCTCACA ACGTTTGACC 3780 TCGACTGGTT TTTCTAAGTT ATTTTGTACA TTTTTCAGCA GCAAAACCAA ACTGGGTCTT 3840 CAGCTTTATC CCCGTTTCTT GCAAGGGAAG AGCCTTTATA CAATTGGACG CATTTTGGTT 3900 TTTCCTCATT GAGAATTCAA ATCCTCTTTT GTATTGTTTC TACAATAATT TGTAAACATA 3960 TTTATTTTTA CCTGCTTTTT TTTTTTTTTT TAATTTTCAG GTCAAGTTTT TTATACTGCA 4020 CTTATTTGTC AAAATAAAGA TTCTCACAT Seq ID NO: 174 Protein sequence: Protein Accession # : AAF36984 1 11 21 31 41 51 MPVQLTTALR WGTSLFALA VLGGILAAYV TGYQFIHTEK HYLSFGLYGA ILGLHLLIQS 60 LFAFLEHRRM RRAGQALKLP SPRRGSVALC IAAYQEDPDY LRKCLRSAQR ISFPDLKVVM 120 WDGNRQEDA YMLDIFHEVL GGTEQAGFFV WRSNFHEAGE GETEASLQEG MDRVRDWRA 180 STFSCIMQKW GGKREVMYTA FKALGDSVDY IQVCDSDTVL DPACTIEMLR VLEEDPQVGG 240 VGGDVQILNK YDSWISFLSS VRYWMAFNVE RACQSYFGCV QCISGPLGMY RNSLLQQFLE 300 DWYHQKFLGS KCSFGDDRHL TNRVLSLGYR TKYTARSKCL TETPTKYLRW LNQQTRWSKS 360 YFREWLYNSL WFHKHHLWMT YESWTGFFP FFLIATVIQL FYRGRIWNIL LFLLTVQLVG 420 IIKATYACFL RGNAEMIFMS LYSLLYMSSL LPAKIFAIAT INKSGWGTSG RKTIWNFIG 480 LIPVSIWVAV LLEGLAYTAY CQDLFSETEL AFLVSGAILY GCYWVALLML YLAIIARRCG 540 KKPEQYSLAF AEV Seq ID NO: 175 DNA sequence Nucleic Acid Accession # : NM 000691 Coding sequence: 43.. 1404 1 11 21 31 41 51 # # # # # # CCAGGAGCCC CAGTTACCGG GAGAGGCTGT GTCAAAGGCG CCATGAGCAA GATCAGCGAG 60 GCCGTGAAGC GCGCCCGCGC CGCCTTCAGC TCGGGCAGGA CCCGTCCGCT GCAGTTCCGA 120 TTCCAGCAGC TGGAGGCGCT GCAGCGCCTG ATCCAGGAGC AGGAGCAGGA GCTGGTGGGC 180 GCGCTGGCCG CAGACCTGCA CAAGAATGAA TGGAACGCCT ACTATGAGGA GGTGGTGTAC 240 GTCCTAGAGG AGATCGAGTA CATGATCCAG AAGCTCCCTG AGTGGGCCGC GGATGAGCCC 300 GTGGAGAAGA CGCCCCAGAC TCAGCAGGAC GAGCTCTACA TCCACTCGGA GCCACTGGGC 360 GTGGTCCTCG TCATTGGCAC CTGGAACTAC CCCTTCAACC TCACCATCCA GCCCATGGTG 420 GGCGCCATCG CTGCAGGGAA CGCAGTGGTC CTCAAGCCCT CGGAGCTGAG TGAGAACATG 480 GCGAGCCTGC TGGCTACCAT CATCCCCCAG TACCTGGACA AGGATCTGTA CCCAGTAATC 540 AATGGGGGTG TCCCTGAGAC CACGGAGCTG CTCAAGGAGA GGTTCGACCA TATCCTGTAC 600 ACGGGCAGCA CGGGGGTGGG GAAGATCATC ATGACGGCTG CTGCCAAGCA CCTGACCCCT 660 GTCACGCTGG AGCTGGGAGG GAAGAGTCCC TGCTACGTGG ACAAGAACTG TGACCTGGAC 720 GTGGCCTGCC GACGCATCGC CTGGGGGAAA TTCATGAACA GTGGCCAGAC CTGCGTGGCC 780 CCAGACTACA TCCTCTGTGA CCCCTCGATC CAGAACCAAA TTGTGGAGAA GCTCAAGAAG 840 TCACTGAAAG AGTTCTACGG GGAAGATGCT AAGAAATCCC GGGACTATGG AAGAATCATT 900 AGTGCCCGGC ACTTCCAGAG GGTGATGGGC CTGATTGAGG GCCAGAAGGT GGCTTATGGG 960 GGCACCGGGG ATGCCGCCAC TCGCTACATA GCCCCCACCA TCCTCACGGA CGTGGACCCC 1020

AACACATTCA TTCATAACAC TGGGAAAACA GTGGAAATTA ATCTCACTAA TGACTACCGT 480 GTCAGCGGAG GAGTTTCAGA AATGGTGTTT AAAGCAAGCA AGATAACTTT TCACTGGGGA 540 AAATGCAATA TGTCATCTGA TGGATCAGAG CATAGTTTAG AAGGACAAAA ATTTCCACTT 600 GAGATGCAAA TCTACTGCTT TGATGCGGAC CGATTTTCAA GTTTTGAGGA AGCAGTCAAA 660 GGAAAAGGGA AGTTAAGAGC TTTATCCATT TTGTTTGAGG TTGGGACAGA AGAAAATTTG 720 GATTTCAAAG CGATTATTGA TGGAGTCGAA AGTGTTAGTC GTTTTGGGAA GCAGGCTGCT 780 TTAGATCCAT TCATACTGTT GAACCTTCTG CCAAACTCAA CTGACAAGTA TTACATTTAC 840 AATGGCTCAT TGACATCTCC TCCCTGCACA GACACAGTTG ACTGGATTGT TTTTAAAGAT 900 ACAGTTAGCA TCTCTGAAAG CCAGTTGGCT GTTTTTTGTG AAGTTCTTAC AATGCAACAA 960 TCTGGTTATG TCATGCTGAT GGACTACTTA CAAAACAATT TTCGAGAGCA ACAGTACAAG 1020 TTCTCTAGAC AGGTGTTTTC CTCATACACT GGAAAGGAAG AGATTCATGA AGCAGTTTGT 1080 AGTTCAGAAC CAGAAAATGT TCAGGCTGAC CCAGAGAATT ATACCAGCCT TCTTGTTACA 1140 TGGGAAAGAC CTCGAGTCGT TTATGATACC ATGATTGAGA AGTTTGCAGT TTTGTACCAG 1200 CAGTTGGATG GAGAGGACCA AACCAAGCAT GAATTTTTGA CAGATGGCTA TCAAGACTTG 1260 GGTGCTATTC TCAATAATTT GCTACCCAAT ATGAGTTATG TTCTTCAGAT AGTAGCCATA 1320 TGCACTAATG GCTTATATGG AAAATACAGC GACCAACTGA TTGTCGACAT GCCTACTGAT 1380 AATCCTGAAC TTGATCTTTT CCCTGAATTA ATTGGAACTG AAGAAATAAT CAAGGAGGAG 1440 GAAGAGGGAA AAGACATTGA AGAAGGCGCT ATTGTGAATC CTGGTAGAGA CAGTGCTACA 1500 AACCAAATCA GGAAAAAGGA ACCCCAGATT TCTACCACAA CACACTACAA TCGCATAGGG 1560 ACGAAATACA ATGAAGCCAA GACTAACCGA TCCCCAACAA GAGGAAGTGA ATTCTCTGGA 1620 AAGGGTGATG TTCCCAATAC ATCTTTAAAT TCCACTTCCC AACCAGTCAC TAAATTAGCC 1680 ACAGAAAAAG ATATTTCCTT GACTTCTCAG ACTGTGACTG AACTGCCACC TCACACTGTG 1740 GAAGGTACTT CAGCCTCTTT AAATGATGGC TCTAAAACTG TTCTTAGATC TCCACATATG 1800 AACTTGTCGG GGACTGCAGA ATCCTTAAAT ACAGTTTCTA TAACAGAATA TGAGGAGGAG 1860 AGTTTATTGA CCAGTTTCAA GCTTGATACT GGAGCTGAAG ATTCTTCAGG CTCCAGTCCC 1920 GCAACTTCTG CTATCCCATT CATCTCTGAG AACATATCCC AAGGGTATAT ATTTTCCTCC 1980 GAAAACCCAG AGACAATAAC ATATGATGTC CTTATACCAG AATCTGCTAG AAATGCTTCC 2040 GAAGATTCAA CTTCATCAGG TTCAGAAGAA TCACTAAAGG ATCCTTCTAT GGAGGGAAAT 2100 GTGTGGTTTC CTAGCTCTAC AGACATAACA GCACAGCCCG ATGTTGGATC AGGCAGAGAG 2160 AGCTTTCTCC AGACTAATTA CACTGAGATA CGTGTTGATG AATCTGAGAA GACAACCAAG 2220 TCCTTTTCTG CAGGCCCAGT GATGTCACAG GGTCCCTCAG TTACAGATCT GGAAATGCCA 2280 CATTATTCTA CCTTTGCCTA CTTCCCAACT GAGGTAACAC CTCATGCTTT TACCCCATCC 2340 TCCAGACAAC AGGATTTGGT CTCCACGGTC AACGTGGTAT ACTCGCAGAC AACCCAACCG 2400 GTATACAATG GTGAGACACC TCTTCAACCT TCCTACAGTA GTGAAGTCTT TCCTCTAGTC 2460 ACCCCTTTGT TGCTTGACAA TCAGATCCTC AACACTACCC CTGCTGCTTC AAGTAGTGAT 2520 TCGGCCTTGC ATGCTACGCC TGTATTTCCC AGTGTCGATG TGTCATTTGA ATCCATCCTG 2580 TCTTCCTATG ATGGTGCACC TTTGCTTCCA TTTTCCTCTG CTTCCTTCAG TAGTGAATTG 2640 TTTCGCCATC TGCATACAGT TTCTCAAATC CTTCCACAAG TTACTTCAGC TACCGAGAGT 2700 GATAAGGTGC CCTTGCATGC TTCTCTGCCA GTGGCTGGGG GTGATTTGCT ATTAGAGCCC 2760 AGCCTTGCTC AGTATTCTGA TGTGCTGTCC ACTACTCATG CTGCTTCAGA GACGCTGGAA 2820 TTTGGTAGTG AATCTGGTGT TCTTTATAAA ACGCTTATGT TTTCTCAAGT TGAACCACCC 2880 AGCAGTGATG CCATGATGCA TGCACGTTCT TCAGGGCCTG AACCTTCTTA TGCCTTGTCT 2940 GATAATGAGG GCTCCCAACA CATCTTCACT GTTTCTTACA GTTCTGCAAT ACCTGTGCAT 3000 GATTCTGTGG GTGTAACTTA TCAGGGTTCC TTATTTAGCG GCCCTAGCCA TATACCAATA 3060 CCTAAGTCTT CGTTAATAAC CCCAACTGCA TCATTACTGC AGCCTACTCA TGCCCTCTCT 3120 GGTGATGGGG AATGGTCTGG AGCCTCTTCT GATAGTGAAT TTCTTTTACC TGACACAGAT 3180 GGGCTGACAG CCCTTAACAT TTCTTCACCT GTTTCTGTAG CTGAATTTAC ATATACAACA 3240 TCTGTGTTTG GTGATGATAA TAAGGCGCTT TCTAAAAGTG AAATAATATA TGGAAATGAG 3300 ACTGAACTGC AAATTCCTTC TTTCAATGAG ATGGTTTACC CTTCTGAAAG CACAGTCATG 3360 CCCAACATGT ATGATAATGT AAATAAGTTG AATGCGTCTT TACAAGAAAC CTCTGTTTCC 3420 ATTTCTAGCA CCAAGGGCAT GTTTCCAGGG TCCCTTGCTC ATACCACCAC TAAGGTTTTT 3480 GATCATGAGA TTAGTCAAGT TCCAGAAAAT AACTTTTCAG TTCAACCTAC ACATACTGTC 3540 TCTCAAGCAT CTGGTGACAC TTCGCTTAAA CCTGTGCTTA GTGCAAACTC AGAGCCAGCA 3600 TCCTCTGACC CTGCTTCTAG TGAAATGTTA TCTCCTTCAA CTCAGCTCTT ATTTTATGAG 3660 ACCTCAGCTT CTTTTAGTAC TGAAGTATTG CTACAACCTT CCTTTCAGGC TTCTGATGTT 3720 GACACCTTGC TTAAAACTGT TCTTCCAGCT GTGCCCAGTG ATCCAATATT GGTTGAAACC 3780 CCCAAAGTTG ATAAAATTAG TTCTACAATG TTGCATCTCA TTGTATCAAA TTCTGCTTCA 3840 AGTGAAAACA TGCTGCACTC TACATCTGTA CCAGTTTTTG ATGTGTCGCC TACTTCTCAT 3900 ATGCACTCTG CTTCACTTCA AGGTTTGACC ATTTCCTATG CAAGTGAGAA ATATGAACCA 3960 GTTTTGTTAA AAAGTGAAAG TTCCCACCAA GTGGTACCTT CTTTGTACAG TAATGATGAG 4020 TTGTTCCAAA CGGCCAATTT GGAGATTAAC CAGGCCCATC CCCCAAAAGG AAGGCATGTA 4080 TTTGCTACAC CTGTTTTATC AATTGATGAA CCATTAAATA CACTAATAAA TAAGCTTATA 4140 CATTCCGATG AAATTTTAAC CTCCACCAAA AGTTCTGTTA CTGGTAAGGT ATTTGCTGGT 4200 ATTCCAACAG TTGCTTCTGA TACATTTGTA TCTACTGATC ATTCTGTTCC TATAGGAAAT 4260 GGGCATGTTG CCATTACAGC TGTTTCTCCC CACAGAGATG GTTCTGTAAC CTCAACAAAG 4320 TTGCTGTTTC CTTCTAAGGC AACTTCTGAG CTGAGTCATA GTGCCAAATC TGATGCCGGT 4380 TTAGTGGGTG GTGGTGAAGA TGGTGACACT GATGATGATG GTGATGATGA TGATGATGAC 4440 AGAGGTAGTG ATGGCTTATC CATTCATAAG TGTATGTCAT GCTCATCCTA TAGAGAATCA 4500 CAGGAAAAGG TAATGAATGA TTCAGACACC CACGAAAACA GTCTTATGGA TCAGAATAAT 4560 CCAATCTCAT ACTCACTATC TGAGAATTCT GAAGAAGATA ATAGAGTCAC AAGTGTATCC 4620 TCAGACAGTC AAACTGGTAT GGACAGAAGT CCTGGTAAAT CACCATCAGC AAATGGGCTA 4680 TCCCAAAAGC ACAATGATGG AAAAGAGGAA AATGACATTC AGACTGGTAG TGCTCTGCTT 4740 CCTCTCAGCC CTGAATCTAA AGCATGGGCA GTTCTGACAA GTGATGAAGA AAGTGGATCA 4800 <BR> <BR> GGGCAAGGTA CCTCAGATAG CCTTAATGAG AATGAGACTT CCACAGATTT CAGTTTTGCA 4860 GACACTAATG AAAAAGATGC TGATGGGATC CTGGCAGCAG GTGACTCAGA AATAACTCCT 4920 GGATTCCCAC AGTCCCCAAC ATCATCTGTT ACTAGCGAGA ACTCAGAAGT GTTCCACGTT 4980 TCAGAGGCAG AGGCCAGTAA TAGTAGCCAT GAGTCTCGTA TTGGTCTAGC TGAGGGGTTG 5040 GAATCCGAGA AGAAGGCAGT TATACCCCTT GTGATCGTGT CAGCCCTGAC TTTTATCTGT 5100 CTAGTGGTTC TTGTGGGTAT TCTCATCTAC TGGAGGAAAT GCTTCCAGAC TGCACACTTT 5160 TACTTAGAGG ACAGTACATC CCCTAGAGTT ATATCCACAC CTCCAACACC TATCTTTCCA 5220 ATTTCAGATG ATGTCGGAGC AATTCCAATA AAGCACTTTC CAAAGCATGT TGCAGATTTA 5280 CATGCAAGTA GTGGGTTTAC TGAAGAATTT GAGACACTGA AAGAGTTTTA CCAGGAAGTG 5340 CAGAGCTGTA CTGTTGACTT AGGTATTACA GCAGACAGCT CCAACCACCC AGACAACAAG 5400 CACAAGAATC GATACATAAA TATCGTTGCC TATGATCATA GCAGGGTTAA GCTAGCACAG 5460 CTTGCTGAAA AGGATGGCAA ACTGACTGAT TATATCAATG CCAATTATGT TGATGGCTAC 5520 AACAGACCAA AAGCTTATAT TGCTGCCCAA GGCCCACTGA AATCCACAGC TGAAGATTTC 5580 TGGAGAATGA TATGGGAACA TAATGTGGAA GTTATTGTCA TGATAACAAA CCTCGTGGAG 5640

CACAAGAATC GATACATAAA TATCGTTGCC TATGATCATA GCAGGGTTAA GCTAGCACAG 2880 CTTGCTGAAA AGGATGGCAA ACTGACTGAT TATATCAATG CCAATTATGT TGATGGCTAC 2940 AACAGACCAA AAGCTTATAT TGCTGCCCAA GGCCCACTGA AATCCACAGC TGAAGATTTC 3000 TGGAGAATGA TATGGGAACA TAATGTGGAA GTTATTGTCA TGATAACAAA CCTCGTGGAG 3060 AAAGGAAGGA GAAAATGTGA TCAGTACTGG CCTGCCGATG GGAGTGAGGA GTACGGGAAC 3120 TTTCTGGTCA CTCAGAAGAG TGTGCAAGTG CTTGCCTATT ATACTGTGAG GAATTTTACT 3180 CTAAGAAACA CAAAAATAAA AAAGGGCTCC CAGAAAGGAA GACCCAGTGG ACGTGTGGTC 3240 ACACAGTATC ACTACACGCA GTGGCCTGAC ATGGGAGTAC CAGAGTACTC CCTGCCAGTG 3300 CTGACCTTTG TGAGAAAGGC AGCCTATGCC AAGCGCCATG CAGTGGGGCC TGTTGTCGTC 3360 CACTGCAGTG CTGGAGTTGG AAGAACAGGC ACATATATTG TGCTAGACAG TATGTTGCAG 3420 CAGATTCAAC ACGAAGGAAC TGTCAACATA TTTGGCTTCT TAAAACACAT CCGTTCACAA 3480 AGAAATTATT TGGTACAAAC TGAGGAGCAA TATGTCTTCA TTCATGATAC ACTGGTTGAG 3540 GCCATACTTA GTAAAGAAAC TGAGGTGCTG GACAGTCATA TTCATGCCTA TGTTAATGCA 3600 CTCCTCATTC CTGGACCAGC AGGCAAAACA AAGCTAGAGA AACAATTCCA GGGTCTCACT 3660 CTGTCACCCA GGCTGGAGTG CAGAGGCACA ATCTCGGCTC ACTGCAACCT TCCTCTCCCT 3720 GGCTTAACTG ATCCTCCTAC CTCAGCCTCC CGAGTGGCTG GGACTATACT CCTGAGCCAG 3780 TCAAATATAC AGCAGAGTGA CTATTCTGCA GCCCTAAAGC AATGCAACAG GGAAAAGAAT 3840 CGAACTTCTT CTATCATCCC TGTGGAAAGA TCAAGGGTTG GCATTTCATC CCTGAGTGGA 3900 GAAGGCACAG ACTACATCAA TGCCTCCTAT ATCATGGGCT ATTACCAGAG CAATGAATTC 3960 ATCATTACCC AGCACCCTCT CCTTCATACC ATCAAGGATT TCTGGAGGAT GATATGGGAC 4020 CATAATGCCC AACTGGTGGT TATGATTCCT GATGGCCAAA ACATGGCAGA AGATGAATTT 4080 GTTTACTGGC CAAATAAAGA TGAGCCTATA AATTGTGAGA GCTTTAAGGT CACTCTTATG 4140 GCTGAAGAAC ACAAATGTCT ATCTAATGAG GAAAAACTTA TAATTCAGGA CTTTATCTTA 4200 GAAGCTACAC AGGATGATTA TGTACTTGAA GTGAGGCACT TTCAGTGTCC TAAATGGCCA 4260 AATCCAGATA GCCCCATTAG TAAAACTTTT GAACTTATAA GTGTTATAAA AGAAGAAGCT 4320 GCCAATAGGG ATGGGCCTAT GATTGTTCAT GATGAGCATG GAGGAGTGAC GGCAGGAACT 4380 TTCTGTGCTC TGACAACCCT TATGCACCAA CTAGAAAAAG AAAATTCCGT GGATGTTTAC 4440 CAGGTAGCCA AGATGATCAA TCTGATGAGG CCAGGAGTCT TTGCTGACAT TGAGCAGTAT 4500 CAGTTTCTCT ACAAAGTGAT CCTCAGCCTT GTGGGCACAA GGCAGGAAGA GAATCCATCC 4560 ACCTCTCTGG ACAGTAATGG TGCAGCATTG CCTGATGGAA ATATAGCTGA GAGCTTAGAG 4620 TCTTTAGTTT AACACAGAAA GGGGTGGGGG GACTCACATC TGAGCATTGT TTTCCTCTTC 4680 CTAAAATTAG GCAGGAAAAT CAGTCTAGTT CTGTTATCTG TTGATTTCCC ATCACCTGAC 4740 AGTAACTTTC ATGACATAGG ATTCTGCCGC CAAATTTATA TCATTAACAA TGTGTGCCTT 4800 TTTGCAAGAC TTGTAATTTA CTTATTATGT TTGAACTAAA ATGATTGAAT TTTACAGTAT 4860 TTCTAAGAAT GGAATTGTGG TATTTTTTTC TGTATTGATT TTAACAGAAA ATTTCAATTT 4920 ATAGAGGTTA GGAATTCCAA ACTACAGAAA ATGTTTGTTT TTAGTGTCAA ATTTTTAGCT 4980 GTATTTGTAG CAATTATCAG GTTTGCTAGA AATATAACTT TTAATACAGT AGCCTGTAAA 5040 TAAAACACTC TTCCATATGA TATTCAACAT TTTACAACTG CAGTATTCAC CTAAAGTAGA 5100 AATAATCTGT TACTTATTGT AAATACTGCC CTAGTGTCTC CATGGACCAA ATTTATATTT 5160 ATAATTGTAG ATTTTTATAT TTTACTACTG AGTCAAGTTT TCTAGTTCTG TGTAATTGTT 5220 TAGTTTAATG ACGTAGTTCA TTAGCTGGTC TTACTCTACC AGTTTTCTGA CATTGTATTG 5280 TGTTACCTAA GTCATTAACT TTGTTTCAGC ATGTAATTTT AACTTTTGTG GAAAATAGAA 5340 ATACCTTCAT TTTGAAAGAA GTTTTTATGA GAATAACACC TTACCAAACA TTGTTCAAAT 5400 GGTTTTTATC CAAGGAATTG CAAAAATAAA TATAAATATT GCCATTAAAA AAAAAAAAAA 5460 AAAAAAAAAA AAAAAAAAAA A Seq ID NO: 188 Protein sequence: Protein Accession # : EOS sequence 1 11 21 31 41 51 MRILKRFLAC IQLLCVCRLD WANGYYRQQR KLVEEIGWSY TGALNQKNWG KKYPTCNSPK 60 QSPINIDEDL TQVNVNLKKL KFQGWDKTSL ENTFIHNTGK TVEINLTNDY RVSGGVSEMV 120 FKASKITFHW GKCNMSSDGS EHSLEGQKFP LEMQIYCFDA DRFSSFEEAV KGKGKLRALS 180 ILFEVGTEEN LDFKAIIDGV ESVSRFGKQA ALDPFILLNL LPNSTDKYYI YNGSLTSPPC 240 TDTVDWIVFK DTVSISESQL AVFCEVLTMQ QSGYVMLMDY LQNNFREQQY KFSRQVFSSY 300 TGKEEIHEAV CSSEPENVQA DPENYTSLLV TWERPRWYD TMIEKFAVLY QQLDGEDQTK 360 HEFLTDGYQD LGAILNNLLP NMSYVLQIVA ICTNGLYGKY SDQLIVDMPT DNPELDLFPE 420 LIGTEEIIKE EEEGKDIEEG AIVNPGRDSA TNQIRKKEPQ ISTTTHYNRI GTKYNEAKTN 480 RSPTRGSEFS GKGDVPNTSL NSTSQPVTKL ATEKDISLTS QTVTELPPHT VEGTSASLND 540 GSKTVLRSPH MNLSGTAESL NTVSITEYEE ESLLTSFKLD TGAEDSSGSS PATSAIPFIS 600 ENISQGYIFS SENPETITYD VLIPESARNA SEDSTSSGSE ESLKDPSMEG NVWFPSSTDI 660 TAQPDVGSGR ESFLQTNYTE IRVDESEKTT KSFSAGPVMS QGPSVTDLEM PHYSTFAYFP 720 TEVTPHAFTP SSRQQDLVST VNWYSQTTQ PVYNEASNSS HESRIGLAEG LESEKKAVIP 780 LVIVSALTFI CLWLVGILI YWRKCFQTAH FYLEDSTSPR VISTPPTPIF PISDDVGAIP 840 IKHFPKHVAD LHASSGFTEE FETLKEFYQE VQSCTVDLGI TADSSNHPDN KHKNRYINIV 900 AYDHSRVKLA QLAEKDGKLT DYINANYVDG YNRPKAYIAA QGPLKSTAED FWRMIWEHNV 960 . EVIVMITNLV EKGRRKCDQY WPADGSEEYG NFLVTQKSVQ VLAYYTVRNF TLRNTKIKKG 1020 SQKGRPSGRV VTQYHYTQWP DMGVPEYSLP VLTFVRKAAY AKRHAVGPW VHCSAGVGRT 1080 GTYIVLDSML QQIQHEGTVN IFGFLKHIRS QRNYLVQTEE QYVFIHDTLV EAILSKETEV 1140 LDSHIHAYVN ALLIPGPAGK TKLEKQFQGL TLSPRLECRG TISAHCNLPL PGLTDPPTSA 1200 SRVAGTILLS QSNIQQSDYS AALKQCNREK NRTSSIIPVE RSRVGISSLS GEGTDYINAS 1260 YIMGYYQSNE FIITQHPLLH TIKDFWRMIW DHNAQLWMI PDGQNMAEDE FVYWPNKDEP 1320 INCESFKVTL MAEEHKCLSN EEKLIIQDFI LEATQDDYVL EVRHFQCPKW PNPDSPISKT 1380 FELISVIKEE AANRDGPMIV HDEHGGVTAG TFCALTTLMH QLEKENSVDV YQVAKMINLM 1440 RPGVFADIEQ YQFLYKVILS LVGTRQEENP STSLDSNGAA LPDGNIAESL ESLV Seq ID NO : 189 DNA sequence Nucleic Acid Accession &num : NM 002820 Coding sequence: 304.. 831 1 11 21 31 41 51 1 1 1 1 1 1 CCGGTTCGCA AAGAAGCTGA CTTCAGAGGG GGAAACTTTC TTCTTTTAGG AGGCGGTTAG 60 CCCTGTTCCA CGAACCCAGG AGAACTGCTG GCCAGATTAA TTAGACATTG CTATGGGAGA 120 CGTGTAAACA CACTACTTAT CATTGATGCA TATATAAAAC CATTTTATTT TCGCTATTAT 180

TTCAGAGGAA GCGCCTCTGA TTTGTTTCTT TTTTCCCTTT TTGCTCTTTC TGGCTGTGTG 240 GTTTGGAGAA AGCACAGTTG GAGTAGCCGG TTGCTAAATA AGTCCCGAGC GCGAGCGGAG 300 ACGATGCAGC GGAGACTGGT TCAGCAGTGG AGCGTCGCGG TGTTCCTGCT GAGCTACGCG 360 GTGCCCTCCT GCGGGCGCTC GGTGGAGGGT CTCAGCCGCC GCCTCAAAAG AGCTGTGTCT 420 GAACATCAGC TCCTCCATGA CAAGGGGAAG TCCATCCAAG ATTTACGGCG ACGATTCTTC 480 CTTCACCATC TGATCGCAGA AATCCACACA GCTGAAATCA GAGCTACCTC GGAGGTGTCC 540 CCTAACTCCA AGCCCTCTCC CAACACAAAG AACCACCCCG TCCGATTTGG GTCTGATGAT 600 GAGGGCAGAT ACCTAACTCA GGAAACTAAC AAGGTGGAGA CGTACAAAGA GCAGCCGCTC 660 AAGACACCTG GGAAGAAAAA GAAAGGCAAG CCCGGGAAAC GCAAGGAGCA GGAAAAGAAA 720 AAACGGCGAA CTCGCTCTGC CTGGTTAGAC TCTGGAGTGA CTGGGAGTGG GCTAGAAGGG 780 GACCACCTGT CTGACACCTC CACAACGTCG CTGGAGCTCG ATTCACGGTA ACAGGCTTCT 840 CTGGCCCGTA GCCTCAGCGG GGTGCTCTCA GCTGGGTTTT GGAGCCTCCC TTCTGCCTTG 900 GCTTGGACAA ACCTAGAATT TTCTCCCTTT ATGTATCTCT ATCGATTGTG TAGCAATTGA 960 CAGAGAATAA CTCAGAATAT TGTCTGCCTT AAAGCAGTAC CCCCCTACCA CACACACCCC 1020 TGTCCTCCAG CACCATAGAG AGGCGCTAGA GCCCATTCCT CTTTCTCCAC CGTCACCCAA 1080 CATCAATCCT TTACCACTCT ACCAAATAAT TTCATATTCA AGCTTCAGAA GCTAGTGACC 1140 ATCTTCATAA TTTGCTGGAG AAGTGTATTT CTTCCCCTTA CTCTCACACC TGGGCAAACT 1200 TTCTTCAGTG TTTTTCATTT CTTACGTTCT TTCACTTCAA GGGAGAATAT AGAAGCATTT 1260 GATATTATCT ACAAACACTG CAGAACAGCA TCATGTCATA AACGATTCTG AGCCATTCAC 1320 ACTTTTTATT TAATTAAATG TATTTAATTA AATCTCAAAT TTATTTTAAT GTAAAGAACT 1380 TAAATTATGT TTTAAACACA TGCCTTAAAT TTGTTTAATT AAATTTAACT CTGGTTTCTA 1440 CCAGCTCATA CAAAATAAAT GGTTTCTGAA AATGTTTAAG TATTAACTTA CAAGGATATA 1500 GGTTTTTCTC ATGTATCTTT TTGTTCATTG GCAAGATGAA ATAATTTTTC TAGGGTAATG 1560 CCGTAGGAAA AATAAAACTT CACATTTAAA AAAAA Seq ID NO: 190 Protein sequence: Protein Accession # : NP 002811 1 11 21 31 41 51 MQRRLVQQWS VAVFLLSYAV PSCGRSVEGL SRRLKRAVSE HQLLHDKGKS IQDLRRRFFL 60 HHLIAEIHTA EIRATSEVSP NSKPSPNTKN HPVRFGSDDE GRYLTQETNK VETYKEQPLK 120 TPGKKKKGKP GKRKEQEKKK RRTRSAWLDS GVTGSGLEGD HLSDTSTTSL ELDSR Seq ID NO : 191 DNA sequence Nucleic Acid Accession # : XM 059328 Coding sequence: 52.. 1023 1 11 21 31 41 51 GGGCTGTCCG GCCCACTCCC CTGGGAGCGC GAGCGGTGGA CCCAGGCGGC CATGTCCCGC 60 CCTCGCATGC GCCTGGTGGT CACCGCGGAC GACTTTGGTT ACTGCCCGCG ACGCGATGAG 120 GGTATCGTGG AGGCCTTTCT GGCCGGGGCT GTGACCAGCG TGTCCCTGCT GGTCAACGGT 180 GCGGCCACGG AGAGCGCGGC GGAGCTGGCC CGCAGGCACA GCATCCCCAC GGGCCTCCAC 240 GCCAACCTGT CCGAGGGCCG CCCCGTGGGT CCGGCCCGCC GTGGCGCCTC ATCGCTGCTC 300 GGCCCGGAAG GCTTCTTCCT TGGCAAGATG GGATTCCGGG AGGCGGTGGC GGCCGGAGAC 360 GTGGATTTGC CTCAGGTGCG GGAGGAGCTC GAGGCCCAAC TAAGCTGCTT CCGGGAGCTG 420 CTGGGCAGGG CCCCCACGCA CGCGGACGGG CACCAGCACG TGCACGTGCT CCCAGGCGTG 480 TGCCAGGTGT TCGCCGAGGC GCTGCAGGCC TATGGGGTGC GCTTTACGCG ACTGCCGCTG 540 GAGCGCGGTG TGGGTGGCTG CACTTGGCTG GAGGCCCCCG CGCGTGCCTT CGCCTGCGCC 600 GTGGAGCGCG ACGCCCGGGC CGCCGTGGGC CCCTTCTCCC GCCACGGCCT GCGGTGGACA 660 GACGCCTTCG TGGGCCTGAG CACTTGCGGC CGGCACATGT CCGCTCACCG CGTGTCCGGG 720 GCCCTGGCGC GGGTCCTGGA AGGTACCCTA GCGGGCCACA CCCTGACAGC CGAGCTGATG 780 GCGCACCCCG GCTACCCCAG TGTGCCTCCC ACCGGCGGCT GCGGTGAAGG CCCCGACGCT 840 TTCTCTTGCT CTTGGGAGCG GCTGCATGAG CTGCGCGTCC TCACCGCGCC CACGCTGCGG 900 GCCCAGCTTG CCCAGGATGG CGTGCAGCTT TGCGCCCTCG ACGACCTGGA CTCCAAGAGG 960 CCAGGGGAGG AGGTCCCCTG TGAGCCCACT CTGGAACCCT TCCTGGAACC CTCCCTACTC 1020 TGACCCCCTA CAGACAACCA AGCACTAATC CCCTTAGTAC CAAGAAAGGG GAGCCAGGAT 1080 TTAGTCCTGG CCCAGCCCAG AGCTGGGACC TGGAGCACGA TCTGTTGACT TCCCTGGGTA 1140 GGACACTGCC ACCTCTGGGC TCAGGTCCTC ATGCCTCCAA ATGGCATCTA GAGTTTGAGC 1200 AGCCTTCTTG GCTGCAGGCA GGCCTAGCCT GTGGCAGCGG GCTAGGGCCC GCAGAGCATT 1260 TGGTGCCCCT CCATGTTGCA ATGCAAACAC CTTCACCACT GGGGCAGTGG GGAGAGATGG 1320 CTATATTAAT AAAATAACGT GTGTCTTTC Seq ID NO: 192 Protein sequence : Protein Accession &num : XP 059328 1 11 21 31 41 51 MSRPRMRLW TADDFGYCPR RDEGIVEAFL AGAVTSVSLL VNGAATESAA ELARRHSIPT 60 GLHANLSEGR PVGPARRGAS SLLGPEGFFL GKMGFREAVA AGDVDLPQVR EELEAQLSCF 120 RELLGRAPTH ADGHQHVHVL PGVCQVFAEA LQAYGVRFTR LPLERGVGGC TWLEAPARAF 180 ACAVERDARA AVGPFSRHGL RWTDAFVGLS TCGRHMSAHR VSGALARVLE GTLAGHTLTA 240 ELMAHPGYP, S VPPTGGCGEG PDAFSCSWER LHELRVLTAP TLRAQLAQDG VQLCALDDLD 300 SKRPGEEVPC EPTLEPFLEP SLL Seq ID NO : 193 DNA sequence Nucleic Acid Accession # : NM 005688. 1 Coding sequence: 126.. 4439 1 11 21 31 41 51 CCGGGCAGGT GGCTCATGCT CGGGAGCGTG GTTGAGCGGC TGGCGCGGTT GTCCTGGAGC 60 AGGGGCGCAG GAATTCTGAT GTGAAACTAA CAGTCTGTGA GCCCTGGAAC CTCCGCTCAG 120

AGAAGATGAA GGATATCGAC ATAGGAAAAG AGTATATCAT CCCCAGTCCT GGGTATAGAA 180 GTGTGAGGGA GAGAACCAGC ACTTCTGGGA CGCACAGAGA CCGTGAAGAT TCCAAGTTCA 240 GGAGAACTCG ACCGTTGGAA TGCCAAGATG CCTTGGAAAC AGCAGCCCGA GCCGAGGGCC 300 TCTCTCTTGA TGCCTCCATG CATTCTCAGC TCAGAATCCT GGATGAGGAG CATCCCAAGG 360 GAAAGTACCA TCATGGCTTG AGTGCTCTGA AGCCCATCCG GACTACTTCC AAACACCAGC 420 ACCCAGTGGA CAATGCTGGG CTTTTTTCCT GTATGACTTT TTCGTGGCTT TCTTCTCTGG 480 CCCGTGTGGC CCACAAGAAG GGGGAGCTCT CAATGGAAGA CGTGTGGTCT CTGTCCAAGC 540 ACGAGTCTTC TGACGTGAAC TGCAGAAGAC TAGAGAGACT GTGGCAAGAA GAGCTGAATG 600 AAGTTGGGCC AGACGCTGCT TCCCTGCGAA GGGTTGTGTG GATCTTCTGC CGCACCAGGC 660 TCATCCTGTC CATCGTGTGC CTGATGATCA CGCAGCTGGC TGGCTTCAGT GGACCAGCCT 720 TCATGGTGAA ACACCTCTTG GAGTATACCC AGGCAACAGA GTCTAACCTG CAGTACAGCT 780 TGTTGTTAGT GCTGGGCCTC CTCCTGACGG AAATCGTGCG GTCTTGGTCG CTTGCACTGA 840 CTTGGGCATT GAATTACCGA ACCGGTGTCC GCTTGCGGGG GGCCATCCTA ACCATGGCAT 900 TTAAGAAGAT CCTTAAGTTA AAGAACATTA AAGAGAAATC CCTGGGTGAG CTCATCAACA 960 TTTGCTCCAA CGATGGGCAG AGAATGTTTG AGGCAGCAGC CGTTGGCAGC CTGCTGGCTG 1020 GAGGACCCGT TGTTGCCATC TTAGGCATGA TTTATAATGT AATTATTCTG GGACCAACAG 1080 GCTTCCTGGG ATCAGCTGTT TTTATCCTCT TTTACCCAGC AATGATGTTT GCATCACGGC 1140 TCACAGCATA TTTCAGGAGA AAATGCGTGG CCGCCACGGA TGAACGTGTC CAGAAGATGA 1200 ATGAAGTTCT TACTTACATT AAATTTATCA AAATGTATGC CTGGGTCAAA GCATTTTCTC 1260 AGAGTGTTCA AAAAATCCGC GAGGAGGAGC GTCGGATATT GGAAAAAGCC GGGTACTTCC 1320 AGGGTATCAC TGTGGGTGTG GCTCCCATTG TGGTGGTGAT TGCCAGCGTG GTGACCTTCT 1380 CTGTTCATAT GACCCTGGGC TTCGATCTGA CAGCAGCACA GGCTTTCACA GTGGTGACAG 1440 TCTTCAATTC CATGACTTTT GCTTTGAAAG TAACACCGTT TTCAGTAAAG TCCCTCTCAG 1500 AAGCCTCAGT GGCTGTTGAC AGATTTAAGA GTTTGTTTCT AATGGAAGAG GTTCACATGA 1560 TAAAGAACAA ACCAGCCAGT CCTCACATCA AGATAGAGAT GAAAAATGCC ACCTTGGCAT 1620 GGGACTCCTC CCACTCCAGT ATCCAGAACT CGCCCAAGCT GACCCCCAAA ATGAAAAAAG 1680 ACAAGAGGGC TTCCAGGGGC AAGAAAGAGA AGGTGAGGCA GCTGCAGCGC ACTGAGCATC 1740 AGGCGGTGCT GGCAGAGCAG AAAGGCCACC TCCTCCTGGA CAGTGACGAG CGGCCCAGTC 1800 CCGAAGAGGA AGAAGGCAAG CACATCCACC TGGGCCACCT GCGCTTACAG AGGACACTGC 1860 ACAGCATCGA TCTGGAGATC CAAGAGGGTA AACTGGTTGG AATCTGCGGC AGTGTGGGAA 1920 GTGGAAAAAC CTCTCTCATT TCAGCCATTT TAGGCCAGAT GACGCTTCTA GAGGGCAGCA 1980 TTGCAATCAG TGGAACCTTC GCTTATGTGG CCCAGCAGGC CTGGATCCTC AATGCTACTC 2040 TGAGAGACAA CATCCTGTTT GGGAAGGAAT ATGATGAAGA AAGATACAAC TCTGTGCTGA 2100 ACAGCTGCTG CCTGAGGCCT GACCTGGCCA TTCTTCCCAG CAGCGACCTG ACGGAGATTG 2160 GAGAGCGAGG AGCCAACCTG AGCGGTGGGC AGCGCCAGAG GATCAGCCTT GCCCGGGCCT 2220 TGTATAGTGA CAGGAGCATC TACATCCTGG ACGACCCCCT CAGTGCCTTA GATGCCCATG 2280 TGGGCAACCA CATCTTCAAT AGTGCTATCC GGAAACATCT CAAGTCCAAG ACAGTTCTGT 2340 TTGTTACCCA CCAGTTACAG TACCTGGTTG ACTGTGATGA AGTGATCTTC ATGAAAGAGG 2400 GCTGTATTAC GGAAAGAGGC ACCCATGAGG AACTGATGAA TTTAAATGGT GACTATGCTA 2460 CCATTTTTAA TAACCTGTTG CTGGGAGAGA CACCGCCAGT TGAGATCAAT TCAAAAAAGG 2520 AAACCAGTGG TTCACAGAAG AAGTCACAAG ACAAGGGTCC TAAAACAGGA TCAGTAAAGA 2580 AGGAAAAAGC AGTAAAGCCA GAGGAAGGGC AGCTTGTGCA GCTGGAAGAG AAAGGGCAGG 2640 GTTCAGTGCC CTGGTCAGTA TATGGTGTCT ACATCCAGGC TGCTGGGGGC CCCTTGGCAT 2700 TCCTGGTTAT TATGGCCCTT TTCATGCTGA ATGTAGGCAG CACCGCCTTC AGCACCTGGT 2760 GGTTGAGTTA CTGGATCAAG CAAGGAAGCG GGAACACCAC TGTGACTCGA GGGAACGAGA 2820 CCTCGGTGAG TGACAGCATG AAGGACAATC CTCATATGCA GTACTATGCC AGCATCTACG 2880 CCCTCTCCAT GGCAGTCATG CTGATCCTGA AAGCCATTCG AGGAGTTGTC TTTGTCAAGG 2940 GCACGCTGCG AGCTTCCTCC CGGCTGCATG ACGAGCTTTT CCGAAGGATC CTTCGAAGCC 3000 CTATGAAGTT TTTTGACACG ACCCCCACAG GGAGGATTCT CAACAGGTTT TCCAAAGACA 3060 TGGATGAAGT TGACGTGCGG CTGCCGTTCC AGGCCGAGAT GTTCATCCAG AACGTTATCC 3120 TGGTGTTCTT CTGTGTGGGA ATGATCGCAG GAGTCTTCCC GTGGTTCCTT GTGGCAGTGG 3180 GGCCCCTTGT CATCCTCTTT TCAGTCCTGC ACATTGTCTC CAGGGTCCTG ATTCGGGAGC 3240 TGAAGCGTCT GGACAATATC ACGCAGTCAC CTTTCCTCTC CCACATCACG TCCAGCATAC 3300 AGGGCCTTGC CACCATCCAC GCCTACAATA AAGGGCAGGA GTTTCTGCAC AGATACCAGG 3360 AGCTGCTGGA TGACAACCAA GCTCCTTTTT TTTTGTTTAC GTGTGCGATG CGGTGGCTGG 3420 CTGTGCGGCT GGACCTCATC AGCATCGCCC TCATCACCAC CACGGGGCTG ATGATCGTTC 3480 TTATGCACGG GCAGATTCCC CCAGCCTATG CGGGTCTCGC CATCTCTTAT GCTGTCCAGT 3540 TAACGGGGCT GTTCCAGTTT ACGGTCAGAC TGGCATCTGA GACAGAAGCT CGATTCACCT 3600 CGGTGGAGAG GATCAATCAC TACATTAAGA CTCTGTCCTT GGAAGCACCT GCCAGAATTA 3660 AGAACAAGGC TCCCTCCCCT GACTGGCCCC AGGAGGGAGA GGTGACCTTT GAGAACGCAG 3720 AGATGAGGTA CCGAGAAAAC CTCCCTCTTG TCCTAAAGAA AGTATCCTTC ACGATCAAAC'3780 CTAAAGAGAA GATTGGCATT GTGGGGCGGA CAGGATCAGG GAAGTCCTCG CTGGGGATGG 3840 CCCTCTTCCG TCTGGTGGAG TTATCTGGAG GCTGCATCAA GATTGATGGA GTGAGAATCA 3900 GTGATATTGG CCTTGCCGAC CTCCGAAGCA AACTCTCTAT CATTCCTCAA GAGCCGGTGC 3960 TGTTCAGTGG CACTGTCAGA TCAAATTTGG ACCCCTTCAA CCAGTACACT GAAGACCAGA 4020 TTTGGGATGC CCTGGAGAGG ACACACATGA AAGAATGTAT TGCTCAGCTA CCTCTGAAAC 4080 TTGAATCTGA AGTGATGGAG AATGGGGATA ACTTCTCAGT GGGGGAACGG CAGCTCTTGT 4140 GCATAGCTAG AGCCCTGCTC CGCCACTGTA AGATTCTGAT TTTAGATGAA GCCACAGCTG 4200 CCATGGACAC AGAGACAGAC TTATTGATTC AAGAGACCAT CCGAGAAGCA TTTGCAGACT 4260 GTACCATGCT GACCATTGCC CATCGCCTGC ACACGGTTCT AGGCTCCGAT AGGATTATGG 4320 TGCTGGCCCA GGGACAGGTG GTGGAGTTTG ACACCCCATC GGTCCTTCTG TCCAACGACA 4380 GTTCCCGATT CTATGCCATG TTTGCTGCTG CAGAGAACAA GGTCGCTGTC AAGGGCTGAC 4440 TCCTCCCTGT TGACGAAGTC TCTTTTCTTT AGAGCATTGC CATTCCCTGC CTGGGGCGGG 4500 CCCCTCATCG CGTCCTCCTA CCGAAACCTT GCCTTTCTCG ATTTTATCTT TCGCACAGCA 4560 GTTCCGGATT GGCTTGTGTG TTTCACTTTT AGGGAGAGTC ATATTTTGAT TATTGTATTT 4620 ATTCCATATT CATGTAAACA AAATTTAGTT TTTGTTCTTA ATTGCACTCT AAAAGGTTCA 4680 GGGAACCGTT ATTATAATTG TATCAGAGGC CTATAATGAA GCTTTATACG TGTAGCTATA 4740 TCTATATATA ATTCTGTACA TAGCCTATAT TTACAGTGAA AATGTAAGCT GTTTATTTTA 4800 TATTAAAATA AGCACTGTGC TAATAACAGT GCATATTCCT TTCTATCATT TTTGTACAGT 4860 TTGCTGTACT AGAGATCTGG TTTTGCTATT AGACTGTAGG AAGAGTAGCA TTTCATTCTT 4920 CTCTAGCTGG TGGTTTCACG GTGCCAGGTT TTCTGGGTGT CCAAAGGAAG ACGTGTGGCA 4980 ATAGTGGGCC CTCCGACAGC CCCCTCTGCC GCCTCCCCAC AGCCGCTCCA GGGGTGGCTG 5040 GAGACGGGTG GGCGGCTGGA GACCATGCAG AGCGCCGTGA GTTCTCAGGG CTCCTGCCTT 5100 CTGTCCTGGT GTCACTTACT GTTTCTGTCA GGAGAGCAGC GGGGCGAAGC CCAGGCCCCT 5160 TTTCACTCCC TCCATCAAGA ATGGGGATCA CAGAGACATT CCTCCGAGCC GGGGAGTTTC 5220 TTTCCTGCCT TCTTCTTTTT GCTGTTGTTT CTAAACAAGA ATCAGTCTAT CCACAGAGAG 5280 TCCCACTGCC TCAGGTTCCT ATGGCTGGCC ACTGCACAGA GCTCTCCAGC TCCAAGACCT 5340

GTTGGTTCCA AGCCCTGGAG CCAACTGCTG CTTTTTGAGG TGGCACTTTT TCATTTGCCT 5400 ATTCCCACAC CTCCACAGTT CAGTGGCAGG GCTCAGGATT TCGTGGGTCT GTTTTCCTTT 5460 CTCACCGCAG TCGTCGCACA GTCTCTCTCT CTCTCTCCCC TCAAAGTCTG CAACTTTAAG 5520 CAGCTCTTGC TAATCAGTGT CTCACACTGG CGTAGAAGTT TTTGTACTGT AAAGAGACCT 5580 ACCTCAGGTT GCTGGTTGCT GTGTGGTTTG GTGTGTTCCC GCAAACCCCC TTTGTGCTGT 5640 GGGGCTGGTA GCTCAGGTGG GCGTGGTCAC TGCTGTCATC AGTTGAATGG TCAGCGTTGC 5700 ATGTCGTGAC CAACTAGACA TTCTGTCGCC TTAGCATGTT TGCTGAACAC CTTGTGGAAG 5760 CAAAAATCTG AAAATGTGAA TAAAATTATT TTGGATTTTG TAAAAAAAAA AAAAAAAAAA 5820 AAAAAAAAAA AAAAAAAA Seq ID NO: 194 Protein sequence : Protein Accession &num : NP005679. 1 1 11 21 31 41 51 I I 1 I I I MKDIDIGKEY IIPSPGYRSV RERTSTSGTH RDREDSKFRR TRPLECQDAL ETAARAEGLS 60 LDASMHSQLR ILDEEHPKGK YHHGLSALKP IRTTSKHQHP VDNAGLFSCM TFSWLSSLAR 120 VAHKKGELSM EDVWSLSKHE SSDVNCRRLE RLWQEELNEV GPDAASLRRV VWIFCRTRLI 180 LSIVCLMITQ LAGFSGPAFM VKHLLEYTQA TESNLQYSLL LVLGLLLTEI VRSWSLALTW 240 ALNYRTGVRL RGAILTMAFK KILKLKNIKE KSLGELINIC SNDGQRMFEA AAVGSLLAGG 300 PWAILGMIY NVIILGPTGF LGSAVFILFY PAMMFASRLT AYFRRKCVAA TDERVQKMNE 360 VLTYIKFIKM YAWVKAFSQS VQKIREEERR ILEKAGYFQG ITVGVAPIW VIASWTFSV 420 HMTLGFDLTA AQAFTWTVF NSMTFALKVT PFSVKSLSEA SVAVDRFKSL FLMEEVHMIK 480 NKPASPHIKI EMKNATLAWD SSHSSIQNSP KLTPKMKKDK RASRGKKEKV RQLQRTEHQA 540 VLAEQKGHLL LDSDERPSPE EEEGKHIHLG HLRLQRTLHS IDLEIQEGKL VGICGSVGSG 600 KTSLISAILG QMTLLEGSIA ISGTFAYVAQ QAWILNATLR DNILFGKEYD EERYNSVLNS 660 CCLRPDLAIL PSSDLTEIGE RGANLSGGQR QRISLARALY SDRSIYILDD PLSALDAHVG 720 NHIFNSAIRK HLKSKTVLFV THQLQYLVDC DEVIFMKEGC ITERGTHEEL MNLNGDYATI 780 FNNLLLGETP PVEINSKKET SGSQKKSQDK GPKTGSVKKE KAVKPEEGQL VQLEEKGQGS 840 VPWSVYGVYI QAAGGPLAFL VIMALFMLNV GSTAFSTWWL SYWIKQGSGN TTVTRGNETS 900 VSDSMKDNPH MQYYASIYAL SMAVMLILKA IRGWFVKGT LRASSRLHDE LFRRILRSPM 960 KFFDTTPTGR ILNRFSKDMD EVDVRLPFQA EMFIQNVILV FFCVGMIAGV FPWFLVAVGP 1020 LVILFSVLHI VSRVLIRELK RLDNITQSPF LSHITSSIQG LATIHAYNKG QEFLHRYQEL 1080 LDDNQAPFFL FTCAMRWLAV RLDLISIALI TTTGLMIVLM HGQIPPAYAG LAISYAVQLT 1140 GLFQFTVRLA SETEARFTSV ERINHYIKTL SLEAPARIKN KAPSPDWPQE GEVTFENAEM 1200 RYRENLPLVL KKVSFTIKPK EKIGIVGRTG SGKSSLGMAL FRLVELSGGC IKIDGVRISD 1260 IGLADLRSKL SIIPQEPVLF SGTVRSNLDP FNQYTEDQIW DALERTHMKE CIAQLPLKLE 1320 SEVMENGDNF SVGERQLLCI ARALLRHCKI LILDEATAAM DTETDLLIQE TIREAFADCT 1380 MLTIAHRLHT VLGSDRIMVL AQGQWEFDT PSVLLSNDSS RFYAMFAAAE NKVAVKG Seq ID NO : 195 DNA sequence Nucleic Acid Accession # : NM 006470 Coding sequence: 228.. 1922 1 11 21 31 41 51 # # # # # # GCTGTCCTGA GCCTGAGTAC TCTAGCTGCC TTGTCGCCAT CGCATCTGGC TGCATCCAG 60 CGCCAGCACA CAGTAATGAG TGGCCGAGCT TCCTCTGGGA GGGAGGAAAC AGTTAAAATC 120 TTGCAGCAGC TGCAATCATC TAGGCGTGGT TCTCTTGTCT GACTTGGGCT GCACAGATCC 180 TGGGCCAAGG GACAGAAGAA AGACAGCCTA GGAGCAGAGC CTCCCAGATG GCTGAGTTGG 240 ATCTAATGGC TCCAGGGCCA CTGCCCAGGG CCACTGCTCA GCCCCCAGCC CCTCTCAGCC 300 CAGACTCTGG GTCACCCAGC CCAGATTCTG GGTCAGCCAG CCCAGTGGAA GAAGAGGACG 360 TGGGCTCCTC GGAGAAGCTT GGCAGGGAGA CGGAGGAACA GGACAGCGAC TCTGCAGAGC 420 AGGGGGATCC TGCTGGTGAG GGGAAAGAGG TCCTGTGTGA CTTCTGCCTT GATGACACCA 480 GAAGAGTGAA GGCAGTGAAG TCCTGTCTAA CCTGCATGGT GAATTACTGT GAAGAGCACT 540 TGCAGCCGCA TCAGGTGAAC ATCAAACTGC AAAGCCACCT GCTGACCGAG CCAGTGAAGG 600 ACCACAACTG GCGATACTGC CCTGCCCACC ACAGCCCACT GTCTGCTTTC TGCTGCCCTG 660 ATCAGCAGTG CATCTGCCAG GACTGTTGCC AGGAGCACAG TGGCCACACC ATAGTCTCCC 720 TGGATGCAGC CCGCAGGGAC AAGGAGGCTG AACTCCAGTG CACCCAGTTA GACTTGGAGC 780 GGAAACTCAA GTTGAATGAA AATGCCATCT CCAGGCTCCA GGCTAACCAA AAGTCTGTTC 840 TGGTGTCGGT GTCAGAGGTC AAAGCGGTGG CTGAAATGCA GTTTGGGGAA CTCCTTGCTG 900 CTGTGAGGAA GGCCCAGGCC AATGTGATGC TCTTCTTAGA GGAGAAGGAG CAAGCTGCGC 960 TGAGCCAGGC CAACGGTATC AAGGCCCACC TGGAGTACAG GAGTGCCGAG ATGGAGAAGA 1020 GCAAGCAGGA GCTGGAGAGG ATGGCGGCCA TCAGCAACAC TGTCCAGTTC TTGGAGGAGT 1080 ACTGCAAGTT TAAGAACACT GAAGACATCA CCTTCCCTAG TGTTTACGTA GGGCTGAAGG 1140 ATAAACTCTC GGGCATCCGC AAAGTTATCA CGGAATCCAC TGTACACTTA ATCCAGTTGC 1200 TGGAGAACTA TAAGAAAAAG CTCCAGGAGT TTTCCAAGGA AGAGGAGTAT GACATCAGAA 1260 CTCAAGTGTC TGCCGTTGTT CAGCGCAAAT ATTGGACTTC CAAACCTGAG CCCAGCACCA 1320 GGGAACAGTT CCTCCAATAT GCGTATGACA TCACGTTTGA CCCGGACACA GCACACAAGT 1380 ATCTCCGGCT GCAGGAGGAG AACCGCAAGG TCACCAACAC CACGCCCTGG GAGCATCCCT 1440 ACCCGGACCT CCCCAGCAGG TTCCTGCACT GGCGGCAGGT GCTGTCCCAG CAGAGTCTGT 1500 ACCTGCACAG GTACTATTTT GAGGTGGAGA TCTTCGGGGC AGGCACCTAT GTTGGCCTGA 1560 CCTGCAAAGG CATCGACCGG AAAGGGGAGG AGCGCAACAG TTGCATTTCC GGAAACAACT 1620 TCTCCTGGAG CCTCCAATGG AACGGGAAGG AGTTCACGGC CTGGTACAGT GACATGGAGA 1680 CCCCACTCAA AGCTGGCCCT TTCCGGAGGC TCGGGGTCTA TATCGACTTC CCGGGAGGGA 1740 TCCTTTCCTT CTATGGCGTA GAGTATGATA CCATGACTCT GGTTCACAAG TTTGCCTGCA 1800 AATTTTCAGA ACCAGTCTAT GCTGCCTTCT GGCTTTCCAA GAAGGAAAAC GCCATCCGGA 1860 TTGTAGATCT GGGAGAGGAA CCCGAGAAGC CAGCACCGTC CTTGGGGGTG ACTGCTCCCT 1920 AGACTCCAGG AGCCATATCC CAGACCTTTG CCAGCTACAG TGATGGGATT TGCATTTTAG 1980 GGTGATTTGT GGGCAGAAAT AACTGCTGAT GGTAGCTGGC TTTTGAAATC CTATGGGGTC 2040 TCTGAATGAA AACATTCTCC AGCTGCTCTC TTTTGCTCCA TATGGTGCTG TTCTCTATGT 2100 GTTTGCAGTA ATTCTTTTTT TTTTTTTTGA GACGGAGTCT CGCACTGTTG CCCAGGCTGG 2160 AGAGCAGTGG CGCGATCTTG GCTCACTGCA AGCTCCGCCT CCCGAGTTCA AGCAATTCTC 2220 CTGCCTCAGC CTCCCGAGTA GCTGGGATTA CAGGTGCCTG CCACCACACC CAGCTAATGT 2280 TTTGTATTTT TAGTAGAGAT GGGGTTTCAC CATGTTGGCC AGGCAGATCT CAAACTCCTG 2340

GGACAGCCCC AGATCTAAGC GGTGCGGTAA TCTGAGTACT TGCATGCTGG GCACATACAC 360 GCAGGACTTC AACAAGTTTC ACACGTTCCC CCAAACTGCA ATTGGGGTTG GAGCACCTGG 420 AAAGAAAAGG GATATGTCCA GCGACTTGGA GAGAGACCAT CGCCCTCATG TTAGCATGCC 480 CCAGAATGCC AACTAAACTC CTCCCTTTCC TTCCTAATTT CCCTTCTTGC ATCCTTCCTA 540 TAACTTGATG CATGTGGTTT GGTTCCTCTC TGGTGGCTCT TTGGGCTGGT ATTGGTGGCT 600 TTCCTTGTGG CAGAGGATGT CTCAAACTTC AGATGGGAGG AAAGAGAGCA GGACTCACAG 660 GTTGGAAGAG AATCACCTGG GAAAATACCA GAAAATGAGG GCCGCTTTGA GTCCCCCAGA 720 GATGTCATCA GAGCTCCTCT GTCCTGCTTC TGAATGTGCT GATCATTTGA GGAATAAAAT 780 TATTTTTCCC C Seq ID NO : 204 Protein sequence: Protein Accession # : NP 001732 1 11 21 31 41 51 MGFQKFSPFL ALSILVLLQA GSLHAAPFRS ALESSPADPA TLSEDEARLL LAALVQDYVQ 60 MKASELEQEQ EREGSSLDSP RSKRCGNLST CMLGTYTQDF NKFHTFPQTA IGVGAPGKKR 120 DMSSDLERDH RPHVSMPQNA N Seq ID NO : 205 DNA sequence Nucleic Acid Accession # : NM 005361 Coding sequence : 1-945 1 11 21 31 41 51 ATGCCTCTTG AGCAGAGGAG TCAGCACTGC AAGCCTGAAG AAGGCCTTGA GGCCCGAGGA 60 GAGGCCCTGG GCCTGGTGGG TGCGCAGGCT CCTGCTACTG AGGAGCAGCA GACCGCTTCT 120 TCCTCTTCTA CTCTAGTGGA AGTTACCCTG GGGGAGGTGC CTGCTGCCGA CTCACCGAGT 180 CCTCCCCACA GTCCTCAGGG AGCCTCCAGC TTCTCGACTA CCATCAACTA CACTCTTTGG 240 AGACAATCCG ATGAGGGCTC CAGCAACCAA GAAGAGGAGG GGCCAAGAAT GTTTCCCGAC 300 CTGGAGTCCG AGTTCCAAGC AGCAATCAGT AGGAAGATGG TTGAGTTGGT TCATTTTCTG 360 CTCCTCAAGT ATCGAGCCAG GGAGCCGGTC ACAAAGGCAG AAATGCTGGA GAGTGTCCTC 420 AGAAATTGCC AGGACTTCTT TCCCGTGATC TTCAGCAAAG CCTCCGAGTA CTTGCAGCTG 480 GTCTTTGGCA TCGAGGTGGT GGAAGTGGTC CCCATCAGCC ACTTGTACAT CCTTGTCACC 540 TGCCTGGGCC TCTCCTACGA TGGCCTGCTG GGCGACAATC AGGTCATGCC CAAGACAGGC 600 CTCCTGATAA TCGTCCTGGC CATAATCGCA ATAGAGGGCG ACTGTGCCCC TGAGGAGAAA 660 ATCTGGGAGG AGCTGAGTAT GTTGGAGGTG TTTGAGGGGA GGGAGGACAG TGTCTTCGCA 720 CATCCCAGGA AGCTGCTCAT GCAAGATCTG GTGCAGGAAA ACTACCTGGA GTACCGGCAG 780 GTGCCCGGCA GTGATCCTGC ATGCTACGAG TTCCTGTGGG GTCCAAGGGC CCTCATTGAA 840 ACCAGCTATG TGAAAGTCCT GCACCATACA CTAAAGATCG GTGGAGAACC TCACATTTCC 900 TACCCACCCC TGCATGAACG GGCTTTGAGA GAGGGAGAAG AGTGA Seq ID NO: 206 Protein sequence: Protein Accession # : NP 005352 1 11 21 31 41 51 MPLEQRSQHC KPEEGLEARG EALGLVGAQA PATEEQQTAS SSSTLVEVTL GEVPAADSPS 60 PPHSPQGASS FSTTINYTLW RQSDEGSSNQ EEEGPRMFPD LESEFQAAIS RKMVELVHFL 120 LLKYRAREPV TKAEMLESVL RNCQDFFPVI FSKASEYLQL VFGIEWEW PISHLYILVT 180 CLGLSYDGLL GDNQVMPKTG LLIIVLAIIA IEGDCAPEEK IWEELSMLEV FEGREDSVFA 240 HPRKLLMQDL VQENYLEYRQ VPGSDPACYE FLWGPRALIE TSYVKVLHHT LKIGGEPHIS 300 YPPLHERALR EGEE Seq ID NO : 207 DNA sequence Nucleic Acid Accession &num : NM 021115 Coding sequence : 743-2893 1 11 21 31 41 51 # # # # # # AAAGGAAGGG AGGGAGGGAG AAAGGAGAAG TTGGTTTAGA GGCCAGCCGG ACGAGCTTTG 60 GGCACCGCCC TTAGGAGGGC CACCCTCAGA GTCTGACAGC AGGTGAAGGT CCTAAATCTC 120 CCCAAACTAA CTGGTGTCTT TTCTCCTCTT CCAAGATGCT CTTCCCGAGG GAGATGCTAG 180 CCCTTTGGGT CCTTACCTCC TGCCCTCAGG AGCCCCGGAG AGAGGCAGTC CTGGCAAAGA 240 GCACCCTGAA GAGAGAGTGG TAACAGCGCC CCCCAGTTCC TCACAGTCGG CGGAAGTGCT 300 GGGCGAGCTG GTGCTGGATG GGACCGCACC CTCTGCACAT CACGACATCC CAGCCCTGTC 360 ACCGCTGCTT CCAGAGGAGG CCCGCCCCAA GCACGCCTTG CCCCCCAAGA AGAAACTGCC 420 TTCGCTCAAG CAGGTGAACT CTGCCAGGAA GCAGCTGAGG CCCAAGGCCA CCTCCGCAGC 480 CACTGTCCAA AGGGCAGGGT CCCAGCCAGC GTCCCAGGGC CTAGATCTCC TCTCCTCCTC 540 CACGGAGAAG CCTGGCCCAC CGGGGGACCC GGACCCCATC GTGGCCTCCG AGGAGGCATC 600 AGAAGTGCCC CTTTGGCTGG ACCGAAAGGA GAGTGCGGTC CCTACAACAC CCGCACCCCT 660 GCAAATCTCC CCCTTCACTT CGCAGCCCTA TGTGGCCCAC ACACTCCCCC AGAGGCCAGA 720 ACCCGGGGAG CCTGGGCCTG ACATGGCCCA GGAGGCCCCC CAGGAGGACA CCAGCCCCAT 780 GGCCCTGATG GACAAAGGTG AGAATGAGCT GACTGGGTCA GCCTCAGAGG AGAGCCAGGA 840 GACCACTACC TCCACCATTA TCACCACCAC GGTCATCACC ACCGAGCAGG CACCAGCTCT 900 CTGCAGTGTG AGCTTCTCCA ATCCTGAGGG GTACATTGAC TCCAGCGACT ACCCACTGCT 960 GCCCCTCAAC AACTTTCTGG AGTGCACATA CAACGTGACA GTCTACACTG GCTATGGGGT 1020 GGAGCTCCAG GTGAAGAGTG TGAACCTGTC CGATGGGGAA CTGCTCTCCA TCCGCGGGGT 1080 GGACGGCCCT ACCCTGACCG TCCTGGCCAA CCAGACACTC CTGGTGGAGG GGCAGGTAAT 1140 CCGAAGCCCC ACCAACACCA TCTCCGTCTA CTTCCGGACC TTCCAGGACG ACGGCCTTGG 1200 GACCTTCCAG CTTCACTACC AGGCCTTCAT GCTGAGCTGC AACTTTCCCC GCCGGCCTGA 1260 CTCTGGGGAT GTCACGGTGA TGGACCTGCA CTCAGGTGGG GTGGCCCACT TTCACTGCCA 1320 CCTGGGCTAT GAGCTCCAGG GCGCTAAGAT GCTGACATGC ATCAATGCCT CCAAGCCGCA 1380 CTGGAGCAGC CAGGAGCCCA TCTGCTCAGC TCCTTGTGGA GGGGCAGTGC ACAATGCCAC 1440 CATCGGCCGC GTCCTCTCCC CAAGTTACCC TGAAAACACA AATGGGAGCC AATTCTGCAT 1500 CTGGACGATT GAAGCTCCAG AGGGCCAGAA GCTGCACCTG CACTTTGAGA GGCTGTTGCT 1560

TCCATCTTAC TTTTAATCGA GTATAAGGAA ATGTTTCTTT ATGGCCATTT TGGAGGGAGC 3960 AGGGGATGAG GCTTGGCATA GTCCAAAATT TAAGNCTCCA ATAATTAATT GCATTTTAAA 4020 TTGTTTTAAA TTGGCCCACT TTCAAGGCAA TTTTTTTTGT GTGTCTGTAA CTGAGCTCCT 4080 CCACCCCTGT CATTCACTTC CAATTTTACC CAATCCAATT TTAGCACTCA AGTTCCATTG 4140 TGTTAATTTT TGCACGGTCT ACACACATCA AGTCAGCAAG CATTTGCCAC CACTCCCTAT 4200 ACTTCTCCCT CTTTTTTACA CACACACACA CACACACACA CACAATCCAT CTCTTGCTTG 4260 TTCCTACCTC CCTGATTTTT CTTCCCTACA GAAATAGAAA TAGGGACAAA GAAGGGGAAA 4320 ATGTATATAT TGGGGCTGGG CTGAACAACT AACTTCATAA GTAGTATTAA CTAGGGGTAA 4380 ATTGAGAGAA AAGCTCCTTT TCTCTTCACT GTTTTGGAAA GGATAGCCAT TAGCATGACT 4440 GCTTTGTGTC CTTATGGACT TTAGTATTAG CCTAGATTGA ATTATAGCGT TTTTCTAGCT 4500 GAAGGAACCT TAAGATCACA TCATCTACTC CTCTACTCCA AATTTCTCAT TCTTCAGGCC 4560 AGGAAACCGA GACACAGAGG TAAAGTAATT TCCCCAAGGT CACACAGCTG GCTGGGGCAG 4620 GATTGGGTTT ACAACCCACA TCTCCTGGCT CTTATTCCAG GGCCTTTTCC CACTAAGTAG 4680 TATTGCCTTC CATTAGGCTC CTGAGAGTTA TTTCTCAGGG TCATGTTGCA TCTTGGAGCC 4740 ACATGCTGCT GCCCTGATCT CAGTGGGAAA TNCACCCAGC AACCTAATAC AGCCCCTTTT 4800 CCCTGCATTC ACCTGGTTCC CATCCACATG GGTTGCAGAT GTCCTTGAAG AGAGTGAGGC 4860 ATTGAGGGCC AATAGGAGCA ATGGGGTCCC TGGCCTTGTC CATCTGATTC AGGAGATCAC 4920 TGCTCCATCG TGAGGAGCCC TCTGAATAGC CCCCCACTGA ATGCTTGCCT TGCCCAAATG 4980 GAATGGAGGA AGATTGATTT TCTCCATCAG TTCACCTTGT GTCATCTCAT AATGGTTGGT 5040 CTTTCCAGGC TGAGGGAAAT GTTTCTTGTT TCCANAGTAN AAAAAAGAAA GAGTGGAACA 5100 ATANCTTTGT TCATCCTAAC TTTCTGAGAT GGCTTTTCAA CATTTAAAAA AAACTAGTGT 5160 GGTACCATTC ACTGGCANGA TTTNTTTTAG AATATGGGAG TAAGATGAGG TAGAGAAAAT 5220 AACCTGGTCT CACTGTGGTT GCCCTCATCC ACAATGTCCC CAAAGCCATC CTGCTNTGAT 5280 GAGGACAATT TCCAGGTATA AGCAAGGGGC TTTGTGACAA AAATGTACCC TGGCTGATGT 5340 TAAACATTGG CTCCTGTGTT TGCACCAAAA TAGCAAGCTG TGTGCTCTAT ACACTCTTCC 5400 CATCGTCTTG TGTACACTGC TCCTGTGGCC TTCCACAGCA GAAACCAGGG CAAAAGGGTC 5460 CAAACACATG GTTTTCCTTG CTGCAAGGCT NTTCCTGGGA ACTAAGGGGG TATTTATTAG 5520 TTCAGTTNTA AGAGACCTCC TTCTGGGCTT ACCCCACTCC TCAGGTACTT CTCTCTCCTT 5580 CCTCCTTCTC CTCCACAGTC ACAAGTAACC AAGGAACCTG AAAGTGGATG TGTAGCTATT 5640 TGAAGAAGGC AAGGAACCCT GAGATTCTTC TTTGAATCCT TTAGTCCAAG TCTTAGACCA 5700 GTGATTGGTG CTTACCTTGA ACAAAATTTT GTCTGTGTTC CTAATCCCTT CAATACTNTG 5760 GGTACAATGC TCCCAATCAC CCTGCACATT TGATTCTAAA TGGCTTTTAT TTTTTAAAAA 5820 TCCATATCCC TAGGACAAGA NAACAGGATG CCTATATCCC CAAAATGAGC TCCAGGACAC 5880 TGATGGGAAT GATCCCAANG ATCACCCCAC CTCAGAAAAC GTCTGTGCCA ANAGACTTCC 5940 CCAGATAGAA NCACTGGGAC AGTGGTTTGA ACGACTTCTT TTATGGTTGT CCAGTTTGCT 6000 ATGGAAATAA AAGGCATTGA TTTTTTAAAA AAGATGATTG GAACCTGTCT TTGGCCACAT 6060 AGGGCCACTT GGATCCATTT CCAGGCCTTA CTCATATATT GCCTTCACTG AAGGGCTTTG 6120 GCTTTAAGTC CCAGACTGGT CTCCCAAGTG AACCATAAGT GTTTTGGAGC TCATCTGGGG 6180 TGAGGCATGA GAATGTTGCC CCATCTATCC CTTCAGGAAA AGGTGCCTTC CCTCCCTTTC 6240 TCCTAAAGCC TGGTCCCCAA AAATTGTTTT TGTCTCCAAA AGTCTAGTAT GGTCTTTATA 6300 CACCCANACT CTTAGTGTTG CGTCCTGCCT TGTTTCCTTG TTAAGGATCT ATGCANACCT 6360 CCCGCTTTGG CTTAGCTAGC GTGACATTGG CTATCATTTG ACAAGACTAA CTTTTTTTTT 6420 TTTTTTTTTG ACTGAGTCTC CCTCTGTCAC CTAGGCTGGA GTGCAGTGGC ACAATCTTGG 6480 CTCGCTGCAA CCTTCACCCT TCACCTCCCA GGTCGAAGCG ATTCTCCTGC CTCAGTCTCC 6540 CGAGTAGCTG GGATTACAGG CGTGCGCCAC CAAATCTGGC TATTTTTTTA TTATTATTAT 6600 TTTTAGTAGA GATGGGGTTT CACCATGTTG GCCAGACTGG TCTTGAACTC TTGGCCTCAA 6660 ATTATCTGCC CACCTCGGCC TCCCAAAGTG CTGGGATTAC AGGCATGAGC ACCATGCCCA 6720 GCTGACAAGA CTAATTTTTT ATCCCTTGGT TTATTGGCTT CAACATCTTC TGGAATCAGA 6780 GGTGATTTTT TCTTACCTTG GATGCCTGAG ACTAGGGGAG TATAGAATTC CAATTGGTAA 6840 TTAAGGCATC TTTCTGCTCC TGATCAGAAG GGCAGGTTAG TTGGGAGAGG TCAGATGGCA 6900 CAACAGAAGT CACCTTGTAA GTAAGGCAAA GACTTTGAAG GCATTAGCGT TTCTCATTAC 6960 TTAGGTCAAT AACCTTGAGG GAATCAATGG CTTTTTTGCC GCTCTACCTC TTTGTGTATC 7020 TCTTTGACTT TTCTTTCTCT GTCTAGTTTC CTCTGTTCTC AGTTTATATT CTATGTTATC 7080 AGTCTCTCTT TCCACAGTAC AAACATCCAT CCTTTCTCCT GTGCAATTCT GTCTCTCCCT 7140 CTTATTATCT TTATTTGTAC TTTTTCCTTC CTCCCTGTCT AGGCATTGGG CATGTGCCTC 7200 TTCTTAGCCT GTGATTTTGC CTTGGGACTG ATGATAAATT ATTTCCAGAT TCAATCAGCC 7260 CTGGTCCTAC CCCAGTCCAA TCAGAAGTAT GTTGGTGGGG AATCAACCTG ATCCTGGCCC 7320 TTTCTTCTTC TCCATTTTCA TTCGTAATCC CCCTCAGCAG ATCTTTACAA GCAGTTTCCT 7380 TATAGCTCAT GTATCTTTAG GTCTTTGCCT TCCAAGCACT GTACAGAATA CTTTGTGGTT 7440 CCTTTTTAGT CTGACATTTT GTGGAGCAGT GAAGCGTGCT CAGAGACATA ATCAGCTGAA 7500 GAGAAAAAAT CCACCCATGG ATTTATATCA GCTAAATACT AATAATTGAT TTTGTTTGAT 7560 GTGCCCATAA TTTTTAAAGC TGCAATATAA TATAATGAGG GACCACAGGT AATTTCTCCT 7620 GTCATTTGTT TTGGCTGGAT GGGGGTGGGG GAGTAATTGC TTAAAGTTTT ACCATTACAC 7680 ATTAAACTCT CTATAATAAT CTTGTTTGGG GCTTGCTAAC TGTTGAGCTG TTTTAACTAA 7740 ACTGGTAGGC AATCGGAGTT GATTTAAATG AAAAGATAAT TTAACAAATC TATACTATAA 7800 AAAGAGACAT TTGCTTAATT GACATGTATT TTTTCCTTCT GAGTCACCTA AACATTTACT 7860 CTTGACACCA ACTGTTCATG ATACTGAATA GACAGTCCAT ATAAGAGAAA TTAGTGGACC 7920 TAAAGAAGCC AGATTGTAGG TGTTAATTTA TTAAACAGAA TTGCAAAGCC CTTGGAAATG 7980 TCACTGCTTG GCAATACCAT ATGGCATGCC AAAATTTACA ATGACTTTTC TTTATAAGTT 8040 ATCCAAAAGG GATTTGAACA AGTAAGAGGT TATGCCAAAA TGTCTCCAAT GTATGGTCCT 8100 GTAATATATT GCAGCTTGAA GCCAATGATC CCTTATGACT TGTATACAAC TAATGCATGT 8160 TTTATTGAAT TTTGCATTTC CCACGTGTGG TAAGTCTTTA AAATGTTTTT GATCACCTTT 8220 NTGTGCCATT AAACTTGTAC AGAAAATGTT TTTATGGCCA TTTTCAAAGG GAGAAAGTTT 8280 AAAATGGAAA CAGCCCACCC TTTCTGCCCT ATAGCTGTAG TTAGAATTGA GTACCTGTAG 8340 CAAAACAGCT GTAATTGGTG GTTGTAGTGT TAGAGGTGTT AGCTTGCTAG TGACTAGCTT 8400 TGGAGAGTAA ATGCATGGTA TTGTACATCA CATTTCTTAA CTCGTTTTAA CCTCTGAAAA 8460 GAATATATTC TTCTTTGTAG TCCTTCTTCC CACCCCCTTG CCCTCTCCCT CTCCCTGCTC 8520 CCAGTTGTCT TACAGTTGTA AATATCTGAT TTGAGGCCCA ATAACTCTTG CCAAGTAAAG 8580 TCAGCAAACA ACAAACAAAC CAAAATGTGG GGAAAAGGCA TTTCTCAACC ATCTCTCAGC 8640 AGTTATTGAT CATTTCTTAA GGAACAGCAT TGTGATCAAA GACTCAACTT TACGTAAAAA 8700 TCAGTGGTAA ATTGGGGTTG TATTGGCCAT TGATTACATT CAGGATTGAA TAGTTTTCAG 8760 AATCACATGT AATCCAAAGA CAGTAGGTAG TGATGTCCCT TATCCCTGCA GCTGTTTTAA 8820 GATAGAGACC TCAGAAGACT CTGCTTGACC GATGACCAAT AATTATTTGA AAAAAAAAGA 8880 AAAAATGAGA GAAATAAAAC AGATATTTAA GAACTTTAGC CACCTATTTA GAATAGTTAT 8940 AGCCAGAAAA AAAAACAAGG GCATGAGTTC AAATGCATTA CTATCAGTGT CCTAGGCAAT 9000 ACCTAACCTA CTCTGAAATT GTGATTCAAA AGCAGTATTT CAAGAGGCAT TCTCCTTTTT 9060 TGGTTTGCTG ACCCCACTTG GACTGGTAGG TTTGGTGAGG CCCCCATAAA CCAGCTGGAG 9120

# # # # # # AACGCTGGGC AGGGCCGGCG CGGGTCGGGG GGCGCCCGAG GGGCCCGGGC CGAGCGGCGG 60 CGCGCAGGGC GGCAGCATCC ACTCGGGCCG CATCGCCGCG GTGCACAACG TGCCGCTGAG 120 CGTGCTCATC CGGCCGCTGC CGTCCGTGTT GGACCCCGCC AAGGTGCAGA GCCTCGTGGA 180 CACGATCCGG GAGGACCCAG ACAGCGTGCC CCCCATCGAT GTCCTCTGGA TCAAAGGGGC 240 CCAGGGAGGT GACTACTTCT ACTCCTTTGG GGGCTGCCAC CGCTACGCGG CCTACCAGCA 300 ACTGCAGCGA GAGACCATCC CCGCCAAGCT TGTCCAGTCC ACTCTCTCAG ACCTAAGGGT 360 GTACCTGGGA GCATCCACAC CAGACTTGCA GTAGCAGCCT CCTTGGCACC TGCTGCCACC 420 TTCAAGAGCC CAGAAGACAC ACCTGGCCTC CAGCAGGCTG GGCCATGCAG AAGGGATAGC 480 AGGGGTGCAT TCTCTTTGCA CCTGGCGAGA GGGTCTGACT CTGGGCACCC CTCTCACCGG 540 CTACAAGGCC TTGGACTCAC TGTACAGTGT GGGAGCCCCA GTTCCCACCT CTGTGACAAT 600 AGGATCATGG CCTTACCCTT GAAGCATTAC CGAGAAGGAG AACAGAGATG GGCTTGAAGA 660 GCCACGTGCT GCCGGCTCCA AATTCCCAAG GACAAGGATC CCTCTGCATT TTTGTCTATG 720 TAACCTCTTA TATGGACTAC ATTCAGCTGC AAGGAAAGGA AAACCTTGAT TGCAGTGGTT 780 TAAACAAACA GAAGATTGTT TTTCCACATA GCATGGATTC TGGAGATGGG TGGCTAATGG 840 TATTGGTTCA ACAACTCCAC GGAGGTAGGG GTCACGTCTT GGATCCTTTT GCCTTAATCT 900 CAGTGCTCGT TACTTCATGG TCCCAAGATG GCTGCTGTAT CCCCAAGAAT CATGTCTGCG 960 TTCAAGGAAG GAGGGGTGGA GGAAGAGGAA GGGCCAAACT AGCTGGACCC GTCACCTTCT 1020 ATCAGAAAGT AAAACCTCGT CAGAAGTCTG TTTCCTGCTC TCTCCCTCTG CATATCTTCA 1080 CTTAGATGCC CTTGGCCCGA GCCAGCTACC ATTGCACCTC TAGCTGCAAA CAAAGCTAAG 1140 ACAGCAGGGA ACAGAATTGT CATGGCTGAA TAGACCAATC GTGTTCCATC TACTGAGACT 1200 GGCACACTGC CTCCTGCAAT AAAACTGGGA TCCCATTACC AAGAGAGAAA TGCAGAATTG 1260 TGTACCAGTT AGCTTTTGCT GTGTAACAAA CCATCCCCAA ACTTGGCAGC TAGAAACAAA 1320 CCCTGTATTT TCCCACAATC CTATGGGTTG GCAATTTGGG CTGGGCTCAA CAGGGCAGTT 1380 CTGCTGCTCA CACCTGGGAT CCCTCATGGA GCTAAGGTCA GCTGTTACCT CAGCTGGGCC 1440 TGGATGGTCT AGGATAGCCT TACTCACTTG CCTGGCAGGT GACAGGCTGT TGGCTGGAAT 1500 TGCTTGGTTC TCCTCCATGT GGCCTCTCCA GCAGGCTAGC TCAGGCTTAT TCACATGATG 1560 GCTTCAGGAT TCCAAAGAGA GTGAGAGTAG AAGCTGAAAG ACTTCTTGAG TTCTTGGCCT 1620 GGAACTGGGA CTAGGACAGT GTCACTTCTG CTAAGTTCTT TTGGTCAGAG CAAATCACAA 1680 GGCTTTACCC AGATTCAAGG GATGAGAAAC AGACTACATG TCTTGATGAG GGGAACCACA 1740 AAGAGCTTGT GGCCATTTTT CACCTATCAC AAATAATTTT GGATGGGTAT TTATTTGGAT 1800 AAAGGTATTT CCCTCTTCCC CCTTTCTCTC TGTCTCATGG GGCCTCACTC TGCCAAGTTG 1860 GAAGGCACTA AGACATTGTC CTGGCCCTCA GGGTCTAGGG GAAGAGGTGT TGGGGCAGGA 1920 AGTGAGTCTC TCCATGGGCT GGACCCACTG TAGTAGGAGT GCCTCCTTGT CTGCACTGCT 1980 GGTATGGGGT TAGGCCAGGT AGGACATTCC AGAGGGGCTT CTGAAAACCA AGAGTCCCTG 2040 GGGAAAGGGA ACAGAGTAAG GCAGGCCTTG TTCTCACTGC CCTCTAAGGG AACTTGGTCA 2100 CTCGGCACTT TTAAGCCTCA GTTTCTCCAG TTCAATAATA AGGACAAGAG CTTTTCCCAT 2160 GCATTCTCTT TCCCCGGGAA AGTTGACTGA GGTGACCAGT AATAGAATTG AAAAGGGAGA 2220 GTGTCTTCAG TGCAATGTGG CATCCTGGAT TGGGTCTTGG AACAAAAACA GGACATTAGT 2280 GGGAAAATTG GAAATCTGAA AAAAGTCTGA ATTTTAGTTA ATATACCAAT TTCAGTCTCT. 2340 TGGTTTTGAC AGATGTACCA TGGTGATGTA AGATGTTGAC CTTGGGGTAG GCTGGGTGAA 2400 GGGTATACAG GAACTCTTTG TACTATCTCT GCAACTTCTC TGTAAATCTA GTATCATTCC 2460 AAAATAAAAG TTTATTTAAT TTAAAAAAAA AAAAAAAAAA AA Seq ID NO : 224 Protein sequence: Protein Accession &num : AAH17001. 1 1 11 21 31 41 51 # # # # # # TLGRAGAGRG APEGPGPSGG AQGGSIHSGR IAAVHNVPLS VLIRPLPSVL DPAKVQSLVD 60 TIREDPDSVP PIDVLWIKGA QGGDYFYSFG GCHRYAAYQQ LQRETIPAKL VQSTLSDLRV 120 YLGASTPDLQ Seq ID NO : 225 DNA sequence Nucleic Acid Accession # : NM 021048 Coding sequence: 1.. 1110 1 11 21 31 41 51 1 1 1 1 1 1 ATGCCTCGAG CTCCAAAGCG TCAGCGCTGC ATGCCTGAAG AAGATCTTCA ATCCCAAAGT 60 GAGACACAGG GCCTCGAGGG TGCACAGGCT CCCCTGGCTG TGGAGGAGGA TGCTTCATCA 120 TCCACTTCCA CCAGCTCCTC TTTTCCATCC TCTTTTCCCT CCTCCTCCTC TTCCTCCTCC 180 TCCTCCTGCT ATCCTCTAAT ACCAAGCACC CCAGAGGAGG TTTCTGCTGA TGATGAGACA 240 CCAAATCCTC CCCAGAGTGC TCAGATAGCC TGCTCCTCCC CCTCGGTCGT TGCTTCCCTT 300 CCATTAGATC AATCTGATGA GGGCTCCAGC AGCCAAAAGG AGGAGAGTCC AAGCACCCTA 360 CAGGTCCTGC CAGACAGTGA GTCTTTACCC AGAAGTGAGA TAGATGAAAA GGTGACTGAT 420 TTGGTGCAGT TTCTGCTCTT CAAGTATCAA ATGAAGGAGC CGATCACAAA GGCAGAAATA 480 CTGGAGAGTG TCATAAAAAA TTATGAAGAC CACTTCCCTT TGTTGTTTAG TGAAGCCTCC 540 GAGTGCATGC TGCTGGTCTT TGGCATTGAT GTAAAGGAAG TGGATCCCAC TGGCCACTCC 600 TTTGTCCTTG TCACCTCCCT GGGCCTCACC TATGATGGGA TGCTGAGTGA TGTCCAGAGC 660 ATGCCCAAGA CTGGCATTCT CATACTTATC CTAAGCATAA TCTTCATAGA GGGCTACTGC 720 ACCCCTGAGG AGGTCATCTG GGAAGCACTG AATATGATGG GGCTGTATGA TGGGATGGAG 780 CACCTCATTT ATGGGGAGCC CAGGAAGCTG CTCACCCAAG ATTGGGTGCA GGAAAACTAC 840 CTGGAGTACC GGCAGGTGCC TGGCAGTGAT CCTGCACGGT ATGAGTTTCT GTGGGGTCCA 900 AGGGCTCATG CTGAAATTAG GAAGATGAGT CTCCTGAAAT TTTTGGCCAA GGTAAATGGG 960 AGTGATCCAA GATCCTTCCC ACTGTGGTAT GAGGAGGCTT TGAAAGATGA GGAAGAGAGA 1020 GCCCAGGACA GAATTGCCAC CACAGATGAT ACTACTGCCA TGGCCAGTGC AAGTTCTAGC 1080 GCTACAGGTA GCTTCTCCTA CCCTGAATAA Seq ID NO: 226 Protein sequence : Protein Accession &num : NP 066386 1 11 21 31 41 51 MPRAPKRQRC MPEEDLQSQS ETQGLEGAQA PLAVEEDASS STSTSSSFPS SFPSSSSSSS 60

1 11 21 31 41 51 CCGGGCAGGT GGCTCATGCT CGGGAGCGTG GTTGAGCGGC TGGCGCGGTT GTCCTGGAGC 60 AGGGGCGCAG GAATTCTGAT GTGAAACTAA CAGTCTGTGA GCCCTGGAAC CTCCACTCAG 120 AGAAGATGAA GGATATCGAC ATAGGAAAAG AGTATATCAT CCCCAGTCCT GGGTATAGAA 180 GTGTGAGGGA GAGAACCAGC ACTTCTGGGA CGCACAGAGA CCGTGAAGAT TCCAAGTTCA 240 GGAGAACTCG ACCGTTGGAA TGCCAAGATG CCTTGGAAAC AGCAGCCCGA GCCGAGGGCC 300 TCTCTCTTGA TGCCTCCATG CATTCTCAGC TCAGAATCCT GGATGAGGAG CATCCCAAGG 360 GAAAGTACCA TCATGGCTTG AGTGCTCTGA AGCCCATCCG GACTACTTCC AAACACCAGC 420 ACCCAGTGGA CAATGCTGGG CTTTTTTCCT GTATGACTTT TTCGTGGCTT TCTTCTCTGG 480 CCCGTGTGGC CCACAAGAAG GGGGAGCTCT CAATGGAAGA CGTGTGGTCT CTGTCCAAGC 540 ACGAGTCTTC TGACGTGAAC TGCAGAAGAC TAGAGAGACT GTGGCAAGAA GAGCTGAATG 600 AAGTTGGGCC AGACGCTGCT TCCCTGCGAA GGGTTGTGTG GATCTTCTGC CGCACCAGGC 660 TCATCCTGTC CATCGTGTGC CTGATGATCA CGCAGCTGGC TGGCTTCAGT GGACCAAATT 720 TTCAGGATGG CTGTATTCTG CGGTCAGAAT GAGAGAGTCA AGCTGGGCAG AATCTCTCGC 780 CAAGAGTTCA GCCTTCCTTT GGAGACTGCT CCATCAGTGC CGAGGTGTGT GGGAACAGGC 840 TTCACTGCAC CGCCATCTTA CTGAGTTGCT TCACGTGAGG AAAAGGGGGC TTTGGCCCTG 900 TGACTCAGTT CCACATTTTG GATTGCATAC TGGAAAAGAA GCCAATCTTC TTGCTAGTAA 960 ACCAGCAACC CGGCTGTATA CAGTGGTGAC CCAAGCAATG GATATAAACC TAAAAATCTG 1020 AGGGAGGGGA GAGGTGGAAT ACAGTAGTTC TTGGAATCTG AAGTCTCCTA TTTGATCAGG 1080 TTATTTCCTG GGACTTGGCA AAAATCTGAT TGGTGGGGAT CTCCTAGGAC CTAGTGGACA 1140 TCTGGTATTA ATTTAATCTC AGGAAAAACA AGAAATTAAC CCAGAGAGAG TCTGGGTTTT 1200 GGAATTCAGC GTAGCTACCT CCAGACCGTG GTGTCTGGCC TCCATTTTTG TCTGTCATTC 1260 AGCTCTGACT TACAGCTGCA GTCACCTTTG CTATAAGGCA CCTGGGTAGA AGGGTGGATG 1320 GGCTTCACAT CAATTTTTTT CTTCCTTTAG GGTGGGGGAT TGGTTTGGCT TTCTTTTGTT 1380 GTGGTTTTTT GTTTTATTTT TGTCAAGATT GATTTTTAGA TGCAAGGACT TGAAAAGACC 1440 CAGAAGGATG CCACCAGTTT TTCCTTGAGG CCTAGGATTT TTTATTCTGT CCCGAGCAGA 1500 GGTAATTCCT CACAACTTAG TGCACCAGTA GCACCAGCCA TTTTGAGCAG AGTACCTCTT 1560 TGGGGAGCTT TTCGTTTTGT TTTGTTTTTA ATTCTCTTTC CTTAGCAGCA AGGTCTTTTT 1620 TCCTAGAGAA TCTACTCCGT TGCAGAATCA TTGCAACCTC AGGAGCCCTC ACTGATTGAG 1680 TGCTGTCAGC CTGATATACT ACTTTGGACT CTGGAAACAG ATATGGGTTC TATTCTCTAT 1740 TTCTACTGTG TGTCGTTAAA CAACCGTCGG AGACCAGATG ACCTGTTAGA TGGCTAGTCC 1800 TGTATAACTC GACTCTGTAT GTTTCAATGT ATGTTACTGC AATGCTTCAC CTGCTGTACA 1860 GTGTTTGTGA GATGCTCTTT GAAGATGGTA CTTTTATATT T Seq ID NO: 232 Protein sequence : Protein Accession # : Eos sequence 1 11 21 31 41 51 1 1 1 1 1 1 MKDIDIGKEY IIPSPGYRSV RERTSTSGTH RDREDSKFRR TRPLECQDAL ETAARAEGLS 60 LDASMHSQLR ILDEEHPKGK YHHGLSALKP IRTTSKHQHP VDNAGLFSCM TFSWLSSLAR 120 VAHKKGELSM EDVWSLSKHE SSDVNCRRLE RLWQEELNEV GPDAASLRRV VWIFCRTRLI ISO LSIVCLMITQ LAGFSGPNFQ DGCILRSE Seq ID NO: 233 DNA sequence Nucleic Acid Accession # : CAT cluster 1 11 21 31 41 51 TTTTAATGGT GCTCATATAT ACTGTATTTT TTGTTGTTTA GTTTTACTTA TTGAGAGTGT 60 CACAACATGA ATCACATAAT CATGATTTTT TTTTTTTACT TTTACTCCCC AAATTATTCA 120 TGTTTCTTAG ATCGTAGTCA TTGAGAAGTC CCAATAACTC TAAACTTTTG AGTTATAACG 180 TAGTAAACTT CTCTTTCATC TTTGTGTTAG CTCTGTAGTC TTAACCTGGA TTTTAATTTT 240 TTTGTTTCCA AAGTCACAAT TGAATTATTC TTAGATACCT TAAGCCACTG AATTCAGTTC 300 TGTTTGACTG AAAGCAAAAC AACGTGACAG TTTATTTTCA AACACTAACT TCTTGATATT 360 TTGTTATGGT ATATCTTTTT ATTAAATATT TATTTTGACT AAGCTTTCAT AAAATATTTG 420 AAGCTATTTT AATCATCAAG TATGGAAAAC AAATTACTAT TGCATTTTCC TATATATGCA 480 TATATTATGG ATTAACCAGA ATTGTATCAT TTTTGGCCTA ATGTCTGGAT ATAAAAGATA 540 ATTAGCCTAC TATAGTATTA ATAAATTTTT CAGTTGGTTT GGGCAAATTT AAACCTGAAA 600 AATAGGTTAA AAAGTAGTTA CAAATTAAAC TTACTAATTT ATACCTGATT TTTTTTCTTG 660 AATTAAAGTA CATTTTAAAT GAGCTTTATA ATACCTTAAA AAGTTGGTTC TAATTTAAAA 720 TATGAAAGCT CTGGCTATCA TCCTGGGATA GTAATTTCTA ATTATATAGT ATTTCAAAAC 780 TATATATTTT TTAGTTCCTT TGAGATAACT AATTTCTAAT TATATATGTT TCAAAAACCA 840 TATCCTGTAT TTTTTTTAAG AATTGTTTTA TAAATAGGTC ATAAGATACA AGGTCTGCAT 900 TAGAAGACCC ACTCTTACTA GGTTCCCTAA GGATCTGCCA TAGATTTTTT TTTTTTTTTT 960 TTTTTTTTAG GTAGTTTAAA GCAAGCACTG ATACCAGTGG GAGTTGGTCT TGATCTAGGA 1020 GATTCTGTTA AGCATCCAAA AACAATGCCT AATTTCAGTT CTTAGGTTAT GGCTTGTGAC 1080 TCCAGATAAA AGATGGAGAA TACCTCATGT ACTGTGACTT GAAAATGAAT TCTTAAAATT 1140 CTTAGGCTCT CTCCATGTAT CTTTCTTAAG GAAAAGTTTC TGAGTGTGAT CTCTCTTTTG 1200 CCATAGTATC AAGTGGAGGG TAGTTCAGAA AAGTTAATAG GAAATCTTTT GTGACAGCAG 1260 ACTATAATAG AAGTTTGAGT AATATTTTAA TAAATTTATA TAATTCAAAT GATAAAAATG 1320 TATCAATGTT ATCCAATGAT TTTTATTAAA AAATTACCTT ATTATTAGAA CTGTGCCTAT 1380 TACATAAAAA GTGCTCATGT ATTTGAATTT TAAATAATTT ATTTAAATCA AGACCACCAT 1440 AAGTCATTAA TAATTTAATA ATTGTTTTAA ATCAGTGGTT TTCAACCCTC ACTTCATATT 1500 AGAATCATCT GAGGACTTTT AATATGGAAT CCACCTCATA ACAATTAAGT CTAAATTTCT 1560 GGAAGATGGA GCCATGCTTG TTTTTCCAAA AGCTCTTTGA GTGATTCTAA TTTGTAGTCA 1620 GAGTTGAAGA CCACTGCTCT AAATTAGTGC AGGAAAATGC TTTTATTTCT CCCATGTTAA 1680 CTTTTAAAAC TAGTAATGTA CCCAGTTAAG TTTTGATGGT TTAAATTCCA CTAAAGAACA 1740 TATTCTTCTA ATAACTAGCA TTTATTACAT GAAATTTAAG AGTTTAAGTT CCATCAAACT 1800 AGCCCTTGTG TAAGATTATT ATTTCTTCTC TATAACTTCA AAATAGATAT TTCATTCAAA 1860 CTGTTCAGGT GAGAAAACAT AATGGATTTT TTTTTTTTTC CTCTGGAGCT GCCTGTTCAG 1920 TGAGATGGAG GAGGTGGGCA CATTTAAGGT CAGTTCACTA ACCTATGGTT CAGAGTTCTG 1980 ATCATATGGA AGTTTGGAAA AGAGAGCTTA TCACAGGTTT GTATGCTGGT GAATGGATAG 2040 TTTTAATTCT CACTGTCTCA AAAGAGAATC AGCTCTCCAG CAGTTCTAGA AAAGCTTTGA 2100 CAATCCCCAA GGGGCAGTGT TACCTTACTC CTTCACTGCT TCTTAGAAGG TAGAATTAAG 2160 TTTCTGGAAT TGCACCTACA TGTTTTCTTA TTAACATTCA GAATTGGGAA TATTAATTTT 2220

TCCAGTGAGT AGTTTTCTGA AATTGGTAAC TTGGAGAGTA AAATAACGTA TTTTGCTTTT 2280 CAATTTTGTG TTTGTTTACT TTTATGTAAA AATTTGATAT GTGAATTACA CAGTTCTAAT 2340 AAAACCTCAT GCCTTTTCAT TACATCTAAT TTGAACTCTC AACTTCAGTG CCAGAAGTGC 2400 TTTAAAGATG CTTTAATGAA AAGTATTAAG AAAATATATA GATTTGTATG TCAGTTTATA 2460 CTTCAGAAAT CCATATATTT GTCATATTTA TTTTTTTAGA AACCTCCTAA TTGGATAACT 2520 AGATGGTATT TAAAATGAAT GCCCAAAAAT ATCTTGTACC TTTGTCCAAA AGTTTATCTG 2580 TTGGAAGCCG CCAGCCATTC ATGTAGAGAG TTTATAAGAA AATAATTTAA AATTGTATGC 2640 ATTTTATATT ACTATGGTAT CTGTGTACCA TATTTCTAAG TATTCATTAT TAAATTGGTA 2700 CTTCTTAAAA CCATAACCTG GCTTGCCTTT TAGTGTTAAA CACAAAATCC AACATTGTAT 2760 ATAGAGATTC TTCTTTTATG AAGAAGAGCT GACGTAATTT ATTACCAGTG CATCTGCACA 2820 AAGACATTAA CATAAGTCTC TGAGCAGTGA TACATTTTCA AACATGAAGA GTGACAACCA 2880 CCACATTAAA CAACCACGGC AACACTCAGA CTTGGCACTT TCCTACGAAT CCATCCTATA 2940 TGTGCCTGGT ATCGCCTCTG GCATAACTTA CACGAATCGT CCTCCCTACT TGTCTACGCT 3000 CCTTCATCAA GCACTTGCCA ACACATTCAC CTCTAACTTG TACAACCTTA CCAACTCACC 3060 ACAACATCTG CAACTCTACC CTATCAACTG CCAACCTAAA GACCCCCAAC ACAACACAAC 3120 CCCCAAACAC AAAACCACTA AATCATAACC ACCACACACG CCACACACCA CACACCCACC 3180 CACACAACCA ACACACCACG ACCAAACACC CCACCACAAA CAAGCTAACA ACCACAAACA, 3240 GACAACACAT CACATACACT CACTACCCCC CCATACTCCC ACCCACCA Seq ID NO : 234 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 27-281 1 11 21 31 41 51 # # # # # # AGCAGGAGGA GAGCTGGCGG GAAGACATGC ACCCCTTGAA GACCCAGGA GAGGCCGTCT 60 GTCTACCGCG TAGCAGTTAC ATCAGACTGA GACACTTCCT GTTTACAGGA GACTATAAAA 120 TTCCTGCCCC GTGCTCATTT GGGGCTGACG CCATTTTAGG CCTCAGCCCA TCTGCACCCA 180 GGCGCTCACT GAAACAGTGT GTTGCTCCAC ACCGCCTTGT TTTGCTTGTT GGCGCGCTCT 240 CAGGGTTCCG ACCAATCCAA GAGCCTTGCA GAAAGCATTA ACGTGCTTTT CTCTTTGGCA 300 GAGTTTTTCT TTGCTCTGAT CTTGGAGACA TCCCTCTGCC TAGTGGAAAC ATAAGGAATA 360 CAGAAAGAAT GCAAGGAGAT AGACCAACGT GAGATTCTCC TTCATGCACT CAAGAGAAAG 420 ATGTTGCAGG AAGAGCTAGT CTTTCAGGCT GGGCTGGTGA CCTGAGAAAG AATGTCCAGC 480 TTTTCTTCTC CACTTGGCAT ATCAAGAGCC AGGCGTGGAA GACTAAAACA GGAAATGTTT 540 ATAAAAACTG TTCAGCGGTT CGCCAACAAG AAGTGGTAAA GTAGCAAAAA TGGGGATGGA 600 GATGCCAGGA GGAAAGATGC CAGGGGTAAA GTGGGAAAAT GGGAACCTGA AGCCAGGAGG 660 TCAAGCCAAG CCAACAGGTG TTCTGTTTTT CATCACAGAA CTAATAAGTG GTGCTGAGGA 720 CTCAAACCCG GGGAAGCCCA CTCTAGAACC CATGCTGGTC ATCCATATCC CCAAGGCCCT 780 GGTCAGAACA CAGCTAAGCA GATGGCTTGG GTCATCAGGA CGTCCATTAC ATCCAAAGGA 840 AGACAGCCTG TGACGTTTCA AAAGCAAAAG TCCCCTACCA GCCAGTGAAG CTACCTGATT 900 TCTCAGTATC TTACGCCCAG TGACACGATC TACCCTCAAA ACTTAAAAAA AAAAGGGAAA 960 CATAAACACA TAACAGCAGC AGCAATAATT AAAGATGAGA TGAGAACAAT TAAGAAAAAA 1020 GGAAAGGTCT CCTGTGACTG TTTTATTTTT AGGGAAACAG AGAGGAAGAA GAATGATTTT 1080 TCTTTTGATG ACTCTATATC CAACTCTGAG GTTTGATTAA AGAAATGACC TTGAACCACA 1140 GCAAAGAAAA ATAAAAGACA ATTTCCAGTA AGTATGCCAG TTCGAATTAA TGATTTACTT 1200 TTTATTTTTA AACTGAATTC AGCAGAGATT TACATGCATT ACGATGATTA ACATCTGAAA 1260 TTTGACCTTG AAATAATCTT TACATTGTAA ATTCTTAATG ATCAAAACAA GGTTCTCAGT 1320 GATTAAAACA TATTAGTAAT TAATTATTAA AGGAGAATAA TTGCAAATAC AACATTCCTA 1380 AAATCTCAAG GCTTTTAAAG CATTTGTACA AATGACTGGA CATTTTTTAA ATTTGAAAAA 1440 AAAAAAAAGC CCTCCATCTG ATTCTCATTT TCATTGTCAG TGCAACAACA AAAAAGGTAT 1500 GCACTTCTCT TCTCATTTTC CACTGTCTCG CAAGCTAGAA ATTCTCACGA CTACCTTTGA 1560 TCCCATCAAA GCCAAAGAAA GAAAAGAAAA TTGTTCTGTA CAGATATATG ACATTAAAAA 1620 ATAATCCC Seq ID NO : 235 Protein sequence: Protein Accession # : Eos sequence 1 11 21 31 41 51 MHPLKTQREA VCLPRSSYIR LRHFLFTGDY KIPAPCSFGA DAILGLSPSA PRRSLKQCVA 60 PHRLVLLVGA LSGFRPIQEP CRKH Seq ID NO: 236 DNA sequence Nucleic Acid Accession # : NM 002075 Coding sequence: 406.. 1428 1 11 21 31 41 51 1 1 1 1 1 1 CCACAATAGG GGCAGACCTG TCCATCCTTC TCTGTGGGTC CCCTGTACCT TTCTCCCCCA 60 ACAGGATCAG ACCCAGAGGC AGCTGGTTGG GGTTTGTCGA GAAGAAGGAT TATCCAGATC 120 AGTCCTTTCT AATCTCAGCT CCTGCCTGTA CCCTCCCATA CTCACCAAAC CCTCTTCCCC 180 ACCACCCTGA GCTGAGGAGC ACAGTTTGAG GCCCCCCCAA CCCCCCGCCG GTCGGGGCCA 240 GGCCAGGCCA GGCCAGCTCC TCTGGCAGCA GAGCCTGGGC AGGTGACGGG CGGGCGCGGG 300 CGTCGCAGCT GAGGGAGTAA GGAGGCTCCC AGGAACCGGA GCTGGAAACC CGGCCGAGGT 360 CCAGCCAGAG CCCAAGAGCC AGAGTGACCC CTCGACCTGT CAGCCATGGG GGAGATGGAG 420 CAACTGCGTC AGGAAGCGGA GCAGCTCAAG AAGCAGATTG CAGATGCCAG GAAAGCCTGT 480 GCTGACGTTA CTCTGGCAGA GCTGGTGTCT GGCCTAGAGG TGGTGGGACG AGTCCAGATG 540 CGGACGCGGC GGACGTTAAG GGGACACCTG GCCAAGATTT ACGCCATGCA CTGGGCCACT 600 GATTCTAAGC TGCTGGTAAG TGCCTCGCAA GATGGGAAGC TGATCGTGTG GGACAGCTAC 660 ACCACCAACA AGGTGCACGC CATCCCACTG CGCTCCTCCT GGGTCATGAC CTGTGCCTAT 720 GCCCCATCAG GGAACTTTGT GGCATGTGGG GGGCTGGACA ACATGTGTTC CATCTACAAC 780 CTCAAATCCC GTGAGGGCAA TGTCAAGGTC AGCCGGGAGC TTTCTGCTCA CACAGGTTAT 840 CTCTCCTGCT GCCGCTTCCT GGATGACAAC AATATTGTGA CCAGCTCGGG GGACACCACG 900 TGTGCCTTGT GGGACATTGA GACTGGGCAG CAGAAGACTG TATTTGTGGG ACACACGGGT 960 GACTGCATGA GCCTGGCTGT GTCTCCTGAC TTCAATCTCT TCATTTCGGG GGCCTGTGAT 1020 GCCAGTGCCA AGCTCTGGGA TGTGCGAGAG GGGACCTGCC GTCAGACTTT CACTGGCCAC 1080

GAGTCGGACA TCAACGCCAT CTGTTTCTTC CCCAATGGAG AGGCCATCTG CACGGGCTCG 1140 GATGACGCTT CCTGCCGCTT GTTTGACCTG CGGGCAGACC AGGAGCTGAT CTGCTTCTCC 1200 CACGAGAGCA TCATCTGCGG CATCACGTCC GTGGCCTTCT CCCTCAGTGG CCGCCTACTA 1260 TTCGCTGGCT ACGACGACTT CAACTGCAAT GTCTGGGACT CCATGAAGTC TGAGCGTGTG 1320 GGCATCCTCT CTGGCCACGA TAACAGGGTG AGCTGCCTGG GAGTCACAGC TGACGGGATG 1380 GCTGTGGCCA CAGGTTCCTG GGACAGCTTC CTCAAAATCT GGAACTGAGG AGGCTGGAGA 1440 AAGGGAAGTG GAAGGCAGTG AACACACTCA GCAGCCCCCT GCCCGACCCC ATCTCATTCA 1500 GGTGTTCTCT TCTATATTCC GGGTGCCATT CCCACTAAGC TTTCTCCTTT GAGGGCAGTG 1560 GGGAGCATGG GACTGTGCCT TTGGGAGGCA GCATCAGGGA CACAGGGGCA AAGAACTGCC 1620 CCATCTCCTC CCATGGCCTT CCCTCCCCAC AGTCCTCACA GCCTCTCCCT TAATGAGCAA 1680 GGACAACCTG CCCCTCCCCA GCCCTTTGCA GGCCCAGCAG ACTTGAGTCT GAGGCCCCAG 1740 GCCCTAGGAT TCCTCCCCCA GAGCCACTAC CTTTGTCCAG GCCTGGGTGG TATAGGGCGT 1800 TTGGCCCTGT GACTATGGCT CTGGCACCAC TAGGGTCCTG GCCCTCTTCT TATTCATGCT 1860 TTCTCCTTTT TCTACCTTTT TTTCTCTCCT AAGACACCTG CAATAAAGTG TAGCACCCTG 1920 GT Seq ID NO : 237 Protein sequence: Protein Accession &num : NP 002066 1 11 21 31 41 51 MGEMEQLRQE AEQLKKQIAD ARKACADVTL AELVSGLEW GRVQMRTRRT LRGHLAKIYA 60 MHWATDSKLL VSASQDGKLI VWDSYTTNKV HAIPLRSSWV MTCAYAPSGN FVACGGLDNM 120 CSIYNLKSRE GNVKVSRELS AHTGYLSCCR FLDDNNIVTS SGDTTCALWD IETGQQKTVF 180 VGHTGDCMSL AVSPDFNLFI SGACDASAKL WDVREGTCRQ TFTGHESDIN AICFFPNGEA 240 ICTGSDDASC RLFDLRADQE LICFSHESII CGITSVAFSL SGRLLFAGYD DFNCNVWDSM 300 KSERVGILSG HDNRVSCLGV TADGMAVATG SWDSFLKIWN Seq ID NO : 238 DNA sequence Nucleic Acid Accession &num : CAT cluster 1 11 21 31 41 51 I I I I I I TCCCAATGTG TNGAACCTAC CATAAATTCT TTTCTTACNG GACAATCTTA TNCTAANCAA 60 TACCATTTGC TTTTAAGGCA GATAATCCTC CAAGTTTTCT AATGATATCT GAAACTATTA 120 ACTGATTCTG TGAATTATGA AATCTGAAAA GGAATTGGAA GTTGCTAAAA ATCTATCATT 180 TGCATTGACC AGTGTGAAGC ACAGTGGAAT GAGAATGCGT GCCCTGACAC CAAAGAAAAA 240 TAAGTGACTG GAAAGCTGAA GAATCACCGG CTTCAGTGAC ATGGAACCCA GTGATTTGAT 300 TTTTGACGAG TATCGGGTGA CTTTGAGGTG GTCAAGAAAC CACACTTTAA GAACAATGTC 360 CAAAAAGGGG AAAAAAAAGA GCAACCAAAG AAAAAAAATC CATAAAATTG CACAGAAGAA 420 AAGAAAGAAA AATAAAATAC ACAATATGGA CGATGGAGAA AAACAGTTAC ATTTCTTTAT 480 GGATCAAGAA GTTTGTGTAC ACATAATCTC ATTTTGAGAT ATATAACTAT TTTTGTCTTT 540 CAGAAGTGAA TCAAAATATT TCAAAATGCT GTCTTATGAA ACTACAATAT TCTCACAGAT 600 TAGAAAAGTT TTTCTGTAAA AGTCAGATAG TAAATATTTT AGGTTTTGCA GTGTCTTTTG 660 CAACTACTCA ACTTTCCTAC TGTAGCACAA GAGTAGCTGT GGTACTGTGC AAATAAATTG 720 CTTGTGTTCC AATAAAGCTT CATTTACAAA AACATGCCAT GGGCCATATT TGGCCTGTAC 780 ACTGTTGTTT GCCAAGTCCT AATATAGTTG CTTAGCAAGT ATTGTGAGCT ATTTGAGGAA 840 <BR> <BR> GACATGAAAG TTCATTGGGT TGCTAAAAAG TATGTAGAAA TTCAAAGGAA AATTAAAATT 900 TAGGCTAAGT TATAATACAC TGTTTTAACA ATTGTAAAAT GTAAGAGAAA TTTACAAATA 960 AAAATCCCAA ATAAAA Seq ID NO : 239 DNA sequence Nucleic Acid Accession # : NM 001786. 1 Coding sequence: 130-1023 1 11 21 31 41 51 GGGGGGGGGG GGCACTTGGC TTCAAAGCTG GCTCTTGGAA ATTGAGCGGA GAGCGACGCG 60 GTTGTTGTAG CTGCCGCTGC GGCCGCCGCG GAATAATAAG CCGGGATCTA CCATACCCAT 120 TGACTAACTA TGGAAGATTA TACCAAAATA GAGAAAATTG GAGAAGGTAC CTATGGAGTT 180 GTGTATAAGG GTAGACACAA AACTACAGGT CAAGTGGTAG CCATGAAAAA AATCAGACTA 240 GAAAGTGAAG AGGAAGGGGT TCCTAGTACT GCAATTCGGG AAATTTCTCT ATTAAAGGAA 300 CTTCGTCATC CAAATATAGT CAGTCTTCAG GATGTGCTTA TGCAGGATTC CAGGTTATAT 360 CTCATCTTTG AGTTTCTTTC CATGGATCTG AAGAAATACT TGGATTCTAT CCCTCCTGGT 420 CAGTACATGG ATTCTTCACT TGTTAAGAGT TATTTATACC AAATCCTACA GGGGATTGTG 480 TTTTGTCACT CTAGAAGAGT TCTTCACAGA GACTTAAAAC CTCAAAATCT CTTGATTGAT 540 GACAAAGGAA CAATTAAACT GGCTGATTTT GGCCTTGCCA GAGCTTTTGG AATACCTATC 600 AGAGTATATA CACATGAGGT AGTAACACTC TGGTACAGAT CTCCAGAAGT ATTGCTGGGG 660 TCAGCTCGTT ACTCAACTCC AGTTGACATT TGGAGTATAG GCACCATATT TGCTGAACTA 720 GCAACTAAGA AACCACTTTT CCATGGGGAT TCAGAAATTG ATCAACTCTT CAGGATTTTC 780 AGAGCTTTGG GCACTCCCAA TAATGAAGTG TGGCCAGAAG TGGAATCTTT ACAGGACTAT 840 AAGAATACAT TTCCCAAATG GAAACCAGGA AGCCTAGCAT CCCATGTCAA AAACTTGGAT 900 GAAAATGGCT TGGATTTGCT CTCGAAAATG TTAATCTATG ATCCAGCCAA ACGAATTTCT 960 GGCAAAATGG CACTGAATCA TCCATATTTT AATGATTTGG ACAATCAGAT TAAGAAGATG 1020 TAGCTTTCTG ACAAAAAGTT TCCATATGTT ATGTCAACAG ATAGTTGTGT TTTTATTGTT 1080 AACTCTTGTC TATTTTTGTC TTATATATAT TTCTTTGTTA TCAAACTTCA GCTGTACTTC 1140 GTCTTCTAAT TTCAAAAATA TAACTTAAAA ATGTAAATAT TCTATATGAA TTTAAATATA 1200 ATTCTGTAAA TGTGAAAAAA AAAAAAAAAA AAAAA Seq ID NO : 240 Protein sequence: Protein Accession &num : NP 001777. 1 1 11 21 31 41 51 MEDYTKIEKI GEGTYGWYK GRHKTTGQW AMKKIRLESE EEGVPSTAIR EISLLKELRH 60 PNIVSLQDVL MQDSRLYLIF EFLSMDLKKY LDSIPPGQYM DSSLVKSYLY QILQGIVFCH 120

SRRVLHRDLK PQNLLIDDKG TIKLADFGLA RAFGIPIRVY THEVVTLWYR SPEVLLGSAR 180 YSTPVDIWSI GTIFAELATK KPLFHGDSEI DQLFRIFRAL GTPNNEVWPE VESLQDYKNT 240 FPKWKPGSLA SHVKNLDENG LDLLSKMLIY DPAKRISGKM ALNHPYFNDL DNQIKKM Seq ID NO : 241 DNA sequence Nucleic Acid Accession # : NM 033379. 1 Coding sequence: 132-854 1 11 21 31 41 51 # # # # # # CGCCCGCGCG CGGGCTCAAC TTTGTAGAGC GAGGGGCCAA CTTGGCAGAG CGCGCGGCCA 60 GCTTTGCAGA GAGCGCCCTC CAGGGACTAT GCGTGCGGGG ACACGGGATC TACCCATACC 120 ATTGACTAAC TATGGAAGAT TATACCAAAA TAGAGAAAAT TGGAGAAGGT ACCTATGGAG 180 TTGTGTATAA GGGTAGACAC AAAACTACAG GTCAAGTGGT AGCCATGAAA AAAATCAGAC 240 TAGAAAGTGA AGAGGAAGGG GTTCCTAGTA CTGCAATTCG GGAAATTTCT CTATTAAAGG 300 AACTTCGTCA TCCAAATATA GTCAGTCTTC AGGATGTGCT TATGCAGGAT TCCAGGTTAT 360 ATCTCATCTT TGAGTTTCTT TCCATGGATC TGAAGAAATA CTTGGATTCT ATCCCTCCTG 420 GTCAGTACAT GGATTCTTCA CTTGTTAAGG TAGTAACACT CTGGTACAGA TCTCCAGAAG 480 TATTGCTGGG GTCAGCTCGT TACTCAACTC CAGTTGACAT TTGGAGTATA GGCACCATAT 540 TTGCTGAACT AGCAACTAAG AAACCACTTT TCCATGGGGA TTCAGAAATT GATCAACTCT 600 TCAGGATTTT CAGAGCTTTG GGCACTCCCA ATAATGAAGT GTGGCCAGAA GTGGAATCTT 660 TACAGGACTA TAAGAATACA TTTCCCAAAT GGAAACCAGG AAGCCTAGCA TCCCATGTCA 720 AAAACTTGGA TGAAAATGGC TTGGATTTGC TCTCGAAAAT GTTAATCTAT GATCCAGCCA 780 AACGAATTTC TGGCAAAATG GCACTGAATC ATCCATATTT TAATGATTTG GACAATCAGA 840 TTAAGAAGAT GTAGCTTTCT GACAAAAAGT TTCCATATGT TATGTCAACA GATAGTTGTG 900 TTTTTATTGT TAACTCTTGT CTATTTTTGT CTTATATATA TTTCTTTGTT ATCAAACTTC 960 AGCTGTACTT CGTCTTCTAA TTTCAAAAAT ATAACTTAAA AATGTAAATA TTCTATATGA 1020 ATTTAAATAT AATTCTGTAA ATGTGAAAAA AAAAAAAAAA AAAAAA Seq ID NO : 242 Protein sequence: Protein Accession # : NP 203698. 1 1 11 21 31 41 51 MEDYTKIEKI GEGTYGWYK GRHKTTGQW AMKKIRLESE EEGVPSTAIR EISLLKELRH 60 PNIVSLQDVL MQDSRLYLIF EFLSMDLKKY LDSIPPGQYM DSSLVKWTL WYRSPEVLLG 120 SARYSTPVDI WSIGTIFAEL ATKKPLFHGD SEIDQLFRIF RALGTPNNEV WPEVESLQDY 180 KNTFPKWKPG SLASHVKNLD ENGLDLLSKM LIYDPAKRIS GKMALNHPYP NDLDNQIKKM Seq ID NO : 243 DNA sequence Nucleic Acid Accession # : AF101051. 1 Coding sequence: 221-856 1 11 21 31 41 51 GAGCAACCTC AGCTTCTAGT ATCCAGACTC CAGCGCCGCC CCGGGCGCGG ACCCCAACCC 60 CGACCCAGAG CTTCTCCAGC GGCGGCGCAG CGAGCAGGGC TCCCCGCCTT AACTTCCTCC 120 GCGGGGCCCA GCCACCTTCG GGAGTCCGGG TTGCCCACCT GCAAACTCTC CGCCTTCTGC 180 ACCTGCCACC CCTGAGCCAG CGCGGGCGCC CGAGCGAGTC ATGGCCAACG CGGGGCTGCA 240 GCTGTTGGGC TTCATTCTCG CCTTCCTGGG ATGGATCGGC GCCATCGTCA GCACTGCCCT 300 GCCCCAGTGG AGGATTTACT CCTATGCCGG CGACAACATC GTGACCGCCC AGGCCATGTA 360 CGAGGGGCTG TGGATGTCCT GCGTGTCGCA GAGCACCGGG CAGATCCAGT GCAAAGTCTT 420 TGACTCCTTG CTGAATCTGA GCAGCACATT GCAAGCAACC CGTGCCTTGA TGGTGGTTGG 480 CATCCTCCTG GGAGTGATAG CAATCTTTGT GGCCACCGTT GGCATGAAGT GTATGAAGTG 540 CTTGGAAGAC GATGAGGTGC AGAAGATGAG GATGGCTGTC ATTGGGGGTG CGATATTTCT 600 TCTTGCAGGT CTGGCTATTT TAGTTGCCAC AGCATGGTAT GGCAATAGAA TCGTTCAAGA 660 ATTCTATGAC CCTATGACCC CAGTCAATGC CAGGTACGAA TTTGGTCAGG CTCTCTTCAC 720 TGGCTGGGCT GCTGCTTCTC TCTGCCTTCT GGGAGGTGCC CTACTTTGCT GTTCCTGTCC 780 CCGAAAAACA ACCTCTTACC CAACACCAAG GCCCTATCCA AAACCTGCAC CTTCCAGCGG 840 GAAAGACTAC GTGTGACACA GAGGCAAAAG GAGAAAATCA TGTTGAAACA AACCGAAAAT 900 GGACATTGAG ATACTATCAT TAACATTAGG ACCTTAGAAT TTTGGGTATT GTAATCTGAA 960 GTATGGTATT ACAAAACAAA CAAACAAACA AAAAACCCAT GTGTTAAAAT ACTCAGTGCT 1020 AAACATGGCT TAATCTTATT TTATCTTCTT TCCTCAATAT AGGAGGGAAG ATTTTACCAT 1080 TTGTATTACT GCTTCCCATT GAGTAATCAT ACTCAAATGG GGGAAGGGGT GCTCCTTAAA 1140 TATATATAGA TATGTATATA TACATGTTTT TCTATTAAAA ATAGACAGTA AAATACTATT 1200 CTCATTATGT TGATACTAGC ATACTTAAAA TATCTCTAAA ATAGGTAAAT GTATTTAATT 1260 CCATATTGAT GAAGATGTTT ATTGGTATAT TTTCTTTTTC GTCCTTATAT ACATATGTAA 1320 CAGTCAAATA TCATTTACTC TTCTTCATTA GCTTTGGGTG CCTTTGCCAC AAGACCTAGC 1380 CTAATTTACC AAGGATGAAT TCTTTCAATT CTTCATGCGT GCCCTTTTCA TATACTTATT 1440 TTATTTTTTA CCATAATCTT ATAGCACTTG CATCGTTATT AAGCCCTTAT TTGTTTTGTG 1500 TTTCATTGGT CTCTATCTCC TGAATCTAAC ACATTTCATA GCCTACATTT TAGTTTCTAA 1560 AGCCAAGAAG AATTTATTAC AAATCAGAAC TTTGGAGGCA AATCTTTCTG CATGACCAAA 1620 GTGATAAATT CCTGTTGACC TTCCCACACA ATCCCTGTAC TCTGACCCAT AGCACTCTTG 1680 TTTGCTTTGA AAATATTTGT CCAATTGAGT AGCTGCATGC TGTTCCCCCA GGTGTTGTAA 1740 CACAACTTTA TTGATTGAAT TTTTAAGCTA CTTATTCATA GTTTTATATC CCCCTAAACT 1800 ACCTTTTTGT TCCCCATTCC TTAATTGTAT TGTTTTCCCA AGTGTAATTA TCATGCGTTT 1860 TATATCTTCC TAATAAGGTG TGGTCTGTTT GTCTGAACAA AGTGCTAGAC TTTCTGGAGT 1920 GATAATCTGG TGACAAATAT TCTCTCTGTA GCTGTAAGCA AGTCACTTAA TCTTTCTACC 1980 TCTTTTTTCT ATCTGCCAAA TTGAGATAAT GATACTTAAC CAGTTAGAAG AGGTAGTGTG 2040 AATATTAATT AGTTTATATT ACTCTCATTC TTTGAACATG AACTATGCCT ATGTAGTGTC 2100 TTTATTTGCT CAGCTGGCTG AGACACTGAA GAAGTCACTG AACAAAACCT ACACACGTAC 2160 CTTCATGTGA TTCACTGCCT TCCTCTCTCT ACCAGTCTAT TTCCACTGAA CAAAACCTAC 2220 ACACATACCT TCATGTGGTT CAGTGCCTTC CTCTCTCTAC CAGTCTATTT CCACTGAACA 2280 AAACCTACGC ACATACCTTC ATGTGGCTCA GTGCCTTCCT CTCTCTACCA GTCTATTTCC 2340 ATTCTTTCAG CTGTGTCTGA CATGTTTGTG CTCTGTTCCA TTTTAACAAC TGCTCTTACT 2400 TTTCCAGTCT GTACAGAATG CTATTTCACT TGAGCAAGAT GATGTATGGA AAGGGTGTTG 2460

MAGSAMSSKF FLVALAIFFS FAQVVIEANS WWSLGMNNPV QMSEVYIIGA QPLCSQLAGL 60 SQGQKKLCHL YQDHMQYIGE GAKTGIKECQ YQFRHRRWNC STVDNTSVFG RVMQIGSRET 120 AFTYAVSAAG WNAMSRACR EGELSTCGCS RAARPKDLPR DWLWGGCGDN IDYGYRFAKE 180 FVDARERERI HAKGSYESAR ILMNLHNNEA GRRTVYNLAD VACKCHGVSG SCSLKTCWLQ 240 LADFRKVGDA LKEKYDSAAA MRLNSRGKLV QVNSRFNSPT TQDLVYIDPS PDYCVRNEST 300 GSLGTQGRLC NKTSEGMDGC ELMCCGRGYD QFKTVQTERC HCKFHWCCYV KCKKCTEIVD 360 QFVCK Seq ID NO : 250 DNA sequence Nucleic Acid Accession # : NM 014058 Coding sequence: 56.. 1324 1 11 21 31 41 51 TGACTTGGAT GTAGACCTCG ACCTTCACAG GACTCTTCAT TGCTGGTTGG CAATGATGTA 60 TCGGCCAGAT GTGGTGAGGG CTAGGAAAAG AGTTTGTTGG GAACCCTGGG TTATCGGCCT 120 CGTCATCTTC ATATCCCTGA TTGTCCTGGC AGTGTGCATT GGACTCACTG TTCATTATGT 180 GAGATATAAT CAAAAGAAGA CCTACAATTA CTATAGCACA TTGTCATTTA CAACTGACAA 240 ACTATATGCT GAGTTTGGCA GAGAGGCTTC TAACAATTTT ACAGAAATGA GCCAGAGACT 300 TGAATCAATG GTGAAAAATG CATTTTATAA ATCTCCATTA AGGGAAGAAT TTGTCAAGTC 360 TCAGGTTATC AAGTTCAGTC AACAGAAGCA TGGAGTGTTG GCTCATATGC TGTTGATTTG 420 TAGATTTCAC TCTACTGAGG ATCCTGAAAC TGTAGATAAA ATTGTTCAAC TTGTTTTACA 480 TGAAAAGCTG CAAGATGCTG TAGGACCCCC TAAAGTAGAT CCTCACTCAG TTAAAATTAA 540 AAAAATCAAC AAGACAGAAA CAGACAGCTA TCTAAACCAT TGCTGCGGAA CACGAAGAAG 600 TAAAACTCTA GGTCAGAGTC TCAGGATCGT TGGTGGGACA GAAGTAGAAG AGGGTGAATG 660 GCCCTGGCAG GCTAGCCTGC AGTGGGATGG GAGTCATCGC TGTGGAGCAA CCTTAATTAA 720 TGCCACATGG CTTGTGAGTG CTGCTCACTG TTTTACAACA TATAAGAACC CTGCCAGATG 780 GACTGCTTCC TTTGGAGTAA CAATAAAACC TTCGAAAATG AAACGGGGTC TCCGGAGAAT 840 AATTGTCCAT GAAAAATACA AACACCCATC ACATGACTAT GATATTTCTC TTGCAGAGCT 900 TTCTAGCCCT GTTCCCTACA CAAATGCAGT ACATAGAGTT TGTCTCCCTG ATGCATCCTA 960 TGAGTTTCAA CCAGGTGATG TGATGTTTGT GACAGGATTT GGAGCACTGA AAAATGATGG 1020 TTACAGTCAA AATCATCTTC GACAAGCACA GGTGACTCTC ATAGACGCTA CAACTTGCAA 1080 TGAACCTCAA GCTTACAATG ACGCCATAAC TCCTAGAATG TTATGTGCTG GCTCCTTAGA 1140 AGGAAAAACA GATGCATGCC AGGGTGACTC TGGAGGACCA CTGGTTAGTT CAGATGCTAG 1200 AGATATCTGG TACCTTGCTG GAATAGTGAG CTGGGGAGAT GAATGTGCGA AACCCAACAA 1260 GCCTGGTGTT TATACTAGAG TTACGGCCTT GCGGGACTGG ATTACTTCAA AAACTGGTAT 1320 CTAAGAGAGA AAAGCCTCAT GGAACAGATA ACATTTTTTT TTGTTTTTTG GGTGTGGAGG 1380 CCATTTTTAG AGATACAGAA TTGGAGAAGA CTTGCAAAAC AGCTAGATTT GACTGATCTC 1440 AATAAACTGT TTGCTTGATG CAAAAAAAAA A Seq ID NO : 251 Protein sequence: Protein Accession # : NP 054777 1 11 21 31 41 51 MYRPDWRAR KRVCWEPNVI GLVIFISMV LAVCIGLTVH YVRYNQKKTY NYYSTLSFTT 60 DKLYAEFGRE ASNNFTEMSQ RLESMVKNAF YKSPLREEFV KSQVIKFSQQ KHGVLAHMLL 120 ICRFHSTEDP ETVDKIVQLV LHEKLQDAVG PPKVDPHSVK IKKINKTETD SYLNHCCGTR 180 RSKTLGQSLR IVGGTEVEEG EWPWQASLQW DGSHRCGATL INATWLVSAA HCFTTYKNPA 240 RWTASFGVTI KPSKMKRGLR RIIVHEKYKH PSHDYDISLA ELSSPVPYTN AVHRVCLPDA 300 SYEFQPGDVM FVTGFGALKN DGYSQNHLRQ AQVTLIDATT CNEPQAYNDA ITPRMLCAGS 360 LEGKTDACQG DSGGPLVSSD ARDIWYLAGI VSWGDECAKP NKPGVYTRVT ALRDWITSKT 420 GI Seq ID NO : 252 DNA sequence Nucleic Acid Accession &num : NM 003504. 2 Coding sequence: 71-1771 1 11 21 31 41 51 GGCACGAGGC CTCGTGCCGC CGGGCTCTTG GTACCTCAGC GCGAGCGCCA GGCGTCCGGC 60 CGCCGTGGCT ATGTTCGTGT CCGATTTCCG CAAAGAGTTC TACGAGGTGG TCCAGAGCCA 120 GAGGGTCCTT CTCTTCGTGG CCTCGGACGT GGATGCTCTG TGTGCGTGCA AGATCCTTCA 180 GGCCTTGTTC CAGTGTGACC ACGTGCAATA TACGCTGGTT CCAGTTTCTG GGTGGCAAGA 240 ACTTGAAACT GCATTTCTTG AGCATAAAGA ACAGTTTCAT TATTTTATTC TCATAAACTG 300 TGGAGCTAAT GTAGACCTAT TGGATATTCT TCAACCTGAT GAAGACACTA TATTCTTTGT 360 GTGTGACACC CATAGGCCAG TCAATGTCGT CAATGTATAC AACGATACCC AGATCAAATT 420 ACTCATTAAA CAAGATGATG ACCTTGAAGT TCCCGCCTAT GAAGACATCT TCAGGGATGA 480 AGAGGAGGAT GAAGAGCATT CAGGAAATGA CAGTGATGGG TCAGAGCCTT CTGAGAAGCG 540 CACACGGTTA GAAGAGGAGA TAGTGGAGCA AACCATGCGG AGGAGGCAGC GGCGAGAGTG 600 GGAGGCCCGG AGAAGAGACA TCCTCTTTGA CTACGAGCAG TATGAATATC ATGGGACATC 660 GTCAGCCATG GTGATGTTTG AGCTGGCTTG GATGCTGTCC AAGGACCTGA ATGACATGCT 720 GTGGTGGGCC ATCGTTGGAC TAACAGACCA GTGGGTGCAA GACAAGATCA CTCAAATGAA 780 ATACGTGACT GATGTTGGTG TCCTGCAGCG CCACGTTTCC CGCCACAACC ACCGGAACGA 840 GGATGAGGAG AACACACTCT CCGTGGACTG CACACGGATC TCCTTTGAGT ATGACCTCCG 900 CCTGGTGCTC TACCAGCACT GGTCCCTCCA TGACAGCCTG TGCAACACCA GCTATACCGC 960 AGCCAGGTTC AAGCTGTGGT CTGTGCATGG ACAGAAGCGG CTCCAGGAGT TCCTTGCAGA 1020 CATGGGTCTT CCCCTGAAGC AGGTGAAGCA GAAGTTCCAG GCCATGGACA TCTCCTTGAA 1080 GGAGAATTTG CGGGAAATGA TTGAAGAGTC TGCAAATAAA TTTGGGATGA AGGACATGCG 1140 CGTGCAGACT TTCAGCATTC ATTTTGGGTT CAAGCACAAG TTTCTGGCCA GCGACGTGGT 1200 CTTTGCCACC ATGTCTTTGA TGGAGAGCCC CGAGAAGGAT GGCTCAGGGA CAGATCACTT 1260 CATCCAGGCT CTGGACAGCC TCTCCAGGAG TAACCTGGAC AAGCTGTACC ATGGCCTGGA 1320 ACTCGCCAAG AAGCAGCTGC GAGCCACCCA GCAGACCATT GCCAGCTGCC TTTGCACCAA 1380 CCTCGTCATC TCCCAGGGGC CTTTCCTGTA CTGCTCTCTC ATGGAGGGCA CTCCAGATGT 1440 CATGCTGTTC TCTAGGCCGG CATCCCTAAG CCTGCTCAGC AAACACCTGC TCAAGTCCTT 1500 TGTGTGTTCG ACAAAGAACC GGCGCTGCAA ACTGCTGCCC CTGGTGATGG CTGCCCCCCT 1560

# # # # # # GTCTACTTAT CAATAAGCAG CTGCCTGTGC AGAGTGCAGG CTGCACCTTT GGACAGCCTT 60 TAAAACTGAA TTCTCAGAAT TTTAGAACAA ATTTTTGTCT AGAAATGCTG ACTTTGGTTC 120 ATTAGGTAGT GGTAAAACAG GCTCCCTTCG AAGCTCTCCT TCATCACCTT CCTAAGTGCA 180 TGTACAGGGA AGCTCTCCTT CATCACCTTC CTAAGTGCAT GGGGGAAAAT ACCTAGGGCT 240 CAACAGTCTT GAGAAGTGTG GAAACATTTT CTTTGTGAGT GAGAACAGAT CACCTAGAGA 300 AAGGAAACCA GATTCCCATC ACTGCTTCTG GGTATCAGAT GCTAGCGCTG CACTCCATTT 360 TGCAATGGCC TCCCTTGCTG CAGCAAATGC AGAGTTTTGC TTCAACCTGT TCAGAGAGAT 420 GGATGACAAT CAAGGAAATG GAAATGTGTT CTTTTCCTCT CTGAGCCTCT TCGCTGCCCT 480 GGCCCTGGTC CGCTTGGGCG CTCAAGATGA CTCCCTCTCT CAGATTGATA AGTTGCTTCA 540 TGTTAACACT GCCTCAGGAT ATGGAAACTC TTCTAATAGT CAGTCAGGGC TCCAGTCTCA 600 ACTGAAAAGA GTTTTTTCTG ATATAAATGC ATCCCACAAG GATTATGATC TCAGCATTGT 660 GAATGGGCTT TTTGCTGAAA AAGTGTATGG CTTTCATAAG GACTACATTG AGTGTGCCGA 720 AAAATTATAC GATGCCAAAG TGGAGCGAGT TGACTTTACG AATCATTTAG AAGACACTAG 780 ACGTAATATT AATAAGTGGG TTGAAAATGA AACACATGGC AAAATCAAGA ACGTGATTGG 840 TGAAGGTGGC ATAAGCTCAT CTGCTGTAAT GGTGCTGGTG AATGCTGTGT ACTTCAAAGG 900 CAAGTGGCAA TCAGCCTTCA CCAAGAGCGA AACCATAAAT TGCCATTTCA AATCTCCCAA 960 GTGCTCTGGG AAGGCAGTCG CCATGATGCA TCAGGAACGG AAGTTCAATT TGTCTGTTAT 1020 TGAGGACCCA TCAATGAAGA TTCTTGAGCT CAGATACAAT GGTGGCATAA ACATGTACGT 1080 TCTGCTGCCT GAGAATGACC TCTCTGAAAT TGAAAACAAA CTGACCTTTC AGAATCTAAT 1140 GGAATGGACC AATCCAAGGC GAATGACCTC TAAGTATGTT GAGGTATTTT TTCCTCAGTT 1200 CAAGATAGAG AAGAATTATG AAATGAAACA ATATTTGAGA GCCCTAGGGC TGAAAGATAT 1260 CTTTGATGAA TCCAAAGCAG ATCTCTCTGG GATTGCTTCG GGGGGTCGTC TGTATATATC 1320 AAGGATGATG CACAAATCTT ACATAGAGGT CACTGAGGAG GGCACCGAGG CTACTGCTGC 1380 CACAGGAAGT AATATTGTAG AAAAGCAACT CCCTCAGTCC ACGCTGTTTA GAGCTGACCA 1440 CCCATTCCTA TTTGTTATCA GGAAGGATGA CATCATCTTA TTCAGTGGCA AAGTTTCTTG 1500 CCCTTGAAAA TCCAATTGGT TTCTGTTATA GCAGTCCCCA CAACATCAAA GRACCACCAC 1560 AAGTCAATAG ATYTGRGTTT AATTGGAAAA ATGTGGTGTT TCCTTTGAGT TTATTTCTTC 1620 CTAACATTGG TCAGCAGATG ACACTGGTGA CTTGACCCTT CCTAGACACC TGGTTGATTG 1680 TCCTGATCCC TGCTCTTAGC ATTCTACCAC CATGTGTCTC ACCCATTTCT AATTTCATTG 1740 TCTTTCTTCC CACGCTCATT TCTATCATTC TCCCCCATGA CCCGTCTGGA AATTATGGAG 1800 RGTGCTCAAC TGGTAAGGAG AACGTAGAAG TAGCCCTAGG GATCCTTTTT GAAACTCTAC 1860 AGTTATCGCA GATATTCTAG CTTCATTGTA AGCAATCTAG GAAATAAGCC CTGCTGCTTT 1920 CTAGAAATAA GTGTGAAGGA TAAATTTTCT TTGTTGACCT ATGAAGATTT TAGAGTTTAC 1980 CTTCATATGT TTGATTTTAA ATCAGTGTAT AATCTAGATG GTAAAAAATG TGAAATTGGG 2040 ATTAGGGACC TACCAAAATA TTTCATTAAT GCTTTCAATT GACAAATTTT GGCCTTTCTT 2100 TGATAAGACA ATATGTACAT GTTTTTTCAA ATATTAAAGA TCTTTTAACT GTTGGCAGTT 2160 GTTATCTACA GAATCATATT TCATATGCTG TGTAGTTTAT AAGTTTTTCC TCTATTTATC 2220 AGAATAAAGA AATACAACAT ACCTGTAAA Seq ID NO : 263 Protein sequence: Protein Accession # : NP 003775 1 11 21 31 41 51 MASLAAANAE FCFNLFREMD DNQGNGNVFF SSLSLFAALA LVRLGAQDDS LSQIDKLLHV 60 NTASGYGNSS NSQSGLQSQL KRVFSDINAS HKDYDLSIVN GLFAEKVYGF HKDYIECAEK 120 LYDAKVERVD FTNHLEDTRR NINKWVENET HGKIKNVIGE GGISSSAVMV LVNAVYFKGK 180 WQSAFTKSET INCHFKSPKC SGKAVAMMHQ ERKFNLSVIE DPSMKILELR YNGGINMYVL 240 LPENDLSEIE NKLTFQNLME WTNPRRMTSK YVEVFFPQFK IEKNYEMKQY LRALGLKDIF 300 DESKADLSGI ASGGRLYISR MMHKSYIEVT EEGTEATAAT GSNIVEKQLP QSTLFRADHP 360 FLFVIRKDDI ILFSGKVSCP Seq ID NO : 264 DNA sequence Nucleic Acid Accession &num : AB052906 Coding sequence: 74-814 1 11 21 31 41 51 AAAACCTTGA GGTGATTCAT CTTCCAGGCT CTCCTTCCAT CAAGTCTCTC CTCCCTAGCG'60 CTCTGGGTCC TTAATGGCAG CAGCCGCCGC TACCAAGATC CTTCTGTGCC TCCCGCTTCT 120 GCTCCTGCTG TCCGGCTGGT CCCGGGCTGG GCGAGCCGAC CCTCACTCTC TTTGCTATGA 180 CATCACCGTC ATCCCTAAGT TCAGACCTGG ACCACGGTGG TGTGCGGTTC AAGGCCAGGT 240 GGATGAAAAG ACTTTTCTTC ACTATGACTG TGGCAACAAG ACAGTCACAC CTGTCAGTCC 300 CCTGGGGAAG AAACTAAATG TCACAACGGC CTGGAAAGCA CAGAACCCAG TACTGAGAGA 360 GGTGGTGGAC ATACTTACAG AGCAACTGCG TGACATTCAG CTGGAGAATT ACACACCCAA 420 GGAACCCCTC ACCCTGCAGG CCAGGATGTC TTGTGAGCAG AAAGCTGAAG GACACAGCAG 480 TGGATCTTGG CAGTTCAGTT TCGATGGGCA GATCTTCCTC CTCTTTGACT CAGAGAAGAG 540 AATGTGGACA ACGGTTCATC CTGGAGCCAG AAAGATGAAA GAAAAGTGGG AGAATGACAA 600 GGTTGTGGCC ATGTCCTTCC ATTACTTCTC AATGGGAGAC TGTATAGGAT GGCTTGAGGA 660 CTTCTTGATG GGCATGGACA GCACCCTGGA GCCAAGTGCA GGAGCACCAC TCGCCATGTC 720 CTCAGGCACA ACCCAACTCA GGGCCACAGC CACCACCCTC ATCCTTTGCT GCCTCCTCAT 780 CATCCTCCCC TGCTTCATCC TCCCTGGCAT CTGAGGAGAG TCCTTTAGAG TGACAGGTTA 840 AAGCTGATAC CAAAAGGCTC CTGTGAGCAC GGTCTTGATC AAACTCGCCC TTCTGTCTGG 900 CCAGCTGCCC ACGACCTACG GTGTATGTCC AGTGGCCTCC AGCAGATCAT GATGACATCA 960 TGGACCCAAT AGCTCATTCA CTGCCTTGAT TCCTTTTGCC AACAATTTTA CCAGCAGTTA 1020 TACCTAACAT ATTATGCAAT TTTCTCTTGG TGCTACCTGA TGGAATTCCT GCACTTAAAG 1080 TTCTGGCTGA CTAAACAAGA TATATCATTT TCTTTCTTCT CTTTTTGTTT GGAAAATCAA 1140 GTACTTCTTT GAATGATGAT CTCTTTCTTG CAAATGATAT TGTCAGTAAA ATAATCACGT 1200 TAGACTTCAG ACCTCTGGGG ATTCTTTCCG TGTCCTGAAA GAGAATTTTT AAATTATTTA 1260 ATAAGAAAAA ATTTATATTA ATGATTGTTT CCTTTAGTAA TTTATTGTTC TGTACTGATA 1320 TTTAAATAAA GAGTTCTATT TCCCAAAAAA AAAAAAAAAA A Seq ID NO : 265 Protein sequence: Protein Accession &num : BAB61048. 1

GTGTTGGAGA AGAAACAACA AAAGCCAATT AGAACCACTA TTTTTAAAAA GTGCTTACTG 4800 TGCACAGATA CTCTTCAAGC ACTGGACGTG GATTCTCTCT CTAGCCCTCA GCACCCCTGC 4860 GGTAGGAGTG CCGCCTCTAC CCACTTGTGA TGGGGTACAG AGGCACTTGC TCTTCTGCAT 4920 GGTGTTCAAT AGGCTGGGAG TTTTATTTAT CTCTTCAAAC TTTGTACAAG AGCTCATGGC 4980 TTGTCTTGGG CTTTCGTCAT TAAACCAAAG GAAATGGAAG CCATTCCCCT GTTGCTCTCC 5040 TTAGTCTTGG TCATCAGAAC CTCACTTGGT ACCATATAGA TCAAAAGCTT TGTAACCACA 5100 GGAAAAAATA AACTCTTCCA TCCCTTAAAG AATAGAATAG TTTGTCCCTC TCATGGGAAT 5160 TGGGCTGTAT GTATATTGTT CTTCCTCCTT AGAATTTAGA GATACAAGAG TTCTACTTAG 5220 AACTTTTCAT GGACACAATT TCCACAACCT TTCAGATGCT GATGTAGAGC TATTGGGAAA 5280 GAACTTCCAA ACTCAGGAAG TTTGCAGAGA GCAGACAGCT AGAGATAACT CGGGACCCAG 5340 AGTTGGTCGA CAGATGTTAG ATGTATCCTA GCTTTTAGCC ATAAACCACT CAAAGATTCA 5400 GCCCCCAGAT CCCACAGTCA GAACTGAATC TGCGTTGTTG GGAAGCCAGC AGTGGCCTTG 5460 GGAAGGAAGC CATGGCTGTG GTTCAGAGAG GGTGGGCTGG CAAGCCACTT CCGGGGAAAA 5520 CTCCTTCCGC CCCAGGTTTC TTCTTCTCTT AAGGAGAGAT TGTTCTCACC AACCCGCTGC 5580 CTTCATGCTG CCTTCAAAGC TAGATCATGT TTGCCTTGCT TAGAGAATTA CTGCAAATCA 5640 GCCCCAGTGC TTGGCGATGC ATTTACAGAT TTCTAGGCCC TCAGGGTTTT GTAGAGTGTG 5700 AGCCCTGGTG GGCAGGGTTG GGGGGTCTGT CTTCTGCTGG ATGCTGCTTG TAATCCATTT 5760 GGTGTACAGA ATCAACAATA AATAATATAC ATGTAT Seq ID NO : 286 Protein sequence: Protein Accession # : NP 570843. 1 1 11 21 31 41 51 MPLKHYLLLL VGCQAWGAGL AYHGCPSECT CSRASQVECT GARIVAVPTP LPWNAMSLQI 60 LNTHITELNE SPFLNISALI ALRIEKNELS RITPGAFRNL GSLRYLSLAN NKLQVLPIGL 120 FQGLDSLESL LLSSNQLLQI QPAHFSQCSN LKELQLHGNH LEYIPDGAFD HLVGLTKLNL 180 GKNSLTHISP RVFQHLGNLQ VLRLYENRLT DIPMGTFDGL VNLQELALQQ NQIGLLSPGL 240 FHNNHNLQRL YLSNNHISQL PPSIFMQLPQ LNRLTLFGNS LKELSLGIFG PMPNLRELWL 300 YDNHISSLPD NVFSNLRQLQ VLILSRNQIS FISPGAFNGL TELRELSLHT NALQDLDGNV 360 FRMLANLQNI SLQNNRLRQL PGNIFANVNG LMAIQLQNNQ LENLPLGIFD HLGKLCELRL 420 YDNPWRCDSD ILPLRNWLLL NQPRLGTDTV PVCFSPANVR GQSLIIINVN VAVPSVHVPE 480 VPSYPETPWY PDTPSYPDTT SVSSTTELTS PVEDYTDLTT IQVTDDRSVW GMTQAQSGLA 540 IAAIVIGIVA LACSLAACVG CCCCKKRSQA VLMQMKAPNE C Seq ID NO: 287 DNA sequence Nucleic Acid Accession # : NM 002362 Coding sequence : 1.. 954 1 11 21 31 41 51 ATGTCTTCTG AGCAGAAGAG TCAGCACTGC AAGCCTGAGG AAGGCGTTGA GGCCCAAGAA 60 GAGGCCCTGG GCCTGGTGGG TGCACAGGCT CCTACTACTG AGGAGCAGGA GGCTGCTGTC 120 TCCTCCTCCT CTCCTCTGGT CCCTGGCACC CTGGAGGAAG TGCCTGCTGC TGAGTCAGCA 180 GGTCCTCCCC AGAGTCCTCA GGGAGCCTCT GCCTTACCCA CTACCATCAG CTTCACTTGC 240 TGGAGGCAAC CCAATGAGGG TTCCAGCAGC CAAGAAGAGG AGGGGCCAAG CACCTCGCCT 300 GACGCAGAGT CCTTGTTCCG AGAAGCACTC AGTAACAAGG TGGATGAGTT GGCTCATTTT 360 CTGCTCCGCA AGTATCGAGC CAAGGAGCTG GTCACAAAGG CAGAAATGCT GGAGAGAGTC 420 ATCAAAAATT ACAAGCGCTG CTTTCCTGTG ATCTTCGGCA AAGCCTCCGA GTCCCTGAAG 480 ATGATCTTTG GCATTGACGT GAAGGAAGTG GACCCCGCCA GCAACACCTA CACCCTTGTC 540 ACCTGCCTGG GCCTTTCCTA TGATGGCCTG CTGGGTAATA ATCAGATCTT TCCCAAGACA 600 GGCCTTCTGA TAATCGTCCT GGGCACAATT GCAATGGAGG GCGACAGCGC CTCTGAGGAG 660 GAAATCTGGG AGGAGCTGGG TGTGATGGGG GTGTATGATG GGAGGGAGCA CACTGTCTAT 720 GGGGAGCCCA GGAAACTGCT CACCCAAGAT TGGGTGCAGG AAAACTACCT GGAGTACCGG 780 CAGGTACCCG GCAGTAATCC TGCGCGCTAT GAGTTCCTGT GGGGTCCAAG GGCTCTGGCT 840 GAAACCAGCT ATGTGAAAGT CCTGGAGCAT GTGGTCAGGG TCAATGCAAG AGTTCGCATT 900 GCCTACCCAT CCCTGCGTGA AGCAGCTTTG TTAGAGGAGG AAGAGGGAGT CTGA Seq ID NO : 288 Protein sequence: Protein Accession &num : NP 002353. 1 1 11 21 31 41 51 t MSSEQKSQHC KPEEGVEAQE EALGLVGAQA PTTEEQEAAV SSSSPLVPGT LEEVPAAESA 60 GPPQSPQGAS ALPTTISFTC WRQPNEGSSS QEEEGPSTSP DAESLFREAL SNKVDELAHF 120 LLRKYRAKEL VTKAEMLERV IKNYKRCFPV IFGKASESLK MIFGIDVKEV DPASNTYTLV 180 TCLGLSYDGL LGNNQIFPKT GLLIIVLGTI AMEGDSASEE EIWEELGVMG VYDGREHTVY 240 GEPRKLLTQD WVQENYLEYR QVPGSNPARY EFLWGPRALA ETSYVKVLEH WRVNARVRI 300 AYPSLREAAL LEEEEGV Seq ID NO : 289 DNA sequence Nucleic Acid Accession # : NM 002362 Coding sequence: 46.. 1344 1 11 21 31 41 51 I I I I I I CGGCGGCCGC GCCCTGGTTG GGTCCCCACT GCTCTCGGGG GCGCCATGGA CGAGGCCGTG 60 GGCGACCTGA AGCAGGCGCT TCCCTGTGTG GCCGAGTCGC CAACGGTCCA CGTGGAGGTG 120 CATCAGCGCG GCAGCAGCAC TGCAAAGAAA GAAGACATAA ACCTGAGTGT TAGAAAGCTA 180 CTCAACAGAC ATAATATTGT GTTTGGTGAT TACACATGGA CTGAGTTTGA TGAACCTTTT 240 TTGACCAGAA ATGTGCAGTC TGTGTCTATT ATTGACACAG AATTAAAGGT TAAAGACTCA 300 CAGCCCATCG ATTTGAGTGC ATGCACTGTT GCACTTCACA TTTTCCAGCT GAATGAAGAT 360 GGCCCCAGCA GTGAAAATCT GGAGGAAGAG ACAGAAAACA TAATTGCAGC AAATCACTGG 420 GTTCTACCTG CAGCTGAATT CCATGGGCTT TGGGACAGCT TGGTATACGA TGTGGAAGTC 480 AAATCCCATC TCCTCGATTA TGTGATGACA ACTTTACTGT TTTCAGACAA GAACGTCAAC 540

AGCAACCTCA TCACCTGGAA CCGGGTGGTG CTGCTCCACG GTCCTCCTGG CACTGGAAAA 600 ACATCCCTGT GTAAAGCGTT AGCCCAGAAA TTGACAATTA GACTTTCAAG CAGGTACCGA 660 TATGGCCAAT TAATTGAAAT AAACAGCCAC AGCCTCTTTT CTAAGTGGTT TTCGGAAAGT 720 GGCAAGCTGG TAACCAAGAT GTTTCAGAAG ATTCAGGATT TGATTGATGA TAAAGACGCC 780 CTGGTGTTCG TGCTGATTGA TGAGGTGGAG AGTCTCACAG CCGCCCGAAA TGCCTGCAGG 840 GCGGGCACCG AGCCATCAGA TGCCATCCGC GTGGTCAATG CTGTCTTGAC CCAAATTGAT 900 CAGATTAAAA GGCATTCCAA TGTTGTGATT CTGACCACTT CTAACATCAC CGAGAAGATC 960 GACGTGGCCT TCGTGGACAG GGCTGACATC AAGCAGTACA TTGGGCCACC CTCTGCAGCA 1020 GCCATCTTCA AAATCTACCT CTCTTGTTTG GAAGAACTGA TGAAGTGTCA GATCATATAC 1080 CCTCGCCAGC AGCTGCTGAC CCTCCGAGAG CTAGAGATGA TTGGCTTCAT TGAAAACAAC 1140 GTGTCAAAAT TGAGCCTTCT TTTGAATGAC ATTTCAAGGA AGAGCGAGGG CCTCAGCGGC 1200 CGGGTCCTGA GAAAACTCCC CTTTCTGGCT CATGCGCTGT ATGTCCAGGC CCCCACCGTC 1260 ACCATAGAGG GGTTCCTCCA GGCCCTGTCT CTGGCAGTGG ACAAGCAGTT TGAAGAGAGA 1320 AAGAAGCTTG CAGCTTACAT CTGATCCTGG GCTTCCCCAT CTGGTGCTTT TCCCATGGAG 1380 AACACACAAC CAGTAAGTGA GGTTGCCCCA CACAGCCGTC TCCCAGGGAA TCCCTTCTGC 1440 AAACCAAACG TTACTTAGAC TGCAAGCTAG AAAGCCACCA AGGCCAGGCT TTGTTAAAAG 1500 AAGTGTATTC TATTTATGTT GTTTTAAAAT GCATACTGAG AGACAAACAT CTTGTCATTT 1560 TCACTGTTTG TAAAAGATAA TTCAGATTGT TTGTCTCCTT GTGAAGAACC ATCGAAACCT 1620 GTTTGTTCCC AGCCCACCCC CAGTGGATGG GATGCATAAT GCCAGCAAGT TTTGTTTAAC 1680 AGCAAAAAAG GAAGATTAAT GCAGGTGTTA TAGAAGCCAG AAGAGAAACT GTGTCACCCT 1740 AAAGAAGCAT ATAATCATAG CATTAAAAAT GCACACATTA CTCCAGGTGG AAGGTGGCAA 1800 TTGCTTTCTG ATATCAGCTC GTTTGATTTA GTGCAAAAAT GTTTTCAAGA CTATTTAATG 1860 GATGTAAAAA AGCCTATTTC TACATTATAC CAACTGAGAA AAAAATGGTC GGTAAAGTGT 1920 TCTTTCATAA TAAATAATCA AGACATGGTC CCATTTGCAG GAAAAGTGCA GACTCTGAGT 1980 GTTCCAGGGA AACACATGCT GGACATCCCT TGTAACCCGG TATGGGCGCC CCTGCATTGC 2040 TGGGATGTTT CTGCCCACGG TTTTGTTTGT GCAATAACGT TATCACATTT CTAATGAGGA 2100 TTCACATTAA TATAATATAA AATAAATAGG TCAGTTACTG GTCTCTTTCT GCCGAATGTT 2160 ATGTTTTGCT TTTATCTCAC AGTAAAATAA ATATAATTAA AAA Seq ID NO : 290 Protein sequence: Protein Accession # : NP004228 1 11 21 31 41 51 MDEAVGDLKQ ALPCVAESPT VHVEVHQRGS STAKKEDINL SVRKLLNRHN IVFGDYTWTE 60 FDEPFLTRNV QSVSIIDTEL KVKDSQPIDL SACTVALHIF QLNEDGPSSE NLEEETENII 120 AANHWVLPAA EFHGLWDSLV YDVEVKSHLL DYVMTTLLFS DKNVNSNLIT WNRWLLHGP 180 PGTGKTSLCK ALAQKLTIRL SSRYRYGQLI EINSHSLFSK WFSESGKLVT KMFQKIQDLI 240 DDKDALVFVL IDEVESLTAA RNACRAGTEP SDAIRWNAV LTQIDQIKRH SNWILTTSN 300 ITEKIDVAFV DRADIKQYIG PPSAAAIFKI YLSCLEELMK CQIIYPRQQL LTLRELEMIG 360 FIENNVSKLS LLLNDISRKS EGLSGRVLRK LPFLAHALYV QAPTVTIEGF LQALSLAVDK 420 QFEERKKLAA YI Seq ID NO : 291 DNA sequence Nucleic Acid Accession &num : NM 002658. 1 Coding sequence: 77-1372 1 11 21 31 41 51 GTCCCCGCAG CGCCGTCGCG CCCTCCTGCC GCAGGCCACC GAGGCCGCCG CCGTCTAGCG 60 CCCCGACCTC GCCACCATGA GAGCCCTGCT GGCGCGCCTG CTTCTCTGCG TCCTGGTCGT 120 GAGCGACTCC AAAGGCAGCA ATGAACTTCA TCAAGTTCCA TCGAACTGTG ACTGTCTAAA 180 TGGAGGAACA TGTGTGTCCA ACAAGTACTT CTCCAACATT CACTGGTGCA ACTGCCCAAA 240 GAAATTCGGA GGGCAGCACT GTGAAATAGA TAAGTCAAAA ACCTGCTATG AGGGGAATGG 300 TCACTTTTAC CGAGGAAAGG CCAGCACTGA CACCATGGGC CGGCCCTGCC TGCCCTGGAA 360 CTCTGCCACT GTCCTTCAGC AAACGTACCA TGCCCACAGA TCTGATGCTC TTCAGCTGGG 420 CCTGGGGAAA CATAATTACT GCAGGAACCC AGACAACCGG AGGCGACCCT GGTGCTATGT 480 GCAGGTGGGC CTAAAGCCGC TTGTCCAAGA GTGCATGGTG CATGACTGCG CAGATGGAAA 540 AAAGCCCTCC TCTCCTCCAG AAGAATTAAA ATTTCAGTGT GGCCAAAAGA CTCTGAGGCC 600 CCGCTTTAAG ATTATTGGGG GAGAATTCAC CACCATCGAG AACCAGCCCT GGTTTGCGGC 660 CATCTACAGG AGGCACCGGG GGGGCTCTGT CACCTACGTG TGTGGAGGCA GCCTCATCAG 720 CCCTTGCTGG GTGATCAGCG CCACACACTG CTTCATTGAT TACCCAAAGA AGGAGGACTA 780 CATCGTCTAC CTGGGTCGCT CAAGGCTTAA CTCCAACACG CAAGGGGAGA TGAAGTTTGA 840 GGTGGAAAAC CTCATCCTAC ACAAGGACTA CAGCGCTGAC ACGCTTGCTC ACCACAACGA 900 CATTGCCTTG CTGAAGATCC GTTCCAAGGA GGGCAGGTGT GCGCAGCCAT CCCGGACTAT 960 ACAGACCATC TGCCTGCCCT CGATGTATAA CGATCCCCAG TTTGGCACAA GCTGTGAGAT 1020 CACTGGCTTT GGAAAAGAGA ATTCTACCGA CTATCTCTAT CCGGAGCAGC TGAAAATGAC 1080 TGTTGTGAAG CTGATTTCCC ACCGGGAGTG TCAGCAGCCC CACTACTACG GCTCTGAAGT 1140 CACCACCAAA ATGCTATGTG CTGCTGACCC CCAATGGAAA ACAGATTCCT GCCAGGGAGA 1200 CTCAGGGGGA CCCCTCGTCT GTTCCCTCCA AGGCCGCATG ACTTTGACTG GAATTGTGAG 1260 CTGGGGCCGT GGATGTGCCC TGAAGGACAA GCCAGGCGTC TACACGAGAG TCTCACACTT 1320 CTTACCCTGG ATCCGCAGTC ACACCAAGGA AGAGAATGGC CTGGCCCTCT GAGGGTCCCC 1380 AGGGAGGAAA CGGGCACCAC CCGCTTTCTT GCTGGTTGTC ATTTTTGCAG TAGAGTCATC 1440 TCCATCAGCT GTAAGAAGAG ACTGGGAAGA TAGGCTCTGC ACAGATGGAT TTGCCTGTGG 1500 CACCACCAGG GTGAACGACA ATAGCTTTAC CCTCACGGAT AGGCCTGGGT GCTGGCTGCC 1560 CAGACCCTCT GGCCAGGATG GAGGGGTGGT CCTGACTCAA CATGTTACTG ACCAGCAACT 1620 TGTCTTTTTC TGGACTGAAG CCTGCAGGAG TTAAAAAGGG CAGGGCATCT CCTGTGCATG 1680 GGCTCGAAGG GAGAGCCAGC TCCCCCGACC GGTGGGCATT TGTGAGGCCC ATGGTTGAGA 1740 AATGAATAAT TTCCCAATTA GGAAGTGTAA GCAGCTGAGG TCTCTTGAGG GAGCTTAGCC 1800 AATGTGGGAG CAGCGGTTTG GGGAGCAGAG ACACTAACGA CTTCAGGGCA GGGCTCTGAT 1860 ATTCCATGAA TGTATCAGGA AATATATATG TGTGTGTATG TTTGCACACT TGTTGTGTGG 1920 GCTGTGAGTG TAAGTGTGAG TAAGAGCTGG TGTCTGATTG TTAAGTCTAA ATATTTCCTT 1980 AAACTGTGTG GACTGTGATG CCACACAGAG TGGTCTTTCT GGAGAGGTTA TAGGTCACTC 2040 CTGGGGCCTC TTGGGTCCCC CACGTGACAG TGCCTGGGAA TGTACTTATT CTGCAGCATG 2100 ACCTGTGACC AGCACTGTCT CAGTTTCACT TTCACATAGA TGTCCCTTTC TTGGCCAGTT 2160 ATCCCTTCCT TTTAGCCTAG TTCATCCAAT CCTCACTGGG TGGGGTGAGG ACCACTCCTT 2220 ACACTGAATA TTTATATTTC ACTATTTTTA TTTATATTTT TGTAATTTTA AATAAAAGTG 2280

TATGAATCAC TGAAATCCAG GGTCCAGAGT TATTTTGATG GTATAAAAGC TGATTGGTTG 420 GATAGCATAA GACCACAAAA AGAAGGAGAC TTCAGAAAGG AGATTAACAA GTGGTGGAAT 480 AACCTAAGTG ATGGCCAGCG GACTGTGACA GGTATTATAG CTGCAAATGT CCTTGTATTC 540 TGTTTATGGA GAGTACCTTC TCTGCAGCGG ACAATGATCA GATATTTCAC ATCGAATCCA 600 GCCTCAAAGG TCCTTTGTTC TCCAATGTTG CTGTCAACAT TCAGTCACTT CTCCTTATTT 660 CACATGGCAG CAAATATGTA TGTTTTGTGG AGCTTCTCTT CCAGCATAGT GAACATTCTG 720 GGTCAAGAGC AGTTCATGGC AGTGTACCTA TCTGCAGGTG TTATTTCCAA TTTTGTCAGT 780 TACCTGGGTA AAGTTGCCAC AGGAAGATAT GGACCATCAC TTGGTGCATC TGGTGCCATC 840 ATGACAGTCC TCGCAGCTGT CTGCACTAAG ATCCCAGAAG GGAGGCTTGC CATTATTTTC 900 CTTCCGATGT TCACGTTCAC AGCAGGGAAT GCCCTGAAAG CCATTATCGC CATGGATACA 960 GCAGGAATGA TCCTGGGATG GAAATTTTTT GATCATGCGG CACATCTTGG GGGAGCTCTT 1020 TTTGGAATAT GGTATGTTAC TTACGGTCAT GAACTGATTT GGAAGAACAG GGAGCCGCTA 1080 GTGAAAATCT GGCATGAAAT AAGGACTAAT GGCCCCAAAA AAGGAGGTGG CTCTAAGTAA Seq ID NO : 311 Protein sequence: Protein Accession # : NP 061092. 2 1 11 21 31 41 51 MAWRGWAQRG WGCGQAWGAS VGGRSCEELT AVLTPPQLLG RRFNFFIQQK CGFRKAPRKV 60 EPRRSDPGTS GEAYKRSALI PPVEETVFYP SPYPIRSLIK PLFFTVGFTG CAFGSAAIWQ 120 YESLKSRVQS YFDGIKADWL DSIRPQKEGD FRKEINKWWN NLSDGQRTVT GIIAANVLVP 180 CLWRVPSLQR TMIRYFTSNP ASKVLCSPML LSTFSHFSLF HMAANMYVLW SFSSSIVNIL 240 GQEQFMAVYL SAGVISNFVS YLGKVATGRY GPSLGASGAI MTVLAAVCTK IPEGRLAIIF 300 LPMFTFTAGN ALKAIIAMDT AGMILGWKFP DHAAHLGGAL FGIWYVTYGH ELIWKNREPL 360 VKIWHEIRTN GPKKGGGSK Seq ID NO : 312 DNA sequence Nucleic Acid Accession # : NM 000625 Coding sequence : 195.. 3656 1 11 21 31 41 51 <BR> <BR> <BR> <BR> <BR> CTCTCGGCCA CCTTTGATGA GGGGACTGGG CAGTTCTAGA CAGTCCCGAA GTTCTCAAGG 60 CACAGGTCTC TTCCTGGTTT GACTGTCCTT ACCCCGGGGA GGCAGTGCAG CCAGCTGCAA 120 GCCCCACAGT GAAGAACATC TGAGCTCAAA TCCAGATAAG TGACATAAGT GACCTGCTTT 180 GTAAAGCCAT AGAGATGGCC TGTCCTTGGA AATTTCTGTT CAAGACCAAA TTCCACCAGT 240 ATGCAATGAA TGGGGAAAAA GGCATCAACA ACAATGTGGA GAAAGCCCCC TGTGCCACCT 300 CCAGTCCAGT GACACAGGAT GACCTTCAGT ATCACAACCT CAGCAAGCAG CAGAATGAGT 360 CCCCGCAGCC CCTCGTGGAG ACGGGAAAGA AGTCTCCAGA ATCTCTGGTC AAGCTGGATG 420 CAACCCCATT GTCCTCCCCA CGGCATGTGA GGATCAAAAA CTGGGGCAGC GGGATGACTT 480 TCCAAGACAC ACTTCACCAT AAGGCCAAAG GGATTTTAAC TTGCAGGTCC AAATCTTGCC 540 TGGGGTCCAT TATGACTCCC AAAAGTTTGA CCAGAGGACC CAGGGACAAG CCTACCCCTC 600 CAGATGAGCT TCTACCTCAA GCTATCGAAT TTGTCAACCA ATATTACGGC TCCCTCAAAG 660 AGGCAAAAAT AGAGGAACAT CTGGCCAGGG TGGAAGCGGT AACAAAGGAG ATAGAAACAA 720 CAGTAACCTA CCAACTGACG GGAGATGAGC TCATCTTCGC CACCAAGCAG GCCTGGCGCA 780 ATGCCCCACG CTGCATTGGG AGGATCCAGT GGTCCAACCT GCAGGTCTTC GATGCCCGCA 840 GCTGTTCCAC TGCCCGGGAA ATGTTTGAAC ACATCTGCAG ACACGTGCGT TACTCCACCA 900 ACAATGGCAA CATCAGGTCG GCCATCACCG TGTTCCCCCA GCGGAGTGAT GGCAAGCACG 960 ACTTCCGGGT GTGGAATGCT CAGCTCATCC GCTATGCTGG CTACCAGATG CCAGATGGCA 1020 GCATCAGAGG GGACCCTGCC AACGTGGAAT TCACTCAGCT GTGCATCGAC CTGGGCTGGA 1080 AGCCCAAGTA CGGCCGCTTC GATGTGGTCC CCCTGGTCCT GCAGGCCAAT GGCCGTGACC 1140 CTGAGCTCTT CGAAATCCCA CCTGACCTTG TGCTTGAGGT GGCCATGGAA CATCCCAAAT 1200 ACGAGTGGTT TCGGGAACTG GAGCTAAAGT GGTACGCCCT GCCTGCAGTG GCCAACATGC 1260 TGCTTGAGGT GGGCGGCCTG GAGTTCCCAG GGTGCCCCTT CAATGGCTGG TACATGGGCA 1320 CAGAGATCGG AGTCCGGGAC TTCTGTGATG TCCAGCGCTA CAACATCCTG GAGGAAGTGG 1380 GCAGGAGAAT GGGCCTGGAA ACGCACAAGC TGGCCTCGCT CTGGAAAGAC CAGGCTGTCG 1440 TTGAGATCAA CATTGCTGTG CTCCATAGTT TCCAGAAGCA GAATGTGACC ATCATGGACC 1500 ACCACTCGGC TGCAGAATCC TTCATGAAGT ACATGCAGAA TGAATACCGG TCCCGTGGGG 1560 GCTGCCCGGC AGACTGGATT TGGCTGGTCC CTCCCATGTC TGGGAGCATC ACCCCCGTGT 1620 TTCACCAGGA GATGCTGAAC TACGTCCTGT CCCCTTTCTA CTACTATCAG GTAGAGGCCT 1680 GGAAAACCCA TGTCTGGCAG GACGAGAAGC GGAGACCCAA GAGAAGAGAG ATTCCATTGA 1740 AAGTCTTGGT CAAAGCTGTG CTCTTTGCCT GTATGCTGAT GCGCAAGACA ATGGCGTCCC 1800 GAGTCAGAGT CACCATCCTC TTTGCGACAG AGACAGGAAA ATCAGAGGCG CTGGCCTGGG 1860 ACCTGGGGGC CTTATTCAGC TGTGCCTTCA ACCCCAAGGT TGTCTGCATG GATAAGTACA 1920 GGCTGAGCTG CCTGGAGGAG GAACGGCTGC TGTTGGTGGT GACCAGTACG TTTGGCAATG 1980 GAGACTGCCC TGGCAATGGA GAGAAACTGA AGAAATCGCT CTTCATGCTG AAAGAGCTCA 2040 ACAACAAATT CAGGTACGCT GTGTTTGGCC TCGGCTCCAG CATGTACCCT CGGTTCTGCG 2100 CCTTTGCTCA TGACATTGAT CAGAAGCTGT CCCACCTGGG GGCCTCTCAG CTCACCCCGA 2160 TGGGAGAAGG GGATGAGCTC AGTGGGCAGG AGGACGCCTT CCGCAGCTGG GCCGTGCAAA 2220 CCTTCAAGGC AGCCTGTGAG ACGTTTGATG TCCGAGGCAA ACAGCACATT CAGATCCCCA 2280 AGCTCTACAC CTCCAATGTG ACCTGGGACC CGCACCACTA CAGGCTCGTG CAGGACTCAC 2340 AGCCTTTGGA CCTCAGCAAA GCCCTCAGCA GCATGCATGC CAAGAACGTG TTCACCATGA 2400 GGCTCAAATC TCGGCAGAAT CTACAAAGTC CGACATCCAG CCGTGCCACC ATCCTGGTGG 2460 AACTCTCCTG TGAGGATGGC CAAGGCCTGA ACTACCTGCC GGGGGAGCAC CTTGGGGTTT 2520 GCCCAGGCAA CCAGCCGGCC CTGGTCCAAG GCATCCTGGA GCGAGTGGTG GATGGCCCCA 2580 CACCCCACCA GGCAGTGCGC CTGGAGGCCC TGGATGAGAG TGGCAGCTAC TGGGTCAGTG 2640 ACAAGAGGCT GCCCCCCTGC TCACTCAGCC AGGCCCTCAC CTACTTCCTG GACATCACCA 2700 CACCCCCAAC CCAGCTGCTG CTCCAAAAGC TGGCCCAGGT GGCCACAGAA GAGCCTGAGA 2760 GACAGAGGCT GGAGGCCCTG TGCCAGCCCT CAGAGTACAG CAAGTGGAAG TTCACCAACA 2820 GCCCCACATT CCTGGAGGTG CTAGAGGAGT TCCCGTCCCT GCGGGTGTCT GCTGGCTTCC 2880 TGCTTTCCCA GCTCCCCATT CTGAAGCCCA GGTTCTACTC CATCAGCTCC CCCCGGGATC 2940 ACACGCCCAC GGAGATCCAC CTGACTGTGG CCGTGGTCAC CTACCACACC CGAGATGGCC 3000 AGGGTCCCCT GCACCACGGC GTCTGCAGCA CATGGCTCAA CAGCCTGAAG CCCCAAGACC 3060 CAGTGCCCTG CTTTGTGCGG AATGCCAGCG GCTTCCACCT CCCCGAGGAT CCCTCCCATC 3120

CTTGCATCCT CATCGGGCCT GGCACAGGCA TCGCGCCCTT CCGCAGTTTC TGGCAGCAAC 3180 GGCTCCATGA CTCCCAGCAC AAGGGAGTGC GGGGAGGCCG CATGACCTTG GTGTTTGGGT 3240 GCCGCCGCCC AGATGAGGAC CACATCTACC AGGAGGAGAT GCTGGAGATG GCCCAGAAGG 3300 GGGTGCTGCA TGCGGTGCAC ACAGCCTATT CCCGCCTGCC TGGCAAGCCC AAGGTCTATG 3360 TTCAGGACAT CCTGCGGCAG CAGCTGGCCA GCGAGGTGCT CCGTGTGCTC CACAAGGAGC 3420 CAGGCCACCT CTATGTTTGC GGGGATGTGC GCATGGCCCG GGACGTGGCC CACACCCTGA 3480 AGCAGCTGGT GGCTGCCAAG CTGAAATTGA ATGAGGAGCA GGTCGAGGAC TATTTCTTTC 3540 AGCTCAAGAG CCAGAAGCGC TATCACGAAG ATATCTTTGG TGCTGTATTT CCTTACGAGG 3600 CGAAGAAGGA CAGGGTGGCG GTGCAGCCCA GCAGCCTGGA GATGTCAGCG CTCTGAGGGC 3660 CTACAGGAGG GGTTAAAGCT GCCGGCACAG AACTTAAGGA TGGAGCCAGC TCTGCATTAT 3720 CTGAGGTCAC AGGGCCTGGG GAGATGGAGG AAAGTGATAT CCCCCAGCCT CAAGTCTTAT 3780 TTCCTCAACG TTGCTCCCCA TCAAGCCCTT TACTTGACCT CCTAACAAGT AGCACCCTGG 3840 ATTGATCGGA GCCTC Seq ID NO: 313 Protein sequence: Protein Accession # : NP 000616 1 11 21 31 41 51 1 1 1 1 1 1 MACPWKFLFK TKFHQYAMNG EKGINNNVEK APCATSSPVT QDDLQYHNLS KQQNESPQPL 60 VETGKKSPES LVKLDATPLS SPRHVRIKNW GSGMTFQDTL HHKAKGILTC RSKSCLGSIM 120 TPKSLTRGPR DKPTPPDELL PQAIEFVNQY YGSLKEAKIE EHLARVEAVT KEIETTVTYQ 180 LTGDELIFAT KQAWRNAPRC IGRIQWSNLQ VFDARSCSTA REMFEHICRH VRYSTNNGNI 240 RSAITVFPQR SDGKHDFRVW NAQLIRYAGY QMPDGSIRGD PANVEFTQLC IDLGWKPKYG 300 RFDWPLVLQ ANGRDPELFE IPPDLVLEVA MEHPKYEWFR ELELKWYALP AVANMLLEVG 360 GLEFPGCPFN GWYMGTEIGV RDFCDVQRYN ILEEVGRRMG LETHKLASLW KDQAWEINI 420 AVLHSFQKQN VTIMDHHSAA ESFMKYMQNE YRSRGGCPAD WIWLVPPMSG SITPVFHQEM 480 LNYVLSPFYY YQVEAWKTHV WQDEKRRPKR REIPLKVLVK AVLFACMLMR KTMASRVRVT 540 ILFATETGKS EALAWDLGAL FSCAFNPKW CMDKYRLSCL EEERLLLWT STFGNGDCPG 600 NGEKLKKSLF MLKELNNKFR YAVFGLGSSM YPRFCAFAHD IDQKLSHLGA SQLTPMGEGD 660 ELSGQEDAFR SWAVQTFKAA CETFDVRGKQ HIQIPKLYTS NVTWDPHHYR LVQDSQPLDL 720 SKALSSMHAK NVFTMRLKSR QNLQSPTSSR ATILVELSCE DGQGLNYLPG EHLGVCPGNQ 780 PALVQGILER VVDGPTPHQA VRLEALDESG SYWVSDKRLP PCSLSQALTY FLDITTPPTQ 840 LLLQKLAQVA TEEPERQRLE ALCQPSEYSK WKFTNSPTFL EVLEEFPSLR VSAGFLLSQL 900 PILKPRFYSI SSPRDHTPTE IHLTVAWTY HTRDGQGPLH HGVCSTWLNS LKPQDPVPCF 960 VRNASGFHLP EDPSHPCILI GPGTGIAPFR SFWQQRLHDS QHKGVRGGRM TLVFGCRRPD 1020 EDHIYQEEML EMAQKGVLHA VHTAYSRLPG KPKVYVQDIL RQQLASEVLR VLHKEPGHLY 1080 VCGDVRMARD VAHTLKQLVA AKLKLNEEQV EDYFFQLKSQ KRYHEDIFGA VFPYEAKKDR 1140 VAVQPSSLEM SAL Seq ID NO: 314 DNA sequence Nucleic Acid Accession it : XM 087254 Coding sequence : 47.. 2332 1 11 21 31 41 51 # # # # # # AGAGTACGTG TTTACAGATA AAACTGGTAC ACTGACAGAA AATGAGATGC AGTTTCGGGA 60 ATGTTCAATT AATGGCATGA AATACCAAGA AATTAATGGT AGACTTGTAC CCGAAGGACC 120 AACACCAGAC TCTTCAGAAG GAAACTTATC TTATCTTAGT AGTTTATCCC ATCTTAACAA 180 CTTATCCCAT CTTACAACCA GTTCCTCTTT CAGAACCAGT CCTGAAAATG AAACTGAACT 240 AATTAAAGAA CATGATCTCT TCTTTAAAGC AGTCAGTCTC TGTCACACTG TACAGATTAG 300 CAATGTTCAA ACTGACTGCA CTGGTGATGG TCCCTGGCAA TCCAACCTGG CACCATCGCA 360 GTTGGAGTAC TATGCATCTT CACCAGATGA AAAGGCTCTA GTAGAAGCTG CTGCAAGGAT 420 TGGTATTGTG TTTATTGGCA ATTCTGAAGA AACTATGGAG GTTAAAACTC TTGGAAAACT 480 GGAACGGTAC AAACTGCTTC ATATTCTGGA ATTTGATTCA GATCGTAGGA GAATGAGTGT 540 AATTGTTCAG GCACCTTCAG GTGAGAAGTT ATTATTTGCT AAAGGAGCTG AGTCATCAAT 600 TCTCCCTAAA TGTATAGGTG GAGAAATAGA AAAAACCAGA ATTCATGTAG ATGAATTTGC 660 TTTGAAAGGG CTAAGAACTC TGTGTATAGC ATATAGAAAA TTTACATCAA AAGAGTATGA 720 GGAAATAGAT AAACGCATAT TTGAAGCCAG GACTGCCTTG CAGCAGCGGG AAGAGAAATT 780 GGCAGCTGTT TTCCAGTTCA TAGAGAAAGA CCTGATATTA CTTGGAGCCA CAGCAGTAGA 840 AGACAGACTA CAAGATAAAG TTCGAGAAAC TATTGAAGCA TTGAGAATGG CTGGTATCAA 900 AGTATGGGTA CTTACTGGGG ATAAACATGA AACAGCTGTT AGTGTGAGTT TATCATGTGG 960 CCATTTTCAT AGAACCATGA ACATCCTTGA ACTTATAAAC CAGAAATCAG ACAGCGAGTG 1020 TGCTGAACAA TTGAGGCAGC TTGCCAGAAG AATTACAGAG GATCATGTGA TTCAGCATGG 1080 GCTGGTAGTG GATGGGACCA GCCTATCTCT TGCACTCAGG GAGCATGAAA AACTATTTAT 1140 GGAAGTTTGC AGAAATTGTT CAGCTGTATT ATGCTGTCGT ATGGCTCCAC TGCAGAAAGC 1200 AAAAGTAATA AGACTAATAA AAATATCACC TGAGAAACCT ATAACATTGG CTGTTGGTGA 1260 TGGTGCTAAT GACGTAAGCA TGATACAAGA AGCCCATGTT GGCATAGGAA TCATGGGTAA 1320 AGAAGGAAGA CAGGCTGCAA GAAACAGTGA CTATGCAATA GCCAGATTTA AGTTCCTCTC 1380 CAAATTGCTT TTTGTTCATG GTCATTTTTA TTATATTAGA ATAGCTACCC TTGTACAGTA 1440 TTTTTTTTAT AAGAATGTGT GCTTTATCAC ACCCCAGTTT TTATATCAGT TCTACTGTTT 1500 GTTTTCTCAG CAAACATTGT ATGACAGCGT GTACCTGACT TTATACAATA TTTGTTTTAC 1560 TTCCCTACCT ATTCTGATAT ATAGTCTTTT GGAACAGCAT GTAGACCCTC ATGTGTTACA 1620 AAATAAGCCC ACCCTTTATC GAGACATTAG TAAAAACCGC CTCTTAAGTA TTAAAACATT 1680 TCTTTATTGG ACCATCCTGG GCTTCAGTCA TGCCTTTATT TTCTTTTTTG GATCCTATTT 1740 ACTAATAGGG AAAGATACAT CTCTGCTTGG AAATGGCCAG ATGTTTGGAA ACTGGACATT 1800 TGGCACTTTG GTCTTCACAG TCATGGTTAT TACAGTCACA GTAAAGATGG CTCTGGAAAC 1860 TCATTTTTGG ACTTGGATCA ACCATCTCGT TACCTGGGGA TCTATTATAT TTTATTTTGT 1920 ATTTTCCTTG TTTTATGGAG GGATTCTCTG GCCATTTTTG GGCTCCCAGA ATATGTATTT 1980 TGTGTTTATT CAGCTCCTGT CAAGTGGTTC TGCTTGGTTT GCCATAATCC TCATGGTTGT 2040 TACATGTCTA TTTCTTGATA TCATAAAGAA GGTCTTTGAC CGACACCTCC ACCCTACAAG 2100 TACTGAAAAG GCACAGCTTA CTGAAACAAA TGCAGGTATC AAGTGCTTGG ACTCCATGTG 2160 CTGTTTCCCG GAAGGAGAAG CAGCGTGTGC ATCTGTTGGA AGAATGCTGG AACGAGTTAT 2220 AGGAAGATGT AGTCCAACCC ACATCAGCAG ATCATGGAGT GCATCGGATC CTTTCTATAC 2280 CAACGACAGG AGCATCTTGA CTCTCTCCAC AATGGACTCA TCTACTTGTT AAAGGGGCAG 2340

TAGTACTTTG TGGGAGCCAG TTCACCTCCT TTCCTAAAAT TCAGTGTGAT CACCCTGTTA 2400 ATGGCCACAC TAGCTCTGAA ATTAATTTCC AAAATCTTTG TAGTAGTTCA TACCCACTCA 2460 GAGTTATAAT GGCAAACAAA CAGAAAGCAT TAGTACAAGC CCCTCCCAAC ACCCTTAATT 2520 TGAATCTGAA CATGTTAAAA TTTGAGAATA AAGAGACATT TTTCATCTCT TTGTCTGGTT 2580 TGTCCCTTGT GCTTATGGGA CTCCTAATGG CATTTCAGTC TGTTGCTGAG GCCATTATAT 2640 TTTAATATAA ATGTAGAAAA AAGAGAGAAA TCTTAGTAAA GAGTATTTTT TAGTATTAGC 2700 TTGATTATTG ACTCTTCTAT TTAAATCTGC TTCTGTAAAT TATGCTGAAA GTTTGCCTTG 2760 AGAACTCTAT TTTTTTATTA GAGTTATATT TAAAGCTTTT CATGGGAAAA GTTAATGTGA 2820 ATACTGAGGA ATTTTGGTCC CTCAGTGACC TGTGTTGTTA ATTCATTAAT GCATTCTGAG 2880 TTCACAGAGC AAATTAGGAG AATCATTTCC AACCATTATT TACTGCAGTA TGGGGAGTAA 2940 ATTTATACCA ATTCCTCTAA CTGTACTGTA ACACAGCCTG TAAAGTTAGC CATATAAATG 3000 CAAGGGTATA TCATATATAC AAATCAGGAA TCAGGTCCGT TCACCGAACT TCAAATTGAT 3060 GTTTACTAAT ATTTTTGTGA CAGAGTATAA AGACCCTATA GTGGGTAAAT TAGATACTAT 3120 TAGCATATTA TTAATTTAAT GTCTTTATCA TTGGATCTTT TGCATGCTTT AATCTGGTTA 3180 ACATATTTAA ATTTGCTTTT TTTCTCTTTA CCTGAAGGCT CTGTGTATAG TATTTCATGA 3240 CATCGTTGTA CAGTTTAACT ATATCAATAA AAAGTTTGGA CAGTATTTAA ATATTGCAAA 3300 TATGTTTAAT TATACAAATC AGAATAGTAT GGGTAATTAA ATGAATACAA AAAGAAGAGC 3360 CTCTTTCTGC AGCCGACTTA GACATGCTCT TCCCTTTCTA TAAGCTAGAT TTTAGAATAA 3420 AGGGTTTCAG TTAATAATCT TATTTTCAGG TTATGTCATC TAACTTATAG CAAACTACCA 3480 CAATACAGTG AGTTCTGCCA GTGTCCCAGT ACAAGGCATA TTTCAGGTGT GGCTGTGGAA 3540 TGTAAAAATG CTCAACTTGT ATCAGGTAAT GTTAGCAATA AATTAAATGC TAAGAATGAT 3600 TAATCGGGTA CATGTTACTG TAATTAACTC ATTGCACTTC AAAACCTAAC TTCCATCCTG 3660 AATTTATCAA GTAGTTCAGT ATTGTCATTT GTTTTTGTTT TATTGAAAAG TAATGTTGTC 3720 TTAAGATTTA GAAGTGATTA TTAGCTTGAG AACTATTACC CAGCTCTAAG CAAATAATGA 3780 TTGTATACAT ATTAAGATAA TGGTTAAATG CGGTTTTACC AAGTTTTCCC TTGAAAATGT 3840 AATTCCTTTA TGGAGATTTA TTGTGCAGCC CTAAGCTTCC TTCCCATTTC ATGAATATAA 3900 GGCTTCTAGA ATTGGACTGG CAGGGGAAAG AATGGTAGAG ACAGAAATTA AGACTTTATC 3960 CTTGTTTGCT TGTAAACTAT TATTTTCTTG CTAATGTAAC ATTTGTCTGT TCCAGTGATG 4020 TAAGGATATT AAGTTATTAA GCTAAATATT AATTTTCAAA AATAGTCCTT CTTTAACTTA 4080 GATATTTCAT AGCTGGATTT AGGAAGATCT GTTATTCTGG AAGTACTAAA AAGAATAATA 4140 CAACGTACAA TGTCTGCATT CACTAATTCA TGTTCCAGAA GAGGAAATAA TGAAGATATA 4200 CTCAGTAGAG TACTAGGTGG GAGGATATGG AAATTTGCTC ATAAAATCTC TTATAAAACG 4260 TGCATATAAC AAAATGACAC CCAGTAGGCC TGCATTACAT TTACATGACC GTGTTTATTT 4320 GCCATCAAAT AAACTGAGTA CTGACACCAG ACAAAGACTC CAAAGTCATA AAATAGCCTA 4380 TGACCAACTG CAGCAAGACA GGAGGTCAGC TCGCCTATAA TGGTGCTTAA AGTGTGATTG 4440 ATGTAATTTT CTGTACTCAC CATTTGAAGT TAGTTAAGGA GAACTTTATT TTTTTAAAAA 4500 AAGTAAATGG CAACCACTAG TGTGCTCATC CTGAACTGTT ACTCCAAATC CACTCCGTTT 4560 TTAAAGCAAA ATTATCTTGT GATTTTAAGA AAAGAGTTTT CTATTTATTT AAGAAAGTAA 4620 CAATGCAGTC TGCAAGCTTT CAGTAGTTTT CTAGTGCTAT ATTCATCCTG TAAAACTCTT 4680 ACTACGTAAC CAGTAATCAC AAGGAAAGTG TCCCCTTTGC ATATTTCTTT AAAATTCTTT 4740 CTTTGGAAAG TATGATGTTG ATAATTAACT TACCCTTATC TGCCAAAACC AGAGCAAAAT 4800 GCTAAATACG TTATTGCTAA TCAGTGGTCT CAAATCGATT TGCCTCCCTT TGCCTCGTCT 4860 GAGGGCTGTA AGCCTGAAGA TAGTGGCAAG CACCAAGTCA GTTTCCAAAA TTGCCCCTCA 4920 GCTGCTTTAA GTGACTCAGC ACCCTGCCTC AGCTTCAGCA GGCGTAGGCT CACCCTGGGC 4980 GGAGCAAAGT ATGGGCCAGG GAGAACTACA GCTACGAAGA CCTGCTGTCG AGTTGAGAAA 5040 AGGGGAGAAT TTATGGTCTG AATTTTCTAA CTGTCCTCTT TCTTGGGTCT AAAGCTCATA 5100 ATACACAAAG GCTTCCAGAC CTGAGCCACA CCCAGGCCCT ATCCTGAACA GGAGACTAAA 5160 CAGAGGCAAA TCAACCCTAG GAAATACTTG CATTCTGCCC TACGGTTAGT ACCAGGACTG 5220 AGGTCATTTC TACTGGAAAA GATTGTGAGA TTGAACTTAT CTGATCGCTT GAGACTCCTA 5280 ATAGGCAGGA GTCAAGGCCA CTAGAAAATT GACAGTTAAG AGCCAAAAGT TTTTAAAATA 5340 TGCTACTCTG AAAAATCTCG TGAAGGCTGT AGGAAAAGGG AGAATCTTCC ATGTTGGTGT 5400 TTTTCCTGTA AAGATCAGTT TGGGGTATGA TATAAGCAGG TATTAATAAA AATAACACAC 5460 CAAAGAGTTA CGTAAAACAT GTTTTATTAA TTTTGGTCCC CACGTACAGA CATTTTATTT 5520 CTATTTTGAA ATGAGTTATC TATTTTCATA AAAGTAAAAC ACTATTAAAG TGCTGTTTTA 5580 TGTGAAATAA CTTGAATGTT GTTCCTATAA AAAATAGATC ATAACTCATG ATATGTTTGT 5640 AATCATGGTA ATTTAGATTT TTATGAGGAA TGAGTATCTG GAAATATTGT AGCAATACTT 5700 GGTTTAAAAT TTTGGACCTG AGACACTGTG GCTGTCTAAT GTAATCCTTT AAAAATTCTC 5760 TGCATTGTCA GTAAATGTAG TATATTATTG TACAGCTACT CATAATTTTT TAAAGTTTAT 5820 GAAGTTATAT TTATCAAATA AAAACTTTCC TATAT Seq ID NO : 315 Protein sequence: Protein Accession # : XP 087254 1 11 21 31 41 51 MQFRECSING MKYQEINGRL VPEGPTPDSS EGNLSYLSSL SHLNNLSHLT TSSSFRTSPE 60 NETELIKEHD LFFKAVSLCH TVQISNVQTD CTGDGPWQSN LAPSQLEYYA SSPDEKALVE 120 AAARIGIVFI GNSEETMEVK TLGKLERYKL LHILEFDSDR RRMSVIVQAP SGEKLLFAKG 180 AESSILPKCI GGEIEKTRIH VDEFALKGLR TLCIAYRKFT SKEYEEIDKR IFEARTALQQ 240 REEKLAAVFQ FIEKDLILLG ATAVEDRLQD KVRETIEALR MAGIKVWVLT GDKHETAVSV 300 SLSCGHFHRT MNILELINQK SDSECAEQLR QLARRITEDH VIQHGLWDG TSLSLALREH 360 EKLFMEVCRN CSAVLCCRMA PLQKAKVIRL IKISPEKPIT LAVGDGANDV SMIQEAHVGI 420 GIMGKEGRQA ARNSDYAIAR FKFLSKLLFV HGHFYYIRIA TLVQYFFYKN VCFITPQFLY 480 QFYCLFSQQT LYDSVYLTLY NICFTSLPIL IYSLLEQHVD PHVLQNKPTL YRDISKNRLL 540 SIKTFLYWTI LGFSHAFIFF FGSYLLIGKD TSLLGNGQMF GNWTFGTLVF TVMVITVTVK 600 MALETHFWTW INHLVTWGSI IFYFVFSLFY GGILWPFLGS QNMYFVFIQL LSSGSAWFAI 660 ILMWTCLFL DIIKKVFDRH LHPTSTEKAQ LTETNAGIKC LDSMCCFPEG EAACASVGRM 720 LERVIGRCSP THISRSWSAS DPFYTNDRSI LTLSTMDSST C Seq ID NO : 316 DNA sequence Nucleic Acid Accession &num : NM 004473 Coding sequence: 661.. 1791 1 11 21 31 41 51 CTCGCCAGCG GTCCGCGGGG CTGGAGACCC ACGCCGTGGA GAGGACCAGC CTCAGGTCGC 60

CCCGCCTGGG CCCGCGCCCC GACCTCGCTG CCCCCGCCTC GCCTCTCTGC CCGTGGCGCT 120 'TACCGCCACC TTGGCCTCGG GGGCAGGGCA TGGGCGGCCC CCGCCAGATC GCCCAGCGCC 180 AGTACTAACT GCCCTCGCTC TGGCCTTCGA GCCCGAAGCC TCTTCTGCGC GCACAACCTA 240 GGCAGTAATC CTAAACTAGC GGGCACCACA GACCAGCTGC AGCCACCCCA ACCCAGGGAT 300 CACTTCCGGA CCCCTCGACC GCCCGGCACC AGCGCGCAAG GGACCCTTCA GCCGGAGACC 360 AGAGTCCAGT CCCGGTCGCG AGGCCACCGC CGCTGCCCGC CTCGAGAAGC ACAACGCGGG 420 CTGAGCCGTC GGCTAGCGGG TCACTCCCGA GCCTCTGTCT GCACCGCGCC AGCCCCAGAC 480 CACGGACGCT GAGCCTCCAG CGCGCGCCAG CCTGGGCCGC TGGGCTCTCC GGGCCAGCCC 540 GCGACGATCC CCTGAGCTCT CCGCAGAAGG GCCGAGCGTC CGTTCCGGGG ACGCCAGGCC 600 CGCCCCCGCC CCCCGACAGC CGCGGGGATC CAGAGCCCGG GGGTGCGGGA CGCCCGCGCC 660 ATGACTGCCG AGAGCGGGCC GCCGCCGCCG CAGCCGGAGG TGCTGGCTAC CGTGAAGGAA 720 GAGCGCGGCG AGACGGCAGC AGGGGCCGGG GTCCCAGGGG AGGCCACGGG CCGCGGGGCG 780 GGCGGGCGGC GCCGCAAGCG CCCCCTGCAG CGCGGGAAGC CGCCCTACAG CTACATCGCG 840 CTCATCGCCA TGGCCATCGC GCACGCGCCC GAGCGCCGCC TCACGCTGGG CGGCATCTAC 900 AAGTTCATCA CCGAGCGCTT CCCCTTCTAC CGCGACAACC CCAAAAAGTG GCAGAACAGC 960 ATCCGCCACA ACCTCACACT CAACGACTGC TTCCTCAAGA TCCCGCGCGA GGCCGGCCGC 1020 CCGGGTAAGG GCAACTACTG GGCGCTCGAC CCCAACGCGG AGGACATGTT CGAGAGCGGC 1080 AGCTTCCTGC GCCGCCGCAA GCGCTTCAAG CGCTCGGACC TCTCCACCTA CCCGGCTTAC 1140 ATGCACGACG CGGCGGCTGC CGCAGCCGCC GCTGCCGCAG CCGCCGCCGC CGCCGCCGCC 1200 GCCGCCATCT TCCCAGGCGC GGTGCCCGCC GCGCGCCCCC CCTACCCGGG CGCCGTCTAT 1260 GCAGGCTACG CGCCGCCGTC GCTGGCCGCG CCGCCTCCAG TCTACTACCC CGCGGCGTCG 1320 CCCGGCCCTT GCCGCGTCTT CGGCCTGGTT CCTGAGCGGC CGCTCAGCCC AGAGCTGGGG 1380 CCCGCACCGT CGGGGCCCGG CGGCTCTTGC GCCTTTGCCT CCGCCGGCGC CCCCGCTACC 1440 ACCACCGGCT ACCAGCCCGC AGGCTGCACC GGGGCCCGGC CGGCCAACCC CTCTGCCTAT 1500 GCGGCTGCCT ACGCGGGCCC CGACGGCGCG TACCCGCAGG GCGCCGGCAG TGCGATCTTT 1560 GCCGCTGCTG GCCGCCTGGC GGGACCCGCT TCGCCCCCAG CGGGCGGCAG CAGTGGCGGC 1620 GTGGAGACCA CGGTGGACTT CTACGGGCGC ACGTCGCCCG GCCAGTTCGG AGCGCTGGGA 1680 GCCTGCTACA ACCCTGGCGG GCAGCTCGGA GGGGCCAGTG CAGGCGCCTA CCATGCTCGC 1740 CATGCTGCCG CTTATCCCGG TGGGATAGAT CGGTTCGTGT CCGCCATGTG AGCCAGCGTA 1800 GGGACGAAAA CTCATAGACA CATCGGCTGT TCACACGTTC CCCGCAACCT GAGAACGAAC 1860 AGGAATGGAG AGAGGACTCA ACTGGGACCC ACGTGGAAAA GACCGAGCAG GCCACAGAGG 1920 CTCGGTCTCC CCGCGCACAG CGTAGGCACC CTGTGTACTC TGTAAACGGG AGGAGGTGGG 1980 GCGAGGCAGC CAGAGCCCTT GGACTGGCAC AGGGACCCTC GATGGAGCGA AGCCCTCAAA 2040 CGGGATGCTT TCTGGCATTC TATCGGGGAG GGTCCTTGGC GGTAACCAGA GGGCAGCGTA 2100 GTGTCAACAC CAGAGACCAG GATCCAAATT GTGGGGAATC AGTTTCAGCC TTCCATGTGC 2160 TGCCGGAACT CGGGCCTTTT TACGCGGTTC GTCCTCTAGT GCCTTTAACT GCGTTACTAC 2220 AATAAAAGGC TGCGGCAGCG CCTTTCTTCT TAAAGTGAGG AGGACAAATT TGCAAAAGAA 2280 ATAGGCTTTT CTTCTTTTTT AAATTGGAGA AATCTCTGCT CTGGTTGACC TGGGCTGGTT 2340 TTCCCTGTCT CTGAGAACTT GAGACCTAGC TCCGAGTTGA ACTGTGCGTC AGCACTCCAG 2400 TCCCATCACC TGAACCTTCA GTCTCCCCCA TCTGTTACAC TAGAGGGCTG CAGGACTCTA 2460 TCCACCGCCC CCGGGTTATC ATTCAGGGCC CCATCATCTT GGATGCTGCC CTGCGTATTT 2520 GGCAGCAATG GTGGGCCACC CAGGGCCTCT GAGTAGCCAC CCAAAGCCTA GCCGCTGTTC 2580 TAGGGAACGG AAAAGAGTTC ATGGCCAAGC GTCTAACCTA AAGTCCCAGG ATTGGCTCCA 2640 GGCAGCAATT ATATCATAAC TTATTGAACT TTTGAGCAGG ACGTGCTGGT AATTTCATGG 2700 CTGTTACTGC CCAGTCATAA ATCTGCTTTT CCATTATAAG GCAGAGAGAA GTACATTCGT 2760 TCATTTGTCC ACTGTTTCTT GTCATCACGC AGCCCTGGAC CCAAAGGGTG AACTAAAGTT 2820 TAAGGAGATG AGAGGATTCA AGGAGCCCGT TGGTGACGCC TTTCAGTAGC TGGGGAGGGC 2880 TCTTCCATCC CCAGCACCCC CTGCTACACC TCAGCAGCCT CCCCCATGCA AAAAGGAAAG 2940 AGAAAAATTA AGTTAGGGCA GTCAGTAAAG TGAGCTTTAG AAAGAAACTG GAATTTTAAC 3000 TTCATTTTGT ATCTTGCTTA AGTAGCAGGC TCACTAAAAT TAGAGAAAGT CCAATAACTC 3060 TCCCCCTTTC CCTTGAGAAA TCTTTAAGTT TCGATTCTGG AGCAAAAACT TTCAGCATTA 3120 AATATTTCAG AGGCTCCATT CACAGCTTTC AGATAAACTG GAGTGTTCAG ATGGACTGTT 3180 TTAATAAAAA TCTTTGAGCA AGTGAGTTAT GGCAAGAGAA ACTCAGCCTC TTTCTGTATA 3240 AACTTAACAG GGAAGGGCTG GGGTGTGAAA AAGAAGATTG TATGAAAACC ATTGGTAATT 3300 TTTATTTTTT ATTTTTGGGA CTGCACTATC CTGTTCACGA AGACATGTGA ACTTGGTTCA 3360 GTCCAAATGG GGATTTGTAT AAACCAGTGC TCTCCATTAG AAATATGGTG CAAGCCACAT 3420 ATGTAATTTT AAATATTCTA GTAGCCACAT TAATAAAGTN AAAAGAAACA AAAAAAAAAA 3480 AA Seq ID NO : 317 Protein sequence: Protein Accession # : NP 004464 1 11 21 31 41 51 FKHLTHYROI DTRANSCRIP TIONFACTOR TTFMTAESGP PPPQPEVLAT VKEERGETAA 60 GAGVPGEATG RGAGGRRRKR PLQRGKPPYS YIALIAMAIA HAPERRLTLG GIYKFITERF 120 PFYRDNPKKW QNSIRHNLTL NDCFLKIPRE AGRPGKGNYW ALDPNAEDMF ESGSFLRRRK 180 RFKRSDLSTY PAYMHDAAAA AAAAAAAAAA AAAAAIFPGA VPAARPPYPG AVYAGYAPPS 240 LAAPPPVYYP AASPGPCRVF GLVPERPLSP ELGPAPSGPG GSCAFASAGA PATTTGYQPA 300 GCTGARPANP SAYAAAYAGP DGAYPQGAGS AIFAAAGRLA GPASPPAGGS SGGVETTVDF 360 YGRTSPGQFG ALGACYNPGG QLGGASAGAY HARHAAAYPG GIDRFVSAM Seq ID NO : 318 DNA sequence Nucleic Acid Accession # : NM 005688 Coding sequence : 126.. 4439 1 11 21 31 41 51 CCGGGCAGGT GGCTCATGCT CGGGAGCGTG GTTGAGCGGC TGGCGCGGTT GTCCTGGAGC 60 AGGGGCGCAG GAATTCTGAT GTGAAACTAA CAGTCTGTGA GCCCTGGAAC CTCCGCTCAG 120 AGAAGATGAA GGATATCGAC ATAGGAAAAG AGTATATCAT CCCCAGTCCT GGGTATAGAA 180 GTGTGAGGGA GAGAACCAGC ACTTCTGGGA CGCACAGAGA CCGTGAAGAT TCCAAGTTCA 240 GGAGAACTCG ACCGTTGGAA TGCCAAGATG CCTTGGAAAC AGCAGCCCGA GCCGAGGGCC 300 TCTCTCTTGA TGCCTCCATG CATTCTCAGC TCAGAATCCT GGATGAGGAG CATCCCAAGG 360 GAAAGTACCA TCATGGCTTG AGTGCTCTGA AGCCCATCCG GACTACTTCC AAACACCAGC 420 ACCCAGTGGA CAATGCTGGG CTTTTTTCCT GTATGACTTT TTCGTGGCTT TCTTCTCTGG 480

CCCGTGTGGC CCACAAGAAG GGGGAGCTCT CAATGGAAGA CGTGTGGTCT CTGTCCAAGC 540 ACGAGTCTTC TGACGTGAAC TGCAGAAGAC TAGAGAGACT GTGGCAAGAA GAGCTGAATG 600 AAGTTGGGCC AGACGCTGCT TCCCTGCGAA GGGTTGTGTG GATCTTCTGC CGCACCAGGC 660 TCATCCTGTC CATCGTGTGC CTGATGATCA CGCAGCTGGC TGGCTTCAGT GGACCAGCCT 720 TCATGGTGAA ACACCTCTTG GAGTATACCC AGGCAACAGA GTCTAACCTG CAGTACAGCT 780 TGTTGTTAGT GCTGGGCCTC CTCCTGACGG AAATCGTGCG GTCTTGGTCG CTTGCACTGA 840 CTTGGGCATT GAATTACCGA ACCGGTGTCC GCTTGCGGGG GGCCATCCTA ACCATGGCAT 900 TTAAGAAGAT CCTTAAGTTA AAGAACATTA AAGAGAAATC CCTGGGTGAG CTCATCAACA 960 TTTGCTCCAA CGATGGGCAG AGAATGTTTG AGGCAGCAGC CGTTGGCAGC CTGCTGGCTG 1020 GAGGACCCGT TGTTGCCATC TTAGGCATGA TTTATAATGT AATTATTCTG GGACCAACAG 1080 GCTTCCTGGG ATCAGCTGTT TTTATCCTCT TTTACCCAGC AATGATGTTT GCATCACGGC 1140 TCACAGCATA TTTCAGGAGA AAATGCGTGG CCGCCACGGA TGAACGTGTC CAGAAGATGA 1200 ATGAAGTTCT TACTTACATT AAATTTATCA AAATGTATGC CTGGGTCAAA GCATTTTCTC 1260 AGAGTGTTCA AAAAATCCGC GAGGAGGAGC GTCGGATATT GGAAAAAGCC GGGTACTTCC 1320 AGGGTATCAC TGTGGGTGTG GCTCCCATTG TGGTGGTGAT TGCCAGCGTG GTGACCTTCT 1380 CTGTTCATAT GACCCTGGGC TTCGATCTGA CAGCAGCACA GGCTTTCACA GTGGTGACAG 1440 TCTTCAATTC CATGACTTTT GCTTTGAAAG TAACACCGTT TTCAGTAAAG TCCCTCTCAG 1500 AAGCCTCAGT GGCTGTTGAC AGATTTAAGA GTTTGTTTCT AATGGAAGAG GTTCACATGA 1560 TAAAGAACAA ACCAGCCAGT CCTCACATCA AGATAGAGAT GAAAAATGCC ACCTTGGCAT 1620 GGGACTCCTC CCACTCCAGT ATCCAGAACT CGCCCAAGCT GACCCCCAAA ATGAAAAAAG 1680 ACAAGAGGGC TTCCAGGGGC AAGAAAGAGA AGGTGAGGCA GCTGCAGCGC ACTGAGCATC 1740 AGGCGGTGCT GGCAGAGCAG AAAGGCCACC TCCTCCTGGA CAGTGACGAG CGGCCCAGTC 1800 CCGAAGAGGA AGAAGGCAAG CACATCCACC TGGGCCACCT GCGCTTACAG AGGACACTGC 1860 ACAGCATCGA TCTGGAGATC CAAGAGGGTA AACTGGTTGG AATCTGCGGC AGTGTGGGAA 1920 GTGGAAAAAC CTCTCTCATT TCAGCCATTT TAGGCCAGAT GACGCTTCTA GAGGGCAGCA 1980 TTGCAATCAG TGGAACCTTC GCTTATGTGG CCCAGCAGGC CTGGATCCTC AATGCTACTC 2040 TGAGAGACAA CATCCTGTTT GGGAAGGAAT ATGATGAAGA AAGATACAAC TCTGTGCTGA 2100 ACAGCTGCTG CCTGAGGCCT GACCTGGCCA TTCTTCCCAG CAGCGACCTG ACGGAGATTG 2160 GAGAGCGAGG AGCCAACCTG AGCGGTGGGC AGCGCCAGAG GATCAGCCTT GCCCGGGCCT 2220 TGTATAGTGA CAGGAGCATC TACATCCTGG ACGACCCCCT CAGTGCCTTA GATGCCCATG 2280 TGGGCAACCA CATCTTCAAT AGTGCTATCC GGAAACATCT CAAGTCCAAG ACAGTTCTGT 2340 TTGTTACCCA CCAGTTACAG TACCTGGTTG ACTGTGATGA AGTGATCTTC ATGAAAGAGG 2400 GCTGTATTAC GGAAAGAGGC ACCCATGAGG AACTGATGAA TTTAAATGGT GACTATGCTA 2460 CCATTTTTAA TAACCTGTTG CTGGGAGAGA CACCGCCAGT TGAGATCAAT TCAAAAAAGG 2520 AAACCAGTGG TTCACAGAAG AAGTCACAAG ACAAGGGTCC TAAAACAGGA TCAGTAAAGA 2580 AGGAAAAAGC AGTAAAGCCA GAGGAAGGGC AGCTTGTGCA GCTGGAAGAG AAAGGGCAGG 2640 GTTCAGTGCC CTGGTCAGTA TATGGTGTCT ACATCCAGGC TGCTGGGGGC CCCTTGGCAT 2700 TCCTGGTTAT TATGGCCCTT TTCATGCTGA ATGTAGGCAG CACCGCCTTC AGCACCTGGT 2760 GGTTGAGTTA CTGGATCAAG CAAGGAAGCG GGAACACCAC TGTGACTCGA GGGAACGAGA 2820 CCTCGGTGAG TGACAGCATG AAGGACAATC CTCATATGCA GTACTATGCC AGCATCTACG 2880 CCCTCTCCAT GGCAGTCATG CTGATCCTGA AAGCCATTCG AGGAGTTGTC TTTGTCAAGG 2940 GCACGCTGCG AGCTTCCTCC CGGCTGCATG ACGAGCTTTT CCGAAGGATC CTTCGAAGCC 3000 CTATGAAGTT TTTTGACACG ACCCCCACAG GGAGGATTCT CAACAGGTTT TCCAAAGACA 3060 TGGATGAAGT TGACGTGCGG CTGCCGTTCC AGGCCGAGAT GTTCATCCAG AACGTTATCC 3120 TGGTGTTCTT CTGTGTGGGA ATGATCGCAG GAGTCTTCCC GTGGTTCCTT GTGGCAGTGG 3180 GGCCCCTTGT CATCCTCTTT TCAGTCCTGC ACATTGTCTC CAGGGTCCTG ATTCGGGAGC 3240 TGAAGCGTCT GGACAATATC ACGCAGTCAC CTTTCCTCTC CCACATCACG TCCAGCATAC 3300 AGGGCCTTGC CACCATCCAC GCCTACAATA AAGGGCAGGA GTTTCTGCAC AGATACCAGG 3360 AGCTGCTGGA TGACAACCAA GCTCCTTTTT TTTTGTTTAC GTGTGCGATG CGGTGGCTGG 3420 CTGTGCGGCT GGACCTCATC AGCATCGCCC TCATCACCAC CACGGGGCTG ATGATCGTTC 3480 TTATGCACGG GCAGATTCCC CCAGCCTATG CGGGTCTCGC CATCTCTTAT GCTGTCCAGT 3540 TAACGGGGCT GTTCCAGTTT ACGGTCAGAC TGGCATCTGA GACAGAAGCT CGATTCACCT 3600 CGGTGGAGAG GATCAATCAC TACATTAAGA CTCTGTCCTT GGAAGCACCT GCCAGAATTA 3660 AGAACAAGGC TCCCTCCCCT GACTGGCCCC AGGAGGGAGA GGTGACCTTT GAGAACGCAG 3720 AGATGAGGTA CCGAGAAAAC CTCCCTCTTG TCCTAAAGAA AGTATCCTTC ACGATCAAAC 3780 CTAAAGAGAA GATTGGCATT GTGGGGCGGA CAGGATCAGG GAAGTCCTCG CTGGGGATGG 3840 CCCTCTTCCG TCTGGTGGAG TTATCTGGAG GCTGCATCAA GATTGATGGA GTGAGAATCA 3900 GTGATATTGG CCTTGCCGAC CTCCGAAGCA AACTCTCTAT CATTCCTCAA GAGCCGGTGC 3960 TGTTCAGTGG CACTGTCAGA TCAAATTTGG ACCCCTTCAA CCAGTACACT GAAGACCAGA 4020 TTTGGGATGC CCTGGAGAGG ACACACATGA AAGAATGTAT TGCTCAGCTA CCTCTGAAAC 4080 TTGAATCTGA AGTGATGGAG AATGGGGATA ACTTCTCAGT GGGGGAACGG CAGCTCTTGT 4140 GCATAGCTAG AGCCCTGCTC CGCCACTGTA AGATTCTGAT TTTAGATGAA GCCACAGCTG 4200 CCATGGACAC AGAGACAGAC TTATTGATTC AAGAGACCAT CCGAGAAGCA TTTGCAGACT 4260 GTACCATGCT GACCATTGCC CATCGCCTGC ACACGGTTCT AGGCTCCGAT AGGATTATGG 4320 TGCTGGCCCA GGGACAGGTG GTGGAGTTTG ACACCCCATC GGTCCTTCTG TCCAACGACA 4380 GTTCCCGATT CTATGCCATG TTTGCTGCTG CAGAGAACAA GGTCGCTGTC AAGGGCTGAC 4440 TCCTCCCTGT TGACGAAGTC TCTTTTCTTT AGAGCATTGC CATTCCCTGC CTGGGGCGGG 4500 CCCCTCATCG CGTCCTCCTA CCGAAACCTT GCCTTTCTCG ATTTTATCTT TCGCACAGCA 4560 GTTCCGGATT GGCTTGTGTG TTTCACTTTT AGGGAGAGTC ATATTTTGAT TATTGTATTT 4620 ATTCCATATT CATGTAAACA AAATTTAGTT TTTGTTCTTA ATTGCACTCT AAAAGGTTCA 4680 GGGAACCGTT ATTATAATTG TATCAGAGGC CTATAATGAA GCTTTATACG TGTAGCTATA 4740 TCTATATATA ATTCTGTACA TAGCCTATAT TTACAGTGAA AATGTAAGCT GTTTATTTTA 4800 TATTAAAATA AGCACTGTGC TAATAACAGT GCATATTCCT TTCTATCATT TTTGTACAGT 4860 TTGCTGTACT AGAGATCTGG TTTTGCTATT AGACTGTAGG AAGAGTAGCA TTTCATTCTT 4920 CTCTAGCTGG TGGTTTCACG GTGCCAGGTT TTCTGGGTGT CCAAAGGAAG ACGTGTGGCA 4980 ATAGTGGGCC CTCCGACAGC CCCCTCTGCC GCCTCCCCAC AGCCGCTCCA GGGGTGGCTG 5040 GAGACGGGTG GGCGGCTGGA GACCATGCAG AGCGCCGTGA GTTCTCAGGG CTCCTGCCTT 5100 CTGTCCTGGT GTCACTTACT GTTTCTGTCA GGAGAGCAGC GGGGCGAAGC CCAGGCCCCT 5160 TTTCACTCCC TCCATCAAGA ATGGGGATCA CAGAGACATT CCTCCGAGCC GGGGAGTTTC 5220 TTTCCTGCCT TCTTCTTTTT GCTGTTGTTT CTAAACAAGA ATCAGTCTAT CCACAGAGAG 5280 TCCCACTGCC TCAGGTTCCT ATGGCTGGCC ACTGCACAGA GCTCTCCAGC TCCAAGACCT 5340 GTTGGTTCCA AGCCCTGGAG CCAACTGCTG CTTTTTGAGG TGGCACTTTT TCATTTGCCT 5400 ATTCCCACAC CTCCACAGTT CAGTGGCAGG GCTCAGGATT TCGTGGGTCT GTTTTCCTTT 5460 CTCACCGCAG TCGTCGCACA GTCTCTCTCT CTCTCTCCCC TCAAAGTCTG CAACTTTAAG 5520 CAGCTCTTGC TAATCAGTGT CTCACACTGG CGTAGAAGTT TTTGTACTGT AAAGAGACCT 5580 ACCTCAGGTT GCTGGTTGCT GTGTGGTTTG GTGTGTTCCC GCAAACCCCC TTTGTGCTGT 5640 GGGGCTGGTA GCTCAGGTGG GCGTGGTCAC TGCTGTCATC AGTTGAATGG TCAGCGTTGC 5700

ACAATCAGAA ATCACGCAGG CATTTTGGGT AGGCGGCCTC CAGTTTTCCT TTGAGTCGCG 2760 AACGCTGTGC GTTTGTCAGA ATGAAGTATA CAAGTCAATG TTTTTCCCCC TTTTTATATA 2820 ATAATTATAT AACTTATGCA TTTATACACT ACGAGTTGAT CTCGGCCAGC CAAAGACACA 2880 CGACAAAAGA GACAATCGAT ATAATGTGGC CTTGAATTTT AACTCTGTAT GCTTAATGTT 2940 TACAATATGA AGTTATTAGT TCTTAGAATG CAGAATGTAT GTAATAAAAT AAGCTTGGCC 3000 TAGCATGGCA AATCAGATTT ATACAGGAGT CTGCATTTGC ACTTTTTTTA GTGACTAAAG 3060 TTGCTTAATG AAAACATGTG CTGAATGTTG TGGATTTTGT GTTATAATTT ACTTTGTCCA 3120 GGAACTTGTG CAAGGGAGAG CCAAGGAAAT AGGATGTTTG GCACCC Seq ID NO : 331 Protein sequence Protein Accession # : AAA52398 1 11 21 31 41 51 MIQTVPDPAA HIKEALSWS EDQSLFECAY GTPHLAKTEM TASSSSDYGQ TSKMSPRVPQ 60 QDWLSQPPAR VTIKMECNPS QVNGSRNSPD ECSVAKGGKM VGSPDTVGMN YGSYMEEKHM 120 PPPNMTTNER RVIVPADPTL WSTDHVRQWL EWAVKEYGLP DVNILLFQNI DGKELCKMTK 180 DDFQRLTPSY NADILLSHLH YLRETPLPHL TSDDVDKALQ NSPRLMHARN TDLPYEPPRR 240 SAWTGHGHPT PQSKAAQPSP STVPKTEDQR PQLDPYQILG PTSSRLANPG SGQIQLWQFL 300 LELLSDSSNS SCITWEGTNG EFKMTDPDEV ARRWGERKSK PNMNYDKLSR ALRYYYDKNI 360 MTKVHGKRYA YKFDFHGIAQ ALQPHPPESS LYKYPSDLPY MGSYHAHPQK MNFVAPHPPA 420 LPVTSSSFFA APNPYWNSPT GGIYPNTRLP TSHMPSHLGT YY 462 Seq ID NO : 332 DNA sequence Nucleic Acid Accession # : NM 000020 Coding sequence: 283-1794 1 11 21 31 41 51 AGGAAACGGT TTATTAGGAG GGAGTGGTGG AGCTGGGCCA GGCAGGAAGA CGCTGGAATA 60 AGAAACATTT TTGCTCCAGC CCCCATCCCA GTCCCGGGAG GCTGCCGCGC CAGCTGCGCC 120 GAGCGAGCCC CTCCCCGGCT CCAGCCCGGT CCGGGGCCGC GCCGGACCCC AGCCCGCCGT 180 CCAGCGCTGG CGGTGCAACT GCGGCCGCGC GGTGGAGGGG AGGTGGCCCC GGTCCGCCGA 240 AGGCTAGCGC CCCGCCACCC GCAGAGCGGG CCCAGAGGGA CCATGACCTT GGGCTCCCCC 300 AGGAAAGGCC TTCTGATGCT GCTGATGGCC TTGGTGACCC AGGGAGACCC TGTGAAGCCG 360 TCTCGGGGCC CGCTGGTGAC CTGCACGTGT GAGAGCCCAC ATTGCAAGGG GCCTACCTGC 420 CGGGGGGCCT GGTGCACAGT AGTGCTGGTG CGGGAGGAGG GGAGGCACCC CCAGGAACAT 480 CGGGGCTGCG GGAACTTGCA CAGGGAGCTC TGCAGGGGGC GCCCCACCGA GTTCGTCAAC 540 CACTACTGCT GCGACAGCCA CCTCTGCAAC CACAACGTGT CCCTGGTGCT GGAGGCCACC 600 CAACCTCCTT CGGAGCAGCC GGGAACAGAT GGCCAGCTGG CCCTGATCCT GGGCCCCGTG 660 CTGGCCTTGC TGGCCCTGGT GGCCCTGGGT GTCCTGGGCC TGTGGCATGT CCGACGGAGG 720 CAGGAGAAGC AGCGTGGCCT GCACAGCGAG CTGGGAGAGT CCAGTCTCAT CCTGAAAGCA 780 TCTGAGCAGG GCGACACGAT GTTGGGGGAC CTCCTGGACA GTGACTGCAC CACAGGGAGT 840 GGCTCAGGGC TCCCCTTCCT GGTGCAGAGG ACAGTGGCAC GGCAGGTTGC CTTGGTGGAG 900 TGTGTGGGAA AAGGCCGCTA TGGCGAAGTG TGGCGGGGCT TGTGGCACGG TGAGAGTGTG 960 GCCGTCAAGA TCTTCTCCTC GAGGGATGAA CAGTCCTGGT TCCGGGAGAC TGAGATCTAT 1020 AACACAGTAT TGCTCAGACA CGACAACATC CTAGGCTTCA TCGCCTCAGA CATGACCTCC 1080 CGCAACTCGA GCACGCAGCT GTGGCTCATC ACGCACTACC ACGAGCACGG CTCCCTCTAC 1140 GACTTTCTGC AGAGACAGAC GCTGGAGCCC CATCTGGCTC TGAGGCTAGC TGTGTCCGCG 1200 GCATGCGGCC TGGCGCACCT GCACGTGGAG ATCTTCGGTA CACAGGGCAA ACCAGCCATT 1260 GCCCACCGCG ACTTCAAGAG CCGCAATGTG CTGGTCAAGA GCAACCTGCA GTGTTGCATC 1320 GCCGACCTGG GCCTGGCTGT GATGCACTCA CAGGGCAGCG ATTACCTGGA CATCGGCAAC 1380 AACCCGAGAG TGGGCACCAA GCGGTACATG GCACCCGAGG TGCTGGACGA GCAGATCCGC 1440 ACGGACTGCT TTGAGTCCTA CAAGTGGACT GACATCTGGG CCTTTGGCCT GGTGCTGTGG 1500 GAGATTGCCC GCCGGACCAT CGTGAATGGC ATCGTGGAGG ACTATAGACC ACCCTTCTAT 1560 GATGTGGTGC CCAATGACCC CAGCTTTGAG GACATGAAGA AGGTGGTGTG TGTGGATCAG 1620 CAGACCCCCA CCATCCCTAA CCGGCTGGCT GCAGACCCGG TCCTCTCAGG CCTAGCTCAG 1680 ATGATGCGGG AGTGCTGGTA CCCAAACCCC TCTGCCCGAC TCACCGCGCT GCGGATCAAG 1740 AAGACACTAC AAAAAATTAG CAACAGTCCA GAGAAGCCTA AAGTGATTCA ATAGCCCAGG 1800 AGCACCTGAT TCCTTTCTGC CTGCAGGGGG CTGGGGGGGT GGGGGGCAGT GGATGGTGCC 1860 CTATCTGGGT AGAGGTAGTG TGAGTGTGGT GTGTGCTGGG GATGGGCAGC TGCGCCTGCC 1920 TGCTCGGCCC CCAGCCCACC CAGCCAAAAA TACAGCTGGG CTGAAACCTG ATCCCCTGCT 1980 GTCTGGCCTG CTCAAAGCGG CAGGCTCCCT GACGCCTGGC TCTCTCCCCA CCCCTATGGC 2040 CAGCATGGTG CACCCCCTAC CACTCCCGGG ACAGGATGCA AAAGAGGCTC CAGAGTCAGA 2100 GTGCCAAGCC AGGGAATCCC AGTCCCAGAC TCAGAGCCCG GGCCTGCACT TTGCCCCCTG 2160 CCCTTGATCA ACCCCACTGC CCCACCAGAG CTGCCAGGGT GGCACAGGGC CCTGTCCAGC 2220 CCCTGGCACA CACTTCCCTG CCAGGCCTCA GCCTCTAGCA TAAGCTCCAG AGAGCCAGGG 2280 CCCATCAGTT TCTCTCTGTG GATTTGTATC TCAGCTCCAT GATGCCTTGG GCTTTCTGTC 2340 TCCTCAACAA GAGTGCAGCT TGCTGAATGT CAGCTGCCTG AGAGAGCTGG GGCCTGACTT 2400 ACTAGGGCAT TAAATCCTAA GAGGTCCTAC TGAGGTGTGG CAGGATCACA GGCCAGTGGA 2460 AAAAGGGCAG GTCAGATGGG CAAGGCCCAG GACTTTCAGA TTAACTGAGA GGATATCGAG 2520 GCCAAGCATG GCAGGGGGAA GGTCAGTGGG TGTCAAGAGA CCCAGGTCTG ACCCCGGATG 2580 TTTGCTCCAT GTGACAAAAG CAGGCCTGTC TCAGGACCTT TTCTTTTCTT TTTTCCTTCT 2640 TTTTTTTTTT GACACGGAGT TTCGCTCTTG TTGTCCAGGC TAGAGTGCAA TGGCATGATC 2700 CCAGCTCACC GCAACGTCTA CCTCCCAGGT TCAAATCATT CTCTTGCCTC AGACTCCCGA 2760 GTAGCTGGGA TTACAGGCAC ATGCCACCAT GCCTGGCTAA TTTTGTATAT TTAGTAGAAA 2820 CAGGGTTTCA CCATGCTGGC CATGCTGGTT CTCGAACTCC TGACCTCAGG TGTTCCACCT 2880 ACCTCAGCCT CCCAAAGTGC TGGGGTTACA GGTGTGAGCC ATCGCGCCTG GCCAGGACCT 2940 TTGTTTCTTA TCTACATATT GGAAGATTTG GTCCTGATGT CCTTTGAGGC TTCTTTAGCT 3000 CTAGTTCTCT GACACTTCAG CCTATATCAC AGCTAACTTC YTCAGTCTCA TCTATTCCTT 3060 ATGCTCCAGC CCCTGGCAAT TTGCCTCAAG ATGGGGGTTT GAAAATAACT TTACCTGACT 3120 CAAGGAGTGT CTGGAGCACC TCCTAGTCTA AGTCTGCAAG CTCCAGTTCT TGCCTAAAAC 3180 CATGCCAGTG GCCACCCTTG GGCTCAGACA GCTCTGGGCC TTTTGACCAC AAGCCAGCCC 3240 CTCGCCCTCT CTGTGGCATA GTCTTCTCTG CCCCAGGACT GCAGGGCGGC TTCCTCCAAG 3300 GCTTCCAAGG CTCAAAAGAA ATTTGGCTCC ATCCAAGAAG GCTCCAGCTC CCCTACTGGC 3360 CCCTGGCTTC AGGCCCACAC CCCTGGGCCA GGSCCAGAGA GTGTGTCTCA GGAGAATTCA 3420 ATGGGCTCTA GAGAGACACA CAGAAAGTTT GGGCATTTGG GAAATTTTCA AGGRTGTATG 3480

TATGGYTCAC GTATGGWGCA GGTTGTCCTG GTCCYKGGGT GCAGGGAAGT GGGCTGCAGG 3540 GAAGTGGATT GGAGGGGAGC TTGAGGAATA TAAGGAGCGG GGGTGGAGAC TCAGGCTATG 3600 GACAAGGACA GCCCCAAGGT TGGGAAGACC TGGCCTTAGT CGTCCTCAGC CTAGGGCAGG 3660 GCAGTGAAGA AAGCTCTCCC CGCTCCTGCT GTAATGACCC AGAGTAGCCT CCCCAGGCCG 3720 GCATCTTATG TGTGTCTTCC ACCATCCTCA TGGTGGCACT TTTCTAGGCC TGTCTCCCAG 3780 CATTGTGCAA GGCTCGGAAG AGAACCAGGA AGTGAAACTG GGTGAAAACA GAAAGCTCAA 3840 TGGATGGGCT AGGTTCCCAG ATCATTAGGG CAGAGTTTGC ACGTCCTCTG GTTCACTGGG 3900 AATCCACCCA GCCCACGAAT CATCTCCCTC TTTGAAGGAT TTTWATTTCT ACTGGGTTTT 3960 GGAACAAACT CCTGCTGAGA CCCCACAGCC AGAAACTGAA AGCAGCAGCT CCCCAAAGCC 4020 TGGAAAATCC CTAAGAGAAG GCCTGGGGGA MAGGAAKTGG AGTGACAGGG GACAGGTAGA 4080 GAGAAGGGGG CCCAATGGCC AGGGAGTGAA GGAGGTGGCG TTGCTGAGAG CAGTCTGCAC 4140 ATGCTTCTGT CTGAGTGCAG GAAGGTGTTC CAGGGTCGAA ATTACACTTC TCGTACCTGG 4200 AGACGCTGTT TGTGGGAGCA CTGGGCTCAT GCCTGGCACA CAATAGGTCT GCAATAAACC 4260 ATGGTTAAAT CCTGAAAAAA AAAAAAAAA Seq ID NO : 333 Protein sequence Protein Accession &num : NP 000011 1 11 21 31 41 51 MTLGSPRKGL LMLLMALVTQ GDPVKPSRGP LVTCTCBSPH CKGPTCRGAW CTWLVREEG 60 RHPQEHRGCG NLHRELCRGR PTEFVNHYCC DSHLCNHNVS LVLEATQPPS EQPGTDGQLA 120 LILGPVLALL ALVALGVLGL WHVRRRQEKQ RGLHSELGES SLILKASEQG DTMLGDLLDS 180 DCTTGSGSGL PFLVQRTVAR QVALVECVGK GRYGEVWRGL WHGESVAVKI FSSRDEQSWF 240 RETEIYNTVL LRHDNILGFI ASDMTSRNSS TQLWLITHYH EHGSLYDFLQ RQTLEPHLAL 300 RLAVSAACGL AHLHVEIFGT QGKPAIAHRD FKSRNVLVKS NLQCCIADLG LAVMHSQGSD 360 YLDIGNNPRV GTKRYMAPEV LDEQIRTDCF ESYKWTDIWA FGLVLWEIAR RTIVNGIVED 420 YRPPFYDWP NDPSFEDMKK WCVDQQTPT IPNRLAADPV LSGLAQMMRE CWYPNPSARL 480 TALRIKKTLQ KISNSPEKPK VIQ Seq ID NO : 334 DNA sequence Nucleic Acid Accession &num : NM 004126. 1 Coding sequence: 108-329 1 11 21 31 41 51 GGCACGAGCT CGTGCCGGCC TTCAGTTGTT TCGGGACGCG CCGAGCTTCG CCGCTCTTCC 60 AGCGGCTCCG CTGCCAGAGC TAGCCCGAGC CCGGTTCTGG GGCGAAAATG CCTGCCCTTC 120 ACATCGAAGA TTTGCCAGAG AAGGAAAAAC TGAAAATGGA AGTTGAGCAG CTTCGCAAAG 180 AAGTGAAGTT GCAGAGACAA CAAGTGTCTA AATGTTCTGA AGAAATAAAG AACTATATTG 240 AAGAACGTTC TGGAGAGGAT CCTCTAGTAA AGGGAATTCC AGAAGACAAG AACCCCTTTA 300 AAGAAAAAGG CAGCTGTGTT ATTTCATAAA TAACTTGGGA GAAACTGCAT CCTAAGTGGA 360 AGAACTAGTT TGTTTTAGTT TTCCCAGATA AAACCAACAT GCTTTTTAAG GAAGGAAGAA 420 TGAAATTAAA AGGAGACTTT CTTAAGCACC ATATAGATAG GGTTATGTAT AAAAGCATAT 480 GTGCTACTCA TCTTTGCTCA CTATGCAGTC TTTTTTAAGA GAGCAGAGAG TATCAGATGT 540 ACAATTATGG AAATAAGAAC ATTACTTGAG CATGACACTT CTTTCAGTAT ATTGCTTGAT 600 GCTTCAAATA AAGTTTTGTC TT Seq ID NO: 335 Protein sequence Protein Accession &num : NP 004117. 1 1 11 21 31 41 51 I I I I I I MPALHIEDLP EKEKLKMEVE QLRKEVKLQR QQVSKCSEEI KNYIEERSGE DPLVKGIPED 60 KNPFKEKGSC VIS Seq ID NO : 336 DNA sequence Nucleic Acid Accession &num : NM 005795 Coding sequence: 555-1940 1 11 21 31 41 51 GCACGAGGGA ACAACCTCTC TCTCTSCAGC AGAGAGTGTC ACCTCCTGCT TTAGGACCAT 60 CAAGCTCTGC TAACTGAATC TCATCCTAAT TGCAGGATCA CATTGCAAAG CTTTCACTCT 120 TTCCCACCTT GCTTGTGGGT AAATCTCTTC TGCGGAATCT CAGAAAGTAA AGTTCCATCC 180 TGAGAATATT TCACAAAGAA TTTCCTTAAG AGCTGGACTG GGTCTTGACC CCTGGAATTT 240 AAGAAATTCT TAAAGACAAT GTCAAATATG ATCCAAGAGA AAATGTGATT TGAGTCTGGA 300 GACAATTGTG CATATCGTCT AATAATAAAA ACCCATACTA GCCTATAGAA AACAATATTT 360 GAATAATAAA AACCCATACT AGCCTATAGA AAACAATATT TGAAAGATTG CTACCACTAA 420 AAAGAAAACT ACTACAACTT GACAAGACTG CTGCAAACTT CAATTGGTCA CCACAACTTG 480 ACAAGGTTGC TATAAAACAA GATTGCTACA ACTTCTAGTT TATGTTATAC AGCATATTTC 540 ATTTGGGCTT AATGATGGAG AAAAAGTGTA CCCTGTATTT TCTGGTTCTC TTGCCTTTTT 600 TTATGATTCT TGTTACAGCA GAATTAGAAG AGAGTCCTGA GGACTCAATT CAGTTGGGAG 660 TTACTAGAAA TAAAATCATG ACAGCTCAAT ATGAATGTTA CCAAAAGATT ATGCAAGACC 720 CCATTCAACA AGCAGAAGGC GTTTACTGCA ACAGAACCTG GGATGGATGG CTCTGCTGGA 780 ACGATGTTGC AGCAGGAACT GAATCAATGC AGCTCTGCCC TGATTACTTT CAGGACTTTG 840 ATCCATCAGA AAAAGTTACA AAGATCTGTG ACCAAGATGG AAACTGGTTT AGACATCCAG 900 CAAGCAACAG AACATGGACA AATTATACCC AGTGTAATGT TAACACCCAC GAGAAAGTGA 960 AGACTGCACT AAATTTGTTT TACCTGACCA TAATTGGACA CGGATTGTCT ATTGCATCAC 1020 TGCTTATCTC GCTTGGCATA TTCTTTTATT TCAAGAGCCT AAGTTGCCAA AGGATTACCT 1080 TACACAAAAA TCTGTTCTTC TCATTTGTTT GTAACTCTGT TGTAACAATC ATTCACCTCA 1140 CTGCAGTGGC CAACAACCAG GCCTTAGTAG CCACAAATCC TGTTAGTTGC AAAGTGTCCC 1200 AGTTCATTCA TCTTTACCTG ATGGGCTGTA ATTACTTTTG GATGCTCTGT GAAGGCATTT 1260 ACCTACACAC ACTCATTGTG GTGGCCGTGT TTGCAGAGAA GCAACATTTA ATGTGGTATT 1320 ATTTTCTTGG CTGGGGATTT CCACTGATTC CTGCTTGTAT ACATGCCATT GCTAGAAGCT 1380

TCTGACGTGG ATTACGACTT CCTTAACGAC TGGGGACCCA GGTTTAAGAT GCTGGCTGAG 2340 CTGTACGGCT CGGACCCCCG GGAGGAGCTG CTGTATTAGG CGGCCGAGGT CACTCTGGGC 2400 CTGGGGACCC AAACCCCCTG CAGCCCAGGC CAGTCAGACT CCAGGCACCA CAGCCTCCAA 2460 AAATGGCAGT GACTCCCCAG CCCAGCACCC CTTCCTCGTG GGTCCCAGAG ACCTCATCAG 2520 CCTTGGGATA GCAAACTCCA GGTTCCTGAA ATATCCAGGA ATATATGTCA GTGATGACTA 2580 TTCTCAAATG CTGGCAAATC CAGGCTGGTG TTCTGTCTGG GCTCAGACAT CCACATAACC 2640 CTGTCACCCA CAGACCGCCG TCTAACTCAA AGACTTCCTC TGGCTCCCCA AGGCTGCAAA 2700 GCAAAACAGA CTGTGTTTAA CTGCTGCAGG GTCTTTTTCT AGGGTCCCTG AACGCCCTGG 2760 TAAGGCTGGT GAGGTCCTGG TGCCTATCTG CCTGGAGGCA AAGGCCTGGA CAGCTTGACT 2820 TGTGGGGCAG GATTCTCTGC AGCCCATTCC CAAGGGAGAC TGACCATCAT GCCCTCTCTC 2880 GGGAGCCCTA GCCCTGCTCC AACTCCATAC TCCACTCCAA GTGCCCCACC ACTCCCCAAC 2940 CCCTCTCCAG GCCTGTCAAG AGGGAGGAAG GGGCCCCATG GCAGCTCCTG'ACCTTGGGTC 3000 CTGAAGTGAC CTCACTGGCC TGCCATGCCA GTAACTGTGC TGTACTGAGC ACTGAACCAC 3060 ATTCAGGGAA ATGCTTATTA AACCTTGAAG CAACTGTGAA TTCATTCTGG AGGGGCAGTG 3120 GAGATCAGGA GTGACAGATC ACAGGGTGAG GGCCACCTCC ACACCCACCC CCTCTGGAGA 3180 AGGCCTGGAA GAGCTGAGAC CTTGCTTTGA GACTCCTCAG CACCCCTCCA GTTTTGCCTG 3240 AGAAGGGGCA GATGTTCCCG GAGATCAGAA GACGTCTCCC CTTCTCTGCC TCACCTGGTC 3300 GCCAATCCAT GCTCTCTTTC TTTTCTCTGT CTACTCCTTA TCCCTTGGTT TAGAGGAACC 3360 CAAGATGTGG CCTTTAGCAA AACTGACAAT GTCCAAACCC ACTCATGACT GCATGACGGA 3420 GCCGAGCATG TGTCTTTACA CCTCGCTGTT GTCACATCTC AGGGAACTGA CCCTCAGGCA 3480 CACCTTGCAG AAGGAAGGCC CTGCCCTGCC CAACCTCTGT GGTCACCCAT GCATCATTCC 3540 ACTGGAACGT TTCACTGCAA ACACACCTTG GAGAAGTGGC ATCAGTCAAC AGAGAGGGGC 3600 AGGGAAGGAG ACACCAAGCT CACCCTTCGT CATGGACCGA GGTTCCCACT CTGGCAAAGC 3660 CCCTCACACT GCAAGGGATT GTAGATAACA CTGACTTGTT TGTTTTAACC AATAACTAGC 3720 TTCTTATAAT GATTTTTTTA CTAATGATAC TTACAAGTTT CTAGCTCTCA CAGACATATA 3780 GAATAAGGGT TTTTGCATAA TAAGCAGGTT GTTATTTAGG TTAACAATAT TAATTCAGGT 3840 TTTTTAGTTG GAAAAACAAT TCCTGTAACC TTCTATTTTC TATAATTGTA GTAATTGCTC 3900 TACAGATAAT GTCTATATAT TGGCCAAACT GGTGCATGAC AAGTACTGTA TTTTTTTATA 3960 CCTAAATAAA GAAAAATCTT TAGCCTGGGC AACAAAAAAA Seq ID NO : 339 Protein sequence Protein Accession # : NP 001786 1 11 21 31 41 51 MQRLMMLLAT SGACLGLLAV AAVAAAGANP AQRDTHSLLP THRRQKRDWI WNQMHIDEEK 60 NTSLPHHVGK IKSSVSRKNA KYLLKGEYVG KVFRVDAETG DVFAIERLDR ENISEYHLTA 120 VIVDKDTGEN LETPSSFTIK VHDVNDNWPV FTHRLFNASV PESSAVGTSV ISVTAVDADD 180 PTVGDHASVM YQILKGKEYF AIDNSGRIIT ITKSLDREKQ ARYEIWEAR DAQGLRGDSG 240 TATVLVTLQD INDNFPFFTQ TKYTFWPED TRVGTSVGSL FVEDPDEPQN RMTKYSILRG 300 DYQDAFTIET NPAHNEGIIK PMKPLDYEYI QQYSFIVEAT DPTIDLRYMS PPAGNRAQVI 360 INITDVDEPP IFQQPFYHFQ LKENQKKPLI GTVLAMDPDA ARHSIGYSIR RTSDKGQFFR 420 VTKKGDIYNE KELDREVYPW YNLTVEAKEL DSTGTPTGKE SIVQVHIEVL DENDNAPEFA 480 KPYQPKVCEN AVHGQLVLQI SAIDKDITPR NVKFKFTLNT ENNFTLTDNH DNTANITVKY 540 GQFDREHTKV HFLPWISDN GMPSRTGTST LTVAVCKCNE QGEFTFCEDM AAQVGVSIQA 600 WAILLCILT ITVITLLIFL RRRLRKQARA HGKSVPEIHE QLVTYDEEGG GEMDTTSYDV 660 SVLNSVRRGG AKPPRPALDA RPSLYAQVQK PPRHAPGAHG GPGEMAAMIE VKKDEADHDG 720 DGPPYDTLHI YGYEGSESIA ESLSSLGTDS SDSDVDYDFL NDWGPRFKML AELYGSDPRE 780 ELLY Seq ID NO : 340 DNA sequence Nucleic Acid Accession # : NM 003088 Coding sequence: 112-1593 1 11 21 31 41 51 GCGGAGGGTG CGTGCGGGCC GCGGCAGCCG AACAAAGGAG CAGGGGCGCC GCCGCAGGGA 60 CCCGCCACCC ACCTCCCGGG GCCGCGCAGC GGCCTCTCGT CTACTGCCAC CATGACCGCC 120 AACGGCACAG CCGAGGCGGT GCAGATCCAG TTCGGCCTCA TCAACTGCGG CAACAAGTAC 180 CTGACGGCCG AGGCGTTCGG GTTCAAGGTG AACGCGTCCG CCAGCAGCCT GAAGAAGAAG 240 CAGATCTGGA CGCTGGAGCA GCCCCCTGAC GAGGCGGGCA GCGCGGCCGT GTGCCTGCGC 300 AGCCACCTGG GCCGCTACCT GGCGGCGGAC AAGGACGGCA ACGTGACCTG CGAGCGCGAG 360 GTGCCCGGTC CCGACTGCCG TTTCCTCATC GTGGCGCACG ACGACGGTCG CTGGTCGCTG 420 CAGTCCGAGG CGCACCGGCG CTACTTCGGC GGCACCGAGG ACCGCCTGTC CTGCTTCGCG 480 CAGACGGTGT CCCCCGCCGA GAAGTGGAGC GTGCACATCG CCATGCACCC TCAGGTCAAC 540 ATCTACAGTG TCACCCGTAA GCGCTACGCG CACCTGAGCG CGCGGCCGGC CGACGAGATC 600 GCCGTGGACC GCGACGTGCC CTGGGGCGTC GACTCGCTCA TCACCCTCGC CTTCCAGGAC 660 CAGCGCTACA GCGTGCAGAC CGCCGACCAC CGCTTCCTGC GCCACGACGG GCGCCTGGTG 720 GCGCGCCCCG AGCCGGCCAC TGGCTACACG CTGGAGTTCC GCTCCGGCAA GGTGGCCTTC 780 CGCGACTGCG AGGGCCGTTA CCTGGCGCCG TCGGGGCCCA GCGGCACGCT CAAGGCGGGC 840 AAGGCCACCA AGGTGGGCAA GGACGAGCTC TTTGCTCTGG AGCAGAGCTG CGCCCAGGTC 900 GTGCTGCAGG CGGCCAACGA GAGGAACGTG TCCACGCGCC AGGGTATGGA CCTGTCTGCC 960 AATCAGGACG AGGAGACCGA CCAGGAGACC TTCCAGCTGG AGATCGACCG CGACACCAAA 1020 AAGTGTGCCT TCCGTACCCA CACGGGCAAG TACTGGACGC TGACGGCCAC CGGGGGCGTG 1080 CAGTCCACCG CCTCCAGCAA GAATGCCAGC TGCTACTTTG ACATCGAGTG GCGTGACCGG 1140 CGCATCACAC TGAGGGCGTC CAATGGCAAG TTTGTGACCT CCAAGAAGAA TGGGCAGCTG 1200 GCCGCCTCGG TGGAGACAGC AGGGGACTCA GAGCTCTTCC TCATGAAGCT CATCAACCGC 1260 CCCATCATCG TGTTCCGCGG GGAGCATGGC TTCATCGGCT GCCGCAAGGT CACGGGCACC 1320 CTGGACGCCA ACCGCTCCAG CTATGACGTC TTCCAGCTGG AGTTCAACGA TGGCGCCTAC 1380 AACATCAAAG ACTCCACAGG CAAATACTGG ACGGTGGGCA GTGACTCCGC GGTCACCAGC 1440 AGCGGCGACA CTCCTGTGGA CTTCTTCTTC GAGTTCTGCG ACTATAACAA GGTGGCCATC 1500 AAGGTGGGCG GGCGCTACCT GAAGGGCGAC CACGCAGGCG TCCTGAAGGC CTCGGCGGAA 1560 ACCGTGGACC CCGCCTCGCT CTGGGAGTAC TAGGGCCGGC CCGTCCTTCC CCGCCCCTGC 1620 CCACATGGCG GCTCCTGCCA ACCCTCCCTG CTAACCCCTT CTCCGCCAGG TGGGCTCCAG 1680 GGCGGGAGGC AAGCCCCCTT GCCTTTCAAA CTGGAAACCC CAGAGAAAAC GGTGCCCCCA 1740 CCTGTCGCCC CTATGGACTC CCCACTCTCC CCTCCGCCCG GGTTCCCTAC TCCCCTCGGG 1800

Seq ID NO : 344 DNA sequence Nucleic Acid Accession # : NM 012072 Coding sequence: 149-2107 1 11 21 31 41 51 1 1 1 1 1 1 AAAGCCCTCA GCCTTTGTGT CCTTCTCTGC GCCGGAGTGG CTGCAGCTCA CCCCTCAGCT 60 CCCCTTGGGG CCCAGCTGGG AGCCGAGATA GAAGCTCCTG TCGCCGCTGG GCTTCTCGCC 120 TCCCGCAGAG GGCCACACAG AGACCGGGAT GGCCACCTCC ATGGGCCTGC TGCTGCTGCT 180 GCTGCTGCTC CTGACCCAGC CCGGGGCGGG GACGGGAGCT GACACGGAGG CGGTGGTCTG 240 CGTGGGGACC GCCTGCTACA CGGCCCACTC GGGCAAGCTG AGCGCTGCCG AGGCCCAGAA 300 CCACTGCAAC CAGAACGGGG GCAACCTGGC CACTGTGAAG AGCAAGGAGG AGGCCCAGCA 360 CGTCCAGCGA GTACTGGCCC AGCTCCTGAG GCGGGAGGCA GCCCTGACGG CGAGGATGAG 420 CAAGTTCTGG ATTGGGCTCC AGCGAGAGAA GGGCAAGTGC CTGGACCCTA GTCTGCCGCT 480 GAAGGGCTTC AGCTGGGTGG GCGGGGGGGA GGACACGCCT TACTCTAACT GGCACAAGGA 540 GCTCCGGAAC TCGTGCATCT CCAAGCGCTG TGTGTCTCTG CTGCTGGACC TGTCCCAGCC 600 GCTCCTTCCC AACCGCCTGC CCAAGTGGTC TGAGGGCCCC TGTGGGAGCC CAGGCTCCCC 660 CGGAAGTAAC ATTGAGGGCT TCGTGTGCAA GTTCAGCTTC AAAGGCATGT GCCGGCCTCT 720 GGCCCTGGGG GGCCCAGGTC AGGTGACCTA CACCACCCCC TTCCAGACCA CCAGTTCCTC 780 CTTGGAGGCT GTGCCCTTTG CCTCTGCGGC CAATGTAGCC TGTGGGGAAG GTGACAAGGA 840 CGAGACTCAG AGTCATTATT TCCTGTGCAA GGAGAAGGCC CCCGATGTGT TCGACTGGGG 900 CAGCTCGGGC CCCCTCTGTG TCAGCCCCAA GTATGGCTGC AACTTCAACA ATGGGGGCTG 960 CCACCAGGAC TGCTTTGAAG GGGGGGATGG CTCCTTCCTC TGCGGCTGCC GACCAGGATT 1020 CCGGCTGCTG GATGACCTGG TGACCTGTGC CTCTCGAAAC CCTTGCAGCT CCAGCCCATG 1080 TCGTGGGGGG GCCACGTGCG TCCTGGGACC CCATGGGAAA AACTACACGT GCCGCTGCCC 1140 CCAAGGGTAC CAGCTGGACT CGAGTCAGCT GGACTGTGTG GACGTGGATG AATGCCAGGA 1200 CTCCCCCTGT GCCCAGGAGT GTGTCAACAC CCCTGGGGGC TTCCGCTGCG AATGCTGGGT 1260 TGGCTATGAG CCGGGCGGTC CTGGAGAGGG GGCCTGTCAG GATGTGGATG AGTGTGCTCT 1320 GGGTCGCTCG CCTTGCGCCC AGGGCTGCAC CAACACAGAT GGCTCATTTC ACTGCTCCTG 1380 TGAGGAGGGC TACGTCCTGG CCGGGGAGGA CGGGACTCAG TGCCAGGACG TGGATGAGTG 1440 TGTGGGCCCG GGGGGCCCCC TCTGCGACAG CTTGTGCTTC AACACACAAG GGTCCTTCCA 1500 CTGTGGCTGC CTGCCAGGCT GGGTGCTGGC CCCAAATGGG GTCTCTTGCA CCATGGGGCC 1560 TGTGTCTCTG GGACCACCAT CTGGGCCCCC CGATGAGGAG GACAAAGGAG AGAAAGAAGG 1620 GAGCACCGTG CCCCGCGCTG CAACAGCCAG TCCCACAAGG GGCCCCGAGG GCACCCCCAA 1680 GGCTACACCC ACCACAAGTA GACCTTCGCT GTCATCTGAC GCCCCCATCA CATCTGCCCC 1740 ACTCAAGATG CTGGCCCCCA GTGGGTCCTC AGGCGTCTGG AGGGAGCCCA GCATCCATCA 1800 CGCCACAGCT GCCTCTGGCC CCCAGGAGCC TGCAGGTGGG GACTCCTCCG TGGCCACACA 1860 AAACAACGAT GGCACTGACG GGCAAAAGCT GCTTTTATTC TACATCCTAG GCACCGTGGT 1920 GGCCATCCTA CTCCTGCTGG CCCTGGCTCT GGGGCTACTG GTCTATCGCA AGCGGAGAGC 1980 GAAGAGGGAG GAGAAGAAGG AGAAGAAGCC CCAGAATGCG GCAGACAGTT ACTCCTGGGT 2040 TCCAGAGCGA GCTGAGAGCA GGGCCATGGA GAACCAGTAC AGTCCGACAC CTGGGACAGA 2100 CTGCTGAAAG TGAGGTGGCC CTAGAGACAC TAGAGTCACC AGCCACCATC CTCAGAGCTT 2160 TGAACTCCCC ATTCCAAAGG GGCACCCACA TTTTTTTGAA AGACTGGACT GGAATCTTAG 2220 CAAACAATTG TAAGTCTCCT CCTTAAAGGC CCCTTGGAAC ATGCAGGTAT TTTCTACGGG 2280 TGTTTGATGT TCCTGAAGTG GAAGCTGTGT GTTGGCGTGC CACGGTGGGG ATTTCGTGAC 2340 TCTATAATGA TTGTTACTCC CCCTCCCTTT TCAAATTCCA ATGTGACCAA TTCCGGATCA 2400 GGGTGTGAGG AGGCTGGGGC TAAGGGGCTC CCCTGAATAT CTTCTCTGCT CACTTCCACC 2460 ATCTAAGAGG AAAAGGTGAG TTGCTCATGC TGATTAGGAT TGAAATGATT TGTTTCTCTT 2520 CCTAGGATGA AAACTAAATC AATTAATTAT TCAATTAGGT AAGAAGATCT GGTTTTTTGG 2580 TCAAAGGGAA CATGTTCGGA CTGGAAACAT TTCTTTACAT TTGCATTCCT CCATTTCGCC 2640 AGCACAAGTC TTGCTAAATG TGATACTGTT GACATCCTCC AGAATGGCCA GAAGTGCAAT 2700 TAACCTCTTA GGTGGCAAGG AGGCAGGAAG TGCCTCTTTA GTTCTTACAT TTCTAATAGC 2760 CTTGGGTTTA TTTGCAAAGG AAGCTTGAAA AATATGAGAA AAGTTGCTTG AAGTGCATTA 2820 CAGGTGTTTG TGAAGTCACA TAATCTACGG GGCTAGGGCG AGAGAGGCCA GGGATTTGTT 2880 CACAGATACT TGAATTAATT CATCCAAATG TACTGAGGTT ACCACACACT TGACTACGGA 2940 TGTGATCAAC ACTAACAAGG AAACAAATTC AAGGACAACC TGTCTTTGAG CCAGGGCAGG 3000 CCTCAGACAC CCTGCCTGTG GCCCCGCCTC CACTTCATCC TGCCCGGAAT GCCAGTGCTC 3060 CGAGCTCAGA CAGAGGAAGC CCTGCAGAAA GTTCCATCAG GCTGTTTCCT AAAGGATGTG 3120 TGAACGGGAG ATGATGCACT GTGTTTTGAA AGTTGTCATT TTAAAGCATT TTAGCACAGT 3180 TCATAGTCCA CAGTTGATGC AGCATCCTGA GATTTTAAAT CCTGAAGTGT GGGTGGCGCA 3240 CACACCAAGT AGGGAGCTAG TCAGGCAGTT TGCTTAAGGA ACTTTTGTTC TCTGTCTCTT 3300 TTCCTTAAAA TTGGGGGTAA GGAGGGAAGG AAGAGGGAAA GAGATGACTA ACTAAAATCA 3360 TTTTTACAGC AAAAACTGCT CAAAGCCATT TAAATTATAT CCTCATTTTA AAAGTTACAT 3420 TTGCAAATAT TTCTCCCTAT GATAATGCAG TCGATAGTGT GCACTCTTTC TCTCTCTCTC 3480 TCTCTCTCAC ACACACACAC ACACACACAC ACACACACAC AGAGACACGG CACCATTCTG 3540 CCTGGGGCAC TGGAACACAT TCCTGGGGGT CACCGATGGT CAGAGTCACT AGAAGTTACC 3600 TGAGTATCTC TGGGAGGCCT CATGTCTCCT GTGGGCTTTT TACCACCACT GTGCAGGAGA 3660 ACAGACAGAG GAAATGTGTC TCCCTCCAAG GCCCCAAAGC CTCAGAGAAA GGGTGTTTCT 3720 GGTTTTGCCT TAGCAATGCA TCGGTCTCTG AGGTGACACT CTGGAGTGGT TGAAGGGCCA 3780 CAAGGTGCAG GGTTAATACT CTTGCCAGTT TTGAAATATA GATGCTATGG TTCAGATTGT 3840 TTTTAATAGA AAACTAAAGG GGCAGGGGAA GTGAAAGGAA AGATGGAGGT TTTGTGCGGC 3900 TCGATGGGGC ATTTGGAACT TCTTTTTAAA GTCATCTCAT GGTCTCCAGT TTTCAGTTGG 3960 AACTCTGGTG TTTAACACTT AAGGGAGACA AAGGCTGTGT CCATTTGGCA AAACTTCCTT 4020 GGCCACGAGA CTCTAGGTGA TGTGTGAAGC TGGGCAGTCT GTGGTGTGGA GAGCAGCCAT 4080 CTGTCTGGCC ATTCAGAGGA TTCTAAAGAC ATGGCTGGAT GCGCTGCTGA CCAACATCAG 4140 CACTTAAATA AATGCAAATG CAACATTTCT CCCTCTGGGC CTTGAAAATC CTTGCCCTTA 4200 TCATTTGGGG TGAAGGAGAC ATTTCTGTCC TTGGCTTCCC ACAGCCCCAA CGCAGTCTGT 4260 GTATGATTCC TGGGATCCAA CGAGCCCTCC TATTTTCACA GTGTTCTGAT TGCTCTCACA 4320 GCCCAGGCCC ATCGTCTGTT CTCTGAATGC AGCCCTGTTC TCAACAACAG GGAGGTCATG 4380 GAACCCCTCT GTGGAACCCA CAAGGGGAGA AATGGGTGAT AAAGAATCCA GTTCCTCAAA 4440 ACCTTCCCTG GCAGGCTGGG TCCCTCTCCT GCTGGGTGGT GCTTTCTCTT GCACACCACT 4500 CCCACCACGG GGGGAGAGCC AGCAACCCAA CCAGACAGCT CAGGTTGTGC ATCTGATGGA 4560 AACCACTGGG CTCAAACACG TGCTTTATTC TCCTGTTTAT TTTTGCTGTT ACTTTGAAGC 4620 ATGGAAATTC TTGTTTGGGG GATCTTGGGG CTACAGTAGT GGGTAAACAA ATGCCCACCG 4680 GCCAAGAGGC CATTAACAAA TCGTCCTTGT CCTGAGGGGC CCCAGCTTGC TCGGGCGTGG 4740 CACAGTGGGG AATCCAAGGG TCACAGTATG GGGAGAGGTG CACCCTGCCA CCTGCTAACT 4800

i i i i i i MQDGNFLLSA LQPEAGVCSL ALPSDLQLDR RGAEGPEAER LRAARVQEQV RARLLQLGQQ 60 PRHNGAAEPE PEAETARGTS RGQYHTLQAG FSSRSQGLSG DKTSGFRPIA KPAYSPASWS 120 SRSAVDLSCS RRLSSAHNGG SAFGAAGYGG AQPTPPMPTR PVSFHERGGV GSRADYDTLS 180 LRSLRLGPGG LDDRYSLVSE QLEPAATSTY RAFAYERQAS SSSSRAGGLD WPEATEVSPS 240 RTIRAPAVRT LQRFQSSHRS RGVGGAVPGA VLEPVARAPS VRSLSLSLAD SGHLPDVHGF 300 NSYGSHRTLQ RLSSGFDDID LPSAVKYLMA SDPNLQVLGA AYIQHKCYSD AAAKKQARSL 360 QAVPRLVKLF NHANQEVQRH ATGAMRNLIY DNADNKLALV EENGIFELLR TLREQDDELR 420 KNVTGILWNL SSSDHLKDRL ARDTLEQLTD LVLSPLSGAG GPPLIQQNAS EAEIFYNATG 480 FLRNLSSASQ ATRQKMRECH GLVDALVTSI NHALDAGKCE DKSVENAVCV LRNLSYRLYD 540 EMPPSALQRL EGRGRRDLAG APPGEWGCF TPQSRRLREL PLAADALTFA EVSKDPKGLE 600 WLWSPQIVGL YNRLLQRCEL NRHTTEAAAG ALQNITAGDR RWAGVLSRLA LEQERILNPL 660 LDRVRTADHH QLRSLTGLIR NLSRNARNKD EMSTKWSHL IEKLPGSVGE KSPPAEVLVN 720 IIAVLNNLW ASPIAARDLL YFDGLRKLIF IKKKRDSPDS EKSSRAASSL LANLWQYNKL 780 HRDFRAKGYR KEDFLGP Seq ID NO : 352 DNA sequence Nucleic Acid Accession &num : M31469 Coding sequence: 1-651 1 11 21 31 41 51 ATGGCTGCGC AGGGAGAGCC CCAGGTCCAG TTCAAACTTG TATTGGTTGG TGATGGTGGT 60 ACTGGAAAAA CGACCTTCGT GAAACGTCAT TTGACTGGTG AATTTGAGAA GAAGTATGTA 120 GCCACCTTGG GTGTTGAGGT TCATCCCCTA GTGTTCCACA CCAACAGAGG ACCTATTAAG 180 TTCAATGTAT GGGACACAGC CGGCCAGGAG AAATTCGGTG GACTGAGAGA TGGCTATTAT 240 ATCCAAGCCC AGTGTGCCAT CATAATGTTT GATGTAACAT CGAGAGTTAC TTACAAGAAT 300 GTGCCTAACT GGCATAGAGA TCTGGTACGA GTGTGTGAAA ACATCCCCAT TGTGTTGTGT 360 GGCAACAAAG TGGATATTAA GGACAGGAAA GTGAAGGCGA AATCCATTGT CTTCCACCGA 420 AAGAAGAATC TTCAGTACTA CGACATTTCT GCCAAAAGTA ACTACAACTT TGAAAAGCCC 480 TTCCTCTGGC TTGCTAGGAA GCTCATTGGA GACCCTAACT TGGAATTTGT TGCCATGCCT 540 GCTCTCGCCC CACCAGAAGT TGTCATGGAC CCAGCTTTGG CAGCACAGTA TGAGCACGAC 600 TTAGAGGTTG CTCAGACAAC TGCTCTCCCG GATGAGGATG ATGACCTGTG A Seq ID NO : 353 Protein sequence Protein Accession &num : MA36546 1 11 21 31 41 51 MAAQGEPQVQ FKLVLVGDGG TGKTTFVKRH LTGEFEKKYV ATLGVEVHPL VFHTNRGPIK 60 FNVWDTAGQE KFGGLRDGYY IQAQCAIIMF DVTSRVTYKN VPNWHRDLVR VCENIPIVLC 120 GNKVDIKDRK VKAKSIVFHR KKNLQYYDIS AKSNYNFEKP FLWLARKLIG DPNLEFVAMP 180 ALAPPEWMD PALAAQYEHD LEVAQTTALP DEDDDL Seq ID NO : 354 DNA sequence Nucleic Acid Accession &num : NM 002820 Coding sequence : 304-831 1 11 21 31 41 51 I CCGGTTCGCA AAGAAGCTGA CTTCAGAGGG GGAAACTTTC TTCTTTTAGG AGGCGGTTAG 60 CCCTGTTCCA CGAACCCAGG AGAACTGCTG GCCAGATTAA TTAGACATTG CTATGGGAGA 120 CGTGTAAACA CACTACTTAT CATTGATGCA TATATAAAAC CATTTTATTT TCGCTATTAT 180 TTCAGAGGAA GCGCCTCTGA TTTGTTTCTT TTTTCCCTTT TTGCTCTTTC TGGCTGTGTG 240 GTTTGGAGAA AGCACAGTTG GAGTAGCCGG TTGCTAAATA AGTCCCGAGC GCGAGCGGAG 300 ACGATGCAGC GGAGACTGGT TCAGCAGTGG AGCGTCGCGG TGTTCCTGCT GAGCTACGCG 360 GTGCCCTCCT GCGGGCGCTC GGTGGAGGGT CTCAGCCGCC GCCTCAAAAG AGCTGTGTCT 420 GAACATCAGC TCCTCCATGA CAAGGGGAAG TCCATCCAAG ATTTACGGCG ACGATTCTTC 480 CTTCACCATC TGATCGCAGA AATCCACACA GCTGAAATCA GAGCTACCTC GGAGGTGTCC 540 CCTAACTCCA AGCCCTCTCC CAACACAAAG AACCACCCCG TCCGATTTGG GTCTGATGAT 600 GAGGGCAGAT ACCTAACTCA GGAAACTAAC AAGGTGGAGA CGTACAAAGA GCAGCCGCTC 660 AAGACACCTG GGAAGAAAAA GAAAGGCAAG CCCGGGAAAC GCAAGGAGCA GGAAAAGAAA 720 AAACGGCGAA CTCGCTCTGC CTGGTTAGAC TCTGGAGTGA CTGGGAGTGG GCTAGAAGGG 780 GACCACCTGT CTGACACCTC CACAACGTCG CTGGAGCTCG ATTCACGGTA ACAGGCTTCT 840 CTGGCCCGTA GCCTCAGCGG GGTGCTCTCA GCTGGGTTTT GGAGCCTCCC TTCTGCCTTG 900 GCTTGGACAA ACCTAGAATT TTCTCCCTTT ATGTATCTCT ATCGATTGTG TAGCAATTGA 960 CAGAGAATAA CTCAGAATAT TGTCTGCCTT AAAGCAGTAC CCCCCTACCA CACACACCCC 1020 TGTCCTCCAG CACCATAGAG AGGCGCTAGA GCCCATTCCT CTTTCTCCAC CGTCACCCAA 1080 CATCAATCCT TTACCACTCT ACCAAATAAT TTCATATTCA AGCTTCAGAA GCTAGTGACC 1140 ATCTTCATAA TTTGCTGGAG AAGTGTATTT CTTCCCCTTA CTCTCACACC TGGGCAAACT 1200 TTCTTCAGTG TTTTTCATTT CTTACGTTCT TTCACTTCAA GGGAGAATAT AGAAGCATTT 1260 GATATTATCT ACAAACACTG CAGAACAGCA TCATGTCATA AACGATTCTG AGCCATTCAC 1320 ACTTTTTATT TAATTAAATG TATTTAATTA AATCTCAAAT TTATTTTAAT GTAAAGAACT 1380 TAAATTATGT TTTAAACACA TGCCTTAAAT TTGTTTAATT AAATTTAACT CTGGTTTCTA 1440 CCAGCTCATA CAAAATAAAT GGTTTCTGAA AATGTTTAAG TATTAACTTA CAAGGATATA 1500 GGTTTTTCTC ATGTATCTTT TTGTTCATTG GCAAGATGAA ATAATTTTTC TAGGGTAATG 1560 CCGTAGGAAA AATAAAACTT CACATTTAAA AAAAA Seq ID NO: 355 Protein sequence Protein Accession &num : NM 002820 1 11 21 31 41 51 MQRRLVQQWS VAVFLLSYAV PSCGRSVEGL SRRLKRAVSE HQLLHDKGKS IQDLRRRFFL 60 HHLIAEIHTA EIRATSEVSP NSKPSPNTKN HPVRFGSDDE GRYLTQETNK VETYKEQPLK 120

GAGGCCCTCA AGGTCCCAAT GGAGCTGATG GACCACAAGG ACCCCCAGGT TCTGTTGGTT 3900 CAGTTGGTGG TGTTGGAGAA AAGGGTGAAC CTGGAGAAGC AGGAAACCCA GGGCCTCCTG 3960 GGGAAGCAGG TGTAGGCGGT CCCAAAGGAG AAAGAGGAGA GAAAGGGGAA GCTGGTCCAC 4020 CTGGAGCTGC TGGACCTCCA GGTGCCAAGG GGCCGCCAGG TGATGATGGC CCTAAGGGTA 4080 ACCCGGGTCC TGTTGGTTTT CCTGGAGATC CTGGTCCTCC TGGGGAACTT GGCCCTGCAG 4140 GTCAAGATGG TGTTGGTGGT GACAAGGGTG AAGATGGAGA TCCTGGTCAA CCGGGTCCTC 4200 CTGGCCCATC TGGTGAGGCT GGCCCACCAG GTCCTCCTGG AAAACGAGGT CCTCCTGGAG 4260 CTGCAGGTGC AGAGGGAAGA CAAGGTGAAA AAGGTGCTAA GGGGGAAGCA GGTGCAGAAG 4320 GTCCTCCTGG AAAAACCGGC CCAGTCGGTC CTCAGGGACC TGCAGGAAAG CCTGGTCCAG 4380 AAGGTCTTCG GGGCATCCCT GGTCCTGTGG GAGAACAAGG TCTCCCTGGA GCTGCAGGCC 4440 AAGATGGACC ACCTGGTCCT ATGGGACCTC CTGGCTTACC TGGTCTCAAA GGTGACCCTG 4500 GCTCCAAGGG TGAAAAGGGA CATCCTGGTT TAATTGGCCT GATTGGTCCT CCAGGAGAAC 4560 AAGGGGAAAA AGGTGACCGA GGGCTCCCTG GAACTCAAGG ATCTCCAGGA GCAAAAGGGG 4620 ATGGGGGAAT TCCTGGTCCT GCTGGTCCCT TAGGTCCACC TGGTCCTCCA GGCTTACCAG 4680 GTCCTCAAGG CCCAAAGGGT AACAAAGGCT CTACTGGACC CGCTGGCCAG AAAGGTGACA 4740 GTGGTCTTCC AGGGCCTCCT GGGCCTCCAG GTCCACCTGG TGAAGTCATT CAGCCTTTAC 4800 CAATCTTGTC CTCCAAAAAA ACGAGAAGAC ATACTGAAGG CATGCAAGCA GATGCAGATG 4860 ATAATATTCT TGATTACTCG GATGGAATGG AAGAAATATT TGGTTCCCTC AATTCCCTGA 4920 AACAAGACAT CGAGCATATG AAATTTCCAA TGGGTACTCA GACCAATCCA GCCCGAACTT 4980 GTAAAGACCT GCAACTCAGC CATCCTGACT TCCCAGATGG TGAATATTGG ATTGATCCTA 5040 ACCAAGGTTG CTCAGGAGAT TCCTTCAAAG TTTACTGTAA TTTCACATCT GGTGGTGAGA 5100 CTTGCATTTA TCCAGACAAA AAATCTGAGG GAGTAAGAAT TTCATCATGG CCAAAGGAGA 5160 AACCAGGAAG TTGGTTTAGT GAATTTAAGA GGGGAAAACT GCTTTCATAC TTAGATGTTG 5220 AAGGAAATTC CATCAATATG GTGCAAATGA CATTCCTGAA ACTTCTGACT GCCTCTGCTC 5280 GGCAAAATTT CACCTACCAC TGTCATCAGT CAGCAGCCTG GTATGATGTG TCATCAGGAA 5340 GTTATGACAA AGCACTTCGC TTCCTGGGAT CAAATGATGA GGAGATGTCC TATGACAATA 5400 ATCCTTTTAT CAAAACACTG TATGATGGTT GTACGTCCAG AAAAGGCTAT GAAAAAACTG 5460 TCATTGAAAT CAATACACCA AAAATTGATC AAGTACCTAT TGTTGATGTC ATGATCAGTG 5520 ACTTTGGTGA TCAGAATCAG AAGTTCGGAT TTGAAGTTGG TCCTGTTTGT TTTCTTGGCT 5580 AAGATTAAGA CAAAGAACAT ATCAAATCAA CAGAAAATGT ACCTTGGTGC CACCAACCCA 5640 TTTTGTGCCA CATGCAAGTT TTGAATAAGG ATGTATGGAA AACAACGCTG CATATACAGG 5700 TACCATTTAG GAAATACCGA TGCCTTTGTG GGGGCAGAAT CACAGACAAA AGCTTTGAAA 5760 ATCATAAAGA TATAAGTTGG TGTGGCTAAG ATGGAAACAG GGCTGATTCT TGATTCCCAA 5820 TTCTCAACTC TCCTTTTCCT ATTTGAATTT CTTTGGTGCT GTAGAAAACA AAAAAAGAAA 5880 AATATATATT CATAAAAAAT ATGGTGCTCA TTCTCATCCA TCCAGGATGT ACTAAAACAG 5940 TGTGTTTAAT AAATTGTAAT TATTTTGTGT ACAGTTCTAT ACTGTTATCT GTGTCCATTT 6000 CCAAAACTTG CACGTGTCCC TGAATTCCGC TGACTCTAAT TTATGAGGAT GCCGAACTCT 6060 GATGGCAATA ATATATGTAT TATGAAAATG AAGTTATGAT TTCCGATGAC CCTAAGTCCC 6120 TTTCTTTGGT TAATGATGAA ATTCCTTTGT GTGTGTTT Seq ID NO : 361 Protein sequence Protein Accession &num : NP 001845 1 11 21 31 41 51 MEPWSSRWKT KRWLWDFTVT TLALTFLFQA REVRGAAPVD VLKALDFHNS PEGISKTTGF 60 CTNRKNSKGS DTAYRVSKQA QLSAPTKQLF PGGTFPEDFS ILFTVKPKKG IQSFLLSIYN 120 EHGIQQIGVE VGRSPVFLFE DHTGKPAPED YPLFRTVNIA DGKWHRVAIS VEKKTVTMIV 180 DCKKKTTKPL DRSERAIVDT NGITVFGTRI LDEEVFEGDI QQFLITGDPK AAYDYCEHYS 240 PDCDSSAPKA AQAQEPQIDE YAPEDIIEYD YEYGEAEYKE AESVTEGPTV TEETIAQTEA 300 NIVDDFQEYN YGTMESYQTE APRHVSGTNE PNPVEEIFTE EYLTGEDYDS QRKNSEDTLY 360 ENKEIDGRDS DLLVDGDLGE YDFYEYKEYE DKPTSPPNEE FGPGVPAETD ITETSINGHG 420 AYGEKGQKGE PAWEPGMLV EGPPGPAGPA GIMGPPGLQG PTGPPGDPGD RGPPGRPGLP 480 GADGLPGPPG TMLMLPFRYG GDGSKGPTIS AQEAQAQAIL QQARIALRGP PGPMGLTGRP 540 GPVGGPGSSG AKGESGDPGP QGPRGVQGPP GPTGKPGKRG RPGADGGRGM PGEPGAKGDR 600 GFDGLPGLPG DKGHRGERGP QGPPGPPGDD GMRGEDGEIG PRGLPGEAGP RGLLGPRGTP 660 GAPGQPGMAG VDGPPGPKGN MGPQGEPGPP GQQGNPGPQG LPGPQGPIGP PGEKGPQGKP 720 GLAGLPGADG PPGHPGKEGQ SGEKGALGPP GPQGPIGXPG PRGVKGADGV RGLKGSKGEK 780 GEDGFPGFKG DMGLKGDRGE VGQIGPRGXD GPEGPKGRAG PTGDPGPSGQ AGEKGKLGVP 840 GLPGYPGRQG PKGSTGFPGF PGANGEKGAR GVAGKPGPRG QRGPTGPRGS RGARGPTGKP 900 GPKGTSGGDG PPGPPGERGP QGPQGPVGFP GPKGPPGPPG RMGCPGHPGQ RGETGFQGKT 960 GPPGPGGWG PQGPTGETGP IGERGYPGPP GPPGEQGLPG AAGKEGAKGD PGPQGISGKD 1020 GPAGLRGFPG ERGLPGAQGA PGLKGGEGPQ GPPGPVGSPG ERGSAGTAGP IGLRGRPGPQ 1080 GPPGPAGEKG APGEKGPQGP AGRDGVQGPV GLPGPAGPAG SPGEDGDKGE IGEPGQKGSK 1140 GGKGENGPPG PPGLQGPVGA PGIAGGDGEP GPRGQQGMFG QKGDEGARGF PGPPGPIGLQ 1200 GLPGPPGEKG ENGDVGPWGP PGPPGPRGPQ GPNGADGPQG PPGSVGSVGG VGEKGEPGEA 1260 GNPGPPGEAG VGGPKGERGE KGEAGPPGAA GPPGAKGPPG DDGPKGNPGP VGFPGDPGPP 1320 GELGPAGQDG VGGDKGEDGD PGQPGPPGPS GEAGPPGPPG KRGPPGAAGA EGRQGEKGAK 1380 GEAGAEGPPG KTGPVGPQGP AGKPGPEGLR GIPGPVGEQG LPGAAGQDGP PGPMGPPGLP 1440 GLKGDPGSKG EKGHPGLIGL IGPPGEQGEK GDRGLPGTQG SPGAKGDGGI PGPAGPLGPP 1500 GPPGLPGPQG PKGNKGSTGP AGQKGDSGLP GPPGPPGPPG EVIQPLPILS SKKTRRHTEG 1560 MQADADDNIL DYSDGMEEIF GSLNSLKQDI EHMKFPMGTQ TNPARTCKDL QLSHPDFPDG 1620 EYWIDPNQGC SGDSFKVYCN FTSGGETCIY PDKKSEGVRI SSWPKEKPGS WFSEFKRGKL 1680 LSYLDVEGNS INMVQMTFLK LLTASARQNF TYHCHQSAAW YDVSSGSYDK ALRFLGSNDE 1740 EMSYDNNPFI KTLYDGCTSR KGYEKTVIEI NTPKIDQVPI VDVMISDFGD QNQKFGFEVG 1800 PVCFLG Seq ID NO : 362 DNA sequence Nucleic Acid Accession &num : NM 003107 Coding sequence: 351-1775 1 11 21 31 41 51 TTCCCCAGCA TTCGAGAAAC TCCTCTCTAC TTTAGCACGG TCTCCAGACT CAGCCGAGAG 60 ACAGCAAACT GCAGCGCGGT GAGAGAGCGA GAGAGAGGGA GAGAGAGACT CTCCAGCCTG 120 GGAACTATAA CTCCTCTGCG AGAGGCGGAG AACTCCTTCC CCAAATCTTT TGGGGACTTT 180

TCTCTCTTTA CCCACCTCCG CCCCTGCGAG GAGTTGAGGG GCCAGTTCGG CCGCCGCGCG 240 CGTCTTCCCG TTCGGCGTGT GCTTGGCCCG GGGAACCGGG AGGGCCCGGC GATCGCGCGG 300 CGGCCGCCGC GAGGGTGTGA GCGCGCGTGG GCGCCCGCCG AGCCGAGGCC ATGGTGCAGC 360 AAACCAACAA TGCCGAGAAC ACGGAAGCGC TGCTGGCCGG CGAGAGCTCG GACTCGGGCG 420 CCGGCCTCGA GCTGGGAATC GCCTCCTCCC CCACGCCCGG CTCCACCGCC TCCACGGGCG 480 GCAAGGCCGA CGACCCGAGC TGGTGCAAGA CCCCGAGTGG GCACATCAAG CGACCCATGA 540 ACGCCTTCAT GGTGTGGTCG CAGATCGAGC GGCGCAAGAT CATGGAGCAG TCGCCCGACA 600 TGCACAACGC CGAGATCTCC AAGCGGCTGG GCAAACGCTG GAAGCTGCTC AAAGACAGCG 660 ACAAGATCCC TTTCATTCGA GAGGCGGAGC GGCTGCGCCT CAAGCACATG GCTGACTACC 720 CCGACTACAA GTACCGGCCC AGGAAGAAGG TGAAGTCCGG CAACGCCAAC TCCAGCTCCT 780 CGGCCGCCGC CTCCTCCAAG CCGGGGGAGA AGGGAGACAA GGTCGGTGGC AGTGGCGGGG 840 GCGGCCATGG GGGCGGCGGC GGCGGCGGGA GCAGCAACGC GGGGGGAGGA GGCGGCGGTG 900 CGAGTGGCGG CGGCGCCAAC TCCAAACCGG CGCAGAAAAA GAGCTGCGGC TCCAAAGTGG 960 CGGGCGGCGC GGGCGGTGGG GTTAGCAAAC CGCACGCCAA GCTCATCCTG GCAGGCGGCG 1020 GCGGCGGCGG GAAAGCAGCG GCTGCCGCCG CCGCCTCCTT CGCCGCCGAA CAGGCGGGGG 1080 CCGCCGCCCT GCTGCCCCTG GGCGCCGCCG CCGACCACCA CTCGCTGTAC AAGGCGCGGA 1140 CTCCCAGCGC CTCGGCCTCC GCCTCCTCGG CAGCCTCGGC CTCCGCAGCG CTCGCGGCCC 1200 CGGGCAAGCA CCTGGCGGAG AAGAAGGTGA AGCGCGTCTA CCTGTTCGGC GGCCTGGGCA 1260 CGTCGTCGTC GCCCGTGGGC GGCGTGGGCG CGGGAGCCGA CCCCAGCGAC CCCCTGGGCC 1320 TGTACGAGGA GGAGGGCGCG GGCTGCTCGC CCGACGCGCC CAGCCTGAGC GGCCGCAGCA 1380 GCGCCGCCTC GTCCCCCGCC GCCGGCCGCT CGCCCGCCGA CCACCGCGGC TACGCCAGCC 1440 TGCGCGCCGC CTCGCCCGCC CCGTCCAGCG CGCCCTCGCA CGCGTCCTCC TCGGCCTCGT 1500 CCCACTCCTC CTCTTCCTCC TCCTCGGGCT CCTCGTCCTC CGACGACGAG TTCGAAGACG 1560 ACCTGCTCGA CCTGAACCCC AGCTCAAACT TTGAGAGCAT GTCCCTGGGC AGCTTCAGTT 1620 CGTCGTCGGC GCTCGACCGG GACCTGGATT TTAACTTCGA GCCCGGCTCC GGCTCGCACT 1680 TCGAGTTCCC GGACTACTGC ACGCCCGAGG TGAGCGAGAT GATCTCGGGA GACTGGCTCG 1740 AGTCCAGCAT CTCCAACCTG GTTTTCACCT ACTGAAGGGC GCGCAGGCAG GGAGAAGGGC 1800 CGGGGGGGGT AGGAGAGGAG AAAAAAAAAG TGAAAAAAAG AAACGAAAAG GACAGACGAA 1860 GAGTTTAAAG AGAAAAGGGA AAAAAGAAAG AAAAAGTAAG CAGGGCTCGT TCGCCCGCGT 1920 TCTCGTCGTC GGATCAAGGA GCGCGGCGGC GTTTTGGACC CGCGCTCCCA TCCCCCACCT 1980 TCCCGGGCCG GGGACCCACT CTGCCCAGCC GGAGGGACGC GGAGGAGGAA GAGGGTAGAC 2040 AGGGGCGACC TGTGATTGTT GTTATTGATG TTGTTGTTGA TGGCAAAAAA AAAAAGCGAC 2100 TTCGAGTTTG CTCCCCTTTG CTTGAAGAGA CCCCCTCCCC CTTCCAACGA GCTTCCGGAC 2160 TTGTCTGCAC CCCCAGCAAG AAGGCGAGTT AGTTTTCTAG AGACTTGAAG GAGTCTCCCC 2220 CTTCCTGCAT CACCACCTTG GTTTTGTTTT ATTTTGCTTC TTGGTCAAGA AAGGAGGGGA 2280 GAACCCAGCG CACCCCTCCC CCCCTTTTTT TAAACGCGTG ATGAAGACAG AAGGCTCCGG 2340 GGTGACGAAT TTGGCCGATG GCAGATGTTT TGGGGGAACG CCGGGACTGA GAGACTCCAC 2400 GCAGGCGAAT TCCCGTTTGG GGCCTTTTTT TCCTCCCTCT TTTCCCCTTG CCCCCTCTGC 2460 AGCCGGAGGA GGAGATGTTG AGGGGAGGAG GCCAGCCAGT GTGACCGGCG CTAGGAAATG 2520 ACCCGAGAAC CCCGTTGGAA GCGCAGCAGC GGGAGCTAGG GGCGGGGGCG GAGGAGGACA 2580 CGAACTGGAA GGGGGTTCAC GGTCAAACTG AAATGGATTT GCACGTTGGG GAGCTGGCGG 2640 CGGCGGCTGC TGGGCCTCCG CCTTCTTTTC TACGTGAAAT CAGTGAGGTG AGACTTCCCA 2700 GACCCCGGAG GCGTGGAGGA GAGGAGACTG TTTGATGTGG TACAGGGGCA GTCAGTGGAG 2760 GGCGAGTGGT TTCGGAAAAA AAAAAAGAAA AAAAGGG Seq ID NO : 363 Protein sequence Protein Accession nu-003098 1 11 21 31 41 51 MVQQTNNAEN TEALLAGESS DSGAGLELGI ASSPTPGSTA STGGKADDPS WCKTPSGHIK 60 RPMNAFMVWS QIERRKIMEQ SPDMHNAEIS KRLGKRWKLL KDSDKIPFIR EAERLRLKHM 120 ADYPDYKYRP RKKVKSGNAN SSSSAAASSK PGEKGDKVGG SGGGGHGGGG GGGSSNAGGG 180 GGGASGGGAN SKPAQKKSCG SKVAGGAGGG VSKPHAKLIL AGGGGGGKAA AAAAASFAAE 240 QAGAAALLPL GAAADHHSLY KARTPSASAS ASSAASASAA LAAPGKHLAE KKVKRVYLFG 300 GLGTSSSPVG GVGAGADPSD PLGLYEEEGA GCSPDAPSLS GRSSAASSPA AGRSPADHRG 360 YASLRAASPA PSSAPSHASS SASSHSSSSS SSGSSSSDDE FEDDLLDLNP SSNFESMSLG 420 SFSSSSALDR DLDFNFEPGS GSHFEFPDYC TPEVSEMISG DWLESSISNL VFTY Seq ID NO : 364 DNA sequence Nucleic Acid Accession # : U10860 Coding sequence: 123-2204 1 11 21 31 41 51 TGCCGGCTGC TCCTCGACCA GGCCTCCTTC TCAACCTCAG CCCGCGGCGC CGACCCTTCC 60 GGCACCCTCC CGCCCCGTCT CGTACTGTCG CCGTCACCGC CGCGGCTCCG GCCCTGGCCC 120 CGATGGCTCT GTGCAACGGA GACTCCAAGC TGGAGAATGC TGGAGGAGAC CTTAAGGATG 180 GCCACCACCA CTATGAAGGA GCTGTTGTCA TTCTGGATGC TGGTGCTCAG TACGGGAAAG 240 TCATAGACCG AAGAGTGAGG GAACTGTTCG TGCAGTCTGA AATTTTCCCC TTGGAAACAC 300 CAGCATTTGC TATAAAGGAA CAAGGATTCC GTGCTATTAT CATCTCTGGA GGACCTAATT 360 CTGTGTATGC TGAAGATGCT CCCTGGTTTG ATCCAGCAAT ATTCACTATT GGCAAGCCTG 420 TTCTTGGAAT TTGCTATGGT ATGCAGATGA TGAATAAGGT ATTTGGAGGT ACTGTGCACA 480 AAAAAAGTGT CAGAGAAGAT GGAGTTTTCA ACATTAGTGT GGATAATACA TGTTCATTAT 540 TCAGGGGCCT TCAGAAGGAA GAAGTTGTTT TGCTTACACA TGGAGATAGT GTAGACAAAG 600 TAGCTGATGG ATTCAAGGTT GTGGCACGTT CTGGAAACAT AGTAGCAGGC ATAGCAAATG 660 AATCTAAAAA GTTATATGGA GCACAGTTCC ACCCTGAAGT TGGCCTTACA GAAAATGGAA 720 AAGTAATACT GAAGAATTTC CTTTATGATA TAGCTGGATG CAGTGGAACC TTCACCGTGC 780 AGAACAGAGA ACTTGAGTGT ATTCGAGAGA TCAAAGAGAG AGTAGGCACG TCAAAAGTTT 840 TGGTTTTACT CAGTGGTGGA GTAGACTCAA CAGTTTGTAC AGCTTTGCTA AATCGTGCTT 900 TGAACCAAGA ACAAGTCATT GCTGTGCACA TTGATAATGG CTTTATGAGA AAACGAGAAA 960 GCCAGTCTGT TGAAGAGGCC CTCAAAAAGC TTGGAATTCA GGTCAAAGTG ATAAATGCTG 1020 CTCATTCTTT CTACAATGGA ACAACAACCC TACCAATATC AGATGAAGAT AGAACCCCAC 1080 GGAAAAGAAT TAGCAAAACG TTAAATATGA CCACAAGTCC TGAAGAGAAA AGAAAAATCA 1140 TTGGGGATAC TTTTGTTAAG ATTGCCAATG AAGTAATTGG AGAAATGAAC TTGAAACCAG 1200 AGGAGGTTTT CCTTGCCCAA GGTACTTTAC GGCCTGATCT AATTGAAAGT GCATCCCTTG 1260

TCCACCATGC GCCTTCCGGA TGAGCGGGGC CCTCTGGAGC ACCTCTACTC CCTGCACATC 900 CCCAACTGTG ACAAGCATGG CCTGTACAAC CTCAAACAGT GCAAGATGTC TCTGAACGGG 960 CAGCGTGGGG AGTGCTGGTG TGTGAACCCC AACACCGGGA AGCTGATCCA GGGAGCCCCC 1020 ACCATCCGGG GGGACCCCGA GTGTCATCTC TTCTACAATG AGCAGCAGGA GGCTTGCGGG 1080 GTGCACACCC AGCGGATGCA GTAGACCGCA GCCAGCCGGT GCCTGGCGCC CCTGCCCCCC 1140 GCCCCTCTCC AAACACCGGC AGAAAACGGA GAGTGCTTGG GTGGTGGGTG CTGGAGGATT 1200 TTCCAGTTCT GACACACGTA TTTATATTTG GAAAGAGACC AGCACCGAGC TCGGCACCTC 1260 CCCGGCCTCT CTCTTCCCAG CTGCAGATGC CACACCTGCT CCTTCTTGCT TTCCCCGGGG 1320 GAGGAAGGGG GTTGTGGTCG GGGAGCTGGG GTACAGGTTT GGGGAGGGGG AAGAGAAATT 1380 TTTATTTTTG AACCCCTGTG TCCCTTTTGC ATAAGATTAA AGGAAGGAAA AGT Seq ID NO : 369 Protein sequence Protein Accession # : NP 000588 1 11 21 31 41 51 # # # # # # MLPRVGCPAL PLPPPPLLPL LPLLLLLLGA SGGGGGARAE VLFRCPPCTP ERLAACGPPP 60 VAPPAAVAAV AGGARMPCAE LVREPGCGCC SVCARLEGEA CGVYTPRCGQ GLRCYPHPGS 120 ELPLQALVMG EGTCEKRRDA EYGASPEQVA DNGDDHSEGG LVENHVDSTM NMLGGGGSAG 180 RKPLKSGMKE LAVFREKVTE QHRQMGKGGK HHLGLEEPKK LRPPPARTPC QQELDQVLER 240 ISTMRLPDER GPLEHLYSLH IPNCDKHGLY NLKQCKMSLN GQRGECWCVN PNTGKLIQGA 300 PTIRGDPECH LPYNEQQEAC GVHTQRMQ Seq ID NO: 370 DNA sequence Nucleic Acid Accession 4 : NM 004264 Coding sequence : 6-440 1 11 21 31 41 51 <BR> <BR> <BR> <BR> <BR> <BR> GGAACATGGC GGATCGGCTC ACGCAGCTTC AGGACGCTGT GAATTCGCTT GCAGATCAGT 60 TTTGTAATGC CATTGGAGTA TTGCAGCAAT GTGGTCCTCC TGCCTCTTTC AATAATATTC 120 AGACAGCAAT TAACAAAGAC CAGCCAGCTA ACCCTACAGA AGAGTATGCC CAGCTTTTTG 1B0 CAGCACTGAT TGCACGAACA GCAAAAGACA TTGATGTTTT GATAGATTCC TTACCCAGTG 240 AAGAATCTAC AGCTGCTTTA CAGGCTGCTA GCTTGTATAA GCTAGAAGAA GAAAACCATG 300 AAGCTGCTAC ATGTGTGGAG GATGTTGTTT ATCGAGGAGA CATGCTTCTG GAGAAGATAC 360 AAAGCGCACT TGCTGATATT GCACAGTCAC AGCTGAAGAC AAGAAGTGGT ACCCATAGCC 420 AGTCTCTTCC AGACTCATAG CATCAGTGGA TACCATGTGG CTGAGAAAAG AACTGTTTGA 480 GTGCCATTAA GAATTCTGCA TCAGACTTAG ATACAAGCCT TACCAACAAT TACAGAAACA 540 TTAAACACTA TGACACATTA CCTTTTTAGC TATTTTTAAT AGTCTTCTAT TTTCACTCTT 600 GATAAGCTTA TAAATCATGA TTGAATCAGC TTTAAAGCAT CATACCATCA TTTTTTAACT 660 GAGTGAAATT ATTAAGGCAT GTAATACATT AATGAACATA ATATAAGGAA ACATATGTAA 720 AATTCTGTTA TGACATAATT TATGTCTCCA TTTTGTTGTA TTGGCCAGTA CTTTTACAAT 780 C Seq ID NO : 371 Protein sequence Protein Accession &num : NP 004255 1 11 21 31 41 51 # # # # # # MADRLTQLQD AVNSLADQFC NAIGVLQQCG PPASFNNIQT AINKDQPANP TEEYAQLFAA 60 LIARTAKDID VLIDSLPSEE STAALQAASL YKLEEENHEA ATCVEDWYR GDMLLEKIQS 120 ALADIAQSQL KTRSGTHSQS LPDS Seq ID NO : 372 DNA sequence Nucleic Acid Accession # : AJ271091 Coding sequence : 1-1113 1 11 21 31 41 51 ATGGAGAATC AGGTGTTGAC GCCGCATGTC TACTGGGCTC AGCGACACCG CGAGCTATAT 60 CTGCGCGTGG AGCTGAGTGA CGTACAGAAC CCTGCCATCA GCATCACTGA AAACGTGCTG 120 CATTTCAAAG CTCAAGGACA TGGTGCCAAA GGAGACAATG TCTATGAATT TCACCTGGAG 180 TTCTTAGACC TTGTGAAACC AGAGCCTGTT TACAAACTGA CCCAGAGGCA GGTAAACATT 240 ACAGTACAGA AGAAAGTGAG TCAGTGGTGG GAGAGACTCA CAAAGCAGGA AAAGCGACCA 300 CTGTTTTTGG CTCCTGACTT TGATCGTTGG CTGGATGAAT CTGATGCGGA AATGGAGCTC 360 AGAGCTAAGG AAGAAGAGCG CCTAAATAAA CTCCGACTGG AAAGCGAAGG CTCTCCTGAA 420 ACTCTTACAA ACTTAAGGAA AGGATACCTG TTTATGTATA ATCTTGTGCA ATTCTTGGGA 480 TTCTCCTGGA TCTTTGTCAA CCTGACTGTG CGATTCTGTA TCTTGGGAAA AGAGTCCTTT 540 TATGACACAT TCCATACTGT GGCTGACATG ATGTATTTCT GCCAGATGCT GGCAGTTGTG 600 GAAACTATCA ATGCAGCAAT TGGAGTCACT ACGTCACCGG TGCTGCCTTC TCTGATCCAG 660 CTTCTTGGAA GAAATTTTAT TTTGTTTATC ATCTTTGGCA CCATGGAAGA AATGCAGAAC 720 AAAGCTGTGG TTTTCTTTGT GTTTTATTTG TGGAGTGCAA TTGAAATTTT CAGGTACTCT 780 TTCTACATGC TGACGTGCAT TGACATGGAT TGGAAGGTGC TCACATGGCT TCGTTACACT 840 CTGTGGATTC CCTTATATCC ACTGGGATGT TTGGCGGAAG CTGTCTCAGT GATTCAGTCC 900 ATTCCAATAT TCAATGAGAC CGGACGATTC AGTTTCACAT TGCCATATCC AGTGAAAATC 960 AAAGTTAGAT TTTCCTTTTT TCTTCAGATT TATCTTATAA TGATATTTTT AGGTTTATAC 1020 ATAAATTTTC GTCACCTTTA TAAACAGCGC AGACTGAAAA TGAGGGCAGG CGCAGTGGCT 1080 CATGCCTGTG ATCCCAGCGC TTTGGGAGGC TGA Seq ID NO : 373 Protein sequence Protein Accession # : CAB69070 1 11 21 31 41 51 # # # # # # MENQVLTPHVYWAQRHRELY LRVELSDVQN PAISITENVL HFKAQGHGAK GDNVYEFHLE 60 FLDLVKPEPV YKLTQRQVNI TVQKKVSQWW ERLTKQEKRP LFLAPDFDRW LDESDAEMEL 120 RAKEEERLNK LRLESEGSPE TLTNLRKGYL FMYNLVQFLG FSWIFVNLTV RFCILGKESF 180

ATGGTCAGAA AGCCTGTTGT GTCCACCATC TCCAAAGGAG GTTACCTGCA GGGAAATGTT 60 AACGGGAGGC TGCCTTCCCT GGGCAACAAG GAGCCACCTG GGCAGGAGAA AGTGCAGCTG 120 AAGAGGAAAG TCACTTTACT GAGGGGAGTC TCCATTATCA TTGGCACCAT CATTGGAGCA 180 GGAATCTTCA TCTCTCCTAA GGGCGTGCTC CAGAACACGG GCAGCGTGGG CATGTCTCTG 240 ACCATCTGGA CGGTGTGTGG GGTCCTGTCA CTATTTGGAG CTTTGTCTTA TGCTGAATTG 300 GGAACAACTA TAAAGAAATC TGGAGGTCAT TACACATATA TTTTGGAAGT CTTTGGTCCA 360 TTACCAGCTT TTGTACGAGT CTGGGTGGAA CTCCTCATAA TACGCCCTGC AGCTACTGCT 420 GTGATATCCC TGGCATTTGG ACGCTACATT CTGGAACCAT TTTTTATTCA ATGTGAAATC 480 CCTGAACTTG CGATCAAGCT CATTACAGCT GTGGGCATAA CTGTAGTGAT GGTCCTAAAT 540 AGCATGAGTG TCAGCTGGAG CGCCCGGATC CAGATTTTCT TAACCTTTTG CAAGCTCACA 600 GCAATTCTGA TAATTATAGT CCCTGGAGTT ATGCAGCTAA TTAAAGGTCA AACGCAGAAC 660 TTTAAAGACG CGTTTTCAGG AAGAGATTCA AGTATTACGC GGTTGCCACT GGCTTTTTAT 720 TATGGAATGT ATGCATATGC TGGCTGGTTT TACCTCAACT TTGTTACTGA AGAAGTAGAA 780 AACCCTGAAA AAACCATTCC CCTTGCAATA TGTATATCCA TGGCCATTGT CACCATTGGC 840 TATGTGCTGA CAAATGTGGC CTACTTTACG ACCATTAATG CTGAGGAGCT GCTGCTTTCA 900 AATGCAGTGG CAGTGACCTT TTCTGAGCGG CTACTGGGAA ATTTCTCATT AGCAGTTCCG 960 ATCTTTGTTG CCCTCTCCTG CTTTGGCTCC ATGAACGGTG GTGTGTTTGC TGTCTCCAGG 1020 TTATTCTATG TTGCGTCTCG AGAGGGTCAC CTTCCAGAAA TCCTCTCCAT GATTCATGTC 1080 CGCAAGCACA CTCCTCTACC AGCTGTTATT GTTTTGCACC CTTTGACAAT GATAATGCTC 1140 TTCTCTGGAG ACCTCGACAG TCTTTTGAAT TTCCTCAGTT TTGCCAGGTG GCTTTTTATT 1200 GGGCTGGCAG TTGCTGGGCT GATTTATCTT CGATACAAAT GCCCAGATAT GCATCGTCCT 1260 TTCAAGGTGC CACTGTTCAT CCCAGCTTTG TTTTCCTTCA CATGCCTCTT CATGGTTGCC 1320 CTTTCCCTCT ATTCGGACCC ATTTAGTACA GGGATTGGCT TCGTCATCAC TCTGACTGGA 1380 GTCCCTGCGT ATTATCTCTT TATTATATGG GACAAGAAAC CCAGGTGGTT TAGAATAATG 1440 TCAGAGAAAA TAACCAGAAC ATTACAAATA ATACTGGAAG TTGTACCAGA AGAAGATAAG 1500 TTATGAACTA ATGGACTTGA GATCTTGGCA ATCTGCCCAA GGGGAGACAC AAAATAGGGA 1560 TTTTTACTTC ATTTTCTGAA AGTCTAGAGA ATTACAACTT TGGTGATAAA CAAAAGGAGT 1620 CAGTTATTTT TATTCATATA TTTTAGCATA TTCGAACTAA TTTCTAAGAA ATTTAGTTAT 1680 AACTCTATGT AGTTATAGAA AGTGAATATG CAGTTATTCT ATGAGTCGCA CAATTCTTGA 1740 GTCTCTGATA CCTACCTATT GGGGTTAGGA GAAAAGACTA GACAATTACT ATGTGGTCAT 1800 TCTCTACAAC ATATGTTAGC ACGGCAAAGA ACCTTCAAAT TGAAGACTGA GATTTTTCTG 1860 TATATATGGG TTTTGTAAAG ATGGTTTTAC ACACTACAGA TGTCTATACT GTGAAAAGTG 1920 TTTTCAATTC TGAAAAAAAG CATACATCAT GATTATGGCA AAGAGGAGAG AAAGAAATTT 1980 ATTTTACATT GACATTGCAT TGCTTCCCCT TAGATACCAA TTTAGATAAC AAACACTCAT 2040 GCTTTAATGG ATTATACCCA GAGCACTTTG AACAAAGGTC AGTGGGGATT GTTGAATACA 2100 TTAAAGAAGA GTTTCTAGGG GCTACTGTTT ATGAGACACA TCCAGGAGTT ATGTTTAAGT 2160 AAAAATCCTT GAGAATTTAT TATGTCAGAT GTTTTTTCAT TCATTATCAG GAAGTTTTAG 2220 TTATCTGTCA TTTTTTTTTT TCACATCAGT TTGATCAGGA AAGTGTATAA CACATCTTAG 2280 AGCAAGAGTT AGTTTGGTAT TAAATCCTCA TTAGAACAAC CACCTGTTTC ACTAATAACT 2340 TACCCCTGAT GAGTCTATCT AAACATATGC ATTTTAAGCC TTCAAATTAC ATTATCAACA 2400 TGAGAGAAAT AACCAACAAA GAAGATGTTC AAAATAATAG TCCCATATCT GTAATCATAT 2460 CTACATGCAA TGTTAGTAAT TCTGAAGTTT TTTAAATTTA TGGCTATTTT TACACGATGA 2520 TGAATTTTGA CAGTTTGTGC ATTTTCTTTA TACATTTTAT ATTCTTCTGT TAAAATATCT 2580 CTTCAGATGA AACTGTCCAG ATTAATTAGG AAAAGGCATA TATTAACATA AAAATTGCAA 2640 AAGAAATGTC GCTGTAAATA AGATTTACAA CTGATGTTTC TAGAAAATTT CCACTTCTAT 2700 ATCTAGGCTT TGTCAGTAAT TTCCACACCT TAATTATCAT TCAACTTGCA AAAGAGACAA 2760 CTGATAAGAA GAAAATTGAA ATGAGAATCT GTGGATAAGT GTTTGTGTTC AGAAGATGTT 2820 GTTTTGCCAG TATTAGAAAA TACTGTGAGC CGGGCATGGT GGCTTACATC TGTAATCCCA 2880 GCACTTTGGG AGGCTGAGGG GGTGGATCAC CTGAGGTCGG GAGTTCTAGA CCAGCCTGAC 2940 CAACATGGAG AAACCCCATC TCTACTAAAA ATACAAAATT AGCTGGGCAT GGTGGCACAT 3000 GCTGGTAATC TCAGCTATTG AGGAGGCTGA GGCAGGAGAA TTGCTTGAAC CCGGGAGGCG 3060 GAGGTTGCAG TGAGCCAAGA TTGCACCACT GTACTCCAGC CTGGGTGACA AAGTCAGACT 3120 CCATCTCCAA AAAAAAAAAA AAAA Seq ID NO : 395 Protein sequence Protein Accession # : NP 055146. 1 1 11 21 31 41 51 MVRKPWSTI SKGGYLQGNV NGRLPSLGNK EPPGQEKVQL KRKVTLLRGV SIIIGTIIGA 60 GIFISPKGVL QNTGSVGMSL TIWTVCGVLS LFGALSYAEL GTTIKKSGGH YTYILEVFGP 120 LPAFVRVWVE LLIIRPAATA VISLAFGRYI LEPFFIQCEI PELAIKLITA VGITWMVLN 180 SMSVSWSARI QIFLTFCKLT AILIIIVPGV MQLIKGQTQN FKDAFSGRDS SITRLPLAFY 240 YGMYAYAGWF YLNFVTEEVE NPEKTIPLAI CISMAITIGV YVLTNVAYFT TINAEELLLS 300 NAVAVTFSER LLGNFSLAVP IFVALSCFGS MNGGVFAVSR LFYVASREGH LPEILSMIHV 360 RKHTPLPAVI VLHPLTMIML FSGDLDSLLN FLSFARWLFI GLAVAGLIYL RYKCPDMHRP 420 FKVPLFIPAL FSFTCLFMVA LSLYSDPFST GIGFVITLTG VPAYYLFIIW DKKPRWFRIM 480 SEKITRTLQI ILEWPEEDK L Seq ID NO : 396 DNA sequence Nucleic Acid Accession # : NM 006528 Coding sequence : 57.. 764 1 11 21 31 41 51 GCCGCCAGCG GCTTTCTCGG ACGCCTTGCC CAGCGGGCCG CCCGACCCCC TGCACCATGG 60 ACCCCGCTCG CCCCCTGGGG CTGTCGATTC TGCTGCTTTT CCTGACGGAG GCTGCACTGG 120 GCGATGCTGC TCAGGAGCCA ACAGGAAATA ACGCGGAGAT CTGTCTCCTG CCCCTAGACT 180 ACGGACCCTG CCGGGCCCTA CTTCTCCGTT ACTACTACGA CAGGTACACG CAGAGCTGCC 240 GCCAGTTCCT GTACGGGGGC TGCGAGGGCA ACGCCAACAA TTTCTACACC TGGGAGGCTT 300 GCGACGATGC TTGCTGGAGG ATAGAAAAAG TTCCCAAAGT TTGCCGGCTG CAAGTGAGTG 360 TGGACGACCA GTGTGAGGGG TCCACAGAAA AGTATTTCTT TAATCTAAGT TCCATGACAT 420 GTGAAAAATT CTTTTCCGGT GGGTGTCACC GGAACCGGAT TGAGAACAGG TTTCCAGATG 480 AAGCTACTTG TATGGGCTTC TGCGCACCAA AGAAAATTCC ATCATTTTGC TACAGTCCAA 540 AAGATGAGGG ACTGTGCTCT GCCAATGTGA CTCGCTATTA TTTTAATCCA AGATACAGAA 600 CCTGTGATGC TTTCACCTAT ACTGGCTGTG GAGGGAATGA CAATAACTTT GTTAGCAGGG 660

AGGATTGCAA ACGTGCATGT GCAAAAGCTT TGAAAAAGAA AAAGAAGATG CCAAAGCTTC 720 GCTTTGCCAG TAGAATCCGG AAAATTCGGA AGAAGCAATT TTAAACATTC TTAATATGTC 780 ATCTTGTTTG TCTTTATGGC TTATTTGCCT TTATGGTTGT ATCTGAAGAA TAATATGACA 840 GCATGAGGAA ACAAATCATT GGTGATTTAT TCACCAGTTT TTATTAATAC AAGTCACTTT 900 TTCAAAAATT TGGATTTTTT TATATATAAC TAGCTGCTAT TCAAATGTGA GTCTACCATT 960 TTTAATTTAT GGTTCAACTG TTTGTGAGAC GAATTCTTGC AATGCATAAG ATATAAAAGC 1020 AAATATGACT CACTCATTTC TTGGGGTCGT ATTCCTGATT TCAGAAGAGG ATCATAACTG 1080 AAACAACATA AGACAATATA ATCATGTGCT TTTAACATAT TTGAGAATAA AAAGGACTAG 1140 CC Seq ID NO: 397 Protein sequence Protein Accession # : NP006519 1 11 21 31 41 51 MDPARPLGLS ILLLFLTEAA LGDAAQEPTG NNAEICLLPL DYGPCRALLL RYYYDRYTQS 60 CRQFLYGGCE GNANNFYTWE ACDDACWRIE KVPKVCRLQV SVDDQCEGST EKYFFNLSSM 120 TCEKFFSGGC HRNRIENRFP DEATCMGFCA PKKIPSFCYS PKDEGLCSAN VTRYYFNPRY 180 RTCDAFTYTG CGGNDNNFVS REDCKRACAK ALKKKKKMPK LRFASRIRKI RKKQF Seq ID NO : 398 DNA sequence Nucleic Acid Accession # : NM 001508. 1 Coding sequence: 1.. 1361 1 11 21 31 41 51 ATGGCTTCAC CCAGCCTCCC GGGCAGTGAC TGCTCCCAAA TCATTGATCA CAGTCATGTC 60 CCCGAGTTTG AGGTGGCCAC CTGGATCAAA ATCACCCTTA TTCTGGTGTA CCTGATCATC 120 TTCGTGATGG GCCTTCTGGG GAACAGCGTC ACCATTCGGG TCACCCAGGT GCTGCAGAAG 180 AAAGGATACT TGCAGAAGGA GGTGACAGAC CACATGGTGA GTTTGGCTTG CTCGGACATC 240 TTGGTGTTCC TCATCGGCAT GCCCATGGAG TTCTACAGCA TCATCTGGAA TCCCCTGACC 300 ACGTCCAGCT ACACCCTGTC CTGCAAGCTG CACACTTTCC TCTTCGAGGC CTGCAGCTAC 360 GCTACGCTGC TGCACGTGCT GACGCTCAGC TTTGAGCGCT ACATCGCCAT CTGTCACCCC 420 TTCAGGTACA AGGCTGTGTC GGGACCTTGC CAGGTGAAGC TGCTGATTGG CTTCGTCTGG 480 GTCACCTCCG CCCTGGTGGC ACTGCCCTTG CTGTTTGCCA TGGGTACTGA GTACCCCCTG 540 GTGAACGTGC CCAGCCACCG GGGTCTCACT TGCAACCGCT CCAGCACCCG CCACCACGAG 600 CAGCCCGAGA CCTCCAATAT GTCCATCTGT ACCAACCTCT CCAGCCGCTG GACCGTGTTC 660 CAGTCCAGCA TCTTCGGCGC CTTCGTGGTC TACCTCGTGG TCCTGCTCTC CGTAGCCTTC 720 ATGTGCTGGA ACATGATGCA GGTGCTCATG AAAAGCCAGA AGGGCTCGCT GGCCGGGGGC 780 ACGCGGCCTC CGCAGCTGAG GAAGTCCGAG AGCGAAGAGA GCAGGACCGC CAGGAGGCAG 840 ACCATCATCT TCCTGAGGCT GATTGTTGTG ACATTGGCCG TATGCTGGAT GCCCAACCAG 900 ATTCGGAGGA TCATGSCTGC GGCCAAACCC AAGCACGACT GGACGAGGTC CTACTTCCGG 960 GCGTACATGA TCCTCCTCCC CTTCTCGGAG ACGTTTTTCT ACCTCAGCTC GGTCATCAAC 1020 CCGCTCCTGT ACACGGTGTC CTCGCAGCAG TTTCGGCGGG TGTTCGTGCA GGTGCTGTGC 1080 TGCCGCCTGT CGCTGCAGCA CGCCAACCAC GAGAAGCGCC TGCGCGTACA TGCGCACTCC 1140 ACCACCGACA GCGCCCGCTT TGTGCAGCGC CCGTTGCTCT TCGCGTCCCG GCGCCAGTCC 1200 TCTGCAAGGA GAACTGAGAA GATTTTCTTA AGCACTTTTC AGAGCGAGGC CGAGCCCCAG 1260 TCTAAGTCCC AGTCATTGAG TCTCGAGTCA CTAGAGCCCA ACTCAGGCGC GAAACCAGCC 1320 AATTCTGCTG CAGAGAATGG TTTTCAGGAG CATGAAGTTT GA Seq ID NO : 399 Protein sequence Protein Accession # : NP 001499. 1 1 11 21 31 41 51 MASPSLPGSD CSQIIDHSHV PEFEVATWIK ITLILVYLII FVMGLLGNSV TIRVTQVLQK 60 KGYLQKEVTD HMVSLACSDI LVFLIGMPME FYSIIWNPLT TSSYTLSCKL HTFLFEACSY 120 ATLLHVLTLS FERYIAICHP FRYKAVSGPC QVKLLIGFVW VTSALVALPL LFAMGTEYPL 180 VNVPSHRGLT CNRSSTRHHE QPETSNMSIC TNLSSRWTVF QSSIFGAFW YLWLLSVAF 240 MCMMMQVLM KSQKGSLAGG TRPPQLRKSE SEESRTARRQ TIIFLRLIW TLAVCWMPNQ 300 IRRIMAAAKP KHDWTRSYFR AYMILLPFSE TFFYLSSVIN PLLYTVSSQQ FRRVFVQVLC 360 CRLSLQHANH EKRLRVHAHS TTDSARFVQR PLLFASRRQS SARRTEKIFL STFQSEAEPQ 420 SKSQSLSLES LEPNSGAKPA NSAAENGFQE HEV Seq ID NO : 400 DNA sequence Nucleic Acid Accession # : NM 006475. 1 Coding sequence: 28.. 2538 1 11 21 31 41 51 # # # # # # AACAGAACTG CAACGGAGAG ACTCAAGATG ATTCCCTTTT TACCCATGTT TTCTCTACTA 60 TTGCTGCTTA TTGTTAACCC TATAAACGCC AACAATCATT ATGACAAGAT CTTGGCTCAT 120 AGTCGTATCA GGGGTCGGGA CCAAGGCCCA AATGTCTGTG CCCTTCAACA GATTTTGGGC 180 ACCAAAAAGA AATACTTCAG CACTTGTAAG AACTGGTATA AAAAGTCCAT CTGTGGACAG 240 AAAACGACTG TTTTATATGA ATGTTGCCCT GGTTATATGA GAATGGAAGG AATGAAAGGC 300 TGCCCAGCAG TTTTGCCCAT TGACCATGTT TATGGCACTC TGGGCATCGT GGGAGCCACC 360 ACAACGCAGC GCTATTCTGA CGCCTCAAAA CTGAGGGAGG AGATCGAGGG AAAGGGATCC 420 TTCACTTACT TTGCACCGAG TAATGAGGCT TGGGACAACT TGGATTCTGA TATCCGTAGA 480 GGTTTGGAGA GCAACGTGAA TGTTGAATTA CTGAATGCTT TACATAGTCA CATGATTAAT 540 AAGAGAATGT TGACCAAGGA CTTAAAAAAT GGCATGATTA TTCCTTCAAT GTATAACAAT 600 TTGGGGCTTT TCATTAACCA TTATCCTAAT GGGGTTGTCA CTGTTAATTG TGCTCGAATC 660 ATCCATGGGA ACCAGATTGC AACAAATGGT GTTGTCCATG TCATTGACCG TGTGCTTACA 720 CAAATTGGTA CCTCAATTCA AGACTTCATT GAAGCAGAAG ATGACCTTTC ATCTTTTAGA 780 GCAGCTGCCA TCACATCGGA CATATTGGAG GCCCTTGGAA GAGACGGTCA CTTCACACTC 840 TTTGCTCCCA CCAATGAGGC TTTTGAGAAA CTTCCACGAG GTGTCCTAGA AAGGTTCATG 900 GGAGACAAAG TGGCTTCCGA AGCTCTTATG AAGTACCACA TCTTAAATAC TCTCCAGTGT 960 TCTGAGTCTA TTATGGGAGG AGCAGTCTTT GAGACGCTGG AAGGAAATAC AATTGAGATA 1020

1 11 21 31 41 51 ATGCCCAAGC GCGCGCACTG GGGGGCCCTC TCCGTGGTGC TGATCCTGCT TTGGGGCCAT 60 CCGCGAGTGG CGCTGGCCTG CCCGCATCCT TGTGCCTGCT ACGTCCCCAG CGAGGTCCAC 120 TGCACGTTCC GATCCCTGGC TTCCGTGCCC GCTGGCATTG CTAGACACGT GGAAAGAATC 180 AATTTGGGGT TTAATAGCAT ACAGGCCCTG TCAGAAACCT CATTTGCAGG ACTGACCAAG 240 TTGGAGCTAC TTATGATTCA CGGCAATGAG ATCCCAAGCA TCCCCGATGG AGCTTTAAGA 300 GACCTCAGCT CTCTTCAGGT TTTCAAGTTC AGCTACAACA AGCTGAGAGT GATCACAGGA 360 CAGACCCTCC AGGGTCTCTC TAACTTAATG AGGCTGCACA TTGACCACAA CAAGATCGAG 420 TTTATCCACC CTCAAGCTTT CAACGGCTTA ACGTCTCTGA GGCTACTCCA TTTGGAAGGA 480 AATCTCCTCC ACCAGCTGCA CCCCAGCACC TTCTCCACGT TCACATTTTT GGATTATTTC 540 AGACTCTCCA CCATAAGGCA CCTCTACTTA GCAGAGAACA TGGTTAGAAC TCTTCCTGCC 600 AGCATGCTTC GGAACATGCC GCTTCTGGAG AATCTTTACT TGCAGGGAAA TCCGTGGACC 660 TGCGATTGTG AGATGAGATG GTTTTTGGAA TGGGATGCAA AATCCAGAGG AATTCTGAAG 720 TGTAAAAAGG ACAAAGCTTA TGAAGGCGGT CAGTTGTGTG CAATGTGCTT CAGTCCAAAG 780 AAGTTGTACA AACATGAGAT ACACAAGCTG AAGGACATGA CTTGTCTGAA GCCTTCAATA 840 GAGTCCCCTC TGAGACAGAA CAGGAGCAGG AGTATTGAGG AGGAGCAAGA ACAGGAAGAG 900 GATGGTGGCA GCCAGCTCAT CCTGGAGAAA TTCCAACTGC CCCAGTGGAG CATCTCTTTG 960 AATATGACCG ACGAGCACGG GAACATGGTG AACTTGGTCT GTGACATCAA GAAACCAATG 1020 GATGTGTACA AGATTCACTT GAACCAAACG GATCCTCCAG ATATTGACAT AAATGCAACA 1080 GTTGCCTTGG ACTTTGAGTG TCCAATGACC CGAGAAAACT ATGAAAAGCT ATGGAAATTG 1140 ATAGCATACT ACAGTGAAGT TCCCGTGAAG CTACACAGAG AGCTCATGCT CAGCAAAGAC 1200 CCCAGAGTCA GCTACCAGTA CAGGCAGGAT GCTGATGAGG AAGCTCTTTA CTACACAGGT 1260 GTGAGAGCCC AGATTCTTGC AGAACCAGAA TGGGTCATGC AGCCATCCAT AGATATCCAG 1320 CTGAACCGAC GTCAGAGTAC GGCCAAGAAG GTGCTACTTT CCTACTACAC CCAGTATTCT 1380 CAAACAATAT CCACCAAAGA TACAAGGCAG GCTCGGGGCA GAAGCTGGGT AATGATTGAG 1440 CCTAGTGGAG CTGTGCAAAG AGATCAGACT GTCCTGGAAG GGGGTCCATG CCAGTTGAGC 1500 TGCAACGTGA AAGCTTCTGA GAGTCCATCT ATCTTCTGGG TGCTTCCAGA TGGCTCCATC 1560 CTGAAAGCGC CCATGGATGA CCCAGACAGC AAGTTCTCCA TTCTCAGCAG TGGCTGGCTG 1620 AGGATCAAGT CCATGGAGCC ATCTGACTCA GGCTTGTACC AGTGCATTGC TCAAGTGAGG 1680 GATGAAATGG ACCGCATGGT ATATAGGGTA CTTGTGCAGT CTCCCTCCAC TCAGCCAGCC 1740 GAGAAAGACA CAGTGACAAT TGGCAAGAAC CCAGGGGAGT CGGTGACATT GCCTTGCAAT 1800 GCTTTAGCAA TACCCGAAGC CCACCTTAGC TGGATTCTTC CAAACAGAAG GATAATTAAT 1860 GATTTGGCTA ACACATCACA TGTATACATG TTGCCAAATG GAACTCTTTC CATCCCAAAG 1920 GTCCAAGTCA GTGATAGTGG TTACTACAGA TGTGTGGCTG TCAACCAGCA AGGGGCAGAC 1980 CATTTTACGG TGGGAATCAC AGTGACCAAG AAAGGGTCTG GCTTGCCATC CAAAAGAGGC 2040 AGACGCCCAG GTGCAAAGGC TCTTTCCAGA GTCAGAGAAG ACATCGTGGA GGATGAAGGG 2100 GGCTCGGGCA TGGGAGATGA AGAGAACACT TCAAGGAGAC TTCTGCATCC AAAGGACCAA 2160 GAGGTGTTCC TCAAAACAAA GGATGATGCC ATCAATGGAG ACAAGAAAGC CAAGAAAGGG 2220 AGAAGAAAGC TGAAACTCTG GAAGCATTCG GAAAAAGAAC CAGAGACCAA TGTTGCAGAA 2280 GGTCGCAGAG TGTTTGAATC TAGACGAAGG ATAAACATGG CAAACAAACA GATTAATCCG 2340 GAGCGCTGGG CTGATATTTT AGCCAAAGTC CGTGGGAAAA ATCTCCCTAA GGGCACAGAA 2400 GTACCCCCGT TGATTAAAAC CACAAGTCCT CCATCCTTGA GCCTAGAAGT CACACCACCT 2460 TTTCCTGCTG TTTCTCCCCC CTCAGCATCT CCTGTGCAGA CAGTAACCAG TGCTGAAGAA 2520 TCCTCAGCAG ATGTACCTCT ACTTGGTGAA GAAGAGCACG TTTTGGGTAC CATTTCCTCA 2580 GCCAGCATGG GGCTAGAACA CAACCACAAT GGAGTTATTC TTGTTGAACC TGAAGTAACA 2640 AGCACACCTC TGGAGGAAGT TGTTGATGAC CTTTCTGAGA AGACTGAGGA GATAACTTCC 2700 ACTGAAGGAG ACCTGAAGGG GACAGCAGCC CCTACACTTA TATCTGAGCC TTATGAACCA 2760 TCTCCTACTC TGCACACATT AGACACAGTC TATGAAAAGC CCACCCATGA AGAGACGGCA 2820 ACAGAGGGTT GGTCTGCAGC AGATGTTGGA TCGTCACCAG AGCCCACATC CAGTGAGTAT 2880 GAGCCTCCAT TGGATGCTGT CTCCTTGGCT GAGTCTGAGC CCATGCAATA CTTTGACCCA 2940 GATTTGGAGA CTAAGTCACA ACCAGATGAG GATAAGATGA AAGAAGACAC CTTTGCACAC 3000 CTTACTCCAA CCCCCACCAT CTGGGTTAAT GACTCCAGTA CATCACAGTT ATTTGAGGAT 3060 TCTACTATAG GGGAACCAGG TGTCCCAGGC CAATCACATC TACAAGGACT GACAGACAAC 3120 ATCCACCTTG TGAAAAGTAG TCTAAGCACT CAAGACACCT TACTGATTAA AAAGGGTATG 3180 AAAGAGATGT CTCAGACACT ACAGGGAGGA AATATGCTAG AGGGAGACCC CACACACTCC 3240 AGAAGTTCTG AGAGTGAGGG CCAAGAGAGC AAATCCATCA CTTTGCCTGA CTCCACACTG 3300 GGTATAATGA GCAGTATGTC TCCAGTTAAG AAGCCTGCGG AAACCACAGT TGGTACCCTC 3360 CTAGACAAAG ACACCACAAC AGTAACAACA ACACCAAGGC AAAAAGTTGC TCCGTCATCC 3420 ACCATGAGCA CTCACCCTTC TCGAAGGAGA CCCAACGGGA GAAGGAGATT ACGCCCCAAC 3480 AAATTCCGCC ACCGGCACAA GCAAACCCCA CCCACAACTT TTGCCCCATC AGAGACTTTT 3540 TCTACTCAAC CAACTCAAGC ACCTGACATT AAGATTTCAA GTCAAGTGGA GAGTTCTCTG 3600 GTTCCTACAG CTTGGGTGGA TAACACAGTT AATACCCCCA AACAGTTGGA AATGGAGAAG 3660 AATGCAGAAC CCACATCCAA GGGAACACCA CGGAGAAAAC ACGGGAAGAG GCCAAACAAA 3720 CATCGATATA CCCCTTCTAC AGTGAGCTCA AGAGCGTCCG GATCCAAGCC CAGCCCTTCT 3780 CCAGAAAATA AACATAGAAA CATTGTTACT CCCAGTTCAG AAACTATACT TTTGCCTAGA 3840 ACTGTTTCTC TGAAAACTGA GGGCCCTTAT GATTCCTTAG ATTACATGAC AACCACCAGA 3900 AAAATATATT CATCTTACCC TAAAGTCCAA GAGACACTTC CAGTCACATA TAAACCCACA 3960 TCAGATGGAA AAGAAATTAA GGATGATGTT GCCACAAATG TTGACAAACA TAAAAGTGAC 4020 ATTTTAGTCA CTGGTGAATC AATTACTAAT GCCATACCAA CTTCTCGCTC CTTGGTCTCC 4080 ACTATGGGAG AATTTAAGGA AGAATCCTCT CCTGTAGGCT TTCCAGGAAC TCCAACCTGG 4140 AATCCCTCAA GGACGGCCCA GCCTGGGAGG CTACAGACAG ACATACCTGT TACCACTTCT 4200 GGGGAAAATC TTACAGACCC TCCCCTTCTT AAAGAGCTTG AGGATGTGGA TTTCACTTCC 4260 GAGTTTTTGT CCTCTTTGAC AGTCTCCACA CCATTTCACC AGGAAGAAGC TGGTTCTTCC 4320 ACAACTCTCT CAAGCATAAA AGTGGAGGTG GCTTCAAGTC AGGCAGAAAC CACCACCCTT 4380 GATCAAGATC ATCTTGAAAC CACTGTGGCT ATTCTCCTTT CTGAAACTAG ACCACAGAAT 4440 CACACCCCTA CTGCTGCCCG GATGAAGGAG CCAGCATCCT CGTCCCCATC CACAATTCTC 4500 ATGTCTTTGG GACAAACCAC CACCACTAAG CCAGCACTTC CCAGTCCAAG AATATCTCAA 4560 GCATCTAGAG ATTCCAAGGA AAATGTTTTC TTGAATTATG TGGGGAATCC AGAAACAGAA 4620 GCAACCCCAG TCAACAATGA AGGAACACAG CATATGTCAG GGCCAAATGA ATTATCAACA 4680 CCCTCTTCCG ACCGGGATGC ATTTAACTTG TCTACAAAGC TGGAATTGGA AAAGCAAGTA 4740 TTTGGTAGTA GGAGTCTACC ACGTGGCCCA GATAGCCAAC GCCAGGATGG AAGAGTTCAT 4800 GCTTCTCATC AACTAACCAG AGTCCCTGCC AAACCCATCC TACCAACAGC AACAGTGAGG 4860 CTACCTGAAA TGTCCACACA AAGCGCTTCC AGATACTTTG TAACTTCCCA GTCACCTCGT 4920 CACTGGACCA ACAAACCGGA AATAACTACA TATCCTTCTG GGGCTTTGCC AGAGAACAAA 4980 CAGTTTACAA CTCCAAGATT ATCAAGTACA ACAATTCCTC TCCCATTGCA CATGTCCAAA 5040

CCCAGCATTC CTAGTAAGTT TACTGACCGA AGAACTGACC AATTCAATGG TTACTCCAAA 5100 GTGTTTGGAA ATAACAACAT CCCTGAGGCA AGAAACCCAG TTGGAAAGCC TCCCAGTCCA 5160 AGAATTCCTC ATTATTCCAA TGGAAGACTC CCTTTCTTTA CCAACAAGAC TCTTTCTTTT 5220 CCACAGTTGG GAGTCACCCG GAGACCCCAG ATACCCACTT CTCCTGCCCC AGTAATGAGA 5280 GAGAGAAAAG TTATTCCAGG TTCCTACAAC AGGATACATT CCCATAGCAC CTTCCATCTG 5340 GACTTTGGCC CTCCGGCACC TCCGTTGTTG CACACTCCGC AGACCACGGG ATCACCCTCA 5400 ACTAACTTAC AGAATATCCC TATGGTCTCT TCCACCCAGA GTTCTATCTC CTTTATAACA 5460 TCTTCTGTCC AGTCCTCAGG AAGCTTCCAC CAGAGCAGCT CAAAGTTCTT TGCAGGAGGA 5520 CCTCCTGCAT CCAAATTCTG GTCTCTTGGG GAAAAGCCCC AAATCCTCAC CAAGTCCCCA 5580 CAGACTGTGT CCGTCACCGC TGAGACAGAC ACTGTGTTCC CCTGTGAGGC AACAGGAAAA 5640 CCAAAGCCTT TCGTTACTTG GACAAAGGTT TCCACAGGAG CTCTTATGAC TCCGAATACC 5700 AGGATACAAC GGTTTGAGGT TCTCAAGAAC GGTACCTTAG TGATACGGAA GGTTCAAGTA 5760 CAAGATCGAG GCCAGTATAT GTGCACCGCC AGCAACCTGC ACGGCCTGGA CAGGATGGTG 5820 GTCTTGCTTT CGGTCACCGT GCAGCAACCT CAAATCCTAG CCTCCCACTA CCAGGACGTC 5880 ACTGTCTACC TGGGAGACAC CATTGCAATG GAGTGTCTGG CCAAAGGGAC CCCAGCCCCC 5940 CAAATTTCCT GGATCTTCCC TGACAGGAGG GTGTGGCAAA CTGTGTCCCC CGTGGAGAGC 6000 CGCATCACCC TGCACGAAAA CCGGACCCTT TCCATCAAGG AGGCGTCCTT CTCAGACAGA 6060 GGCGTCTATA AGTGCGTGGC CAGCAATGCA GCCGGGGCGG ACAGCCTGGC CATCCGCCTG 6120 CACGTGGCGG CACTGCCCCC CGTTATCCAC CAGGAGAAGC TGGAGAACAT CTCGCTGCCC 6180 CCGGGGCTCA GCATTCACAT TCACTGCACT GCCAAGGCTG CGCCCCTGCC CAGCGTGCGC 6240 TGGGTGCTCG GGGACGGTAC CCAGATCCGC CCCTCGCAGT TCCTCCACGG GAACTTGTTT 6300 GTTTTCCCCA ACGGGACGCT CTACATCCGC AACCTCGCGC CCAAGGACAG CGGGCGCTAT 6360 GAGTGCGTGG CCGCCAACCT GGTAGGCTCC GCGCGCAGGA CGGTGCAGCT GAACGTGCAG 6420 CGTGCAGCAG CCAACGCGCG CATCACGGGC ACCTCCCCGC GGAGGACGGA CGTCAGGTAC 6480 GGAGGAACCC TCAAGCTGGA CTGCAGCGCC TCGGGGGACC CCTGGCCGCG CATCCTCTGG 6540 AGGCTGCCGT CCAAGAGGAT GATCGACGCG CTCTTCAGTT TTGATAGCAG AATCAAGGTG 6600 TTTGCCAATG GGACCCTGGT GGTGAAATCA GTGACGGACA AAGATGCCGG AGATTACCTG 6660 TGCGTAGCTC GAAATAAGGT TGGTGATGAC TACGTGGTGC TCAAAGTGGA TGTGGTGATG 6720 AAACCGGCCA AGATTGAACA CAAGGAGGAG AACGACCACA AAGTCTTCTA CGGGGGTGAC 6780 CTGAAAGTGG ACTGTGTGGC CACCGGGCTT CCCAATCCCG AGATCTCCTG GAGCCTCCCA 6840 GACGGGAGTC TGGTGAACTC CTTCATGCAG TCGGATGACA GCGGTGGACG CACCAAGCGC 6900 TATGTCGTCT TCAACAATGG GACACTCTAC TTTAACGAAG TGGGGATGAG GGAGGAAGGA 6960 GACTACACCT GCTTTGCTGA AAATCAGGTC GGGAAGGACG AGATGAGAGT CAGAGTCAAG 7020 GTGGTGACAG CGCCCGCCAC CATCCGGAAC AAGACTTACT TGGCGGTTCA GGTGCCCTAT 7080 GGAGACGTGG TCACTGTAGC CTGTGAGGCC AAAGGAGAAC CCATGCCCAA GGTGACTTGG 7140 TTGTCCCCAA CCAACAAGGT GATCCCCACC TCCTCTGAGA AGTATCAGAT ATACCAAGAT 7200 GGCACTCTCC TTATTCAGAA AGCCCAGCGT TCTGACAGCG GCAACTACAC CTGCCTGGTC 7260 AGGAACAGCG CGGGAGAGGA TAGGAAGACG GTGTGGATTC ACGTCAACGT CCAGCCACCC 7320 AAGATCAACG GTAACCCCAA CCCCATCACC ACCGTGCGGG AGATAGCAGC CGGGGGCAGT 7380 CGGAAACTGA TTGACTGCAA AGCTGAAGGC ATCCCCACCC CGAGGGTGTT ATGGGCTTTT 7440 CCCGAGGGTG TGGTTCTGCC AGCTCCATAC TATGGAAACC GGATCACTGT CCATGGCAAC 7500 GGTTCCCTGG ACATCAGGAG TTTGAGGAAG AGCGACTCCG TCCAGCTGGT ATGCATGGCA 7560 CGCAACGAGG GAGGGGAGGC GAGGTTGATC GTGCAGCTCA CTGTCCTGGA GCCCATGGAG 7620 AAACCCATCT TCCACGACCC GATCAGCGAG AAGATCACGG CCATGGCGGG CCACACCATC 7680 AGCCTCAACT GCTCTGCCGC GGGGACCCCG ACACCCAGCC TGGTGTGGGT CCTTCCCAAT 7740 GGCACCGATC TGCAGAGTGG ACAGCAGCTG CAGCGCTTCT ACCACAAGGC TGACGGCATG 7800 CTACACATTA GCGGTCTCTC CTCGGTGGAC GCTGGGGCCT ACCGCTGCGT GGCCCGCAAT 7860 GCCGCTGGCC ACACGGAGAG GCTGGTCTCC CTGAAGGTGG GACTGAAGCC AGAAGCAAAC 7920 AAGCAGTATC ATAACCTGGT CAGCATCATC AATGGTGAGA CCCTGAAGCT CCCCTGCACC 7980 CCTCCCGGGG CTGGGCAGGG ACGTTTCTCC TGGACGCTCC CCAATGGCAT GCATCTGGAG 8040 GGCCCCCAAA CCCTGGGACG CGTTTCTCTT CTGGACAATG GCACCCTCAC GGTTCGTGAG 8100 GCCTCGGTGT TTGACAGGGG TACCTATGTA TGCAGGATGG AGACGGAGTA CGGCCCTTCG 8160 GTCACCAGCA TCCCCGTGAT TGTGATCGCC TATCCTCCCC GGATCACCAG CGAGCCCACC 8220 CCGGTCATCT ACACCCGGCC CGGGAACACC GTGAAACTGA ACTGCATGGC TATGGGGATT 8280 CCCAAAGCTG ACATCACGTG GGAGTTACCG GATAAGTCGC ATCTGAAGGC AGGGGTTCAG 8340 GCTCGTCTGT ATGGAAACAG ATTTCTTCAC CCCCAGGGAT CACTGACCAT CCAGCATGCC 8400 ACACAGAGAG ATGCCGGCTT CTACAAGTGC ATGGCAAAAA ACATTCTCGG CAGTGACTCC 8460 AAAACAACTT ACATCCACGT CTTCTGAAAT GTGGATTCCA GAATGATTGC TTAGGAACTG 8520 ACAACAAAGC GGGGTTTGTA AGGGAAGCCA GGTTGGGGAA TAGGAGCTCT TAAATAATGT 8580 GTCACAGTGC ATGGTGGCCT CTGGTGGGTT TCAAGTTGAG GTTGATCTTG ATCTACAATT 8640 GTTGGGAAAA GGAAGCAATG CAGACACGAG AAGGAGGGCT CAGCCTTGCT GAGACACTTT 8700 CTTTTGTGTT TACATCATGC CAGGGGCTTC ATTCAGGGTG TCTGTGCTCT GACTGCAATT 8760 TTTCTTCTTT TGCAAATGCC ACTCGACTGC CTTCATAAGC GTCCATAGGA TATCTGAGGA 8820 ACATTCATCA AAAATAAGCC ATAGACATGA ACAACACCTC ACTACCCCAT TGAAGACGCA 8880 TCACCTAGTT AACCTGCTGC AGTTTTTACA TGATAGACTT TGTTCCAGAT TGACAAGTCA 8940 TCTTTCAGTT ATTTCCTCTG TCACTTCAAA ACTCCAGCTT GCCCAATAAG GATTTAGAAC 9000 CAGAGTGACT GATATATATA TATATATTTT AATTCAGAGT TACATACATA CAGCTACCAT 9060 TTTATATGAA AAAAGAAAAA CATTTCTTCC TGGAACTCAC TTTTTATATA ATGTTTTATA 9120 TATATATTTT TTCCTTTCAA ATCAGACGAT GAGACTAGAA GGAGAAATAC TTTCTGTCTT 9180 ATTAAAATTA ATAAATTATT GGTCTTTACA AGACTTGGAT ACATTACAGC AGACATGGAA 9240 ATATAATTTT AAAAAATTTC TCTCCAACCT CCTTCAAATT CAGTCACCAC TGTTATATTA 9300 CCTTCTCCAG GAACCCTCCA GTGGGGAAGG CTGCGATATT AGATTTCCTT GTATGCAAAG 9360 TTTTTGTTGA AAGCTGTGCT CAGAGGAGGT GAGAGGAGAG GAAGGAGAAA ACTGCATCAT 9420 AACTTTACAG AATTGAATCT AGAGTCTTCC CCGAAAAGCC CAGAAACTTC TCTGCAGTAT 9480 CTGGCTTGTC CATCTGGTCT AAGGTGGCTG CTTCTTCCCC AGCCATGAGT CAGTTTGTGC 9540 CCATGAATAA TACACGACCT GTTATTTCCA TGACTGCTTT ACTGTATTTT TAAGGTCAAT 9600 ATACTGTACA TTTGATAATA AAATAATATT CTCCCAAAAA AAAAA Seq ID NO : 417 Protein sequence Protein Accession # : NP 056234. 1 1 11 21 31 41 51 MPKRAHWGAL SWLILLWGH PRVALACPHP CACYVPSEVH CTFRSLASVP AGIARHVERI 60 NLGFNSIQAL SETSFAGLTK LELLMIHGNE IPSIPDGALR DLSSLQVFKF SYNKLRVITG 120 QTLQGLSNLM RLHIDHNKIE FIHPQAFNGL TSLRLLHLEG NLLHQLHPST FSTFTFLDYF 180 RLSTIRHLYL AENMVRTLPA SMLRNMPLLE NLYLQGNPWT CDCEMRWFLE WDAKSRGILK 240

ARAKEAAASL PKHQQVBSPT GAGAGGDHRS QRGHAASPAR PSRPGGPQSR ARVPSRAAPG 1020 KSEPPSKRPL SSKSQQSVSA EDEEEEDAGF FKGGKEDLLS SSVPKWPSSS TPRGGKDADG 1080 SLAKEEREPA IALAPRGGSL APVKRPLPPP PGSSPRASHV PSRPPPRSAA TVSPVAGTHP 1140 WPRYTTRAPP GHFSTTPMLS LRQRMMHARF RNPLSRQPAR PSYRQGYNGR PNVEGKVLPG 1200 SNGKPNGQRI INGPQGTKWV VDLDRGLVLN AEGRYLQDSH GNPLRIKLGG DGRTIVDLEG 1260 TPWSPDGLP LFGQGRHGTP LANAQDKPIL SLGGKPLVGL EVIKKTTHPP TTTMQPTTTT 1320 TPLPTTTTPR PTTATTMQPT TTTTPLPTTT PRPTTATTRR TTTRRPTTTV RTTTRTTTTT 1380 TPKPTTPIPT CPPGTLERHD DDGNLIMSSN GIPECYAEED EFSGLETDTA VPTEEAYVIY 1440 DEDYEFETSR PPTTTEPSTT ATTPRVIPEE GAISSFPEEE FDLAGRKRFV APYVTYLNKD 1500 PSAPCSLTDA LDHFQVDSLD EIIPNDLKKS DLPPQHAPRN ITWAVEGCH SFVIVDWDKA 1560 TPGDLVTGYL VYSASYEDFI RNKFSTQASS VTHLPIENLK PNTRYYFKVQ AQNPHGYGPI 1620 SPSVSFVTES DNPLLWRPP GGELSGSHSL SNMIPATRTA MDGNM Seq ID NO : 420 DNA sequence Nucleic Acid Accession # : NM 022743 Coding sequence: 128.. 1237 1 11 21 31 41 51 GTGGATTTTA GAGATACCTC CCCTCCTTCT GCTCAGCTGC CTTGCAGTAA TTAAACTCTT 60 TCTCTGCTGC AACACCCCTA CTGTTCTCCG TGTATTGGCT TTTCTGGGCA GCAGGAAGGA 120 AAAGCTGATG CGATGCTCTC AGTGCCGCGT CGCCAAATAC TGTAGTGCTA AGTGTCAGAA 180 AAAAGCTTGG CCAGACCACA AGCGGGAATG CAAATGCCTT AAAAGCTGCA AACCCAGATA 240 TCCTCCAGAC TCCGTTCGAC TTCTTGGCAG AGTTGTCTTC AAACTTATGG ATGGAGCACC 300 TTCAGAATCA GAGAAGCTTT ACTCATTTTA TGATCTGGAG TCAAATATTA ACAAACTGAC 360 TGAAGATAAG AAAGAGGGCC TCAGGCAACT CGTAATGACA TTTCAACATT TCATGAGAGA 420 AGAAATACAG GATGCCTCTC AGCTGCCACC TGCCTTTGAC CTTTTTGAAG CCTTTGCAAA 480 AGTGATCTGC AACTCTTTCA CCATCTGTAA TGCGGAGATG CAGGAAGTTG GTGTTGGCCT 540 ATATCCCAGT ATCTCTTTGC TCAATCACAG CTGTGACCCC AACTGTTCGA TTGTGTTCAA 600 TGGGCCCCAC CTCTTACTGC GAGCAGTCCG AGACATCGAG GTGGGAGAGG AGCTCACCAT 660 CTGCTACCTG GATATGCTGA TGACCAGTGA GGAGCGCCGG AAGCAGCTGA GGGACCAGTA 720 CTGCTTTGAA TGTGACTGTT TCCGTTGCCA AACCCAGGAC AAGGATGCTG ATATGCTAAC 780 TGGTGATGAG CAAGTATGGA AGGAAGTTCA AGAATCCCTG AAAAAAATTG AAGAACTGAA 840 GGCACACTGG AAGTGGGAGC AGGTTCTGGC CATGTGCCAG GCGATCATAA GCAGCAATTC 900 TGAACGGCTT CCCGATATCA ACATCTACCA GCTGAAGGTG CTCGACTGCG CCATGGATGC 960 CTGCATCAAC CTCGGCCTGT TGGAGGAAGC CTTGTTCTAT GGTACTCGGA CCATGGAGCC 1020 ATACAGGATT TTTTTCCCAG GAAGCCATCC CGTCAGAGGG GTTCAAGTGA TGAAAGTTGG 1080 CAAACTGCAG CTACATCAAG GCATGTTTCC CCAAGCAATG AAGAATCTGA GACTGGCTTT 1140 TGATATTATG AGAGTGACAC ATGGCAGAGA ACACAGCCTG ATTGAAGATT TGATTCTACT 1200 TTTAGAAGAA TGCGACGCCA ACATCAGAGC ATCCTAAGGG AACGCAGTCA GAGGGAAATA 1260 CGGCGTGTGT CTTTGTTGAA TGCCTTATTG AGGTCACACA CTCTATGCTT TGTTAGCTGT 1320 GTGAACCTCT CTTATTGGAA ATTCTGTTCC'GTGTTTGTGT AGGTAAATAA AGGCAGACAT 1380 GGTTTGCAAA CCACAAGAAT CATTAGTTGT AGAGAAGCAC GATTATAATA AATTCAAAAC 1440 ATTTGGTTGA GGATGCCAAA AAAAAAAAAA AAAAAAA Seq ID NO : 421 Protein sequence Protein Accession &num : NP 073580 1 11 21 31 41 51 MRCSQCRVAK YCSAKCQKKA WPDHKRECKC LKSCKPRYPP DSVRLLGRW FKLMDGAPSE 60 SEKLYSFYDL ESNINKLTED KKEGLRQLVM TFQHFMREEI QDASQLPPAF DLFEAFAKVI 120 CNSFTICNAE MQEVGVGLYP SISLLNHSCD PNCSIVFNGP HLLLRAVRDI EVGEELTICY 180 LDMLMTSEER RKQLRDQYCF ECDCFRCQTQ DKDADMLTGD EQVWKEVQES LKKIEELKAH 240 WKWEQVLAMC QAIISSNSER LPDINIYQLK VLDCAMDACI NLGLLEEALF YGTRTMEPYR 300 IFFPGSHPVR GVQVMKVGKL QLHQGMFPQA MKNLRLAFDI MRVTHGREHS LIEDLILLLE 360 ECDANIRAS Seq ID NO : 422 DNA sequence Nucleic Acid Accession &num NM 003014. 2 Coding sequence: 238.. 648 1 11 21 31 41 51 # # # # # # GGCGGGTTCG CGCCCCGAAG GCTGAGAGCT GGCGCTGCTC GTGCCCTGTG TGCCAGACGG 60 CGGAGCTCCG CGGCCGGACC CCGCGGCCCC GCTTTGCTGC CGACTGGAGT TTGGGGGAAG 120 AAACTCTCCT GCGCCCCAGA AGATTTCTTC CTCGGCGAAG GGACAGCGAA AGATGAGGGT 180 GGCAGGAAGA GAAGGCGCTT TCTGTCTGCC GGGGTCGCAG CGCGAGAGGG CAGTGCCATG 240 TTCCTCTCCA TCCTAGTGGC GCTGTGCCTG TGGCTGCACC TGGCGCTGGG CGTGCGCGGC 300 GCGCCCTGCG AGGCGGTGCG CATCCCTATG TGCCGGCACA TGCCCTGGAA CATCACGCGG 360 ATGCCCAACC ACCTGCACCA CAGCACGCAG GAGAACGCCA TCCTGGCCAT CGAGCAGTAC 420 GAGGAGCTGG TGGACGTGAA CTGCAGCGCC GTGCTGCGCT TCTTCTTCTG TGCCATGTAC 480 GCGCCCATTT GCACCCTGGA GTTCCTGCAC GACCCTATCA AGCCGTGCAA GTCGGTGTGC 540 CAACGCGCGC GCGACGACTG CGAGCCCCTC ATGAAGATGT ACAACCACAG CTGGCCCGAA 600 AGCCTGGCCT GCGACGAGCT GCCTGTCTAT GACCGTGGCG TGTGCATTTC GCCTGAAGCC 660 ATCGTCACGG ACCTCCCGGA GGATGTTAAG TGGATAGACA TCACACCAGA CATGATGGTA 720 CAGGAAAGGC CTCTTGATGT TGACTGTAAA CGCCTAAGCC CCGATCGGTG CAAGTGTAAA 780 AAGGTGAAGC CAACTTTGGC AACGTATCTC AGCAAAAACT ACAGCTATGT TATTCATGCC 840 AAAATAAAAG CTGTGCAGAG GAGTGGCTGC AATGAGGTCA CAACGGTGGT GGATGTAAAA 900 GAGATCTTCA AGTCCTCATC ACCCATCCCT CGAACTCAAG TCCCGCTCAT TACAAATTCT 960 TCTTGCCAGT GTCCACACAT CCTGCCCCAT CAAGATGTTC TCATCATGTG TTACGAGTGG 1020 CGTTCAAGGA TGATGCTTCT TGAAAATTGC TTAGTTGAAA AATGGAGAGA TCAGCTTAGT 1080 AAAAGATCCA TACAGTGGGA AGAGAGGCTG CAGGAACAGC GGAGAACAGT TCAGGACAAG 1140 AAGAAAACAG CCGGGCGCAC CAGTCGTAGT AATCCCCCCA AACCAAAGGG AAAGCCTCCT 1200 GCTCCCAAAC CAGCCAGTCC CAAGAAGAAC ATTAAAACTA GGAGTGCCCA GAAGAGAACA 1260 AACCCGAAAA GAGTGTGAGC TAACTAGTTT CCAAAGCGGA GACTTCCGAC TTCCTTACAG 1320 GATGAGGCTG GGCATTGCCT GGGACAGCCT ATGTAAGGCC ATGTGCCCCT TGCCCTAACA 1380

ACTCACTGCA GTGCTCTTCA TAGACACATC TTGCAGCATT TTTCTTAAGG CTATGCTTCA 1440 GTTTTTCTTT GTAAGCCATC ACAAGCCATA GTGGTAGGTT TGCCCTTTGG TACAGAAGGT 1500 GAGTTAAAGC TGGTGGAAAA GGCTTATTGC ATTGCATTCA GAGTAACCTG TGTGCATACT 1560 CTAGAAGAGT AGGGAAAATA ATGCTTGTTA CAATTCGACC TAATATGTGC ATTGTAAAAT 1620 AAATGCCATA TTTCAAACAA AACACGTAAT TTTTTTACAG TATGTTTTAT TACCTTTTGA 1680 TATCTGTTGT TGCAATGTTA GTGATGTTTT AAAATGTGAT GAAAATATAA TGTTTTTAAG 1740 AAGGAACAGT AGTGGAATGA ATGTTAAAAG ATCTTTATGT GTTTATGGTC TGCAGAAGGA 1800 TTTTTGTGAT GAAAGGGGAT TTTTTGAAAA ATTAGAGAAG TAGCATATGG AAAATTATAA 1860 TGTGTTTTTT TACCAATGAC TTCAGTTTCT GTTTTTAGCT AGAAACTTAA AAACAAAAAT 1920 AATAATAAAG AAAAATAAAT AAAAAGGAGA GGCAGACAAT GTCTGGATTC CTGTTTTTTG 1980 GTTACCTGAT TTCCATGATC ATGATGCTTC TTGTCAACAC CCTCTTAAGC AGCACCAGAA 2040 ACAGTGAGTT TGTCTGTACC ATTAGGAGTT AGGTACTAAT TAGTTGGCTA ATGCTCAAGT 2100 ATTTTATACC CACAAGAGAG GTATGTCACT CATCTTACTT CCCAGGACAT CCACCCTGAG 2160 AATAATTTGA CAAGCTTAAA AATGGCCTTC ATGTGAGTGC CAAATTTTGT TTTTCTTCAT 2220 TTAAATATTT TCTTTGCCTA AATACATGTG AGAGGAGTTA AATATAAATG TACAGAGAGG 2280 AAAGTTGAGT TCCACCTCTG AAATGAGAAT TACTTGACAG TTGGGATACT TTAATCAGAA 2340 AAAAAGAACT TATTTGCAGC ATTTTATCAA CAAATTTCAT AATTGTGGAC AATTGGAGGC 2400 ATTTATTTTA AAAAACAATT TTATTGGCCT TTTGCTAACA CAGTAAGCAT GTATTTTATA 2460 AGGCATTCAA TAAATGCACA ACGCCCAAAG GAAATAAAAT CCTATCTAAT CCTACTCTCC 2520 ACTACACAGA GGTAATCACT ATTAGTATTT TGGCATATTA TTCTCCAGGT GTTTGCTTAT 2580 GCACTTATAA AATGATTTGA ACAAATAAAA CTAGGAACCT GTATACATGT GTTTCATAAC 2640 CTGCCTCCTT TGCTTGGCCC TTTATTGAGA TAAGTTTTCC TGTCAAGAAA GCAGAAACCA 2700 TCTCATTTCT AACAGCTGTG TTATATTCCA TAGTATGCAT TACTCAACAA ACTGTTGTGC 2760 TATTGGATAC TTAGGTGGTT TCTTCACTGA CAATACTGAA TAAACATCTC ACCGGAATTC Seq ID NO : 423 Protein sequence Protein Accession &num : NP 003005. 1 1 11 21 31 41 51 MFLSILVALC LWLHLALGVR GAPCEAVRIP MCRHMPWNIT RMPNHLHHST QENAILAIEQ 60 YEELVDVNCS AVLRFFFCAM YAPICTLEFL HDPIKPCKSV CQRARDDCEP LMKMYNHSWP 120 ESLACDELPV YDRGVCISPE AIVTDLPEDV KWIDITPDMM VQERPLDVDC KRLSPDRCKC 180 KKVKPTLATY LSKNYSYVIH AKIKAVQRSG CNEVTTWDV KEIFKSSSPI PRTQVPLITN 240 SSCQCPHILP HQDVLIMCYE WRSRMMLLEN CLVEKWRDQL SKRSIQWEER LQEQRRTVQD 300 KKKTAGRTSR SNPPKPKGKP PAPKPASPKK NIKTRSAQKR TNPKRV Seq ID NO : 424 DNA sequence Nucleic Acid Accession &num : BC010423 Coding sequence: 248.. 1780 1 11 21 31 41 51 CACAGCGTGG GAAGCAGCTC TGGGGGAGCT CGGAGCTCCC GATCACGGCT TCTTGGGGGT 60 AGCTACGGCT GGGTGTGTAG AACGGGGCCG GGGCTGGGGC TGGGTCCCCT AGTGGAGACC 120 CAAGTGCGAG AGGCAAGAAC TCTGCAGCTT CCTGCCTTCT GGGTCAGTTC CTTATTCAAG 180 TCTGCAGCCG GCTCCCAGGG AGATCTCGGT GGAACTTCAG AAACGCTGGG CAGTCTGCCT 240 TTCAACCATG CCCCTGTCCC TGGGAGCCGA GATGTGGGGG CCTGAGGCCT GGCTGCTGCT 300 GCTGCTACTG CTGGCATCAT TTACAGGCCG GTGCCCCGCG GGTGAGCTGG AGACCTCAGA 360 CGTGGTAACT GTGGTGCTGG GCCAGGACGC AAAACTGCCC TGCTTCTACC GAGGGGACTC 420 CGGCGAGCAA GTGGGGCAAG TGGCATGGGC TCGGGTGGAC GCGGGCGAAG GCGCCCAGGA 480 ACTAGCGCTA CTGCACTCCA AATACGGGCT TCATGTGAGC CCGGCTTACG AGGGCCGCGT 540 GGAGCAGCCG CCGCCCCCAC GCAACCCCCT GGACGGCTCA GTGCTCCTGC GCAACGCAGT 600 GCAGGCGGAT GAGGGCGAGT ACGAGTGCCG GGTCAGCACC TTCCCCGCCG GCAGCTTCCA 660 GGCGCGGCTG CGGCTCCGAG TGCTGGTGCC TCCCCTGCCC TCACTGAATC CTGGTCCAGC 720 ACTAGAAGAG GGCCAGGGCC TGACCCTGGC AGCCTCCTGC ACAGCTGAGG GCAGCCCAGC 780 CCCCAGCGTG ACCTGGGACA CGGAGGTCAA AGGCACAACG TCCAGCCGTT CCTTCAAGCA 840 CTCCCGCTCT GCTGCCGTCA CCTCAGAGTT CCACTTGGTG CCTAGCCGCA GCATGAATGG 900 GCAGCCACTG ACTTGTGTGG TGTCCCATCC TGGCCTGCTC CAGGACCAAA GGATCACCCA 960 CATCCTCCAC GTGTCCTTCC TTGCTGAGGC CTCTGTGAGG GGCCTTGAAG ACCAAAATCT 1020 GTGGCACATT GGCAGAGAAG GAGCTATGCT CAAGTGCCTG AGTGAAGGGC AGCCCCCTCC 1080 CTCATACAAC TGGACACGGC TGGATGGGCC TCTGCCCAGT GGGGTACGAG TGGATGGGGA 1140 CACTTTGGGC TTTCCCCCAC TGACCACTGA GCACAGCGGC ATCTACGTCT GCCATGTCAG 1200 CAATGAGTTC TCCTCAAGGG ATTCTCAGGT CACTGTGGAT GTTCTTGACC CCCAGGAAGA 1260 CTCTGGGAAG CAGGTGGACC TAGTGTCAGC CTCGGTGGTG GTGGTGGGTG TGATCGCCGC 1320 ACTCTTGTTC TGCCTTCTGG TGGTGGTGGT GGTGCTCATG TCCCGATACC ATCGGCGCAA 1380 GGCCCAGCAG ATGACCCAGA AATATGAGGA GGAGCTGACC CTGACCAGGG AGAACTCCAT 1440 CCGGAGGCTG CATTCCCATC ACACGGACCC CAGGAGCCAG CCGGAGGAGA GTGTAGGGCT 1500 GAGAGCCGAG GGCCACCCTG ATAGTCTCAA GGACAACAGT AGCTGCTCTG TGATGAGTGA 1560 AGAGCCCGAG GGCCGCAGTT ACTCCACGCT GACCACGGTG AGGGAGATAG AAACACAGAC 1620 TGAACTGCTG TCTCCAGGCT CTGGGCGGGC CGAGGAGGAG GAAGATCAGG ATGAAGGCAT 1680 CAAACAGGCC ATGAACCATT TTGTTCAGGA GAATGGGACC CTACGGGCCA AGCCCACGGG 1740 CAATGGCATC TACATCAATG GGCGGGGACA CCTGGTCTGA CCCAGGCCTG CCTCCCTTCC 1800 CTAGGCCTGG CTCCTTCTGT TGACATGGGA GATTTTAGCT CATCTTGGGG GCCTCCTTAA 1860 ACACCCCCAT TTCTTGCGGA AGATGCTCCC CATCCCACTG ACTGCTTGAC CTTTACCTCC 1920 AACCCTTCTG TTCATCGGGA GGGCTCCACC AATTGAGTCT CTCCCACCAT GCATGCAGGT 1980 CACTGTGTGT GTGCATGTGT GCCTGTGTGA GTGTTGACTG ACTGTGTGTG TGTGGAGGGG 2040 TGACTGTCCG TGGAGGGGTG ACTGTGTCCG TGGTGTGTAT TATGCTGTCA TATCAGAGTC 2100 AAGTGAACTG TGGTGTATGT GCCACGGGAT TTGAGTGGTT GCGTGGGCAA CACTGTCAGG 2160 GTTTGGCGTG TGTGTCATGT GGCTGTGTGT GACCTCTGCC TGAAAAAGCA GGTATTTTCT 2220 CAGACCCCAG AGCAGTATTA ATGATGCAGA GGTTGGAGGA GAGAGGTGGA GACTGTGGCT 2280 CAGACCCAGG TGTGCGGGCA TAGCTGGAGC TGGAATCTGC CTCCGGTGTG AGGGAACCTG 2340 TCTCCTACCA CTTCGGAGCC ATGGGGGCAA GTGTGAAGCA GCCAGTCCCT GGGTCAGCCA 2400 GAGGCTTGAA CTGTTACAGA AGCCCTCTGC CCTCTGGTGG CCTCTGGGCC TGCTGCATGT 2460 ACATATTTTC TGTAAATATA CATGCGCCGG GAGCTTCTTG CAGGAATACT GCTCCGAATC 2520 ACTTTTAATT TTTTTCTTTT TTTTTTCTTG CCCTTTCCAT TAGTTGTATT TTTTATTTAT 2580 TTTTATTTTT ATTTTTTTTT AGAGTTTGAG TCCAGCCTGG ACGATATAGC CAGACCCTGT 2640

CTGTAAAAAA ACCAAAACCC AAAAAAAAAA AAAAAAAAAA Seq ID NO : 425 Protein sequence Protein Accession # : AAH10423 1 11 21 31 41 51 I MPLSLGAEMW GPEAWLLLLL LLASFTGRCP AGELETSDW TWLGQDAKL PCFYRGDSGE 60 QVGQVAWARV DAGEGAQELA LLHSKYGLHV SPAYEGRVEQ PPPPRNPLDG SVLLRNAVQA 120 DEGEYECRVS TFPAGSFQAR LRLRVLVPPL PSLNPGPALE EGQGLTLAAS CTAEGSPAPS 180 VTWDTEVKGT TSSRSFKHSR SAAVTSEFHL VPSRSMNGQP LTCWSHPGL LQDQRITHIL 240 HVSFLAEASV RGLEDQNLWH IGREGAMLKC LSEGQPPPSY NWTRLDGPLP SGVRVDGDTL 300 GFPPLTTEHS GIYVCHVSNE FSSRDSQVTV DVLDPQEDSG KQVDLVSASV WVGVIAALL 360 FCLLWVWL MSRYHRRKAQ QMTQKYEEEL TLTRENSIRR LHSHHTDPRS QPEESVGLRA 420 EGHPDSLKDN SSCSVMSEEP EGRSYSTLTT VREIETQTEL LSPGSGRAEE EEDQDEGIKQ 480 AMNHFVQENG TLRAKPTGNG IYINGRGHLV Seq ID NO : 426 DNA sequence Nucleic Acid Accession # : NM 003474. 2 Coding sequence: 37.. 3036 1 11 21 31 41 51 # # # # # # CACTAACGCT CTTCCTAGTC CCCGGGCCAA CTCGGACAGT TTGCTCATTT ATTGCAACGG 60 TCAAGGCTGG CTTGTGCCAG AACGGCGCGC GCGCGACGCA CGCACACACA CGGGGGGAAA 120 CTTTTTTAAA AATGAAAGGC TAGAAGAGCT CAGCGGCGGC GCGGGCCGTG CGCGAGGGCT 180 CCGGAGCTGA CTCGCCGAGG CAGGAAATCC CTCCGGTCGC GACGCCCGGC CCCGCTCGGC 240 GCCCGCGTGG GATGGTGCAG CGCTCGCCGC CGGGCCCGAG AGCTGCTGCA CTGAAGGCCG 300 GCGACGATGG CAGCGCGCCC GCTGCCCGTG TCCCCCGCCC GCGCCCTCCT GCTCGCCCTG 360 GCCGGTGCTC TGCTCGCGCC CTGCGAGGCC CGAGGGGTGA GCTTATGGAA CGAAGGAAGA 420 GCTGATGAAG TTGTCAGTGC CTCTGTTCGG AGTGGGGACC TCTGGATCCC AGTGAAGAGC 480 TTCGACTCCA AGAATCATCC AGAAGTGCTG AATATTCGAC TACAACGGGA AAGCAAAGAA 540 CTGATCATAA ATCTGGAAAG AAATGAAGGT CTCATTGCCA GCAGTTTCAC GGAAACCCAC 600 TATCTGCAAG ACGGTACTGA TGTCTCCCTC GCTCGAAATT ACACGGTAAT TCTGGGTCAC 660 TGTTACTACC ATGGACATGT ACGGGGATAT TCTGATTCAG CAGTCAGTCT CAGCACGTGT 720 TCTGGTCTCA GGGGACTTAT TGTGTTTGAA AATGAAAGCT ATGTCTTAGA ACCAATGAAA 780 AGTGCAACCA ACAGATACAA ACTCTTCCCA GCGAAGAAGC TGAAAAGCGT CCGGGGATCA 840 TGTGGATCAC ATCACAACAC ACCAAACCTC GCTGCAAAGA ATGTGTTTCC ACCACCCTCT 900 CAGACATGGG CAAGAAGGCA TAAAAGAGAG ACCCTCAAGG CAACTAAGTA TGTGGAGCTG 960 GTGATCGTGG CAGACAACCG AGAGTTTCAG AGGCAAGGAA AAGATCTGGA AAAAGTTAAG 1020 CAGCGATTAA TAGAGATTGC TAATCACGTT GACAAGTTTT ACAGACCACT GAACATTCGG 1080 ATCGTGTTGG TAGGCGTGGA AGTGTGGAAT GACATGGACA AATGCTCTGT AAGTCAGGAC 1140 CCATTCACCA GCCTCCATGA ATTTCTGGAC TGGAGGAAGA TGAAGCTTCT ACCTCGCAAA 1200 TCCCATGACA ATGCGCAGCT TGTCAGTGGG GTTTATTTCC AAGGGACCAC CATCGGCATG 1260 GCCCCAATCA TGAGCATGTG CACGGCAGAC CAGTCTGGGG GAATTGTCAT GGACCATTCA 1320 GACAATCCCC TTGGTGCAGC CGTGACCCTG GCACATGAGC TGGGCCACAA TTTCGGGATG 1380 AATCATGACA CACTGGACAG GGGCTGTAGC TGTCAAATGG CGGTTGAGAA AGGAGGCTGC 1440 ATCATGAACG CTTCCACCGG GTACCCATTT CCCATGGTGT TCAGCAGTTG CAGCAGGAAG 1500 GACTTGGAGA CCAGCCTGGA GAAAGGAATG GGGGTGTGCC TGTTTAACCT GCCGGAAGTC 1560 AGGGAGTCTT TCGGGGGCCA GAAGTGTGGG AACAGATTTG TGGAAGAAGG AGAGGAGTGT 1620 GACTGTGGGG AGCCAGAGGA ATGTATGAAT CGCTGCTGCA ATGCCACCAC CTGTACCCTG 1680 AAGCCGGACG CTGTGTGCGC ACATGGGCTG TGCTGTGAAG ACTGCCAGCT GAAGCCTGCA 1740 GGAACAGCGT GCAGGGACTC CAGCAACTCC TGTGACCTCC CAGAGTTCTG CACAGGGGCC 1800 AGCCCTCACT GCCCAGCCAA CGTGTACCTG CACGATGGGC ACTCATGTCA GGATGTGGAC 1860 GGCTACTGCT ACAATGGCAT CTGCCAGACT CACGAGCAGC AGTGTGTCAC ACTCTGGGGA 1920 CCAGGTGCTA AACCTGCCCC TGGGATCTGC TTTGAGAGAG TCAATTCTGC AGGTGATCCT 1980 TATGGCAACT GTGGCAAAGT CTCGAAGAGT TCCTTTGCCA AATGCGAGAT GAGAGATGCT 2040 AAATGTGGAA AAATCCAGTG TCAAGGAGGT GCCAGCCGGC CAGTCATTGG TACCAATGCC 2100 GTTTCCATAG AAACAAACAT CCCCCTGCAG CAAGGAGGCC GGATTCTGTG CCGGGGGACC 2160 CACGTGTACT TGGGCGATGA CATGCCGGAC CCAGGGCTTG TGCTTGCAGG CACAAAGTGT 2220 GCAGATGGAA AAATCTGCCT GAATCGTCAA TGTCAAAATA TTAGTGTCTT TGGGGTTCAC 2280 GAGTGTGCAA TGCAGTGCCA CGGCAGAGGG GTGTGCAACA ACAGGAAGAA CTGCCACTGC 2340 GAGGCCCACT GGGCACCTCC CTTCTGTGAC AAGTTTGGCT TTGGAGGAAG CACAGACAGC 2400 GGCCCCATCC GGCAAGCAGA TAACCAAGGT TTAACCATAG GAATTCTGGT GACCATCCTG 2460 TGTCTTCTTG CTGCCGGATT TGTGGTTTAT CTCAAAAGGA AGACCTTGAT ACGACTGCTG 2520 TTTACAAATA AGAAGACCAC CATTGAAAAA CTAAGGTGTG TGCGCCCTTC CCGGCCACCC 2580 CGTGGCTTCC AACCCTGTCA GGCTCACCTC GGCCACCTTG GAAAAGGCCT GATGAGGAAG 2640 CCGCCAGATT CCTACCCACC GAAGGACAAT CCCAGGAGAT TGCTGCAGTG TCAGAATGTT 2700 GACATCAGCA GACCCCTCAA CGGCCTGAAT GTCCCTCAGC CCCAGTCAAC TCAGCGAGTG 2760 CTTCCTCCCC TCCACCGGGC CCCACGTGCA CCTAGCGTCC CTGCCAGACC CCTGCCAGCC 2820 AAGCCTGCAC TTAGGCAGGC CCAGGGGACC TGTAAGCCAA ACCCCCCTCA GAAGCCTCTG 2880 CCTGCAGATC CTCTGGCCAG AACAACTCGG CTCACTCATG CCTTGGCCAG GACCCCAGGA 2940 CAATGGGAGA CTGGGCTCCG CCTGGCACCC CTCAGACCTG CTCCACAATA TCCACACCAA 3000 GTGCCCAGAT CCACCCACAC CGCCTATATT AAGTGAGAAG CCGACACCTT TTTTCAACAG 3060 TGAAGACAGA AGTTTGCACT ATCTTTCAGC TCCAGTTGGA GTTTTTTGTA CCAACTTTTA 3120 GGATTTTTTT TAATGTTTAA AACATCATTA CTATAAGAAC TTTGAGCTAC TGCCGTCAGT 3180 GCTGTGCTGT GCTATGGTGC TCTGTCTACT TGCACAGGTA CTTGTAAATT ATTAATTTAT 3240 GCAGAATGTT GATTACAGTG CAGTGCGCTG TAGTAGGCAT TTTTACCATC ACTGAGTTTT 3300 CCATGGCAGG AAGGCTTGTT GTGCTTTTAG TATTTTAGTG AACTTGAAAT ATCCTGCTTG 3360 ATGGGATTCT GGACAGGATG TGTTTGCTTT CTGATCAAGG CCTTATTGGA AAGCAGTCCC 3420 CCAACTACCC CCAGCTGTGC TTATGGTACC AGATGCAGCT CAAGAGATCC CAAGTAGAAT 3480 CTCAGTTGAT TTTCTGGATT CCCCATCTCA GGCCAGAGCC AAGGGGCTTC AGGTCCAGGC 3540 TGTGTTTGGC TTTCAGGGAG GCCCTGTGCC CCTTGACAAC TGGCAGGCAG GCTCCCAGGG 3600 ACACCTGGGA GAAATCTGGC TTCTGGCCAG GAAGCTTTGG TGAGAACCTG GGTTGCAGAC 3660 AGGAATCTTA AGGTGTAGCC ACACCAGGAT AGAGACTGGA ACACTAGACA AGCCAGAACT 3720 TGACCCTGAG CTGACCAGCC GTGAGCATGT TTGGAAGGGG TCTGTAGTGT CACTCAAGGC 3780 GGTGCTTGAT AGAAATGCCA AGCACTTCTT TTTCTCGCTG TCCTTTCTAG AGCACTGCCA 3840

CCAGTAGGTT ATTTAGCTTG GGAAAGGTGG TGTTTCTGTA AGAAACCTAC TGCCCAGGCA 3900 CTGCAAACCG CCACCTCCCT ATACTGCTTG GAGCTGAGCA AATCACCACA AACTGTAATA 3960 CAATGATCCT GTATTCAGAC AGATGAGGAC TTTCCATGGG ACCACAACTA TTTTCAGATG 4020 TGAACCATTA ACCAGATCTA GTCAATCAAG TCTGTTTACT GCAAGGTTCA ACTTATTAAC 4080 AATTAGGCAG ACTCTTTATG CTTGCAAAAA CTACAACCAA TGGAATGTGA TGTTCATGGG 4140 TATAGTTCAT GTCTGCTATC ATTATTCGTA GATATTGGAC AAAGAACCTT CTCTATGGGG 4200 CATCCTCTTT TTCCAACTTG GCTGCAGGAA TCTTTAAAAG ATGCTTTTAA CAGAGTCTGA 4260 ACCTATTTCT TAAACACTTG CAACCTACCT GTTGAGCATC ACAGAATGTG ATAAGGAAAT 4320 CAACTTGCTT ATCAACTTCC TAAATATTAT GAGATGTGGC TTGGGCAGCA TCCCCTTGAA 4380 CTCTTCACTC TTCAAATGCC TGACTAGGGA GCCATGTTTC ACAAGGTCTT TAAAGTGACT 4440 AATGGCATGA GAAATACAAA AATACTCAGA TAAGGTAAAA TGCCATGATG CCTCTGTCTT 4500 CTGGACTGGT TTTCACATTA GAAGACAATT GACAACAGTT ACATAATTCA CTCTGAGTGT 4560 TTTATGAGAA AGCCTTCTTT TGGGGTCAAC AGTTTTCCTA TGCTTTGAAA CAGAAAAATA 4620 TGTACCAAGA ATCTTGGTTT GCCTTCCAGA AAACAAAACT GCATTTCACT TTCCCGGTGT 4680 TCCCCACTGT ATCTAGGCAA CATAGTATTC ATGACTATGG ATAAACTAAA CACGTGACAC 4740 AAACACACAC AAAAGGGAAC CCAGCTCTAA TACATTCCAA CTCGTATAGC ATGCATCTGT 4800 TTATTCTATA GTTATTAAGT TCTTTAAAAT GTAAAGCCAT GCTGGAAAAT AATACTGCTG 4860 AGATACATAC AGAATTACTG TAACTGATTA CACTTGGTAA TTGTACTAAA GCCAAACATA 4920 TATATACTAT TAAAAAGGTT TACAGAATTT TATGGTGCAT TACGTGGGCA TTGTCTTTTT 4980 AGATGCCCAA ATCCTTAGAT CTGGCATGTT AGCCCTTCCT CCAATTATAA GAGGATATGA 5040 ACCAAAAAAA AAAAAAAAAA AA Seq ID NO : 427 Protein sequence Protein Accession &num : NP 003465 1 11 21 31 41 51 1 1 1 1 1 1 MAARPLPVSP ARALLLALAG ALLAPCEARG VSLWNEGRAD EWSASVRSG DLWIPVKSFD 60 SKNHPEVLNI RLQRESKELI INLERNEGLI ASSFTETHYL QDGTDVSLAR NYTVILGHCY 120 YHGHVRGYSD SAVSLSTCSG LRGLIVFENE SYVLEPMKSA TNRYKLFPAK KLKSVRGSCG 180 SHHNTPNLAA KNVFPPPSQT WARRHKRETL KATKYVELVI VADNREFQRQ GKDLEKVKQR 240 LIEIANHVDK FYRPLNIRIV LVGVEVWNDM DKCSVSQDPF TSLHEFLDWR KMKLLPRKSH 300 DNAQLVSGVY FQGTTIGMAP IMSMCTADQS GGIVMDHSDN PLGAAVTLAH ELGHNFGMNH 360 DTLDRGCSCQ MAVEKGGCIM NASTGYPFPM VFSSCSRKDL ETSLEKGMGV CLFNLPEVRE 420 SFGGQKCGNR FVEEGEECDC GEPEECMNRC CNATTCTLKP DAVCAHGLCC EDCQLKPAGT 480 ACRDSSNSCD LPEFCTGASP HCPANVYLHD GHSCQDVDGY CYNGICQTHE QQCVTLWGPG 540 AKPAPGICFE RVNSAGDPYG NCGKVSKSSF AKCEMRDAKC GKIQCQGGAS RPVIGTNAVS 600 IETNIPLQQG GRILCRGTHV YLGDDMPDPG LVLAGTKCAD GKICLNRQCQ NISVFGVHEC 660 AMQCHGRGVC NNRKNCHCEA HWAPPFCDKF GFGGSTDSGP IRQADNQGLT IGILVTILCL 720 LAAGFWYLK RKTLIRLLFT NKKTTIEKLR CVRPSRPPRG FQPCQAHLGH LGKGLMRKPP 780 DSYPPKDNPR RLLQCQNVDI SRPLNGLNVP QPQSTQRVLP PLHRAPRAPS VPARPLPAKP 840 ALRQAQGTCK PNPPQKPLPA DPLARTTRLT HALARTPGQW ETGLRLAPLR PAPQYPHQVP 900 RSTHTAYIK Seq ID NO: 428 DNA sequence Nucleic Acid Accession # : NM 003714 Coding sequence: 135.. 1043 1 11 21 31 41 51 I I I I I I GAGGAGGAGG GAAAAGGCGA GCAAAAAGGA AGAGTGGGAG GAGGAGGGGA AGCGGCGAAG 60 GAGGAAGAGG AGGAGGAGGA AGAGGGGAGC ACAAAGGATC CAGGTCTCCC GACGGGAGGT 120 TAATACCAAG AACCATGTGT GCCGAGCGGC TGGGCCAGTT CATGACCCTG GCTTTGGTGT 180 TGGCCACCTT TGACCCGGCG CGGGGGACCG ACGCCACCAA CCCACCCGAG GGTCCCCAAG 240 ACAGGAGCTC CCAGCAGAAA GGCCGCCTGT CCCTGCAGAA TACAGCGGAG ATCCAGCACT 300 GTTTGGTCAA CGCTGGCGAT GTGGGGTGTG GCGTGTTTGA ATGTTTCGAG AACAACTCTT 360 GTGAGATTCG GGGCTTACAT GGGATTTGCA TGACTTTTCT GCACAACGCT GGAAAATTTG 420 ATGCCCAGGG CAAGTCATTC ATCAAAGACG CCTTGAAATG TAAGGCCCAC GCTCTGCGGC 480 ACAGGTTCGG CTGCATAAGC CGGAAGTGCC CGGCCATCAG GGAAATGGTG TCCCAGTTGC 540 AGCGGGAATG CTACCTCAAG CACGACCTGT GCGCGGCTGC CCAGGAGAAC ACCCGGGTGA 600 TAGTGGAGAT GATCCATTTC AAGGACTTGC TGCTGCACGA ACCCTACGTG GACCTCGTGA 660 ACTTGCTGCT GACCTGTGGG GAGGAGGTGA AGGAGGCCAT CACCCACAGC GTGCAGGTTC 720 AGTGTGAGCA GAACTGGGGA AGCCTGTGCT CCATCTTGAG CTTCTGCACC TCGGCCATCC 780 AGAAGCCTCC CACGGCGCCC CCCGAGCGCC AGCCCCAGGT GGACAGAACC AAGCTCTCCA 840 GGGCCCACCA CGGGGAAGCA GGACATCACC TCCCAGAGCC CAGCAGTAGG GAGACTGGCC 900 GAGGTGCCAA GGGTGAGCGA GGTAGCAAGA GCCACCCAAA CGCCCATGCC CGAGGCAGAG 960 TCGGGGGCCT TGGGGCTCAG GGACCTTCCG GAAGCAGCGA GTGGGAAGAC GAACAGTCTG 1020 AGTATTCTGA TATCCGGAGG TGAAATGAAA GGCCTGGCCA CGAAATCTTT CCTCCACGCC 1080 GTCCATTTTC TTATCTATGG ACATTCCAAA ACATTTACCA TTAGAGAGGG GGGATGTCAC 1140 ACGCAGGATT CTGTGGGGAC TGTGGACTTC ATCGAGGTGT GTGTTCGCGG AACGGACAGG 1200 TGAGATGGAG ACCCCTGGGG CCGTGGGGTC TCAGGGGTGC CTGGTGAATT CTGCACTTAC 1260 ACGTACTCAA GGGAGCGCGC CCGCGTTATC CTCGTACCTT TGTCTTCTTT CCATCTGTGG 1320 AGTCAGTGGG TGTCGGCCGC TCTGTTGTGG GGGAGGTGAA CCAGGGAGGG GCAGGGCAAG 1380 GCAGGGCCCC CAGAGCTGGG CCACACAGTG GGTGCTGGGC CTCGCCCCGA AGCTTCTGGT 1440 GCAGCAGCCT CTGGTGCTGT CTCCGCGGAA GTCAGGGCGG CTGGATTCCA GGACAGGAGT 1500 GAATGTAAAA ATAAATATCG CTTAGAATGC AGGAGAAGGG TGGAGAGGAG GCAGGGGCCG 1560 AGGGGGTGCT TGGTGCCAAA CTGAAATTCA GTTTCTTGTG TGGGGCCTTG CGGTTCAGAG 1620 CTCTTGGCGA GGGTGGAGGG AGGAGTGTCA TTTCTATGTG TAATTTCTGA GCCATTGTAC 1680 TGTCTGGGCT GGGGGGGACA CTGTCCAAGG GAGTGGCCCC TATGAGTTTA TATTTTAACC 1740 ACTGCTTCAA ATCTCGATTT CACTTTTTTT ATTTATCCAG TTATATCTAC ATATCTGTCA 1800 TCTAAATAAA TGGCTTTCAA ACAAAGCAAC TGGGTCATTA AAACCAGCTC AAAGGGGGTT 1860 TAAAAAAAAA AAAACCAGCC CATCCTTTGA GGCTGATTTT TCTTTTTTTT AAGTTCTATT 1920 TTAAAAGCTA TCAAACAGCG ACATAGCCAT ACATCTGACT GCCTGACATG GACTCCTGCC 1980 CACTTGGGGG AAACCTTATA CCCAGAGGAA AATACACACC TGGGGAGTAC ATTTGACAAA 2040 TTTCCCTTAG GATTTCGTTA TCTCACCTTG ACCCTCAGCC AAGATTGGTA AAGCTGCGTC 2100 CTGGCGATTC CAGGAGACCC AGCTGGAAAC CTGGCTTCTC CATGTGAGGG GATGGGAAAG 2160 GAAAGAAGAG AATGAAGACT ACTTAGTAAT TCCCATCAGG AAATGCTGAC CTTTTACATA 2220

AAGAACGTGT GCTACGATCA CTACTTCCCC ATCTCCCACA TCCGGCTATG GGCCCTGCAG 240 CTGATCTTCG TGTCCAGCCC AGCGCTCCTA GTGGCCATGC ACGTGGCCTA CCGGAGACAT 300 GAGAAGAAGA GGAAGTTCAT CAAGGGGGAG ATAAAGAGTG AATTTAAGGA CATCGAGGAG 360 ATCAAAACCC AGAAGGTCCG CATCGAAGGC TCCCTGTGGT GGACCTACAC AAGCAGCATC 420 TTCTTCCGGG TCATCTTCGA AGCCGCCTTC ATGTACGTCT TCTATGTCAT GTACGACGGC 480 TTCTCCATGC AGCGGCTGGT GAAGTGCAAC GCCTGGCCTT GTCCCAACAC TGTGGACTGC 540 TTTGTGTCCC GGCCCACGGA GAAGACTGTC TTCACAGTGT TCATGATTGC AGTGTCTGGA 600 ATTTGCATCC TGCTGAATGT CACTGAATTG TGTTATTTGC TAATTAGATA TTGTTCTGGG 660 AAGTCAAAAA AGCCAGTTTA A Seq ID NO : 439 Protein sequence Protein Accession # : NP 003995. 1 1 11 21 31 41 51 MDWGTLQTIL GGVNKHSTSI GKINLTVLFI FRIMILWAA KEVWGDEQAD FVCNTLQPGC 60 KNVCYDHYFP ISHIRLWALQ LIFVSSPALL VAMHVAYRRH EKKRKFIKGE IKSEFKDIEE 120 IKTQKVRIEG SLWWTYTSSI FFRVIFEAAF MYVFYVMYDG FSMQRLVKCN AWPCPNTVDC 180 PVSRPTEKTV FTVFMIAVSG ICILLNVTEL CYLLIRYCSG KSXKPV Seq ID NO : 440 DNA sequence Nucleic Acid Accession &num : XM 061091. 1 Coding sequence: 1.. 2481 1 11 21 31 41 51 I I I I I I ATGCCAAATA CTTCAGGAAC AACCAGGATT GAAATTTGGC TTCTCCAAGA GCCGCCCGGG 60 CACCGAGCGC TGGTCGCCGC TCTCCTTCCG GTGAGTCCCA GCCCCGAGTT GGCTCTGGCG 120 CCCGGGTACC CGCCAGTGCC GGCTGCCGAT GACCGATTCA CGCTCCCGAT GATTGGAGGT 180 CAGATGCATG GTGAGAAGGT AGATCTCTGG AGCCTTGGTG TTCTTTGCTA TGAATTTTTA 240 GTTGGGAAGC CTCCTTTTGA GGCAAACGAA GTCCATGTAA GCAAAGAAAC CATCGGGAAG 300 ATTTCAGCTG CCAGCAAAAT GATGTGGTGC TCGGCTGCAG TGGACATCAT GTTTCTGTTA 360 GATGGGTCTA ACAGCGTCGG GAAAGGGAGC TTTGAAAGGT CCAAGCACTT TGCCATCACA 420 GTCTGTGACG GTCTGGACAT CAGCCCCGAG AGGGTCAGAG TGGGAGCATT CCAGTTCAGT 480 TCCACTCCTC ATCTGGAATT CCCCTTGGAT TCATTTTCAA CCCAACAGGA AGTGAAGGCA 540 AGAATCAAGA GGATGGTTTT CAAAGGAGGG CGCACGGAGA CGGAACTTGC TCTGAAATAC 600 CTTCTGCACA GAGGGTTGCC TGGAGGCAGA AATGCTTCTG TGCCCCAGAT CCTCATCATC 660 GTCACTGATG GGAAGTCCCA GGGGGATGTG GCACTGCCAT CCAAGCAGCT GAAGGAAAGG 720 GGTGTCACTG TGTTTGCTGT GGGGGTCAGG TTTCCCAGGT GGGAGGAGCT GCATGCACTG 780 GCCAGCGAGC CTAGAGGGCA GCACGTGCTG TTGGCTGAGC AGGTGGAGGA TGCCACCAAC 840 GGCCTCTTCA GCACCCTCAG CAGCTCGGCC ATCTGCTCCA GCGCCACGCC AGCTGGGAGC 900 CCCGAGCTTG TCTTCATGGA GCGGTTAATG GGCATCTCTC TGATAGGCCC CTGTGACTCG 960 CAGCCCTGCC AGAATGGAGG CACATGTGTT CCAGAAGGAC TGGACGGCTA CCAGTGCCTC 1020 TGCCCGCTGG CCTTTGGAGG GGAGGCTAAC TGTGCCCTGA AGCTGAGCCT GGAATGCAGG 1080 GTCGACCTCC TCTTCCTGCT GGACAGCTCT GCGGGCACCA CTCTGGACGG CTTCCTGCGG 1140 GCCAAAGTCT TCGTGAAGCG GTTTGTGCGG GCCGTGCTGA GCGAGGACTC TCGGGCCCGA 1200 GTGGGTGTGG CCACATACAG CAGGGAGCTG CTGGTGGCGG TGCCTGTGGG GGAGTACCAG 1260 GATGTGCCTG ACCTGGTCTG GAGCCTCGAT GGCATTCCCT TCCGTGGTGG CCCCACCCTG 1320 ACGGGCAGTG CCTTGCGGCA GGCGGCAGAG CGTGGCTTCG GGAGCGCCAC CAGGACAGGC 1380 CAGGACCGGC CACGTAGAGT GGTGGTTTTG CTCACTGAGT CACACTCCGA GGATGAGGTT 1440 GCGGGCCCAG CGCGTCACGC AAGGGCGCGA GAGCTGCTCC TGCTGGGTGT AGGCAGTGAG 1500 GCCGTGCGGG CAGAGCTGGA GGAGATCACA GGCAGCCCAA AGCATGTGAT GGTCTACTCG 1560 GATCCTCAGG ATCTGTTCAA CCAAATCCCT GAGCTGCAGG GGAAGCTGTG CAGCCGGCAG 1620 CGGCCAGGGT GCCGGACACA AGCCCTGGAC CTCGTCTTCA TGTTGGACAC CTCTGCCTCA 1680 GTAGGGCCCG AGAATTTTGC TCAGATGCAG AGCTTTGTGA GAAGCTGTGC CCTCCAGTTT 1740 GAGGTGAACC CTGACGTGAC ACAGGTCGGC CTGGTGGTGT ATGGCAGCCA GGTGCAGACT 1800 GCCTTCGGGC TGGACACCAA ACCCACCCGG GCTGCGATGC TGCGGGCCAT TAGCCAGGCC 1860 CCCTACCTAG GTGGGGTGGG CTCAGCCGGC ACCGCCCTGC TGCACATCTA TGACAAAGTG 1920 ATGACCGTCC AGAGGGGTGC CCGGCCTGGT GTCCCCAAAG CTGTGGTGGT GCTCACAGGC 1980 GGGAGAGGCG CAGAGGATGC AGCCGTTCCT GCCCAGAAGC TGAGGAACAA TGGCATCTCT 2040 GTCTTGGTCG TGGGCGTGGG GCCTGTCCTA AGTGAGGGTC TGCGGAGGCT TGCAGGTCCC 2100 CGGGATTCCC TGATCCACGT GGCAGCTTAC GCCGACCTGC GGTACCACCA GGACGTGCTC 2160 ATTGAGTGGC TGTGTGGAGA AGCCAAGCAG CCAGTCAACC TCTGCAAACC CAGCCCGTGC 2220 ATGAATGAGG GCAGCTGCGT CCTGCAGAAT GGGAGCTACC GCTGCAAGTG TCGGGATGGC 2280 TGGGAGGGCC CCCACTGCGA GAACCGTGAG TGGAGCTCTT GCTCTGTATG TGTGAGCCAG 2340 GGATGGATTC TTGAGACGCC CCTGAGGCAC ATGGCTCCCG TGCAGGAGGG CAGCAGCCGT 2400 ACCCCTCCCA GCAACTACAG AGAAGGCCTG GGCACTGAAA TGGTGCCTAC CTTCTGGAAT 2460 GTCTGTGCCC CAGGTCCTTA G Seq ID NO : 441 Protein sequence Protein Accession &num : XP 061091. 1 1 11 21 31 41 51 # # # # # # MPNTSGTTRI EIWLLQEPPG HRALVALLLP VSPSPELALA PGYPPVPAAD DRFTLPMIGG 60 QMHGEKVDLW SLGVLCYEFL VGKPPFEANE VHVSKETIGK ISAASKMMWC SAAVDIMFLL 120 DGSNSVGKGS FERSKHFAIT VCDGLDISPE RVRVGAFQFS STPHLEFPLD SFSTQQEVKA 180 RIKRMVFKGG RTETELALKY LLHRGLPGGR NASVPQILII VTDGKSQGDV ALPSKQLKER 240 GVTVFAVGVR FPRWEELHAL ASEPRGQHVL LAEQVEDATN GLFSTLSSSA ICSSATPAGS 300 PELVFMERLM GISLIGPCDS QPCQNGGTCV PEGLDGYQCL CPLAFGGEAN CALKLSLECR 360 VDLLFLLDSS AGTTLDGFLR AKVFVKRFVR AVLSEDSRAR VGVATYSREL LVAVPVGEYQ 420 DVPDLVWSLD GIPFRGGPTL TGSALRQAAE RGFGSATRTG QDRPRRVWL LTESHSEDEV 480 AGPARHARAR ELLLLGVGSE AVRAELEEIT GSPKHVMVYS DPQDLFNQIP ELQGKLCSRQ 540 RPGCRTQALD LVFMLDTSAS VGPENFAQMQ SFVRSCALQF EVNPDVTQVG LWYGSQVQT 600 AFGLDTKPTR AAMLRAISQA PYLGGVGSAG TALLHIYDKV MTVQRGARPG VPKAVWLTG 660 GRGAEDAAVP AQKLRNNGIS VLWGVGPVL SEGLRRLAGP RDSLIHVAAY ADLRYHQDVL 720

IEWLCGEAKQ PVNLCKPSPC MNEGSCVLQN GSYRCKCRDG WEGPHCENRE WSSCSVCVSQ 780 GWILETPLRH MAPVQEGSSR TPPSNYREGL GTEMVPTFWN VCAPGP Seq ID NO : 442 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 1.. 2424 1 11 21 31 41 51 # # # # # # ATGCCCCCTT TCCTGTTGCT GGAGGCCGTC TGTGTTTTCC TGTTTTCCAG AGTGCCCCA 60 TCTCTCCCTC TCCAGGAAGT CCATGTAAGC AAAGAAACCA TCGGGAAGAT TTCAGCTGCC 120 AGCAAAATGA TGTGGTGCTC GGCTGCAGTG GACATCATGT TTCTGTTAGA TGGGTCTAAC 180 AGCGTCGGGA AAGGGAGCTT TGAAAGGTCC AAGCACTTTG CCATCACAGT CTGTGACGGT 240 CTGGACATCA GCCCCGAGAG GGTCAGAGTG GGAGCATTCC AGTTCAGTTC CACTCCTCAT 300 CTGGAATTCC CCTTGGATTC ATTTTCAACC CAACAGGAAG TGAAGGCAAG AATCAAGAGG 360 ATGGTTTTCA AAGGAGGGCG CACGGAGACG GAACTTGCTC TGAAATACCT TCTGCACAGA 420 GGGTTGCCTG GAGGCAGAAA TGCTTCTGTG CCCCAGATCC TCATCATCGT CACTGATGGG 480 AAGTCCCAGG GGGATGTGGC ACTGCCATCC AAGCAGCTGA AGGAAAGGGG TGTCACTGTG 540 TTTGCTGTGG GGGTCAGGTT TCCCAGGTGG GAGGAGCTGC ATGCACTGGC CAGCGAGCCT 600 AGAGGGCAGC ACGTGCTGTT GGCTGAGCAG GTGGAGGATG CCACCAACGG CCTCTTCAGC 660 ACCCTCAGCA GCTCGGCCAT CTGCTCCAGC GCCACGCCAG ACTGCAGGGT CGAGGCTCAC 720 CCCTGTGAGC ACAGGACGCT GGAGATGGTC CGGGAGTTCG CTGGCAATGC CCCATGCTGG 780 AGAGGATCGC GGCGGACCCT TGCGGTGCTG GCTGCACACT GTCCCTTCTA CAGCTGGAAG 840 AGAGTGTTCC TAACCCACCC TGCCACCTGC TACAGGACCA CCTGCCCAGG CCCCTGTGAC 900 TCGCAGCCCT GCCAGAATGG AGGCACATGT GTTCCAGAAG GACTGGACGG CTACCAGTGC 960 CTCTGCCCGC TGGCCTTTGG AGGGGAGGCT AACTGTGCCC TGAAGCTGAG CCTGGAATGC 1020 AGGGTCGACC TCCTCTTCCT GCTGGACAGC TCTGCGGGCA CCACTCTGGA CGGCTTCCTG 1080 CGGGCCAAAG TCTTCGTGAA GCGGTTTGTG CGGGCCGTGC TGAGCGAGGA CTCTCGGGCC 1140 CGAGTGGGTG TGGCCACATA CAGCAGGGAG CTGCTGGTGG CGGTGCCTGT GGGGGAGTAC 1200 CAGGATGTGC CTGACCTGGT CTGGAGCCTC GATGGCATTC CCTTCCGTGG TGGCCCCACC 1260 CTGACGGGCA GTGCCTTGCG GCAGGCGGCA GAGCGTGGCT TCGGGAGCGC CACCAGGACA 1320 GGCCAGGACC GGCCACGTAG AGTGGTGGTT TTGCTCACTG AGTCACACTC CGAGGATGAG 1380 GTTGCGGGCC CAGCGCGTCA CGCAAGGGCG CGAGAGCTGC TCCTGCTGGG TGTAGGCAGT 1440 GAGGCCGTGC GGGCAGAGCT GGAGGAGATC ACAGGCAGCC CAAAGCATGT GATGGTCTAC 1500 TCGGATCCTC AGGATCTGTT CAACCAAATC CCTGAGCTGC AGGGGAAGCT GTGCAGCCGG 1560 CAGCGGCCAG GGTGCCGGAC ACAAGCCCTG GACCTCGTCT TCATGTTGGA CACCTCTGCC 1620 TCAGTAGGGC CCGAGAATTT TGCTCAGATG CAGAGCTTTG TGAGAAGCTG TGCCCTCCAG 1680 TTTGAGGTGA ACCCTGACGT GACACAGGTC GGCCTGGTGG TGTATGGCAG CCAGGTGCAG 1740 ACTGCCTTCG GGCTGGACAC CAAACCCACC CGGGCTGCGA TGCTGCGGGC CATTAGCCAG 1800 GCCCCCTACC TAGGTGGGGT GGGCTCAGCC GGCACCGCCC TGCTGCACAT CTATGACAAA 1860 GTGATGACCG TCCAGAGGGG TGCCCGGCCT GGTGTCCCCA AAGCTGTGGT GGTGCTCACA 1920 GGCGGGAGAG GCGCAGAGGA TGCAGCCGTT CCTGCCCAGA AGCTGAGGAA CAATGGCATC 1980 TCTGTCTTGG TCGTGGGCGT GGGGCCTGTC CTAAGTGAGG GTCTGCGGAG GCTTGCAGGT 2040 CCCCGGGATT CCCTGATCCA CGTGGCAGCT TACGCCGACC TGCGGTACCA CCAGGACGTG 2100 CTCATTGAGT GGCTGTGTGG AGAAGCCAAG CAGCCAGTCA ACCTCTGCAA ACCCAGCCCG 2160 TGCATGAATG AGGGCAGCTG CGTCCTGCAG AATGGGAGCT ACCGCTGCAA GTGTCGGGAT 2220 GGCTGGGAGG GCCCCCACTG CGAGAACCGT GAGTGGAGCT CTTGCTCTGT ATGTGTGAGC 2280 CAGGGATGGA TTCTTGAGAC GCCCCTGAGG CACATGGCTC CCGTGCAGGA GGGCAGCAGC 2340 CGTACCCCTC CCAGCAACTA CAGAGAAGGC CTGGGCACTG AAATGGTGCC TACCTTCTGG 2400 AATGTCTGTG CCCCAGGTCC TTAG Seq ID NO : 443 Protein sequence Protein Accession # : Eos sequence 1 11 21 31 41 51 1 1 1 1 1 1 MPPFLLLEAV CVFLFSRVPP SLPLQEVHVS KETIGKISAA SKMMWCSAAV DIMFLLDGSN 60 SVGKGSFERS KHFAITVCDG LDISPERVRV GAFQFSSTPH LEFPLDSFST QQEVKARIKR 120 MVFKGGRTET ELALKYLLHR GLPGGRNASV PQILIIVTDG KSQGDVALPS KQLKERGVTV 180 FAVGVRFPRW EELHALASEP RGQHVLLAEQ VEDATNGLFS TLSSSAICSS ATPDCRVEAH 240 PCEHRTLEMV REFAGNAPCW RGSRRTLAVL AAHCPFYSWK RVFLTHPATC YRTTCPGPCD 300 SQPCQNGGTC VPEGLDGYQC LCPLAFGGEA NCALKLSLEC RVDLLFLLDS SAGTTLDGFL 360 RAKVFVKRFV RAVLSEDSRA RVGVATYSRE LLVAVPVGEY QDVPDLVWSL DGIPFRGGPT 420 LTGSALRQAA ERGFGSATRT GQDRPRRVW LLTESHSEDE VAGPARHARA RELLLLGVGS 480 EAVRAELEEI TGSPKHVMVY SDPQDLFNQI PELQGKLCSR QRPGCRTQAL DLVFMLDTSA 540 SVGPENFAQM QSFVRSCALQ FEVNPDVTQV GLWYGSQVQ TAFGLDTKPT RAAMLRAISQ 600 APYLGGVGSA GTALLHIYDK VMTVQRGARP GVPKAVWLT GGRGAEDAAV PAQKLRNNGI 660 SVLWGVGPV LSEGLRRLAG PRDSLIHVAA YADLRYHQDV LIEWLCGEAK QPVNLCKPSP 720 CMNEGSCVLQ NGSYRCKCRD GWEGPHCENR EWSSCSVCVS QGWILETPLR HMAPVQEGSS 780 RTPPSNYREG LGTEMVPTFW NVCAPGP Seq ID NO : 444 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 89.. 2356 1 11 21 31 41 51 # # # # # # GCCCCCTGGC CCGAGCCGCG CCCGGGTCTG TGAGTAGAGC CGCCCGGGCA CCGAGCGCTG 60 GTCGCCGCTC TCCTTCCGTT ATATCAACAT GCCCCCTTTC CTGTTGCTGG AAGCCGTCTG 120 TGTTTTCCTG TTTTCCAGAG TGCCCCCATC TCTCCCTCTC CAGGAAGTCC ATGTAAGCAA 180 AGAAACCATC GGGAAGATTT CAGCTGCCAG CAAAATGATG TGGTGCTCGG CTGCAGTGGA 240 CATCATGTTT CTGTTAGATG GGTCTAACAG CGTCGGGAAA GGGAGCTTTG AAAGGTCCAA 300 GCACTTTGCC ATCACAGTCT GTGACGGTCT GGACATCAGC CCCGAGAGGG TCAGAGTGGG 360 AGCATTCCAG TTCAGTTCCA CTCCTCATCT GGAATTCCCC TTGGATTCAT TTTCAACCCA 420 ACAGGAAGTG AAGGCAAGAA TCAAGAGGAT GGTTTTCAAA GGAGGGCGCA CGGAGACGGA 480 ACTTGCTCTG AAATACCTTC TGCACAGAGG GTTGCCTGGA GGCAGAAATG CTTCTGTGCC 540 CCAGATCCTC ATCATCGTCA CTGATGGGAA GTCCCAGGGG GATGTGGCAC TGCCATCCAA 600

GCAGCTGAAG GAAAGGGGTG TCACTGTGTT TGCTGTGGGG GTCAGGTTTC CCAGGTGGGA 660 GGAGCTGCAT GCACTGGCCA GCGAGCCTAG AGGGCAGCAC GTGCTGTTGG CTGAGCAGGT 720 GGAGGATGCC ACCAACGGCC TCTTCAGCAC CCTCAGCAGC TCGGCCATCT GCTCCAGCGC 780 CACGCCAGAC TGCAGGGTCG AGGCTCACCC CTGTGAGCAC AGGACGCTGG AGATGGTCCG 840 GGAGTTCGCT GGCAATGCCC CATGCTGGAG AGGATCGCGG CGGACCCTTG CGGTGCTGGC 900 TGCACACTGT CCCTTCTACA GCTGGAAGAG AGTGTTCCTA ACCCACCCTG CCACCTGCTA 960 CAGGACCACC TGCCCAGGCC CCTGTGACTC GCAGCCCTGC CAGAATGGAG GCACATGTGT 1020 TCCAGAAGGA CTGGACGGCT ACCAGTGCCT CTGCCCGCTG GCCTTTGGAG GGGAGGCTAA 1080 CTGTGCCCTG AAGCTGAGCC TGGAATGCAG GGTCGACCTC CTCTTCCTGC TGGACAGCTC 1140 TGCGGGCACC ACTCTGGACG GCTTCCTGCG GGCCAAAGTC TTCGTGAAGC GGTTTGTGCG 1200 GGCCGTGCTG AGCGAGGACT CTCGGGCCCG AGTGGGTGTG GCCACATACA GCAGGGAGCT 1260 GCTGGTGGCG GTGCCTGTGG GGGAGTACCA GGATGTGCCT GACCTGGTCT GGAGCCTCGA 1320 TGGCATTCCC TTCCGTGGTG GCCCCACCCT GACGGGCAGT GCCTTGCGGC AGGCGGCAGA 1380 GCGTGGCTTC GGGAGCGCCA CCAGGACAGG CCAGGACCGG CCACGTAGAG TGGTGGTTTT 1440 GCTCACTGAG TCACACTCCG AGGATGAGGT TGCGGGCCCA GCGCGTCACG CAAGGGCGCG 1500 AGAGCTGCTC CTGCTGGGTG TAGGCAGTGA GGCCGTGCGG GCAGAGCTGG AGGAGATCAC 1560 AGGCAGCCCA AAGCATGTGA TGGTCTACTC GGATCCTCAG GATCTGTTCA ACCAAATCCC 1620 TGAGCTGCAG GGGAAGCTGT GCAGCCGGCA GCGGCCAGGG TGCCGGACAC AAGCCCTGGA 1680 CCTCGTCTTC ATGTTGGACA CCTCTGCCTC AGTAGGGCCC GAGAATTTTG CTCAGATGCA 1740 GAGCTTTGTG AGAAGCTGTG CCCTCCAGTT TGAGGTGAAC CCTGACGTGA CACAGGTCGG 1800 CCTGGTGGTG TATGGCAGCC AGGTGCAGAC TGCCTTCGGG CTGGACACCA AACCCACCCG 1860 GGCTGCGATG CTGCGGGCCA TTAGCCAGGC CCCCTACCTA GGTGGGGTGG GCTCAGCCGG 1920 CACCGCCCTG CTGCACATCT ATGACAAAGT GATGACCGTC CAGAGGGGTG CCCGGCCTGG 1980 TGTCCCCAAA GCTGTGGTGG TGCTCACAGG CGGGAGAGGC GCAGAGGATG CAGCCGTTCC 2040 TGCCCAGAAG CTGAGGAACA ATGGCATCTC TGTCTTGGTC GTGGGCGTGG GGCCTGTCCT 2100 AAGTGAGGGT CTGCGGAGGC TTGCAGGTCC CCGGGATTCC CTGATCCACG TGGCAGCTTA 2160 CGCCGACCTG CGGTACCACC AGGACGTGCT CATTGAGTGG CTGTGTGGAG AAGCCAAGCA 2220 GCCAGTCAAC CTCTGCAAAC CCAGCCCGTG CATGAATGAG GGCAGCTGCG TCCTGCAGAA 2280 TGGGAGCTAC CGCTGCAAGT GTCGGGATGG CTGGGAGGGC CCCCACTGCG AGAACCGATT 2340 CTTGAGACGC CCCTGAGGCA CATGGCTCCC GTGCAGGAGG GCAGCAGCCG TACCCCTCCC 2400 AGCAACTACA GAGAAGGCCT GGGCACTGAA ATGGTGCCTA CCTTCTGGAA TGTCTGTGCC 2460 CCAGGTCCTT AGAATGTCTG CTTCCCGCCG TGGCCAGGAC CACTATTCTC ACTGAGGGAG 2520 GAGGATGTCC CAACTGCAGC CATGCTGCTT AGAGACAAGA AAGCAGCTGA TGTCACCCAC 2580 AAACGATGTT GTTGAAAAGT TTTGATGTGT AAGTAAATAC CCACTTTCTG TACCTGCTGT 2640 GCCTTGTTGA GGCTATGTCA TCTGCCACCT TTCCCTTGAG GATAAACAAG GGGTCCTGAA 2700 GACTTAAATT TAGCGGCCTG ACGTTCCTTT GCACACAATC AATGCTCGCC AGAATGTTGT 2760 TGACACAGTA ATGCCCAGCA GAGGCCTTTA CTAGAGCATC CTTTGGACGG Seq ID NO : 445 Protein sequence Protein Accession &num : Eos sequence 1 11 21 31 41 51 MPPPLLLEAV CVFLFSRVPP SLPLQEVHVS KETIGKISAA SKMMWCSAAV DIMFLLDGSN 60 SVGKGSFERS KHFAITVCDG LDISPERVRV GAFQFSSTPH LEFPLDSFST QQEVKARIKR 120 MVFKGGRTET ELALKYLLHR GLPGGRNASV PQILIIVTDG KSQGDVALPS KQLKERGVTV 180 FAVGVRFPRW EELHALASEP RGQHVLLAEQ VEDATNGLFS TLSSSAICSS ATPDCRVEAH 240 PCEHRTLEMV REFAGNAPCW RGSRRTLAVL AAHCPFYSWK RVPLTHPATC YRTTCPGPCD 300 SQPCQNGGTC VPEGLDGYQC LCPLAFGGEA NCALKLSLEC RVDLLFLLDS SAGTTLDGFL 360 RAKVFVKRFV RAVLSEDSRA RVGVATYSRE LLVAVPVGEY QDVPDLVWSL DGIPFRGGPT 420 LTGSALRQAA ERGFGSATRT GQDRPRRVW LLTESHSEDE VAGPARHARA RELLLLGVGS 480 EAVRAELEEI TGSPKHVMVY SDPQDLFNQI PELQGKLCSR QRPGCRTQAL DLVFMLDTSA 540 SVGPENFAQM QSFVRSCALQ FEVNPDVTQV GLWYGSQVQ TAFGLDTKPT RAAMLRAISQ 600 APYLGGVGSA GTALLHIYDK VMTVQRGARP GVPKAVWLT GGRGAEDAAV PAQKLRNNGI 660 SVLWGVGPV LSEGLRRLAG PRDSLIHVAA YADLRYHQDV LIEWLCGEAK QPVNLCKPSP 720 CMNEGSCVLQ NGSYRCKCRD GWEGPHCENR FLRRP Seq ID NO : 446 DNA sequence Nucleic Acid Accession # : NM 031942. 1 Coding sequence : 145.. 1260 1 11 21 31 41 51 CCCGAGCCCC GCCCCTCCGG GCCCGGGTCG GCGCGCCCAG CCTGCCAGCC GCGCTGCTGC 60 TGCTCCTCCT GCTGTGGGAC CGCTGACCGC GCGGCTGCTC CGCTCTCCCC GCTCCAAGCG 120 CCGATCTGGG CACCCGCCAC CAGCATGGAC GCTCGCCGCG TGCCGCAGAA AGATCTCAGA 180 GTAAAGAAGA ACTTAAAGAA ATTCAGATAT GTGAAGTTGA TTTCCATGGA AACCTCGTCA 240 TCCTCTGATG ACAGTTGTGA CAGCTTTGCT TCTGATAATT TTGCAAACAC GAGGCTGCAG 300 TCAGTTCGGG AAGGCTGTAG GACCCGCAGC CAGTGCAGGC ACTCTGGACC TCTCAGGGTG 360 GCGATGAAGT TTCCAGCGCG GAGTACCAGG GGAGCAACCA ACAAAAAAGC AGAGTCCCGC 420 CAGCCCTCAG AGAATTCTGT GACTGATTCC AACTCCGATT CAGAAGATGA AAGTGGAATG 480 AATTTTTTGG AGAAAAGGGC TTTAAATATA AAGCAAAACA AAGCAATGCT TGCAAAACTC 540 ATGTCTGAAT TAGAAAGCTT CCCTGGCTCG TTCCGTGGAA GACATCCCCT CCCAGGCTCC 600 GACTCACAAT CAAGGAGACC GCGAAGGCGT ACATTCCCGG GTGTTGCTTC CAGGAGAAAC 660 CCTGAACGGA GAGCTCGTCC TCTTACCAGG TCAAGGTCCC GGATCCTCGG GTCCCTTGAC 720 GCTCTACCCA TGGAGGAGGA GGAGGAAGAG GATAAGTACA TGTTGGTGAG AAAGAGGAAG 780 ACCGTGGATG GCTACATGAA TGAAGATGAC CTGCCCAGAA GCCGTCGCTC CAGATCATCC 840 GTGACCCTTC CGCATATAAT TCGCCCAGTG GAAGAAATTA CAGAGGAGGA GTTGGAGAAC 900 GTCTGCAGCA ATTCTCGAGA GAAGATATAT AACCGTTCAC TGGGCTCTAC TTGTCATCAA 960 TGCCGTCAGA AGACTATTGA TACCAAAACA AACTGCAGAA ACCCAGACTG CTGGGGCGTT 1020 CGAGGCCAGT TCTGTGGCCC CTGCCTTCGA AACCGTTATG GTGAAGAGGT CAGGGATGCT 1080 CTGCTGGATC CGAACTGGCA TTGCCCGCCT TGTCGAGGAA TCTGCAACTG CAGTTTCTGC 1140 CGGCAGCGAG ATGGACGGTG TGCGACTGGG GTCCTTGTGT ATTTAGCCAA ATATCATGGC 1200 TTTGGGAATG TGCATGCCTA CTTGAAAAGC CTGAAACAGG AATTTGAAAT GCAAGCATAA 1260 TATCTGGAAA ATTTGCTGCC TGCCTTCTAC TTCTCAAATC TTTCTTGTAA AAGTTTCCAA 1320 TTTTTTCACT GAAACCTGAG TTAAAAATCT TGATGATCAG CCTGTTTCAT AAGAAACTCC 1380 AATCAAGTTA ATCTTAGCAG ACATGTGTTT CTGGAGCATC ACAGAAGGTA TATTGCTAGT 1440

TACACTTTGC CCTCCTGCAG TTTCTTCTCT GCTCCCAACC CCCATCTCAT AGCATCCCCC 1500 TCTATTTCCA ATGCTCCTCT CCAACCGCTT AGTTTCTGAA TTTCTTTTAA ATTACAGTTT 1560 TATGAAAGCA TATTTTATTT ACTTGGTGTT GAAATAGCCC TCATAAAACC TAAGCACTTG 1620 GAAACACAAT AATAGTATTA ACTAACTAGA TCTATTGAAT TTCAGAGAAG AGCCTTCTAA 1680 CTTGTTTACA CAAAAACGAG TATGATTTAG CACTCATACT AGTTGAAATT TTTAATAGAA 1740 TCAAGGCACA AAAGTCTTAA AACCATGTGG AAAAATTAGG TAATTATTGC AGATTGATGT 1800 CTCTCAATCC CATGTATTGC GCTTATGTTA CAAGTTGTTG TCACAGTTGA GACTTAATTT 1860 CTCCTAATTT CTTCTGCCCG AAGGGTAAGT GGTGCGTCCA GCTTACACGA TCATAATTCA 1920 AAGGTTGGTG GGCAATGTAA TACTTAATTA AAATAATGAT GGAAGAGCTA TCTGGAGATT 1980 ATGAGTAAGC TGATTTGAAT TTTCAGTATA AAACTTTAGT ATAATTGTAG TTTGCAAAGT 2040 TTATTTCAGT TCACATGTAA GGTATTGCAA ATAAATTCTT GGACAATTTT GTATGGAAAC 2100 TTGATATTAA AAACTAGTCT GTGGTTCTTT GCAGTTTCTT GTAAATTTAT AAACCAGGCA 2160 CAAGGTTCAA GTTTAGATTT TAAGCACTTT TATAACAATG ATAAGTGCCT TTTTGGAGAT 2220 GTAACTTTTA GCAGTTTGTT AACCTGACAT CTCTGCCAGT CTAGTTTCTG GGCAGGTTTC 2280 CTGTGTCAGT ATTCCCCCTC CTCTTTGCAT TAATCAAGGT ATTTGGTAGA GGTGGAATCT 2340 AAGTGTTTGT ATGTCCAATT TACTTGCATA TGTAAACCAT TGCTGTGCCA TTCAATGTTT 2400 GATGCATAAT TGGACCTTGA ATCGATAAGT GTAAATACAG CTTTTGATCT GTAATGCTTT 2460 TATACAAAAG TTTATTTTAA TAATAAAATG TTTGTTCTAA AAAAAAAAAA Seq ID NO : 447 Protein sequence Protein Accession # : NP 114148. 1 1 11 21 31 41 51 MDARRVPQKD LRVKKNLKKF RYVKLISMET SSSSDDSCDS FASDNFANTR LQSVREGCRT 60 RSQCRHSGPL RVAMKFPARS TRGATNKKAE SRQPSENSVT DSNSDSEDES GMNFLEKRAL 120 NIKQNKAMLA KLMSELESFP GSFRGRHPLP GSDSQSRRPR RRTFPGVASR RNPERRARPL 180 TRSRSRILGS LDALPMEEEE EEDKYMLVRK RKTVDGYMNE DDLPRSRRSR SSVTLPHIIR 240 PVEEITEEEL ENVCSNSREK IYNRSLGSTC HQCRQKTIDT KTNCRNPDCW GVRGQFCGPC 300 LRNRYGEEVR DALLDPNWHC PPCRGICNCS FCRQRDGRCA TGVLVYLAKY HGFGNVHAYL 360 KSLKQEFEMQ A Seq ID NO: 448 DNA sequence Nucleic Acid Accession &num : NM 019894 Coding sequence: 1.. 1314 1 11 21 31 41 51 1 1 1 1 1 1 ATGTTACAGG ATCCTGACAG TGATCAACCT CTGAACAGCC TCGATGTCAA ACCCCTGCGC 60 AAACCCCGTA TCCCCATGGA GACCTTCAGA AAGGTGGGGA TCCCCATCAT CATAGCACTA 120 CTGAGCCTGG CGAGTATCAT CATTGTGGTT GTCCTCATCA AGGTGATTCT GGATAAATAC 180 TACTTCCTCT GCGGGCAGCC TCTCCACTTC ATCCCGAGGA AGCAGCTGTG TGACGGAGAG 240 CTGGACTGTC CCTTGGGGGA GGACGAGGAG CACTGTGTCA AGAGCTTCCC CGAAGGGCCT 300 GCAGTGGCAG TCCGCCTCTC CAAGGACCGA TCCACACTGC AGGTGCTGGA CTCGGCCACA 360 GGGAACTGGT TCTCTGCCTG TTTCGACAAC TTCACAGAAG CTCTCGCTGA GACAGCCTGT 420 AGGCAGATGG GCTACAGCAG CAAACCCACT TTCAGAGCTG TGGAGATTGG CCCAGACCAG 480 GATCTGGATG TTGTTGAAAT CACAGAAAAC AGCCAGGAGC TTCGCATGCG GAACTCAAGT 540 GGGCCCTGTC TCTCAGGCTC CCTGGTCTCC CTGCACTGTC TTGCCTGTGG GAAGAGCCTG 600 AAGACCCCCC GTGTGGTGGG TGGGGAGGAG GCCTCTGTGG ATTCTTGGCC TTGGCAGGTC 660 AGCATCCAGT ACGACAAACA GCACGTCTGT GGAGGGAGCA TCCTGGACCC CCACTGGGTC 720 CTCACGGCAG CCCACTGCTT CAGGAAACAT ACCGATGTGT TCAACTGGAA GGTGCGGGCA 780 GGCTCAGACA AACTGGGCAG CTTCCCATCC CTGGCTGTGG CCAAGATCAT CATCATTGAA 840 TTCAACCCCA TGTACCCCAA AGACAATGAC ATCGCCCTCA TGAAGCTGCA GTTCCCACTC 900 ACTTTCTCAG GCACAGTCAG GCCCATCTGT CTGCCCTTCT TTGATGAGGA GCTCACTCCA 960 GCCACCCCAC TCTGGATCAT TGGATGGGGC TTTACGAAGC AGAATGGAGG GAAGATGTCT 1020 GACATACTGC TGCAGGCGTC AGTCCAGGTC ATTGACAGCA CACGGTGCAA TGCAGACGAT 1080 GCGTACCAGG GGGAAGTCAC CGAGAAGATG ATGTGTGCAG GCATCCCGGA AGGGGGTGTG 1140 GACACCTGCC AGGGTGACAG TGGTGGGCCC CTGATGTACC AATCTGACCA GTGGCATGTG 1200 GTGGGCATCG TTAGCTGGGG CTATGGCTGC GGGGGCCCGA GCACCCCAGG AGTATACACC 1260 AAGGTCTCAG CCTATCTCAA CTGGATCTAC AATGTCTGGA AGGCTGAGCT GTAA Seq ID NO: 449 Protein sequence Protein Accession &num : NP 063947. 1 1 11 21 31 41 51 MLQDPDSDQP LNSLDVKPLR KPRIPMETFR KVGIPIIIAL LSLASIIIW VLIKVILDKY 60 YFLCGQPLHF IPRKQLCDGE LDCPLGEDEE HCVKSFPEGP AVAVRLSKDR STLQVLDSAT 120 GNWFSACFDN FTEALAETAC RQMGYSSKPT FRAVEIGPDQ DLDWEITEN SQELRMRNSS 180 GPCLSGSLVS LHCLACGKSL KTPRWGGEE ASVDSWPWQV SIQYDKQHVC GGSILDPHWV 240 LTAAHCFRKH TDVFNWKVRA GSDKLGSFPS LAVAKIIIIE FNPMYPKDND IALMKLQFPL 300 TFSGTVRPIC LPFFDEELTP ATPLWIIGWG FTKQNGGKMS DILLQASVQV IDSTRCNADD 360 AYQGEVTEKM MCAGIPEGGV DTCQGDSGGP LMYQSDQWHV VGIVSWGYGC GGPSTPGVYT 420 Seq ID NO : 450 DNA sequence Nucleic Acid Accession &num : XM 051860. 2 Coding sequence: 52.. 3042 1 11 21 31 41 51 GCTCACCCAG GAAAAATATG CAATCGTCCC ATTGATATAC AGGCCACTAC AATGGATGGA 60 GTTAACCTCA GCACCGAGGT TGTCTACAAA AAAGGCCAGG ATTATAGGTT TGCTTGCTAC 120 GACCGGGGCA GAGCCTGCCG GAGCTACCGT GTACGGTTCC TCTGTGGGAA GCCTGTGAGG ISO CCCAAACTCA CAGTCACCAT TGACACCAAT GTGAACAGCA CCATTCTGAA CTTGGAGGAT 240 AATGTACAGT CATGGAAACC TGGAGATACC CTGGTCATTG CCAGTACTGA TTACTCCATG 300 TACCAGGCAG AAGAGTTCCA GGTGCTTCCC TGCAGATCCT GCGCCCCCAA CCAGGTCAAA 360

GTGGCAGGGA AACCAATGTA CCTGCACATC GGGGAGGAGA TAGACGGCGT GGACATGCGG 420 GCGGAGGTTG GGCTTCTGAG CCGGAACATC ATAGTGATGG GGGAGATGGA GGACAAATGC 480 TACCCCTACA GAAACCACAT CTGCAATTTC TTTGACTTCG ATACCTTTGG GGGCCACATC 540 AAGTTTGCTC TGGGATTTAA GGCAGCACAC TTGGAGGGCA CGGAGCTGAA GCATATGGGA 600 CAGCAGCTGG TGGGTCAGTA CCCGATTCAC TTCCACCTGG CCGGTGATGT AGACGAAAGG 660 GGAGGTTATG ACCCACCCAC ATACATCAGG GACCTCTCCA TCCATCATAC ATTCTCTCGC 720 TGCGTCACAG TCCATGGCTC CAATGGCTTG TTGATCAAGG ACGTTGTGGG CTATAACTCT 780 TTGGGCCACT GCTTCTTCAC GGAAGATGGG CCGGAGGAAC GCAACACTTT TGACCACTGT 840 CTTGGCCTCC TTGTCAAGTC TGGAACCCTC CTCCCCTCGG ACCGTGACAG CAAGATGTGC 900 AAGATGATCA CAGGAGACTC CTACCCAGGG TACATCCCCA AGCCCAGGCA AGACTGCAAT 960 GCTGTGTCCA CCTTCTGGAT GGCCAATCCC AACAACAACC TCATCAACTG TGCCGCTGCA 1020 GGATCTGAGG AAACTGGATT TTGGTTTATT TTTCACCACG TACCAACGGG CCCCTCCGTG 1080 GGAATGTACT CCCCAGGTTA TTCAGAGCAC ATTCCACTGG GAAAATTCTA TAACAACCGA 1140 GCACATTCCA ACTACCGGGC TGGCATGATC ATAGACAACG GAGTCAAAAC CACCGAGGCC 1200 TCTGCCAAGG ACAAGCGGCC GTTCCTCTCA ATCATCTCTG CCAGATACAG CCCTCACCAG 1260 GACGCCGACC CGCTGAAGCC CCGGGAGCCG GCCATCATCA GACACTTCAT TGCCTACAAG 1320 AACCAGGACC ACGGGGCCTG GCTGCGCGGC GGGGATGTGT GGCTGGACAG CTGCCGGTTT 1380 GCTGACAATG GCATTGGCCT GACCCTGGCC AGTGGTGGAA CCTTCCCGTA TGACGACGGC 1440 TCCAAGCAAG AGATAAAGAA CAGCTTGTTT GTTGGCGAGA GTGGCAACGT GGGGACGGAA 1500 ATGATGGACA ATAGGATCTG GGGCCCTGGC GGCTTGGACC ATAGCGGAAG GACCCTCCCT 1560 ATAGGCCAGA ATTTTCCAAT TAGAGGAATT CAGTTATATG ATGGCCCCAT CAACATCCAA 1620 AACTGCACTT TCCGAAAGTT TGTGGCCCTG GAGGGCCGGC ACACCAGCGC CCTGGCCTTC 1680 CGCCTGAATA ATGCCTGGCA GAGCTGCCCC CATAACAACG TGACCGGCAT TGCCTTTGAG 1740 GACGTTCCGA TTACTTCCAG AGTGTTCTTC GGAGAGCCTG GGCCCTGGTT CAACCAGCTG 1800 GACATGGATG GGGATAAGAC ATCTGTGTTC CATGACGTCG ACGGCTCCGT GTCCGAGTAC 1860 CCTGGCTCCT ACCTCACGAA GAATGACAAC TGGCTGGTCC GGCACCCAGA CTGCATCAAT 1920 GTTCCCGACT GGAGAGGGGC CATTTGCAGT GGGTGCTATG CACAGATGTA CATTCAAGCC 1980 TACAAGACCA GTAACCTGCG AATGAAGATC ATCAAGAATG ACTTCCCCAG CCACCCTCTT 2040 TACCTGGAGG GGGCGCTCAC CAGGAGCACC CATTACCAGC AATACCAACC GGTTGTCACC 2100 CTGCAGAAGG GCTACACCAT CCACTGGGAC CAGACGGCCC CCGCCGAACT CGCCATCTGG 2160 CTCATCAACT TCAACAAGGG CGACTGGATC CGAGTGGGGC TCTGCTACCC GCGAGGCACC 2220 ACATTCTCCA TCCTCTCGGA TGTTCACAAT CGCCTGCTGA AGCAAACGTC CAAGACGGGC 2280 GTCTTCGTGA GGACCTTGCA GATGGACAAA GTGGAGCAGA GCTACCCTGG CAGGAGCCAC 2340 TACTACTGGG ACGAGGACTC AGGGCTGTTG TTCCTGAAGC TGAAAGCTCA GAACGAGAGA 2400 GAGAAGTTTG CTTTCTGCTC CATGAAAGGC TGTGAGAGGA TAAAGATTAA AGCTCTGATT 2460 CCAAAGAACG CAGGCGTCAG TGACTGCACA GCCACAGCTT ACCCCAAGTT CACCGAGAGG 2520 GCTGTCGTAG ACGTGCCGAT GCCCAAGAAG CTCTTTGGTT CTCAGCTGAA AACAAAGGAC 2580 CATTTCTTGG AGGTGAAGAT GGAGAGTTCC AAGCAGCACT TCTTCCACCT CTGGAACGAC 2640 TTCGCTTACA TTGAAGTGGA TGGGAAGAAG TACCCCAGTT CGGAGGATGG CATCCAGGTG 2700 GTGGTGATTG ACGGGAACCA AGGGCGCGTG GTGAGCCACA CGAGCTTCAG GAACTCCATT 2760 CTGCAAGGCA TACCATGGCA GCTTTTCAAC TATGTGGCGA CCATCCCTGA CAATTCCATA 2820 GTGCTTATGG CATCAAAGGG AAGATACGTC TCCAGAGGCC CATGGACCAG AGTGCTGGAA 2880 AAGCTTGGGG CAGACAGGGG TCTCAAGTTG AAAGAGCAAA TGGCATTCGT TGGCTTCAAA 2940 GGCAGCTTCC GGCCCATCTG GGTGACACTG GACACTGAGG ATCACAAAGC CAAAATCTTC 3000 CAAGTTGTGC CCATCCCTGT GGTGAAGAAG AAGAAGTTGT GAGGACAGCT GCCGCCCGGT 3060 GCCACCTCGT GGTAGACTAT GACGGTGACT CTTGGCAGCA GACCAGTGGG GGATGGCTGG 3120 GTCCCCCAGC CCCTGCCAGC AGCTGCCTGG GAAGGCCGTG TTTCAGCCCT GATGGGCCAA 3180 GGGAAGGCTA TCAGAGACCC TGGTGCTGCC ACCTGCCCCT ACTCAAGTGT CTACCTGGAG 3240 CCCCTGGGGC GGTGCTGGCC AATGCTGGAA ACATTCACTT TCCTGCAGCC TCTTGGGTGC 3300 TTCTCTCCTA TCTGTGCCTC TTCAGTGGGG GTTTGGGGAC CATATCAGGA GACCTGGGTT 3360 GTGCTGACAG CAAAGATCCA CTTTGGCAGG AGCCCTGACC CAGCTAGGAG GTAGTCTGGA 3420 GGGCTGGTCA TTCACAGATC CCCATGGTCT TCAGCAGACA AGTGAGGGTG GTAAATGTAG 3480 GAGAAAGAGC CTTGGCCTTA AGGAAATCTT TACTCCTGTA AGCAAGAGCC AACCTCACAG 3540 GATTAGGAGC TGGGGTAGAA CTGGCTATCC TTGGGGAAGA GGCAAGCCCT GCCTCTGGCC 3600 GTGTCCACCT TTCAGGAGAC TTTGAGTGGC AGGTTTGGAC TTGGACTAGA TGACTCTCAA 3660 AGGCCCTTTT AGTTCTGAGA TTCCAGAAAT CTGCTGCATT TCACATGGTA CCTGGAACCC 3720 AACAGTTCAT GGATATCCAC TGATATCCAT GATGCTGGGT GCCCCAGCGC ACACGGGATG 3780 GAGAGGTGAG AACTAATGCC TAGCTTGAGG GGTCTGCAGT CCAGTAGGGC AGGCAGTCAG 3840 GTCCATGTGC ACTGCAATGC CAGGTGGAGA AATCACAGAG AGGTAAAATG GAGGCCAGTG 3900 CCATTTCAGA GGGGAGGCTC AGGAAGGCTT CTTGCTTACA GGAATGAAGG CTGGGGGCAT 3960 TTTGCTGGGG GGAGATGAGG CAGCCTCTGG AATGGCTCAG GGATTCAGCC CTCCCTGCCG 4020 CTGCCTGCTG AAGCTGGTGA CTACGGGGTC GCCCTTTGCT CACGTCTCTC TGGCCCACTC 4080 ATGATGGAGA AGTGTGGTCA GAGGGGAGCA ATGGGCTTTG CTGCTTATGA GCACAGAGGA 4140 ATTCAGTCCC CAGGCAGCCC TGCCTCTGAC TCCAAGAGGG TGAAGTCCAC AGAAGTGAGC 4200 TCCTGCCTTA GGGCCTCATT TGCTCTTCAT CCAGGGAACT GAGCACAGGG GGCCTCCAGG 4260 AGACCCTAGA TGTGCTCGTA CTCCCTCGGC CTGGGATTTC AGAGCTGGAA ATATAGAAAA 4320 TATCTAGCCC AAAGCCTTCA TTTTAACAGA TGGGGAAAGT GAGCCCCCAA GATGGGAAAG 4380 AACCACACAG CTAAGGGAGG GCCTGGGGAG CCCCACCCTA GCCCTTGCTG CCACACCACA 4440 TTGCCTCAAC AACCGGCCCC AGAGTGCCCA GGCACTCCTG AGGTAGCTTC TGGAAATGGG 4500 GACAAGTCCC CTCGAAGGAA AGGAAATGAC TAGAGTAGAA TGACAGCTAG CAGATCTCTT 4560 CCCTCCTGCT CCCAGCGCAC ACAAACCCGC CCTCCCCTTG GTGTTGGCGG TCCCTGTGGC 4620 CTTCACTTTG TTCACTACCT GTCAGCCCAG CCTGGGTGCA CAGTAGCTGC AACTCCCCAT 4680 TGGTGCTACC TGGCTCTCCT GTCTCTGCAG CTCTACAGGT GAGGCCCAGC AGAGGGAGTA 4740 GGGCTCGCCA TGTTTCTGGT GAGCCAATTT GGCTGATCTT GGGTGTCTGA ACAGCTATTG 4800 GGTCCACCCC AGTCCCTTTC AGCTGCTGCT TAATGCCCTG CTCTCTCCCT GGCCCACCTT 4860 ATAGAGAGCC CAAAGAGCTC CTGTAAGAGG GAGAACTCTA TCTGTGGTTT ATAATCTTGC 4920 ACGAGGCACC AGAGTCTCCC TGGGTCTTGT GATGAACTAC ATTTATCCCC TTTCCTGCCC 4980 CAACCACAAA CTCTTTCCTT CAAAGAGGGC CTGCCTGGCT CCCTCCACCC AACTGCACCC 5040 ATGAGACTCG GTCCAAGAGT CCATTCCCCA GGTGGGAGCC AACTGTCAGG GAGGTCTTTC 5100 CCACCAAACA TCTTTCAGCT GCTGGGAGGT GACCATAGGG CTCTGCTTTT AAAGATATGG 5160 CTGCTTCAAA GGCCAGAGTC ACAGGAAGGA CTTCTTCCAG GGAGATTAGT GGTGATGGAG 5220 AGGAGAGTTA AAATGACCTC ATGTCCTTCT TGTCCACGGT TTTGTTGAGT TTTCACTCTT 5280 CTAATGCAAG GGTCTCACAC TGTGAACCAC TTAGGATGTG ATCACTTTCA GGTGGCCAGG 5340 AATGTTGAAT GTCTTTGGCT CAGTTCATTT AAAAAAGATA TCTATTTGAA AGTTCTCAGA 5400 GTTGTACATA TGTTTCACAG TACAGGATCT GTACATAAAA GTTTCTTTCC TAAACCATTC 5460 ACCAAGAGCC AATATCTAGG CATTTTCTTG GTAGCACAAA TTTTCTTATT GCTTAGAAAA 5520 TTGTCCTCCT TGTTATTTCT GTTTGTAAGA CTTAAGTGAG TTAGGTCTTT AAGGAAAGCA 5580

ACGCTCCTCT GAAATGCTTG TCTTTTTTCT GTTGCCGAAA TAGCTGGTCC TTTTTCGGGA 5640 GTTAGATGTA TAGAGTGTTT GTATGTAAAC ATTTCTTGTA GGCATCACCA TGAACAAAGA 5700 TATATTTTCT ATTTATTTAT TATATGTGCA CTTCAAGAAG TCACTGTCAG AGAAATAAAG 5760 AATTGTCTTA AATGTCAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAA Seq ID NO: 451 Protein sequence Protein Accession # : POU1860. 2 1 11 21 31 41 51 MDGVNLSTEV VYKKGQDYRF ACYDRGRACR SYRVRFLCGK PVRPKLTVTI DTNVNSTILN 60 LEDNVQSWKP GDTLVIASTD YSMYQAEEFQ VLPCRSCAPN QVKVAGKPMY LHIGEEIDGV 120 DMRAEVGLLS RNIIVMGEME DKCYPYRNHI CNFFDFDTFG GHIKFALGFK AAHLEGTELK 180 HMGQQLVGQY PIHFHLAGDV DERGGYDPPT YIRDLSIHHT FSRCVTVHGS NGLLIKDWG 240 YNSLGHCFFT EDGPEERNTF DHCLGLLVKS GTLLPSDRDS KMCKMITGDS YPGYIPKPRQ 300 DCNAVSTFWM ANPNNNLINC AAAGSEETGF WFIFHHVPTG PSVGMYSPGY SEHIPLGKFY 360 NNRAHSNYRA GMIIDNGVKT TEASAKDKRP FLSIISARYS PHQDADPLKP REPAIIRHFI 420 AYKNQDHGAW LRGGDVWLDS CRFADNGIGL TLASGGTFPY DDGSKQEIKN SLFVGESGNV 480 GTEMMDNRIW GPGGLDHSGR TLPIGQNFPI RGIQLYDGPI NIQNCTFRKF VALEGRHTSA 540 LAFRLNNAWQ SCPHNNVTGI AFEDVPITSR VFFGEPGPWF NQLDMDGDKT SVFHDVDGSV 600 SEYPGSYLTK NDNWLVRHPD CINVPDWRGA ICSGCYAQMY IQAYKTSNLR MKIIKNDFPS 660 HPLYLEGALT RSTHYQQYQP WTLQKGYTI HWDQTAPAEL AIWLINFNKG DWIRVGLCYP 720 RGTTFSILSD VHNRLLKQTS KTGVFVRTLQ MDKVEQSYPG RSHYYWDEDS GLLFLKLKAQ 780 NEREKFAFCS MKGCERIKIK ALIPKNAGVS DCTATAYPKF TERAVWVPM PKKLFGSQLK 840 TKDHFLEVKM ESSKQHFFHL WNDFAYIEVD GKKYPSSEDG IQVWIDGNQ GRWSHTSFR 900 NSILQGIPWQ LFNYVATIPD NSIVLMASKG RYVSRGPWTR VLEKLGADRG LKLKEQMAFV 960 GFKGSFRPIW VTLDTEDHKA KIFQWPIPV VKKKKL Seq ID NO : 452 DNA sequence Nucleic Acid Accession &num : Eos sequence Coding sequence: 261.. 2861 1 11 21 31 41 51 # # # # # # GAGCTAGCGC TCAAGCAGAG CCCAGCGCGG TGCTATCGGA CAGAGCCTGG CGAGCGCAAG 60 CGGCGCGGGG AGCCAGCGGG GCTGAGCGCG GCCAGGGTCT GAACCCAGAT TTCCCAGACT 120 AGCTACCACT CCGCTTGCCC ACGCCCCGGG AGCTCGCGGC GCCTGGCGGT CAGCGACCAG 180 ACGTCCGGGG CCGCTGCGCT CCTGGCCCGC GAGGCGTGAC ACTGTCTCGG CTACAGACCC 240 AGAGGGAGCA CACTGCCAGG ATGGGAGCTG CTGGGAGGCA GGACTTCCTC TTCAAGGCCA 300 TGCTGACCAT CAGCTGGCTC ACTCTGACCT GCTTCCCTGG GGCCACATCC ACAGTGGCTG 360 CTGGGTGCCC TGACCAGAGC CCTGAGTTGC AACCCTGGAA CCCTGGCCAT GACCAAGACC 420 ACCATGTGCA TATCGGCCAG GGCAAGACAC TGCTGCTCAC CTCTTCTGCC ACGGTCTATT 480 CCATCCACAT CTCAGAGGGA GGCAAGCTGG TCATTAAAGA CCACGACGAG CCGATTGTTT 540 TGCGAACCCG GCACATCCTG ATTGACAACG GAGGAGAGCT GCATGCTGGG AGTGCCCTCT 600 GCCCTTTCCA GGGCAATTTC ACCATCATTT TGTATGGAAG GGCTGATGAA GGTATTCAGC 660 CGGATCCTTA CTATGGTCTG AAGTACATTG GGGTTGGTAA AGGAGGCGCT CTTGAGTTGC 720 ATGGACAGAA AAAGCTCTCC TGGACATTTC TGAACAAGAC CCTTCACCCA GGTGGCATGG 780 CAGAAGGAGG CTATTTTTTT GAAAGGAGCT GGGGCCACCG TGGAGTTATT GTTCATGTCA 840 TCGACCCCAA ATCAGGCACA GTCATCCATT CTGACCGGTT TGACACCTAT AGATCCAAGA 900 AAGAGAGTGA ACGTCTGGTC CAGTATTTGA ACGCGGTGCC CGATGGCAGG ATCCTTTCTG 960 TTGCAGTGAA TGATGAAGGT TCTCGAAATC TGGATGACAT GGCCAGGAAG GCGATGACCA 1020 AATTGGGAAG CAAACACTTC CTGCACCTTG GATTTAGACA CCCTTGGAGT TTTCTAACTG 1080 TGAAAGGAAA TCCATCATCT TCAGTGGAAG ACCATATTGA ATATCATGGA CATCGAGGCT 1140 CTGCTGCTGC CCGGGTATTC AAATTGTTCC AGACAGAGCA TGGCGAATAT TTCAATGTTT 1200 CTTTGTCCAG TGAGTGGGTT CAAGACGTGG AGTGGACGGA GTGGTTCGAT CATGATAAAG 1260 TATCTCAGAC TAAAGGTGGG GAGAAAATTT CAGACCTCTG GAAAGCTCAC CCAGGAAAAA 1320 TATGCAATCG TCCCATTGAT ATACAGGCCA CTACAATGGA TGGAGTTAAC CTCAGCACCG 1380 AGGTTGTCTA CAAAAAAGGC CAGGATTATA GGTTTGCTTG CTACGACCGG GGCAGAGCCT 1440 GCCGGAGCTA CCGTGTACGG TTCCTCTGTG GGAAGCCTGT GAGGCCCAAA CTCACAGTCA 1500 CCATTGACAC CAATGTGAAC AGCACCATTC TGAACTTGGA GGATAATGTA CAGTCATGGA 1560 AACCTGGAGA TACCCTGGTC ATTGCCAGTA CTGATTACTC CATGTACCAG GCAGAAGAGT 1620 TCCAGGTGCT TCCCTGCAGA TCCTGCGCCC CCAACCAGGT CAAAGTGGCA GGGAAACCAA 1680 TGTACCTGCA CATCGGGGAG GAGATAGACG GCGTGGACAT GCGGGCGGAG GTTGGGCTTC 1740 TGAGCCGGAA CATCATAGTG ATGGGGGAGA TGGAGGACAA ATGCTACCCC TACAGAAACC 1800 ACATCTGCAA TTTCTTTGAC TTCGATACCT TTGGGGGCCA CATCAAGTTT GCTCTGGGAT 1860 TTAAGGCAGC ACACTTGGAG GGCACGGAGC TGAAGCATAT GGGACAGCAG CTGGTGGGTC 1920 AGTACCCGAT TCACTTCCAC CTGGCCGGTG ATGTAGACGA AAGGGGAGGT TATGACCCAC 1980 CCACATACAT CAGGGACCTC TCCATCCATC ATACATTCTC TCGCTGCGTC ACAGTCCATG 2040 GCTCCAATGG CTTGTTGATC AAGGACGTTG TGGGCTATAA CTCTTTGGGC CACTGCTTCT 2100 TCACGGAAGA TGGGCCGGAG GAACGCAACA CTTTTGACCA CTGTCTTGGC CTCCTTGTCA 2160 AGTCTGGAAC CCTCCTCCCC TCGGACCGTG ACAGCAAGAT GTGCAAGATG ATCACAGAGG 2220 ACTCCTACCC AGGGTACATC CCCAAGCCCA GGCAAGACTG CAATGCTGTG TCCACCTTCT 2280 GGATGGCCAA TCCCAACAAC AACCTCATCA ACTGTGCCGC TGCAGGATCT GAGGAAACTG 2340 GATTTTGGTT TATTTTTCAC CACGTACCAA CGGGCCCCTC CGTGGGAATG TACTCCCCAG 2400 GTTATTCAGA GCACATTCCA CTGGGAAAAT TCTATAACAA CCGAGCACAT TCCAACTACC 2460 GGGCTGGCAT GATCATAGAC AACGGAGTCA AAACCACCGA GGCCTCTGCC AAGGACAAGC 2520 GGCCGTTCCT CTCAATCATC TCTGCCAGAT ACAGCCCTCA CCAGGACGCC GACCCGCTGA 2580 AGCCCCGGGA GCCGGCCATC ATCAGACACT TCATTGCCTA CAAGAACCAG GACCACGGGG 2640 CCTGGCTGCG CGGCGGGGAT GTGTGGCTGG ACAGCTGCCA TTTCAGAGGG GAGGCTCAGG 2700 AAGGCTTCTT GCTTACAGGA ATGAAGGCTG GGGGCATTTT GCTGGGGGGA GATGAGGCAG 2760 CCTCTGGAAT GGCTCAGGGA TTCAGCCCTC CCTGCCGCTG CCTGCTGAAG CTGGTGACTA 2820 CGGGGTCGCC CTTTGCTCAC GTCTCTCTGG CCCACTCATG ATGGAGAAGT GTGGTCAGAG 2880 GGGAGCAATG GGCTTTGCTG CTTATGAGCA CAGAGGAATT CAGTCCCCAG GCAGCCCTGC 2940 CTCTGACTCC AAGAGGGTGA AGTCCACAGA AGTGAGCTCC TGCCTTAGGG CCTCATTTGC 3000 TCTTCATCCA GGGAACTGAG CACAGGGGGC CTCCAGGAGA CCCTAGATGT GCTCGTACTC 3060 CCTCGGCCTG GGATTTCAGA GCTGGAAATA TAGAAAATAT CTAGCCCAAA GCCTTCATTT 3120

1 11 21 31 41 51 MVAGTRCLLA LLLPQVLLGG AAGLVPELGR RKFAAASSGR PSSQPSDEVL SEFELRLLSM 60 FGLKQRPTPS RDAWPPYML DLYRRHSGQP GSPAPDHRLE RAASRANTVR SFHHEESLEE 120 LPETSGKTTR RFFFNLSSIP TEEFITSAEL QVFREQMQDA LGNNSSFHHR INIYEIIKPA 180 TANSKFPVTR LLDT Seq ID NO : 458 DNA sequence Nucleic Acid Accession # : NM 001999. 2 Coding sequence: 1.. 8736 1 11 21 31 41 51 ATGGGGAGAA GACGGAGGCT GTGTCTCCAG CTCTACTTCC TGTGGCTGGG CTGTGTGGTG 60 CTCTGGGCGC AGGGCACGGC CGGCCAGCCT CAGCCTCCTC CGCCCAAGCC GCCCCGGCCC 120 CAGCCGCCGC CGCAACAGGT TCGGTCCGCT ACAGCAGGCT CTGAAGGCGG GTTTCTAGCG 180 CCCGAGTATC GCGAGGAGGG TGCCGCAGTG GCCAGCCGCG TCCGCCGGCG AGGACAGCAG 240 GACGTGCTCC GAGGGCCCAA CGTGTGCGGC TCCAGATTCC ACTCCTACTG CTGCCCTGGA 300 TGGAAGACGC TCCCTGGAGG AAACCAGTGC ATTGTCCCGA TTTGTAGAAA TAGTTGTGGA 360 GATGGATTTT GTTCCCGTCC TAACATGTGT ACTTGTTCCA GTGGGCAAAT ATCATCAACC 420 TGTGGATCAA AATCAATTCA GCAGTGCAGT GTGAGATGCA TGAATGGTGG GACCTGTGCA 480 GATGACCACT GCCAGTGCCA GAAAGGATAT ATTGGAACTT ATTGTGGACA ACCTGTCTGT 540 GAAAATGGAT GTCAGAATGG TGGACGTTGC ATCGCCCAAC CGTGTGCTTG TGTTTATGGG 600 TTCACTGGTC CACAGTGTGA AAGAGATTAC AGGACAGGCC CGTGTTTCAC TCAGGTCAAC 660 AACCAGATGT GCCAAGGGCA GCTGACAGGC ATTGTCTGCA CGAAGACTCT GTGCTGTGCC 720 ACCACTGGAC GGGCGTGGGG CCATCCCTGT GAGATGTGTC CAGCCCAGCC TCAGCCCTGC 780 CGACGGGGTT TCATCCCCAA CATCCGCACT GGAGCTTGCC AAGATGTTGA TGAATGCCAG 840 GCTATCCCAG GGATATGCCA AGGAGGAAAC TGTATCAATA CAGTGGGCTC TTTTGAATGC 900 AGATGCCCTG CTGGTCACAA ACAGAGTGAA ACTACTCAGA AATGTGAAGA CATTGATGAG 960 TGCAGCATCA TTCCTGGGAT ATGTGAAACT GGTGAATGTT CCAACACCGT GGGAAGCTAT 1020 TTTTGTGTTT GTCCACGTGG ATATGTAACC TCAACAGATG GCTCTCGATG CATCGATCAG 1080 AGAACAGGCA TGTGTTTCTC GGGCCTGGTG AATGGCCGCT GTGCACAAGA GCTCCCGGGG 1140 AGAATGACGA AAATGCAGTG CTGCTGTGAG CCTGGCCGCT GCTGGGGCAT CGGAACCATT 1200 CCTGAAGCCT GTCCTGTCAG AGGTTCTGAG GAATATCGCA GACTTTGCAT GGATGGACTT 1260 CCAATGGGAG GAATTCCAGG GAGTGCTGGT TCCAGACCTG GAGGCACTGG GGGAAATGGC 1320 TTTGCCCCAA GTGGCAATGG CAATGGCTAT GGCCCAGGAG GGACAGGCTT CATCCCCATC 1380 CCTGGAGGCA ATGGCTTTTC TCCTGGCGTT GGGGGAGCCG GTGTGGGGGC CGGGGGACAG 1440 GGACCTATCA TCACTGGACT AACAATTCTG AACCAGACAA TAGATATCTG TAAGCATCAT 1500 GCTAACCTTT GTTTAAATGG ACGCTGTATA CCAACTGTCT CAAGCTACCG ATGTGAATGC 1560 AACATGGGTT ATAAGCAGGA TGCAAATGGA GATTGTATAG ATGTTGATGA ATGCACATCA 1620 AATCCCTGCA CTAATGGAGA TTGTGTTAAC ACACCTGGTT CCTATTATTG TAAATGTCAT 1680 GCTGGATTCC AGAGGACTCC TACCAAGCAA GCATGCATTG ATATTGATGA GTGCATCCAG 1740 AATGGGGTTC TTTGTAAAAA CGGTCGATGC GTGAACTCAG ATGGAAGTTT CCAGTGCATT 1800 TGCAATGCCG GCTTTGAATT AACTACAGAT GGAAAAAACT GTGTTGATCA TGATGAATGT 1860 ACAACTACCA ACATGTGTTT GAATGGAATG TGCATCAATG AAGATGGCAG CTTCAAGTGC 1920 ATCTGCAAAC CAGGATTTGT CTTGGCTCCA AATGGGCGTT ACTGTACTGA TGTTGATGAA 1980 TGCCAGACCC CAGGAATCTG CATGAATGGG CACTGCATCA ACAGTGAAGG GTCCTTCCGC 2040 TGTGACTGTC CCCCAGGCCT GGCTGTGGGC ATGGATGGAC GTGTGTGTGT TGATACTCAC 2100 ATGCGCAGTA CCTGCTATGG AGGAATCAAG AAAGGAGTGT GTGTGCGTCC TTTCCCCGGT 2160 GCAGTGACCA AGTCCGAATG CTGCTGTGCC AATCCAGACT ATGGTTTTGG AGAACCCTGC 2220 CAGCCATGCC CTGCAAAAAA TTCAGCTGAA TTCCACGGCC TTTGTAGTAG TGGAGTAGGT 2280 ATCACTGTGG ATGGAAGAGA TATCAATGAA TGTGCTTTGG ATCCTGATAT ATGTGCCAAT 2340 GGGATTTGTG AAAACTTACG TGGTAGTTAC CGTTGTAATT GCAACAGTGG CTATGAACCA 2400 GATGCCTCTG GAAGAAACTG TATTGACATT GATGAATGTT TAGTAAACAG ACTGCTTTGT 2460 GATAACGGAT TGTGCCGAAA CACGCCAGGA AGTTACAGCT GTACGTGCCC ACCAGGGTAT 2520 GTGTTCAGGA CTGAGACAGA GACCTGTGAA GATATAAATG AATGTGAAAG CAACCCATGT 2580 GTCAATGGGG CCTGCAGAAA CAACCTTGGA TCTTTCAATT GTGAATGTTC GCCCGGCAGC 2640 AAACTCAGCT CCACAGGATT GATCTGTATT GACAGCCTGA AGGGGACCTG TTGGCTCAAC 2700 ATCCAGGACA GCCGCTGTGA GGTGAATATT AATGGAGCCA CTCTGAAATC TGAATGCTGT 2760 GCCACCCTCG GAGCCGCCTG GGGGAGCCCC TGTGAGCGGT GTGAACTAGA TACAGCTTGC 2820 CCAAGAGGGC TTGCCAGGAT TAAAGGTGTT ACGTGTGAAG ATGTTAATGA GTGTGAGGTG 2880 TTCCCTGGCG TTTGTCCAAA TGGACGCTGT GTCAACAGTA AGGGATCTTT TCATTGCGAG 2940 TGCCCTGAAG GCCTTACGTT GGATGGGACT GGCCGTGTAT GTTTGGATAT TCGCATGGAG 3000 CAGTGTTACT TGAAGTGGGA TGAAGATGAA TGCATCCACC CCGTTCCTGG AAAGTTCCGC 3060 ATGGATGCCT GCTGCTGTGC TGTCGGGGCG GCTTGGGGCA CCGAGTGTGA GGAGTGCCCC 3120 AAACCTGGCA CCAAGGAATA CGAGACACTG TGCCCCCGCG GGGCTGGCTT TGCTAACCGA 3180 GGGGATGTTC TTACTGGGCG GCCATTTTAC AAAGACATCA ATGAATGCAA AGCATTTCCT 3240 GGGATGTGCA CTTATGGGAA GTGCAGAAAT ACAATCGGAA GCTTCAAATG CCGTTGCAAT 3300 AGTGGCTTTG CTCTAGACAT GGAGGAAAGA AACTGCACGG ACATCGACGA GTGCAGGATT 3360 TCTCCTGACC TCTGTGGCAG TGGAATCTGC GTCAATACAC CGGGCAGCTT TGAGTGCGAG 3420 TGCTTCGAAG GCTATGAAAG TGGCTTCATG ATGATGAAGA ACTGCATGGA CATTGACGGA 3480 TGTGAACGTA ACCCTCTCCT TTGTAGGGGT GGCACCTGTG TGAACACTGA GGGCAGCTTT 3540 CAGTGTGACT GCCCACTGGG ACACGAGCTG TCACCATCCC GTGAGGACTG TGTGGATATT 3600 AATGAATGCT CCCTGAGTGA CAATCTCTGC AGAAATGGAA AATGTGTGAA CATGATTGGA 3660 ACCTATCAGT GCTCTTGCAA TCCTGGATAT CAGGCTACGC CAGACCGCCA GGGCTGTACA 3720 GATATTGATG AATGTATGAT AATGAACGGA GGCTGTGACA CCCAGTGCAC AAATTCAGAG 3780 GGAAGCTACG AATGCAGCTG CAGTGAGGGT TATGCCCTGA TGCCAGATGG GAGATCGTGT 3840 GCAGACATTG ATGAATGTGA AAACAATCCT GATATCTGTG ATGGCGGCCA GTGTACCAAC 3900 ATTCCTGGAG AGTATCGCTG CCTCTGCTAT GATGGCTTCA TGGCTTCCAT GGACATGAAA 3960 ACATGCATTG ATGTCAATGA ATGTGACCTA AATTCAAATA TCTGCATGTT TGGGGAATGT 4020 GAGAACACAA AGGGATCCTT CATTTGCCAC TGTCAGCTGG GTTACTCAGT GAAGAAGGGG 4080 ACCACAGGAT GTACAGATGT GGATGAGTGT GAAATTGGTG CTCATAACTG CGACATGCAT 4140 GCCTCATGTC TGAATATCCC AGGAAGCTTC AAGTGTAGCT GCAGAGAAGG CTGGATTGGA 4200 AACGGCATCA AGTGTATTGA TCTGGACGAA TGTTCTAATG GAACCCACCA GTGTAGCATC 4260 AATGCTCAGT GTGTAAATAC CCCGGGCTCA TACCGCTGTG CCTGCTCCGA AGGTTTCACT 4320 GGTGATGGCT TTACCTGCTC AGATGTTGAT GAGTGTGCAG AAAACATAAA CCTCTGTGAG 4380

AACGGACAGT GCCTTAATGT CCCGGGTGCA TATCGCTGCG AGTGTGAGAT GGGCTTCACT 4440 CCAGCCTCAG ACAGCAGATC CTGCCAAGAT ATTGATGAAT GCTCCTTCCA AAACATTTGT 4500 GTCTCTGGAA CATGTAATAA CCTGCCTGGA ATGTTTCATT GCATCTGCGA TGATGGTTAT 4560 GAATTGGACA GAACAGGAGG GAACTGTACA GATATTGATG AGTGTGCAGA TCCTATAAAC 4620 TGTGTCAATG GCCTATGTGT CAACACGCCT GGTCGCTATG AGTGTAACTG CCCACCCGAT 4680 TTTCAGTTGA ACCCAACTGG TGTGGGTTGT GTTGACAACC GTGTGGGCAA CTGCTACCTG 4740 AAGTTTGGAC CTCGAGGAGA TGGGAGTCTG TCTTGCAACA CCGAGATCGG GGTGGGCGTC 4800 AGTCGCTCTT CATGCTGCTG CTCTCTGGGA AAGGCCTGGG GAAACCCCTG TGAGACATGC 4860 CCCCCTGTCA ATAGCACTGA ATATTACACC CTGTGTCCCG GAGGTGAAGG CTTCAGACCT 4920 AACCCCATCA CAATCATTTT AGAAGACATT GACGAATGCC AGGAGTTACC AGGTCTCTGC 4980 CAGGGTGGAA ACTGCATCAA CACTTTTGGG AGCTTCCAGT GTGAGTGCCC ACAAGGCTAC 5040 TACCTCAGCG AGGATACCCG CATCTGTGAG GATATTGATG AGTGTTTTGC ACATCCTGGT 5100 GTGTGTGGGC CTGGGACCTG CTATAACACC CTGGGAAATT ACACCTGCAT TTGCCCACCT 5160 GAGTACATGC AGGTCAATGG AGGCCACAAC TGCATGGACA TGAGAAAAAG CTTTTGCTAC 5220 CGAAGCTATA ATGGAACCAC TTGTGAGAAT GAGTTGCCTT TCAATGTGAC AAAAAGGATG 5280 TGCTGCTGCA CATATAATGT GGGCAAAGCT GGGAACAAAC CTTGTGAACC ATGCCCAACT 5340 CCAGGAACAG CTGACTTTAA AACCATATGT GGAAATATTC CTGGATTCAC CTTTGACATT 5400 CACACAGGAA AAGCTGTTGA CATTGATGAA TGTAAAGAGA TTCCAGGCAT TTGTGCAAAT 5460 GGTGTGTGCA TTAACCAGAT TGGCAGTTTC CGCTGTGAAT GCCCTACAGG ATTCAGTTAC 5520 AATGACCTGC TGTTGGTTTG TGAAGATATA GATGAGTGCA GCAATGGTGA TAATCTCTGC 5580 CAGCGGAATG CAGACTGCAT CAATAGTCCT GGTAGTTACC GCTGTGAATG TGCCGCGGGT 5640 TTCAAACTTT CACCCAATGG GGCCTGTGTA GATCGCAATG AATGTTTAGA AATTCCTAAC 5700 GTTTGCAGTC ATGGCTTGTG TGTTGATCTG CAAGGAAGTT ACCAGTGCAT CTGCCACAAT 5760 GGCTTTAAGG CTTCTCAGGA CCAGACCATG TGCATGGATG TTGATGAGTG CGAGCGGCAC 5820 CCATGTGGAA ATGGAACTTG TAAAAACACC. GTTGGATCCT ATAACTGTCT GTGCTACCCA 5880 GGGTTTGAAC TCACTCATAA TAATGATTGC CTGGACATAG ATGAGTGCAG TTCCTTTTTT 5940 GGTCAGGTGT GCAGAAATGG ACGTTGTTTT AATGAAATTG GTTCTTTCAA GTGTCTATGT 6000 AACGAAGGTT ATGAACTTAC CCCAGATGGC AAAAACTGTA TAGACACTAA TGAGTGTGTC 6060 GCCCTTCCCG GCTCTTGCTC TCCTGGTACC TGTCAGAATT TGGAGGGATC CTTCAGATGC 6120 ATCTGTCCCC CAGGGTATGA AGTAAAAAGC GAGAACTGCA TTGATATAAA TGAATGTGAT 6180 GAAGATCCCA ACATTTGTCT TTTTGGTTCC TGTACTAATA CTCCAGGGGG CTTCCAGTGC 6240 CTCTGCCCCC CTGGCTTTGT ACTATCTGAT AATGGACGGA GATGCTTTGA TACTCGCCAG 6300 AGCTTCTGCT TCACAAATTT TGAAAATGGA AAGTGTTCTG TACCCAAAGC TTTCAACACC 6360 ACAAAAGCAA AATGCTGCTG TAGTAAGATG CCAGGAGAGG GCTGGGGGGA CCCCTGTGAG 6420 CTGTGCCCCA AAGACGATGA AGTTGCATTT CAGGATTTGT GTCCATATGG CCATGGAACT 6480 GTCCCTAGTC TTCATGATAC ACGTGAAGAT GTCAATGAGT GTCTTGAGAG CCCAGGCATT 6540 TGTTCAAATG GTCAATGTAT CAACACCGAC GGATCTTTTC GCTGTGAATG TCCAATGGGC 6600 TACAACCTTG ACTACACTGG AGTACGCTGT GTGGATACTG ATGAGTGTTC AATCGGCAAT 6660 CCGTGTGGAA ATGGTACATG CACCAATGTT ATTGGGAGTT TTGAATGCAA TTGCAATGAA 6720 GGCTTTGAGC CAGGGCCCAT GATGAATTGT GAAGATATCA ACGAATGTGC CCAGAACCCA 6780 CTGCTGTGTG CTTTACGCTG CATGAACACT TTTGGGTCCT ATGAATGCAC GTGCCCGATT 6840 GGCTATGCCC TCAGGGAAGA TCAAAAGATG TGCAAAGATC TGGATGAATG TGCTGAAGGG 6900 TTACACGACT GTGAATCTAG GGGCATGATG TGTAAGAATC TAATCGGCAC CTTCATGTGC 6960 ATCTGCCCTC CTGGAATGGC CCGAAGGCCC GATGGAGAAG GCTGTGTAGA TGAAAATGAA 7020 TGCAGGACCA AGCCAGGAAT CTGTGAAAAT GGACGTTGTG TTAACATTAT TGGAAGCTAT 7080 AGATGTGAGT GTAATGAAGG ATTCCAGTCA AGTTCTTCAG GCACTGAATG CCTTGACAAT 7140 CGACAGGGTC TCTGCTTTGC AGAGGTACTG CAGACAATAT GTCAAATGGC ATCCAGTAGT 7200 CGCAATCTCG TCACTAAGTC AGAATGCTGC TGTGATGGTG GGCGAGGCTG GGGCCACCAG 7260 TGCGAGCTTT GCCCACTTCC TGGAACTGCC CAGTACAAAA AGATATGTCC TCATGGCCCA 7320 GGATATACAA CTGATGGAAG AGATATTGAT GAATGTAAGG TAATGCCAAA CCTCTGCACC 7380 AATGGTCAGT GCATCAATAC CATGGGCTCA TTCCGATGCT TCTGCAAGGT TGGCTACACC 7440 ACAGACATCA GTGGAACCTC TTGTATAGAC, CTTGATGAAT GCTCCCAGTC CCCGAAACCA 7500 TGCAACTACA TCTGCAAGAA CACTGAGGGG AGTTATCAGT GTTCATGTCC GAGGGGGTAT 7560 GTCCTGCAAG AGGATGGAAA GACATGCAAA GACCTTGATG AATGTCAAAC AAAGCAGCAT 7620 AACTGCCAGT TCCTCTGTGT CAACACCCTG GGGGGGTTTA CCTGTAAATG TCCACCTGGT 7680 TTCACACAGC ATCACACTGC TTGTATCGAC AACAACGAAT GTGGGTCTCA ACCTTTGCTT 7740 TGTGGAGGAA AGGGAATCTG TCAAAACACT CCAGGCAGTT TCAGCTGTGA ATGCCAAAGA 7800 GGGTTCTCTC TTGATGCCAC CGGACTGAAC TGTGAAGATG TTGATGAATG TGATGGGAAC 7860 CACAGGTGCC AACACGGCTG CCAGAACATC CTGGGTGGCT ACAGATGTGG CTGCCCCCAA 7920 GGCTACATCC AGCACTACCA GTGGAATCAG TGTGTCGATG AGAATGAATG CTCCAATCCC 7980 AATGCCTGTG GCTCTGCTTC CTGCTACAAC ACCCTGGGGA GTTACAAGTG CGCCTGCCCC 8040 TCGGGGTTCT CCTTCGACCA GTTCTCCAGT GCCTGCCACG ACGTGAATGA GTGCTCGTCC 8100 TCCAAGAACC CCTGCAATTA CGGCTGCTCT AACACGGAGG GGGGCTACCT CTGTGGCTGC 8160 CCCCCTGGGT ATTACAGAGT GGGACAAGGC CACTGTGTCT CAGGAATGGG ATTTAACAAG 8220 GGGCAGTACC TGTCACTGGA TACAGAGGTC GATGAGGAAA ATGCTCTGTC CCCAGAAGCA 8280 TGCTACGAGT GCAAAATCAA CGGCTATCCT AAGAAAGACA GCAGGCAGAA GAGAAGTATT 8340 CATGAACCTG ATCCCACTGC TGTTGAACAG ATCAGCCTAG AGAGTGTCGA CATGGACAGC 8400 CCCGTCAACA TGAAGTTCAA CCTCTCCCAC CTCGGCTCTA AGGAGCACAT CCTGGAACTA 8460 AGGCCCGCCA TCCAGCCCCT CAACAACCAC ATCCGTTATG TCATCTCTCA AGGGAACGAT 8520 GACAGCGTCT TCCGCATCCA CCAAAGGAAT GGGCTCAGCT ACTTGCACAC GGCCAAGAAG 8580 AAGCTCATGC CCGGCACATA CACACTGGAA ATCACTAGCA TCCCTCTCTA CAAGAAGAAG 8640 GAGCTTAAGA AACTGGAAGA GAGCAATGAG GATGACTACC TCCTAGGGGA GCTTGGGGAG 8700 GCTCTCAGAA TGAGGCTGCA GATTCAGCTC TATTAACCGT TCACAGACTT GGGCCCAGGC 8760 TCAAATCCTA GCACAGCCAG TCTGCAGAAG CATTTGAAAA GTCAAGGACT AATTTTAAAG 8820 AGGAAAAATA ATAATAACTC TTGTTTCTTT CCTCCCTGTC TTAGACTTTG AATGTTGACC 8880 CTCACAGGGA GGGATAATTT AGACTCTGGT ATGGCCAAAG ATTTGAGCTC AAAGGCAACC 8940 GTGGTTACTG TATTTTTTAT ATAACTTCAT TTTAAAATAT ATTAAAAGAA ACCTAAATGT 9000 TCAAGATATC AGCATATGGC ACTAAATGCA CAAAAATAAT GTGAGCTTTT TTTTTTTTTT 9060 CCTGTTAGCA GTCTGTAACA CTTTGGGTAT TTTGCTATAG TTGCTAATTA AAAAAATATA 9120 GATGTTTATT TATTTTTAAT GCAGTAATAT ATGGAGAAAT GAACAAACTA TGTAAACAAA 9180 AAGGGAAACT CACTTGTTTT TCTTTAGATT TATAAATTTG AGCTATTTTT TTTAGAGGTG 9240 CTTTTTAAAA ATCCAATAGA TACAAGAGAT GTTTCCTTTG GTTTTCTGCC AGTCATCCAG 9300 CTGATACACA CCTGATCGAT TTTAAAGAAA GCCACACAGA GCTGAATCGG GCAGTGCTAA 9360 TCAATAATTT AAAAGACATG AATGTCATTA GATCCTTTAT AACGTAGATC GAAGCCAAAG 9420 CAGCTCATTT GTGACAACAT TTCATATCAC CAGACACACC AGGCAACAGA AGTTGAAGCA 9480 CAACCACTGT AGCAAAATAC CTTGACTGCT TGTGAGACCA TTAGCATTGC AGGCCAAACC 9540 GTACTGTATT TCCTTCTCAT AACCTCAAGG AACCATATGT GCTACCCACA ACACCTCATT 9600

GRYSIYIANY AYGNVGPDAL IEMDPEASDL SRGILALRDV AAEAGVSKYT GGRGVSVGPI 240 LSSSASDIFC DNENGPNFLF HNRGDGTFVD AAASAGVDDP HQHGRGVALA DFNRDGKVDI 300 VYGNWNGPHR LYLQMSTHGK VRFRDIASPK FSMPSPVRTV ITADFDNDQE LEIFFNNIAY 360 RSSSANRLFR VIRREHGDPL IEELNPGDAL EPEGRGTGGV VTDFDGDGML DLILSHGESM 420 AQPLSVFRGN QGFNNNWLRV VPRTRFGAFA RGAKWLYTK KSGAHLRIID GGSGYLCEME 480 PVAHPGLGKD EASSVEVTWP DGKMVSRNVA SGEMNSVLEI LYPRDEDTLQ DPAPLECGQG 540 FSQQENGHCM DTNECIQFPF VCPRDKPVCV NTYGSYRCRT NKKCSRGYEP NEDGTACVGT 600 LGQSPGPRPT TPTAAAATAA AAAAAGAATA APVLVDGDLN LGSWKESCE PSC Seq ID NO : 472 DNA sequence Nucleic Acid Accession # : FGENESHH Coding sequence ; 1.. 4794 1 11 21 31 41 51 ATGGCGTGTC CGGGAGGACT CCCAGCCCGT TGCTCTGGTT GGATGGGACT GGGTGGGCCC 60 AGCGGCTCCT CCCCAGCATC CCCTCCCCAT TCCTCCTCCA GGTACAATGG ACCCAACCTG 120 GTTCTGAAGT ATGACCGGGC CCAGAAGCGG CTGGTGAACA TCGCGGTCGA TGAGCGCAGC 180 TCACCCTACT ACGCGCTGCG GGACCGGCAG GGGAACGCCA TCGGGGTCAC AGCCTGCGAC 240 ATCGACGGGG ACGGCCGGGA GGAGATCTAC TTCCTCAACA CCAATAATGC CTTCTCGGGC 300 CACAGCAGCT CAGCGCAGGT CCCTTCTGGG CTCCACAGAA ACAGGCCTGT GCTGAAGCCT 360 CCACCTACAA CCCCTGCAGG CCTCCTGGGT CTGCCTCCAC TCAGCGGAAG GGACTTTTCC 420 TCCTCCCTGG GTCAGGCTTC TCCGGACAGC AGGCAGGGAG AGAGGGTGCC GGTTCCCTGC 480 TGTCGGGGTG GACTGAGACC TACCCATGAA CCAGAACCAT TTCTTCTGAG ACCCAAATCA 540 GGGGTGGCCA CGTACACCGA CAAGTTGTTC AAGTTCCGCA ATAACCGGTG GGAAGACATC 600 CTGAGCGATG AGGTCAACGT GGCCCGTGGT GTGGCCAGCC TCTTTGCCGG ACGCTCTGTG 660 GCCTGTGTGG ACAGAAAGGG CTCTGGACGC TACTCTATCT ACATTGCCAA TTACGCCTAC 720 GGTAATGTGG GCCCTGATGC CCTCATTGAA ATGGACCCTG AGGCCAGTGA CCTCTCCCGG 780 GGCATTCTGG CGCTCAGAGA TGTGGCTGCT GAGGCTGGGG TCAGCAAATA TACAGAAGGC 840 TTCTCCCACA CTGCCTCTCC AAGCATTGGT GAGATATCTG GCAGAACCGA GGAGCGGGAA 900 GGAGGAGACC CAGAGGAGGC AGATGAGGAG CACAGTGGGG ATGGAAGCAC CAGCCAACTG 960 TGCCGGCTGG GCTGGAAGGA CGGGCAGTTC AAGGAAGAAG CAGCAGCTTT GGTGGAGGAA 1020 CAGAGGGAGG CTGGGGCAGC TGGCGTGCCC AGAGGACGTG TTCGAACAGC TCTGCAGACT 1080 TCCAAAAGCC ATTTGGCTGA CAAGAACCTA TTTGGCCCAC CATGTTACTA TTCTGTCTGC 1140 GCGCCTTCTC CAGCCCACCC TTTCCCTGCC CGCCAAGCCC CCCAACACTA CCCTGTAGCC 1200 CCCCTTGTCA CTCAGCTAAT GACACATGGA CGTCTGGCTG GAAAACTAGC CCGGAGTGTC 1260 CCCCACCCCC GAGCCCCAGG AATGGACCCC AAATGTAAGG GCCGCCATGC TGAGCCCGGC 1320 CTGATGGCTG AGGCTTTGGG CGCGTGGCCA GCGCTCAGCA CCACTGTGGT GCCAGGGGGC 1380 CTGAGAAGCT GGGAGGAAAG CAGGCAGAAG GGGCAGGCCA TGTCCAGATG TGCACTCAGG 1440 GAGCTGGGAG GTCCCTGGAG CCAAGCCACA CAGCACCTGC CTGCTAGAGA GCTGTATGAC 1500 CTGGGAGAAC CTCCCATTTT ACAAAGAACA GACGGAGATC CAGGGAGGAG AAGGGACTCG 1560 CCCAAGGTCA CACAGGAGTG CCATCTAGTG GCCACCATGC CAGCTCTCGG GGGACTCGAG 1620 GGCCCCGGGA GGGTGGCCAA GCGAGAGATT GGGAGAGAGA CTGGGGCAGT AGGAAGACCA 1680 CTCTCCCATC CCCTGGTCCC CAACTTCCCC AGCTGCTTGA GGCCTCTTGA AGCCGGGACA 1740 GTGCCGGGAG CTGCCCTGCC TGGGAATCCT GGGAACTGGG TTCTGGACAT GGCCAAGGCC 1800 CTGGCGTGGA ACCAGATGGA AAAAGAGGAG GGGAAGATTC ATGGAGACCA TGAGCCCAGA 1860 TTTAGGCTCA GGAAAGCACG GGAAGCAGAA TTCCCCCCAG GCTCCTCTGA GGAGCCTCTG 1920 CTGCAGTTCC CCTCAGGCCT CAGAGGCAGC CCTGTCCTCC AGGTGGGCCT GGGGCTTGCT 1980 TCTGCCACTC ACTGTGGGTC GATGTCTTTT CTAGGGGGCC GAGGCGTCAG CGTGGGCCCC 2040 ATCCTCAGCA GCAGTGCCTC GGATATCTTC TGCGACAATG AGAATGGGCC TAACTTCCTT 2100 TTCCACAACC GGGGCGATGG CACCTTTGTG GACGCTGCGG CCAGTGCTGA ACGTCGTTTA 2160 GCCTTCATCG TTCACCTCAA ATATCACCTC TGCAGAGATT TTCCTCACTC CCTGTGCCAC 2220 CTAGCAGAAA CTGGTCCTTC CTCCTCCTGC TGCCCGTGGC ATGCACGTCT TCTTCAGGCT 2280 CCACATTGCC ATCATGGTTT GTCTATGAGC TTTACAAGGA CCGGGTCACG GTTCTATTCA 2340 TTCTTGACGC AAGGCTTGGC CTCCAGTGCC CACCGGAGGA CACTCAGCCT CCAGGGTTCT 2400 CAGGGGGCCC CACCCTGCCT TCTGGCAAGA GCTCCCTGTG TCCTGGGGTC TCTGATCCCC 2460 ACTGCCTATT ACATTGTCCT GTGGTCTGCC ATCCCAGAGA GCCTGATGAC CCACAGCTAT 2520 TTGTCCTCTG AAAGAGTCAA CGTGGGTGTG GACGACCCCC ACCAGCATGG GCGAGGTGTC 2580 GCCCTGGCTG ACTTCAACCG TGATGGCAAA GTGGACATCG TCTATGGCAA CTGGAATGGC 2640 CCCCACCGCC TCTATCTGCA AATGAGCACC CATGGGAAGG TCCGCTTCCG GGACATCGCC 2700 TCACCCAAGT TCTCCATGCC CTCCCCTGTC CGCACGGTCA TCACCGCCGA CTTTGACAAT 2760 GACCAGGAGC TGGAGATCTT CTTCAACAAC ATTGCCTACC GCAGCTCCTC AGCCAACCGC 2820 CTCTTCCGAT GCTCCATCCT GGCTCGTGGC TCTTCATCCT TGACAGCTGG TGGGAGGAAC 2880 GGTCAGGGAG AAGGTTTAAG AATCAGAAGG GGAGGGTTCC CAGGGCCAGG GGGTCAGGCC 2940 AAGGTCAACA CAGGTCCCCT GATGAAGAAA CAGAAAGGAA GGAAGGACGA GGACTGGGCA 3000 AGAGGCTGTG GGAATGCAGG GCAAAGCCTG GCCAAGGAGC CGGCCTCTGC TATTGCAGGG 3060 AAAGGGAAGG GAAATGTGGC CCAAAGTGTG CCCAGAACCC AAGCGCCACA AGATACAAAG 3120 CCACACTACC ACAAAAAGGG GCTACAGGGT CCAATCACTA CCAGGAAAAG GGGCTACGGG 3180 GTCCAATCAC TACCAGGAAA AGGGGCTACG GGGTCCAATC ACTACCAGGA AAAGGGGCTA 3240 CGGGGTCCAA TCACTACCAG GAAAAGGGGC TACGGGGTCC AATCACTACC AGGAAAAGGG 3300 GCTACGGGCT CCAATCACTA CCAGGAAAAG GGGCTACAGG GTCCAATCAC TACCAGGAAA 3360 AGGGGCTACG GGCTCCAATC ACTACCAGGA AAAGGGGCTA CAGGGTCCAA TCACTACCAC 3420 AGAAAGGGGC TACGGGCTCC AATCACTACC AGGAAAAGGG GCTACGGGGT CCAATCACTA 3480 CCAGGAAAAG GGGCTACAGG GTCCAATCAC TACCAGGAAA AGGGGCTACG GGGTCCAATC 3540 ACTACCAGGA AAAGGGGCTA CGGGCTCCAA TCACTACCAG GAAAAGGGGC TACGGGGTCC 3600 AATCACTACC AGGAAAAGGG GCTACAGGGT CCAATCACTA CCAGGAAAAG GGGCTACAGG 3660 GTCCAATCAC TACCACAGAA AGGGGCTACG GGCTCCAATC ACTACCAGGA AAAGGGGCTA 3720 CGGGGTCCAA TCACTACCAG GAAAAGGGGC TACGGGCTCC AATCACTACC AGGAAAAGAG 3780 GCTATGGGGT CCAATCACTA CCAGGAAAAG GGGCTACGGG CTCCAATCAC TACCAGGAAA 3840 AGGGGCTATG GGGTCCAATC ACTACCACAG AAAGGGGCTA CGGGGTCCAA CGTCATCCGT 3900 AGAGAGCACG GAGACCCCCT CATCGAGGAG CTCAATCCCG GCGACGCCTT GGAGCCTGAG 3960 GGCCGGGGCA CAGGGGGTGT GGTGACCGAC TTCGACGGAG ACGGGATGCT GGACCTCATC 4020 TTGTCCCATG GAGAGTCCAT GGCTCAGCCG CTGTCCGTCT TCCGGGGCAA TCAGGGCTTC 4080 AACAACAACT GGCTGCGAGT GGTGCCACGC ACCCGGTTTG GGGCCTTTGC CAGGGGAGCT 4140 AAGGTCGTGC TCTACACCAA GAAGAGTGGG GCCCACCTGA GGATCATCGA CGGGGGCTCA 4200 GGCTACCTGT GTGAGATGGA GCCCGTGGCA CACTTTGGCC TGGGGAAGGA TGAAGCCAGC 4260 AGTGTGGAGG TGACGTGGCC AGATGGCAAG ATGGTGAGCC GGAACGTGGC CAGCGGGGAG 4320

TGAACTTAGT TTATGGGTTA TTCAAGGATG TTTTTGGTTA TTTGGAACTG TCATACTTAA 780 ATACTTGACA TCTAAAATTT TTGGTATTGC AGATGACGCT CATATTGGCA ACTTACTAAC 840 ATCAAAATTC TTTAGTTATA AGGATTTTGA TACTTTATTG TATACCTGTG CAGCGGAGTT 900 TGACTTTATG GAAAAAGAGA CTCCACTGAG ATACACAAAG ACATTATTGC TTCCAGTTGT 960 TCTTGTAGTG TTTGTTGCTA TTGTTAGAAA GATTATTAGT GATATGTGGG GTGTCTTAGC 1020 TAAACAACAG ACACATGTAA GAAAACACCA GTTTGATCAT GGAGAGCTGG TTTACCATGC 1080 ATTGCAATTG TTAGCATATA CAGCCCTTGG TATTTTAATT ATGAGACTAA AACTCTTCTT 1140 GACACCACAC ATGTGTGTTA TGGCATCACT GATCTGCTCA AGACAGCTAT TTGGATGGCT 1200 CTTTTGCAAA GTACATCCTG GTGCTATTGT GTTTGCTATA TTAGCAGCAA TGTCAATACA 1260 AGGTTCAGCA AATCTGCAAA CCCAGTGGAA TATTGTAGGG GAGTTCAGCA ATTTGCCCCA 1320 AGAAGAACTT ATAGAATGGA TCAAATATAG TACTAAACCA GATGCAGTGT TTGCGGGTGC 1380 CATGCCCACG ATGGCAAGTG TTAAGCTCTC TGCACTTCGG CCCATTGTGA ATCATCCACA 1440 TTATGAAGAC GCAGGCTTGA GAGCCAGAAC AAAAATAGTA TACTCAATGT ATAGTCGGAA 1500 AGCAGCCGAA GAAGTGAAGC GAGAACTGAT AAAGTTAAAA GTGAACTATT ACATTCTAGA 1560 AGAGTCATGG TGTGTAAGAA GATCCAAGCC TGGTTGCAGT ATGCCTGAAA TTTGGGATGT 1620 AGAAGATCCT GCCAATGCTG GGAAAACTCC CTTATGTAAC CTCTTGGTGA AGGATTCCAA 1680 ACCTCACTTC ACCACTGTAT TCCAGAACAG TGTTTACAAA GTCCTAGAAG TTGTAAAAGA 1740 ATGACTGCTA CATGACCTGC TGCCTACGGA GAACTACATC TGTAATGGTT TTAATGTTTT 1800 GCTAAGTCAT GTGTTGTTCA TATCCCAAAA ACTTTTATAG GTAACTGTTT TCAAATAGAA 1860 AACGTTTTAT TTGGTCAATT TGAATGTCAT TCTAATTATA AAAATGACTT ACACCTTTAT 1920 CAATTGGTTA CTATTTCAAT GCACCCTTTA AAATTTGCTA TGCAAATGAG TATATGCTTG 1980 TACTTGACTT TAATATTTGT GCTAAAGTGA GCAAAGCTAC CTGTATAAAG AAAACACAGT 2040 GGGTTGTGAC AAGGATGACA TGAAAATACA GGACAATTCT GACAATGTAG GGGCTGATTT 2100 TATAGTGTAA GAACTATTAA TGCCCCTTGC TTCTTTTTTC TGCCTCTTGC TCTTGTCTTT 2160 TGGACATTTC AGTGATTGTA AGTTCTTCGG TCATGTCAGC CCCTGTCATC AACTTGAGTT 2220 ACAGTAGATG GGGCAGACAT GGAGTGTTTG CTATATAAAA CTATCTGTTT GTTTTACTTC 2280 CTTGTGCGCT TTTTGTTCTC TGTTCTCTTG TTAATGAAGC TTTTCCTGCC CATTATTAAT 2340 CCAAACTCTT GGACCTTGTG GTTAGGAAAT TCCCTTAACT TCCAGCCATA TGGCATTATC 2400 GTGTCTCTTT CTCTCTCTCT CTTGCTCTCT CTCTTCTCCT CTTCCCCATA TTTTCTGTCA 2460 AATAAGTACT GTTTACTCAT TTAGTTGCTT ATCAAGTACT TATTCTTGGT TTTAAAAAAA 2520 ATTAATGGTA ACTGTATTTT TCTCATTTTT AGCATTATTC AAATGTTTAT ATTTTAATAC 2580 CTTTAAACCA CTTTAAAGTT TTTTCATGTT TAATTATAGT TTTAAGAAAA ACTATTTTGA 2640 ACAACCCCAA ATATAGTGCA TCTAGAAACT AATGTATATT TGATTAGACA TCATTTATAG 2700 TGGAACAGTA GACTGTAGTA CATGGTAATT TTTCTTTTAC TATTAAGATA CAATAAAACA 2760 TGACTAATTT TGCTGTCAAA AATGTAAAGA ATAATGATAA ATGGAGTTTT TTATATTTTA 2820 CTTTTAAGAT TGCCTGTCTT TAATAAGACA AAGCCTTAAG CCTTATGTTA TAATTTTGGT 2880 TCTAAAAACC ATCATTTCAG TATAAGGAAT AAGTATATTT CGTCCTCCTC TTTAGTTTTT 2940 TTCTTCCTAT TTATTTTTAT TTTGAAAAAT TTCTACACCT TCTTTGAATT CCTTGTATGA 3000 ATTTTTGTTT CTTAGAAGTT AATTTGTGTG AAATGAGATT CTTCAAAACG ATGAAACCTC 3060 ATAGCTCTGA GAAAAGGTTT TAGGGTTTTA AATTCTAAGC AAAGCGTGAC TATGGCTGAC 3120 AGACTACACA TTTAATTATA CAGCTTCTCT TTCTTAACCA CAGGCAGATT AACCTCATTG 3180 TGGATTGTCC TTCAGACCTT AGTCCTCAGG CATGGTTTCT GGTGCCCACT CCTGGAAGCC 3240 GCTGTTCCCT TTCTACCTTC TTACCAGAGC CCAAGGGCAG GCCTGGTCCC GGGGAAGCAG 3300 CAGCTTGCTG ACATAAGTCA GCTGCAAAGG CTGAGGAGTG TGCCCTCAGA GAAGCACCGC 3360 CCCCCAGTCT TGTGCCAGCG CCTAGAGCCG CAGCTCCCAG GGATGCTCCT TCCCTGGAGG 3420 'CAGCCCAGGA GAGGGACTCT GGCAGCGTTC TTCAGATTTG TGGCCACTGT TTCTCATTTG 3480 CTGGTTGACT GTTTTTATTT CTTAGGCTTT TGCTAGTTTT AGAAAATAGG GAAGCAGCCC 3540 TTGATTTGTG GATTAAAAGC AACATTTGAG CGATGATGCA CAACAGTCCA GGAAAATGGG 3600 CGGTGGACAC TTGAGGCTGA GGATGGGAGT TGACATGAGC AGGGAGAGGG AGGTGCGCGC 3660 TGCTTATCTG TGATTGTTGC TCACCTGAGT GTGGCTGATT GTGTACATCC AGCAGTTACA 3720 ATTTTTAAAA ATTATACTTT TACATTTATT TTATATTTTT CTCACCCCCA GTAATTTCCT 3780 TCCAAAGAAG TTCACATGTA ATAAGTAGAA ATTCTGTATA GGAAAAAAGC ATTAAAAATA 3840 CTATTATAAC TGCTTCATTT GCTGGGAACC ATTAAAAGTA ATATAAATTA GCTTTTTCCA 3900 GAAGGATCCT TTTGTAGCAG TGTTTATGAA TGTAACCCCC AGCAAAATAT GGCTATATAT 3960 TAGGGGAGCC AGTTTGGAGC AGAGGCCTGA AGGTCCCTGC TATGCAGCCG TGGCCACAGC 4020 TCGCAGCCCA AGCACTGTGG AGCATCCACA CCTTTGATGG CAATGCAGAT TGGTAGCAGG 4080 TTCCATAGGC GTACAAAACA GTATTAAAGC TCAGTGTTTT GCATATTGTT AGCATTTACA 4140 AATATTTTTG CTTTAGTATG AGGAAAGTAA GGATGGGCAA AGAAGCGATC AAAATAGCTA 4200 TTGCTACAAC ATTTTCGAAA ACAAAGTTGG GGCTGTATTT CTTTAAAAAG ATAAGCCTCT 4260 AAAAATGCTT GGCAAAAAAA ATATAGTGTT AAAATAGGCC AGTGATATTA ATGAGAAAAT 4320 GAAAGTATGT ATCAGGAATA AAGTGATATT GCATAGGAGT ATTGTATTTT TATGAATTTT 4380 ATGCCAGTTG TTTACATGTA CTATATATGT TAAATTAAAA AAAATCATGA GAAATG Seq ID NO: 499 Protein sequence Protein Accession &num : BAA74900.1 1 11 21 31 41 51 # # # # # # PLVINTLKRF NLYPEVILAS WYRIYTKIMD LIGIQTKICW TVTRGEGLSP IESCEGLGDP 60 ACFYVAVIFI LNGLMMALFF IYGTYLSGSR LGGLVTVLCF FFNHGECTRV MWTPPLRESF 120 SYPFLVLQML LVTHILRATK LYRGSLIALC ISNVFFMLPW QFAQFVLLTQ IASLFAVYW 180 GYIDICKLRK IIYIHMISLA LCFVLMFGNS MLLTSYYASS LVIIWGILAM KPHFLKINVS 240 ELSLWVIQGC FWLFGTVILK YLTSKIFGIA DDAHIGNLLT SKFFSYKDFD TLLYTCAAEF 300 DFMEKETPLR YTKTLLLP LWFVAIVRK IISDMWGVLA KQQTHVRKHQ FDHGELVYHA 360 LQLLAYTALG ILIMRLKLFL TPHMCVMASL ICSRQLFGWL FCKVHPGAIV FAILAAMSIQ 420 GSANLQTQWN IVGEFSNLPQ EELIEWIKYS TKPDAVFAGA MPTMASVKLS ALRPIVNHPH 480 YEDAGLRART KIVYSMYSRK AAEEVKRELI KLKVNYYILE ESWCVRRSKP GCSMPEIWDV 540 EDPANAGKTP LCNLLVKDSK PHFTTVFQNS VYKVLEWKE Seq ID NO : 500 DNA sequence Nucleic Acid Accession &num : NM 001276. 1 Coding sequence: 127.. 1278 1 11 21 31 41 51 AGTGGAGTGG GACAGGTATA TAAAGGAAGT ACAGGGCCTG GGGAAGAGGC CCTGTCTAGG 60 TAGCTGGCAC CAGGAGCCGT GGGCAAGGGA AGAGGCCACA CCCTGCCCTG CTCTGCTGCA 120

AGTGAAGAGG ATTCACCCAG AGAGGAGGAT CCACCCGGAG AGGAGGATCT ACCTGGAGAG 300 GAGGATCTAC CTGGAGAGGA GGATCTACCT GAAGTTAAGC CTAAATCAGA AGAAGAGGGC 360 TCCCTGAAGT TAGAGGATCT ACCTACTGTT GAGGCTCCTG GAGATCCTCA AGAACCCCAG 420 AATAATGCCC ACAGGGACAA AGAAGGGGAT GACCAGAGTC ATTGGCGCTA TGGAGGCGAC 480 CCGCCCTGGC CCCGGGTGTC CCCAGCCTGC GCGGGCCGCT TCCAGTCCCC GGTGGATATC 540 CGCCCCCAGC TCGCCGCCTT CTGCCCGGCC CTGCGCCCCC TGGAACTCCT GGGCTTCCAG 600 CTCCCGCCGC TCCCAGAACT GCGCCTGCGC AACAATGGCC ACAGTGTGCA ACTGACCCTG 660 CCTCCTGGGC TAGAGATGGC TCTGGGTCCC GGGCGGGAGT ACCGGGCTCT GCAGCTGCAT 720 CTGCACTGGG GGGCTGCAGG TCGTCCGGGC TCGGAGCACA CTGTGGAAGG CCACCGTTTC 780 CCTGCCGAGA TCCACGTGGT TCACCTCAGC ACCGCCTTTG CCAGAGTTGA CGAGGCCTTG 840 GGGCGCCCGG GAGGCCTGGC CGTGTTGGCC GCCTTTCTGG AGGAGGGCCC GGAAGAAAAC 900 AGTGCCTATG AGCAGTTGCT GTCTCGCTTG GAAGAAATCG CTGAGGAAGG CTCAGAGACT 960 CAGGTCCCAG GACTGGACAT ATCTGCACTC CTGCCCTCTG ACTTCAGCCG CTACTTCCAA 1020 TATGAGGGGT CTCTGACTAC ACCGCCCTGT GCCCAGGGTG TCATCTGGAC TGTGTTTAAC 1080 CAGACAGTGA TGCTGAGTGC TAAGCAGCTC CACACCCTCT CTGACACCCT GTGGGGACCT 1140 GGTGACTCTC GGCTACAGCT GAACTTCCGA GCGACGCAGC CTTTGAATGG GCGAGTGATT 1200 GAGGCCTCCT TCCCTGCTGG AGTGGACAGC AGTCCTCGGG CTGCTGAGCC AGTCCAGCTG 1260 AATTCCTGCC TGGCTGCTGG TGACATCCTA GCCCTGGTTT TTGGCCTCCT TTTTGCTGTC 1320 ACCAGCGTCG CGTTCCTTGT GCAGATGAGA AGGCAGCACA GAAGGGGAAC CAAAGGGGGT 1380 GTGAGCTACC GCCCAGCAGA GGTAGCCGAG ACTGGAGCCT AGAGGCTGGA TCTTGGAGAA 1440 TGTGAGAAGC CAGCCAGAGG CATCTGAGGG GGAGCCGGTA ACTGTCCTGT CCTGCTCATT 1500 ATGCCACTTC CTTTTAACTG CCAAGAAATT TTTTAAAATA AATATTTATA AT Seq ID NO : 511 Protein sequence Protein Accession &num : NP 001207. 1 1 11 21 31 41 51 # # # # # # MAPLCPSPWL PLLIPAPAPG LTVQLLLSLL LLMPVHPQRL PRMQEDSPLG GGSSGEDDPL 60 GEEDLPSEED SPREEDPPGE EDLPGEEDLP GEEDLPEVKP KSEEEGSLKL EDLPTVEAPG 120 DPQEPQNNAH RDKEGDDQSH WRYGGDPPWP RVSPACAGRF QSPVDIRPQL AAFCPALRPL 180 ELLGFQLPPL PELRLRNNGH SVQLTLPPGL EMALGPGREY RALQLHLHWG AAGRPGSEHT 240 VEGHRFPAEI HWHLSTAFA RVDEALGRPG GLAVLAAFLE EGPEENSAYE QLLSRLEEIA 300 EEGSETQVPG LDISALLPSD FSRYFQYEGS LTTPPCAQGV IWTVFNQTVM LSAKQLHTLS 360 DTLWGPGDSR LQLNFRATQP LNGRVIEASF PAGVDSSPRA AEPVQLNSCL AAGDILALVF 420 GLLFAVTSVA FLVQMRRQHR RGTKGGVSYR PAEVAETGA Seq ID NO: 512 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 1.. 3978 1 11 21 31 41 51 # # # # # # ATGGTGGGTG AAGGACCCTA CCTTATCTCA GATCTGGACC AGCGAGGCCG GCGGAGATCC 60 TTTGCAGAAA GATATGACCC CAGCCTGAAG ACCATGATCC CAGTGCGACC CTGTGCAAGG 120 TTAGCACCCA ACCCGGTGGA TGATGCCGGG CTACTCTCCT TCGCCACATT TTCCTGGCTC 180 ACGCCGGTGA TGGTGAAAGG CTACCGGCAA AGGCTGACCG TAGACACCCT GCCCCCATTG 240 TCGACATATG ACTCATCTGA CACCAATGCC AAAAGATTTC GAGTCCTTTG GGATGAAGAG 300 GTAGCAAGGG TGGGTCCTGA GAAGGCCTCT CTGAGCCACG TGGTGTGGAA ATTCCAGAGG 360 ACACGCGTGT TGATGGACAT CGTGGCCAAC ATCCTGTGCA TCATCATGGC AGCCATAGGG 420 CCGACAGTTC TCATTCACCA AATCCTCCAG CAGACTGAGA GGACCTCTGG GAAAGTCTGG 480 GTTGGCATTG GACTGTGCAT AGCCCTTTTT GCCACCGAGT TTACCAAAGT CTTCTTTTGG 540 GCCCTTGCCT GGGCCATCAA CTACCGCACG GCCATCCGGT TGAAGGTGGC GCTCTCCACC 600 TTGGTT. TTTG AAAACCTAGT GTCCTTCAAG ACATTGACCC ACATCTCTGT TGGCGAGGTG 660 CTCAATATAC TGTCAAGTGA TAGCTATTCT TTGTTTGAAG CTGCCTTGTT TTGTCCTTTG 720 CCAGCCACCA TCCCGATCCT AATGGTCTTT TGTGCGGCGT ACGCCTTTTT CATTCTGGGG 780 CCCACAGCTC TCATCGGGAT ATCAGTGTAT GTCATATTCA TACCCGTCCA GATGTTTATG 840 GCCAAGCTCA ATTCAGCTTT CCGAAGGTCA GCAATTTTGG TGACAGACAA GCGAGTTCAG 900 ACAATGAATG AGTTTCTGAC CTGCATCAGG CTGATCAAAA TGTATGCCTG GGAGAAATCT 960 TTTACCAACA CTATCCAAGA TATAAGAAGG AGGGAAAGAA AATTACTGGA AAAAGCTGGA 1020 TTTGTCCAAA GTGGAAACTC TGCCCTGGCC CCCATCGTGT CCACCATAGC CATCGTGCTG 1080 ACATTATCCT GCCACATCCT CCTGAGACGC AAACTCACCG CACCCGTGGC ATTTAGTGTG 1140 ATTGCCATGT TTAATGTAAT GAAGTTTTCC ATTGCAATCT TGCCCTTCTC CATCAAAGCA 1200 ATGGCTGAAG CGAATGTCTC TCTAAGGAGA ATGAAGAAAA TTCTCATAGA TAAAAGCCCC 1260 CCATCTTACA TCACCCAACC AGAAGACCCA GATACTGTCT TGCTTTTAGC AAATGCCACC 1320 TTGACATGGG AGCATGAAGC CAGCAGGAAA AGTACCCCAA AGAAATTGCA GAACCAGAAA 1380 AGGCATTTAT GCAAGAAACA GAGGTCAGAG GCATACAGTG AGAGGAGTCC ACCAGCCAAG 1440 GGAGCCACTG GCCCAGAGGA GCAAAGTGAC AGCCTCAAAT CGGTTCTGCA CAGCATAAGC 1500 TTTGTGGTGA GAAAGTTATG TCGTTATCCC GAAGCCCAGC TCCTGGCTTG GAGGTGGCCA 1560 GCAGTGTTTG TTGGGAGAAT CATCAGAGGA TACAGGCCTC ATGGATTTTC TGCTAAAGAC 1620 AAGGATGAAT CTAGAAGGCT TCTTACTTGG CCCCAAGAAG TGGATAGGAC TCAAAGGGCA 1680 GCCAAATACC TGGGGAAGAT CTTGGGAATA TGTGGGAATG TGGGAAGTGG AAAGAGCTCC 1740 CTCCTTGCAG CTCTCCTAGG ACAGATGCAG CTGCAGAAAG GGGTGGTGGC AGTCAATGGA 1800 ACTTTGGCCT ACGTTTCACA GCAGGCATGG ATCTTTCATG GAAATGTGAG AGAAAACATA 1860 CTCTTTGGAG AAAAGTATGA TCACCAAAGG TATCAGCACA CAGTCCGCGT CTGTGGCCTC 1920 CAGAAGGACC TGAGCAACCT CCCCTATGGA GACCTGACTG AGATTGGGGA GCGGGGCCTC 1980 AACCTCTCTG GGGGGCAGAG GCAGAGGATT AGCCTGGCCC GCGCTGTCTA CTCCGACCGT 2040 CAGCTCTACC TGCTGGACGA CCCCCTGTCG GCCGTGGACG CCCACGTGGG GAAGCACGTC 2100 TTTGAGGAGT GCATTAAGAA GACGCTCAGG GGAAAGACAG TCGTCCTGGT GACCCACCAG 2160 CTACAGTTCT TAGAGTCTTG TGATGAAGTT ATTTTATTAG AAGATGGAGA GATTTGTGAA 2220 AAGGGAACCC ACAAGGAGTT AATGGAGGAG AGAGGGCGCT ATGCAAAACT GATTCACAAC 2280 CTGCGAGGAT TGCAGTTCAA GGATCCTGAA CACCTTTACA ATGCAGCAAT GGTGGAAGCC 2340 TTCAAGGAGA GCCCTGCTGA GAGAGAGGAA GATGCTGGTA TAATCGGGTA CCTCCTTTCT 2400 CTCTTCACTG TGTTCCTCTT CCTCCTGATG ATTGGCAGCG CTGCCTTCAG CAACTGGTGG 2460 CTGGGTCTCT GGTTGGACAA GGGCTCACGG ATGACCTGTG GGCCCCAGGG CAACAGGACC 2520 ATGTGTGAGG TCGGCGCGGT GCTGGCAGAC ATCGGTCAGC ATGTGTACCA GTGGGTGTAC 2580 ACTGCAAGCA TGGTGTTCAT GCTGGTGTTT GGCGTCACCA AAGGCTTCGT CTTCACCAAG 2640

ACCACACTGA TGGCATCCTC CTCTCTGCAT GACACGGTGT TTGATAAGAT CTTAAAGAGC 2700 CCAATGAGTT TCTTTGACAC GACTCCCACT GGCAGGCTAA TGAACCGTTT TTCCAAGGAT 2760 ATGGACGAGC TGGATGTGAG GCTGCCGTTT CACGCAGAGA ACTTTCTGCA GCAGTTTTTT 2820 ATGGTGGTGT TTATTCTCGT GATCTTGGCT GCTGTGTTTC CTGCTGTCCT TTTAGTCGTG 2880 GCCAGCCTTG CTGTAGGCTT CTTCATTCTG TTACGCATTT TCCACAGAGG AGTCCAGGAG 2940 CTCAAGAAGG TGGAGAATGT CAGCCGGTCA CCCTGGTTCA CCCACATCAC CTCCTCCATG 3000 CAGGGCCTGG GCATCATTCA CGCCTATGGC AAGAAGGAGA GCTGCATCAC CTATACTTCA 3060 TCCAAAGGCC TGTCATTGTC ATACATCATC CAGCTGAGCG GACTGCTCCA AGTGTGTGTG 3120 CGAACGGGAA CAGAGACGCA AGCCAAATTC ACCTCCGTGG AGCTGCTCAG GGAATACATT 3180 TCGACCTGTG TTCCTGAATG CACTCATCCC CTCAAAGTGG GGACCTGTCC CAAGGACTGG 3240 CCCAGCTGTG GGGAGATCAC CTTCAGAGAC TATCAGATGA GATACAGAGA CAACACCCCC 3300 CTTGTTCTCG ACAGCCTGAA CTTGAACATA CAAAGTGGGC AGACAGTCGG GATTGTTGGA 3360 AGAACAGGTT CCGGAAAGTC ATCGTTAGGA ATGGCTTTGT TTCGTCTGGT GGAGCCAGCC 3420 AGTGGCACAA TCTTTATTGA TGAGGTGGAT ATCTGCATTC TCAGCTTGGA AGACCTCAGA 3480 ACCAAGCTGA CTGTGATCCC ACAGGATCCT GTCCTGTTTG TAGGTACAGT AAGGTACAAC 3540 TTGGATCCCT TTGAGAGTCA CACCGATGAG ATGCTCTGGC AGGTTCTGGA GAGAACATTC 3600 ATGAGAGACA CAATAATGAA ACTCCCAGAA AAATTACAGG CAGAAGTCAC AGAAAATGGA 3660 GAAAACTTCT CAGTAGGGGA ACGTCAGCTG CTTTGTGTGG CCCGAGCTCT TCTCCGTAAT 3720 TCAAAGATCA TTCTCCTTGA TGAAGCCACC GCCTCTATGG ACTCCAAGAC TGACACCCTG 3780 GTTCAGAACA CCATCAAAGA TGCCTTCAAG GGCTGCACTG TGCTGACCAT CGCCCACCGC 3840 CTCAACACAG TTCTCAACTG CGATCACGTC CTGGTTATGG AAAATGGGAA GGTGATTGAG 3900 TTTGACAAGC CTGAAGTCCT TGCAGAGAAG CCAGATTCTG CATTTGCGAT GTTACTAGCA 3960 GCAGAAGTCA GATTGTAG Seq ID NO : 513 Protein sequence Protein Accession # : Eos sequence 1 11 21 31 41 51 MVGEGPYLIS DLDQRGRRRS FAERYDPSLK TMIPVRPCAR LAPNPVDDAG LLSFATFSWL 60 TPVMVKGYRQ RLTVDTLPPL STYDSSDTNA KRFRVLWDEE VARVGPEKAS LSHWNKFQR 120 TRVLMDIVAN ILCIIMAAIG PTVLIHQILQ QTERTSGKVW VGIGLCIALF ATEFTKVFFW 180 ALAWAINYRT AIRLKVALST LVFENLVSFK TLTHISVGEV LNILSSDSYS LFEAALFCPL 240 PATIPILMVF CAAYAFFILG PTALIGISVY VIFIPVQMFM AKLNSAFRRS AILVTDKRVQ 300 TMNEFLTCIR LIKMYAWEKS FTNTIQDIRR RERKLLEKAG FVQSGNSALA PIVSTIAIVL 360 TLSCHILLRR KLTAPVAFSV IAMFNVMKFS IAILPFSIKA MAEANVSLRR MKKILIDKSP 420 PSYITQPEDP DTVLLLANAT LTWEHEASRK STPKKLQNQK RHLCKKQRSE AYSERSPPAK 480 GATGPEEQSD SLKSVLHSIS FWRRKLCRYP EAQLLAWRWP AVFVGRIIRG YRPHGFSAKD 540 KDESRRLLTW PQEVDRTQRA AKYLGKILGI CGNVGSGKSS LLAALLGQMQ LQKGWAVNG 600 TLAYVSQQAW IFHGNVRENI LFGEKYDHQR YQHTVRVCGL QKDLSNLPYG DLTEIGERGL 660 NLSGGQRQRI SLARAVYSDR QLYLLDDPLS AVDAHVGKHV FEECIKKTLR GKTWLVTHQ 720 LQFLESCDEV ILLEDGEICE KGTHKELMEE RGRYAKLIHN LRGLQFKDPE HLYNAAMVEA 780 FKESPAEREE DAGIIGYLLS LFTVFLFLLM IGSAAFSNWW LGLWLDKGSR MTCGPQGNRT 840 MCEVGAVLAD IGQHVYQWVY TASMVFMLVF GVTKGFVFTK TTLMASSSLH DTVFDKILKS 900 PMSFFDTTPT GRLMNRFSKD MDELDVRLPF HAENFLQQFF MWFILVILA AVFPAVLLW 960 ASLAVGFFIL LRIFHRGVQE LKKVENVSRS PWFTHITSSM QGLGIIHAYG KKESCITYTS 1020 SKGLSLSYII QLSGLLQVCV RTGTETQAKF TSVELLREYI STCVPECTHP LKVGTCPKDW 1080 PSCGEITFRD YQMRYRDNTP LVLDSLNLNI QSGQTVGIVG RTGSGKSSLG MALFRLVEPA 1140 SGTIFIDEVD ICILSLEDLR TKLTVIPQDP VLFVGTVRYN LDPFESHTDE MLWQVLERTF 1200 MRDTIMKLPE KLQAEVTENG ENFSVGERQL LCVARALLRN SKIILLDEAT ASMDSKTDTL 1260 VQNTIKDAFK GCTVLTIAHR LNTVLNCDHV LVMENGKVIE FDKPEVLAEK PDSAFAMLLA 1320 AEVRL Seq ID NO : 514 DNA sequence Nucleic Acid Accession # : Z31560 Coding sequence: 1-966 1 11 21 31 41 51 CACAGCGCCC GCATGTACAA CATGATGGAG ACGGAGCTGA AGCCGCCGGG CCCGCAGCAA 60 ACTTCGGGGG GCGGCGGCGG CAACTCCACC GCGGCGGCGG CCGGCGGCAA CCAGAAAAAC 120 AGCCCGGACC GCGTCAAGCG GCCCATGAAT GCCTTCATGG TGTGGTCCCG CGGGCAGCGG 180 CGCAAGATGG CCCAGGAGAA CCCCAAGATG CACAACTCGG AGATCAGCAA GCGCCTGGGC 240 GCCGAGTGGA AACTTTTGTC GGAGACGGAG AAGCGGCCGT TCATCGACGA GGCTAAGCGG 300 CTGCGAGCGC TGCACATGAA GGAGCACCCG GATTATAAAT ACCGGCCCCG GCGGAAAACC 360 AAGACGCTCA TGAAGAAGGA TAAGTACACG CTGCCCGGCG GGCTGCTGGC CCCCGGCGGC 420 AATAGCATGG CGAGCGGGGT CGGGGTGGGC GCCGGCCTGG GCGCGGGCGT GAACCAGCGC 480 ATGGACAGTT ACGCGCACAT GAACGGCTGG AGCAACGGCA GCTACAGCAT GATGCAGGAC 540 CAGCTGGGCT ACCCGCAGCA CCCGGGCCTC AATGCGCACG GCGCAGCGCA GATGCAGCCC 600 ATGCACCGCT ACGACGTGAG CGCCCTGCAG TACAACTCCA TGACCAGCTC GCAGACCTAC 660 ATGAACGGCT CGCCCACCTA CAGCATGTCC TACTCGCAGC AGGGCACCCC TGGCATGGCT 720 CTTGGCTCCA TGGGTTCGGT GGTCAAGTCC GAGGCCAGCT CCAGCCCCCC TGTGGTTACC 780 TCTTCCTCCC ACTCCAGGGC GCCCTGCCAG GCCGGGGACC TCCGGGACAT GATCAGCATG 840 TATCTCCCCG GCGCCGAGGT GCCGGAACCC GCCGCCCCCA GCAGACTTCA CATGTCCCAG 900 CACTACCAGA GCGGCCCGGT GCCCGGCACG GCCATTAACG GCACACTGCC CCTCTCACAC 960 ATGTGAGGGC CGGACAGCGA ACTGGAGGGG GGAGAAATTT TCAAAGAAAA ACGAGGGAAA 1020 TGGGAGGGGT GCAAAAGAGG AGAGTAAGAA ACAGCATGGA GAAAACCCGG TACGCTCAAA 1080 AAAAA Seq ID NO : 515 Protein sequence Protein Accession # : CAA83435 1 11 21 31 41 51 HSARMYNMME TELKPPGPQQ TSGGGGGNST AAAAGGNQKN SPDRVKRPMN AFMVWSRGQR 60 RKMAQENPKM HNSEISKRLG AEWKLLSETE KRPFIDEAKR LRALHMKEHP DYKYRPRRKT 120 KTLMKKDKYT LPGGLLAPGG NSMASGVGVG AGLGAGVNQR MDSYAHMNGW SNGSYSMMQD 180

QLGYPQHPGL NAHGAAQMQP MHRYDVSALQ YNSMTSSQTY MNGSPTYSMS YSQQGTPGMA 240 LGSMGSWKS EASSSPPWT SSSHSRAPCQ AGDLRDMISM YLPGAEVPEP AAPSRLHMSQ 300 HYQSGPVPGT AINGTLPLSH M Seq ID NO : 516 DNA sequence Nucleic Acid Accession &num : U91618 Coding sequence: 29.. 541 1 11 21 31 41 51 CGGACTTGGC TTGTTAGAAG GCTGAAAGAT GATGGCAGGA ATGAAAATCC AGCTTGTATG 60 CATGCTACTC CTGGCTTTCA GCTCCTGGAG TCTGTGCTCA GATTCAGAAG AGGAAATGAA 120 AGCATTAGAA GCAGATTTCT TGACCAATAT GCATACATCA AAGATTAGTA AAGCACATGT 180 TCCCTCTTGG AAGATGACTC TGCTAAATGT TTGCAGTCTT GTAAATAATT TGAACAGCCC 240 AGCTGAGGAA ACAGGAGAAG TTCATGAAGA GGAGCTTGTT GCAAGAAGGA AACTTCCTAC 300 TGCTTTAGAT GGCTTTAGCT TGGAAGCAAT GTTGACAATA TACCAGCTCC ACAAAATCTG 360 TCACAGCAGG GCTTTTCAAC ACTGGGAGTT AATCCAGGAA GATATTCTTG ATACTGGAAA 420 TGACAAAAAT GGAAAGGAAG AAGTCATAAA GAGAAAAATT CCTTATATTC TGAAACGGCA 480 GCTGTATGAG AATAAACCCA GAAGACCCTA CATACTCAAA AGAGATTCTT ACTATTACTG 540 AGAGAATAAA TCATTTATTT ACATGTGATT GTGATTCATC ATCCCTTAAT TAAATATCAA 600 ATTATATTTG TGTGAAAATG TGACAAACAC ACTTATCTGT CTCTTCTACA ATTGTGGTTT 660 ATTGAATGTG TTTTTCTGCA CTAATAGAAA TTAGACTAAG TGTTTTCAAA TAAATCTAAA 720 TCTTCAAAAA AAAAAAAAAA AAATGGGGCC GCAATT Seq ID NO : 517 Protein sequence Protein Accession &num : AAB50564 1 11 21 31 41 51 # # # # # # MMAGMKIQLV CMLLLAFSSW SLCSDSEEEM KALEADFLTN MHTSKISKAH VPSWKMTLLN 60 VCSLVNNLNS PAEETGEVHE EELVARRKLP TALDGFSLEA MLTIYQLHKI CHSRAFQHWE 120 LIQEDILDTG NDKNGKEEVI KRKIPYILKR QLYENKPRRP YILKRDSYYY Seq ID NO : 518 DNA sequence Nucleic Acid Accession # : NM 006536. 2 Coding sequence : 109.. 2940 1 11 21 31 41 51 <BR> <BR> <BR> <BR> <BR> <BR> ACCTAAAACC TTGCAAGTTC AGGAAGAAAC CATCTGCATC CATATTGAAA ACCTGACACA 60 ATGTATGCAG CAGGCTCAGT GTGAGTGAAC TGGAGGCTTC TCTACAACAT GACCCAAAGG 120 AGCATTGCAG GTCCTATTTG CAACCTGAAG TTTGTGACTC TCCTGGTTGC CTTAAGTTCA 180 GAACTCCCAT TCCTGGGAGC TGGAGTACAG CTTCAAGACA ATGGGTATAA TGGATTGCTC 240 ATTGCAATTA ATCCTCAGGT ACCTGAGAAT CAGAACCTCA TCTCAAACAT TAAGGAAATG 300 ATAACTGAAG CTTCATTTTA CCTATTTAAT GCTACCAAGA GAAGAGTATT TTTCAGAAAT 360 ATAAAGATTT TAATACCTGC CACATGGAAA GCTAATAATA ACAGCAAAAT AAAACAAGAA 420 TCATATGAAA AGGCAAATGT CATAGTGACT GACTGGTATG GGGCACATGG AGATGATCCA 480 TACACCCTAC AATACAGAGG GTGTGGAAAA GAGGGAAAAT ACATTCATTT CACACCTAAT 540 TTCCTACTGA ATGATAACTT AACAGCTGGC TACGGATCAC GAGGCCGAGT GTTTGTCCAT 600 GAATGGGCCC ACCTCCGTTG GGGTGTGTTC GATGAGTATA ACAATGACAA ACCTTTCTAC 660 ATAAATGGGC AAAATCAAAT TAAAGTGACA AGGTGTTCAT CTGACATCAC AGGCATTTTT 720 GTGTGTGAAA AAGGTCCTTG CCCCCAAGAA AACTGTATTA TTAGTAAGCT TTTTAAAGAA 780 GGATGCACCT TTATCTACAA TAGCACCCAA AATGCAACTG CATCAATAAT GTTCATGCAA 840 AGTTTATCTT CTGTGGTTGA ATTTTGTAAT GCAAGTACCC ACAACCAAGA AGCACCAAAC 900 CTACAGAACC AGATGTGCAG CCTCAGAAGT GCATGGGATG TAATCACAGA CTCTGCTGAC 960 TTTCACCACA GCTTTCCCAT GAATGGGACT GAGCTTCCAC CTCCTCCCAC ATTCTCGCTT 1020 GTACAGGCTG GTGACAAAGT GGTCTGTTTA GTGCTGGATG TGTCCAGCAA GATGGCAGAG 1080 GCTGACAGAC TCCTTCAACT ACAACAAGCC GCAGAATTTT ATTTGATGCA GATTGTTGAA 1140 ATTCATACCT TCGTGGGCAT TGCCAGTTTC GACAGCAAAG GAGAGATCAG AGCCCAGCTA 1200 CACCAAATTA ACAGCAATGA TGATCGAAAG TTGCTGGTTT CATATCTGCC CACCACTGTA 1260 TCAGCTAAAA CAGACATCAG CATTTGTTCA GGGCTTAAGA AAGGATTTGA GGTGGTTGAA 1320 AAACTGAATG GAAAAGCTTA TGGCTCTGTG ATGATATTAG TGACCAGCGG AGATGATAAG 1380 CTTCTTGGCA ATTGCTTACC CACTGTGCTC AGCAGTGGTT CAACAATTCA CTCCATTGCC 1440 CTGGGTTCAT CTGCAGCCCC AAATCTGGAG GAATTATCAC GTCTTACAGG AGGTTTAAAG 1500 TTCTTTGTTC CAGATATATC AAACTCCAAT AGCATGATTG ATGCTTTCAG TAGAATTTCC 1560 TCTGGAACTG GAGACATTTT CCAGCAACAT ATTCAGCTTG AAAGTACAGG TGAAAATGTC 1620 AAACCTCACC ATCAATTGAA AAACACAGTG ACTGTGGATA ATACTGTGGG CAACGACACT 1680 ATGTTTCTAG TTACGTGGCA GGCCAGTGGT CCTCCTGAGA TTATATTATT TGATCCTGAT 1740 GGACGAAAAT ACTACACAAA TAATTTTATC ACCAATCTAA CTTTTCGGAC AGCTAGTCTT 1800 TGGATTCCAG GAACAGCTAA GCCTGGGCAC TGGACTTACA CCCTGAACAA TACCCATCAT 1860 TCTCTGCAAG CCCTGAAAGT GACAGTGACC TCTCGCGCCT CCAACTCAGC TGTGCCCCCA 1920 GCCACTGTGG AAGCCTTTGT GGAAAGAGAC AGCCTCCATT TTCCTCATCC TGTGATGATT 1980 TATGCCAATG TGAAACAGGG ATTTTATCCC ATTCTTAATG CCACTGTCAC TGCCACAGTT 2040 GAGCCAGAGA CTGGAGATCC TGTTACGCTG AGACTCCTTG ATGATGGAGC AGGTGCTGAT 2100 GTTATAAAAA ATGATGGAAT TTACTCGAGG TATTTTTTCT CCTTTGCTGC AAATGGTAGA 2160 TATAGCTTGA AAGTGCATGT CAATCACTCT CCCAGCATAA GCACCCCAGC CCACTCTATT 2220 CCAGGGAGTC ATGCTATGTA TGTACCAGGT TACACAGCAA ACGGTAATAT TCAGATGAAT 2280 GCTCCAAGGA AATCAGTAGG CAGAAATGAG GAGGAGCGAA AGTGGGGCTT TAGCCGAGTC 2340 AGCTCAGGAG GCTCCTTTTC AGTGCTGGGA GTTCCAGCTG GCCCCCACCC TGATGTGTTT 2400 CCACCATGCA AAATTATTGA CCTGGAAGCT GTAAAAGTAG AAGAGGAATT GACCCTATCT 2460 TGGACAGCAC CTGGAGAAGA CTTTGATCAG GGCCAGGCTA CAAGCTATGA AATAAGAATG 2520 AGTAAAAGTC TACAGAATAT CCAAGATGAC TTTAACAATG CTATTTTAGT AAATACATCA 2580 AAGCGAAATC CTCAGCAAGC TGGCATCAGG GAGATATTTA CGTTCTCACC CCAGATTTCC 2640 ACGAATGGAC CTGAACATCA GCCAAATGGA GAAACACATG AAAGCCACAG AATTTATGTT 2700 GCAATACGAG CAATGGATAG GAACTCCTTA CAGTCTGCTG TATCTAACAT TGCCCAGGCG 2760 CCTCTGTTTA TTCCCCCCAA TTCTGATCCT GTACCTGCCA GAGATTATCT TATATTGAAA 2820 GGAGTTTTAA CAGCAATGGG TTTGATAGGA ATCATTTGCC TTATTATAGT TGTGACACAT 2880

AGGGCAGCCG AGGAATCTGC CTCACAGATT CAATCCAGTG CCCAGCGCTT GGAGACCCAG 2700 GTGAGCGCCA GCCGCTCCCA GATGGAGGAA GATGTCAGAC GCACACGGCT CCTAATCCAG 2760 CAGGTCCGGG ACTTCCTAAC AGACCCCGAC ACTGATGCAG CCACTATCCA GGAGGTCAGC 2820 GAGGCCGTGC TGGCCCTGTG GCTGCCCACA GACTCAGCTA CTGTTCTGCA GAAGATGAAT 2880 GAGATCCAGG CCATTGCAGC CAGGCTCCCC AACGTGGACT TGGTGCTGTC CCAGACCAAG 2940 CAGGACATTG CGCGTGCCCG CCGGTTGCAG GCTGAGGCTG AGGAAGCCAG GAGCCGAGCC 3000 CATGCAGTGG AGGGCCAGGT GGAAGATGTG GTTGGGAACC TGCGGCAGGG GACAGTGGCA 3060 CTGCAGGAAG CTCAGGACAC CATGCAAGGC ACCAGCCGCT CCCTTCGGCT TATCCAGGAC 3120 AGGGTTGCTG AGGTTCAGCA GGTACTGCGG CCAGCAGAAA AGCTGGTGAC AAGCATGACC 3180 AAGCAGCTGG GTGACTTCTG GACACGGATG GAGGAGCTCC GCCACCAAGC CCGGCAGCAG 3240 GGGGCAGAGG CAGTCCAGGC CCAGCAGCTT GCGGAAGGTG CCAGCGAGCA GGCATTGAGT 3300 GCCCAAGAGG GATTTGAGAG AATAAAACAA AAGTATGCTG AGTTGAAGGA CCGGTTGGGT 3360 CAGAGTTCCA TGCTGGGTGA GCAGGGTGCC CGGATCCAGA GTGTGAAGAC AGAGGCAGAG 3420 GAGCTGTTTG GGGAGACCAT GGAGATGATG GACAGGATGA AAGACATGGA GTTGGAGCTG 3480 CTGCGGGGCA GCCAGGCCAT CATGCTGCGC TCGGCGGACC TGACAGGACT GGAGAAGCGT 3540 GTGGAGCAGA TCCGTGACCA CATCAATGGG CGCGTGCTCT ACTATGCCAC CTGCAAGTGA 3600 TGCTACAGCT TCCAGCCCGT TGCCCCACTC ATCTGCCGCC TTTGCTTTTG GTTGGGGGCA 3660 GATTGGGTTG GAATGCTTTC CATCTCCAGG AGACTTTCAT GCAGCCTAAA GTACAGCCTG 3720 GACCACCCCT GGTGTGTAGC TAGTAAGATT ACCCTGAGCT GCAGCTGAGC CTGAGCCAAT 3780 GGGACAGTTA CACTTGACAG ACAAAGATGG TGGAGATTGG CATGCCATTG AAACTAAGAG 3840 CTCTCAAGTC AAGGAAGCTG GGCTGGGCAG TATCCCCCGC CTTTAGTTCT CCACTGGGGA 3900 GGAATCCTGG ACCAAGCACA AAAACTTAAC AAAAGTGATG TAAAAATGAA AAGCCAAATA 3960 AAAATCTTTG G Seq ID NO : 521 Protein sequence Protein Accession # : NP 000219. 1 1 11 21 31 41 51 MRPFFLLCFA LPGLLHAQQA CSRGACYPPV GDLLVGRTRF LRASSTCGLT KPETYCTQYG 60 EWQMKCCKCD SRQPHNYYSH RVENVASSSG PMRWWQSQND VNPVSLQLDL DRRFQLQEVM 120 MEFQGPMPAG MLIERSSDFG KTWRVYQYLA ADCTSTFPRV RQGRPQSWQD VRCQSLPQRP 180 NARLNGGKVQ LNLMDLVSGI PATQSQKIQE VGEITNLRVN FTRLAPVPQR GYHPPSAYYA 240 VSQLRLQGSC FCHGHADRCA PKPGASAGPS TAVQVHDVCV CQHNTAGPNC ERCAPFYNNR 300 PWRPAEGQDA HECQRCDCNG HSETCHFDPA VFAASQGAYG GVCDNCRDHT EGKNCERCQL 360 HYFRNRRPGA SIQETCISCE CDPDGAVPGA PCDPVTGQCV CKEHVQGERC DLCKPGFTGL 420 TYANPQGCHR CDCNILGSRR DMPCDEESGR CLCLPNWGP KCDQCAPYHW KLASGQGCEP 480 CACDPHNSPQ PTVQPVHRAV PCREGFGGLM CSAAAIRQCP DRTYGDVATG CRACDCDFRG 540 TEGPGCDKAS GRCLCRPGLT GPRCDQCQRG YCNRYPVCVA CHPCFQTYDA DLREQALRFG 600 RLRNATASLW SGPGLEDRGL ASRILDAKSK IEQIRAVLSS PAVTEQEVAQ VASAILSLRR 660 TLQGLQLDLP LEEETLSLPR DLESLDRSFN GLLTMYQRKR EQFEKISSAD PSGAFRMLST 720 AYEQSAQAAQ QVSDSSRLLD QLRDSRREAE RLVRQAGGGG GTGSPKLVAL RLEMSSLPDL 780 TPTFNKLCGN SRQMACTPIS CPGELCPQDN GTACGSRCRG VLPRAGGAFL MAGQVAEQLR 840 GFNAQLQRTR QMIRAAEESA SQIQSSAQRL ETQVSASRSQ MEEDVRRTRL LIQQVRDFLT 900 DPDTDAATIQ EVSEAVLALW LPTDSATVLQ KMNEIQAIAA RLPNVDLVLS QTKQDIARAR 960 RLQAEAEEAR SRAHAVEGQV EDWGNLRQG TVALQEAQDT MQGTSRSLRL IQDRVAEVQQ 1020 VLRPAEKLVT SMTKQLGDFW TRMEELRHQA RQQGAEAVQA QQLAEGASEQ ALSAQEGFER 1080 IKQKYAELKD RLGQSSMLGE QGARIQSVKT EAEELFGETM EMMDRMKDME LELLRGSQAI 1140 MLRSADLTGL EKRVEQIRDH INGRVLYYAT CK Seq ID NO : 522 DNA sequence Nucleic Acid Accession # : NM 001944. 1 Coding sequence: 84.. 3083 1 11 21 31 41 51 TTTTCTTAGA CATTAACTGC AGACGGCTGG CAGGATAGAA GCAGCGGCTC ACTTGGACTT 60 TTTCACCAGG GAAATCAGAG ACAATGATGG GGCTCTTCCC CAGAACTACA GGGGCTCTGG-120 CCATCTTCGT GGTGGTCATA TTGGTTCATG GAGAATTGCG AATAGAGACT AAAGGTCAAT 180 ATGATGAAGA AGAGATGACT ATGCAACAAG CTAAAAGAAG GCAAAAACGT GAATGGGTGA 240 AATTTGCCAA ACCCTGCAGA GAAGGAGAAG ATAACTCAAA AAGAAACCCA ATTGCCAAGA 300 TTACTTCAGA TTACCAAGCA ACCCAGAAAA TCACCTACCG AATCTCTGGA GTGGGAATCG 360 ATCAGCCGCC TTTTGGAATC TTTGTTGTTG ACAAAAACAC TGGAGATATT AACATAACAG 420 CTATAGTCGA CCGGGAGGAA ACTCCAAGCT TCCTGATCAC ATGTCGGGCT CTAAATGCCC 480 AAGGACTAGA TGTAGAGAAA CCACTTATAC TAACGGTTAA AATTTTGGAT ATTAATGATA 540 ATCCTCCAGT ATTTTCACAA CAAATTTTCA TGGGTGAAAT TGAAGAAAAT AGTGCCTCAA 600 ACTCACTGGT GATGATACTA AATGCCACAG ATGCAGATGA ACCAAACCAC TTGAATTCTA 660 AAATTGCCTT CAAAATTGTC TCTCAGGAAC CAGCAGGCAC ACCCATGTTC CTCCTAAGCA 720 GAAACACTGG GGAAGTCCGT ACTTTGACCA ATTCTCTTGA CCGAGAGCAA GCTAGCAGCT 780 ATCGTCTGGT TGTGAGTGGT GCAGACAAAG ATGGAGAAGG ACTATCAACT CAATGTGAAT 840 GTAATATTAA AGTGAAAGAT GTCAACGATA ACTTCCCAAT GTTTAGAGAC TCTCAGTATT 900 CAGCACGTAT TGAAGAAAAT ATTTTAAGTT CTGAATTACT TCGATTTCAA GTAACAGATT 960 TGGATGAAGA GTACACAGAT AATTGGCTTG CAGTATATTT CTTTACCTCT GGGAATGAAG 1020 GAAATTGGTT TGAAATACAA ACTGATCCTA GAACTAATGA AGGCATCCTG AAAGTGGTGA 1080 AGGCTCTAGA TTATGAACAA CTACAAAGCG TGAAACTTAG TATTGCTGTC AAAAACAAAG 1140 CTGAATTTCA CCAATCAGTT ATCTCTCGAT ACCGAGTTCA GTCAACCCCA GTCACAATTC 1200 AGGTAATAAA TGTAAGAGAA GGAATTGCAT TCCGTCCTGC TTCCAAGACA TTTACTGTGC 1260 AAAAAGGCAT AAGTAGCAAA AAATTGGTGG ATTATATCCT GGGAACATAT CAAGCCATCG 1320 ATGAGGACAC TAACAAAGCT GCCTCAAATG TCAAATATGT CATGGGACGT AACGATGGTG 1380 GATACCTAAT GATTGATTCA AAAACTGCTG AAATCAAATT TGTCAAAAAT ATGAACCGAG 1440 ATTCTACTTT CATAGTTAAC AAAACAATCA CAGCTGAGGT TCTGGCCATA GATGAATACA 1500 CGGGTAAAAC TTCTACAGGC ACGGTATATG TTAGAGTACC CGATTTCAAT GACAATTGTC, 1560 CAACAGCTGT CCTCGAAAAA GATGCAGTTT GCAGTTCTTC ACCTTCCGTG GTTGTCTCCG 1620 CTAGAACACT GAATAATAGA TACACTGGCC CCTATACATT TGCACTGGAA GATCAACCTG 1680 TAAAGTTGCC TGCCGTATGG AGTATCACAA CCCTCAATGC TACCTCGGCC CTCCTCAGAG 1740 CCCAGGAACA GATACCTCCT GGAGTATACC ACATCTCCCT GGTACTTACA GACAGTCAGA 1800 ACAATCGGTG TGAGATGCCA CGCAGCTTGA CACTGGAAGT CTGTCAGTGT GACAACAGGG 1860

YTPDMNREDV DYAIRKAFQV WSNVTPLKFS KINTGMADIL WFARGAHGD FHAFDGKGGI 180 LAHAFGPGSG IGGDAHFDED EFWTTHSGGT NLFLTAVHEI GHSLGLGHSS DPKAVMFPTY 240 KYVDINTFRL SADDIRGIQS LYGDPKENQR LPNPDNSEPA LCDPNLSFDA VTTVGNKIFF 300 FKDRFFWLKV SERPKTSVNL ISSLWPTLPS GIEAAYEIEA RNQVFLFKDD KYWLISNLRP 360 EPNYPKSIHS FGFPNFVKKI DAAVFNPRFY RTYFFVDNQY WRYDERRQMM DPGYPKLITK 420 NFQGIGPKID AVFYSKNKYY YFFQGSNQFE YDFLLQRITK TLKSNSWFGC Seq ID NO: 526 DNA sequence Nucleic Acid Accession # : NM 024423. 1 Coding sequence: 64.. 2590 1 11 21 31 41 51 GGCAGGTCTC GCTCTCGGCA CCCTCCCGGC GCCCGCGTTC TCCTGGCCCT GCCCGGCATC 60 CCGATGGCCG CCGCTGGGCC CCGGCGCTCC GTGCGCGGAG CCGTCTGCCT GCATCTGCTG 120 CTGACCCTCG TGATCTTCAG TCGTGATGGT GAAGCCTGCA AAAAGGTGAT ACTTAATGTA 180 CCTTCTAAAC TAGAGGCAGA CAAAATAATT GGCAGAGTTA ATTTGGAAGA GTGCTTCAGG 240 TCTGCAGACC TCATCCGGTC AAGTGATCCT GATTTCAGAG TTCTAAATGA TGGGTCAGTG 300 TACACAGCCA GGGCTGTTGC GCTGTCTGAT AAGAAAAGAT CATTTACCAT ATGGCTTTCT 360 GACAAAAGGA AACAGACACA GAAAGAGGTT ACTGTGCTGC TAGAACATCA GAAGAAGGTA 420 TCGAAGACAA GACACACTAG AGAAACTGTT CTCAGGCGTG CCAAGAGGAG ATGGGCACCT 480 ATTCCTTGCT CTATGCAAGA GAATTCCTTG GGCCCTTTCC CATTGTTTCT TCAACAAGTT 540 GAATCTGATG CAGCACAGAA CTATACTGTC TTCTACTCAA TAAGTGGACG TGGAGTTGAT 600 AAAGAACCTT TAAATTTGTT TTATATAGAA AGAGACACTG GAAATCTATT TTGCACTCGG 660 CCTGTGGATC GTGAAGAATA TGATGTTTTT GATTTGATTG CTTATGCGTC AACTGCAGAT 720 GGATATTCAG CAGATCTGCC CCTCCCACTA CCCATCAGGG TAGAGGATGA AAATGACAAC 780 CACCCTGTTT TCACAGAAGC AATTTATAAT TTTGAAGTTT TGGAAAGTAG TAGACCTGGT 840 ACTACAGTGG GGGTGGTTTG TGCCACAGAC AGAGATGAAC CGGACACAAT GCATACGCGC 900 CTGAAATACA GCATTTTGCA GCAGACACCA AGGTCACCTG GGCTCTTTTC TGTGCATCCC 960 AGCACAGGCG TAATCACCAC AGTCTCTCAT TATTTGGACA GAGAGGTTGT AGACAAGTAC 1020 TCATTGATAA TGAAAGTACA AGACATGGAT GGCCAGTTTT TTGGATTGAT AGGCACATCA 1080 ACTTGTATCA TAACAGTAAC AGATTCAAAT GATAATGCAC CCACTTTCAG ACAAAATGCT 1140 TATGAAGCAT TTGTAGAGGA AAATGCATTC AATGTGGAAA TCTTACGAAT ACCTATAGAA 1200 GATAAGGATT TAATTAACAC TGCCAATTGG AGAGTCAATT TTACCATTTT AAAGGGAAAT 1260 GAAAATGGAC ATTTCAAAAT CAGCACAGAC AAAGAAACTA ATGAAGGTGT TCTTTCTGTT 1320 GTAAAGCCAC TGAATTATGA AGAAAACCGT CAAGTGAACC TGGAAATTGG AGTAAACAAT 1380 GAAGCGCCAT TTGCTAGAGA TATTCCCAGA GTGACAGCCT TGAACAGAGC CTTGGTTACA 1440 GTTCATGTGA GGGATCTGGA TGAGGGGCCT GAATGCACTC CTGCAGCCCA ATATGTGCGG 1500 ATTAAAGAAA ACTTAGCAGT GGGGTCAAAG ATCAACGGCT ATAAGGCATA TGACCCCGAA 1560 AATAGAAATG GCAATGGTTT AAGGTACAAA AAATTGCATG ATCCTAAAGG TTGGATCACC 1620 ATTGATGAAA TTTCAGGGTC AATCATAACT TCCAAAATCC TGGATAGGGA GGTTGAAACT 1680 CCCAAAAATG AGTTGTATAA TATTACAGTC CTGGCAATAG ACAAAGATGA TAGATCATGT 1740 ACTGGAACAC TTGCTGTGAA CATTGAAGAT GTAAATGATA ATCCACCAGA AATACTTCAA 1800 GAATATGTAG TCATTTGCAA ACCAAAAATG GGGTATACCG ACATTTTAGC TGTTGATCCT 1860 GATGAACCTG TCCATGGAGC TCCATTTTAT TTCAGTTTGC CCAATACTTC TCCAGAAATC 1920 AGTAGACTGT GGAGCCTCAC CAAAGTTAAT GATACAGCTG CCCGTCTTTC ATATCAGAAA 1980 AATGCTGGAT TTCAAGAATA TACCATTCCT ATTACTGTAA AAGACAGGGC CGGCCAAGCT 2040 GCAACAAAAT TATTGAGAGT TAATCTGTGT GAATGTACTC ATCCAACTCA GTGTCGTGCG 2100 ACTTCAAGGA GTACAGGAGT AATACTTGGA AAATGGGCAA TCCTTGCAAT ATTACTGGGT 2160 ATAGCACTGC TCTTTTCTGT ATTGCTAACT TTAGTATGTG GAGTTTTTGG TGCAACTAAA 2220 GGGAAACGTT TTCCTGAAGA TTTAGCACAG CAAAACTTAA TTATATCAAA CACAGAAGCA 2280 CCTGGAGACG ATAGAGTGTG CTCTGCCAAT GGATTTATGA CCCAAACTAC CAACAACTCT 2340 AGCCAAGGTT TTTGTGGTAC TATGGGATCA GGAATGAAAA ATGGAGGGCA GGAAACCATT 2400 GAAATGATGA AAGGAGGAAA CCAGACCTTG GAATCCTGCC GGGGGGCTGG GCATCATCAT 2460 ACCCTGGACT CCTGCAGGGG AGGACACACG GAGGTGGACA ACTGCAGATA CACTTACTCG 2520 GAGTGGCACA GTTTTACTCA ACCCCGTCTC GGTGAAGAAT CCATTAGAGG ACACACTGGT 2580 TAAAAATTAA ACATAAAAGA AATTGCATCG ATGTAATCAG AATGAAGACC GCATGCCATC 2640 CCAAGATTAT GTCCTCACTT ATAACTATGA GGGAAGAGGA TCTCCAGCTG GTTCTGTGGG 2700 CTGCTGCAGT GAAAAGCAGG AAGAAGATGG CCTTGACTTT TTAAATAATT TGGAACCCAA 2760 ATTTATTACA TTAGCAGAAG CATGCACAAA GAGATAATGT CACAGTGCTA CAATTAGGTC 2820 TTTGTCAGAC ATTCTGGAGG TTTCCAAAAA TAATATTGTA AAGTTCAATT TCAACATGTA 2880 TGTATATGAT GATTTTTTTC TCAATTTTGA ATTATGCTAC TCACCAATTT ATATTTTTAA 2940 AGCCAGTTGT TGCTTATCTT TTCCAAAAAG TGAAAAATGT TAAAACAGAC AACTGGTAAA 3000 TCTCAAACTC CAGCACTGGA ATTAAGGTCT CTAAAGCATC TGCTCTTTTT TTTTTTTACG 3060 GATATTTTAG TAATAAATAT GCTGGATAAA TATTAGTCCA ACAATAGCTA AGTTATGCTA 3120 ATATCACATT ATTATGTATT CACTTTAAGT GATAGTTTAA AAAATAAACA AGAAATATTG 3180 AGTATCACTA TGTGAAGAAA GTTTTGGAAA AGAAACAATG AAGACTGAAT TAAATTAAAA 3240 ATGTTGCAGC TCATAAAGAA TTGGGACTCA CCCCTACTGC ACTACCAAAT TCATTTGACT 3300 TTGGAGGCAA AATGTGTTGA AGTGCCCTAT GAAGTAGCAA TTTTCTATAG GAATATAGTT 3360 GGAAATAAAT GTGTGTGTGT ATATTATTAT TAATCAATGC AATATTTAAA ATGAAATGAG 3420 AACAAAGAGG AAAATGGTAA AAACTTGAAA TGAGGCTGGG GTATAGTTTG TCCTACAATA 3480 GAAAAAAGAG AGAGCTTCCT AGGCCTGGGC TCTTAAATGC TGCATTATAA CTGAGTCTAT 3540 GAGGAAATAG TTCCTGTCCA ATTTGTGTAA TTTGTTTAAA ATTGTAAATA AATTAAACTT 3600 TTCTGGTTTC TGTGGGAAGG AAATAGGGAA TCCAATGGAA CAGTAGCTTT GCTTTGCAGT 3660 CTGTTTCAAG ATTTCTGCAT CCACAAGTTA GTAGCAAACT GGGGAATACT CGCTGCAGCT 3720 GGGGTTCCCT GCTTTTTGGT AGCAAGGGTC CAGAGATGAG GTGTTTTTTT CGGGGAGCTA 3780 ATAACAAAAA CATTTTAAAA CTTACCTTTA CTGAAGTTAA ATCCTCTATT GCTGTTTCTA 3840 TTCTCTCTTA TAGTGACCAA CATCTTTTTA ATTTAGATCC AAATAACCAT GTCCTCCTAG 3900 AGTTTAGAGG CTAGAGGGAG CTGAGGGGAG GATCTTACTG AAAGCACCCT GGGGAGATTG 3960 ATTGTCCTTA AACCTAAGCC CCACAAACTT GACACCTGAT CAGGTCTGGG AGCTACAAAA 4020 TTTCATTTTT CTCCTCACTG CCCTTCTTCT GAGTGGCATT GGCCTGAATC AAGGAAAGCC 4080 AGGCCTTGTG GGCCCCCTTC TTTCGGCTTT CTGCTAAAGC AACACCTCCA GCAGAGATTC 4140 CCTTAAGTGA CTCCAGGTTT TCCACCATCC TTCAGCGTGA ATTAATTTTT AATCAGTTTG 4200 CTTTCTCCAG AGAAATTTTA AAATAATAGA AGAAATAGAA ATTTTGAATG TATAAAAGAA 4260 AAAGATCAAG TTGTCATTTT AGAACAGAGG GAACTTTGGG AGAAAGCAGC CCAAGTAGGT 4320 TATTTGTACA GTCAGAGGGC AACAGGAAGA TGCAGGCCTT CAAGGGCAAG GAGAGGCCAC 4380 AAGGAATATG GGTGGGAGTA AAAGCAACAT CGTCTGCTTC ATACTTTTTC CTAGGCTTGG 4440

CACTGCCTTT TCCTTTCTCA GGCCAATGGC AACTGCCATT TGAGTCCGGT GAGGGATCAG 4500 CCAACCTCTT CTCTATGGCT CACCTTATTT GGAGTGAGAA ATCAAGGAGA CAGAGCTGAC 4560 TGCATGATGA GTCTGAAGGC ATTTGCAGGA TGAGCCTGAA CTGGTTGTGC AGAACAAACA 4620 AGGCATTCAT GGGAATTGTT GTATTCCTTC TGCAGCCCTC CTTCTGGGCA CTAAGAAGGT 4680 CTATGAATTA AATGCCTATC TAAAATTCTG ATTTATTCCT ACATTTTCTG TTTTCTAATT 4740 TGACCCTAAA ATCTATGTGT TTTAGACTTA GACTTTTTAT TGCCCCCCCC CCCTTTTTTT 4800 TTGAGACGGA GTCTCGCTCT GACGCACAGG CTGGAGTGCA GTGGCTCCGA TCTCTGCTCA 4860 CTGAAAGCTC CGCCTCCCGG GTTCATGCCA TTCTCCTGCC TCAGCCTCCT GAGTAGCTGG 4920 GACTACAGGC GCCCACCACC ACGCCCGGCT AATTTTTTGT ATTTTTAATA GAGACGGGGT 4980 TTCACTGTGT TAGCCAGGAT GGTCTCGATC TCCTGACCTC GTGATCCGCC TGCCTCGGCC 5040 TCCCAAAGTG CTGGGATTAC AGGCATGACC CACCGCTCCC GGCCTTGTTT TCCGTTTAAA 5100 GTCGTCTTCT TTTAATGTAA TCATTTTGAA CATGTGTGAA AGTTGATCAT ACGAATTGGA 5160 TCAATCTTGA AATACTCAAC CAAAAGACAG TCGAGAAGCC AGGGGGAGAA AGAACTCAGG 5220 GCACAAAATA TTGGTCTGAG AATGGAATTC TCTGTAAGCC TAGTTGCTGA AATTTCCTGC 5280 TGTAACCAGA AGCCAGTTTT ATCTAACGGC TACTGAAACA CCCACTGTGT TTTGCTCACT 5340 CCCACTCACC GATCAAAACC TGCTACCTCC CCAAGACTTT ACTAGTGCCG ATAAACTTTC 5400 TCAAAGAGCA ACCAGTATCA CTTCCCTGTT TATAAAACCT CTAACCATCT CTTTGTTCTT 5460 TGAACATGCT GAAAACCACC TGGTCTGCAT GTATGCCCGA ATTTGTAATT CTTTTCTCTC 5520 AAATGAAAAT TTAATTTTAG GGATTCATTT CTATATTTTC ACATATGTAG TATTATTATT 5580 TCCTTATATG TGTAAGGTGA AATTTATGGT ATTTGAGTGT GCAAGAAAAT ATATTTTTAA 5640 AGCTTTCATT TTTCCCCCAG TGAATGATTT AGAATTTTTT ATGTAAATAT ACAGAATGTT 5700 TTTTCTTACT TTTATAAGGA AGCAGCTGTC TAAAATGCAG TGGGGTTTGT TTTGCAATGT 5760 TTTAAACAGA GTTTTAGTAT TGCTATTAAA AGAAGTTACT TTGCTTTTAA AGAAACTTGG 5820 CTGCTTAAAA TAAGCAAAAA TTGGATGCAT AAAGTAATAT TTACAGATGT GGGGAGATGT 5880 AATAAAACAA TATTAACTTG GCTGCTTAAA ATAAGCAAAA ATTGGATGCA TAAAGTAATA 5940 TTTACAGATG TGGGGAGATG TAATAAAACA ATATTAACTT GGTTTCTTGT TTTTGCTGTA 6000 TTTAGAGATT. AAATAATTCT AAGATGATCA CTTTGCAAAA TTATGCTTAT GGCTGGCATG 6060 GAAATAGAAA TACTCAATTA TGTCTTTGTT GTATTAATGG GGAATATTTT GGACAATGTT 6120 TCATTATCAA ATTGTCGACA TCATTAATAT ATATTGTAAT GTTGGGAAGA GATCACTATT 6180 TTGAAGCACA GCTTTACAGA TGAGTATCTA TGATACATAT GTATAATAAA TTTTGATCGG 6240 GTATTAAAAG TATTAGAAGG TGGTTATAAT TGCAGAGTAT TCCATGAATA GTACACTGAC 6300 ACAGGGGTTT TACTTTGAGG ACCAGTGTAG TCAAGGGAAA ACATGAGTTA AAAAGAAAAG 6360 CAGGCAATAT TGCAGTCTTG ATTCTGCCAC TTACAGGATA GATAATGCCT GAACTTTAAT 6420 GACAAGATGA TCCAACCATA AAGGTGCTCT GTGCTTCACA GTGAATCTTT TCCCCATGCA 6480 GGAGTGTGCT CCCCTACAAA CGTTAAGACT GATCATTTCA AAAATCTATT AGCTATATCA 6540 AAAGCCTTAC ATTTTAATAT AGGTTGAACC AAAATTTCAA TTCCAGTAAC TTCTATTGTA 6600 ACCATTATTT TTGTGTATGT CTTCAAGAAT GTTCATTGGA TTTTTGTTTG TAATAGTAAA 6660 ATACCGGATA CATTTCACGT GTCCTTCAGT ATTGATTTGG TTGAATATTG GGTCATAATG 6720 GTTGAGAAGC ATGGACACTA GAGCCAGAAT GCTTGGATAT GAATCCTGGA TCTGTCACTT 6780 ACTTCTGTGT GACCTTTGAA AGGCTACTTA TTTCCTCTCT TAGCTTTCTC ATTAAAATCA 6840 ATGAACAATG CCAGCCTCAT GGGGTTGTTG AATGATTAAA TTAGTTAATA TACCTAAAGT 6900 ACATAGAACA CTGCCTGCAC ATAGTAAAAG AATTATAAGT GTGAGGTAGT TGGTAAAATT 6960 ATGTAGTTGG ATATACTACC GAACAATATC TAATCTCTTT TTAGGGAAAT AAAGTTTGTG 7020 CATATATATA ATCCCGAAAC ATG Seq ID NO: 527 Protein sequence Protein Accession &num : NP 077741. 1 1 11 21 31 41 51 MAAAGPRRSV RGAVCLHLLL TLVIFSRDGE ACKKVILNVP SKLEADKIIG RVNLEECFRS 60 ADLIRSSDPD FRVLNDGSVY TARAVALSDK KRSFTIWLSD KRKQTQKEVT VLLEHQKKVS 120 KTRHTRETVL RRAKRRWAPI PCSMQENSLG PFPLFLQQVE SDAAQNYTVF YSISGRGVDK 180 EPLNLFYIER DTGNLFCTRP VDREEYDVFD LIAYASTADG YSADLPLPLP IRVEDENDNH 240 PVFTEAIYNF EVLESSRPGT TVGWCATDR DEPDTMHTRL KYSILQQTPR SPGLFSVHPS 300 TGVITTVSHY LDREWDKYS LIMKVQDMDG QFFGLIGTST CIITVTDSND NAPTFRQNAY 360 EAFVEENAFN VEILRIPIED KDLINTANWR VNFTILKGNE NGHFKISTDK ETNEGVLSW 420 KPLNYEENRQ VNLEIGVNNE APFARDIPRV TALNRALVTV HVRDLDEGPE CTPAAQYVRI 480 KENLAVGSKI NGYKAYDPEN RNGNGLRYKK LHDPKGWITI DEISGSIITS KILDREVETP 540 KNELYNITVL AIDKDDRSCT GTLAVNIEDV NDNPPEILQE YWICKPKMG YTDILAVDPD 600 EPVHGAPFYF SLPNTSPEIS RLWSLTKVND TAARLSYQKN AGFQEYTIPI TVKDRAGQAA 660 TKLLRVNLCE CTHPTQCRAT SRSTGVILGK WAILAILLGI ALLFSVLLTL VCGVFGATKG 720 KRFPEDLAQQ NLIISNTEAP GDDRVCSANG FMTQTTNNSS QGFCGTMGSG MKNGGQETIE 780 MMKGGNQTLE SCRGAGHHHT LDSCRGGHTE VDNCRYTYSE WHSFTQPRLG EESIRGHTG Seq ID NO : 528 DNA sequence Nucleic Acid Accession # : NM 001941. 2 Coding sequence: 64.. 2754 1 11 21 31 41 51 GGCAGGTCTC GCTCTCGGCA CCCTCCCGGC GCCCGCGTTC TCCTGGCCCT GCCCGGCATC 60 CCGATGGCCG CCGCTGGGCC CCGGCGCTCC GTGCGCGGAG CCGTCTGCCT GCATCTGCTG 120 CTGACCCTCG TGATCTTCAG TCGTGATGGT GAAGCCTGCA AAAAGGTGAT ACTTAATGTA 180 CCTTCTAAAC TAGAGGCAGA CAAAATAATT GGCAGAGTTA ATTTGGAAGA GTGCTTCAGG 240 TCTGCAGACC TCATCCGGTC AAGTGATCCT GATTTCAGAG TTCTAAATGA TGGGTCAGTG 300 TACACAGCCA GGGCTGTTGC GCTGTCTGAT AAGAAAAGAT CATTTACCAT ATGGCTTTCT 360 GACAAAAGGA AACAGACACA GAAAGAGGTT ACTGTGCTGC TAGAACATCA GAAGAAGGTA 420 TCGAAGACAA GACACACTAG AGAAACTGTT CTCAGGCGTG CCAAGAGGAG ATGGGCACCT 480 ATTCCTTGCT CTATGCAAGA GAATTCCTTG GGCCCTTTCC CATTGTTTCT TCAACAAGTT 540 GAATCTGATG CAGCACAGAA CTATACTGTC TTCTACTCAA TAAGTGGACG TGGAGTTGAT 600 AAAGAACCTT TAAATTTGTT TTATATAGAA AGAGACACTG GAAATCTATT TTGCACTCGG 660 CCTGTGGATC GTGAAGAATA TGATGTTTTT GATTTGATTG CTTATGCGTC AACTGCAGAT 720 GGATATTCAG CAGATCTGCC CCTCCCACTA CCCATCAGGG TAGAGGATGA AAATGACAAC 780 CACCCTGTTT TCACAGAAGC AATTTATAAT TTTGAAGTTT TGGAAAGTAG TAGACCTGGT 840 ACTACAGTGG GGGTGGTTTG TGCCACAGAC AGAGATGAAC CGGACACAAT GCATACGCGC 900 CTGAAATACA GCATTTTGCA GCAGACACCA AGGTCACCTG GGCTCTTTTC TGTGCATCCC 960

AGCACAGGCG TAATCACCAC AGTCTCTCAT TATTTGGACA GAGAGGTTGT AGACAAGTAC 1020 TCATTGATAA TGAAAGTACA AGACATGGAT GGCCAGTTTT TTGGATTGAT AGGCACATCA 1080 ACTTGTATCA TAACAGTAAC AGATTCAAAT GATAATGCAC CCACTTTCAG ACAAAATGCT 1140 TATGAAGCAT TTGTAGAGGA AAATGCATTC AATGTGGAAA TCTTACGAAT ACCTATAGAA 1200 GATAAGGATT TAATTAACAC TGCCAATTGG AGAGTCAATT TTACCATTTT AAAGGGAAAT 1260 GAAAATGGAC ATTTCAAAAT CAGCACAGAC AAAGAAACTA ATGAAGGTGT TCTTTCTGTT 1320 GTAAAGCCAC TGAATTATGA AGAAAACCGT CAAGTGAACC TGGAAATTGG AGTAAACAAT 1380 GAAGCGCCAT TTGCTAGAGA TATTCCCAGA GTGACAGCCT TGAACAGAGC CTTGGTTACA 1440 GTTCATGTGA GGGATCTGGA TGAGGGGCCT GAATGCACTC CTGCAGCCCA ATATGTGCGG 1500 ATTAAAGAAA ACTTAGCAGT GGGGTCAAAG ATCAACGGCT ATAAGGCATA TGACCCCGAA 1560 AATAGAAATG GCAATGGTTT AAGGTACAAA AAATTGCATG ATCCTAAAGG TTGGATCACC 1620 ATTGATGAAA TTTCAGGGTC AATCATAACT TCCAAAATCC TGGATAGGGA GGTTGAAACT 1680 CCCAAAAATG AGTTGTATAA TATTACAGTC CTGGCAATAG ACAAAGATGA TAGATCATGT 1740 ACTGGAACAC TTGCTGTGAA CATTGAAGAT GTAAATGATA ATCCACCAGA AATACTTCAA 1800 GAATATGTAG TCATTTGCAA ACCAAAAATG GGGTATACCG ACATTTTAGC TGTTGATCCT 1860 GATGAACCTG TCCATGGAGC TCCATTTTAT TTCAGTTTGC CCAATACTTC TCCAGAAATC 1920 AGTAGACTGT GGAGCCTCAC CAAAGTTAAT GATACAGCTG CCCGTCTTTC ATATCAGAAA 1980 AATGCTGGAT TTCAAGAATA TACCATTCCT ATTACTGTAA AAGACAGGGC CGGCCAAGCT 2040 GCAACAAAAT TATTGAGAGT TAATCTGTGT GAATGTACTC ATCCAACTCA GTGTCGTGCG 2100 ACTTCAAGGA GTACAGGAGT AATACTTGGA AAATGGGCAA TCCTTGCAAT ATTACTGGGT 2160 ATAGCACTGC TCTTTTCTGT ATTGCTAACT TTAGTATGTG GAGTTTTTGG TGCAACTAAA 2220 GGGAAACGTT TTCCTGAAGA TTTAGCACAG CAAAACTTAA TTATATCAAA CACAGAAGCA 2280 CCTGGAGACG ATAGAGTGTG CTCTGCCAAT GGATTTATGA CCCAAACTAC CAACAACTCT 2340 AGCCAAGGTT TTTGTGGTAC TATGGGATCA GGAATGAAAA ATGGAGGGCA GGAAACCATT 2400 GAAATGATGA AAGGAGGAAA CCAGACCTTG GAATCCTGCC GGGGGGCTGG GCATCATCAT 2460 ACCCTGGACT CCTGCAGGGG AGGACACACG GAGGTGGACA ACTGCAGATA CACTTACTCG 2520 GAGTGGCACA GTTTTACTCA ACCCCGTCTC GGTGAAAAAT TGCATCGATG TAATCAGAAT 2580 GAAGACCGCA TGCCATCCCA AGATTATGTC CTCACTTATA ACTATGAGGG AAGAGGATCT 2640 CCAGCTGGTT CTGTGGGCTG CTGCAGTGAA AAGCAGGAAG AAGATGGCCT TGACTTTTTA 2700 AATAATTTGG AACCCAAATT TATTACATTA GCAGAAGCAT GCACAAAGAG ATAATGTCAC 2760 AGTGCTACAA TTAGGTCTTT GTCAGACATT CTGGAGGTTT CCAAAAATAA TATTGTAAAG 2820 TTCAATTTCA ACATGTATGT ATATGATGAT TTTTTTCTCA ATTTTGAATT ATGCTACTCA 2880 CCAATTTATA TTTTTAAAGC CAGTTGTTGC TTATCTTTTC CAAAAAGTGA AAAATGTTAA 2940 AACAGACAAC TGGTAAATCT CAAACTCCAG CACTGGAATT AAGGTCTCTA AAGCATCTGC 3000 TCTTTTTTTT TTTTACGGAT ATTTTAGTAA TAAATATGCT GGATAAATAT TAGTCCAACA 3060 ATAGCTAAGT TATGCTAATA TCACATTATT ATGTATTCAC TTTAAGTGAT AGTTTAAAAA 3120 ATAAACAAGA AATATTGAGT ATCACTATGT GAAGAAAGTT TTGGAAAAGA AACAATGAAG 3180 ACTGAATTAA ATTAAAAATG TTGCAGCTCA TAAAGAATTG GGACTCACCC CTACTGCACT 3240 ACCAAATTCA TTTGACTTTG GAGGCAAAAT GTGTTGAAGT GCCCTATGAA GTAGCAATTT 3300 TCTATAGGAA TATAGTTGGA AATAAATGTG TGTGTGTATA TTATTATTAA TCAATGCAAT 3360 ATTTAAAATG AAATGAGAAC AAAGAGGAAA ATGGTAAAAA CTTGAAATGA GGCTGGGGTA 3420 TAGTTTGTCC TACAATAGAA AAAAGAGAGA GCTTCCTAGG CCTGGGCTCT TAAATGCTGC 3480 ATTATAACTG AGTCTATGAG GAAATAGTTC CTGTCCAATT TGTGTAATTT GTTTAAAATT 3540 GTAAATAAAT TAAACTTTTC TGGTTTCTGT GGGAAGGAAA TAGGGAATCC AATGGAACAG 3600 TAGCTTTGCT TTGCAGTCTG TTTCAAGATT TCTGCATCCA CAAGTTAGTA GCAAACTGGG 3660 GAATACTCGC TGCAGCTGGG GTTCCCTGCT TTTTGGTAGC AAGGGTCCAG AGATGAGGTG 3720 TTTTTTTCGG GGAGCTAATA ACAAAAACAT TTTAAAACTT ACCTTTACTG AAGTTAAATC 3780 CTCTATTGCT GTTTCTATTC TCTCTTATAG TGACCAACAT CTTTTTAATT TAGATCCAAA 3840 TAACCATGTC CTCCTAGAGT TTAGAGGCTA GAGGGAGCTG AGGGGAGGAT CTTACTGAAA 3900 GCACCCTGGG GAGATTGATT GTCCTTAAAC CTAAGCCCCA CAAACTTGAC ACCTGATCAG 3960 GTCTGGGAGC TACAAAATTT CATTTTTCTC CTCACTGCCC TTCTTCTGAG TGGCATTGGC 4020 CTGAATCAAG GAAAGCCAGG CCTTGTGGGC CCCCTTCTTT CGGCTTTCTG CTAAAGCAAC 4080 ACCTCCAGCA GAGATTCCCT TAAGTGACTC CAGGTTTTCC ACCATCCTTC AGCGTGAATT 4140 AATTTTTAAT CAGTTTGCTT TCTCCAGAGA AATTTTAAAA TAATAGAAGA AATAGAAATT 4200 TTGAATGTAT AAAAGAAAAA GATCAAGTTG TCATTTTAGA ACAGAGGGAA CTTTGGGAGA 4260 AAGCAGCCCA AGTAGGTTAT TTGTACAGTC AGAGGGCAAC AGGAAGATGC AGGCCTTCAA 4320 GGGCAAGGAG AGGCCACAAG GAATATGGGT GGGAGTAAAA GCAACATCGT CTGCTTCATA 4380 CTTTTTCCTA GGCTTGGCAC TGCCTTTTCC TTTCTCAGGC CAATGGCAAC TGCCATTTGA 4440 GTCCGGTGAG GGATCAGCCA ACCTCTTCTC TATGGCTCAC CTTATTTGGA GTGAGAAATC 4500 AAGGAGACAG AGCTGACTGC ATGATGAGTC TGAAGGCATT TGCAGGATGA GCCTGAACTG 4560 GTTGTGCAGA ACAAACAAGG CATTCATGGG AATTGTTGTA TTCCTTCTGC AGCCCTCCTT 4620 CTGGGCACTA AGAAGGTCTA TGAATTAAAT GCCTATCTAA AATTCTGATT TATTCCTACA 4680 TTTTCTGTTT TCTAATTTGA CCCTAAAATC TATGTGTTTT AGACTTAGAC TTTTTATTGC 4740 CCCCCCCCCC TTTTTTTTTG AGACGGAGTC TCGCTCTGAC GCACAGGCTG GAGTGCAGTG 4800 GCTCCGATCT CTGCTCACTG AAAGCTCCGC CTCCCGGGTT CATGCCATTC TCCTGCCTCA 4860 GCCTCCTGAG TAGCTGGGAC TACAGGCGCC CACCACCACG CCCGGCTAAT TTTTTGTATT 4920 TTTAATAGAG ACGGGGTTTC ACTGTGTTAG CCAGGATGGT CTCGATCTCC TGACCTCGTG 4980 ATCCGCCTGC CTCGGCCTCC CAAAGTGCTG GGATTACAGG CATGACCCAC CGCTCCCGGC 5040 CTTGTTTTCC GTTTAAAGTC GTCTTCTTTT AATGTAATCA TTTTGAACAT GTGTGAAAGT 5100 TGATCATACG AATTGGATCA ATCTTGAAAT ACTCAACCAA AAGACAGTCG AGAAGCCAGG 5160 GGGAGAAAGA ACTCAGGGCA CAAAATATTG GTCTGAGAAT GGAATTCTCT GTAAGCCTAG 5220 TTGCTGAAAT TTCCTGCTGT AACCAGAAGC CAGTTTTATC TAACGGCTAC TGAAACACCC 5280 ACTGTGTTTT GCTCACTCCC TCACTCACCG ATCAAAACCT GCTACCTCCC CAAGACTTTA 5340 CTAGTGCCGA TAAACTTTCT CAAAGAGCAA CCAGTATCAC TTCCCTGTTT ATAAAACCTC 5400 TAACCATCTC TTTGTTCTTT GAACATGCTG AAAACCACCT GGTCTGCATG TATGCCCGAA 5460 TTTGTAATTC TTTTCTCTCA AATGAAAATT TAATTTTAGG GATTCATTTC TATATTTTCA 5520 CATATGTAGT ATTATTATTT CCTTATATGT GTAAGGTGAA ATTTATGGTA TTTGAGTGTG 5580 CAAGAAAATA TATTTTTAAA GCTTTCATTT TTCCCCCAGT GAATGATTTA GAATTTTTTA 5640 TGTAAATATA CAGAATGTTT TTTCTTACTT TTATAAGGAA GCAGCTGTCT AAAATGCAGT 5700 GGGGTTTGTT TTGCAATGTT TTAAACAGAG TTTTAGTATT GCTATTAAAA GAAGTTACTT 5760 TGCTTTTAAA GAAACTTGGC TGCTTAAAAT AAGCAAAAAT TGGATGCATA AAGTAATATT 5820 TACAGATGTG GGGAGATGTA ATAAAACAAT ATTAACTTGG TTTCTTGTTT TTGCTGTATT 5880 TAGAGATTAA ATAATTCTAA GATGATCACT TTGCAAAATT ATGCTTATGG CTGGCATGGA 5940 AATAGAAATA CTCAATTATG TCTTTGTTGT ATTAATGGGG AATATTTTGG ACAATGTTTC 6000 ATTATCAAAT TGTCGACATC ATTAATATAT ATTGTAATGT TGGGAAGAGA TCACTATTTT 6060 GAAGCACAGC TTTACAGATG AGTATCTATG ATACATATGT ATAATAAATT TTGATCGGGT 6120 ATTAAAAGTA TTAGAAGGTG GTTATAATTG CAGAGTATTC CATGAATAGT ACACTGACAC 6180

MAKDNSTVRC FQGLLIFGNV IIGCCGIALT AECIFFVSDQ HSLYPLLEAT DNDDIYGAAW 60 IGIFVGICLF CLSVLGIVGI MKSSRKILLA YFILMFIVYA FEVASCITAA TQRDFFTPNL 120 FLKQMLERYQ NNSPPNNDDQ WKNNGVTKTW DRLMLQDNCC GVNGPSDWQK YTSAFRTENN 180 DADYPWPRQC CVMNNLKEPL NLEACKLGVP GFYHNQGCYE LISGPMNRHA WGVAWFGFAI 240 LCWTFWVLLG TMFYWSRIEY Seq ID NO : 536 DNA sequence Nucleic Acid Accession # : NM 002638. 1 Coding sequence: 120.. 473 1 11 21 31 41 51 CAATACAGCT AAGGAATTAT CCCTTGTAAA TACCACAGAC CCGCCCTGGA GCCAGGCCAA 60 GCTGGACTGC ATAAAGATTG GTATGGCCTT AGCTCTTAGC CAAACACCTT CCTGACACCA 120 TGAGGGCCAG CAGCTTCTTG ATCGTGGTGG TGTTCCTCAT CGCTGGGACG CTGGTTCTAG 180 AGGCAGCTGT CACGGGAGTT CCTGTTAAAG GTCAAGACAC TGTCAAAGGC CGTGTTCCAT 240 TCAATGGACA AGATCCCGTT AAAGGACAAG TTTCAGTTAA AGGTCAAGAT AAAGTCAAAG 300 CGCAAGAGCC AGTCAAAGGT CCAGTCTCCA CTAAGCCTGG CTCCTGCCCC ATTATCTTGA 360 TCCGGTGCGC CATGTTGAAT CCCCCTAACC GCTGCTTGAA AGATACTGAC TGCCCAGGAA 420 TCAAGAAGTG CTGTGAAGGC TCTTGCGGGA TGGCCTGTTT CGTTCCCCAG TGAAGGGAGC 480 CGGTCCTTGC TGCACCTGTG CCGTCCCCAG AGCTACAGGC CCCATCTGGT CCTAAGTCCC 540 TGCTGCCCTT CCCCTTCCCA CACTGTCCAT TCTTCCTCCC ATTCAGGATG CCCACGGCTG 600 GAGCTGCCTC TCTCATCCAC TTTCCAATAA A Seq ID NO : 537 Protein sequence Protein Accession # : NP 002629. 1 1 11 21 31 41 51 # # # # # # MRASSFLIVV VFLIAGTLVL EAAVTGVPVK GQDTVKGRVP FNGQDPVKGQ VSVKGQDKVK 60 AQEPVKGPVS TKPGSCPIIL IRCAMLNPPN RCLKDTDCPG IKKCCEGSCG MACFVPQ Seq ID NO : 538 DNA sequence Nucleic Acid Accession &num : NM001793. 2 Coding sequence: 71.. 2560 1 11 21 31 41 51 AAAGGGGCAA GAGCTGAGCG GAACACCGGC CCGCCGTCGC GGCAGCTGCT TCACCCCTCT 60 CTCTGCAGCC ATGGGGCTCC CTCGTGGACC TCTCGCGTCT CTCCTCCTTC TCCAGGTTTG 120 CTGGCTGCAG TGCGCGGCCT CCGAGCCGTG CCGGGCGGTC TTCAGGGAGG CTGAAGTGAC 180 CTTGGAGGCG GGAGGCGCGG AGCAGGAGCC CGGCCAGGCG CTGGGGAAAG TATTCATGGG 240 CTGCCCTGGG CAAGAGCCAG CTCTGTTTAG CACTGATAAT GATGACTTCA CTGTGCGGAA 300 TGGCGAGACA GTCCAGGAAA GAAGGTCACT GAAGGAAAGG AATCCATTGA AGATCTTCCC 360 ATCCAAACGT ATCTTACGAA GACACAAGAG AGATTGGGTG GTTGCTCCAA TATCTGTCCC 420 TGAAAATGGC AAGGGTCCCT TCCCCCAGAG ACTGAATCAG CTCAAGTCTA ATAAAGATAG 480 AGACACCAAG ATTTTCTACA GCATCACGGG GCCGGGGGCA GACAGCCCCC CTGAGGGTGT 540 CTTCGCTGTA GAGAAGGAGA CAGGCTGGTT GTTGTTGAAT AAGCCACTGG ACCGGGAGGA 600 GATTGCCAAG TATGAGCTCT TTGGCCACGC TGTGTCAGAG AATGGTGCCT CAGTGGAGGA 660 CCCCATGAAC ATCTCCATCA TCGTGACCGA CCAGAATGAC CACAAGCCCA AGTTTACCCA 720 GGACACCTTC CGAGGGAGTG TCTTAGAGGG AGTCCTACCA GGTACTTCTG TGATGCAGGT 780 GACAGCCACG GATGAGGATG ATGCCATCTA CACCTACAAT GGGGTGGTTG CTTACTCCAT 840 CCATAGCCAA GAACCAAAGG ACCCACACGA CCTCATGTTC ACCATTCACC GGAGCACAGG 900 CACCATCAGC GTCATCTCCA GTGGCCTGGA CCGGGAAAAA GTCCCTGAGT ACACACTGAC 960 CATCCAGGCC ACAGACATGG ATGGGGACGG CTCCACCACC ACGGCAGTGG CAGTAGTGGA 1020 GATCCTTGAT GCCAATGACA ATGCTCCCAT GTTTGACCCC CAGAAGTACG AGGCCCATGT 1080 GCCTGAGAAT GCAGTGGGCC ATGAGGTGCA GAGGCTGACG GTCACTGATC TGGACGCCCC 1140 CAACTCACCA GCGTGGCGTG CCACCTACCT TATCATGGGC GGTGACGACG GGGACCATTT 1200 TACCATCACC ACCCACCCTG AGAGCAACCA GGGCATCCTG ACAACCAGGA AGGGTTTGGA 1260 TTTTGAGGCC AAAAACCAGC ACACCCTGTA CGTTGAAGTG ACCAACGAGG CCCCTTTTGT 1320 GCTGAAGCTC CCAACCTCCA CAGCCACCAT AGTGGTCCAC GTGGAGGATG TGAATGAGGC 1380 ACCTGTGTTT GTCCCACCCT CCAAAGTCGT TGAGGTCCAG GAGGGCATCC CCACTGGGGA 1440 GCCTGTGTGT GTCTACACTG CAGAAGACCC TGACAAGGAG AATCAAAAGA TCAGCTACCG 1500 CATCCTGAGA GACCCAGCAG GGTGGCTAGC CATGGACCCA GACAGTGGGC AGGTCACAGC 1560 TGTGGGCACC CTCGACCGTG AGGATGAGCA GTTTGTGAGG AACAACATCT ATGAAGTCAT 1620 GGTCTTGGCC ATGGACAATG GAAGCCCTCC CACCACTGGC ACGGGAACCC TTCTGCTAAC 1680 ACTGATTGAT GTCAATGACC ATGGCCCAGT CCCTGAGCCC CGTCAGATCA CCATCTGCAA 1740 CCAAAGCCCT GTGCGCCAGG TGCTGAACAT CACGGACAAG GACCTGTCTC CCCACACCTC 1800 CCCTTTCCAG GCCCAGCTCA CAGATGACTC AGACATCTAC TGGACGGCAG AGGTCAACGA 1860 GGAAGGTGAC ACAGTGGTCT TGTCCCTGAA GAAGTTCCTG AAGCAGGATA CATATGACGT 1920 GCACCTTTCT CTGTCTGACC ATGGCAACAA AGAGCAGCTG ACGGTGATCA GGGCCACTGT 1980 GTGCGACTGC CATGGCCATG TCGAAACCTG CCCTGGACCC TGGAAGGGAG GTTTCATCCT 2040 CCCTGTGCTG GGGGCTGTCC TGGCTCTGCT GTTCCTCCTG CTGGTGCTGC TTTTGTTGGT 2100 GAGAAAGAAG CGGAAGATCA AGGAGCCCCT CCTACTCCCA GAAGATGACA CCCGTGACAA 2160 CGTCTTCTAC TATGGCGAAG AGGGGGGTGG CGAAGAGGAC CAGGACTATG ACATCACCCA 2220 GCTCCACCGA GGTCTGGAGG CCAGGCCGGA GGTGGTTCTC CGCAATGACG TGGCACCAAC 2280 CATCATCCCG ACACCCATGT ACCGTCCTCG GCCAGCCAAC CCAGATGAAA TCGGCAACTT 2340 TATAATTGAG AACCTGAAGG CGGCTAACAC AGACCCCACA GCCCCGCCCT ACGACACCCT 2400 CTTGGTGTTC GACTATGAGG GCAGCGGCTC CGACGCCGCG TCCCTGAGCT CCCTCACCTC 2460 CTCCGCCTCC GACCAAGACC AAGATTACGA TTATCTGAAC GAGTGGGGCA GCCGCTTCAA 2520 GAAGCTGGCA GACATGTACG GTGGCGGGGA GGACGACTAG GCGGCCTGCC TGCAGGGCTG 2580 GGGACCAAAC GTCAGGCCAC AGAGCATCTC CAAGGGGTCT CAGTTCCCCC TTCAGCTGAG 2640 GACTTCGGAG CTTGTCAGGA AGTGGCCGTA GCAACTTGGC GGAGACAGGC TATGAGTCTG 2700 ACGTTAGAGT GGTTGCTTCC TTAGCCTTTC AGGATGGAGG AATGTGGGCA GTTTGACTTC 2760 AGCACTGAAA ACCTCTCCAC CTGGGCCAGG GTTGCCTCAG AGGCCAAGTT TCCAGAAGCC 2820 TCTTACCTGC CGTAAAATGC TCAACCCTGT GTCCTGGGCC TGGGCCTGCT GTGACTGACC 2880 TACAGTGGAC TTTCTCTCTG GAATGGAACC TTCTTAGGCC TCCTGGTGCA ACTTAATTTT 2940

AATTGGGACA TAATTTTGGA GCAGAACATG ATCCGGATGG TCTAGCAGAA TGTGCCCCGA 1440 ATGAGGACCA GGGAGGGAAA TATGTCATGT ATCCCATAGC TGTGAGTGGC GATCACGAGA 1500 ACAATAAGAT GTTTTCAAAC TGCAGTAAAC AATCAATCTA TAAGACCATT GAAAGTAAGG 1560 CCCAGGAGTG TTTTCAAGAA CGCAGCAATA AAGTTTGTGG GAACTCGAGG GTGGATGAAG 1620 GAGAAGAGTG TGATCCTGGC ATCATGTATC TGAACAACGA CACCTGCTGC AACAGCGACT 1680 GCACGTTGAA GGAAGGTGTC CAGTGCAGTG ACAGGAACAG TCCTTGCTGT AAAAACTGTC 1740 AGTTTGAGAC TGCCCAGAAG AAGTGCCAGG AGGCGATTAA TGCTACTTGC AAAGGCGTGT 1800 CCTACTGCAC AGGTAATAGC AGTGAGTGCC CGCCTCCAGG AAATGCTGAA AATGACACTG 1860 TTTGCTTGGA TCTTGGCAAG TGTAAGGATG GGAAATGCAT CCCTTTCTGC GAGAGGGAAC 1920 AGCAGCTGGA GTCCTGTGCA TGTAATGAAA CTGACAACTC CTGCAAGGTG TGCTGCAGGG 1980 ACCTTTCTGG CCGCTGTGTG CCCTATGTCG ATGCTGAACA AAAGAACTTA TTTTTGAGGA 2040 AAGGAAAGCC CTGTACAGTA GGATTTTGTG ACATGAATGG CAAATGTGAG AAACGAGTAC 2100 AGGATGTAAT TGAACGATTT TGGGATTTCA TTGACCAGCT GAGCATCAAT ACTTTTGGAA 2160 AGTTTTTAGC AGACAACATC GTTGGGTCTG TCCTGGTTTT CTCCTTGATA TTTTGGATTC 2220 CTTTCAGCAT TCTTGTCCAT TGTGTGGATA AGAAATTGGA TAAACAGTAT GAATCTCTGT 2280 CTCTGTTTCA CCCCAGTAAC GTCGAAATGC TGAGCAGCAT GGATTCTGCA TCGGTTCGCA 2340 TTATCAAACC CTTTCCTGCG CCCCAGACTC CAGGCCGCCT GCAGCCTGCC CCTGTGATCC 2400 CTTCGGCGCC AGCAGCTCCA AAACTGGACC ACCAGAGAAT GGACACCATC CAGGAAGACC 2460 CCAGCACAGA CTCCCATATG GACGAGGATG GGTTTGAGAA GGACCCCTTC CCAAATAGCA 2520 GCACAGCTGC CAAGTCATTT GAGGATCTCA CGGACCATCC GGTCGCCAGA AGTGAAAAGG 2580 CTGCCTCCTT TAAACTGCAG CGTCAGAATC GTGTTAACAG CAAAGAAACA GAGTGCTAAT 2640 TTAGTTCTCA GCTCTTCTGA CTTAAGTGTG CAAAATATTT TTATAGATTT GACCTACAAA 2700 TCAATCACAG CTTGTATTTT GTGAAGACTG GGAAGTGACT TAGCAGATGC TGGTCATGTG 2760 TTTGAACTTC CTGCAGGTAA ACAGTTCTTG TGTGGTTTGG CCCTTCTCCT TTTGAAAAGG 2820 TAAGGTGAAA GTGAATCTAC TTATTTTGAG GCTTTCAGGT TTTAGTTTTT AAAATATCTT 2880 TTGACCTGTG GTGCAAAAGC AGAAAATACA GCTGGATTGG GTTATGAATA TTTACGTTTT 2940 TGTAAATTAA TCTTTTATAT TGATAACAGC ACTGACTAGG GAAATGATCA GTTTTTTTTT 3000 ATACACTGTA ATGAACCGCT GAATATGAAG CATTTGGCAT TTATTTGTGA GAAAAGTGGA 3060 ATAGTTTTTT TTTTTTTTTT TTTTTTTTGC CTTCAACTAA AAACAAAGGA GATAAATTTA 3120 GTATACATTG TATCTAAATT GTGGGTCTAT TTCTAGTTAT TACCCAGAGT TTTTATGTAG 3180 CAGGGAAAAT ATATATCTAA ATTTAGAAAT CATTTGGGTT AATATGGCTC TTCATAATTC 3240 TAAGACTAAT GCTCAGAACC TAACCACTAC CTTACAGTGA GGGCTATACA TGGTAGCCAG 3300 TTGAATTTAT GGAATCTACC AACTGTTTAG GGCCCTGATT TGCTGGGCAG TTTTTCTGTA 3360 TTTTATAAGT ATCTTCATGT ATCCCTGTTA CTGATAGGGA TACATGTCTT AGAAAATTCA 3420 CTATTGGCTG GGAGTGGTGG CTCATGCCTG TAATCCCAGC ACTTGGAGAG GCTGAGGTTG 3480 CGCCACTACA CTCCAGCCTG GGTGACAGAG TGAGATCTGC CTC Seq ID NO : 555 Protein sequence Protein Accession # : NP 003174. 2 1 11 21 31 41 51 MRQSLLFLTS WPFVLAPRP PDDPGFGPHQ RLEKLDSLLS DYDILSLSNI QQHSVRKRDL 60 QTSTHVETLL TFSALKRHFK LYLTSSTERF SQNFKWWD GKNESEYTAK WQDFFTGHW 120 GEPDSRVLAH IRDDDVIIRI NTDGAEYNIE PLWRFVNDTK DKRMLVYKSE DIKNVSRLQS 180 PKVCGYLKVD NEELLPKGLV DREPPEELVH RVKRRADPDP MKNTCKLLW ADHRFYRYMG 240 RGEESTTTNY LIELIDRVDD IYRNTSWDNA GFKGYGIQIE QIRILKSPQE VKPGEKHYNM 300 AKSYPNEEKD AWDVKMLLEQ FSFDIAEEAS KVCLAHLFTY QDFDMGTLGL AYVGSPRANS 360 HGGVCPKAYY SPVGKKNIYL NSGLTSTKNY GKTILTKEAD LVTTHELGHN FGAEHDPDGL 420 AECAPNEDQG GKYVMYPIAV SGDHENNKMF SNCSKQSIYK TIESKAQECF QERSNKVCGN 480 SRVDEGEECD PGIMYLNNDT CCNSDCTLKE GVQCSDRNSP CCKNCQFETA QKKCQEAINA 540 TCKGVSYCTG NSSECPPPGN AENDTVCLDL GKCKDGKCIP FCEREQQLES CACNETDNSC 600 KVCCRDLSGR CVPYVDAEQK NLFLRKGKPC TVGFCDMNGK CEKRVQDVIE RFWDFIDQLS 660 INTFGKFLAD NIVGSVLVFS LIFWIPFSIL VHCVDKKLDK QYESLSLFHP SNVEMLSSMD 720 SASVRIIKPF PAPQTPGRLQ PAPVIPSAPA APKLDHQRMD TIQEDPSTDS HMDEDGFEKD 780 PFPNSSTAAK SFEDLTDHPV ARSEKAASFK LQRQNRVNSK ETEC Seq ID NO : 556 DNA sequence Nucleic Acid Accession # : NM 021832. 1 Coding sequence : 164.. 2248 1 11 21 31 41 51 TCGAGCCTGG CGGTAGAATC TTCCCAGTAG GCGGCGCGGG AGGAAAAGAG GATTGAGGGG 60 CTAGGCCGGG CGGATCCCGT CCTCCCCCGA TGTGAGCAGT TTTCCGAAAC CCCGTCAGGC 120 GAAGGCTGCC CAGAGAGGTG GAGTCGGTAG CGGGGCCGGG AACATGAGGC AGTCTCTCCT 180 ATTCCTGACC AGCGTGGTTC CTTTCGTGCT GGCGCCGCGA CCTCCGGATG ACCCGGGCTT 240 CGGCCCCCAC CAGAGACTCG AGAAGCTTGA TTCTTTGCTC TCAGACTACG ATATTCTCTC 300 TTTATCTAAT ATCCAGCAGC ATTCGGTAAG AAAAAGAGAT CTACAGACTT CAACACATGT 360 AGAAACACTA CTAACTTTTT CAGCTTTGAA AAGGCATTTT AAATTATACC TGACATCAAG 420 TACTGAACGT TTTTCACAAA ATTTCAAGGT CGTGGTGGTG GATGGTAAAA ACGAAAGCGA 480 GTACACTGTA AAATGGCAGG ACTTCTTCAC TGGACACGTG GTTGGTGAGC CTGACTCTAG 540 GGTTCTAGCC CACATAAGAG ATGATGATGT TATAATCAGA ATCAACACAG ATGGGGCCGA 600 ATATAACATA GAGCCACTTT GGAGATTTGT TAATGATACC AAAGACAAAA GAATGTTAGT 660 TTATAAATCT GAAGATATCA AGAATGTTTC ACGTTTGCAG TCTCCAAAAG TGTGTGGTTA 720 TTTAAAAGTG GATAATGAAG AGTTGCTCCC AAAAGGGTTA GTAGACAGAG AACCACCTGA 780 AGAGCTTGTT CATCGAGTGA AAAGAAGAGC TGACCCAGAT CCCATGAAGA ACACGTGTAA 840 ATTATTGGTG GTAGCAGATC ATCGCTTCTA CAGATACATG GGCAGAGGGG AAGAGAGTAC 900 AACTACAAAT TACTTAATAG AGCTAATTGA CAGAGTTGAT GACATCTATC GGAACACTTC 960 ATGGGATAAT GCAGGTTTTA AAGGCTATGG AATACAGATA GAGCAGATTC GCATTCTCAA 1020 GTCTCCACAA GAGGTAAAAC CTGGTGAAAA GCACTACAAC ATGGCAAAAA GTTACCCAAA 1080 TGAAGAAAAG GATGCTTGGG ATGTGAAGAT GTTGCTAGAG CAATTTAGCT TTGATATAGC 1140 TGAGGAAGCA TCTAAAGTTT GCTTGGCACA CCTTTTCACA TACCAAGATT TTGATATGGG 1200 AACTCTTGGA TTAGCTTATG TTGGCTCTCC CAGAGCAAAC AGCCATGGAG GTGTTTGTCC 1260 AAAGGCTTAT TATAGCCCAG TTGGGAAGAA AAATATCTAT TTGAATAGTG GTTTGACGAG 1320 CACAAAGAAT TATGGTAAAA CCATCCTTAC AAAGGAAGCT GACCTGGTTA CAACTCATGA 1380 ATTGGGACAT AATTTTGGAG CAGAACATGA TCCGGATGGT CTAGCAGAAT GTGCCCCGAA 1440

TGAGGACCAG GGAGGGAAAT ATGTCATGTA TCCCATAGCT GTGAGTGGCG ATCACGAGAA 1500 CAATAAGATG TTTTCAAACT GCAGTAAACA ATCAATCTAT AAGACCATTG AAAGTAAGGC 1560 CCAGGAGTGT TTTCAAGAAC GCAGCAATAA AGTTTGTGGG AACTCGAGGG TGGATGAAGG 1620 AGAAGAGTGT GATCCTGGCA TCATGTATCT GAACAACGAC ACCTGCTGCA ACAGCGACTG 1680 CACGTTGAAG GAAGGTGTCC AGTGCAGTGA CAGGAACAGT CCTTGCTGTA AAAACTGTCA 1740 GTTTGAGACT GCCCAGAAGA AGTGCCAGGA GGCGATTAAT GCTACTTGCA AAGGCGTGTC 1800 CTACTGCACA GGTAATAGCA GTGAGTGCCC GCCTCCAGGA AATGCTGAAG ATGACACTGT 1860 TTGCTTGGAT CTTGGCAAGT GTAAGGATGG GAAATGCATC CCTTTCTGCG AGAGGGAACA 1920 GCAGCTGGAG TCCTGTGCAT GTAATGAAAC TGACAACTCC TGCAAGGTGT GCTGCAGGGA 1980 CCTTTCCGGC CGCTGTGTGC CCTATGTCGA TGCTGAACAA AAGAACTTAT TTTTGAGGAA 2040 AGGAAAGCCC TGTACAGTAG GATTTTGTGA CATGAATGGC AAATGTGAGA AACGAGTACA 2100 GGATGTAATT GAACGATTTT GGGATTTCAT TGACCAGCTG AGCATCAATA CTTTTGGAAA 2160 GTTTTTAGCA GACAACATCG TTGGGTCTGT CCTGGTTTTC TCCTTGATAT TTTGGATTCC 2220 TTTCAGCATT CTTGTCCATT GTGTGTAACG TCGAAATGCT GAGCAGCATG GATTCTGCAT 2280 CGGTTCGCAT TATCAAACCC TTTCCTGCGC CCCAGACTCC AGGCCGCCTG CAGCCTGCCC 2340 CTGTGATCCC TTCGGCGCCA GCAGCTCCAA AACTGGACCA CCAGAGAATG GACACCATCC 2400 AGGAAGACCC CAGCACAGAC TCACATATGG ACGAGGATGG GTTTGAGAAG GACCCCTTCC 2460 CAAATAGCAG CACAGCTGCC AAGTCATTTG AGGATCTCAC GGACCATCCG GTCACCAGAA 2520 GTGAAAAGGC TGCCTCCTTT AAACTGCAGC GTCAGAATCG TGTTGACAGC AAAGAAACAG 2580 AGTGCTAATT TAGTTCTCAG CTCTTCTGAC TTAAGTGTGC AAAATATTTT TATAGATTTG 2640 ACCTACAATC AATCACAGCT TATATTTTGT GAAGACTGGG AAGTGACTTA GCAGATGCTG 2700 GTCATGTGTT TGAACTTCCT GCAGGTAAAC AGTTCTTGTG TGGTTTGGCC CTTCTCCTTT 2760 TGAAAAGGTA AGGTGAAGGT GAATCTAGCT TATTTTGAGG CTTTCAGGTT TTAGTTTTTA 2820 AAATATCTTT TGACCTGTGG TGCAAAAGCA GAAAATACAG CTGGATTGGG TTATGAGTAT 2880 TTACGTTTTT GTAAATTAAT CTTTTATATT GATAACAGGC ACTGACTAGG GAAATGATCA 2940 GTTTTTTTTT ATACACTGTA ATGAACCGCT GAATATGAAG CATTTGGCAT TTATTTGTGA 3000 GAAAAGTGGA ATAGTTTTTT TTTTTTTTTT TTTTTTTTGC CTTCAACTAA AAACAAAGGA 3060 GATAAATTTA GTATACATTG TATCTAAATT GTGGGTCTAT TTCTAGTTAT TACCCAGAGT 3120 TTTTATGTAG CAGGGAAAAT ATATATCTAA ATTTAGAAAT CATTTGGGTT AATATGGCTC 3180 TTCATAATTC TAAGACTAAT GCTCAGAACC TAACCACTAC CTTACAGTGA GGGCTATACA 3240 TGGTAGCCAG TTGAATTTAT GGAATCTACC AACTGTTTAG GGCCCTGATT TGCTGGGCAG 3300 TTTTTCTGTA TTTTATAAGT ATCTTCATGT ATCCCTGTTA CTGATAGGGA TACATGTCTT 3360 AGAAAATTCA CTATTGGCTG GGAGTGGTGG CTCATGCCTG TAATCCCAGC ACTTGGAGAG 3420 3421 GCTGAGGTTG CGCCACTACA CTCCAGCCTG GGTGACAGAG TGAGATCTGC CTC Seq ID NO : 557 Protein sequence Protein Accession &num : NP 068604. 1 1 11 21 31 41 51 MRQSLLFLTS WPFVLAPRP PDDPGFGPHQ RLEKLDSLLS DYDILSLSNI QQHSVRKRDL 60 QTSTHVETLL TFSALKRHFK LYLTSSTERF SQNFKWWD GKNESEYTVK WQDFFTGHW 120 GEPDSRVLAH IRDDDVIIRI NTDGAEYNIE PLWRFVNDTK DKRMLVYKSE DIKNVSRLQS 180 PKVCGYLKVD NEELLPKGLV DREPPEELVH RVKRRADPDP MKNTCKLLW ADHRFYRYMG 240 RGEESTTTNY LIELIDRVDD IYRNTSWDNA GFKGYGIQIE QIRILKSPQE VKPGEKHYNM 300 AKSYPNEEKD AWDVKMLLEQ FSFDIAEEAS KVCLAHLFTY QDFDMGTLGL AYVGSPRANS 360 HGGVCPKAYY SPVGKKNIYL NSGLTSTKNY GKTILTKEAD LVTTHELGHN FGAEHDPDGL 420 AECAPNEDQG GKYVMYPIAV SGDHENNKMF SNCSKQSIYK TIESKAQECF QERSNKVCGN 480 SRVDEGEECD PGIMYLNNDT CCNSDCTLKE GVQCSDRNSP CCKNCQFETA QKKCQEAINA 540 TCKGVSYCTG NSSECPPPGN AEDDTVCLDL GKCKDGKCIP FCEREQQLES CACNETDNSC'600 KVCCRDLSGR CVPYVDAEQK NLFLRKGKPC TVGFCDMNGK CEKRVQDVIE RFWDFIDQLS 660 INTFGKFLAD NIVGSVLVFS LIFWIPFSIL VHCV Seq ID NO: 558 DNA sequence Nucleic Acid Accession &num : NM 004994. 1 Coding sequence: 20.. 2143 1 11 21 31 41 51 AGACACCTCT GCCCTCACCA TGAGCCTCTG GCAGCCCCTG GTCCTGGTGC TCCTGGTGCT 60 GGGCTGCTGC TTTGCTGCCC CCAGACAGCG CCAGTCCACC CTTGTGCTCT TCCCTGGAGA 120 CCTGAGAACC AATCTCACCG ACAGGCAGCT GGCAGAGGAA TACCTGTACC GCTATGGTTA 180 CACTCGGGTG GCAGAGATGC GTGGAGAGTC GAAATCTCTG GGGCCTGCGC TGCTGCTTCT 240 CCAGAAGCAA CTGTCCCTGC CCGAGACCGG TGAGCTGGAT AGCGCCACGC TGAAGGCCAT 300 GCGAACCCCA CGGTGCGGGG TCCCAGACCT GGGCAGATTC CAAACCTTTG AGGGCGACCT 360 CAAGTGGCAC CACCACAACA TCACCTATTG GATCCAAAAC TACTCGGAAG ACTTGCCGCG 420 GGCGGTGATT GACGACGCCT TTGCCCGCGC CTTCGCACTG TGGAGCGCGG TGACGCCGCT 480 CACCTTCACT CGCGTGTACA GCCGGGACGC AGACATCGTC ATCCAGTTTG GTGTCGCGGA 540 GCACGGAGAC GGGTATCCCT TCGACGGGAA GGACGGGCTC CTGGCACACG CCTTTCCTCC 600 TGGCCCCGGC ATTCAGGGAG ACGCCCATTT CGACGATGAC GAGTTGTGGT CCCTGGGCAA 660 GGGCGTCGTG GTTCCAACTC GGTTTGGAAA CGCAGATGGC GCGGCCTGCC ACTTCCCCTT 720 CATCTTCGAG GGCCGCTCCT ACTCTGCCTG CACCACCGAC GGTCGCTCCG ACGGCTTGCC 780 CTGGTGCAGT ACCACGGCCA ACTACGACAC CGACGACCGG TTTGGCTTCT GCCCCAGCGA 840 GAGACTCTAC ACCCGGGACG GCAATGCTGA TGGGAAACCC TGCCAGTTTC CATTCATCTT 900 CCAAGGCCAA TCCTACTCCG CCTGCACCAC GGACGGTCGC TCCGACGGCT ACCGCTGGTG 960 CGCCACCACC GCCAACTACG ACCGGGACAA GCTCTTCGGC TTCTGCCCGA CCCGAGCTGA 1020 CTCGACGGTG ATGGGGGGCA ACTCGGCGGG GGAGCTGTGC GTCTTCCCCT TCACTTTCCT 1080 GGGTAAGGAG TACTCGACCT GTACCAGCGA GGGCCGCGGA GATGGGCGCC TCTGGTGCGC 1140 TACCACCTCG AACTTTGACA GCGACAAGAA GTGGGGCTTC TGCCCGGACC AAGGATACAG 1200 TTTGTTCCTC GTGGCGGCGC ATGAGTTCGG CCACGCGCTG GGCTTAGATC ATTCCTCAGT 1260 GCCGGAGGCG CTCATGTACC CTATGTACCG CTTCACTGAG GGGCCCCCCT TGCATAAGGA 1320 CGACGTGAAT GGCATCCGGC ACCTCTATGG TCCTCGCCCT GAACCTGAGC CACGGCCTCC 1380 AACCACCACC ACACCGCAGC CCACGGCTCC CCCGACGGTC TGCCCCACCG GACCCCCCAC 1440 TGTCCACCCC TCAGAGCGCC CCACAGCTGG CCCCACAGGT CCCCCCTCAG CTGGCCCCAC 1500 AGGTCCCCCC ACTGCTGGCC CTTCTACGGC CACTACTGTG CCTTTGAGTC CGGTGGACGA 1560 TGCCTGCAAC GTGAACATCT TCGACGCCAT CGCGGAGATT GGGAACCAGC TGTATTTGTT 1620 CAAGGATGGG AAGTACTGGC GATTCTCTGA GGGCAGGGGG AGCCGGCCGC AGGGCCCCTT 1680

CCTTATCGCC GACAAGTGGC CCGCGCTGCC CCGCAAGCTG GACTCGGTCT TTGAGGAGCC 1740 GCTCTCCAAG AAGCTTTTCT TCTTCTCTGG GCGCCAGGTG TGGGTGTACA CAGGCGCGTC 1800 GGTGCTGGGC CCGAGGCGTC TGGACAAGCT GGGCCTGGGA GCCGACGTGG CCCAGGTGAC 1860 CGGGGCCCTC CGGAGTGGCA GGGGGAAGAT GCTGCTGTTC AGCGGGCGGC GCCTCTGGAG 1920 GTTCGACGTG AAGGCGCAGA TGGTGGATCC CCGGAGCGCC AGCGAGGTGG ACCGGATGTT 1980 CCCCGGGGTG CCTTTGGACA CGCACGACGT CTTCCAGTAC CGAGAGAAAG CCTATTTCTG 2040 CCAGGACCGC TTCTACTGGC GCGTGAGTTC CCGGAGTGAG TTGAACCAGG TGGACCAAGT 2100 GGGCTACGTG ACCTATGACA TCCTGCAGTG CCCTGAGGAC TAGGGCTCCC GTCCTGCTTT 2160 GCAGTGCCAT GTAAATCCCC ACTGGGACCA ACCCTGGGGA AGGAGCCAGT TTGCCGGATA 2220 CAAACTGGTA TTCTGTTCTG GAGGAAAGGG AGGAGTGGAG GTGGGCTGGG CCCTCTCTTC 2280 TCACCTTTGT TTTTTGTTGG AGTGTTTCTA ATAAACTTGG ATTCTCTAAC CTTT Seq ID NO : 559 Protein sequence Protein Accession # : NP 004985. 1 1 11 21 31 41 51 MSLWQPLVLV LLVLGCCFAA PRQRQSTLVL FPGDLRTNLT DRQLAEEYLY RYGYTRVAEM 60 RGESKSLGPA LLLLQKQLSL PETGELDSAT LKAMRTPRCG VPDLGRFQTF EGDLKWHHHN 120 ITYWIQNYSE DLPRAVIDDA FARAFALWSA VTPLTFTRVY SRDADIVIQF GVAEHGDGYP 180 FDGKDGLLAH AFPPGPGIQG DAHFDDDELW SLGKGVWPT RFGNADGAAC HFPFIFEGRS 240 YSACTTDGRS DGLPWCSTTA NYDTDDRFGF CPSERLYTRD GNADGKPCQF PFIFQGQSYS 300 ACTTDGRSDG YRWCATTANY DRDKLFGFCP TRADSTVMGG NSAGELCVFP FTFLGKEYST 360 CTSEGRGDGR LWCATTSNFD SDKKWGFCPD QGYSLFLVAA HEFGHALGLD HSSVPEALMY 420 PMYRFTEGPP LHKDDVNGIR HLYGPRPEPE PRPPTTTTPQ PTAPPTVCPT GPPTVHPSER 480 PTAGPTGPPS AGPTGPPTAG PSTATTVPLS PVDDACNVNI FDAIAEIGNQ LYLFKDGKYW 540 RFSEGRGSRP QGPFLIADKW PALPRKLDSV FEEPLSKKLF FFSGRQVWVY TGASVLGPRR 600 LDKLGLGADV AQVTGALRSG RGKMLLFSGR RLWRFDVKAQ MVDPRSASEV DRMFPGVPLD 660 THDVFQYREK AYFCQDRFYW RVSSRSELNQ VDQVGYVTYD ILQCPED Seq ID NO : 560 DNA sequence Nucleic Acid Accession &num : NM 000213. 1 Coding sequence: 127.. 5385 1 11 21 31 41 51 CGCCCGCGCG CTGCAGCCCC ATCTCCTAGC GGCAGCCCAG GCGCGGAGGG AGCGAGTCCG 60 CCCCGAGGTA GGTCCAGGAC GGGCGCACAG CAGCAGCCGA GGCTGGCCGG GAGAGGGAGG 120 AAGAGGATGG CAGGGCCACG CCCCAGCCCA TGGGCCAGGC TGCTCCTGGC AGCCTTGATC 180 AGCGTCAGCC TCTCTGGGAC CTTGGCAAAC CGCTGCAAGA AGGCCCCAGT GAAGAGCTGC 240 ACGGAGTGTG TCCGTGTGGA TAAGGACTGC GCCTACTGCA CAGACGAGAT GTTCAGGGAC 300 CGGCGCTGCA ACACCCAGGC GGAGCTGCTG GCCGCGGGCT GCCAGCGGGA GAGCATCGTG 360 GTCATGGAGA GCAGCTTCCA AATCACAGAG GAGACCCAGA TTGACACCAC CCTGCGGCGC 420 AGCCAGATGT CCCCCCAAGG CCTGCGGGTC CGTCTGCGGC CCGGTGAGGA GCGGCATTTT 480 GAGCTGGAGG TGTTTGAGCC ACTGGAGAGC CCCGTGGACC TGTACATCCT CATGGACTTC 540 TCCAACTCCA TGTCCGATGA TCTGGACAAC CTCAAGAAGA TGGGGCAGAA CCTGGCTCGG 600 GTCCTGAGCC AGCTCACCAG CGACTACACT ATTGGATTTG GCAAGTTTGT GGACAAAGTC 660 AGCGTCCCGC AGACGGACAT GAGGCCTGAG AAGCTGAAGG AGCCCTGGCC CAACAGTGAC 720 CCCCCCTTCT CCTTCAAGAA CGTCATCAGC CTGACAGAAG ATGTGGATGA GTTCCGGAAT 780 AAACTGCAGG GAGAGCGGAT CTCAGGCAAC CTGGATGCTC CTGAGGGCGG CTTCGATGCC 840 ATCCTGCAGA CAGCTGTGTG CACGAGGGAC ATTGGCTGGC GCCCGGACAG CACCCACCTG 900 CTGGTCTTCT CCACCGAGTC AGCCTTCCAC TATGAGGCTG ATGGCGCCAA CGTGCTGGCT 960 GGCATCATGA GCCGCAACGA TGAACGGTGC CACCTGGACA CCACGGGCAC CTACACCCAG 1020 TACAGGACAC AGGACTACCC GTCGGTGCCC ACCCTGGTGC GCCTGCTCGC CAAGCACAAC 1080 ATCATCCCCA TCTTTGCTGT CACCAACTAC TCCTATAGCT ACTACGAGAA GCTTCACACC 1140 TATTTCCCTG TCTCCTCACT GGGGGTGCTG CAGGAGGACT CGTCCAACAT CGTGGAGCTG 1200 CTGGAGGAGG CCTTCAATCG GATCCGCTCC AACCTGGACA TCCGGGCCCT AGACAGCCCC 1260 CGAGGCCTTC GGACAGAGGT CACCTCCAAG ATGTTCCAGA AGACGAGGAC TGGGTCCTTT 1320 CACATCCGGC GGGGGGAAGT GGGTATATAC CAGGTGCAGC TGCGGGCCCT TGAGCACGTG 1380 GATGGGACGC ACGTGTGCCA GCTGCCGGAG GACCAGAAGG GCAACATCCA TCTGAAACCT 1440 TCCTTCTCCG ACGGCCTCAA GATGGACGCG GGCATCATCT GTGATGTGTG CACCTGCGAG 1500 CTGCAAAAAG AGGTGCGGTC AGCTCGCTGC AGCTTCAACG GAGACTTCGT GTGCGGACAG 1560 TGTGTGTGCA GCGAGGGCTG GAGTGGCCAG ACCTGCAACT GCTCCACCGG CTCTCTGAGT 1620 GACATTCAGC CCTGCCTGCG GGAGGGCGAG GACAAGCCGT GCTCCGGCCG TGGGGAGTGC 1680 CAGTGCGGGC ACTGTGTGTG CTACGGCGAA GGCCGCTACG AGGGTCAGTT CTGCGAGTAT 1740 GACAACTTCC AGTGTCCCCG CACTTCCGGG TTCCTCTGCA ATGACCGAGG ACGCTGCTCC 1800 ATGGGCCAGT GTGTGTGTGA GCCTGGTTGG ACAGGCCCAA GCTGTGACTG TCCCCTCAGC 1860 AATGCCACCT GCATCGACAG CAATGGGGGC ATCTGTAATG GACGTGGCCA CTGTGAGTGT 1920 GGCCGCTGCC ACTGCCACCA GCAGTCGCTC TACACGGACA CCATCTGCGA GATCAACTAC 1980 TCGGCGATCC ACCCGGGCCT CTGCGAGGAC CTACGCTCCT GCGTGCAGTG CCAGGCGTGG 2040 GGCACCGGCG AGAAGAAGGG. GCGCACGTGT GAGGAATGCA ACTTCAAGGT CAAGATGGTG 2100 GACGAGCTTA AGAGAGCCGA GGAGGTGGTG GTGCGCTGCT CCTTCCGGGA CGAGGATGAC 2160 GACTGCACCT ACAGCTACAC CATGGAAGGT GACGGCGCCC CTGGGCCCAA CAGCACTGTC 2220 CTGGTGCACA AGAAGAAGGA CTGCCCTCCG GGCTCCTTCT GGTGGCTCAT CCCCCTGCTC 2280 CTCCTCCTCC TGCCGCTCCT GGCCCTGCTA CTGCTGCTAT GCTGGAAGTA CTGTGCCTGC 2340 TGCAAGGCCT GCCTGGCACT TCTCCCGTGC TGCAACCGAG GTCACATGGT GGGCTTTAAG 2400 GAAGACCACT ACATGCTGCG GGAGAACCTG ATGGCCTCTG ACCACTTGGA CACGCCCATG 2460 CTGCGCAGCG GGAACCTCAA GGGCCGTGAC GTGGTCCGCT GGAAGGTCAC CAACAACATG 2520 CAGCGGCCTG GCTTTGCCAC TCATGCCGCC AGCATCAACC CCACAGAGCT GGTGCCCTAC 2580 GGGCTGTCCT TGCGCCTGGC CCGCCTTTGC ACCGAGAACC TGCTGAAGCC TGACACTCGG 2640 GAGTGCGCCC AGCTGCGCCA GGAGGTGGAG GAGAACCTGA ACGAGGTCTA CAGGCAGATC 2700 TCCGGTGTAC ACAAGCTCCA GCAGACCAAG TTCCGGCAGC AGCCCAATGC CGGGAAAAAG 2760 CAAGACCACA CCATTGTGGA CACAGTGCTG ATGGCGCCCC GCTCGGCCAA GCCGGCCCTG 2820 CTGAAGCTTA CAGAGAAGCA GGTGGAACAG AGGGCCTTCC ACGACCTCAA GGTGGCCCCC 2880 GGCTACTACA CCCTCACTGC AGACCAGGAC GCCCGGGGCA TGGTGGAGTT CCAGGAGGGC 2940 GTGGAGCTGG TGGACGTACG GGTGCCCCTC TTTATCCGGC CTGAGGATGA CGACGAGAAG 3000 CAGCTGCTGG TGGAGGCCAT CGACGTGCCC GCAGGCACTG CCACCCTCGG CCGCCGCCTG 3060

CACAAATATC GAGTCAAGGA GCCGGTCACA AAGGCAGAAA TGCTGGAGAG CGTCATCAAA 420 AATTACAAGC GCTACTTTCC TGTGATCTTC GGCAAAGCCT CCGAGTTCAT GCAGGTGATC 480 TTTGGCACTG ATGTGAAGGA GGTGGACCCC GCCGGCCACT CCTACATCCT TGTCACTGCT 540 CTTGGCCTCT CGTGCGATAG CATGCTGGGT GATGGTCATA GCATGCCCAA GGCCGCCCTC 600 CTGATCATTG TCCTGGGTGT GATCCTAACC AAAGACAACT GCGCCCCTGA AGAGGTTATC 660 TGGGAAGCGT TGAGTGTGAT GGGGGTGTAT GTTGGGAAGG AGCACATGTT CTACGGGGAG 720 CCCAGGAAGC TGCTCACCCA AGATTGGGTG CAGGAAAACT ACCTGGAGTA CCGGCAGGTG 780 CCCGGCAGTG ATCCTGCGCA CTACGAGTTC CTGTGGGGTT CCAAGGCCCA CGCTGAAACC 840 AGCTATGAGA AGGTCATAAA TTATTTGGTC ATGCTCAATG CAAGAGAGCC CATCTGCTAC 900 CCATCCCTTT ATGAAGAGGT TTTGGGAGAG GAGCAAGAGG GAGTCTGA Seq ID NO : 567 Protein sequence Protein Accession # : NP 005356. 1 1 11 21 31 41 51 MSLEQRSPHC KPDEDLEAQG EDLGLMGAQE PTGEEEETTS SSDSKEEEVS AAGSSSPPQS 60 PQGGASSSIS VYYTLWSQFD EGSSSQEEEE PSSSVDPAQL EFMFQEALKL KVAELVHFLL 120 HKYRVKEPVT KAEMLESVIK NYKRYFPVIF GKASEFMQVI FGTDVKEVDP AGHSYILVTA 180 LGLSCDSMLG DGHSMPKAAL LIIVLGVILT KDNCAPEEVI WEALSVMGVY VGKEHMFYGE 240 PRKLLTQDWV QENYLEYRQV PGSDPAHYEF LWGSKAHAET SYEKVINYLV MLNAREPICY 300 PSLYEEVLGE EQEGV Seq ID NO : 568 DNA sequence Nucleic Acid Accession &num : NM 014400 Coding sequence: 86.. 1126 1 11 21 31 41 51 I GGTTACTCAT CCTGGGCTCA GGTAAGAGGG CCCGAGCTCG GAGGCGGCAC ACCCAGGGGG 60 GACGCCAAGG GAGCAGGACG GAGCCATGGA CCCCGCCAGG AAAGCAGGTG CCCAGGCCAT 120 GATCTGGACT GCAGGCTGGC TGCTGCTGCT GCTGCTTCGC GGAGGAGCGC AGGCCCTGGA 180 GTGCTACAGC TGCGTGCAGA AAGCAGATGA CGGATGCTCC CCGAACAAGA TGAAGACAGT 240 GAAGTGCGCG CCGGGCGTGG ACGTCTGCAC CGAGGCCGTG GGGGCGGTGG AGACCATCCA 300 CGGACAATTC TCGCTGGCAG TGCSGGGTTG CGGTTCGGGA CTCCCCGGCA AGAATGACCG 360 CGGCCTGGAT CTTCACGGGC TTCTGGCGTT CATCCAGCTG CAGCAATGCG CTCAGGATCG 420 CTGCAACGCC AAGCTCAACC TCACCTCGCG GGCGCTCGAC CCGGCAGGTA ATGAGAGTGC 480 ATACCCGCCC AACGGCGTGG AGTGCTACAG CTGTGTGGGC CTGAGCCGGG AGGCGTGCCA 540 GGGTACATCG CCGCCGGTCG TGAGCTGCTA CAACGCCAGC GATCATGTCT ACAAGGGCTG 600 CTTCGACGGC AACGTCACCT TGACGGCAGC TAATGTGACT GTGTCCTTGC CTGTCCGGGG 660 CTGTGTCCAG GATGAATTCT GCACTCGGGA TGGAGTAACA GGCCCAGGGT TCACGCTCAG 720 TGGCTCCTGT TGCCAGGGGT CCCGCTGTAA CTCTGACCTC CGCAACAAGA CCTACTTCTC 780 CCCTCGAATC CCACCCCTTG TCCGGCTGCC CCCTCCAGAG CCCACGACTG TGGCCTCAAC 840 CACATCTGTC ACCACTTCTA CCTCGGCCCC AGTGAGACCC ACATCCACCA CCAAACCCAT 900 GCCAGCGCCA ACCAGTCAGA CTCCGAGACA GGGAGTAGAA CACGAGGCCT CCCGGGATGA 960 GGAGCCCAGG TTGACTGGAG GCGCCGCTGG CCACCAGGAC CGCAGCAATT CAGGGCAGTA 1020 TCCTGCAAAA GGGGGGCCCC AGCAGCCCCA TAATAAAGGC TGTGTGGCTC CCACAGCTGG 1080 ATTGGCAGCC CTTCTGTTGG CCGTGGCTGC TGGTGTCCTA CTGTGAGCTT CTCCACCTGG 1140 AAATTTCCCT CTCACCTACT TCTCTGGCCC TGGGTACCCC TCTTCTCATC ACTTCCTGTT 1200 CCCACCACTG GACTGGGCTG GCCCAGCCCC TGTTTTTCCA ACATTCCCCA GTATCCCCAG 1260 CTTCTGCTGC GCTGGTTTGC GGCTTTGGGA AATAAAATAC CGTTGTATAT ATTCTGGCAG 1320 GGGTGTTCTA GCTTTTTGAG GACAGCTCCT GTATCCTTCT CATCCTTGTC TCTCCGCTTG 1380 TCCTCTTGTG ATGTTAGGAC AGAGTGAGAG AAGTCAGCTG TCACGGGGAA GGTGAGAGAG 1440 AGGATGCTAA GCTTCCTACT CACTTTCTCC TAGCCAGCCT GGACTTTGGA GCGTGGGGTG 1500 GGTGGGACAA TGGCTCCCCA CTCTAAGCAC TGCCTCCCCT ACTCCCCGCA TCTTTGGGGA 1560 ATCGGTTCCC CATATGTCTT CCTTACTAGA CTGTGAGCTC CTCGAGGGCA GGGACCGTGC 1620 CTTATGTCTG TGTGTGATCA GTTTCTGGCA CATAAATGCC TCAATAAAGA TTTAATTACT 1680 TTGTATAGTG AAAAAAAA Seq ID NO : 569 Protein sequence Protein Accession # : NP 055215 1 11 21 31 41 51 MDPARKAGAQ AMIWTAGWLL LLLLRGGAQA LECYSCVQKA DDGCSPNKMK TVKCAPGVDV 60 CTEAVGAVET IHGQFSLAVX GCGSGLPGKN DRGLDLHGLL AFIQLQQCAQ DRCNAKLNLT 120 SRALDPAGNE SAYPPNGVEC YSCVGLSREA CQGTSPPWS CYNASDHVYK GCFDGNVTLT 180 AANVTVSLPV RGCVQDEFCT RDGVTGPGFT LSGSCCQGSR CNSDLRNKTY FSPRIPPLVR 240 LPPPEPTTVA STTSVTTSTS APVRPTSTTK PMPAPTSQTP RQGVEHEASR DEEPRLTGGA 300 AGHQDRSNSG QYPAKGGPQQ PHNKGCVAPT AGLAALLLAV AAGVLL Seq ID NO : 570 DNA sequence Nucleic Acid Accession # : NM 005329. 1 Coding sequence: 1.. 1662 1 11 21 31 41 51 ATGCCGGTGC AGCTGACGAC AGCCCTGCGT GTGGTGGGCA CCAGCCTGTT TGCCCTGGCA 60 GTGCTGGGTG GCATCCTGGC AGCCTATGTG ACGGGCTACC AGTTCATCCA CACGGAAAAG 120 CACTACCTGT CCTTCGGCCT GTACGGCGCC ATCCTGGGCC TGCACCTGCT CATTCAGAGC 180 CTTTTTGCCT TCCTGGAGCA CCGGCGCATG CGACGTGCCG GCCAGGCCCT GAAGCTGCCC 240 TCCCCGCGGC GGGGCTCGGT GGCACTGTGC ATTGCCGCGT ACCAGGAGGA CCCTGACTAC 300 TTGCGCAAGT GCCTGCGCTC GGCCCAGCGC ATCTCCTTCC CTGACCTCAA GGTGGTCATG 360 GTGGTGGATG GCAACCGCCA GGAGGACGCC TACATGCTGG ACATCTTCCA CGAGGTGCTG 420 GGCGGCACCG AGCAGGCCGG CTTCTTTGTG TGGCGCAGCA ACTTCCATGA GGCAGGCGAG 480 GGTGAGACGG AGGCCAGCCT GCAGGAGGGC ATGGACCGTG TGCGGGATGT GGTGCGGGCC 540 AGCACCTTCT CGTGCATCAT GCAGAAGTGG GGAGGCAAGC GCGAGGTCAT GTACACGGCC 600

AGCCTTGCTC AGTATTCTGA TGTGCTGTCC ACTACTCATG CTGCTTCAGA GACGCTGGAA 2820 TTTGGTAGTG AATCTGGTGT TCTTTATAAA ACGCTTATGT TTTCTCAAGT TGAACCACCC 2880 AGCAGTGATG CCATGATGCA TGCACGTTCT TCAGGGCCTG AACCTTCTTA TGCCTTGTCT 2940 GATAATGAGG GCTCCCAACA CATCTTCACT GTTTCTTACA GTTCTGCAAT ACCTGTGCAT 3000 GATTCTGTGG GTGTAACTTA TCAGGGTTCC TTATTTAGCG GCCCTAGCCA TATACCAATA 3060 CCTAAGTCTT CGTTAATAAC CCCAACTGCA TCATTACTGC AGCCTACTCA TGCCCTCTCT 3120 GGTGATGGGG AATGGTCTGG AGCCTCTTCT GATAGTGAAT TTCTTTTACC TGACACAGAT 3180 GGGCTGACAG CCCTTAACAT TTCTTCACCT GTTTCTGTAG CTGAATTTAC ATATACAACA 3240 TCTGTGTTTG GTGATGATAA TAAGGCGCTT TCTAAAAGTG AAATAATATA TGGAAATGAG 3300 ACTGAACTGC AAATTCCTTC TTTCAATGAG ATGGTTTACC CTTCTGAAAG CACAGTCATG 3360 CCCAACATGT ATGATAATGT AAATAAGTTG AATGCGTCTT TACAAGAAAC CTCTGTTTCC 3420 ATTTCTAGCA CCAAGGGCAT GTTTCCAGGG TCCCTTGCTC ATACCACCAC TAAGGTTTTT 3480 GATCATGAGA TTAGTCAAGT TCCAGAAAAT AACTTTTCAG TTCAACCTAC ACATACTGTC 3540 TCTCAAGCAT CTGGTGACAC TTCGCTTAAA CCTGTGCTTA GTGCAAACTC AGAGCCAGCA 3600 TCCTCTGACC CTGCTTCTAG TGAAATGTTA TCTCCTTCAA CTCAGCTCTT ATTTTATGAG 3660 ACCTCAGCTT CTTTTAGTAC TGAAGTATTG CTACAACCTT CCTTTCAGGC TTCTGATGTT 3720 GACACCTTGC TTAAAACTGT TCTTCCAGCT GTGCCCAGTG ATCCAATATT GGTTGAAACC 3780 CCCAAAGTTG ATAAAATTAG TTCTACAATG TTGCATCTCA TTGTATCAAA TTCTGCTTCA 3840 AGTGAAAACA TGCTGCACTC TACATCTGTA CCAGTTTTTG ATGTGTCGCC TACTTCTCAT 3900 ATGCACTCTG CTTCACTTCA AGGTTTGACC ATTTCCTATG CAAGTGAGAA ATATGAACCA 3960 GTTTTGTTAA AAAGTGAAAG TTCCCACCAA GTGGTACCTT CTTTGTACAG TAATGATGAG 4020 TTGTTCCAAA CGGCCAATTT GGAGATTAAC CAGGCCCATC CCCCAAAAGG AAGGCATGTA 4080 TTTGCTACAC CTGTTTTATC AATTGATGAA CCATTAAATA CACTAATAAA TAAGCTTATA 4140 CATTCCGATG AAATTTTAAC CTCCACCAAA AGTTCTGTTA CTGGTAAGGT ATTTGCTGGT 4200 ATTCCAACAG TTGCTTCTGA TACATTTGTA TCTACTGATC ATTCTGTTCC TATAGGAAAT 4260 GGGCATGTTG CCATTACAGC TGTTTCTCCC CACAGAGATG GTTCTGTAAC CTCAACAAAG 4320 TTGCTGTTTC CTTCTAAGGC AACTTCTGAG CTGAGTCATA GTGCCAAATC TGATGCCGGT 4380 TTAGTGGGTG GTGGTGAAGA TGGTGACACT GATGATGATG GTGATGATGA TGATGATGAC 4440 AGAGGTAGTG ATGGCTTATC CATTCATAAG TGTATGTCAT GCTCATCCTA TAGAGAATCA 4500 CAGGAAAAGG TAATGAATGA TTCAGACACC CACGAAAACA GTCTTATGGA TCAGAATAAT 4560 CCAATCTCAT ACTCACTATC TGAGAATTCT GAAGAAGATA ATAGAGTCAC AAGTGTATCC 4620 TCAGACAGTC AAACTGGTAT GGACAGAAGT CCTGGTAAAT CACCATCAGC AAATGGGCTA 4680 TCCCAAAAGC ACAATGATGG AAAAGAGGAA AATGACATTC AGACTGGTAG TGCTCTGCTT 4740 CCTCTCAGCC CTGAATCTAA AGCATGGGCA GTTCTGACAA GTGATGAAGA AAGTGGATCA 4800 GGGCAAGGTA CCTCAGATAG CCTTAATGAG AATGAGACTT CCACAGATTT CAGTTTTGCA 4860 GACACTAATG AAAAAGATGC TGATGGGATC CTGGCAGCAG GTGACTCAGA AATAACTCCT 4920 GGATTCCCAC AGTCCCCAAC ATCATCTGTT ACTAGCGAGA ACTCAGAAGT GTTCCACGTT 4980 TCAGAGGCAG AGGCCAGTAA TAGTAGCCAT GAGTCTCGTA TTGGTCTAGC TGAGGGGTTG 5040 GAATCCGAGA AGAAGGCAGT TATACCCCTT GTGATCGTGT CAGCCCTGAC TTTTATCTGT 5100 CTAGTGGTTC TTGTGGGTAT TCTCATCTAC TGGAGGAAAT GCTTCCAGAC TGCACACTTT 5160 TACTTAGAGG ACAGTACATC CCCTAGAGTT ATATCCACAC CTCCAACACC TATCTTTCCA 5220 ATTTCAGATG ATGTCGGAGC AATTCCAATA AAGCACTTTC CAAAGCATGT TGCAGATTTA 5280 CATGCAAGTA GTGGGTTTAC TGAAGAATTT GAGACACTGA AAGAGTTTTA CCAGGAAGTG 5340 CAGAGCTGTA CTGTTGACTT AGGTATTACA GCAGACAGCT CCAACCACCC AGACAACAAG 5400 CACAAGAATC GATACATAAA TATCGTTGCC TATGATCATA GCAGGGTTAA GCTAGCACAG 5460 CTTGCTGAAA AGGATGGCAA ACTGACTGAT TATATCAATG CCAATTATGT TGATGGCTAC 5520 AACAGACCAA AAGCTTATAT TGCTGCCCAA GGCCCACTGA AATCCACAGC TGAAGATTTC 5580 TGGAGAATGA TATGGGAACA TAATGTGGAA GTTATTGTCA TGATAACAAA CCTCGTGGAG 5640 AAAGGAAGGA GAAAATGTGA TCAGTACTGG CCTGCCGATG GGAGTGAGGA GTACGGGAAC 5700 TTTCTGGTCA CTCAGAAGAG TGTGCAAGTG CTTGCCTATT ATACTGTGAG GAATTTTACT 5760 CTAAGAAACA CAAAAATAAA AAAGGGCTCC CAGAAAGGAA GACCCAGTGG ACGTGTGGTC 5820 ACACAGTATC ACTACACGCA GTGGCCTGAC ATGGGAGTAC CAGAGTACTC CCTGCCAGTG 5880 CTGACCTTTG TGAGAAAGGC AGCCTATGCC AAGCGCCATG CAGTGGGGCC TGTTGTCGTC 5940 CACTGCAGTG CTGGAGTTGG AAGAACAGGC ACATATATTG TGCTAGACAG TATGTTGCAG 6000 CAGATTCAAC ACGAAGGAAC TGTCAACATA TTTGGCTTCT TAAAACACAT CCGTTCACAA 6060 AGAAATTATT TGGTACAAAC TGAGGAGCAA TATGTCTTCA TTCATGATAC ACTGGTTGAG 6120 GCCATACTTA GTAAAGAAAC TGAGGTGCTG GACAGTCATA TTCATGCCTA TGTTAATGCA 6180 CTCCTCATTC CTGGACCAGC AGGCAAAACA AAGCTAGAGA AACAATTCCA GCTCCTGAGC 6240 CAGTCAAATA TACAGCAGAG TGACTATTCT GCAGCCCTAA AGCAATGCAA CAGGGAAAAG 6300 AATCGAACTT CTTCTATCAT CCCTGTGGAA AGATCAAGGG TTGGCATTTC ATCCCTGAGT 6360 GGAGAAGGCA CAGACTACAT CAATGCCTCC TATATCATGG GCTATTACCA GAGCAATGAA 6420 TTCATCATTA CCCAGCACCC TCTCCTTCAT ACCATCAAGG ATTTCTGGAG GATGATATGG 6480 GACCATAATG CCCAACTGGT GGTTATGATT CCTGATGGCC AAAACATGGC AGAAGATGAA 6540 TTTGTTTACT GGCCAAATAA AGATGAGCCT ATAAATTGTG AGAGCTTTAA GGTCACTCTT 6600 ATGGCTGAAG AACACAAATG TCTATCTAAT GAGGAAAAAC TTATAATTCA GGACTTTATC 6660 TTAGAAGCTA CACAGGATGA TTATGTACTT GAAGTGAGGC ACTTTCAGTG TCCTAAATGG 6720 CCAAATCCAG ATAGCCCCAT TAGTAAAACT TTTGAACTTA TAAGTGTTAT AAAAGAAGAA 6780 GCTGCCAATA GGGATGGGCC TATGATTGTT CATGATGAGC ATGGAGGAGT GACGGCAGGA 6840 ACTTTCTGTG CTCTGACAAC CCTTATGCAC CAACTAGAAA AAGAAAATTC CGTGGATGTT 6900 TACCAGGTAG CCAAGATGAT CAATCTGATG AGGCCAGGAG TCTTTGCTGA CATTGAGCAG 6960 TATCAGTTTC TCTACAAAGT GATCCTCAGC CTTGTGAGCA CAAGGCAGGA AGAGAATCCA 7020 TCCACCTCTC TGGACAGTAA TGGTGCAGCA TTGCCTGATG GAAATATAGC TGAGAGCTTA 7080 GAGTCTTTAG TTTAACACAG AAAGGGGTGG GGGGACTCAC ATCTGAGCAT TGTTTTCCTC 7140 TTCCTAAAAT TAGGCAGGAA AATCAGTCTA GTTCTGTTAT CTGTTGATTT CCCATCACCT 7200 GACAGTAACT TTCATGACAT AGGATTCTGC CGCCAAATTT ATATCATTAA CAATGTGTGC 7260 CTTTTTGCAA GACTTGTAAT TTACTTATTA TGTTTGAACT AAAATGATTG AATTTTACAG 7320 TATTTCTAAG AATGGAATTG TGGTATTTTT TTCTGTATTG ATTTTAACAG AAAATTTCAA 7380 TTTATAGAGG TTAGGAATTC CAAACTACAG AAAATGTTTG TTTTTAGTGT CAAATTTTTA 7440 GCTGTATTTG TAGCAATTAT CAGGTTTGCT AGAAATATAA CTTTTAATAC AGTAGCCTGT 7500 AAATAAAACA CTCTTCCATA TGATATTCAA CATTTTACAA CTGCAGTATT CACCTAAAGT 7560 AGAAATAATC TGTTACTTAT TGTAAATACT GCCCTAGTGT CTCCATGGAC CAAATTTATA 7620 TTTATAATTG TAGATTTTTA TATTTTACTA CTGAGTCAAG TTTTCTAGTT CTGTGTAATT 7680 GTTTAGTTTA ATGACGTAGT TCATTAGCTG GTCTTACTCT ACCAGTTTTC TGACATTGTA 7740 TTGTGTTACC TAAGTCATTA ACTTTGTTTC AGCATGTAAT TTTAACTTTT GTGGAAAATA 7800 GAAATACCTT CATTTTGAAA GAAGTTTTTA TGAGAATAAC ACCTTACCAA ACATTGTTCA 7860 AATGGTTTTT ATCCAAGGAA TTGCAAAAAT AAATATAAAT ATTGCCATTA AAAAAAAAAA 7920 AAAAAAAAAA AAAAAAAAAA AAAA

TCGGCCTTGC ATGCTACGCC TGTATTTCCC AGTGTCGATG TGTCATTTGA ATCCATCCTG 2580 TCTTCCTATG ATGGTGCACC TTTGCTTCCA TTTTCCTCTG CTTCCTTCAG TAGTGAATTG 2640 TTTCGCCATC TGCATACAGT TTCTCAAATC CTTCCACAAG TTACTTCAGC TACCGAGAGT 2700 GATAAGGTGC CCTTGCATGC TTCTCTGCCA GTGGCTGGGG GTGATTTGCT ATTAGAGCCC 2760 AGCCTTGCTC AGTATTCTGA TGTGCTGTCC ACTACTCATG CTGCTTCAGA GACGCTGGAA 2820 TTTGGTAGTG AATCTGGTGT TCTTTATAAA ACGCTTATGT TTTCTCAAGT TGAACCACCC 2880 AGCAGTGATG CCATGATGCA TGCACGTTCT TCAGGGCCTG AACCTTCTTA TGCCTTGTCT 2940 GATAATGAGG GCTCCCAACA CATCTTCACT GTTTCTTACA GTTCTGCAAT ACCTGTGCAT 3000 GATTCTGTGG GTGTAACTTA TCAGGGTTCC TTATTTAGCG GCCCTAGCCA TATACCAATA 3060 CCTAAGTCTT CGTTAATAAC CCCAACTGCA TCATTACTGC AGCCTACTCA TGCCCTCTCT 3120 GGTGATGGGG AATGGTCTGG AGCCTCTTCT GATAGTGAAT TTCTTTTACC TGACACAGAT 3180 GGGCTGACAG CCCTTAACAT TTCTTCACCT GTTTCTGTAG CTGAATTTAC ATATACAACA 3240 TCTGTGTTTG GTGATGATAA TAAGGCGCTT TCTAAAAGTG AAATAATATA TGGAAATGAG 3300 ACTGAACTGC AAATTCCTTC TTTCAATGAG ATGGTTTACC CTTCTGAAAG CACAGTCATG 3360 CCCAACATGT ATGATAATGT AAATAAGTTG AATGCGTCTT TACAAGAAAC CTCTGTTTCC 3420 ATTTCTAGCA CCAAGGGCAT GTTTCCAGGG TCCCTTGCTC ATACCACCAC TAAGGTTTTT 3480 GATCATGAGA TTAGTCAAGT TCCAGAAAAT AACTTTTCAG TTCAACCTAC ACATACTGTC 3540 TCTCAAGCAT CTGGTGACAC TTCGCTTAAA CCTGTGCTTA GTGCAAACTC AGAGCCAGCA 3600 TCCTCTGACC CTGCTTCTAG TGAAATGTTA TCTCCTTCAA CTCAGCTCTT ATTTTATGAG 3660 ACCTCAGCTT CTTTTAGTAC TGAAGTATTG CTACAACCTT CCTTTCAGGC TTCTGATGTT 3720 GACACCTTGC TTAAAACTGT TCTTCCAGCT GTGCCCAGTG ATCCAATATT GGTTGAAACC 3780 CCCAAAGTTG ATAAAATTAG TTCTACAATG TTGCATCTCA TTGTATCAAA TTCTGCTTCA 3840 AGTGAAAACA TGCTGCACTC TACATCTGTA CCAGTTTTTG ATGTGTCGCC TACTTCTCAT 3900 ATGCACTCTG CTTCACTTCA AGGTTTGACC ATTTCCTATG CAAGTGAGAA ATATGAACCA 3960 GTTTTGTTAA AAAGTGAAAG TTCCCACCAA GTGGTACCTT CTTTGTACAG TAATGATGAG 4020 TTGTTCCAAA CGGCCAATTT GGAGATTAAC CAGGCCCATC CCCCAAAAGG AAGGCATGTA 4080 TTTGCTACAC CTGTTTTATC AATTGATGAA CCATTAAATA CACTAATAAA TAAGCTTATA 4140 CATTCCGATG AAATTTTAAC CTCCACCAAA AGTTCTGTTA CTGGTAAGGT ATTTGCTGGT 4200 ATTCCAACAG TTGCTTCTGA TACATTTGTA TCTACTGATC ATTCTGTTCC TATAGGAAAT 4260 GGGCATGTTG CCATTACAGC TGTTTCTCCC CACAGAGATG GTTCTGTAAC CTCAACAAAG 4320 TTGCTGTTTC CTTCTAAGGC AACTTCTGAG CTGAGTCATA GTGCCAAATC TGATGCCGGT 4380 TTAGTGGGTG GTGGTGAAGA TGGTGACACT GATGATGATG GTGATGATGA TGATGACAGA 4440 GATAGTGATG GCTTATCCAT TCATAAGTGT ATGTCATGCT CATCCTATAG AGAATCACAG 4500 GAAAAGGTAA TGAATGATTC AGACACCCAC GAAAACAGTC TTATGGATCA GAATAATCCA 4560 ATCTCATACT CACTATCTGA GAATTCTGAA GAAGATAATA GAGTCACAAG TGTATCCTCA 4620 GACAGTCAAA CTGGTATGGA CAGAAGTCCT GGTAAATCAC CATCAGCAAA TGGGCTATCC 4680 CAAAAGCACA ATGATGGAAA AGAGGAAAAT GACATTCAGA CTGGTAGTGC TCTGCTTCCT 4740 CTCAGCCCTG AATCTAAAGC ATGGGCAGTT CTGACAAGTG ATGAAGAAAG TGGATCAGGG 4800 CAAGGTACCT CAGATAGCCT TAATGAGAAT GAGACTTCCA CAGATTTCAG TTTTGCAGAC 4860 ACTAATGAAA AAGATGCTGA TGGGATCCTG GCAGCAGGTG ACTCAGAAAT AACTCCTGGA 4920 TTCCCACAGT CCCCAACATC ATCTGTTACT AGCGAGAACT CAGAAGTGTT CCACGTTTCA 4980 GAGGCAGAGG CCAGTAATAG TAGCCATGAG TCTCGTATTG GTCTAGCTGA GGGGTTGGAA 5040 TCCGAGAAGA AGGCAGTTAT ACCCCTTGTG ATCGTGTCAG CCCTGACTTT TATCTGTCTA 5100 GTGGTTCTTG TGGGTATTCT CATCTACTGG AGGAAATGCT TCCAGACTGC ACACTTTTAC 5160 TTAGAGGACA GTACATCCCC TAGAGTTATA TCCACACCTC CAACACCTAT CTTTCCAATT 5220 TCAGATGATG TCGGAGCAAT TCCAATAAAG CACTTTCCAA AGCATGTTGC AGATTTACAT 5280 GCAAGTAGTG GGTTTACTGA AGAATTTGAG ACACTGAAAG AGTTTTACCA GGAAGTGCAG 5340 AGCTGTACTG TTGACTTAGG TATTACAGCA GACAGCTCCA ACCACCCAGA CAACAAGCAC 5400 AAGAATCGAT ACATAAATAT CGTTGCCTAT GATCATAGCA GGGTTAAGCT AGCACAGCTT 5460 GCTGAAAAGG ATGGCAAACT GACTGATTAT ATCAATGCCA ATTATGTTGA TGGCTACAAC 5520 AGACCAAAAG CTTATATTGC TGCCCAAGGC CCACTGAAAT CCACAGCTGA AGATTTCTGG 5580 AGAATGATAT GGGAACATAA TGTGGAAGTT ATTGTCATGA TAACAAACCT CGTGGAGAAA 5640 GGAAGGAGAA AATGTGATCA GTACTGGCCT GCCGATGGGA GTGAGGAGTA CGGGAACTTT 5700 CTGGTCACTC AGAAGAGTGT GCAAGTGCTT GCCTATTATA CTGTGAGGAA TTTTACTCTA 5760 AGAAACACAA AAATAAAAAA GGGCTCCCAG AAAGGAAGAC CCAGTGGACG TGTGGTCACA 5820 CAGTATCACT ACACGCAGTG GCCTGACATG GGAGTACCAG AGTACTCCCT GCCAGTGCTG 5880 ACCTTTGTGA GAAAGGCAGC CTATGCCAAG CGCCATGCAG TGGGGCCTGT TGTCGTCCAC 5940 TGCAGTGCTG GAGTTGGAAG AACAGGCACA TATATTGTGC TAGACAGTAT GTTGCAGCAG 6000 ATTCAACACG AAGGAACTGT CAACATATTT GGCTTCTTAA AACACATCCG TTCACAAAGA 6060 AATTATTTGG TACAAACTGA GGAGCAATAT GTCTTCATTC ATGATACACT GGTTGAGGCC 6120 ATACTTAGTA AAGAAACTGA GGTGCTGGAC AGTCATATTC ATGCCTATGT TAATGCACTC 6180 CTCATTCCTG GACCAGCAGG CAAAACAAAG CTAGAGAAAC AATTCCAGCT CCTGAGCCAG 6240 TCAAATATAC AGCAGAGTGA CTATTCTGCA GCCCTAAAGC AATGCAACAG GGAAAAGAAT 6300 CGAACTTCTT CTATCATCCC TGTGGAAAGA TCAAGGGTTG GCATTTCATC CCTGAGTGGA 6360 GAAGGCACAG ACTACATCAA TGCCTCCTAT ATCATGGGCT ATTACCAGAG CAATGAATTC 6420 ATCATTACCC AGCACCCTCT CCTTCATACC ATCAAGGATT TCTGGAGGAT GATATGGGAC 6480 CATAATGCCC AACTGGTGGT TATGATTCCT GATGGCCAAA ACATGGCAGA AGATGAATTT 6540 GTTTACTGGC CAAATAAAGA TGAGCCTATA AATTGTGAGA GCTTTAAGGT CACTCTTATG 6600 GCTGAAGAAC ACAAATGTCT ATCTAATGAG GAAAAACTTA TAATTCAGGA CTTTATCTTA 6660 GAAGCTACAC AGGATGATTA TGTACTTGAA GTGAGGCACT TTCAGTGTCC TAAATGGCCA 6720 AATCCAGATA GCCCCATTAG TAAAACTTTT GAACTTATAA GTGTTATAAA AGAAGAAGCT 6780 GCCAATAGGG ATGGGCCTAT GATTGTTCAT GATGAGCATG GAGGAGTGAC GGCAGGAACT 6840 TTCTGTGCTC TGACAACCCT TATGCACCAA CTAGAAAAAG AAAATTCCGT GGATGTTTAC 6900 CAGGTAGCCA AGATGATCAA TCTGATGAGG CCAGGAGTCT TTGCTGACAT TGAGCAGTAT 6960 CAGTTTCTCT ACAAAGTGAT CCTCAGCCTT GTGAGCACAA GGCAGGAAGA GAATCCATCC 7020 ACCTCTCTGG ACAGTAATGG TGCAGCATTG CCTGATGGAA ATATAGCTGA GAGCTTAGAG 7080 TCTTTAGTTT AACACAGAAA GGGGTGGGGG GACTCACATC TGAGCATTGT TTTCCTCTTC 7140 CTAAAATTAG GCAGGAAAAT CAGTCTAGTT CTGTTATCTG TTGATTTCCC ATCACCTGAC 7200 AGTAACTTTC ATGACATAGG ATTCTGCCGC CAAATTTATA TCATTAACAA TGTGTGCCTT 7260 TTTGCAAGAC TTGTAATTTA CTTATTATGT TTGAACTAAA ATGATTGAAT TTTACAGTAT 7320 TTCTAAGAAT GGAATTGTGG TATTTTTTTC TGTATTGATT TTAACAGAAA ATTTCAATTT 7380 ATAGAGGTTA GGAATTCCAA ACTACAGAAA ATGTTTGTTT TTAGTGTCAA ATTTTTAGCT 7440 GTATTTGTAG CAATTATCAG GTTTGCTAGA AATATAACTT TTAATACAGT AGCCTGTAAA 7500 TAAAACACTC TTCCATATGA TATTCAACAT TTTACAACTG CAGTATTCAC CTAAAGTAGA 7560 AATAATCTGT TACTTATTGT AAATACTGCC CTAGTGTCTC CATGGACCAA ATTTATATTT 7620 ATAATTGTAG ATTTTTATAT TTTACTACTG AGTCAAGTTT TCTAGTTCTG TGTAATTGTT 7680 TAGTTTAATG ACGTAGTTCA TTAGCTGGTC TTACTCTACC AGTTTTCTGA CATTGTATTG 7740

ACAGCATCGA TCTGGAGATC CAAGAGGGTA AACTGGTTGG AATCTGCGGC AGTGTGGGAA 1920 GTGGAAAAAC CTCTCTCATT TCAGCCATTT TAGGCCAGAT GACGCTTCTA GAGGGCAGCA 1980 TTGCAATCAG TGGAACCTTC GCTTATGTGG CCCAGCAGGC CTGGATCCTC AATGCTACTC 2040 TGAGAGACAA CATCCTGTTT GGGAAGGAAT ATGATGAAGA AAGATACAAC TCTGTGCTGA 2100 ACAGCTGCTG CCTGAGGCCT GACCTGGCCA TTCTTCCCAG CAGCGACCTG ACGGAGATTG 2160 GAGAGCGAGG AGCCAACCTG AGCGGTGGGC AGCGCCAGAG GATCAGCCTT GCCCGGGCCT 2220 TGTATAGTGA CAGGAGCATC TACATCCTGG ACGACCCCCT CAGTGCCTTA GATGCCCATG 2280 TGGGCAACCA CATCTTCAAT AGTGCTATCC GGAAACATCT CAAGTCCAAG ACAGTTCTGT 2340 TTGTTACCCA CCAGTTACAG TACCTGGTTG ACTGTGATGA AGTGATCTTC ATGAAAGAGG 2400 GCTGTATTAC GGAAAGAGGC ACCCATGAGG AACTGATGAA TTTAAATGGT GACTATGCTA 2460 CCATTTTTAA TAACCTGTTG CTGGGAGAGA CACCGCCAGT TGAGATCAAT TCAAAAAAGG 2520 <BR> <BR> AAACCAGTGG TTCACAGAAG AAGTCACAAG ACAAGGGTCC TAAAACAGGA TCAGTAAAGA 2580 AGGAAAAAGC AGTAAAGCCA GAGGAAGGGC AGCTTGTGCA GCTGGAAGAG AAAGGGCAGG 2640 GTTCAGTGCC CTGGTCAGTA TATGGTGTCT ACATCCAGGC TGCTGGGGGC CCCTTGGCAT 2700 TCCTGGTTAT TATGGCCCTT TTCATGCTGA ATGTAGGCAG CACCGCCTTC AGCACCTGGT 2760 GGTTGAGTTA CTGGATCAAG CAAGGAAGCG GGAACACCAC TGTGACTCGA GGGAACGAGA 2820 CCTCGGTGAG TGACAGCATG AAGGACAATC CTCATATGCA GTACTATGCC AGCATCTACG 2880 CCCTCTCCAT GGCAGTCATG CTGATCCTGA AAGCCATTCG AGGAGTTGTC TTTGTCAAGG 2940 GCACGCTGCG AGCTTCCTCC CGGCTGCATG ACGAGCTTTT CCGAAGGATC CTTCGAAGCC 3000 CTATGAAGTT TTTTGACACG ACCCCCACAG GGAGGATTCT CAACAGGTTT TCCAAAGACA 3060 TGGATGAAGT TGACGTGCGG CTGCCGTTCC AGGCCGAGAT GTTCATCCAG AACGTTATCC 3120 TGGTGTTCTT CTGTGTGGGA ATGATCGCAG GAGTCTTCCC GTGGTTCCTT GTGGCAGTGG 3180 GGCCCCTTGT CATCCTCTTT TCAGTCCTGC ACATTGTCTC CAGGGTCCTG ATTCGGGAGC 3240 TGAAGCGTCT GGACAATATC ACGCAGTCAC CTTTCCTCTC CCACATCACG TCCAGCATAC 3300 AGGGCCTTGC CACCATCCAC GCCTACAATA AAGGGCAGGA GTTTCTGCAC AGATACCAGG 3360 AGCTGCTGGA TGACAACCAA GCTCCTTTTT TTTTGTTTAC GTGTGCGATG CGGTGGCTGG 3420 CTGTGCGGCT GGACCTCATC AGCATCGCCC TCATCACCAC CACGGGGCTG ATGATCGTTC 3480 TTATGCACGG GCAGATTCCC CCAGCCTATG CGGGTCTCGC CATCTCTTAT GCTGTCCAGT 3540 TAACGGGGCT GTTCCAGTTT ACGGTCAGAC TGGCATCTGA GACAGAAGCT CGATTCACCT 3600 CGGTGGAGAG GATCAATCAC TACATTAAGA CTCTGTCCTT GGAAGCACCT GCCAGAATTA 3660 AGAACAAGGC TCCCTCCCCT GACTGGCCCC AGGAGGGAGA GGTGACCTTT GAGAACGCAG 3720 AGATGAGGTA CCGAGAAAAC CTCCCTCTTG TCCTAAAGAA AGTATCCTTC ACGATCAAAC 3780 CTAAAGAGAA GATTGGCATT GTGGGGCGGA CAGGATCAGG GAAGTCCTCG CTGGGGATGG 3840 CCCTCTTCCG TCTGGTGGAG TTATCTGGAG GCTGCATCAA GATTGATGGA GTGAGAATCA 3900 GTGATATTGG CCTTGCCGAC CTCCGAAGCA AACTCTCTAT CATTCCTCAA GAGCCGGTGC 3960 TGTTCAGTGG CACTGTCAGA TCAAATTTGG ACCCCTTCAA CCAGTACACT GAAGACCAGA 4020 TTTGGGATGC CCTGGAGAGG ACACACATGA AAGAATGTAT TGCTCAGCTA CCTCTGAAAC 4080 TTGAATCTGA AGTGATGGAG AATGGGGATA ACTTCTCAGT GGGGGAACGG CAGCTCTTGT 4140 GCATAGCTAG AGCCCTGCTC CGCCACTGTA AGATTCTGAT TTTAGATGAA GCCACAGCTG 4200 CCATGGACAC AGAGACAGAC TTATTGATTC AAGAGACCAT CCGAGAAGCA TTTGCAGACT 4260 GTACCATGCT GACCATTGCC CATCGCCTGC ACACGGTTCT AGGCTCCGAT AGGATTATGG 4320 TGCTGGCCCA GGGACAGGTG GTGGAGTTTG ACACCCCATC GGTCCTTCTG TCCAACGACA 4380 GTTCCCGATT CTATGCCATG TTTGCTGCTG CAGAGAACAA GGTCGCTGTC AAGGGCTGAC 4440 TCCTCCCTGT TGACGAAGTC TCTTTTCTTT AGAGCATTGC CATTCCCTGC CTGGGGCGGG 4500 CCCCTCATCG CGTCCTCCTA CCGAAACCTT GCCTTTCTCG ATTTTATCTT TCGCACAGCA 4560 GTTCCGGATT GGCTTGTGTG TTTCACTTTT AGGGAGAGTC ATATTTTGAT TATTGTATTT 4620 ATTCCATATT CATGTAAACA AAATTTAGTT TTTGTTCTTA ATTGCACTCT AAAAGGTTCA 4680 GGGAACCGTT ATTATAATTG TATCAGAGGC CTATAATGAA GCTTTATACG TGTAGCTATA 4740 TCTATATATA ATTCTGTACA TAGCCTATAT TTACAGTGAA AATGTAAGCT GTTTATTTTA 4800 TATTAAAATA AGCACTGTGC TAATAACAGT GCATATTCCT TTCTATCATT TTTGTACAGT 4860 TTGCTGTACT AGAGATCTGG TTTTGCTATT AGACTGTAGG AAGAGTAGCA TTTCATTCTT 4920 CTCTAGCTGG TGGTTTCACG GTGCCAGGTT TTCTGGGTGT CCAAAGGAAG ACGTGTGGCA 4980 ATAGTGGGCC CTCCGACAGC CCCCTCTGCC GCCTCCCCAC AGCCGCTCCA GGGGTGGCTG 5040 GAGACGGGTG GGCGGCTGGA GACCATGCAG AGCGCCGTGA GTTCTCAGGG CTCCTGCCTT 5100 CTGTCCTGGT GTCACTTACT GTTTCTGTCA GGAGAGCAGC GGGGCGAAGC CCAGGCCCCT 5160 TTTCACTCCC TCCATCAAGA ATGGGGATCA CAGAGACATT CCTCCGAGCC GGGGAGTTTC 5220 TTTCCTGCCT TCTTCTTTTT GCTGTTGTTT CTAAACAAGA ATCAGTCTAT CCACAGAGAG 5280 TCCCACTGCC TCAGGTTCCT ATGGCTGGCC ACTGCACAGA GCTCTCCAGC TCCAAGACCT 5340 GTTGGTTCCA AGCCCTGGAG CCAACTGCTG CTTTTTGAGG TGGCACTTTT TCATTTGCCT 5400 ATTCCCACAC CTCCACAGTT CAGTGGCAGG GCTCAGGATT TCGTGGGTCT GTTTTCCTTT 5460 CTCACCGCAG TCGTCGCACA GTCTCTCTCT CTCTCTCCCC TCAAAGTCTG CAACTTTAAG 5520 CAGCTCTTGC TAATCAGTGT CTCACACTGG CGTAGAAGTT TTTGTACTGT AAAGAGACCT 5580 ACCTCAGGTT GCTGGTTGCT GTGTGGTTTG GTGTGTTCCC GCAAACCCCC TTTGTGCTGT 5640 GGGGCTGGTA GCTCAGGTGG GCGTGGTCAC TGCTGTCATC AGTTGAATGG TCAGCGTTGC 5700 ATGTCGTGAC CAACTAGACA TTCTGTCGCC TTAGCATGTT TGCTGAACAC CTTGTGGAAG 5760 CAAAAATCTG AAAATGTGAA TAAAATTATT TTGGATTTTG TAAAAAAAAA AAAAAAAAAA 5820 AAAAAAAAAA AAAAAAAA Seq ID NO : 585 Protein sequence Protein Accession # : NP 005679. 1 1 11 21 31 41 51 MKDIDIGKEY IIPSPGYRSV RERTSTSGTH RDREDSKFRR TRPLECQDAL ETAARAEGLS 60 LDASMHSQLR ILDEEHPKGK YHHGLSALKP IRTTSKHQHP VDNAGLFSCM TFSWLSSLAR 120 VAHKKGELSM EDVWSLSKHE SSDVNCRRLE RLWQEELNEV GPDAASLRRV VWIFCRTRLI 180 LSIVCLMITQ LAGFSGPAFM VKHLLEYTQA TESNLQYSLL LVLGLLLTEI VRSWSLALTW 240 ALNYRTGVRL RGAILTMAFK KILKLKNIKE KSLGELINIC SNDGQRMFEA AAVGSLLAGG 300 PWAILGMIY NVIILGPTGF LGSAVFILFY PAMMFASRLT AYFRRKCVAA TDERVQKMNE 360 VLTYIKFIKM YAWVKAFSQS VQKIREEERR ILEKAGYFQG ITVGVAPIW VIASWTFSV 420 HMTLGFDLTA AQAFTWTVF NSMTFALKVT PFSVKSLSEA SVAVDRFKSL FLMEEVHMIK 480 NKPASPHIKI EMKNATLAWD SSHSSIQNSP KLTPKMKKDK RASRGKKEKV RQLQRTEHQA 540 VLAEQKGHLL LDSDERPSPE EEEGKHIHLG HLRLQRTLHS IDLEIQEGKL VGICGSVGSG 600 KTSLISAILG QMTLLEGSIA ISGTFAYVAQ QAWILNATLR DNILFGKEYD EERYNSVLNS 660 CCLRPDLAIL PSSDLTEIGE RGANLSGGQR QRISLARALY SDRSIYILDD PLSALDAHVG 720 NHIFNSAIRK HLKSKTVLFV THQLQYLVDC DEVIFMKEGC ITERGTHEEL MNLNGDYATI 780 FNNLLLGETP PVEINSKKET SGSQKKSQDK GPKTGSVKKE KAVKPEEGQL VQLEEKGQGS 840

VPWSVYGVYI QAAGGPLAFL VIMALFMLNV GSTAFSTWWL SYWIKQGSGN TTVTRGNETS 900 VSDSMKDNPH MQYYASIYAL SMAVMLILKA IRGVVFVKGT LRASSRLHDE LFRRILRSPM 960 KFFDTTPTGR ILNRFSKDMD EVDVRLPFQA EMFIQNVILV FFCVGMIAGV FPWFLVAVGP 1020 LVILFSVLHI VSRVLIRELK RLDNITQSPF LSHITSSIQG LATIHAYNKG QEFLHRYQEL 1080 LDDNQAPFFL FTCAMRWLAV RLDLISIALI TTTGLMIVLM HGQIPPAYAG LAISYAVQLT 1140 GLFQFTVRLA SETEARFTSV ERINHYIKTL SLEAPARIKN KAPSPDWPQE GEVTFENAEM 1200 RYRENLPLVL KKVSFTIKPK EKIGIVGRTG SGKSSLGMAL FRLVELSGGC IKIDGVRISD 1260 IGLADLRSKL SIIPQEPVLF SGTVRSNLDP FNQYTEDQIW DALERTHMKE CIAQLPLKLE 1320 SEVMENGDNF SVGERQLLCI ARALLRHCKI LILDEATAAM DTETDLLIQE TIREAFADCT 1380 MLTIAHRLHT VLGSDRIMVL AQGQWEFDT PSVLLSNDSS RFYAMFAAAE NKVAVKG Seq ID NO : 586 DNA sequence Nucleic Acid Accession # : NM 001327. 1 Coding sequence: 89.. 631 1 11 21 31 41 51 AGCAGGGGGC GCTGTGTGTA CCGAGAATAC GAGAATACCT CGTGGGCCCT GACCTTCTCT 60 CTGAGAGCCG GGCAGAGGCT CCGGAGCCAT GCAGGCCGAA GGCCGGGGCA CAGGGGGTTC 120 GACGGGCGAT GCTGATGGCC CAGGAGGCCC TGGCATTCCT GATGGCCCAG GGGGCAATGC 180 TGGCGGCCCA GGAGAGGCGG GTGCCACGGG CGGCAGAGGT CCCCGGGGCG CAGGGGCAGC 240 AAGGGCCTCG GGGCCGGGAG GAGGCGCCCC GCGGGGTCCG CATGGCGGCG CGGCTTCAGG 300 GCTGAATGGA TGCTGCAGAT GCGGGGCCAG GGGGCCGGAG AGCCGCCTGC TTGAGTTCTA 360 CCTCGCCATG CCTTTCGCGA CACCCATGGA AGCAGAGCTG GCCCGCAGGA GCCTGGCCCA 420 GGATGCCCCA CCGCTTCCCG TGCCAGGGGT GCTTCTGAAG GAGTTCACTG TGTCCGGCAA 480 CATACTGACT ATCCGACTGA CTGCTGCAGA CCACCGCCAA CTGCAGCTCT CCATCAGCTC 540 CTGTCTCCAG CAGCTTTCCC TGTTGATGTG GATCACGCAG TGCTTTCTGC CCGTGTTTTT 600 GGCTCAGCCT CCCTCAGGGC AGAGGCGCTA AGCCCAGCCT GGCGCCCCTT CCTAGGTCAT 660 GCCTCCTCCC CTAGGGAATG GTCCCAGCAC GAGTGGCCAG TTCATTGTGG GGGCCTGATT 720 GTTTGTCGCT GGAGGAGGAC GGCTTACATG TTTGTTTCTG TAGAAAATAA AACTGAGCTA Seq ID NO : 587 Protein sequence Protein Accession # : NP 001318. 1 1 11 21 31 41 51 # # # # # # MQAEGRGTGG STGDADGPGG PGIPDGPGGN AGGPGEAGAT GGRGPRGAGA ARASGPGGGA 60 PRGPHGGAAS GLNGCCRCGA RGPESRLLEF YLAMPFATPM EAELARRSLA QDAPPLPVPG 120 VLLKEFTVSG NILTIRLTAA DHRQLQLSIS SCLQQLSLLM WITQCFLPVF LAQPPSGQRR Seq ID NO: 588 DNA sequence Nucleic Acid Accession &num : Eos sequence Coding sequence: 52.. 459 1 11 21 31 41 51 CCTCGTGGGC CCTGACCTTC TCTCTGAGAG CCGGGCAGAG GCTCCGGAGC CATGCAGGCC 60 GAAGGCCAGG GCACAGGGGG TTCGACGGGC GATGCTGATG GCCCAGGAGG CCCTGGCATT 120 CCTGATGGCC CAGGGGGCAA TGCTGGCGGC CCAGGAGAGG CGGGTGCCAC GGGCGGCAGA 180 GGTCCCCGGG GCGCAGGGGC AGCAAGGGCC TCGGGGCCGA GAGGAGGCGC CCCGCGGGGT 240 CCGCATGGCG GTGCCGCTTC TGCGCAGGAT GGAAGGTGCC CCTGCGGGGC CAGGAGGCCG 300 GACAGCCGCC TGCTTCAGTT CCGACTGACT GCTGCAGACC ACCGCCAACT GCAGCTCTCC 360 ATCAGCTCCT GTCTCCAGCA GCTTTCCCTG TTGATGTGGA TCACGCAGTG CTTTCTGCCC 420 GTGTTTTTGG CTCAGGCTCC CTCAGGGCAG AGGCGCTAAG CCCAGCCTGG CGCCCCTTCC 480 TAGGTCATGC CTCCTCCCCT AGGGAATGGT CCCAGCACGA GTGGCCAGTT CATTGTGGGG 540 GCCTGATTGT TTGTCGCTGG AGGAGGACGG CTTACATGTT TGTTTCTGTA GAAAATAAAG 600 CTGAGCTA Seq ID NO: 589 Protein sequence Protein Accession # : Eos sequence 1 11 21 31 41 51 1 1 1 1 1 1 MQAEGQGTGG STGDADGPGG PGIPDGPGGN AGGPGEAGAT GGRGPRGAGA ARASGPRGGA 60 PRGPHGGAAS AQDGRCPCGA RRPDSRLLQF RLTAADHRQL QLSISSCLQQ LSLLMWITQC 120 FLPVFLAQAP SGQRR Seq ID NO: 590 DNA sequence Nucleic Acid Accession &num : NM 005562. 1 Coding sequence: 90.. 3671 1 11 21 31 41 51 ACAGCGGAGC GCAGAGTGAG AACCACCAAC CGAGGCGCCG GGCAGCGACC CCTGCAGCGG 60 AGACAGAGAC TGAGCGGCCC GGCACCGCCA TGCCTGCGCT CTGGCTGGGC TGCTGCCTCT 120 GCTTCTCGCT CCTCCTGCCC GCAGCCCGGG CCACCTCCAG GAGGGAAGTC TGTGATTGCA 180 ATGGGAAGTC CAGGCAGTGT ATCTTTGATC GGGAACTTCA CAGACAAACT GGTAATGGAT 240 TCCGCTGCCT CAACTGCAAT GACAACACTG ATGGCATTCA CTGCGAGAAG TGCAAGAATG 300 GCTTTTACCG GCACAGAGAA AGGGACCGCT GTTTGCCCTG CAATTGTAAC TCCAAAGGTT 360 CTCTTAGTGC TCGATGTGAC AACTCTGGAC GGTGCAGCTG TAAACCAGGT GTGACAGGAG 420 CCAGATGCGA CCGATGTCTG CCAGGCTTCC ACATGCTCAC GGATGCGGGG TGCACCCAAG 480 ACCAGAGACT GCTAGACTCC AAGTGTGACT GTGACCCAGC TGGCATCGCA GGGCCCTGTG 540 ACGCGGGCCG CTGTGTCTGC AAGCCAGCTG TTACTGGAGA ACGCTGTGAT AGGTGTCGAT 600 CAGGTTACTA TAATCTGGAT GGGGGGAACC CTGAGGGCTG TACCCAGTGT TTCTGCTATG 660 GGCATTCAGC CAGCTGCCGC AGCTCTGCAG AATACAGTGT CCATAAGATC ACCTCTACCT 720 TTCATCAAGA TGTTGATGGC TGGAAGGCTG TCCAACGAAA TGGGTCTCCT GCAAAGCTCC 780 AATGGTCACA GCGCCATCAA GATGTGTTTA GCTCAGCCCA ACGACTAGAC CCTGTCTATT 840

TTGTGGCTCC TGCCAAATTT CTTGGGAATC AACAGGTGAG CTATGGGCAA AGCCTGTCCT 900 TTGACTACCG TGTGGACAGA GGAGGCAGAC ACCCATCTGC CCATGATGTG ATTCTGGAAG 960 GTGCTGGTCT ACGGATCACA GCTCCCTTGA TGCCACTTGG CAAGACACTG CCTTGTGGGC 1020 TCACCAAGAC TTACACATTC AGGTTAAATG AGCATCCAAG CAATAATTGG AGCCCCCAGC 1080 TGAGTTACTT TGAGTATCGA AGGTTACTGC GGAATCTCAC AGCCCTCCGC ATCCGAGCTA 1140 CATATGGAGA ATACAGTACT GGGTACATTG ACAATGTGAC CCTGATTTCA GCCCGCCCTG 1200 TCTCTGGAGC CCCAGCACCC TGGGTTGAAC AGTGTATATG TCCTGTTGGG TACAAGGGGC 1260 'AATTCTGCCA GGATTGTGCT TCTGGCTACA AGAGAGATTC AGCGAGACTG GGGCCTTTTG 1320 GCACCTGTAT TCCTTGTAAC TGTCAAGGGG GAGGGGCCTG TGATCCAGAC ACAGGAGATT 1380 GTTATTCAGG GGATGAGAAT CCTGACATTG AGTGTGCTGA CTGCCCAATT GGTTTCTACA 1440 ACGATCCGCA CGACCCCCGC AGCTGCAAGC CATGTCCCTG TCATAACGGG TTCAGCTGCT 1500 CAGTGATGCC GGAGACGGAG GAGGTGGTGT GCAATAACTG CCCTCCCGGG GTCACCGGTG 1560 CCCGCTGTGA GCTCTGTGCT GATGGCTACT TTGGGGACCC CTTTGGTGAA CATGGCCCAG 1620 TGAGGCCTTG TCAGCCCTGT CAATGCAACA ACAATGTGGA CCCCAGTGCC TCTGGGAATT 1680 GTGACCGGCT GACAGGCAGG TGTTTGAAGT GTATCCACAA CACAGCCGGC ATCTACTGCG 1740 ACCAGTGCAA AGCAGGCTAC TTCGGGGACC CATTGGCTCC CAACCCAGCA GACAAGTGTC 1800 GAGCTTGCAA CTGTAACCCC ATGGGCTCAG AGCCTGTAGG ATGTCGAAGT GATGGCACCT 1860 GTGTTTGCAA GCCAGGATTT GGTGGCCCCA ACTGTGAGCA TGGAGCATTC AGCTGTCCAG 1920 CTTGCTATAA TCAAGTGAAG ATTCAGATGG ATCAGTTTAT GCAGCAGCTT CAGAGAATGG 1980 AGGCCCTGAT TTCAAAGGCT CAGGGTGGTG ATGGAGTAGT ACCTGATACA GAGCTGGAAG 2040 GCAGGATGCA GCAGGCTGAG CAGGCCCTTC AGGACATTCT GAGAGATGCC CAGATTTCAG 2100 AAGGTGCTAG CAGATCCCTT GGTCTCCAGT TGGCCAAGGT GAGGAGCCAA GAGAACAGCT 2160 ACCAGAGCCG CCTGGATGAC CTCAAGATGA CTGTGGAAAG AGTTCGGGCT CTGGGAAGTC 2220 AGTACCAGAA CCGAGTTCGG GATACTCACA GGCTCATCAC TCAGATGCAG CTGAGCCTGG 2280 CAGAAAGTGA AGCTTCCTTG GGAAACACTA ACATTCCTGC CTCAGACCAC TACGTGGGGC 2340 CAAATGGCTT TAAAAGTCTG GCTCAGGAGG CCACAAGATT AGCAGAAAGC CACGTTGAGT 2400 CAGCCAGTAA CATGGAGCAA CTGACAAGGG AAACTGAGGA CTATTCCAAA CAAGCCCTCT 2460 CACTGGTGCG CAAGGCCCTG CATGAAGGAG TCGGAAGCGG AAGCGGTAGC CCGGACGGTG 2520 CTGTGGTGCA AGGGCTTGTG GAAAAATTGG AGAAAACCAA GTCCCTGGCC CAGCAGTTGA 2580 CAAGGGAGGC CACTCAAGCG GAAATTGAAG CAGATAGGTC TTATCAGCAC AGTCTCCGCC 2640 TCCTGGATTC AGTGTCTCGG CTTCAGGGAG TCAGTGATCA GTCCTTTCAG GTGGAAGAAG 2700 CAAAGAGGAT CAAACAAAAA GCGGATTCAC TCTCAACGCT GGTAACCAGG CATATGGATG 2760 AGTTCAAGCG TACACAAAAG AATCTGGGAA ACTGGAAAGA AGAAGCACAG CAGCTCTTAC 2820 AGAATGGAAA AAGTGGGAGA GAGAAATCAG ATCAGCTGCT TTCCCGTGCC AATCTTGCTA 2880 AAAGCAGAGC ACAAGAAGCA CTGAGTATGG GCAATGCCAC TTTTTATGAA GTTGAGAGCA 2940 TCCTTAAAAA CCTCAGAGAG TTTGACCTGC AGGTGGACAA CAGAAAAGCA GAAGCTGAAG 3000 AAGCCATGAA GAGACTCTCC TACATCAGCC AGAAGGTTTC AGATGCCAGT GACAAGACCC 3060 AGCAAGCAGA AAGAGCCCTG GGGAGCGCTG CTGCTGATGC ACAGAGGGCA AAGAATGGGG 3120 CCGGGGAGGC CCTGGAAATC TCCAGTGAGA TTGAACAGGA GATTGGGAGT CTGAACTTGG 3180 AAGCCAATGT GACAGCAGAT GGAGCCTTGG CCATGGAAAA GGGACTGGCC TCTCTGAAGA 3240 GTGAGATGAG GGAAGTGGAA GGAGAGCTGG AAAGGAAGGA GCTGGAGTTT GACACGAATA 3300 TGGATGCAGT ACAGATGGTG ATTACAGAAG CCCAGAAGGT TGATACCAGA GCCAAGAACG 3360 CTGGGGTTAC AATCCAAGAC ACACTCAACA CATTAGACGG CCTCCTGCAT CTGATGGACC 3420 AGCCTCTCAG TGTAGATGAA GAGGGGCTGG TCTTACTGGA GCAGAAGCTT TCCCGAGCCA 3480 AGACCCAGAT CAACAGCCAA CTGCGGCCCA TGATGTCAGA GCTGGAAGAG AGGGCACGTC 3540 AGCAGAGGGG CCACCTCCAT TTGCTGGAGA CAAGCATAGA TGGGATTCTG GCTGATGTGA 3600 AGAACTTGGA GAACATTAGG GACAACCTGC CCCCAGGCTG CTACAATACC CAGGCTCTTG 3660 AGCAACAGTG AAGCTGCCAT AAATATTTCT CAACTGAGGT TCTTGGGATA CAGATCTCAG 3720 GGCTCGGGAG CCATGTCATG TGAGTGGGTG GGATGGGGAC ATTTGAACAT GTTTAATGGG 3780 TATGCTCAGG TCAACTGACC TGACCCCATT CCTGATCCCA TGGCCAGGTG GTTGTCTTAT 3840 TGCACCATAC TCCTTGCTTC CTGATGCTGG GCAATGAGGC AGATAGCACT GGGTGTGAGA 3900 ATGATCAAGG ATCTGGACCC CAAAGAATAG ACTGGATGGA AAGACAAACT GCACAGGCAG 3960 ATGTTTGCCT CATAATAGTC GTAAGTGGAG TCCTGGAATT TGGACAAGTG CTGTTGGGAT 4020 ATAGTCAACT TATTCTTTGA GTAATGTGAC TAAAGGAAAA AACTTTGACT TTGCCCAGGC 4080 ATGAAATTCT TCCTAATGTC AGAACAGAGT GCAACCCAGT CACACTGTGG CCAGTAAAAT 4140 ACTATTGCCT CATATTGTCC TCTGCAAGCT TCTTGCTGAT CAGAGTTCCT CCTACTTACA 4200 ACCCAGGGTG TGAACATGTT CTCCATTTTC AAGCTGGAAG AAGTGAGCAG TGTTGGAGTG 4260 AGGACCTGTA AGGCAGGCCC ATTCAGAGCT ATGGTGCTTG CTGGTGCCTG CCACCTTCAA 4320 GTTCTGGACC TGGGCATGAC ATCCTTTCTT TTAATGATGC CATGGCAACT TAGAGATTGC 4380 ATTTTTATTA AAGCATTTCC TACCAGCAAA GCAAATGTTG GGAAAGTATT TACTTTTTCG 4440 GTTTCAAAGT GATAGAAAAG TGTGGCTTGG GCATTGAAAG AGGTAAAATT CTCTAGATTT 4500 ATTAGTCCTA ATTCAATCCT ACTTTTCGAA CACCAAAAAT GATGCGCATC AATGTATTTT 4560 ATCTTATTTT CTCAATCTCC TCTCTCTTTC CTCCACCCAT AATAAGAGAA TGTTCCTACT 4620 CACACTTCAG CTGGGTCACA TCCATCCCTC CATTCATCCT TCCATCCATC TTTCCATCCA 4680 TTACCTCCAT CCATCCTTCC AACATATATT TATTGAGTAC CTACTGTGTG CCAGGGGCTG 4740 GTGGGACAGT GGTGACATAG TCTCTGCCCT CATAGAGTTG ATTGTCTAGT GAGGAAGACA 4800 AGCATTTTTA AAAAATAAAT TTAAACTTAC AAACTTTGTT TGTCACAAGT GGTGTTTATT 4860 GCAATAACCG CTTGGTTTGC AACCTCTTTG CTCAACAGAA CATATGTTGC AAGACCCTCC 4920 CATGGGGGCA CTTGAGTTTT GGCAAGGCTG ACAGAGCTCT GGGTTGTGCA CATTTCTTTG 4980 CATTCCAGCT GTCACTCTGT GCCTTTCTAC AACTGATTGC AACAGACTGT TGAGTTATGA 5040 TAACACCAGT GGGAATTGCT GGAGGAACCA GAGGCACTTC CACCTTGGCT GGGAAGACTA 5100 TGGTGCTGCC TTGCTTCTGT ATTTCCTTGG ATTTTCCTGA AAGTGTTTTT AAATAAAGAA 5160 CAATTGTTAG ATGCC Seq ID NO: 591 Protein sequence Protein Accession &num : NP 005553. 1 1 11 21 31 41 51 MPALWLGCCL CFSLI. LPAAR ATSRREVCDC NGKSRQCIFD RELHRQTGNG FRCLNCNDNT 60 DGIHCEKCKN GFYRHRERDR CLPCNCNSKG SLSARCDNSG RCSCKPGVTG ARCDRCLPGF 120 HMLTDAGCTQ DQRLLDSKCD CDPAGIAGPC DAGRCVCKPA VTGERCDRCR SGYYNLDGGN 180 PEGCTQCFCY GHSASCRSSA EYSVHKITST FHQDVDGWKA VQRNGSPAKL QWSQRHQDVF 240 SSAQRLDPVY FVAPAKFLGN QQVSYGQSLS FDYRVDRGGR HPSAHDVILE GAGLRITAPL 300 MPLGKTLPCG LTKTYTFRLN EHPSNNWSPQ LSYFEYRRLL RNLTALRIRA TYGEYSTGYI 360 DNVTLISARP VSGAPAPWVE QCICPVGYKG QFCQDCASGY KRDSARLGPF GTCIPCNCQG 420 GGACDPDTGD CYSGDENPDI ECADCPIGFY NDPHDPRSCK PCPCHNGFSC SVMPETEEW 480

CNNCPPGVTG ARCELCADGY FGDPFGEHGP VRPCQPCQCN NNVDPSASGN CDRLTGRCLK 540 CIHNTAGIYC DQCKAGYFGD PLAPNPADKC RACNCNPMGS EPVGCRSDGT CVCKPGFGGP 600 NCEHGAFSCP ACYNQVKIQM DQFMQQLQRM EALISKAQGG DGWPDTELE GRMQQAEQAL 660 QDILRDAQIS EGASRSLGLQ LAKVRSQENS YQSRLDDLKM TVERVRALGS QYQNRVRDTH 720 RLITQMQLSL AESEASLGNT NIPASDHYVG PNGFKSLAQE ATRLAESHVE SASNMEQLTR 780 ETEDYSKQAL SLVRKALHEG VGSGSGSPDG AWQGLVEKL EKTKSLAQQL TREATQAEIE 840 ADRSYQHSLR LLDSVSRLQG VSDQSFQVEE AKRIKQKADS LSTLVTRHMD EFKRTQKNLG 900 NWKEEAQQLL QNGKSGREKS DQLLSRANLA KSRAQEALSM GNATFYEVES ILKNLREFDL 960 QVDNRKAEAE EAMKRLSYIS QKVSDASDKT QQAERALGSA AADAQRAKNG AGEALEISSE 1020 IEQEIGSLNL EANVTADGAL AMEKGLASLK SEMREVEGEL ERKELEFDTN MDAVQMVITE 1080 AQKVDTRAKN AGVTIQDTLN TLDGLLHLMD QPLSVDEEGL VLLEQKLSRA KTQINSQLRP 1140 MMSELEERAR QQRGHLHLLE TSIDGILADV KNLENIRDNL PPGCYNTQAL EQQ Seq ID NO : 592 DNA sequence Nucleic Acid Accession # : AF101051. 1 Coding sequence: 221.856 1 11 21 31 41 51 # # # # # # GAGCAACTC AGCTTCTAGT ATCCAGACTC CAGCGCCGCC CCGGGCGCGG ACCCCAACCC 60 CGACCCAGAG CTTCTCCAGC GGCGGCGCAG CGAGCAGGGC TCCCCGCCTT AACTTCCTCC 120 GCGGGGCCCA GCCACCTTCG GGAGTCCGGG TTGCCCACCT GCAAACTCTC CGCCTTCTGC 180 ACCTGCCACC CCTGAGCCAG CGCGGGCGCC CGAGCGAGTC ATGGCCAACG CGGGGCTGCA 240 GCTGTTGGGC TTCATTCTCG CCTTCCTGGG ATGGATCGGC GCCATCGTCA GCACTGCCCT 300 GCCCCAGTGG AGGATTTACT CCTATGCCGG CGACAACATC GTGACCGCCC AGGCCATGTA 360 CGAGGGGCTG TGGATGTCCT GCGTGTCGCA GAGCACCGGG CAGATCCAGT GCAAAGTCTT 420 TGACTCCTTG CTGAATCTGA GCAGCACATT GCAAGCAACC CGTGCCTTGA TGGTGGTTGG 480 CATCCTCCTG GGAGTGATAG CAATCTTTGT GGCCACCGTT GGCATGAAGT GTATGAAGTG 540 CTTGGAAGAC GATGAGGTGC AGAAGATGAG GATGGCTGTC ATTGGGGGTG CGATATTTCT 600 TCTTGCAGGT CTGGCTATTT TAGTTGCCAC AGCATGGTAT GGCAATAGAA TCGTTCAAGA 660 ATTCTATGAC CCTATGACCC CAGTCAATGC CAGGTACGAA TTTGGTCAGG CTCTCTTCAC 720 TGGCTGGGCT GCTGCTTCTC TCTGCCTTCT GGGAGGTGCC CTACTTTGCT GTTCCTGTCC 780 CCGAAAAACA ACCTCTTACC CAACACCAAG GCCCTATCCA AAACCTGCAC CTTCCAGCGG 840 GAAAGACTAC GTGTGACACA GAGGCAAAAG GAGAAAATCA TGTTGAAACA AACCGAAAAT 900 GGACATTGAG ATACTATCAT TAACATTAGG ACCTTAGAAT TTTGGGTATT GTAATCTGAA 960 GTATGGTATT ACAAAACAAA CAAACAAACA AAAAACCCAT GTGTTAAAAT ACTCAGTGCT 1020 AAACATGGCT TAATCTTATT TTATCTTCTT TCCTCAATAT AGGAGGGAAG ATTTTACCAT 1080 TTGTATTACT GCTTCCCATT GAGTAATCAT ACTCAAATGG GGGAAGGGGT GCTCCTTAAA 1140 TATATATAGA TATGTATATA TACATGTTTT TCTATTAAAA ATAGACAGTA AAATACTATT 1200 CTCATTATGT TGATACTAGC ATACTTAAAA TATCTCTAAA ATAGGTAAAT GTATTTAATT 1260 CCATATTGAT GAAGATGTTT ATTGGTATAT TTTCTTTTTC GTCCTTATAT ACATATGTAA 1320 CAGTCAAATA TCATTTACTC TTCTTCATTA GCTTTGGGTG CCTTTGCCAC AAGACCTAGC 1380 CTAATTTACC AAGGATGAAT TCTTTCAATT CTTCATGCGT GCCCTTTTCA TATACTTATT 1440 TTATTTTTTA CCATAATCTT ATAGCACTTG CATCGTTATT AAGCCCTTAT TTGTTTTGTG 1500 TTTCATTGGT CTCTATCTCC TGAATCTAAC ACATTTCATA GCCTACATTT TAGTTTCTAA 1560 AGCCAAGAAG AATTTATTAC AAATCAGAAC TTTGGAGGCA AATCTTTCTG CATGACCAAA 1620 GTGATAAATT CCTGTTGACC TTCCCACACA ATCCCTGTAC TCTGACCCAT AGCACTCTTG 1680 TTTGCTTTGA AAATATTTGT CCAATTGAGT AGCTGCATGC TGTTCCCCCA GGTGTTGTAA 1740 CACAACTTTA TTGATTGAAT TTTTAAGCTA CTTATTCATA GTTTTATATC CCCCTAAACT 1800 ACCTTTTTGT TCCCCATTCC TTAATTGTAT TGTTTTCCCA AGTGTAATTA TCATGCGTTT 1860 TATATCTTCC TAATAAGGTG TGGTCTGTTT GTCTGAACAA AGTGCTAGAC TTTCTGGAGT 1920 GATAATCTGG TGACAAATAT TCTCTCTGTA GCTGTAAGCA AGTCACTTAA TCTTTCTACC 1980 TCTTTTTTCT ATCTGCCAAA TTGAGATAAT GATACTTAAC CAGTTAGAAG AGGTAGTGTG 2040 AATATTAATT AGTTTATATT ACTCTCATTC TTTGAACATG AACTATGCCT ATGTAGTGTC 2100 TTTATTTGCT CAGCTGGCTG AGACACTGAA GAAGTCACTG AACAAAACCT ACACACGTAC 2160 CTTCATGTGA TTCACTGCCT TCCTCTCTCT ACCAGTCTAT TTCCACTGAA CAAAACCTAC 2220 ACACATACCT TCATGTGGTT CAGTGCCTTC CTCTCTCTAC CAGTCTATTT CCACTGAACA 2280 AAACCTACGC ACATACCTTC ATGTGGCTCA GTGCCTTCCT CTCTCTACCA GTCTATTTCC 2340 ATTCTTTCAG CTGTGTCTGA CATGTTTGTG CTCTGTTCCA TTTTAACAAC TGCTCTTACT 2400 TTTCCAGTCT GTACAGAATG CTATTTCACT TGAGCAAGAT GATGTATGGA AAGGGTGTTG 2460 GCACTGGTGT CTGGAGACCT GGATTTGAGT CTTGGTGCTA TCAATCACCG TCTGTGTTTG 2520 AGCAAGGCAT TTGGCTGCTG TAAGCTTATT GCTTCATCTG TAAGCGGTGG TTTGTAATTC 2580 CTGATCTTCC CACCTCACAG TGATGTTGTG GGGATCCAGT GAGATAGAAT ACATGTAAGT 2640 GTGGTTTTGT AATTTGAAAA GTGCTATACT AAGGGAAAGA ATTGAGGAAT TAACTGCATA 2700 CGTTTTGGTG TTGCTTTTCA AATGTTTGAA AATAAAAAAA TGTTAAGAAA TGGGTTTCTT 2760 GCCTTAACCA GTCTCTCAAG TGATGAGACA GTGAAGTAAA ATTGAGTGCA CTAAACGAAT 2820 AAGATTCTGA GGAAGTCTTA TCTTCTGCAG TGAGTATGGC CCAATGCTTT CTGTGGCTAA 2880 ACAGATGTAA TGGGAAGAAA TAAAAGCCTA CGTGTTGGTA AATCCAACAG CAAGGGAGAT 2940 TTTTGAATCA TAATAACTCA TAAGGTGCTA TCTGTTCAGT GATGCCCTCA GAGCTCTTGC 3000 TGTTAGCTGG CAGCTGACGC TGCTAGGATA GTTAGTTTGG AAATGGTACT TCATAATAAA 3060 CTACACAAGG AAAGTCAGCC ACCGTGTCTT ATGAGGAATT-GGACCTAATA AATTTTAGTG 3120 TGCCTTCCAA ACCTGAGAAT ATATGCTTTT GGAAGTTAAA ATTTAAATGG CTTTTGCCAC 3180 ATACATAGAT CTTCATGATG TGTGAGTGTA ATTCCATGTG GATATCAGTT ACCAAACATT 3240 ACAAAAAAAT TTTATGGCCC AAAATGACCA ACGAAATTGT TACAATAGAA TTTATCCAAT 3300 TTTGATCTTT TTATATTCTT CTACCACACC TGGAAACAGA CCAATAGACA TTTTGGGGTT 3360 TTATAATGGG AATTTGTATA AAGCATTACT CTTTTTCAAT AAATTGTTTT TTAATTTAAA 3420 AAAAGGAAAA AAAAAAAAAA AAA Seq ID NO : 593 Protein sequence Protein Accession &num : AAD16433.1 1 11 21 31 41 51 MANAGLQLLG FILAFLGWIG AIVSTALPQW RIYSYAGDNI VTAQAMYEGL WMSCVSQSTG 60 QIQCKVFDSL LNLSSTLQAT RALMWGILL GVIAIFVATV GMKCMKCLED DEVQKMRMAV 120 IGGAIFLLAG LAILVATAWY GNRIVQEFYD PMTPVNARYE FGQALFTGWA AASLCLLGGA 180 LLCCSCPRKT TSYPTPRPYP KPARSSGKDY V

NETSHTQGSL RITNISSDDS GKQISCVAEN LVGEDQDSVN LTVHFAPTIT FLESPTSDHH 300 WCIPFTVKGN PKPALQWFYN GAILNESKYI CTKIHVTNHT EYHGCLQLDN PTHMNNGDYT 360 LIAKNEYGKD EKQISAHFMG WPGIDDGANP NYPDVIYEDY GTAANDIGDT TNRSNEIPST 420 DVTDKTGREH LSVYAVWIA SWGFCLLVM LFLLKLARHS KFGMKDFSWF GFGKVKSRQG 480 VGPASVISND DDSASPLHHI SNGSNTPSSS EGGPDAVIIG MTKIPVIENP QYFGITNSQL 540 KPDTFVQHIK RHNIVLKREL GEGAFGKVFL AECYNLCPEQ DKILVAVKTL KDASDNARKD 600 FHREAELLTN LQHEHIVKFY GVCVEGDPLI MVFEYMKHGD LNKFLRAHGP DAVLMAEGNP 660 PTELTQSQML HIAQQIAAGM VYLASQHFVH RDLATRNCLV GENLLVKIGD FGMSRDVYST 720 DYYRVGGHTM LPIRWMPPES IMYRKFTTES DVWSLGWLW EIFTYGKQPW YQLSNNEVIE 780 CITQGRVLQR PRTCPQEVYE LMLGCWQREP HMRKNIKGIH TLLQNLAKAS PVYLDILG Seq ID NO : 598 DNA sequence Nucleic Acid Accession # : AB052906 Coding sequence: 74.. 814 1 11 21 31 41 51 AAAACCTTGA GGTGATTCAT CTTCCAGGCT CTCCTTCCAT CAAGTCTCTC CTCCCTAGCG 60 CTCTGGGTCC TTAATGGCAG CAGCCGCCGC TACCAAGATC CTTCTGTGCC TCCCGCTTCT 120 GCTCCTGCTG TCCGGCTGGT CCCGGGCTGG GCGAGCCGAC CCTCACTCTC TTTGCTATGA 180 CATCACCGTC ATCCCTAAGT TCAGACCTGG ACCACGGTGG TGTGCGGTTC AAGGCCAGGT 240 GGATGAAAAG ACTTTTCTTC ACTATGACTG TGGCAACAAG ACAGTCACAC CTGTCAGTCC 300 CCTGGGGAAG AAACTAAATG TCACAACGGC CTGGAAAGCA CAGAACCCAG TACTGAGAGA 360 GGTGGTGGAC ATACTTACAG AGCAACTGCG TGACATTCAG CTGGAGAATT ACACACCCAA 420 GGAACCCCTC ACCCTGCAGG CCAGGATGTC TTGTGAGCAG AAAGCTGAAG GACACAGCAG 480 TGGATCTTGG CAGTTCAGTT TCGATGGGCA'GATCTTCCTC CTCTTTGACT CAGAGAAGAG 540 AATGTGGACA ACGGTTCATC CTGGAGCCAG AAAGATGAAA GAAAAGTGGG AGAATGACAA 600 GGTTGTGGCC ATGTCCTTCC ATTACTTCTC AATGGGAGAC TGTATAGGAT GGCTTGAGGA 660 CTTCTTGATG GGCATGGACA GCACCCTGGA GCCAAGTGCA GGAGCACCAC TCGCCATGTC 720 CTCAGGCACA ACCCAACTCA GGGCCACAGC CACCACCCTC ATCCTTTGCT GCCTCCTCAT 780 CATCCTCCCC TGCTTCATCC TCCCTGGCAT CTGAGGAGAG TCCTTTAGAG TGACAGGTTA 840 AAGCTGATAC CAAAAGGCTC CTGTGAGCAC GGTCTTGATC AAACTCGCCC TTCTGTCTGG 900 CCAGCTGCCC ACGACCTACG GTGTATGTCC AGTGGCCTCC AGCAGATCAT GATGACATCA 960 TGGACCCAAT AGCTCATTCA CTGCCTTGAT TCCTTTTGCC AACAATTTTA CCAGCAGTTA 1020 TACCTAACAT ATTATGCAAT TTTCTCTTGG TGCTACCTGA TGGAATTCCT GCACTTAAAG 1080 TTCTGGCTGA CTAAACAAGA TATATCATTT TCTTTCTTCT CTTTTTGTTT GGAAAATCAA 1140 GTACTTCTTT GAATGATGAT CTCTTTCTTG CAAATGATAT TGTCAGTAAA ATAATCACGT 1200 TAGACTTCAG ACCTCTGGGG ATTCTTTCCG TGTCCTGAAA GAGAATTTTT AAATTATTTA 1260 ATAAGAAAAA ATTTATATTA ATGATTGTTT CCTTTAGTAA TTTATTGTTC TGTACTGATA 1320 TTTAAATAAA GAGTTCTATT TCCCAAAAAA AAAAAAAAAA AA Seq ID NO: 599 Protein sequence Protein Accession # : BAB61048. 1 1 11 21 31 41 51 # # # # # # MAAAAATKIL LCLPLLLLLS GWSRAGRADP HSLCYDITVI PKFRPGPRWC AVQGQVDEKT 60 FLHYDCGNKT VTPVSPLGKK LNVTTAWKAQ NPVLREWDI LTEQLRDIQL ENYTPKEPLT 120 LQARMSCEQK AEGHSSGSWQ FSFDGQIFLL FDSEKRMWTT VHPGARKMKE KWENDKWAM 180 SFHYFSMGDC IGWLEDFLMG MDSTLEPSAG APLAMSSGTT QLRATATTLI LCCLLIILPC 240 FILPGI Seq ID NO : 600 DNA sequence Nucleic Acid Accession # : NM 001898. 1 Coding sequence : 57.. 482 1 11 21 31 41 51 # # # # # # GGCTCTCACC CTCCTCTCCT GCAGCTCCAG CTTTGTGCTC TGCCTCTGAG GAGACCATGG 60 CCCAGTATCT GAGTACCCTG CTGCTCCTGC TGGCCACCCT AGCTGTGGCC CTGGCCTGGA 120 GCCCCAAGGA GGAGGATAGG ATAATCCCGG GTGGCATCTA TAACGCAGAC CTCAATGATG 180 AGTGGGTACA GCGTGCCCTT CACTTCGCCA TCAGCGAGTA TAACAAGGCC ACCAAAGATG 240 ACTACTACAG ACGTCCGCTG CGGGTACTAA GAGCCAGGCA ACAGACCGTT GGGGGGGTGA 300 ATTACTTCTT CGACGTAGAG GTGGGCCGCA CCATATGTAC CAAGTCCCAG CCCAACTTGG 360 ACACCTGTGC CTTCCATGAA CAGCCAGAAC TGCAGAAGAA ACAGTTGTGC TCTTTCGAGA 420 TCTACGAAGT TCCCTGGGAG AACAGAAGGT CCCTGGTGAA ATCCAGGTGT CAAGAATCCT 480 AGGGATCTGT GCCAGGCCAT TCGCACCAGC CACCACCCAC TCCCACCCCC TGTAGTGCTC 540 CCACCCCTGG ACTGGTGGCC CCCACCCTGC GGGAGGCCTC CCCATGTGCC TGCGCCAAGA 600 GACAGACAGA GAAGGCTGCA GGAGTCCTTT GTTGCTCAGC AGGGCGCTCT GCCCTCCCTC 660 CTTCCTTCTT GCTTCTAATA GCCCTGGTAC ATGGTACACA CCCCCCCACC TCCTGCAATT 720 AAACAGTAGC ATCGCC Seq ID NO : 601 Protein sequence Protein Accession # : NP 001889. 1 1 11 21 31 41 51 MAQYLSTLLL LLATLAVALA WSPKEEDRII PGGIYNADLN DEWVQRALHF AISEYNKATK 60 DDYYRRPLRV LRARQQTVGG VNYFFDVEVG RTICTKSQPN LDTCAPHEQP ELQKKQLCSF 120 EIYEVPWENR RSLVKSRCQE S Seq ID NO: 602 DNA sequence Nucleic Acid Accession # : NM 003976. 2 Coding sequence: 299.961 1 11 21 31 41 51 1 1 1 1 1 1

CTCTGAGCTT CTCTGAGCCT TGTTTGCTCA TCTGGAAAAA GGGGATTAAA CCATTTACCT 60 CATGGAGTTG TGAAAGAATA GCTGCAAAGC ACCTAACACA TAGTAAGGTT CCCAGTGCAG 120 CTACTTCTGC TGGGTTGAGT CTAGCTGTGT AGGCCCCTTG TTCCTCACCT GGAGAAACTG 180 GGGTGGCAGG CCGGTCCCCC ACAAAAGATA ACTCATCTCT TAATTTGCAA GCTGCCTCAA 240 CAGGAGGGTG GGGGAACAGC TCAACAATGG CTGATGGGCG CTCCTGGTGT TGATAGAGAT 300 GGAACTTGGA CTTGGAGGCC TCTCCACGCT GTCCCACTGC CCCTGGCCTA GGCGGCAGCC 360 TGCCCTGTGG CCCACCCTGG CCGCTCTGGC TCTGCTGAGC AGCGTCGCAG AGGCCTCCCT 420 GGGCTCCGCG CCCCGCAGCC CTGCCCCCCG CGAAGGCCCC CCGCCTGTCC TGGCGTCCCC 480 CGCCGGCCAC CTGCCGGGGG GACGCACGGC CCGCTGGTGC AGTGGAAGAG CCCGGCGGCC 540 GCCGCCGCAG CCTTCTCGGC CCGCGCCCCC GCCGCCTGCA CCCCCATCTG CTCTTCCCCG 600 CGGGGGCCGC GCGGCGCGGG CTGGGGGCCC GGGCAGCCGC GCTCGGGCAG CGGGGGCGCG 660 GGGCTGCCGC CTGCGCTCGC AGCTGGTGCC GGTGCGCGCG CTCGGCCTGG GCCACCGCTC 720 CGACGAGCTG GTGCGTTTCC GCTTCTGCAG CGGCTCCTGC CGCCGCGCGC GCTCTCCACA 780 CGACCTCAGC CTGGCCAGCC TACTGGGCGC CGGGGCCCTG CGACCGCCCC CGGGCTCCCG 840 GCCCGTCAGC CAGCCCTGCT GCCGACCCAC GCGCTACGAA GCGGTCTCCT TCATGGACGT 900 CAACAGCACC TGGAGAACCG TGGACCGCCT CTCCGCCACC GCCTGCGGCT GCCTGGGCTG 960 AGGGCTCGCT CCAGGGCTTT GCAGACTGGA CCCTTACCGG TGGCTCTTCC TGCCTGGGAC 1020 CCTCCCGCAG AGTCCCACTA GCCAGCGGCC TCAGCCAGGG ACGAAGGCCT CAAAGCTGAG 1080 AGGCCCCTAC CGGTGGGTGA TGGATATCAT CCCCGAACAG GTGAAGGGAC AACTGACTAG 1140 CAGCCCCAGA GCCCTCACCC TGCGGATCCC AGCCTAAAAG ACACCAGAGA CCTCAGCTAT 1200 GGAGCCCTTC GGACCCACTT CTCACAGACT CTGGCACTGG CCAGGCCTCG AACCTGGGAC 1260 CCCTCCTCTG ATGAACACTA CAGTGGCTGA GGCATCAGCC CCCGCCCAGG CCCTGTAGGG 1320 ACAGCATTTG AAGGACACAT ATTGCAGTTG CTTGGTTGAA AGTGCCTGTG CTGGAACTGG 1380 CCTGTACTCA CTCATGGGAG CTGGCCCC Seq ID NO : 603 Protein sequence Protein Accession &num : NP 003967. 1 1 11 21 31 41 51 MELGLGGLST LSHCPWPRRQ PALWPTLAAL ALLSSVAEAS LGSAPRSPAP REGPPPVLAS 60 PAGHLPGGRT ARWCSGRARR PPPQPSRPAP PPPAPPSALP RGGRAARAGG PGSRARAAGA 120 RGCRLRSQLV PVRALGLGHR SDELVRFRFC SGSCRRARSP HDLSLASLLG AGALRPPPGS 180 RPVSQPCCRP TRYEAVSFMD VNSTWRTVDR LSATACGCLG Seq ID NO: 604 DNA sequence Nucleic Acid Accession # : NM 057091. 1 Coding sequence : 783.. 1445 1 11 21 31 41 51 1 1 1 1 1 1<BR> <BR> <BR> ACTGGCCGCT GAGAGAAGAA TCGGGTGGAG CAGAGAGCAG CTGCTGCAGG GCAGACAGCC 60 GGACCCCCAA ATCTGCACGT ACCAGCAGTC AGCCGCCCCA CGCAGGGACC GGCTTACCCC 120 TCGCTCCCCG CCCTCACTCA CTTTCTCCCG CCCTCGGCCC GGCCTCCCAG CTCTCTACTT 180 CGCGTGTCTA CAAACTCAAC TCCCGGTTTC CGTGCCTCTC CACCGCTCGA GTTCTCTACT 240 CTCCATATCC GAGGGGCCCC TCCCAGCATC TACCCCCCTC CCAACCTCGG GGGACCTAGC 300 CAAGCTAGGG GGGACTGGAT CCGACGGGTG GAGCAGCCAG GTGAGCCCCG AAAGGTGGGG 360 CGGGGCAGGG GCGCTCCCAG CCCCACCCCG GGATCTGGTG ACGCTGGGGC TGGAATTTGA 420 CACCGGACGG CTGCGGCGGC GGGCAGGAGG CTGCTGAGGG ATGGAGTTGG GCCCGGCCCC 480 CAGACAAGGC CCGGGGGCTC CGCCAGCAGC AGGTCCCTCG GGCCCCAGCC CTCGCTGCCA 540 CCCGGGCCTG GAGCCCCACA CCCGAGGGTG CAGACTGGCT GCCAAGGCCA CACTTTTGGC 600 TAAAAGAGGC ACTGCCAGGT GTACAGTCCT GGGCATGCGC TGTTTGAGCT TCGGGGGAGA 660 GCCCAGCACT GGTCCCCGGA AAGGTGCCTA GAAGAACAAG GTGCAGGACC CCGTGCTGCC 720 TCAACAGGAG GGTGGGGGAA CAGCTCAACA ATGGCTGATG GGCGCTCCTG GTGTTGATAG 780 AGATGGAACT TGGACTTGGA GGCCTCTCCA CGCTGTCCCA CTGCCCCTGG CCTAGGCGGC 840 AGCCTGCCCT GTGGCCCACC CTGGCCGCTC TGGCTCTGCT GAGCAGCGTC GCAGAGGCCT 900 CCCTGGGCTC CGCGCCCCGC AGCCCTGCCC CCCGCGAAGG CCCCCCGCCT GTCCTGGCGT 960 CCCCCGCCGG CCACCTGCCG GGGGGACGCA CGGCCCGCTG GTGCAGTGGA AGAGCCCGGC 1020 GGCCGCCGCC GCAGCCTTCT CGGCCCGCGC CCCCGCCGCC TGCACCCCCA TCTGCTCTTC 1080 CCCGCGGGGG CCGCGCGGCG CGGGCTGGGG GCCCGGGCAG CCGCGCTCGG GCAGCGGGGG 1140 CGCGGGGCTG CCGCCTGCGC TCGCAGCTGG TGCCGGTGCG CGCGCTCGGC CTGGGCCACC 1200 GCTCCGACGA GCTGGTGCGT TTCCGCTTCT GCAGCGGCTC CTGCCGCCGC GCGCGCTCTC 1260 CACACGACCT CAGCCTGGCC AGCCTACTGG GCGCCGGGGC CCTGCGACCG CCCCCGGGCT 1320 CCCGGCCCGT CAGCCAGCCC TGCTGCCGAC CCACGCGCTA CGAAGCGGTC TCCTTCATGG 1380 ACGTCAACAG CACCTGGAGA ACCGTGGACC GCCTCTCCGC CACCGCCTGC GGCTGCCTGG 1440 GCTGAGGGCT CGCTCCAGGG CTTTGCAGAC TGGACCCTTA CCGGTGGCTC TTCCTGCCTG 1500 GGACCCTCCC GCAGAGTCCC ACTAGCCAGC GGCCTCAGCC AGGGACGAAG GCCTCAAAGC 1560 TGAGAGGCCC CTACCGGTGG GTGATGGATA TCATCCCCGA ACAGGTGAAG GGACAACTGA 1620 CTAGCAGCCC CAGAGCCCTC ACCCTGCGGA TCCCAGCCTA AAAGACACCA GAGACCTCAG 1680 CTATGGAGCC CTTCGGACCC ACTTCTCACA GACTCTGGCA CTGGCCAGGC CTCGAACCTG 1740 GGACCCCTCC TCTGATGAAC ACTACAGTGG CTGAGGCATC AGCCCCCGCC CAGGCCCTGT 1800 AGGGACAGCA TTTGAAGGAC ACATATTGCA GTTGCTTGGT TGAAAGTGCC TGTGCTGGAA 1860 CTGGCCTGTA CTCACTCATG GGAGCTGGCC CC Seq ID NO : 605 Protein sequence Protein Accession # : NP 003967. 1 1 11 21 31 41 51 MELGLGGLST LSHCPWPRRQ PALWPTLAAL ALLSSVAEAS LGSAPRSPAP REGPPPVLAS 60 PAGHLPGGRT ARWCSGRARR PPPQPSRPAP PPPAPPSALP RGGRAARAGG PGSRARAAGA 120 RGCRLRSQLV PVRALGLGHR SDELVRFRFC SGSCRRARSP HDLSLASLLG AGALRPPPGS 180 RPVSQPCCRP TRYEAVSFMD VNSTWRTVDR LSATACGCLG Seq ID NO : 606 DNA sequence Nucleic Acid Accession # : NM 057160. 1

GGCAAGAATA GCCTCACCCA CATCTCACCC AGGGTCTTCC AGCACCTGGG CAATCTCCAG 600 GTCCTCCGGC TGTATGAGAA CAGGCTCACG GATATCCCCA TGGGCACTTT TGATGGGCTT 660 GTTAACCTGC AGGAACTGGC TCTACAGCAG AACCAGATTG GACTGCTCTC CCCTGGTCTC 720 TTCCACAACA ACCACAACCT CCAGAGACTC TACCTGTCCA ACAACCACAT CTCCCAGCTG 780 CCACCCAGCA TCTTCATGCA GCTGCCCCAG CTCAACCGTC TTACTCTCTT TGGGAATTCC 840 CTGAAGGAGC TCTCTCTGGG GATCTTCGGG CCCATGCCCA ACCTGCGGGA GCTTTGGCTC 900 TATGACAACC ACATCTCTTC TCTACCCGAC AATGTCTTCA GCAACCTCCG CCAGTTGCAG 960 GTCCTGATTC TTAGCCGCAA TCAGATCAGC TTCATCTCCC CGGGTGCCTT CAACGGGCTA 1020 ACGGAGCTTC GGGAGCTGTC CCTCCACACC AACGCACTGC AGGACCTGGA CGGGAATGTC 1080 TTCCGCATGT TGGCCAACCT GCAGAACATC TCCCTGCAGA ACAATCGCCT CAGACAGCTC 1140 CCAGGGAATA TCTTCGCCAA CGTCAATGGC CTCATGGCCA TCCAGCTGCA GAACAACCAG 1200 CTGGAGAACT TGCCCCTCGG CATCTTCGAT CACCTGGGGA AACTGTGTGA GCTGCGGCTG 1260 TATGACAATC CCTGGAGGTG TGACTCAGAC ATCCTTCCGC TCCGCAACTG GCTCCTGCTC 1320 AACCAGCCTA GGTTAGGGAC GGACACTGTA CCTGTGTGTT TCAGCCCAGC CAATGTCCGA 1380 GGCCAGTCCC TCATTATCAT CAATGTCAAC GTTGCTGTTC CAAGCGTCCA TGTCCCTGAG 1440 GTGCCTAGTT ACCCAGAAAC ACCATGGTAC CCAGACACAC CCAGTTACCC TGACACCACA 1500 TCCGTCTCTT CTACCACTGA GCTAACCAGC CCTGTGGAAG ACTACACTGA TCTGACTACC 1560 ATTCAGGTCA CTGATGACCG CAGCGTTTGG GGCATGACCC AGGCCCAGAG CGGGCTGGCC 1620 ATTGCCGCCA TTGTAATTGG CATTGTCGCC CTGGCCTGCT CCCTGGCTGC CTGCGTCGGC 1680 TGTTGCTGCT GCAAGAAGAG GAGCCAAGCT GTCCTGATGC AGATGAAGGC ACCCAATGAG 1740 TGTTAAAGAG GCAGGCTGGA GCAGGGCTGG GGAATGATGG GACTGGAGGA CCTGGGAATT 1800 TCATCTTTCT GCCTCCACCC CTGGGTCCAT GGAGCTTTCC CGTGATTGCT CTTTCTGGCC 1860 CTAGATAAAG GTGTGCCTAC CTCTTCCTGA CTTGCCTGAT TCTCCCGTAG AGAAGCAGGT 1920 CGTGCCGGAC CTTCCTACAA TCAGGAAGAT AGATCCAACT GGCCATGGCA AAAGCCCTGG 1980 GGATTTCCGA TTCATACCCC TGGGCTTCCT TCGAGAGGGC TCTTCCTCCA AATCCTCCCC 2040 ACCTGTCCTC CAAGAACAGC CTTCCCTGCG CCCAGGCCCC CTCCGGGCCT CTGTAGACTC 2100 AGTTAGTCCA CAGCCTGCTC ACTTCGTGGG AATAGTTCTC CGCTGAGATA GCCCCTCTCG 2160 CCTAAGTATT ATGTAAGTTG ATTTCCCTTC TTTTGTTTCT CTTGTTTGTG CTATGGCTTG 2220 ACCCAGCATG TCCCCTCAAA TGAAAGTTCT CCCCTTGATT TTCTGCTCCT GAAGGCAGGG 2280 TGAGTTCTCT CCTCAAAGAA GACTTCAAAC CATTTAACTG GTTTCTTAAG AGCCGTCAAT 2340 CAGCCTGGTT TTGGGGATGC TATGAAAGAG AGAAGGAAAA TCATGCCGCT CAGTTCCTGG 2400 AGACAGAAGA GCCGTCATCA GTGTCTCACT TGTGATTTTT ATCTGGAAAA GGAAGAAACA 2460 CCCCAGCACA GCAAGCTCAG CCTTTTAGAG AAGGATATTT CCAAACTGCA AACTTTGCTT 2520 TGAAAAGTTT AGCCCTTTAA GGAATGAAAT CATGTAGAAT TTTGGACTTC TAAAAACATT 2580 AAAATCAGCT TATTAATACG GGATAGAGAA AGAAATCTGG TGCCTGGGGG TCCCTGTGTT 2640 CACCCCTAGA GTTTGTTTTA AAATTTTTAA TTGAAGCATG TGAAGTGTAC STGCAGAAAA 2700 GTGGGAACAT GATAGTGTAT GGCTTGGTGG ATTTTCACAA ACTGAACATA CCTGTGTAAT 2760 CAGCATCTAG ACCCAGACCC AGAGCATCAC AAATATCCCC CATCCTGGGC TTTTCCCAGA 2820 GGAGATGGGG GCTTCTGAAG ATGGACTTAC CTGGGACCTG CCCCCCATGA GCCAGGACGG 2880 TCCCCCCACA GTCAGCCTGT GCAAAGGCCC CGTGGCCAGG GGTGGAGGAG AATATGTGGG 2940 TGTGGACAGG ATGGGAGACT GTGGCCTGAA CAGGAGATTT TATTATATCT GGAGACCCTG 3000 AGAGACCCTG AGACCTGGGG CACCATGGCT GGCCAGGTCA GAAGCATCCT GACTGCAGAG 3060 GTCCGTGCAG CCACACCCTC TTCCCTGCCA GCAAGTTGTC TGCGGCTCAT CGGAGGCCCC 3120 TCCGCCTGGA GCCTTCTATG GACGTGATAT GCCTGTATCT GTTTTTAATT TTCATTCTTC 3180 ACTTAGGGGA AGTGAAATCG CTCAGAGATG AGATCCTTTA ATTGAAAACG AAGTGTAACG 3240 GAATCTAGTG TCTTTCTAAT GTGGTAAAAT TCTCCATCAA CATCACAGTC AGCTGGCAGC 3300 TGAACTTCAG AATCTCACTT ACAGCAGGCG ACACGGGGGT ACACCGATGG GTCACACTGG 3360 GTCTGGGGGC TCCCTGGAGC TCCTCCTGCG TGTGGTCTGG TTAGGAGTTG AGTTGTTTGC 3420 TCCAGGGTTA TTCTCCTCCT CGAGTCACAG TCACACGAAT ACCTGCCTTC TCTGGCTTTC 3480 CTGCTATACA CATATTCACA TGGCGCTCAA GAAGTTAGGC TCATGGCAAC GTGTGTCTTT 3540 CTCTGGACAA CTGGCCCAGT TTACAGTGAA ATGGAGAATT TCAGGTCTCC ACGTCTGCCC 3600 AGGAAAGAAC TTCAGCTGAC TCCACGGGGA TCTGGAAATC CACGACCAAT CCCGATCGGC 3660 TCTTATTAGC TCCCCGCTCC ACAAGACACC TGTGCTTTGG AAATCCACCA CCAATCCCGA 3720 TCGGCTCTTA TTAGCTCCCC GCTCCACAAG ACACCTGTGA TCTGGAAATC TACCACCAAT 3780 CCCGATCGGC TCTTATTAGC TCCCCGCTCC ACAAGACACC TGTGACATCC TCCAGGGCCA 3840 CAGGAGCACG TGCTGACCAG TTTTCCCTTC CAGTTCCTGC ACAAAAAGTG TCCAGAGGGC 3900 TGTTTGCAAA CACTAGTGCA CTTTGTAGCT TTTCACCCTC TGTCCCAGGG AATCTAGGAG 3960 AGATGAGGCC CGTCAGAGTC AAGAGATGTC ATCCCCCCAG GGTCTCCAAG GCATTTCCAC 4020 ACTATTGGTG GCACCTGGAG GACATGCACC AAGGCTTGCC AGAGCCAACA GGAAGTGAGC 4080 CCAGAGCATG GCACATGAGC ATCACCCGCT GATGGTGGCC TGCTGTGCCT GGTGCCAACA 4140 GGGGCATCCC GGCCCGTACC CCTCCAGACA GGAAGCATGG GTTTGCCCAC AGACCTGTCG 4200 GGTGCTCCTG TGAGTGGCCT CCAGATGTCT TTGTGCATAG GCACAAGTGG GCCAGGGCTG 4260 GAGGGAGGTG GGAAACCTCA TCATCCGGTG GGCCCTGCCA ATCTTAACCC AGAACCCTTA 4320 GGTATTCCTG GCAGTAGCCA TGACATTGGA GCACCTTCCT CTCCAGCCAG AGGCTGACCT 4380 GAGGGCCACT GTCCTCAGAT GACACCACCC AGGAGCACCC TAGGTGAGGG GTGAGGGCCC 4440 CCTTATGTGA ACCTCTTGCC TCTTCCTTTC TCCCATCAGA GTGGTTGGAT GGAGCCATTG 4500 GCCTCCTTTT CTTCAGCGGG CCCTTCAACC TCTCTGCACC ATGTTGTCTG GCTGAGGAGC 4560 TACTAGAAAA GCTGAGTGGA GTCTCCTTTC CAACAGGATG ATGCATTTGC TCAATTCTCA 4620 GGGCTGGAAT GAGCCGGCTG GTCCCCCAGA AAGCTGGAGT GGGGTACAGA GTTCAGTTTT 4680 CCTCTCTGTT TACAGCTCCT TGACAGTCCC ACGCCCATCT GGAGTGGGAG CTGGGAGTTA 4740 GTGTTGGAGA AGAAACAACA AAAGCCAATT AGAACCACTA TTTTTAAAAA GTGCTTACTG 4800 TGCACAGATA CTCTTCAAGC ACTGGACGTG GATTCTCTCT CTAGCCCTCA GCACCCCTGC 4860 GGTAGGAGTG CCGCCTCTAC CCACTTGTGA TGGGGTACAG AGGCACTTGC TCTTCTGCAT 4920 GGTGTTCAAT AGGCTGGGAG TTTTATTTAT CTCTTCAAAC TTTGTACAAG AGCTCATGGC 4980 TTGTCTTGGG CTTTCGTCAT TAAACCAAAG GAAATGGAAG CCATTCCCCT GTTGCTCTCC 5040 TTAGTCTTGG TCATCAGAAC CTCACTTGGT ACCATATAGA TCAAAAGCTT TGTAACCACA 5100 <BR> <BR> GGAAAAAATA AACTCTTCCA TCCCTTAAAG AATAGAATAG TTTGTCCCTC TCATGGGAAT 5160 TGGGCTGTAT GTATATTGTT CTTCCTCCTT AGAATTTAGA GATACAAGAG TTCTACTTAG 5220 AACTTTTCAT GGACACAATT TCCACAACCT TTCAGATGCT GATGTAGAGC TATTGGGAAA 5280 GAACTTCCAA ACTCAGGAAG TTTGCAGAGA GCAGACAGCT AGAGATAACT CGGGACCCAG 5340 AGTTGGTCGA CAGATGTTAG ATGTATCCTA GCTTTTAGCC ATAAACCACT CAAAGATTCA 5400 GCCCCCAGAT CCCACAGTCA GAACTGAATC TGCGTTGTTG GGAAGCCAGC AGTGGCCTTG 5460 GGAAGGAAGC CATGGCTGTG GTTCAGAGAG GGTGGGCTGG CAAGCCACTT CCGGGGAAAA 5520 CTCCTTCCGC CCCAGGTTTC TTCTTCTCTT AAGGAGAGAT TGTTCTCACC AACCCGCTGC 5580 CTTCATGCTG CCTTCAAAGC TAGATCATGT TTGCCTTGCT TAGAGAATTA CTGCAAATCA 5640 GCCCCAGTGC TTGGCGATGC ATTTACAGAT TTCTAGGCCC TCAGGGTTTT GTAGAGTGTG 5700 AGCCCTGGTG GGCAGGGTTG GGGGGTCTGT CTTCTGCTGG ATGCTGCTTG TAATCCATTT 5760

GGTGTACAGA ATCAACAATA AATAATATAC ATGTAT Seq ID NO: 611 Protein sequence Protein Accession # : BAB84587. 1 1 11 21 31 41 51 MPLKHYLLLL VGCQAWGAGL AYHGCPSECT CSRASQVECT GARIVAVPTP LPWNAMSLQI 60 LNTHITELNE SPFLNISALI ALRIEKNELS RITPGAFRNL GSLRYLSLAN NKLQVLPIGL 120 FQGLDSLESL LLSSNQLLQI QPAHFSQCSN LKELQLHGNH LEYIPDGAFD HLVGLTKLNL 180 GKNSLTHISP RVFQHLGNLQ VLRLYENRLT DIPMGTFDGL VNLQELALQQ NQIGLLSPGL 240 FHNNHNLQRL YLSNNHISQL PPSIFMQLPQ LNRLTLFGNS LKELSLGIFG PMPNLRELWL 300 YDNHISSLPD NVFSNLRQLQ VLILSRNQIS FISPGAFNGL TELRELSLHT NALQDLDGNV 360 FRMLANLQNI SLQNNRLRQL PGNIFANVNG LMAIQLQNNQ LENLPLGIFD HLGKLCELRL 420 YDNPWRCDSD ILPLRNWLLL NQPRLGTDTV PVCFSPANVR GQSLIIINVN VAVPSVHVPE 480 VPSYPETPWY PDTPSYPDTT SVSSTTELTS PVEDYTDLTT IQVTDDRSVW GMTQAQSGLA 540 IAAIVIGIVA LACSLAACVG CCCCKKRSQA VLMQMKAPNE C Seq ID NO : 612 DNA sequence Nucleic Acid Accession # : XM 098151 Coding sequence : 1.. 447 1 11 21 31 41 51 ATGATGCATT TGCTCAATTC TCAGGGCTGG AATGAGCCGG CTGGTCCCCC AGAAAGCTGG 60 AGTGGGGTAC AGAGTTCAGT TTTCCTCTCT GTTTACAGCT CCTTGACAGT CCCACGCCCA 120 TCTGGAGTGG GAGCTGGGAG TCAGTGTTGG AGAAGAAACA ACAAAAGCCA ATTAGAACCA 180 CTATTTTTAA AAAGTGCTTA CTGTGCACAG ATACTCTTCA AGCACTGGAC GTGGATTCTC 240 TCTCTAGCCC TCAGCACCCC TGCGGTAGGA GTGCCGCCTC TACCCACTTG TGATGGGGTA 300 CAGAGGCACT TGCTCTTCTG CATGGTGTTC AATAGGCTGG GAGTTTTATT TATCTCTTCA 360 AACTTTGTAC AAGAGCTCAT GGCTTGTCTT GGGCTTTCGT CATTAAACCA AAGGAAATGG 420 AAGCCATTCC CCTGTTGCTC TCCTTAG Seq ID NO : 613 Protein sequence Protein Accession &num : XP 098151 1 11 21 31 41 51 1 1 1 1 1 1 MMHLLNSQGW NEPAGPPESW SGVQSSVFLS VYSSLTVPRP SGVGAGSQCW RRNNKSQLEP 60 LFLKSAYCAQ ILFKHWTWIL SLALSTPAVG VPPLPTCDGV QRHLLFCMVF NRLGVLFISS 120 NFVQELMACL GLSSLNQRKW KPFPCCSP Seq ID NO: 614 DNA sequence Nucleic Acid Accession # : NM 002658. 1 Coding sequence: 77.. 1372 1 11 21 31 41 51 # # # # # # GTCCCCGCAG CGCCGTCGCG CCTCCTGCC GCAGGCCACC GAGGCCGCCG CCGTCTAGCG 60 CCCCGACCTC GCCACCATGA GAGCCCTGCT GGCGCGCCTG CTTCTCTGCG TCCTGGTCGT 120 GAGCGACTCC AAAGGCAGCA ATGAACTTCA TCAAGTTCCA TCGAACTGTG ACTGTCTAAA 180 TGGAGGAACA TGTGTGTCCA ACAAGTACTT CTCCAACATT CACTGGTGCA ACTGCCCAAA 240 GAAATTCGGA GGGCAGCACT GTGAAATAGA TAAGTCAAAA ACCTGCTATG AGGGGAATGG 300 TCACTTTTAC CGAGGAAAGG CCAGCACTGA CACCATGGGC CGGCCCTGCC TGCCCTGGAA 360 CTCTGCCACT GTCCTTCAGC AAACGTACCA TGCCCACAGA TCTGATGCTC TTCAGCTGGG 420 CCTGGGGAAA CATAATTACT GCAGGAACCC AGACAACCGG AGGCGACCCT GGTGCTATGT 480 GCAGGTGGGC CTAAAGCCGC TTGTCCAAGA GTGCATGGTG CATGACTGCG CAGATGGAAA 540 AAAGCCCTCC TCTCCTCCAG AAGAATTAAA ATTTCAGTGT GGCCAAAAGA CTCTGAGGCC 600 CCGCTTTAAG ATTATTGGGG GAGAATTCAC CACCATCGAG AACCAGCCCT GGTTTGCGGC 660 CATCTACAGG AGGCACCGGG GGGGCTCTGT CACCTACGTG TGTGGAGGCA GCCTCATCAG 720 CCCTTGCTGG GTGATCAGCG CCACACACTG CTTCATTGAT TACCCAAAGA AGGAGGACTA 780 CATCGTCTAC CTGGGTCGCT CAAGGCTTAA CTCCAACACG CAAGGGGAGA TGAAGTTTGA 840 GGTGGAAAAC CTCATCCTAC ACAAGGACTA CAGCGCTGAC ACGCTTGCTC ACCACAACGA 900 CATTGCCTTG CTGAAGATCC GTTCCAAGGA GGGCAGGTGT GCGCAGCCAT CCCGGACTAT 960 ACAGACCATC TGCCTGCCCT CGATGTATAA CGATCCCCAG TTTGGCACAA GCTGTGAGAT 1020 CACTGGCTTT GGAAAAGAGA ATTCTACCGA CTATCTCTAT CCGGAGCAGC TGAAAATGAC 1080 TGTTGTGAAG CTGATTTCCC ACCGGGAGTG TCAGCAGCCC CACTACTACG GCTCTGAAGT 1140 CACCACCAAA ATGCTATGTG CTGCTGACCC CCAATGGAAA ACAGATTCCT GCCAGGGAGA 1200 CTCAGGGGGA CCCCTCGTCT GTTCCCTCCA AGGCCGCATG ACTTTGACTG GAATTGTGAG 1260 CTGGGGCCGT GGATGTGCCC TGAAGGACAA GCCAGGCGTC TACACGAGAG TCTCACACTT 1320 CTTACCCTGG ATCCGCAGTC ACACCAAGGA AGAGAATGGC CTGGCCCTCT GAGGGTCCCC 1380 AGGGAGGAAA CGGGCACCAC CCGCTTTCTT GCTGGTTGTC ATTTTTGCAG TAGAGTCATC 1440 TCCATCAGCT GTAAGAAGAG ACTGGGAAGA TAGGCTCTGC ACAGATGGAT TTGCCTGTGG 1500 CACCACCAGG GTGAACGACA ATAGCTTTAC CCTCACGGAT AGGCCTGGGT GCTGGCTGCC 1560 CAGACCCTCT GGCCAGGATG GAGGGGTGGT CCTGACTCAA CATGTTACTG ACCAGCAACT 1620 TGTCTTTTTC TGGACTGAAG CCTGCAGGAG TTAAAAAGGG CAGGGCATCT CCTGTGCATG 1680 GGCTCGAAGG GAGAGCCAGC TCCCCCGACC GGTGGGCATT TGTGAGGCCC ATGGTTGAGA 1740 AATGAATAAT TTCCCAATTA GGAAGTGTAA GCAGCTGAGG TCTCTTGAGG GAGCTTAGCC 1800 AATGTGGGAG CAGCGGTTTG GGGAGCAGAG ACACTAACGA CTTCAGGGCA GGGCTCTGAT 1860 ATTCCATGAA TGTATCAGGA AATATATATG TGTGTGTATG TTTGCACACT TGTTGTGTGG 1920 GCTGTGAGTG TAAGTGTGAG TAAGAGCTGG TGTCTGATTG TTAAGTCTAA ATATTTCCTT 1980 AAACTGTGTG GACTGTGATG CCACACAGAG TGGTCTTTCT GGAGAGGTTA TAGGTCACTC 2040 CTGGGGCCTC TTGGGTCCCC CACGTGACAG TGCCTGGGAA TGTACTTATT CTGCAGCATG 2100 ACCTGTGACC AGCACTGTCT CAGTTTCACT TTCACATAGA TGTCCCTTTC TTGGCCAGTT 2160 ATCCCTTCCT TTTAGCCTAG TTCATCCAAT CCTCACTGGG TGGGGTGAGG ACCACTCCTT 2220 ACACTGAATA TTTATATTTC ACTATTTTTA TTTATATTTT TGTAATTTTA AATAAAAGTG 2280 ATCAATAAAA TGTGATTTTT CTGA

KKRHTKEKVL RRAKRRWAPI PCSMLENSLG PFPLFLQQVQ SDTAQNYTIY YSIRGPGVDQ ISO EPRNLFYVER DTGNLYCTRP VDREQYESFE IIAFATTPDG YTPELPLPLI IKIEDENDNY 240 PIFTEETYTF TIFENCRVGT TVGQVCATDK DEPDTMHTRL KYSIIGQVPP SPTLFSMHPT 300 TGVITTTSSQ LDRELIDKYQ LKIKVQDMDG QYFGLQTTST CIINIDDVND HLPTFTRTSY 360 VTSVEENTVD VEILRVTVED KDLVNTANWR ANYTILKGNE NGNFKIVTDA KTNEGVLCVV 420 KPLNYEEKQQ MILQIGWNE APFSREASPR SAMSTATVTV NVEDQDEGPE CNPPIQTVRM 480 KENAEVGTTS NGYKAYDPET RSSSGIRYKK LTDPTGWVTI DENTGSIKVF RSLDREAETI 540 KNGIYNITVL ASDQGGRTCT GTLGIILQDV NDNSPFIPKK TVIICKPTMS SAEIVAVDPD 600 EPIHGPPFDF SLESSTSEVQ RMWRLKAIND TAARLSYQND PPFGSYWPI TVRDRLGMSS 660 VTSLDVTLCD CITENDCTHR VDPRIGGGGV QLGKWAILAI LLGIALLFCI LFTLVCGASG 720 TSKQPKVIPD DLAQQNLIVS NTEAPGDDKV YSANGFTTQT VGASAQGVCG TVGSGIKNGG 780 QETIEMVKGG HQTSESCRGA GHHHTLDSCR GGHTEVDNCR YTYSEWHSFT QPRLGEKVYL 840 CNQDENHKHA QDYVLTYNYE GRGSVAGSVG CCSERQEEDG LEFLDNLEPK FRTLAEACMK 900 R Seq ID NO: 618 DNA sequence Nucleic Acid Accession &num : NM 004949. 1 Coding sequence: 202.. 2745 1 11 21 31 41 51 # # # # # # CGCCAAAGGA AAAGCCCCTT GGATGAGAGG CAGGCGCTTC AGAGAAGCTA AGAAAAGCAC 60 CTCTCCGCGC GCCCCACCTC CTCCGCCTCG CGCTCCTCCT GAGCAGCGGG CCCAGACTGC 120 GCTCCGGCCG CGGCCCTCGC CCCGCGGAGC CCTCCTACCC CGGCCCGACG CTCGGCCCGC 180 GACCTGCCCC GAGCCCTCTC CATGGAGGCA GCCCGCCCCT CCGGCTCCTG GAACGGAGCC 240 CTCTGCCGGC TGCTCCTGCT GACCCTCGCG ATCTTAATAT TTGCCAGTGA TGCCTGCAAA 300 AATGTGACAT TACATGTTCC CTCCAAACTA GATGCCGAGA AACTTGTTGG TAGAGTTAAC 360 CTGAAAGAGT GCTTTACAGC TGCAAATCTA ATTCATTCAA GTGATCCTGA CTTCCAAATT 420 TTGGAGGATG GTTCAGTCTA TACAACAAAT ACTATTCTAT TGTCCTCGGA GAAGAGAAGT 480 TTTACCATAT TACTTTCCAA CACTGAGAAC CAAGAAAAGA AGAAAATATT TGTCTTTTTG 540 GAGCATCAAA CAAAGGTCCT AAAGAAAAGA CATACTAAAG AAAAAGTTCT AAGGCGCGCC 600 AAGAGAAGAT GGGCTCCAAT TCCTTGTTCG ATGCTAGAAA ACTCCTTGGG TCCTTTTCCA 660 CTTTTCCTTC AACAGGTTCA ATCTGACACG GCCCAAAACT ATACCATATA CTATTCCATA 720 AGAGGTCCTG GAGTTGACCA AGAACCTCGG AATTTATTTT ATGTGGAGAG AGACACTGGA 780 AACTTGTATT GTACTCGTCC TGTAGATCGT GAGCAGTATG AATCTTTTGA GATAATTGCC 840 TTTGCAACAA CTCCAGATGG GTATACTCCA GAACTTCCAC TGCCCCTAAT AATCAAAATA 900 GAGGATGAAA ATGATAACTA CCCAATTTTT ACAGAAGAAA CTTATACTTT TACAATTTTT 960 GAAAATTGCA GAGTGGGCAC TACTGTGGGA CAAGTGTGTG CTACTGACAA AGATGAGCCT 1020 GACACGATGC ACACACGCCT GAAGTACTCC ATCATTGGGC AGGTGCCACC ATCACCCACC 1080 CTATTTTCTA TGCATCCAAC TACAGGCGTG ATCACCACAA CATCATCTCA GCTAGACAGA 1140 GAGTTAATTG ACAAGTACCA GTTGAAAATA AAAGTACAAG ACATGGATGG TCAGTATTTT 1200 GGTCTACAGA CAACTTCAAC TTGTATCATT AACATTGATG ATGTAAATGA CCACTTGCCA 1260 ACATTTACTC GTACTTCTTA TGTGACATCA GTGGAAGAAA ATACAGTTGA TGTGGAAATC 1320 TTACGAGTTA CTGTTGAGGA TAAGGACTTA GTGAATACTG CTAACTGGAG AGCTAATTAT 1380 ACCATTTTAA AGGGCAATGA AAATGGCAAT TTTAAAATTG TAACAGATGC CAAAACCAAT 1440 GAAGGAGTTC TTTGTGTAGT TAAGCCTTTG AATTATGAAG AAAAGCAACA GATGATCTTG 1500 CAAATTGGTG TAGTTAATGA AGCTCCATTT TCCAGAGAGG CTAGTCCAAG ATCAGCCATG 1560 AGCACAGCAA CAGTTACTGT TAATGTAGAA GATCAGGATG AGGGCCCTGA GTGTAACCCT 1620 CCAATACAGA CTGTTCGCAT GAAAGAAAAT GCAGAAGTGG GAACAACAAG CAATGGATAT 1680 AAAGCATATG ACCCAGAAAC AAGAAGTAGC AGTGGCATAA GGTATAAGAA ATTAACTGAT 1740 CCAACAGGGT GGGTCACCAT TGATGAAAAT ACAGGATCAA TCAAAGTTTT CAGAAGCCTG 1800 GATAGAGAGG CAGAGACCAT CAAAAATGGC ATATATAATA TTACAGTCCT TGCATCAGAC 1860 CAAGGAGGGA GAACATGTAC GGGGACACTG GGCATTATAC TTCAAGACGT GAATGATAAC 1920 AGCCCATTCA TACCTAAAAA GACAGTGATC ATCTGCAAAC CCACCATGTC ATCTGCGGAG 1980 ATTGTTGCGG TTGATCCTGA TGAGCCTATC CATGGCCCAC CCTTTGACTT TAGTCTGGAG 2040 AGTTCTACTT CAGAAGTACA GAGAATGTGG AGACTGAAAG CAATTAATGA TACAGCAGCA 2100 CGTCTTTCCT ATCAGAATGA TCCTCCATTT GGCTCATATG TAGTACCTAT AACAGTGAGA 2160 GATAGACTTG GCATGTCTAG TGTCACTTCA TTGGATGTTA CACTGTGTGA CTGCATTACC 2220 GAAAATGACT GCACACATCG TGTAGATCCA AGGATTGGCG GTGGAGGAGT ACAACTTGGA 2280 AAGTGGGCCA TCCTTGCAAT ATTGTTGGGC ATAGCATTGC TCTTTTGCAT CCTGTTTACG 2340 CTGGTCTGTG GGGCTTCTGG GACGTCTAAA CAACCAAAAG TAATTCCTGA TGATTTAGCC 2400 CAGCAGAACC TAATTGTATC AAACACAGAA GCTCCTGGAG ATGACAAAGT GTATTCTGCG 2460 AATGGCTTCA CAACCCAAAC TGTGGGCGCT TCTGCTCAGG GAGTTTGTGG CACCGTGGGA 2520 TCAGGAATCA AAAACGGAGG TCAGGAGACC ATCGAAATGG TGAAAGGAGG ACACCAGACC 2580 TCGGAATCCT GCCGGGGGGC TGGCCACCAT CACACCCTGG ACTCCTGCAG GGGAGGACAC 2640 ACGGAGGTGG ACAACTGCAG ATACACTTAC TCGGAGTGGC ACAGTTTTAC TCAGCCCCGT 2700 CTTGGTGAAG AATCCATTAG AGGACACACT CTGATTAAAA ATTAAACAAT GAAAGAAAGT 2760 GTATCTGTGT AATCAAGATG AAAATCACAA GCATGCCCAA GACTATGTCC TGACATATAA 2820 CTATGAAGGA AGAGGATCGG TGGCTGGGTC TGTAGGTTGT TGCAGTGAAC GACAAGAAGA 2880 AGATGGGCTT GAATTTTTGG ATAATTTGGA GCCCAAATTT AGGACACTAG CAGAAGCATG 2940 CATGAAGAGA TGAGTGTGTT CTAATAAGTC TCTGAAAGCC AGTGGCTTTA TGACTTTTAA 3000 AAAAAATTAC AAACCAAGAA TTTTTTAAAG CAGAAGATGC TATTTGTGGG GGTTTTTCTC 3060 TCATTATTTG GATGGAATCT CTTTGGTCAA ATGCACATTT ACAGAGAGAC ACTATAAACA 3120 AGTACACAAA TTTTTCAATT TTTACATATT TTTAAATTAC TTATCTTCTA TCCAAGGAGG 3180 TCTACAGAGA AATTAAAGTC TGCCTTATTT GTTACATTTG GGTATAATGA CAACAGCCAA 3240 TTTATAGTGC AATAAAATGT AATTAATTCA AGTCCTTATT ATAGACTATT TGAAGCACAA 3300 CCTAATGGAA AATTGTAGAG ACCTTGCTTT AACATTATCT CCAGTTAATT AAGTGTTCAT 3360 GTGGTGCTTG GAAACTGTTG TTTTCCTGAA CATCTAAAGT GTGTAGACTG CATTCTTGCT 3420 ATTATTTTAT TCTTGTAATG TGACCTTTTC ACTGTGCAAA GGGAGATTTC TAGCCAGGCA 3480 TTGACTATTA CAATTTCATT Seq ID NO : 619 Protein sequence Protein Accession # : NP 004940. 1 1 11 21 31 41 51 MEAARPSGSW NGALCRLLLL TLAILIFASD ACKNVTLHVP SKLDAEKLVG RVNLKECFTA 60

ANLIHSSDPD FQILEDGSVY TTNTILLSSE KRSFTILLSN TENQEKKKIF VFLEHQTKVL 120 KKRHTKEKVL RRAKRRWAPI PCSMLENSLG PFPLFLQQVQ SDTAQNYTIY YSIRGPGVDQ 180 EPRNLFYVER DTGNLYCTRP VDREQYESFE IIAFATTPDG YTPELPLPLI IKIEDENDNY 240 PIFTEETYTF TIFENCRVGT TVGQVCATDK DEPDTMHTRL KYSIIGQVPP SPTLFSMHPT 300 TGVITTTSSQ LDRELIDKYQ LKIKVQDMDG QYFGLQTTST CIINIDDVND HLPTFTRTSY 360 VTSVEENTVD VEILRVTVED KDLVNTANWR ANYTILKGNE NGNFKIVTDA KTNEGVLCVV 420 KPLNYEEKQQ MILQIGWNE APFSREASPR SAMSTATVTV NVEDQDEGPE CNPPIQTVRM 480 KENAEVGTTS NGYKAYDPET RSSSGIRYKK LTDPTGWVTI DENTGSIKVF RSLDREAETI 540 KNGIYNITVL ASDQGGRTCT GTLGIILQDV NDNSPFIPKK TVIICKPTMS SAEIVAVDPD 600 EPIHGPPFDF SLESSTSEVQ RMWRLKAIND TAARLSYQND PPFGSYVVPI TVRDRLGMSS 660 VTSLDVTLCD CITENDCTHR VDPRIGGGGV QLGKWAILAI LLGIALLFCI LFTLVCGASG 720 TSKQPKVIPD DLAQQNLIVS NTEAPGDDKV YSANGFTTQT VGASAQGVCG TVGSGIKNGG 780 QETIEMVKGG HQTSESCRGA GHHHTLDSCR GGHTEVDNCR YTYSEWHSFT QPRLGEESIR 840 GHTLIKN Seq ID NO: 620 DNA sequence Nucleic Acid Accession &num : NM 032545. 1 Coding sequence: 46.. 718 1 11 21 31 41 51 # # # # # # AAACTGATCT TCAATGCACT AAGAGAAGGA GACTCTCAAA CCAAAATGA CCTGGAGGCA 60 CCATGTCAGG CTTCTGTTTA CGGTCAGTTT GGCATTACAG ATCATCAATT TGGGAAACAG 120 CTATCAAAGA GAGAAACATA ACGGCGGTAG AGAGGAAGTC ACCAAGGTTG CCACTCAGAA 180 GCACCGACAG TCACCGCTCA ACTGGACCTC CAGTCATTTC GGAGAGGTGA CTGGGAGCGC 240 CGAGGGCTGG GGGCCGGAGG AGCCGCTCCC CTACTCCCGG GCTTTCGGAG AGGGTGCGTC 300 CGCGCGGCCG CGCTGCTGCA GGAACGGCGG TACCTGCGTG CTGGGCAGCT TCTGCGTGTG 360 CCCGGCCCAC TTCACCGGCC GCTACTGCGA GCATGACCAG AGGCGCAGTG AATGCGGCGC 420 CCTGGAGCAC GGAGCCTGGA CCCTCCGCGC CTGCCACCTC TGCAGGTGCA TCTTCGGGGC 480 CCTGCACTGC CTCCCCCTCC AGACGCCTGA CCGCTGTGAC CCGAAAGACT TCCTGGCCTC 540 CCACGCTCAC GGGCCGAGCG CCGGGGGCGC GCCCAGCCTG CTACTCTTGC TGCCCTGCGC 600 ACTCCTGCAC CGCCTCCTGC GCCCGGATGC GCCCGCGCAC CCTCGGTCCC TGGTCCCTTC 660 CGTCCTCCAG CGGGAGCGGC GCCCCTGCGG AAGGCCGGGA CTTGGGCATC GCCTTTAATT 720 TTCTATGTTG TAAATAATAG ATGTGTTTAG TTTACCGTAA GCTGAAGCAC TGGGTGAATA 780 TTTTTATTGG GTAATAAATA TTTTCATGAA AGCGCCAAAA AAAAAAAAAA AAAAAAAAAA 840 AAAAAA Seq ID NO: 621 Protein sequence Protein Accession &num : NP 115934. 1 1 11 21 31 41 51 MTWRHHVRLL FTVSLALQII NLGNSYQREK HNGGREEVTK VATQKHRQSP LNWTSSHFGE 60 VTGSAEGWGP EEPLPYSRAF GEGASARPRC CRNGGTCVLG SFCVCPAHFT GRYCEHDQRR 120 SECGALEHGA WTLRACHLCR CIFGALHCLP LQTPDRCDPK DFLASHAHGP SAGGAPSLLL 180 LLPCALLHRL LRPDAPAHPR SLVPSVLQRE RRPCGRPGLG HRL Seq ID NO : 622 DNA sequence Nucleic Acid Accession # : FGENESH predicted Coding sequence: 1.. 390 1 11 21 31 41 51 <BR> <BR> <BR> <BR> <BR> ATGAGGTTCA GTGTCTCAGG CATGAGGACC GACTACCCCA GGAGTGTGCT GGCTCCTGCT 60 TATGTGTCAG TCTGTCTCCT CCTCTTGTGT CCAAGGGAAG TCATCGCTCC CGCTGGCTCA 120 GAACCATGGC TGTGCCAGCC GGCACCCAGG TGTGGAGACA AGATCTACAA CCCCTTGGAG 180 CAGTGCTGTT ACAATGACGC CATCGTGTCC CTGAGCGAGA CCCGCCAATG TGGTCCCCCC 240 TGCACCTTCT GGCCCTGCTT TGAGCTCTGC TGTCTTGATT CCTTTGGCCT CACAAACGAT 300 TTTGTTGTGA AGCTGAAGGT TCAGGGTGTG AATTCCCAGT GCCACTCATC TCCCATCTCC 360 AGTAAATGTG AAAGAGGCCG GATATGTTAG Seq ID NO : 623 Protein sequence Protein Accession &num : FGENESH predicted 1 11 21 31 41 51 1 1 1 1 1 1 MRFSVSGMRT DYPRSVLAPA YVSVCLLLLC PREVIAPAGS EPWLCQPAPR CGDKIYNPLE 60 QCCYNDAIVS LSETRQCGPP CTFWPCFELC CLDSFGLTND FWKLKVQGV NSQCHSSPIS 120 SKCERGRIC Seq ID NO: 624 DNA sequence Nucleic Acid Accession # : M18728.1 Coding sequence: 51.. 1085 1 11 21 31 41 51 # # # # # # GGAGCTCAAG CTCCTCTACA AAGAGGTGGA CAGAGAAGAC AGCAGAGACC ATGGGACCCC 60 CCTCAGCCCC TCCCTGCAGA TTGCATGTCC CCTGGAAGGA GGTCCTGCTC ACAGCCTCAC 120 TTCTAACCTT CTGGAACCCA CCCACCACTG CCAAGCTCAC TATTGAATCC ACGCCATTCA ISO ATGTCGCAGA GGGGAAGGAG GTTCTTCTAC TCGCCCACAA CCTGCCCCAG AATCGTATTG 240 GTTACAGCTG GTACAAAGGC GAAAGAGTGG ATGGCAACAG TCTAATTGTA GGATATGTAA 300 TAGGAACTCA ACAAGCTACC CCAGGGCCCG CATACAGTGG TCGAGAGACA ATATACCCCA 360 ATGCATCCCT GCTGATCCAG AACGTCACCC AGAATGACAC AGGATTCTAT ACCCTACAAG 420 TCATAAAGTC AGATCTTGTG AATGAAGAAG CAACCGGACA GTTCCATGTA TACCCGGAGC 480 TGCCCAAGCC CTCCATCTCC AGCAACAACT CCAACCCCGT GGAGGACAAG GATGCTGTGG 540 CCTTCACCTG TGAACCTGAG GTTCAGAACA CAACCTACCT GTGGTGGGTA AATGGTCAGA 600 GCCTCCCGGT CAGTCCCAGG CTGCAGCTGT CCAATGGCAA CATGACCCTC ACTCTACTCA 660

GCGTCAAAAG GAACGATGCA GGATCCTATG AATGTGAAAT ACAGAACCCA GCGAGTGCCA 720 ACCGCAGTGA CCCAGTCACC CTGAATGTCC TCTATGGCCC AGATGTCCCC ACCATTTCCC 780 CCTCAAAGGC CAATTACCGT CCAGGGGAAA ATCTGAACCT CTCCTGCCAC GCAGCCTCTA 840 ACCCACCTGC ACAGTACTCT TGGTTTATCA ATGGGACGTT CCAGCAATCC ACACAAGAGC 900 TCTTTATCCC CAACATCACT GTGAATAATA GCGGATCCTA TATGTGCCAA GCCCATAACT 960 CAGCCACTGG CCTCAATAGG ACCACAGTCA CGATGATCAC AGTCTCTGGA AGTGCTCCTG 1020 TCCTCTCAGC TGTGGCCACC GTCGGCATCA CGATTGGAGT GCTGGCCAGG GTGGCTCTGA 1080 TATAGCAGCC CTGGTGTATT TTCGATATTT CAGGAAGACT GGCAGATTGG ACCAGACCCT. 1140 GAATTCTTCT AGCTCCTCCA ATCCCATTTT ATCCCATGGA ACCACTAAAA ACAAGGTCTG 1200 CTCTGCTCCT GAAGCCCTAT ATGCTGGAGA TGGACAACTC AATGAAAATT TAAAGGGAAA 1260 ACCCTCAGGC CTGAGGTGTG TGCCACTCAG AGACTTCACC TAACTAGAGA CAGTCAAACT 1320 GCAAACCATG GTGAGAAATT GACGACTTCA CACTATGGAC AGCTTTTCCC AAGATGTCAA 1380 AACAAGACTC CTCATCATGA TAAGGCTCTT ACCCCCTTTT AATTTGTCCT TGCTTATGCC 1440 TGCCTCTTTC GCTTGGCAGG ATGATGCTGT CATTAGTATT TCACAAGAAG TAGCTTCAGA 1500 GGGTAACTTA ACAGAGTGTC AGATCTATCT TGTCAATCCC AACGTTTTAC ATAAAATAAG 1560 AGATCCTTTA GTGCACCCAG TGACTGACAT TAGCAGCATC TTTAACACAG CCGTGTGTTC 1620 AAATGTACAG TGGTCCTTTT CAGAGTTGGA CTTCTAGACT CACCTGTTCT CACTCCCTGT 1680 TTTAATTCAA CCCAGCCATG CAATGCCAAA TAATAGAATT GCTCCCTACC AGCTGAACAG 1740 GGAGGAGTCT GTGCAGTTTC TGACACTTGT TGTTGAACAT GGCTAAATAC AATGGGTATC 1800 GCTGAGACTA AGTTGTAGAA ATTAACAAAT GTGCTGCTTG GTTAAAATGG CTACACTCAT 1860 CTGACTCATT CTTTATTCTA TTTTAGTTGG TTTGTATCTT GCCTAAGGTG CGTAGTCCAA 1920 CTCTTGGTAT TACCCTCCTA ATAGTCATAC TAGTAGTCAT ACTCCCTGGT GTAGTGTATT 1980 CTCTAAAAGC TTTAAATGTC TGCATGCAGC CAGCCATCAA ATAGTGAATG GTCTCTCTTT 2040 GGCTGGAATT ACAAAACTCA GAGAAATGTG TCATCAGGAG AACATCATAA CCCATGAAGG 2100 ATAAAAGCCC CAAATGGTGG TAACTGATAA TAGCACTAAT GCTTTAAGAT TTGGTCACAC 2160 TCTCACCTAG GTGAGCGCAT TGAGCCAGTG GTGCTAAATG CTACATACTC CAACTGAAAT 2220 GTTAAGGAAG AAGATAGATC CAATTAAAAA AAATTAAAAC CAATTTAAAA AAAAAAAAGA 2280 ACACAGGAGA TTCCAGTCTA CTTGAGTTAG CATAATACAG AAGTCCCCTC TACTTTAACT 2340 TTTACAAAAA AGTAACCTGA ACTAATCTGA TGTTAACCAA TGTATTTATT TCTGTGGTTC 2400 TGTTTCCTTG TTCCAATTTG ACAAAACCCA CTGTTCTTGT ATTGTATTGC CCAGGGGGAG 2460 CTATCACTGT ACTTGTAGAG TGGTGCTGCT TTAATTCATA AATCACAAAT AAAAGCCAAT 2520 TAGCTCTATA ACT Seq ID NO : 625 Protein sequence Protein Accession # : AAA59907.1 1 11 21 31 41 51 1 1 1 1 1 1 MGPPSAPPCR LHVPWKEVLL TASLLTFWNP PTTAKLTIES TPFNVAEGKE VLLLAHNLPQ 60 NRIGYSWYKG ERVDGNSLIV GYVIGTQQAT PGPAYSGRET IYPNASLLIQ NVTQNDTGFY 120 TLQVIKSDLV NEEATGQFHV YPELPKPSIS SNNSNPVEDK DAVAFTCEPE VQNTTYLWWV ISO NGQSLPVSPR LQLSNGNMTL TLLSVKRNDA GSYECEIQNP ASANRSDPVT LNVLYGPDVP 240 TISPSKANYR PGENLNLSCH AASNPPAQYS WFINGTFQQS TQELFIPNIT VNNSGSYMCQ 300 AHNSATGLNR TTVTMITVSG SAPVLSAVAT VGITIGVLAR VALI Seq ID NO: 626 DNA sequence Nucleic Acid Accession # : M18728.1 Coding sequence: 1355.. 1657 1 11 21 31 41 51 GGAGCTCAAG CTCCTCTACA AAGAGGTGGA CAGAGAAGAC AGCAGAGACC ATGGGACCCC 60 CCTCAGCCCC TCCCTGCAGA TTGCATGTCC CCTGGAAGGA GGTCCTGCTC ACAGCCTCAC 120 TTCTAACCTT CTGGAACCCA CCCACCACTG CCAAGCTCAC TATTGAATCC ACGCCATTCA 180 ATGTCGCAGA GGGGAAGGAG GTTCTTCTAC TCGCCCACAA CCTGCCCCAG AATCGTATTG 240 GTTACAGCTG GTACAAAGGC GAAAGAGTGG ATGGCAACAG TCTAATTGTA GGATATGTAA 300 TAGGAACTCA ACAAGCTACC CCAGGGCCCG CATACAGTGG TCGAGAGACA ATATACCCCA 360 ATGCATCCCT GCTGATCCAG AACGTCACCC AGAATGACAC AGGATTCTAT ACCCTACAAG 420 TCATAAAGTC AGATCTTGTG AATGAAGAAG CAACCGGACA GTTCCATGTA TACCCGGAGC 480 TGCCCAAGCC CTCCATCTCC AGCAACAACT CCAACCCCGT GGAGGACAAG GATGCTGTGG 540 CCTTCACCTG TGAACCTGAG GTTCAGAACA CAACCTACCT GTGGTGGGTA AATGGTCAGA 600 GCCTCCCGGT CAGTCCCAGG CTGCAGCTGT CCAATGGCAA CATGACCCTC ACTCTACTCA 660 GCGTCAAAAG GAACGATGCA GGATCCTATG AATGTGAAAT ACAGAACCCA GCGAGTGCCA 720 ACCGCAGTGA CCCAGTCACC CTGAATGTCC TCTATGGCCC AGATGTCCCC ACCATTTCCC 780 CCTCAAAGGC CAATTACCGT CCAGGGGAAA ATCTGAACCT CTCCTGCCAC GCAGCCTCTA 840 ACCCACCTGC ACAGTACTCT TGGTTTATCA ATGGGACGTT CCAGCAATCC ACACAAGAGC 900 TCTTTATCCC CAACATCACT GTGAATAATA GCGGATCCTA TATGTGCCAA GCCCATAACT 960 CAGCCACTGG CCTCAATAGG ACCACAGTCA CGATGATCAC AGTCTCTGGA AGTGCTCCTG 1020 TCCTCTCAGC TGTGGCCACC GTCGGCATCA CGATTGGAGT GCTGGCCAGG GTGGCTCTGA 1080 TATAGCAGCC CTGGTGTATT TTCGATATTT CAGGAAGACT GGCAGATTGG ACCAGACCCT 1140 GAATTCTTCT AGCTCCTCCA ATCCCATTTT ATCCCATGGA ACCACTAAAA ACAAGGTCTG 1200 CTCTGCTCCT GAAGCCCTAT ATGCTGGAGA TGGACAACTC AATGAAAATT TAAAGGGAAA 1260 ACCCTCAGGC CTGAGGTGTG TGCCACTCAG AGACTTCACC TAACTAGAGA CAGTCAAACT 1320 GCAAACCATG GTGAGAAATT GACGACTTCA CACTATGGAC AGCTTTTCCC AAGATGTCAA 1380 AACAAGACTC CTCATCATGA TAAGGCTCTT ACCCCCTTTT AATTTGTCCT TGCTTATGCC 1440 TGCCTCTTTC GCTTGGCAGG ATGATGCTGT CATTAGTATT TCACAAGAAG TAGCTTCAGA 1500 GGGTAACTTA ACAGAGTGTC AGATCTATCT TGTCAATCCC AACGTTTTAC ATAAAATAAG 1560 AGATCCTTTA GTGCACCCAG TGACTGACAT TAGCAGCATC TTTAACACAG CCGTGTGTTC 1620 AAATGTACAG TGGTCCTTTT CAGAGTTGGA CTTCTAGACT CACCTGTTCT CACTCCCTGT 1680 TTTAATTCAA CCCAGCCATG CAATGCCAAA TAATAGAATT GCTCCCTACC AGCTGAACAG 1740 GGAGGAGTCT GTGCAGTTTC TGACACTTGT TGTTGAACAT GGCTAAATAC AATGGGTATC 1800 GCTGAGACTA AGTTGTAGAA ATTAACAAAT GTGCTGCTTG GTTAAAATGG CTACACTCAT 1860 CTGACTCATT CTTTATTCTA TTTTAGTTGG TTTGTATCTT GCCTAAGGTG CGTAGTCCAA 1920 CTCTTGGTAT TACCCTCCTA ATAGTCATAC TAGTAGTCAT ACTCCCTGGT GTAGTGTATT 1980 CTCTAAAAGC TTTAAATGTC TGCATGCAGC CAGCCATCAA ATAGTGAATG GTCTCTCTTT 2040 GGCTGGAATT ACAAAACTCA GAGAAATGTG TCATCAGGAG AACATCATAA CCCATGAAGG 2100 ATAAAAGCCC CAAATGGTGG TAACTGATAA TAGCACTAAT GCTTTAAGAT TTGGTCACAC 2160

ATCCAGTGAC AATGTGCCCC CTGCCAGCCG GGGCTCGCCC ACTCATCATT CATTCATCCA 480 TTCTAGAGCC AGTCTCTGCC TCCCAGACGC GGCGGGAGCC AAGCTCCTCC AACCACAAGG 540 GGGGTGGGGG GCGGTGAATC ACCTCTGAGG CCTGGGCCCA GGGTTCAGGG GAACCTTCCA 600 AGGTGTCTGG TTGCCCTGCC TCTGGCTCCA GAACAGAAAG GGAGCCTCAC GCTGGCTCAC 660 ACAAAACAGC TGACACTGAC TAAGGAACTG CAGCATTTGC ACAGGGGAGG GGGGTGCCCT 720 CCTTCCTTAG GACCTGGGGG CCAGGCTGAC TTGGGGGGCA GACTTGACAC TAGGCCCCAC 780 TCACTCAGAT GTCCTGAAAT TCCACCACGG GGGTCACCCT GGGGGGTTAG GGACCTATTT 840 TTAACACTAG GGGCTGGCCC ACTAGGAGGG CTGGCCCTAA GATACAGACC CCCCCAACTC 900 CCCAAAGCGG GGAGGAGATA TTTATTTTGG GGAGAGTTTG GAGGGGAGGG AGAATTTATT 960 AATAAAAGAA TCTTTAACTT TAAAAAAAAA AAAAAAAA Seq ID NO : 631 Protein sequence Protein Accession # : NP 057723. 1 1 11 21 31 41 51 I I I I I I MARGSLRRLL RLLVLGLWLA LLRSVAGEQA PGTAPCSRGS SWSADLDKCM DCASCRARPH 60 SDFCLGCAAA PPAPFRLLWP ILGGALSLTF VLGLLSGFLV WRRCRRREKF TTPIEETGGE 120 GCPAVALIQ Seq ID NO : 632 DNA sequence Nucleic Acid Accession &num : NM 003816. 1 Coding sequence: 79.. 2538 1 11 21 31 41 51 CGGCAGGGTT GGAAAATGAT GGAAGAGGCG GAGGTGGAGG CGACCGAGTG CTGAGAGGAA 60 CCTGCGGAAT CGGCCGAGAT GGGGTCTGGC GCGCGCTTTC CCTCGGGGAC CCTTCGTGTC 120 CGGTGGTTGC TGTTGCTTGG CCTGGTGGGC CCAGTCCTCG GTGCGGCGCG GCCAGGCTTT 180 CAACAGACCT CACATCTTTC TTCTTATGAA ATTATAACTC CTTGGAGATT AACTAGAGAA 240 AGAAGAGAAG CCCCTAGGCC CTATTCAAAA CAAGTATCTT ATGTTATTCA GGCTGAAGGA 300 AAAGAGCATA TTATTCACTT GGAAAGGAAC AAAGACCTTT TGCCTGAAGA TTTTGTGGTT 360 TATACTTACA ACAAGGAAGG GACTTTAATC ACTGACCATC CCAATATACA GAATCATTGT 420 CATTATCGGG GCTATGTGGA GGGAGTTCAT AATTCATCCA TTGCTCTTAG CGACTGTTTT 480 GGACTCAGAG GATTGCTGCA TTTAGAGAAT GCGAGTTATG GGATTGAACC CCTGCAGAAC 540 AGCTCTCATT TTGAGCACAT CATTTATCGA ATGGATGATG TCTACAAAGA GCCTCTGAAA 600 TGTGGAGTTT CCAACAAGGA TATAGAGAAA GAAACTGCAA AGGATGAAGA GGAAGAGCCT 660 CCCAGCATGA CTCAGCTACT TCGAAGAAGA AGAGCTGTCT TGCCACAGAC CCGGTATGTG 720 GAGCTGTTCA TTGTCGTAGA CAAGGAAAGG TATGACATGA TGGGAAGAAA TCAGACTGCT 780 GTGAGAGAAG AGATGATTCT CCTGGCAAAC TACTTGGATA GTATGTATAT TATGTTAAAT 840 ATTCGAATTG TGCTAGTTGG ACTGGAGATT TGGACCAATG GAAACCTGAT CAACATAGTT 900 GGGGGTGCTG GTGATGTGCT GGGGAACTTC GTGCAGTGGC GGGAAAAGTT TCTTATCACA 960 CGTCGGAGAC ATGACAGTGC ACAGCTAGTT CTAAAGAAAG GTTTTGGTGG AACTGCAGGA 1020 ATGGCATTTG TGGGAACAGT GTGTTCAAGG AGCCACGCAG GCGGGATTAA TGTGTTTGGA 1080 CAAATCACTG TGGAGACATT TGCTTCCATT GTTGCTCATG AATTGGGTCA TAATCTTGGA 1140 ATGAATCACG ATGATGGGAG AGATTGTTCC TGTGGAGCAA AGAGCTGCAT CATGAATTCA 1200 GGAGCATCGG GTTCCAGAAA CTTTAGCAGT TGCAGTGCAG AGGACTTTGA GAAGTTAACT 1260 TTAAATAAAG GAGGAAACTG CCTTCTTAAT ATTCCAAAGC CTGATGAAGC CTATAGTGCT 1320 CCCTCCTGTG GTAATAAGTT GGTGGACGCT GGGGAAGAGT GTGACTGTGG TACTCCAAAG 1380 GAATGTGAAT TGGACCCTTG CTGCGAAGGA AGTACCTGTA AGCTTAAATC ATTTGCTGAG 1440 TGTGCATATG GTGACTGTTG TAAAGACTGT CGGTTCCTTC CAGGAGGTAC TTTATGCCGA 1500 GGAAAAACCA GTGAGTGTGA TGTTCCAGAG TACTGCAATG GTTCTTCTCA GTTCTGTCAG 1560 CCAGATGTTT TTATTCAGAA TGGATATCCT TGCCAGAATA ACAAAGCCTA TTGCTACAAC 1620 GGCATGTGCC AGTATTATGA TGCTCAATGT CAAGTCATCT TTGGCTCAAA AGCCAAGGCT 1680 GCCCCCAAAG ATTGTTTCAT TGAAGTGAAT TCTAAAGGTG ACAGATTTGG CAATTGTGGT 1740 TTCTCTGGCA ATGAATACAA GAAGTGTGCC ACTGGGAATG CTTTGTGTGG AAAGCTTCAG 1800 TGTGAGAATG TACAAGAGAT ACCTGTATTT GGAATTGTGC CTGCTATTAT TCAAACGCCT 1860 AGTCGAGGCA CCAAATGTTG GGGTGTGGAT TTCCAGCTAG GATCAGATGT TCCAGATCCT 1920 GGGATGGTTA ACGAAGGCAC AAAATGTGGT GCTGGAAAGA TCTGTAGAAA CTTCCAGTGT 1980 GTAGATGCTT CTGTTCTGAA TTATGACTGT GATGTTCAGA AAAAGTGTCA TGGACATGGG 2040 GTATGTAATA GCAATAAGAA TTGTCACTGT'GAAAATGGCT GGGCTCCCCC AAATTGTGAG 2100 ACTAAAGGAT ACGGAGGAAG TGTGGACAGT GGACCTACAT ACAATGAAAT GAATACTGCA 2160 TTGAGGGACG GACTTCTGGT CTTCTTCTTC CTAATTGTTC CCCTTATTGT CTGTGCTATT 2220 TTTATCTTCA TCAAGAGGGA TCAACTGTGG AGAAGCTACT TCAGAAAGAA GAGATCACAA 2280 ACATATGAGT CAGATGGCAA AAATCAAGCA AACCCTTCTA GACAGCCGGG GAGTGTTCCT 2340 CGACATGTTT CTCCAGTGAC ACCTCCCAGA GAAGTTCCTA TATATGCAAA CAGATTTGCA 2400 GTACCAACCT ATGCAGCCAA GCAACCTCAG CAGTTCCCAT CAAGGCCACC TCCACCACAA 2460 CCGAAAGTAT CATCTCAGGG AAACTTAATT CCTGCCCGTC CTGCTCCTGC ACCTCCTTTA 2520 TATAGTTCCC TCACTTGATT TTTTTAACCT TCTTTTTGCA AATGTCTTCA GGGAACTGAG 2580 CTAATACTTT TTTTTTTTCT TGATGTTTTC TTGAAAAGCC TTTCTGTTGC AACTATGAAT 2640 GAAAACAAAA CACCACAAAA CAGACTTCAC TAACACAGAA AAACAGAAAC TGAGTGTGAG 2700 AGTTGTGAAA TACAAGGAAA TGCAGTAAAG CCAGGGAATT TACAATAACA TTTCCGTTTC 2760 CATCATTGAA TAAGTCTTAT TCAGTCATCG GTGAGGTTAA TGCACTAATC ATGGATTTTT 2820 TGAACATGTT ATTGCAGTGA TTCTCAAATT AACTGTATTG GTGTAAGATT TTTGTCATTA 2880 AGTGTTTAAG TGTTATTCTG AATTTTCTAC CTTAGTTATC ATTAATGTAG TTCCTCATTG 2940 AACATGTGAT AATCTAATAC CTGTGAAAAC TGACTAATCA GCTGCCAATA ATATCTAATA 3000 TTTTTCATCA TGCACGAATT AATAATCATC ATACTCTAGA ATCTTGTCTG TCACTCACTA 3060 CATGAATAAG CAAATATTGT CTTCAAAAGA ATGCACAAGA ACCACAATTA AGATGTCATA 3120 TTATTTTGAA AGTACAAAAT ATACTAAAAG AGTGTGTGTG TATTCACGCA GTTACTCGCT 3180 TCCATTTTTA TGACCTTTCA ACTATAGGTA ATAACTCTTA GAGAAATTAA TTTAATATTA 3240 GAATTTCTAT TATGAATCAT GTGAAAGCAT GACATTCGTT CACAATAGCA CTATTTTAAA 3300 TAAATTATAA GCTTTAAGGT ACGAAGTATT TAATAGATCT AATCAAATAT GTTGATTCAT 3360 GGCTATAATA AAGCAGGAGC AATTATAAAA TCTTCAATCA ATTGAACTTT TACAAAACCA 3420 CTTGAGAATT TCATGAGCAC TTTAAAATCT GAACTTTCAA AGCTTGCTAT TAAATCATTT 3480 AGAATGTTTA CATTTACTAA GGTGTGCTGG GTCATGTAAA ATATTAGACA CTAATATTTT 3540 CATAGAAATT AGGCTGGAGA AAGAAGGAAG AAATGGTTTT CTTAAATACC TACAAAAAAG 3600 TTACTGTGGT ATCTATGAGT TATCATCTTA GCTGTGTTAA AAATGAATTT TTACTATGGC 3660

AGATATGGTA TGGATCGTAA AATTTTAAGC ACTAAAAATT TTTTCATAAC CTTTCATAAT 3720 AAAGTTTAAT AATAGGTTTA TTAACTGAAT TTCATTAGTT TTTTAAAAGT GTTTTTGGTT 3780 TGTGTATATA TACATATACA AATACAACAT TTACAATAAA TAAAATACTT GAAATTCTCA 3840 AAAAAAAAAA AAAAAAAAAA AAAAA Seq ID NO : 633 Protein sequence Protein Accession &num : NP 003807. 1 1 11 21 31 41 51 MGSGARFPSG TLRVRWLLLL GLVGPVLGAA RPGEQQTSHL SSYEIITPWR LTRERREAPR 60 PYSKQVSYVI QAEGKEHIIH LERNKDLLPE DFVVYTYNKE GTLITDHPNI QNHCHYRGYV 120 EGVHNSSIAL SDCFGLRGLL HLENASYGIE PLQNSSHFEH IIYRMDDVYK EPLKCGVSNK 180 DIEKETAKDE EEEPPSMTQL LRRRRAVLPQ TRYVELFIW DKERYDMMGR NQTAVREEMI 240 LLANYLDSMY IMLNIRIVLV GLEIWTNGNL INIVGGAGDV LGNFVQWREK FLITRRRHDS 300 AQLVLKKGFG GTAGMAFVGT VCSRSHAGGI NVFGQITVET FASIVAHELG HNLGMNHDDG 360 RDCSCGAKSC IMNSGASGSR NFSSCSAEDF EKLTLNKGGN CLLNIPKPDE AYSAPSCGNK 420 LVDAGEECDC GTPKECELDP CCEGSTCKLK SFAECAYGDC CKDCRFLPGG TLCRGKTSEC 480 DVPEYCNGSS QFCQPDVFIQ NGYPCQNNKA YCYNGMCQYY DAQCQVIFGS KAKAAPKDCF 540 IEVNSKGDRF GNCGFSGNEY KKCATGNALC GKLQCENVQE IPVFGIVPAI IQTPSRGTKC 600 WGVDFQLGSD VPDPGMVNEG TKCGAGKICR NFQCVDASVL NYDCDVQKKC HGHGVCNSNK 660 NCHCENGWAP PNCETKGYGG SVDSGPTYNE MNTALRDGLL VFFFLIVPLI VCAIFIFIKR 720 DQLWRSYFRK KRSQTYESDG KNQANPSRQP GSVPRHVSPV TPPREVPIYA NRFAVPTYAA 780 KQPQQFPSRP PPPQPKVSSQ GNLIPARPAP APPLYSSLT Seq ID NO: 634 DNA sequence Nucleic Acid Accession # : NM 002091. 1 Coding sequence: 56.. 503 1 11 21 31 41 51 # # # # # # AGTCTCTGCT CTTCCCAGCC TCTCCGGCGC GCTCCAAGGG CTTCCCGTCG GGACCATGCG 60 CGGCAGTGAG CTCCCGCTGG TCCTGCTGGC GCTGGTCCTC TGCCTAGCGC CCCGGGGGCG 120 AGCGGTCCCG CTGCCTGCGG GCGGAGGGAC CGTGCTGACC AAGATGTACC CGCGCGGCAA 180 CCACTGGGCG GTGGGGCACT TAATGGGGAA AAAGAGCACA GGGGAGTCTT CTTCTGTTTC 240 TGAGAGAGGG AGCCTGAAGC AGCAGCTGAG AGAGTACATC AGGTGGGAAG AAGCTGCAAG 300 GAATTTGCTG GGTCTCATAG AAGCAAAGGA GAACAGAAAC CACCAGCCAC CTCAACCCAA 360 GGCCTTGGGC AATCAGCAGC CTTCGTGGGA TTCAGAGGAT AGCAGCAACT TCAAAGATGT 420 AGGTTCAAAA GGCAAAGTTG GTAGACTCTC TGCTCCAGGT TCTCAACGTG AAGGAAGGAA 480 CCCCCAGCTG AACCAGCAAT GATAATGATG GCCTCTCTCA AAAGAGAAAA ACAAAACCCC 540 TAAGAGACTG AGTTCTGCAA GCATCAGTTC TACGGATCAT CAACAAGATT TCCTTGTGCA 600 AAATATTTGA CTATTCTGTA TCTTTCATCC TTGACTAAAT TCGTGATTTT CAAGCAGCAT 660 CTTCTGGTTT AAACTTGTTT GCTGTGAACA ATTGTCGAAA AGAGTCTTCC AATTAATGCT 720 TTTTTATATC TAGGCTACCT GTTGGTTAGA TTCAAGGCCC CGAGCTGTTA CCATTCACAA 780 TAAAAGCTTA AACACAT Seq ID NO : 635 Protein sequence Protein Accession # : NP 002082. 1 1 11 21 31 41 51 (I 1 1 1 1 MRGSELPLVL LALVLCLAPR GRAVPLPAGG GTVLTKMYPR GNHWAVGHLM GKKSTGESSS 60 VSERGSLKQQ LREYIRWEEA ARNLLGLIEA KENRNHQPPQ PKALGNQQPS WDSEDSSNFK 120 DVGSKGKVGR LSAPGSQREG RNPQLNQQ Seq ID NO : 636 DNA sequence Nucleic Acid Accession # : NM 016522. 1 Coding sequence: 265.. 1299 1 11 21 31 41 51 1 1 1 1 1 1 GCGGAAGCAG CGAGGAGGGA GCCCCCTTTG GCCGTCCTCC GTGGAACCGG TTTTCCGAGG 60 CTGGCAAAAG CCGAGGCTGG ATTTGGGGGA GGAATATTAG ACTCGGAGGA GTCTGCGCGC 120 TTTTCTCCTC CCCGCGCCTC CCGGTCGCCG CGGGTTCACC GCTCAGTCCC CGCGCTCGCT 180 CCGCACCCCA CCCACTTCCT GTGCTCGCCC GGGGGGCGTG TGCCGTGCGG CTGCCGGAGT 240 TCGGGGAAGT TGTGGCTGTC GAGAATGGGG GTCTGTGGGT ACCTGTTCCT GCCCTGGAAG 300 TGCCTCGTGG TCGTGTCTCT CAGGCTGCTG TTCCTTGTAC CCACAGGAGT GCCCGTGCGC 360 AGCGGAGATG CCACCTTCCC CAAAGCTATG GACAACGTGA CGGTCCGGCA GGGGGAGAGC 420 GCCACCCTCA GGTGCACTAT TGACAACCGG GTCACCCGGG TGGCCTGGCT AAACCGCAGC 480 ACCATCCTCT ATGCTGGGAA TGACAAGTGG TGCCTGGATC CTCGCGTGGT CCTTCTGAGC 540 AACACCCAAA CGCAGTACAG CATCGAGATC CAGAACGTGG ATGTGTATGA CGAGGGCCCT 600 TACACCTGCT CGGTGCAGAC AGACAACCAC CCAAAGACCT CTAGGGTCCA CCTCATTGTG 660 CAAGTATCTC CCAAAATTGT AGAGATTTCT TCAGATATCT CCATTAATGA AGGGAACAAT 720 ATTAGCCTCA CCTGCATAGC AACTGGTAGA CCAGAGCCTA CGGTTACTTG GAGACACATC 780 TCTCCCAAAG CGGTTGGCTT TGTGAGTGAA GACGAATACT TGGAAATTCA GGGCATCACC 840 CGGGAACAGT CAGGGGACTA CGAGTGCAGT GCCTCCAATG ACGTGGCCGC GCCCGTGGTA 900 CGGAGAGTAA AGGTCACCGT GAACTATCCA CCATACATTT CAGAAGCCAA GGGTACAGGT 960 GTCCCCGTGG GACAAAAGGG GACACTGCAG TGTGAAGCCT CAGCAGTCCC CTCAGCAGAA 1020 TTCCAGTGGT ACAAGGATGA CAAAAGACTG ATTGAAGGAA AGAAAGGGGT GAAAGTGGAA 1080 AACAGACCTT TCCTCTCAAA ACTCATCTTC TTCAATGTCT CTGAACATGA CTATGGGAAC 1140 TACACTTGCG TGGCCTCCAA CAAGCTGGGC CACACCAATG CCAGCATCAT GCTATTTGGT 1200 CCAGGCGCCG TCAGCGAGGT GAGCAACGGC ACGTCGAGGA GGGCAGGCTG CGTCTGGCTG 1260 CTGCCTCTTC TGGTCTTGCA CCTGCTTCTC AAATTTTGAT GTGAGTGCCA CTTCCCCACC 1320 CGGGAAAGGC TGCCGCCACC ACCACCACCA ACACAACAGC AATGGCAACA CCGACAGCAA 1380 CCAATCAGAT ATATACAAAT GAAATTAGAA GAAACACAGC CTCATGGGAC AGAAATTTGA 1440 GGGAGGGGAA CAAAGAATAC TTTGGGGGGA AAAGAGTTTT AAAAAAGAAA TTGAAAATTG 1500 CCTTGCAGAT ATTTAGGTAC AATGGAGTTT TCTTTTCCCA AACGGGAAGA ACACAGCACA 1560

TCTTTACCCT AGGATGCTAT TTAAGTTGTA CTGTATTAGA ACACTGGGTG TGTCATACCG 960 TTATCTGTGC AGAATATATT TCCTTATTCA GAATTTCTAA AAATTTAAGT TCTGTAAGGG 1020 CTAATATATT CTCTTCCTAT GGTTTTAGAT GTTTGATGTC TTCTTAGTAT GGCATAATGT 1080 CATGATTTAC TCATTAAACT TTGATTTTGT ATGCTATTTT TTCACTATAG GATGACTATA 1140 ATTCTGGTCA CTAAATATAC ACTTTAGATA GATGAAGAAG CCCAAAAACA GATAAATTCC 1200 TGATTGCTAA TTTACATAGA AATGTATTCT CTTGGTTTTT TAAATAAAAG CAAAATTAAC 1260 AATGATCTGT GCTCTGCAAA GTTTTGAAAA TATATTTGAA CAATTTGAAT ATAAATTCAT 1320 CATTTAGTCC TCAAAATATA TACAGCATTG CTAAGATTTT CAGATATCTA TTGTGGATCT 1380 TTTAAAGGTT TTGACCATTT TGTTATGAGG AATTATACAT GTATCACATT CACTATATTA 1440 AAATTGCACT TTTATTTTTT CCTGTGTGTC ATGTTGGTTT TTGGTACTTG TATTGTCATT 1500 TGGAGAAACA ATAAAAGATT TCTAAACCAA AAAAAAAAAA AAAAAAA Seq ID NO : 641 Protein sequence Protein Accession # : NP 002984. 1 1 11 21 31 41 51 MSLPSSRAAR VPGPSGSLCA LLALLLLLTP PGPLASAGPV SAVLTELRCT CLRVTLRVNP 60 KTIGKLQVFP AGPQCSKVEV VASLKNGKQV CLDPEAPFLK KVIQKILDSG NKKN Seq ID NO: 642 DNA sequence Nucleic Acid Accession &num : NM 013271. 1 Coding sequence: 27.. 809' 1 11 21 31 41 51 # # # # # # TCCGGAGCCA GGCTCGCTGG GGCAGCATGG CGGGGTCGCC GCTGCTCTGG GGGCCGCGGG 60 CCGGGGGCGT CGGCCTTTTG GTGCTGCTGC TGCTCGGCCT GTTTCGGCCG CCCCCCGCGC 120 TCTGCGCGCG GCCGGTAAAG GAACCCCGCG GCCTAAGCGC AGCGTCTCCG CCCTTGGCTG 180 AGACTGGCGC TCCTCGCCGC TTCCGGCGGT CAGTGCCCCG AGGTGAGGCG GCGGGGGCGG 240 TGCAGGAGCT GGCGCGGGCG CTGGCGCATC TGCTGGAGGC CGAACGTCAG GAGCGGGCGC 300 GGGCCGAGGC GCAGGAGGCT GAGGATCAGC AGGCGCGCGT CCTGGCGCAG CTGCTGCGCG 360 TCTGGGGCGC CCCCCGCAAC TCTGATCCGG CTCTGGGCCT GGACGACGAC CCCGACGCGC 420 CTGCAGCGCA GCTCGCTCGC GCTCTGCTCC GCGCCCGCCT TGACCCTGCC GCCCTAGCAG 480 CCCAGCTTGT CCCCGCGCCC GTCCCCGCCG CGGCGCTCCG ACCCCGGCCC CCGGTCTACG 540 ACGACGGCCC CGCGGGCCCG GATGCTGAGG AGGCAGGCGA CGAGACACCC GACGTGGACC 600 CCGAGCTGTT GAGGTACTTG CTGGGACGGA TTCTTGCGGG AAGCGCGGAC TCCGAGGGGG 660 TGGCAGCCCC GCGCCGCCTC CGCCGTGCCG CCGACCACGA TGTGGGCTCT GAGCTGCCCC 720 CTGAGGGCGT GCTGGGGGCG CTGCTGCGTG TGAAACGCCT AGAGACCCCG GCGCCCCAGG 780 TGCCTGCACG CCGCCTCTTG CCACCCTGAG CACTGCCCGG ATCCCGTGCA CCCTGGGACC 840 CAGAAGTGCC CCCGCCATCC CGCCACCAGG ACTTCTCCCC GCCAGCACGT CCAGAGCAAC 900 TTACCCCGGC CAGCCAGCCC TCTCACCCGA GGATCCCTAC CCCCTGGCCC ACAATAACAT 960 GATCTGAGC Seq ID NO : 643 Protein sequence Protein Accession # : NP 037403. 1 1 11 21 31 41 51 MAGSPLLWGP RAGGVGLLVL LLLGLFRPPP ALCARPVKEP RGLSAASPPL AETGAPRRFR 60 RSVPRGEAAG AVQELARALA HLLEAERQER ARAEAQEAED QQARVLAQLL RVWGAPRNSD 120 PALGLDDDPD APAAQLARAL LRARLDPAAL AAQLVPAPVP AAALRPRPPV YDDGPAGPDA 180 EEAGDETPDV DPELLRYLLG RILAGSADSE GVAAPRRLRR AADHDVGSEL PPEGVLGALL 240 RVKRLETPAP QVPARRLLPP Seq ID NO : 644 DNA sequence Nucleic Acid Accession &num : NM 002214 Coding sequence: 681.. 2990 1 11 21 31 41 51 CCCAGAGCCG CCTCCCCCTG TTGCTGGCAT CCCGAGCTTC CTCCCTTGCC AGCCAGGACG 60 CTGCCGACTT GTCTTTGCCC GCTGCTCCGC AGACGGGGCT GCAAAGCTGC AACTAATGGT 120 GTTGGCCTCC CTGCCCACCT GTGGAAGCAA CTGCGCTGAT TGATGCGCCA CAGACTTTTT 180 TCCCCTCGAC CTCGCCGGCG TACCCTCCCA CAGATCCAGC ATCACCCAGT GAATGTACAT 240 TAGGGTGGTT TCCCCCCCAG CTTCGGGCTT TGTTTGGGTT TGATTGTGTT TGGCTCTTCG 300 CTAAGCTGAT TTATGCAGCA GAAGCCCCAC CGGCTGGAGA GAAACAAAAG CTCTTTTCTT 360 TGTCCCGGAG CAGGCTGCGG AGCCCTTGCA GAGCCCTCTC TCCAGTCGCC GCCGGGCCCT 420 TGGCCGTCGA AGGAGGTGCT TCTCGCGGAG ACCGCGGGAC CCGCCGTGCC GAGCCGGGAG 480 GGCCGTAGGG GCCCTGAGAT GCCGAGCGGT GCCCGGGCCC GCTTACCTGC ACCGCTTGCT 540 CCGAGCCGCG GGGTCCGCCT GCTAGGCCTG CGGAAAACGT CCTAGCGACA CTCGCCCGCG 600 GGCCCCGAGG TCGCCCGGGA GGCCGAGCCC GCGTCCGGAA GGCAGCCAGG CGGCGGGCGC 660 GGGGCGGGCT GTTTTGCATT ATGTGCGGCT CGGCCCTGGC TTTTTTTACC GCTGCATTTG 720 TCTGCCTGCA AAACGACCGG CGAGGTCCCG CCTCGTTCCT CTGGGCAGCC TGGGTGTTTT 780 CACTTGTTCT TGGACTGGGC CAAGGTGAAG ACAATAGATG TGCATCTTCA AATGCAGCAT 840 CCTGTGCCAG GTGCCTTGCG CTGGGTCCAG AATGTGGATG GTGTGTTCAA GAGGATTTCA 900 TTTCAGGTGG ATCAAGAAGT GAACGTTGTG ATATTGTTTC CAATTTAATA AGCAAAGGCT 960 GCTCAGTTGA TTCAATAGAA TACCCATCTG TGCATGTTAT AATACCCACT GAAAATGAAA 1020 TTAATACCCA GGTGACACCA GGAGAAGTGT CTATCCAGCT GCGTCCAGGA GCCGAAGCTA 1080 ATTTTATGCT GAAAGTTCAT CCTCTGAAGA AATATCCTGT GGATCTTTAT TATCTTGTTG 1140 ATGTCTCAGC ATCAATGCAC AATAATATAG AAAAATTAAA TTCCGTTGGA AACGATTTAT 1200 CTAGAAAAAT GGCATTTTTC TCCCGTGACT TTCGTCTTGG ATTTGGCTCA TACGTTGATA 1260 AAACAGTTTC ACCATACATT AGCATCCACC CCGAAAGGAT TCATAATCAA TGCAGTGACT 1320 ACAATTTAGA CTGCATGCCT CCCCATGGAT ACATCCATGT GCTGTCTTTG ACAGAGAACA 1380 TCACTGAGTT TGAGAAAGCA GTTCATAGAC AGAAGATCTC TGGAAACATA GATACACCAG 1440 AAGGAGGTTT TGACGCCATG CTTCAGGCAG CTGTCTGTGA AAGTCATATC GGATGGCGAA 1500 AAGAGGCTAA AAGATTGCTG CTGGTGATGA CAGATCAGAC GTCTCATCTC GCTCTTGATA 1560

MEMFTFLLTC IFLPLLRGHS LFTCEPITVP RCMKMAYNMT FFPNLMGHYD QSIAAVEMEH 60 FLPLANLECS PNIETFLCKA FVPTCIEQIH WPPCRKLCE KVYSDCKKLI DTFGIRWPEE 120 LECDRLQYCD ETVPVTFDPH TEFLGPQKKT EQVQRDIGFW CPRHLKTSGG QGYKFLGIDQ 180 CAPPCPNMYF KSDELEFAKS FIGTVSIFCL CATLFTFLTF LIDVRRFRYP ERPIIYYSVC 240 YSIVSLMYFI GFLLGDSTAC NKADEKLELG DTWLGSQNK ACTVLFMLLY FFTMAGTVWW 300 VILTITWFLA AGRKWSCEAI EQKAVWFHAV AWGTPGFLTV MLLALNKVEG DNISGVCFVG 360 LYDLDASRYF VLLPLCLCVF VGLSLLLAGI ISLNHVRQVI QHDGRNQEKL KKFMIRIGVF 420 SGLYLVPLVT LLGCYVYEQV NRITWEITWV SDHCRQYHIP CPYQAKAKAR PELALFMIKY 480 LMTLIVGISA VFWVGSKKTC TEWAGFFKRN RKRDPISESR RVLQESCEFF LKHNSKVKHK 540 KKHYKPSSHK LKVISKSMGT STGATANHGT SAVAITSHDY LGQETLTEIQ TSPETSMREV 600 KADGASTPRL REQDCGEPAS PAASISRLSG EQVDGKGQAG SVSESARSEG RISPKSDITD 660 TGLAQSNNLQ VPSSSEPSSL KGSTSLLVHP VSGVRKEQGG GCHSDT Seq ID NO : 652 DNA sequence Nucleic Acid Accession # : NM 014791. 1 Coding sequence: 171.. 2126 1 11 21 31 41 51 1 1 1 1 1 1 TTGGCGGGCG GAAGCGGCCA CAACCCGGCG ATCGAAAAGA TTCTTAGGAA CGCCGTACCA 60 GCCGCGTCTC TCAGGACAGC AGGCCCCTGT CCTTCTGTCG GGCGCCGCTC AGCCGTGCCC 120 TCCGCCCCTC AGGTTCTTTT TCTAATTCCA AATAAACTTG CAAGAGGACT ATGAAAGATT 180 ATGATGAACT TCTCAAATAT TATGAATTAC ATGAAACTAT TGGGACAGGT GGCTTTGCAA 240 AGGTCAAACT TGCCTGCCAT ATCCTTACTG GAGAGATGGT AGCTATAAAA ATCATGGATA 300 AAAACACACT AGGGAGTGAT TTGCCCCGGA TCAAAACGGA GATTGAGGCC TTGAAGAACC 360 TGAGACATCA GCATATATGT CAACTCTACC ATGTGCTAGA GACAGCCAAC AAAATATTCA 420 TGGTTCTTGA GTACTGCCCT GGAGGAGAGC TGTTTGACTA TATAATTTCC CAGGATCGCC 480 TGTCAGAAGA GGAGACCCGG GTTGTCTTCC GTCAGATAGT ATCTGCTGTT GCTTATGTGC 540 ACAGCCAGGG CTATGCTCAC AGGGACCTCA AGCCAGAAAA TTTGCTGTTT GATGAATATC 600 ATAAATTAAA GCTGATTGAC TTTGGTCTCT GTGCAAAACC CAAGGGTAAC AAGGATTACC 660 ATCTACAGAC ATGCTGTGGG AGTCTGGCTT ATGCAGCACC TGAGTTAATA CAAGGCAAAT 720 CATATCTTGG ATCAGAGGCA GATGTTTGGA GCATGGGCAT ACTGTTATAT GTTCTTATGT 780 GTGGATTTCT ACCATTTGAT GATGATAATG TAATGGCTTT ATACAAGAAG ATTATGAGAG 840 GAAAATATGA TGTTCCCAAG TGGCTCTCTC CCAGTAGCAT TCTGCTTCTT CAACAAATGC 900 TGCAGGTGGA CCCAAAGAAA CGGATTTCTA TGAAAAATCT ATTGAACCAT CCCTGGATCA 960 TGCAAGATTA CAACTATCCT GTTGAGTGGC AAAGCAAGAA TCCTTTTATT CACCTCGATG 1020 ATGATTGCGT AACAGAACTT TCTGTACATC ACAGAAACAA CAGGCAAACA ATGGAGGATT 1080 TAATTTCACT GTGGCAGTAT GATCACCTCA CGGCTACCTA TCTTCTGCTT CTAGCCAAGA 1140 AGGCTCGGGG AAAACCAGTT CGTTTAAGGC TTTCTTCTTT CTCCTGTGGA CAAGCCAGTG 1200 CTACCCCATT CACAGACATC AAGTCAAATA ATTGGAGTCT GGAAGATGTG ACCGCAAGTG 1260 ATAAAAATTA TGTGGCGGGA TTAATAGACT ATGATTGGTG TGAAGATGAT TTATCAACAG 1320 GTGCTGCTAC TCCCCGAACA TCACAGTTTA CCAAGTACTG GACAGAATCA AATGGGGTGG 1380 AATCTAAATC ATTAACTCCA GCCTTATGCA GAACACCTGC AAATAAATTA AAGAACAAAG 1440 AAAATGTATA TACTCCTAAG TCTGCTGTAA AGAATGAAGA GTACTTTATG TTTCCTGAGC 1500 CAAAGACTCC AGTTAATAAG AACCAGCATA AGAGAGAAAT ACTCACTACG CCAAATCGTT 1560 ACACTACACC CTCAAAAGCT AGAAACCAGT GCCTGAAAGA AACTCCAATT AAAATACCAG 1620 TAAATTCAAC AGGAACAGAC AAGTTAATGA CAGGTGTCAT TAGCCCTGAG AGGCGGTGCC 1680 GCTCAGTGGA ATTGGATCTC AACCAAGCAC ATATGGAGGA GACTCCAAAA AGAAAGGGAG 1740 CCAAAGTGTT TGGGAGCCTT GAAAGGGGGT TGGATAAGGT TATCACTGTG CTCACCAGGA 1800 GCAAAAGGAA GGGTTCTGCC AGAGACGGGC CCAGAAGACT AAAGCTTCAC TATAATGTGA 1860 CTACAACTAG ATTAGTGAAT CCAGATCAAC TGTTGAATGA AATAATGTCT ATTCTTCCAA 1920 AGAAGCATGT TGACTTTGTA CAAAAGGGTT ATACACTGAA GTGTCAAACA CAGTCAGATT 1980 TTGGGAAAGT GACAATGCAA TTTGAATTAG AAGTGTGCCA GCTTCAAAAA CCCGATGTGG 2040 TGGGTATCAG GAGGCAGCGG CTTAAGGGCG ATGCCTGGGT TTACAAAAGA TTAGTGGAAG 2100 ACATCCTATC TAGCTGCAAG GTATAATTGA TGGATTCTTC CATCCTGCCG GATGAGTGTG 2160 GGTGTGATAC AGCCTACATA AAGACTGTTA TGATCGCTTT GATTTTAAAG TTCATTGGAA 2220 CTACCAACTT GTTTCTAAAG AGCTATCTTA AGACCAATAT CTCTTTGTTT TTAAACAAAA 2280 GATATTATTT TGTGTATGAA TCTAAATCAA GCCCATCTGT CATTATGTTA CTGTCTTTTT 2340 TAATCATGTG GTTTTGTATA TTAATAATTG TTGACTTTCT TAGATTCACT TCCATATGTG 2400 AATGTAAGCT CTTAACTATG TCTCTTTGTA ATGTGTAATT TCTTTCTGAA ATAAAACCAT 2460 TTGTGAATAT Seq ID NO : 653 Protein sequence Protein Accession # : NP 055606. 1 1 11 21 31 41 51 I i I I I I MKDYDELLKY YELHETIGTG GFAKVKLACH ILTGEMVAIK IMDKNTLGSD LPRIKTEIEA 60 LKNLRHQHIC QLYHVLETAN KIFMVLEYCP GGELFDYIIS QDRLSEEETR WFRQIVSAV 120 AYVHSQGYAH RDLKPENLLF DEYHKLKLID FGLCAKPKGN KDYHLQTCCG SLAYAAPELI 180 QGKSYLGSEA DVWSMGILLY VLMCGFLPFD DDNVMALYKK IMRGKYDVPK WLSPSSILLL 240 QQMLQVDPKK RISMKNLLNH PWIMQDYNYP VEWQSKNPFI HLDDDCVTEL SVHHRNNRQT 300 MEDLISLWQY DHLTATYLLL LAKKARGKPV RLRLSSFSCG QASATPFTDI KSNNWSLEDV 360 TASDKNYVAG LIDYDWCEDD LSTGAATPRT SQFTKYWTES NGVESKSLTP ALCRTPANKL 420 KNKENVYTPK SAVKNEEYFM FPEPKTPVNK NQHKREILTT PNRYTTPSKA RNQCLKETPI 480 KIPVNSTGTD KLMTGVISPE RRCRSVELDL NQAHMEETPK RKGAKVFGSL ERGLDKVITV 540 LTRSKRKGSA RDGPRRLKLH YNVTTTRLVN PDQLLNEIMS ILPKKHVDFV QKGYTLKCQT 600 QSDFGKVTMQ FELEVCQLQK PDWGIRRQR LKGDAWVYKR LVEDILSSCK V Seq ID NO : 654 DNA sequence Nucleic Acid Accession &num : NM 000582 Coding sequence: 88.. 990 1 11 21 31 41 51 # # # # # # GCAGAGCACA GCATCGTCGG GACCAGACTC GTCTCAGGCC AGTTGCAGCC TTCTCAGCCA 60 AACGCCGACC AAGGAAAACT CACTACCATG AGAATTGCAG TGATTTGCTT TTGCCTCCTA 120

QEPDEEDEEP PHQQLLQPPG QQPSQLLRRY NVAKVPASPT LSSSAESPEG ASLYDEVRAG 300 ATSGAGGGSR LYYSFKNITK QHPPPLAQPA LSPASSRSVS TSSSSSSGSS SGSSGEDADD 360 LMFDLSLNFS QSAHSASEQQ LGGGAAAGNL SLSLVDKDLD SFSEGSLGSH FEFPDYCTPE 420 LSEMIAGDWL EANFSDLVFT Y Seq ID NO : 658 DNA sequence Nucleic Acid Accession # : NM 001719 Coding sequence: 123.. 1418 1 11 21 31 41 51 # # # # # # GGGCGCAGCG GGGCCCGTCT GCAGCAAGTG ACCGACGGCC GGGACGGCCG CCTGCCCCCT 60 CTGCCACCTG GGGCGGTGCG GGCCCGGAGC CCGGAGCCCG GGTAGCGCGT AGAGCCGGCG 120 CGATGCACGT GCGCTCACTG CGAGCTGCGG CGCCGCACAG CTTCGTGGCG CTCTGGGCAC 180 CCCTGTTCCT GCTGCGCTCC GCCCTGGCCG ACTTCAGCCT GGACAACGAG GTGCACTCGA 240 GCTTCATCCA CCGGCGCCTC CGCAGCCAGG AGCGGCGGGA GATGCAGCGC GAGATCCTCT 300 CCATTTTGGG CTTGCCCCAC CGCCCGCGCC CGCACCTCCA GGGCAAGCAC AACTCGGCAC 360 CCATGTTCAT GCTGGACCTG TACAACGCCA TGGCGGTGGA GGAGGGCGGC GGGCCCGGCG 420 GCCAGGGCTT CTCCTACCCC TACAAGGCCG TCTTCAGTAC CCAGGGCCCC CCTCTGGCCA 480 GCCTGCAAGA TAGCCATTTC CTCACCGACG CCGACATGGT CATGAGCTTC GTCAACCTCG 540 TGGAACATGA CAAGGAATTC TTCCACCCAC GCTACCACCA TCGAGAGTTC CGGTTTGATC 600 TTTCCAAGAT CCCAGAAGGG GAAGCTGTCA CGGCAGCCGA ATTCCGGATC TACAAGGACT 660 ACATCCGGGA ACGCTTCGAC AATGAGACGT TCCGGATCAG CGTTTATCAG GTGCTCCAGG 720 AGCACTTGGG CAGGGAATCG GATCTCTTCC TGCTCGACAG CCGTACCCTC TGGGCCTCGG 780 AGGAGGGCTG GCTGGTGTTT GACATCACAG CCACCAGCAA CCACTGGGTG GTCAATCCGC 840 GGCACAACCT GGGCCTGCAG CTCTCGGTGG AGACGCTGGA TGGGCAGAGC ATCAACCCCA 900 AGTTGGCGGG CCTGATTGGG CGGCACGGGC CCCAGAACAA GCAGCCCTTC ATGGTGGCTT 960 TCTTCAAGGC CACGGAGGTC CACTTCCGCA GCATCCGGTC CACGGGGAGC AAACAGCGCA 1020 GCCAGAACCG CTCCAAGACG CCCAAGAACC AGGAAGCCCT GCGGATGGCC AACGTGGCAG 1080 AGAACAGCAG CAGCGACCAG AGGCAGGCCT GTAAGAAGCA CGAGCTGTAT GTCAGCTTCC 1140 GAGACCTGGG CTGGCAGGAC TGGATCATCG CGCCTGAAGG CTACGCCGCC TACTACTGTG 1200 AGGGGGAGTG TGCCTTCCCT CTGAACTCCT ACATGAACGC CACCAACCAC GCCATCGTGC 1260 AGACGCTGGT CCACTTCATC AACCCGGAAA CGGTGCCCAA GCCCTGCTGT GCGCCCACGC 1320 AGCTCAATGC CATCTCCGTC CTCTACTTCG ATGACAGCTC CAACGTCATC CTGAAGAAAT 1380 ACAGAAACAT GGTGGTCCGG GCCTGTGGCT GCCACTAGCT CCTCCGAGAA TTCAGACCCT 1440 TTGGGGCCAA GTTTTTCTGG ATCCTCCATT GCTCGCCTTG GCCAGGAACC AGCAGACCAA 1500 CTGCCTTTTG TGAGACCTTC CCCTCCCTAT CCCCAACTTT AAAGGTGTGA GAGTATTAGG 1560 AAACATGAGC AGCATATGGC TTTTGATCAG TTTTTCAGTG GCAGCATCCA ATGAACAAGA 1620 TCCTACAAGC TGTGCAGGCA AAACCTAGCA GGAAAAAAAA ACAACGCATA AAGAAAAATG 1680 GCCGGGCCAG GTCATTGGCT GGGAAGTCTC AGCCATGCAC GGACTCGTTT CCAGAGGTAA. 1740 TTATGAGCGC CTACCAGCCA GGCCACCCAG CCGTGGGAGG AAGGGGGCGT GGCAAGGGGT 1800 GGGCACATTG GTGTCTGTGC GAAAGGAAAA TTGACCCGGA AGTTCCTGTA ATAAATGTCA 1860 CAATAAAACG AATGAATG Seq ID NO : 659 Protein sequence Protein Accession # : NP 001710 1 11 21 31 41 51 # # # # # # MHVRSLRAAA PHSFVALWAP LFLLRSALAD FSLDNEVHSS FIHRRLRSQE RREMQREILS 60 ILGLPHRPRP HLQGKHNSAP MFMLDLYNAM AVEEGGGPGG QGFSYPYKAV FSTQGPPLAS 120 LQDSHFLTDA DMVMSFVNLV EHDKEFFHPR YHHREFRFDL SKIPEGEAVT AAEFRIYKDY 180 IRERFDNETF RISVYQVLQE HLGRESDLFL LDSRTLWASE EGWLVFDITA TSNHWWNPR 240 HNLGLQLSVE TLDGQSINPK LAGLIGRHGP QNKQPFMVAF FKATEVHFRS IRSTGSKQRS 300 QNRSKTPKNQ EALRMANVAE NSSSDQRQAC KKHELYVSFR DLGWQDWIIA PEGYAAYYCE 360 GECAFPLNSY MNATNHAIVQ TLVHFINPET VPKPCCAPTQ LNAISVLYFD DSSNVILKKY 420 RNMVVRACGC H Seq ID NO : 660 DNA sequence Nucleic Acid Accession # : Eos sequence Coding sequence: 211.. 1895 1 11 21 31 41 51 # # # # # # GGATCTGAGGGGCGCCCAGT CACTTCCTCC ACGTTCTCGT GCTGGGCGGG AGGAGCGGAT 60 GGGGCTTGGG AGGCAGCCTG CTCTCCAGTC CCTATCCACC CACAGGTTTT TTGGGTCGGA 120 GAGGAATTAT CTGATAAAAT TCCTGGGTTA ATATTTTTAA AAACGGAGAG TTTTTAAAAA 180 TGATTTTTTT CCCTCGAAAA TGACCTTTTT ATGCTTCGAA GCAGTTTGTC AACCAGCATA 240 GTGCTTTTTC TTTTCTCTTC TTTTTCTACG ATAAATGAAA GCATTTCTTC AAGAAAAAGG 300 CACAGGTTCC TTGAACAGCT GGATTCTGAT GGCACCATTA CTATAGAGGA GCAGATTGTC 360 CTTGTGCTGA AAGCGAAAGT ACAATGTGAA CTCAACATCA CAGCTCAACT CCAGGAGGGA 420 GAAGGTAATT GTTTCCCTGA ATGGGATGGA CTCATTTGTT GGCCCAGAGG AACAGTGGGG 480 AAAATATCGG CTGTTCCATG CCCTCCTTAT ATTTATGACT TCAACCATAA AGGAGTTGCT 540 TTCCGACACT GTAACCCCAA TGGAACATGG GATTTTATGC ACAGCTTAAA TAAAACATGG 600 GCCAATTATT CAGACTGCCT TCGCTTTCTG CAGCCAGATA TCAGCATAGG AAAGCAAGAA 660 TTCTTTGAAC GCCTCTATGT AATGTATACC GTTGGCTACT CCATCTCTTT TGGTTCCTTG 720 GCTGTGGCTA TTCTCATCAT TGGTTACTTC AGACGATTGC ATTGCACTAG GAACTATATC 780 CACATGCACT TATTTGTGTC TTTCATGCTG AGAGCTACAA GCATCTTTGT CAAAGACAGA 840 GTAGTCCATG CTCACATAGG AGTAAAGGAG CTGGAGTCCC TAATAATGCA GGATGACCCA 900 CAAAATTCCA TTGAGGCAAC TTCTGTGGAC AAATCACAAT ATATCGGGTG CAAGATTGCT 960 GTTGTGATGT TTATTTACTT CCTGGCTACA AATTATTATT GGATCCTGGT GGAAGGTCTC 1020 TACCTGCATA ATCTCATCTT TGTGGCTTTC TTTTCGGACA CCAAATACCT GTGGGGCTTC 1080 ATCTTGATAG GCTGGGGGTT TCCAGCAGCA TTTGTTGCAG CATGGGCTGT GGCACGAGCA 1140 ACTCTGGCTG ATGCGAGGTG CTGGGAACTT AGTGCTGGAG ACATCAAGTG GATTTATCAA 1200 GCACCGATCT TAGCAGCTAT TGGGCTGAAT TTTATTCTGT TTCTGAATAC GGTTAGAGTT 1260 CTAGCTACCA AAATCTGGGA GACCAATGCA GTTGGGCATG ACACAAGGAA GCAATACAGG 1320 AAACTGGCCA AATCGACACT GGTCCTGGTC CTAGTCTTTG GAGTGCATTA CATCGTGTTC 1380

GTATGCCTGC CTCACTCCTT CACTGGGCTC GGGTGGGAGA TCCGCATGCA CTGTGAGCTC 1440 TTCTTCAACT CCTTTCAGGG TTTCTTTGTG TCTATCATCT ACTGCTACTG CAATGGAGAG 1500 GTTCAGGCAG AGGTGAAGAA GATGTGGAGT CGGTGGAATC TCTCCGTGGA CTGGAAAAGG 1560 ACACCGCCAT GTGGCAGCCG CAGATGCGGC TCAGTGCTCA CCACCGTGAC GCACAGCACC 1620 AGCAGCCAGT CACAGGTGGC GGCCAGCACA CGCATGGTGC TTATCTCTGG CAAAGCTGCC 1680 AAGATCGCCA GCAGACAGCC TGACAGCCAC ATCACTTTAC CTGGCTATGT CTGGAGTAAC 1740 TCAGAGCAGG ACTGCCTGCC ACACTCTTTC CACGAGGAGA CCAAGGAAGA TAGTGGGAGG 1800 CAGGGAGATG ATATTCTAAT GGAGAAGCCT TCCAGGCCTA TGGAATCTAA CCCAGACACT 1860 GAAGGATGCC AAGGAGAAAC TGAGGATGTT CTCTGA Seq ID NO: 661 Protein sequence Protein Accession # : Eos sequence 1 11 21 31 41 51 MLRSSLSTSI VLFLFSSFST INESISSRKR HRFLEQLDSD GTITIEEQIV LVLKAKVQCE 60 LNITAQLQEG EGNCFPEWDG LICWPRGTVG KISAVPCPPY IYDFNHKGVA FRHCNPNGTW 120 DFMHSLNKTW ANYSDCLRFL QPDISIGKQE FFERLYVMYT VGYSISFGSL AVAILIIGYF 180 RRLHCTRNYI HMHLFVSFML RATSIFVKDR WHAHIGVKE LESLIMQDDP QNSIEATSVD 240 KSQYIGCKIA WMFIYFLAT NYYWILVEGL YLHNLIFVAF FSDTKYLWGF ILIGWGFPAA 300 FVAAWAVARA TLADARCWEL SAGDIKWIYQ APILAAIGLN FILFLNTVRV LATKIWETNA 360 VGHDTRKQYR KLAKSTLVLV LVFGVHYIVF VCLPHSFTGL GWEIRMHCEL FFNSFQGFFV 420 SIIYCYCNGE VQAEVKKMWS RWNLSVDWKR TPPCGSRRCG SVLTTVTHST SSQSQVAAST 480 RMVLISGKAA KIASRQPDSH ITLPGYVWSN SEQDCLPHSF HEETKEDSGR QGDDILMEKP 540 SRPMESNPDT EGCQGETEDV L Seq ID NO: 662 DNA sequence Nucleic Acid Accession &num : NM 005048 Coding sequence : 143.. 1795 1 11 21 31 41 51 GGCCGGTGGC CCGGGCCCGA CCACCCCAGC TGCGCGTCGT TACTGGCCAC AAGTTTGCTC 60 TGGGCCAGCC AAGTTGGCAA CTTGGAAGCT TCTCCCGGGC TCTGGAGGAG GGTCCCTGCT 120 TCTTCCTACA GCCGTTCCGG GCATGGCCGG GCTGGGGGCG TCGCTCCACG TCTGGGGTTG 180 GCTAATGCTC GGCAGCTGCC TCCTGGCCAG AGCCCAGCTG GATTCTGATG GCACCATTAC 240 TATAGAGGAG CAGATTGTCC TTGTGCTGAA, AGCGAAAGTA CAATGTGAAC TCAACATCAC 300 AGCTCAACTC CAGGAGGGAG AAGGTAATTG TTTCCCTGAA TGGGATGGAC TCATTTGTTG 360 GCCCAGAGGA ACAGTGGGGA AAATATCGGC TGTTCCATGC CCTCCTTATA TTTATGACTT 420 CAACCATAAA GGAGTTGCTT TCCGACACTG TAACCCCAAT GGAACATGGG ATTTTATGCA 480 CAGCTTAAAT AAAACATGGG CCAATTATTC AGACTGCCTT CGCTTTCTGC AGCCAGATAT 540 CAGCATAGGA AAGCAAGAAT TCTTTGAACG CCTCTATGTA ATGTATACCG TTGGCTACTC 600 CATCTCTTTT GGTTCCTTGG CTGTGGCTAT TCTCATCATT GGTTACTTCA GACGATTGCA 660 TTGCACTAGG AACTATATCC ACATGCACTT ATTTGTGTCT TTCATGCTGA GAGCTACAAG 720 CATCTTTGTC AAAGACAGAG TAGTCCATGC TCACATAGGA GTAAAGGAGC TGGAGTCCCT 780 AATAATGCAG GATGACCCAC AAAATTCCAT TGAGGCAACT TCTGTGGACA AATCACAATA 840 TATCGGGTGC AAGATTGCTG TTGTGATGTT TATTTACTTC CTGGCTACAA ATTATTATTG 900 GATCCTGGTG GAAGGTCTCT ACCTGCATAA TCTCATCTTT GTGGCTTTCT TTTCGGACAC 960 CAAATACCTG TGGGGCTTCA TCTTGATAGG CTGGGGGTTT CCAGCAGCAT TTGTTGCAGC 1020 ATGGGCTGTG GCACGAGCAA CTCTGGCTGA TGCGAGGTGC TGGGAACTTA GTGCTGGAGA 1080 CATCAAGTGG ATTTATCAAG CACCGATCTT AGCAGCTATT GGGCTGAATT TTATTCTGTT 1140 TCTGAATACG GTTAGAGTTC TAGCTACCAA AATCTGGGAG ACCAATGCAG TTGGGCATGA 1200 <BR> <BR> CACAAGGAAG CAATACAGGA AACTGGCCAA ATCGACACTG GTCCTGGTCC TAGTCTTTGG 1260 AGTGCATTAC ATCGTGTTCG TATGCCTGCC TCACTCCTTC ACTGGGCTCG GGTGGGAGAT 1320 CCGCATGCAC TGTGAGCTCT TCTTCAACTC CTTTCAGGGT TTCTTTGTGT CTATCATCTA 1380 CTGCTACTGC AATGGAGAGG TTCAGGCAGA GGTGAAGAAG ATGTGGAGTC GGTGGAATCT 1440 CTCCGTGGAC TGGAAAAGGA CACCGCCATG TGGCAGCCGC AGATGCGGCT CAGTGCTCAC 1500 CACCGTGACG CACAGCACCA GCAGCCAGTC ACAGGTGGCG GCCAGCACAC GCATGGTGCT 1560 TATCTCTGGC AAAGCTGCCA AGATCGCCAG CAGACAGCCT GACAGCCACA TCACTTTACC 1620 TGGCTATGTC TGGAGTAACT CAGAGCAGGA CTGCCTGCCA CACTCTTTCC ACGAGGAGAC 1680 CAAGGAAGAT AGTGGGAGGC AGGGAGATGA TATTCTAATG GAGAAGCCTT CCAGGCCTAT 1740 GGAATCTAAC CCAGACACTG AAGGATGCCA AGGAGAAACT GAGGATGTTC TCTGAATGGA 1800 CATTTGTGGC TGACTTTCAT GGGCTGGTCC AATGGCTGGT TGTGTGAGAG GGCTTGGCTG 1860 ATACTCCTAT GCTTGAGTTC AAAGGCTGAA AATTCAGTTA AGGTGTTACT TAATAATAGT 1920 TTTTAGGCTC CATGAATTGG CTCCTGTAAA TACTAACGAC ATGAAAATGC AAGTGTCAAT 1980 GGAGTAGTTT ATTACCTTCT ATTGGCATCA AGTTTTCCTC TAAATTAATG TATGGTATTT 2040 GCTCTGTGAT TGTTCATTTT TTTCTGCTAC TTTTGGGTAG AAAAAAGATT CAATTGCTTG 2100 GCTGTAGCTT TCTCTCATAT ATATCACCCT AAATATAATG AAGATCTTTT AGTGTGTATC 2160 ATTTTCCTTT TAGAAACTAG TATTCTCTTA TTTCTTACTT TAATGTACTT CTATCACTGC 2220 ATTTATTTTG CCTGTGCATA GGAGCAATTA GGATCTAAAA AAATATATGG GAAGATAAAA 2280 GATCTAAGAA CAAGTACTTG CTGGAAAATT AGTTGGCTGG ACATTGATAA AATAATGCAT 2340 TTATAACAAT TACATGTGTT TTTGGGAACA AGGAAAATTT CTCAAAAAAG AATATTTCAC 2400 ACATCCCTTC TTTTGAATGG CCTCTTTGTG ACCAGCCAGA CCTCAGGTCT TCACTCTTTC 2460 TTCTTTGTAA ACCATGTCAT GTGGAAAGAT TTCCTCAGTT AGTGAGCTTG TGTCTGCAAA 2520 TTGATTTTGT TTGTAATGTA TTTTGATAGC AAATCATGCT GCATCTATAT CTTTTTCTTG 2580 TTTGAGCTGT TACTACATTG TACATGGCAT GTGGGATCAA TTAAAAATTT GTTTTAAAAA 2640 T Seq ID NO: 663 Protein sequence Protein Accession # : NP 005039 1 11 21 31 41 51 MAGLGASLHV WGWLMLGSCL LARAQLDSDG TITIEEQIVL VLKAKVQCEL NITAQLQEGE 60 GNCFPEWDGL ICWPRGTVGK ISAVPCPPYI YDFNHKGVAF RHCNPNGTWD FMHSLNKTWA 120 NYSDCLRFLQ PDISIGKQEF FERLYVMYTV GYSISFGSLA VAILIIGYFR RLHCTRNYIH 180 MHLFVSFMLR ATSIFVKDRV VHAHIGVKEL ESLIMQDDPQ NSIEATSVDK SQYIGCKIAV 240

It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein ncorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.